sarscov<NUMBER> class enveloped viruses positivesense rna genome come betacoronavirus group phylogenetic similarity previous severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov <NUMBER> <NUMBER> thus <NUMBER> rd coronavirus epidemic result evolution virus spread covid<NUMBER> severe previous sarscov merscov <NUMBER> sarscov<NUMBER> pandemic forced researchers invent new strategies rapid antiviral treatment hostbased antiviral agents target host cellular machinery essential viral infections innate immune responses interfere viral pathogenesis <NUMBER> augmented employing wellvalidated drug discovery approaches two basic strategies drug discovery conventional drug development drug repositioning <NUMBER> besides success rate low conventional way typically takes <NUMBER> years expensive needs high investments drug repositioning instead reuses old drugs exploring new therapeutics making efficient economical riskless <NUMBER> <NUMBER> pioneering clinical trials instigated present test coronavirus treatment including potential old drugs investigational new drugs <NUMBER> recycling reusing old drugs recovering shelved drugs increasing patients lives makes drug repositioning appealing system drug discovery requires thorough indepth knowledge present practices acquired assessing biological pharmaceutical learning interpreted mechanismofaction drugs regard pharmaceutical industry also looking novel leadingedge technologies track monitor restrict dissemination covid<NUMBER> disease <NUMBER> <NUMBER> ai one parallel technology provide support virus population screening medical help notification suggestions infection control ai also implemented field design inception learningprediction model performs swift virtual screening accurately display congruent outputs drug repositioning strategy ai briefly screen drugs potential fight minacious diseases covid<NUMBER> evidencebased medical tool technology potential improve drug discovery planning design treatment outline followups covid<NUMBER> patients review describes current application ai drug repurposing treating covid<NUMBER> pandemic drug discovery highrisk lengthy expensive process <NUMBER> <NUMBER> according report eastern research group erg takes <NUMBER> years develop new molecular entity success rate <NUMBER> <NUMBER> concept drug repurposing reuses old drugs treatment neverconsidered therapeutic indication experimental approach identifying preapproved preclinical testing clinical trials omitting initial steps thus narrowing risks lowering costs fundamental principle drug repurposing common molecular pathway associated accountable numerable diseases multitude explicit information accessible formulation dose toxicity pharmacology clinical trial data authorized approved shelved discontinued drugs <NUMBER> drug repurposing article refers use existing approved drugs treatment neverconsidered therapeutic indication case covid<NUMBER> discovery development new molecular entities lengthy timekilling highpriced clinical trials earn regulatory authorizations sanctions momentary passage thus potential treatments repurposing repositioning prevailing approved drugs treatment covid<NUMBER> context chloroquine cq hydroxyl analogue hydroxychloroquine hcq reported treatment viral infection drugs antimalarial activity also showed vitro treatment covid <NUMBER> <NUMBER> similarly antiviral drug remdesivir primarily used treatment ebola virus clinical studies exposed new successful effects covid<NUMBER> vitro adenosine analogue basically integrates nascent viral rna chains shows early termination <NUMBER> lopinavir ritonavir used ministration covid<NUMBER> patients two antiviral agents mainly affect proteolysis coronavirus replication cycle <NUMBER> ribavirin analog ribonucleic inhibitor rna polymerization drug shown vitro activity sarscov<NUMBER> preclinical studies <NUMBER> furthermore tocilizumab immunosuppressive drug also used treatment covid<NUMBER> patients vivo china chiefly employed aid rheumatoid arthritis tested covid<NUMBER> patients drug successfully mitigates clinical symptoms viral infection numbers patients investigated study <NUMBER> antiflu drug japan revealed significant results clinical trials <NUMBER> patients <NUMBER> china drug accepted treatment influenza also shown efficient different type viruses including sarscov<NUMBER> similarly ascorbic acid vitamin c combination antiviral drug shown supportive treatment covid<NUMBER> patients context studies suggested future drug covid<NUMBER> <NUMBER> main hindrance drug repositioning diagnosing identifying unique drugdisease relationship address issue variety approaches developed including computational approaches ai biological experimental approaches mixed approaches thus chances application ai approach drug discovery feasible <NUMBER> researchers found many similarities covid<NUMBER> virus <NUMBER> sars virus based existing data caused sars ai learning models created predict drug structures could potentially treat covid <NUMBER> <NUMBER> notwithstanding effectively affirmed repurposed drugs requirement recognizing repurposed drugs <NUMBER> ai machine learning ml support procedure rapidly recognizing drugs adequacy covid<NUMBER> thus overcome barrier large number repurposed drugs laboratory clinical testing final drug authorization good amount information discharged different health agencies organizations accessible open stages <NUMBER> ai likewise contains subfield called ml utilizes factual strategies capacity learn without modified external user machine learning divided supervised unsupervised reinforcement learning <NUMBER> supervised learning contains characterization relapse strategies prescient model created dependent information information yield sources ie output unsupervised learning includes bunching strategies gathering deciphering information dependent input information another field ml deep learning uses ai neural network multiple hidden layers apart input output layer deep learning permits machines take care complex issues event utilizing informational index exceptionally differing unstructured deep learning calculations learn better perform development dl seen expanding measure information nonstop development computer power striking distinction dl makes adaptability design neural systems repetitive neural networks rnn convolutional neural networks cnn deep belief networks dbn completely associated feedforward systems whole explanation better understood figure <NUMBER> presents aiempowered drug repurposing strategy need repurposed drug database open chemicaldrug database input model different algorithms could applied input required drug could obtained <NUMBER> unique medication information goal ai scientists apply calculations determine noteworthy bits knowledge world offices policymakers need step push huge pharma organizations exploration labs unite littler examination associations pool information sources foresee increasingly exact outcomes specialists need arrangements good information accessible therefore constrained lack data much noisy data associations globe taking vital activities utilize ai testing empowering may requirement progressively symptomatic testing <NUMBER> two popular instances <NUMBER> data set effectiveness medicines may good input ai model organizations utilizing ai repurposing existing medications covid<NUMBER> listed table <NUMBER> article explores recent advances aiempowered drug repurposing covid<NUMBER> age big data drug repurposing done efficiently using deep learning methods aibased drug repurposing cheaper faster effective approach minimize failures clinical trials repurposed drug directly enter advanced phase trial without initial trials toxicity tests though presently aiempowered drug repurposing nascent materiamedicapartnerswithcyclicaforcovid<NUMBER>html <NUMBER> guilliams healx joins forces boehringer ingelheim discover new treatment approaches rare neurological diseases healx news <NUMBER>httpshealxiohealxjoinsforceswithboehringeringelheimtodiscovernewtreatmentapproachesforrareneurologicaldiseases uk based organization known mammoth ai medicate revelation industry organization utilizing ai repurpose current affirmed drugs novel coronavirus inside month limited competitors six encouraging particles baricitinib medication rheumatoid joint pain sedate generally encouraging treatment <NUMBER> <NUMBER> innoplexus indogerman organization started assessing capability treatments like hydroxychloroquine remdesivir <NUMBER>ncov utilizing information originating patients ai stage proposed higher viability mix chloroquine tocilizumab medication rheumatoid joint pain chloroquine remdesivir third mix hydroxychloroquine clarithromycin antimicrobial plerixafor antiretroviral <NUMBER> <NUMBER> deargen korean organization team dankook university anticipated action accessible antiviral medications novel coronavirus ai stage recommended atazanavir medication hiv treatment high power abbvie running preliminary comparative hivantivirals lopinavir ritonavir wuhan <NUMBER> singaporean organization recognized <NUMBER> medications utilizing ai stage among top particles anticipated adequacy coronavirus niclosamide nitazoxanide wide range hostile parasitic viral medications <NUMBER> canadian organization reported screening <NUMBER> atoms fda affirmed nothing else phase human preliminaries aibased medication repurposing stage matchmaker joined forces chinas institute materiamedica vitro vivo evaluation <NUMBER> uk based organization utilizing foundation reveal biand trimixes affirmed drugs infection <NUMBER> organizations capacities lie uncommon infections remarkably situated use information mortality higher comorbidities respiratory heart frameworks vantai new yorkbased organization utilizing frameworks science way deal comprehend interchange collaborations viral proteins perhaps <NUMBER> human proteins span disease organization planning recognize drugs focuses may disregarded different organizations revealed promising objective pathways instance obstructing infections movement golgi contraption viral rebundling framework human cell helps additionally spread present screening around <NUMBER> leads cro tentatively research sway viral contamination <NUMBER> highlights drugrepositioning strategy ai quickly detect drugs fight covid<NUMBER> pandemic aiempowered drug repurposing cheaper faster effective approach reduce failures clinical trials aibased deep learning models predict drug structures could potentially treat covid <NUMBER> novel coronavirus disease <NUMBER> caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> continues spread aggressively mortality rate <NUMBER> <NUMBER> countries territories around world reported total <NUMBER> confirmed cases death toll <NUMBER> started patients reporting pneumonialike symptoms unknown etiology wuhan district china hubei province declared pandemic world health organization march <NUMBER> <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> class enveloped viruses positivesense rna genome come betacoronavirus group phylogenetic similarity previous severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov <NUMBER> <NUMBER> thus <NUMBER>rd coronavirus epidemic result evolution virus spread covid<NUMBER> severe previous sarscov merscov <NUMBER> sarscov<NUMBER> pandemic forced researchers invent new strategies rapid antiviral treatment hostbased antiviral agents target host cellular machinery essential viral infections innate immune responses interfere viral pathogenesis <NUMBER> augmented employing wellvalidated drug discovery approaches two basic strategies drug discovery conventional drug development drug repositioning <NUMBER> besides success rate low conventional way typically takes <NUMBER>e<NUMBER> years expensive needs high investments drug repositioning instead reuses old drugs exploring new therapeutics making efficient economical riskless <NUMBER> <NUMBER> pioneering clinical trials instigated present test coronavirus treatment including potential old drugs investigational new drugs <NUMBER> recycling reusing old drugs recovering shelved drugs increasing patients lives makes drug repositioning appealing system drug discovery requires thorough indepth knowledge present practices acquired assessing biological pharmaceutical learning interpreted mechanismofaction drugs regard pharmaceutical industry also looking novel leadingedge technologies track monitor restrict dissemination covid<NUMBER> disease <NUMBER> <NUMBER> ai one parallel technology provide support virus population screening medical help notification suggestions infection control ai also implemented field design inception learningprediction model performs swift virtual screening accurately display congruent outputs drug repositioning strategy ai briefly screen drugs potential fight minacious diseases covid<NUMBER> evidencebased medical tool technology potential improve drug discovery planning design treatment outline followups covid<NUMBER> patients review describes current application ai drug repurposing treating covid<NUMBER> pandemic drug discovery highrisk lengthy expensive process <NUMBER> <NUMBER> according report eastern research group erg takes <NUMBER>e<NUMBER> years develop new molecular entity success rate <NUMBER> <NUMBER> concept drug repurposing reuses old drugs treatment neverconsidered therapeutic indication experimental approach identifying preapproved discontinued shelved investigational drugs authorized restatement treatment diseases conventional drug development usually includes five stages discovery development ii preclinical research iii clinical research iv fda review v fda postmarket safety monitoring development however four steps drug repurposing compound identification ii compound acquisition iii clinical research iv fda postmarket safety monitoring development fig <NUMBER> <NUMBER> repositioned drug goes directly preclinical testing clinical trials omitting initial steps thus narrowing risks lowering costs fundamental principle drug repurposing common molecular pathway associated accountable numerable diseases multitude explicit information accessible formulation dose toxicity pharmacology clinical trial data authorized approved shelved discontinued drugs <NUMBER> drug repurposing article refers use existing approved drugs treatment neverconsidered therapeutic indication case covid<NUMBER> discovery development new molecular entities lengthy timekilling highpriced clinical trials earn regulatory authorizations sanctions momentary passage thus potential treatments repurposing repositioning prevailing approved drugs treatment covid<NUMBER> context chloroquine cq hydroxyl analogue hydroxychloroquine hcq reported treatment viral infection drugs antimalarial activity also showed vitro treatment covid <NUMBER> <NUMBER> similarly antiviral drug remdesivir primarily used treatment ebola virus clinical studies exposed new successful effects covid<NUMBER> vitro adenosine analogue basically integrates nascent viral rna chains shows early termination <NUMBER> lopinavir ritonavir used ministration covid<NUMBER> patients two antiviral agents mainly affect proteolysis coronavirus replication cycle <NUMBER> ribavirin analogue ribonucleic inhibitor rna polymerization drug shown vitro activity sarscov<NUMBER> preclinical studies <NUMBER> furthermore tocilizumab immunosuppressive drug also used treatment covid<NUMBER> patients vivo china chiefly employed aid rheumatoid arthritis tested covid<NUMBER> patients drug successfully mitigates clinical symptoms viral infection numbers patients investigated study <NUMBER> antiflu drug japan revealed significant results clinical trials <NUMBER> patients <NUMBER> china drug accepted treatment influenza also shown efficient different type viruses including sarscov<NUMBER> similarly ascorbic acid vitamin c combination antiviral drug shown supportive treatment covid<NUMBER> patients context studies suggested future drug covid<NUMBER> <NUMBER> main hindrance drug repositioning diagnosing identifying unique drugdisease relationship address issue variety approaches developed including computational approaches ai biological experimental approaches mixed approaches thus chances application ai approach drug discovery feasible <NUMBER> researchers found many similarities covid<NUMBER> virus <NUMBER> sars virus based existing data caused sars ai learning models created predict drug structures could potentially treat covid <NUMBER> <NUMBER> notwithstanding effectively affirmed repurposed drugs requirement recognizing repurposed drugs <NUMBER> ai machine learning ml support procedure rapidly recognizing drugs adequacy covid<NUMBER> thus overcome barrier large number repurposed drugs laboratory clinical testing final drug authorization good amount information discharged different health agencies organizations accessible open stages <NUMBER> ai likewise contains subfield called ml utilizes factual strategies capacity learn without modified external user machine learning divided supervised unsupervised reinforcement learning <NUMBER> supervised learning contains characterization relapse strategies prescient model created dependent information information yield sources e output unsupervised learning includes bunching strategies gathering deciphering information dependent input information another field ml deep learning uses ai neural network multiple hidden layers apart input output layer deep learning permits machines take care complex issues event utilizing informational index exceptionally differing unstructured deep learning calculations learn better perform development dl seen expanding measure information nonstop development computer power striking distinction dl makes adaptability design neural systems repetitive neural networks rnn convolutional neural networks cnn deep belief networks dbn completely associated feedforward systems whole explanation better understood fig <NUMBER> presents aiempowered drug repurposing strategy need repurposed drug database open chemicaldrug database input model different algorithms could applied input required drug could obtained <NUMBER> best truly necessary technique circumstances order unique medication information goal ai scientists apply calculations determine noteworthy bits knowledge world offices policymakers need step push huge pharma organizations exploration labs unite littler examination associations pool information sources foresee increasingly exact outcomes specialists need arrangements good information accessible therefore constrained lack data much noisy data associations globe taking vital activities utilize ai testing empowering may requirement progressively symptomatic testing <NUMBER> associations begun use advancements quicken covid<NUMBER> medication disclosure better fathom resistant framework battles infection toward beginning april pharmaceutical organizations glaxosmithkline gsk vir biotechnology joined forces progress coronavirus treatment advancement utilizing computerized reasoning crispr furthermore scholarly area harvard chan school public health late united human vaccines project dispatch human immunomics initiative uses manmade reasoning models quicken antibodies scope infections including covid<NUMBER> <NUMBER> group southern illinois university siu late built information representation device uses gps data show users locations known covid<NUMBER> cases google apple likewise collaborated build contact following application powered bluetooth innovation methods may prove effective data collection great accurate amount <NUMBER> organizations running experimentation explores different avenues regarding effectively approved drugs built wellbeing profiles people based fundamental comprehension infection regards covid<NUMBER> hydroxychloroquine endorsed treat malaria remdesivir ebola two popular instances <NUMBER> data set effectiveness medicines may good input ai model organizations utilizing ai repurposing existing medications covid<NUMBER> listed table <NUMBER> article explores recent advances aiempowered drug repurposing covid<NUMBER> age big data drug repurposing done efficiently using deep learning methods aibased drug repurposing cheaper faster effective approach minimize failures clinical trials repurposed drug directly enter advanced phase trial without initial trials toxicity tests though presently aiempowered drug repurposing nascent stage approach promising solution development potential drugs cure covid<NUMBER> computational intelligence aided drug molecule design repositioning drug molecules help prediction excellent antiviral therapeutics however prediction efficiency increase systematic training database development relevant learning algorithms technological advancements ai coupled increased computational power aiempowered drug repurposing prove beneficial covid<NUMBER> scenario table <NUMBER> list companies using ai drug repurposing description implication ai drug repurposing references benevolentai uk based organization known mammoth ai medicate revelation industry organization utilizing ai repurpose current affirmed drugs novel coronavirus inside month limited competitors six encouraging particles baricitinib medication rheumatoid joint pain sedate generally encouraging treatment <NUMBER> <NUMBER> innoplexus indogerman organization started assessing capability treatments like hydroxychloroquine remdesivir <NUMBER>ncov utilizing information originating patients ai stage proposed higher viability mix chloroquine tocilizumab medication rheumatoid joint pain chloroquine remdesivir third mix hydroxychloroquine clarithromycin antimicrobial plerixafor antiretroviral <NUMBER> <NUMBER> deargen korean organization team dankook university anticipated action accessible antiviral medications novel coronavirus ai stage recommended atazanavir medication hiv treatment high power abbvie running preliminary comparative hivantivirals lopinavir ritonavir wuhan <NUMBER> singaporean organization recognized <NUMBER> medications utilizing ai stage among top particles anticipated adequacy coronavirus niclosamide nitazoxanide wide range hostile parasitic viral medications <NUMBER> canadian organization reported screening <NUMBER> atoms fda affirmed nothing else phase human preliminaries aibased medication repurposing stage matchmaker joined forces chinas institute materiamedica vitro vivo evaluation <NUMBER> healx uk based organization utilizing foundation reveal biand trimixes affirmed drugs infection organizations capacities lie uncommon infections remarkably situated use information mortality higher comorbidities respiratory heart frameworks <NUMBER> new yorkbased organization utilizing frameworks science way deal comprehend interchange collaborations viral proteins perhaps <NUMBER> human proteins span disease organization planning recognize drugs focuses may disregarded different organizations revealed promising objective pathways instance obstructing infections movement golgi contraption viral rebundling framework human cell helps additionally spread present screening around <NUMBER> leads cro tentatively research sway viral contamination <NUMBER> saverunner algorithm requires input list drug targets list disease genes evaluate extent given drug repositioned treat given disease present study diseaseassociated genes downloaded phenopedia <NUMBER> provides diseasecentered view genetic association studies whereas drugtarget associations obtained drugbank <NUMBER> collects huge amount drugrelated data recently enabling discovery repurposing relevant number existing drugs treat rare newly identified diseases <NUMBER> <NUMBER> figure <NUMBER>a tested performance saverunner panel <NUMBER> diseases found related covid<NUMBER> genetic similarity comorbidity association drugs potential shorten recovery time seriously ill covid<NUMBER> patients thus included severe acute respiratory syndrome sars since caused coronavirus highest nucleotide sequence identity sarscov<NUMBER> <NUMBER> <NUMBER> unlike covid<NUMBER> still partial knowledge associated disease genes sars widely studied reliable list molecular determinants available common databases human genetic associations <NUMBER> yet comprehended cardiovascular diseases diabetes hypertension whose comorbidity covid<NUMBER> patients well documented <NUMBER> <NUMBER> addition included viral infections ie malaria hiv ebola immune disorders ie rheumatoid arthritis since drugs authorized treatment ie chloroquinehydroxychloroquine lopinavirritonavir remdesivir tocilizumab respectively investigated worldwide potential treat coronavirus disease covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> concerns drugtarget associations assembled target information total <NUMBER> fdaapproved drugs addition considered input list drug targets also combination remdesivir four antiviral agents ie hydroxycloriquine chloriquine lopinavir ritonavir referred <NUMBER>cocktail well combination two ie lopinavir ritonavir referred kaletra whose antiviral action coronavirus infections demonstrated vitro vivo studies <NUMBER> <NUMBER> fact despite significant progress covid<NUMBER> management pointing remdesivir promising therapeutic candidate mortality remains high indicating treatment antiviral drug alone likely sufficient combinations antiviral agents evaluated future strategies improve patient outcomes covid<NUMBER> <NUMBER> complete lists analyzed diseases drugs provided supplementary table <NUMBER> rationale behind saverunner algorithm lies hypothesis drug effective specific disease associated targets drug module diseasespecific associated genes disease module nearby human interactome <NUMBER> figure <NUMBER>b quantify vicinity drug disease modules saverunner implements novel network similarity measure p network proximity measure defined <NUMBER> represents average shortest path length drug targets drug module nearest disease genes disease module quality cluster score steepness midpoint respectively see materials methods assess statistical significance new defined networkbased similarity measure saverunner applies degreepreserving randomization procedure expecting pvalue ≤ <NUMBER> proximal drug disease modules novelty approach resides implemented procedure prioritize predicted offlabel drug indications given disease see materials methods section prioritization procedure exploits clustering analysis reward associations drugs diseases belonging network cluster based assumption drug disease group together likely drug effectively repurposed disease sense say drugs disease members group cluster similar members groups clusters saverunner algorithm releases output weighted bipartite drugdisease network one set nodes corresponds drugs one corresponds diseases link drug disease occurs corresponding drug targets disease genes nearby interactome expected chance pvalue ≤ <NUMBER> weight interaction corresponds new defined networkbased similarity measure study final drugdisease network composed total <NUMBER> nodes ie <NUMBER> diseases associated <NUMBER> drugs <NUMBER> edges drugdisease network naturally rendered matrix reporting <NUMBER> diseases rows <NUMBER> drugs columns figure <NUMBER> labeled original medical indication according therapeutic target database ttd matrix cell colored according corresponding similarity value given drugdisease pair shades yellow denote drugassociated targets proximal high similarity diseaseassociated genes human interactome whereas shades blue denote drug targets distal low similarity disease genes figure <NUMBER> elucidating drugsdiseases relatedness terms network similarity computed hierarchical biclustering drugdisease similarity matrix analysis pointed two main disease clusters one including sars rds multiple sclerosis rheumatoid arthritis malaria viral infection diseases magenta box figure <NUMBER> one including cardiovascular diseases risk factors ie diabetes mellitus hypertension green box figure <NUMBER> proof validity saverunner among predicted drugdisease associations found several already known associations example tocilizumab interferonbeta <NUMBER>ab chloroquine hydroxychloroquine lopinavirritonavir resulted significantly associated pvalue ≤ <NUMBER> diseases approved ie rheumatoid arthritis multiple sclerosis malaria hiv infection respectively total found <NUMBER> host proteins associated sarscov specific subnetwork within human interactome shown figure <NUMBER>a mapping known drugtarget network sarscovhost interactome revealed <NUMBER> <NUMBER> <NUMBER> light blue nodes figure <NUMBER>a figure <NUMBER>b mirroring enrichment results found total <NUMBER> sarscovassociated disease genes figure <NUMBER>c high druggability sarscovhost interactome relevance pathways <NUMBER> druggable sarscovassociated disease genes involved strongly supports drug repurposing strategy potential treatment covid<NUMBER> specifically targeting cellular proteins associated sars remaining <NUMBER> nontargetable sarscovassociated disease genes include proteins eg cd<NUMBER> ifna<NUMBER> ifnb<NUMBER> il<NUMBER> il<NUMBER> ccl<NUMBER> key roles immuneinflammatory response viral infection well strongly supports networkbased view drug action according disease phenotypes difficult reverse use single magic bullet intervention affects single node network encourages inspect molecules situated neighborhood targetable proteins leading also detect possible sideeffects <NUMBER> total saverunner identified <NUMBER> repurposable drugs significantly associated pvalue ≤ <NUMBER> sarscov infection supplementary table <NUMBER> figure <NUMBER>a illustrates sketch sars drugdisease network sars connected analyzed diseases via highconfidence predicted drugs original medical indications could repurposed potential sars fighting network composed two independent sets nodes one set corresponds <NUMBER> diseases ie sars <NUMBER> diseases sharing least one drug sars represented red circles whose size scales degree one corresponds <NUMBER> fdaapproved nonsars drugs known therapeutic indications available ttd drugs combination proposed new potential medical indication colored accordingly two nodes two independent sets connected whether network similarity drug targets disease genes human interactome statistically significant pvalue ≤ <NUMBER> looking figure <NUMBER>a clearly emerges exist several candidate repurposable drugs treatment sars among pointed <NUMBER>cocktail adjusted similarity <NUMBER> pvalue <NUMBER> appeared promising candidate targeting sars showing quite high network similarity total among candidate repurposable drugs sars already known medical indication found <NUMBER> drugs indicated hypertension treatment including enalapril also top potential anti hydroxycloriquine adjusted similarity <NUMBER> pvalue <NUMBER> <NUMBER> <NUMBER> <NUMBER> drugs influenza figure <NUMBER>b analyzing distribution known medical indications associated drugs shared sars infection analyzed disease hypertensionand cardiacassociated drugs appeared highly frequent drugs followed rheumatoid arthritisand respiratory diseaseassociated ones figure <NUMBER>c findings appear accordance fact patients sarscov<NUMBER> infection also showed potential hypertension cardiac injuries including arrhythmia myocardial dysfunction <NUMBER> <NUMBER> <NUMBER> <NUMBER> could owed disruption subtle balance angiotensinconverting enzyme <NUMBER> ace<NUMBER> angiotensinconverting enzyme <NUMBER> ace<NUMBER> identified functional receptor sarscovsarscov<NUMBER> host cell entry <NUMBER> normally devoted present various cardiovascular protective effects <NUMBER> order validate <NUMBER> antisars repurposable drugs predicted saverunner performed gene set enrichment analysis gsea <NUMBER> using transcriptome data sarscov infected cells gene signature sars gene expression data drugtreated human cell lines connectivity map cmap database exploited obtain drug signatures thus calculate gsea score drug indication insilico validation particular sars dataset selected drugs score <NUMBER> order focus drugs able potential treatment effect genes hallmark phenotype assigned gsea score ranging <NUMBER> <NUMBER> corresponded number datasets satisfying criterion specific drug gsea analysis validated total <NUMBER> <NUMBER> candidate drugs repositioned sars infection including <NUMBER> gsea score <NUMBER> <NUMBER> gsea score equal <NUMBER> supplementary table <NUMBER> study focused sars disease caused coronavirus higher genetic similarity sarscov<NUMBER> <NUMBER> <NUMBER> specific disease genes known conversely given novelty new coronavirus covid<NUMBER> spectrum human disease knowledge covid<NUMBER>associated genes far completeness however study recently published authors identified <NUMBER> human proteins interacting <NUMBER> sarscov<NUMBER> proteins using affinity purification mass spectrometry <NUMBER> although authors verified proteins preferentially highly expressed lung tissue typical environment virus causes major damage study carried human hek<NUMBER>t kidney cells represent primary physiological site infection generalizable understanding human coronaviruses infection completed analysis applying saverunner <NUMBER> human proteins preliminarily associated sarscov<NUMBER> obtained results encouraging appears accordance analysis carried sarscov indeed performing hierarchical clustering network predicted drugdisease associations found covid<NUMBER> cluster sars rds multiple sclerosis rheumatoid arthritis malaria viral infection diseases figure <NUMBER>a accordance recent studies attempting repurpose covid<NUMBER> treatment drugs approved treat viral infections influenza malaria hiv ebola immunerelated disorders rheumatoid arthritis multiple sclerosis <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> list networkpredicted drugs potentially able treat sarscov<NUMBER> infection contains total <NUMBER> drugs including <NUMBER> ie <NUMBER> covid<NUMBER> specific <NUMBER> ie <NUMBER> common <NUMBER> candidate repurposing candidates shared sarscov<NUMBER> sarscov also reflected result greedy clustering algorithm implemented saverunner places covid<NUMBER> sars together cluster highest quality cluster score investigated whether networkpredicted repurposable drugs could counteract gene expression perturbations caused sarscov<NUMBER> ie could upregulate genes downregulated infection viceversa verify performed gsea analysis using covid<NUMBER> gene signature <NUMBER> differentially expressed genes sarscov<NUMBER>infected a<NUMBER> cells reported <NUMBER> drug signatures gene expression data drugtreated human cell lines cmap database <NUMBER> interestingly analysis revealed <NUMBER> <NUMBER> candidate drugs repositioned covid<NUMBER> treatment achieved highest gsea score particular <NUMBER> encompassing lopinavir included <NUMBER> specificsarscov<NUMBER> predicted drugs supplementary table <NUMBER> figure <NUMBER>b recent study <NUMBER> authors exploited new knowledge sarscov<NUMBER> host interactome <NUMBER> integrated several networkbased drug repurposing strategies prioritize <NUMBER> promising repurposing candidates covid<NUMBER> overlap <NUMBER> repurposable drugs <NUMBER> ones predicted saverunner <NUMBER> drugs ie isoniazid lopinavir romidepsin sulfinpyrazone tadalafil order predict potential comorbidity patterns among diseases analyzed study disease module corresponding <NUMBER> analyzed disorders computed noneuclidean separation distance measures modules overlap <NUMBER> network proximity defined shortest distance disease gene module disease gene module positive value separation measure indicates two disease modules topologically wellseparated human interactome whereas negative value separation measure indicates two disease modules located network neighborhood thus overlap found sarscov disease module directly overlapped rds influenza disease modules <NUMBER> appeared closest malaria smallest followed cardiomyopathies figure <NUMBER>a hand using sarscov<NUMBER> disease genes found covid<NUMBER> disease module directly overlap disease module analyzed figure <NUMBER>b however among closest diseases smallest found cardiovascular diseases ie cardiomyopathies arrhythmia heart arrest whose comorbidity covid<NUMBER> patients already discussed <NUMBER> <NUMBER> last years several computational networkbased methods proposed predict direct drugdisease associations drug repositioning <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> among mbirw algorithm adopts adopted effective mechanism measure similarity drugs diseases applied birandom walk birw algorithm predict potential new indications existing drugs <NUMBER> methodology shown outperform wellknown networkbased prediction methods <NUMBER> <NUMBER> <NUMBER> correctly predicting true drugdisease associations captivating results prompted us implement birwbased algorithm see materials methods compared performance saverunner effectiveness drugdisease predictions provided birw saverunner evaluated compared terms receiver operating characteristic roc probability curves corresponding area curve auc see materials methods particular found saverunner yielded <NUMBER> accuracy auc <NUMBER> identifying wellknown drugdisease relationships overcame one obtained birwbased algorithm auc <NUMBER> words <NUMBER> chance saverunner algorithm able distinguish positive class known drugdisease associations negative class unknown drugdisease associations <NUMBER> birwbased algorithm thus far proven effective therapies novel coronavirus disease covid<NUMBER> exist majority available data based expert opinions anecdotal experiences <NUMBER> reports china suggest chloroquine shown superiority reducing severity duration clinical disease without significant adverse events almost one hundred patients <NUMBER> <NUMBER> <NUMBER> light results expert consensus group china recommended chloroquine covid<NUMBER> treatment <NUMBER> hydroxychloroquine brand name plaquenil analogue chloroquine demonstrated much less toxic chloroquine animals similar vitro efficacy sarscov<NUMBER> <NUMBER> <NUMBER> lopinavirritonavir brand name kaletra wellknown protease inhibitor widely used many years treatment hiv infection compared remdesivir lopinavirritonavir advantage widely available established toxicity drugdrug interactions profile one promising monoclonal antibodies investigation management covid<NUMBER> tocilizumab tcz specifically tcz antihuman il<NUMBER> receptor monoclonal antibody inhibits signal transduction binding sil<NUMBER>r mil<NUMBER>r currently tcz licensed treatment adult patients moderately severely active rheumatoid arthritis several studies china showed possible correlation massive inflammation severe lung damage rapid evolution fatal pneumonia indeed covid<NUMBER> patients significant differences il<NUMBER> plasmatic levels observed different stage disease higher expression severe cases <NUMBER> despite lack clinical trials tcz efficacy safety covid<NUMBER> treatment offlabel tcz used potential treatment strategy severe critical covid<NUMBER> patients currently italy multicenter study efficacy tolerability tocilizumab treatment patients covid<NUMBER> pneumonia ongoing another remarkable candidate treatment covid<NUMBER> lmwh aim improve coagulation dysfunction covid<NUMBER> really course sarscov<NUMBER> infection increased incidence acute pulmonary embolism episodes detected often covid<NUMBER> patients risk factors embolism increased ddimer deterioration general conditions respiratory failure recently tong n et al <NUMBER> showed anticoagulant therapy mainly lmwh appears associated better prognosis severe covid<NUMBER> patients meeting criteria sepsisinduced coagulopathy score markedly elevated ddimer however efficacy remains validated large clinical trials interestingly lmwh seems exert antiinflammatory effects reducing il<NUMBER> increasing lymphocyte potential lmwh could mitigate cytokine storm severe covid<NUMBER> patients complete clinical landscape potential adjunctive therapy covid<NUMBER> mention also use convalescent plasma hyperimmune immunoglobulins obtained recovered patients <NUMBER> rationale treatment antibodies recovered patients may help immune clearance sarscov<NUMBER> conclusion several drugs demonstrate vitro activity sarscov<NUMBER> several repurposed currently randomized clinical trials proven drugs undoubtedly effective study developed novel networkbased algorithm drug repurposing called saverunner aim offer promising framework efficiently screen potential novel indications currently marketed drugs covid<NUMBER> findings accordance several recent works <NUMBER> <NUMBER> <NUMBER> suggested discovery efficacious repurposable drugs drug combinations could benefit exploration relationship drug targets disease genes human interactome novelty saverunner relies definition new networkbased similarity measure quantifies vicinity drug disease modules considers drugdisease network modular structure reward predicted associations drugs diseases located network neighborhoods focusing sars disease caused coronavirus higher genetic similarity sarscov<NUMBER> <NUMBER> <NUMBER> specific disease genes known identified <NUMBER> candidate repurposable drugs among recovered rumored offlabel drugs like chloroquine hydroxycloriquine tocilizumab heparin lopinavirritonavir remdesivir found significantly associated sars combination together chloroquine hydroxycloriquine referred <NUMBER>cocktail predicted promising antisarscov repurposable drug although <NUMBER> repurposable drugs predicted saverunner warrant explored prioritization drugs according decreasing value network similarity value sars may offer possibility maximize efficiency subsequent experimental screening clinical trial validation mean drugs located lowerranking potential efficacy must priori excluded exploration thus found <NUMBER> th percentile similarity values distribution includes aceinhibitors ie indication insilico validation <NUMBER> candidate repurposable drugs predicted saverunner performed gsea analysis allowed investigate whether repositioning candidates potential treatment effect sarscov infection gsea analysis validated total <NUMBER> <NUMBER> antisars repurposable drugs among drugs achieving highest gsea scores found aceinhibitors abovementioned ie enalapril benazepril quinapril fosinopril rescinnamine well aceinhibitors multiple targets ie perindopril captopril moexipril ramipril chloroquine addition analysis came interesting less obvious drugs falling far outside antiviral use ruxolitinib lovastatin group h<NUMBER>antihistamines ie loratadine fexofenadine levocetirizine desloratadine clemastine ketotifen diphenhydramine cetirizine ruxolitinib potent selective janusassociated kinase jak inhibitor approved treatment myelofibrosis thanks powerful antiinflammatory effect could likely effective consequences elevated levels cytokines typically observed patients covid<NUMBER> <NUMBER> <NUMBER> lovastatin widely prescribed reduce levels cholesterol blood prevent cardiovascular diseases experimental evidence suggested statininduced reduction cholesterol plasma membrane results lower viral titers failure internalize virus <NUMBER> h<NUMBER>antihistamines mostly used treat allergic reactions potentially could beneficial antiinflammatory effects immune dysregulation covid <NUMBER> infection indeed histamine biologically active substance potentiates inflammatory immune responses body regulates physiological function gut acts neurotransmitter notably among repurposable drugs sarscov sarscov<NUMBER> predicted saverunner validated gsea analysis found <NUMBER> common offlabel drugs encompassing ace inhibitors ie enalapril quinapril antihistamines ie cetirizine fexofenadine moreover among repurposable drugs validated gsea analysis potential treatment effect sarscov<NUMBER> infection found protease inhibitor lopinavir moving beyond one drug one target vision prompted us explore molecules situated interactome neighborhood drugs targetable proteins may altered drug activity well may cause sideeffects figure <NUMBER> interestingly observe drug subnetworks include genes involved immuneinflammatory drugs characterized highly complex interaction networks whereas others like case remdesivir seem poorly connected substructure however worth noting observed network complexity scale potential drug effectiveness lack interactions may likely ascribable current incompleteness human interactome shortage drugtarget information case remdesivir designed target specifically virus proteins little known human targetable proteins leading less wired subgraph case heparin subnetwork figure <NUMBER>f highly complexity interaction network perfectly matches versatile role anticoagulant antiinflammatory antiviral drug turning strong multifactorial impact new human coronavirus <NUMBER> human proteinprotein interactome downloaded supplementary data <NUMBER> diseaseassociated genes downloaded phenopedia <NUMBER> provides diseasecentered view genetic association studies collecting online human genome epidemiology huge encyclopedia <NUMBER> updated version phenopedia released <NUMBER> collects gene associations <NUMBER> diseases among selected panel <NUMBER> diseases interest associated genes supplementary table <NUMBER> drugtarget interactions acquired drugbank <NUMBER> comprehensive freely accessible online database containing information drugs drug targets <NUMBER> database particular remdesivir antivirus drug designed target specifically virus proteins extracted human target information ttd known drug medical indications obtained ttd <NUMBER> whose last version released <NUMBER> nov saverunner searching offlabel drug network networkbased algorithm drug repurposing taking input list drug targets disease genes constructs drugdisease network predicted drugdisease associations performing steps next discussed figure <NUMBER> order investigate extent disease drug modules close human interactome saverunner implements networkbased proximity measure defined <NUMBER> average shortest path length drug targets drug module nearest disease genes disease module figure <NUMBER>b evaluate statistical significance observed network proximity two modules saverunner builds reference distance distribution corresponding expected distance two randomly selected groups proteins size degree distribution original sets disease proteins drug targets human interactome procedure repeated <NUMBER> times z statistics together corresponding pvalue computed using mean standard deviation reference distance distribution step <NUMBER> computation network similarity network proximity measure translated similarity measure assuming values range <NUMBER> null similarity means corresponding disease drug modules distal human interactome ie maximum whereas maximum similarity means corresponding disease drug modules proximal human interactome ie equal zero order filter statistically insignificant drugdisease associations significance level pvalues set means given disease drug b pvalue associated distance human interactome smaller chosen significance level probability offlabel drug b would effective disease greater expected chance analysis predicted drugdisease associations pvalue ≤ <NUMBER> selected next saverunner performs cluster analysis detect groups drugs diseases way members group cluster similar groups clusters saverunner exploits cluster detection algorithm based greedy optimization network modularity <NUMBER> specifically modularity measures strength network division clusters ie networks high modularity dense connections nodes within clusters sparse connections nodes different clusters greedy clustering algorithm adopted view good performance high speed detecting community structure large networks <NUMBER> quality cluster evaluated saverunner computing following quality cluster score denotes total weight edges within cluster denotes total weight edges connecting cluster rest network penalty term considers node density within cluster step <NUMBER> adjustment network similarity quality cluster score serves reward associations drugs diseases belonging cluster based assumption drug disease group together likely drug effectively repurposed disease sense say drug disease members cluster tend similar translates following adjustment similarity thus whether two nodes fall cluster similarity value increases factor proportional score cluster belong otherwise whether two nodes fall cluster set zero similarity value change step <NUMBER> normalization network similarity bound similarity measure defined eq <NUMBER> values monotonically increase <NUMBER> <NUMBER> saverunner performed normalization procedure applying following sigmoid function adjusted similarity measure eq <NUMBER> sigmoid midpoint ie value function approaches <NUMBER> c sigmoid steepness set max <NUMBER> <NUMBER> end step saverunner offers list predictedprioritized associations drugs diseases weighted bipartite drugdisease network one set nodes corresponds drugs one corresponds diseases link drug disease occurs corresponding drug targets disease genes nearby interactome expected chance pvalue ≤ <NUMBER> weight interaction corresponds adjusted normalized similarity value effectiveness predicted drugdisease associations provided saverunner algorithm evaluated terms receiver operating characteristic roc probability curve analysis drugdisease associations ranked according increasing pvalues real association assigned according ttd information <NUMBER> predicted drugdisease association known <NUMBER> otherwise specified pvalue threshold true positive rate ie sensitivity calculated fraction known associations correctly predicted false positive rate ie <NUMBER>specificity computed fraction unknown associations predicted roc probability curve drawn based measures different thresholds corresponding area curve auc computed higher auc better algorithm distinguishing two classes ie known drugdisease associations versus unknown drugdisease associations inspired already existing algorithm drug repurposing called mbirw <NUMBER> exploited birandom walkbased birw approach infer potential reuse existing drugs started known drugdisease associations available ttd <NUMBER> figure <NUMBER>a analogy <NUMBER> matrices adjusted based known drugdisease associations underlying hypothesis drug disease pairs whose similarity value greater expected chance likely share common diseases drugs adjusted matrix weighted drug similarity network built nodes approved drugs edge occurs two nodes share least one target gene weight given corresponding element matrix likewise adjusted matrix weighted disease similarity network built nodes diseases edge occurs two diseases share least one disease gene weight given corresponding element matrix next new drugdisease associations predicted iterative random walk process drug disease similarity networks simultaneously denoting parameters walks drug network left walks disease network right walks birandom walk described following equations <NUMBER> denotes drugdisease association <NUMBER> matrix represent predicted drugdisease associations iteration starting left right respectively hypothesis behind association drug r<NUMBER> disease d<NUMBER> added following two avenues figure <NUMBER>b <NUMBER> random walker starts random vertex r<NUMBER> drug similarity network step walks one neighboring vertices instance r<NUMBER> known previously predicted association d<NUMBER> probability proportional weight edge traversed ie corresponding element <NUMBER> random walker starts random vertex d<NUMBER> disease similarity network step walks one neighboring vertices instance d<NUMBER> known previously predicted association r<NUMBER> probability proportional weight edge traversed ie corresponding element cases existence known association drug r<NUMBER> disease d<NUMBER> considered probability <NUMBER> − α step iteration process predicted drugdisease associations matrix given mean finally bipartite drugdisease network constructed consisting two sets nodes one set corresponding disease set corresponding approved drugs edge drug disease occurs association already known predicted among performance birwbased algorithm predicting new drugdisease associations evaluated tenfold cross validation <NUMBER> technique investigate predictive power algorithm partitioning original sample training test set particular tenfold crossvalidation consists randomly partitioning original sample case drugdisease associations <NUMBER> equal size subsamples <NUMBER> subsamples single subsample retained test set remaining <NUMBER> subsamples used training set crossvalidation process repeated <NUMBER> iterations <NUMBER> subsamples used exactly test set results iteration evaluated terms roc probability curves particular time predicted drugdisease associations ranked according similarity score estimated birwbased algorithm ie corresponding element matrix n topranked drugdisease associations selected evaluated roc curve analysis n length test set worth stress crossvalidation trial didnt use information known drugdisease associations test set put zero first iteration birandom walk process roc curve constructed different values specified threshold true drugdisease association considered correctly predicted estimated similarity score association higher specified threshold results roc curve analysis obtained iteration averaged obtain mean roc curve corresponding area curve auc calculated higher auc better algorithm distinguishing two classes ie known drugdisease associations versus unknown drugdisease associations kyoto encyclopedia genes genomes kegg enrichment analysis aiming evaluate functional pathways sarscovassociated disease genes performed using r statistical software package clusterprofiler <NUMBER> pvalues adjusted false discovery rate fdr method threshold equal <NUMBER> set identify functional annotations significantly enriched amongst selected gene lists order test whether selected antisars repurposable drugs counteract gene expression perturbations caused virus ie whether downregulate genes upregulated virus vice versa performed gene set enrichment analysis gsea <NUMBER> first collected gene expression datasets hosts infected sarscov available geo public repository particular transcriptome data sarscovinfected samples patients peripheral blood gse<NUMBER> calu<NUMBER> cells gse<NUMBER> define differentially expressed genes selected adjusted pvalues less <NUMBER> <NUMBER> gse<NUMBER> gse<NUMBER> dataset respectively differentially expressed genes used networkpredicted repurposable drugs sars along rows ttd classification along columns plot circles scaled colored according adjusted similarity measure increasing light purple low similarity dark purple high similarity barplot placed top reports total number candidate repurposable drugs sars grouped colored according ttd classification c common drugs sars diseases analyzed disease barplot reports total number drugs shared sars grouped colored according ttd classification statistically significant pvalue ≤ <NUMBER> network adjusted similarity values clustered according rows diseases columns drugs complete linkage hierarchical clustering algorithm using euclidean distance distance metric heatmap color key denotes adjusted similarity drug targets disease genes human interactome increasing blue less similar yellow similar drugs colored according therapeutic target heparin f aceinhibitors gh ruxolitinib h<NUMBER>antistamines l subnetwork designed point shortest paths drug targets sars disease genes human interactome subnetwork disease genes specifically targeted drug marked yellow star major histocompatibility complex class mchi proinflammatory cytokines shared drug networks marked orange green circle respectively legend red circles refer sars disease genes blue squares refer drug targets red squares refer sars disease genes also drug targets violet circles refer first nearest neighbors disease genes drug targets human interactome antiace drugs panel g refer enalapril trandolapril fosinopril benazepril cilazapril zofenopril spirapril rescinnamine quinapril h<NUMBER>anistamines panel l refer fexofenadine levocetirizine desloratadine clemastine cetirizine weights either proximity similarity measure <NUMBER> compute normalized adjusted similarity measure correct weights drugdisease network prioritize predicted drugdisease associations legend qc quality cluster score total weight edges within cluster total weight edges connecting cluster rest network p node density within cluster c parameters sigmoid steepness midpoint respectively severe acute respiratory syndrome coronavirus two sarscov<NUMBER> virus responsible coronavirus disease <NUMBER> covid<NUMBER> pandemic discovered wuhan china december <NUMBER> <NUMBER> sarscov<NUMBER> member betacoronaviruses genus enveloped positivesense singlestranded rna viruses symptom profile covid<NUMBER> infections vary dry cough fever often reported <NUMBER> resulting mild illness cases however severe illness reported occurring many <NUMBER> laboratoryconfirmed infections <NUMBER> depending population demographics countryspecific testing protocols symptoms including acute myocardial injury <NUMBER> acute kidney injury <NUMBER> two highly pathogenic coronaviruses known <NUMBER> unlike sarscov<NUMBER> merscov however sarscov<NUMBER> widely reported cause asymptomatic carriage <NUMBER> individuals contributed rapid global spread <NUMBER> subsequent radical worldwide restrictions daily life control transmission disease represents unprecedented global health challenge understanding mechanism pathogenesis piecemeal process one process particularly well understood entry sarscov<NUMBER> human cells occurs via two major methods tmprss<NUMBER>dependent entry tmprss<NUMBER>independent entry <NUMBER> first method relies two human transmembrane proteins ace<NUMBER> tmprss<NUMBER> spike proteins sarscov<NUMBER> mediate coronavirus entry human cells shown strong affinity human protein ace<NUMBER> highly expressed surface different cell types including lung epithelial cells type ii alveolar cells <NUMBER> viral spike proteins bound ace<NUMBER> localised tmprss<NUMBER> activate viral spike proteins cleave cytoplasmfacing domain ace<NUMBER> mechanism causes virus membrane fuse human cells membrane allowing viral genomic rna enter cell replicate facilitate production new virions absence localised tmprss<NUMBER> sarscov<NUMBER> enter human cells expressing ace<NUMBER> via another mechanism process viral spike proteins bind ace<NUMBER> ace<NUMBER> receptor protein recruits clathrin initiates endocytosis virus usually following endocytosis proton pumps transport h ions endosomes lowering internal ph allowing endosome begin process becoming endolysosome breaking anything within however phdependent enzyme cathepsin l present endosomes used sarscov<NUMBER> activate viral spike proteins allow virus fuse endosomal membrane release genomic rna host cell preparation replication production virions repurposing drugs treatment covid<NUMBER> due rapid increase covid<NUMBER> cases large amount research disease pathogenesis potential treatment carried short space time given rapid onset pandemic urgent need identify new drugs able treat disease improve patient outcomes <NUMBER> <NUMBER> developing novel drugs taking market typically takes many years traditional pathways unlikely provide timely treatment current pandemic time pressures new treatments make drug repurposing particularly attractive drugs approved one indication disease may also happen efficacious another likely candidates repurposing identified time approval drug reduced months drawing pool many thousands drugs already regulatory approval process therefore wellcharacterised identifying high quality drug repurposing candidates challenging many discoveries serendipitous example observations clinics trials <NUMBER> however advent network approaches studying biology systems level new computational approaches emerged allow systematic approach drug repurposing <NUMBER> <NUMBER> <NUMBER> networks convenient method represent drugs genes proteins diseases etc relationships support human investigation visual exploration time amenable computational analysis enabling automated systematic analysis drug repurposing algorithms derive new relationships drugs targets diseases genes etc based existing knowledge relationships <NUMBER> new relationships lead hypotheses novel repurposing opportunities evidence reviewed hypotheses tested laboratory clinic computational drug repurposing prediction human curation require availability variety data sources describe molecular processes cell interaction drugs data typically distributed range different data sources databases may integrated represented networks form integrated network knowledge graph <NUMBER> <NUMBER> <NUMBER> repurposing algorithms operate data vary simple pattern matching network module analysis application artificial intelligence <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> output algorithms systematic computational predictions therefore need human curation range expertise assess value therefore computational prediction repurposable drugs usually applied iterative fashion coupled input human expert able verify generate hypotheses new repurposing opportunities need new drugs treat covid<NUMBER> resulted large number recent studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> antiviral drugs obvious target since shown active sars example drugs elbasvir scrutiny effect <NUMBER> antiviral drugs remdesivir originally employed treatment ebola recently approved treatment covid<NUMBER> <NUMBER> however still pressing need candidate drugs especially addressing abnormal immune response seen patients <NUMBER> <NUMBER> wider search repurposable drugs remains field active development studies computational nature resulted many potential new drug candidates studies employed variety strategies including network based analyses candidates undergoing clinical trials test effectiveness <NUMBER> work used combination network algorithms human curation search integrated knowledge graphs drug repurposing opportunities covid<NUMBER> aimed highlight potential repurposing opportunities possibly novel comparison published far also introduce newer features analytical process effort improve accuracy incorporating measures take data quality account speed data verification facilitating multiple curation many studies example kumar <NUMBER> <NUMBER> employed protein interaction networks study relationships covid<NUMBER> proteins proteins interact molecular interaction networks cell however data quality important factor assignment protein interactions received little attention studies todate instead using standard protein interaction graph developed probabilistic functional interaction network human proteins uses highly curated interactions biogrid gold standard produce weighted protein interaction network weight indicates confidence functional interaction mapped onto human probabilistic function integrated network pfin interactions covid<NUMBER> proteins discovered experimentally gordon et al <NUMBER> <NUMBER> process curating computational predictions manually analysing networks new opportunities largescale time consuming task division labour network partitioning crowdsourcing promising approaches rapid verification results <NUMBER> <NUMBER> however one challenges facing approach assignment appropriate sections complex network curator since working pfins included weighted edges able employ clustering algorithm partition probabilistic network functionally related subgraphs subgraphs containing covid<NUMBER> protein interactors enriched information previously integrated networks add relationships drugs diseases genes pathways subgraph represents unit network systematically assigned curator analysis fashion large scale task broken becomes faster curators participating exercise present details approach development partitioning knowledge network resulting predictions potentially repurposable drugs work extends approaches developed mullen et al <NUMBER> brief semantic knowledge graph constructed neo<NUMBER>j comprising data existing approved drugs data sources contributing knowledge graph shown table <NUMBER> genes goldstandard absent goldstandard respectively pl andpl represent prior expectation linkages genes goldstandard absent goldstandard respectively datasets lls <NUMBER> lower discarded remaining datasets sorted order lls integrated using following formula l <NUMBER> highest lls score l n lowest set n datasets denominator selected give weight datasets higher confidence <NUMBER> used previous work james et al <NUMBER> visualisation purposes functional interaction relationships omitted confidence score lower <NUMBER> pfin clustered using weighted mcl algorithm default parameters viewed cytoscape <NUMBER> <NUMBER> next set homo sapiens proteins identified interacting sarscov<NUMBER> proteins gordon et al <NUMBER> clusters pfin containing genes encode least one proteins extracted decorated edges nodes knowledge base fig <NUMBER> returned theophylline theophylline iupac name <NUMBER>dimethyl<NUMBER>tetrahydro<NUMBER>hpurine<NUMBER>dione methylxanthine drug activities including smooth muscle relaxation bronchial dilation indicated conditions chronic obstructive pulmonary disorder copd asthma theophylline exerts activity competitive inhibition type iii iv phosphodiesterase <NUMBER> clustering pfin revealed cluster genes one dnajc<NUMBER> encodes dna j homolog subfamily c member <NUMBER> protein q<NUMBER>nvh<NUMBER> gordon et al <NUMBER> reported interacting sarscov<NUMBER> e protein sarscov<NUMBER> e encodes envelope protein e plays role structure maturation virus <NUMBER> dnajc<NUMBER> mitochondrial protein required mitochondrial inner membrane organization associates mitochondrial contact site cristae organizing system micos complex <NUMBER> <NUMBER> pfin suggests dnajc<NUMBER> high likelihood functionally related ric<NUMBER> encodes protein ric<NUMBER> q<NUMBER>z<NUMBER>b<NUMBER> protein target theophylline fig <NUMBER> <NUMBER> ric<NUMBER> promotes functional expression homomeric alpha<NUMBER> alpha<NUMBER> nicotinic acetylcholine receptors cell surface found endoplasmic reticulum golgi apparatus <NUMBER> relevance functional relationship dnajc<NUMBER> ric<NUMBER> unclear however interaction identified affinity capturemass spectroscopy implies physical binding possible therefore ric<NUMBER> complexes dnajc<NUMBER> although current evidence expressed different organelles theophylline could block binding dnajc<NUMBER> sarscov<NUMBER> e interestingly dnajc<NUMBER> wellconserved orthologues species mouse rat dog <NUMBER> calmodulin ubiquitous calcium binding protein binds transmembrane proteins ace <NUMBER> described introduction ace transmembrane proteins distinct role covid<NUMBER> infection <NUMBER> calmodulin plays crucial role regulating ace<NUMBER> presence cell surface binding cytoplasmic tail ace<NUMBER> <NUMBER> potential target decreasing infection viral loading could therefore use calmodulin inhibitors acting decrease association two proteins without binding calmodulin ace<NUMBER> cells start shed ectodomain ace<NUMBER> leading decreased expression catalytic activity <NUMBER> querying knowledge graph approved drugs inhibit calm<NUMBER> p<NUMBER>dp<NUMBER> identified <NUMBER> existing approved drugs labelled inhibitors calmodulin indicated range conditions including hypertension seasonal allergies antidepressants full list table s<NUMBER> angiotensinogen small peptide hormone part reninangiotensinaldosterone system raas involved regulation blood pressure <NUMBER> via action renin angiotensinogen converted angiotensin turn angiotensin via action angiotensin converting enzyme ace converted angiotensin ii critically ace<NUMBER> converts angiotensin ii angiotensin <NUMBER> effector nitric oxidedependent vasodilation implicated attenuating acute lung injury <NUMBER> role drugs inhibit raas commonly prescribed antihypertensive agents eg ace inhibitors angiotensin receptor blockers controversial arguments proposed harmful protective effects <NUMBER> <NUMBER> <NUMBER> given angiotensin ii approved drug may therapeutic use covid<NUMBER> via actions angiotensin <NUMBER> angiotensin ii already suggested possible therapeutic agent currently investigated nct<NUMBER> whilst inhibition ace<NUMBER> receptor may seem ideal target treating covid<NUMBER> required major mechanisms viral entry host cells shown ace<NUMBER> essential repairing damage lung tissues instead may possible inhibit tmprss<NUMBER> could lead virus particles entering host cell via endosomes cathepsin l also inhibited endosomeenclosed viruses unable escape allowing endosomes progress fully endolysosomes destroy virus particles way may possible prevent entry host cell subsequent replication also reduce overall viral load enabling body destroy sarscov<NUMBER> previous studies suggested already approved drug camostat mesylate could used tmprss<NUMBER> inhibitor <NUMBER> study rational querying knowledge graph drug candidates putative cathepsin l inhibitors identified table <NUMBER> candidates approved drugs two drugs telaprevir boceprevir used previously help treat chronic hepatitis c infections however since discontinued due common side effects severe rashes anemia decreased neutrophils fatigue sodium aurothiomalate goldcontaining compound approved use treating rheumatoid arthritis drug currently commonly sold due difficulty sourcing sodium aurothiomalate final potential cathepsin l inhibitor identified study fostamatinib approved use chronic immune thrombocytopenia drug repurposing studies covid<NUMBER> also identified drug potential candidate ace<NUMBER> inhibitor <NUMBER> studies however evaluate cathepsin l inhibitor based previous studies therefore possible combined therapy camostat mesylate fostamatinib may aid treating covid<NUMBER> interestingly fostamatinib separately identified drug candidate via pfin clustering approach fig <NUMBER> fostamatinib serinethreonineprotein kinase tbk<NUMBER> q<NUMBER>uhd<NUMBER> drug target also identified gordon et al <NUMBER> protein interacts sarscov<NUMBER> protein however relevance interaction unclear us severe covid<NUMBER> disease often includes exaggerated inflammatory response stebbing et al suggested combining antiviral antiinflammatory treatments possible means reducing disease severity <NUMBER> study examined affinity antiviral drugs particular inhibition numbassociated kinases naks drug targets may useful attenuating inflammation eg inhibition janus kinases jaks result study stebbing et al identified discussed range drugs including baricitinib tofacitinib ruxolitinib determine whether additional drug candidates discussed stebbing et al <NUMBER> queried dataset drugs targeting naks jaks identified paper proteins follows aak<NUMBER> q<NUMBER>m<NUMBER>i<NUMBER> bike q<NUMBER>nsy<NUMBER> gak o<NUMBER> jak<NUMBER> p<NUMBER> jak<NUMBER> o<NUMBER> jak<NUMBER> p<NUMBER> tyk<NUMBER> p<NUMBER> addition baricitinib tofacitinib ruxolitinib also identified fostamatinib potential drug candidate fact knowledge graph fostamatinib drug recorded aforementioned proteins drug targets epidermal growth factor receptor egfr inhibitors egfr p<NUMBER> protein implicated tissue fibrosis due role tgfβ<NUMBER> dependent fibroblastmyofibroblast differentiation venkataraman frieman <NUMBER> <NUMBER> suggested inhibiting egfr signalling prevents excessive fibrotic responses thus lung damage sars infections running query fig <NUMBER> identified eight approved drugs possible egfr inhibitors brigatinib afatinib osimertinib fostamatinib dacomitinib neratinib vandetanib panitumumab two covid proteins orf<NUMBER>c nsp<NUMBER> interactions mitochondriarelated human proteins znt<NUMBER> q<NUMBER>nxt<NUMBER> encoded slc<NUMBER>a<NUMBER> gene transmembrane zinc transporter located golgi apparatus tim<NUMBER> q<NUMBER>bsf<NUMBER> encoded timm<NUMBER> gene inner mitochondrial membrane translocase respectively <NUMBER> genes encoding proteins identified highconfidence functional interaction neuronal acetylcholine receptor subunit alpha<NUMBER> nachr<NUMBER> protein q<NUMBER>ugm<NUMBER> gene name chrna<NUMBER> <NUMBER> <NUMBER> relationships shown fig <NUMBER> nachr<NUMBER> part ligandgated ionic channel nicotinic acetylcholine receptor superfamilies forms homoor heterooligomeric divalent cation channels plasma membrane <NUMBER> according drugbank nachr<NUMBER> targeted following small molecules lobeline galantamine nicotine tetraethylammonium rpi<NUMBER>m atg<NUMBER> lobeline natural form plants lobelia genus proposed applied therapeutic uses including respiratory disorders asthma stimulant treat wheezing uncontrollable coughing chest tightness <NUMBER> reported improve acute lung injury cell lines <NUMBER> promising studies carried mice lobeline helped treat acute lung injury <NUMBER> human studies still required nicotine induces ace<NUMBER> overexpression human bronchial epithelial cells hbepc via alpha<NUMBER>nicotinic receptor ɑ<NUMBER>nachr <NUMBER> paralog nachr<NUMBER> galantamine reversible competitive inhibitor acetylcholinesterase ache catalyses breakdown ace allosteric modulator nachrs currently approved mild moderate dementia alzheimers quercetin polyphenol flavonoid found many plants <NUMBER> reported antiinflammatory antiviral properties <NUMBER> <NUMBER> one pfin clusters quercetin identified targeting human protein casein kinase ii subunit beta ck<NUMBER>beta protein p<NUMBER> localised throughout cell gordon et al reported highconfidence interactor sarscov<NUMBER> n protein <NUMBER> two ck<NUMBER>beta molecules together single alpha alpha subunit together form tetramer casein kinases ii ck<NUMBER> ck<NUMBER> acts serinethreonineselective protein kinase involved cell cycle regulation implicated disorders cell proliferation eg tumours <NUMBER> interestingly ck<NUMBER> found stimulated viral infections <NUMBER> various roles infection cycles different viruses <NUMBER> <NUMBER> gordon et al suggested ck<NUMBER> inhibition possible therapeutic approach covid<NUMBER> <NUMBER> ck<NUMBER> downregulates stress granule formation <NUMBER> associated enhanced viral replication coronavirus infections <NUMBER> thus depending nature interaction quercetin ck<NUMBER> may benefit quercetin already suggested possible therapeutic mitigate severity sarscov<NUMBER> infection quercetin alters expression <NUMBER> human proteins targets sarscov<NUMBER> proteins <NUMBER> summary study aimed build existing studies used knowledge frameworks generate hypotheses drug repurposing opportunities covid<NUMBER> studies integrated dataset developed extending drug repurposing framework developed mullen et al <NUMBER> aimed enhance knowledge network approach use pfins act framework guide hypothesis generation process use pfins allowed us scale data curation process systematic fashion exploiting combined effort multiple curators approach could act template future studies richer knowledge graphs incorporation algorithmic predictions drug repurposing much larger set curators drugs identified repurposing illustrative value approach due rapidly developing nature studies sarscov<NUMBER> covid<NUMBER> difficult identify candidates truly novel however even instances candidates already suggested studies approach still provide additional supporting refuting evidence results presented study grouped drug class possible tried avoid suggesting specific instances drugs focused classes instead part recognise database complete ethically may socioeconomic reasons selecting one member drug class another supply demand dependence subpopulation given drug however noteworthy cases focusing specific drugs within class necessary example fostamatinib emerged drug candidate number different contexts antiinflammatory agent egfr inhibitor cathepsin l inhibitor establishing promising candidate one limitation silico drug repurposing studies depending algorithms employed many drug repurposing candidates suggested refinement large set drug candidates often requires many personhours time curate particularly including time taken understand mechanisms pathways involved <NUMBER> leveraging pfinbased clustering approach <NUMBER> focusing clusters containing highconfidence interactors sarscov<NUMBER> proteins able reduce drug candidate search space significantly using crowdsourcing approach analyse clusters allowed individuals curate sets drug candidates likely mechanistically related providing logical partitioning work curation allowed us focus drugs additional context eg pharmacological biological evidence support refute drugs discussed thus providing balanced perspective drugs discussed future studies might interesting research systematic computational approaches integrating ranking findings curators perhaps building larger systems data sharing integration fairdomhub <NUMBER> number caveats research need addressed ensure results taken appropriate context firstly data sources contributing integrated semantic network limited scope could expanded example graph includes connections drugs protein targets nature eg inhibitory stimulatory suppressor always recorded secondly computational prediction ever generate suggestions hypotheses based analysis limited data available thus drug repurposing candidates suggested critical manually curated experts medicine pharmacology human biology due recent concerns potential harm covid<NUMBER> preprints want stress research used inform clinical practice people change behaviour basis <NUMBER> supporting information s<NUMBER> coronaviruses covs typically affect respiratory tract mammals including humans lead mild severe respiratory tract infections <NUMBER> past <NUMBER> decades two highly pathogenic human covs hcovs including severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov emerging animal reservoirs led global epidemics high morbidity mortality <NUMBER> example <NUMBER> individuals infected <NUMBER> died sarscov pandemic cost global economy estimated <NUMBER> <NUMBER> billion <NUMBER> <NUMBER> according world health organization november <NUMBER> merscov total <NUMBER> diagnosed cases causing <NUMBER> deaths majority saudi arabia <NUMBER> december <NUMBER> third pathogenic hcov named <NUMBER> novel coronavirus <NUMBER>ncov found wuhan china february <NUMBER> <NUMBER> <NUMBER> cases <NUMBER> deaths <NUMBER>ncov pandemic httpswwwcdcgovcoronavirus<NUMBER>ncovindexhtml furthermore humantohuman transmission occurred among close contacts <NUMBER> however currently effective medications <NUMBER>ncov several national international research ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint groups working development vaccines prevent treat <NUMBER>ncov effective vaccines available yet urgent need development effective prevention treatment strategies <NUMBER>ncov outbreak although investment biomedical pharmaceutical research development increased significantly past two decades annual number new treatments approved us food drug administration fda remained relatively constant limited <NUMBER> recent study estimated pharmaceutical companies spent <NUMBER> billion <NUMBER> <NUMBER> million <NUMBER> development fdaapproved new chemical entity drug <NUMBER> drug repurposing represented effective drug discovery strategy existing drugs could significantly shorten time reduce cost compared de novo drug discovery randomized clinical trials <NUMBER> <NUMBER> <NUMBER> however experimental approaches drug repurposing costly timeconsuming <NUMBER> computational approaches offer novel testable hypotheses systematic drug repositioning <NUMBER> <NUMBER> <NUMBER> however traditional structurebased methods limited threedimensional <NUMBER>d structures proteins unavailable unfortunately case majority human viral targets addition targeting single virus proteins often high risk drug resistance rapid evolution virus genomes <NUMBER> viruses including hcov require host cellular factors successful replication infections <NUMBER> systematic identification virushost proteinprotein interactions ppis offers effective way toward elucidation mechanisms viral infection <NUMBER> infections <NUMBER> including sarscov <NUMBER> merscov <NUMBER> ebola virus <NUMBER> zika virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> recently presented integrated antiviral drug discovery pipeline incorporated genetrap insertional mutagenesis known functional druggene network bioinformatics analyses <NUMBER> methodology allows identify several candidate repurposable drugs ebola virus <NUMBER> <NUMBER> work last decade demonstrated network strategies example used identify effective repurposable drugs <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> drug combinations <NUMBER> multiple human diseases example networkbased drugdisease proximity sheds light relationship drugs eg drug targets disease modules molecular determinants disease pathobiology modules within ppis serve useful tool efficient screening potentially new indications approved drugs well drug combinations demonstrated recent studies <NUMBER> <NUMBER> <NUMBER> study present integrative antiviral drug repurposing methodology combines systems pharmacologybased network medicine platform quantifies interplay virushost interactome drug targets human ppi network basis experiments rests notions proteins functionally associate viral infection including hcov localized corresponding subnetwork within comprehensive human ppi network <NUMBER> ii proteins serve drug targets specific disease may also suitable drug targets potential antiviral infection owing common ppis functional pathways elucidated human interactome figure <NUMBER> follow analysis bioinformatics validation druginduced gene signatures hcovinduced ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint transcriptomics human cell lines inspect postulated mechanismofaction specific hcov propose repurposing figure <NUMBER> date <NUMBER> pathogenic hcovs figure <NUMBER>a <NUMBER>b found <NUMBER> <NUMBER> <NUMBER>ncov sarscov merscov hcovoc<NUMBER> hcovhku<NUMBER> b genera ii hcovnl<NUMBER> hcov<NUMBER>e genera performed phylogenetic analyses using whole genome sequence data <NUMBER> hcovs inspect evolutionary relationship <NUMBER>ncov hcovs found whole genomes <NUMBER>ncov <NUMBER> nucleotide sequence identity across three diagnosed patients supplementary table s<NUMBER> <NUMBER>ncov shares highest nucleotide sequence identity <NUMBER> sarscov among <NUMBER> known pathogenic hcovs revealing conserved evolutionary relationship <NUMBER>ncov sarscov figure <NUMBER>a hcovs five major protein regions virus structure assembly viral replications <NUMBER> including replicase complex orf<NUMBER>ab spike envelope e membrane nucleocapsid n proteins figure <NUMBER>b orf<NUMBER>ab gene encodes nonstructural proteins nsp viral rna synthesis complex proteolytic processing <NUMBER> nsp<NUMBER> viral rnadependent rna polymerase together cofactors nsp<NUMBER> nsp<NUMBER> possessing high polymerase activity protein threedimensional <NUMBER>d structure view sarscov nsp<NUMBER> contains larger nterminal extension binds nsp<NUMBER> nsp<NUMBER> polymerase domain figure <NUMBER>c ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint spike transmembrane glycoprotein plays pivotal role mediating viral infection binding host receptor <NUMBER> <NUMBER> figure <NUMBER>d shows <NUMBER>d structure spike protein bound host receptor angiotensin converting enznyme<NUMBER> ace<NUMBER> sarscov pdb id <NUMBER>ack recent study showed <NUMBER>ncov able utilize ace<NUMBER> entry receptor ace<NUMBER>expressing cells <NUMBER> suggesting potential drug targets therapeutic development addition nucleocapsid also important subunit packaging viral genome protein oligomerization <NUMBER> single nucleocapsid structure shown figure <NUMBER>e protein sequence alignment analyses indicated <NUMBER>ncov evolutionarily conserved sarscov supplementary table s<NUMBER> specifically envelope nucleocapsid proteins <NUMBER>ncov two evolutionarily conserved regions sequence identities <NUMBER> <NUMBER> respectively compared sars table s<NUMBER> however spike protein exhibited lowest sequence conservation sequence identity <NUMBER> <NUMBER>ncov sarscov meanwhile spike protein <NUMBER>ncov <NUMBER> sequence identity compared merscov first assembled covassociated host proteins <NUMBER> known hcovs sarscov merscov hcov<NUMBER>e hcovnl<NUMBER> one mouse mhv one avian ibv n protein supplementary table s<NUMBER> total obtained <NUMBER> host proteins associated covs various experimental evidences specifically host ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint proteins either direct targets hcov proteins involved crucial pathways hcov infection hcovhost interactome network shown figure <NUMBER>a identified several hub proteins including jun xpo<NUMBER> npm<NUMBER> hnrnpa<NUMBER> highest number connections within <NUMBER> proteins kegg pathway enrichment analysis revealed multiple significant biological pathways adjusted p value <NUMBER> including measles rna transport nfkappa b signaling epsteinbarr virus infection influenza figure <NUMBER>b gene ontology go biological process enrichment analyses confirmed multiple viral infectionrelated processes adjusted p value <NUMBER> including viral life cycle modulation virus host morphology physiology viral process positive regulation viral life cycle transport virus virion attachment host cell figure <NUMBER>c mapped known drugtarget network see methods hcovhost interactome search druggable cellular targets found <NUMBER> human proteins <NUMBER> blue nodes figure <NUMBER>a targeted least one approved drug experimental drug clinical trial example gsk<NUMBER>b dpp<NUMBER> smad<NUMBER> parp<NUMBER> ikbkb targetable proteins high druggability hcovhost interactome motivates us develop therapeutic strategy specifically targeting cellular proteins associated hcovs drug repurposing basis proposed networkbased drug repurposing methodologies rests notions proteins associate functionally govern viral infection localized corresponding subnetwork figure <NUMBER>a within comprehensive human interactome network drug multiple targets effective ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint hcov target proteins within immediate vicinity corresponding subnetwork human interactome figure <NUMBER> demonstrated multiple diseases <NUMBER> <NUMBER> <NUMBER> <NUMBER> using drug repurposing strategy used stateoftheart network proximity measure quantify relationship hcovspecific subnetwork figure <NUMBER>a drug targets human proteinprotein interactome constructed drugtarget network assembling target information <NUMBER> fdaapproved experimental drugs see methods improve quality completeness human protein interactome network integrated ppis five types experimental data <NUMBER> binary ppis <NUMBER>d protein structures <NUMBER> binary ppis unbiased highthroughput yeasttwohybrid assays <NUMBER> experimentally identified kinasesubstrate interactions <NUMBER> signaling networks derived experimental data <NUMBER> literaturederived ppis various experimental evidences see methods used zscore z measure permutation test reduce study bias network proximity analyses including hub nodes human interactome network literaturederived ppi data bias described recent studies <NUMBER> <NUMBER> total computationally identified <NUMBER> drugs associated z <NUMBER> p <NUMBER> permutation test hcovhost interactome figure <NUMBER>a authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint vs sarscov p <NUMBER> distribution <NUMBER> vs merscov p <NUMBER> <NUMBER> vs ibv p <NUMBER> <NUMBER> vs mhv p <NUMBER> network proximity analyses offer putative repurposable candidates potential prevention treatment hcovs validate <NUMBER> repurposable drugs hcovs first performed gene set enrichment analysis gsea using transcriptome data merscov sarscov infected host cells see methods transcriptome data used gene signatures hcovs additionally downloaded expression data drugtreated human cell lines connectivity map cmap database <NUMBER> obtain druggene signatures calculated gsea score see methods drug used score indication bioinformatics validation <NUMBER> drugs specifically enrichment score es calculated hcov data set es <NUMBER> p <NUMBER> permutation test used cutoff significant association gene signatures drug specific hcov gsea score ranging <NUMBER> <NUMBER> number data sets met criteria specific drug mesalazine approved drug inflammatory bowel disease sirolimus approved immunosuppressive drug equilin approved agonist estrogen receptor menopausal symptoms achieved highest gsea scores <NUMBER> followed paroxetine melatonin gsea scores <NUMBER> next selected <NUMBER> potential repurposable drugs figure <NUMBER>a table <NUMBER> hcovs using subject matter expertise based combination factors strength networkpredicted associations smaller network proximity score supplementary table s<NUMBER> ii validation gsea analyses ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint iii literaturereported antiviral evidences iv fewer clinically reported side effects specifically showcased several selected repurposable drugs literaturereported antiviral evidences selective estrogen receptor modulators serms overexpression estrogen receptor shown play crucial role inhibiting viral replication <NUMBER> serms reported play broader role inhibiting viral replication nonclassical pathways associated estrogen receptor <NUMBER> serms interfere post viral entry step affect triggering fusion serms antiviral activity still observed absence detectable estrogen receptor expression <NUMBER> toremifene z <NUMBER> figure <NUMBER>a first generation nonsteroidal serm exhibits potential effects blocking various viral infections including merscov sarscov ebola virus established cell lines <NUMBER> <NUMBER> interestingly different classical esr<NUMBER>related antiviral pathway toremifene prevents fusion viral endosomal membrane interacting destabilizing virus membrane glycoprotein eventually inhibiting viral replication <NUMBER> shown figure <NUMBER>b toremifene potentially affects several key host proteins associated hcov rpl<NUMBER> hnrnpa<NUMBER> npm<NUMBER> eif<NUMBER>i eif<NUMBER>f eif<NUMBER>e <NUMBER> <NUMBER> equilin z <NUMBER> gsea score <NUMBER> estrogenic steroid produced horses also proven moderate activity inhibiting entry zaire ebola virusglycoprotein human immunodeficiency virus zebovgphiv <NUMBER> altogether networkpredicted serms toremifene equilin offer potential repurposable candidates hcovs viral infection including hcovs <NUMBER> <NUMBER> <NUMBER> irbesartan z <NUMBER> typical arb ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint approved fda treatment hypertension diabetic nephropathy network proximity analysis shows significant association irbesartans targets hcovassociated host proteins human interactome shown figure <NUMBER>c irbesartan targets slc<NUMBER>a<NUMBER> encoding sodiumbile acid cotransporter ntcp protein identified functional pres<NUMBER>specific receptor hepatitis b virus hbv hepatitis delta virus hdv irbesartan inhibit ntcp thus inhibiting viral entry <NUMBER> <NUMBER> slc<NUMBER>a<NUMBER> interacts c<NUMBER>orf<NUMBER> potential transcriptional repressor interacts nsp<NUMBER> sarscov <NUMBER> several arbs eletriptan frovatriptan zolmitriptan targets potentially associated hcovassociated host proteins human interactome confirmed mammalian target rapamycin complex <NUMBER> mtorc<NUMBER> key factor regulating various viruses replications including andes orthohantavirus coronavirus <NUMBER> <NUMBER> sirolimus z <NUMBER> gsea score <NUMBER> inhibitor mammalian target rapamycin mtor reported effectively block viral protein expression virion release effectively <NUMBER> indeed latest study revealed clinical application sirolimus reduced merscov infection <NUMBER> <NUMBER> moreover sirolimus usage managing patients severe h<NUMBER>n<NUMBER> pneumonia acute respiratory failure improve patients prognosis significantly <NUMBER> mercaptopurine z <NUMBER> gsea score <NUMBER> antineoplastic agent immunosuppressant property used treat cancer since <NUMBER>s expanded application several autoimmune diseases including rheumatoid arthritis systemic lupus erythematosus crohns disease <NUMBER> mercaptopurine reported selective inhibitor ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint sarscov merscov targeting papainlike protease plays key roles viral maturation antagonism interferon stimulation <NUMBER> <NUMBER> mechanistically mercaptopurine potentially target several host proteins hcovs jun pabpc<NUMBER> npm<NUMBER> ncl <NUMBER> <NUMBER> figure <NUMBER>d antiinflammatory agents inflammatory pathways play essential roles viral infections <NUMBER> <NUMBER> biogenic amine melatonin nacetyl<NUMBER>methoxytryptamine z <NUMBER> gsea score <NUMBER> plays key role various biological processes offers potential strategy management viral infections <NUMBER> <NUMBER> viral infections often associated immuneinflammatory injury level oxidative stress increases significantly leaves negative effects multiple organ functions <NUMBER> antioxidant effect melatonin makes putative candidate drug relieve patients clinical symptoms antiviral treatment even though melatonin cannot eradicate even curb viral replication transcription <NUMBER> <NUMBER> addition application melatonin may prolong patients survival time may provide chance patients immune systems recover eventually eradicate virus shown figure <NUMBER>e melatonin indirectly targets several hcov cellular targets including ace<NUMBER> bcl<NUMBER>l<NUMBER> jun ikbkb eplerenone z <NUMBER> aldosterone receptor antagonist reported similar antiinflammatory effect melatonin inhibiting mastcellderived proteinases suppressing fibrosis eplerenone improve survival mice infected encephalomyocarditis virus <NUMBER> summary network proximity analyses offer multiple putative repurposable drugs target diverse cellular pathways potential prevention treatment ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint hcovs however preclinical experiments clinical trials required verify clinical benefits networkpredicted candidates clinical use drug combinations offering increased therapeutic efficacy reduced toxicity play important role treating various viral infections <NUMBER> however ability identify validate effective combinations limited combinatorial explosion driven large number drug pairs dosage combinations recent study proposed novel networkbased methodology identify clinically efficacious drug combinations <NUMBER> relying approved drug combinations hypertension cancer found drug combination therapeutically effective captured complementary exposure pattern targets drugs hit disease module target separate neighborhoods figure <NUMBER>a sought identify drug combinations may provide synergistic effect treating hcovs welldefined mechanismofaction network analysis <NUMBER> potential repurposable drugs figure <NUMBER>a showcased three networkpredicted candidate drug combinations potential treatment hcovs sirolimus inhibitor mtor antifungal antineoplastic properties demonstrated improves outcomes patients severe h<NUMBER>n<NUMBER> pneumonia acute respiratory failure <NUMBER> mtor signaling plays essential role merscov infection <NUMBER> dactinomycin also known actinomycin approved rna synthesis inhibitor treatment various cancer ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint types early study showed dactinomycin <NUMBER> microgramml inhibited growth feline enteric cov <NUMBER> shown figure <NUMBER>b network analysis shows sirolimus dactinomycin synergistically target hcovassociated host protein subnetwork complementary exposure pattern offering potential combination regimens treatment hcov specifically sirolimus dactinomycin may inhibit mtor signaling rna synthesis pathway including dna topoisomerase <NUMBER>alpha top<NUMBER>a dna topoisomerase <NUMBER>beta top<NUMBER>b hcov infected cells figure <NUMBER>b toremifene approved first generation nonsteroidal serms treatment metastatic breast cancer <NUMBER> serms including toremifene inhibited ebola virus infection <NUMBER> interacting destabilizing ebola virus glycoprotein <NUMBER> vitro assays demonstrated toremifene inhibited growth merscov <NUMBER> <NUMBER> saracov <NUMBER> table <NUMBER> emodin anthraquinone derivative extracted roots rheum tanguticum reported various antivirus effects specifically emdoin inhibited sarscov associated <NUMBER>a protein <NUMBER> blocked interaction sarscov spike protein ace<NUMBER> <NUMBER> altogether network analyses published experimental data suggested combining toremifene emdoin offered potential therapeutic approach hcovs figure <NUMBER>c figure <NUMBER>a targets mercaptopurine melatonin showed strong network proximity hcovassociated host proteins human interactome network recent vitro vivo studies identified mercaptopurine selective inhibitor sarscov merscov targeting papainlike protease <NUMBER> <NUMBER> melatonin reported potential treatment ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint viral infection via antiinflammatory antioxidant effects <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> melatonin indirectly regulates ace<NUMBER> expression key entry receptor involved viral infection hcovs including <NUMBER>ncov <NUMBER> jun also known cjun key host protein involving hcov infectious bronchitis virus <NUMBER> shown figure <NUMBER>d mercaptopurine melatonin may synergistically block cjun signaling targeting multiple cellular targets summary combination mercaptopurine melatonin may offer potential combination therapy <NUMBER>ncov synergistically targeting papainlike protease ace<NUMBER> cjun signaling antiinflammatory pathways figure <NUMBER>d however experimental clinical validations highly warranted study presented networkbased methodology systematic identification putative repurposable drugs drug combinations potential treatment hcov integration drugtarget networks hcovhost interactions hcovinduced transcriptome human cell lines human proteinprotein interactome network essential identification based comprehensive evaluation prioritized <NUMBER> putative repurposable drugs figure <NUMBER> <NUMBER> putative drug combinations figure <NUMBER> potential treatment hcovs including <NUMBER>ncov however networkpredicted repurposable drugs drug combinations must validated preclinical models randomized clinical trials used patients acknowledge several limitations current study study used low binding affinity value <NUMBER> µm threshold define physical drugtarget ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint interaction however stronger binding affinity threshold eg <NUMBER>µm may suitable cutoff drug discovery although generate smaller drugtarget network although sizeable efforts made assembling largescale experimentally reported drugtarget networks publicly available databases network data may incomplete drugprotein interactions may functional associations instead physical bindings may use computational approaches systematically predict drugtarget interactions <NUMBER> <NUMBER> addition collected virushost interactions far complete quality influenced multiple factors including different experimental assays human cell line models may computationally predict new virushost interactome hcovs using sequencebased structurebased approaches <NUMBER> current systems pharmacology model cannot separate therapeutic antiviral effects predictions due lack detailed pharmacological effects drug targets unknown functional consequences virushost interactions drug targets representing nodes within cellular networks often intrinsically coupled therapeutic adverse profiles <NUMBER> drugs inhibit activate protein functions including antagonists versus agonists comprehensive identification virushost interactome <NUMBER>ncov specific biological effects using functional genomics assays <NUMBER> <NUMBER> significantly improve accuracy current networkbased methodologies owing lack complete drug target information molecular promiscuity drugs doseresponse dosetoxicity effects repurposable drugs drug combinations cannot identified current network models example mesalazine approved drug inflammatory bowel disease ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint top networkpredicted candidate drug figure <NUMBER>a associated hcovs yet several clinical studies showed potential pulmonary toxicities including pneumonia associated mesalazine usage <NUMBER> <NUMBER> preclinical studies warranted evaluate vivo efficiency side effects clinical trials furthermore limited predict pairwise drug combinations based previous networkbased framework <NUMBER> however expect methodology reminds useful networkbased tools prediction combining multiple drugs toward exploring network relationships multiple drugs targets hcovhost subnetwork human interactome finally aimed systematically identify repurposable drugs specifically targeting ncov host proteins thus current network models cannot predict repurposable drugs existing antivirus drugs target virus proteins thus combination existing antivirus drugs remdesivir <NUMBER> networkpredicted repurposable drugs figure <NUMBER> drug combinations figure <NUMBER> may improve coverage current networkbased methodologies utilizing multilayer network framework conclusion study offers powerful integrated networkbased systems pharmacology methodology rapid identification repurposable drugs drug combinations potential treatment hcov approach minimize translational gap preclinical testing results clinical outcomes significant problem rapid development efficient treatment strategies emerging <NUMBER>ncov outbreak translational perspective broadly applied network tools developed could help develop effective treatment strategies types virus human diseases well ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint total collected dna sequences protein sequences <NUMBER> hcovs including three recent <NUMBER>ncov genomes ncbi genbank database january <NUMBER> <NUMBER> supplementary table s<NUMBER> whole genome alignment protein sequence identity calculation performed multiple sequence alignment emblebi database default parameters neighbor joining nj tree computed pairwise phylogenetic distance matrix using mega x <NUMBER> <NUMBER> bootstrap replicates protein alignment phylogenetic tree hcovs constructed mega x collected hcovhost protein interactions various literatures based sizeable efforts hcovassociated host proteins several hcovs including sarscov merscov ibv mhv hcov<NUMBER>e hcovnl<NUMBER> pooled proteins either direct targets hcov proteins involved critical pathways hcov infection identified multiple experimental sources including high throughput yeasttwohybrid y<NUMBER>h systems viral protein pulldown assay vitro coimmunoprecipitation rna knock experiment total virushost interaction network included <NUMBER> hcovs <NUMBER> host proteins supplementary table s<NUMBER> ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint next performed kyoto encyclopedia genes genomes kegg gene ontology go enrichment analyses evaluate biological relevance functional pathways hcovassociated proteins functional analyses performed using enrichr <NUMBER> collected drugtarget interaction information drugbank database v<NUMBER> <NUMBER> therapeutic target database ttd <NUMBER> pharmgkb database chembl v<NUMBER> <NUMBER> bindingdb <NUMBER> iupharbps guide pharmacology <NUMBER> chemical structure drug smiles format extracted drugbank <NUMBER> drugtarget interactions meeting following three criteria used binding affinities including ki kd ic<NUMBER> ec<NUMBER> ≤ <NUMBER> μm ii target marked reviewed uniprot database <NUMBER> iii human target represented unique uniprot accession number details building experimentally validated drugtarget network provided recent study <NUMBER> build comprehensive list human ppis assembled data total <NUMBER> bioinformatics systems biology databases five types experimental ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint evidences binary ppis tested highthroughput yeasttwohybrid y<NUMBER>h systems ii binary physical ppis protein threedimensional <NUMBER>d structures iii kinasesubstrate interactions literaturederived lowthroughput highthroughput experiments iv signaling network literaturederived lowthroughput experiments v literaturecurated ppis identified affinity purification followed mass spectrometry apms y<NUMBER>h literaturederived lowthroughput experiments inferred data including evolutionary analysis gene expression data metabolic associations excluded genes mapped entrez id based ncbi database <NUMBER> well official gene symbols based genecards httpswwwgenecardsorg total resulting human proteinprotein interactome used study includes <NUMBER> unique ppis edges links connecting <NUMBER> proteins nodes representing <NUMBER> increase number ppis used previously detailed descriptions building human proteinprotein interactome provided previous studies <NUMBER> <NUMBER> <NUMBER> posit human ppis provide unbiased rational roadmap repurposing drugs potential treatment hcovs originally approved given set host genes associated specific hcov set drug targets computed network proximity target set drug using closest method ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint shortest distance gene human protein interactome network proximity converted zscore based permutation tests e ccc e mean standard deviation permutation test repeated <NUMBER> times time two randomly selected gene lists similar degree distributions corresponding p value calculated based permutation test results zscore <NUMBER> p <NUMBER> considered significantly proximal drughcov associations networks visualized using gephi <NUMBER> httpsgephiorg networkbased approach drug combinations effective need establish topological relationship two drugtarget modules reflects biological pharmacological relationships also quantifying networkbased relationship drugtargets hcovassociated host proteins drugdrughcov combinations identify potential drug combinations combined top lists drugs separation measure hi calculated pair drugs using following method ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint 〈 • 〉 calculated based closest method key methodology drug combination therapeutically effective follows specific relationship disease module captured complementary exposure patterns targets modules drugs without overlapping toxic mechanisms <NUMBER> performed gene set enrichment analysis additional prioritization method first collected three differential gene expression data sets hosts infected hcovs ncbi gene expression omnibus geo among two transcriptome data sets sarscov infected samples patients peripheral blood <NUMBER> gse<NUMBER> calu<NUMBER> cells <NUMBER> gse<NUMBER> respectively one transcriptome data set merscov infected calu<NUMBER> cells <NUMBER> gse<NUMBER> adjusted p value less <NUMBER> defined differentially expressed genes data sets used hcov host signatures evaluate treatment effects drugs differential gene expression cells treated various drugs retrieved connectivity map cmap database <NUMBER> used gene profiles drugs drug cmap data set drugtarget network calculated enrichment score es hcov signature data set based previously described methods <NUMBER> follows ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint combinations effective drug combination captured complementary exposure pattern targets drugs hit hcovhost subnetwork target separate neighborhoods human interactome network zca zcb denote network proximity zscore targets drugs b specific hcov ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity peerreviewed copyright holder preprint httpsdoiorg<NUMBER> doi medrxiv preprint human coronaviruses hcovs including severe acute respiratory syndrome coronavirus sarscov <NUMBER> novel coronavirus <NUMBER>ncov also known sarscov<NUMBER> lead global epidemics high morbidity mortality however currently effective drugs targeting <NUMBER>ncovsarscov<NUMBER> drug repurposing representing effective drug discovery strategy existing drugs could shorten time reduce cost compared de novo drug discovery study present integrative antiviral drug repurposing methodology implementing systems pharmacologybased network medicine platform quantifying interplay hcov–host interactome drug targets human protein–protein interaction network phylogenetic analyses <NUMBER> hcov whole genomes reveal <NUMBER>ncovsarscov<NUMBER> shares highest nucleotide sequence identity sarscov <NUMBER> specifically envelope nucleocapsid proteins <NUMBER>ncovsarscov<NUMBER> two evolutionarily conserved regions sequence identities <NUMBER> <NUMBER> respectively compared sarscov using network proximity analyses drug targets hcov–host interactions human interactome prioritize <NUMBER> potential antihcov repurposable drugs eg melatonin mercaptopurine sirolimus validated enrichment analyses druggene signatures hcovinduced transcriptomics data human cell lines identify three potential drug combinations eg sirolimus plus dactinomycin mercaptopurine plus melatonin toremifene plus emodin captured “complementary exposure” pattern targets drugs hit hcov–host subnetwork target separate neighborhoods human interactome network summary study offers powerful networkbased methodologies rapid identification candidate repurposable drugs potential drug combinations targeting <NUMBER>ncovsarscov<NUMBER> networkbased drug repurposing novel coronavirus <NUMBER>ncovsarscov<NUMBER> coronaviruses covs typically affect respiratory tract mammals including humans lead mild severe respiratory tract infections <NUMBER> past two decades two highly pathogenic human covs hcovs including severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov emerging animal reservoirs led global epidemics high morbidity mortality <NUMBER> example <NUMBER> individuals infected <NUMBER> died sarscov pandemic cost global economy estimated <NUMBER> <NUMBER> billion <NUMBER> <NUMBER> according world health organization november <NUMBER> merscov total <NUMBER> diagnosed cases causing <NUMBER> deaths majority saudi arabia <NUMBER> december <NUMBER> third pathogenic hcov named <NUMBER> novel coronavirus <NUMBER>ncovsarscov<NUMBER> cause coronavirus disease <NUMBER> abbreviated covid <NUMBER> <NUMBER> found wuhan china <NUMBER> february <NUMBER> <NUMBER> cases <NUMBER> deaths <NUMBER>ncovsarscov<NUMBER> outbreak worldwide furthermore humantohuman transmission occurred among close contacts <NUMBER> however currently effective medications <NUMBER>ncovsarscov<NUMBER> several national international research groups working development vaccines prevent treat <NUMBER>ncovsarscov<NUMBER> effective vaccines available yet urgent need development effective prevention treatment strategies <NUMBER>ncovsarscov<NUMBER> outbreak although investment biomedical pharmaceutical research development increased significantly past two decades annual number new treatments approved us food drug administration fda remained relatively constant limited <NUMBER> recent study estimated pharmaceutical companies spent <NUMBER> billion <NUMBER> <NUMBER> million <NUMBER> development fdaapproved new chemical entity drug <NUMBER> drug repurposing represented effective drug discovery strategy existing drugs could significantly shorten time reduce cost compared de novo drug discovery randomized clinical trials <NUMBER> <NUMBER> <NUMBER> however experimental approaches drug repurposing costly timeconsuming <NUMBER> computational approaches offer novel testable hypotheses systematic drug repositioning <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however traditional structurebased methods limited threedimensional <NUMBER>d structures proteins unavailable unfortunately case majority human viral targets addition targeting single virus proteins often high risk drug resistance rapid evolution virus genomes <NUMBER> viruses including hcov require host cellular factors successful replication infection <NUMBER> systematic identification virushost proteinprotein interactions ppis offers effective way toward elucidating mechanisms viral infection <NUMBER> <NUMBER> subsequently targeting cellular antiviral targets virushost interactome may offer novel strategy development effective treatments viral infections <NUMBER> including sarscov <NUMBER> merscov <NUMBER> ebola virus <NUMBER> zika virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> recently presented integrated antiviral drug discovery pipeline incorporated genetrap insertional mutagenesis known functional druggene network bioinformatics analyses <NUMBER> methodology allows identify several candidate repurposable drugs ebola virus <NUMBER> <NUMBER> work last decade demonstrated network strategies example used identify effective repurposable drugs <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> drug combinations <NUMBER> multiple human diseases example networkbased drugdisease proximity sheds light relationship drugs eg drug targets disease modules molecular determinants disease pathobiology modules within ppis serve useful tool efficient screening potentially new indications approved drugs well drug combinations demonstrated recent studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> study present integrative antiviral drug repurposing methodology combines systems pharmacologybased network medicine platform quantifies interplay virushost interactome drug targets human ppi network basis experiments rests notions proteins functionally associate viral infection including hcov localized corresponding subnetwork within comprehensive human ppi network ii proteins serve drug targets specific disease may also suitable drug targets potential antiviral infection owing common ppis functional pathways elucidated human interactome fig <NUMBER> follow analysis bioinformatics validation druginduced gene signatures hcovinduced transcriptomics human cell lines inspect postulated mechanismofaction specific hcov propose repurposing fig <NUMBER> date seven pathogenic hcovs fig <NUMBER>a b found <NUMBER> <NUMBER> <NUMBER>ncovsarscov<NUMBER> sarscov merscov hcovoc<NUMBER> hcovhku<NUMBER> β genera ii hcovnl<NUMBER> hcov<NUMBER>e α genera performed phylogenetic analyses using wholegenome sequence data <NUMBER> hcovs inspect evolutionary relationship <NUMBER>ncovsarscov<NUMBER> hcovs found whole genomes <NUMBER>ncovsarscov<NUMBER> had<NUMBER> nucleotide sequence identity across three diagnosed patients supplementary table s<NUMBER> <NUMBER>ncovsarscov<NUMBER> shares highest nucleotide sequence identity <NUMBER> sarscov among six known pathogenic hcovs revealing conserved evolutionary relationship <NUMBER>ncovsarscov<NUMBER> sarscov fig <NUMBER>a hcovs five major protein regions virus structure assembly viral replications <NUMBER> including replicase complex orf<NUMBER>ab spike envelope e membrane nucleocapsid n proteins fig <NUMBER>b orf<NUMBER>ab gene encodes nonstructural proteins nsp viral rna synthesis complex proteolytic processing <NUMBER> nsp<NUMBER> viral rnadependent rna polymerase together cofactors nsp<NUMBER> nsp<NUMBER> possessing high polymerase activity protein <NUMBER>d structure view sarscov nsp<NUMBER> contains larger nterminal extension binds nsp<NUMBER> nsp<NUMBER> polymerase domain fig <NUMBER>c spike transmembrane glycoprotein plays pivotal role mediating viral infection binding host receptor <NUMBER> <NUMBER> figure <NUMBER>d shows <NUMBER>d structure spike protein bound host receptor angiotensin converting enznyme<NUMBER> ace<NUMBER> sarscov pdb id <NUMBER>ack recent study showed <NUMBER>ncovsarscov<NUMBER> able utilize ace<NUMBER> entry receptor ace<NUMBER>expressing cells <NUMBER> suggesting potential drug targets therapeutic development furthermore cryoem structure spike biophysical assays reveal <NUMBER>ncovsarscov<NUMBER> spike binds ace<NUMBER> higher affinity sarscov <NUMBER> addition nucleocapsid also important subunit packaging viral genome protein oligomerization <NUMBER> single nucleocapsid structure shown fig <NUMBER>e protein sequence alignment analyses indicated <NUMBER>ncovsarscov<NUMBER> evolutionarily conserved sarscov supplementary table s<NUMBER> specifically envelope nucleocapsid proteins <NUMBER>ncovsarscov<NUMBER> two evolutionarily conserved regions sequence identities <NUMBER> <NUMBER> respectively compared sarscov supplementary table s<NUMBER> however spike protein exhibited lowest sequence conservation sequence identity <NUMBER> <NUMBER>ncovsarscov<NUMBER> sarscov meanwhile spike protein <NUMBER>ncovsarscov<NUMBER> <NUMBER> sequence identity compared merscov fig <NUMBER> overall workflow study networkbased methodology combines systems pharmacologybased network medicine platform quantifies interplay virushost interactome drug targets human ppi network human coronavirus hcovassociated host proteins collected literatures pooled generate panhcov protein subnetwork b network proximity drug targets hcovassociated proteins calculated screen candidate repurposable drugs hcovs human protein interactome model c gene set enrichment analysis utilized validate networkbased prediction e top candidates prioritized drug combinations using networkbased method captured complementary exposure pattern targets drugs hit hcovhost subnetwork target separate neighborhoods human interactome network f overall hypothesis networkbased methodology proteins functionally associate hcovs localized corresponding subnetwork within comprehensive human interactome network ii proteins serve drug targets specific disease may also suitable drug targets potential antiviral infection owing common proteinprotein interactions elucidated human interactome depict hcovhost interactome network assembled covassociated host proteins four known hcovs sarscov merscov hcov<NUMBER>e hcovnl<NUMBER> one mouse mhv one avian ibv n protein supplementary table s<NUMBER> total obtained <NUMBER> host proteins associated covs various experimental evidence specifically host proteins either direct targets hcov proteins involved crucial pathways hcov infection hcovhost interactome network shown fig <NUMBER>a identified several hub proteins including jun xpo<NUMBER> npm<NUMBER> hnrnpa<NUMBER> highest number connections within <NUMBER> proteins kegg pathway enrichment analysis revealed multiple significant biological pathways adjusted p value <NUMBER> including measles rna transport nfkappa b signaling epsteinbarr virus infection influenza fig <NUMBER>b gene ontology go biological process enrichment analysis confirmed multiple viral infectionrelated processes adjusted p value <NUMBER> including viral life cycle modulation virus host morphology physiology viral process positive regulation viral life cycle transport virus virion attachment host cell fig <NUMBER>c mapped known drugtarget network see materials methods hcovhost interactome search druggable cellular targets found <NUMBER> human proteins <NUMBER> blue nodes fig <NUMBER>a targeted least one approved drug experimental drug clinical trials example gsk<NUMBER>b dpp<NUMBER> smad<NUMBER> parp<NUMBER> ikbkb targetable proteins high druggability hcovhost interactome motivates us develop drug repurposing strategy specifically targeting cellular proteins associated hcovs potential treatment <NUMBER>ncovsarscov<NUMBER> basis proposed networkbased drug repurposing methodologies rests notions proteins associate functionally govern viral infection localized corresponding subnetwork fig <NUMBER>a within comprehensive human interactome network drug multiple targets effective hcov target proteins within immediate vicinity corresponding subnetwork human proteinprotein interactome fig <NUMBER> demonstrated multiple diseases <NUMBER> <NUMBER> <NUMBER> <NUMBER> using networkbased strategy used stateoftheart network proximity measure quantify relationship hcovspecific subnetwork fig <NUMBER>a drug targets human interactome constructed drugtarget network assembling target information <NUMBER> fdaapproved experimental drugs see materials methods improve quality completeness human protein interactome network integrated ppis five types experimental data <NUMBER> binary ppis <NUMBER>d protein structures <NUMBER> binary ppis unbiased highthroughput yeasttwohybrid assays <NUMBER> experimentally identified kinasesubstrate interactions <NUMBER> signaling networks derived experimental data <NUMBER> literaturederived ppis various experimental evidence see materials methods used zscore z measure permutation test reduce study bias network proximity analyses including hub nodes human interactome network literaturederived ppi data bias described recent studies <NUMBER> <NUMBER> total computationally identified <NUMBER> drugs associated z −<NUMBER> p <NUMBER> permutation test hcovhost interactome fig <NUMBER>a supplementary tables s<NUMBER> <NUMBER> validate bias pooled cellular proteins six covs calculated network proximities drugs four covs large number know host proteins including sarscov merscov ibv mhv separately found zscores showed consistency among pooled <NUMBER> hcovassociated proteins four individual covs fig <NUMBER>b pearson correlation coefficients proximities drugs pooled hcov <NUMBER> vs sarscov p <NUMBER> distribution <NUMBER> vs merscov p <NUMBER> <NUMBER> vs ibv p <NUMBER> <NUMBER> vs mhv p <NUMBER> network proximity analyses offer putative repurposable candidates potential prevention treatment hcovs validate <NUMBER> repurposable drugs hcovs first performed gene set enrichment analysis gsea using transcriptome data merscov sarscov infected host cells see methods transcriptome data used gene signatures hcovs additionally downloaded gene expression data drugtreated human cell lines connectivity map cmap database <NUMBER> obtain druggene signatures calculated gsea score see methods drug used score indication bioinformatics validation <NUMBER> drugs specifically enrichment score es calculated hcov data set es <NUMBER> p <NUMBER> permutation test used cutoff significant association gene signatures drug specific hcov data set gsea score ranging <NUMBER> <NUMBER> number data sets met criteria specific drug mesalazine fig <NUMBER> discovered drughcov network subnetwork highlighting networkpredicted drughcov associations connecting <NUMBER> drugs hcovs <NUMBER> drugs evaluated <NUMBER> ones achieved significant proximities drug targets hcovassociated proteins human interactome network drugs colored firstlevel anatomical therapeutic chemical atc classification system code b heatmap highlighting network proximity values sarscov merscov ibv mhv respectively color key denotes network proximity zscore drug targets hcovassociated proteins human interactome network p value computed permutation test approved drug inflammatory bowel disease sirolimus approved immunosuppressive drug equilin approved agonist estrogen receptor menopausal symptoms achieved highest gsea scores <NUMBER> followed paroxetine melatonin gsea scores <NUMBER> next selected <NUMBER> highconfidence repurposable drugs fig <NUMBER>a table <NUMBER> hcovs using subject matter expertise based combination factors strength networkpredicted associations smaller network proximity score supplementary table s<NUMBER> ii validation gsea analyses iii literaturereported antiviral evidence iv fewer clinically reported side effects specifically showcased several selected repurposable drugs literaturereported antiviral evidence overexpression estrogen receptor shown play crucial role inhibiting viral replication <NUMBER> selective estrogen receptor modulators serms reported play broader role inhibiting viral replication nonclassical pathways associated estrogen receptor <NUMBER> serms interfere post viral entry step affect triggering fusion serms antiviral activity still observed absence detectable estrogen receptor expression <NUMBER> toremifene z <NUMBER> fig <NUMBER>a first generation nonsteroidal serm exhibits potential effects blocking various viral infections including merscov sarscov ebola virus established cell lines <NUMBER> <NUMBER> compared classical esr<NUMBER>related antiviral pathway toremifene prevents fusion viral endosomal membrane interacting destabilizing virus membrane glycoprotein eventually inhibiting viral replication <NUMBER> shown fig <NUMBER>b toremifene potentially affects several key host proteins associated hcov rpl<NUMBER> hnrnpa<NUMBER> npm<NUMBER> eif<NUMBER>i eif<NUMBER>f eif<NUMBER>e <NUMBER> <NUMBER> equilin z <NUMBER> gsea score <NUMBER> estrogenic steroid produced horses also proven moderate activity inhibiting entry zaire ebola virus glycoprotein human immunodeficiency virus zebovgphiv <NUMBER> altogether networkpredicted serms toremifene equilin offer candidate repurposable drugs <NUMBER>ncovsarscov<NUMBER> angiotensin receptor blockers arbs reported associate viral infection including hcovs <NUMBER> <NUMBER> <NUMBER> irbesartan z <NUMBER> typical arb approved fda treatment hypertension diabetic nephropathy network proximity analysis shows significant association irbesartans targets hcovassociated host proteins human interactome shown fig <NUMBER>c irbesartan targets slc<NUMBER>a<NUMBER> encoding sodiumbile acid cotransporter ntcp protein identified functional pres<NUMBER>specific receptor hepatitis b virus hbv hepatitis delta virus hdv irbesartan inhibit ntcp thus inhibiting viral entry <NUMBER> <NUMBER> slc<NUMBER>a<NUMBER> interacts c<NUMBER>orf<NUMBER> potential transcriptional repressor interacts nsp<NUMBER> sarscov <NUMBER> several arbs eletriptan frovatriptan zolmitriptan targets potentially associated hcovassociated host proteins human interactome previous studies confirmed mammalian target rapamycin complex <NUMBER> mtorc<NUMBER> key factor regulating various viruses replications including andes orthohantavirus coronavirus <NUMBER> <NUMBER> sirolimus z <NUMBER> gsea score <NUMBER> inhibitor mammalian target rapamycin mtor reported effectively block viral protein expression virion release effectively <NUMBER> indeed latest study revealed clinical application sirolimus reduced merscov infection <NUMBER> <NUMBER> moreover sirolimus usage managing patients severe h<NUMBER>n<NUMBER> pneumonia acute respiratory failure improve patients prognosis significantly <NUMBER> mercaptopurine z <NUMBER> gsea score <NUMBER> antineoplastic agent immunosuppressant property used treat cancer since <NUMBER>s expanded application several autoimmune diseases including rheumatoid arthritis systemic lupus erythematosus crohns disease <NUMBER> see figure previous page fig <NUMBER> discovered drugproteinhcov network <NUMBER> candidate repurposable drugs networkpredicted evidence gene set enrichment analysis gsea scores <NUMBER> potential repurposable drugs hcovs overall connectivity top drug candidates hcovassociated proteins examined drugs indirectly target hcovassociated proteins via human proteinprotein interaction networks drugtargethcovassociated protein connections examined proteins least five connections shown box heights proteins indicate number connections gsea scores eight drugs available na due lack transcriptome profiles drugs inferred mechanismofaction networks four selected drugs b toremifene firstgeneration nonsteroidalselective estrogen receptor modulator c irbesartan angiotensin receptor blocker mercaptopurine antimetabolite antineoplastic agent immunosuppressant properties e melatonin biogenic amine treating circadian rhythm sleep disorders <NUMBER> <NUMBER> mechanistically mercaptopurine potentially target several host proteins hcovs jun pabpc<NUMBER> npm<NUMBER> ncl <NUMBER> <NUMBER> fig <NUMBER>d inflammatory pathways play essential roles viral infections <NUMBER> <NUMBER> biogenic amine melatonin nacetyl<NUMBER>methoxytryptamine z <NUMBER> gsea score <NUMBER> plays key role various biological processes offers potential strategy management viral infections <NUMBER> <NUMBER> viral infections often associated immuneinflammatory injury level oxidative stress increases significantly leaves negative effects function multiple organs <NUMBER> antioxidant effect melatonin makes putative candidate drug relieve patients clinical symptoms antiviral treatment even though melatonin cannot eradicate even curb viral replication transcription <NUMBER> <NUMBER> addition application melatonin may prolong patients survival time may provide chance patients immune systems recover eventually eradicate virus shown fig <NUMBER>e melatonin indirectly targets several hcov cellular targets including ace<NUMBER> bcl<NUMBER>l<NUMBER> jun ikbkb eplerenone z <NUMBER> aldosterone receptor antagonist reported similar antiinflammatory effect melatonin inhibiting mastcellderived proteinases suppressing fibrosis eplerenone improve survival mice infected encephalomyocarditis virus <NUMBER> summary network proximity analyses offer multiple candidate repurposable drugs target diverse cellular pathways potential prevention treatment <NUMBER>ncovsarscov<NUMBER> however preclinical experiments <NUMBER> clinical trials required verify clinical benefits networkpredicted candidates clinical use drug combinations offering increased therapeutic efficacy reduced toxicity play important role treating various viral infections <NUMBER> however ability identify validate effective combinations limited combinatorial explosion driven large number drug pairs dosage combinations recent study proposed novel networkbased methodology identify clinically efficacious drug combinations <NUMBER> relying approved drug combinations hypertension cancer found drug combination therapeutically effective captured complementary exposure pattern targets drugs hit disease module target separate neighborhoods fig <NUMBER>a sought identify drug combinations may provide synergistic effect potentially treating <NUMBER>ncovsarscov<NUMBER> welldefined mechanismofaction network analysis <NUMBER> potential repurposable drugs fig <NUMBER>a table <NUMBER> showcased three networkpredicted candidate drug combinations <NUMBER>ncovsarscov<NUMBER> predicted possible combinations found supplementary table s<NUMBER> sirolimus inhibitor mtor antifungal antineoplastic properties demonstrated improve outcomes patients severe h<NUMBER>n<NUMBER> pneumonia acute respiratory failure <NUMBER> mtor signaling plays essential role merscov infection <NUMBER> dactinomycin also known actinomycin approved rna synthesis inhibitor treatment various cancer types early study showed dactinomycin <NUMBER> μgml inhibited growth feline enteric cov <NUMBER> shown fig <NUMBER>b network analysis shows sirolimus dactinomycin synergistically target hcovassociated host protein subnetwork complementary exposure pattern offering potential combination regimens treatment hcov specifically sirolimus dactinomycin may inhibit mtor signaling rna synthesis pathway including dna topoisomerase <NUMBER>alpha top<NUMBER>a dna topoisomerase <NUMBER>beta top<NUMBER>b hcovinfected cells fig <NUMBER>b toremifene among approved firstgeneration nonsteroidal serms treatment metastatic breast cancer <NUMBER> serms including toremifene inhibited ebola virus infection <NUMBER> interacting destabilizing ebola virus glycoprotein <NUMBER> vitro assays demonstrated toremifene inhibited growth merscov <NUMBER> saracov <NUMBER> table <NUMBER> emodin anthraquinone derivative extracted roots rheum tanguticum reported various antivirus effects specifically emdoin inhibited sarscovassociated <NUMBER>a protein <NUMBER> blocked interaction sarscov spike protein ace<NUMBER> ref <NUMBER> altogether network analyses published experimental data suggested combining toremifene emdoin offered potential therapeutic approach <NUMBER>ncov sarscov<NUMBER> fig <NUMBER>c shown fig <NUMBER>a targets mercaptopurine melatonin showed strong network proximity hcovassociated host proteins human interactome network recent vitro vivo studies identified mercaptopurine selective inhibitor sarscov merscov targeting papainlike protease <NUMBER> <NUMBER> melatonin reported potential antiviral infection via antiinflammatory antioxidant effects <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> melatonin indirectly regulates ace<NUMBER> expression key entry receptor involved viral infection hcovs including <NUMBER>ncovsarscov<NUMBER> ref <NUMBER> specifically melatonin reported inhibit calmodulin calmodulin interacts ace<NUMBER> inhibiting shedding ectodomain key infectious process sarscov <NUMBER> <NUMBER> jun also known cjun key host protein involving hcov infectious bronchitis virus <NUMBER> shown fig <NUMBER>d mercaptopurine melatonin may synergistically block cjun signaling targeting multiple cellular targets summary combination mercaptopurine melatonin may offer potential combination therapy <NUMBER>ncovsarscov<NUMBER> synergistically targeting papainlike protease ace<NUMBER> cjun signaling antiinflammatory pathways fig <NUMBER>d however experimental observations ace<NUMBER> pathways melatonin <NUMBER>ncovsarscov<NUMBER> highly warranted study presented networkbased methodology systematic identification putative repurposable drugs drug combinations potential treatment <NUMBER>ncovsarscov<NUMBER> integration drugtarget networks hcovhost interactions hcovinduced transcriptome human cell lines human proteinprotein interactome network essential identification based comprehensive evaluation prioritized <NUMBER> candidate repurposable drugs fig <NUMBER> <NUMBER> potential drug combinations fig <NUMBER> targeting <NUMBER>ncovsarscov<NUMBER> however although majority predictions validated various literature data table <NUMBER> networkpredicted repurposable drugs drug combinations must validated various <NUMBER>ncovsarscov<NUMBER> experimental assays <NUMBER> randomized clinical trials used patients acknowledge several limitations current study although <NUMBER>ncovsarscov<NUMBER> shared high nucleotide sequence identity hcovs fig <NUMBER> predictions <NUMBER>ncovsarscov<NUMBER> specific lack known host proteins <NUMBER>ncovsarscov<NUMBER> used low binding affinity value <NUMBER> μm threshold define physical drugtarget interaction however stronger binding affinity threshold eg <NUMBER> μm may suitable cutoff drug discovery although generate smaller drugtarget network although sizeable efforts made assembling large scale experimentally reported drugtarget networks publicly available databases network data may incomplete drugtarget interactions may functional associations instead physical bindings example silvestrol natural product flavagline found antiviral activity ebola <NUMBER> coronaviruses <NUMBER> adding target rna helicase enzyme eif<NUMBER>a <NUMBER> silvestrol predicted significantly associated hcovs z <NUMBER> p <NUMBER> network proximity analysis increase coverage drugtarget networks may use computational approaches systematically predict drugtarget interactions <NUMBER> <NUMBER> addition collected virushost interactions far completeness quality influenced multiple factors including different experimental assays human cell line models may computationally predict new virushost interactome <NUMBER>ncovsarscov<NUMBER> using sequencebased structurebased approaches <NUMBER> drug targets representing nodes within cellular networks often intrinsically coupled therapeutic adverse profiles <NUMBER> drugs inhibit activate protein functions including antagonists vs agonists current systems pharmacology model cannot separate therapeutic antiviral effects predictions due lack detailed pharmacological effects drug targets unknown functional consequences virushost interactions comprehensive identification virushost interactome <NUMBER>ncovsarscov<NUMBER> specific biological effects using functional genomics assays <NUMBER> <NUMBER> significantly improve accuracy proposed networkbased methodologies owing lack complete drugtarget information molecular promiscuity drugs doseresponse dosetoxicity effects see figure previous page fig <NUMBER> networkbased rational design drug combinations <NUMBER>ncovsarscov<NUMBER> possible exposure mode hcovassociated protein module pairwise drug combinations effective drug combination captured complementary exposure pattern targets drugs hit hcovhost subnetwork target separate neighborhoods human interactome network z ca z cb denote network proximity zscore targets drugs b specific hcov ab denotes separation score see materials methods targets drug drug b bd inferred mechanismofaction networks three selected pairwise drug combinations b sirolimus potent immunosuppressant antifungal antineoplastic properties plus dactinomycin rna synthesis inhibitor treatment various tumors c toremifene firstgeneration nonsteroidalselective estrogen receptor modulator plus emodin experimental drug treatment polycystic kidney melatonin biogenic amine treating circadian rhythm sleep disorders plus mercaptopurine antimetabolite antineoplastic agent immunosuppressant properties repurposable drugs drug combinations cannot identified current network models example mesalazine approved drug inflammatory bowel disease top networkpredicted repurposable drug associated hcovs fig <NUMBER>a yet several clinical studies showed potential pulmonary toxicities including pneumonia associated mesalazine usage <NUMBER> <NUMBER> integration lungspecific gene expression <NUMBER> <NUMBER>ncovsarscov<NUMBER> host proteins physiologically based pharmacokinetic modeling <NUMBER> may reduce side effects repurposable drugs drug combinations preclinical studies warranted evaluate vivo efficiency side effects clinical trials furthermore limited predict pairwise drug combinations based previous networkbased framework <NUMBER> however expect methodology remain useful networkbased tool prediction combining multiple drugs toward exploring network relationships multiple drugs targets hcovhost subnetwork human interactome finally aimed systematically identify repurposable drugs specifically targeting ncov host proteins thus current network models cannot predict repurposable drugs existing antivirus drugs target virus proteins thus combination existing antivirus drugs remdesivir <NUMBER> networkpredicted repurposable drugs fig <NUMBER> drug combinations fig <NUMBER> may improve coverage current networkbased methodologies utilizing multilayer network framework <NUMBER> conclusion study offers powerful integrative networkbased systems pharmacology methodology rapid identification repurposable drugs drug combinations potential treatment <NUMBER>ncov sarscov<NUMBER> approach minimize translational gap preclinical testing results clinical outcomes significant problem rapid development efficient treatment strategies emerging <NUMBER>ncovsarscov<NUMBER> outbreak translational perspective broadly applied network tools developed could help develop effective treatment strategies emerging viral infections human complex diseases well total collected dna sequences protein sequences <NUMBER> hcovs including three recent <NUMBER>ncovsarscov<NUMBER> genomes ncbi genbank database <NUMBER> january <NUMBER> supplementary table s<NUMBER> wholegenome alignment protein sequence identity calculation performed multiple sequence alignment emblebi database https wwwebiacuk default parameters neighbor joining nj tree computed pairwise phylogenetic distance matrix using mega x <NUMBER> <NUMBER> bootstrap replicates protein alignment phylogenetic tree hcovs constructed mega x <NUMBER> collected hcovhost protein interactions various literatures based sizeable efforts hcovassociated host proteins several hcovs including sarscov merscov ibv mhv hcov<NUMBER>e hcovnl<NUMBER> pooled proteins either direct targets hcov proteins involved critical pathways hcov infection identified multiple experimental sources including highthroughput yeasttwohybrid y<NUMBER>h systems viral protein pulldown assay vitro coimmunoprecipitation rna knock experiment total virushost interaction network included <NUMBER> hcovs <NUMBER> host proteins supplementary table s<NUMBER> next performed kyoto encyclopedia genes genomes kegg gene ontology go enrichment analyses evaluate biological relevance functional pathways hcovassociated proteins functional analyses performed using enrichr <NUMBER> collected drugtarget interaction information drugbank database v<NUMBER> <NUMBER> therapeutic target database ttd <NUMBER> pharmgkb database chembl v<NUMBER> <NUMBER> bindingdb <NUMBER> iupharbps guide pharmacology <NUMBER> chemical structure drug smiles format extracted drugbank <NUMBER> drugtarget interactions meeting following three criteria used binding affinities including k k ic <NUMBER> ec <NUMBER> ≤<NUMBER> μm ii target marked reviewed uniprot database <NUMBER> iii human target represented unique uniprot accession number details building experimentally validated drugtarget network provided recent studies <NUMBER> <NUMBER> <NUMBER> build comprehensive list human ppis assembled data total <NUMBER> bioinformatics systems biology databases five types experimental evidence binary ppis tested highthroughput yeasttwohybrid y<NUMBER>h systems ii binary physical ppis protein <NUMBER>d structures iii kinasesubstrate interactions literaturederived lowthroughput highthroughput experiments iv signaling network literaturederived lowthroughput experiments v literaturecurated ppis identified affinity purification followed mass spectrometry apms y<NUMBER>h literaturederived lowthroughput experiments inferred data including evolutionary analysis gene expression data metabolic associations excluded genes mapped entrez id based ncbi database <NUMBER> well official gene symbols based genecards https wwwgenecardsorg total resulting human proteinprotein interactome used study includes <NUMBER> unique ppis edges links connecting <NUMBER> proteins nodes representing <NUMBER> increase number ppis used previously detailed descriptions building human proteinprotein interactome provided previous studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> posit human ppis provide unbiased rational roadmap repurposing drugs potential treatment hcovs originally approved given c set host genes associated specific hcov set drug targets computed network proximity c target set drug using closest method dc shortest distance gene c human protein interactome network proximity converted zscore based permutation tests r σ r mean standard deviation permutation test repeated <NUMBER> times time two randomly selected gene lists similar degree distributions c corresponding p value calculated based permutation test results zscore −<NUMBER> p <NUMBER> considered significantly proximal drughcov associations networks visualized using gephi <NUMBER> httpsgephiorg networkbased approach drug combinations effective need establish topological relationship two drugtarget modules reflects biological pharmacological relationships also quantifying networkbased relationship drug targets hcovassociated host proteins drugdrughcov combinations identify potential drug combinations combined top lists drugs separation measure ab calculated pair drugs b using following method á h calculated based closest method key methodology drug combination therapeutically effective follows specific relationship disease module captured complementary exposure patterns targets modules drugs without overlapping toxic mechanisms <NUMBER> performed gene set enrichment analysis additional prioritization method first collected three differential gene expression data sets hosts infected hcovs ncbi gene expression omnibus geo among two transcriptome data sets sarscovinfected samples patients peripheral blood <NUMBER> gse<NUMBER> calu<NUMBER> cells <NUMBER> gse<NUMBER> respectively one transcriptome data set merscovinfected calu<NUMBER> cells <NUMBER> gse<NUMBER> adjusted p value less <NUMBER> defined differentially expressed genes data sets used hcovhost signatures evaluate treatment effects drugs differential gene expression cells treated various drugs retrieved connectivity map cmap database <NUMBER> used gene profiles drugs drug cmap data set drugtarget network calculated enrichment score es hcov signature data set based previously described methods <NUMBER> j <NUMBER> <NUMBER> … genes hcov signature data set sorted ascending order rank gene profiles drug evaluated rank gene j denoted vj <NUMBER> ≤ vj ≤ r r number genes <NUMBER> drug profile es updown set updown updown b updown set −b updown b updown updown permutation tests repeated <NUMBER> times using randomly generated gene lists number upand downregulated genes hcov signature data set performed measure significance es scores drugs considered potential treatment effect es <NUMBER> p <NUMBER> number hcov signature data sets used final gsea score ranges <NUMBER> <NUMBER> highly contagious pathogenic novel severe acute respiratory syndrome coronavirus<NUMBER> sarscov<NUMBER> causative agent ongoing covid<NUMBER> pandemic spread rapidly posed health threat unprecedented magnitude global population novel sarscov<NUMBER> first reported december <NUMBER> emerged live wildlife market wuhan region hubei province caused mystic pneumonialike respiratory illnesses human population affected area <NUMBER> according data presented covid<NUMBER> situation report world health organization may <NUMBER> <NUMBER> virus infected <NUMBER> people around world including staggering <NUMBER> deaths cumulative mortality rate <NUMBER> exponentially increased march april <NUMBER> despite instantaneous monumental research efforts scientific community around globe present effective antiviral treatment vaccine available j u r n l p r e p r f covid<NUMBER> however significant efforts made development vaccines therapeutic drugs small scale clinical trials <NUMBER> <NUMBER> presently sarscov<NUMBER> infected patients treatments limited use prophylactic symptomatic management like mild symptoms dry cough sore throat fever various fatal complications including organ failure septic shock pulmonary edema severe pneumonia acute respiratory distress syndrome ards <NUMBER> therefore urgent need discovery potential treatment therapy check control sarscov<NUMBER> pandemic coronaviruses covs belong family coronaviridae viruses constitute important class pathogens humans vertebrates <NUMBER> severe respiratory illness humans <NUMBER> causative agent current outbreak sarscov<NUMBER> also belongs beta coronaviruses <NUMBER> closely related sarscov overall genomic sequence similarity <NUMBER> covs belong coronaviridae family viruses possess positivesense singlestranded rna genome <NUMBER> virion sarscov<NUMBER> consists crownshaped peplomers <NUMBER> nm diameter consists <NUMBER> kb long singlestranded rna molecule positive polarity <NUMBER> cap <NUMBER> polya tail <NUMBER> rna genome composed least six open reading frames orfs first orf orf<NUMBER>ab makes <NUMBER>twothird encodes two polypeptides pp<NUMBER>a pp<NUMBER>ab furthermore leads production <NUMBER> nonstructural proteins nsps orfs make remaining onethird viral genome give rise production four main structural factors virion spike protein envelope protein e membrane protein nucleocapsid protein n <NUMBER> sarscov<NUMBER> virus uses heterotrimeric spike protein consists s<NUMBER> s<NUMBER> subunit surface interacts ace<NUMBER> angiotensinconverting enzyme <NUMBER> cellular receptor abundantly expressed many cell types human tissues <NUMBER> upon internalization cell genomic rna used template direct translation two polyprotein pp<NUMBER>a pp<NUMBER>ab encodes several crucial nonstructural proteins nsps including two proteases chymotrypsinlike protease <NUMBER>cl pr main protease pro nsp<NUMBER> papainlike protease p pr nsp<NUMBER> processes polypeptide pp<NUMBER>a pp<NUMBER>ab sequencespecific manner produce <NUMBER> different nsps <NUMBER> <NUMBER> papain protease processes polyprotein generate nsp<NUMBER> time pro operates many <NUMBER> cleavage sites specifically recognizing sequence leuglnseralagly marks cleavage site generate rest critical nsps including helicase methyltransferase rna dependent rna polymerase rdrp play critical role viral infection cycle forming replicationtranscription complex rtc <NUMBER> therefore main protease constitutes major attractive drug target block production nonstructural viral components thereby hamper replication event virus life cycle additionally human protease similar cleavage specificity known rule possibility cellular toxicity upon potential inhibition main viral protease <NUMBER> recent years drug repurposing methodology emerged resourceful alternative fasten drug development process rapidly spreading emerging infections one sarscov<NUMBER> <NUMBER> approach drug repurposing successfully led discoveries potential drug candidates several diseases ebola disease hepatitis c virus zika virus infection <NUMBER> <NUMBER> recently several repurposing studies sarscov<NUMBER> performed using clinically approved drugs <NUMBER> among new study comes clinical trial lopinavirritonavir drug covid<NUMBER> indicated top drug repurposing study <NUMBER> present study performed silico based drug repurposing method using molecular docking studies spectrum food drug administration fda approved antiviral drugs sarscov<NUMBER> pro end recently elucidated xray crystal structure sarscov<NUMBER> pro pdb id <NUMBER>y<NUMBER>f shown αketoamide potent inhibitor enzymes active site chosen screened several fda approved antiviral drugs simulate proαketoamide interactions thereby blocking active j u r n l p r e p r f pocket <NUMBER> crystal structure sarscov<NUMBER> pro apo form pdb id <NUMBER>y<NUMBER>e αketoamide bound form pdb id <NUMBER>y<NUMBER>f shows protein makes crystallographic dimer composed two monomers identical conformations protomer furthermore made three domains interface domain domain ii form active site protein composed cys <NUMBER> <NUMBER> dyad αketoamide derivative <NUMBER>b bound fig <NUMBER>a uniquely globular domain iii linked domain ii linker region deemed essential catalytic activity chymotrypsinlike proteas <NUMBER> αketoamide derivative <NUMBER>b shown bound active site stabilized several interactions active site residues <NUMBER> cys <NUMBER> adjacent residues substrate binding cleft gly <NUMBER> ser <NUMBER> <NUMBER> fig <NUMBER>b selected several existing fda approved drugs reported used humans countering certain viral infections screened binding active cleft pro results shown drugs occupied active site pro even increased binding affinity bound αketoamide <NUMBER>b rest compounds shown appreciable binding holding crucial active site determinants envisage vitro examination inhibitory potential drugs catalytic activity main protease could lead way repurpose one tested fda approved drugs study treatment therapy sarscov<NUMBER> induced disease understand evolutionary relationship previously known human coronavirus novel sarscov<NUMBER> performed phylogenetic analysis analysis closely related complete reference genome sequences sarscov<NUMBER> downloaded ncbi genbank database total <NUMBER> genomes considered study mega <NUMBER> used multiple sequence alignment construction phylogenetic tree <NUMBER> bootstrap replicates performed using neighborjoining method <NUMBER> recently elucidated xray crystal structure coordinates sarcov<NUMBER> pro downloaded rcsb pdb pdb id <NUMBER>y<NUMBER>f <NUMBER>å resolution structure pro cocrystallized improved bound αketoamide <NUMBER>b inhibitor multiple intermolecular interactions ligand active site residues characterized <NUMBER> identify potent inhibitors sarcov<NUMBER> pro among fda approved antiviral drugs downloaded <NUMBER> drug compounds pubchem chemical database <NUMBER> molecular docking based drug repurposing download <NUMBER>d structures compounds protein prepared docking study performed autodock vina <NUMBER> uses lamarckian genetic algorithm ga combination gridbased energy estimation check docking accuracy software performed redocking cocrystal bound ligand main aim molecular interaction study identify highly interacting drug sarcov<NUMBER> protein crystal structure propose drug insilico repurposing method interaction visualization analysis studies performed discoverystudio visualizer ds pymol molecular visualization tool ligplot <NUMBER> <NUMBER> molecular dynamics md simulations performed yasara version <NUMBER>w<NUMBER> yet another scientific artificial reality application commercial package <NUMBER> throughout <NUMBER> nanoseconds <NUMBER> snapshots amber<NUMBER> force field md computationally see physical movement atoms molecules provides structural level integrity conformational changes occur proteinligand docked complex present study docked complexes virtually screened top three drugs lopinavirritonavir tipranavir raltegravir xray crystal structure sarscov<NUMBER> pro pdb id <NUMBER>y<NUMBER>f analyzed md simulations md simulations parameters kept follows temperature kept <NUMBER> k pressure bar coulomb electrostatics cutoff <NUMBER> <NUMBER> nacl ph <NUMBER> solvent density <NUMBER> <NUMBER>femtosecond fs time steps periodic boundaries one simulation box <NUMBER> conformational changes structural level integrity docked complexes analyzed using root mean square deviation rmsd root mean square fluctuation rmsf evaluations <NUMBER> sequence alignment sarcov<NUMBER> genome shows high similarity closely related reference genomes coronaviruses blastn search complete genome sarcov<NUMBER> reveals closely related virus available genbank slcovzxc<NUMBER> embecovirus importantly phylogenetic analysis revealed divergence sarcov<NUMBER> genome sequence different sarcov<NUMBER> viruses isolated different countries ongoing outbreak fig <NUMBER> coronaviruses use chymotrypsinlike protease along papain protease process cleaves long polyprotein precursor individually functional nsps multiple sequence analysis main protease sarscov<NUMBER> sarscov reveals amino acid sequence conserved sequence identity <NUMBER> fig <NUMBER> active site residues thoroughly conserved make catalytic cys <NUMBER> <NUMBER> dyad additionally substratebinding subsites positioned active site groove protease specific subsite residues located enzyme active site named s<NUMBER> s<NUMBER> s<NUMBER> s<NUMBER> s<NUMBER> depending relative position cleavage site subsites p<NUMBER> p<NUMBER> p<NUMBER> p<NUMBER> p<NUMBER> polyprotein subsite p<NUMBER> corresponds amino acid cleavage site position p<NUMBER> corresponds residue immediately cleavage site <NUMBER> <NUMBER> pro sarscov<NUMBER> active site region s<NUMBER> residues contributed cys<NUMBER> gly<NUMBER> ser<NUMBER> also serve oxyanion hole s<NUMBER> residue his<NUMBER> glu<NUMBER> gln<NUMBER> located s<NUMBER> position bulky gln<NUMBER> pro<NUMBER> make s<NUMBER> site <NUMBER> fig <NUMBER>a main protease recognizes binds specific residues subsite peptide substrate determine initiation proteolysis production nsps formation replicationtranscription complex molecular docking based virtual screening fda approved antiviral drugs sarscov<NUMBER> pro revealed strong interaction higher docking energy binding affinities potential drugs docked independent confirmation active site protein cocrystal structure ligand improved αketoamide <NUMBER>b bound molecular docking binding affinity docked analyzed drugs binding energy ranking shown table s<NUMBER> molecular redocking also performed check docking accuracy software autodock vina observed cocrystal bound ligand redocked ligand shows rmsd value <NUMBER> å suggesting high fidelity docking method fig <NUMBER>b present study focused top <NUMBER> docking results analysis drug compounds showing higher binding affinity lopinavirritonavir <NUMBER> docking studies molecular dynamics performed screened top three drugs lopinavirritonavir tipranavir raltegravir know binding stability docked complexes simulation performed <NUMBER>ns study conformational stability complexes information retrieved trajectory used investigate stability secondary structure complexes plotting root mean square deviation rmsd root mean square fluctuations rmsf fig <NUMBER> showing rmsd values bound unbound ligands different time interval summarizing conformational changes ligands <NUMBER> nanoseconds procedure delivers information movement ligand binding pocket figure <NUMBER> showing total energy kjmol versus time interval complexes atoms distribution energy <NUMBER> <NUMBER> kjmol <NUMBER> ns time interval whereas fig <NUMBER> rmsf per solute amino acid residues calculated average rmsf constituting residues fig s<NUMBER> showing hydrogen bond interaction ligands atoms protein also representing number hydrogen bonds formed solute solvent three selected complexes rapidly spreading disease caused novel sarscov<NUMBER> called covid<NUMBER> <NUMBER> world health organization declared outbreak pandemic increasing form second week march <NUMBER> affected nearly countries around globe <NUMBER> although phylogenetic analysis different isolates sarscov<NUMBER> samples across world clearly shows sarscov<NUMBER> evolutionarily closely related genomes sarslike coronavirus batslcov coronavirus present bat china identified <NUMBER> study also reveals might possible sarscov<NUMBER> originated batslcov<NUMBER> mutations share <NUMBER> genome identity till potent drug vaccine reported approved treat sarscov<NUMBER> infected individuals symptomatic treatment given sever patients j u r n l p r e p r f <NUMBER> however efforts scientific community exceptional advancing research effort towards development therapeutic intervention finding viral drug targets end crystal structure important viral proteins spike protein viral papain protease chymotrypsinlike protease deduced <NUMBER> recently published studies sarscov<NUMBER> observed virus binds angiotensinconverting enzymes <NUMBER> ace<NUMBER> receptors lower respiratory tracts infected patients gain entry lungs study reveals sarscov<NUMBER> main protease pro best drug target among coronaviruses <NUMBER> interestingly one characterized promising drug targeting coronavirus infection main protease pro also known <NUMBER>cl pro cocrystallized bound ligand improved αketoamide <NUMBER>b case sarscov<NUMBER> main protease <NUMBER> crystal structure reveals αketoamide <NUMBER>b occupying active site protein making several hydrogen bonds hydrophobic interactions active site residues well substratebinding residues binding pocket present study screened <NUMBER> antiviral anticancer antimalarial drugs identification potential drug molecules using drug repurposing virtual screening methods molecular docking studies revealed maximum screened drug compounds interact sarscov<NUMBER> pro protein share binding pocket similar interacting amino acid residues sarscov<NUMBER> bound ligand improvedαketoamide shows strong bond interactions surrounding amino acids within region <NUMBER>å different subsites his<NUMBER> glu<NUMBER> gly<NUMBER> his<NUMBER> cys<NUMBER> his<NUMBER> phe<NUMBER> forms hydrogen bonds active site his<NUMBER> also accept hydrogen bond backbone amides gly<NUMBER> cys<NUMBER> ser<NUMBER> proteinligand interaction reveals strong inhibition virus protease fig <NUMBER>d <NUMBER> screening molecular docking least <NUMBER> preexisting drugs carried shown fit active site protease independent conformation appreciable binding energy score fig <NUMBER>ad analyzed repurposing top <NUMBER> drugs showed higher similar binding affinity compared cocrystal bound ligand sarscov<NUMBER> top <NUMBER> drugs exhibiting interaction amino acid residues αketoamide main proteases lopinavirritonavir showing binding affinity <NUMBER> kcalmol tipranavir <NUMBER> kcalmol whereas raltegravirhas binding affinity <NUMBER> kcalmol j u r n l p r e p r f similar improvedαketoamide <NUMBER>b <NUMBER>kcalmol rest drug compounds also shown good binding energy score presented table<NUMBER> drug lopinavirritonavir combination product contains two medications lopinavir ritonavir drug mainly used hivaids control hiv infection inhibiting protease help decrease amount hiv body promoting function bodys natural immune system work better <NUMBER> enzyme sarscov<NUMBER> pro along papainlike proteases essential processing polyproteins various nonstructural proteins cleaving specific sites translated viral rna leu <NUMBER> fig<NUMBER>a fig <NUMBER>b interestingly binding energy score lopinavirritonavir proteinligand docking found even better docked αketoamide silico inhibition constant ki obtained <NUMBER> nm silico inhibition constant ki obtained docking given table <NUMBER> top <NUMBER> drugs drug tipranavir tipranavir disodium another nonpeptidic protease inhibitor used combination ritonavir treat hiv infection <NUMBER> study drug shows interaction gln<NUMBER> met<NUMBER> form hydrogen bonding gln<NUMBER> asp<NUMBER> met<NUMBER> arg<NUMBER> ser<NUMBER> cys<NUMBER> thr<NUMBER> his<NUMBER> different conformation αketoamide inhibitor fig <NUMBER>b fig <NUMBER>d hypothesize tipranavir derivatives even improved binding affinity combination ritonavir could serve potential protease inhibitor counter srascov<NUMBER> multiplication cellbased assay another drug shown comparable binding affinity binding energy docked αketoamide pro active site raltegraviris characterized antiretroviral medication works inhibiting integrase strand transfer used combination j u r n l p r e p r f drugs relieve hiv infection <NUMBER> present study raltegravir drug shows interaction his<NUMBER> arg<NUMBER> gln<NUMBER> glu<NUMBER> residues bonded strong hydrogen bond met<NUMBER> met<NUMBER> phe<NUMBER> pro<NUMBER> leu<NUMBER> drug shows four hbonds nearest interacting amino acids sarscov<NUMBER> pro enzyme indicates good inhibition fig <NUMBER>c fig <NUMBER>c drug could also used combinations like raltegravir lopinavir treatment covid<NUMBER> found producing desirable inhibitory effect sarscov<NUMBER> protease biochemical activity assay cellbased assays additionally drugs screened docked substratebinding cleft pro shown good binding energy score comparably similar original compound protein crystal structure many drugs dolutegravir letermovir nelfinavir commonly used treating different infections ranging hiv cytomegalovirus employing different mechanisms action <NUMBER> <NUMBER> <NUMBER> identified repurposed drug interaction binding amino acids pro active site shown table <NUMBER> however believe drugs studied screened repurposing covid<NUMBER> study furthermore tested vitro inhibitory potential needs investigated robust biochemical proteolytic activity assays biophysical structural studies conclusion study reveals potential repurposed antiviral drugs bind active site sarscov<NUMBER> main protease highly specific binding pattern similar crystal bound αketoamide mpro structure three screened drugs lopinavirritonavir raltegravir tipranavir shown strongest binding md simulation study confirmed stability conformational flexibility drugs enzyme active site since drugs identified study known pharmacokinetics standards approved fda human use treatment respective illneses may possible move straight clinical trials per standard approved fda new indication therefore fasten process therapeutics development sarscov<NUMBER> infection molecular dynamics studies performed study screened top three drugs also proving binding conformational stability cov<NUMBER> pro phylogenetic analysis available genomes sarscov<NUMBER> isolated different sources also reveals virus showing sign severing mutation diversification rapidly therefore repurposed drug combinations could used sarscov<NUMBER> pancommunity level furthermore suggest efficacy repurposed drugs study needs experimentally confirmed carrying biochemical structural studies prevention treatment covid<NUMBER> authors declare conflict amino acids marked underneath represent catalytic residues residues marked underneath represent substratebinding residues various subsites xray crystal structure including cocrystal bound ligand improvedαketoamide  highly contagious pathogenic novel severe acute respiratory syndrome coronavirus<NUMBER> sarscov<NUMBER> causative agent ongoing covid<NUMBER> pandemic spread rapidly posed health threat unprecedented magnitude global population novel sarscov<NUMBER> first reported december <NUMBER> emerged live wildlife market wuhan region hubei province caused mystic pneumonialike respiratory illnesses human population affected area <NUMBER> accordhttpsdoiorg<NUMBER>jjiph<NUMBER> <NUMBER>© <NUMBER> published elsevier ltd behalf king saud bin abdulaziz university health sciences open access article cc byncnd license httpcreativecommonsorglicensesbyncnd<NUMBER> ing data presented covid<NUMBER> situation report world health organization may <NUMBER> <NUMBER> virus infected <NUMBER> people around world including staggering <NUMBER> deaths cumulative mortality rate <NUMBER> exponentially increased march april <NUMBER> despite instantaneous monumental research efforts scientific community around globe present effective antiviral treatment vaccine available covid<NUMBER> however significant efforts made development vaccines therapeutic drugs small scale clinical trials <NUMBER> <NUMBER> presently sarscov<NUMBER> infected patients treatments limited use prophylactic symptomatic management like mild symptoms dry cough sore throat fever various fatal complications including organ failure septic shock pulmonary edema severe pneumonia acute respiratory distress syndrome ards <NUMBER> therefore urgent need discovery potential treatment therapy check control sarscov<NUMBER> pandemic coronaviruses covs belong family coronaviridae viruses constitute important class pathogens humans vertebrates <NUMBER> current sarscov<NUMBER> six covs known cause mild severe illnesses humans novel human coronavirus hcov<NUMBER>e hcovnl<NUMBER> fall genera alphacoronavirus cause milder upper respiratory disease adults sometimes also cause severe infection infants young children whereas betacoronaviruses like hcovoc<NUMBER> hku<NUMBER> sarscov severe acute respiratory syndrome coronavirus triggered epidemic china <NUMBER>−<NUMBER> merscov middle east respiratory syndrome coronavirus etiological agent middle east coronavirus epidemic <NUMBER> potential cause infection lower respiratory tract along cough fever triggers severe respiratory illness humans <NUMBER> causative agent current outbreak sarscov<NUMBER> also belongs beta coronaviruses <NUMBER> closely related sarscov overall genomic sequence similarity <NUMBER> covs belong coronaviridae family viruses possess positivesense singlestranded rna genome <NUMBER> virion sarscov<NUMBER> consists crownshaped peplomers <NUMBER>−<NUMBER> nm diameter consists ∼<NUMBER> kb long singlestranded rna molecule positive polarity <NUMBER> cap <NUMBER> polya tail <NUMBER> rna genome composed least six open reading frames orfs first orf orf<NUMBER>ab makes <NUMBER> twothird encodes two polypeptides pp<NUMBER>a pp<NUMBER>ab furthermore leads production <NUMBER> nonstructural proteins nsps orfs make remaining onethird viral genome give rise production four main structural factors virion spike protein envelope protein e membrane protein nucleocapsid protein n <NUMBER> sarscov<NUMBER> virus uses heterotrimeric spike protein consists s<NUMBER> s<NUMBER> subunit surface interacts ace<NUMBER> angiotensinconverting enzyme <NUMBER> cellular receptor abundantly expressed many cell types human tissues <NUMBER> upon internalization cell genomic rna used template direct translation two polyprotein pp<NUMBER>a pp<NUMBER>ab encodes several crucial nonstructural proteins nsps including two proteases chymotrypsinlike protease <NUMBER>cl pr main protease pro nsp<NUMBER> papainlike protease p pr nsp<NUMBER> processes polypeptide pp<NUMBER>a pp<NUMBER>ab sequencespecific manner produce <NUMBER> different nsps <NUMBER> <NUMBER> papain protease processes polyprotein generate nsp<NUMBER>−<NUMBER> time pro operates many <NUMBER> cleavage sites specifically recognizing sequence leuglnseralagly marks cleavage site generate rest critical nsps including helicase methyltransferase rna dependent rna polymerase rdrp play critical role viral infection cycle forming replicationtranscription complex rtc <NUMBER> therefore main protease constitutes major attractive drug target block production nonstructural viral components thereby hamper replication event virus life cycle additionally human protease similar cleavage specificity known rule possibility cellular toxicity upon potential inhibition main viral protease <NUMBER> recent years drug repurposing methodology emerged resourceful alternative fasten drug development process rapidly spreading emerging infections one sarscov<NUMBER> <NUMBER> approach drug repurposing successfully led discoveries potential drug candidates several diseases ebola disease hepatitis c virus zika virus infection <NUMBER> <NUMBER> recently several repurposing studies sarscov<NUMBER> performed using clinically approved drugs <NUMBER> among new study comes clinical trial lopinavirritonavir drug covid<NUMBER> indicated top drug repurposing study <NUMBER> present study performed silico based drug repurposing method using molecular docking studies spectrum food drug administration fda approved antiviral drugs sarscov<NUMBER> pro end recently elucidated xray crystal structure sarscov<NUMBER> pro pdb id <NUMBER>y<NUMBER>f shown ␣ketoamide potent inhibitor enzymes active site chosen screened several fda approved antiviral drugs simulate pro ␣ketoamide interactions thereby blocking active pocket <NUMBER> crystal structure sarscov<NUMBER> pro apo form pdb id <NUMBER>y<NUMBER>e ␣ketoamide bound form pdb id <NUMBER>y<NUMBER>f shows protein makes crystallographic dimer composed two monomers identical conformations protomer furthermore made three domains interface domain domain ii form active site protein composed cys <NUMBER> <NUMBER> dyad ␣ketoamide derivative <NUMBER>b bound fig <NUMBER>a uniquely globular domain iii linked domain ii linker region deemed essential catalytic activity chymotrypsinlike proteas <NUMBER> ␣ketoamide derivative <NUMBER>b shown bound active site stabilized several interactions active site residues <NUMBER> cys <NUMBER> adjacent residues substrate binding cleft gly <NUMBER> ser <NUMBER> <NUMBER> fig <NUMBER>b selected several existing fda approved drugs reported used humans countering certain viral infections screened binding active cleft pro results shown drugs occupied active site pro even increased binding affinity bound ␣ketoamide <NUMBER>b rest compounds shown appreciable binding holding crucial active site determinants envisage vitro examination inhibitory potential drugs catalytic activity main protease could lead way repurpose one tested fda approved drugs study treatment therapy sarscov<NUMBER> induced disease understand evolutionary relationship previously known human coronavirus novel sarscov<NUMBER> performed phylogenetic analysis analysis closely related complete reference genome sequences sarscov<NUMBER> downloaded ncbi genbank database total <NUMBER> genomes considered study mega <NUMBER> used multiple sequence alignment construction phylogenetic tree <NUMBER> bootstrap replicates performed using neighborjoining method <NUMBER> recently elucidated xray crystal structure coordinates sarcov<NUMBER> pro downloaded rcsb pdb pdb id <NUMBER>y<NUMBER>f <NUMBER> å resolution structure pro cocrystallized improved bound ␣ketoamide <NUMBER>b inhibitor multiple intermolecular interactions ligand active site residues characterized <NUMBER> identify potent inhibitors sarcov<NUMBER> pro among fda approved antiviral drugs downloaded <NUMBER> drug compounds pubchem chemical database <NUMBER> molecular docking based drug repurposing download <NUMBER>d structures compounds protein prepared docking study performed autodock vina <NUMBER> uses lamarckian genetic algorithm ga combination gridbased energy estimation check docking accuracy software performed redocking cocrystal bound ligand main aim molecular interaction study identify highly interacting drug sarcov<NUMBER> protein crystal structure propose drug insilico repurposing method interaction visualization analysis studies performed discoverystudio visualizer ds pymol molecular visualization tool ligplot <NUMBER> <NUMBER> molecular dynamics md simulations performed yasara version <NUMBER>w<NUMBER> yet another scientific artificial reality application commercial package <NUMBER> throughout <NUMBER> nanoseconds <NUMBER> snapshots amber<NUMBER> force field md computationally see physical movement atoms molecules provides structural level integrity conformational changes occur proteinligand docked complex present study docked complexes virtually screened top three drugs lopinavirritonavir tipranavir raltegravir xray crystal structure sarscov<NUMBER> pro pdb id <NUMBER>y<NUMBER>f analyzed md simulations md simulations parameters kept follows temperature kept <NUMBER> k pressure bar coulomb electrostatics cutoff <NUMBER> <NUMBER> nacl ph <NUMBER> solvent density <NUMBER> <NUMBER>femtosecond fs time steps periodic boundaries one simulation box <NUMBER> conformational changes structural level integrity docked complexes analyzed using root mean square deviation rmsd root mean square fluctuation rmsf evaluations <NUMBER> genome sequence alignment phylogenetic analysis sarcov<NUMBER> sequence alignment sarcov<NUMBER> genome shows high similarity closely related reference genomes coronaviruses blastn search complete genome sarcov<NUMBER> reveals closely related virus available genbank slcovzxc<NUMBER> mg<NUMBER> bat sarslike coronavirus showing <NUMBER> query coverage <NUMBER> identity contrast another bat sarscov genome slcovzxc<NUMBER> mg<NUMBER> showed <NUMBER> query coverage <NUMBER> sequence identity isolated china majorly phylogenetic tree clustered three clades ii clade iii clade consists <NUMBER> sarscov batslcov complete genome share sequence identity range <NUMBER> <NUMBER> sequence aligned using blastn tool whereas clade ii consists total <NUMBER> complete genomes sarscov<NUMBER> batslcov ten genomes sarscov<NUMBER> isolated patients different countries coronaviruses use chymotrypsinlike protease along papain protease process cleaves long polyprotein precursor individually functional nsps multiple sequence analysis main protease sarscov<NUMBER> sarscov reveals amino acid sequence conserved sequence identity <NUMBER> fig <NUMBER> active site residues thoroughly conserved make catalytic cys <NUMBER> <NUMBER> dyad additionally substratebinding subsites positioned active site groove protease specific subsite residues located enzyme active site named s<NUMBER> s<NUMBER> s<NUMBER> s<NUMBER> s<NUMBER> depending relative position cleavage site subsites p<NUMBER> p<NUMBER> p<NUMBER> p<NUMBER> p<NUMBER> polyprotein subsite p<NUMBER> corresponds amino acid cleavage site position p<NUMBER> please cite article press kumar et al silico prediction potential inhibitors main protease sarscov<NUMBER> using molecular docking dynamics simulation based drugrepurposing j infect public health <NUMBER> httpsdoiorg<NUMBER>jjiph<NUMBER> corresponds residue immediately cleavage site <NUMBER> <NUMBER> pro sarscov<NUMBER> active site region s<NUMBER> residues contributed cys<NUMBER> gly<NUMBER> ser<NUMBER> also serve oxyanion hole s<NUMBER> residue his<NUMBER> glu<NUMBER> gln<NUMBER> located s<NUMBER> position bulky gln<NUMBER> pro<NUMBER> make s<NUMBER> site <NUMBER> fig <NUMBER>a main protease recognizes binds specific residues subsite peptide substrate determine initiation proteolysis production nsps formation replicationtranscription complex molecular docking based virtual screening fda approved antiviral drugs sarscov<NUMBER> pro revealed strong interaction higher docking energy binding affinities potential drugs docked independent confirmation active site protein cocrystal structure ligand improved ␣ketoamide <NUMBER>b bound molecular docking binding affinity docked analyzed drugs binding energy ranking shown table s<NUMBER> molecular redocking also performed check docking accuracy software autodock vina observed cocrystal bound ligand redocked ligand shows rmsd value <NUMBER> å suggesting high fidelity docking method fig <NUMBER>b present study focused top <NUMBER> docking results analysis drug compounds showing higher binding affinity lopinavirritonavir <NUMBER> kcalmol tipranavir <NUMBER> kcalmol raltegravir docking studies molecular dynamics performed screened top three drugs lopinavirritonavir tipranavir raltegravir know binding stability docked complexes simulation performed <NUMBER> ns study conformational stability complexes information retrieved trajectory used investigate stability secondary structure complexes plotting root mean square deviation rmsd root mean square fluctuations rmsf fig <NUMBER> showing rmsd values bound unbound ligands different time interval summarizing conformational changes ligands <NUMBER> nanoseconds procedure delivers information movement ligand binding pocket fig <NUMBER> showing total energy kjmol versus time interval complexes atoms distribution energy <NUMBER> <NUMBER> kjmol <NUMBER> ns time interval whereas fig <NUMBER> rmsf per solute amino acid residues calculated average rmsf constituting residues fig s<NUMBER> showing hydrogen bond interaction ligands atoms protein also representing number hydrogen bonds formed solute solvent three selected complexes rapidly spreading disease caused novel sarscov<NUMBER> called covid<NUMBER> <NUMBER> world health organization declared outbreak pandemic increasing form second week march <NUMBER> affected nearly countries around globe <NUMBER> although phylogenetic analysis different isolates sarscov<NUMBER> samples across world clearly shows sarscov<NUMBER> evolutionarily closely related genomes sarslike coronavirus batslcov coronavirus present bat china identified <NUMBER> study also reveals might possible sarscov<NUMBER> origiplease cite article press kumar et al silico prediction potential inhibitors main protease sarscov<NUMBER> using molecular docking dynamics simulation based drugrepurposing j infect public health <NUMBER> httpsdoiorg<NUMBER>jjiph<NUMBER> nated batslcov<NUMBER> mutations share <NUMBER> genome identity till potent drug vaccine reported approved treat sarscov<NUMBER> infected individuals symptomatic treatment given sever patients <NUMBER> however efforts scientific community exceptional advancing research effort towards development therapeutic intervention finding viral drug targets end crystal structure important viral proteins spike protein viral papain protease chymotrypsinlike protease deduced <NUMBER> recently published studies sarscov<NUMBER> observed virus binds angiotensinconverting enzymes <NUMBER> ace<NUMBER> receptors lower respiratory tracts infected patients gain entry lungs study reveals sarscov<NUMBER> main protease pro best drug target among coronaviruses <NUMBER> interestingly one characterized promising drug targeting coronavirus infection main protease pro also known <NUMBER>cl pro cocrystallized bound ligand improved ␣ketoamide <NUMBER>b case sarscov<NUMBER> main protease <NUMBER> crystal structure reveals ␣ketoamide <NUMBER>b occupying active site protein making several hydrogen bonds hydrophobic interactions active site residues well substratebinding residues binding pocket present study screened <NUMBER> antiviral anticancer antimalarial drugs identification potential drug molecules using drug repurposing virtual screening methods molecular docking studies revealed table <NUMBER> showing top<NUMBER> drug compounds <NUMBER>dimensional representation docking poses interacting amino acids target sarcov<NUMBER> pro xray crystal structure including cocrystal bound ligand improved␣ketoamide ligand binding affinity kcalmol schematic intermolecular interactions maximum screened drug compounds interact sarscov<NUMBER> pro protein share binding pocket similar interacting amino acid residues sarscov<NUMBER> bound ligand improved␣ketoamide shows strong bond interactions surrounding amino acids within region <NUMBER> å different subsites his<NUMBER> glu<NUMBER> gly<NUMBER> his<NUMBER> cys<NUMBER> his<NUMBER> phe<NUMBER> forms hydrogen bonds active site his<NUMBER> also accept hydrogen bond backbone amides gly<NUMBER> cys<NUMBER> ser<NUMBER> proteinligand interaction reveals strong inhibition virus protease fig <NUMBER>d <NUMBER> screening molecular docking least <NUMBER> preexisting drugs carried shown fit active site protease independent conformation appreciable binding energy score fig <NUMBER>ad analyzed repurposing top <NUMBER> drugs showed higher similar binding affinity compared cocrystal bound ligand sarscov<NUMBER> top <NUMBER> drugs exhibiting interaction amino acid residues ␣ketoamide main proteases lopinavirritonavir showing binding affinity <NUMBER> kcalmol tipranavir <NUMBER> kcalmol whereas raltegravirhas binding affinity <NUMBER> kcalmol similar improved␣ketoamide <NUMBER>b <NUMBER> kcalmol rest drug compounds also shown good binding energy score presented table<NUMBER> drug lopinavirritonavir combination product contains two medications lopinavir ritonavir drug mainly used hivaids control hiv infection inhibiting protease help decrease amount hiv body promoting function bodys natural immune system work better <NUMBER> enzyme sarscov<NUMBER> pro along papainlike proteases essential processing polyproteins various nonstructural proteins cleaving specific sites translated viral rna interacting amino acids pro enzyme active site reported leu gln ser ala gly along cyshis dyad marks cleavage site similarly silico docking study shows top screened drug lopinavirritonavir combination interacts glu <NUMBER> also form strong hydrogen bonding gln <NUMBER> leu <NUMBER> met <NUMBER> asp <NUMBER> met <NUMBER> <NUMBER> cys <NUMBER> leu <NUMBER> fig<NUMBER>a fig <NUMBER>b please cite article press kumar interestingly binding energy score lopinavirritonavir proteinligand docking found even better docked ␣ketoamide silico inhibition constant k obtained <NUMBER> nm silico inhibition constant k obtained docking given table <NUMBER> top <NUMBER> drugs drug tipranavir tipranavir disodium another nonpeptidic protease inhibitor used combination ritonavir treat hiv infection <NUMBER> study drug shows interaction gln<NUMBER> met<NUMBER> form hydrogen bonding gln<NUMBER> asp<NUMBER> met<NUMBER> arg<NUMBER> ser<NUMBER> cys<NUMBER> thr<NUMBER> his<NUMBER> different conformation ␣ketoamide inhibitor figs <NUMBER>b <NUMBER>d hypothplease cite article press kumar et al silico prediction potential inhibitors main protease sarscov<NUMBER> using molecular docking dynamics simulation based drugrepurposing j infect public health <NUMBER> httpsdoiorg<NUMBER>jjiph<NUMBER> esize tipranavir derivatives even improved binding affinity combination ritonavir could serve potential protease inhibitor counter srascov<NUMBER> multiplication cellbased assay another drug shown comparable binding affinity binding energy docked ␣ketoamide pro active site raltegraviris characterized antiretroviral medication works inhibiting integrase strand transfer used combination drugs relieve hiv infection <NUMBER> present study raltegravir drug shows interaction his<NUMBER> arg<NUMBER> gln<NUMBER> glu<NUMBER> residues bonded strong hydrogen bond met<NUMBER> met<NUMBER> phe<NUMBER> pro<NUMBER> leu<NUMBER> drug shows four hbonds nearest interacting amino acids sarscov<NUMBER> pro enzyme indicates good inhibition figs <NUMBER>c <NUMBER>c drug could also used combinations like raltegravir lopinavir treatment covid<NUMBER> found producing desirable inhibitory effect sarscov<NUMBER> protease biochemical activity assay cellbased assays additionally drugs screened docked substratebinding cleft pro shown good binding energy score comparably similar original compound protein crystal structure many drugs dolutegravir letermovir nelfinavir commonly used treating different infections ranging hiv cytomegalovirus employing different mechanisms action <NUMBER> <NUMBER> <NUMBER> identified repurposed drug interaction binding amino acids pro active site shown table <NUMBER> screening different fda approved drugs present study enabled us understand mode interaction approved antiretroviral drugs new coronavirus sarscov<NUMBER> main protease enzyme top three drugs lopinavirritonavir raltegravir tipranavir run md simulations studies period <NUMBER> ns results see three ligands intact bound binding site later protein backbone rmsd analysis complexes performed reveals nearly three complexes stable <NUMBER> ns showing rmsd calculations within range <NUMBER> å starting <NUMBER> å fig <NUMBER> total binding energies showing drug lopinavirritonavir showing stable energy values fig <NUMBER> order know effect ligands binding sarscov<NUMBER> pro performed rmsf analysis average rmsf protein constituting residues atoms since trajectories complexes become stable minor fluctuations range <NUMBER> å fig <NUMBER> analysis observed lopinavirritonavir shows hydrogen bonds made nine acceptors two donors whereas total number <NUMBER> hydrogen bonds possible fig s<NUMBER> raltegravir <NUMBER> acceptors three donors hbonds formed whereas total number <NUMBER> hydrogen bonds possible similarly drug tipranavir formed eight acceptors two donors hbonds contrast total number <NUMBER> hydrogen bonds possible fig s<NUMBER> md simulation analysis shows promising binding stability drug compounds binding pocket cov<NUMBER> pro pdb id <NUMBER>y<NUMBER>f however believe drugs studied screened repurposing covid<NUMBER> study furthermore tested vitro inhibitory potential needs investigated robust biochemical proteolytic activity assays biophysical structural studies conclusion study reveals potential repurposed antiviral drugs bind active site sarscov<NUMBER> main protease highly specific binding pattern similar crystal bound ␣ketoamide mpro structure three screened drugs lopinavirritonavir raltegravir tipranavir shown strongest binding md simulation study confirmed stability conformational flexibility drugs enzyme active site since drugs identified study known pharmacokinetics standards approved fda human use treatment respective illneses may possible move straight clinical trials per standard approved fda new indication therefore fasten process therapeutics development sarscov<NUMBER> infection molecular dynamics studies performed study screened top three drugs also proving binding conformational stability cov<NUMBER> pro phylogenetic analysis available genomes sarscov<NUMBER> isolated different sources also reveals virus showing sign severing mutation diversification rapidly therefore repurposed drug combinations could used sarscov<NUMBER> pancommunity level furthermore suggest efficacy repurposed drugs study needs experimentally confirmed carrying biochemical structural studies prevention treatment covid<NUMBER> h uman coronaviruses including severe respiratory syndrome coronavirus sarscov <NUMBER> novel coronavirus sarscov<NUMBER> cause pandemics currently effective drugs targeting sarscov sarscov<NUMBER> although plenty media coverage regarding potential drugs hydroxychloroquine azithromycin <NUMBER> drugs avoid nonsteroidal antiinflammatories angiotensinconverting enzyme inhibitors <NUMBER> advice harmful using standard care people viral illnesses clinical groups appropriately distanced advice evidence available <NUMBER> <NUMBER> current covid<NUMBER> epidemic suggests urgent investment repurposed drugs necessary strategy <NUMBER> drug repurposing involves identifying new uses approved investigational drugs outside scope original intended approved medical use <NUMBER> <NUMBER> represents appropriate alternative strategy current era reducing development time costs compared de novo drug discovery development relatively new term process happening many years simple terms involves identifying existing compounds biological plausibility vitro vivo silico studies serendipitous clinical observation provision compounds patients compassionate use clinical trials setting current pandemic raises many ethical questions include example opportunity cost patient given drug little efficacy precludes taking effective one selection hospitalbased clinical trial reduces ability patients partake better trials future needs clear however drug repurposing strategy requires time funding drug development knowledge understand use drugs appropriately prevent toxicity required clinical pharmacology clinical trial knowledge support use albeit based smaller shorter studies compared full dossier needed new chemical entity must still undertaken appropriate drug prescribing registration occur sometimes however bioequivalence studies required registration clinical use new strength formulation indication morphine sulfate pentahydrate required single randomised controlled trial literature review <NUMBER> although methodology around time profile drug repurposing recently risen three main reasons firstly using existing drugs new purposes reduces drug development time utilising already known drugs including pharmacokinetics pharmacodynamics common uncommon toxicities dosing schedule mechanism action means secondly steps preclinical early clinical development phases bypassed <NUMBER> drug repurposing presents significantly faster pathway phase <NUMBER> trials compared traditional drug discovery development safety dosing toxicity profile new drugs known thirdly result developmentrelated financial investment substantially reduced <NUMBER> discovery development new drugs remains essential new drug requires <NUMBER> years processing time investment us<NUMBER> billion achieve regulatory approval contrast repurposing existing drug new therapeutic use takes average <NUMBER> years obtain approval investment us<NUMBER> million <NUMBER> combination traditional drug development drug repurposing therefore prudent make timely inroads treating human coronaviruses efficiently deliver significant impact human health drug repurposing used successfully many clinical settings extensively reviewed pushpakom colleagues <NUMBER> famous example incidental discovery sildenafil viagra pfizer originally used relieve symptoms angina also effective erectile dysfunction receiving united states food drug administration approval <NUMBER> <NUMBER> within first <NUMBER> years approval nearly <NUMBER> million men taking sildenafil us alone annual sales us<NUMBER> billion <NUMBER> similarly thalidomide first marketed <NUMBER> sedative perspectives mja <NUMBER> <NUMBER> ▪ <NUMBER> june <NUMBER> withdrawn <NUMBER> caused skeletal defects <NUMBER> <NUMBER> children thirty years later antiangiogenic actions thalidomide discovered making attractive drug repurpose cancer treatment within <NUMBER> years thalidomide approved treatment multiple myeloma <NUMBER> thalidomide story shows drug ever understood completely repositioning matter unlikely often remains possibility <NUMBER> time important middle pandemic however research development funding often available pharmaceutical industry significant government investment therefore needed • pharmacology scientists • drug repurposing groups around australia work national drug discovery centre led walter eliza hall institute clinicians immunology microbiology infectious diseases clinical pharmacology enable drug options provide knowledge clinical trial design • experts translational drug development including clinical pharmacologists pharmacists clinician trialists infectious diseases although media commonly appear willing portray development laboratory miracle drug long way rediscovering drugs laboratory understanding mechanism action doseresponse relationship inhibitory effective concentrations efficacy safety humans chemicals affect pathophysiology people disease doses use timing important new lab discoveries revisited older work cell lines underpowered poorly designed clinical trials even biologically plausible assumed mean drug certain dose regimen used patients recent example covid<NUMBER> era president donald trump announced antimalarial hydroxychloroquine available patients united states shown encouraging early results treating covid<NUMBER> <NUMBER> announcement followed number letters concern clinicians scientists <NUMBER> us food drug administration clarified use drug context still requires clinical trial registration <NUMBER> appropriate method developing repurposed drug interest us president tweeting use theoretical proposition world pandemic hope must tempered clinical scientific reality funding deliver translational knowledge specifically must cognisant fact use drugs may cause toxicity case fatal arrhythmias doses likely needed antiviral efficacy toxicity without efficacy worse still use drugs may reduce opportunities patient receive another useful therapy stifle investment potentially beneficial options second similar example two antivirals used treating human immunodeficiency virus infection lopinavir ritonavir also touted potential treatment covid<NUMBER> clinical trial reported combination ineffective also cause toxicity <NUMBER> recent media coverage reported similar toxicity <NUMBER> remdesivir nucleotide analogue prodrug inhibits viral rna polymerases shown vitro activity sarscov<NUMBER> supportive data recent pharmaceutical company funded peer reviewed study <NUMBER> severe covid<NUMBER>positive patients <NUMBER> clinical improvement observed <NUMBER> <NUMBER> patients <NUMBER> trials currently underway major issue highlighted study <NUMBER> one wish highlight drug repurposing field moves forward study design including appropriate drug dosage regimen new indication must based sound biology immunology pharmacology clinical pharmacology deliberations study around choice dose provided thus remains unclear whether lopinavirritonavir study <NUMBER> negative drugs work pharmacology knowledge inadequate optimal dose comedications incorrect discussion authors state <NUMBER> effective concentrations ec <NUMBER> suggest inadequate dosing virus example ec <NUMBER> lopinavir vitro sarscov ranged <NUMBER> <NUMBER> μgml although studies reported lopinavir inactive higher concentrations <NUMBER> μgml required inhibition authors also question whether ec <NUMBER> value adequate threshold whether unbound lopinavir concentrations human plasma doses used sufficient inhibition sarscov<NUMBER> importantly lopinavir exposure study measured critically unwell patients different doseexposure relationships chronically unwell patients owing role third spacing also effects inflammation drug clearance therefore unclear whether study negative drugs work rather pharmacology knowledge inadequate move field forward rapidly firstly need integrative antiviral drug repurposing methodology us systems pharmacologybased network medicine platform developed <NUMBER> quantifying interplay human coronavirushost interactome drug targets human proteinprotein interaction network potential antihuman coronavirus repurposable drugs eg melatonin mercaptopurine sirolimus validated enrichment analyses druggene signatures human coronavirusinduced transcriptomics data human cell lines three potential drug combinations identified eg sirolimusdactinomycin mja <NUMBER> <NUMBER> ▪ <NUMBER> june <NUMBER> <NUMBER> mercaptopurinemelatonin toremifeneemodin <NUMBER> helpful shortcut enable clinical pharmacology platform developed future clinical trials also considerable discussion angiotensinconverting enzyme <NUMBER> ace<NUMBER> inhibitors detrimental covid<NUMBER> treatment <NUMBER> ace<NUMBER> monocarboxypeptidase homologue ace negatively regulating reninangiotensin system converting angiotensin ang ii ang<NUMBER> thereby reducing ang ii primary effector reninangiotensin system decreasing vasoconstriction increasing production vasodilatory ang<NUMBER> ace<NUMBER> membrane bound role membrane bound versus soluble ace<NUMBER> unclear human pathogenic coronaviruses bind target cells ace<NUMBER> expressed epithelial cells lung intestine kidney blood vessels ace<NUMBER> substantially increased patients type <NUMBER> type <NUMBER> diabetes along patients hypertension often treated ace inhibitors ang ii type <NUMBER> <NUMBER> receptor blockers upregulation ace<NUMBER> common patient groups ace<NUMBER> levels also increased ibuprofen therefore hypothesised increased expression ace<NUMBER> occurs treatment many people diabetes hypertension would facilitate infection covid<NUMBER> <NUMBER> readers interested field activators ace<NUMBER> diminazene xnt <NUMBER>dimethylamino ethylamino<NUMBER>hydroxymethyl<NUMBER>methylphenyl sulfonyloxy<NUMBER>hxanthene<NUMBER>one reduce mrna levels renin ace angiotensinogen <NUMBER> receptor receptors proinflammatory cytokines increase levels antiinflammatory cytokine interleukin<NUMBER> occurs humans chemicals terms toxicity efficacy dosage known <NUMBER> distinction using thorough knowledge biology pharmacology physiological reninangiotensin system outcomes us multicentre doubleblind study patients covid<NUMBER> requiring inpatient hospital admission randomised <NUMBER> pharmacologically plausible dose losartan angiotensin receptor blocker placebo <NUMBER> days httpsclini caltr ialsgov ct<NUMBER>shownct<NUMBER> <NUMBER> significant interest drugs available appears time focus health care driven drug repurposing initiatives input pharmaceutical industry together experienced scientists clinicians medicines regulators enable us rapidly assess test potentially efficacious drugs ease burden pandemics covid<NUMBER> limited lack effective sarscov<NUMBER> antiviral drugs although steroidal antiinflammatory treatment <NUMBER> helpful variety potential antiviral targets sarscov<NUMBER> considered including <NUMBER> spike protein replicase based upon previous successful antiviral drug development hiv<NUMBER> <NUMBER> hepatitis c sarscov<NUMBER> main protease mpro appears attractive target drug development <NUMBER> show existing pharmacopeia contains many drugs potential therapeutic repurposing <NUMBER> selective potent inhibitors sarscov<NUMBER> mpro screened collection <NUMBER> drugs <NUMBER> previous history use humans compounds inhibit activity mpro vitro primary <NUMBER> screen found <NUMBER> compounds activity mpro overall hit rate <NUMBER> subsequent dose <NUMBER> validation studies demonstrated <NUMBER> dose responsive hits ic<NUMBER> <NUMBER> m hits screen <NUMBER> enriched hepatitis c ns<NUMBER>a protease targeting drugs including boceprevir ic<NUMBER> m <NUMBER> ciluprevir <NUMBER>m narlaprevir ic<NUMBER>m telaprevir <NUMBER>m results demonstrate <NUMBER> existing approved drugs inhibit sarscov<NUMBER> mpro screen saturation approved <NUMBER> drugs feasible warranted taken together work suggests previous largescale commercial <NUMBER> drug development initiatives targeting hepatitis c ns<NUMBER>a viral protease revisited <NUMBER> previous lead compounds may potent sarscov<NUMBER> mpro boceprevir suitable <NUMBER> rapid repurposing <NUMBER> sars virus sarscov<NUMBER> cause covid<NUMBER> pandemic zoonotic coronaviruses <NUMBER> found bats infect humans initial symptoms sarscov<NUMBER> infection include fever myalgia <NUMBER> cough headache infection usually resolves without active medical intervention subset <NUMBER> cases infection progress viral pneumonia variety complications including acute lung <NUMBER> targetable activities covid<NUMBER> coronavirus mpro seems likely choice rapid drug <NUMBER> accelerate drug development employed drug repurposing strategy approach utilizing <NUMBER> previously approved drugs new indications <NUMBER> previous work suggests libraries enriched known <NUMBER> bioactive druglike compounds provide best opportunity finding new lead compounds <NUMBER> thus <NUMBER> attempted selective optimization side activities sosa approach <NUMBER> rapid cost effective <NUMBER> means identify candidate hits minimizing number compounds screened sosa <NUMBER> approach proceeds two steps first limited set carefully chosen structurally diverse well<NUMBER> characterized drug molecules screened approved drugs bioavailability toxicity efficacy <NUMBER> human therapy already demonstrated <NUMBER> <NUMBER> screen much available approved drug <NUMBER> space possible easily accessible format chose screen broad institute drug repurposing <NUMBER> library <NUMBER> compounds see table s<NUMBER> <NUMBER> represents half approximately <NUMBER> <NUMBER> approved experimental drugs known human clinical medicine <NUMBER> significant cost time <NUMBER> advantages realized drug repurposing accelerate preclinical phase development <NUMBER> streamline clinical trials focus efficacy rather safety <NUMBER> repositioning existing approved drugs capacity inhibit covid<NUMBER> virus replication <NUMBER> infection would profound utility immediately impact health care current pandemic <NUMBER> drugs clinical use specifically targeting coronavirus replication major advantage <NUMBER> approach taken screening drugs history previous clinical use focusing <NUMBER> compounds known properties terms pharmacokinetics pk pharmacodynamics pd <NUMBER> toxicity thus broad repurposing library screened consists compounds suitable rapid <NUMBER> translation human efficacy trials <NUMBER> began assay development selecting potentially suitable synthetic mpro substrates compared <NUMBER> catalyzed hydrolysis curves <NUMBER> fluorescently labeled substrates acabutleleuglnafc <NUMBER> <NUMBER> dabcylvklqedans acvklqafc dabcyltsavlqsgfrkmedans <NUMBER> mca<NUMBER> <NUMBER> chose use recently published acabutleleuglnafc <NUMBER> abu<NUMBER>aminobutyrate tletbutylglycine synthetic noncanonical aminoacid containing peptide <NUMBER> mpro readily cleaves preferred sequence compared native vklq sequence <NUMBER> fig <NUMBER>a <NUMBER> substrates dabcyltsavlqsgfrkmedans mcaavlqsgfrkdnpknh<NUMBER> <NUMBER> drastically lower rates mpro catalyzed hydrolysis considered assay <NUMBER> development fig <NUMBER>a determine concentration ratios mpro substrate next preformed <NUMBER> twodimensional titration chose <NUMBER>nm mpro <NUMBER>µm substrate balance relatively modest <NUMBER> mpro protein requirement robust fluorescence intensity fig <NUMBER>b screening broad library <NUMBER> piloted assay conditions nih clinical collections library <NUMBER> compounds <NUMBER> calculated zfactor plate <NUMBER> <NUMBER> fig <NUMBER>c zfactor score suitability <NUMBER> assays highthroughput screening derived equation z factor <NUMBER> − <NUMBER> − <NUMBER> σ standard deviation µmean ppositive controls nnegative controls score greater <NUMBER> <NUMBER> indicates screenable assay although promising compounds identified smaller library <NUMBER> demonstrated assay sufficiently robust screening much larger broad repurposing <NUMBER> library <NUMBER> window considered zscore ≤ <NUMBER> calculated zscore δrfu <NUMBER> minutes <NUMBER> corresponding linear portion curve xaxis indicates arbitrary compound number arranged <NUMBER> increasing zscore zfactor two nih clinical collection <NUMBER>well plates pink circles indicate <NUMBER> negative control dmso black circles represent positive controls protein zfactor calculated <NUMBER> <NUMBER> <NUMBER> plates <NUMBER> <NUMBER> respectively axis represents change rfu <NUMBER> minutes <NUMBER> <NUMBER> concept drug repurposing utilize existing therapeutic drugs treat new disease indication <NUMBER> approach particularly relevant covid<NUMBER> potential accelerated clinical <NUMBER> impact compared de novo drug development systematic approach facilitate drug repurposing <NUMBER> recently described <NUMBER> http wwwbroadinstituteorgrepurposing made large collection <NUMBER> drugs previous history use humans available high throughput screening acquired <NUMBER>well density using optimized kinetic mpro assay described fig <NUMBER> overall repurposing <NUMBER> strategy described fig <NUMBER>a conducted single point screen <NUMBER> m compound concentration <NUMBER> observed <NUMBER> compounds activity sarscov<NUMBER> mpro overall hit rate <NUMBER> <NUMBER> compounds screened parallel natural amino acid substrate acvklqafc well <NUMBER> kinetically preferred substrate acabutleleuglnafc fig <NUMBER>b individual compounds shown <NUMBER> table <NUMBER> virtually hit broad library zscore ≤ <NUMBER> validated doseresponsiveness suitable <NUMBER> compounds passing filter satisfactory curve fitting potency ordered powder re<NUMBER> validated future efforts test selectivity orthogonal assays suitability although outside <NUMBER> scope report determination viral antireplicative properties well toxic profile required <NUMBER> dosage determined goal paradigm find suitable candidates development <NUMBER> tools probing underlying mechanisms sarscov<NUMBER> well translational potential b <NUMBER> screen broad repurposing library library screened concentration <NUMBER>µm <NUMBER> acvklqafc black acabutleleuglnafc purple hit window considered <NUMBER> compounds falling zscore ≤ <NUMBER> substrates consisted <NUMBER> compounds compounds <NUMBER> ordered average zscore <NUMBER> <NUMBER> validated hits primary screen conducting <NUMBER>point doseresponse analysis drug <NUMBER> concentration range <NUMBER> m <NUMBER> nm <NUMBER>fold dilution series doseresponse analysis repurposing library using approach derived docking score compound see table s<NUMBER> <NUMBER> broad repurposing library docking scores observe poor correlation pearson r<NUMBER> <NUMBER> mpro docking score zscore protease inhibition assay fig <NUMBER>a furthermore top hits <NUMBER> screen also exhibit weak correlation pearson r<NUMBER> compound potency <NUMBER> docking score fig <NUMBER>b <NUMBER>nm final concentration reaction buffer detailed added multiflo fx liquid <NUMBER> dispenser using <NUMBER>µl cassette compounds incubated mpro <NUMBER> minutes rt <NUMBER>ul substrate <NUMBER>um final concentration either acvklqafc acabutleleuglnafc <NUMBER> dispensed plate read using cytation <NUMBER> multimode reader immediately <NUMBER> nm excitation <NUMBER> <NUMBER> nm emission wavelengths every <NUMBER> minutes <NUMBER> minutes data analyzed using biotek <NUMBER> gen<NUMBER> software microsoft excel graphpad prism <NUMBER> <NUMBER> <NUMBER> hit compounds ordered broad institute preplated <NUMBER>well format greiner <NUMBER> <NUMBER> <NUMBER>point serial dilutions <NUMBER>fold <NUMBER>nl per well mpro <NUMBER>nm final concentration substrate ac<NUMBER> abutleleuglnafc <NUMBER>µm final concentration dispensed manner described coronavirus disease <NUMBER> covid<NUMBER> highly contagious respiratory disease resulting lifethreatening novel coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> spread rapidly throughout globe causing <NUMBER> million infections <NUMBER> thousand deaths early may <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> enveloped rna virus belongs genus betacoronavirus family coronaviridae includes wellknown severe acute respiratory syndrome coronavirus sarscov well middle east respiratory syndrome coronavirus merscov <NUMBER> advancement management coronaviruses viruses like influenza virus h<NUMBER>n<NUMBER> ebola infections provided insight treating covid<NUMBER> <NUMBER> active clinical trials covid<NUMBER> performed <NUMBER> <NUMBER> chloroquine <NUMBER> <NUMBER> hydroxyl analogue hydroxychloroquine <NUMBER> lopinavirritonavir <NUMBER> <NUMBER> <NUMBER> remdesivir <NUMBER> <NUMBER> developed treating malaria human immunodeficiency virus hiv ebola virus respectively provided benefits treat covid<NUMBER> tested ongoing trials although covid<NUMBER> less fatal sars mers older patients comorbidities tend experience severe symptoms making vulnerable majority sarscov<NUMBER> infected patients displayed mild symptoms generally good prognosis classified mild covid<NUMBER> <NUMBER> <NUMBER> however large proportion patients especially among older men underlying chronic diseases rapidly progressed severe covid<NUMBER> suffered respiratory distress requiring emergent medical interventions <NUMBER> unfortunately evidence randomized clinical trials supporting vaccines efficient treatment covid<NUMBER> <NUMBER> <NUMBER> additionally recent studies shown important roles host immune responses protection pathogenesis respiratory viral infections instance sarscov merscov influenza viruses <NUMBER> <NUMBER> liao et al <NUMBER> reported increased immune cell recruitment covid<NUMBER> patients suggested crucial role cd<NUMBER> cells successful viral control proposed support therapeutic strategies target myeloid cell compartment treat covid<NUMBER>associated inflammation however little known drug screens diseaserelevant cell types drug repurposing essential universal strategy development new drugs <NUMBER> may facilitate discovery new mechanisms action existing drugs less timeconsuming costeffective let alone existing pharmaceutical supply chains formulation distribution <NUMBER> <NUMBER> considering rna virus exhibits considerable degree sequence variation drugs targeting host factors may cause less mutational resistance effective broad antivirus spectrum potential hence urgent need identify potential therapeutics new strategies emerging infectious diseases repurposing clinically assessed drugs represents one practicable strategies rapid identification treatments combat covid<NUMBER> study analyzed publicly available singlecell rna sequencing scrnaseq dataset bronchoalveolar lavage fluid balf collected mild severe cases well bulk rnaseq balf covid<NUMBER> patients different experiments figure <NUMBER> data mining performed using library integrated networkbased cellular signatures lincs <NUMBER> drug perturbation database identify potential therapies covid<NUMBER> disease total <NUMBER> candidates different courses covid<NUMBER> independent cell subtypes identified <NUMBER> clinical trials covid<NUMBER> including lopinavirritonavir <NUMBER> dexamethasone niclosamide lenalidomide hydrocortisone metformin atorvastatin sildenafil verapamil subsequently utilized side effect prediction based l<NUMBER> sepl<NUMBER> project predict adverse drug reactions adrs constructed drugadr association <NUMBER> <NUMBER> findings may aid rapid preclinical clinical evaluation therapeutics provide important drug discovery pipeline accelerate facilitate development potential treatments covid<NUMBER> genebarcode matrix files <NUMBER> donors containing <NUMBER> mild cases <NUMBER> severe cases lung balf <NUMBER> healthy control lung tissues downloaded ncbi gene expression omnibus database accession id gse<NUMBER> <NUMBER> expression matrices loaded r statistical analysis platform using seurat v<NUMBER> <NUMBER> keeping cells gene number <NUMBER> <NUMBER> unique molecular identifier umi count <NUMBER> mitochondrial gene percentage <NUMBER> total <NUMBER> cells collected three healthy subjects three mild covid<NUMBER> patients three severe covid<NUMBER> patients used analyses also collected list differentially expressed genes degs sarscov<NUMBER>infected lung balf using bulk rnaseq analysis compare singlecellbased data deg list obtained chinese national genomics data center httpsbigdbigaccn accession id cra<NUMBER> <NUMBER> lognormalize method seurat used normalizing filtered genebarcode matrix principal component analysis pca done using top <NUMBER> variable genes uniform manifold approximation projection umap performed top <NUMBER> principal components visualizing cells graphbased clustering performed pcareduced data seurat v<NUMBER> <NUMBER> mast seurat v<NUMBER> used perform differential analysis degs identified comparing cluster three groups genes average log<NUMBER>fc <NUMBER> adjusted pvalue <NUMBER> deemed degs degs first sorted log<NUMBER>fc values upregulated downregulated genes chosen identify drugs compounds lincs database using connectivity map linked user environment clue platform <NUMBER> drug connectivity score cs negative value smaller <NUMBER> used determine candidate drugs compounds covid<NUMBER> database international clinical trials registry platform ictrp httpswwwwhointictrpen updated may <NUMBER> th <NUMBER> searched clinical trials information associated drugs onlabel offlabel adverse drug reactions adrs candidate drugs collected sepl<NUMBER> database httpsmaayanlabnetsepl<NUMBER> sepl<NUMBER> data include onlabel adrs fdaapproved drugs collected sider <NUMBER> offlabel adrs pharmgkb database <NUMBER> based postmarketing adr reports fda adverse event report system faers study highlighted identification different therapeutic effects varied disease course high variability cellular compartments underlying disease progression drug repurposing profiles major cell subtypes included b nk cells macrophages epithelial cells total <NUMBER> scrnaseq balf samples including <NUMBER> healthy cases <NUMBER> mild cases <NUMBER> severe cases collected publicly available scrnaseq data supplemental table s<NUMBER> quality filtering approximately <NUMBER> gene expression values <NUMBER> cells collected clustering analysis identified six major clusters macrophage nk figure s<NUMBER> determined based unique signature genes cd<NUMBER> macrophage cell il<NUMBER>r cd<NUMBER> cd<NUMBER> cell cd<NUMBER>a cd<NUMBER> cell ms<NUMBER>a<NUMBER> b cells tppp<NUMBER> epithelial cells respectively supplemental figure s<NUMBER> compared six major clusters across healthy mild severe covid<NUMBER> cases identified differentially expressed genes two courses supplemental tables s<NUMBER>s<NUMBER> connecting lincs database smallmolecule perturbations gene expression identified candidate drugs compounds reverse upregulated downregulated genes via clue platform closer cs <NUMBER> score indicating complete reversal higher chance identification drugadverse effect associations upregulated downregulated degs words drugs may show better response reverse expression degs upregulated downregulated major cell subtypes balf total <NUMBER> candidates selected clue cs lower <NUMBER> based degs among three comparisons two courses supplementary table s<NUMBER> enable prioritization known drugs preclinical clinical evaluation therapy efficiency sarscov<NUMBER> summary among major cell subtypes patients disease course publicly disclosed clinical trial phases annotated tables <NUMBER> supplementary table s<NUMBER> provides complete list potential anticoronavirus agents current analysis focusing fda approved drugs experimental agents already tested clinical trials select candidates mild cases drugs compounds ranked according css supplementary table s<NUMBER> <NUMBER> candidate drugs identified compared controls mild vs healthy group <NUMBER> involved one cell subtype table <NUMBER> including hiv protease inhibitors lopinavirritonavir <NUMBER> combination phase <NUMBER> glucocorticoid receptor agonist dexamethasone phase <NUMBER> <NUMBER> dna replication inhibitor niclosamide phase <NUMBER> antineoplastic lenalidomide phase <NUMBER> tubulin inhibitor flubendazole widely used treating intestinal parasites potent inducer autophagy initiation decrease infection dendritic cells hiv <NUMBER> azacytidine could partially reverse aberrant dna methylation phase clinical trial combination chemotherapy conducted assess therapeutic effects children leukemia combination apr<NUMBER> myelodysplastic syndrome phase <NUMBER> clinical trial <NUMBER> bcl inhibitor abt<NUMBER> exhibits potential proapoptotic antineoplastic activities <NUMBER> <NUMBER> lopinavir widely used treatment hiv formulated combination ritonavir increase halflife lopinavir <NUMBER> <NUMBER> <NUMBER> repurposing analysis severe covid<NUMBER> patients <NUMBER> potent drugs also selected severe cases compared controls severe vs healthy group according average cs replicates <NUMBER> involved one cell subtype figure <NUMBER>b supplementary tables s<NUMBER> s<NUMBER> listed table <NUMBER> protein synthesis inhibitor brefeldina used inhibit entry viruses like human papillomavirus polyomavirus <NUMBER> egress others herpesviruses paramyxoviruses <NUMBER> indirubin active ingredient traditional chinese medicine tcm danggui longui wan potent activity myelocytic leukemia <NUMBER> therapeutic potential iavinfection <NUMBER> total <NUMBER> candidate drugs identified severe cases compared mild ones severe vs mild group <NUMBER> involved one cell subtype figure <NUMBER>c supplementary tables s<NUMBER> s<NUMBER> listed table <NUMBER> nine drugs drugs selected three separate cell types including fostamatinib syk inhibitor ver<NUMBER> hsp inhibitor ku<NUMBER> mtor inhibitor pik<NUMBER> pi<NUMBER>k inhibitor linsitinib igf<NUMBER> inhibitor tak<NUMBER> p<NUMBER> mapk inhibitor y<NUMBER> rhoassociated kinase inhibitor az<NUMBER> raf inhibitor lestaurtinib flt<NUMBER> inhibitor group except lopinavir also following listed <NUMBER> drugs clinical trials treatment covid<NUMBER> table <NUMBER> syk inhibitor fostamatinib produced clinicallymeaningful responses adult persistent chronic immune thrombocytopenia two parallel phase <NUMBER> randomized trials <NUMBER> hsp inhibitor ver<NUMBER> regulates kaposis sarcomaassociated herpesvirus lytic replication highlights potential novel antiviral agent <NUMBER> flt<NUMBER> inhibitor lestaurtinib obtained orphan drug approval fda acute myeloid leukemia <NUMBER> phase ii trial advanced multiple myeloma phase trials prostate cancer shown figures <NUMBER>a <NUMBER>b supplemental table s<NUMBER> lopinavir one identified three comparisons interestingly ritonavir common two analyses <NUMBER> additional common drugs sb<NUMBER> abt<NUMBER> jte<NUMBER> brefeldina pkcbetainhibitor indirubin gw<NUMBER> flubendazole tyrphostinag<NUMBER> memantine calyculin kinetinriboside ascorbylpalmitate on<NUMBER> mirin verrucarina emetine tpca<NUMBER> rhokinaseinhibitoriiirockout pd<NUMBER> nvpauy<NUMBER> example glycogen synthase kinase inhibitor sb<NUMBER> acts neuroprotectant <NUMBER> prevents cardiac ischemia <NUMBER> jte<NUMBER> cannabinoid receptor inverse agonist producing antiinflammatory effects <NUMBER> demonstrate usefulness strategy accomplished identification therapeutic drugs transcriptional changes balf covid<NUMBER> patients bulk rnaseq data <NUMBER> ten efficient candidates identified using analysis pipeline two including glycogen synthase kinase inhibitor sb<NUMBER> ppar receptor antagonist gw<NUMBER> also included singlecellbased candidate lists supplemental table s<NUMBER> investigations necessary characterize adrs central consideration drug development <NUMBER> therefore conducted computational approach using sepl<NUMBER> database predictive relationships drugs emergence adrs supplemental tables s<NUMBER> s<NUMBER> figure <NUMBER> shows heatmap top <NUMBER> drugadr association onlabel figure <NUMBER>a offlabel figure <NUMBER>b adrs findings highlighted drugadr associations may lead inform clinical decisions regarding treatments covid<NUMBER> covid<NUMBER> spread rapidly proven vaccine drug yet identified treat generally speaking several ways control prevent emerging coronavirus disease including antivirals smallmolecule drugs biologics vaccines <NUMBER> <NUMBER> due lack effective therapeutic agents long development cycles vaccines therefore reasonable consider repurposing existing drugs compounds covid<NUMBER> drug repurposing potentially important strategy discovery existing medicines tackle covid<NUMBER> <NUMBER> gordon et al <NUMBER> identified <NUMBER> highconfidence sarscov<NUMBER>human proteinprotein interactions drug repurposing additional study <NUMBER> tested antiviral activity <NUMBER> fda approved drugs sarscov<NUMBER> previously shown inhibit sarscov merscov another research team <NUMBER> conducted highthroughput analysis reframe library identify <NUMBER> candidates existing drugs prevent covid<NUMBER> virus replicating mammalian cells study <NUMBER> based public data patients pulmonary fibrosis database lincs several drugs identified covd<NUMBER> targets ace<NUMBER> host immune responses particularly important protection pathogenesis respiratory viral infections like sarscov merscov influenza viruses <NUMBER> <NUMBER> liao et al <NUMBER> observed nk cells accumulated epithelial cells decreased covid<NUMBER> patients compared controls meanwhile macrophages dysregulated cell compartments differed mild severe disease courses nk cells decreased severe cases cd<NUMBER> cells increased mild cases however drug screening diseaserelevant cell types still unclear analyzed publicly available data covid<NUMBER> patients performed data mining using lincs l<NUMBER> database identify potential therapies covid<NUMBER> disease sepl<NUMBER> database predict side effects approach different previous methods drug repurposing coronavirus since merely rapidly identify likely effective therapeutic agents preventing treating covid<NUMBER> tries filter specific medications patients disease courses furthermore data transcriptome derived human samples real patients two independent sets experiments lastly explore underlying risk factors associated side effects candidates overall data guide future development therapies different durations covid<NUMBER> viral respiratory infections study several limitations note first public scrnaseq data small number clinical samples n<NUMBER> without available patient information makes comparisons studies difficult fast pace expected large number published literature using patient samples candidate lists may need revised second findings may apply children sequencing data adults future work largescale data mining would help us better identification antiviral drugs pandemic covid<NUMBER> represents greatest global public health crisis generation far proven vaccines therapies identified based study thoroughly investigated potential candidates treatment covid<NUMBER> progression predicted possible adverse effects findings guide additional repurposing studies tailored different stages disease progression authors declare competing interests jh ch mw kg designed project collected data performed analysis prepared figures kg zw collected data prepared figures wrote manuscript pg performed analysis prepared tables qp revised manuscript work partially supported national institutes health p<NUMBER>gm<NUMBER> pilot grant jh codes data available httpsgithubcomguokai<NUMBER>covid<NUMBER> table <NUMBER> list potential drugs treating covid<NUMBER> based lincs database degs mild healthy samples b cd<NUMBER> cd<NUMBER> epithelial nk cells macrophage connectivity scores calculated clue platform asterisk represents clinical trial efficacy covid<NUMBER> disease indicates drugs meeting sc <NUMBER> criteria indicates drugs meeting criterion table <NUMBER> list potential drugs treating covid<NUMBER> based lincs database degs severe mild samples b cd<NUMBER> cd<NUMBER> epithelial nk cells macrophage connectivity scores calculated clue platform asterisk represents clinical trial efficacy covid<NUMBER> disease indicates drugs meeting sc <NUMBER> criteria indicates drugs meeting criterion input publicly available scrnaseq data transcriptomic data balf covid<NUMBER> patients lincs database using clue platform candidates selected national center advancing translational sciences ncats developed online open science data portal covid<NUMBER> drug repurposing campaign named opendata goal making data across range sarscov<NUMBER> related assays available realtime assays developed cover wide spectrum sarscov<NUMBER> life cycle including viral human host targets total <NUMBER> compounds tested full concentrationresponse ranges across multiple annotated small molecule libraries including approved drug repurposing candidates experimental therapeutics designed modulate wide range cellular targets goal support research scientists clinical investigators public health officials open data sharing analysis tools expedite development sarscov<NUMBER> interventions prioritize promising compounds repurposed drugs development treating covid<NUMBER> pandemic atypical pneumonia coronavirus disease covid<NUMBER> caused novel beta coronavirus sarscov<NUMBER> significantly impacted global society economic public health standpoint result biomedical scientists around world academic government laboratories biotechnology companies pharmaceutical corporations mobilized understand disease develop therapeutic interventions mitigate impact develop protective vaccines rapid research response resulted initiation repurposing clinical trials range agents including three received emergency use authorizations euas federal drug agency fda united states remdesivir <NUMBER> chloroquine hydroxychloroquine drugs others entered clinical trials prioritized based clinical observations contemporary understanding sarscov<NUMBER> biology addition numerous drug repurposing efforts undertaken screening approved experimental agents <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> yet many published reports solely focus active hits disclose majority usually <NUMBER> tested compounds inactiveinformation critical understanding validating disease drug mechanismofaction nominating repurposed novel clinical lead candidates rapid open sharing complete screening datasets including negative results greatly accelerate research discovery process essential covid<NUMBER> pandemic response address national center advancing translational sciences ncats developed online open science data portal covid<NUMBER> drug repurposing campaign named opendata goal making data across range sarscov<NUMBER> related assays available realtime figure <NUMBER> approach allows researchers rapid access drug repurposing datasets support subsequent mechanistic study compounds perturb viral infectivity <NUMBER> manner open data sharing facilitate important insight associated publications towards development interventions covid<NUMBER> opendata dashboard first shared publicly may <NUMBER> <NUMBER> makes quantitative highthroughput screening hts data detailed protocol information available every assay screened goal provide clinicians researchers userfriendly tool allows direct comparison compounds across multiple assays primary concentrationresponse data made freely available direct download httpsopendatancatsnihgovcovid<NUMBER> live virus infectivity counterscreens could flag false positives due assay interference artifacts cytotoxic effects assays encompass proteinbased assays sarscov<NUMBER> spike proteinace<NUMBER> interaction viral enzyme activity assays addition cellbased pseudotyped particle entry live virus cytopathic effect assays additional assays validated screened list expanded updated importantly assay documentation including assay overview methodology detailed assay protocols available readily retrievable opendata site facilitate adoption ensure laboratories replicate assays table <NUMBER> <NUMBER> trials importantly unique compounds <NUMBER> <NUMBER> least one annotated target providing insight potential mechanismofaction underlying active compounds perturb sarscov<NUMBER> life cycle manner key goal opendata portal allow users view inspect concentrationresponse data compounds screened limited active compounds complete datasets including full concentrationresponse information compound annotations directly downloaded providing extensive information analysis data mining addition userfriendly heatmap visualization implemented allow direct convenient comparison compound activity across panel assays tested including orthogonal counter assays figure <NUMBER> currently opendata portal queried search term eg drug name primary mechanismofaction gene symbol ordered assay data field increased interpretability highlevel overview compound activity across multiple different assays displayed heatmap sort functions based curve class efficacy potency heatmap darker colors indicate compounds potent efficacious ie highquality actives lighter colors indicate less potent efficacious compounds lowquality actives beige represents inactive compounds slashed boxes denote compoundsassays yet tested addition ncats covid<NUMBER> drug repurposing screening data described two regularly updated external resource sections also incorporated opendata portal collection publications focusing small molecule drug repurposing screens list publicly available multiomics datasets generated evaluate aberrant biochemical pathways identify putative biomarkers covid<NUMBER> summary opendata portal described herein designed share ncats sarscov<NUMBER> complete datasets openly without restriction importantly realtime given time urgency covid<NUMBER> pandemic response addition constructed portal hts datasets studies published investigators integrated portal allow global view covid<NUMBER> drug repurposing efforts enable comparison screening hits across multiple centers envisage site could act central portal unique resource compare complete repurposing data generated public private sectorsthe authors welcome contributions external hts data hope platform help research scientists clinical investigators public health officials facilitate open data sharing analysis expedite development sarscov<NUMBER> interventions prioritize promising compounds repurposed drugs development treating covid<NUMBER> opendata portal objective goal opendata portal provide actionable data validated methodologies global research community support rapid development therapeutics sarscov<NUMBER> assays developed date cover wide spectrum sarscov<NUMBER> life cycle figure <NUMBER> including viral human host targets grouped following five categories based different mechanisms experimental design viral entry viral replication vitro infectivity live virus infectivity counterscreens could flag false positives due assay interference artifacts cytotoxic effects assays encompass proteinbased assays sarscov<NUMBER> spike proteinace<NUMBER> interaction viral enzyme activity assays addition cellbased pseudotyped particle entry live virus cytopathic effect assays additional assays validated screened list expanded updated importantly assay documentation including assay overview methodology detailed assay protocols available readily retrievable opendata site facilitate adoption ensure laboratories replicate assays table <NUMBER> ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint <NUMBER> least one annotated target providing insight potential mechanismofaction underlying active compounds perturb sarscov<NUMBER> life cycle manner key goal opendata portal allow users view inspect concentrationresponse data compounds screened limited active compounds complete datasets including full concentrationresponse information compound annotations directly downloaded providing extensive information analysis data mining addition userfriendly heatmap visualization implemented allow direct convenient comparison compound activity across panel assays tested including orthogonal counter assays figure <NUMBER> currently opendata portal queried search term eg drug name primary mechanismofaction gene symbol ordered assay data field increased interpretability highlevel overview compound activity across multiple different assays displayed heatmap sort functions based curve class efficacy potency heatmap darker colors indicate compounds potent efficacious ie highquality actives lighter colors indicate less potent efficacious compounds lowquality actives beige represents inactive compounds slashed boxes denote compoundsassays yet tested addition ncats covid<NUMBER> drug repurposing screening data described two regularly updated external resource sections also incorporated opendata portal collection publications focusing small molecule drug repurposing screens list publicly available multiomics datasets generated evaluate aberrant biochemical pathways identify putative biomarkers covid<NUMBER> summary opendata portal described herein designed share ncats sarscov<NUMBER> complete datasets openly without restriction importantly realtime given time urgency covid<NUMBER> pandemic response addition constructed portal hts datasets studies published investigators integrated portal allow global view covid<NUMBER> drug repurposing efforts enable comparison screening hits across multiple centers envisage site could act central portal unique resource compare complete repurposing data generated public private sectorsthe authors welcome contributions external hts data hope platform help research scientists clinical investigators public health officials facilitate open data sharing analysis expedite development sarscov<NUMBER> interventions prioritize promising compounds repurposed drugs development treating covid<NUMBER> ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint middle east respiratory syndrome mers respiratory disease caused mers coronavirus merscov <NUMBER> <NUMBER> merscov first reported <NUMBER> saudi arabia spread countries mostly arabian peninsula united arab emirates qatar oman jordan kuwait yemen lebanon march <NUMBER> world health organization reported <NUMBER> confirmed mers cases including <NUMBER> deaths <NUMBER> countries mers spreads among people causing severe complications leads death hence need development effective therapeutic prophylactic agents prevention treatment shown hospital outbreak mers due humantohuman transmission <NUMBER> currently registered treatment vaccine disease merscov infection rather managed drug treatment regime addition preventive measures infection reinfection <NUMBER> several studies demonstrated variety therapeutics inhibit merscov replication cell culture <NUMBER> <NUMBER> review summarize important merscov drug targets ii present therapeutic options available mers describe efficacies iii discuss role peptide research virology importance antimicrobial peptides amps potential therapeutic options mers rapid development computational biology approaches envisaged novel effective mers therapy could developed using amps human coronaviruses broadly classified either alphacoronavirus betacoronavirus merscov belongs betacoronavirus family <NUMBER> causal transmission pathway merscov demonstrated <NUMBER> may originated bats dromedary camels serving intermediate hosts human infection <NUMBER> merscov shown modulate innate immune response antigen presentation mitogenactivated protein kinase mapk apoptotic pathways <NUMBER> structure merscov consists four structural proteins shown fig <NUMBER>a including spike protein envelope e protein membrane protein nucleocapsid n protein protein type transmembrane glycoprotein located viral envelope surface trimer state consists s<NUMBER> s<NUMBER> subunits plays role viral entry binding fusion s<NUMBER> subunit receptorbinding domain rbd fig <NUMBER>b rbd responsible binding cellular receptor dipeptidyl peptidase <NUMBER> dpp<NUMBER> s<NUMBER> subunit involves two regions namely heptad repeats <NUMBER> <NUMBER> hr<NUMBER> hr<NUMBER> fig <NUMBER>c assemble complex called fusion core represents key membrane fusion architecture <NUMBER> <NUMBER> e protein present mainly intracellular membranes virus <NUMBER> plays major role viral assembly budding intracellular trafficking <NUMBER> <NUMBER> surya et al reported coronavirus e proteins <NUMBER> amino acids long predicted least one ␣helical transmembrane <NUMBER> later found e protein total length <NUMBER> amino acid residues <NUMBER> protein component viral envelope plays role virus morphogenesis assembly via interactions viral proteins <NUMBER> e proteins inserted membrane rough endoplasmic reticulum get transported vicinity endoplasmic reticulumgolgi area interact n proteins form particles <NUMBER> interaction eventually interfere fusion cellular viral membranes thus developing fusion peptides great importance peptidebased therapeutic options addition merscov comprised two large polyproteins namely pp<NUMBER>a pp<NUMBER>ab polyproteins cleaved <NUMBER> nonstructural proteins nsps <NUMBER> two proteases papainlike protease plpro nsp<NUMBER> <NUMBER>clike protease <NUMBER>clpro nsp<NUMBER> responsible processing <NUMBER> nsps required replication transcription <NUMBER> plpro responsible cleavage position <NUMBER> develop three nsps whereas <NUMBER>clpro cleaves remaining positions <NUMBER> nsps responsible viral rnadependent rna polymerase activity nsp<NUMBER> primase activity nsp<NUMBER> rna helicase activity nsp<NUMBER> exoribonuclease activity nsp<NUMBER> endoribonuclease activity nsp<NUMBER> <NUMBER> omethyltransferase activity nsp<NUMBER> <NUMBER> <NUMBER> omethyltransferase activity stimulated nsp<NUMBER> acts allosteric activator nsp<NUMBER> <NUMBER> studies reveal coronavirus nsps could used drug targets developing new therapies <NUMBER> <NUMBER> <NUMBER> fig <NUMBER>e shows nsp<NUMBER> <NUMBER>clpro protease bound designed inhibitor structural nonstructural proteins act therapeutic targets various therapeutic options implemented discussed sectionsvarious therapeutic agents merscov infectionändmechanism action peptides antiviral activity various coronaviruses several ways inhibit spread merscov repurposing clinically developed drugs ii using convalescent plasma cp whole blood therapy iii intravenous immunoglobulin ivig iv monoclonal antibodies v therapeutics discussed following subsections repurposing method targeting existing drug molecules treat new diseases repurposing viable target profile developed drug receptor molecule screening compounds different molecule libraries occur repurposing become possible faster pace latest developments computational biology rational design development novel approved agents potent antiviral activity repurposing existing clinically fda approved drugs used target viral entry high throughput screening compounds small molecules helped researchers evaluate large libraries drugs vitro antiviral activity novel targets <NUMBER> <NUMBER> advantages repurposing method saves time ii lowers cost developing new drug <NUMBER> repurposed drugs may potential antiviral effects merscov examples repurposed drugs shown anti b shows spike protein subunits s<NUMBER> s<NUMBER> form fusion core sp signal peptide fp fusion peptide hr<NUMBER> hr<NUMBER> heptad repeats <NUMBER> <NUMBER> tm transmembrane domain cp cytoplasmic domain c shows hr<NUMBER> hr<NUMBER> linker shows merscov structure complexed human dpp<NUMBER> pdb id <NUMBER>l<NUMBER> visualised biovia ds visualizer <NUMBER> e shows structure merscov nsp<NUMBER> protease bound designed inhibitor pdb id <NUMBER>rsp visualised biovia ds visualizer <NUMBER> coronavirus validated activity include ribavirin hexachloropene nitazoxanide homoharringtonine <NUMBER> ribavirin reported antimerscov activity <NUMBER> adverse side effects occurrence hemolysis <NUMBER> nitazoxanide shown vitro activity merscov coronavirus infections inhibiting expression viral nucleocapsid protein <NUMBER> vitro studies show cyclosporine inhibits merscov human monkey cell lines recent study shihchao et al tested antiviral activities resveratrol phytocompound grape seeds red wine showed resveratrol could significantly inhibit merscov nucleocapsid expression <NUMBER> examples use small molecules therapeutic options merscov given table <NUMBER> various studies repurposed drugs employing hybrid two drugs example wilde et al employed alisporivir inhibits replication merscov sarscov however found alisporivir combination ribavirin enhanced antiviral efficacy alisporivir done using cellculture based screening <NUMBER> another study showed combination lopinavirritonavir interferon␤<NUMBER>b found effect marmosets infected merscov <NUMBER> interferons shown potent inhibitors merscov replication <NUMBER> however combination interferonalpha <NUMBER>b ribavirin drugs routinely used treat hepatitis c reduced merscov replication administered rhesus macaques <NUMBER> addition ribavirin interferonalfa<NUMBER>a administered patients severe merscov infection survival improved <NUMBER> another case report lopinavirritonavirbased combination antiviral therapy used merscov infection south korea <NUMBER> tawalah et al evaluated virological clinical progresses response lopinavirritonavir administering different treatment options mers patients study suggested effective therapeutic regimen low dose ribavirinpegylated interferon ˛ combination <NUMBER> several studies shown effectiveness ribavirin coupled interferons <NUMBER> <NUMBER> <NUMBER> mycophenolic acid immunosuppressant drug together interferon␤<NUMBER>b found strong inhibitory action merscov combination mycophenolic acid interferon␤<NUMBER>b lowered ec <NUMBER> <NUMBER> <NUMBER> use convalescent plasma cp whole blood therapy suggested potential treatment infectious diseases mers ebola sars cp use whole blood plasma collected patients recovered viral diseases used treatment outbreaks <NUMBER> cp therapeutically administered specific vaccines drugs available treating diseases <NUMBER> arabi et al analysed feasibility cp therapy well safety clinical laboratory effects critically ill patients merscov infection suggested cp neutralizing antibodies immunotherapeutic hyperimmune immunoglobulins monoclonal antibodies potential treatment merscov infection however study noted largescale screening would required limited availability eligible potential donors sufficient levels antibodies <NUMBER> one drawback cp unavailable lack evidence prove safety efficacy <NUMBER> intravenous immunoglobulin ivig blood product prepared serum generally used treating number autoimmune inflammatory conditions <NUMBER> administration ivig well studied various diseases including heart failure mycobacterial infection epilepsy alzheimers etc <NUMBER> treatment antibodies administered intravenously may lead renal failure thrombosis mers patients <NUMBER> however evidence ivig antimers activity luke et al reported study transchromosomic tc bovines produced human polyclonal immunoglobulin g antibodies neutralized merscov vitro assays animal models <NUMBER> implication study shows potentially offers method manufacture therapeutic immunoglobulin prevent andor treat merscov infection andor new infectious diseases monoclonal antibodies mabs used clinically diagnose various diseases several years considered potential method intervention monoclonal polyclonal antibodies dpp<NUMBER> reported inhibit merscov infection primary human bronchial epithelia cells huh<NUMBER> cells <NUMBER> lca<NUMBER> antibody developed using cell clone technology immortalized b cells human donor recovering mers considered treatment option severe merscov infections <NUMBER> <NUMBER> recent study identified characterized set seven human neutralizing abs nabs <NUMBER> two monoclonal antibodies mabs namely mers<NUMBER> mers<NUMBER> <NUMBER> agents rbd specific potent inhibitors show strong neutralizing activity merscov another study succeeded developing two potential antibodies regn<NUMBER> regn<NUMBER> proven effective animal models merscov infection <NUMBER> mabs shown activity merscov include <NUMBER>e<NUMBER> if<NUMBER> <NUMBER>a<NUMBER> <NUMBER>b<NUMBER> <NUMBER>c<NUMBER> <NUMBER>b<NUMBER> m<NUMBER>d<NUMBER> <NUMBER> ii <NUMBER>b<NUMBER>n <NUMBER> iii m<NUMBER> m<NUMBER> m<NUMBER> <NUMBER> <NUMBER> <NUMBER> iv hms<NUMBER> <NUMBER> v <NUMBER>c<NUMBER> h <NUMBER> despite utility production monoclonal antibodies time consuming difficult <NUMBER> therapeutics block merscov smediated cell entry virus cell membrane fusion include cathespin inhibitors <NUMBER> tmprss<NUMBER> inhibitors <NUMBER> furin inhibitors <NUMBER> kinase inhibitors <NUMBER> ifitm proteins <NUMBER> study china used high flow nasal cannula hfnc treating patient mers <NUMBER> summary therapeutic options namely repurposing clinically developed drugs cp whole blood therapy ivig use monoclonal antibodies advantages disadvantages terms generation cost overall applications led interest peptides alternative therapeutic option discussed coming sections interest peptide therapeutics mimetics potential antagonists various pathogens peptide research important aspect pharmaceutical research approximately <NUMBER> peptide therapeutics currently evaluated clinical trials <NUMBER> reasons using peptides inhibit proteinprotein interactions ii used alternative diseases difficult target iii advance tech <NUMBER> niques improve peptide halflife iv shorter market time <NUMBER> peptide drugs little side effects little drug tolerance compared chemical drugs meanwhile specificity treatment high peptide drugs need special storage conditions otherwise protein function becomes inactive causing low oral bioavailability propensity rapidly metabolized <NUMBER> many peptide inhibitors shown activity viruses <NUMBER> <NUMBER> <NUMBER> instance rvfv<NUMBER> peptide derived membrane proximal stem region rvfv glycoprotein gc prevents viral fusion rift valley fever virus <NUMBER> rvfv<NUMBER> peptide specific rift valley fever virus closely related variants also shows activity unrelated viruses ebov vsv <NUMBER> <NUMBER> scorpion venom peptide derivative kn<NUMBER> identified potential antihiv<NUMBER> peptide shows low cytotoxic effects biological assays <NUMBER> lack effective treatment encouraged development additional therapeutic agents increased efficacy overcome adverse side effects occur current mers treatment growing interest field peptide therapeutics last decade due numerous adverse effects chemical based drugs <NUMBER> amps excellent candidates novel therapeutic agents since reported possess anticoronavirus activity <NUMBER> amps components first line defence immune system produced eukaryotic prokaryotic species small positively charged gene encoded peptides selective toxicity towards grampositive gramnegative bacteria protozoa fungi viruses <NUMBER> <NUMBER> <NUMBER> <NUMBER> selective toxicity due fact microbes membrane bilayer rich lipopolysaccharides lps lipoteichoic acid lpa thus negatively charged contrast positive charge amps <NUMBER> antiviral amps several modes actions including blocking viral entry heparan sulphate interaction inhibition viral entry fusing specific cellular receptors stopping viral fusion interacting glycoproteins membrane envelope virus <NUMBER> various antiviral mechanisms action antimicrobial peptides include direct interaction virolysis ii blockage host cell surface receptors iii inhibition viral fusion host cells iv inhibition viral replication v activation adaptive immune response <NUMBER> life cycle coronavirus begins fusing spike protein host receptor ii viral entry host cell iii intracellular viral replication transcription iv protein production assembly release new virus particles <NUMBER> therefore therapeutic strategies focus four important processes main mechanism action antiviral peptides categorized generally three major groups <NUMBER> peptides inhibit fusion <NUMBER> peptides inhibit virus entry <NUMBER> peptides inhibit replication <NUMBER> peptides inhibit assembly release virus coronaviruses enter target cells inducing fusion viral cellular membranes process mediated viral spike glycoprotein <NUMBER> s<NUMBER> subunit protein facilitates receptor binding <NUMBER> whereas s<NUMBER> subunit responsible driving viral target cell membrane fusion <NUMBER> various approaches creating peptidebased therapeutics including peptides interrupt rbd interaction peptides block hr<NUMBER> hr<NUMBER> interaction forming fusionactive core peptides interfere cleavage protein <NUMBER> strategies employed inhibit fusion protein either deriving peptides hr<NUMBER> hr<NUMBER> regions deriving peptides antimicrobial peptide note peptides derived either protein antimicrobial peptides antiviral compounds difference peptides derived antimicrobial peptides broad spectrum may roles immunomodulatory activity <NUMBER> derived organism virus described follows peptides derived hr<NUMBER> hr<NUMBER> rbd subunits spike protein fusion inhibiting peptides derived protein shown table <NUMBER> example lu et al designed two synthetic peptides hr<NUMBER>p hr<NUMBER>p amino acid residues spanning <NUMBER> hr<NUMBER> <NUMBER> hr<NUMBER> domains form stable sixhelical bundle <NUMBER>hb fusion core structure <NUMBER> <NUMBER>hb structure ensures fusion viral envelope host cell membrane <NUMBER> two peptides hr<NUMBER>p inhibits merscov replication spike proteinmediated cellcell fusion <NUMBER> previous study showed derivation five regions span length s<NUMBER> subunits sarscov murine hepatitis virus mhv study three peptides sars wwiii sars wwiv mhv wwiv exhibited antiviral activity greater peptides studied inhibitory concentration ic <NUMBER> values ranging <NUMBER> <NUMBER> b peptides derived antimicrobial peptides peptides derived antimicrobial peptides either truncating fragments original peptide replacing certain residue amp another residue instance replacement lysine arginine derived peptides shown activities various microorganisms <NUMBER> <NUMBER> instance antiviral activity <NUMBER> peptides derived mouse ␤defensin<NUMBER> tested one p<NUMBER> exhibited potent broad spectrum antiviral effects multiple respiratory viruses vitro vivo including influenza virus h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> sarscov merscov <NUMBER> entry replication process coronaviruses infected host commences glycoprotein located surface coronavirus virion fusing receptor ace<NUMBER> dpp<NUMBER> facilitate viral entry host chain events leads release viral genomic rna host cytoplasm replication viral rna final release viral particles <NUMBER> <NUMBER> several studies employed inhibit viral entry replication shown table <NUMBER> b c peptides classified major subgroups peptides derived hr<NUMBER> hr<NUMBER> subunits spike protein hr<NUMBER>p peptide derived hr<NUMBER> domain hr<NUMBER>p shown activity merscov inhibiting viral replication calu<NUMBER> hfl cells <NUMBER> b peptides derived antimicrobial peptides mutant mucropinm<NUMBER> peptide derived mucropin amp glycine proline residues mucropin substituted lysine arginine respectively mutant mucropinm<NUMBER> shown activity sarscov inhibiting viral replication <NUMBER> c peptides derived nonstructural protein nsp two peptides k<NUMBER> k<NUMBER> derived nonstructural protein nsp<NUMBER> sarscov two peptides inhibit replication sarscov inhibitory concentration <NUMBER> <NUMBER> though much known assembly release process enzymes involved assembly release process inhibition assembly release virus could good future target <NUMBER> examples anticoronavirus peptides sarscov tgev mhv provided antiviral peptide database avpdb <NUMBER> database consists various anticoronavirus peptides numerous mechanisms action sarscov tgev mhv employed potential therapeutic options merscov coronaviruses share similar structure mechanism action <NUMBER> understanding peptide research suggests peptides may capacity lead molecules potential drugs mers advantage peptide repurposing lead identification peptidebased therapeutics treatment mers potentially wider utility therapeutics use treatment infections caused different human coronaviruses furthermore help maintain quality reduce cost new medicine development urgent need developing effective mers therapy developing protocols used randomizedcontrolled trials studies shown peptides evolved highly potent signal transduction agents viral diseases suggest amps successful therapeutic option emerging mers pathogen computational biology coupled virology accelerate advanced design developing peptide therapeutics merscov greater efficacy addition study suggests repurposing existing clinically approved anticoronavirus antiviral peptide drugs may used promising leads development new antimerscov agents work supported king abdullah international medical research center grant rc<NUMBER> none declared required covid<NUMBER> coronavirus disease <NUMBER> infectious virus outbreak rapidly developed pandemic health crisis novel coronavirus sarscov<NUMBER>ncov<NUMBER> causative agent disease <NUMBER> several groups responded urgent need effective therapeutics leading systemslevel efforts identify drugs repurposable covid<NUMBER> lens virushost protein interactome <NUMBER> interactomes sarscov<NUMBER>modulated host proteins <NUMBER> host proteins modulated human corona viruses sarscov repurposing nding alternate uses approved drugs proved better strategy de novo identi cation terms time cost effectiveness <NUMBER> <NUMBER> <NUMBER> discovery therapeutic agents infectious diseases past largely serendipitous focused screening prioritizing drugs target viral system <NUMBER> last years focus shifted towards computationally identifying drugs could counter virus attack primary strategy repurpose drugs ability revert genes differentially expressed host upon viral infection normal levels ie revert host transcriptional pro le induced upon viral infection normal state <NUMBER> inverse genomic signature approach involves identifying drugs induce gene expression pro les negatively correlated hostspeci c gene signatures induced viral infection used select candidates repurposable uenza viruses merscov <NUMBER> availability diseaseassociated druginduced transcriptomic pro les online repositories ncbi geo gene expression omnibus cmap connectivity map <NUMBER> allow pro les compared using bioinformatics data analysis software suites basespace correlation engine <NUMBER> changes host transcriptome induced viral infection also ected host proteome speci cally perturbations interaction networks host proteins complex page <NUMBER> network proteinprotein interactions ppis called interactome potential restrict viral replication host cells conversely taken virus replication previously presented host protein interactome hop interactome <NUMBER> human proteins identi ed interact <NUMBER> sarscov<NUMBER> viral proteins gordon et al <NUMBER> <NUMBER> interactome consisting <NUMBER> ppis host proteins including <NUMBER> novel interactions predicted hippip provided integrated view host genes various high throughput covid<NUMBER> sars transcriptomicproteomic studies functionally linked <NUMBER> study identi ed drugs targeting proteins interactome studied correlation gene expression pro les induced drugs various cell lines sarscovidassociated pro les observed lungderived mrc<NUMBER> calu<NUMBER> nhbe a<NUMBER> cell lines peripheral blood mononuclear cells pbmcs sars patients work differs previous efforts identify drugs repurposable covid<NUMBER> <NUMBER> considers host protein interactome includes computationally predicted novel interactors host proteins may lead identi cation drugs hitherto prioritized compared druginduced versus sarsassociated differential expression using basespace correlation engine previously called nextbio httpswwwnextbiocom <NUMBER> identify drugs ncov<NUMBER> compiled list <NUMBER> chemical compounds whose differential gene expression pro le drug versus drug negatively correlated least one four sars differential gene expression datasets infected versus noninfected <NUMBER> sars datasets studied calu<NUMBER> epithelial cells infected <NUMBER> hours sars coronavirus versus mock infected cells gse<NUMBER> calu<NUMBER> lung cells infected <NUMBER> hours sars cov urbani versus mock infected cells gse<NUMBER> lung broblast mrc<NUMBER> cells <NUMBER> hours post sars coronavirus infection high multiplicity infection moi versus mock infection gse<NUMBER> peripheral blood mononuclear cells pbmcs patients sars versus healthy subjects gse<NUMBER> <NUMBER> also compiled list <NUMBER> chemical compounds gene expression pro les negatively correlated pro le induced human bronchial epithelial nhbe lung cancer a<NUMBER> cells infected sarscov<NUMBER> strain usawa<NUMBER> gse<NUMBER> <NUMBER> although case would genes differentially expressed direction drug disease ie cause genes overexpress cause genes express overall effect entire transcriptome would anticorrelation correlation score generated nextbio based strength overlap drug disease datasets statistical criteria correction multiple hypothesis testing applied correlated datasets ranked statistical signi cance numerical score <NUMBER> assigned signi cant result scores results normalized respect topranked result next identi ed <NUMBER> drugs target least one protein hop interactome using webgestalt <NUMBER> used redundancy reduction feature provided webgestalt prioritize drugs highly signi cant overlaps interactome also capturing unique target gene sets feature used nity propagation algorithm clusters sets genes interactome targeted speci c drugs using jaccard index similarity metric identi es representative cluster one drug targets signi cant pvalue among gene sets cluster resulted <NUMBER> drugs consideration given class drugs targeting set proteins method ensures individual drugs target statistically signi cant number proteins interactome prioritized analysis fiftysix drugs found common two analyses ie drugs targeted genes hop interactome also induced gene expression pro les negatively correlated induced sarscov supplementary table s<NUMBER> sarscov<NUMBER> supplementary table s<NUMBER> integrated computational analysis interactome conjunction druginduced transcriptomic data revealed <NUMBER> drugs may repurposable covid<NUMBER> included drugs proven vitro activity sarscov<NUMBER> already tested clinical activity sarscov<NUMBER> proven activity sarscovmerscov broadspectrum antiviral drugs identi edprioritized computational repurposing studies information literature supporting shortlisted drugs cyclosporine sorafenib tamoxifen anisomycin identi ed inhibitory effects sarscov<NUMBER> four independent cellbased assays <NUMBER> drugs also shown effective viruses similar sarscov<NUMBER> viruses cyclosporine combination interferon alpha reduced merscov replication reduction associated greater induction interferon stimulated genes <NUMBER> sorafenib shown suppress gene expression hbv hepatitis b virus inhibiting jnk pathway constitutes fxr transcription factor promotes hbv replication gene expression <NUMBER> tamoxifen shown inhibitory effect vesicular stomatitis virus whose effect vero cells correlated activation macrophages elevated interferoni response <NUMBER> anisomycin reduced viral load zika virus blood ag<NUMBER> mice <NUMBER> testing nitric oxide gas inhalation therapy already underway covid<NUMBER> patients see wwwclinicaltrialsgov ongoing clinical trials nitric oxide nitric oxide usually produced phagocytes response interferonγ however also rapidly produced primary broblasts response viral dsrna especially absence intact interferon system noted case ncov<NUMBER> infection <NUMBER> resveratrol shown antiviral activity mersinfected vero e<NUMBER> kidney epithelial cells <NUMBER> inhibited viral infection prolonged survival host cell infection downregulating virusinduced apoptosis reduced expression viral nucleocapsid protein essential viral replication <NUMBER> mtor inhibitor sirolimus reduced merscov infection <NUMBER> huh<NUMBER> hepatocytederived cell line <NUMBER> mycophenolic acid shown inhibit papainlike protease merscov <NUMBER> signi cant lack ifni ifniii type iii interferons expression noted ncov<NUMBER> infected human bronchial epithelial lung alveolar carcinoma cells <NUMBER> prioritizing recombinant interferons exogenously produced laboratory conditions potential therapeutic options covid<NUMBER> may essential scenario interferonalpha<NUMBER>b combination ribavirin reduces viral replication regulates host response improves clinical outcome rhesus macaques infected merscov <NUMBER> sarscov infection human bronchial epithelial calu<NUMBER> cells shown inhibited interferon alfacon<NUMBER> <NUMBER> ramipril inhibitor angiotensin converting enzyme ace<NUMBER> belongs class entry receptors targeted ncov<NUMBER> current evidence shows spike protein sarscov<NUMBER> binds ace<NUMBER> ace<NUMBER> <NUMBER> even though two enzymes coded homologous genes ace<NUMBER> inhibitors incapable acting ace<NUMBER> physiological actions ace<NUMBER> differ ace<NUMBER> vasoconstriction versus vasodilation however since enzymes function two counterbalancing arms reninangiotensin system investigations necessary ascertain whether ace<NUMBER> yet unidenti ed role viral pathogenesis <NUMBER> quercetin inhibits infection various uenza viruses including h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> suspected inhibition arises interaction viral ha<NUMBER> hemagglutinin subunit <NUMBER> calcium channel blocker verapamil inhibits uenza virus late replication cycle madindarby canine kidney cells murine pulmonary macrophages <NUMBER> progesterone shown promote faster recovery female mice uenza virus infection reducing pulmonary ammation repairing damaged lung epithelium generally improving lung function <NUMBER> clotrimazole inhibits entry recombinant vesicular stomatitis virus pseudotypes arenavirus a<NUMBER> human lung epithelial cells targeting membrane fusion mechanism virus <NUMBER> didanosine nucleoside analogue reverse transcriptase inhibitor used treat hivaids host cell didanosine converted dideoxyadenosine<NUMBER>triphosphate ddatp whose incorporation viral dna terminates dna chain elongation preventing formation <NUMBER> study shortlisted drugs potentially repurposable covid<NUMBER> based negative correlation druginduced versus diseaseassociated gene expression pro les although approach validated past several limitations drug associated expression pro les analyzed study induced several types cell lines including cancer cell lines may directly relevant covid<NUMBER> sarscov<NUMBER> infection effect proposed repurposable drugs studied human bronchial epithelial cells andor human lung cancer cell lines recently used study host transcriptional response upon sarscov<NUMBER> infection <NUMBER> summary showed drugs repurposable covid<NUMBER> identi ed host protein interactome based gene expression pro les induced drug versus associated disease dissemination list repurposable drugs scienti c community enable clinical translation results list chemical compounds whose gene expression pro les correlated negatively four sars datatsets one covid<NUMBER> dataset compiled using basespace correlation software httpswwwnextbiocom following protocol described prior work <NUMBER> list <NUMBER> datasets considered human bronchial epithelial nhbe lung cancer a<NUMBER> cells infected sarscov<NUMBER> strain usawa<NUMBER> gse<NUMBER> <NUMBER> calu<NUMBER> epithelial cells infected <NUMBER> hours sars coronavirus versus mock infected cells gse<NUMBER> calu<NUMBER> lung cells infected <NUMBER> hours sars cov urbani versus mock infected cells gse<NUMBER> lung broblast mrc<NUMBER> cells <NUMBER> hours post sars coronavirus infection high moi <NUMBER> versus mock infection gse<NUMBER> peripheral blood mononuclear cells pbmcs patients sars versus healthy subjects gse<NUMBER> <NUMBER> next identi ed drugs targeted least one gene hop interactome using webgestalt <NUMBER> employing redundancy reduction feature webgestalt reduce search space drugs left fewer number drugs list <NUMBER> feature nity propagation algorithm clusters gene sets interactome targeted speci c drugs using jaccard index similarity metric identi es representative cluster one drug targets signi cant pvalue among gene sets cluster compared list <NUMBER> list <NUMBER> identify drugs target proteins interactome also negatively correlated sarscovid<NUMBER> list drugs validated effective sarscov<NUMBER> cellbased assays obtained covid<NUMBER> gene drug set library httpsamppharmmssmeducovid<NUMBER> <NUMBER> drugprotein interactome gure created using cytoscape <NUMBER> list drugs negatively correlated sars covid<NUMBER> available supplementary table s<NUMBER> supplementary table s<NUMBER> author contributions kbk carried analyses supervision nb mkg mkg constructed protein interactome manuscript drafted kbk edited approved authors competing interests authors declare competing interests severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> causative agent coronavirus disease <NUMBER> represents major global public health threat time writing report covid<NUMBER> detected <NUMBER> countriesregions <NUMBER> million confirmed cases nearly <NUMBER> deaths johns hopkins university <NUMBER> although rates new cases plateaued regions due social distancing measures transmission dynamics suggest absence vaccine combination intermittent social distancing expanded critical care capacity effective therapeutic treatment necessary facilitate acquisition sufficient herd immunity mitigate resurgence infection near future kissler et al <NUMBER> sarscov<NUMBER> positivesense singlestranded rna virus belonging b genus coronaviridae family sarscov<NUMBER> virion consists least four <NUMBER> structural proteins spike protein membrane protein envelope e protein nucleocapsid n protein spike protein confers distinguishing crown appearance consistent coronaviruses facilitates binding viral entry host angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor ge et al <NUMBER> also target neutralizing antibodies vaccines du et al <NUMBER> contrast key nonstructural proteins include papain like protease plpro main protease mpro responsible cleavage viral polypeptide functional units rnadependent rnapolymerase rdrp critical viral proliferation ziebuhr et al <NUMBER> expectedly proteins identified important drug targets dong et al <NUMBER> currently confirmed treatment vaccine prevention strategy covid<NUMBER> due urgency situation drug repurposing widely accepted fastest way identify possible effective therapeutic options ciliberto cardone <NUMBER> ekins et al <NUMBER> parks smith <NUMBER> clinical trials investigated efficacy various existing drugs possible repurposing including lopinavir ritonavir antihiv protease inhibitors hydroxychloroquine antimalarial decreases acidity endosomes probably affects entry virus cell azithromycin antibacterial agent molina et al <NUMBER> rosenberg et al <NUMBER> remdesivir <NUMBER> <NUMBER> cyanosubstituted adenosine nucleotide analogue prodrug established activity ebola virus rdrp shah et al <NUMBER> tchesnokov et al <NUMBER> despite remdesivir showing promising results preliminary analysis national institutes health <NUMBER> search additional safe efficacious costeffective drug candidates repurposing continues wellestablished method identifying drugs repurposing via computational means also termed silico insilico drug screening techniques experienced docking experiments allow evaluation available drug candidates viral protein host receptor structures ekins et al <NUMBER> hodos et al <NUMBER> fast costeffective way identifying new uses old drugs successful identifying drugs variety conditions ekins et al <NUMBER> since structures sarscov<NUMBER> viral proteins characterized published early february <NUMBER> surge silico studies seeking potential drugs could repurposed treat covid<NUMBER> mohamed et al <NUMBER> one drug may hold potential cefuroxime several anecdotal accounts social media sarscov<NUMBER> positive patients received oral cefuroxime experiencing often rapid symptomatic improvement aquino <NUMBER> barreto <NUMBER> sheathomas <NUMBER> sur <NUMBER> turnipseed <NUMBER> cefuroxime second generation cephalosporin antibiotic broad spectrum activity commonly used treatment upper lower respiratory tract infections lyme disease genitourinary tract infections readily available affordable exists oral parenteral forms cefuroxime axetil cefuroxime sodium respectively undergone extensive toxicological investigation postmarketing surveillance known good safety profile emmerson <NUMBER> common adverse events gastrointestinal disturbances including nausea vomiting diarrhea emmerson <NUMBER> ocallaghan et al <NUMBER> perry brogden <NUMBER> estimated occur <NUMBER> <NUMBER> recipients perry brogden <NUMBER> less common side effects include headaches hypersensitivity reactions hematological derangements pseudomembranous colitis vaginitis skin rashes appear dosedependent gold rodriguez <NUMBER> perry brogden <NUMBER> aim paper identify summarize available silico evidence molecular basis possible activity cefuroxime sarscov<NUMBER> adopted preferred reporting items systematic review metaanalyses extension scoping reviews prismascr guidelines tricco et al <NUMBER> eligible studies identified search articles published medline embase scopus web science google scholar february <NUMBER>st <NUMBER> may <NUMBER>th employed broad search strategy peerreviewed databases using following search key silico virtual screening computational sarscov<NUMBER> coronavirus covid <NUMBER> drugs drug repurposing given google scholar allows searching within fulltext employed directed search strategy using search key cefuroxime coronavirus covid<NUMBER> sarscov<NUMBER> drug repurposing primary research articles written english fulfilled following criteria included analysis described testing potential inhibitors sarscov<NUMBER> structural nonstructural proteins ii included screening potential inhibitor drugs drug library containing united states food drug administration fda approved drugs preselected list included cefuroxime iii identified cefuroxime topranked top x drugs x ¼ <NUMBER> potential inhibitor drug studies following excluded analysis articles report results primary research ii articles written english iii studies investigated natural traditional drugs iv studies described testing specific drugs preselected drugs list include cefuroxime v studies identify cefuroxime topranked potential inhibitor drug two investigators ad cw independently searched reviewed titles abstracts retrieved studies identify potentially relevant articles full text publications potentially relevant articles retrieved rescreened two investigators disagreements resolved consensus two investigators final selected articles reviewed data extracted methodology findings summarized paper primary study outcome identify summarize silico evidence suggest molecular basis possible activity cefuroxime sarscov<NUMBER> data eligible study extracted two investigators extracted data included name first author country origin corresponding author peer reviewed status methodological approach software tool used fda approved drugs drug library screened sarscov<NUMBER> protein targets cefuroxime rank total <NUMBER> articles found initial search <NUMBER> unique articles remained identification removal duplicates remaining studies <NUMBER> studies removed relevant <NUMBER> studies retained fulltext review following fulltext review <NUMBER> studies beck et al <NUMBER> cava et al <NUMBER> chen et al <NUMBER> elfiky <NUMBER> elmezayen et al <NUMBER> encinar menendez <NUMBER> gordon et al <NUMBER> hall ji <NUMBER> ortega et al <NUMBER> pant et al <NUMBER> peele et al <NUMBER> sarma et al <NUMBER> ton et al <NUMBER> tsuji <NUMBER> wang <NUMBER> excluded cefuroxime identified topranked candidate drug included study elfiky <NUMBER> investigated binding affinity selected drugs including cefuroxime rdrp without explicitly ranking drugs six studies alkhafaji et al <NUMBER> alm ecigad ıaz et al <NUMBER> darya et al <NUMBER> galvez et al <NUMBER> koulgi et al <NUMBER> wu et al <NUMBER> reported cefuroxime topranked candidate drug included study study flow depicted figure <NUMBER> characteristics <NUMBER> studies presented table <NUMBER> target based summary identified studies presented four studies alkhafaji et al <NUMBER> alm ecigad ıaz et al <NUMBER> jorge galvez et al <NUMBER> koulgi et al <NUMBER> reported cefuroxime topranked inhibitor drug mpro galvez colleagues jorge galvez et al <NUMBER> employed molecular topology mt methodology successful identifying drugs cancer alzheimers disease malaria j galvez et al <NUMBER> mt approach involves representing structure extension pharmacologic activity drugs molecules set numbers called topological indices based topological indices drugs partitioned groups similar mathematical patterns mathematical model topological model trained learn desired mathematical pattern validated topological model used search drug libraries identify drugs desired mathematical pattern hence desired pharmacologic activity j galvez et al <NUMBER> jorge galvez et al <NUMBER> galvez colleagues took lopinavir hiv<NUMBER> protease predicted studies activity mpro gold standard drug using mt approach screened <NUMBER> molecules <NUMBER> drug libraries identified <NUMBER> drugs including cefuroxime predicted bind tighter lopinavir predicted inhibitory potency drugs expressed arbitrary index lopinavir index score <NUMBER> cefuroxime index score <NUMBER> almecigadiaz colleagues alm ecigad ıaz et al <NUMBER> used proprietary algorithm alm ecigadiaz et al <NUMBER> screen subset zinc library drugs could bind active cavity mpro prior screening demonstrated algorithm correctly predicted binding number inhibitor molecules reported mpro including n<NUMBER> aketonamidebased inhibitors observed strong correlation r <NUMBER> ¼ <NUMBER> binding energy reported ic <NUMBER> inhibitors consequently predicted ic <NUMBER> based binding energy screening <NUMBER> drugs identified <NUMBER> potential inhibitor drugs including cefuroxime smaller binding energy previously reported inhibitors cefuroxime ranked <NUMBER>th predicted bind affinity energy <NUMBER> kcalmol ic <NUMBER> <NUMBER> mm topranked drug affinity energy <NUMBER> kcalmol ic <NUMBER> <NUMBER> mm koulgi colleagues koulgi et al <NUMBER> using direct docking ensemble docking approach direct docking straightforward docking potential drugs crystal structure mpro ensemble approach involved docking variations conformation active site mpro usually leads better results achieve ensemble approach performed molecular dynamic simulation mds via root mean square deviation rmsd based clustering markov state modeling analysis obtain <NUMBER> conformations mpro grid scores drugs two drug libraries one official fda approved drug list reported approaches expectedly ensemble approach produced better docking scores cefuroxime via trade name ceftin identified secondbest drug fda drug library via ensemble approach grid score <NUMBER> score better score <NUMBER> best ranked drug direct docking approach alkhafaji colleagues alkhafaji et al <NUMBER> employed covalent docking screening identify potential drugs could bind covalently hence irreversibly cys<NUMBER> active site mpro cys<NUMBER> mpro identified vital residue covalently bound drugs inhibit activity mpro dai et al <NUMBER> xue et al <NUMBER> zhang et al <NUMBER> end obtained crystal structures <NUMBER> prescreened fdaapproved drugs antiviral agents including cefuroxime known bind covalently targets drugs ranked binding energies determined using prime mmgbsa genheden ryde <NUMBER> concluded top <NUMBER> drugs showed higher affinity form covalent irreversible bond cys<NUMBER> active site mpro cefuroxime <NUMBER>th highest ranking drug binding energy <NUMBER> kcalmol remdesivir ranked third binding energy <NUMBER> kcalmol wu et al one earliest one cited paper silico experiments sarscov<NUMBER> time writing paper authors screened fdaapproved drugs zinc database database known antiviral agents active sites sarscov<NUMBER> proteins drug candidates scored based well established internal coordinate mechanics icm abagyan et al <NUMBER> binding energies potential drug candidates expressed icm scores icm mfscores mean force scores icm score measure overall empirical function predicted physical interaction icm mfscore independent score strength drugreceptor interaction abagyan et al <NUMBER> muegge martin <NUMBER> neves et al <NUMBER> per icm user guide score considered best scoring use docking result analysis icm scores less <NUMBER> generally considered good scores abagyan et al <NUMBER> wu colleagues considered drug candidates icm scores less <NUMBER> icm mfscores less <NUMBER> potential activity targeted proteins sarscov<NUMBER> cefuroxime among topranked drugs predicted inhibit rdrp icm score data provided supplementary files rdrp cefuroxime icm score <NUMBER> highest mfscore <NUMBER> remdesivir score <NUMBER> mfscore <NUMBER> although excluded meeting eligibility criteria report study elfiky <NUMBER> also reported potential binding cefuroxime rdrp author conducted mds molecular docking investigate binding handful preselected drugs including antiviral agents cefuroxime rdrp average binding energy cefuroxime <NUMBER> kcalmol within margin error remdesivir <NUMBER> kcalmol darya colleagues darya et al <NUMBER> predicted cefuroxime may inhibit ace<NUMBER>spike complex first created resource called polypharmdb contained predicted binding profiles <NUMBER> approved experimental drugs resource built using proprietary tool matchmaker uses artificial intelligence via deep learning predict binding drugs <NUMBER> human viral proteins polypharmdb queried potential drugs could inhibit sarscov<NUMBER> proteins interest revealed cefuroxime top <NUMBER> drugs may inhibit ace<NUMBER>spike protein complex covid<NUMBER> pandemic major public health threat requires immediate action despite intense efforts develop novel drugs sarscov<NUMBER> process time consuming limited progress date therefore drug repurposing identified fastest way realizing therapeutic agents covid<NUMBER> meet urgency situation anecdotal evidence suggesting various drugs may effective sarscov<NUMBER> prospective studies investigating initially touted agents hydroxychloroquine azithromycin failed show whether hydroxychloroquine alone combination azithromycin effectively alter disease course patients severe covid<NUMBER> taccone et al <NUMBER> however preliminary data analysis national institutes health nih sponsored randomized clinical trial rct remdesivir involving patients advanced covid<NUMBER> suggested patients received remdesivir significant <NUMBER>day difference median time recovery compared received placebo national institutes health <NUMBER> therefore inkeeping commitment expediting development availability potential covid<NUMBER> treatments fda issued emergency use authorization <NUMBER>st may <NUMBER> remdesivir used treatment suspected laboratoryconfirmed covid<NUMBER> adults children hospitalized severe disease us food drug administration <NUMBER> potential mortality benefit remdesivir less clear clinical trial china showing mortality benefit wang et al <NUMBER> conclusive results nih trial awaited nevertheless preliminary results nih trial suggest virus inhibited vivo resulting clinically meaningful outcomes despite early success many unanswered questions remain remdesivir including availability route administration exists intravenous form cost indication use nonsevere hospitalized nonhospitalized patients reasons additional therapeutic agents needed fight sarscov<NUMBER> study set determine molecular basis possible activity cefuroxime sarscov<NUMBER> conducting scoping review literature silico drugrepurposing experiments sarscov<NUMBER> identified <NUMBER> original articles <NUMBER> continents large library existing drugs reported cefuroxime topranked potential inhibitor <NUMBER> key sarscov<NUMBER> proteins four studies reported cefuroxime may inhibit mpro one study reported cefuroxime may inhibit rdrp another reported cefuroxime may inhibit ace<NUMBER>spike protein binding complex findings suggest silico basis assume cefuroxime may active sarscov<NUMBER> although previously known antiviral activity glaxosmithkline <NUMBER> given reported strong binding <NUMBER> sarscov<NUMBER> proteins silico cefuroxime may multitarget inhibitor sarscov<NUMBER> multitarget agents carry prospect robust likely live expectations tend less affected individual differences response modifications key diseaserelevant biological pathways activation compensatory mechanism talevi <NUMBER> xie et al <NUMBER> zimmermann et al <NUMBER> best knowledge first review suggest cefuroxime possible weapon fight sarscov<NUMBER> however clinical usefulness cefuroxime covid<NUMBER> depend clinical efficacy safety profile determine clinical efficacy phase iiiii clinical trials needed regarding safety cefuroxime good profile common adverse drugs reactions gastrointestinal effects nausea vomiting diarrhea effects dose dependent occurring higher doses longer duration use emmerson <NUMBER> henry et al <NUMBER> one large study gastrointestinal adverse effects seen less <NUMBER> patients <NUMBER> discontinuing use predominantly due gastrointestinal side effects perry brogden <NUMBER> consequently one concern may arise use covid<NUMBER> possibility exacerbation gastrointestinal symptoms covid<NUMBER> systematic reviewmetaanalysis <NUMBER> studies gastrointestinal symptoms covid<NUMBER> reported pooled prevalence <NUMBER> higher prevalence <NUMBER> patients severe disease patients nonsevere disease <NUMBER> commonly reported symptoms anorexia <NUMBER> diarrhea <NUMBER> nausea vomiting <NUMBER> abdominal pain <NUMBER> cheung et al <NUMBER> therefore cefuroxime prescribed covid<NUMBER> worsening gastrointestinal symptoms would suggest either disease progression adverse drug effects two distinguished presence symptoms dry cough shortness breath loss smell loss taste seen covid<NUMBER> cefuroxime adverse effects cefuroxime occur less commonly estimated occur <NUMBER> <NUMBER> subjects several multipledose trials glaxosmithkline <NUMBER> besides possibility inhibitor sarscov<NUMBER> may additional benefit using cefuroxime covid<NUMBER> though actual numbers may vary uncommon patients covid<NUMBER> suspected confirmed bacterial superinfection coinfection requiring antibiotic coverage single site study zhou et al <NUMBER> china reported <NUMBER> prevalence secondary bacterial infection among hospitalized patients rapid review literature bacterial fungal coinfection among covid<NUMBER> patients rawson et al <NUMBER> reported <NUMBER> bacterialfungal coinfection nevertheless <NUMBER> hospitalized patients received empiric antibiotics suspected bacterial infection cox et al <NUMBER> rawson et al <NUMBER> since cefuroxime broad spectrum antibiotic excellent activity many respiratory pathogens reasonable consider option empiric therapy suspected cases bacterial superinfectioncoinfection particularly patients mild disease nonhospitalized patients hospitalized patients without respiratory compromise pending isolation specific pathogen patients moderatetosevere disease suspicion bacterial superinfection likely benefit broader empiric coverage offered cefuroxime higher risk mortality lippi plebani <NUMBER> zhou et al <NUMBER> certain limitations scoping review acknowledged first significant heterogeneity among studies reviewed especially regards methodology regarded strength also hints need reproducibility second studies reported cefuroxime topranked drug included study many studies identify cefuroxime topranked drug consequently unclear <NUMBER> studies included review represent significant finding larger body literature silico drug repurposing covid<NUMBER> early systematic review silico drug repurposing coivd<NUMBER> identified <NUMBER> studies mohamed et al <NUMBER> included one paper study since several studies published consequently new systematic reviews needed evaluate significance findings third review silico studies vitro vivo studies required determine efficacy cefuroxime potential therapeutic agent sarscov<NUMBER> covid<NUMBER> significant public health emergency carries pressing demand effective therapeutic due urgency health crisis drug repurposing efficient method meeting need successful interventions may require action multiple targets sarscov<NUMBER> virus secondgeneration cephalosporin cefuroxime demonstrates potential activity three sarscov<NUMBER> proteins silico experiments may promising multitarget inhibitor cefuroximes long history population monitoring makes reliable option vitro vivo studies fight covid<NUMBER> potential conflict interest reported authors george stamatiades httporcidorg<NUMBER> starting december <NUMBER> outbreak pneumonia unknown cause took place wuhan hubei province china chaolin huang et al <NUMBER> short time chinese authorities rapidly isolated characterized novel coronavirus closely related sarscov caused outbreak severe acute respiratory syndrome <NUMBER> years ago china zhou et al <NUMBER> newly identified coronavirus initially represented <NUMBER>ncov formally named sarscov<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> international committee taxonomy viruses ictv february <NUMBER> th <NUMBER> meanwhile disease caused virus named covid<NUMBER> world health organization although china adopted unprecedented policies control spread virus including temporarily shutting wuhan city january <NUMBER> rd <NUMBER> sarscov<NUMBER> resulted <NUMBER> covid<NUMBER> patients <NUMBER> fatalities worldwide february <NUMBER> th <NUMBER> estimated case fatality rate <NUMBER> growing patient numbers sarscov<NUMBER> poses serious health threat whole world httpswwwwhointemergenciesdiseasesnovelcoronavirus<NUMBER>situationreports unfortunately specific clinical treatments rapidly escalating international crisis caused sarscov<NUMBER> limited one reasons high mortality rate due deficiency targeted drugs current clinical treatment covid<NUMBER> focuses supportive care symptom relief remdesivir experimental drug developed treat middle east respiratory syndrome coronavirus merscov reported effective treating several covid<NUMBER> cases systematic clinical trial drug still ongoing wuhan china clinicaltrialsgov identifier nct<NUMBER> similarly chloroquine lopinavirritonavir many drugs also reported potentially effective supportive clinical data available maxmen <NUMBER> therefore great value identify potential drugs targeting sarscov<NUMBER> save covid<NUMBER> patients traditional process development drug need <NUMBER> years target identification target validation hit discovery lead optimization preclinical clinical trials kaitin <NUMBER> therefore virtually possible develop de novo drugs time frame needed impact current sarscov<NUMBER> crisis hence feasible approach find potential cures clinical drugs drug repurposing also known drug repositioning reprofiling redirecting rediscovering drug repurposing rapidly expand target disease indications existing drug saving time money since data human pharmacokinetics safety preclinical results already available cha et al <NUMBER> successful examples drug repurposing include use sildenafil treating erectile dysfunction anticancer uses thalidomide pushpakom et al <NUMBER> previously described computeraided drug discovery protocol named scar stericclashes alleviating receptors ai et al <NUMBER> screening covalent inhibitors target proteins enlightened silico protein design strategy liao et al <NUMBER> realizing potential use scar discovering covalent noncovalent inhibitors recently demonstrated scar also quite efficient drug repurposing zhang et al <NUMBER> compared noncovalent drugs covalent drugs following advantages mah et al <NUMBER> covalent drugs better biochemical efficiency since competitive many noncovalent endogenous substrates cofactors ii covalent drugs cause lower patient burden delay emergence drug resistance due lower less frequent dosing iii covalent drugs might better target specificity reacting nonconserved nucleophilic amino acid careful designs cuesta et al <NUMBER> therefore recent years witnessed resurgence discovery covalent drugs result set use scar identify possible covalent drugs targeting sarscov<NUMBER> drug repurposing work protein pocket shown surface inhibitor sticks covalent bond indicated arrow b binding poses identified hits putative reactive atoms drugs indicated black arrows protein without scar mutation c<NUMBER>g used representation yellow surface close arrow represents cys<NUMBER> steric conflicts reactive atoms cys<NUMBER> expected eliminated covalent bonding drug cys<NUMBER> table <NUMBER> potential drugs might repurposed covalent inhibitors sarscov<NUMBER> <NUMBER>clpro scar strategy docking score conformation rank listed identified pose atom distance distance putative reactive atom drug cys<NUMBER>sg scar enriching score calculated top docking score drug docked wildtype <NUMBER>clpro minus listed docking score structure files compounds downloaded mol<NUMBER> files zinc<NUMBER> database httpzinc<NUMBER>dockingorg described zinc<NUMBER> <NUMBER>d conformations protonated physiological ph biologically relevant tautomers generated molecule sterling irwin <NUMBER> intrials catalog <NUMBER> version downloaded contains <NUMBER> approved investigational clinically tested approved drugs worldwide mgltools version <NUMBER> used generate pdbqt files mol<NUMBER> files docking sarscov<NUMBER> <NUMBER>clpro structure downloaded pdb pdb id <NUMBER>lu<NUMBER> complex structure sarscov<NUMBER> <NUMBER>clpro inhibitor covalently bonding cys<NUMBER> structure energetically minimized rosetta leaverfay et al <NUMBER> applying harmonic distance angle constraints bonding atoms inhibitor cys<NUMBER> backbone protein fixed minimization lowest score model chosen <NUMBER> models scar docking cys<NUMBER> mutated gly mgltools version <NUMBER> used generate pdbqt file docking computational docking process similar previously described ai et al <NUMBER> liao et al <NUMBER> briefly autodock vina trott olson <NUMBER> version <NUMBER> used dock small molecules substrate binding pocket sarscov<NUMBER> <NUMBER>clpro docked poses manually evaluated docking score ranking distance reactive atom sulfur atom cys<NUMBER> original structure previously described ai et al <NUMBER> sarscov <NUMBER>clike proteinase <NUMBER>clpro main protease cleaves large replicase polyprotein <NUMBER>a pp<NUMBER>a pp<NUMBER>ab produce nonstructural proteins nsps transcription replication virus zumla et al <NUMBER> therefore <NUMBER>clpro key drug target inhibiting sarscov recent data showed sarscov<NUMBER> <NUMBER>clpro highly similar sarscov <NUMBER>clpro sequence structure pdb id <NUMBER>lu<NUMBER> previous studies demonstrated cys<NUMBER> key residue active site <NUMBER>clpro changkang huang et al <NUMBER> makes residue attractive target covalent bonding covalent <NUMBER>clpro inhibitors cysteine also popular target covalent inhibitors high intrinsic reactivity physiological ph permits use relatively unreactive electrophiles cuesta et al <NUMBER> meanwhile targeting cysteine renders high selectivity covalent inhibitors due low prevalence cysteine proteome cuesta et al <NUMBER> repurpose potential covalent drugs targeting sarscov<NUMBER> <NUMBER>clpro firstly optimized xray complex structure protein inhibitor using macromolecule modeling suite rosetta leaverfay et al <NUMBER> figure <NUMBER>a demonstrated previous work structural optimization could benefit docking result ai et al <NUMBER> next mutated cys<NUMBER> gly required scar protocol prepare docking target ai et al <NUMBER> intrials dataset <NUMBER> compoundsconformations obtained zinc<NUMBER> filtered generally used warhead groups targeting cysteine <NUMBER> compoundsconformations used docking process represented scardock among <NUMBER> left manual checking score filtering <NUMBER> listed table <NUMBER> identified <NUMBER> potential covalent inhibitors <NUMBER>clpro sarscov<NUMBER> following scar protocol described previously ai et al <NUMBER> hits contain five different covalent warhead groups suitable targeting cysteine represents diverse structural options shown figure <NUMBER>b putative covalent poses identified hits fit binding pocket reasonably drug distance putative nucleophilic atom sg atom cys<NUMBER> shown table <NUMBER> <NUMBER>lu<NUMBER> pdb id distance covalent carbon atom inhibitor sg atom cys<NUMBER> <NUMBER> å therefore proximity two atoms indicates high potential covalent bonding drug cys<NUMBER> investigate scar strategy helped enriching hits redocked compounds sarscov<NUMBER> <NUMBER>clpro without mutating cys<NUMBER> represented regulardock quantitative comparison took lowest score compound regulardock results compared difference lowest score score compound scardock results represented scar enriching score note used score pose oriented covalent bonding scardock lowest score rank conformation <NUMBER> table <NUMBER> shown table <NUMBER> <NUMBER> <NUMBER> compounds <NUMBER> scardock protocol generated lower scores higher affinities corresponding positive scar enriching scores result might indicate scar protocol generate better binding poses regular docking protocol compounds covalently bind cys<NUMBER> although experimental validations necessary base parameters table <NUMBER> suggest following ones might higher priorities telcagepant vidupiprant poziotinib fostamatinib summary identified eleven approved investigational drugs might repurposed covalently inhibit <NUMBER>clpro sarscov<NUMBER> according previous studies hits scar protocol could different reactive bonding activities one reason scar protocol consider reactive activity warhead compound reason reactive activity warhead affected attached scaffold prediction warheads reactive activity still profoundly challenging issue considering worldwide health risk posed sarscov<NUMBER> although wet experiments needed validate computational hits hope work provide options rapid identification targeted drugs inhibit sarscov<NUMBER> save covid<NUMBER> patients time background coronavirus disease <NUMBER> covid<NUMBER> caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> declared pandemic world health organization identification effective therapeutic strategy need hour combat sarscov<NUMBER> infection scenario drug repurposing approach widely used rapid identification potential drugs sarscov<NUMBER> considering viral host factors methods adopted host transcriptomebased drug repurposing strategy utilizing publicly available high throughput gene expression data sarscov<NUMBER> respiratory infection viruses based consistency expression status host factors different cell types previous evidence reported literature proviral factors sarscov<NUMBER> identified subject drug repurposing analysis based drugbank connectivity map cmap using web tool clue results upregulated proviral factors tymp ptgs<NUMBER> c<NUMBER>s cfb ifi<NUMBER> xaf<NUMBER> cxcl<NUMBER> cxcl<NUMBER> identified early infection models sarscov<NUMBER> analysis drugperturbed expression profiles connectivity map <NUMBER> drugs reverse expression proviral factors identified importantly twelve reported antiviral activity direct inhibition ptgs<NUMBER> gene product considered another therapeutic strategy sarscov<NUMBER> infection could suggest six approved ptgs<NUMBER> inhibitor drugs treatment covid<NUMBER> computational study could propose candidate repurposable drugs covid<NUMBER> experimental studies required validation host transcriptomeguided drug repurposing covid<NUMBER> treatment metaanalysis based approach covid<NUMBER> pulmonary syndrome caused novel strain coronavirus according world health organization report <NUMBER>th april <NUMBER> <NUMBER> people infected <NUMBER> deaths globally coronavirus disease <NUMBER> primary mode sars cov<NUMBER> transmission respiratory droplets generated coughing sneezing infected patients symptoms include dry cough fatigue myalgia fever dyspnea however disease progresses severe illness leads death <NUMBER> confirmed cases due massive alveolar damage progressive respiratory failure rothe et al <NUMBER> coronaviruses possess largest genomes <NUMBER> kb rna viruses encoding four main structural proteins contain spike membrane envelope e nucleocapsid n proteins virus enters host cell genome transcribed translated cascella et al <NUMBER> invading respiratory viruses would either suppress evade innate immune adaptive responses hosts side increase virulence leads disease outcome limited genome size virus extensively utilizes host factors replication via inducing alterations host gene expression resulting modulated immune response de wilde et al <NUMBER> therefore transcriptome analysis host cell upon virus infection useful identifying host immune response dynamics also significant host factors would facilitate virus infection develop effective therapeutic strategies necessary understand expression host factors upon sarscov<NUMBER> infection according current treatment scenario drug repurposing fda approved drugs would effective alternative method would improve host factor sarscov<NUMBER> virus infection transcriptome guided drug repurposing approaches utilize drug perturbed expression profiles identify potential drug candidates show anticorrelation disease signature arakelyan et al <NUMBER> present study initially attempted conduct transcriptome analyses utilizing publicly available host transcriptome profiles sarscov<NUMBER> also respiratory virus infections could provide information altered host factors upon infection next based identified sarscov<NUMBER> induced proviral host factors drug repurposing analyses performed identify possible drugs treatment pandemic infection caused covid<NUMBER> would help decrease mortality covid<NUMBER> patients globally gene expression profile datasets based expression profiling highthroughput sequencing microarray response different coronaviruses middle east respiratory syndrome coronavirus merscov sarscov<NUMBER> sarscov<NUMBER> infection human host retrieved gene expression omnibus geo database httpwwwncbinlmnihgovgeo omicsdi httpswwwomicsdiorg datasets coronavirus infected group mock control group included study sixteen datasets obtained three based expression profiling highthroughput sequencing rnaseq remaining thirteen microarray experiments cell types identified datasets human airway epithelium cells hae calu<NUMBER> lung adenocarcinoma primary fibroblasts primary human microvascular endothelial cells primary human dendritic cells available transcriptome profile dataset sarscov<NUMBER> <NUMBER>th april <NUMBER> gse<NUMBER> based expression profiling <NUMBER>h infected cells blancomelo et al <NUMBER> selected samples <NUMBER>h infected conditions corresponding mock controls metaanalysis based criteria thirteen datasets gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> gse<NUMBER> selected metaanalysis total <NUMBER> samples thirteen datasets selected metaanalysis table s<NUMBER> among <NUMBER> samples <NUMBER> samples belong respiratory virusinfected condition <NUMBER> mock control samples overall workflow implemented study reported fig <NUMBER> preprocessing statistical metaanalysis selected <NUMBER> samples performed using webbased tool networkanalyst zhou et al <NUMBER> identifiers transcripts high throughput sequencing different microarray platforms converted entrez gene ids preprocessed microarray rnaseq datasets normalized using log<NUMBER> transformation datasets passed integrity check subjected studyspecific batch effect adjustment using combat methods network analyst tool density plot pca<NUMBER>d plot batcheffect adjustment indicate proper incorporation datasets fig s<NUMBER> total <NUMBER> features <NUMBER> samples consists different respiratory virus infection models two experimental conditions <NUMBER>h infected condition mock control subjected analysis metaanalysis performed based combining effect sizes method using fixed effect model significance level <NUMBER> differentially expressed genes <NUMBER> h infection conditions different respiratory viruses vs mock control obtained rnaseq dataset geo id gse<NUMBER> used identify genes altered sarscov<NUMBER> infected conditions dataset consists host transcriptome profiling based two cell lines a<NUMBER> nhbe <NUMBER> h sarscov<NUMBER> infected mock control samples two cell lines subjected separate differential expression analysis using gene expression table option network analyst dataset consists <NUMBER> samples corresponding <NUMBER> h sarscov<NUMBER> mockcontrol gene expression table uploaded options organismhuman data typebulk rnaseq gene level summarizationmean <NUMBER> <NUMBER> features selected a<NUMBER> nhbe cells respectively unannotated genes filtered log<NUMBER>counts per million normalization applied normalization graphical outputs box plots pca density plots verified check quality data differential expression analysis case vs mock condition performed using method deseq<NUMBER> differentially expressed genes obtained significant thresholds adjusted pvalue <NUMBER> log<NUMBER> fold change <NUMBER> applied identify significantly differentially expressed genes among significant genes genes showing consistent tendency nhbe a<NUMBER> cells <NUMBER> genes selected analysis among <NUMBER> genes pro antiviral factors identified based literature survey heatmap<NUMBER> tool galaxy used generate heat map differentially expressed genes protein level interaction analysis performed using string program szklarczyk et al <NUMBER> selected differentially expressed genes submitted multigene entry option string obtain protein level interaction network cluster option used identify cluster interactions network obtained interaction details used construct proteinprotein interaction network using cytoscape shannon et al <NUMBER> pathway gene ontology enrichment details obtained string based fdr cut <NUMBER> drugbank version <NUMBER> httpwwwdrugbankca used obtain drugtarget link existing drug molecules degs differentially expressed genes showing consistent tendency subjected target search drugbank approved experimental drug groups included study drug repurposing analysis performed using connectivity map using web application clue httpsclueio subramanian et al <NUMBER> query option tools selected find perturbagens give rise opposing expression signature proviral factors identified study query requires minimum <NUMBER> genes <NUMBER> proviral factors tymp ptgs<NUMBER> c<NUMBER>s cfb ifi<NUMBER> xaf<NUMBER> cxcl<NUMBER> cxcl<NUMBER> showing consistent upregulation nhbe a<NUMBER> cells two proviral factors nfkb<NUMBER> tlr<NUMBER> upregulated nhbe cells subjected analysis upregulated proviral factors compared signature cmap reference gene expression l<NUMBER> touchstone database heatmap connectivity score tau perturbagens <NUMBER> smallmolecule compounds obtained topscored compounds cmap tau score −<NUMBER> highest anticorrelation upregulated ten proviral genes identified study host factors response sarscov<NUMBER> coronavirus infections analyzed using computational approach metaanalysis strategy utilized identify differentially expressed genes common human host infection mediated different respiratory infection viruses <NUMBER> datasets gene expression profiling studies based highthroughput sequencing microarray experiments obtained geo table s<NUMBER> publicly available host gene expression profiles respiratory infection viruses till <NUMBER>th april <NUMBER> used analysis dataset sarscov<NUMBER> geo id gse<NUMBER> consists <NUMBER>h infected mockcontrol samples primary human lung epithelium nhbe transformed lung alveolara<NUMBER> cells blancomelo et al <NUMBER> total <NUMBER> samples <NUMBER> respiratory virusinfected <NUMBER> mock control samples selected metaanalysis considering <NUMBER> h infected samples different datasets consisting respiratory virusinfected human host models sarscov<NUMBER> sarscov merscov respiratory syncytial virus rsv differential expression analysis various respiratory infection viruses vs mockcontrol metaanalysis reported <NUMBER> genes based fdr <NUMBER> table s<NUMBER> next differentially expressed genes specifically sarscov<NUMBER> infected conditions identified a<NUMBER> nhbe cells table s<NUMBER> reports <NUMBER> <NUMBER> differentially expressed genes a<NUMBER> nhbe cells respectively based adjusted p value cutoff <NUMBER> together nhbe a<NUMBER> cells total <NUMBER> unique genes reported differentially expressed table s<NUMBER> venn diagram reports overlap common genes metaanalysis different respiratory virus infection vs mock sarscov<NUMBER> vs mock conditions <NUMBER> h infection models fig <NUMBER>a <NUMBER> differentially expressed genes found common metaanalysis different respiratory infection viruses sarscov<NUMBER> specific analysis different cell lines indicate sarscov<NUMBER> specific gene signatures <NUMBER> h host infection models venn diagram reports <NUMBER> genes common a<NUMBER> nhbe cells highlighted table s<NUMBER> among <NUMBER> genes noticed upregulated nhbe a<NUMBER> cells remaining one gene krt<NUMBER> found downregulated a<NUMBER> upregulated nhbe cells <NUMBER> genes showing consistent upregulation tendency sarscov<NUMBER> infected nhbe a<NUMBER> cells selected analysis table <NUMBER> among <NUMBER> genes overlapping metaanalysis data fig <NUMBER>a observed upregulation tendency included table <NUMBER> therefore <NUMBER> genes common <NUMBER>h infection models different respiratory infection viruses includes ifi<NUMBER> ifit<NUMBER> mx<NUMBER> irf<NUMBER> irf<NUMBER> oas<NUMBER> ifih<NUMBER> ifi<NUMBER> plscr<NUMBER> oas<NUMBER> ifitm<NUMBER> cxcl<NUMBER> ifi<NUMBER> ptgs<NUMBER> bcl<NUMBER>a<NUMBER> cxcl<NUMBER> xaf<NUMBER> edn<NUMBER> heat map thirtyone significant genes reported fig <NUMBER>b shown tendency table <NUMBER> original analysis reported blancomelo et al <NUMBER> though statistical parameters found vary genes upregulated sarscov<NUMBER> mainly included interferoninducible genes genes mx<NUMBER> mx dynaminlike gtpase <NUMBER> irf<NUMBER> interferon regulatory factor <NUMBER> oas<NUMBER> oas<NUMBER> <NUMBER>′<NUMBER>′oligoadenylate synthetase ifi<NUMBER> interferonalpha inducible protein <NUMBER> showed consistently twofold upregulation sarscov<NUMBER> infected a<NUMBER> nhbe cells table <NUMBER> among <NUMBER> significantly upregulated genes eight genes found proviral host factors required efficient viral replication included tymp ptgs<NUMBER> c<NUMBER>s cfb ifi<NUMBER> xaf<NUMBER> cxcl<NUMBER> cxcl<NUMBER> considered drug repurposing analysis average expression level reported proviral factors sarscov<NUMBER> infected mockcontrol conditions shown fig <NUMBER>c selected <NUMBER> genes reported table <NUMBER> subjected protein level interaction functional enrichment analysis using web tool string proteinprotein interaction network constructed mainly considering interactions high confidence score <NUMBER> significant network <NUMBER> edges obtained ppi enrichment pvalue <NUMBER>e−<NUMBER> fourteen nodes network formed cluster dense overlap <NUMBER> edges nodes included ifi<NUMBER> ifi<NUMBER> ifit<NUMBER> ifit<NUMBER> ifitm<NUMBER> ifitm<NUMBER> fig <NUMBER>a node size network indicates connectivity degree gene irf<NUMBER> found highest degree <NUMBER> cluster forming genes part interferon alphabeta signaling importantly pathway enrichment analysis based reactome pathway reports signaling top enriched pathway significant fdr <NUMBER>e−<NUMBER> enriched <NUMBER> genes table <NUMBER> significant pathways cytokine signaling immune system enriched <NUMBER> genes immune system pathway <NUMBER> genes antiviral mechanism ifnstimulated gens six enriched genes top enriched pathways biological processes reported table <NUMBER> relevant pathways kegg reactome enriched set genes reported table s<NUMBER> gene ontology go enrichment analysis <NUMBER> genes reported table s<NUMBER> top five biological processes include defense response type interferon signaling pathway innate immune response response virus response organisms enriched molecular functions <NUMBER>′<NUMBER>′oligoadenylate synthetase activity doublestranded rna binding table s<NUMBER> find potential drug molecules repurposing sarscov<NUMBER> infection done drugbank search <NUMBER> upregulated genes drug groups approved experimental status considered analysis identified drug molecules target genes tabulated table <NUMBER> approved experimental drugs identified modulators protein product three genes cfb ass<NUMBER> ifngr<NUMBER> ptgs<NUMBER> pharmacological action unknown drugs targeting cfb ass<NUMBER> protein binder reported ifngr<NUMBER> importantly ptgs<NUMBER> proviral factor <NUMBER> approved drug molecules identified inhibitorantagonist ptgs<NUMBER> protein table <NUMBER> next utilized gene expression signaturebased drug repurposing strategy based cmap connectivity map using web tool clue gene set queried drug perturbation signatures identify rank drugs according similarity gene expression positive score indicates similarity negative score indicate reverse effect drug signatures queried genes magnitude contributes magnitude similarity among <NUMBER> significantly upregulated genes eight genes found proviral factors important viral infection need targeted therapy point view along eight genes nfkb<NUMBER> tlr<NUMBER> also found proviral upregulated sarscov<NUMBER> infected nhbe cells therefore ten upregulated genes tymp ptgs<NUMBER> c<NUMBER>s cfb ifi<NUMBER> xaf<NUMBER> cxcl<NUMBER> cxcl<NUMBER> nfkb<NUMBER> tlr<NUMBER> subjected connectivity mapbased gene expression signature search find therapeutic compounds could identify compounds significantly correlated anticorrelated signatures ten proviral host factors considered analysis topscored compounds cmap connectivity score tau score −<NUMBER> highest anticorrelation upregulated ten proviral genes reported table <NUMBER> <NUMBER> compounds significant anticorrelation heat map obtained clue analysis shown fig <NUMBER>b table <NUMBER> approved drugs among include estrone estrogen receptor agonist hexylresorcinol polyphenol oxidase inhibitor pentobarbital gaba receptor modulator nitrendipine calcium channel blocker phenazopyridine targeting scn<NUMBER>a heraclenol cobamamide alprazolam benzodiazepine receptor agonist bromocriptine dopamine receptor agonist wt<NUMBER> vorinostat hdac inhibitor twelve <NUMBER> top drugs found reported antiviral activity different viruses includes ritanserin jak<NUMBER>inhibitori brdk<NUMBER> tipifarnib w<NUMBER> topoisomerase inhibitor brdk<NUMBER> hexylresorcinol ly<NUMBER> sb<NUMBER> sd<NUMBER> alprazolam dilazep danoprevir highlighted table <NUMBER> structure drug molecules shown fig <NUMBER>a next analyzed potential impact reported <NUMBER> drugs natural defense infection checked correlation drugperturbed expression profile <NUMBER> antiviral proteins reported study using connectivity map among <NUMBER> drugs obtained based proviral factors seven drugs tipifarnib dilazep gw<NUMBER>x estrone myricetin guggulsterone bromocriptine reported mean connectivity score −<NUMBER> downregulate antiviral proteins therefore mentioned seven drugs impact host natural defense viral infection therefore caution needs taken also checked connectivity score ptgs<NUMBER> inhibitors obtained drugbank table <NUMBER> among <NUMBER> drugs targeting ptgs<NUMBER> six noticed high negative tau score tau score −<NUMBER> indicates possibility reducing expression proviral factors table <NUMBER> drugs include lenalidomide antiinflammatory drug celecoxib antiinflammatory drug tenoxicam antiinflammatory agent analgesic antipyretic properties meclofenamic acid antiinflammatory antipyretic properties sulfasalazine antiinflammatory drug loxoprofennonsteroidal antiinflammatory drug fig <NUMBER>b antiinflammatory drugs target ptgs<NUMBER> mefenamic acid tolmetin ibuprofen dexketoprofen generic medication drug triamcinolone generic medication anticancer drug etoposide found report high positive tau score indicates high correlation expression level proviral host factors noticed sarscov<NUMBER> infection possibility promoting viral infection medication based current analysis potential ptgs<NUMBER> inhibitors considered drug repurposing sarscov<NUMBER> reported fig <NUMBER>b metaanalysis publicly available gene expression profiles adopted identify respiratory virus infection mediated host response could identify common host genes <NUMBER>h infection models different respiratory infection viruses sarscov<NUMBER> set differentially expressed <NUMBER> genes showing consistent expression pattern sarscov<NUMBER> infected conditions nhbe a<NUMBER> cells identified apart mouse epithelial cell lines nhbe a<NUMBER> commonly used human lung epithelialderived cell lines study sars coronaviruses classical cov<NUMBER> infection though a<NUMBER> cells susceptible sarscov infection owing low expression level ace<NUMBER> receptor cell line highly permissive sarscov<NUMBER> infection rate low harcourt et al <NUMBER> a<NUMBER> cells supplemented vector expressing ace<NUMBER> enabled sarscov<NUMBER> replicate even low infection conditions blancomelo et al <NUMBER> based updates geo dataset gse<NUMBER> upregulated host factors common a<NUMBER> cells expressing exogenous ace<NUMBER> receptor calu<NUMBER> cell lines addition nhbe cells analyzed nine common genes noticed includes cxcl<NUMBER> ass<NUMBER> ube<NUMBER>l<NUMBER> irf<NUMBER> c<NUMBER>s serpina<NUMBER> irf<NUMBER> ifi<NUMBER> cfb present study based limited number datasets sarscov<NUMBER> possible candidate genes samples increased sequencing depth however study tried pick robust set genes consistent expression patterns two different cell types pathway enrichment analysis highlights interferon alphabeta signaling pathway cytokine signaling immune system enriched pathways defense immune response associated process enriched biological processes consistent host response observed various virusinfected conditions initial stage virus infection innate immune system stimulated establish first line defense interferons ifn multigene family inducible cytokines plays critical role initiating host antiviral responses boasso <NUMBER> commonly grouped type includes ifna leukocyte ifnβ fibroblast ifnω type ii ifn also known immune ifn ifnγ schlaepfer et al <NUMBER> mild cases type ifn highly effective inhibiting viral replication early short periods viremia however severe forms viral replication ability type ifn inhibit viral replication overwhelmed long et al <NUMBER> studies showed balbc mice infected severe acute respiratory syndrome sars delay type inf response leading enhanced viral replication resulting elevated lung cytokinechemokine levels vascular leakage impaired virusspecific cell responses channappanavar et al <NUMBER> ifn induces immune responses activating jakstat pathway turn forms complex interferon regulatory factor irf migrates nucleus order stimulate expressions <NUMBER> ifnstimulated genes isgs necessary inhibit viral replication teijaro <NUMBER> among isgs analysis showed ifnainducible protein <NUMBER> ifi<NUMBER> ifnainducible protein <NUMBER> elevated response viral infection among irf family members particularly irf<NUMBER> irf<NUMBER> irf<NUMBER> necessary production type ifn also ifninducible genes bego mercier cohen <NUMBER> analyses also observed increase irf<NUMBER> log<NUMBER>fc<NUMBER> irf<NUMBER> log<NUMBER>fc <NUMBER> sarscov<NUMBER> infection also respiratory virus infection altogether increase level ifn irfs isgs plays central role antiviral responses might early stage infection suggest could used diagnostic marker upon virus infection like sarscov<NUMBER> moreover another study shown multiplication sarscov cell culture strongly inhibited pretreatment interferonbeta spiegel et al <NUMBER> could suggest treatment interferonaβ mimics immediately infection might stimulate jakstat pathway turn stimulates isgs ultimately enhance antiviral effects interferoninducible transmembrane proteins ifitms identified key isgs induced interferon interfere virus entry ifitms ifitm<NUMBER> induced ifn necessary innate immunity chen et al <NUMBER> ifitm<NUMBER> ifitm<NUMBER> might reduce infectivity viruses regulating virusendosome fusion rates accelerating trafficking virusendosome lysosomes spence et al <NUMBER> similar ifitm <NUMBER>′<NUMBER>′oligoadenylate synthetases oas<NUMBER> oas<NUMBER> oas<NUMBER> induced type ifn interferons presence viral dsrna oas catalyze oligomerisation atp form <NUMBER>′<NUMBER>′linked adenosine oligomers <NUMBER>a would involve activation rnase l degradative pathway would cleave viral rna ultimately control viral infection kristiansen et al <NUMBER> leisching et al <NUMBER> analyses observed upregulation ifitm <NUMBER> <NUMBER> oas <NUMBER> virusinfected cells could due early stage infection interferoninduced protein tetratricopeptide repeats ifits strongly induced ifnaβ strong inducers whereas ifnγ acts weak inducer fensterl sen <NUMBER> ifit<NUMBER> necessary maintaining cell survival decreasing rate apoptotic cell death knockdown ifit<NUMBER> decreased production antiviral cytokine ifnβ hsu et al <NUMBER> observation showed increased expression ifit <NUMBER> <NUMBER> virusinfected cells additionally significant increase antiapoptotic protein bcl<NUMBER> related protein might involve protecting cell death viral infection interferoninduced helicase c domain <NUMBER> ifih<NUMBER> gene belonging helicase family encodes cytoplasmic receptor critical viral rna sensing viral entry ifih interacts viral rna leads polymerization ifih<NUMBER> molecules filament assembly assemble initiate signaling cascade induce type <NUMBER> ifn production leads activation antiviral genes asgari et al <NUMBER> lsam hd domaincontaining deoxynucleoside triphosphate triphosphohydrolase<NUMBER> samhd<NUMBER> protein binds viral rna exhibits exonuclease activity singlestranded nucleic acids studies showed degradation samhd<NUMBER> might enhance replication herpes viruses coinfected patients kim et al <NUMBER> mx dynaminlike gtpase <NUMBER> protein recognize binds nucleocapsids invading viruses prevents intracellular transport nucleocapsids cell nucleus ultimately leads early block viral transcription replication patzina haller kochs <NUMBER> analyses increase ifih<NUMBER> samhd<NUMBER> mx<NUMBER>during viral infection might due early stage infection e<NUMBER> ubiquitin ligase deltex <NUMBER>l another protein induced interferon forms complex poly adpribose polymerase parp<NUMBER> targets host histone h<NUMBER>bj promote isg expression also viral <NUMBER>c protease disrupt viral assembly nucleus cytoplasm zhang et al <NUMBER> phospholipid scramblase plscr<NUMBER>a multiply palmitoylated lipidraftassociated endofacial plasma membrane protein induced inf upon induction newly synthesized plscr<NUMBER> palmitoylated easily enters nuclei via importin aβ nucleopore transport binds dna induces expression certain critical antiviral genes including isg<NUMBER> isg<NUMBER> p<NUMBER> guanylate binding proteins wiedmer et al <NUMBER> dong et al <NUMBER> serine protease inhibitors serpins elements innate immune system belong largest diverse family protease inhibitors serpins reportedly interfere viral replication entry reverse transcription stages asmal et al <NUMBER> gene serpine encodes plasminogen activator inhibitor pai reported pai<NUMBER> expression significantly reduced surface expression virus receptor molecules daf car icam<NUMBER> thereby inhibits binding virus exhibits antiviral effect congote <NUMBER> study observed increase level serpine virusinfected cells argininosuccinate synthase ass catalyzes reversible atpdependent ligation citrulline aspartate generate argininosuccinate importantly ass physically interacts bacterial lipopolysaccharides lipid inactivates biological activities satoh et al <NUMBER> however much detailed mechanism investigated study along ass<NUMBER> increased e<NUMBER> ubiquitin ligase deltex <NUMBER>l plscr<NUMBER> serpin increased might one antiviral effects induced host cell early stage viral infection besides antiviral proteins host system proviral proteins consistently increased mrna level involved virusmediated infection include tp cox<NUMBER> complement <NUMBER>s factor b ifi<NUMBER> xaf<NUMBER> cxcl<NUMBER> thymidine phosphorylase tp potent angiogenic factor putative marker cellular oxidative stress upregulated patients hbv hcv infected liver tissue early event becomes prominent disease progresses cirrhosis however research carried tp viral infection mimidis et al <NUMBER> endothelin<NUMBER> et<NUMBER> shown exhibit several physiologic functions including salt water homeostasis vascular tone inflammation increased cytokines production viral infection would increase levels endothelin<NUMBER> cells bouallegue boudaou srivastava <NUMBER> upon stimulation et<NUMBER> reported increase production il<NUMBER> tnfalpha icam vcam eselectin would potentiate inflammation christcrain schuetz müller <NUMBER> thus use endothelin blockers might effectively reduce virusinduced lung inflammation prostaglandinendoperoxide synthase <NUMBER> ptgs<NUMBER> cyclooxygenase<NUMBER> cox<NUMBER> inducible proinflammatory enzyme structural proteins sarscov reported induce expression cox<NUMBER> vitro liu et al <NUMBER> increased expression pgs blood sarscovinfected individuals lee et al <NUMBER> additionally activity cox might required efficient entry also initial step rna replication suggested could targeted anticov therapy raaben et al <NUMBER> cox<NUMBER> also reported play crucial role limiting antiviral cytokineinterferon response viral infection thereby thus use effective cox<NUMBER> selective inhibitor early viral infection may enhance andor prolong endogenous interferon responses thereby might increase antiviral immunity kirkby et al <NUMBER> analyses observed cox<NUMBER> expression increased virusinfected cells complement important element innate immunity functions recognize eliminate invading microbes current study observed increased expression classical pathway protein c<NUMBER>s alternative pathway protein factor b viral infection sarscovinfected mice study reported complement activation results immunemediated damage lung c<NUMBER> deficient mice suggested inhibition complement pathway might effective therapeutic strategy inhibit coronavirusmediated respiratory diseases gralinski et al <NUMBER> chemokines family small secretory proteins expressed constitutively inducible manner important role chemokines attract leukocytes sites infectioninflammation reported chemokines cxcl<NUMBER> cxcl<NUMBER> increased herpes virus arenavirus rhabdovirus melchjorsen sørensen paludan <NUMBER> thus targeting cxcl<NUMBER> could effective therapeutic target viral infection ifi<NUMBER> cytoplasmic protein type ifninduced protein upregulated upon variety virus infections generally isgs display antiviral functions however ifi<NUMBER> reported negatively modulate antiviral responses induced multiple viral systems ifi<NUMBER> inhibiting activates nfκb migrates nucleus activates proinflammatory cytokines dediego et al <NUMBER> ifi<NUMBER> responsible pathogenesis viruses including coronaviruses dediego et al <NUMBER> xaf<NUMBER> apoptosispromoting factor binding xiap involves caspase suppression inhibits cell death reported xaf<NUMBER> promotes apoptosis denv<NUMBER>infected huvecs binding xiap also collaborates tnfrelated apoptosisinducing ligand trailinduced cell death leaman et al <NUMBER> analysis observed xaf<NUMBER> ifi<NUMBER> protein virusinfected cells could targeted viral infection present drugrepurposing approaches sarscov<NUMBER> based different host factor carried zhou et al <NUMBER> ge et al <NUMBER> used host transcriptome based proviral factors drug repurposing sarscov<NUMBER> early infection conditions among <NUMBER> upregulated genes proviral host factors sarscov<NUMBER> infection identified literaturesurvey includes tymp ptgs<NUMBER> c<NUMBER>s cfb ifi<NUMBER> xaf<NUMBER> cxcl<NUMBER> cxcl<NUMBER> genes tymp c<NUMBER>s cfb found unique sarscov<NUMBER> infection genes ptgs<NUMBER> ifi<NUMBER> xaf<NUMBER> cxcl<NUMBER> cxcl<NUMBER> reports upregulation tendency respiratory virus infections well considering proviral factors identified study therapeutic strategies sarscov<NUMBER> drugs targeting ptgs<NUMBER> found potential use obtained drugbank search could notice six antiinflammatory drugs targeting ptgs<NUMBER> lenalidomide celecoxib tenoxicam meclofenamic acid sulfasalazine loxoprofen induce anticorrelated expression signature proviral factors considered therapeutic purpose sarscov<NUMBER> infection importantly ptgs<NUMBER> inhibiting drugs celecoxib loxoprofen already reported useful treatment viral infection drug celecoxib shown decrease inflammatory gene expression context tc<NUMBER> virus infection risner et al <NUMBER> drug loxoprofen found useful patients acute upper respiratory tract infection including influenza infection azuma et al <NUMBER> importantly ptgs<NUMBER> inhibitors reported study indomethacin naproxen ibuprofen thalidomide currently clinical trials treating covid<NUMBER> approved drug molecules obtained cmap analysis different therapy area including menopausal hormone therapy estrone antiseptic hexylresorcinol antianxiety agent pentobarbital antihypertensive agent nitrendipine analgesic phenazopyridine neurological heraclenol anxiety disorder alprazolam dopaminergic activity bromocriptine anticoagulant activity wt<NUMBER> vorinostat however antianxiety agent pentobarbital reported various adverse effects hepatotoxicity laryngospasam anemia bradycardia respiratory depression aboukhaled hirsch <NUMBER> antiviral activity reported many experimental investigational compounds identified study study nukuzuma et al <NUMBER> reports <NUMBER>ht<NUMBER>ar antagonist ritanserin inhibitory effect human polyomavirus jcv infection reproduction jak<NUMBER> inhibition another antiviral strategy found block multiple cytokines protect super inflammatory response xu et al <NUMBER> tipifarnib may inhibit prenylation step hepatitis delta virus hdv replication lempp urban <NUMBER> antiviral effect species associated upper respiratory tract infection urtis known cause acute sore throat observed drug hexylresorcinol shephard zybeshari <NUMBER> alprazolam dilazep found effective influenza virus infection hiv respectively danaprevir hepatitis c virus protease inhibitor freiregarabal et al <NUMBER> zeng et al <NUMBER> gane et al <NUMBER> apart calmodulin antagonist topoisomerase inhibitor reported antiviral activity dengue virus hiv infection bautistacarbajal <NUMBER> showalter blair <NUMBER> therapeutically targeting kinases pi<NUMBER>k p<NUMBER> kinase found useful viral infection wu et al <NUMBER> griego et al <NUMBER> proposed compounds study considered validation experiments summary used publicly available human host gene expression profiles early infection conditions sarscov<NUMBER> respiratory infection viruses identified important host factors sarscov<NUMBER> infection considering consistent expression signature literature evidence could identify <NUMBER> upregulated host factors eight proviral factors sarscov<NUMBER> infection study effort identify repurposed drugs treatment sarscov<NUMBER> infection considering proviral host factors connectivity map based repurposing proposed twelve compounds evident antiviral activity literature survey apart could propose inhibition ptgs<NUMBER> potential therapeutic strategy viral infection proposed six approved ptgs<NUMBER> inhibitor drugs repurposed treatment sarscov<NUMBER> infection study based presently available dataset public domain databases may fluctuate based sample selection analysis therefore considered strict criteria consistency expression patterns evidence literature selection host factors repurposing studies rapid therapeutic recommendations computational approach repeated rnaseq datasets become available could done proteinlevel need validated wetlab experiments clinical trials recent outbreak coronavirus disease <NUMBER> outbreak could force impose major changes health system across globe possible bring major challenges human survival followed struggling keep global economy correct pace spread virus eff ectively controlled <NUMBER> <NUMBER> causative agent devastating disease covid<NUMBER> belongs beta coronavirus shares <NUMBER> nucleotide similarity acute respiratory syndrome coronavirus sarscov <NUMBER> key amino acid residues conserved many viral key drug targets including found sarscov covid<NUMBER> pathogens consequently many common viral targets structurally similar sarscov likely inhibited compounds emergence covid<NUMBER> severely compromised arsenal antiviral antibiotic drugs new compounds targets needed meet growing threat beta coronavirus possibility covid<NUMBER> virusesbacteria perniciously engineered biowarfare agents creates another demand new treatment options drug discovery multistep process high attrition rate substantial cost slow pace development new molecules clinical candidate side drug repurposing also called old drugs new uses attractive alternative approach new application fda approved investigational drugs outside scope original medical condition <NUMBER> plethora literature evidence indicated vital application drug repurposing various infectious diseases <NUMBER> <NUMBER> <NUMBER> given current scenario covid<NUMBER> outbreak across world complex nature disease repurposing existing fda approved drugs first line treatment given pandemic nature disease hardpressing need uncover possible treatments early possible researchers physicians putting sincere efforts understand new virus pathophysiology disease possible therapeutic effective agents vaccines tremendous effects done study newly emerged virus find potent drugs clinical usage pubmed search key work covid<NUMBER> resulted <NUMBER> publications november <NUMBER> <NUMBER> april <NUMBER> <NUMBER> glance title papers indicated majority focused manifestations treatment options shown literature fda approved antimalarial autoimmune disease drug chloroquine cq hydroxychloroquine hcq known inhibit viral infection raising endosomal ph necessary interaction viruscell fusion <NUMBER> <NUMBER> <NUMBER> cq hcq interferes ace<NUMBER> glycosylation glycosyltransferases within human cells inhibits sialic acid biosynthesis inhibiting quinone reductase <NUMBER> immunomodulatory property chloroquine synergistically involved antiviral property antiviral drug remdesivir rdv inhibit growth covid<NUMBER> found efficacious clinic combination <NUMBER> <NUMBER> <NUMBER> <NUMBER>the mechanism action rdv investigation however high sequence similarity <NUMBER> covid<NUMBER> sarscov rnadependent rna polymerase rdrp indicating inhibition rdrp similarly broadspectrum virushost cell fusion inhibitor marketed antiviral drug arbidol abd prevents entry virus entry host cell acting ace<NUMBER> entered clinical trial treatment covid<NUMBER> <NUMBER> <NUMBER> inspired current pandemic situation experience drug repurposingdrug design computational medicinal chemistry tools carried docking studies selected fda approved drugs covid<NUMBER> selected key protein targets given complex nature rapidly severely infecting lower respiratory system disease hypothesis identify fda approved drug combinations targeting different key viral proteins selection key proteins based virus life cycle starting attachment onto human host replication viral latency invasion immunity release complex nature disease selection four key targets pdb id <NUMBER>lzg structure novel coronavirus spike receptorbinding domain complexed receptor ace<NUMBER> pdb id <NUMBER>nur recently identified sarscoronavirus nsp<NUMBER> bound nsp<NUMBER> expand specificity performed online docking using covid improve next publications table <NUMBER> receptor pocket top <NUMBER> conformers shown figure <NUMBER> b figure <NUMBER>b negative free energy calculation <NUMBER> kcalmole shown table <NUMBER> indication interaction abd nonstructural viral proteins docking studies abd nsp<NUMBER>nsp<NUMBER> however docking methodology work well target resulted high positive values binding energy data shown improve next publications report preliminary docking studies selected fda approved drugs shown promising anticovid<NUMBER> activity literature evidences indicating single drug probably effective treatment disease viral polymerases proteases known suitable targets treatment viral born disease therefore selected targets cover range targets starting entry point multiplication release viruses advent devastating covid<NUMBER> pandemic <NUMBER> left <NUMBER> million people infected <NUMBER> deaths world httpswwwwhointemergenciesdiseasesnovelcoronavirus<NUMBER> numbers demonstrate largescale damage virus caused global scale covid<NUMBER> world health organization designated disease caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> du toit <NUMBER> httpswwwwhointemergencies diseasesnovelcoronavirus<NUMBER>technicalguidance namingthecoronavirusdiseasecovid<NUMBER>andthevirusthatcausesit since absolute definitive drug vaccine available contain spread deadly virus management strategy disease primarily aimed treating symptoms jin et al <NUMBER> lack treatment options led increased number fatalities due disease abbas et al <NUMBER> et al <NUMBER> academic labs drug discovery organizations world working tirelessly evaluate compounds inhibit spread sarscov<NUMBER> humans achieve essential first identify drug targets subsequently identify evaluate compounds biologics effectively engage targets inhibit spread alexander et al <NUMBER>a b dong et al <NUMBER> however efforts arduous involve painstakingly long process therefore parallel also evaluate known antivirals repurpose either single agents combinations effectively contain spread virus ahn et al hijikata et al <NUMBER> jeon et al <NUMBER> order global concerted efforts required rapid clinical trials need conducted evaluate role potential candidate compounds particular disease population setting since onset century coronaviruses created pandemiclike situation least two earlier events first severe acute respiratory syndrome sars pandemic beginning <NUMBER>st century middle east respiratory syndrome mers outbreak almost decade alomari et al <NUMBER> centers disease prevention <NUMBER> holmes <NUMBER> pandemics caused viruses belonging coronavirus family viruses benvenuto et al <NUMBER> fact symptoms sars current covid<NUMBER> pandemic patients quite similar reaffirming fact viruses quite similar genomic constitution mode transmission kandeel et al <NUMBER> kumar et al <NUMBER> xie chen <NUMBER>a however since sars epidemic sarscov<NUMBER> virus undergone mutations becerraflores cardozo <NUMBER> biswas et al <NUMBER> bzowka et al <NUMBER> poterico mestanza <NUMBER> yin <NUMBER> thus drugs developed sars virus might effective containing virus spread order understand drug targets appreciate ongoing efforts directed towards identification therapies sarscov<NUMBER> important understand virus biology mode transmission replication cycle especially important since effective therapy sarscov<NUMBER> preferably target stages virus life cycle review potential drug targets drug candidates sarscov<NUMBER> discussed overview current status drug development sarscov<NUMBER> infection provided equally important efforts towards vaccine development excluded review topic covered separate indepth review mukherjee <NUMBER> sarscov<NUMBER> member coronaviruses cov class viruses cov essentially positivestranded rna viruses display crownlike appearance surface observed electron microscope due presence crownlike structure class viruses called coronaviruses coronam latin term crown alanagreh et al <NUMBER> rehman et al <NUMBER> structurally crownlike structures glycoprotein present viral envelope facilitate virus entry host cells coutard et al <NUMBER> four known subfamilies coronaviruses classified alphacoronavirus betacoronavirus gammacoronavorus deltacoronavirus li et al <NUMBER>a although zoological evolution coronaviruses still active research subject widely accepted alphaand betacoronaviruses predominant bats rodents whereas deltaand gammacoronavirus gene sources avian species brussow <NUMBER>a cascella et al <NUMBER> coronaviridae study group international committee taxonomy <NUMBER> causative virus covid<NUMBER> pandemic sarscov<NUMBER> virus part betacoronavirus subfamily believed crossed species barrier infect humans due zoonotic transmission mackenzie smith <NUMBER> zimmermann curtis <NUMBER> hallmark coronavirus transcription production multiple subgenomic rnas containing sequences corresponding genomic ends song et al <NUMBER> viruses utilize rnadependent rna synthesis generate mrnas transcribed host genome genetically sarscov<NUMBER> positivesense singlestranded rna virus genome size <NUMBER> kb encodes two open reading frames orfs ceraolo giorgi <NUMBER> dabravolski kavalionak <NUMBER> yang et al <NUMBER> orfs designated <NUMBER>a <NUMBER>b code protease <NUMBER>clpro plpro proteases cleave polypeptide <NUMBER> nonstructural proteins nsp essentially viral enzymes involved replication packaging virus within host cell four structural proteins contribute outer structure virus jean et al <NUMBER> mckee et al <NUMBER> van boheemen et al <NUMBER> like coronaviruses outer surface sarscov<NUMBER> virus made spike protein envelope e protein membrane protein nucleocapsid n protein e proteins involved virus morphogenesis assembly spike protein forefront infection interacts ace<NUMBER> receptor host cell surface thereby promoting viruscell membrane fusion initiation viral infection envelope e membrane protein constitute cover outside viral genetic material inside shell e proteins rna guarded nucleocapsid protein glebov <NUMBER> nietotorres et al <NUMBER> nietotorres et al <NUMBER> wellaccepted fact sarscov<NUMBER> transmission facilitated respiratory secretions form dropletaerosol person comes close contact infected person guo et al <NUMBER>a b recent reports suggest infection also spread stool urine respiratory secretions casanova et al <NUMBER> ding et al <NUMBER> wang et al <NUMBER>b soon sarscov<NUMBER> virus enters human body establishes cycle replication binding cell types enterocytes pneumocytes virus also infect tubular renal epithelial cells bao et al <NUMBER> immune cells annweiler et al <NUMBER> cerebral neurons bilinska et al <NUMBER> xie chen <NUMBER>b spike protein present surface sarscov<NUMBER> responsible primary establishment hostprotein interaction spike protein binds angiotensinconverting enzyme<NUMBER> ace<NUMBER> receptor present host cell plasma membrane annweiler et al <NUMBER> hasan et al <NUMBER>b post receptor recognition viral genome including nucleocapsid released cytoplasm host cell shown figure <NUMBER> mentioned sarscov<NUMBER> viral genome two orfs <NUMBER>a <NUMBER>b orfs translate two polypeptides pp pp<NUMBER>a pp<NUMBER>b turn hijack host cellular ribosomes translational process thereby making replicationtranscription complex bojkova et al <NUMBER> dong et al <NUMBER> polypeptide processed proteases processing results <NUMBER> nonstructural proteins nsps specific function replication transcription hillen et al <NUMBER> te velthuis et al <NUMBER> nsp<NUMBER> <NUMBER> involved suppression host gene expression nsp<NUMBER> involved replication whereas nsp<NUMBER> <NUMBER> transmembrane proteins kandeel et al <NUMBER> stobart et al <NUMBER> zhang et al <NUMBER>b nsp<NUMBER> <NUMBER> act primases nsp<NUMBER> rnabinding protein dimeric form nsp<NUMBER> critical viral infection disruption dimerization could potential strategy inhibit infection nsp<NUMBER> involved replication nsp<NUMBER> rnadependent rna polymerase nsp<NUMBER> helicase activity nsp<NUMBER> demonstrates exonuclease activity nsp<NUMBER> endoribonuclease activity nsp<NUMBER> possesses methyltransferase activity athmer et al <NUMBER> hillen et al <NUMBER> hu et al <NUMBER> jia et al <NUMBER> mirza froeyen <NUMBER> neogi et al <NUMBER> nsps help host machinery translate rna coding viral spike envelope nucleocapsid membrane proteins proteins enter endoplasmic reticulum er golgi apparatus involved viral assembly packaging viral genome binds nucleocapsid n protein results formation ribonucleoprotein complex rnp cong et al <NUMBER> gui et al <NUMBER> narayanan et al <NUMBER> narayanan et al <NUMBER> depicted figure <NUMBER> coronaviruses exploit hosts endosomal pathway gain entry host cell virus entry host cell energetically unfavorable process brielle et al <NUMBER> viruses able overcome barrier due low ph environment phdependent endosomal cysteine protease du et al <NUMBER> simmons et al <NUMBER> zhang et al <NUMBER> host proteases transmembrane protease serine <NUMBER> tmprss<NUMBER> tmprss<NUMBER>d also known airway trypsinlike protease involved processing spike protein constituent subunits s<NUMBER> s<NUMBER> promote virus entry plasma membrane host iwatayoshikawa et al <NUMBER> maggio corsini <NUMBER> matsuyama et al <NUMBER> agents modify ph inhibit proteases potential drug targets anticoronavirus therapy baglivo et al <NUMBER> bein et al <NUMBER> finally virus particle assembled exploits hosts exosomal pathway fuses plasma membrane resulting release virus particles extracellular region upon infection viral load increases host body results increase proinflammatory cytokines alosaimi et al conti et al <NUMBER> magro <NUMBER> chemokines alosaimi et al <NUMBER> channappanavar perlman <NUMBER> gralinski et al <NUMBER> skinner et al <NUMBER> potential damage lung tissue tanaka et al <NUMBER> leading deterioration lung function finally lung failure brussow <NUMBER>b antiviral drugs targeting sarscov<NUMBER> classified two major classes first group targeting virushost interactions inhibiting viral assembly zhou et al <NUMBER>b approach would include drugs modulate broadspectrum host innate immune responses interfere signaling pathways involved viral replication drugs may capable engaging host receptors proteases utilized viral entry may impact endocytosis pathway channappanavar perlman <NUMBER> dong et al <NUMBER> hijikata et al <NUMBER> jeon et al <NUMBER> liu et al <NUMBER>b mckee et al <NUMBER> sanders et al <NUMBER> essentially three general approaches utilized screening antiviral compounds capable inhibiting covid<NUMBER> infection first approach check existing antiviral compounds molecules estimate effect viral replication packaging molecules like interferon alpha beta gamma ribavirin chemical inhibitors cyclophilin <NUMBER> malauer et al <NUMBER> zhang et al <NUMBER>a evaluated antiviral activities known antivirals strategic advantage since active clinical use pharmacokinetic pharmacodynamic properties well studied flip side drugs might lack specificity sarscov<NUMBER> thus may severe adverse effects ahn et al <NUMBER> busquet et al <NUMBER> second approach involves screening chemical libraries constitute compounds targeting transcriptional machinery various cell lines highthroughput screening technology potential screen large libraries druglikely chemical compounds chemical entities antiviral effects even libraries existing drugs screened support drug repurposing efforts thereby leading identification new functions many known drug molecules berdigaliyev aljofan <NUMBER> de wilde et al <NUMBER> dyall et al <NUMBER> kindrachuk et al <NUMBER> lu et al <NUMBER> marketed drugs like lopinavirritonavir earlier intended used antihiv therapy subsequently used treat sars emerged result successful execution screening programs chu et al <NUMBER> cvetkovic goa <NUMBER> however serious disadvantage approach hits obtained screenings may immunosuppressive cytotoxic effects higher concentrations another disadvantage halfmaximal effective concentration ec<NUMBER> drugs required effective sarscov<NUMBER> infection might exceed highest serum concentration cmax levels achieved pharmacological dosing mirza froeyen <NUMBER> third approach could involve development specific novel agents resulting strong basic research around genomic biophysical understanding sarscov<NUMBER> life cycle sirna molecules inhibitors capability inhibit specific viral enzymes involved viral replication cycle monoclonal antibodies targeting host receptor ace<NUMBER> could result endeavor hasan et al <NUMBER>b approach potential return large number virusspecific promising therapies sarscov<NUMBER> virus one major hurdles therapies specific drug delivery molecules lack understanding sirnabased therapy lesch et al <NUMBER> sohrab et al <NUMBER> due immense financial implications resource implications time implications involved novel drug discovery process pharmaceutical companies researchers field inclining towards relying drug repurposing efforts ashburn thor <NUMBER> name suggests using approach known drug investigational drug candidate drug studied new uses beyond scope original intended medical indication researchers institutions also term drug repurposing drug repositioning drug reprofiling drug retasking depending final outcome studies scannell et al <NUMBER> strategy considerably lower risk failure investigational drugs since toxicity profile drug already well evaluated cases adverse effects well documented pammolli et al <NUMBER> importantly strategy help save time involved drug development since preclinical testing safety assessment even formulation development already completed repurposed drugs nosengo <NUMBER> also since drugs undergone clinical trials earlier repurposed drugs potentially skip phases <NUMBER> <NUMBER> trials based therapeutic indication adverse effect profile repurposed drugs considered directly large scale phase <NUMBER> trials breckenridge jacob <NUMBER> another important use repurposed drugs drug combination therapy use drugs modulated effective novel drug combinations urquhart <NUMBER> also initial drug repurposing experiments require elaborate laboratory settings often new indications combinations postulated using insilico approaches hurle <NUMBER> time exciting approach suffers pitfalls cautious consideration required positioning drug new therapeutic indication mostly drug repurposing studies driven drug targets identified drug targets might demonstrate polypharmacology thereby leading adverse side effects aguilera et al <NUMBER> cheng <NUMBER> karuppasamy et al <NUMBER> also experimental screening studies usually higher dose used might lead misidentification compound active corresponding pharmacological dose might toxic time effective plasma concentrations drugs might higher maximum tolerable pharmacological dose oreover substantial structural modification drug might change toxicity profile thereby warranting fresh toxicity studies colson raoult <NUMBER> strittmatter <NUMBER> many pharmaceutical companies still shy completely harnessing potential drug repurposing due attached intellectual property burden associated costs farha brown <NUMBER> fetro scherman <NUMBER> talevi bellera <NUMBER> yildirim et al <NUMBER> nevertheless drug repurposing approaches broadly divided two broad categories <NUMBER> computational approach bioinformatics tools used identify new indications drugs already use approach relies big data analysis artificial intelligence ai issa et al <NUMBER> ke et al <NUMBER> lee chen <NUMBER> <NUMBER> experimental approach traditional approach relies vitro experiments postulate new applications drugs cha et al <NUMBER> martorana et al <NUMBER> figure <NUMBER> shows hierarchical view approaches used drug repurposing computational approaches drug repurposing largely datadriven involve systematic analysis gene expression chemical structure proteomic data electronic healthcare records commonly used computational approaches include signature matching koudijs et al <NUMBER> computational molecular docking pinzi rastelli <NUMBER> trosset cave <NUMBER> genomic association analysis nabirotchkin et al <NUMBER> pathway network mapping infante et al <NUMBER> zhou et al <NUMBER>b retrospective analysis using electronic health records approved drugs karaman sippl <NUMBER> pereira et al <NUMBER> shi et al <NUMBER>b <NUMBER> signature matching every drug investigational drug candidate possesses unique characteristics signature like transcriptomic effect profile structural adverse effect profile matching characteristicssignatures another disease drug repurposing achieved karaman sippl <NUMBER> koudijs et al <NUMBER> using approach drug repurposing researchers rely either drugdisease comparison drugdrug comparison first case signatures particular drugs gene expression profile treatment compared differential gene expression profile obtained similarly comparing profiles healthy diseased jhamb et al <NUMBER> khosravi et al <NUMBER> one drug repurposing example taken approach topiramate normally used antiepileptic drug acts agonist gamma amino butyric acid gaba activity dudley <NUMBER> dudley et al <NUMBER> based studies dudley coworkers using drugdisease approach established topiramate also used inflammatory bowel disease ibd signatures comparable prednisolone treatment choice ibd dudley <NUMBER> drugdrug similarity approach identifies common mechanism action drugs belong different classes usually structurally <NUMBER> computational molecular docking computational molecular docking indispensable tool drug repurposing activities chen et al <NUMBER> cicaloni et al <NUMBER> using structurebased computational strategy binding efficiency predicted drug target molecule elfiky <NUMBER> method largeand smallscale screens conducted known drugs disease target brindha et al <NUMBER> kitchen et al <NUMBER> however technique limitations many targets <NUMBER>d structure elucidated lack available screenable macromolecular database provide structural information varied molecular class drug xia <NUMBER> zhou et al <NUMBER> <NUMBER> network mapping molecular pathway network mapping one commonly used methods drug repurposing many identified drug targets directly druggable direct inhibition might lead severe adverse effects thus network mapping inform upstream downstream druggable targets thereby enabling drug repurposing oulas et al <NUMBER> zhou et al <NUMBER>b based gene expression pattern disease pathology drug disease networks created using network mapping tools gns et al <NUMBER> janardhan et al <NUMBER> maps networks open enormous possibilities drug repurposing advances information technology artificial intelligence ai bigdata analysis revolutionizing drug repurposing efforts studies mucke <NUMBER> help machine learning tools computational algorithms developed predict new drug target engagement far greater accuracy earlier used methods alvarezmachancoses et al approaches drug repurposing also utilized scout drugs effective antivirals screening database small molecules viral drug targets using computational methods drugs molecules identified may possess antiviral activity pizzorno et al <NUMBER> cao et al <NUMBER> rossignol <NUMBER> also found active viral infections lessons sars mers epidemic used develop therapies sarscov<NUMBER> infection zumla et al <NUMBER> veronese et al <NUMBER> scenario given similarity sarscov mers virus along sarscov<NUMBER> virus insight treatment options available sars mers could provide valuable inspirations drug discovery repurposing zumla et al <NUMBER> however sars mers specific treatment recommended rather recommended managing disease based patients symptoms graham et al <NUMBER> year <NUMBER> sars pandemic like covid<NUMBER> caught world surprise early days sars pandemic patients hong kong canada treated combination ribavirin corticosteroids rainer <NUMBER> however subsequent reports indicated towards ribavirins high rate toxicity lack ability control infection spread booth stewart <NUMBER> sung et al <NUMBER> wong et al <NUMBER> use corticosteroid methylprednisolone controversial far sars concerned multiple cases doserelated toxicity observed lower dose methylprednisolone <NUMBER>mgday demonstrated improvement subset critical sars patients however prolonged usage absence specific antimicrobial agent predisposed patients disseminated fungal infection chan et al <NUMBER>a b tsang seto <NUMBER> tsang lam <NUMBER> avascular necrosis chan et al <NUMBER>a b based localized singlecenter uncontrolled clinical studies recommended corticosteroids used rescue therapy treatment might impair host viral clearance sung et al <NUMBER> viral infections hepatitis b c successfully treated interferon treatment christian et al <NUMBER> since interferon also broadspectrum antiviral used singlecenter openlabelled uncontrolled clinical settings sars small trials patients stable posttreatment interferon combination corticosteroids results pointed perhaps interferon treatment lung deterioration delayed although could proven statistically zhao et al <NUMBER> also post treatment improved oxygen saturation levels lower creatine phosphokinase levels observed critically ill patients however warranted properly designed clinical trials globally loutfy et al <NUMBER> combination viral protease inhibitor ritonavir <NUMBER> mg lopinavir <NUMBER> mg administered orally <NUMBER> h interval <NUMBER> <NUMBER> days standard therapy yielded promising outcome hong kongbased clinical studies chan et al <NUMBER>a b subjects showed reduction steroid dependency nosocomial infections time reduction viral load concomitant increase peripheral lymphocyte count observed combination appears promising even covid<NUMBER> well combination tested clinical trials however serious adverse effects also reported patients undergoing treatment sars infection combination subjects observed suffer pancreatitis diarrhea abdominal pain liver dysfunction among associated discomforts like abdominal pain asthenia headache nausea insomnia skin rash chu et al <NUMBER> date specific definite antiviral drug available treatment covassociated pathologies table <NUMBER> summarizes drug targets compounds active sarscov<NUMBER> current development status pros cons proposed therapy sarscov<NUMBER> utilizes spike protein present viral surface gain entry host cells proteinprotein interaction takes place subunits spike protein active site ace<NUMBER> receptor targeted identify effective treatment strategy wrapp <NUMBER> dediego et al <NUMBER> hasan et al <NUMBER>a mathewson et al <NUMBER> specifically receptor binding domain rbd spike protein critical target antibodymediated disruption binding many antibodies demonstrating ability disrupt binding preclinical stages development chen et al <NUMBER> tai et al <NUMBER> tian et al <NUMBER> another strategy engage overwhelm ace<NUMBER> receptor recombinant human ace<NUMBER> normally present cell surface delivering excess soluble ace<NUMBER> helps neutralize virus competitively binding sarscov<NUMBER> rhace<NUMBER> gsk<NUMBER> ameratunga et al basit et al <NUMBER> openlabeled randomized controlled pilot clinical trial progress evaluate approach nct<NUMBER> apart ace<NUMBER> receptor cellular serine protease tmprss<NUMBER> also plays important role facilitating entry virus host cells hoffmann <NUMBER> clinically proven chemical inhibitor tmprss<NUMBER> camostat mesylate also able significantly reduce infection cell lines human lung origin rahman et al <NUMBER> shirato et al <NUMBER> sternberg et al <NUMBER> addition heptad repeat <NUMBER> hr<NUMBER> heptad repeat <NUMBER> hr<NUMBER> present sarscov<NUMBER> also implicated facilitation cell membrane fusion hr<NUMBER>derived peptides exhibit effective fusion inhibitory activity bosch et al <NUMBER> huang et al <NUMBER> wang et al <NUMBER> xia et al <NUMBER>a xia et al <NUMBER>b known post fusion spike protein ace<NUMBER> receptor virus ingested cells ph receptordependent endocytosis chu et al <NUMBER> glebov <NUMBER> targeting endocytosis another potential strategy towards developing potential drug candidates sarscov<NUMBER> clathrinmediated endocytosis regulated ap<NUMBER>associated protein kinase <NUMBER> aak<NUMBER> uitdehaag et al <NUMBER> based library screening janus kinase inhibitor baricitinib identified possible candidate drug sarscov<NUMBER> baglivo et al cantini et al <NUMBER> lo caputo et al <NUMBER> also oubain another inhibitor clathrinmediated tested efficacy drug trials sarscov<NUMBER> positive patients sisk et al <NUMBER> recently chloroquine derivative hydroxychloroquine garnered great interest therapy sarscov<NUMBER> infection alexander et al <NUMBER>a alia grantkels <NUMBER> arnold buckner <NUMBER> ballout et al <NUMBER> costanzo et al <NUMBER> several clinical trials underway assess contribution chloroquine therapy inhibiting sarsc<NUMBER>v<NUMBER> viral progression keshtkarjahromi bavari <NUMBER> also shown vitro derivative chloroquine hydroxychloroquine ec<NUMBER> <NUMBER>lm far potent inhibiting sarscov<NUMBER> infection chloroquine ec<NUMBER> <NUMBER> lm savarino et al <NUMBER> yao et al <NUMBER> although exact molecular mechanism hydroxychloroquine treatment covid<NUMBER> remains elusive believed hydroxychloroquine may impair endosomemediated viral entry late stages viral replication devaux et al <NUMBER> result aggressive antiviral drug development discovery programs undertaken past multiple drugs developed viral proteases polymerases helicases martinez <NUMBER>b drugs developed viral diseases remdesivir wang <NUMBER> flavipiravir li et al <NUMBER>b lopinavirritonavir beck et al <NUMBER> costanzo et al <NUMBER> gyebi et al <NUMBER> schoergenhofer et al <NUMBER> presently evaluated clinical trials efficacy containing covid<NUMBER> pandemic remdesivir antiviral drug developed ebola adenosine analog inserts viral rna chains rnadependent rna polymerases rdrps results premature transcription termination cao et al <NUMBER> gordon et al <NUMBER> similarly favipiravir ribaviorin guanine analogs approved viral diseases costanzo et al <NUMBER> fan et al <NUMBER> eidd<NUMBER> another oral antiviral drug acts nucleotide analog like remdisivir albeit lower ec<NUMBER> orally administrable agostini et al <NUMBER> antiviral compounds lopinavir ritonavir protease inhibitors target <NUMBER>clike protease <NUMBER>clpro sarscov<NUMBER> bhatnagar et al <NUMBER> main coronavirus protease <NUMBER>clpro responsible processing polypeptide nsps using highthroughput screening compounds <NUMBER>clpro four molecules viz prulifloxacin tegobuvir bictegravirand nelfinavir identified barnard et al inhibition viral envelope membrane nucleocapsid accessory proteins sarscov<NUMBER> envelope e membrane nucleocapsid n protein critical virus survival propagation therefore structural proteins best drug targets since viral proteins structurally different host proteins drug targeting proteins minimal adverse effects apart protecting viral genome structural proteins also involved suppressing host immune system thereby providing virus strategic advantage host bojkova et al <NUMBER> borgio et al <NUMBER> cherian et al <NUMBER> n protein acts suppress rna silencing suppresses rna interferencemediated sirna therefore many sirna based therapeutics target viral e n protein translation inhibit viral replication least vitro nur et al <NUMBER> sohrab et al <NUMBER> song et al <NUMBER> however sirnabased therapies still available human use due inherent stability issues unavailability reliable delivery methods de clercq <NUMBER> e protein also serves ion channel action inhibited hexamethylene amiloride pervushin et al <NUMBER> another chemical inhibitor pj<NUMBER> targets unique ribonucleotidebinding pocket nterminal domain n protein lin et al <NUMBER> important note inhibitors designed sars virus due mutations sarscov<NUMBER> virus inhibitors may effective fighting ongoing covid<NUMBER> pandemic lj<NUMBER> lj<NUMBER> broadspectrum antiviral compounds inhibit viral entry host cells also damage viral membrane producing singlet oxygen molecules unfortunately lj<NUMBER> physiologically unstable photodependent barlow et al <NUMBER> nevertheless lj<NUMBER> defines new class antiviral compounds research class compounds yield encouraging results wellorchestrated cytokine response critical host immune response reported sarscov<NUMBER> infected patients demonstrate hyperinflammatory response possibly due deregulated cytokine response reported covid<NUMBER> patients icu high cytokines plasma compared nonicu patients suggesting cytokine dysregulation involved severe form covid<NUMBER> disease channappanavar perlman <NUMBER> liu et al <NUMBER>c additionally sarscov<NUMBER>infected patients admitted icu display increased levels gmcsf il<NUMBER> cd<NUMBER> cells compared icu naïve patients boettcher et al <NUMBER> facts point possibility inhibition excessive inflammatory response might reduce severity covid<NUMBER> disease corticosteroids known excellent pharmacological potential suppressing systemic inflammation liu et al <NUMBER>a zha et al <NUMBER> however use covid<NUMBER> patients still debatable requires detailed study demonstrated onset sarscov<NUMBER> infection cd<NUMBER> cells activated produce gmcsf inflammatory cytokines thus resulting induction cd<NUMBER> cd<NUMBER> monocytes high expression interleukin <NUMBER> il<NUMBER> conti et al <NUMBER> liu et al <NUMBER>a observation leads possibility blocking il<NUMBER> receptor could potentially reduce immune stress caused sarscov<NUMBER> line observation multicenter randomized controlled clinical trial currently underway using il<NUMBER> receptorspecific antibody another recent advance covid <NUMBER> treatments convalescent plasma treatment infection rates growing specific therapy available therapy convalescent plasma cp proposed principal treatment therapy plasma obtained donor recovered disease used develop humoral immunity sarscov<NUMBER>infected patients plasma donor patient acts source human antibodies infection jawhara <NUMBER> shi et al <NUMBER>a b however large scale human trials need conducted better understand evaluate cp method treatment covid<NUMBER> many pharmaceutical giants jumped race find drug sarscov<NUMBER> infected patients given high number fatalities across globe even regulatory authorities giving rapid approvals conduct clinical trials promising candidate drugs table <NUMBER> shows list companies conducting clinical trials seeking approval regulatory authorities conduct trials since onset sars epidemic much knowledge generated drug targets candidate molecules developed well kumar et al <NUMBER> however molecules could taken clinical trials since enough patients suffering sars virus time drugs developed nevertheless information tremendous use since sarscov sarscov<NUMBER> share striking similarities genome replication cycle even symptoms experienced patients su lai <NUMBER> systemic genomic comparisons revealed striking <NUMBER> similarity nucleotide level sarscov<NUMBER> sarscov however <NUMBER> nucleotide similarity observed spike protein viruses zhang holmes <NUMBER> biochemical level virus display preferential binding ace<NUMBER> receptor even clinical level chest xrays patients infected either sarscov sarscov<NUMBER> display multilobar ground glass like opacities similarly ct scan patients infected either virus display lobar consolidations ceccarelli et al <NUMBER> however since sars epidemic virus mutated considerably result spike protein quite different previous version fact makes efforts find drugs inhibit virus entry host cells quite difficult cts humans started next four months <NUMBER> information collected company web sites press release ct clinical trial na status known companies also relying drug repurposing beck et al <NUMBER> wang et al <NUMBER> like chloroquine sanofi planned tested coronavirus patients world meanwhile companies like abbvie gilead regeneron testing known antiviral combinations patients affected sarscov<NUMBER> virus httpswwwabbviecom coronavirushtml approach provides strategic advantage ongoing efforts pharmacological effect single drugs wellstudied human body also know exact mechanism action dose regimen antivirals using combination inhibit <NUMBER> drug targets winning combination borges nascimento et al <NUMBER> globally scientists health authorities eagerly waiting interpret results obtained trials meantime companies like takeda lilly working antibody therapy evaluating efficacy therapeutic molecules breakneck speed aegis solidarity clinical trial underway evaluate treatment opportunities available covid<NUMBER> patients trial conducted simultaneously <NUMBER> countries trial four treatment options compared standard care options sarscov<NUMBER>infected patients trial test efficacies remdesivir chloroquine hydroxychloroquine single agents lopinavir combination ritonavir lopinavir ritonavir plus interferon beta<NUMBER>a httpswwwwhoint emergenciesdiseasesnovelcoronavirus<NUMBER>globalresearchonnovelcoronavirus<NUMBER>ncovsolidarityclinicaltrialforcovid<NUMBER>treatments unfortunately time writing article <NUMBER> confirmed patients suffering sarscov<NUMBER> <NUMBER> reported deaths across globe novel infectious diseases resulting zoonotic transmission everevolving mutating coronaviruses continue pose global threat peoples lives global economy today despite suffered two major coronavirusrelated outbreaks like sars mers world remains underprepared formidably accept challenge global pandemic like covid<NUMBER> still clueless handling disease far away definite line treatment sarscov<NUMBER> virus extremely critical concerted effort across globe undertaken find robust cure coronavirusesrelated illness given arduous costsensitive road map novel drug development utmost importance develop broadspectrum antivirals act common features coronavirus lifecycle drug repurposing broadened combination drugs evaluated patient trials allow inhibition disease one target although lot learn sars mers epidemic lot research performed develop suitable cure cannot applied covid <NUMBER> due viral evolution across globe serious efforts ongoing find compounds drugs decrease covid<NUMBER> progression likely prospects covered review collaboration microsoft maintains active database ongoing trials compounds active sarscov<NUMBER> httpswwwwhointictrp searchen extraordinary collaborations technology exchange area antiviral drug discovery clinical trials expedite patient access reliable drugs improved therapeutic potential also considerably reduce timetomarket candidate drugs current ongoing research lead collective drug discovery efforts partnership research institutes industries paramount importance repurposing approved pharmaceutical drugs additional applications efficient alternative approach advancing therapeutic development costand timeeffective manner advantages repurposing drugs existence clinical data availability affordable drugs patients viral infection major problem morbidity mortality animals humans worldwide <NUMBER> therapeutic drugs approved fda treat viral infections since <NUMBER> among agents ten used treat hepatitis c virus hcv hiv one used treat cytomegalovirus cmv one used treat influenza virus ifv limitations available agents controlling viral infections emerging resistance antiviral drugs underline urgent need effective drugs manage viral infections coronavirus cov ifv see glossary full list abbreviations two major respiratory pathogens causing significant morbidity mortality animals humans worldwide cov enveloped positivesense rna virus classified coronaviridae family including severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov human coronavirus<NUMBER>e hcov<NUMBER>e sars mers well recognized globally owing outbreaks severe infection <NUMBER> however lack effective therapeutic drugs control sars mers means high morbidity mortality rates reduced <NUMBER> addition high morbidity mortality emergence new widehostrange viral members potential domestic animal adaptation difficulty identifying intermediate hosts major concerns control cov infection ifv enveloped negativesense rna virus associated orthomyxoviridae family consisting ifva b c genera ifv causes seasonal outbreaks pandemic zoonotic diseases <NUMBER> vaccination used control epidemic ifv decades antiviral agents developed target ifv m<NUMBER> ion channels amantadine rimantadine neuraminidases zanamivir oseltamivir however use agents results substantial drug resistance <NUMBER> <NUMBER> directacting antivirals daas including vaccines therapeutic agents developed directly target specific viral components however concerns approaches include ineffective control viral infections resistance daas result mutationassociated variations evolved new viral variants thus therapeutics targeting host cellular machineries essential viral infection considered developing broadspectrum agents overcome viral variations drug resistance hosttargeted antivirals htas designed target specific steps viral infection including viral binding host cells viral entry host cells viral replication viral budding example fdaapproved ccr<NUMBER> receptor antagonist maraviroc mvc effective inhibit r<NUMBER>tropic hiv<NUMBER> entry cells <NUMBER> treatment humanized igg<NUMBER> monoclonal antibody ibalizuman blocks entry hiv<NUMBER> cells noncompetitive binding cd<NUMBER> showed <NUMBER> <NUMBER> patients viral load <NUMBER> <NUMBER> copies per milliliter respectively week <NUMBER> <NUMBER> however unclear sideeffects result longterm use htas review discuss progress challenges repurposing clinically approved preclinically promising therapeutic htas targeting viral entry viral replication innate immune responses treating cov ifv infections entry cov ifv host cells relies binding viral particles cellsurface receptors endocytosis virusreceptor complexes fig <NUMBER> endosomal pathway initiates fusion viral envelope host cell membrane deliver viral nucleocapsid cell cov also enters cells via nonendosomal pathway thus endosomal nonendosomal pathways considered targets development therapeutic drugs block viral entry host cells depicted fig <NUMBER> promising drugs listed table <NUMBER> cov entry requires host proteases cleave viral trimeric transmembrane spike glycoprotein fig <NUMBER> cleavage involves cysteine protease cathepsin l endosomal pathway host transmembrane serine protease <NUMBER> tmprss<NUMBER> nonendosomal pathway <NUMBER> ifv entry requires envelope fusion host membrane via viral hemagglutinin ha followed proteolytic cleavage ha tmprss<NUMBER>d also hat initiate endocytosis <NUMBER> thus host proteases endosomal nonendosomal pathways targeted block viral entry host cells <NUMBER> tmprss<NUMBER> activates glycoprotein sarscov merscov viral entry plasma membrane <NUMBER> <NUMBER> camostat synthetic lowmolecularweight serine protease inhibitor used treat human dyspepsia associated mild pancreatic disease <NUMBER> inhibition tmprss<NUMBER> camostat results <NUMBER>fold reduction merscov production human bronchial submucosal glandderived calu<NUMBER> cells <NUMBER> camostat also effective protecting mice sarscov infection <NUMBER> treatment human tracheal epithelial hte cells camostat significantly reduces infection ifvah<NUMBER>n<NUMBER> ah<NUMBER>n<NUMBER> viruses <NUMBER> nafamostat fdaapproved serine protease inhibitor treat pancreatitis disseminated intravascular coagulation <NUMBER> <NUMBER> treatment human airway epithelial calu<NUMBER> cells nafamostat blocks merscov infection inhibiting tmprss<NUMBER> results significant reduction viral production <NUMBER> ec <NUMBER> <NUMBER> bhh already approved fda ingredient mucolytic cough suppressants likely developed treat cov ifv infection cathepsins important roles cov entry cathepsin l b serve targets antiviral agents <NUMBER> <NUMBER> vinylsulfone k<NUMBER> irreversible cysteine protease inhibitor used control various parasitic infections schistosomiasis <NUMBER> k<NUMBER> reportedly effective controlling cathepsinmediated viral entry <NUMBER> including sarscov hcov<NUMBER>e nipah virus paramyxovirus ebola virus filovirus however k<NUMBER> treatment fails result statistically significant reduction mortality induced sarscov animals <NUMBER> cov ifv enter host cells via phand receptormediated endocytosis involving clathrinand caveolaedependent independent endocytic pathways <NUMBER> <NUMBER> <NUMBER> ifv also utilizes macropinocytosis alternative entry pathway acidic lateendosomal compartment <NUMBER> <NUMBER> chlorpromazine cpz inhibitor clathrindependent endocytosis first antipsy scheme targeting cov ifv infection hostbased repurposed drugs cov entry cells relies either nonendosomal pathway endosomal pathway involving host protease tmprss<NUMBER> host adapter protein clathrin respectively ifv entry utilizes endosomal pathway macropinocytic pathway pathways render release vrna cytoplasm followed importing vrna nucleus viral replication host protein kinases raf mek erk cdks important roles regulation transcription translation various stages viral replication cov ifv utilize host eifinvolved capdependent translational machinery produce viral proteins activation host protein kinases pkr perk hri gcn<NUMBER> phosphorylate eif<NUMBER>a attenuate translation assembly viral particles requires host tmprss<NUMBER> cleavage cov spike ifv ha golgi apparatus produce viral progeny released budding addition nfkb pathway activated inactivation ikba induce proinflammatory cytokines ifns innate immune response viral infection hostbased pathways targetable repurposed agents control viral infection representative repurposed drugs pink background green thick arrows indicate induction green thick stop signs indicate inhibition scissor signs indicate proteolytic cleavage chotic drug treating schizophrenia <NUMBER> <NUMBER> cpz identified screening fdaapproved drugs effective inhibiting merscov replication low micromolar levels huh <NUMBER> cells cpz inhibits merscov replication early postentry stage indicating ability inhibit early clathrinmediated endocytosis machineries <NUMBER> cpz also inhibits sarscov animal coronaviruses ic <NUMBER> value <NUMBER> mm vero cells <NUMBER> <NUMBER> <NUMBER> treatment caveolin<NUMBER>negative hepg<NUMBER> cells cpz significantly reduces entry sarscov cells <NUMBER> findings indicate cov mainly utilizes clathrinmediated endocytic pathway enter cells amiloride potassiumsparing diuretic used treat cardiovascular disease blocking epithelial sodium channels within distal tubule kidney <NUMBER> amiloride derivative <NUMBER>nethylnisopropyl amiloride eipa routinely used specifically inhibit macropinocytic endocytosis <NUMBER> recent report revealed combination eipa cpz synergistically reduces ability ifva infect bovine kidney mdck cells <NUMBER> indicating clathrinmediated endocytic macropinocytic pathways used ifv enter cells thus combining complementary agents needs developed achieve effective control viral entry host cells cellular vacuolar atpase vatpase located intracellular organelles cytoplasmic membranes acidifies late endosome pumping protons across endosomal membrane crucial step cov ifv entry <NUMBER> <NUMBER> blocking vatpase activity interferes viral infection preventing phdependent membrane fusion viral envelops endosomal membrane saliphenylhalamide saliphe anticancer compound capable inhibiting vatpase <NUMBER> saliphe inhibits acidification endosomes reduces production progeny viruses ic <NUMBER> values <NUMBER> <NUMBER> mm ifvainfected mdck human lung adenocarcinoma epithelial a<NUMBER> cells respectively <NUMBER> <NUMBER> administrating mice <NUMBER> mgkg saliphe threetimes daily <NUMBER> days resulted <NUMBER> survival rate lethal ifv infection mice recovered <NUMBER> days <NUMBER> packing saliphe nanoparticles enhances vitro stability antiviral activity low cytotoxicity <NUMBER> diphyllin natural compound isolated cleistanthus collinus identified novel vatpase inhibitor <NUMBER> diphyllin inhibits endosomal acidification human osteoclasts reduces vatpase expression gastric adenocarcinoma cells <NUMBER> diphyllin shown effectively inhibit ifv infection mdck cells ic <NUMBER> values ranging <NUMBER> <NUMBER> mm <NUMBER> diphyllin also effectively inhibits clinically isolated oseltamivirresistant ifvasan diego<NUMBER> h<NUMBER>n<NUMBER> strain carries drugresistant mutation h<NUMBER>y na gene amantadineresistant apr<NUMBER> strain <NUMBER> diphyllin well tolerated mice <NUMBER> delivery diphyllin nanoparticles increases antiviral effects feline cov also well tolerated mice <NUMBER> niclosamide salicylanilide used treat parasitic helminthic infestations humans <NUMBER> years <NUMBER> niclosamide acts proton carrier target acidic endosomes neutralize ph coated vesicles synthetic liposomes <NUMBER> niclosamide effectively inhibits ifva a<NUMBER> cells <NUMBER> phdependent sarscov infection <NUMBER> amiodarone antiarrhythmic agent used clinically treat supraventricular ventricular arrhythmias <NUMBER> amiodarone inhibits sarscov infection postendosomal stage pretreatment amiodarone results <NUMBER> <NUMBER>fold reduction viral production vero cells <NUMBER> imatinib inhibitor nonreceptor tyrosine kinase abelson abl involved regulation cellular pathways cell migration adhesion actin reorganization <NUMBER> imatinib used anticancer agent reduce cmlrelated disease progression death <NUMBER> <NUMBER> imatinib also endosomal membrane fusion inhibitor capable inhibiting sarscov merscov infection ec <NUMBER> values <NUMBER> <NUMBER> mm respectively <NUMBER> <NUMBER> pretreatment imatinib reduces <NUMBER>fold merscov sarscov production vero cells safe vero cells cc <NUMBER> value <NUMBER> mm <NUMBER> however use <NUMBER> mg imatinib daily myeloid leukemia patients comes sideeffects dizziness blurred vision somnolence fda guide administration imatinib <NUMBER> <NUMBER> mgkgday resulted statistically significant reduction longevity males females respectively tmprss<NUMBER> plays important part nonendosomal pathways support entry viruses cells assembly viral particles cov ifv inhibition nonendosomal tmprss<NUMBER> camostat nafamostat result suppression cov infection inhibition endosomal cathepsin k<NUMBER> thus tmprss<NUMBER> cathepsins promising target antiviral therapeutic development camostat nafamostat fdaapproved drugs camostat shown exhibit potent antiviral activity vitro vivo thus logical determine efficacy camostat control cov ifv clinical studies endosomal acidification facilitates membrane fusion endosomes virions viral entry imatinib fdaapproved agent inhibits cov fusion endosomal membrane vitro <NUMBER> <NUMBER> thus vivo efficacy imatinib control viral infection needs determined animal model treatment animals vatpase inhibitors saliphe diphyllin reduces acidification suppresses viral infection packing nanoparticles helps increase efficacy inhibitors controlling viral infection tolerable adverse effects animals thus agents promising pursuing fda approval clinical application control viral infection viral replication utilizes host cell machineries transcription translation signaling pathways cell cycle accordingly cellular machineries become targets development therapeutic drugs block viral replication depicted fig <NUMBER> promising drugs listed table <NUMBER> viral replication requires pyrimidine nucleotides continued biosynthesis pyrimidine <NUMBER> pyrimidine nucleosides include uridine cytidine thymidine dihydroorotate dehydrogenase dhodh dehydrogenizes dihydroorotate orotic acid key step biosynthesis de novo pyrimidine generate uracil binds ribose sugar form ribonucleoside uridine transcription <NUMBER> dhodh inhibitors teriflunomide prodrug leflunomide brequinar used immunosuppressive agents treat rheumatoid arthritis multiple sclerosis patients <NUMBER> although agents showed ability inhibit de novo pyrimidine synthesis contributes broadspectrum antiviral activity vitro antiviral activity ineffective vivo resulting exogenously provided uridine bypassing inhibited biosynthesis pyrimidine sustain viral repli drug discovery today volume <NUMBER> number <NUMBER> march <NUMBER> cation <NUMBER> <NUMBER> recent studies showed smallmolecule gsk<NUMBER> capable inhibiting dhodh effective blocking replication various viruses arresting cell growth <NUMBER> <NUMBER> supplying exogenous deoxycytidine sustain cellular dna synthesis rna results reducing gsk<NUMBER> cytotoxicity without reducing gsk<NUMBER>mediated inhibition dengue virus denv replication <NUMBER> thus combined use deoxycytidine gsk<NUMBER> provides intriguing strategy reduced cytotoxicity safely use dhodh inhibitors controlling rna viruses gemcitabine fdaapproved anticancer agent fluorouracil analog capable inhibiting pyrimidine biosynthesis <NUMBER> although gemcitabine expected interfere pyrimidine biosynthesis viral replication <NUMBER> gemcitabine showed limited antiviral ability <NUMBER> whether gemcitabine repurposed control viral infection remains clarified protein translation process consists three steps initiation elongation termination initiation translation eukaryotes ratelimiting step protein synthesis involving family eukaryotic initiation factors eifs eif<NUMBER>f consisting eif<NUMBER>a eif<NUMBER>e eif<NUMBER>g recruits small ribosome subunit binds <NUMBER> gtp residue <NUMBER> <NUMBER> end mrnas capdependent translation <NUMBER> many viruses utilize host eifs initiate translation <NUMBER> phosphorylation eif<NUMBER> plays important part regulating initiation <NUMBER> thus eif eif phosphorylation could targeted develop antiviral agents dsrnaactivated protein kinase pkr pkrlike endoplasmicreticulumresident protein kinase perk phosphorylate asubunit eif<NUMBER> eif<NUMBER>a response stress leading attenuation protein synthesis <NUMBER> <NUMBER> indomethacin indo cyclooxygenase<NUMBER> inhibitor routinely used managing inflammation pain clinics <NUMBER> <NUMBER> indo treatment cells activates pkr interferon ifnand dsrnaindependent manner resulting rapid <NUMBER> min phosphorylation eif<NUMBER>a <NUMBER> termination viral translation sarscovinfected vero cells ic <NUMBER> value <NUMBER> mm <NUMBER> indo reduces production canine cov canine adenocarcinoma a<NUMBER> cells ic <NUMBER> value <NUMBER> mm <NUMBER> mm indo significantly reduce viral production <NUMBER>fold a<NUMBER> cells cc <NUMBER> <NUMBER> mm oral administration <NUMBER> mgkg indo daily <NUMBER> days reduced production canine cov dogs <NUMBER>fold <NUMBER> similarly bioactive lipid n<NUMBER>hydroxyphenyl retinamide <NUMBER>hpr fenretinide used control cancer <NUMBER> reduce denv replication inducing eif<NUMBER>a phosphorylation <NUMBER> oral administration mice <NUMBER>hpr protects <NUMBER> mice fully recovered denv infection <NUMBER> safety bioavailability indo <NUMBER>hpr clinically determined thus compounds promising candidates ready repurposing antiviral agents addition antiulcer drug geranylgeranylacetone gga reported augment expression pkr gene promote eif<NUMBER>a phosphorylation counteract ifva infection <NUMBER> <NUMBER> gga given orally every <NUMBER> days daily doses <NUMBER> mgkg resulting <NUMBER> reduction mean tumor burden compared control mice group <NUMBER> mice treated orally gga <NUMBER> mgkg twice daily <NUMBER> h intervals completely eradicated virus without notable replication within <NUMBER> days <NUMBER> accordingly therapeutic induction eif<NUMBER>a phosphorylation promising approach development broadspectrum antiviral agents helicase eif<NUMBER>a unwinds mrna <NUMBER> <NUMBER> untranslated region facilitating assembly translation preinitiation complexes <NUMBER> silvestrol natural compound isolated plant aglaia foveolata inhibitor eif<NUMBER>a <NUMBER> silvestrol shown control cancer cells vitro vivo <NUMBER> <NUMBER> silvestrol inhibit translation replication merscov hcov<NUMBER>e human embryonic lung fibroblast mrc<NUMBER> cells ec <NUMBER> values <NUMBER> <NUMBER> mm respectively <NUMBER> cov uses capindependent cisacting rna internal ribosome entry site ires elements eif<NUMBER>a viral translation also inhibited silvestrol <NUMBER> interestingly silvestrol exhibits potent modest ability inhibit ifva infection a<NUMBER> cells mdck cells respectively fails inhibit viral infection vero cells <NUMBER> antiviral effect silvestrol ifv infection reversible drug withdrawal results rapid dissolution stalled preinitiation complexes stress granules resumption viral protein synthesis inhibition ifva silvestrol associated cytotoxicity <NUMBER> contrast pateamine irreversibly binds eif<NUMBER>a result extended blockade ifva replication drug withdrawal inhibits ifva replication a<NUMBER> mdck vero cells minimal cytotoxicity <NUMBER> findings indicate eif<NUMBER>a promising target therapeutic development inhibit viral translation replication agents silvestrol pateamine kinaseinvolved signaling pathways widely involved regulation cellular machineries metabolism transcription translation cell proliferation differentiation death among others studies shown erk pathway cyclindependent kinases cdks essential viral replication cov ifv <NUMBER> <NUMBER> targeting protein kinases signaling pathways becomes focus therapeutic development broadspectrum antiviral agents erk pathway mainly mediates intracellular signals membraneassociated ras cytoplasmic kinase cascade raf mek erk <NUMBER> erk pathway plays important part regulation gene transcription protein translation cell death cell cycle machinery oncogenic mutation braf gene v<NUMBER>e frequently detectable human cancers <NUMBER> braf v<NUMBER>e inhibitor vemurafenib effectively inhibits erk pathway approved fda treat orbital erdheimchester disease ecd <NUMBER> <NUMBER> vemurafenib low micromolar levels inhibit ifva replication <NUMBER>fold reduction via suppression viral translation <NUMBER> interestingly vemurafenib also inhibits virusinduced apoptosis a<NUMBER> cells via suppression apoptosisinducing cytokines <NUMBER> raf inhibitors dabrafenib sorafenib fdaapproved treat cancer raf inhibitors could studied repurpose control viral infection reported blockage erk pathway limits replication cov ifv treatment u<NUMBER> specific inhibitor mek<NUMBER> suppresses early steps replication mouse hepatitis virus mhv various cell lines <NUMBER> treatment cells u<NUMBER> significantly reduces replication ifva nasal administration u<NUMBER> protects mice lethal infection ifva without developing adverse effects <NUMBER> treatment h<NUMBER>n<NUMBER>infected mice mek inhibitor ci<NUMBER> reduces <NUMBER> viral production lung <NUMBER> however low bioavailability ci<NUMBER> needs improving effective antiviral agent <NUMBER> mek<NUMBER> inhibitor trametinib erk<NUMBER> inhibitor selumetinib fdaapproved anticancer agents effectively inhibit merscov infection <NUMBER> trametinib also inhibits replication various ifv strains fpvh<NUMBER>n<NUMBER> sc<NUMBER>mh<NUMBER>n<NUMBER> pr<NUMBER>mh<NUMBER>n<NUMBER> vitro vivo interfering export progeny vrnps nucleus pretreatment trametinib ec <NUMBER> <NUMBER> mm blocks ifvinduced cytopathogenic effect decreases viral production a<NUMBER> cells oral administration <NUMBER> mgkg trametinib mice daily effective treating rheumatoid arthritis <NUMBER> <NUMBER> oral administration <NUMBER> mgkg trametinib daily five consecutive days reduces ifv production <NUMBER> results indicate application targeting erk pathway development broadspectrum therapeutic antiviral agents cdks family protein kinases activation dependent interaction cyclin family members regulate cell cycle gene transcription rna processing cell survival cdks cdk<NUMBER> cdk<NUMBER> cdk<NUMBER> cdk<NUMBER> required efficient replication ifv <NUMBER> studies showed cyclint<NUMBER>cdk<NUMBER> interacts viral rnadependent rna polymerase rdrp facilitates vrnp association cellular rna polymerase ii pol ii viral transcription replication <NUMBER> recent hts human kinase inhibitor library target ifva strain h<NUMBER>n<NUMBER> a<NUMBER> cells revealed <NUMBER> structurally diverse cellpermeable compounds known bioactivity safety profiles <NUMBER> among compounds dinaciclib inhibitor cdk<NUMBER> flavopiridol inhibitor cdk<NUMBER> exhibited potent antiviral activity various ifva strains without detectable cytotoxicity <NUMBER> dinaciclib flavopiridol currently undergoing clinical trials human cancers <NUMBER> <NUMBER> sns<NUMBER> inhibitor cdk<NUMBER> shown inhibit viral gene expression <NUMBER> <NUMBER> sns<NUMBER> treatment fully protects mice h<NUMBER>n<NUMBER> infection contrast <NUMBER> mortality untreated mice <NUMBER> results indicate development cdk inhibitors highly promising control ifv infection polyamines small molecules polyamine carries two amino groups <NUMBER> polyamines involved conformational changes dna modulation transcription translation signaling pathways cells <NUMBER> <NUMBER> <NUMBER> <NUMBER> polyamines shown regulate transcription translation dna rna viruses <NUMBER> <NUMBER> difluoromethylornithine dfmo also eflornithine polyamine inhibitor approved fda treat african trypanosomiasis cancer <NUMBER> <NUMBER> dfmo shown reduce viral production merscov <NUMBER>fold vero cells <NUMBER> dfmo needs studied clarify vivo toxicity efficacy targeting translation indo induce phosphorylation eif<NUMBER>a shown inhibit viral replication vitro safely protect animals viral infection indo fdaapproved control inflammation pain targeting signaling pathways involved cell proliferation blocking erk pathway trametinib inhibiting cdk function sns<NUMBER> also effective controlling viral replication vitro protecting mice viral infection trametinib fdaapproved treat cancer thus indo trametinib clinically studied efficiently repurposed treat viral infection agents vemurafenib gga dinaciclib flavopiridol dfmo combination deoxycytidine gsk<NUMBER> need studied reveal ability control viral infection animal models accordingly agents targeting translation proliferation signaling pathways highly promising potential repurposing broadspectrum antiviral agents host innate immune system capable recruiting immune cells pathogeninfected sites cytokines activating adaptive immune system crucial control pathogenic infection ifns proinflammatory cytokines important roles modulating innate immune response control viral infection repurpose drugs used modulate innate immune system fig <NUMBER> table <NUMBER> expected therapeutic development producing broadspectrum antiviral agents accelerated viral infection generates highly conserved pathogenassociated molecular patterns preferentially activate hosts pattern recognition receptors prrs <NUMBER> resulting activation transcription factors induction type ifn expression induction canonical ikk nfkb activation leading production proinflammatory cytokines <NUMBER> ifns produced virusinfected cells bind cellsurface ifn receptor ifnar induce upregulation hundreds ifnstimulated gene products isgs isgs shown exhibit wide range antiviral abilities degrade viral nucleic acids inhibit viral gene expression serve prrs amplify ifn signals <NUMBER> <NUMBER> <NUMBER> traditional chinese medicine drugs used control inflammation cancer pathogenic infection thousands years herbal medicines shown augment type ifn responses counteract cov ifv infections vitro vivo yzh<NUMBER> rupestonic acid derivative extracted artemisia rupestris l inhibit broad spectrum ifvs ifva h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> ifvb oseltamivirresistant amantadineresistant ifv strains via activation heme oxygenase<NUMBER>mediated ifn response <NUMBER> yzh<NUMBER> treatment reduces viral production lung h<NUMBER>n<NUMBER>infected mice unable fully protect mice lethal infection possibly result ifn suppression viral ns<NUMBER> protein <NUMBER> <NUMBER> <NUMBER> activation nfkb hallmark detecting viral infections <NUMBER> nfkb plays important part regulation genes involved inflammation counteracting viral infection <NUMBER> however ifva take advantage nfkb activation via degradation ikb viral replication <NUMBER> thus nfkb could targetable interfering ifv replication <NUMBER> saikosaponin ssa lipophilic triterpene saponin derived radix bupleurum antiinflammatory immunomodulatory properties <NUMBER> <NUMBER> ssa inhibits nfkb activation effectively attenuates ifva replication ic <NUMBER> values <NUMBER> <NUMBER> <NUMBER> mgml h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> strains respectively a<NUMBER> cells daily subcutaneous injection ssa <NUMBER> mgkg six consecutive days beginning <NUMBER> h postinfection protects mice lethal infection ifva <NUMBER> treatment mice nfkb inhibitor caffeic acid phenethyl ester cape andor parthenolide reduces expression proinflammatory cytokines lung significantly increases animal survival <NUMBER> <NUMBER> sarscov infection <NUMBER> proteasome inhibitor bortezomib ps<NUMBER> anticancer drug suppresses ikb degradation result blocking nfkb activation <NUMBER> <NUMBER> shown ps<NUMBER> noncytotoxic level <NUMBER> mm reduce ifva replication three orders magnitude a<NUMBER> cells however <NUMBER> mm ps<NUMBER> becomes cytotoxic <NUMBER> thus concerning antiviral activity ps<NUMBER> association cytotoxicity ps<NUMBER>associated adverse effects need carefully determined developing optimal antiviral agent addition stronger neominophagen c snmc glycyrrhizin preparation approved japan treat chronic hepatic diseases <NUMBER> glycyrrhizin antioxidant antiinflammatory immunomodulatory antiviral agent <NUMBER> <NUMBER> glycyrrhizin suppresses ifva replication part interference virusinduced proinflammatory gene expression <NUMBER> glycyrrhizin suppress sarscov infection early entry late replication stages vero cells ec <NUMBER> value <NUMBER> mgml <NUMBER> andrographis paniculata antiinflammatory antipyretic analgesic antibacterial hepatoprotective agent <NUMBER> major component <NUMBER>deoxy<NUMBER>dehydroandrographolide dap suppressed gene expression proinflammatory cytokines chemokines well ifva replication <NUMBER> <NUMBER> results suggest antiinflammatory agents could developed therapeutic control ifva sarscov infection broadspectrum antiparasitic drug nitazoxanide safe drug treating intestinal infection cryptosporidium parvum <NUMBER> <NUMBER> nitazoxanide currently undergoing studies control viral infections nitazoxanide interfere posttranslational modification ifv hemagglutinin human animal cells ic <NUMBER> values ranging <NUMBER> <NUMBER> mgml nitazoxanide reportedly effective controlling ifva b infection phase iii clinical study <NUMBER> nitazoxanide also shown inhibit merscov infection mice llcmk<NUMBER> cells ic <NUMBER> value <NUMBER> mgml suppressing expression viral n protein proinflammatory cytokines interleukin il<NUMBER> peripheral blood mononuclear cells <NUMBER> accordingly nitazoxanide regarded highly promising antiviral agent repurposed antiparasitic agent lanthionine synthetase c like <NUMBER> lancl<NUMBER> therapeutic target treating inflammatory chronic metabolic immunemediated infectious diseases <NUMBER> oral administration animals <NUMBER> mgkg nsc<NUMBER> daily <NUMBER> days reduces mortality induced pandemic ifva infection h<NUMBER>n<NUMBER>california<NUMBER> <NUMBER> interfering trafficking inflammatory tissuedamaging cells increasing il<NUMBER>producing cd<NUMBER> cells regulatory macrophages lungs lancl<NUMBER>dependent manner <NUMBER> ligustrum purpurascens yc yang oleaceae ku ding cha tea used antiinflammatory antioxidant hepatoprotectant agent <NUMBER> ligustrum purpurascens extract phenylethanoid drug discovery today volume <NUMBER> number <NUMBER> march <NUMBER> reviews glycoside lpg inhibit ifva replication afm<NUMBER> h<NUMBER>n<NUMBER> fm<NUMBER> vitro vivo inducing ifng <NUMBER> oral administration <NUMBER> mgkg lpg daily <NUMBER> days protects <NUMBER> mice lethal infection ifva h<NUMBER>n<NUMBER> <NUMBER> pandemic zoonotic ifv strains serious concerns public health particularly population lacking preexisting immunity recent development antiviral agents modulating host immune responses substantially advanced fields virology pharmaceutics well significantly contributed healthcare advances humans animals nsc<NUMBER> lpg shown effectively control ifva infection animals activating immune response agents considered clinical trials treating viral infection contrast ssa cape glycyrrhizin dap undergoing vitro vivo studies reveal ability control viral infection however adverse effects immunemodulating agents need seriously clarified developing new drug take <NUMBER> years cost billions us dollars approximately oneinten new promising preclinical drugs identified hundreds compounds might approved clinical use approximately <NUMBER> new drugs fail pass safety protocols clinical trials repurposing fdaapproved drugs timeefficient costeffective safe approach developing therapeutic drugs new indication treating viral infection repurpose fdaapproved drug anticancer agents researchers still need go vitro vivo clinical studies determine value candidate drug treating ifv andor cov diseases vitro studies identify viral strains targeted determine host cell range susceptible viral infection reveal additional molecular targets specifically controlling viral infection value host molecular targets evaluated gene knockdown knockout mutation via methods rna interference crisprcas<NUMBER> vivo studies determine maximal tolerable doses adverse effects efficacy controlling viral infection pharmacokinetics drug concentrations plasma reestablish effective safe regimen protocol treating ifv andor cov diseases new vitro vivo results considered existing data together design clinical studies viral diseases inevitably challenges repurposing drugs antiviral therapeutics general viral infection acute pathogenesis require higher doses repurposed drug doses used treating originally targeted chronic diseases optimal outcome thus administration route toxicity repurposed drug need carefully determined viral infection also results changes hosts immune system also function hosts organs could interfere pharmacological effects repurposed drug cause additional side effects thus beneficial study combination therapies capable targeting viral components modulating cellular machineries alleviating adverse effects achieve optimal outcomes increased antiviral efficacy reduced viral resistance minimized toxicity side effects <NUMBER> wuhan china host new type coronavirus caused sarslike symptoms human beings order better know new virus phylogenetic analysis conducted considering complete viral genome <NUMBER> nucleotides results revealed new virus <NUMBER> nucleotide similarity genus betacoronavirussubgenus sarbecovirusthat previously caused epidemic infectious disease known sars <NUMBER> new virus called covid<NUMBER> contains major structural proteins spike protein envelope e protein membrane protein nucleocapsid n protein schematic representation coronavirus shown fig <NUMBER> among protein promote fusion viral cellular membranes facilitates entry coronavirus host cells <NUMBER> protein <NUMBER> amino acid consists s<NUMBER> s<NUMBER> subunits mediates fusion viral host cell membranes subunits include receptorbinding domain rbd fusion peptide fp heptad repeat <NUMBER> hr<NUMBER> heptad repeat <NUMBER> hr<NUMBER> transmembrane domain tm cytoplasmic domain fusion cp s<NUMBER> s<NUMBER> different roles entry s<NUMBER> plays vital role binding cellular receptor s<NUMBER> facilitate viral fusion entry <NUMBER> conserved receptor binding domain rbd connects angiotensinconverting enzyme <NUMBER> ace<NUMBER> known interact <NUMBER> aa s<NUMBER> sarscov studies also show ace<NUMBER> receptor covid<NUMBER> moreover sequence variations spike protein cleavage site important terms cellular tropism pathogenesis cleavage site sprotein sequence involved pathogenesis virus sequence sprotein covid<NUMBER> <NUMBER> extra nucleotides upstream single arg¯cleavage site <NUMBER> results prrar↓sv sequence solventexposed resembles cleavage site <NUMBER> reason wellorganized spread virus among population new cleavage site previous coronaviruses lacked system mentioned earlier s<NUMBER> subunit covid<NUMBER> responsible facilitation viral fusion entry host cell exists kind interaction regarding cellular membranes heptad repeats <NUMBER> hr<NUMBER> heptad repeat <NUMBER> hr<NUMBER> leads fusion changes interaction pattern hr<NUMBER> hr<NUMBER> domains covid<NUMBER> s<NUMBER> terms fusion cell membranes caused mutations inside hr<NUMBER> core region <NUMBER> <NUMBER> residues <NUMBER> indicate mutation <NUMBER> difference currently claimed ace<NUMBER> could host receptor covid<NUMBER> well perhaps susceptibility symptoms outcome covid<NUMBER> infection resulted expression level pattern ace<NUMBER> tissues according recent research singlecell analysis rnasequencing rnaseq shows higher expression ace<NUMBER> asian males <NUMBER> covid<NUMBER> engages ace<NUMBER> receptor entry host cell employs cellular transmembrane protease serine <NUMBER> tmprss<NUMBER> protein priming tmprss<NUMBER> activates viral protein facilitates viruscell membrane fusions <NUMBER> residues near lysine <NUMBER> tyrosine <NUMBER> <NUMBER> <NUMBER> human ace<NUMBER> play important role binding sprotein coronavirus adipose tissue might weak position regarding covid<NUMBER> ace<NUMBER> expression adipose tissue higher lung tissue considering five different types cancers researchers realized expression ace<NUMBER> remarkably increases tumor tissues compared neighboring tissues hence suggested covid<NUMBER> obese individuals patients suffer five types cancer prioritized <NUMBER> terms gender age mentioned expression ace<NUMBER> positively associated age <NUMBER> <NUMBER> eight hundred kda polypeptide produced transcription covid<NUMBER> genome polypeptide cleaved produce various proteins meanwhile papainlike protease plpro <NUMBER>chymotrypsinlike protease <NUMBER>clpro facilitate proteolytic processing papainlike proteinase plpro responsible cleavages nterminus replicase polyprotein <NUMBER>clpro plays important role coronaviruses strongly preserved family viruses proteins necessary viral replication nonstructural produced <NUMBER>clpro activate polyprotein <NUMBER> distinct sites process would prepare ground virus replication hence find antiviral activities compounds researchers pay careful attention <NUMBER>clpro <NUMBER> options suggested treatment covid<NUMBER> among drug repositioning repurposing considered answer epidemic sudden infectious diseases drug repurposing effective strategy treat new diseases caused infectious agents spread rapidly paper drug repurposing strategy applied using virtual screening identify therapeutic options covid<NUMBER> homology modeling used generate five proteins covid<NUMBER>clpro plpro cleavage site hr<NUMBER> rbd spike protein tmprss<NUMBER> homology models proteins done swissmodel workspace <NUMBER> <NUMBER> httpsswissmodelexpasyorgdocs references protein data bank httpswwwrcsborg used ace<NUMBER> coordinates <NUMBER> httpswww rcsborgstructure<NUMBER>r<NUMBER> first water molecules extracted protein hydrogen atoms added optimized hydrogen bonds <NUMBER>drefine server package gromacs <NUMBER> applied minimize energy optimized model protein <NUMBER> <NUMBER> <NUMBER> box centered specific area position using pockdrug server determined using data uniprot main amino acids bond according previous evidence cleavage site sprotein conserved receptor binding domain rbd important role pathogenesis virus first two targets selected virtual screening fdaapproved drugs drugs desired binding energy stage reported antiviral properties selected next step therefore virtual screening performed table <NUMBER> shown table <NUMBER> glycyrrhizic acid hesperidin showed highest number bonds ace<NUMBER> rbd shown table <NUMBER> paritaprevir simeprevir favorable binding energy target proteins may considered therapeutic options coronavirus drugs originally used treatment chronic hepatitis c effectively bind target proteins <NUMBER> <NUMBER> <NUMBER> drugs good binding energy target protein one ledipasvir according silico study ledipasvir antiviral drug minimum side effects applied treatment covid<NUMBER> <NUMBER> present study medicinal compounds plant origin also attached favorable binding energy target proteins glycyrrhizic acid plant origins obtained roots licorice plant triterpene glycoside glycyrrhetinic acid used pharmacologically latter applied hepatoprotective option treat chronic hepatitis japan china https pubchemncbinlmnihgovcompoundglycyrrhizicacid addition glycyrrhizin nontoxic <NUMBER> also used widely sars treatment option according study <NUMBER> glycyrrhizin preventive role sars <NUMBER> furthermore based studies plays effective role hepatitis c virus hcv influence release phase associated infection cells <NUMBER> using glycyrrhizin treat hepatitis c new method applied treatment <NUMBER> years japan fortunately studies shown preventive role progression cirrhosis hepatocarcinoma side effects <NUMBER> positive effects glycyrrhizin proven many viral diseases herpes simplex type <NUMBER> hsv<NUMBER> varicellazoster virus vzv hepatitis hav b virus hbv human <NUMBER> glycyrrhizic acids preventive impact ace<NUMBER> reported studies <NUMBER> aside glycyrrhizic acid hesperidin tannic acid also considered medical circles plant origins well attach proteins good binding energy hesperidin flavonoid extracted citrus fruit multiple biological antimicrobial activities human viruses based study conducted <NUMBER> glucosyl hesperidin inhibiting role replication influenza virus <NUMBER> study aimed analyzing therapeutic targets covid<NUMBER> computational methods shown hesperidin disrupts interaction ace<NUMBER> rbd <NUMBER> mentioned earlier <NUMBER>clpro effective target treatment coronavirus study investigation effect active compounds inhibition <NUMBER>clpro showed hesperidin potent inhibitor <NUMBER>clpro among compounds tested based docking score reported hesperidin glycyrrhizin favorable terms binding ace<NUMBER> <NUMBER>clpro <NUMBER> tmc<NUMBER> another fdaapproved drug good binding target proteins tmc<NUMBER> new investigational protease inhibitor investigated use hiv<NUMBER> infections tmc<NUMBER> currently investigated potential treatment covid<NUMBER> httpswwwdrugbank ca drug repurposing effective strategy treat new diseases caused infectious agents spread rapidly paper drug repurposing strategy applied using virtual screening identify therapeutic options covid<NUMBER> fdaapproved drugs screened cleavage site rbd spike protein via virtual screening observed <NUMBER> fdaapproved drugs <NUMBER> drugs suitable freebinding energy attached cleavage site rbd spike protein <NUMBER> drugs <NUMBER> drugs antiviral virtual screening performed <NUMBER> selected drugs ace<NUMBER> major covid<NUMBER> receptor <NUMBER>clpro plpro main enzymes viral replication hr<NUMBER> main domain virus fusion host cell membrane tmprss<NUMBER> main enzyme activating viral spike glycoproteins according data study well related literature paritaprevir simeprevir ledipasvir glycyrrhizic acid tmc<NUMBER> hesperidin suitable candidates investigation treatment covid<NUMBER> infection seems investigations rna polymerase inhibitors may effective better selection drugs treatment covid<NUMBER> piece bad news wrapped protein definition virus sir peter medawar despite apparent blandness collective mindset important portion society intrinsic morbidity mortality well related deaths bacterial superinfections exacerbation chronic illnesses make influenza infections major recurrent global public health concern indeed human influenza type b viruses responsible annual flu epidemics marked <NUMBER> billion infections <NUMBER> million severe cases <NUMBER> deaths worldwide huge economic burden terms medical visits hospitalizations workschool absenteeism productivity loss <NUMBER> <NUMBER> <NUMBER> members orthomyxoviridae family influenza viruses type b c enveloped viruses harboring negativesense singlestranded rna segmented genome segmented nature viral genome resides capacity influenza viruses form new reassortant strains following concomitant infection host one strain human andor animal origin phenomenon far observed among type influenza viruses reviewed <NUMBER> owing viral reassortment genetic baggage progeny viruses exactly match one parental strains combination depending specific combination genetic segments notably case human influenza strain acquiring hemagglutinin ha andor neuraminidase na major surface antigens animal origin reassortment events result antigenic shift defined generation new virus antigenic properties drastically different circulating strains new variant sufficiently antigenically different escape repertoire preexisting immunity population might rapidly disseminate replace circulating strains hence triggering global influenza pandemic although relatively rarethree veritable pandemics occurred <NUMBER>th century one far twentyfirst centurythe outbreak pandemics quite unpredictable event might entail potentially devastating effects reviewed <NUMBER> particularly considering contemporary state affairs regarding global transportation trade migration narrowing interface rural overcrowded urban areas influenza vaccination constitutes effective strategy prevent seasonal flu clinical complications mainly among highrisk populations young children elderly pregnant women immunocompromised patients well people obesity diabetes cardiorespiratory comorbidities <NUMBER> <NUMBER> nevertheless current flu vaccination still presents several limitations make fall short expectations terms effectiveness short duration vaccineinduced immunity coupled intrinsic antigenic drift influenza viruses resulting gradual accumulation point mutations antigenic sites ha lesser extent na surface protein underscore need annual reformulation vaccine composition moreover length current vaccine manufacturing process least <NUMBER> months produce sufficiently large vaccine quantities demands continual strain selection done approximately <NUMBER> months next flu season <NUMBER> <NUMBER> antigenic drift occur time window possibility mismatch vaccine composition circulating strains might negatively affect protection even absence seasonal mismatches emergence pandemic strains insufficient vaccine coverage suboptimal uptake specific target groups ie elderly immunocompromised also compromise vaccine effectiveness furthermore despite recent progress made pursue holy grail universal influenza vaccine provide broader longlasting protection matching antigenically diverse influenza strains <NUMBER> <NUMBER> clinical effectiveness remains evaluated hence highlighting need complementary therapeutic approaches manage influenza infections besides vaccination antiviral drugs represent pillar control seasonal influenza epidemics play central role major prophylactic therapeutic agents event pandemic outbreak regard review summarizes stateoftheart current antiviral options influenza infection particular focus recent advances antiinfluenza drug repurposing strategies potential therapeutic regulatory economic benefits review presents examples multiple ways reposition molecules treatment influenza adventitious discovery silicobased screening novel antiviral candidates many target host cell could also used combination conventional virustargeted antiviral agents order reinforce limited therapeutic arsenal influenza virus infections mentioned antivirals key players pandemic preparedness programs first choice treatment infected patients well preventive postexposure prophylaxis potentially exposed new virus especially initial pandemic period vaccine available antivirals well important normal seasonal setting although use mostly focused treatment severely ill patients immunocompromised countries including usa japan regularly resort antivirals management uncomplicated influenza otherwise healthy patients <NUMBER> <NUMBER> date two classes antiviral agents globally approved available treatment influenza infections m<NUMBER> ionchannel blockers neuraminidase na inhibitors first class includes adamantane derivatives amantadine rimantadine inhibit proton conductivity m<NUMBER> ion channel influenza viruses hence preventing viral uncoating step viral replication cycle nevertheless although quite efficient early days widespread dissemination s<NUMBER>n much lesser extent v<NUMBER>a m<NUMBER> resistance mutation post<NUMBER> h<NUMBER>n<NUMBER> post<NUMBER> h<NUMBER>n<NUMBER> circulating strains prompted remove amantadine rimantadine list recommended antiinfluenza agents clinical use <NUMBER> <NUMBER> result na inhibitors stand influenza antivirals currently recommended <NUMBER> na inhibitors competitive analogs sialic acid preferred influenza receptor host cells surface binding broadly conserved active site na na inhibitors interfere sialidase enzymatic activity viral protein essential release newly formed progeny viruses infected cell hence preventing spread infection rest respiratory tissue <NUMBER> three na inhibitors currently licensed worldwide treatment influenza b infections oseltamivir zanamivir peramivir oral oseltamivir administered prodrug oseltamivir phosphate largely used three whereas inhaled zanamivir recommended young children individuals underlying respiratory conditions intravenous peramivir prioritized hospitalized patients cannot receive oral treatment <NUMBER> additionally inhaled laninamivir singledose long lasting na inhibitor approved japan prevention treatment influenza b adult pediatric patients <NUMBER> important note degree skepticism still present regarding real efficacy na inhibitors notably following <NUMBER>s cochrane clinical metaanalysis reported minimal shortening influenza symptoms children adults uncomplicated influenza hospitalized patients <NUMBER> nevertheless actual evidencebased consensus points moderate efficacy na inhibitor treatment reducing symptom duration pneumonia hospitalization mortality especially administered within <NUMBER> h symptom onset <NUMBER> <NUMBER> conversely delayed treatment initiation associated compromised efficacy may yet beneficial atrisk patients moreover emergence na inhibitorresistant virus variants matter concern particularly higher frequencies among children immunocompromised <NUMBER> h<NUMBER>y na substitution main mutation responsible oseltamivir peramivir resistance h<NUMBER>n<NUMBER> viruses r<NUMBER>k e<NUMBER>v commonly reported h<NUMBER>n<NUMBER> viruses latter two also conferring reduced susceptibility zanamivir laninamivir <NUMBER> <NUMBER> even nowadays prevalence drugresistance circulating strains quite low ≤<NUMBER> evidence form pre<NUMBER> seasonal strains proved given appropriate conditions resistance could rapidly disseminate attain prevalence <NUMBER> <NUMBER> <NUMBER> regard relatively recent detection localized clusters na inhibitorresistant h<NUMBER>n<NUMBER>pdm<NUMBER> viruses harboring h<NUMBER>y mutation combined i<NUMBER>rv na substitutions <NUMBER> <NUMBER> strengthens importance continuous surveillance addition m<NUMBER> ion channel blockers na inhibitors two small molecules target viral rnadependent rna polymerase favipiravir baloxavir marboxil undergoing clinical evaluation us europe already obtained approval japanese health authorities favipiravir nucleoside analog acts competitive inhibitor viral polymerase substrate approved since <NUMBER> treatment influenza infections newly emerging strains andor resistant antiviral agents however despite apparent high threshold drug resistance <NUMBER> broadspectrum antiviral potential notably validated context recent ebola virus outbreaks <NUMBER> recent results phase iiiii randomized trials therapeutic efficacy uncomplicated influenza completely conclusive <NUMBER> baloxavir marboxil selective inhibitor capdependent endonuclease activity influenza viral pa polymerase subunit <NUMBER> therefore interfering capsnatching activity viral polymerase complex regard recent report disclosed first time results two randomized phases ii iii clinical trials evaluating efficacy singledose oral treatment baloxavir marboxil otherwise healthy outpatients acute uncomplicated influenza compared placebo regular <NUMBER>day treatment oseltamivir <NUMBER> overall baloxavir marboxil oseltamivir moderately reduced time symptom alleviation compared placebo former outperformed two others reducing viral loads results prompted us food drug administration fda approve xofluza r baloxavir marboxil treatment acute uncomplicated influenza patients <NUMBER> years age older symptomatic <NUMBER> h <NUMBER> nevertheless first antiviral flu treatment novel mechanism action approved fda nearly <NUMBER> years seem escape problem virustargeted antiinfluenza agents emergence virus variants mostly due i<NUMBER>tm pa amino acid substitutions conferring significant levels reduced susceptibility baloxavir marboxil observed <NUMBER> patients receiving drug <NUMBER> <NUMBER> overall table <NUMBER> summarizes main characteristics abovementioned currently available antiviral options influenza limited therapeutic arsenal coupled recurrent risk emerging drugresistance highlights obvious unmet need novel approaches complement existing therapies new antiinfluenza drugs fruitful basis discovery new drug start old drug famously stated <NUMBER> nobel prize physiology medicine laureate sir james black despite enormous scientific technological advances field biomedical research witnessed last <NUMBER> years scenario failed efficiently translate significant improvement success rate classic bench bedside targetcentered mechanistically biased de novo drug discovery process <NUMBER> indeed almost unchanged total number <NUMBER> novel molecules approximately <NUMBER> new drugs yearly approved fda <NUMBER> biopharmaceutical experts estimate <NUMBER> drug candidates make phase clinical trials receive final green light <NUMBER> words <NUMBER> compounds come classic drug discovery one likely approved causes phenomenon multifactorial including targeting intricate diseases limitations reductionist experimental models reproduce biological complexity increased regulatory stringency tolerability issues unexpected side effects altogether total rd process leading introduction new drug market demands average <NUMBER> years us <NUMBER> <NUMBER> billion <NUMBER> <NUMBER> <NUMBER> context drug repurposing stands worthwhile attractive alternative fill part socalled innovation gap drug repurposing also termed drug repositioning defines process identifying validating new therapeutic indication existing developmental drug <NUMBER> <NUMBER> <NUMBER> basis drug repurposing relies bypassing long risky expensive preclinical early clinical evaluation stages focusing available extensive human clinical pharmacokinetics safety data starting point development figure <NUMBER> extended definition could also include already marketed drugs also sleeping candidates seen development abandoned advanced phases clinical evaluation eg phase iiiii trials due nonsatisfactory efficacy first intended medical use might find second life novel therapeutic indication noteworthy repurposing arguably accounts <NUMBER> new drug products approved fda <NUMBER> practice concept drug repurposing represents broad term encompassing many different though mutually exclusive experimental approaches recognize potential new applications outside scope original medical indication <NUMBER> including initial discovery market generally takes <NUMBER> years costs us <NUMBER> billion low success rate <NUMBER> contrast drug repurposing approaches offer several advantages indeed time frame discovery market shorter <NUMBER> years less expensive us <NUMBER> million higher success rate <NUMBER> mostly large part preclinical clinical testings eg safety formulation posology already performed drugs initial therapeutic indication <NUMBER> <NUMBER> bestknown success stories drug repurposing starting point serendipitous observations recorded context either preclinical models disease prepostapproval clinical trials leading subsequent rationalized evaluation validation new treatment potential <NUMBER> thalidomide sildenafil two examples key observations first one initially introduced antinausea pregnant women rapidly removed market due teratogenicity research enabled molecule well derivatives repurposed treatment leprosy multiple myeloma <NUMBER> sildenafil hand never reached market originally intended use treatment hypertension observed sideeffects erectile dysfunction ended approval commercial name viagra r recently sildenafil found third life commercial brand revatio r treatment pulmonary hypertension <NUMBER> although serendipitous observation historically proved usefulness intrinsic necessity casual observation unintended usually infrequent second benefit poses significant hurdle exploiting full potential drug repurposing controlled systematic methodologies needed targetbased repurposing relies previous knowledge specific molecular cellular determinantfunction target recognized drug intended repurposed new research finds target plays important role condition disease original indication potential repurposing note target might necessarily play role conditions example case previously mentioned favipiravir drug plays role viral rna polymerase inhibitor influenza ebola viruses hand abelson tyrosineprotein kinase <NUMBER> abl<NUMBER> target anticancer drug imatinib found required efficient fusion release severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov pseudovirions cytoplasm infected cell key step viral replication <NUMBER> alternative scenario targetbased repurposing happen particular drug known mechanism action found new molecularcellular target previously unrecognized second target associated different disease molecule therefore said present polypharmacologyrelated features meaning capacity act multiple targets <NUMBER> <NUMBER> polypharmacological phenomena includes single drug acting multiple targets unique disease pathway single drug acting multiple targets pertaining multiple disease pathways <NUMBER> fact polypharmacology usually responsible treatment toxicity undesirable adverse events sideeffects might also lead drug repurposing exemplified next sections last decade increasing number studies converged proposing many drugs initially designed unique therapeutics target fact expected hit average <NUMBER> <NUMBER> different targets <NUMBER> <NUMBER> one major limitation targetbased drug repurposing model relies dependence existing scientific knowledge drugdisease mechanisms actionpathology well potential alternative targets usually incomplete words cannot fully anticipate repurposing potential drug unless characterized molecularcellular targets know given drug target plays important role particular disease phenotypic screening bioactive molecule libraries different experimental cellbased vivo disease models without need priori knowledge consideration target andor mechanism action candidate designed modulate provide valuable contribution overcome constraint <NUMBER> indeed despite approach questioned due fact expected altered phenotype readout surrogate exploitable biological effect induced drug candidate might account important number false positive hits nonetheless true contribution highthroughput phenotypic screening firstinclass small molecule drug discovery exceeded targetbased approaches <NUMBER> <NUMBER> regard many wellannotated collections smallmolecule libraries could readily made available different collaborative andor commercial partnerships order accelerate drug repurposing hypothesis biased unbiased phenotypic screening reviewed <NUMBER> <NUMBER> <NUMBER> <NUMBER> advent big data systems biology computerbased approaches gaining increasing acceptance field drug discovery drug repurposing exception besides inclusion constantly emerging omics eg transcriptomic proteomic metabolomic data expand current knowledge drugdiseaseassociated mechanisms silico data mining modeling tools pushed capacity analyze data next level <NUMBER> <NUMBER> <NUMBER> silico methods include screening chemical biological text databases analysis quantitative structureactivity relationships pharmacophores homology models molecular modeling approaches well network analysis biological functions machine learning almost analysis tools include using computer <NUMBER> <NUMBER> <NUMBER> <NUMBER> regard proper mining biological chemical clinical datasets proved effective unveiling novel relationships <NUMBER> <NUMBER> moreover another level complexity added combining example epidemiologic information obtained inhouse andor publicly available literature databases vitro experimental molecule screenings aim identify novel indications case digoxin prostate cancer <NUMBER> <NUMBER> indeed real power computerassisted drug repurposing resides adopting integrative strategy combines predictive analytic capacity silico tools target biased unbiased experimental evaluationvalidation methods previously mentioned systems pharmacology approach <NUMBER> <NUMBER> <NUMBER> across boundaries traditional disciplines would put researchers betterinformed position design comprehensive repurposing strategies effective predictive capacity hopefully improved candidate success rates last <NUMBER> years remarkable growing interest drug repurposing field antiviral drug discovery fueled incontestable reality many known viral infections still lacking specific treatment interest inversely correlated low number classic antiviral molecules marketapproved last <NUMBER> years mostly treatment hepatitis c virus hivrelated pathologies <NUMBER> best example antiviral drug repurposing approaches emerging viruses ebola zika virus merscov urgent costeffective need therapeutics solutions indeed rapidly propose solution context viral outbreak one interesting approach consists look available pharmacopeia used treat pathogens example chloroquine major antimalarial drug proposed treatment filoviral infections largely treatment emerging pathogens targets endosomal acidification pivotal step replication cycle large number viruses <NUMBER> <NUMBER> another interesting illustration previously cited example favipiravir proved repurposing potential treatment zika ebola viral infections <NUMBER> <NUMBER> <NUMBER> mentioned intrinsic everevolving nature virus high transmissibility host promiscuity suboptimal vaccine efficacy limited antiviral arsenal zoonotic pandemic potential convincing factors consider influenza viruses attractive targets drug repurposing despite many interesting omicsbased approaches <NUMBER> highthroughput screening specific drug libraries kinase inhibitors <NUMBER> antiinfluenza agent issued drug repurposing yet reached regulatory market approval however advances made last years forecast optimism following selected examples constitute good illustration diversity capabilities drug repurposing strategies influenza infection exhaustive list antiinfluenza candidates issued drug repurposing approaches presented table <NUMBER> case statins arguably bestknown example antiinfluenza repurposing issued clinical observations early <NUMBER>s clinicians observed besides cardioprotective activity statins hydroxyl methylglutarylcoenzyme hmgcoa reductase inhibitors approved use cholesterol metabolism regulators could pleiotropic antiinflammatory immunomodulatory effects could benefit improve survival patients severe influenza <NUMBER> although many mouse observational studies account protective role statins pneumonia vivo studies reported far failed clearly demonstrate beneficial effect specific context influenza infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> hand observational studies highlighted association statin treatment <NUMBER> reduction <NUMBER>day allcause mortality patients hospitalized laboratoryconfirmed seasonal influenza <NUMBER> <NUMBER> <NUMBER> randomized placebocontrolled phase ii clinical trial nct<NUMBER> aimed evaluating potential effect atorvastatin reduce severity illness influenzainfected patients currently undergoing nitazoxanide another illustration serendipitous repurposing approach probably one promising examples nitazoxanide thiazolide antiinfective initially licensed treatment parasitic infections antiinfluenza properties first documented rossignol et al <NUMBER> interestingly proposed mode action nitazoxanide toward influenza clearly distinct designed initial indication acting posttranslational level selectively blocking maturation viral glycoprotein ha consecutive impact intracellular trafficking insertion host plasma membrane <NUMBER> <NUMBER> drug presents potent antiviral activity large panel circulating strains <NUMBER> effectiveness nitazoxanide treating patients noncomplicated influenza successful phase iibiii trial <NUMBER> currently assessed phase iii clinical trial nct<NUMBER> bay<NUMBER>lasag llysine acetylsalicylateglycine modified version antiinflammatory drug acetylsalicylic acid asa licensed intravenous inhalation delivery currently investigated antiinfluenza treatment result mixed serendipitous targetbased repurposing strategy initially shown asa interesting antiviral effects influenza viruses vitro vivo via inhibition nfkb activating kinase ikkb negatively impacts influenza vrnp transport release infectious viral particles <NUMBER> <NUMBER> <NUMBER> however due pharmacokinetic limitations asa lasag modified version improved stability tolerability developed like asa molecule also demonstrates antiviral activity several human avian influenza viruses vitro mouse infection model inhalation lasag resulted reduced lung viral titers protection mice lethal infection <NUMBER> recently phase ii proofofconcept study comparing lasag versus placebo patients severe influenza patients receiving tamiflu standard care treatment demonstrated aerosolized lasag improved time symptom alleviation compared placebo despite absence statistically significant reduction viral load lasagtreated group <NUMBER> naproxen constitutes nice example insilico targetbased strategy identification new antivirals lejal et al used structurebased modeling approach identify drugs interest directed nucleoprotein np influenza virus using xray structure rnafree np h<NUMBER>n<NUMBER> prototype insilico screening focused defined specific frontiers immunology wwwfrontiersinorg site np structure identified naproxen known inhibitor inducible cyclooxygenase type <NUMBER> cox<NUMBER> commonly used nonsteroidal antiinflammatory drug identified molecule shown antiviral properties influenza virus vitro vivo <NUMBER> recently naproxen analogs improved efficacy developed showing high level inhibition nprna nppolymerase subunit pa complexes without parallel inhibition cox<NUMBER> <NUMBER> <NUMBER> interestingly contrast examples drug repurposing strategies example naproxen remains virustargeted future works determine drug present achilles heel classic antivirals regarding selection antiviral resistance last two examples chapter midodrine diltiazem identified influenza antivirals context insilico assisted strategy based transcriptional profiling emerging approach drug repurposing based signature matching consists comparing specific characteristic drugits cellular signatureto disease <NUMBER> approach mostly based transcriptomic data successfully exploited identify drug repurposing opportunities large range therapeutics areas notably field oncology rare diseases <NUMBER> group first transpose approach field viral infectious diseases thanks development democratization dnamicroarray recently rnaseq techniques proofofconcept study using vitro model infection postulated host global gene expression profiling considered fingerprint signature specific cell state including infection drug treatment hypothesized screening databases compounds counteract virogenomic signatures could enable rapid identification effective antivirals <NUMBER> among molecules identified silico midodrine adrenergic alpha receptor agonist widely used treat hypotension demonstrated interesting vitro antiviral activities <NUMBER> results prompted phase ii clinical evaluation midodrine nct<NUMBER> treatment uncomplicated seasonal flu primary care centers based previous proofofconcept obtained vitro gene expression profiles improved strategy analyzing upper respiratory tract clinical samples collected cohort influenza ah<NUMBER>n<NUMBER>pdm<NUMBER>infected patients determined respective transcriptomic signatures performed insilico drug screening identified list candidate bioactive molecules signatures anticorrelated patients acute infection state potential antiviral properties selected marketapproved molecules firstly validated vitro effective compounds compared oseltamivir treatment influenza ah<NUMBER>n<NUMBER>pdm<NUMBER> virus infections mice physiological vitro model reconstituted human airway epithelia mucilair tm results notably highlighted diltiazem calcium channel blocker used antihypertensive drug promising repurposed hosttargeted inhibitor influenza infection <NUMBER> ongoing french multicenter randomized clinical trial investigating effect diltiazemoseltamivir bitherapy compared standard oseltamivir monotherapy treatment severe influenza infections intensive care units flunext trial nct<NUMBER> two better one good return labor ecclesiastes <NUMBER> concept antiviral combination therapy originally pioneered antiretroviral treatments primary goal preventing least delaying emergence drug resistance via targeting multiple steps viral cycle <NUMBER> another expected complementary goal obtain additive synergistic effects combining drugs doubletrigger effect increase effectiveness andor reduce dosage context influenza infections combination classic antivirals mostly na inhibitors explored several research groups including relatively mixed conclusions example mouse model combination oseltamivir zanamivir shown superior zanamivir monotherapy context influenza ah<NUMBER>n<NUMBER> ah<NUMBER>n<NUMBER>pdm<NUMBER> infection <NUMBER> clinical trial conducted ah<NUMBER>n<NUMBER>pdm<NUMBER> pandemic <NUMBER> combina trial nct<NUMBER> failed demonstrate whether oseltamivirzanamivir combination therapy improved reduced effectiveness oseltamivir alone treatment influenza infections community patients <NUMBER> clinical investigations shown greater effectiveness combination therapy reduce influenza transmissibility <NUMBER> alternative antiviral strategies treatment influenza infections including related drug repurposing targeting host instead viral determinants emerging trend consists propose innovative therapies combine classic antivirals hosttargeting drugs starts show promising results <NUMBER> example belardo et al demonstrated cell culturebased assays using different human avian models combination na inhibitors nitazoxanide presents synergistic antiinfluenza effects <NUMBER> convincing results also obtained using combination treatment including naproxen clinical trial enrolling hospitalized patients infected influenza ah<NUMBER>n<NUMBER> combination therapy naproxen oseltamivir clarithromycin showed improved efficacy terms hospital stay duration patient mortality compared oseltamivir treatment alone <NUMBER> context evaluation antiviral activity diltiazem reconstituted human airway epithelium model mucilair tm group demonstrated diltiazemoseltamivir combination treatment conferred greater reduction apical viral titers measured samedose monotherapy marked delay viral production <NUMBER> ongoing french multicenter randomized clinical trial investigating effect diltiazemoseltamivir bitherapy compared standard oseltamivir monotherapy treatment severe influenza infections intensive care units flunext trial nct<NUMBER> altogether results plead favor use drug repurposing improvement current standard care antiinfluenza therapy contrast technological domains innovation necessary chasing replacing established standard future works still necessary investigate real impact novel host virustargeted multitherapy approaches management control emergence viral resistance need find new drugs rather need find patients benefit existing drugs saying goes although somehow exaggerated statement summarizes pretty clearly essence behind drug repurposing initiative finding new indications alreadyexisting drugs many benefits mainly improving costeffectiveness reducing risks shortening time market <NUMBER> <NUMBER> purpose review foster discussion drug repurposing option complete implement current antiinfluenza therapeutic arsenal facing important need development novel antiviral strategies improve treatment effectivenessespecially case severe diseasesand less prone selection antiviral resistance regard identification validation different complementary means repurposed drugs incontestably great interest notably combination current classic virustargeted inhibitors addition deposition data including negative results public database encouraged would facilitate efforts repurpose licensed orphaned drugs consecutively increase chances find new efficient antiviral drugs growing number academic groups pharmaceutical companies working emerging field certainly see interesting progress efficient novel antiinfluenza therapies reaching regulatory market approval near future context globalized world facing major vicissitudes including population dynamics climate change multiple emergencereemergence zoonotic viruses effectiveness reaction force classic de novo development antivirals challenged despite inherent limits drug repurposing offers large palette possibilities rapidly efficiently find new antiviral drugs authors listed made substantial direct intellectual contribution work approved publication sir james whyte black winner <NUMBER> nobel prize medicine <NUMBER> reported food drug administration fda approved agents <NUMBER> human proteins <NUMBER> <NUMBER> comes classification enzymes transporters g proteincoupled receptors gpcrs cluster differentiation cd markers voltagegated ion channels nuclear receptors fact typical de novo drug discovery program takes <NUMBER> <NUMBER> years <NUMBER> <NUMBER> identification lead molecule market drug probability success rate less <NUMBER> <NUMBER> five years number new drugs approved fda around <NUMBER> per year although billions us dollars spent various pharma industries research development <NUMBER> <NUMBER> <NUMBER> success rate less <NUMBER> new drug discovery development far away addressing unmet clinical need disease treatments effective therapeutics complex diseases like alzheimers disease ad parkinsons disease pd cardiovascular diseases neglected diseases still lacking outcome strongly suggests new strategies approaches technologies needed accelerate drug discovery advance success rate drug development drug repurposing strategy consisting finding new indications already known marketed drugs used various clinical settings highly characterized compounds despite failed drugs <NUMBER> drug discovery program faster safer develop medications diseasesdisorders potential treatment available recent years success rate drug repurposing approach accounts approximately <NUMBER> newly fda approved drugs vaccines one main reasons pharmaceutical companies show interest drug repurposing approach approach require initial six <NUMBER> years typically needed development new drugs additionally many phases de novo drug discovery development bypassed melanin protects human skin radiation continuing irradiation result risk skin damage malignant melanoma cancer melanocytes besides abnormal production melanin leads serious dermatological disorders including melasma <NUMBER> <NUMBER> <NUMBER> <NUMBER> freckles age spots postinflammatory melanoderma <NUMBER> <NUMBER> melanogenesis process synthesis melanin complex enzymatic biochemical catalyzed reactions tyrosinase plays ratelimiting step hydroxylation ltyrosine l<NUMBER>dihydroxyphenylalanine ldopa followed oxidation ldopa ldopaquinone serves substrate production melanin <NUMBER> therefore targeting tyrosinase recognized potential approach controlling abnormal production melanin tyrosinase also important target food industry inhibition tyrosinase prevent enzymatic browning fruits vegetables besides essential wound healing process immune responses many plants sponges invertebrates abnormal activities tyrosinase linked neurodegenerative disorders including parkinsons <NUMBER> huntingtons diseases <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> thiourea analogs tyrosinase inhibitors broadly classified two categories polyphenols mostly natural products arbutin hydroquinone kojic acids b thiourea derivatives since <NUMBER>s phenylthiourea ptu <NUMBER> well known tyrosinase inhibitor <NUMBER> <NUMBER> many research groups including extensively studied structureactivity relationships ptu tyrosinase inhibitors <NUMBER> <NUMBER> choi et al screened fda approved drug library closed structural similarity ptu see figure <NUMBER> <NUMBER> example ethionamide <NUMBER> secondline antituberculosis drug used treatment multidrug resistant tuberculosis shares chemical similarity led discovery new mushroom tyrosinase inhibitor ic <NUMBER> value <NUMBER> µm commercially available analogs <NUMBER> including prothionamide <NUMBER> thioisonicotinamide <NUMBER> pyridine<NUMBER>carbothiomide <NUMBER> pyridine<NUMBER>carbothiomide <NUMBER> thiobenzamide <NUMBER> identified potent tyrosinase inhibitors particular compound <NUMBER> strong inhibitory activity molecules suggests pyridine ring compound <NUMBER> replaced aromatic moieties including benzene ring however poor inhibitory activity isoniazid <NUMBER> firstline antituberculosis drug suggests carbothiomide group crucial tyrosinase inhibitory activity moreover comparing inhibitory activities drugs <NUMBER> <NUMBER> implies additional aliphatic tail required inhibiting tyrosinase inhibitory kinetic studies suggest drug <NUMBER> analogs <NUMBER> reversible noncompetitive cellular assay drugs <NUMBER> <NUMBER> markedly decreased melanin content b<NUMBER> cells values <NUMBER> <NUMBER> respectively without inducing cytotoxicity <NUMBER> µm concentration studies suggest drug <NUMBER> strong inhibition mammalian tyrosinase however inhibition exhibited drug <NUMBER> analogs weaker obtained ptu observed enzyme melanin content assays research group continued search molecules clinical usage contain thiourea moiety <NUMBER> result could retrieve thiourea containing drugs thioacetazone <NUMBER> ambazone <NUMBER> methimazole <NUMBER> carbimazole <NUMBER> thiouracil <NUMBER> methylthiouracil <NUMBER> propylthiouracil <NUMBER> thioacetazone <NUMBER> also called thiacetazone antituberculosis drug <NUMBER> ambazone <NUMBER> oral antiseptic drug used europe <NUMBER> five molecules <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> antithyroid drugs <NUMBER> drugs except <NUMBER> exhibited remarkable inhibitory activities mushroom tyrosinase see ic <NUMBER> values figure <NUMBER> although comparatively weaker <NUMBER> <NUMBER> µm kinetics studies tyrosinase inhibition assigned thioureacontaining drugs noncompetitive inhibitors cellular assay using b<NUMBER> cells drug <NUMBER> among thioureas significantly decreased melanin content <NUMBER> without inducing cytotoxicity <NUMBER> µm enzymatic studies cell extracts b<NUMBER>f<NUMBER> cells confirmed thioureacontaining drugs affected function mammalian tyrosinase extended study group repositioned thiopurine drugs <NUMBER> tyrosinase inhibitors <NUMBER> thioguanine <NUMBER> drug used treatment leukemia one essential medicines required basic health system recommended world health organization inhibited tyrosinase activity k value <NUMBER> µm addition two thiopurine drugs mercaptopurine <NUMBER> azathioprine <NUMBER> discovered tyrosinase inhibitors among drug <NUMBER> showed stronger k value k <NUMBER> µm drug <NUMBER> azathioprine <NUMBER> exhibited poor tyrosinase inhibition results suggest sulfur atom possibly plays important role interaction tyrosinase interestingly thioinosine <NUMBER> metabolic product mercaptopurine attachment sugar moiety exhibited excellent tyrosinase inhibitory activity k value <NUMBER> µm kinetics studies classified drugs <NUMBER> <NUMBER> <NUMBER> competitive inhibitors cellular assay drugs inhibited melanin content without cytotoxicity <NUMBER> µm particular drug <NUMBER> <NUMBER>µm concentration remarkably reduced melanin content <NUMBER> without apparent cytotoxicity thiopurine drugs docked four different crystal structures complexed inhibitors tropolone kojic acid hydroquinone ptu figure <NUMBER> <NUMBER> <NUMBER> <NUMBER> molecular also predicted intramolecular hydrophilic contacts residue e<NUMBER> disappeared mercaptopurine figure <NUMBER>c whereas thioguanine figure <NUMBER>b thioinosine possess contacts within <NUMBER> å thioinosine <NUMBER> represented figure adopted publication choi j et al <NUMBER> drugs repositioning cancer therapy cancer one leading cause death worldwide <NUMBER> pharmaceutical companies invest billions dollars developing new anticancer drugs drug discovery development process cancer treatment takes average <NUMBER> years cost approximately <NUMBER> billion <NUMBER> however <NUMBER> drugs enter clinical trials approved prolonged duration drug development enormous cost preclinical trials approval emphasizes need drug repurposing approach see figure <NUMBER> drugs repurposing cancer therapy aspirin <NUMBER> also known acetylsalicylic acid one nonsteroidal antiinflammatory drugs nsaids widely used analgesic antipyretic prevent heart attack stroke first time gasic coworkers reported possible role aspirin cancer therapy discovered antiplatelet activity <NUMBER> tumorbearing mice associated <NUMBER> reduction lung metastasis <NUMBER> recent study also indicated daily intake drug <NUMBER> <NUMBER> mg produced significant beneficial effect gastrointestinal esophageal pancreatic brain prostate lung cancer <NUMBER> mode action aspirin reported modulate numerous molecules associated tumorigenesis process <NUMBER> preclinical studies revealed anticancer activity drug <NUMBER> attributed inhibition cyclooxygenase cox enzymes promotes carcinogenesis synthesis prostaglandins pg including pge<NUMBER> <NUMBER> besides drug <NUMBER> reported inhibit activation transcription factor nfκb critical regulating expression genes involved apoptosis <NUMBER> study reported li ling et al compound <NUMBER> inhibited proliferations promoted apoptosis cancer cells also delayed overcame acquired resistance targeted therapy underlying mechanism could attributed enhanced cancer stemness activated nfkb signaling acquired resistant tumors suppressed aspirin rendered resistant tumors sensitive aspirin parental sensitive cells terms proliferation apoptosis cancer stemness contrary aspirin effects normal lung mammary epithelial cell proliferation concentrations used lung breast cancer cells hence aspirin could potential candidate combination therapy lung breast cancers <NUMBER> studies suggest anticancer property aspirin <NUMBER> linked phosphatidylinositol<NUMBER>kinase pi<NUMBER>k pathway rasrafmekerk signaling cascade numerous studies suggest potent anticancer activities drug <NUMBER> overall benefit limited associated serious side effects including gastrointestinal renal toxicities therefore clear recommendation take <NUMBER> populationwide use hand primary cancer prevention tool many reports revealed using <NUMBER> would greater benefit population age <NUMBER> thus us preventive services task force recommendation statement uspstf recommended daily intake <NUMBER> patients <NUMBER> years increased risk cardiovascular disease colorectal cancer celecoxib <NUMBER> belongs family nsaid used treat pain inflammation associated rheumatoid arthritis ra osteoarthritis oa <NUMBER> <NUMBER> fda approved celecoxib highly selective reversible inhibitor cox<NUMBER> wellknown inflammatory cancer target cox<NUMBER> inhibitory activity antitumor activities drug <NUMBER> extensively studied shown chemopreventive activities various cancer types cox<NUMBER> celecoxib targets glycogen synthase kinase gsk <NUMBER>β βcatenin nfκb akt<NUMBER> virus oncogene cellular homolog akt b cell lymphoma bcl<NUMBER> families <NUMBER> people familial adenomatous polyposis fap daily dosage drug <NUMBER> <NUMBER> mg significantly reduced risk colorectal adenomas fda approved compound reduce colon rectal polyps people familial adenomatous polyposis <NUMBER> however associated drawbacks including gastrointestinal renal cardiotoxic effects ibuprofen <NUMBER> nsaid primarily used treat fever pain inflammation molecular level ibuprofen inhibits cox converts arachidonic acid prostaglandin however selective towards isoform cox drug marketed treatment rheumatoid arthritis united kingdom <NUMBER> united states <NUMBER> well anticancer activity drug <NUMBER> investigated various cancer cell types ibuprofen shown inhibit growth prostate cancer cells <NUMBER> adenocarcinoma gastric cells drug <NUMBER> showed antitumor effects mediated antiangiogenesis induction apoptosis reduction cell proliferation <NUMBER> administration drug <NUMBER> induces apoptosis metastatic melanoma cell lines <NUMBER> ibuprofen also reported increases chemosensitivity cisplatin decreasing levels heat shock protein <NUMBER>s hsp<NUMBER>s lung cancer cells hsp<NUMBER>s important part cells machinery protein folding function associated resistance apoptosis <NUMBER> therefore blocking hsp<NUMBER>s ibuprofen increased apoptosis increasing sensitivity cisplatin thalidomide <NUMBER> immunomodulatory drug originally developed sedativehypnotic treatment nausea pregnancy however withdrawn due teratogenic effects drug demonstrated whether could used treating patients refractory myeloma antiangiogenic activity successful clinical evaluations fda approved drug <NUMBER> treating multiple myeloma additionally molecule <NUMBER> also showed efficacy several malignancies including acute myeloid leukemia <NUMBER> myelodysplasia <NUMBER> myelodysplastic syndrome <NUMBER> mechanistically thalidomide binds cereblon forms e<NUMBER> ubiquitin ligase complex resulting rapid ubiquitination proteasomal degradation transcription factors ikaros aiolos <NUMBER> two transcription factors transcriptional regulators b cell development <NUMBER> metformin <NUMBER> orally available firstline drug widely used treatment type <NUMBER> diabetes molecular mechanism metformin involves activation adenosine monophosphate ampinduced protein kinase ampk key enzyme regulating cellular metabolism rapamycin mtor gene involved survival cancer cells negatively regulated ampk metformin also able reduce signals mtor inhibiting ragmediated activation mtor <NUMBER> general diabetic patients increased risk several cancer types especially diabetic women <NUMBER> risk developing breast cancer several studies suggested anticancer property drug <NUMBER> drug <NUMBER> dose <NUMBER> mgday shown reduce risk cancer well daily dose reduces incidence gastrological cancer patients diabetes <NUMBER> <NUMBER> several reviews metaanalysis suggests taking drug <NUMBER> associated reduced risk cancer mortality patients diabetes <NUMBER> recent metaanalysis several antidiabetic drugs found patients using drug <NUMBER> overall reduced risk cancer decreased mortality rate <NUMBER> <NUMBER> respectively whereas use insulin associated increased risk cancer mortality recent phase <NUMBER> clinical trial studies using occurrence colorectal adenomas biomarker cancer primary endpoint <NUMBER> year intervention revealed metformin reduced occurrence number adenomaspolyps patients low dosage level methotrexate <NUMBER> competitive inhibitor dihydrofolate reductase dhfr critical enzyme involved synthesis dna rna thymidylates proteins hydrofolate inhibitory activity drug <NUMBER> responsible antileukemia activity besides drug <NUMBER> effective wide range malignancies including breast head neck leukemia lymphoma lung osteosarcoma bladder trophoblastic neoplasms <NUMBER> fda approved compound <NUMBER> treatment osteosarcoma breast cancer acute lymphoblastic leukemia hodgkin lymphoma several reports suggest antitumor activity methotrexate also due ability target inflammatory pathways instance methotrexate reported suppress nfκb release adenosine cancer cells <NUMBER> rapamycin <NUMBER> also known sirolimus originally developed antifungal agent however drug <NUMBER> withdrawn due potent immunosuppressant antitumor activities mechanistically drug inhibits cells b cells decreasing sensitivity il<NUMBER> inhibition mtor highly upregulated many tumor cells <NUMBER> year <NUMBER> fda approved rapamycin prevention allograft rejection drug investigated anticancer properties recent studies drug <NUMBER> reported reduce colony formation leukemia progenitor cells patients acute myeloid leukemia <NUMBER> addition drug <NUMBER> also showed efficacious patients imatinibresistant chronic myelogenous leukemia suppression vascular endothelial growth factor vegf mrna levels leukemia cells mild side effects <NUMBER> diclofenac <NUMBER> acetic acid derivative nsaid class used treat pain inflammatory diseases gout mode action believed suppress <NUMBER> phase ii clinical trial investigated combination calcitriol recurrent prostate cancer results showed combination well tolerated statin family drugs lipidlowering agents inhibit ratelimiting <NUMBER>hydroxy<NUMBER>methylglutarylcoenzyme hmgcoa reductase cholesterol biosynthesis pathway statins commonly prescribed reduce cholesterol synthesis patients high risk cardiovascular disease addition statins inhibit mevalonate pathway provides mevalonate farnesyl geranyl pyrophosphate molecules important cell cycle progression cell proliferation therefore statins represent promising candidates cancer therapeutics chronic myeloid leukemia cells simvastatin <NUMBER> <NUMBER> natural statins including mevastatin <NUMBER> lovastatin <NUMBER> pravastatin <NUMBER> displayed tnfinduced apoptosis downregulation nfκb mediated antiapoptotic gene products <NUMBER> anticancer activity statins also investigated animal studies statins effective reducing incidence growth tumors <NUMBER> several observational studies metaanalysis supports positive correlation using statins chemopreventive effect humans metaanalyses revealed use statins reduced risk patients gastric cancer <NUMBER> well esophageal <NUMBER> hepatocarcinoma cancer types <NUMBER> casecontrol study drug <NUMBER> dosage <NUMBER> mgday <NUMBER> years significantly reduced incidence colorectal cancer <NUMBER> depakine <NUMBER> valproic acid vpa shortchain free fatty acid mainly used treat epilepsy bipolar disorders migraine anticonvulsant activity attributed blockade voltagegated sodium channels increased levels gammaaminobutyric acid gaba brain anticancer activity drug <NUMBER> first established leukemia cells drug <NUMBER> shown inhibit histone deacetylase hdac <NUMBER> depakine also found suppress production cytokine modulate inflammatory signaling cascade human leukemia human glioma cells drug <NUMBER> able suppress production il<NUMBER> tnfα <NUMBER> prostate cancer cells drug <NUMBER> suppressed il<NUMBER> inhibition nfκb activity <NUMBER> clinical trials drug <NUMBER> advanced phase ii sarcomas thyroid cancers acute myelogenous leukemia b cell lymphoma breast cancer melanoma nonsmall smallcell lung cancers prostate cancer recurrent glioblastoma relapsedrefractory leukemia wwwclinicaltrialsgov recently abdullah et al <NUMBER> shown pitavastatin <NUMBER> antagonizing prc<NUMBER> catalytic activity <NUMBER> treatment acute myeloid leukemia aml significantly changed last decades new therapeutic approaches needed achieve prolonged survival rates <NUMBER> bromocriptine <NUMBER> ergoline derivative dopamine agonist used treatment parkinsons disease acromegaly hyperprolactinemia galactorrhoea recently repositioned diabetes mellitus <NUMBER> <NUMBER> repurposing strategy handled laracastillo maría carmen et al shown bromocriptine potent antileukemia drug mainly targets leukemia stem cells <NUMBER> <NUMBER> <NUMBER> <NUMBER> typically drugdiscovery program develop new potent antiviral agents obtain approval clinical use takes <NUMBER> years effective vaccines drugs approved treat infections although many preclinical development hence drugs used treatment diseases disorders may inhibit replication coronaviruses covs might useful attempt save life several affected patients search potential antiviral agents merscov de wilde et al identified four drugs chloroquine <NUMBER> chlorpromazine <NUMBER> loperamide <NUMBER> lopinavir <NUMBER> screening fda approved drugs library figure <NUMBER> <NUMBER> able inhibit replication merscov low micromolar range addition four drugs inhibited sarscov well human coronavirus hcov<NUMBER>e suggests could used broadspectral antiviral activity mode action compounds <NUMBER> yielded series hit compounds primarily categorized anticancer <NUMBER> <NUMBER> antipsychotics <NUMBER> antidepressent <NUMBER> antipsychotic <NUMBER> pathways interestingly cotreatment drug <NUMBER> gemcitabine deoxycytidine analog commonly used treatment cancers <NUMBER> <NUMBER> showed synergistic antiviral effect minimal cytotoxic effect supports hypothesis using combination therapy treat cov diseases dengue fever lifethreatening disease caused four antigenically distinct dengue virus serotypes became global burden causes approximately <NUMBER> million infections year around <NUMBER> <NUMBER> people die even though vaccine dengue available longterm protective action serotypes dengue virus remains yet determined besides currently clinically approved antiviral therapy available combat virus among many approaches applied identify novel drugs dengue fever drug repurposing gained much attention scientific community several antiviral antimalarial antidiabetic antihistamine anticancer antipsychotic antiparasite anticholesteremic drugs repurposed combat dengue virus infection recent publication botta et al discussed class drugs repositioning detail <NUMBER> identify novel potent drug candidates approved drugs lovastatin <NUMBER> chloroquine <NUMBER> prednisolone <NUMBER> balapiravir <NUMBER> celgosivir <NUMBER> investigated proofoff concept clinical trials dengue viral infection figure <NUMBER> although results showed safe patients acute dengue drugs failed meet priordefined trial endpoints <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> besides two clinical trials conducted thailand singapore involving ivermectin <NUMBER> ketotifen <NUMBER> preliminary result quite promising phase <NUMBER> study drug <NUMBER> suggested reduction serum ns<NUMBER> levels body temperature <NUMBER> recently malakar et al screened various classes fda approved drugs including aminolevulinic acid <NUMBER> azelaic acid <NUMBER> mitoxantrone hydrochloride <NUMBER> quinine sulfate <NUMBER> tested ability inhibit dengue virus denv replication <NUMBER> <NUMBER> figure <NUMBER> representative example drugs repurposed dengue infections aminolevulinic acid <NUMBER> endogenous nonproteinogenic amino acid azelaic acid <NUMBER> used treat skin diseases <NUMBER> <NUMBER> mitoxantrone hydrochloride <NUMBER> anthracenedione antineoplastic agent used treatment leukemia <NUMBER> quinine sulfate <NUMBER> natural compound extracted cinchona bark commercially available <NUMBER>mg tablets brand name qualaquin widely used treat chloroquineresistant plasmodium falciparum <NUMBER> ability reduce viral replication also demonstrated herpes simplex virus hsv <NUMBER> influenza virus <NUMBER> among four drugs investigated drug <NUMBER> found effective inhibiting replication denv <NUMBER> compared untreated controls others showed moderate reduction <NUMBER> impressive drug <NUMBER> able reduce virus replication four serotypes denv three different cell lines human origin molecular level inhibited denv replication reducing viral protein rna synthesis dosedependent manner moreover drug <NUMBER> enhanced expression genes related innate immune response findings suggest efficacy drug <NUMBER> stimulating antiviral genes led reduce denv replication another set prescribed drug candidates <NUMBER> tested bloodstage p falciparum cultures figure <NUMBER> liverstage p berghei <NUMBER> <NUMBER> showed promising antimalarial activity ic <NUMBER> values ranged <NUMBER> µm <NUMBER> nm drugs raloxifene hydrochloride <NUMBER> salirasib <NUMBER> figure <NUMBER> promising cancer drug candidate inhibits isoprenylcysteine carboxyl methyltransferase icmt validated target cancer drug development recently salirasib analogs <NUMBER>triazole repuposed pontential antimalarial activity <NUMBER> general triazole derivartives known potent antimalarial activity <NUMBER> compound investigated vitro toxicity p falciparum asexual stages vero cells antiplasmodial activity assay performed using simple highsensitivity methodology based nanoluciferase nluctransfected p falciparum parasites results showed analogs active low micromolar concentration alzheimers common type dementia affects around <NUMBER> people age <NUMBER> <NUMBER> age <NUMBER> third age <NUMBER> <NUMBER> year <NUMBER> approximately <NUMBER> million people worldwide ad dementia resulted <NUMBER> million deaths estimated <NUMBER> million people dementia worldwide <NUMBER> therefore ad represents major rising public health concern urgent need develop therapies effective ad refers devastating condition leading progressive cognitive decline functional impairment loss independence accumulation amyloidβ peptide aβenriched neuritic plaques neurofibrillary tangles synaptic neuronal dysfunction well loss combination associated neurochemical changes brain crucial pathological event ad <NUMBER> recent work suggests higher levels total tau may potentiate toxic effects aβ <NUMBER> factors inflammatory processes mitochondrial function also likely important role <NUMBER> three acetylcholinesterase inhibitors including donepezil <NUMBER> rivastigmine <NUMBER> costeffective <NUMBER> example acetylcholinesterase inhibitors improve cognition pretreatment performance <NUMBER> months availability drugs substantially advanced treatment patients ad persistent need build increasing understanding disease pathogenesis develop effective symptomatic treatments diseasemodifying therapies drugs md simulation results exposed five drugs risperidone domperidone verapamil tamsulosin cinitapride showed better profiles respect rmsd rmsf sasa rg evaluations graphs steady stable behavior docking complexes invitro ache inhibition assay bestscreened drugs performed spectrophotometric method using acetylthiocholine iodide substrate enzyme inhibition kinetic mechanism drugs showed cinitapride <NUMBER> good therapeutic potential respect standard drugs well known cintapride <NUMBER> gastroprokinetic agent antiulcer agent benzamide class <NUMBER> agonist <NUMBER>ht <NUMBER> <NUMBER>ht <NUMBER> receptors antagonist <NUMBER>ht <NUMBER> receptors <NUMBER> based aforementioned results justified cinitapride better repositioning profile may used treatment ad clinical assessment efforts develop effective therapies far unsuccessful several highprofile clinical trial fails demonstrate benefit reasons probably multifactorial majority putative diseasemodifying therapies evaluated targeted amyloid pathology lack breadth treatment approaches criticized commentators argued sophisticated knowledge disease pathways needed develop effective candidate therapies example phase ii trial tarenflurbil <NUMBER> figure <NUMBER> provided suggestion benefit posthoc subgroup analysis <NUMBER> <NUMBER> putative mechanism action via γsecretase modulation related impact amyloid pathology never confirmed patients ad subsequent phase iii trial negative outcomes although results phase ii trial dimebon <NUMBER> much favorable analog <NUMBER> figure <NUMBER> seems significant benefit seen treatment group driven largerthanexpected deterioration group receiving placebo treatment mechanism action well characterized central nervous system cns angiotensin ii mediates key processes including release inflammatory mediators vasoconstriction mitochondrial dysfunction inhibition acetylcholine release central synapses proposed relevant ad potential targets therapeutic intervention <NUMBER> <NUMBER> based background proposed angiotensin receptor blockers arbs may confer symptomatic benefits cognition largescale screen <NUMBER> antihypertensive drugs want et al <NUMBER> identified arb valsartan <NUMBER> figure <NUMBER> compound able reduce aβ accumulation cultured neurons inhibit aβ aggregation vitro group demonstrated reduced plaque burden well improved learning memory cognitive tests including morris water maze task following <NUMBER> months treatment valsartan <NUMBER>monthold tg<NUMBER> transgenic mice result greatest benefits seen dose <NUMBER> mg kgday equivalent <NUMBER> times maximum recommended dose treating patients hypertension using another arb olmesartan <NUMBER> figure <NUMBER> takeda et al <NUMBER> demonstrated daily treatment young app<NUMBER> mice one month improved cerebral blood flow without affecting aβ<NUMBER> aβ<NUMBER> levels aβ<NUMBER>injected mouse model aβ fragments injected intracranially generate deficits pretreatment telmisartan <NUMBER> figure <NUMBER> increased cerebral blood flow inhibited plaque deposition <NUMBER> however physiological relevance model unclear perhaps striking preclinical evidence comes study losartan <NUMBER> figure <NUMBER> administered intranasally apppsen<NUMBER> mice dose much lower mediating hypotensive effects drug <NUMBER> led <NUMBER>fold reduction aβ plaques compared vehicletreated mice also reduced levels proinflammatory mediators increased levels antiinflammatory mediator il<NUMBER> serum animals <NUMBER> <NUMBER> overall significant reduction incidence dementia patients taking arbs compared taking comparator cardiovascular drugs hazard ratio <NUMBER> <NUMBER> confidence interval <NUMBER> taking angiotensinconverting enzyme ace inhibitor lisinopril hazard ratio <NUMBER> <NUMBER> confidence interval <NUMBER> although evidence potential arbs ad conflicting difficult interpret view sufficient indication potential benefit merit vivo work clarify relative importance different mechanisms optimal dose optimal agent could lead proofofconcept study patients ad best evidence vitro vivo studies points either drug <NUMBER> <NUMBER> preferred arb animal studies also highlighting drug <NUMBER> potential candidate however unfortunate disconnect vivo clinical studies formal studies provide direct clinical evidence far conducted promising candidates calcium channel blockers ccbs dihydropyridine class widely used treat hypertension angina vasodilatory activity smooth muscle vasculature drugs class good bloodbrain barrier penetration induces cerebral vasodilatation increased cerebral blood flow animals humans <NUMBER> vitro studies revealed certain ccbs reduce aβ production oligomerization accumulation rescue aβinduced neurotoxicity improve cell survival presence aβ <NUMBER> <NUMBER> <NUMBER> ccbs also shown reduce glutamateinduced cell death levels intracellular calcium <NUMBER> ability ccbs prevent aβ<NUMBER> aβ<NUMBER> production investigated chinese hamster ovary cells cho paris et al iwasaki et al study amlodipine <NUMBER> nilvadipine <NUMBER> figure <NUMBER> identified agents inhibited aβ production <NUMBER> however concentrations studied severalfold higher achieved therapeutically isradipine <NUMBER> figure <NUMBER> shown neuroprotective effect aβinduced apoptosis neuroblastoma mg<NUMBER> cell lines protective effect drosophila melanogaster model aβinduced neurotoxicity brainpenetrant <NUMBER>xtgad mouse model ad also reported <NUMBER> <NUMBER> differential effects ccbs indicate potential benefits ad probably independent antihypertensive activity may specific individual drugs within class dihydropyridines seem effective compounds different chemical structures verapamil diltiazem evidence preclinical studies highlighted nilvadipine <NUMBER> best therapeutic candidate clinical evidence regarding potential benefit ccb nimodipine <NUMBER> figure <NUMBER> patients clinically significant dementia evidence summarized cochrane review <NUMBER> <NUMBER> nimodipine trials <NUMBER> patients dementia review reported treatment showed efficacy improving cognition activities daily living doses <NUMBER> mgday <NUMBER> however evidence limited small size duration mostly <NUMBER> weeks trials well lack operational diagnostic criteria ad vascular dementia tetracycline antibiotics widely used treat bacterial infections well tolerated older people treatment data pertain shortterm periods exposure studies related ad predominantly focused minocycline <NUMBER> figure <NUMBER> lipophilic tetracycline greater bloodbrain barrier penetration agents class concerning preclinical studies drug <NUMBER> shown reduce aβ<NUMBER> aggregation promote disassembly preformed fibrils vitro studies<NUMBER> various groups independently shown drug <NUMBER> reduces levels proinflammatory mediators microglial activation range mouse models ad <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> besides two three studies using transgenic mouse models ad <NUMBER> days treatment shown significant decrease cerebral aβ accumulation improvements behavioral outcomes well <NUMBER> one studies used <NUMBER>monthold <NUMBER>xtgad mice reported reductions cortical amyloid levels following <NUMBER> months minocycline treatment changes tau pathology observed <NUMBER> third study reported benefit concerning amyloid accumulation behavior treatment period <NUMBER> months<NUMBER> additional study rat model diabetes demonstrated reduction aβ<NUMBER> aβ<NUMBER> levels associated improvements behavioral outcomes <NUMBER> weeks treatment <NUMBER> doxycycline <NUMBER> second generation antibiotic tetracycline class promising drugs tested many clinical trials number different pathologies compound <NUMBER> endowed antiamyloidogenic properties better crosses bloodbrain barrier efficacy never tested ad mice balducci claudia et al showed <NUMBER>to <NUMBER>monthold appps<NUMBER>de<NUMBER> appps<NUMBER> ad mice receiving <NUMBER> different treatment regimens recovered memory without plaque reduction acute <NUMBER> treatment also sufficient improve appps<NUMBER> mouse memory suggesting action soluble abos confirmed aboinduced mouse model abomediated memory impairment abolished pretreatment although abos induce memory impairment glial activation assessing antiinflammatory action <NUMBER> found abotreated appps<NUMBER> mice memory recovery associated lower neuroinflammation data promote <NUMBER> hopeful repositioned drug counteracting crucial neuropathological ad targets <NUMBER> drugs activate retinoic acid receptors rars used treat several skinrelated conditions acne psoriasis retinoic acid also vital normal nerve function repair genomic epidemiological evidence suggest impaired retinoic acid signaling may contribute etiology ad <NUMBER> chronic deprivation retinoic acid rats leads deposition aβ vasculature <NUMBER> dysregulation amyloid processing cortex <NUMBER> shown treatment retinoid x receptor rxr agonist bexarotene <NUMBER> figure <NUMBER> approved treatment cutaneous cell lymphoma leads pathological behavioral improvements transgenic mouse models ad acute treatment drug <NUMBER> lasting less <NUMBER> days caused rapid reduction <NUMBER> aβ<NUMBER> aβ<NUMBER> levels aβ plaque burden young old mice <NUMBER> chronic <NUMBER>day treatment resulted sustained reduction <NUMBER> insoluble aβ levels mechanistically drug <NUMBER> resulted upregulation components highdensity lipoprotein hdl pathway apolipoprotein e apoe promotes proteolytic degradation aβ <NUMBER> potential mechanism action retinoids may include upregulation enzymes involved amyloid clearance insulindegrading enzyme <NUMBER> components apoe pathway <NUMBER> retinoids may also induce potentially beneficial changes related insulin signaling increased neurogenesis promote neuronal differentiation progenitor cells <NUMBER> <NUMBER> retinoids also act antioxidants regulating sod inhibiting glutathione depletion reduce mitochondrial damage well antiinflammatory agents reducing production il<NUMBER> vitro activities potential importance ad pathology <NUMBER> <NUMBER> therefore strong mechanistic rationale potential benefit retinoid therapies beyond amyloid modulation need clarify impact treatment pathways vivo studies overall studies literature indicate retinoids strong potential mechanistic plausibility therapies ad owing effects app processing aβ clearance insulin signaling neurogenesis approved drugs data bexarotene provided proof concept potential candidate treatment alzheimers disease noted whereas acitretin <NUMBER> figure <NUMBER> known penetrate tissues including brain may also promising candidate ad <NUMBER> longterm degenerative disorder cns mainly affects motor system <NUMBER> pd affected <NUMBER> million individuals <NUMBER> people died usually occurs people age <NUMBER> one percent affected addition classic motor symptoms caused death dopaminergic neurons parkinsons disease encompasses wide range nonmotor symptoms although novel diseasemodifying medications slow stop parkinsons disease progression developed drug repurposing use existing drugs passed numerous toxicity clinical safety tests new indications used identify treatment compounds strategy revealed tetracyclines <NUMBER> promising candidates treatment parkinsons disease <NUMBER> tetracyclines neuroprotective inhibit proinflammatory molecule production matrix metalloproteinase activity mitochondrial dysfunction protein misfoldingaggregation microglial activation two commonly used semisynthetic secondgeneration tetracycline derivatives minocycline <NUMBER> doxycycline <NUMBER> exhibit effective neuroprotective activity experimental models neurodegenerative neuropsychiatric diseases substantial toxicity moreover novel synthetic tetracyclines different biological properties due chemical tuning available review discuss multiple effects clinical properties tetracyclines potential use parkinsons disease treatment addition examine hypothesis antiinflammatory activities tetracyclines regulate inflammasome signaling based excellent safety profiles humans use <NUMBER> years antibiotics propose repurposing tetracyclines multitarget antibiotic treat parkinsons disease isradipine <NUMBER> ltype calcium channel blocker dihydropyridine class widely used treatment high blood pressure reduce risk heart attack stroke drug <NUMBER> came medical use year <NUMBER> epidemiological data support calcium channel blockers may potential reduce risk developing pd among dihydropyridines drug <NUMBER> attracted much inhibits subtype cav<NUMBER> ca<NUMBER> channels cav<NUMBER> cav<NUMBER> likely mediate risk pd moreover good brain bioavailability drug <NUMBER> made promising candidate repurposing <NUMBER> <NUMBER> studies shown drug <NUMBER> dose repentantly protect dopaminergic neurons <NUMBER>methyl<NUMBER>phenyl<NUMBER>tetrahydropyridine mptp <NUMBER>hydroxydopamine <NUMBER>ohdainduced toxicity reverting dopaminergic neurons latent juvenile pacemaking mechanism independent calcium <NUMBER> <NUMBER> openlabel doseescalation study assessing safety steadypd drug <NUMBER> controlled release <NUMBER> mgday patients early pd suggested acceptable tolerability doses ≤ <NUMBER> mg per day however higher doses caused leg edema dizziness <NUMBER> isradipine <NUMBER> <NUMBER> mg highest dosage confirmed another steadypdii randomized doubleblinded trial undertaken <NUMBER> subjects early pd requiring dopaminergic therapy <NUMBER> results suggest common adverse effect peripheral edema occurred <NUMBER> patients receiving drug <NUMBER> <NUMBER> mg placebocontrolled phase iii clinical study assess efficacy drug <NUMBER> inosine <NUMBER> figure <NUMBER> purine nucleoside used dietary supplement athletes improving aerobic performance shown neuroprotective roles elevating level serum urate natural antioxidant peroxynitrite scavenging property potential benefits patients multiple sclerosis many studies suggest individuals increased levels urate serum reduced risk developing pd well patients pd associated reduced rate disease progression moreover toxinbased models pd increased urate levels conferred protection dopaminergic cell death stimulated mptp <NUMBER>ohda rotenone aktgsk<NUMBER>b signaling nuclear factor erythroidderived<NUMBER>like <NUMBER> nrf<NUMBER> thought involve effects therefore given data supporting neuroprotective role urate inosine repurposed pathogenesis pd ability raise urate level drug <NUMBER> serum demonstrated surepd randomized double blind placebocontrolled <NUMBER> patients early pd yet requiring medication results showed inosine raised mild urate level <NUMBER> mgdl moderate urate elevation <NUMBER> mgdl <NUMBER> months welltolerated favorable progression rate updrs score amounted <NUMBER> point per year total updrs scale hand elevated level urate serum risk hypertension coronary heart disease stroke long term side effects potentially limiting utility older patients pd however patients asian origin pd inosine elevated urate levels <NUMBER> mgdl without side effects <NUMBER> year treatment reported multicenter surepd<NUMBER> trial involves large number patients <NUMBER> patients currently underway intending elevate urate level <NUMBER> mgdl result study expected year <NUMBER> simvastatin <NUMBER> since statins also known modulate various biological processes relevant pathogenesis pd <NUMBER> <NUMBER> simvastatin repurposed treating disease pretreatment simvastatin preserved dopaminergic cells motor behavior rodents treated <NUMBER>hydroxydopamine <NUMBER>ohda promoting antioxidant protein expression via modulation nmda receptor proinflammatory cytokine expression <NUMBER> similarly <NUMBER>methyl<NUMBER>phenyl<NUMBER>tetrahydropyridine mptp models pretreatment simvastatin suppressed activation nfκb protected dopaminergic neurons improved motor function <NUMBER> <NUMBER> although stains general given encouraging preclinical studies epidemiological data regarding association usage statins risk pd unclear moreover modest protective effect statins disappeared adjusted cholesterol level <NUMBER> however due promising biochemical pharmacological properties simvastatin currently examined <NUMBER> patients moderatestage pd phase ii doubleblind randomized controlled multicenter trial nilotinib <NUMBER> figure <NUMBER> selective cabl tyrosine kinase inhibitor approved treatment imatinibresistant chronic myelogenous leukemia cml accumulating evidence suggests cabl activation linked pathogenesis pd synucleinopathies activated phosphorylated cabl found high level postmortem studies patients pd <NUMBER> <NUMBER> also reported activation cabl mice induces neurodegeneration hippocampal striatal brain areas <NUMBER> continuous work demonstrated cabl phosphorylation occurs result mitochondrial dysfunction oxidative stress <NUMBER> promote accumulation αsynuclein effects autophagy mechanisms <NUMBER> promote phosphorylation parkin causing inhibition ubiquitin e<NUMBER> ligase activity inducing mitochondrial dysfunction dopaminergic neuronal death <NUMBER> evidences propose cabl may promising therapeutic target management pd cns penetration nilotinib abl inhibitors favored fetch data pd related studies indeed preclinical models pd drug <NUMBER> shown cross bloodbrain barrier reduces cabl activity ameliorating autophagic clearance αsynuclein transgenic lentiviral genetransfer models <NUMBER> importantly effects seen doses far lower <NUMBER> mgkgday used treat cml considered key characteristics potential drug repurposing furthermore nilotinib prevented dopaminergic cell loss motor impairments induced mptp mice associated inhibition parkin phosphorylation reduced accumulation parkin substrate paris thus hinting another potential mechanism action <NUMBER> <NUMBER> based preclinical data small openlabel proofofconcept study recently conducted evaluate safety tolerability nilotinib <NUMBER> patients pd dementia dementia lewy bodies followedup <NUMBER> weeks followed final assessment <NUMBER> weeks later <NUMBER> necessary lowest choice dose clinical study taken <NUMBER> mg authors reported nilotinib well tolerated though one patient receiving <NUMBER> mg diagnosed myocardial infarction two transient qtc prolongations also evidence cns penetration nilotinib csf plasma ratio <NUMBER> <NUMBER> <NUMBER> <NUMBER> mg respectively due numerous methodological limitations findings interpreted caution <NUMBER> due unwanted offtarget nonselective tyrosine kinase inhibition side effects nilotinib doses used treat cml include cardiac conduction abnormalities therefore claims tolerability interpreted caution indeed effects efficacy also highly impossible concluded besides also reported csf none markers used validated biomarkers pd also vary greatly patients track poorly disease stage progression situation raises questions optimum dose nilotinib brain penetrance assessments cardiovascular effects patients parkinsons disease pd neurodegenerative disorder greater prevalence incidence described men suggests protective effect sex hormones brain intellectual property related issues hinder commercialization repositioned molecule conclusion repurposing drugs potential find improve treatments various diseases drugs listed plenty drugs repurposed various therapies drugs discussed perspective summarized table <NUMBER> compared previous uses drug repurposed use opportunities drug repurposing diverse lot still done exploration drug repurposing drug repositioning offers new strategy academic centers research council programs notforprofit organizations well pharmaceutical biotechnology companies drug development main advantage drug repurposing established safety known candidate compounds compared development novel therapeutic compounds time cost required advance candidate clinical trials substantially reduced vitro vivo screening chemical optimization toxicity studies bulk manufacturing formulation development already completed many cases therefore bypassed moreover drugs market many years consequently side effects already known safety therefore high medicinal chemists repurposing drugs cancer rewarding job global healthcare system possibly step forward people get cheaper safer medicines rather afford cancer therapy however time minimum investment spent conduct studies improve safety success repurposed drugs drug repurposing also offers possibility develop multitarget drugs interact one pathwayprotein time complex diseases neuro inflammatory degenerative disorders development multitarget drugs emerging area treatment multiple advantages synergistic effect ii reduced drugresistance iii better compliance iv simplified pharmacokinetic pharmacodynamic profile reduced risk drugdrug interactions hand limitations drug repurposing also considered involve technical challenges legal requirements intellectual property rights could hamper whole process often hard overcome b serious problem development resistant germs account consuming drug variety diseases c owing target selectivity difficult identify drug cure treat two different diseases nevertheless drug repurposing part solution sinking numbers new diseases treatment however quite hard replace common way identifying new drug candidates furuter approach could improved many differents ways integrating data repositioning drugs available many public platforms pubchem pandemic covid<NUMBER> coronavirus disease<NUMBER> affected <NUMBER> million people far caused <NUMBER> million deaths <NUMBER> countries worldwide httpscoronavirusjhuedumaphtml numbers still increasing rapidly covid<NUMBER> acute respiratory disease caused highly virulent contagious novel coronavirus strain sarscov<NUMBER> enveloped singlestranded rna virus <NUMBER> sensing urgency researchers relentlessly searching possible therapeutic strategies last weeks control rapid spread quest drug repurposing establishes one relevant options drugs approved least preclinically fighting diseases screened possible alternative use disease interest covid<NUMBER> shown lack severe side effects risks immediate application repurposed drugs limited comparison de novo drug design repurposing drugs offers various advantages importantly reduced time frame development suits urgency situation general furthermore recent advanced artificial intelligence ai approaches boosted drug repurposing terms throughput accuracy enormously finally important understand <NUMBER>d structures majority viral proteins remained largely unknown raises puts obstacles direct approaches work even higher foundation ai based drug repurposing molecule interaction data optimally reflecting drugs viral host proteins get contact life cycle virus viral proteins interact various human proteins infected cells interactions virus hijacks host cell machinery replication thereby affecting normal function proteins interacts develop suitable therapeutic strategies design antiviral drugs comprehensive understanding interactions viral human proteins essential <NUMBER> watching drugs repurposed fight virus one realize targeting single virus proteins easily leads viruses escaping rather simpleminded attack raising resistanceinducing mutations therefore host<NUMBER> link existing highquality longterm curated refined large scale drugprotein protein interaction data <NUMBER> molecular interaction data sarscov<NUMBER> raised handful weeks ago <NUMBER> exploit resulting overarching network using advanced ai boosted techniques <NUMBER> repurposing drugs fight sarscov<NUMBER> <NUMBER> frame hdt based strategies <NUMBER> highlight interactions sarscov<NUMBER>host protein human proteins important virus persist using advanced deep learning techniques cater exploiting network data convinced many fairly broad spectrum drugs raise amenable developing successful hdts covid<NUMBER> following first describe workflow analysis pipeline basic ideas support proceed carrying simulation study proves pipeline accurately predicts missing links encompassing drug human protein sarscov<NUMBER>protein network raise analyze namely demonstrate highperformance ai supported prediction pipeline accurately reestablishes links explicitly removed provides sound evidence interactions predict full network likely reflect true interactions molecular interfaces subsequently continue core experiments predict links missing full without artificially removed links encompassing drug human protein sarscov<NUMBER>protein network raised combining links yearlong curated resources one hand recently published covid<NUMBER> resources hand per simulation study large fraction vast majority predictions establish true hence actionable interactions drugs one hand sarscov<NUMBER> associated human proteins hence use hdt hand b c figure <NUMBER> overall workflow proposed method three networks sarscov<NUMBER>host ppi human ppi drugtarget network panela mapped common interactors form integrated representation panelb neighborhood sampling strategy node<NUMBER>vec converts network fixedsize low dimensional representations perverse properties nodes belonging three major components integrated network panelc resulting feature matrix f node embeddings adjacency matrix integrated network used train vgae model used prediction paneld purposes highconfidence validation carry literature study overall <NUMBER> drugs put forward inspect postulated mechanismofaction drugs frame several diseases including sarscov merscov driven diseases particular see figure <NUMBER> workflow analysis pipeline basic ideas support describe important steps paragraphs subsection reduces training time compared general graph autoencoder model tested model performance different number sampled nodes keeping track area roc curve auc average precision ap score model training time frame trainvalidationtest split proportions <NUMBER> table <NUMBER> shows performance model sampled sugraph sizes n <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> sampled nodes models performance sufficiently good enough concerning training time validationauc ap score average test rocauc ap score model n <NUMBER> <NUMBER> ± <NUMBER> <NUMBER> ± <NUMBER> know efficacy model discovering existing edges covhost drug nodes train model n <NUMBER> incomplete version graph links covhost drugs removed compute feature matrix f based incomplete graph use test set consists previously removed edges model performance doubt better discovering edges covhost drug nodes rocauc <NUMBER> ± <NUMBER> ap <NUMBER> ± <NUMBER> <NUMBER> runs fastgae model learned feature matrix f adjacency matrix node feature matrix f obtained using node<NUMBER>vec neighborhood sampling strategy model performance evaluated without using f feature matrix figure <NUMBER> shows average performance model validation sets without f input different number sampling nodes calculate average auc ap scores <NUMBER> complete runs model figure <NUMBER> evident including f feature matrix enhances models performance markedly use node<NUMBER>vec framework learn low dimensional embeddings node compiled network uses skipgram algorithm word<NUMBER>vec model learn embeddings eventually groups nodes similar role similar connection pattern within graph similar role ensures nodes within setsgroups structurally similarequivalent nodes outside groups two nodes said structurally equivalent identical connection patterns rest network <NUMBER> explore analyzed embedding results two steps first explore structurally equivalent nodes identify roles similar connection patterns rest networks later use lovain clustering examine within groupsclusters mostsimilar function node<NUMBER>vec inspects structurally equivalent nodes within network find covhost nodes similar drug nodes expected observe nodes types within neighborhood particular node cases found drugs neighbors covhost proteins high probability pobs <NUMBER> sarscov<NUMBER> <NUMBER>cl protease <NUMBER> drugs clenbuterol fenbendazole probable neighbor ppp<NUMBER>cb eef<NUMBER>a respectively used bronchodilators asthma explore closely connected groups constructed neighborhood graph using kth nearest neighbor algorithm node embeddings apply louvain clustering figure <NUMBER> panelc although clear separation host proteins including covhost cluster drug cluster louvain clusters contain types nodes example louvain cluster<NUMBER> <NUMBER> contain four two drugs along covhost proteins respectively figure <NUMBER> paneld represents network consisting six drugs similar covhost nodes drugcovhost interaction prediction exploit variational graph autoencoder vgae unsupervised graph neural network model first introduced <NUMBER> leverage concept variational autoencoder graphstructured data make learning faster utilized fastgae model take advantage fast decoding phase used two data matrices fastgae model learning one adjacency matrix represents interaction information nodes one feature matrix representing lowdimensional embeddings nodes network create test set nonedges removing existing links drugs covhost proteins possible combinations <NUMBER> covhost × <NUMBER> drugs edges model trained whole network adjacency matrix feature matrix f trained model applied test nonedges know probable links identified total <NUMBER> probable links <NUMBER> drugs <NUMBER> covhost proteins probability threshold <NUMBER> predicted covhost proteins involved different crucial pathways viral infection table <NUMBER> pvalues pathway go enrichment calculated using hypergeometric test <NUMBER> fdr corrections figure <NUMBER> panela shows heatmap probability scores predicted drugs covhost proteins get details predicted bipartite graph figure <NUMBER> drugcovhost predicted interaction panela shows heatmap probability scores <NUMBER> drugs <NUMBER> covhost proteins four predicted bipartite modules annotated b<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> within heatmap drugs colored based clinical phase redlaunched preclinicalblue phase<NUMBER>phase<NUMBER>green phase<NUMBER> phase<NUMBER>black panelb c e represents networks corresponding b<NUMBER> b<NUMBER> b<NUMBER> b<NUMBER> modulesthe drugs annotated using disease area found cmap database <NUMBER> b c e figure <NUMBER> predicted interactions probability threshold <NUMBER> panela shows interaction graph drugs covhost drugs annotated usage panelb c e represents quasibicliques one two three three drugs molecules respectively use weighted bipartite clustering algorithm proposed j beckett <NUMBER> results <NUMBER> bipartite modules panela figure <NUMBER> b<NUMBER> <NUMBER> drugs <NUMBER> covhost b<NUMBER> <NUMBER> drugs <NUMBER> covhost b<NUMBER> <NUMBER> rugs <NUMBER> covhost b<NUMBER> <NUMBER> drugs <NUMBER> covhost panels figure show network diagram four bipartite modules b<NUMBER> contains <NUMBER> drugs including antibiotics anisomycin midecamycin anticancer drugs doxorubicin camptothecin b<NUMBER> also antibiotics puromycin demeclocycline dirithromycin geldanamycin chlortetracycline among first three widely used bronchitis pneumonia respiratory tract infections <NUMBER> drugs lobeline ambroxol included b<NUMBER> module variety therapeutic uses including respiratory disorders bronchitis high confidence predicted interactions threshold <NUMBER> shown figure <NUMBER> panela highlight repurposable drug combination predicted covhost target perform weighted clustering clusterone <NUMBER> network found quasybicluques shown panelbe matched predicted drugs drug list recently published zhou et al <NUMBER> found six common drugs mesalazine vinblastine menadione medrysone fulvestrant apigenin among apigenin known effect antiviral activity together quercetin rutin flavonoids <NUMBER> mesalazine also proven extremely effective treatment viral diseases like influenza ah<NUMBER>n<NUMBER> virus <NUMBER> baclofen benzodiazepine receptor gabaareceptor agonist potential role antiviral associated treatment <NUMBER> antiinflammatory antecedents fisetin also tested antiviral activity inhibition dengue denv virus infection <NUMBER> downregulates production proinflammatory cytokines induced denv infection drugs listed high confidence interaction set three covhosts tapt<NUMBER> interacted sarscov<NUMBER> protein orf<NUMBER>c slc<NUMBER>a<NUMBER> interacted sarscov<NUMBER> protein orf<NUMBER>c trim<NUMBER> interacted sarscov<NUMBER> protein orf<NUMBER>a figure <NUMBER> panelc topoisomerase inhibitors play active role antiviral agents inhibiting viral dna replication <NUMBER> <NUMBER> topoisomerase inhibitors camptothecin daunorubicin doxorubicin irinotecan mitoxantrone predicted interact several covhost proteins demonstrated anticancer drug camptothecin cpt derivative irinotecan potential role antiviral activity <NUMBER> <NUMBER> inhibits host cell enzyme topoisomerasei required initiation well completion viral functions host cell <NUMBER> daunorubicin dnr also demonstrated inhibitor hiv<NUMBER> virus replication human host cells <NUMBER> conventional anticancer antibiotic doxorubicin identified selective inhibitor vitro dengue yellow fever virus replication <NUMBER> also reported doxorubicin coupling monoclonal antibody create immunoconjugate eliminate hiv<NUMBER> infection mice cell <NUMBER> mitoxantrone shows antiviral activity human herpes simplex virus hsv<NUMBER> reducing transcription viral genes many human cells essential dna synthesis <NUMBER> histone deacetylases inhibitors hdaci generally used latencyreversing agents purging hiv<NUMBER> latent reservoir like cd<NUMBER> memory cell <NUMBER> predicted drug list table <NUMBER> contains two hdaci scriptaid vorinostat vorinostrate used achieve latency reversal hiv<NUMBER> virus safely repeatedly <NUMBER> asymptomatic patients infected sarscov<NUMBER> significant concern vulnerable infect large number people symptomatic patients moreover cases <NUMBER> percentile patients develop symptoms average <NUMBER> days longer incubation period sars mers viruses <NUMBER> end hdaci may serve good candidates recognizing clearing cells sarscov<NUMBER> latency reversed heat shock protein <NUMBER> hsp described crucial host factor life cycle several viruses includes entry cell nuclear import transcription replication <NUMBER> <NUMBER> hsp<NUMBER> also shown essential factor sarscov<NUMBER> envelop e protein <NUMBER> <NUMBER> hsp<NUMBER> described promising target antiviral drugs list predicted drugs contains three hsp inhibitors tanespimycin geldanamycin derivative alvespimycin first two substantial effect inhibiting replication herpes simplex virus human enterovirus <NUMBER> ev<NUMBER> respectively recently <NUMBER> geldanamycin derivatives proposed effective drug treatment covid<NUMBER> inhibiting dna synthesis viral replication one critical steps disrupting viral infection list predicted drugs contains six small moleculesdrugs viz niclosamide azacitidine anisomycin novobiocin primaquine menadione metronidazole dna synthesis inhibitor niclosamide great potential treat variety viral infections including sarscov merscov hcv virus <NUMBER> recently described potential candidate fight <NUMBER> sarscov<NUMBER> virus <NUMBER> novobiocin aminocoumarin antibiotic also used treatment zika virus zikv infections due protease inhibitory activity <NUMBER> chloroquine cq demonstrated effective drug spread severe acute respiratory syndrome sars coronavirus sarscov recently hydroxychloroquine hcq sulfate derivative cq evaluated efficiently inhibit sarscov<NUMBER> infection vitro <NUMBER> therefore another antimalarial aminoquinolin drug primaquine may also contribute attenuation inflammatory response covid<NUMBER> patients primaquine also established effective treatment pneumocystis pneumonia pcp <NUMBER> cardiac glycosides shown play crucial role antiviral drugs drugs target cell host proteins help reduce resistance antiviral treatments antiviral effects cardiac glycosides described inhibiting pump function na katpase makes essential drugs human viral infections predicted list drugs contains three cardiac glycosides atpase inhibitors digoxin digitoxigenin ouabain drugs reported effective different viruses herpes simplex influenza chikungunya coronavirus respiratory syncytial virus <NUMBER> mg<NUMBER> proteasomal inhibitor established strong inhibitor sarscov replication early steps viral life cycle <NUMBER> mg<NUMBER> inhibits cysteine protease mcalpain results pronounced inhibition sarscov<NUMBER> replication host cell <NUMBER> resveratrol demonstrated significant inhibitor merscov infection resveratrol treatment decreases expression nucleocapsid n protein merscov essential viral replication mg<NUMBER> resveratrol play vital role inhibiting replication coronaviruses sarscov merscov may potential candidates prevention treatment sarscov<NUMBER> another drug captopril known angiotensin ii receptor blockers arb directly inhibits production angiotensin ii <NUMBER> angiotensinconverting enzyme <NUMBER> ace<NUMBER> demonstrated binding site sarscov<NUMBER> angiotensin ii receptor blockers arb may good candidates use tentative treatment sarscov<NUMBER> infections <NUMBER> summary proposed method predicts several drug targets multiple repurposable drugs prominent literature evidence uses antiviral drugs especially two coronavirus species sarscov merscov drugs also directly associated treatment sarscov<NUMBER> identified recent literature however clinical trials several preclinical experiments required validate clinical benefits potential drugs drug targets work successfully generated list highconfidence candidate drugs repurposed counteract sarscov<NUMBER> infections novelties integrate recently published sarscov<NUMBER> protein interaction data one hand use recent advanced ai deep learning based highperformance prediction machinery hand two major points experiments validated prediction pipeline operates utmost accuracy confirming quality predictions raised recent publication april <NUMBER> <NUMBER> two novel sarscov<NUMBER>human protein interaction resources <NUMBER> <NUMBER> unlocked enormous possibilities studying virulence pathogenicity sarscov<NUMBER> driving mechanisms behind various experimental computational approaches design drugs covid<NUMBER> become conceivable approaches exploited truly systematically sufficiently high throughput accuracy best knowledge done first time integrated new sarscov<NUMBER> protein interaction data well established longterm curated human protein drug interaction data data capture hundreds thousands approved interfaces encompassing sets molecules either reflecting drugs human proteins result obtained comprehensive drughumanvirus interaction network reflects latest state art terms knowledge sarscov<NUMBER> interacts human proteins repurposable drugs exploiting new networkalready establishing new resource rightwe opted recent advanced deep learning based technology generic reason choice surge advances resulting boost operative prediction performance related methods last <NUMBER> years particular reason make use advanced graph neural network based techniques namely variational graph autoencoders deep generative model utmost accuracy practical implementation <NUMBER> presented months ago like relevant network data note recent implementation enables process networks sizes range common molecular interaction data essence graph neural networks learn structure links networks infer rules underlie interplay links based knowledge gained enable predict links output corresponding links together probabilities indeed missing simulation experiments reflecting scenarios links known exist network reestablished prediction upon removal pointed pipeline indeed predict missing links utmost accuracy encouraged simulations proceeded performing core experiments predicted links missing without prior removal links encompassing network core experiments revealed <NUMBER> high confidence interactions relating <NUMBER> drugs experiments focused predicting links drugs human proteins turn known interact sarscov<NUMBER> proteins sarscov<NUMBER> associated host proteins decidedly put focus drug sarscov<NUMBER>protein interactions would reflected direct therapy strategies virus instead focused predicting drugs serve purposes hostdirected therapy hdt options hdt strategies proven sustainable respect mutations virus escapes response therapy applied note hdt strategies particularly cater drug repurposing attempts repurposed drugs already proven lack severe side effects either already use successfully passed preclinical trial stages systematically categorized <NUMBER> repurposable drugs <NUMBER> categories based domains application molecular mechanism according identified highlighted several drugs target host proteins virus needs enter subsequently hijack human cells one example captopril directly inhibits production angiotensinconverting enzyme<NUMBER> ace<NUMBER> turn already known crucial host factor sarscov<NUMBER> identified primaquine antimalaria drug used prevent malaria also pneumocystis pneumonia pcp relapses interacts tim complex timm<NUMBER> alg<NUMBER> moreover highlighted drugs act dna replication inhibitor niclosamide anisomycin glucocorticoid receptor agonists medrysone atpase inhibitors digitoxigenin digoxin topoisomerase inhibitors camptothecin irinotecan proteosomal inhibitors mg<NUMBER> note drugs known rather severe side effects original use doxorubicin vinblastine disrupting effects shortterm usage severe covid<NUMBER> infections may mean sufficient compensation summary compiled list drugs repurposed great potential fight covid<NUMBER> pandemic therapy options urgently needed list predicted drugs suggests options identified thoroughly discussed new opportunities pointed earlier latter class drugs may offer valuable chances pursuing new therapy strategies covid<NUMBER> utilized three categories interaction datasets human proteinprotein interactome data sarscov<NUMBER>host protein interaction data drughost interaction data taken sarscov<NUMBER>host interaction information two recent studies gordon et al dick et al <NUMBER> <NUMBER> <NUMBER> <NUMBER> high confidence interactions sarscov<NUMBER> human proteins predicted using using affinitypurification mass spectrometry apms <NUMBER> <NUMBER> high confidence interactions identified using sequencebased ppi predictors pipe<NUMBER> sprint drugtarget interaction information collected five databases viz drugbank database v<NUMBER> <NUMBER> chembl <NUMBER> database therapeutic target database ttd <NUMBER> pharmgkb database iupharbps guide pharmacology <NUMBER> total number drugs drughost interactions used study <NUMBER> <NUMBER> respectively built comprehensive list human ppis two datasets <NUMBER> ccsb human interactome database consisting <NUMBER> genes <NUMBER> highquality binary interactions <NUMBER> <NUMBER> human protein reference database <NUMBER> consists <NUMBER> proteins <NUMBER> ppis summary datasets provided table <NUMBER> cmap database <NUMBER> used annotate drugs usage different disease areas utilized node<NUMBER>vec <NUMBER> algorithmic framework learning continuous feature representations nodes networks maps nodes lowdimensional feature space maximizes likelihood preserving network neighborhoods principle feature learning framework graph described follows let g v e given graph v represents set nodes e represents set edges feature representation nodes v given mapping function f v → r specify feature dimension f may also represented node feature matrix dimension v × node v ∈ v nn v ⊂ v defines network neighborhood node v generated using neighbourhood sampling strategy sampling strategy described interpolation breadthfirst search depthfirst search technique <NUMBER> objective function described maximizes likelihood observing network neighborhood nn v node v given feature representation f probability observing neighborhood node n ∈ nn v given feature representation source node v given n th neighbor node v neighborhood set nn v conditional likelihood source v neighborhood node n ∈ nn v pair represented softmax dot product features f v f n follows variational graph autoencoder vgae framework unsupervised learning graphstructured data <NUMBER> model uses latent variables effective learning interpretable latent representations undirected graphs graph autoencoder consists two stacked models <NUMBER> encoder <NUMBER> decoder first encoder based graph convolution networks gcn <NUMBER> maps nodes lowdimensional embedding space subsequently decoder attempts reconstruct original graph structure encoder representations models jointly trained optimize quality reconstruction embedding space unsupervised way functions two model described follows encoder uses graph convolution network gcn adjacency matrix feature representation matrix f encoder generates dimensional latent variable z node ∈ v v n corresponds embedding node ≤ n inference model encoder given rz f corresponds normal distribution n z µ σ <NUMBER> µ σ gaussian mean variance parameters actual embedding vectors z samples drawn distributions decoder generative model decodes latent variables z reconstruct matrix using inner products sigmoid activation embedding vector z decoded adjacency matrix objective function variational graph autoencoder vgae written objective function c v gae maximizes likelihood decoding adjacency matrix wrt graph autoencoder weights using stochastic gradient decent kl represents kullbackleibler divergence <NUMBER> pz prior distribution latent variable drugsarscov<NUMBER> link prediction <NUMBER> adjacency matrix preparation work consider undirected graph g v e v n nodes e edges denote binary adjacency matrix g v consists sarscov<NUMBER> proteins covhost proteins drugtarget proteins drugs matrix contains total n <NUMBER> nodes given n nc number sarscov<NUMBER> proteins n dt number drug targets whereas n nt n represent number covhost drugs nodes respectively total number edges given e <NUMBER> represents interactions sarscov<NUMBER> human host proteins e <NUMBER> number interactions among human proteins e <NUMBER> represents number interactions drugs human host proteins neighborhood sampling strategy used prepare feature representation nodes flexible biased random walk procedure employed explore neighborhood node random walk graph g described probability πv x transition probability nodes v x v x ∈ e th node walk length l transition probability given πv x c pq x w vx previous node v n walk w vx static edge weights p q two parameters guides walk coefficient c pq x given distancet x represents shortest path distance nodes node x process feature matrix f n×d generation governed node<NUMBER>vec algorithm starts every nodes simulates r random walks fixed length l every step walk transition probability πv x govern sampling generated walk iteration included walklist finally stochastic gradient descent applied optimize list walks result returned <NUMBER> link prediction scalable fast variational graph autoencoder fastvgae <NUMBER> utilized proposed work reduce computational time vgae large network adjacency matrix feature matrix f given encoder fastvgae encoder uses graph convolution neural network gcn entire graph create latent representation z encoder works full adjacency matrix encoding sampling done decoder works sampled sub graph mechanism decoder fastvgae slightly different traditional vgae regenerate adjacency matrix based subsample graph nodes v uses graph node sampling technique randomly sample reconstructed nodes iteration node assigned probability p selection noes based high score p probability p given following equation f degree node α sharpening parameter take α <NUMBER> study node selection process repeated v n n number sampling nodes decoder reconstructs smaller matrix dimension n × n instead decoding main adjacency matrix decoder function follows following equation j sigmoidz z j ∀i j ∈ v ×v training iteration different subgraph g drawn using sampling method model trained drugcovhost links predicted using following equation j represents possible links combination sarscov<NUMBER> nodes drug nodes combination nodes model gives probability based logistic sigmoid function way overcome time limitation research development needed design therapeutic drug combat pathogen <NUMBER> apart lower risk failure repurposed drugs cleared phase trials require lower investment drug repurposing strategy drastically reduces time frame development <NUMBER> drug repurposing repositioning approach thus facilitate prompt clinical decisions lower costs de novo drug development though drug repurposing sometimes based chance observations targetbased repurposing drugs depends prior understanding precise molecular cellular element recognized proposed drug <NUMBER> <NUMBER> target may may essentially mechanism action diseased states antivirals target viral proteins key events viral life cycle including virushost cell interactions replication assembly egress would belong class drug repurposing identify candidate drug compounds centred targetbased criteria thus generally distinguished virusand hostbased therapeutics review outlines present status virusbased hostbased drug repurposing evaluations covs focus would food drug administration fdaapproved marketed drugs clinical trials covs general sarscov<NUMBER> particular virusbased antiviral agents target specific proteins virus major open reading frame orf<NUMBER>ab sarscov genome encodes large replicase polyprotein pp<NUMBER>ab forms nonstructural proteins nsp<NUMBER> structural proteins include e n <NUMBER> <NUMBER> <NUMBER> viral replication facilitated replicase complex involves processing pp<NUMBER>ab two cysteine proteases namely main protease mpro <NUMBER>clike protease <NUMBER>clpro secondary papainlike protease <NUMBER> pl<NUMBER>pro <NUMBER> <NUMBER> figs <NUMBER> <NUMBER> mpro cleaves <NUMBER> sites central cterminal regions pl<NUMBER>pro cleaves three sites nterminal regions polyprotein majority proteins enzymes covs vital replication process potential drug targets mpro promising viral target design drugs sarsmers polyprotein cleavage mpro facilitates formation rnadependent rna polymerase rdrp helicase major proteins viral replication <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> various classes protease inhibitors halomethylketones phthalhydrazide ketones α βepoxyketones glutamic acid glutamine peptides trifluoromethylketone group zinc mercury conjugates c<NUMBER>symmetric diols peptidomimeticα βunsaturated esters aldehydes anilides nitriles pyrimidinone pyrazole analogues benzotriazole nphenyl<NUMBER>acetamide biphenyl sulphone reported inhibit sarscov<NUMBER> mpro <NUMBER>clpro <NUMBER> <NUMBER> fig <NUMBER> prospective mpro inhibitors common fdaapproved ones wellknown hiv<NUMBER> protease inhibitors <NUMBER> among lopinavir andor ritonavirboosted form lopinavir reported anticov activity vitro also shown improved outcomes nonhuman primates infected merscov nonrandomized trials sars patients <NUMBER> lopinavir ritanovir phase iiiii clinical trials merscov nct<NUMBER> <NUMBER> also reported activity hcov<NUMBER>e hcovnl<NUMBER> animal covs <NUMBER> cinanserin sq <NUMBER> serotonin antagonist demonstrated antiviral activity sarscov<NUMBER> inhibition replication probably blocking activity mpro <NUMBER> flavonoids herbacetin rhoifolin pectolinarin known possess antioxidant effects associated diseases cancer alzheimers disease atherosclerosis also noted efficiently inhibit sarscov<NUMBER> mpro <NUMBER> spectrum antiviral activity several viruses including respiratory syncytial virus hepatitis c e viruses hcv hev chikungunya viral haemorrhagic fevers <NUMBER> <NUMBER> though mechanism action fully understood hypothesized drug may involved inhibition mrna capping viral rna synthesis vitro antiviral activity ribavirin demonstrated sarscov<NUMBER> merscov <NUMBER> rhesus monkeys infected merscov <NUMBER> drug used treatment sars mers patients though benefits ambiguous severely infected cov patients could side effects associated high doses <NUMBER> immucillina galidesivir adenosine analogue shown recently broadspectrum rdrp inhibitor several rna viruses paramyxoviruses flaviviruses togaviruses bunyaviruses arenaviruses picornaviruses filoviruses also sarsmerscovs <NUMBER> though reported treatment option <NUMBER> west africa ebola virus epidemic data animalhuman reported covs recently sarscov<NUMBER> <NUMBER> sheahan et al <NUMBER> modelled threedimensional structures major virus based antiviral targets <NUMBER>clike protease <NUMBER>clpro rnadependent rna polymerase rdrp papainlike protease pl<NUMBER>pro based sarscov<NUMBER> templates obtained protein data bank also depicted structure spike glycoprotein sarscov<NUMBER> released recently <NUMBER>vsbpdb per cent identity coding regions specific viral genomes depicted calculated using pdistance method mega software v<NUMBER> httpswwwmegasoftwarenet source refs <NUMBER> <NUMBER> merscov primary human airway epithelial cells also demonstrated broadspectrum anticov activity batcovs human covs primary human lung cells <NUMBER> <NUMBER> another recent study remdesivir shown possess better vitro antiviral efficacy merscov comparison lopinavir ritanovir <NUMBER> <NUMBER> mice remdesivir improved pulmonary function lower viral loads lungs prophylactic therapeutic <NUMBER> <NUMBER> another nucleoside analogue acyclovir modified incorporating fleximers increase binding affinity reported effective vitro merscov hcovnl<NUMBER> <NUMBER> though best knowledge animal human data available covs possess surface structural spike glycoprotein vital interaction host cell receptor subsequent virus entry cell protein constitutes two subunits s<NUMBER> receptorbinding s<NUMBER> membrane fusion domains <NUMBER> griffithsin lectin extract red algae reported bind oligosaccharides surface various viral glycoproteins including hiv glycoprotein <NUMBER> sarscov glycoproteins <NUMBER> resveratrol natural compound grape clinical phase heart diseases also reported effectively inhibit merscov vitro downregulation apoptosis induced virus <NUMBER> possible site action suggested nucleocapsid protein amodiaquine mefloquine antimalarial drugs also found effective merscov <NUMBER> loperamide antidiarrhoeal agent identified screening fdaapproved compound library showed vitro antiviral activity mers <NUMBER> viral nucleic acids mainly composed nucleosides nucleotides drugs target mycophenolic acid mpa active compound inhibit inosine monophosphate dehydrogenase guanine monophosphate synthesis <NUMBER> broadspectrum activity reported mpa broad range viruses including orthohepadnaviruses hepatitis b flaviviruses hcv arboviruses covs mpa possessed antimerscov activity vitro though shown result worsened outcome marmoset primate model <NUMBER> treatment renal transplant recipients mpa resulted severe mers <NUMBER> combination therapy interferon beta<NUMBER>b ifnβ<NUMBER>b however reported synergistic vitro <NUMBER> implying monotherapy drug might useful treating covs specific host factors utilized covs entry replication anticov potential monoclonal antibodies mabs evoked receptor binding domain rbd s<NUMBER> subunit fusion inhibitors target s<NUMBER> subunit reported vitro andor vivo studies <NUMBER> <NUMBER> <NUMBER> sarscovs hcovnl<NUMBER> preferably utilize angiotensinconverting enzyme <NUMBER> ace<NUMBER> host receptor dipeptidyl peptidase <NUMBER> dpp<NUMBER> used merscov <NUMBER> entry entry covs host cells includes cell surface andor endosomal pathways via host proteases transmembrane protease serine <NUMBER> tmprss<NUMBER> cleave activate viral protein <NUMBER> inhibitors host proteases prevent proteolytic cleavage partially blocking cell entry group drugs target endocytosis cell entry <NUMBER> fig <NUMBER> innate ifn response host also therapeutic potential controls viral replication infection <NUMBER> <NUMBER> additional pathways cell signalling also noted possible therapeutic targets covs <NUMBER> classes inhibitors discussed chlorpromazine antipsychotictranquilizer drug also known affect assembly clathrincoated pits plasma membrane <NUMBER> showed broadspectrum vitro activity viruses hcv alphaviruses sarscov<NUMBER> merscov ouabain bufalin examples class steroids bind sodiumor potassiumtransporting atpase subunit α<NUMBER> also inhibited endocytosis merscov mediated clathrin <NUMBER> however high ec <NUMBER> c max halfmaximal effective concentration valuepeak serum concentration level ratios typical dosages toxicity limit clinical use endocytosis inhibitors acidification endosome also affect endocytosis chloroquine antimalarial drug increase intracellular ph directing protons lysosomes <NUMBER> possesses broadspectrum vitro antiviral activities flaviviruses hiv ebola nipah numerous covs <NUMBER> however show activity sarscovinfected mice <NUMBER> anticov activity different endocytosis inhibitors thus need vivo evaluation specific peptide inhibitors monoclonal polyclonal antibodies used target host receptor <NUMBER> n<NUMBER>aminoethyl<NUMBER>aziridineethanamine smallmolecule inhibitor synthetic ace<NUMBER>derived peptides showed inhibition ace<NUMBER> activity cell fusion via protein sarscov<NUMBER> vitro <NUMBER> <NUMBER> however inhibitors tested cov patients monoclonal antibodies mabs antidipeptidyl peptidase <NUMBER> dpp<NUMBER> also reported block cell entry merscov vitro <NUMBER> ys<NUMBER> antidpp<NUMBER> recombinant humanized igg<NUMBER> mab used phase clinical trial found well tolerated patients advanced malignancies <NUMBER> however considering host cell receptor usage differs different covs anticov activity agents may narrowspectrum based vital biological functions receptors risks immunopathology blood pressure regulation glucose metabolism etc would need assessment <NUMBER> camostat mesylate synthetic serine protease inhibitor used treat patients chronic pancreatitis works serine protease tmprss<NUMBER> <NUMBER> <NUMBER> shown broadspectrum activity enveloped rna viruses covs paramyxoviruses camostat mesylate reported inhibit sars mers ex vivo studies improves survival mice infected sars <NUMBER> nafamostat another serine protease inhibitor used treat disseminated intravascular coagulation pancreatitis blocked merscov infection inhibiting tmprss<NUMBER> human airway epithelial calu<NUMBER> cells <NUMBER> though viral infection suppression ifn response integral part immune evasion several viruses covs noted susceptible ifn treatment effectiveness recombinant ifnβ ifnα demonstrated vitro studies sars mers <NUMBER> ifnα mediated reduction viral titres observed sarscovinfected vivo models <NUMBER> <NUMBER> ifnβ administration via different routes found effective merscov vivo models <NUMBER> nitazoxanide synthetic derivative nitrothiazolylsalicylamide used treatment parasitic infections effective type ifn inducer <NUMBER> shown exhibit antiviral activities several viral families canine covs nitazoxanide found safe phase ii iii clinical trials hcv influenza <NUMBER> drugs interfering viral replication signaling pathways noted broad spectrum activity several viruses hcv hiv vesicular stomatitis virus human papilloma virus vaccinia virus covs <NUMBER> cyclosporine calcineurin pathway inhibitor inhibited broad range covs vitro interacting nsp<NUMBER> protein modulating immune response mediated cells <NUMBER> clinical application drug however restricted due immunesuppressive effects higher ec <NUMBER> c max ratio standard dose levels calcineurin inhibitors alisporivir demonstrated activity hcovnl<NUMBER> <NUMBER> extracellular signalregulated kinase erk pathway mediates intracellular signals membraneassociated ras cytoplasmic kinase cascade raf mek erk <NUMBER> kinase signaling pathway inhibitors trametinib mek inhibitor selumetinib erk inhibitor everolimus rapamycin dasatinib imatinib also demonstrated anticov effects inhibition early viral entry postentry events <NUMBER> however toxicities may concern severe infections initiation translation many viruses happens usage host eukaryotic initiation factors eifs <NUMBER> helicase eif<NUMBER>a unwinds <NUMBER>′untranslated region mrna facilitating assembly translation preinitiation complexes natural compound silvestrol inhibitor eif<NUMBER>a reported show anticancer activity <NUMBER> demonstrated inhibition merscov hcov<NUMBER>e translation replication mrc<NUMBER> lung fibroblast cells <NUMBER> comparison coding regions sarscov<NUMBER> showed possessed similar genomic organization compared batslcovzc<NUMBER> sarscov<NUMBER> <NUMBER> fig <NUMBER> sequence analysis revealed good sequence identity bat human covs different coding regions except spike glycoprotein sarscov<NUMBER> differs covs including sarscov<NUMBER> spike protein <NUMBER> <NUMBER> catalytic pockets cov<NUMBER> using recombinant ifns nct<NUMBER> chictr<NUMBER> <NUMBER> another study artificial intelligencebased knowledge graph comprising systematically curated medical data searched approved drugs sarscov<NUMBER> <NUMBER> baricitinib janus kinase inhibitor consequently identified highaffinity ap<NUMBER>associated protein kinase <NUMBER>binding drug also interacts kinase regulator endocytosis baricitinib thus suggested potential treatment covid<NUMBER> disease ability reduce viral infection lung cells analyzed binding potential hiv<NUMBER> protease inhibitors lopinavir ritanovir <NUMBER>clpro sarscov<NUMBER> using computational docking studies would help gain insight molecular mode action drugs clinical trials sarscov<NUMBER> also estimate comparative inhibitory potency fdaapproved hiv protease inhibitors sarscov<NUMBER> mpro covs cleaves substrates recognizing sequence motif smallxlfmq↓gasx x → amino acid ↓ cleavage site specifically p<NUMBER> site substrate requires gln q <NUMBER> <NUMBER> xray structure sarscov<NUMBER> <NUMBER>clpro dimer bound aza peptide epoxide ape inhibitor <NUMBER>a<NUMBER>kpdb used modelling studies peptide showed major specificity s<NUMBER> subsite partial specificity s<NUMBER> subsite <NUMBER>clpro <NUMBER> detached ape crystal structure complex redocked computationally using protocol two selected study inhibitors obtain docking score found −<NUMBER> kcalmol two inhibitors study better binding potential fig <NUMBER> compared ape comparison docked poses reveals lopinavir occupies s<NUMBER> s<NUMBER> subsites excellent complementarity ritanovir occupies s<NUMBER> s<NUMBER> subsites excellent complementarity benzene <NUMBER> isopropyl thiozole groups respectively structural features indicate possible mechanism inhibitors block function sarscov<NUMBER> <NUMBER>clpro peptide substrate cleavage sites sarscov <NUMBER>clpro noted p<NUMBER>↓ p<NUMBER> p<NUMBER>↓p<NUMBER> <NUMBER> <NUMBER> occupancy respective active site cavities would crucial competitive inhibition polyprotein substrate major nonstructural viral enzymes conserved sequence protein structural level across covs hence repurposing promising mers sars inhibitors sarscov<NUMBER> practical strategy <NUMBER> vitro evaluations test antiviral potency marketed drugs ribavirin penciclovir nitazoxanide nafamostat chloroquine broadspectrum rdrp inhibitors remdesivir gs<NUMBER> favipiravir t<NUMBER> sarscov<NUMBER> recently undertaken <NUMBER> findings shown remdesivir chloroquine efficacious comparison others patient usa covid <NUMBER> treated remdesivir intravenously reported recovered <NUMBER> phase iii trials nct<NUMBER> nct<NUMBER> intravenous remdesivir currently ongoing assess efficacy patients sarscov<NUMBER> chloroquine openlabel trial sarscov<NUMBER> chictr<NUMBER> addition randomized clinical trials initiated sarscov<NUMBER> favipiravir chictrchictr<NUMBER> chictr<NUMBER> ribavirin combination pegylated ifn chictr<NUMBER> results following rapid sequencing sarscov<NUMBER> combined molecular modelling based homologous templates <NUMBER> identified certain compounds along lopinavir ritonavir may efficacious phase iii clinical trials also initiated test hiv protease inhibitors including lopinavir nct<NUMBER> nct<NUMBER> nct<NUMBER> chictr<NUMBER> ritonavir nct<NUMBER> nct<NUMBER> nct<NUMBER> darunavir cobicistat nct<NUMBER> patients infected sarscov<NUMBER> <NUMBER> another hiv protease inhibitor asc<NUMBER>f combination oseltamivir also phase iii clinical trial sarscov<NUMBER> nct<NUMBER> arbidol umifenovir widespectrum antiviral drug inhibiting several flaviviruses influenza viruses whose mechanism action based blocking crucial steps virushost cell interactions <NUMBER> phase iv clinical trial sarscov<NUMBER> nct<NUMBER> nct<NUMBER> nct<NUMBER> oseltamivir influenza neuraminidase inhibitor <NUMBER> also phase iv trial sarscov<NUMBER> nct<NUMBER> direction hostbased treatment strategies randomized trials underway sarsbased requirement findings suggestive ritonavir lopinavir may good potential repurposing sarscov<NUMBER> protease inhibitors molecular dynamics simulation studies complexes obtained study would essential identify specific interactions enzyme drug stable complexes observe hydrogen bond pattern especially presence solvent molecules additionally studies need undertaken binding analyses protease inhibitors specific rdrp inhibitors inhibitors enzymatic targets results would help gain indepth understanding relative binding affinity design derivatives greater binding potential enzyme active site review presented information respect repurposing fdaapproved drugs well clinical trials sarscov<NUMBER> merscovs wherein lot effort gone last decade knowledge fact formed basis efforts towards drug repurposing sarscov<NUMBER> well highlighted review phase iii clinical trials drugs initiated though notably targeting virus directly essentially rdrp chymotrypsinlike protease <NUMBER>clpro spike glycoprotein also needs explored target sarscov<NUMBER> s<NUMBER> domain virus deviates human covs thus important spike protein considered potential sarscov<NUMBER> therapeutic target hand considering strategy targeting viral proteins vulnerable emergence viral resistance coronavirus targets papainlike protease helicase etc also need attempted drug repurposing several potential sars andor mers hostbased inhibitors assessed sarscov<NUMBER> ongoing vigorous efforts would help develop broadspectrum anticov agents sarscov<NUMBER> past centuries outbreaks caused bacteria like yersinia pestis vibrio cholerae <NUMBER> causative agents plague cholera respectivelycohn kutalek <NUMBER> pechous et al <NUMBER> <NUMBER> also viral infectious agents influenza viruses ebolaviruses sarscov<NUMBER> merscov <NUMBER> zika virus lately sarscov<NUMBER> undermined public trust ability modern science <NUMBER> predict prevent global pandemic threats accordingly studying historical epidemics help us <NUMBER> identify patterns viral outbreaks design plan prepare next pandemic provide better picture statistics related asymptomatic infections epidemiologic analysis <NUMBER> phylogeny virology epidemiology sarscov<NUMBER> studied extensively genome <NUMBER> level sarscov<NUMBER> <NUMBER>·<NUMBER> homology sars cov cov<NUMBER> coronaviruses relative ease sample acquisition study widely <NUMBER> accepted drug repositioning promising approach make available effective safetyassured <NUMBER> treatment timely manner review summarize diagnosis approaches risk groups available <NUMBER> treatment options drug repositioning studies related covid<NUMBER> <NUMBER> prior efficient treatment precise diagnosis classification patients based disease severity <NUMBER> probable vulnerability covid<NUMBER> crucial diagnosis several steps prioritized <NUMBER> based provision facilities outbreak generally evaluation symptoms particular <NUMBER> laboratory features associated worse cases come first considering antihypertensive medications advocates use cessation consumption <NUMBER> still unclear whether high mortality rate patients hypertension comorbidity due <NUMBER> pathology disorder treatment used cure angiotensinconverting enzyme inhibitors <NUMBER> aceis angiotensin receptor blockers arbs ace<NUMBER> shown coreceptor viral <NUMBER> entry pathogenesis sarscov li et al <NUMBER> considerable evidence shows <NUMBER> escalated expression level ace<NUMBER> heart brain even urine treatment arbs <NUMBER> however limited evidence showing changes serum pulmonary ace<NUMBER> levels patel <NUMBER> verma <NUMBER> zhang et al <NUMBER>c addition serological radiological histomorphological <NUMBER> similarities covid<NUMBER>associated acute respiratory distress syndrome ards connective tissue <NUMBER> disease ctdild propose postulation triggering simulating form organspecific <NUMBER> autoimmunity predisposed patients also patients showed high titer antiphospholipid antibodies <NUMBER> including anticardiolipin antibodies antiβ<NUMBER> glycoprotein antibodies zhang et al <NUMBER>d <NUMBER> immunosuppressive therapy identified patients autoantibodies may prevent development <NUMBER> respiratory failure <NUMBER> regard treatment immunological pharmaceutical investigations still ongoing specific <NUMBER> therapies covid<NUMBER> approved us food drug administration fda far many <NUMBER> previously approved drugs efficient approach drug discovery named drug repurposing <NUMBER> tested covid<NUMBER> time writing <NUMBER> interventional studies registered <NUMBER> clinicaltrialsgov httpsclinicaltrialsgov related covid<NUMBER> number increasing <NUMBER> progressively table s<NUMBER> particular ongoing clinical trials sponsored named solidarity <NUMBER> compare different treatment options namely remdesivir lopinavirritonavir dual treatment <NUMBER> lopinavirritonavir dual treatment interferon beta <NUMBER>alpha chloroquine hydroxychloroquine <NUMBER> paused temporarily due concerns raised safety drug standard care <NUMBER> may <NUMBER> th <NUMBER> <NUMBER> countries confirmed contribute investigation <NUMBER> interventional drugs clinical trials classified based nature complementary <NUMBER> effect regard antivirals antiparasitic drugs immunosuppressors immunomodulators well<NUMBER> known drugs nutritional drugs addition combination therapies considered ongoing <NUMBER> studies treatment supportive care prevention one barely see mechanism action <NUMBER> inside outside group table <NUMBER> many drugs discovered specific disease <NUMBER> repurposed later another disorder figure <NUMBER> illustrates general path traversed <NUMBER> clinicians days although results may desirable cases due emergent nature <NUMBER> sarscov<NUMBER> insilico drug repurposing methodologies accelerated studies drug discovery use <NUMBER> data mining approaches bioinformatics techniques predictive models determining efficacy <NUMBER> safety drugs however still long way reach high success rates repurposed <NUMBER> drugs eg repurposed candidates succeeded <NUMBER> depending similarity indicated <NUMBER> repurposed therapeutic areas novel molecular entity success rate <NUMBER> reduce possibility hypothesis risk essential increase success rate repurposed <NUMBER> drugs product development process computationbased methodology namely viraltrack applied bronchoalveolar lavage samples <NUMBER> severe mild covid<NUMBER> patients unveils remarkable impact virus immune system <NUMBER> severe patients compared mild cases including replacement tissue resident alveolar macrophages <NUMBER> recruited inflammatory monocytes neutrophils macrophages altered cd<NUMBER> cell <NUMBER> cytotoxic responsebost et al <NUMBER> efforts largescale datasets lead reveal many <NUMBER> mechanistic aspects viral infections yet resolved help develop efficient therapy <NUMBER> strategies <NUMBER> due urgent need posit drug repurposing leading method drug discovery <NUMBER> covid<NUMBER> whether wet lab techniques andor system biology approaches available clinical <NUMBER> trials clinicaltrialsgov httpsclinicaltrialsgov solidarity includes investigation <NUMBER> previously approved drugs different indications taking account past two decades <NUMBER> three coronaviruses emerged animal reservoirs virus family used cause mild <NUMBER> moderate upperrespiratory tract illnesses one cause global concern common <NUMBER> treatment may prevent coronavirus become another lethal annual reoccurrent threat top seasonal <NUMBER> influenza data review identified searches pubmed google scholar references <NUMBER> relevant articles using search terms sarscov<NUMBER> covid<NUMBER> drug repurposing antiviral <NUMBER> therapy clinical trials covid<NUMBER> therapy pandemi articles published english <NUMBER> included <NUMBER> work supported knut alice wallenberg foundation funders role study <NUMBER> design data collection data analysis interpretation writing report mortalities outbreaks exact duration precisely determined nd outbreak <NUMBER> died recurred multiple times region era <NUMBER> aggravating factors laboratorybased tests candidate treatments <NUMBER> boosting arsenal covid<NUMBER> computational drug repurposing coronavirus disease <NUMBER> covid<NUMBER> world health emergency calling scientists unprecedented huge investigation efforts urgently answer key questions natural origin sarscov<NUMBER> virus molecular changes account aggressiveness mortality humans immunological responses specifically activated long acquired immunity last recovered people susceptible exposed population based genetic background patients treated angiotensinconverting enzyme ace inhibitors increased risk covid<NUMBER> infection top best therapeutic options ready help cure covid<NUMBER> patients <NUMBER> patients suffering severe disease hospitals overwhelmed worldwide global mortality rate <NUMBER> <NUMBER> goes without saying new efficacious treatments immediately needed new interventional clinical trials covid<NUMBER> treatment involve use antiviral drug previously used treat ebola virus known remdesivir combination two antivirals ritonavir lopinavir previously approved treat hiv infection additional active clinical trials involve use drugs approved different therapeutic indications case example fdaapproved antimalarial drugs chloroquine hydroxychloroquine owing ability interfere basic cellular pathogenetic mechanisms ii monoclonal antibodies interleukin<NUMBER> receptor antiil<NUMBER>r might helpful reducing abnormal inflammatory response upon cytokine storm thus improving organ functions covid<NUMBER> patients recycling strategy based reuse approved drugs commonly referred drug repurposing largely successful demonstrated examples repurposing treatments cancer human diseases <NUMBER> drug repurposing modern therapeutic strategy substantially reduces risks drug development costs emergency shortens time gap identification potentially useful drug treatment patient owing availability large amounts safety tolerability pharmacokinetic pharmacodynamic clinical data existing drug indeed use drug different therapeutic indication also referred offlabel use take advantage phase iii trials defining potential maximum tolerated dose predicting potential side effects supportive therapies thus presence preliminary clinical efficacy observations strong pharmacological rationale possible immediately test existing drugs novel therapeutic indication human patients efficacious drug repurposing reached drug repurposing often result serendipity might also result experimental drug screening identification target similarities among different diseases involvement common pathogenetic mechanisms among different diseases similarly scientific bases motivated abovedescribed repurposing trials ongoing worldwide cure covid<NUMBER> together current approaches multiple incisive investigation steps immediately undertaken context drug repurposing approaches boost treatment strategies covid<NUMBER> thanks availability omics data implementation biocomputational drug repurposing approaches silico drug repurposing hypothesisdriven approach takes advantage use big data identify drugs treat disease diseaserelated symptoms process based collection coherent integration disease data generated omics studies followed combination pharmacological data ultimate goal integrate disease network drugs mode action network <NUMBER> silico drug repurposing unique advantage transform systems biology data disease phenotypes targets prediction druggable targets ideally provide fdaapproved compound potential modulatory andor inhibitory functions immediate preclinical clinical test importantly data relevant biological clinical features pharmacological responses drug targets even drug offtargets provide unexpected insights understanding covid<NUMBER> pathology symptoms possibly identifying treatments computational tools hands theoretically obvious caution based predictive nature type study could possible generate hypothesisdriven computeraided drug repurposing aimed reduce virus infection replication ii contrast infections adverse symptoms iii understand positive negative interactions among treatments iv identify mechanisms viral infections susceptibility v predict potential side effects treatments antiviral immune response fact could eventually result worse clinical outcome possibility perform drug repurposing abovementioned objectives uniquely limited availability data generate computational modeling diseases relevant investigation direction first step silico drug repurposing sarscov<NUMBER> computational modeling viral pathogenesis diseaserelated symptoms necessary thanks release sarscov<NUMBER> genome sequence <NUMBER> important biological information already emerging phylogenetic studies suggested natural origin sarscov<NUMBER> highest nucleotide sequence identity <NUMBER> sarscov among six known pathogenic hcovs revealing closest evolutionary relationship sarscov<NUMBER> sarscov <NUMBER> similarly sarscov sarscov<NUMBER> also uses ace<NUMBER> protein virus receptor <NUMBER> generate severe lungassociated diseases <NUMBER> available data immediately used biocomputational drug repurposing studies especially related mechanisms hostvirus interaction virus replication pending additional omics data covid<NUMBER> pathogenesis disease modeling also generated using molecular data studies already available sarscov evolutionarily related viruses however different mortality rates divergent molecular evolution clearly show covid<NUMBER> unique peculiar disease key aspect claims caution interpretations silico drugrepurposing results obtained use sarscovbased studies methodological point view many computational tools implemented based different data types methodologies data types include drug chemical structures physicochemical properties known molecular targets omics data types druginduced transcriptional responses metabolic simulations methodologies range classical statistical methods modern machine learning techniques computational drug repurposing tools designed directly attempt drugrepurposing predictions help process example tools based drugdisease association networks immediately suggest novel clinical applications similar disease phenotypes whereas chemical structure similarities exploited prioritize alternatives existing compounds <NUMBER> contrast computational tools support drug repurposing process providing biological insights drug modes action discovering unknown molecular targets existing drugs gene expression data used characterize effects drug treatments reason systematic collection druginduced wholegenome expression profiles produced past connectivity map cmap project latest release within library integrated networkbased cellular signatures lincs project networkbased analytical tool needed explore drug neighborhoods based similarity induced transcriptional responses additional powerful computational tools predict sdtnbi chemmapper sider drugbank wellfulfil implement hypothesisdriven drug repurposing <NUMBER> number studies silico drug repurposing covid<NUMBER> growing rapidly among others worth citing interesting approach generating systemspharmacologybased network medicine platform identified interplay hcovhost interactome drug targets human proteinprotein interaction network identified potential drug repurposing treatments interactions <NUMBER> moreover virtual screening approach used investigate fdaapproved lopac library predict drugs able minimize interaction viral spike sprotein ace<NUMBER> host cell receptor <NUMBER> additional report novel deep learning platform used identify top potential inhibitors sarscov<NUMBER> main protease screening <NUMBER> billion compounds <NUMBER> types reports probably represent tip iceberg ongoing drug repurposing investigations results appear coming weeks indeed computeraided battle virus started also engaging powerful technological platforms satisfy demands massive amounts computational capacity aim recently launched covid<NUMBER> highperformance computing consortium usa aggregate computing capabilities worlds powerful advanced computers help covid<NUMBER> researchers execute complex computational research programs help fight virus <NUMBER> directions researchers silico drug repurposing boost besides identifying novel hypothesisdriven drugs treat covid<NUMBER> patients computational approaches could also help understanding currently used treatments instance antiviral inflammatory response network would help better decipher key mechanisms involved response antiil<NUMBER>r taking advantage large studies inflammatory cytokines available biomarkers similarly inspection drugdrug network side effects could predict whether specific drug proposed investigation would exacerbate severe lung disease symptoms instance would helpful predict whether chloroquine potentially reducing infection efficacy could turn affect antiviral immune response target pathways crucially implicated chronic diseases elderly patients case could draw attention possible chloroquine offtargets side effects certain patients would limit treatment benefits patient survival finally pandemic scenario medications covid<NUMBER> become urgently needed mass quantities could face shortage computational drug repurposing approach might assist quickly identify similar drugs analogous mode action design alternative synthetic plans drug overcome patented routes identify inexpensive diverse starting materials shortages commonly used substrates could occur <NUMBER> although timing efficacious vaccine remains uncertain vibrant multidisciplinary research operation already work provide immediate concrete therapeutic options based drug repurposing hope inspire targeted computeraided drug repurposing studies boost tailor effective therapies covid<NUMBER> pandemic disease ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint background coronavirus disease <NUMBER> covid<NUMBER> pandemic represents one deadliest economically consequential outbreaks around <NUMBER> years <NUMBER> <NUMBER> date remdesivir gilead sciences shown possibly lower time recovery <NUMBER> <NUMBER> past developing antiviral agents taken <NUMBER> years average <NUMBER> current crisis appears feasible timeline significantly reduced early signs efficacy moreover candidate drug could offered emergency use authorization us food drug administration similar designations regulatory authorities across world case remdesivir drug repurposing successful strategy variety therapeutic areas <NUMBER> case covid<NUMBER> compounds interest include previously found either clinically efficacious vitro activity coronaviruses cause severe acute respiratory syndrome sars middle eastern respiratory syndrome mers share significant structural similarities sarscov<NUMBER> virus causes covid<NUMBER> <NUMBER> <NUMBER> information drugs potentially active covid<NUMBER> expected change rapidly results ongoing future studies become available crucial researchers health care providers able access optimum uptodate information inform future ongoing studies provide clinical care objectives current protocol <NUMBER> systematically review existing medications shown potentially effective sars mers could therefore potentially repurposed <NUMBER> present early evidence supports testing readily available drugs sarscov<NUMBER> <NUMBER> provide best available level evidence efficacy individual candidate drug <NUMBER> report harmful effects associated use drugs ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint protocol specifies conduct reporting systematic review compliance preferred reporting items systematic review metaanalysis protocols <NUMBER> statement prismap <NUMBER> intended complete review within <NUMBER> <NUMBER> days protocol registered international prospective register systematic reviews prospero assigned identifier crd<NUMBER> beyond traditional systematic review aim make living document see living systematic review bibliographical databases literature search include medline via entrez pubmed interface embase via embasecom interface clinicaltrialsgov including studies already posted results google scholar also target following preprint servers medrxiv biorxiv chemrxiv preprintsorg chineselanguage server chinaxiv search strategy combines terms covid<NUMBER> sars mers causative agents drug names based following eligibility criteria see also appendix retrieved studies selected according eligibility criteria listed vitro studies animal studies clinical studies eligible study designs singlearm controlled studies without randomization well openlabel blinded designs included ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint interventions studied derived scoping review world health organisation <NUMBER> encompass singleagent combination regimens one following agents atazanavir azithromycin baloxavir marboxil baricitinib bevacizumab chloroquine colchicine darunavircobicistat emtricitabinetenofovir enisamium iodide favipiravir t<NUMBER> fingolimod ganciclovir hydroxychloroquine indinavir lopinavirritonavir mycophenolic acidmofetil nelfinavir niclosamide nitazoxanide nitric oxide novaferon oseltamivir pirfenidone quercetin remdesivir gs<NUMBER> ribavirin ruxolitinib sirolimus sofosbuvir tocilizumab thymosin alpha<NUMBER> triazavirin umifenovir also interested drugs belonging following groups glucocorticosteroids without mineralocorticoids interferons statins lastly targeted studies convalescent serum plasma clinical studies seek evaluate either singlearm study controlled study include patients mildtomoderate severe disease outpatient inpatient settings latter including intensive care unit icu nonicu patients consider important study endpoints include following variables time clinical improvement time viral clearance mortality hospital admission transfer higher ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint level care including transfer icu iculike setting total icu length stay proportion intubations length mechanical ventilation normalization selected laboratory data creactive protein ddimer lactate dehydrogenase ferritin lymphocyte count adverse events two reviewers use eligibility criteria evaluate studies conflicts resolved discussion data studies selected inclusion extracted one reviewer verified another team includes reviewers read scientific papers variety languages including chinese addition outcome measures following characteristics verified rcts extracted <NUMBER> <NUMBER> conclusions assess design execution reporting included studies based approach suggested grading recommendations assessment development evaluation grade working group <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint extracted data collated qualitatively synthesized via interactive mechanism select sort filter columns results tables website wwwcoviddrugsorg one controlled study available similar patient population calculate relative risk <NUMBER> confidence interval via metaanalysis revman stata sensitivity analysis based grade score undertaken evidence high low quality given covid<NUMBER> remain substantial problem foreseeable future ongoing need identify review critically appraise <NUMBER> synthesise new studies aim transform project living systematic review <NUMBER> <NUMBER> <NUMBER> <NUMBER> combine inputs literature databases preprint servers one extensible markup language xml stream made publicly available controlled studies become available aim automate metaanalyses inform stakeholders direction effect one studied drugs changes see finally adapt use methods natural language processing crowdsourcing support review process learning recently developed tools processes <NUMBER> <NUMBER> <NUMBER> make methods results open source intend crowdsource future review efforts may alter number authors review updates permanency history kept made permanently available via website wwwcoviddrugsorg completed review well intermittent updates eg number included studies changes conclusion intervention changes upon welldefined trigger also available via preprint server medrxiv ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint summary systematic review summarize emerging evidence repurposed drugs treatment covid<NUMBER> extrapolating early evidence covid<NUMBER> well sars mers protocol represents rather generic approach studying potential treatment compounds identified previous scoping review except search preprint servers initial synthesis occur rapidly likely qualitative least evidence sparse present protocol written accordance prismap statement registered prospero quality evidence assessed using grade approach challenge posed covid<NUMBER> however requires rapid review drugs repurposed also sustained effort integrate new evidence living systematic review outlined approach particularly useful prioritizing drug candidates finally future investigators could benefit preliminary estimates magnitudes effect efficacious drugs power sample size calculations appropriate study designs could informed terms endpoints studied adverse events monitored ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint background coronavirus disease <NUMBER> covid<NUMBER> pandemic represents one deadliest economically consequential outbreaks around <NUMBER> years <NUMBER> <NUMBER> date remdesivir gilead sciences shown possibly lower time recovery <NUMBER> <NUMBER> past developing antiviral agents taken <NUMBER> years average <NUMBER> current crisis appears feasible timeline significantly reduced early signs efficacy moreover candidate drug could offered emergency use authorization us food drug administration similar designations regulatory authorities across world case remdesivir drug repurposing successful strategy variety therapeutic areas <NUMBER> case covid<NUMBER> compounds interest include previously found either clinically efficacious vitro activity coronaviruses cause severe acute respiratory syndrome sars middle eastern respiratory syndrome mers share significant structural similarities sarscov<NUMBER> virus causes covid<NUMBER> <NUMBER> <NUMBER> information drugs potentially active covid<NUMBER> expected change rapidly results ongoing future studies become available crucial researchers health care providers able access optimum uptodate information inform future ongoing studies provide clinical care objectives current protocol <NUMBER> systematically review existing medications shown potentially effective sars mers could therefore potentially repurposed <NUMBER> present early evidence supports testing readily available drugs sarscov<NUMBER> <NUMBER> provide best available level evidence efficacy individual candidate drug <NUMBER> report harmful effects associated use drugs ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint protocol specifies conduct reporting systematic review compliance preferred reporting items systematic review metaanalysis protocols <NUMBER> statement prismap <NUMBER> intended complete review within <NUMBER> <NUMBER> days protocol registered international prospective register systematic reviews prospero assigned identifier crd<NUMBER> beyond traditional systematic review aim make living document see living systematic review bibliographical databases literature search include medline via entrez pubmed interface embase via embasecom interface clinicaltrialsgov including studies already posted results google scholar also target following preprint servers medrxiv biorxiv chemrxiv preprintsorg chineselanguage server chinaxiv search strategy combines terms covid<NUMBER> sars mers causative agents drug names based following eligibility criteria see also appendix retrieved studies selected according eligibility criteria listed vitro studies animal studies clinical studies eligible study designs singlearm controlled studies without randomization well openlabel blinded designs included ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint interventions studied derived scoping review world health organisation <NUMBER> encompass singleagent combination regimens one following agents atazanavir azithromycin baloxavir marboxil baricitinib bevacizumab chloroquine colchicine darunavircobicistat emtricitabinetenofovir enisamium iodide favipiravir t<NUMBER> fingolimod ganciclovir hydroxychloroquine indinavir lopinavirritonavir mycophenolic acidmofetil nelfinavir niclosamide nitazoxanide nitric oxide novaferon oseltamivir pirfenidone quercetin remdesivir gs<NUMBER> ribavirin ruxolitinib sirolimus sofosbuvir tocilizumab thymosin alpha<NUMBER> triazavirin umifenovir also interested drugs belonging following groups glucocorticosteroids without mineralocorticoids interferons statins lastly targeted studies convalescent serum plasma clinical studies seek evaluate either singlearm study controlled study include patients mildtomoderate severe disease outpatient inpatient settings latter including intensive care unit icu nonicu patients consider important study endpoints include following variables time clinical improvement time viral clearance mortality hospital admission transfer higher ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint level care including transfer icu iculike setting total icu length stay proportion intubations length mechanical ventilation normalization selected laboratory data creactive protein ddimer lactate dehydrogenase ferritin lymphocyte count adverse events two reviewers use eligibility criteria evaluate studies conflicts resolved discussion data studies selected inclusion extracted one reviewer verified another team includes reviewers read scientific papers variety languages including chinese addition outcome measures following characteristics verified rcts extracted <NUMBER> <NUMBER> conclusions assess design execution reporting included studies based approach suggested grading recommendations assessment development evaluation grade working group <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint extracted data collated qualitatively synthesized via interactive mechanism select sort filter columns results tables website wwwcoviddrugsorg one controlled study available similar patient population calculate relative risk <NUMBER> confidence interval via metaanalysis revman stata sensitivity analysis based grade score undertaken evidence high low quality given covid<NUMBER> remain substantial problem foreseeable future ongoing need identify review critically appraise <NUMBER> synthesise new studies aim transform project living systematic review <NUMBER> <NUMBER> <NUMBER> <NUMBER> combine inputs literature databases preprint servers one extensible markup language xml stream made publicly available controlled studies become available aim automate metaanalyses inform stakeholders direction effect one studied drugs changes see finally adapt use methods natural language processing crowdsourcing support review process learning recently developed tools processes <NUMBER> <NUMBER> <NUMBER> make methods results open source intend crowdsource future review efforts may alter number authors review updates permanency history kept made permanently available via website wwwcoviddrugsorg completed review well intermittent updates eg number included studies changes conclusion intervention changes upon welldefined trigger also available via preprint server medrxiv ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint summary systematic review summarize emerging evidence repurposed drugs treatment covid<NUMBER> extrapolating early evidence covid<NUMBER> well sars mers protocol represents rather generic approach studying potential treatment compounds identified previous scoping review except search preprint servers initial synthesis occur rapidly likely qualitative least evidence sparse present protocol written accordance prismap statement registered prospero quality evidence assessed using grade approach challenge posed covid<NUMBER> however requires rapid review drugs repurposed also sustained effort integrate new evidence living systematic review outlined approach particularly useful prioritizing drug candidates finally future investigators could benefit preliminary estimates magnitudes effect efficacious drugs power sample size calculations appropriate study designs could informed terms endpoints studied adverse events monitored ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint drug repurposing effort treatment new disease covid<NUMBER> usually starts virtual screening existing drugs followed experimental validation actual hit rate generally rather low traditional computational methods demonstrated new virtual screening approach accelerated free energy perturbationbased absolute binding free energy fepabfe predictions reach unprecedently high hit rate leading successful identification <NUMBER> pro cleaves pp<NUMBER>a pp<NUMBER>ab release functional proteins nsp<NUMBER>nsp<NUMBER> necessary viral replication <NUMBER> view essential functions pro viral life cycle high level conservation sarscov<NUMBER> pro naturally attractive target treatment covid<NUMBER> hence efforts identify therapeutic candidates targeting pro using various virtual screening methods based pharmacophore molecule docking molecular simulations <NUMBER> result reported efforts six drugs found inhibit sarscov<NUMBER> <NUMBER> pro ic<NUMBER> ranging <NUMBER> <NUMBER> μm <NUMBER> also drug repurposing efforts associated potential targets sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> general drug repurposing effort treatment new disease covid<NUMBER> usually starts virtual screening existing drugs computational modeling simulations followed experimental validation however actual hit rate virtual screening using traditional computational methods rather low vast majority computationally predicted drug candidates false positives difficult reliably predict proteinligand binding free energies recently gorgulla et al <NUMBER> reported interesting new virtual screening platform called virtualflow used screen numerous compounds order identify inhibitors kelchlike echassociated protein <NUMBER> keap<NUMBER> hit rate still high within <NUMBER> compounds predicted virtual screening <NUMBER> found keap<NUMBER> binders hit rate <NUMBER> detectable binding affinity <NUMBER> compounds confirmed displacers nuclear factor erythroidderived <NUMBER>related factor <NUMBER> nrf<NUMBER> halfmaximum inhibitory concentration ic<NUMBER> <NUMBER> μm hit rate <NUMBER> threshold ic<NUMBER> <NUMBER> μm<NUMBER> obviously hit rate virtual screening dependent reliability accuracy receptorligand binding free energy predictions used virtual screening process key success virtual screening effort use reliable computational approach accurately predict binding free energies free energy perturbation fep simulation intermolecular interactions <NUMBER> <NUMBER> recognized reliable method binding free energy calculations satisfactory accuracy <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> traditional fep method limited simulating minor structural changes ligands relative binding free energy rbfe calculations <NUMBER> <NUMBER> rbfe calculations used guide lead optimization starting promising lead compound hit<NUMBER> <NUMBER> <NUMBER> suitable virtual screening completely different molecular structures identify new hits drug repurposing virtual screening identify new hits leads necessary predict absolute binding free energy abfe ligand binding target without requirement use reference ligand structure fepabfe approach advantage predicting binding affinities ligands targets accurately conventional computational methods pharmacophore molecule docking molecular simulations <NUMBER> however previously used fepabfe calculations extremely expensive timeconsuming thus suitable virtual screening purposes required screen large number compounds <NUMBER> <NUMBER> make fepabfe approach practically feasible virtual screening drug repurposing effort report new algorithm using restraint energy distribution red function accelerate fepabfe prediction first application drug repurposing effort targets sarscov<NUMBER> pro fepabfe predictionbased virtual screening predicted <NUMBER> drugs potential inhibitors sarscov<NUMBER> pro followed vitro activity assays confirming <NUMBER> <NUMBER> drugs potently inhibit sarscov<NUMBER> pro <NUMBER> <NUMBER> m remarkably high hit rate <NUMBER> threshold ki <NUMBER> m nine drugs ki <NUMBER> m submicromolar hit rate <NUMBER> particularly among drugs potent inhibitor sarscov<NUMBER> pro dipyridamole dip ki <NUMBER> m following computational prediction vitro activity validation dip tested antiviral activity sarscov<NUMBER> vitro clinical studies treatment patients covid<NUMBER> preliminary clinical data promising actual therapeutic effects clinical data reported separately elsewhere <NUMBER> timely guide clinical studies possibly practical clinical application describe discuss report detailed computational vitro activity <NUMBER> results dip along promising drugs identified encouraging outcomes suggest fepabfe predictionbased virtual screening truly promising approach drug repurposing prior virtual screening drug repurposing accuracy accelerated fepabfe prediction protocol validated using three different protein targets brd<NUMBER> hiv<NUMBER> protease human factor xa <NUMBER> ligands diverse chemical scaffolds according validation data given supporting information si section s<NUMBER> accelerated fepabfe algorithm achieve high accuracy abfe predictions order identify potent sarscov<NUMBER> pro inhibitors first carried fepabfe based virtual screening existing drugs followed vitro activity assays shown figure <NUMBER> specifically existing drugs docked binding site sarscov<NUMBER> pro <NUMBER> molecules specific interactions six key amino acid residues cys<NUMBER> his<NUMBER> ser<NUMBER> his<NUMBER> gly<NUMBER> gln<NUMBER> subjected fepabfe calculations among <NUMBER> drugs <NUMBER> <NUMBER> <NUMBER> electrically neutral negatively charged positively charged respectively since fep method known encounter systematic errors ligands electrically neutral drugs selected basis fepabfe results grouped formal charges ensure error cancelled within group group top <NUMBER> <NUMBER> molecules selected based abfe values result <NUMBER> drugs selected subsequent vitro experimental activity testing according vitro results <NUMBER> <NUMBER> drugs exhibited considerable potency inhibiting sarscov<NUMBER> pro figures <NUMBER> s<NUMBER> dip found potent inhibitor ki <NUMBER> μm following computational prediction vitro activity confirmation dip tested antiviral activity sarscov<NUMBER> demonstrating dip dosedependently suppressed sarscov<NUMBER> replication ec<NUMBER> <NUMBER> m antiviral activity consistent inhibitory activity pro addition dip also tested clinically treatment patients covid<NUMBER> resulting promising therapeutic data reported separately elsewhere along raw antiviral activity data <NUMBER> due urgent need clinical studies possibly practical clinical application fepabfe results calculated confirmed potent sarscov<NUMBER> pro inhibitors given table <NUMBER> comparison subsequently determined experimental activity data <NUMBER> seen table <NUMBER> ki values hydroxychloroquine chloroquine determined using dixon plots using data figure <NUMBER> notably candesartan cilexetil ki <NUMBER> m sarscov<NUMBER> pro prodrug labeled use treatment hypertension congestive heart failure hence also computationally experimentally examined metabolite candesartan active drug corresponding prodrug labeled use drug library screened interestingly candesartan also predicted confirmed potent inhibitor sarscov<NUMBER> pro slightly lower inhibitory activity sarscov<NUMBER> pro ki <NUMBER> m interesting note potential treatment patients covid<NUMBER> prodrug candesartan cilexetil would serve active molecular species sarscov<NUMBER> pro compared candesartan table <NUMBER> <NUMBER> <NUMBER> hydroxychloroquine chloroquine indinavir reported active vitro covid<NUMBER> molecular targets reported <NUMBER> <NUMBER> <NUMBER> montelukast sodium maribavir predicted calculations <NUMBER> <NUMBER> without experimental activity data reported disulfiram served positive control vitro activity ic<NUMBER> value <NUMBER> m literature <NUMBER> m work concentration substrate used high <NUMBER> µm notably summary virtual screening accelerated fepabfe predictions demonstrated excellent accuracy remarkably high hit rate <NUMBER> threshold ki <NUMBER> m anticipate fepabfe predictionbased virtual screening approach useful many drug repurposing discovery efforts accelerated fepabfe approach based use new restraint energy distribution si section s<NUMBER> derivation red function extensive evaluations accelerated fepabfe method given detail si section s<NUMBER> s<NUMBER> pgex<NUMBER>t<NUMBER>m pro plasmid constructed atagenix wuhan transfected e coli strain bl<NUMBER> codonplus stratagene gsttagged protein purified gstglutathione affinity chromatography cleaved thrombin purity recombinant protein greater fluorescence monitored every <NUMBER> initial reaction velocities calculated fitting linear portion curves within first <NUMBER> min progress curves straight line using program softmax pro converted enzyme activity substrate cleavedsecond tel <NUMBER> fax <NUMBER> <NUMBER> email zhanukyedu luohb<NUMBER>mailsysueducn wx<NUMBER>ouceducn cuij<NUMBER>mailsysueducn authors contributed equally study hondermarck et al diseases represents potential fast track effective clinical treatment largescale hypothesisfree drug screening viral infections costly time consuming therefore targeted strategies suitable however major difficulty often limited amount information molecular mechanisms involved pathogenicity virus new outbreak starts viruses cellular parasites infect eukaryotic prokaryotic cells hijack cellular machinery replicate released infect neighboring cells eventually organisms first step viral infection attachment virus plasma membrane entry cell followed intracellular viral replication finally release newly formed viruses regard covid<NUMBER> known angiotensinconverting enzyme <NUMBER> ace<NUMBER> ace<NUMBER> provides cell membrane receptor entry point sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> structurefunction relationships antigenicity viral sarscov<NUMBER> spike glycoprotein also established <NUMBER> structural basis attachment sarscov<NUMBER> cell membrane binding receptor binding domain rbd surface spike glycoprotein protein sarscov<NUMBER> ace<NUMBER> revealed xray crystallography <NUMBER> addition also shown sarscov<NUMBER> uses transmembrane protease serine <NUMBER> tmprss<NUMBER> protein priming cleavage fusion domain inhibition tmprss<NUMBER> clinically approved inhibitor might block infection <NUMBER> narratives currently developing still early initial findings obviously preclude identification molecular partners involved entry replication sarscov<NUMBER> human cells growth factor receptors gfrs transmembrane proteins expressed eukaryotic cells whose primary function bind extracellular polypeptide growth factors binding specific growth factors gfrs results activation intracellular protein kinase domain initiates cascade signaling events ultimately leading regulation cell growth interestingly gfrs also identified necessary entry viruses including coronaviruses gfr signaling involved viral replication many instances drugs targeting gfrs signaling currently used clinical practice treatment cancer given role gfrs virus entry replication drugs could potentially repurposed viral infections article evidence link viral infection gfrs reviewed value repurposing current oncologic drugs targeting gfrs order expand effective antiviral strategies including fight covid<NUMBER> discussed multicellular organisms human body growth factors gfrs essential embryogenesis postnatal development orchestrate cell survival proliferation migration differentiation tissues organs adult body gfrs involved control cellular turnover homeostasis well tissue repair regeneration deregulation lead cancer nerve growth factor ngf epidermal growth factor egf first growth factors identified leading award <NUMBER> nobel prize physiology medicine stanley cohen rita levimontalcini <NUMBER> <NUMBER> subsequently receptor egf egfr characterized shown transmembrane receptor intracellular tyrosine kinase activity initiates cascade downstream protein phosphorylation engaged egf <NUMBER> growth factors identified complex picture associated gfrs emerged date <NUMBER> families gfrs described initially reported egfr gfrs exhibit tyrosine kinase activity <NUMBER> notable exception receptors members transforming growth factor betas tgfbrs exhibit serine threonine kinase activity <NUMBER> tyrosine kinase gfrs activate set intracellular kinases including limited src akt pi<NUMBER>pk ultimately map kinases translocate nucleus regulate gene expression <NUMBER> contrast serinethreonine kinase activity tgfbrs ultimately leads activation nuclear translocation members smad transcription factor family <NUMBER> three common characteristics shared gfrs virtually ubiquitous localization throughout tissues organs existence multiple gfrs genesproteins within family wide range cellular effects induced gfrs well illustrated receptors fibroblast growth factors fgfrs four different fgfrs fgfrs<NUMBER> genes generating seven isoforms expressed human cell types upon ligand binding resultant stimulation tyrosine kinases induces wide range cellular effects including cell proliferation epithelial cells fibroblasts migration endothelial cells well differentiation neurons subsequent neurite outgrowth notably activity fgfrs also coregulated class unbranched glycosaminoglycans heparan sulfates hs abundant cell surface within extracellular matrix hss make many fgffgfr interactions much efficient crossbinding trimeric complexes thus facilitating activation fgfrs downstream signaling pathways <NUMBER> <NUMBER> hondermarck et al evidence gfr involvement viral infections listed table <NUMBER> summarized figure <NUMBER> described early <NUMBER> reported growth cytomegalovirus herpes simplex virus type <NUMBER> human fibroblasts could altered egf <NUMBER> relationship egf viral infection understood result crosstalk egfr viral protein synthesis explored <NUMBER> egfr shown cofactor responsible entry hepatitis c virus hcv human cells <NUMBER> study demonstrated egfrs epha<NUMBER> tyrosine kinase receptors together mediate hcv entry regulating cd<NUMBER>claudin<NUMBER> coreceptor association thus viral glycoproteindependent membrane fusion study also first show tyrosine kinase inhibitors substantial antiviral activity <NUMBER> turn hcv upregulates egfr activation favors viral entry <NUMBER> involvement egfrs virus internalization transport endosomal network confirmed case hepatitis b virus hbv <NUMBER> <NUMBER> well gastroenteritis viruses <NUMBER> <NUMBER> vaccinia virus vacv also shown coopt egfr signaling enhance virus spread stimulation cell motility contributes rapid spread infection <NUMBER> significantly many respiratory viruses shown induce egfr activation leading suppressed interferon regulating factor<NUMBER> irf<NUMBER>dependent interferon λ thus lowered antiviral defense airway epithelium <NUMBER> <NUMBER> thus egfrs portals virus entry also involved suppression immune response host overactivation egfrs could also result longterm issues patients affected respiratory viruses hepatitis c virus entry internalization <NUMBER> <NUMBER> hepatitis b virus entry internalization <NUMBER> <NUMBER> gastroenteritis virus entry internalization <NUMBER> <NUMBER> vaccinia virus spread <NUMBER> suppression interferon mediated immune defense many viruses <NUMBER> shown severe acute respiratory syndrome sars coronavirus egrf overactivation leads increased pulmonary fibrosis <NUMBER> therefore tempting hypothesize egfr inhibition might also reduce risk pulmonary fibrotic damage coronavirus infection first study demonstrating role fgfrs viral infection reported portal cellular entry herpes simplex virus type <NUMBER> presumed binding fgf viral particle presentation receptors <NUMBER> <NUMBER> however subsequent contradictory study found fgfrs required herpes simplex virus type <NUMBER> infection <NUMBER> fgfbinding heparan sulfates hs cell surface pericellular space involved instead <NUMBER> well established hs essential interaction hsbinding fgfs fgfr creates trimolecular fgfhsfgfr complex subsequently triggers fgfr activation <NUMBER> scenario resolved initially conflicting results fgfr<NUMBER> shown coreceptor infection adenoassociated virus <NUMBER> <NUMBER> fgfr signaling also accompanies zika virus infection human fetal brain <NUMBER> using integrative systems approach based genomewide rna interference screening fgfrs found cofactors required earlystage influenza virus replication <NUMBER> reciprocal effect fgfr signaling also reported dengue virus inhibition fgfrs reducing virus rna replication increasing viral particle production <NUMBER> similar case egfrs fgfr activation may trigger longterm consequences virus infected patients activation fgfr<NUMBER> signaling pathway epsteinbarr virusencoded lmp<NUMBER> promotes aerobic glycolysis ultimately cancerous transformation human nasopharyngeal epithelial cells <NUMBER> taken together fgfrs heparan sulfates participate viral infection data strongly suggest could potentially targeted inhibit virus development supporting contention middle east respiratory syndrome coronavirus merscov close relative sarscov<NUMBER> known induce lung cell apoptosis results major lung damage upregulating fgf<NUMBER> <NUMBER> well facilitating fgfr activation hs complexed proteoglycan complexes form hspgs represent cell machinery replicate transcribe viral nucleic acid ultimately leading formation new viral particles released viral entry replication also activated gfr signaling monoclonal antibodies mabs gfrs inhibitors tyrosine kinase signaling used cancer treatment shown reduce viral replication many viruses noteworthy gfr activation viruses reported suppress interferonmediated immune defense also chloroquine inhibitor lysosomal activity currently clinical trial covid<NUMBER> could potentially interfere role gfrs viral infection inhibiting lysomal degradation viruscontaining endosomes separate entry point viruses human cells first shown herpes simplex virus whose initial interaction cells via binding cell surface hspgs <NUMBER> <NUMBER> abundant evidence coronaviruses use hspgs attach plasma membrane internalization first demonstrations provided murine coronavirus <NUMBER> avian bronchitis coronavirus <NUMBER> similarly human coronavirus nl<NUMBER> also utilizes hspgs attachment target nasopharyngeal cells <NUMBER> <NUMBER> interestingly sars virus variant also shown utilize hspg cell entry competitively inhibited lactoferrin <NUMBER> together data coronaviruses suggest sarscov<NUMBER> also likely bind hspg preliminary data recently released reinforce hypothesis <NUMBER> study authors used surface plasmon resonance circular dichroism measure interaction sarscov<NUMBER> spike s<NUMBER> protein receptor binding domain sarscov<NUMBER> s<NUMBER> rbd heparin <NUMBER> data strongly suggested interaction recombinant surface receptor binding domain virus hs therapeutic targeting hspgs thus appears relatively straightforward way inhibit infectivity sarscov<NUMBER> tgfbrs reported cellular entry point viruses however tgfbr stimulation appears regulate viral replication initially shown tgfbr stimulation resulted suppression human immunodeficiency virus hiv expression replication <NUMBER> inhibitory effect tgfbrs found hcv <NUMBER> contrast tgfbrs enhance respiratory syncytial virus rsv replication epithelial cells <NUMBER> via reduction hepatocyte nuclear factor<NUMBER>a expression <NUMBER> note mers coronavirus induces apoptosis lung cells upregulating smad<NUMBER> key protein involved tgfbr signaling <NUMBER> nucleocapsid coronavirus sarscov interacts smad<NUMBER> modulate tgfbr signaling resulting promotion lung fibrosis <NUMBER> possible longterm deleterious effects patients less information role classes gfrs virus infection hepatocyte growth factor receptor hgfr known coreceptor cell entry adenoassociated virus type <NUMBER> infection <NUMBER> pharmacological inhibition ngf receptor trka shown suppress influenza virus replication <NUMBER> ngf stimulates hiv<NUMBER> replication primary macrophages signaling trka involvement reticular calcium protein kinase c extracellular signalregulated kinase p<NUMBER> kinase nuclear factorκb <NUMBER> ngfinduced enhancement hiv<NUMBER> replication occurs late events hiv<NUMBER>replicative cycle concomitant increase viral transcription production <NUMBER> similarly shown human rhinoviruses hrv upregulate ngftrka pathway airway epithelial cells turn amplifies viral replication increasing hrv entry via icam<NUMBER> receptors limiting apoptosis nasopharyngeal cells <NUMBER> <NUMBER> recent evidence suggests influenza virus uses gm<NUMBER>enhanced plateletderived growth factor receptor beta pdgfrb signaling pathway cell penetration <NUMBER> study also reported tyrosine kinase inhibitor ki<NUMBER> disrupts endocytotic process influenza b viruses induced pdgfrb <NUMBER> importantly tyrosine kinase ephrin receptor a<NUMBER> reported participate hcv entry <NUMBER> also epithelial receptor epsteinbarr virus ebv entry epithelial cells thus increasing risk malignancy <NUMBER> evidence described points extensive involvement gfrs processes virus entry replication viruses use gfrs attachment receptor cellular internalization also appears downstream tyrosine kinase activity promotes virus replication importantly range drugs already use oncology target gfrs tyrosine kinase activities treatment cancer patients currently used drugs classified two categories blocking monoclonal antibodies mabs tyrosine kinase inhibitors addition clinical heparin also regulate gfr activation virus entry developed specifically bind extracellular domain gfrs block ligand binding thereby inhibit receptor dimerization autophosphorylation downstream signaling <NUMBER> trastuzumab also called herceptin humanized mab first gfrtargeted drug introduced oncology routinely used treat breast cancers overexpressing egfr family member her<NUMBER> human epidermal growth factor receptor <NUMBER> also called erbb<NUMBER> <NUMBER> patients overexpressing her<NUMBER> classically poor prognosis since introduction trastuzumab combination chemotherapy situation completely changed her<NUMBER>positive patients survival rate similar median breast cancer <NUMBER> hondermarck et al survival rates <NUMBER> terms side effects compared chemotherapy trastuzumab well tolerated mabs egfr cetuximab panitumumab also used clinically particularly colorectal cancer head neck cancers given reported involvement egfrs cellular entry replication many viruses mabs egfrs clearly worthy testing newly emerging viruses also sarscov<NUMBER> tyrosine kinase inhibitors tkis bind atpbinding pockets located within intracellular catalytic kinase domain tyrosine kinase gfrs blocking activation downstream signaling also frontline targeted therapies treatment several cancer types thus hold potential interest drug repurposing viruses tkis first developed target egfr family members first enter clinical use oncology <NUMBER> firstgeneration egfr tkis gefitinib erlotinib reversibly bind egfrs thereby improving survival patients lung cancer harbor egfractivating mutations <NUMBER> secondgeneration egfr tkis afatinib dacomitinib irreversibly bind receptors show increased cellular potency egfr oncogenic variants <NUMBER> several antigfr tkis including targeting specifically her<NUMBER> trka pdgfr already shown block multiple steps replication influenza virus <NUMBER> dengue virus <NUMBER> evidently encouraging results prompt testing emerging coronavirus species hss found cell surface part extracellular matrix essential activation several gfrs mostly virtue facilitation growth factor binding structurally close native ecm glycosaminoglycan hs variant heparin one widely used drugs world heparin derivatives clinically approved anticoagulantsantithrombotics wellknown bioavailability albeit tight safety window heparin derivatives anticoagulant activity importantly heparin shown broad spectrum activity many viruses including zika <NUMBER> hiv<NUMBER> <NUMBER> presumably competitively inhibitive process cellular hs whereby excess heparin prevents virus binding cell surface hs coronaviruses shown bind hs enter target cells <NUMBER> <NUMBER> hypothesized heparin act prevent cell attachment sarscov<NUMBER> preliminary data indicated indeed heparin bind surface protein spike s<NUMBER> virus <NUMBER> may therefore therapeutic covid<NUMBER> literature described herein emphasizes pivotal involvement gfrs coreceptors hspgs viral entry replication face current lack vaccine effective therapies treatment emerging viral diseases covid<NUMBER> dramatic health economic consequences targeting gfrs using existing oncologic drugs represents intriguing opportunity given rapidity covid<NUMBER> spread throughout world drug repurposing offers fast track introduction therapies using known clinically approved molecules value drug repurposing fight sarscov<NUMBER> well illustrated chloroquinehydroxychloroquine inexpensive drug low toxicity used <NUMBER> years treatment malaria shown promising effects reducing viral load duration infection initial clinical trials involving patients covid<NUMBER> <NUMBER> interestingly chloroquine known inhibit activation mitogenactivated protein kinases mapks activated gfrs <NUMBER> hcov<NUMBER> coronavirus chloroquineinduced virus inhibition occurs via inhibition mapk <NUMBER> suggesting mapkactivating gfrs involved although stage yet demonstrated gfrs involved sarscov<NUMBER> cell entry replication current knowledge role gfrs viral infections including coronaviruses constitutes rational basis begin testing value repurposed antigfrs drugs emerging viral diseases covid<NUMBER> particular recently severe highly contagious viral disease evolved wuhan china <NUMBER> causative agent detected new coronavirus termed coronavirus disease <NUMBER> coronavirus associated several infectious epidemics major health hazard concerns <NUMBER> severe acute respiratory syndrome cov sars cov evolved <NUMBER> source infection recorded animal origins including bat intermediate host <NUMBER> decade later middle east respiratory syndrome coronavirus mers cov diagnosed saudi arabia <NUMBER> soon emergence sars mers covs spread outside countries origin causing major worldwide concerns <NUMBER> <NUMBER> lastly covid<NUMBER> emerged wuhan china first isolation related animal market humantohuman transmission recorded <NUMBER> coronavirus polyprotein encodes two proteases share processing release translated nonstructural proteins nsps main protease called <NUMBER>clike protease mpro papainlike protease plpro <NUMBER> plpro mpro vital targets drug discovery studies recent coronavirus epidemics including sars mers cov <NUMBER> <NUMBER> <NUMBER> <NUMBER> first available crystal structure covid<NUMBER> proteins mpro published february <NUMBER> pdb id <NUMBER>lu<NUMBER> study first virtual screening study first known covid<NUMBER> performed obtained results help repurposing already approved drugs combat recent dangerous covid<NUMBER> ncbi genbank gisaid httpswwwgisaidorg used obtain covid<NUMBER> sequences sars cov mers cov sequences obtained genbank pairwise multiple sequence comparisons mpro done using clc genomics software qiagen inc usa sequence comparison matrix generated including number gaps number different residues identity aligned sequences file used generate phylogenetic tree using neighbor joining method implemented clc genomics workbench software fda approved drugs dataset retrieved selleckchem inc wa usa compounds imported ligprep software deslated <NUMBER>d optimized using opls<NUMBER> force field virtual screening implemented using published crystal structure covid<NUMBER> mpro pdb id <NUMBER>lu<NUMBER> protein preparation module maestro software package schrodinger llc ny usa used optimize protein structure docking water nonspecific molecules removed protein protonated add polar hydrogens structure optimized cellular ph conditions structure energy minimized using opls<NUMBER> force field docking grid generated using cocrystalised ligand center docking box <NUMBER> å size schrodinger glide docking module used virtual screening order get accurate results standard precision sp docking selected <NUMBER> <NUMBER> output results ordered docking score set curcumin found strong inhibitor sars mpro <NUMBER> measured ic<NUMBER> <NUMBER> μm obtained docking results reanalyzed include comparison curcumin relative docking scores calculated every compound dividing score docking score curcumin molecular modeling virtual screening computational techniques widely used methods understand phylogenetics molecular aspects proteins proteinligand interactions drug discovery process <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> virtual screening used drug discovery emerging fatal diseases including sars cov proteases <NUMBER> <NUMBER> hepatitis c virus rnadependent rna polymerase <NUMBER> dengue virus <NUMBER> ebola virus <NUMBER> work cover knowledge gap covid<NUMBER> mpro comparison two dangerous coronavirus epidemics sars mers covs addition used first resolved covid<NUMBER> crystal structure mpro find suitable binding agents proved safety context fda approved drugs best starting point way repurposing approved safe drugs covid<NUMBER> first mpro covid<NUMBER> compared sars mers covs fig <NUMBER> comparing covid<NUMBER> mpro sars mpro fig <NUMBER>a mers cov mpro fig <NUMBER>b revealed high degree conservation covid<NUMBER> sars cov mpros little number different residues however mers cov mpro showed large number differences low conservation covid<NUMBER> mpro evidenced phylogenetic relations fig <NUMBER>c showed close relation sars covid<NUMBER> mpros distant relation mers cov statistics sequences comparison generated pairwise sequence comparison matrix table <NUMBER> <NUMBER> identity covid<NUMBER> sars cov mpro low identity <NUMBER> detected covid<NUMBER> mers cov mpro number covid<NUMBER> amino acid differences <NUMBER> <NUMBER> sars cov mers cov respectively results virtual screening fda approved drugs covidmpro presented supplementary table <NUMBER> presented parameters include docking scores ligand efficiency lipophilic hydrogen bonding interactions top <NUMBER> hits showing highest docking score provided table <NUMBER> data presented relative value curcumin previously approved sars mpro inhibitor curcumin docking score ranked <NUMBER> position implying presence wide range expected powerful binding drugs within top <NUMBER> drugs <NUMBER> antivirals <NUMBER> antituberculous agents <NUMBER> vitamins <NUMBER> anticancer miscellaneous systemically acting drugs among antivirals ribavirin telbivudine ranked second third positions showed <NUMBER> folds increase docking scores compared curcumin vitamin b<NUMBER> nicotinamide ranked <NUMBER>th <NUMBER>th positions ribavirin abroad spectrum antiviral agent acting induction mutations viral genome especially rna viruses <NUMBER> ribavirin officially approved treating respiratory syncytial virus rsv infection combination interferon α<NUMBER>b hepatitis c virus <NUMBER> addition used treating sars cov infections <NUMBER> given high similarity sars covid<NUMBER> mpros ribavirin might value treating covid<NUMBER> telbivudine approved treating hepatitis b virus <NUMBER> drug nucleoside analogue best fits viral polymerase high rank telbivudine study suggests repurposing covid<NUMBER> treatment binding mpro comparison curcumin top <NUMBER> ranked compounds showed improved hydrogen bonding profile <NUMBER> fold increase hydrogen bonding interactions contrast hydrophobic interactions kept constant lowered inspection binding mode top ranked drugs hydrogen bonding hydrophobic interactions driving force binding fig <NUMBER> ribavirin formed two hydrogen bonds backbone thr<NUMBER> side chain gln<NUMBER> fig <NUMBER>b c telbivudine formed two hydrogen bonds ser<NUMBER> glv<NUMBER> fig <NUMBER>d e conclusion molecular modeling tools used compare mpro recently evolved covid<NUMBER> previous two coronavirus epidemics sars mers cov covid<NUMBER> mpro phylogenetically related sars mpro virtual screening capmain covid<NUMBER> mpro set antivirals vitamins antimicrobials systemically acting drugs potent binding covid<NUMBER> mpro compared curcumin known mpro inhibitor repurposing ribavirin telbivudine vitamin b<NUMBER> nicotinamide suggested supplementary data article found online https doiorg<NUMBER>jlfs<NUMBER> covid<NUMBER> pandemic situation tremendously turned entire world place horrible death tragedy sarscov<NUMBER> initially named <NUMBER> novel coronavirus <NUMBER>ncov world health organization causative agent recent serious respiratory complications resulting covid<NUMBER> pandemic <NUMBER> <NUMBER> <NUMBER> <NUMBER> though symptoms covid<NUMBER> infection appear incubation period approximately <NUMBER> days period onset covid<NUMBER> symptoms death ranged <NUMBER> <NUMBER> days median <NUMBER> days <NUMBER> <NUMBER> already completed world tour around <NUMBER> countries experiencing deadly scene occurred covid<NUMBER> including <NUMBER> <NUMBER> infected patients <NUMBER> <NUMBER> global death cases till <NUMBER>th may <NUMBER> <NUMBER> scientific community racing explore effective remedy severe health complications till date potential therapeutics approved clinical use <NUMBER> key proteins sarscov<NUMBER> could targeted vaccine drug surface <NUMBER> similar sars mers nonstructural proteins eg <NUMBER>chymotrypsinlike protease coronavirus main protease papainlike protease helicase rnadependent rna polymerase structural proteins eg spike glycoprotein accessory proteins investigated genome sarscov<NUMBER> nonstructural proteins constitute twothirds entire genome <NUMBER> among structural proteins nucleocapsid n protein prerequisite rna genome assembly membrane envelope e proteins associated viral assembly host environment <NUMBER> moreover spike protein mainly responsible viral entry host cell spike protein considered major therapeutic target drug vaccines sarscov<NUMBER> <NUMBER> protein interaction human ace<NUMBER> interface revealed atomic level efficiency ace<NUMBER> usage found main factor coronavirus transmissibility human human <NUMBER> contrary coronavirus main protease pro <NUMBER>clike proteinase <NUMBER>clp reported ability cleave polyproteins individual polypeptides required replication transcription <NUMBER> <NUMBER>clp autocleaved initially polyproteins become mature enzyme leading translation messenger rna <NUMBER> <NUMBER>clp cleaves <NUMBER> downstream nonstructural proteins <NUMBER>clp plays vital role replication cycle virus host reported attractive target human sars virus <NUMBER> rnadependent rna polymerase key target protein sarscov<NUMBER> catalyses synthesis viral rna possibly support nonstructural proteins cofactors <NUMBER> <NUMBER> <NUMBER> computational drug repurposing method could allow immediate search potential antiviral therapy case reemergence viral infections like covid<NUMBER> pandemic situation <NUMBER> <NUMBER> <NUMBER> computational drug repurposing already used identify promising drug candidates virus associated diseases like dengue ebola zika influenza infections <NUMBER> <NUMBER> importantly sarscov<NUMBER> shown evolutionary convergent relations sarscov merscov drug repurposing methods also applied sarscov merscov <NUMBER> <NUMBER> <NUMBER> hence extensive silico studies performed identify potential drug candidates example prulifloxacin bictegravir nelfinavir tegobuvi identified repurposing candidates covid<NUMBER> looking drugs high binding capacity sarscov main protease <NUMBER> nelfinavir hiv<NUMBER> protease inhibitor also predicted potential inhibitor covid<NUMBER> main protease another computationalbased study <NUMBER> however secondary metabolites plant origin found show effective defence mechanism different deadly pathogens widely used conventional remedy treat wide range human diseases since ancient period human civilization <NUMBER> <NUMBER> <NUMBER> pandemic situation researchers trying find effective solution covid<NUMBER> plant metabolites could promising wings screening potential drug candidates even plant secondary metabolites already reported effective coronaviruses <NUMBER> <NUMBER> present study total <NUMBER> plant based drug compound screened check potentiality blocking three important key proteins sarscov<NUMBER> main protease proteins rnadependent rna polymerase spike protein sarscov<NUMBER> employed molecular docking study repurposed drug candidates plant origin find better drug option towards covid<NUMBER> pandemic protein acquisition potential natural therapeutics pdb structures sarscov<NUMBER> main protease proteins <NUMBER>lu<NUMBER> <NUMBER>y<NUMBER>e rnadependent rna polymerase <NUMBER>m<NUMBER> spike protein <NUMBER>vyb retrieved rcsb protein data bank <NUMBER> moreover total <NUMBER> plant based drugs collected pubchem database supplementary table <NUMBER> alphaketoamide cid <NUMBER> also retrieved pubchem database database httpspubchemncbinlmnihgov ncbi <NUMBER> molecular docking effective approach screening potential therapeutics specific drugtargets deadly pathogens <NUMBER> <NUMBER> crystal structure retrieved sarscov<NUMBER> proteins complexed inhibitors refined pymol v<NUMBER> software <NUMBER> unwanted molecules ie water ions inhibitors removed viral retrieved viral protein employed molecular docking experiment <NUMBER> natural therapeutics autodock vina software <NUMBER> analyse binding affinity interactive amino acids alphaketoamide inhibitor sarscov<NUMBER> main protease protein used positive control study <NUMBER> also docked target proteins sarscov<NUMBER> default parameters grid box set <NUMBER> a° x <NUMBER> a° x <NUMBER> a° x z center <NUMBER> a° x <NUMBER> a° x <NUMBER> a° x z perform action moreover <NUMBER>d ligandprotein interaction diagrams generated ligplot find involved amino acids interactive position identified docked complexes <NUMBER> ligand molecules interactions viral proteins visualize analyzed discovery studio <NUMBER> pymol v<NUMBER> software <NUMBER> drug surface hotspot sarscov<NUMBER> proteins identified analysing docked structures protein top natural therapeutics ligplot pymol v<NUMBER> discovery studio software binding patterns azobechalcone rifampin isolophirachalcone tetrandrine fangchinoline sarscov<NUMBER> proteins results allowed comparative structural analysis screened natural therapeutics furthermore interactions alphaketoamide studied proteins also investigated adme absorption distribution metabolism excretion properties top drug candidates analysed swissadme server <NUMBER> pharmacokinetics druglikeness property medicinal chemistry assessed <NUMBER> default parameters used evaluate various physiochemical parameters molar refractivity molecular weight tpsa lipophilicity log pow wlogp log pow mlogp log pow xlogp<NUMBER> log pow silicosit log pow ilogp consensus log pow pharmacokinetics parameters log kp skin permeation water solubility probable drug candidates <NUMBER> inhibition effects natural therapeutics different cytochromes p<NUMBER>s cyp<NUMBER>c<NUMBER> cyp<NUMBER>c<NUMBER> cyp<NUMBER>a<NUMBER> cyp<NUMBER>a<NUMBER> cyp<NUMBER>d<NUMBER> also studied addition admetsar osiris property explorer employed evaluate toxic undesired effects ie mutagenicity tumerogenecity compounds <NUMBER> <NUMBER> <NUMBER> retrieved natural therapeutics employed molecular docking mpp rdrp spike protein sarscov<NUMBER> supplementary table <NUMBER> scoring function autodock vina utilized predict interaction ligands therapeutics proteins top five inhibitors protein identified based free binding energy results showed rifampin highest negative binding energy <NUMBER> kcalmol among top mpp inhibitors table <NUMBER> azobechalcone <NUMBER> kcalmol isolophirachalcone <NUMBER> kcalmol amentoflavone <NUMBER> kcalmol cepharanthine <NUMBER> kcalmol docked mpp sarscov<NUMBER> also exhibited topmost place higher negative binding energy <NUMBER> kcalmol well table <NUMBER> interacting rdrp sarscov<NUMBER> negative binding energy scored azobechalcone <NUMBER> kcal mol following rifampin <NUMBER> kcalmol tetrandrine <NUMBER> kcalmol biflavone <NUMBER> kcalmol biflavone <NUMBER> kcalmol table <NUMBER> moreover azobechalcone rifampin isolophirachalcone fangchinoline tetrandrine found top natural inhibitors spike protein sarscov<NUMBER> azobechalcone required lowest energy <NUMBER> kcalmol interact spike protein rifampin isolophirachalcone fangchinoline tetrandrine scored <NUMBER> kcalmol <NUMBER> kcalmol <NUMBER> kcalmol <NUMBER> kcalmol respectively table <NUMBER> however azobechalcone rifampin isolophirachalcone tetrandrine fangchinoline found effective inhibitory natural compounds docking results compared three sarscov<NUMBER> proteins figure <NUMBER> table <NUMBER> plant based natural inhibitors required minimum energy <NUMBER> kcalmol interact studied protein molecules docking pattern interacting amino acid residues respective position analyzed unravel binding sites studied sarscov<NUMBER> proteins rifampin involved amino acid h<NUMBER> n<NUMBER> s<NUMBER> c<NUMBER> h<NUMBER> m<NUMBER> e<NUMBER> d<NUMBER> r<NUMBER> q<NUMBER> mpp sarscov<NUMBER> figure <NUMBER> position h<NUMBER> c<NUMBER> m<NUMBER> also crucial binding amentoflavone however additional residue t<NUMBER> involved case isolophirachalcone table <NUMBER> p<NUMBER> d<NUMBER> t<NUMBER> p<NUMBER> f<NUMBER> f<NUMBER> also critical binding pattern rifampin sarscov<NUMBER> spike protein potent mpp rdrp spike protein inhibitors azobechalcone rifampin isolophirachalcone tetrandrine fangchinoline investigated spheres physicochemical parameters lipophilicity pharmacokinetics water solubility table <NUMBER> lipophilicity partition coefficient noctanol water log pow also calculated using five widely available predictive models xlogp<NUMBER> wlogp mlogp silicosit ilogp gi absorption lower drug candidates azobechalcone rifampin isolophirachalcone tetrandrine fangchinoline molecules repressive action p<NUMBER> cyp isoforms cyp<NUMBER>a<NUMBER> cyp<NUMBER>c<NUMBER> cyp<NUMBER>c<NUMBER> cyp<NUMBER>d<NUMBER> cyp<NUMBER>a<NUMBER> moreover permeant bbb exists among protein inhibitors mpp rdrp spike compounds sowed water solubility moderate high level ie <NUMBER>e<NUMBER> mgml <NUMBER>e<NUMBER> mgml <NUMBER>e<NUMBER> mgml <NUMBER>e <NUMBER> mgml <NUMBER>e<NUMBER> mgml respectively table <NUMBER> toxicity analysis inhibitors showed carcinogenic effect organ toxicity however rifampin tetrandrine fangchinoline slightly positive terms mutagenesis though azobechalcone isolophirachalcone inhibitors completely negative among top five inhibitors azobechalcone listed acute oral toxicity category <NUMBER> rest listed category <NUMBER> global pandemic caused sarscov<NUMBER> become major concern due excessive infection rate lethality <NUMBER> <NUMBER> <NUMBER> <NUMBER> despite huge research regarding pathogen drugs vaccine proven satisfactory combat infections caused sarscov<NUMBER> <NUMBER> <NUMBER> several investigational drugs exist however none could treat patients unquestionably moreover lack rapid detection procedures made sarscov<NUMBER> diagnosis troublesome <NUMBER> computational approach drug repurposing strategies hold promise face challenges caused sarscov<NUMBER> hence present study attempts taken suggest probable drug candidates checking efficacy natural inhibitors inhibit key proteins sarscov<NUMBER> race covid<NUMBER> pandemic allowed drug repurposing virtual finding drugs could used treatment covid<NUMBER> recent studies prioritized mpp inhibitors sarscov<NUMBER> ie alphaketoamide hydroxy remdesivir chloroquine favipiravir evaluate potency drug <NUMBER> <NUMBER> <NUMBER> several silico approach also adopted screen putative drug candidates sarscov<NUMBER> <NUMBER> <NUMBER> however experiments used either main protease proteins rnadependent rna polymerase sarscov<NUMBER> probable drug targets study screened potential natural therapeutics sarscov<NUMBER> mpp rdrp spike protein molecular docking approach rifampin azobechalcone azobechalcone determined top drug candidates interacted sarscov<NUMBER> mpp rdrp spike protein lowest negative binding energy highest negative binding energy <NUMBER> kcalmol <NUMBER> kcal mol <NUMBER> kcalmol respectively however comparative analysis revealed superiority <NUMBER> drug candidates ie azobechalcone rifampin isolophirachalcone tetrandrine fangchinoline sarscov<NUMBER> table <NUMBER> common drug surface hotspots analyzed along modeling pharmacophore important step drug discovery three amino acid residues ie h<NUMBER> c<NUMBER> m<NUMBER> played crucial role interaction mpp inhibitors ie rifampin amentoflavone cepharanthine table <NUMBER> azobechalcone top scorer among rdrp inhibitors position f<NUMBER> l<NUMBER> l<NUMBER> a<NUMBER> w<NUMBER> l<NUMBER> y<NUMBER> vital binding rdrp tetrandrine biflavone fangchinoline table <NUMBER> importantly binding patterns spike protein isolophirachalcone fangchinoline tetrandrine significantly similar study revealed possibility amino acids efficiently interact drugs though requires validation wet lab trials adme analysis top drug candidates reveled undesirable consequences compounds various physicochemical parameters lipophilicity pharmacokinetics properties water solubility determined table <NUMBER> addition bbb permeant identified among top inhibitors mpp rdrp spike protein consequence association natural inhibitory drugs three key proteins cytochrome p<NUMBER> cyp suggests substantial inhibition occur however toxicity analysis revealed rifampin tetrandrine fangchinoline slightly mutagenic though possibility organ toxicity results suggest azobechalcone rifampin isolophirachalcone tetrandrine fangchinoline could option treat sarscov<NUMBER> infections however study employed various computational approaches screen potent natural therapeutics involve invivo assay currently investigational drugs sarscov<NUMBER> immense experimental evaluation therefore suggest clinical trials experimental validation findings covid<NUMBER> pandemic situation going worst condition throughout world rapid detection social distancing encouraged stage need search immediate therapeutic options effective vaccine candidates battling serious health crisis drug repurposing approaches could screened already approved drugs reusing serious causative agents causing health complications plant metabolites based repurposed drug molecules could promising options sarscov<NUMBER> present study five plantr based therapeutics azobechalcone rifampin isolophirachalcone tetrandrine fangchinoline suggested potential inhibitors main protease protein rna dependent rna polymerase spike protein sarscov<NUMBER> using molecular docking based virtual screening study study initiated window towards thinking plant based therapy covid<NUMBER> though extensive research wet lab validation needs make usable patient december <NUMBER> heralded transformation modernday life new lethal disease named covid<NUMBER> emerging china change world know month propitious timing hundred world’s leading physicians scientists government agency officials nonprofit leaders gathered inaugural <NUMBER>day conference jointly sponsored us food drug administration fda national institutes health nih washington dc topic conference “repurposing offpatent drugs” attendees convened discuss widely used lowcost safe medicines approved one indication might harnessed provide additional novel sometimes unexpected therapeutic benefits diseases dr christopher austin director national center advancing translational sciences nih opened conference welcoming birth new era human medicine asked participants “to skewer sacred cows” emphasizing need embrace controversial thinking improve patients’ lives drug repurposing obscure subject experts well public covid<NUMBER> changed forever publicity generated us president endorsing antimalarial agents hydroxychloroquine chloroquine treatments covid<NUMBER> jolted regulatory authorities worldwide fda felt compelled grant emergencyuse authorization drugs european medicines agency held back urging prescribed outside clinical trials nationally agreed upon protocols absence proven treatments many physicians frontlines covid<NUMBER> battle prescribed drugs resulting worldwide shortage conflicting clinical trial data emerged since regarding use antimalarial drugs covid<NUMBER> <NUMBER> indicate lack benefit even potential harm <NUMBER> underscores need emergency regulatory authorization unproven treatments deemed necessary public health crisis based first foremost robust evidence safety also important relevant agency issues statement emphasizing exploratory nature intervention urgent need robust clinical trial data support ongoing use hydroxychloroquine chloroquine developed antimalarial treatments subsequently repurposed treating systemic lupus erythematosus rheumatoid arthritis repurposing challenging autoimmune diseases facilitated funding pharmaceutical companies recouped investment patentprotected revenues drugs became available generics however small proportion drugrepurposing discoveries enjoy patent protection benefit large costly clinical trials necessary regulatory approval contrast realworld repurposing—the immediate “offlabel” prescribing drugs caring physicians based acumen awareness pilot studies case reports field experience clinical setting—is widely overlooked opportunity prescribing drug offlabel ie use approved legal almost every country worldwide however unforeseen adverse outcome burden liability shifts regulator pharmaceutical company prescribing physician additionally burden payment shifts insurer institutional health care payers patient nevertheless dealing immediate urgent health crises whether individual public level realworld repurposing frequently realistic solution protect public unscrupulous players us fda prohibits pharmaceutical companies promoting offlabel uses drugs could used increase profit avoiding investment clinical trials contrast fda supportive disseminating information promising offlabel uses independent entities point reiterated march <NUMBER> fda’s website <NUMBER> underscores importance vigorous efforts create reliable independent evidentiary repositories disseminate treatment opportunities thereby support decision making frontlines nearly real time two additional critical elements prerequisites realworld repurposing deliver health benefits public level safety affordability former calls decadeslong track record established safety latter requires availability generic lowcost drug candidates fortunately many thousands drugs already available challenge central repository offlabel uses exists way enables immediate intervention times public health crises taking covid<NUMBER> pandemic example selected four wellestablished drugs backed many decades safety data widespread use affordability believe offer opportunity prevent treat viral infection disabling deadly complications ensue although covid<NUMBER> usually presents respiratory symptoms infection spreads beyond lung contributes significantly disease toll uncontrolled outpouring immune cells disturbed clotting multiorgan failure lifethreatening complications extensive clinical support backed solid mechanistic scientific rationale underpinning proposed drugs multimedia appendix <NUMBER> selected based safety affordability ability target multiple aspects underlying disease processes make covid<NUMBER> deadly proposed doses shown achieve target physiological effects demonstrated supporting references cimetidine famotidine approved heartburn caused reflux disease <NUMBER> shown powerful effects immune system <NUMBER> data indicate suppress wide variety common viruses including herpes human papillomaviruses <NUMBER> boost immune response vaccination <NUMBER> additional immunemodulating effects range cancers allergic diseases <NUMBER> also shown efficacy protecting heart excessive workload lowering blood pressure improving cardiac efficiency <NUMBER> reducing inflammation <NUMBER> inhibiting pathological blood clotting <NUMBER> clinical trial famotidine covid<NUMBER> started recently new york following observation yet unpublished certain patients china taking diagnosed covid<NUMBER> better clinical outcomes <NUMBER> data generated new study eagerly awaited antiplatelet agent dipyridamole approved prevent thrombotic events atrisk patients <NUMBER> also caught eye researchers investigating potential treatments covid<NUMBER> recently published study china illustrated ability suppress severe acute respiratory syndrome coronavirus <NUMBER> virus causes covid<NUMBER> leading marked clinical improvements <NUMBER> larger study recently launched china examines dipyridamole <NUMBER> patients covid<NUMBER> chictr<NUMBER> beyond antiviral effects dipyridamole shown antiinflammatory antioxidant vasodilatory activity <NUMBER> one component widely used anticoagulant citratetheophyllineadenosinedipyridamole ctad <NUMBER> clinically cardioprotective effects reported patients chronic heart failure <NUMBER> improved renal function documented patients chronic kidney disease delaying risk progression dialysis reducing mortality <NUMBER> cholesterollowering agents fenofibrate bezafibrate approved treatment dyslipidemias <NUMBER> although bezafibrate unavailable united states widely used europe metaanalyses show reduce disability death atherosclerotic cardiovascular disease stroke independent effects cholesterol <NUMBER> potentially protective effects kidney function reported <NUMBER> along antiviral efficacy patients hepatitis c virus infection <NUMBER> patients fibrates lowered plasma fibrinogen levels statistically significant degree <NUMBER> suggesting potential address dangerous hypercoagulability seen many patients covid<NUMBER> indeed fibrates demonstrated anticoagulant cardiovascular protective effects patients metabolic syndrome <NUMBER> represents hypercoagulable state accompanied inflammation endothelial dysfunction phosphodiesterase<NUMBER> pde<NUMBER> inhibitor sildenafil citrate vasodilator approved <NUMBER> treating erectile dysfunction <NUMBER> recently received indication pulmonary arterial hypertension pah <NUMBER> sildenafil wide range antiinflammatory antioxidant vasodilatory actions across many body systems benefits reported case studies patients type <NUMBER> diabetes <NUMBER> hematological cancers <NUMBER> reported cardioprotective effects stemming improved pulmonary circulation well direct action myocardium <NUMBER> include improved cardiac contractility reduced symptoms patients range cardiac disorders <NUMBER> reduction cardiovascular events mortality patients high risk <NUMBER> studies demonstrating sildenafil’s efficacy tolerability pah continue accrue recent cochrane review metaanalysis concluded patients pah received pde<NUMBER> inhibitors significantly less likely die shortterm receiving placebo <NUMBER> sildenafil may also reduce mortality idiopathic pulmonary fibrosis <NUMBER> interstitial lung disease high mortality preliminary evidence suggests drug class actively renoprotective <NUMBER> sildenafil currently investigation phase <NUMBER> trial patients covid<NUMBER> nct<NUMBER> help clarify therapeutic potential times emergency covid<NUMBER> pandemic call radical review way practice medicine dr austin aptly stated ready “to skewer sacred cows” clinical trials unprofitable generic drugs sponsored governments nonprofit organizations obviously welcome important delay judicious use wellestablished safe costeffective rationally prescribed therapies race find cure covid<NUMBER> resulted unprecedented worldwide research efforts time writing milken foundation compiled list treatments studied covid<NUMBER> <NUMBER> nevertheless time approval expected high cost majority drugs may leave reach large portion world’s population four wellestablished drugs presented consideration alone combination atrisk patients covid<NUMBER> highlight gems buried mountain hundreds thousands clinical studies inaccessible physicians battling frontlines clinical medicine unbeknownst four drugs selected case officially approved handful indications shown efficacy managing <NUMBER> additional diseases propose specifically drugs used rather aim provide pathophysiological rationale use alone combination share understanding may provide benefit spur creative thinking potential use disease illustrating untapped potential therapeutic options may hidden plain sight covid<NUMBER> pandemic represents unparalleled opportunity refocus efforts mining synthesizing cataloging body evidence behind many promising treatment opportunities article invitation kindred spirits curious bold humanitarians pool efforts harness opportunity futureproof health care systems based robust science owe future generations represent valid alternative provided suitable medications selected among enormous number potential already synthesized often already clinically employed compounds drug repurposing already suggested specific drugs treatment current covid<NUMBER> outbreak <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> drugs considered repurposing repositioning therapy covid<NUMBER> outbreak commercially available dosage toxicity humans well known due years even decades clinical use allow utilization faster less expensive phase iiiii clinical trials even within straightforward compassionate use particular remarkable number drugs reconsidered covid<NUMBER> therapy used cancer therapy surprising consider virusinfected cells pushed enhance synthesis nucleic acids protein lipid boost energy metabolism order comply viral program indeed features seen cancer cells making likely drugs interfering specific cancer cell pathways may effective well defeating viral replication knowledge cancer drugs potentially suitable facing sarscov<NUMBER> infection exhaustively reviewed order make rational effective choice drugs amenable repurposing therapy covid<NUMBER> elaborate existing data experimental translational research clinical trials anecdotal reports published information present comprehensive analysis available information potential candidate cancer drugs repurposed treatment coivd<NUMBER> potentially suitable drugs repositioning essentially affecting signal transduction synthesis macromolecules andor bioenergetic pathways able interfere host immune response particular lifethreatening cytokine storm associated severe covid<NUMBER> finally antiviral compounds occasionally effective fighting cancer table <NUMBER> please note research field growing therefore list may incomplete time publication single molecule present one abovementioned mechanisms drugs mechanism action relation sarscov<NUMBER> infection host response depicted fig <NUMBER> rapamycin sirolimus long history repositioning first used antifungal followed immunosuppressive agent organtransplanted patients recently also anticancer agent <NUMBER> <NUMBER> cellular target named mtor mammalian target rapamycin name compound showing specific activity toward mtorc<NUMBER> complex <NUMBER> rapamycin also effective therapy autoimmune lymphoproliferative syndrome <NUMBER> rapamycin decreases mtor phosphorylation mtorc<NUMBER> <NUMBER> causing downstream perturbation signal transduction pathway consequent catabolic inhibition atp shortage evokes activation ampk <NUMBER> substrate acaca promoting autophagy physiological procedure cells recycle old organelles damaged proteins order provide alternative energy supply <NUMBER> <NUMBER> mtor inhibition counteracts viral replication improves outcomes patients infected andes virus <NUMBER> hcv <NUMBER> middleeast respiratory syndrome coronavirus merscov <NUMBER> h<NUMBER>n<NUMBER> pneumonia <NUMBER> addition rapamycin alone combination actinomycin recently proposed interfere sarscov<NUMBER> interactome systems pharmacologybased network medicine platform <NUMBER> specified rapamycin also presents immunosuppressant activity could relevant mitigating sarscov<NUMBER>induced inflammatory response rapamycin derivatives available eg temsirolimus everolimus ridaforolimus display slightly different pharmacokinetic characteristics may worth evaluation treatment covid<NUMBER> among ridaforolimus tested phase ii clinical trial compared progestin investigator choice chemotherapy advanced endometrial carcinoma showing encouraging results elevated toxicity confirming significance mtor pathway neoplasms <NUMBER> chloroquine cq drug characterized several decades clinical use due wellrenowned preventive curative antimalarial activity recently cq attracted oncologists ability interfering late stages autophagy producing cytoplasmic accumulation nonfunctional autophagic vesicles <NUMBER> normal cancer cells utilize autophagy energetic purposes cancer cells due higher energy requirements rely actively autophagy stressed radioor chemotherapy <NUMBER> <NUMBER> <NUMBER> therefore association firstline therapeutic approaches cancer patients autophagy inhibitors largely investigated <NUMBER> <NUMBER> suggested <NUMBER> <NUMBER> <NUMBER> clinically investigated clinical trials mainly cns tumors <NUMBER> <NUMBER> <NUMBER> cq also possesses broad antiinfective antiviral properties <NUMBER> especially flaviviruses retroviruses coronaviruses <NUMBER> indeed cq interfere sialic acid biosynthesis compromising posttranslational modifications transmembrane viral binding proteins <NUMBER> <NUMBER> thus impairing viral penetration inside cell indeed interaction sarscov<NUMBER> membrane receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> maximally expressed lung alveolar epithelial cells enterocytes small intestine leydig cells sertoli cells strongly depends upon glycosylation <NUMBER> cq also induces alkalization endosomes thus inhibiting endocytosis viral particles enzymatic degradation proteases <NUMBER> <NUMBER> <NUMBER> essential step release functional viral nucleic acid <NUMBER> furthermore cq improves viral antigen presentation thus enhances tcellmediated immunity <NUMBER> another major advantage cq ability modulate inflammatory response reduce synthesis proinflammatory cytokines molecule used since decades treatment abnormal inflammatory responses sarcoidosis autoimmune disorders rheumatoid arthritis lupus erythematosus ability cq reduce cytokine immune response <NUMBER> could functional governing cytokine storm associated covid<NUMBER> <NUMBER> mechanism similar one described inhibition autophagosomes could speculated impair formation release virioncontaining vesicles infected cells recently cq used covid<NUMBER> therapy dose <NUMBER> mgday favorable results <NUMBER> butother studies demonstrate high toxicity scarce effect either cq <NUMBER> analogue hydroxychloroquine hcq <NUMBER> <NUMBER> treating patients severe covid<NUMBER> since autophagy regulated interplay mtor <NUMBER> ampk <NUMBER> use cq combination drugs able interfere pathways carefully evaluated cq wellknown safety profile associated toxic retinopathy renal cardiac toxicity occur safe dose exceeded hcq possesses slightly different pharmacokinetic properties displays less overall toxicity hcq commercially available worldwide case cq whose distribution discontinued countries <NUMBER> cq hcq considered use preventing covid<NUMBER> sarscov<NUMBER> postexposure longterm prophylaxis <NUMBER> si<NUMBER> small molecule able inhibit activity sgk<NUMBER> aktrelated kinase involved pi<NUMBER>k mtor pathway emt <NUMBER> kinase plays pivotal role cancer proliferation drug resistance <NUMBER> <NUMBER> sensitive small molecule si<NUMBER> <NUMBER> thus able inhibit cancer cell growth vitro vivo <NUMBER> <NUMBER> via multifaceted mechanism action including inhibition pi<NUMBER>kmtor pathway stimulation autophagy <NUMBER> infection merscov cognate sarscov<NUMBER> induces massive inflammatory response possibly related fibrosis mainly via upregulation helper th <NUMBER> th<NUMBER> cells <NUMBER> note il<NUMBER>producing th cells induced activity sgk<NUMBER> <NUMBER> additionally experimental models inflammatory bowel disease showed role th<NUMBER> sgk<NUMBER> mediators th<NUMBER> switch <NUMBER> therefore si<NUMBER> could deserve evaluation prevention cytokine storminduced lung fibrosis noted si<NUMBER> never used humans effective reducing tumor growth cancerbearing mice appearing also well tolerated nontoxic <NUMBER> <NUMBER> thus si<NUMBER> cannot considered repurposed drug although preclinical models indicate potentially effective covid<NUMBER> therapy included drug present manuscript sake completeness compound humanized monoclonal antibody moab targeting interleukin<NUMBER> receptor il<NUMBER>r pharmacology pharmacokinetics clinical efficacy safety role tocilizumab rheumatoid arthritis ra wellestablished <NUMBER> possibly due also effect aktmtor pathway <NUMBER> tocilizumab also approved treatment cytokine storm associated cancer immunotherapy <NUMBER> often cart therapy <NUMBER> <NUMBER> moab direct antiviral effects effectively contrasts massive cytokine release syndrome displayed severe covid<NUMBER> antagonizing binding il<NUMBER> one cytokines involved process receptor <NUMBER> first report effectiveness tocilizumab restraining cytokine storm deriving sarscov<NUMBER> infection <NUMBER> drug currently evaluation multicenter phase ii clinical investigation italy efficacy safety patients covid<NUMBER> pneumonia <NUMBER> fda approved phase iii randomized doubleblind placebocontrolled study assess effectiveness tocilizumab hospitalized patients severe covid<NUMBER> pneumonia <NUMBER> addition increasing number clinical trials involving use drug treatment covid<NUMBER> ongoing httpsclinicaltrialsgov sarilumab antiil<NUMBER>rα moab approved moderatetosevere rheumatoid arthritis <NUMBER> welldefined role also blocking il<NUMBER> action cancer <NUMBER> emapalumab directed toward interferon ifnγ used therapy hemophagocytic lymphohistiocytosis <NUMBER> <NUMBER> employed combination anakinra il<NUMBER>r antagonist ra patients <NUMBER> tocilizumab also sarilumab emapalumab effectively counteract massive cytokine release related sarscov<NUMBER> infection agenzia italiana del farmaco aifa approved use either sarilumab emapalumab phase iiiii clinical studies involving hospitalized patients covid<NUMBER> pulmonary complications aim counteract cytokine storm <NUMBER> monalizumab moab directed toward nkg<NUMBER>a cd<NUMBER> receptor recognition mhc class hlae molecules nkg<NUMBER>a gaining relevance key player cancermediated immune checkpoint blockade neutralization monalizumab restores host immune response toward cancer <NUMBER> monalizumab clinical investigation advanced gynecologic malignancies <NUMBER> interestingly nkg<NUMBER>a appears overexpressed cytotoxic lymphocytes natural killer cells sarscov<NUMBER>infected patients <NUMBER> <NUMBER> may reestablish host immune response increase survival patients severe pneumonia bacillus calmetteguérin bcg invaluable tool vaccination tuberculosis widely used concomitant therapeutic approach lung cancer <NUMBER> considered overall protection lung cancer incidence <NUMBER> recently bcg successfully used local treatment intermediatehighrisk bladder cancer <NUMBER> bcg presents recognized immunomodulatory properties <NUMBER> associated reduced risk asthma <NUMBER> immunization via bcg provides relief airway inflammation inhibition tgfβ<NUMBER>mediated epithelialtomesenchymal transition emt inhibiting related remodeling respiratory tract accompanied loss lung epithelial integrity fibrotic evolution <NUMBER> covid<NUMBER> setting epithelial integrity respiratory tract fundamental since permanent lung fibrosis serious risk severe critically severe covid<NUMBER> survivors <NUMBER> therefore bcg might reduce risk severe disease progression potentially reduce mortality disability rate clearly drugs consideration repurposing covid<NUMBER> therapy antiviral compounds usually nucleoside analogues ie small molecules mimicking ribonucleosides deoxyribonucleosides able inhibit viral replication incorporated within viral nucleic acid sequence drugs used since decades antivirals although clinical efficacy often associated onset drug resistance antiviral drugs show interesting anticancer properties effective inhibiting important signal transduction pathways vitro vivo <NUMBER> <NUMBER> association protease inhibitors lopinavir ritonavir approved treatment hiv treatment effective restraining growth urological malignancies vitro induces endoplasmic reticulum stress mtor inactivation ampk boosting <NUMBER> drug combination also evaluated treatment cervical cancer patients <NUMBER> association lopinavir ritonavir effective reducing risk adverse clinical outcomes viral load sars patients <NUMBER> bases cocktail proposed treatment covid<NUMBER> recent clinical trial showed benefits adult patients severe disease <NUMBER> drug guanosine analogue rna synthesis inhibitor successfully employed therapy chronic hepatitis c virus hcv infection <NUMBER> far cancer concerned compound induces gtp depletion hela cervical cancer cells <NUMBER> effective inhibiting glioblastoma growth vitro vivo preclinical models <NUMBER> along line efficacy ribavirin oncological setting investigated ongoing clinical trials acute myeloid leukemia oropharyngeal squamous cell carcinoma breast cancer <NUMBER> ribavirin also endowed covid<NUMBER> antirnadependent rna polymerase rdrp activity <NUMBER> clinical trials ongoing based upon available data regarding dosage toxicity derived broad experience use drug antihcv compound compound cancerrelated deserves mentioned paradigmatic case effective repositioning prodrug adenine analogue thus viral rna polymerase inhibitor used ebola outbreak <NUMBER> remdesivir found effective vitro sarscov<NUMBER> infection administered concomitance antimalarial cq see <NUMBER> vivo primate model rhesus macaque either prophylaxis therapy merscov infection <NUMBER> presently clinical trials remdesivir covid<NUMBER> enrolling patients supported national institutes health nih <NUMBER> usa aifa italy <NUMBER> compassionate use remdesivir covid<NUMBER> patients singlearm clinical trial gave positive preliminary outcomes <NUMBER> appear contrast results published another group <NUMBER> debate efficacy drug still open according preliminary results reported actt nih clinical trial <NUMBER> fda given remdesivir emergency use authorization restricted patients affected severe covid<NUMBER> <NUMBER> covid<NUMBER> lesson learned sarscov<NUMBER> pandemic generated new strain coronavirus never previously identified humans virus phylogenetically close sarscov causative agent sars sarscov<NUMBER> reached humans via spillover process animal species possesses peculiar tropism airway epithelium humans showing also elevated contagiousness extremely variable clinical course infection covid<NUMBER> outbreak found world definitely unprepared handle global emergency similar concerns must raised toward potential novel strain possibly responsible future viral outbreaks order replicate extremely negative outcome influenza h<NUMBER>n<NUMBER> <NUMBER> spanish pandemic <NUMBER> end mandatory work prospectively produce identify better antiviral drugs prophylactictherapeutic moab therapies well possibly targeting vital pathogenic factors case sarscov<NUMBER> spike protein rbd <NUMBER> <NUMBER> main protease pro <NUMBER> addition study immune response patients recovered sarscov<NUMBER> infection could great interest line carried ebola survivors <NUMBER> forcedly limited number drugs briefly described review appear act essentially selected mechanisms ie inhibition pi<NUMBER>kaktsgk<NUMBER>mtor signaling cascade b inhibition cytokine storm c inhibition viral nucleic acid synthesis activation pi<NUMBER>k aktsgk<NUMBER>mtor pathway appears fundamental supporting replication various virus species host <NUMBER> <NUMBER> <NUMBER> <NUMBER> boosting energy metabolism reactive oxygen species production especially cells immune system <NUMBER> <NUMBER> therefore drugs able interfere mtorc<NUMBER> signaling produce atp shortage cells virus replicating characterized excess energy requirements metabolic pattern reminiscent peculiar setup energy metabolism cancer cells ie warburg effect <NUMBER> <NUMBER> pivotal role played pi<NUMBER>kaktsgk<NUMBER>mtor signaling cascade <NUMBER> <NUMBER> <NUMBER> given surprising nonspecific antiviral drugs described ie anticancer drugs repositionable covid<NUMBER> therapy deal energy metabolism inflammation set drugs described eg explicit antiviral effect preferred early stages sarscov<NUMBER> infection dedicated restraining cytokine responseand without explicit antiviral effect employed necessary later time points anyway always consider even medications discussed review safely use clinics final decision administration covid<NUMBER> compassionate urgent use absence validated clinical trials taken solely collegial approval clinical team taking care patient strict clinical surveillance indeed unpredictable toxic side effects arise possibly linked patient clinical status simultaneous administration drugs finally interesting evaluation covid<NUMBER> pandemic affect clinical care seven comprehensive cancer centers cancer core europe discussed timely paper <NUMBER> authors illustrate appropriate guidelines transform pandemic opportunity eg assessment clinical effects deescalating anticancer regimens forcedly imposed order prevent reduce iatrogenic neutropenia lymphopenia hope findings may pave way comprehensive clinical experimentation repurposing old drugs treatment covid<NUMBER> line research sustained scant funds prime importance face new worldwide challenge coronavirus disease pandemic caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> far affected <NUMBER> million people worldwide mortality rate approximately <NUMBER> main protease pro <NUMBER>cl pro one extensively studied targets coronaviruses <NUMBER> pro plays essential role cleavage viral rnatranslated virus polypeptide <NUMBER> recognizes least <NUMBER> cleavage sites replicase polyprotein <NUMBER>ab eg lqsag denotes cleavage site covalent inhibitors sarscov<NUMBER> pro recently demonstrated potency toward inhibiting viral replication cellular assays <NUMBER> <NUMBER> underpins druggability pro however compounds remain early stages preclinical studies development new drugs usually takes years lack drugs targeting sarscov<NUMBER>currently poses threat numerous covid<NUMBER> patients covid<NUMBER> pandemic implored repurposing oral drugs <NUMBER> recently approved drugs designed optimized specific targets unlikely completely match interactions sarscov<NUMBER> targets compared <NUMBER> potential drugs drugbank database various stages preclinical studies approval estimated number druglike compounds molecular weight <NUMBER> da reportedly approximately <NUMBER> <NUMBER> therefore possibility uncovering highly potent specific drug sarscov<NUMBER> quite slim conversely lowmolecularweight drugs intermediate potency high safety alternative treatment sarscov<NUMBER> toxicity many lowmolecularweight drugs well understood owing long clinical trials furthermore low structural complexity adds odds fully match interactions antisarscov<NUMBER> targets eg chemical space compounds <NUMBER> nonhydrogen atoms approximately <NUMBER> <NUMBER> cornerstoneof fragmentbased lead discovery <NUMBER> many compounds fragment library indeed extracted pharmacophores approved drugs therefore hypothesize highly possible identify lowmolecularweight drug containing pharmacophores using fragmentbased screening fbs therefore assessed <NUMBER> compounds pharmacophores substructures repurposing drugs proposed virtual screening fragment library <NUMBER> sarscov<NUMBER> target candidates predicted bind high affinity pharmacophores bind well albeit weaker affinity weak binders readily identified using nuclear magnetic resonance nmr fragmentbased approach thereby eliminating distracting false positives virtual screening using nmr fragmentbased approach <NUMBER> <NUMBER> two proteins share <NUMBER> sequence identity key residues proximal catalytic site including h<NUMBER> v<NUMBER> d<NUMBER> n<NUMBER>g<NUMBER> h<NUMBER> v<NUMBER> thus assigned figure s<NUMBER> niacin hit <NUMBER> perturb common residue v<NUMBER> suggesting two hits bind catalytic core sarscov<NUMBER> pro interestingly two hits also recognize different sets residues catalytic core example niacin perturbs h<NUMBER> g<NUMBER> n<NUMBER> v<NUMBER> figure <NUMBER>a whereas hit <NUMBER> induces csps residues m<NUMBER> e<NUMBER> l<NUMBER> figure <NUMBER>b mapping residues surface representation crystal structure sarscov<NUMBER> pro pdb code <NUMBER>lu<NUMBER> <NUMBER> suggested two hits adopted different orientations catalytic site shared anchor point near v<NUMBER> figure <NUMBER>c considering molecular size niacin spatial distribution perturbed residues niacin probably binds one site nevertheless csp pattern suggests catalytic core sarscov<NUMBER> pro accommodates compounds larger niacin hit <NUMBER> therefore searched lowmolecularweight <NUMBER> da drugs containing pharmacophores niacin hit <NUMBER> molecular docking identified carmofur niacin derivative titration carmofur <NUMBER> nlabeled sarscov<NUMBER> pro n induced extra setof cross peaks ligandprotein molar ratio <NUMBER> original signals completely disappeared molar ratio <NUMBER> figure s<NUMBER>a indicated strong binding carmofur sarscov<NUMBER> pro confirmed ic <NUMBER> <NUMBER> ± <NUMBER> µm determined using enzymatic assay pro concentration <NUMBER> µm figure s<NUMBER>b however original nmr signals completely disappeared ligandprotein molar ratio significantly deviated stoichiometry <NUMBER> recently demonstrated carmofur covalent inhibitor main protease thesarscov<NUMBER> ic <NUMBER> value <NUMBER> μm presence <NUMBER> µm enzyme <NUMBER> consistent measurement higher pro concentration used case collectively data suggest covalent linking sarscov<NUMBER> pro driven excess carmofur nevertheless using fragmentbased approach feasible strategy repurposing lowmolecularweight drugs targeting sarscov<NUMBER> pro pharmacophore identification molecular docking nominated several lowmolecularweight analogs hit <NUMBER> example triclabendazole emedastine bendamustine figure s<NUMBER>a singledose enzymatic assay showed three drugs significantly higher potency hit <NUMBER> figure s<NUMBER>b determined dosedependent response bendamustine emedastine inhibition sarscov<NUMBER> pro activity ic <NUMBER> values <NUMBER> ± <NUMBER> μm <NUMBER> ± <NUMBER> μm figure <NUMBER>a ic <NUMBER> value triclabendazole roughly estimated <NUMBER> μm twodose inhibition rates <NUMBER> <NUMBER> inhibition <NUMBER> μm <NUMBER> μm triclabendazole respectively limited low aqueous solubility triclabendazole bendamustine emedastine induced significantly larger csps dosedependent manner hit <NUMBER> figure <NUMBER>b taken together fragmentbased strategy facilitates identification lowmolecularweight drugs sarscov<NUMBER> pro first approachcan readily applied identify lowmolecularweight drugs sarscov<NUMBER> targets eg rnadependent rna polymerase receptorbinding domain spike protein second combination lowmolecularweight drugs may used gain higher potency achieved via single compound binding topologies show evidence steric repulsion finally although carmofur bendamustine show higher potency fragment screening hits toxicity anticancer drugs remains challenge clinical applications conversely triclabendazole emedastine could valuable inhibiting sarscov<NUMBER> replication early stage may also serve starting point next round pharmacophore identification general study provides new insights toward repurposing lowmolecularweight drugs sarscov<NUMBER> potential targets lacking specific drugs severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> novel coronavirus first detected wuhan hubei province china november <NUMBER> infection sarscov<NUMBER> causes coronavirus disease globally <NUMBER> million confirmed covid<NUMBER> cases <NUMBER> reported deaths april <NUMBER> <NUMBER> world health organization declared covid<NUMBER> pandemic march <NUMBER> <NUMBER> many biomedical researchers shifting efforts battle coronavirus covid<NUMBER> pandemic one area activity computationally prioritizing experimentally testing approved drugs repurposing candidate therapies attenuating covid<NUMBER> infection drug repurposing studies present promising avenue quickly offering treatment covid<NUMBER> drugs known safety profiles far drug repurposing studies categorized three groups invitro screens <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> computational predictions based structural biology methods <NUMBER> <NUMBER> <NUMBER> computational predictions based network models transcriptomics <NUMBER> <NUMBER> <NUMBER> studies validated top computational predictions cellbased models covid<NUMBER> cell based models <NUMBER> <NUMBER> <NUMBER> lists drugs mentioned studies analyzed consensus suggested drugs grouped type time many researchers attempt understand molecular mechanisms covid<NUMBER> virus life cycle much attention given study profiled massspectrometry proteomics host proteins interact covid<NUMBER> proteins <NUMBER> another important dataset produced rnaseq gene expression signatures various relevant human cell lines ferret model lungs human lung biopsies covid<NUMBER> infection <NUMBER> two examples many studies produce gene sets organized compared past developed crowdsourcing project asked community identify gene expression signatures drug gene disease perturbations <NUMBER> collection <NUMBER> signatures collected help <NUMBER> contributors around world enabled us produce useful database called creeds similarly project developed crowdsourcing project integrate gene drug sets related covid<NUMBER> research collected assistance research community since emergence covid<NUMBER> epidemic tens thousands new publications related covid<NUMBER> research emerged short period <NUMBER> months continually survey publications identify research describes drug repurposing efforts manually extract drug sets studies populate drug set library also submit platform published drug sets historical sources studies listed drugs showing antiviral activity related viruses far collected <NUMBER> drug repurposing publications table <NUMBER> updated version table maintained httpsdocsgooglecomspreadsheetsd<NUMBER>x<NUMBER>akazgadflqnrqofqwllrhcxfugyirbzwyipion wmedituspsharing assist us developing maintaining collection received help research community allowing researchers upload gene drug sets database submissions manually evaluated making publicly available set <NUMBER> gene expression signatures resulting infections different coronaviruses different cell types tissues expression data originating gene expression omnibus geo database processed using geo<NUMBER>enrichr tool <NUMBER> stored gen<NUMBER>va platform <NUMBER> <NUMBER> entries submitted covid<NUMBER> crowdsourcing platform upregulated downregulated gene set associated signature gen<NUMBER>va report signatures available httpsamppharmmssmedugen<NUMBER>vareport<NUMBER>sars geneshot <NUMBER> platform developed convert pubmed searches gene sets using geneshot gene sets associated search terms sars sarscov merscov ace<NUMBER> tmprss<NUMBER> created using autorif generif <NUMBER> methods additionally top covid<NUMBER> drug repurposing candidates reported recent literature table <NUMBER> including chloroquine hydroxychloroquine included predictions additional genes potentially associated terms also added covid<NUMBER> gene set library predictions based literatureassociated genes using five strategies cooccurrence via autorif generif enrichr <NUMBER> tagger <NUMBER> coexpression using data archs<NUMBER> <NUMBER> twitter important source timely discussions related therapeutics covid<NUMBER> including drug repurposing efforts clinical trials using twitter api query twitter daily list <NUMBER> drug terms synonyms collect tweets mentioned drugs context covid<NUMBER> drug search list curated drugbank <NUMBER> l<NUMBER>fwd <NUMBER> list drugs submitted covid<NUMBER> drug gene set library website filter identified tweets comentioned covid<NUMBER> sars linguistic variations drug counted occurrences tweets recorded tally mentions day data collection continues daily reports tweet ids tweets originating discussions longitudinal drug trends data shared publicly githubhttpsgithubcommaayanlabcovid<NUMBER>drugstrendtrackertreemasterdailyreports day set discussed drugs twitter automatically deposited covid<NUMBER> drug set library via api approach enables real time trend detection discussed drugs potential therapeutics covid<NUMBER> enriching content covid<NUMBER> drug gene set library covid<NUMBER> gene drug set library website five sortable searchable tables list drug gene sets fig <NUMBER> sorting based date submission alphabetical ordering list size two tables searchable via metadata terms title authors descriptions well via data search specific gene drug names users download gene set drug set well entire library addition gene set provided option perform gene set enrichment analysis enrichr <NUMBER> genes linked harmonizome <NUMBER> interrogation individual drugs map known compounds linkable corresponding drugbank landing pages <NUMBER> website enables users submit drug gene sets related covid<NUMBER> research completing simple form form includes dataset title url source description explains set relevant covid<NUMBER> research submitter also provided mechanisms add additional metadata terms describe cell type tissue organism critical information submitted set users specify category metadata provided allowing broad set additional metadata set users also opt submit contact information information kept private users optin make public user submits contribution site dataset directed review queue examine validity relevance contribution reviewing process enables administrator approve reject submitted set approved set added library make easy contributors submit multiple sets users access site via api code behind site open source available httpsgithubcommaayanlabcovid<NUMBER>crowdlibrary drug sets extracted <NUMBER> invitro screens <NUMBER> first identified drugs matched drugs profiled l<NUMBER> assay available gse<NUMBER> average signatures drug computed taking zscore mean gene clusters identified based average signatures using hierarchical clustering differential zscores genes relative two clusters identified using ttest statistic top differentially expressed genes cluster submitted enrichr gene set enrichment analysis quantify zscores genes coexpressed ace<NUMBER> calculated correlation <NUMBER> randomly sampled drug signatures l<NUMBER> database calculated mean zscores top <NUMBER> correlated genes ace<NUMBER> compared values distribution calculated sampling <NUMBER> random genes repeatedly <NUMBER> times pvalues calculated sampled distribution corrected multiple hypothesis testing applying bonferroni correction method code behind analysis open source available httpsgithubcommaayanlabcovid<NUMBER>l<NUMBER> far collected <NUMBER> drug sets composed <NUMBER> unique drugs <NUMBER> gene sets consisting <NUMBER> unique genes drug sets subdivided four categories experimental <NUMBER> computational <NUMBER> twitter <NUMBER> <NUMBER> top <NUMBER> frequent drugs genes across sets displayed fig <NUMBER>a e list experimental drugs supportive evidence hydroxychloroquine mefloquine chloroquine remdesivir fig <NUMBER>a hydroxychloroquine chloroquine remdesivir discussed drugs twitter mefloquine received far less attention fig <NUMBER> mefloquine consistently ranked within top <NUMBER> drugs day antimalaria drug mefloquine <NUMBER> much less discussed may good candidate experimental investigation fig <NUMBER> top <NUMBER> frequently submitted genes members innate immune response fig <NUMBER>e genes include typical interferon cytokine response genes observed involved response human cells pathogens genes also listed top differentially expressed upregulated genes gen<NUMBER>va report <NUMBER> signatures fig <NUMBER> however list also includes immediate early gene ieg module composed transcription factors egr<NUMBER> fos phosphatase dusp<NUMBER> based enrichment analysis enrichr <NUMBER> top <NUMBER> downregulated genes gen<NUMBER>va report include five genes sh<NUMBER>bgrl lgals<NUMBER> cox<NUMBER>a<NUMBER> crip<NUMBER> lyz highly expressed dendritic cells pvalue <NUMBER> fisher exact test suggesting may depletion dendritic cells due sars infections ability collect tweets drugs using twitter api enables us track trends new drugs increasingly discussed social media platform period april <NUMBER>nd april <NUMBER>th <NUMBER> noticed rise fall discussions drug galidesivir fig <NUMBER> galidesivir bcx<NUMBER> adenosine analog previously suggested potential antiviral drug several related viral diseases <NUMBER> <NUMBER> <NUMBER> drug sets library studies utilized computational methods predict drugs largescale approved drug screens <NUMBER> using venn diagram tool developed adhoc analysis sets library compared results six invitro covid<NUMBER> drug screen studies fig <NUMBER> although little overlap across drug screens one two drugs shared across experimental studies interesting less discussed hits emerge namely amuvatinib proscillaridin mefloquine hexachlorophene clofazimine almitrine amuvatinib multitargeted tyrosine kinase inhibitor <NUMBER> proscillaridin organic compound used old cardiotonic steroid recently suggested cancer agent <NUMBER> hexachlorophene disinfectant used dermatological products <NUMBER> clofazimine drug used treat leprosy mechanisms action suggest interferes dna synthesis <NUMBER> almitrine drug stimulates respiratory respiration activating receptors carotid bodies <NUMBER> used treatment chronic obstructive pulmonary disease <NUMBER> relevant covid<NUMBER> symptoms explore molecular effects positive hits invitro drug screens demonstrate utility collected library developed case study asks whether drugs shown inhibit covid<NUMBER> infection human cells invitro upor downregulate ace<NUMBER> gene ace<NUMBER> suspected cell surface receptor covid<NUMBER> <NUMBER> cells express gene shown less prone covid<NUMBER> infection since still undetermined whether desired upor downregulate ace<NUMBER> expression queried drug hit two published invitro drugs screens lincs l<NUMBER> data <NUMBER> identified <NUMBER> drug hits screens profiled l<NUMBER> comprising total <NUMBER> differential gene expression profiles <NUMBER> drugs display average increase ace<NUMBER> expression <NUMBER> drugs display decrease expression ace<NUMBER> overall gene expression signatures <NUMBER> drugs categorized two distinct clusters fig <NUMBER> observed difference gene expression signatures suggest different modes action drugs drugs similar chloroquine exhibit consistent upregulation genes highly correlated ace<NUMBER> chloroquine gene expression signatures average upregulate top <NUMBER> correlated genes ace<NUMBER> p<NUMBER>e<NUMBER> addition cepharanthine fluspirilene bazedoxifene amuvatinib also upregulate set ace<NUMBER> correlated genes p<NUMBER>e<NUMBER> p<NUMBER>e<NUMBER> p<NUMBER>e<NUMBER> p<NUMBER>e<NUMBER> respectively <NUMBER> genes available table <NUMBER> strong dysregulation ace<NUMBER> associated genes could point similar mode action regarding antiviral activity enrichment analysis consensus genes upregulated drugs cocluster chloroquine dislpay regulation immune response genes downregulation cell cycle genes suggests drugs chloroquine cluster proinflammatory cluster drugs contains antiinflammatory drugs genes chloroquine cluster httpsamppharmmssmeduenrichrenrichdatasetd<NUMBER>bbba<NUMBER>dff<NUMBER>bcf<NUMBER>f<NUMBER>db<NUMBER>e<NUMBER>e genes chloroquine cluster httpsamppharmmssmeduenrichrenrichdataset<NUMBER>f<NUMBER>a<NUMBER>fbc<NUMBER>e<NUMBER>da<NUMBER>bce<NUMBER>a<NUMBER> describe platform created collect drug gene sets related covid<NUMBER> research using various methods data accrual top <NUMBER> genes associated covid<NUMBER> interferonrelated isg<NUMBER> irf<NUMBER> oas<NUMBER> ifitm<NUMBER> mx<NUMBER> ifih<NUMBER> stat<NUMBER> ifit<NUMBER> eif<NUMBER>ak<NUMBER> consistent knowledge type ifnα ifnβ type iii interferon ifnλ systems primary defense viral infections hypothesized hyperinflammation covid<NUMBER> could drive disease severity would amenable treatment drugs reduce inflammation <NUMBER> however remains controversial high level antiviral response could reflective increased viral burden rather inappropriate host response <NUMBER> striking result metaanalysis applied content library little overlap across drug screen studies expected experimental validation drugs inhibit covid<NUMBER> invitro consistent inconsistency across studies could due need produce results quickly due urgency discovering potential treatments regardless overlap expectation screens published top leads advance animal models human trials testing prioritize compounds may treat covid<NUMBER> researchers used strategy finding drugs modulate genes related ace<NUMBER> gene expression <NUMBER> found highly significant upregulation genes correlated ace<NUMBER> chloroquine related compounds l<NUMBER> database finding suggests identifying compounds upregulate genes correlated ace<NUMBER> expression could useful approach identifying compounds inhibit covid<NUMBER> mammalian cells however noted considerations must taken account including known side effects compounds whether dosing would allow high enough drug concentration achieve therapeutic effects clear consensus analysis results viewed caution common drugs necessarily efficacious promising treatments time common genes may relevant understand covid<NUMBER> research noted drug sets gene sets equal weight quality relevancy list computationally predicted drugs useful towards identifying therapy covid<NUMBER> compared list experimentally validated drugs list upregulated genes covid<NUMBER> infection cells may provide useful information virus life cycle compared list genes returned geneshot search using term sars hence users data collected library aware limitations limitations mind hope researchers able develop refine hypotheses snapshot overview platform provides delve deeper studies relevant questions example gen<NUMBER>va report revealed downregulation genes known enriched dendritic cells dcs infection sars sarscov<NUMBER> known infect dcs impair dc function <NUMBER> period rapid development methods data related covid<NUMBER> research critical provide means organize accumulated information way summarized reused covid<NUMBER> gene set drug set library provides utility library drug gene sets used identify community consensus make researchers clinicians aware development new potential therapies become available well allow research community work together towards cure covid<NUMBER> social media played critical role enabling scientists communicate results rapidly exchange ideas mining trends discussions twitter drugs context covid<NUMBER> able keep track global trends reported scientific journals table legends table <NUMBER> slc<NUMBER>a<NUMBER> lrrc<NUMBER> havcr<NUMBER> hhla<NUMBER> ct<NUMBER> ldhal<NUMBER>b slc<NUMBER>a<NUMBER> ddx<NUMBER> clcn<NUMBER> slc<NUMBER>a<NUMBER> gipc<NUMBER> gucy<NUMBER>c abcb<NUMBER> tmprss<NUMBER> rbmxl<NUMBER> tm<NUMBER>sf<NUMBER> kdm<NUMBER>d slco<NUMBER>c<NUMBER> prm<NUMBER> rnf<NUMBER> cntn<NUMBER> acsl<NUMBER> ubqln<NUMBER> hnf<NUMBER>g ankrd<NUMBER> mxd<NUMBER> slc<NUMBER>a<NUMBER> il<NUMBER>rb<NUMBER> ankrd<NUMBER>cl slc<NUMBER>a<NUMBER> slc<NUMBER>a<NUMBER> slc<NUMBER>a<NUMBER> acrv<NUMBER> alpi eppin il<NUMBER>a akap<NUMBER> hkdc<NUMBER> brdt tsbp<NUMBER> slc<NUMBER>a<NUMBER> p<NUMBER>ry<NUMBER> foxd<NUMBER> nat<NUMBER>b ascl<NUMBER> il<NUMBER>a creb<NUMBER> dmrt<NUMBER> phf<NUMBER> great application drug repurposing identify drugs developed treating diseases treat new disease drug repurposing achieved conducting systematic drug−drug target interaction dti drug−drug interaction ddi analyses conducted survey dtis collected drugbank database <NUMBER> found average drug <NUMBER> drug targets drug target <NUMBER> drugs <NUMBER> analysis demonstrates polypharmacology common phenomenon important identify potential dtis approved drugs drug candidates serves basis repurposing drugs selection drug targets without dtis may cause side effects polypharmacology opens novel avenues rationally design next generation effective less toxic therapeutic agents computeraided drug design cadd playing essential roles modern drug discovery development balance computational efficiency accuracy hierarchical strategy employing different types scoring functions applied drug lead identification optimization phases docking scoring function one employed glide docking program <NUMBER> efficient thus utilized screen large library accurate hand molecular mechanical force field mmffbased scoring functions physical accurate much less efficient ever increasing computer power mmffbased free energy calculation methods end point mmpbsa molecular mechanics poisson−boltzmann surface area mmgbsa molecular mechanics generalized born surface area methods <NUMBER>−<NUMBER> alchemical thermodynamic integration ti free energy perturbation fep methods <NUMBER> <NUMBER> extensively applied structurebased drug discovery projects developed hierarchical virtual screening hvs balance efficiency accuracy improve success rate rational drug design <NUMBER> <NUMBER> newly released crystal structure sarscov<NUMBER> main protease <NUMBER> provides solid structural basis identification drugs might interact protein target work applied multiscale modeling techniques identify drugs may repurposed target sarscov<NUMBER> main protease flexible docking mmpbsaweighted solventaccessible surface area wsas applied first second filters respectively improve efficiency accuracy hvs inhibitor identification sarscov<NUMBER> main protease compared experimental means caddbased approaches efficient providing possible treatment solutions epidemic disease outbreaks like covid<NUMBER> detailed ligand−residue interaction profile well decomposition binding free energy different components provides insight rationally designing potent selective inhibitors sarscov<NUMBER> main protease conducted hierarchical virtual screening hvs using newly resolved crystal structure sarscov<NUMBER> main protease resolution <NUMBER> å <NUMBER> later crystal structures sarscov<NUMBER> main protease resolved <NUMBER> two types hvs filters employed glide <NUMBER> flexible docking followed mmpbsawsas <NUMBER> <NUMBER> detailed computational methods described <NUMBER> docking screening crystal structure first treated using protein structure preparation wizard provided schrodinger software followed docking grid generation glide flexible docking performed using default settings except formation intramolecular hydrogen bonds rewarded enhancement planarity conjugated π groups turned cocrystal ligand n<NUMBER> covalently bonded cys<NUMBER> generated new version n<NUMBER> n<NUMBER>′ breaking covalent bond filling open valence evaluated whether glide flexible docking reproduce native binding pose addition data set approved drugs prepared using drugbank <NUMBER> set pubchem compounds structurally similar lopinavir enriched docking screenings lopinavir potent inhibitor hiv<NUMBER> protease <NUMBER> found effective treating covid<NUMBER> patients top hits docking screenings advanced next hvs filter mmpbsawsas <NUMBER>dstructures screening compounds generated using openbabel software <NUMBER> <NUMBER> system setup molecular dynamics md simulation free energy calculation md simulations first performed docking hit two purposes <NUMBER> studying relative stability ligand residing binding pocket <NUMBER> sampling set conformations mmpbsawsas binding free energy calculations mmgbsa residue−ligand binding free energy decomposition analysis md system consisted one copy sarscov<NUMBER> main protease one copy docked ligand <NUMBER> tip<NUMBER>p <NUMBER> water molecules <NUMBER> na cl − ions depending charge state ligand whole system neutralized force field parameters partial atomic charges ligands derived using resp <NUMBER> program fit hf<NUMBER>g electrostatic potentials generated using gaussian <NUMBER> software package <NUMBER> force field parameters ligands come gaff <NUMBER> amber ff<NUMBER>sb <NUMBER> force field employed model viral protein residue topologies ligands prepared using antechamber module <NUMBER> implemented amber software package <NUMBER> covalently bonded n<NUMBER> ligand applied residuegen program generate nonstandard amino acid residue topology <NUMBER> md simulation protocols protein−ligand complex md system first relaxed series minimization procedures main chain atoms receptor bound ligand restrained using harmonic potential force constant decreased <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> kcalmolå <NUMBER> progressively five <NUMBER> <NUMBER>step minimizations note last step applied restraint force constant <NUMBER> system relaxed set <NUMBER> ps atomistic md simulations restraint setting minimizations three phases md simulation relaxation phase equilibrium phase sampling phase relaxation phase simulation system heated progressively <NUMBER> <NUMBER> k steps <NUMBER> k temperature <NUMBER> ns md simulation performed without restraints constraints next equilibrium phase system equilibrated <NUMBER> k <NUMBER> bar <NUMBER> ns finally <NUMBER> ns md simulation performed <NUMBER> k <NUMBER> bar produce ntp constant temperature pressure ensembles total <NUMBER> <NUMBER> snapshots recorded last simulation <NUMBER> snapshots evenly selected mmpbsawsas binding free energy calculation <NUMBER> selected mmgbsa ligand−protein binding free energy decomposition analysis additional settings constant pressure md simulations performed work listed follows temperature regulated using langevin dynamics <NUMBER> collision frequency <NUMBER> ps −<NUMBER> pressure regulated using isotropic position scaling algorithm pressure relaxation time set <NUMBER> ps integration equations motion conducted time step <NUMBER> fs relaxation phase <NUMBER> fs equilibrium sampling phases particle mesh ewald pme method <NUMBER> used calculate full electrostatic energy unit cell macroscopic lattice repeating images bonds constrained using shake algorithm <NUMBER> minimization md simulation stages md simulations performed using pmemd program amber <NUMBER> <NUMBER> <NUMBER> mmpbsawsas binding free energy calculation total <NUMBER> md snapshots evenly selected binding free energy calculations selected md snapshot molecular mechanical mm energy e mm mmpbsa solvation free energy calculated without minimization <NUMBER>−<NUMBER> key parameters controlling mmpbsawsas analyses listed follows external dielectric constant <NUMBER> internal dielectric constant <NUMBER> surface tension estimating nonpolar solvation energy using solvent assessible surface area <NUMBER> parse radii <NUMBER> used mmpbsa solvation calculation using delphi package httpcompbioclemsonedudelphi entropic term estimated using method coined wsas weighted solvent accessible surface area described elsewhere <NUMBER> noted entropic contribution cannot neglected protein target ligands large many rotatable bonds <NUMBER> mmgbsa ligand−residue free energy decomposition analysis conducted ligand−residue free energy decomposition analysis <NUMBER> snapshots evenly selected sampled snapshots besides electrostatic van der waals interactions solvation effect taken account using generalized gb model developed hawkins et al <NUMBER> ligand−residue mmgbsa interaction energies calculated using sander program amber <NUMBER> <NUMBER> data analysis performed using internal program developed us hot spot residue recognized ligand−residue mmgbsa interaction stronger −<NUMBER> kcalmol work performed twostep hierarchical virtual screenings identify drugs repurposing target sarscov<NUMBER> main protease set <NUMBER> approved drugs downloaded drugbank <NUMBER> step <NUMBER> glide docking <NUMBER> efficient less accurate method applied enrich repurposing drug candidates step <NUMBER> docking hits evaluated using accurate less efficient method mmpbsawsas final repurposing drug candidates selected based mmpbsawsas binding free energies <NUMBER> docking screenings first evaluated docking power glide program cocrystal ligand sarscov<NUMBER> main protease n<NUMBER> ligand root mean square deviation rmsd best docking pose based docking score −<NUMBER> <NUMBER> å acceptable big ligand <NUMBER> atoms flexible docking applied docking setting conduct docking screenings drug molecules docking scores better −<NUMBER> kcalmol roughly corresponding <NUMBER> μm selected hits advanced next filter mmpbsawsas utilizing cutoff number hits accounted <NUMBER> total screening compounds promising docking hits conducted molecular dynamics simulations using amber software package <NUMBER> total <NUMBER> ligands including cocrystal n<NUMBER> ligand <NUMBER> bioactives structurally similar lopinavir studied second phase hvs top <NUMBER> approved neutral drugs excellent mmpbsawsas binding free energies δg bind ≤ −<NUMBER> kcalmol shown figure <NUMBER> <NUMBER>d structures charged drugs least one form achieving δg bind ≤ −<NUMBER> kcalmol shown figure <NUMBER> also found two bioactives figure <NUMBER> excellent binding free energies section <NUMBER> noted lopinavir observed effective treating covid<NUMBER> patients explored md stability md system figure <NUMBER> showed rmsd fluctuations along md simulation time shown main chain atoms receptor black curves secondary structures red curves reached equilibrium <NUMBER> ns leastsquares ls fitted rmsds ligands green curves around <NUMBER> å reasonable large ligands like sarscov<NUMBER> main protease inhibitors ligands nofit rmsd calculated first performing lsfitting main chain atoms receptor resulting translation−rotation matrix applied ligand rmsd calculated directly evidently ligand nofit rmsd measures conformational changes also translational rotational movements inside binding pocket ligand nofit rmsds blue curves larger lsfit values however values around <NUMBER>−<NUMBER> å still acceptable large ligands pointed sometimes lsfit nofit rmsd values overestimated due rotation symmetrical functional groups ligand summary rmsd fluctuation analysis suggests md trajectories overall stable sampling phase studied md systems first generated average structure collected snapshots md snapshot smallest main chain atom rmsd average structure chosen representative conformation comparisons crystal structure representative md conformations shown figure <NUMBER> native ligand n<NUMBER> figures <NUMBER>−<NUMBER> ligands shown figure <NUMBER> benzene motif located dashed red cycle inserted two hot spot residues his<NUMBER> met<NUMBER> md structure quite distinct crystal structure shows benzene motif direct interactions his<NUMBER> met<NUMBER> believe physiological conditions benzene motif becomes less solvent exposed favorable interactions his<NUMBER> met<NUMBER> inserting side chains two residues known histidine versatile roles protein interactions <NUMBER> sulfide bond formed result nucleophilic attack catalytic cys<NUMBER> n<NUMBER> ligand his<NUMBER> stabilize ligand−protein interaction forming π−π stacking interactions his<NUMBER> benzene motif n<NUMBER> table <NUMBER> calculated entropic term tδs quite different different ligands shown table <NUMBER> suggesting necessity including term binding free energy calculations structures promising drug repurposing candidates excellent docking scores mmpbsawsas binding affinities shown figures <NUMBER>−<NUMBER> known drugs shown figure <NUMBER> neutral better mmpbsawsas affinity −<NUMBER> kcalmol noted cocrystal ligand n<NUMBER> covalently bonded receptor therefore binding free energy directly comparable noncovalent ligands individual terms mmpbsa table s<NUMBER> values energy term van der waals δe vdw electrostatics δe vdw δg pb nonpolar solvation term δg sa entropy tδs vary significantly one system another table <NUMBER> table s<NUMBER> suggesting single energy term dominates protein−ligand interaction charged drug molecules caution taken result interpretation example neutral form streptomycin db<NUMBER> mmpbsawsas binding free energy −<NUMBER> kcalmol much better charged form −<NUMBER> kcalmol difference caused distinct electrostatic properties neutral charged molecules however charged form dominant physiological conditions <NUMBER> therefore use result charged form take penalty protonation consideration using result neutral form decomposition performed mmgbsa binding free energy decomposition identify hot spot residues make substantial contributions protein−ligand binding identified hot spots could enable us rationally design potent selective inhibitors drug target obtain statistically meaningful results studied <NUMBER> md snapshots system average ligand−residue interaction energies δg lig−res rmsd values calculated hot spot residue defined residue δg lig−res equal smaller −<NUMBER> kcalmol identified hot spots ligand summarized table <NUMBER> significant hotspot residues δg lig−res −<NUMBER> illustrated figures <NUMBER>−<NUMBER> common significant hot spot residues ligands bold table <NUMBER> his<NUMBER> met<NUMBER> asn<NUMBER> his<NUMBER> met<NUMBER> glu<NUMBER> gln<NUMBER> asn gly outbreak highly infectious diseases covid<NUMBER> demands identification multiple treatment plans soon possible computational drug repurposing studies provide treatment options short period time study amounts computational time used individual tasks follows docking screenings <NUMBER> approved drugs single cpu core intel xeon cpu e<NUMBER> took <NUMBER> h docking hit need perform ab initio calculations derive point charges ab initio calculation using wb<NUMBER>xd<NUMBER>ghf<NUMBER>g consumed <NUMBER> day using four cpu cores took us <NUMBER> days sample <NUMBER> ns using one gtx<NUMBER> ti gpu following mmpbsawsas calculation consumed <NUMBER> day therefore equipped sufficient numbers cpus gpus current hardware finish drug repurposing screenings within <NUMBER> <NUMBER> days using reliable hvs strategy given inhibitors sarscov<NUMBER> main protease relatively large sizes screening time even shorter drug targets smaller ligands another consideration availability highquality drug target structures luckily highresolution crystal structure sarscov<NUMBER> protease complex ligand resolved quickly allowing us conduct drug repurposing screening highquality structure available one rely homology modeling techniques probably reduced success rate identifying repurposing drugs take sarscov<NUMBER> main protease example performed structural alignments using internal program takes multiplesequencealignment msa input msa generated using promals<NUMBER>d web server <NUMBER> structure sarscov<NUMBER> main protease found similar sarscov protease pdb <NUMBER>tnt <NUMBER> less similar merscov protease pdb <NUMBER>wkk <NUMBER> figure <NUMBER>a comparison structure hepatitis c virus hcv ns<NUMBER>a pdb code <NUMBER>m<NUMBER>l <NUMBER> quite different main proteases coronaviruses rmsd <NUMBER> å hcv sarscov<NUMBER> much larger <NUMBER> residues participating leastsquares fitting figure <NUMBER>b also compared sequences four proteases around seven hot spot residues colored red table <NUMBER> shown sarscov<NUMBER> sarscov share seven hot spot residues merscov sarscov<NUMBER> four seven hot spot residues common hcv ns<NUMBER>a sarscov<NUMBER> one hot spot residue his<NUMBER> common even though sequence identity low sarscov<NUMBER> main protease hcv ns<NUMBER>a shown figure <NUMBER>b cocrystal ligands n<NUMBER> green sticks sarscov<NUMBER> itmn<NUMBER> brown sticks hcv ns<NUMBER>a largely overlap suggests homology models constructed using modeller <NUMBER> sarscov merscov even hcv ns<NUMBER>a templates work conducted computational drug repurposing study sarscov<NUMBER> main protease find robust treatments covid<NUMBER> particularly virus developed different variations necessary screen repurposing drugs targeting proteins essential life cycle virus study took advantage recently released crystal structure sarscov<NUMBER> main protease conducted multiscale drug repurposing screenings five neutral drugs namely carfilzomib eravacycline valrubicin lopinavir elbasvir identified inhibitory activities sarscov<NUMBER> main protease streptomycin charged molecule may also inhibitor sarscov<NUMBER> main protease study suggests computational drug repurposing screening efficient provide potential repurposing drug candidates less <NUMBER> days set hot spot residues make substantial contributions protein−ligand binding urgent need new strategies combat hundreds human diseasecausing intracellular pathogens including viruses intracellular bacteria protozoa currently approved antiviral drugs treat fewer ten viral infections antibacterial agents widely available minority penetrate mammalian cells achieve therapeutic level appropriate intracellular compartment treat intracellular bacterial infections <NUMBER> narrow spectrum coverage antimicrobials target microbial functions particularly viruses another major limitation given high average cost two billion dollars long timeline <NUMBER>−<NUMBER> years develop new drug scalability targeting microbes individually limited lastly resistance typically emerges rapidly conventional drugs target microbial functions used monotherapy attractive solution overcome limitations repurpose already approved drugs target host functions required lifecycle intracellular pathogens antimicrobial agents figure <NUMBER> offlabel use approved drugs requires significantly less capital time diminishes clinical risks drugs already rigorously tested toxicity pharmacokinetics pharmacodynamics dosing etc primary indication since host functions hijacked various viruses intracellular bacteria andor protozoa may represent targets broadspectrum antimicrobials approach therefore increase efficiency antimicrobial development improve drug access patients facilitate readiness future outbreaks emerging pathogens additionally hosttargeted approaches may added benefit higher genetic barrier emergence resistance one promising drug category repurposing antimicrobials inhibitors host kinases widely approved treatment cancer inflammatory conditions <NUMBER> large number host kinases coopted intracellular pathogens thus represent attractive targets broadspectrum antimicrobial therapy <NUMBER> indeed recent efforts demonstrated therapeutic potential kinase inhibitors combat various intracellular microbial infections anticancer epidermal growth factor receptor egfr erbb<NUMBER> kinase inhibitors gefitinib erlotinib lapatinib demonstrate vitro activity number viruses including hepatitis c virus hcv human cytomegalovirus hcmv poxvirus <NUMBER> <NUMBER> gefitinib lapatinib also inhibit hcv hcmv infections mouse guinea pig model respectively <NUMBER> reduce replication mycobacterium tuberculosis mtb lungs infected mice <NUMBER> antiviral effect drugs mediated part inhibition signaling entry stage andor factinmediated intracellular viral trafficking <NUMBER> <NUMBER> enhanced antimicrobial immune effect via inhibition egfrp<NUMBER> mitogen associated protein kinase signaling plays role antimtb activity <NUMBER> another class approved kinase inhibitors demonstrating broad antimicrobial coverage cellular abelson tyrosine kinase cabl inhibitors imatinib nilotinib drugs inhibit replication ebola virus ebov dengue virus denv middle eastern respiratory syndrome coronavirus merscov severe acute respiratory syndrome coronavirus sarscov cultured cells reduce vaccinia virus load spread overall mortality mouse model <NUMBER>−<NUMBER> moreover imatinib treatment impairs entry intracellular survival mtb mycobacterium marinum infected macrophages reduces bacterial load associated pathologies mice infected antibioticsensitive resistant mtb <NUMBER> notably coadministered rifamycins imatinib displays synergy indicating potential utility combination antimtb drug regimens <NUMBER> molecular targets underlying antimicrobial effect cabl inhibitors remain validated moreover inhibition actin motility proposed mechanism antiviral action drugs <NUMBER> precise mechanism mode antibacterial action remain unknown approved anticancer drugs sunitinib erlotinib display potent activity viruses six viral families including denv ebov cultured cells <NUMBER> combinations drugs reduce morbidity mortality dengue ebola infected mice advancing clinical studies dengue possibly ebola future outbreaks https clinicaltrialsgov nct<NUMBER> <NUMBER> inhibition cellular kinases adaptor protein <NUMBER> ap<NUMBER>associated protein kinase <NUMBER> aak<NUMBER> cyclin gassociated kinase gak regulators adaptor proteinmediated intracellular viral trafficking important mechanism action moa antiviral approach <NUMBER> three approved immunosuppressive drugs inhibit phosphatidylinositol <NUMBER>′kinase−akt−mammalian target rapamycin pi<NUMBER>kaktmtor pathway leflunomide everolimus sirolimus reduce viremia nephropathy progression patients infected bk virus member polyomavirus family used individually combination <NUMBER> additionally leflunomide demonstrates activity hcmv vitro rat model <NUMBER> direct suppression viral replication proposed one underlying mechanism approach precise moa molecular targets remain unknown inhibitors cyclophilin host factor facilitates protein folding represent another class drugs beyond kinase inhibitors shows promise antimicrobials cyclosporine immunosuppressant cyclophilin inhibitor disrupts replication multiple viruses including hcv denv flaviviruses human immunodeficiency virus hiv vitro <NUMBER> <NUMBER> two experimental nonimmunosuppressive cyclophilin inhibitors alisporivir scy<NUMBER> also inhibit multiple rna viruses cultured cells yet effect mouse models variable <NUMBER> alisporivir significantly reduced hcv viral load chronically infected patients <NUMBER> however clinical hold placed phase iii trial due toxicity cyclosporine also inhibits erythrocytic stages plasmodium falciparum vitro rodent malaria mouse model <NUMBER> nevertheless remains unknown whether effect results part inhibition host cyclophilin solely parasitic protein another candidate repurposing nitazoxanide drug approved treatment parasiteinduced diarrhea inhibits replication multiple viruses including hcv flaviviruses respiratory viruses hiv hepatitis b virus hbv cultured cells <NUMBER> nitazoxanide blocks maturation influenza hemagglutinin target remains unknown case hcv thought activate protein kinase r leading phosphorylation eukaryotic initiation factor <NUMBER>α blocks viral replication <NUMBER> phase ii trial nitazoxanide modestly reduced time resolution symptoms flu currently evaluated phase iii trial indication <NUMBER> whereas addition nitazoxanide peginterferonribavirin improved sustained virologic response hcv patients phase ii trial improvement observed phase iii trial genotype <NUMBER> infected patients <NUMBER> additionally nitazoxanide effective clinical mtb isolates including resistant standard antituberculosis drugs <NUMBER> disruption membrane potential ph homeostasis mtb one proposed moa <NUMBER> phase ii clinical trial currently ongoing determine efficacy <NUMBER>day nitazoxanide treatment prior initiation standard antituberculosis therapy metformin drug approved treatment type <NUMBER> diabetes inhibits intracellular growth mtb including drug resistant strains enhances efficacy approved antimtb drugs cell culture <NUMBER> murine model metformin mildly reduces mtb load target organs improves lung viewpoint pathology used individually combination drug treatment <NUMBER> notably metformin demonstrated efficacy decreasing disease severity improving clinical outcome adjunct therapy retrospective cohorts tuberculosis patients diabetes also reduced incidence latent tuberculosis diabetic patients <NUMBER> activation adenosine monophosphate−activated protein kinase ampk regulates cellular immune functions involved mediating antibacterial effect <NUMBER> beyond tuberculosis clinical study aims evaluate size hiv reservoirs upon addition metformin antiretroviral regimens currently ongoing statins drugs inhibit <NUMBER>hydroxy<NUMBER>methylglutaryl coenzyme reductase hmgcoar represent another potential class repurposing hosttargeted antimicrobials various statins inhibit replication hcv denv vitro <NUMBER> <NUMBER> nevertheless several retrospective studies demonstrated statins reduce relapse rates patients infected hcv added peginterferonribavirin effect quite variable <NUMBER> mechanism antihcv action statins mediated part effect lipid biosynthesis antiviral activity cells reversed upon addition mevalonate geranylgeraniol resistance drugs coincides increase hmgcoar level <NUMBER> due ability restore endothelial stability statins also proposed strategy treat infections associated endothelial dysfunction formal study conducted reported atorvastatin combination angiotensin receptor blocker reduced mortality <NUMBER> ebola patients sierra leone <NUMBER> antimalarial antiinflammatory drug chloroquine also shows promise antimicrobial agent nonhuman primate dengue model chloroquine reduces viremia cytokine production organ damage <NUMBER> however studied dengue patients reduced pain improved daily activity performance yet reduce disease duration viremia <NUMBER> <NUMBER> mice infected zika virus chloroquine increases life span reduces vertical transmission fetal brain infection <NUMBER> moreover reduces acute lung injury morbidity mortality mouse model avian influenza h<NUMBER>n<NUMBER> <NUMBER> mechanism antiviral activity chloroquine multifaceted thought involve alterations intracellular ph causing impaired fusion cleavage prm protein flaviviral release andor inhibition autophagy <NUMBER> <NUMBER> chloroquine may also show utility addon antituberculosis regimens enhances intracellular killing mtb human macrophages inhibiting bcrp<NUMBER> breast cancer resistance protein<NUMBER>mediated active efflux antituberculosis drugs isoniazid pyrazinamide <NUMBER> collectively data provide proofofconcept useful expansion antimicrobial drug targets focusing host functions therapeutic potential repurposed drugs targeting functions combat intracellular pathogens benefit provided higher genetic barrier resistance associated many hosttargeted approaches whereas emergence resistance complicate treatment hosttargeted approaches case chemokine receptor <NUMBER> antagonist maraviroc <NUMBER> time resistance hosttargeted approaches longer level resistance lower relative typical directacting antimicrobials monotherapy exemplified treatment denv sunitiniberlotinib combinations mtb nitazoxanide hcv cyclophilin inhibitors <NUMBER> <NUMBER> <NUMBER> targeting host proteins genetic control microbes simultaneously inhibiting several host targets drug drug combination thought facilitate increase resistance barrier approaches nevertheless repurposing hosttargeted drugs antimicrobials faces challenges cellular proteins function complex network interactions inhibitors often nonselective thus mechanism antimicrobial action hosttargeted approaches often remains elusive molecular targets underlying effect unvalidated example erlotinibs effect hcv infection first attributed solely effect egfr cancer target yet later demonstrated inhibition gak another target inhibited erlotinib comparable potency egfr also plays role <NUMBER> <NUMBER> drugs nitazoxanide chloroquine moa even less clear appears pathogen specific <NUMBER>−<NUMBER> another challenge antimicrobial effect observed vitro often cannot reproduced vivo example several multi kinase inhibitors lestaurtinib display vitro activity plasmodium falciparum significant effect malariainfected mice <NUMBER> moreover exemplified chloroquine dengue treatment promising effect animal models cannot guarantee effect patients <NUMBER>−<NUMBER> toxicity another major concern srcand cablinhibitor dasatinib demonstrates broadspectrum antiviral activity cultured cells yet murine model vaccinia virus induces immunosuppression rather protection <NUMBER> <NUMBER> thus important investigate antimicrobial activity safety drugs animal models infections nevertheless drugs may feasible find therapeutic window drug level sufficient inhibit microbial replication minimal cellular toxicity shifting indications requiring longterm therapy eg months years cancer shorter duration sufficient treat acute infections help limit toxicity contrast utility approaches treating chronic infections requiring longer duration treatment may limited exemplified unexpected occurrence pancreatitis phase iii trial alisporivir chronically infected hcv patients nevertheless drugs extensively used humans metformin chloroquine likely safe addons standard regimens even chronic infections summary examples provide proofofconcept potential feasibility repurposing approved drugs hosttargeted broadspectrum therapies combat intracellular microbial pathogens effectively meet clinical needs posed emerging intracellular pathogens approaches may find utility combination novel hosttargeted approaches microbialtargeted strategies corresponding author email seinavstanfordedu authors declare competing financial interest research supported grants nih <NUMBER>u<NUMBER> ai<NUMBER> dodcdmrp prmrp pr<NUMBER> ameri viewpoint cancer society rsg<NUMBER> <NUMBER>mpc stanford biox stanford spark program se authors acknowledge contributions field could included review april <NUMBER> <NUMBER> <NUMBER> confirmed cases <NUMBER> deaths coronavirus disease <NUMBER> covid<NUMBER> disease caused virus sarscov<NUMBER> united states alone <NUMBER> however currently proven effective antiviral medications covid<NUMBER> <NUMBER> urgent need development effective treatment strategies covid<NUMBER> traditional de novo drug discovery estimated pharmaceutical companies spent <NUMBER> billion <NUMBER> development fdaapproved new chemical entity drug <NUMBER> drug repurposing drug discovery strategy existing drugs offers promising way development prevention treatment strategies covid<NUMBER> <NUMBER> randomized controlled openlabel trial <NUMBER> prior knowledge networks large scientific corpus publications offers deep biological perspective capturing relationships drugs genes diseases including covid<NUMBER> yet extracting connections largescale repository structured medical information challenging study present stateoftheart knowledge graphbased deep learning methodologies rapid discovery drug candidates treat covid<NUMBER> <NUMBER> million pubmed publications via systematic validation using transcriptomics proteomics data generated sarscov<NUMBER> infected human cells ongoing clinical trial data successfully identified <NUMBER> drug candidates tested largescale randomized control trials potential treatment covid<NUMBER> pipeline covkge <NUMBER> present knowledge graphbased deep learning methodology drug repurposing covid<NUMBER> termed covkge figure <NUMBER> method uses dglke developed amazons aws ai laboratory <NUMBER> efficiently learn embeddings large knowledge graphs specifically construct knowledge graph <NUMBER> million pubmed publications <NUMBER> drugbank <NUMBER> including <NUMBER> million edges across <NUMBER> types relationships connecting drugs diseases genes anatomies pharmacologic classes geneprotein expression others cf supplementary tables <NUMBER> <NUMBER> knowledge graph represent coronaviruses covs assembling multiple types known covs including sarscov<NUMBER> merscov hcov<NUMBER>e hcovnl<NUMBER> described recent study <NUMBER> next utilize dglkes knowledge graph embedding model rotate <NUMBER> learn representations entities eg drugs targets relationships eg inhibition relation drugs targets informative lowdimensional vector space space relationship type eg antagonists agonists defined rotation source entity eg hydroxychloroquine target entity eg tolllike receptor <NUMBER> tlr<NUMBER> cf methods mapping drugs covs treatment relationships complex vector space using rotate top<NUMBER> relevant drugs selected <NUMBER> candidate covs treatment relation space supplementary figure <NUMBER> using ongoing covid<NUMBER> trial data httpscovid<NUMBER>trialscom validation set covkge larger area receive operating characteristic curve auroc <NUMBER> figure <NUMBER> identifying repurposable drugs covid<NUMBER> next employ tsne tdistributed stochastic neighbor embedding algorithm <NUMBER> investigate lowdimensional node representation learned covkge specifically project drugs grouped firstlevel anatomical therapeutic chemical atc classification systems code onto twodimensional space figure <NUMBER>a indicates covkge able distinguish <NUMBER> types drugs grouped atc codes consistent high table <NUMBER> next turn highlight three types predicted drugs covid<NUMBER> including antiinflammatory agents selective estrogen receptor modulators serms antiparasitics figure <NUMBER>a given welldescribed lung pathophysiological characteristics immune responses cytokine storms severe covid<NUMBER> patients drugs dampen immune responses may offer effective treatment approaches covid<NUMBER> <NUMBER> <NUMBER> shown figure <NUMBER>a computationally identified multiple antiinflammatory agents covid<NUMBER> including indomethacin melatonin indomethacin approved cyclooxygenases coxs inhibitor widely used potent antiinflammatory analgesic properties <NUMBER> indomethacin reported antiviral properties including sarscov<NUMBER> <NUMBER> sarscov<NUMBER> <NUMBER> importantly preliminary vivo observation showed oral indomethacin <NUMBER> mgkg body weight daily reduced recovery time sarscov<NUMBER> infected dogs <NUMBER> melatonin plays key role regulation human circadian rhythm alters translation thousands genes including melatoninmediated antiinflammatory <NUMBER> immunerelated effects covid<NUMBER> melatonin various antiviral activities suppressing multiple inflammatory pathways <NUMBER> <NUMBER> including il<NUMBER> il<NUMBER>β tnfα etc inflammatory effects directly relevant given welldescribed lung pathophysiological characteristics severe covid<NUMBER> patients melatonins mechanismofaction may also help explain epidemiologic observation children naturally high melatonin levels relatively resistant covid<NUMBER> disease manifestations older individuals decreasing melatonin levels age highrisk population <NUMBER> addition exogenous melatonin administration may particular benefit older patients given agingrelated reduction endogenous melatonin levels vulnerability older individuals lethality sarscov<NUMBER> <NUMBER> overexpression estrogen receptor played crucial role inhibiting viral replication infection <NUMBER> several selective estrogen receptor modulators serms including clomifene bazedoxifene toremifene identified promising candidate drugs covid<NUMBER> figure <NUMBER>b toremifene first generation nonsteroidal serm reported block various viral infections low micromolar concentration including ebola virus <NUMBER> <NUMBER> mrescov <NUMBER> sarscov<NUMBER> <NUMBER> sarscov<NUMBER> <NUMBER> figure <NUMBER>a toremifene prevents fusion viral endosomal membrane interacting destabilizing virus glycoprotein eventually blocking replications ebola virus <NUMBER> underlying antiviral mechanisms <NUMBER> sarscov<NUMBER> sarscov<NUMBER> toremifene remains unclear currently investigated toremifene approved treatment advanced breast cancer <NUMBER> also studied men prostate cancer <NUMBER> subjects reasonable tolerability <NUMBER> toremifene <NUMBER> bound plasma protein good bioavailability typically administered dosage <NUMBER> mg orally <NUMBER> summary toremifene offers promising candidate drug ideal pharmacokinetics properties tested covid<NUMBER> clinical trials directly hydroxychloroquine chloroquine phosphate two approved antimalarial drugs though lacking strong clinical evidence authorized us fda treatment covid<NUMBER> patients using emergency use authorizations <NUMBER> study identified hydroxychloroquine chloroquine among predicted candidates covid<NUMBER> figure <NUMBER>a two hydroxychloroquines vitro antiviral activity sarscov<NUMBER> stronger chloroquine hydroxychloroquine <NUMBER> effective concentration ec<NUMBER> <NUMBER> μm chloroquine ec<NUMBER> <NUMBER> μm <NUMBER> hydroxychloroquine chloroquine known increase ph endosomes inhibits membrane fusion required mechanism viral entry including sarscov<NUMBER> cell <NUMBER> additionally potential benefit replicates poorly multiple animals including dogs pigs chickens ducks limits preclinical animal studies <NUMBER> study present covkge powerful integrated ai methodology used quickly identify drugs repurposed potential treatment covid<NUMBER> approach minimize translational gap preclinical testing results clinical outcomes significant problem rapid development efficient treatment strategies covid<NUMBER> pandemic translational perspective broadly applied network tools developed could help develop effective treatment strategies emerging infectious diseases emerging complex diseases well study constructed comprehensive knowledge graph kg gnbr <NUMBER> drugbank <NUMBER> first gnbr included kg relations corresponding druggene interactions genegene interactions drugdisease associations genedisease associations second <NUMBER> drugbank selected drugs whose molecular mass greater <NUMBER> daltons also exist gnbrresulting <NUMBER> fdaapproved clinically investigational drugs drugs included kg relationships corresponding drugdrug interactions drugsideeffects drug atc codes drugmechanismofaction drugpharmacodynamics drugtoxicity associations third included experimentally discovered coronavirusesgene relationships recent work kg <NUMBER> fourth treated covid<NUMBER> context assembling six types table <NUMBER> models computing knowledge graph embeddings learn vectors entities relation types satisfy certain properties work learned vectors using rotate model <NUMBER> given edge knowledge graph represented triplet headentity relationtype tailentity rotate defines relation type rotation head entity tail entity complex vector space specifically <NUMBER> ℎ vectors corresponding head tail entities respectively vector corresponding relation type rotae tries minimize distance ∘ denotes hadamard elementwise product order minimize distance head tail entities σ sigmoid function γ margin hyperparameter γ <NUMBER> ℎ negative triplet ℎ probability occurrence corresponding negative sample divide triplets eg relationship among drug treatment disease training set validation set test set <NUMBER> manner selected embedding dimensionality dim<NUMBER> nodes relations rotate trained <NUMBER> epochs batch size <NUMBER> <NUMBER> learning rate choose γ <NUMBER> margin optimization function supplementary note <NUMBER> performed gene set enrichment analysis validate predicted drug candidates covkge first collected three differential <NUMBER> introduced area receiver operating characteristic roc curve auroc several evaluation metrics evaluating performance drugtarget interaction prediction area receiver operating characteristic roc curve auroc <NUMBER> global prediction performance roc curve obtained calculating true positive rate tpr false positive rate fpr via varying cutoff supplemental information found online source code data downloaded httpsgithubcomchengflabcovkge patients <NUMBER> combination therapy antiviral agents toremifene niclosamide antiinflammatoray agents melatonin indomethacin may offer promising treatment approach covid<NUMBER> warranted tested randomized controlled trials intended goal study help research community policy makers keep track highly relevant research drug development seen lens clinical trials covid<NUMBER> since pandemic began large number studies trying understand structure virus transmission mitigation measures studies helped identify key facts virus initial response containing virus efficacy measures face masks hand hygiene reduce reproduction number virus etc <NUMBER> <NUMBER> focus shifted clinical research various organisations collaborating develop cure virus reduce mortality rate many clinical trials centered repurposed drugs repurposing strategy old drugs new use emerging preferred strategy bring drug quickly market treatment disease address specific conditions emerging due rationale behind strategy ie repurposing strategy driven sound logic drug development long process covers clinical trials different phase preclinical animal testing efficacy toxicity clinical trials different phases iii includes testing drugs healthy persons safety phase patients assess efficacy phase ii large scale testing assess efficacy effectiveness safety phase iii chances failures high different stages sinks cost incurred keeping factors consideration estimated new drug reach market costs <NUMBER> million <NUMBER> million <NUMBER> recent study lancet <NUMBER> cautions clinical trial literature riddled drugs looked promising small trials prove ineffective bigger rigorous studies present pandemic calls quick interventions thus due urgent need bring drug market uncertainties involved repurposed drug becomes much safer pathway availability safety data along addressing similar conditions broad spectrum available drugs tested previously diseases hence clinical trials testing accelerated <NUMBER> clinical trials thus much shorter directed combination phases repurposed drugs clinical trials concentrate phase ii onwards thus repurposed drugs much faster bring market thus surprising see common strategy adopted research institutionsuniversities firms covid<NUMBER> many repurposed drugs part clinical trials distinguished promising results earlier coronavirus diseases sarscov<NUMBER> mers drugs effective antivirals solidarity trials undertaken also repositioning drug strategy conducted four drugs remdesivir lopinavirritonavir lopinavirritonavir interferon beta<NUMBER>a clinical trials drugs undertaken multiple countries given consent approach treatments claims thisglobal coordinated clinical trials reduce time taken randomised clinical trials <NUMBER> many drugs effective earlier terms success condition developed also revisited disease another type repurposing good example gilead sciences drug remdesivir found inhibit activity rnadependent rna polymerase rdrp <NUMBER> sarscov<NUMBER> <NUMBER> drug according scavone et al <NUMBER> initially developed treatment ebola marburg infections demonstrate clinical efficacy used covid<NUMBER> treatment national institute allergy infectious diseases niaid also conducting clinical trials remdesivir multicentre randomised placebo controlled phase <NUMBER> trial methods like convalescent plasma therapy antibodies treatment also showing promising results convalescent plasma seen prominent intervention clinical trials passive antibody therapy blood recovered patients taken transfused covid<NUMBER> patient treatment advised previously treatment ebola mers diseases <NUMBER> studies support line treatment covid<NUMBER> include study published lancet <NUMBER> states viral load patients convalescent plasma treatment significantly lower days <NUMBER> <NUMBER> <NUMBER> intensive care unit admission study also pointed reduction risk mortality suppression viramia presence virus bloodstream convalescent plasma trials advanced stages clinical trials owing quick approvals treatment severe adverse effects seen associated treatment elliy lilly developed antibody lycov<NUMBER> targets sarscov<NUMBER> spike protein using plasma recovered patients treat others developed disease another active line treatment according gul et al <NUMBER> convalescent blood products promising potential treatment use covid<NUMBER> another line research developing quick effective vaccine various vaccine models used like weakened inactivated virus model dna rna vaccines viral vector vaccines vaccines based protein subunits spike proteins etc virus like particles empty virus shells without genetic material interesting insight vaccine development landscape seen whos draft landscape covid<NUMBER> candidate vaccines <NUMBER> total <NUMBER> vaccines candidates development around world ten clinical evaluation <NUMBER> preclinical evaluation paper focusses global research drug development successful vaccine effective prevention disease prevent type pandemic seeing paper thus limitation capture ongoing clinical trials vaccine development disease study attempts capture influential research insights ongoing clinical trials surrounding covid<NUMBER> attempts address following research questions • capture key research papers characterisation • draw insights ongoing clinical trials based envisaged draw policy implications research innovation surrounding pandemic data study drawn dimensions database wwwdimensionsai integrated linked database provides data funding agencies grant research publications patents clinical trials key policy documents database captures clinical trials database number international clinical trials registry contains <NUMBER> clinical trials data covid<NUMBER> research papers clinical trials extracted dimensions database using search string covid<NUMBER> sarscov<NUMBER> sarscov<NUMBER> <NUMBER>ncov <NUMBER> june <NUMBER> database full text global research papers clinical trials trends also collected <NUMBER> may <NUMBER> <NUMBER> june <NUMBER> using search string altmetrics article level metrics chosen popularity qualifier field research classification available dimensions database chosen research paper classifier diverse nature classification system unlike systems available dimensions like rcdc completely biomedical provided basis selection <NUMBER> frequently occurring categories covid<NUMBER> papers identified theabove<NUMBER> classifications available papers categories mapped show insights dispersion papers across key research themes paper could placed one category thus summing counting papers across categories would considerably total papers altmetrics score top <NUMBER> popular papers identified data twitter news facebook blog mentions collected altmetricscom audience country paper popular based type tweeter public scientists practitioners total <NUMBER> clinical trials extracted <NUMBER> june <NUMBER> cooccurrence map <NUMBER> interventions occurring atleast <NUMBER> times clinical trials constructed using text analytics software vosviewer pajek cooccurrence calculates number times two words conceptstopics occur together paper used cooccurrence map analyse relationship various rcdc categories interventions intensive research activity clinical trials observed surrounding covid<NUMBER> <NUMBER> research papers <NUMBER> published articles <NUMBER> preprints <NUMBER> clinical trials covering various aspects disease <NUMBER> june <NUMBER> figure <NUMBER> highlights research papers published clinical trials period <NUMBER> may <NUMBER> june <NUMBER> high quality scientific research essential prerequisite drugvaccine development knowing various characteristic sarscov<NUMBER> virus disease covid<NUMBER> caused genome structure phylogenetic analysis virus methods ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted june <NUMBER> <NUMBER> transmission various effects human body treatment efficacy toxicology etc surrounds drugvaccine development intense science driven process behind drugvaccine development primary reason behind intensity large volume research fast tracking covid<NUMBER> research various journals quick availability preprint servers also played major role increase found many <NUMBER> classification category covered research papers medical health sciences clinical sciences economics shows wide impact disease sense motivates research activity across many diverse domains disciplinessubdisciplines research papers indication dispersion research activity figure <NUMBER> highlights main domains wherein research papers visible figure underscores wide diversity terms research topics covered papers fall one topic total count much higher overall papers distribution topic wise shows along research various medical aspects disease also intense research economic social aspects examination ten popular papers table <NUMBER> content analysis provide deeper insight disease ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> <NUMBER> japan <NUMBER> ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> <NUMBER> practitioners <NUMBER> usa <NUMBER> india <NUMBER> france <NUMBER> huang c wang li x ren l zhao j hu et al ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint content analysis papers underscores sense influential aspect paper distinguished large repository papers surrounding disease also interesting note <NUMBER> popular papers many <NUMBER> papers remained top ten papers period time papers indicated start mark table demonstrates impact anderson et al <NUMBER> study popular social media platforms number tweets three times next popular paper showed sarscov<NUMBER> seventh coronavirus infect humans basis comparative analysis genomic features sarscov<NUMBER> alpha beta coronaviruses authors claimed virus optimized binding human receptor ace<NUMBER> spike proteins virus polybasic furin cleavage site s<NUMBER>s<NUMBER> boundary may important determine impact transmissibility pathogenesis animal models claimed sarscov<NUMBER> product purposeful manipulation likely result natural selection human humanlike ace<NUMBER> receptor different aspects covered disease seen highly important thus contributed online impact van doremelen et al <NUMBER> analysed aerosol surface stability sarscov<NUMBER> compared sarscov<NUMBER> closely related human coronavirus study highlighted need protect five environmental conditions aerosols plastic stainless steel copper cardboard showed sarscov<NUMBER> remains viable aerosols <NUMBER> hours plastic stainless steel <NUMBER> days <NUMBER> hours copper cardboard <NUMBER> hours study found stability sarscov<NUMBER> similar plastic stainless steel aerosols sarscov<NUMBER> different sarscov<NUMBER> cardboard <NUMBER> hours copper <NUMBER> hours also indicated though stability viruses similar show exponential decay virus titer difference epidemiologic characteristics viruses may arise due high viral loads upper respiratory tract potential infected persons shed transmit virus asymptomatic implications study clearly seen preventive measures covid<NUMBER> study also cited policy documents leung et al <NUMBER> explored importance respiratory droplet aerosol route transmission quantifying amount respiratory virus namely coronavirus influenza virus rhinoivirus exhaled breath participants acute respiratory virus illness ari <NUMBER> participants divided two groups one wearing surgical face mask wearing face mask study found surgical face masks efficaciously reduce respiratory droplet emission influenza virus particles aerosols also found surgical face masks used ill patients covid<NUMBER> reduce onward transmission face mask getting increasing attention incorporated essential guideline health policies different countries paper provided good empirical support ie face masks ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> travel restrictions study also estimated undocumented cases contagiousness transmission rate <NUMBER> documented infections yet <NUMBER> documented infection cases due undocumented infections suggestion study undocumented infections isolation identification necessary fully control virus important spread virus may seen consequence study also cited policy documents caly et al <NUMBER> reported ivermectin fda approved broad spectrum parasitic agent previously shown antiviral activity broad range viruses vitro inhibits sarscov<NUMBER> study found single dose ivermectin added verohslam cells <NUMBER>hours post infection sarscov<NUMBER> isolate australiavi<NUMBER> <NUMBER> able reduce viral rna approximately <NUMBER>fold within <NUMBER> hours also hypothesized mode action inhibiting impαβ<NUMBER>mediated nuclear import viral proteins doctors struggling control dangerous disease study like gives hope quickly tracked indicated high altmetrics score shen et al <NUMBER> study examined convalescent plasma containing neutralizing antibody transfusion benefit treatment critically ill covid<NUMBER> patients clinical trial conducted <NUMBER> critically ill patients covid<NUMBER> acute respiratory distress syndrome ards along certain conditions study found decline viral load clinical conditions patients improved indicated body temperature reduction improved pao <NUMBER> fio <NUMBER> chest imaging though sample size limited requires clinical trials potential effectiveness treatment incorporated many countries bendavid et al reported new dimension address epidemic models projections public policies covid<NUMBER> basis measurement seroprevalence antibodies sarscov<NUMBER> santa clara county using lateral flow immunoassay world health organization protocol covid<NUMBER> antibody testing serological testing conducted sarscov<NUMBER> antibodies sample <NUMBER> people selected basis three data elements zip code residence sex ethnicityrace basis seroprevalence data antibodies sarscov<NUMBER> <NUMBER> <NUMBER> among population estimated number infections much higher order <NUMBER> fold santa clara indicated number confirmed cases fatality rate <NUMBER> much lower reported average increase <NUMBER> daily april <NUMBER> <NUMBER> wellmeasured data population prevalence estimates provided important understanding calibrate epidemic stage calculate fatality rates frame public policy decisions paper attracting attention several research groups worldwide testing population samples sarscov<NUMBER> antibodies citing paper frequently kampf et al provided comprehensive review persistence human veterinary coronaviruses different type inanimate surfaces well inactivation strategies biocidal agents used surface disinfectants data showed human coronaviruses severe acute respiratory syndrome sarscov middle east respiratory syndrome merscov endemic human coronavirus strain hcov<NUMBER>e remain infectious inanimate surfaces like steel aluminium metal wood paper glass plastic ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> pvc silicon rubber latex disposable gown ceramic teflon <NUMBER> hours <NUMBER> days also captured effect temperature humidity concentration inocculum viral titter persistence coronavirus inactivation coronaviruses variety commonly used biocidal agents namely ethanol <NUMBER> <NUMBER>propanol <NUMBER> combination <NUMBER>and <NUMBER>propanols <NUMBER> <NUMBER> glutardialdehyde <NUMBER> benzalkonium chloride <NUMBER> chlorohexidine digluconate <NUMBER> sodium hypochlorite <NUMBER> hydrogen peroxide <NUMBER> formaldehyde <NUMBER> povidone iodine <NUMBER> also compiled study indicated efficient disinfectants inactivate viruses surfaces within <NUMBER> minute <NUMBER> ethanol <NUMBER> hydrogen peroxide <NUMBER> sodium hypochlorite also expected disinfect sars cov<NUMBER> similarly antiviral treatment sarscov<NUMBER> proven effective till date contamination prevention spread key strategy stop ongoing outbreak review article gained popularity provided inputs best disinfectants used ensure disinfection frequently touched surfaces hand hygiene healthcare set ups public usages large combat spread pandemic important features highlighted article illness infected patients men <NUMBER> less half comorbidities like diabetes hypertension cardiovascular disease <NUMBER> patients direct exposure huanan seafood market patients suffered fever dry cough dyspnoea fatigue bilateral groundglass opacities chest ct scans haemoptysis diarrhoea pathophysiological studies patients infected <NUMBER>ncov indicated amount proinflammatory cytokines il<NUMBER>b ifn ip<NUMBER> mcp<NUMBER> tnfα responsible pulmonary inflammation extensive lung damage increased serum patients higher concentrations gcsf ip<NUMBER> mcp<NUMBER> mip<NUMBER>a tnfα required icu admission suggesting cytokine storm associated disease severity article gained significance one earliest reports provide evidence based information common complications associated infection covid <NUMBER> line treatment adopted doctors wuhan kissleret al projected sarscov<NUMBER> transmission model pandemic period using time series data usa betacoronaviruses namely oc<NUMBER> hku<NUMBER>the assessments based role seasonal variation duration immunity cross immunity transmissibility two viruses model simulations predicted patterns outbreaks substantial outbreaks autumnwinter winterspring annual outbreaks sarscov<NUMBER> establishes shortterm immunity order <NUMBER> weeks biennial long term immunity two years seasonal variation sarscov<NUMBER> differ geographical locations influenza decline elimination incidences betacoronaviruses sarscov<NUMBER> induces <NUMBER> cross immunity hcov<NUMBER> hcovhku<NUMBER> elimination transmission upto three years low level cross immunity <NUMBER> induced initial severe pandemic wave complimentary interventions expanding critical care demand effective therapeutics along success social distancing would hasten acquisition herd immunity study emphasized urgency longitudinal serological studies undertaken determine extent duration immunity sarscov<NUMBER> epidemiological surveillance maintained coming years anticipate possibility resurgence study important gives valuable inputs prediction outbreaks world better prepared terms healthcare therapeutics economic front deal effectively content analysis highlights paper covers various aspects disease understanding structure virus effect disease complications conditions way spreads interventions effective contain spread drugstreatments show initial promise research papers influenced drug development process provided initial evidencepathway also influenced government intervention measures prevent spread contain disease evidence also comes various altmetric measures june <NUMBER> <NUMBER> <NUMBER>clinical trials covid<NUMBER> however details available period <NUMBER>intervention based clinical trials <NUMBER> observational clinical trials <NUMBER> retrospective studies <NUMBER> new treatment measure clinical study figure <NUMBER> shows key <NUMBER> interventions occurring least <NUMBER> clinical trials ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> values brackets show frequency interventions thickness linkages shows strength two interventions linked together deeper analysis based linkages shown map draws attention key insights ongoing clinical research one observe hydroxychloroquine azithromycin remdesivir tozilizumab prominently visible map drugs repurposed drugs clinical trials undertaken find efficacy treatment covid<NUMBER> drugs remedesvir lopinavirritonavir chloroquine hydroxychoroquine currently previously included solidarity trials seen cooccurrence map strong linkage drug trials placebo underscores trails open labels wherein participants know treatment getting variation placebo types may indicate different drug delivery route placebo cant different topic keyword present map cooccurrence highlight different aspects clinical trials umbilical cord mesenchymal stem cells uc msc example also used reduce mortality morbidity among severe covid<NUMBER> patients <NUMBER> keeping view plausible adverse impact repurpose drugs administered along following standard care standard care protocol explains occurrence standard care map map thus speaks large audience looking closely map find repurposed drugs well new trials primarily belong category antiviral drug antiviral drugs also first repurposed drugs sarscov<NUMBER> infection antivirals targets virus life cycle stages like host cell binding uncoating synthesis translation viral mrna release newly synthesised virus etc <NUMBER> due activities antivirals used prophylaxis virus suppression preventing severe outcomes patients etc hydroxychloroquine antimalarial drug shown antiviral activity sarscov<NUMBER> one trace key studies may motivated clinical trial strong linkage seen hydroxychloroquine azithromycin result ongoing clinical trial using drug combination traced study gautret et al <NUMBER> combination two drugs significantly efficient virus elimination similarly research studies also led drug dropped provide caution ongoing trail seen case hydroxychloroquine linkages seen map ivermectinchloroquine ivermectinhydroxychloroquine point clinical trials drugs done together synergistic manner senanayake <NUMBER> offered perspective antiviral combinations double hit effect may offer best chance success clinical translatability ivermectin antiparasitic drug shown caly et al <NUMBER> reduce viral replication hand hydroxychloroquine according patri fabbrocini <NUMBER> could interfere glycosylation angiotensinconverting enzyme <NUMBER> reduce binding efficiency sarscov<NUMBER> spike protein ace<NUMBER> host cells hence combination could act consequential synergistic manner <NUMBER> closer look linkages observed lopinavirritonavir remdesivir hydroxychloroquineremdesivir require deeper analysis types combinations happening clinical trials using various arms single trial words trials using single various drug combinations clinical trial solidarity trails also using strategy national institute health nih recommended remdesivir spo<NUMBER> ≤ <NUMBER> ambient air sea level patients mechanical ventilation drug however according nih insufficient data backing recommend mild moderate patients many trials example asan medical center trial id nct<NUMBER> three arms lopinavirritonavir experimental arm hydroxychloroquine active comparator arm control arm intervention phase <NUMBER> trial divides arm <NUMBER> ratio tries compare effectiveness drugs reduce viral load several trials also using arms <NUMBER> drugs studies therefore linkages pattern drugs seen found sarscov<NUMBER> interferes blood pressure maintaining hormone angiotensin ii leading high blood pressure lung damage <NUMBER> losartan blood pressure medication part dark blue cluster tested block hormone thereby preventing lung damage observed patients inflammation triggering protein interleukin<NUMBER> il<NUMBER> cytokine overexpressed resulting cytokine storms lead hyperinflammation thus causing damage lung organs life threatening therefore tocilizumab block cellular receptors interleukin<NUMBER> il<NUMBER> <NUMBER> used clinical trials prevent cytokine storms patients thus maps bring salient characteristics ongoing clinical trials provides important signals intensive research activity clinical trials observed surrounding covid<NUMBER> present paper attempts capture salient aspects ongoing research clinical trials drawing huge volume ongoing research papers clinical trials using sophisticated analytical tools research trend influential papers map ongoing clinical trials dominate overall landscape clinical trials identified informed assessment made undertaking content analysis influential papers exploring rationale behind linkages observed implications trends global research clinical trials shows speed extensive research clinical trials undertaken understand various aspects disease finding effective treatment disease ten influential papers identified based altmetric score show actively covered news policy documents another common characteristic papers published highly reputed journal plausibly also factor attracting high online influence indicators highlight dissemination papers diverse community public practitioners scientists type fast diverse dissemination research papers underscores importance research academics practitioners society content analysis ten influential papers draw attention importance papers identifying virus characteristic drug treatmenttreatment protocols disease contamination epidemic model etc examining cited policy documents clinical studies shows wide reaching impact ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review httpshealthucsdedunewsreleasespages<NUMBER>arthritisdrugpresentspromiseastreatmentforcovid<NUMBER>pneumoniaaspx ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint coronavirus disease <NUMBER> covid<NUMBER> pandemic infection caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> global spread rapid unprecedented time writing <NUMBER> confirmed cases reported <NUMBER> deaths across <NUMBER> countries <NUMBER> currently treatment options covid<NUMBER> limited however several drugs developed indications shown promising results sarscov<NUMBER> vitro animal models compassionate use trials <NUMBER> <NUMBER> many drugs experimentally repurposed covid<NUMBER> undergoing clinical trials humans <NUMBER> candidates include nitazoxanide remdesivir favipiravir lopinavir darunavir hydroxychloroquine chloroquine ivermectin amongst others <NUMBER> investigations efficacy experimental treatments covid<NUMBER> ongoing meanwhile response positive media coverage speculative rather evidencebased governments stockpiling vast supplies treatments anticipation licensing covid<NUMBER> furthermore national regulatory institutions meant safeguard unsafe use drugs increasing pressure relax approval standards accelerate marketentry covid<NUMBER> treatments example april <NUMBER> th <NUMBER> us food drug administration fda approved antimalarial drug hydroxychloroquine emergency treatment covid<NUMBER> unknown optimal dosage duration treatment <NUMBER> however efficacy hydroxychloroquine still question <NUMBER> furthermore cardiotoxic higher doses may indicated covid<NUMBER> causing qt prolongation leading ventricular tachycardia death <NUMBER> care must taken lose rigorous safety standards usually stipulated pharmaceuticals even pandemic avoid unnecessary morbidity mortality worldwide given pandemic status covid<NUMBER> important ever safety information drugs potentially repurposed publicly available pharmacokinetics many drugs differ phenotype examples include ace inhibitors cautioned people african descent dolutegravir causes greater weight gain women men <NUMBER> <NUMBER> pharmaceutical companies often run trials high income countries treatment cohorts often largely white <NUMBER> furthermore regulatory authorities often conservative including pregnant women trials discouraging female recruitment <NUMBER> experimental treatments covid<NUMBER> may distributed millions people worldwide maximising phenotypic variety well total number personyearsoffollowup available public realm vital ensuring rare adverse events contraindications anticipated many drugs used widely years substantive information safety tolerability pharmacokinetics available public domain including public trial registries yet whilst international committee medical journal editors icmje policy requires prospective registration interventional studies primary registry clinicaltrialsgov icmje currently require researchers report summary results registries <NUMBER> however according fda amendment act <NUMBER> responsible party applicable clinical trials registered clinicaltrialsgov must report results public register within twelve months primary completion ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted june <NUMBER> <NUMBER> date cases risk fine <NUMBER> every day results delayed <NUMBER> <NUMBER> failure share clinical trial results publicly additionally farreaching consequences health public expenditure illustrated widespread stockpiling prescription oseltamivir tamiflu swine flu outbreak <NUMBER> despite lack evidence safety efficacy <NUMBER> clinical trial transparency therefore vital order maximise unify sharing safety information data efficacy pandemic beyond public clinical trial registries important tool transparent collaborative research registries safety efficacy data uploaded freely shortly completion study protocol data collection methods still quality assessed <NUMBER> <NUMBER> contrast academic publication may stall significant periods time costly selective timeintensive writing review processes furthermore clinical trial registry data available free charge pooled without concern silent outcome switching publication bias <NUMBER> <NUMBER> <NUMBER> especially important covid<NUMBER> pandemic interest potential treatments coronavirus generates even greater incentive normal publication studies positive results without rapid sharing datasets drugs may repurposed covid<NUMBER> secondary analyses safety data arduous often incomplete <NUMBER> <NUMBER> may slow biomedical innovation process could lead preventable side effects occurring vulnerable patients safety information remains missing pharmaceutical pipeline accelerated address covid<NUMBER> pandemic enhancing clinical trial transparency important ever study aimed determine scale unpublished clinical trial results may hinder safety reviews repurposed drugs covid<NUMBER> reviewed number completed terminated trials reported results extensive list medications repurposed covid<NUMBER> looking previous indications drugs specifically searched trial results made available public results published either clinicaltrialgov registry academic literature <NUMBER> drugs assessed pirfenidone hydroxychloroquine azithromycin favipiravir oseltamivir sarilumab tocilizumab remdesivir leflunomide interferonalpha lopinavirritonavir darunavirritonavir baloxivir marboxil umifenovir interferonbeta sofosbuvir nitazoxanide apn<NUMBER> ivermectin table <NUMBER> drugs selected based information found potential covid<NUMBER> treatment reviews <NUMBER> <NUMBER> <NUMBER> synonyms chemical names drugs taken pubchemncbinlmnihgov appendix <NUMBER> <NUMBER> us clinical trials registry clinicaltrialsgov searched trials listed drugs intervention results search downloaded <NUMBER> th april <NUMBER> <NUMBER> numbers trials without results registry recorded trials without results trial status determined completed ongoing suspended terminated withdrawn trials listing primary completion date future counted ongoing primary completion date available study completion date used listed trial status used identify ongoing terminated suspended withdrawn trials trials without results clinicaltrialsgov threestep process followed <NUMBER> th <NUMBER> th april <NUMBER> determine whether results reported elsewhere academic publication figure <NUMBER> included based criteria multiple publications listed earliest dated publication selected <NUMBER> results available registry clinical trial identifier nct number used search screen academic publications pubmed <NUMBER> pubmed search retrieve academic publication additional search conducted google scholar using following search terms succession clinical trial identifier listed title intervention name primary investigators name search first twenty results screened ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> publication include clinical trial identifier crossreferenced primary investigator study design intervention outcomes listed clinicaltrialsgov assess relevance excluded publications fewer <NUMBER> words well conference abstracts posters presentations nonenglish texts ry e ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> publications results recorded pmid doi publication date trials results clinicaltrialsgov combined journal publication gave total number trials results results found public domain allowed approximation registered trials without results additionally overdue trials calculated completed trial result registry primary completion date <NUMBER> th april <NUMBER> <NUMBER> days prior final analysis <NUMBER> year <NUMBER>day grace period standard outlined fdaaa <NUMBER> used reference throughout study despite included trials covered law <NUMBER> also consistent international ethical standards timely results dissemination <NUMBER> second review conducted different researcher <NUMBER> trials drug check concordance reviewers protocol second review remained unchanged researchers blinded results first review random number generator used select trials second review concordance calculated simple percent agreement results judgement <NUMBER> deemed acceptable consulting experts line recommendations literature <NUMBER> results published dates first second review <NUMBER> th april <NUMBER> th may <NUMBER> counted concordance patients public involved way research ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> nineteen drugs screened encompassing total <NUMBER> clinical trials registered clinicaltrialsgov table <NUMBER> excluded <NUMBER> <NUMBER> ongoing primary completion date passed <NUMBER> trial status suspended withdrawn figure <NUMBER> shows number trials found clinicaltrialsgov excluded analysis final results status included trials n<NUMBER> recorded percentages text relation <NUMBER> completed trials seen table <NUMBER> authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> blinded second review <NUMBER> <NUMBER> trials results status found <NUMBER> time meeting <NUMBER> threshold acceptable concordance searches ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint discussion <NUMBER> completed clinical trials drugs may repurposed covid<NUMBER> found report results either clinicaltrialsgov academic publication table <NUMBER> shows large gap evidence base drugs limiting attempts comprehensively review safety potential global distribution covid<NUMBER> pandemic <NUMBER> <NUMBER> completed studies available results comprised <NUMBER> <NUMBER> results registry <NUMBER> <NUMBER> without results registry results standardised search literature table <NUMBER> furthermore <NUMBER> <NUMBER> studies without registry results outside <NUMBER> day timeframe results publication mandated fdaaa <NUMBER> <NUMBER> although <NUMBER> results published academic literature <NUMBER> trials include study applicable fdaaa <NUMBER> remains benchmark good scientific practice <NUMBER> <NUMBER> clinical trial results unavailable potential covid<NUMBER> treatments data clinical decision making regarding safety therapeutics limited drug incomplete evidence base used pandemic even compassionate use programmes risk avoidable harm done missing adverse safety data knowledge gap revealed drugs extensive media coverage hydroxychloroquine <NUMBER> without results favipiravir <NUMBER> lopinavir <NUMBER> <NUMBER> <NUMBER> <NUMBER> drugs currently used covid<NUMBER> patients trials across globe sometimes novel regimens doses <NUMBER> <NUMBER> <NUMBER> clinicians treatment options available greater transparency proactiveness clinical trial sponsors regarding posting trial results would less risk unforeseen adverse outcomes especially treatment mildmoderate covid<NUMBER> pioneer trial <NUMBER> public health decisionmakers guideline developers clinicians patients rely clinical trials systematic reviews metaanalyses inform treatment evidence gaps publication bias therefore influence clinical practice drug usage worldwide particularly treatment landscape changeable covid<NUMBER> pandemic clinical decisions based incomplete evidence result avoidable morbidity mortality unsafe drugs ineffective treatments given large scale sponsors researchers alike also carry ethical responsibility towards clinical trial participants consent participate research order contribute scientific understanding improved clinical practice make results publicly available <NUMBER> clinical trial results made available publicly fulfil expectation betraying trust participants may given time health benefit science missing evidence also impacts direction future research informed existing available body literature study reveals important knowledge gap regarding pharmaceuticals potentially repurposed covid<NUMBER> however proportion studies results available academic literature approximation several limitations study trial population limited registered clinicaltrialsgov clinicaltrialsgov largest registry world <NUMBER> registrations writing additional trials therapies may registered elsewhere however unclear would expected report different rate registered clinicaltrialsgov strategy locating publications included listed ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> scholar open resources cover majority published clinical research including proprietary databases like scopus ovid may located additional publications believe would substantially impacted overall results <NUMBER> additionally trials registered published nonenglish language journals without inclusion nct number would captured methodology searcher heterogeneity difficulty identifying results publication academic literature limits accuracy manual publication search however search strategy standardised produced high level agreement assessors check <NUMBER> random sample <NUMBER> however discordance present reviewers illuminates inherent difficulties finding results drugs question especially trial id number included line consort standards <NUMBER> findings add existing evidence dearth clinical trial reporting public registries analysis investigated clinical trials drugs currently considered use covid<NUMBER> however given diversity drug classes included report findings likely representative many pharmaceuticals presents major problem researchers attempting summarise safety efficacy pooling trial data <NUMBER> since academic publications often summarise key findings secondary research efforts impinged clinicaltrialsgov provides forum share complete safety efficacy data reports well facilitating consistent data reporting timely manner <NUMBER> <NUMBER> prior research shown results reported clincialtrialsgov often complete especially safety data compared matched journal publications <NUMBER> <NUMBER> <NUMBER> however depends researchers registering trials uploading results timely manner within twelve months primary completion date international committee medical journal editors icmje editorial offices medical journals could play important role improving lack timely results posting clinical trial registries demanding submission link summary results public registries academic publication although may mean publication bias positive publishable results may trickle reporting public registries well furthermore public funders institutional publication funds could demand trial sponsors post results allocating funding academic publication funding bodies could also deny individual sponsors funding past violated clinical trial reporting rules <NUMBER> least journals conform consort statement ensuring registry ids clearly indicated abstract fulltext metadata published clinical trials order promote easier discoverability record linkage registries publications <NUMBER> finally clinical trial sponsors universities hospitals public research institutions pharmaceutical companies work towards improving institutional clinical trial reporting performance making use available resources provide detailed stepbystep instructions go task <NUMBER> especially covid<NUMBER> pandemic great importance trials sponsors release summary results registries retrospectively inform decision making around existing treatments repurposed covid<NUMBER> overall findings reveal significant evidence gap safety drugs repurposed covid<NUMBER> uncertainty could cause large burden extra morbidity global pandemic ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> recommend caution experimental drug use nonsevere disease urge trial sponsors report missing results retrospectively medicine covid<NUMBER> pandemic cannot evidencebased large proportion evidence missing fr tp conceptualised study devised methodology coordinated research team sk recruited research team authors involved data collection analysis contributed final manuscript data publicly available us national library medicine httpsclinicaltrialsgovct<NUMBER>home submitting author right grant grant behalf authors work defined author licence exclusive licence andor nonexclusive licence contributions authors uk crown employees ii bmj agreed ccby licence shall apply andor iii accordance terms applicable us federal government officers employees acting part official duties worldwide perpetual irrevocable royaltyfree basis bmj publishing group ltd bmj licensees relevant journal coowned bmj coowners journal publish work bmj open bmj products exploit rights set licence submitting author accepts understands supply made terms made bmj submitting author unless acting employee behalf employer postgraduate student affiliated institution paying applicable article publishing charge apc open access articles submitting author wishes make work available open access basis intends pay relevant apc terms reuse open access shall governed creative commons licence details licences creative commons licence apply work set licence referred ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint ccby <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint <NUMBER> million confirmed covid<NUMBER> cases worldwide resulted <NUMBER> deaths <NUMBER> may <NUMBER> <NUMBER> around <NUMBER> cases result mild forms disease study admissions <NUMBER> uk hospitals showed around <NUMBER> patients requiring hospitalization <NUMBER> requiring high dependency intensive care died disease <NUMBER> significant correlation age sex underlying comorbidities elderly males highest mortality risk success repurposing existing antiviral therapies investigational agent remdesivir covid<NUMBER> patients <NUMBER> antiviral agents tend effective applied early disease course would highly desirable understand differential host response patients terms underlying genetic epidemiological clinical factors able predict individuals risk developing severe covid<NUMBER> identify potential therapies later stages disease driven hosts immune response rather coronavirus <NUMBER> severe disease reported <NUMBER> hospitalized cases often requires forced oxygen therapy andor sedation ventilation patients viral sepsis observed many patients thought crucial disease mechanism covid<NUMBER> <NUMBER> admission characteristics associated increased odds hospital mortality among sarscov<NUMBER> confirmed cases covid<NUMBER> include severe hypoxia low platelet count elevated bilirubin hypoalbuminemia reduced glomerular filtration rate <NUMBER> <NUMBER> symptoms also highly correlated severe sepsis cases two diseases also share similar comorbidity risks including dementia type <NUMBER> diabetes mellitus coronary heart disease hypertension chronic renal failure <NUMBER> sepsis observed <NUMBER> hospitalized covid<NUMBER> patients <NUMBER> sepsis lifethreatening condition mortality rate <NUMBER> result patients dysregulated systemic inflammatory response pathogen <NUMBER> one leading causes mortality hospitals us representing major socioeconomic burden <NUMBER> sepsis intersection inflammatory hemostatic pathways simultaneous activation inflammatory coagulation cascades spectrum interaction vary mild thrombocytopenia fulminant disseminated intravascular coagulation dic <NUMBER> perhaps due heterogeneous nature disease gwas found significant genetic loci relating sepsis risk <NUMBER> genes majority relate endothelial cell immune response pathways still little known genetic risk factors underlying susceptibility developing sepsis sepsis represents significant area unmet medical need studies cited provide evidence many patients developed severe response sarscov<NUMBER> also presented sepsis identified significant number riskassociated genes sepsis population aim investigate risk variants also present patients hospitalized severe covid<NUMBER> would provide insights shared risk factors potential novel therapeutic options diseases analyzed dataset using sepsis patients found uk biobank <NUMBER> containing sepsis patients n<NUMBER> <NUMBER> males <NUMBER> females age comorbidity matched controls n<NUMBER> <NUMBER> males <NUMBER> females due limited data availability possible fully sex match controls available genotype data cohorts included <NUMBER> snps quality control cases identified using icd<NUMBER> codes relating hospital admission sepsis following infection number different pathogenic sources case criteria included series seven septicemia related icd<NUMBER> codes see appendix full details construction appropriate control set challenging infectious disease lack disease may result lack exposure much genetic protective effect predisposition resistance overcome included patients exposed common sepsiscausing pathogens staphylococcus streptococcus species gone develop sepsis control group criteria also included least one icd<NUMBER> codes common chronic comorbidities known increase patients risk developing sepsis including patients diabetes hypertension chronic renal andor liver disease ranked controls met criteria age selecting oldest first age also another critical phenotypic risk factor sepsis controls therefore selected maximum risk exposure age matched one limitation uk biobank dataset ethnicity distribution participants heavily skewed white british participants consequently possible fully investigate additional risk factors bame patients case control population comorbidity profile shown figure <NUMBER> used precisionlife combinatorial multiomics platform identify sepsis associated snps genes sepsis casecontrol dataset precisionlife multiomics genomic proteomic transcriptomic phenotypic association platform enables hypothesisfree detection high order disease associated combinations features eg snp genotypes genome wide study scale <NUMBER> finds statistically validates combinations features typically three ten features combination known signatures together strongly associated specific disease diagnosis clinical phenotype eg fast disease progression therapy response combine genomic transcriptomic epidemiological data analyses used analyze genomic data patients precisionlife identify highorder epistatic interactions comprising multiple consistently coassociated snp genotypes analytical mining platform validated multiple disease populations <NUMBER> <NUMBER> analysis annotation sepsis associated combinatorial genomic signatures dataset using precisionlife platform took less day working hypothesisfree running dual cpu <NUMBER> gpu compute server sepsis disease signatures identified analysis annotated diseaseassociated snps mapped human reference genome <NUMBER> order identify diseaseassociated clinically relevant target genes semantic knowledge graph derived multiple public private data sources used annotate snps targets providing sufficient contextual information test targets <NUMBER>rs criteria early drug discovery <NUMBER> forming strong testable hypotheses mechanism action impact sepsis disease phenotype also applied series heuristics resulting sepsis riskassociated genes order identify novel sepsis targets high potential either drug development drug repurposing criteria include strong association target disease pathophysiological mechanisms relevant tissue expression tractability novel disease targets amongst several others additional criteria used prioritizing repurposing targets included known drugs patent scope favorable pharmacokinetic toxicology profiles repurposing targets authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> sought correlate findings covid<NUMBER> uk biobank currently genotype data <NUMBER> patients tested positive covid<NUMBER> hospital <NUMBER> patients tested positive hospitalized although yet additional clinical data available patients given way uk patients admitted treated believe hospitalization disease could used surrogate indicator relatively severe form disease compared significant disease associated combinatorial signatures found sepsis cohort covid<NUMBER> patients order investigate also present covid<NUMBER> population conducting standard plink <NUMBER> gwas analysis uk biobank sepsis dataset generated revealed significant snps figure <NUMBER> unexpected result replicates findings existing sepsis gwas studies yielded results previously <NUMBER> <NUMBER> also consistent initial findings reported covid<NUMBER> host genetics initiative <NUMBER> based data <NUMBER> covid<NUMBER> cases contrast single snp association basis plink precisionlife platform constructs highorder networks coassociated snps signatures associated combination disease phenotype component snps signatures fall gwas pvalue threshold evaluated individually across whole population however combination signatures proven highly significant using multiple discriminative statistical techniques running sepsis dataset using precisionlife platform identified <NUMBER> combinations snp genotypes disease signatures representing different combinations snp genotypes within sepsis patient population table <NUMBER> signatures consisted mainly <NUMBER> <NUMBER> snp genotypes combination constituent snps would discovered using standard gwas analyses snp genotypes combinations scored using random forest rf algorithm based <NUMBER>fold crossvalidation method evaluate accuracy snp genotype combinations predict observed case control split majority critical snps assigned high rf score algorithm thus confirming strong association disease figure <NUMBER>a chromosomal distribution critical snps shown aggregate figure <NUMBER>b detail figure <NUMBER>c ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> mapping highestscoring snps genes revealed <NUMBER> genes strongly associated risk developing sepsis genes several already shown implicated sepsis pathogenesis scientific literature providing validation hypothesisfree combinatorial approach analyzing complex disease populations contrast recent metaanalysis reviewing previous studies investigating genetic variants sepsis risk found <NUMBER> genes significantly associated disease susceptibility <NUMBER> ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> disease architecture sepsis cohort generated precisionlife platform circle represents disease associated snp genotype edges represent coassociation patients colors represent distinct patient subpopulations communities functional enrichment analysis highestscoring genes indicated significant number involved processes stress response leukocyte immune system activation cell adhesion autophagy figure <NUMBER> <NUMBER> sepsis risk genes identified <NUMBER> targeted active chemical compounds seven genes targeted licensed drugs could therefore represent potential drug repurposing opportunities specific genes pathways described appendix outlined discussion section shown figure <NUMBER>b significant cluster snps genes associated x chromosome may coincidence key genes covid<NUMBER> infection eg ace<NUMBER> angiotensin ii located chromosome two copies x chromosome women might offered level protection effects disease small possibility may also related lack complete sex matching controls observation subject study authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> focused current analysis autosomal snps searched sepsis associated combinatorial signatures <NUMBER> patients hospitalized tested positive covid<NUMBER> <NUMBER> <NUMBER> patients least one significant nstates found sepsis population indicating element autosomal genetic overlap patients risking developing sepsis develop severe reactions sarscov<NUMBER> total <NUMBER> sepsis disease signatures found patients observed covid positive patients showing mild symptoms sepsis controls described likely functional impact one disease signatures discussion section many riskassociated genes found using precisionlife platform grouped one four common biological pathways linked sepsis pathogenesis immunerelated genes cns signaling molecules pi<NUMBER>kmtor pathway targets relating endothelium <NUMBER> significant genes found <NUMBER> already investigated context cancer ranging vitro preclinical studies large clinical trials common pathway targets centered around pi<NUMBER>kaktmtor pathway implicated driving oncogenesis effects cell proliferation apoptosis <NUMBER> identified genes direct regulators pi<NUMBER>k phosphoinositide<NUMBER>kinase mutations classes genes associated immune deficiency syndromes resulting chronic viremia recurrent respiratory tract infections defects b cell development <NUMBER> <NUMBER> pi<NUMBER>k plays key role adaptive innate immune response plays critical role development regulatory natural killer nk memory b lymphocytes well functional phagosome formation <NUMBER> also crucial activation il<NUMBER> negative feedback pathway helps resolve inflammation way hypothesize pi<NUMBER>k pathway critical regulating immune response development sepsis theory supported study demonstrated activation pi<NUMBER>kakt signaling attenuated proinflammatory markers neutrophil infiltration apoptosis model sepsisinduced cardiac dysfunction <NUMBER> however contradictory evidence surrounding role pi<NUMBER>k pathway sepsis exemplified model sepsisinduced myocardial dysfunction showed selective inhibition pi<NUMBER>k isoform reduced production proinflammatory cytokines pathological markers sepsis <NUMBER> indicates pi<NUMBER>k also plays crucial role regulation immune system context sepsis pathogenesis found two genes associated mtor mammalian target rapamycin signaling mtor pathway critical regulator tcell differentiation function inhibition mtor activity resulting increased autophagy sustained development memory cd<NUMBER> cells regulatory cd<NUMBER> cells <NUMBER> furthermore study found patients sepsis higher ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> serum levels key molecules mtor signaling pathway <NUMBER> indicating high mtor activity may play role driving key disease processes involved sepsis addition also identified three genes indirectly affect pi<NUMBER>kaktmtor pathway interaction pten one main inhibitors pathway <NUMBER> results indicate whilst apoptosisrelated pathways commonly associated oncogenesis cellular processes also highly important regulation immune system variants genes may also predispose patients inflammatory diseases sepsis well cancer expected analysis found significant genes relating innate adaptive immune response identification <NUMBER> genetic variants range different immunological targets indicates many patients develop sepsis may inherent aberrations immune response system challenged infectious agent targets one gene encodes cell differentiation antigen binds key components grampositive gramnegative bacteria causing agglutination inhibiting virulence factors infusion cd receptor mouse model sepsis resulted improved survival reduced systemic inflammation indicating patients variants gene likely defective pathogen binding abilities greater susceptibility infection sepsiscausing bacteria also identified several transcription factors involved regulation expression certain classes lymphocytes mhc class ii genes one genes encodes transcription factor plays role regulating interferongamma induced genes thereby modulating duration inflammatory response whilst different gene found critical class switch recombination csr activated b cells furthermore found target encoding transcription factor essential development il<NUMBER> producing cells high il<NUMBER> associated proinflammatory phenotype increased risk death mouse model administered toxic shock syndrome toxin tss<NUMBER> <NUMBER> addition identified gene encoding serine protease inhibits function furin enzyme cleaves variety different pathogenic substrates including sarscov<NUMBER> coronavirus <NUMBER> furin upregulated adaptive immune response enhancing virulence pathogens cleavage key sites allowing viral entry host cells <NUMBER> administration furin inhibitor mouse model atherosclerosis attenuated vascular endothelial injury proinflammatory cytokine expression indicating could key target several different facets sepsis pathophysiology <NUMBER> endothelial dysfunction wellestablished mechanism contributes sepsis pathogenesis <NUMBER> recent gwas identified two genes fer man<NUMBER>a<NUMBER> implicated endothelial response pathogens study identified four targets associated vascular endothelium two genes encode cell adhesion ecminteracting molecules linked endothelial inflammation oxidative stress models atherosclerosis one genes inhibited oxidized ldls via lox<NUMBER> receptor resulting increased vascular inflammation lipid accumulation evidence oxidized ldls upregulated inflammatory conditions inhibition lox<NUMBER> may help attenuate proinflammatory cascades seen sepsis <NUMBER> different riskassociated gene regulated angiotensin ii implicated promotion smooth muscle fibrosis oxidative stress endothelial dysfunction way furthermore found transcription factor targets vegf key regulator angiogenesis endothelial cell function high levels vegf observed animal models sepsis potentiates effects tnfα endothelial cells increases vascular permeability key pathogenic event severe sepsis <NUMBER> finally identified several variants genes associated neurogenic signaling pathways cns plays key role regulating immune system cytokine expression well systemic vascular response observed sepsis patients <NUMBER> one variants encoded key enzyme involved production gaba main inhibitory neurotransmitter cns polymorphisms gene associated multiple neuropsychiatric disorders including schizophrenia epilepsy bipolar depression anxiety best knowledge evidence currently linking gabaergic signaling sepsis however studies found increased levels one targets identified models hippocampal inflammation autoimmune conditions another target identified study encodes gproteincoupled receptor regulates gabab ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint neurons indicating polymorphisms affecting function genes involved gaba signaling increase risk developing sepsis alongside gaba related targets study identified also found targets number common neurotransmission pathways including regulation activation kainatetype glutamate receptors adenosine receptor well four genes key neuronal development synaptic plasticity one variants found implicated neurogenic signaling located adora<NUMBER> encodes adenosine a<NUMBER> receptor high levels adenosine already found plasma patients septic shock severe sepsis indicating may play key role development disease <NUMBER> furthermore increased activation adenosine a<NUMBER> receptors lung results increased gramnegativeinduced tissue injury increased proinflammatory mediators <NUMBER> study shown using adenosine a<NUMBER> antagonists attenuates sepsis pathophysiology improves survival rat model disease <NUMBER> wellknown different diseases may share common pathways drugs affect genes pathways may therefore able treat variety disease indications uniquely detailed disease architecture views generated combinatorial approach used study allow systematic repurposing known drugs disease relevant targets identified mapping existing drugs onto genetic metabolic signatures identified patient subgroups indicates areas already good clinical options also trial use existing therapeutics good safety tolerability profiles acceptable routes administration could potential given patient specific combination snps large part determine drug combination drugs likely benefit personally used precisionlife platform identify drug repurposing candidates key diseaseassociated targets mapping existing drug options onto genes found different subgroups patient population applying series heuristics developed rapidly identify candidates may therapeutically beneficial select subsets patient population identify efficiently prioritize greatest repurposing potential investigation <NUMBER> sepsis risk genes identified <NUMBER> targeted active chemical compounds found drugbank <NUMBER> chembl <NUMBER> could therefore represent potential drug repurposing opportunities total <NUMBER> known active drugs identified <NUMBER> targets could form basis repurposing screen graph figure <NUMBER> shows drugs research compounds known active adenosine a<NUMBER> receptor adora<NUMBER> one targets described remaining drug repurposing candidates identified study described appendix ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint signatures observed sepsis severe covid<NUMBER> patients number specific sepsis majority <NUMBER> <NUMBER> <NUMBER> shared sepsis severe covid<NUMBER> patients found <NUMBER> sepsis disease signatures composed autosomal snps present patients tested positive covid<NUMBER> showed severe symptoms observed covid<NUMBER> positive patients showing mild symptoms sepsis controls one snp genotypes combinations signatures found sepsis severe covid<NUMBER> patients sepsis controls patients mild nonhospitalized covid<NUMBER> disease contained three snps mapped six genes table <NUMBER> two snps previously linked cardiovascular hypertension phenotypewide association studies phewas studies <NUMBER> <NUMBER> functional annotations genes revealed several involved neutrophil degranulation leukocyte activation immune effector processes disease signature also observed <NUMBER> <NUMBER> uk biobank participants likely suffer complications immune responses continue investigating likely functional impacts sepsis disease signatures found severe covid<NUMBER> patients study clinical covid<NUMBER> data become available uk biobank patient data sources able analyze clinical impact disease signatures patients authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted may <NUMBER> <NUMBER> using genetic data uk biobank identified <NUMBER> sepsis riskassociated genes would found using conventional gwas approaches using dataset identified <NUMBER> drug repurposing candidates <NUMBER> targets potential directly effective improving survival rates sepsis found several genes strong mechanism action hypotheses connected existing drug targets may form basis novel drug discovery strategies using new insights disease investigate several novel therapeutic strategies may help reduce high mortality rates currently observed patients develop sepsis within without context covid<NUMBER> continue investigate overlap sepsisassociated genetic signatures seen covid<NUMBER>positive patients present lifethreatening symptoms including development viral sepsis data covid<NUMBER> patients becomes available may help gain greater understanding mechanisms latestage disease apparent clinical differences patient responses sarscov<NUMBER> virus new datasets may help elucidate links observed epidemiological risk factors ethnicity blood group smoking data become available direct study may also provide new directions search effective therapies patients outside antiviral space based better understanding host responses ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint overall process mining validation scoring shown simple networks set nstates sharing least one snp genotype critical snp genotype networks validated certain fdr threshold sometimes known validated simple networks merged networks union nstates one networks ccbync <NUMBER> international license made available authorfunder granted medrxiv license display preprint perpetuity certified peer review copyright holder preprint version posted may <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint coronaviruses covs placed within four genera alphacoronavirus betacoronavirus gammacoronavirus deltacoronavirus b c subfamily orthocoronavirinae however members betacoronavirus severe acute respiratory syndrome coronavirus sarscov<NUMBER> sarscov<NUMBER> middle east respiratory syndrome coronavirus merscov involved pneumonia epidemics <NUMBER>st century sarscov<NUMBER> merscov sarscov<NUMBER> outbreaks caused zoonotic viruses lau et al <NUMBER> reusken et al <NUMBER> case fatality ratio <NUMBER> cheng et al <NUMBER> lee et al <NUMBER> zaki et al <NUMBER> <NUMBER> de groot et al <NUMBER> zaki et al <NUMBER> <NUMBER> respectively recent outbreak phenomenal spread sarscov<NUMBER> every nook cranny world <NUMBER> million infections <NUMBER> deaths compelled world health organization declare pandemic march <NUMBER> <NUMBER> virus causing covid<NUMBER> named <NUMBER>ncov <NUMBER> novel coronavirus january <NUMBER> <NUMBER> zhu et al <NUMBER> however international virus classification commission ictv february <NUMBER> <NUMBER> named virus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> threat global concern humanity mainly due unavailability proper treatment pushed investigators discover design therapeutic drugs vaccines combat coronavirus infection symptoms include fever dyspnea shortness breath cough whereas severe cases lead kidney failure death rothan byrareddy <NUMBER> sarscov<NUMBER> composed spike protein membrane protein envelope e protein nucleocapsid n protein anti covs therapies main focus boost human immune system block binding spike protein receptor proteins therefore treatments based targeting coronavirus rely blocking virus binding receptors inhibition virus replication prevention synthesis viral rna inhibition virus selfassembly process bosch et al <NUMBER> khan et al <NUMBER> omrani et al <NUMBER> combat latest covs threats researchers following multiple approaches novel drug development zumla et al <NUMBER> testing efficacy existing drugs one approach experiments performed test existing broadspectrum antiviral drugs ribavirin interferons cyclophilin inhibitors sarscov<NUMBER> chan et al <NUMBER> zumla et al <NUMBER> use antiviral drugs approved viral infections dosages efficacy metabolic characteristic side effects well known however possibility broadspectrum treatment covs would effective second approach molecular databases subjected highthroughput screening potential drug molecules combat infection caused coronavirus de wilde et al <NUMBER> dyall et al <NUMBER> strategy proved successful discovery lopinavirritonavir treatment hiv researchers using genomic pathological information covs development new specific drug scratch theoretically effective approach however time consuming might cost several years even ten years khan et al <NUMBER> omrani et al <NUMBER> structural bioinformatics based approaches fastest way finding potential molecules marketed drugs bioactive compounds effective treatment sarscov<NUMBER> mainprotease <NUMBER>clpro inhibition promising target control recent sarscov<NUMBER> infection due essential role viral maturation replication ul qamar et al <NUMBER> <NUMBER>clpro three important domains iiii correspond positions <NUMBER> <NUMBER> <NUMBER> respectively connecting loop corresponds position <NUMBER> connects domains ii iii structure <NUMBER>clpro important catalytic dyad consist his<NUMBER> cys<NUMBER> study protein sarscov<NUMBER> <NUMBER>clpro also named <NUMBER>chymotrypsinlike protease subjected drug repurposing virtual screening potent drug identification followed molecular dynamics simulation binding free energy calculation findings revealed saquinavir hiv protease inhibitor reported experimentally kim et al <NUMBER> tcm<NUMBER> promising hits need vitro validation antiviral effects hope study provide useful information clinical treatment novel coronavirus associated pneumonia b electrostatic potential <NUMBER>clpro displays important active site residues sticks including two essential residues his<NUMBER> cys<NUMBER> catalytic dyad protein databank httpwwwrcsborg rose et al <NUMBER> used retrieval <NUMBER>clpro <NUMBER>lu<NUMBER> crystal structure using protein preparation implemented schr€ odinger software schr€ odinger llc new york ny structure prepared optimized opls<NUMBER> force field used proteinenergy minimization ligands preparation assigning appropriate ionization stereochemistry ring conformations tautomer release <NUMBER> schrodinger <NUMBER> ligprep module used apbs tool lerner carlson <NUMBER> implemented pymol used electrostatic potential calculation drug repositioning repurposing approach used speed drug development cycle finding new therapeutic application marketed drug licensed particular use sleigh barton <NUMBER> approach fruitful case sildenafil leprosy erectile dysfunction pulmonary hypertension multiple myeloma thalidomide hernandez et al <NUMBER> literature mining carried collect antihiv drugs screening <NUMBER>clpro sarscov<NUMBER> multiple drugs retrieved drugbank database total <NUMBER> drugs shortlisted screening <NUMBER>clpro sarscov<NUMBER> schr€ odinger binding site used finding binding site proteins using default parameters generated maps show binding cavity identified binding sites descriptions regarding hydrogen bonding degree exposure enclosure size linking site points tightness hydrophobic hydrophilic nature grid dimensions <NUMBER> å â <NUMBER> å â <NUMBER> å generated final active site grid identified based experimentally reported residues recent crystallographic study maps generated schr€ odinger maestro three steps virtual screening htvs sp xp used screen antihiv tcm compounds databases furthermore bioactivity compounds predicted using molinspiration cheminformatics tool molinspiration efficient tool used several studies <NUMBER> predict bioactivity results top hits antihiv drugs tcm database subjected molecular dynamics simulation using amber<NUMBER> package case et al <NUMBER> antechamber used generate drugs topologiestip<NUMBER>p water model solvate system na þ counter ions used neutralizing system two steps energy minimization system followed heating equilibration performed particle mesh ewald pme algorithm applied calculate longrange electrostatic interactions price brooks iii <NUMBER> van der waals interactions <NUMBER> nm cutoff values set also shortrange columbic respectively total <NUMBER> ns md simulation performed time step <NUMBER> fs behavior ligandprotein complex stability analyzed postsimulation analysis rmsd rmsf rog hydrogen bonds occupancy performed using cpptraj ptraj roe cheatham iii <NUMBER> script mmpbsapy used calculate free binding energy proteinligand complexes chen et al <NUMBER> hou et al <NUMBER> miller iii et al <NUMBER> sun et al <NUMBER> considering <NUMBER> snapshots md trajectories using following equation equation dg bind represents total free binding energy others show free energy complex protein ligand specific energy term contributes whole free energy calculated equation g bond g ele g vdw specify interactions among bonded electrostatic van der waals states contrast g pol g npol represent polar nonpolar interaction table <NUMBER> list antihiv drugs used docking proteinase enzyme coronavirus sarscov<NUMBER> targeted viruses free energy presumed precise gb generalized born free energy calculation method widely used different studies understand binding energy different ligands wang et al <NUMBER> <NUMBER>clpro structure retrieval preparation crystallographic structure <NUMBER> amino acids long <NUMBER>clpro sarscov<NUMBER> retrieved rcsb database using accession id <NUMBER>lu<NUMBER> structure <NUMBER>clpro analyzed missing residues refinement structure subjected energy minimization structure preparation using maestro structure <NUMBER>clpro three domains given figure <NUMBER> domains iiii correspond position <NUMBER> <NUMBER> <NUMBER> respectively connecting loop corresponds position <NUMBER> connects domains ii iii domains coloured differently ligand active site yellow colour sphere also shown figure <NUMBER> electrostatic potential <NUMBER>clpro shows active site region possesses strong electronegative potential weak electronegative potential around active site also observed however weak electropositive neutral potential distributed active site grid x¼ à<NUMBER> ¼ <NUMBER> z ¼ <NUMBER> generated important residues identified important active site residues his<NUMBER> met<NUMBER> tyr<NUMBER> phe<NUMBER> leu<NUMBER> asn<NUMBER> cys<NUMBER> his<NUMBER> met<NUMBER> glu<NUMBER> leu<NUMBER> phe<NUMBER> asn<NUMBER> gln<NUMBER> identified shown figure <NUMBER> b binding cleft place previously reported sars two critical residues his<NUMBER> cys<NUMBER> forms catalytic dyad current study repurposing antihiv drugs sarscov<NUMBER> main protease carried using structurebased screening methods antihiv drugs lopinavirritonavir reported active sarscov<NUMBER> clinical trials drugs different groups patients showed significant improvement thus antihiv drugs possess potential work srscov<NUMBER> targets therefore immediate testing antihiv drugs may lead discovery potent inhibitor sarscov<NUMBER> list <NUMBER> antihiv drugs drugs prepared molecular docking proteinase enzymes coronavirus sarscov<NUMBER> docking scores ranged à<NUMBER> kcalmol à<NUMBER> kcalmol conformations analyzed best interactions key residues initial criteria set shortlist drugs based binding affinity interactions dyad residues his<NUMBER> cys<NUMBER> docking score à<NUMBER> kcalmol reported hiv protease inhibitor drug saquinavir figure <NUMBER> drug reported inhibit hiv proteinase enzymes case sarscov<NUMBER> saquinavir formed six hydrogen bonds including two central dyad residues his<NUMBER> cya<NUMBER> previous reports different sars octapeptide also stressed blocking two residues interactions include four hydrogen bonds glu<NUMBER> gln<NUMBER> met<NUMBER> gly<NUMBER> pialkyl interactions including one cys<NUMBER> residues also formed thus speculate clinical testing figure <NUMBER> rmsds systems including <NUMBER>clprosquanavir red <NUMBER>clpro<NUMBER> green <NUMBER>clpro<NUMBER> blue <NUMBER>clpro<NUMBER> cyan <NUMBER>clpro<NUMBER> magenta <NUMBER>clpro<NUMBER> navy xaxis shows time nanoseconds yaxis shows rmsd å saquinavir done earliest also reported different scientists hiv drugs could potentially used recent coronavirus virtual screening tcm database <NUMBER>clpro sarscov<NUMBER> furthermore also performed virtual screening traditional chinese medicines database tcm total <NUMBER> compounds screened excluding drugs violating lipinski rules five important residues active site his<NUMBER> cys<NUMBER> targeted top five compounds based docking scores selected best docking score à<NUMBER> kcalmol reported compound <NUMBER> ten bonds including hydrogen bonds van der waals electrostatics pialkyl interactions formed among seven hydrogen bonds two hydrogen bonds residue his<NUMBER> also formed key residue active site dyad among phe<NUMBER> leu<NUMBER> asn<NUMBER> his<NUMBER> glu<NUMBER> thr<NUMBER> also formed hydrogen bonds ligand <NUMBER> hand compound <NUMBER> docking score à<NUMBER> kcalmol formed strong hydrogen bond key residue his<NUMBER> compound <NUMBER> also formed five hydrogen bonds active site residues glu<NUMBER> arg<NUMBER> gln<NUMBER> thr<NUMBER> three compounds <NUMBER> <NUMBER> <NUMBER> also analyzed interaction key residues seen figure <NUMBER> his<NUMBER> mainly involved interaction ligands table <NUMBER> showing <NUMBER>d structures top five compounds docking scores cross validation predicted compounds comparing experimentally tested compounds showed saquinavir tcm<NUMBER> possess similar scaffold myricetrin scutellarin flavonoids reported strong inhibitory effects targeting <NUMBER>clpro hand four compounds tcm<NUMBER> tcm<NUMBER> tcm<NUMBER> tcm<NUMBER> tcm database shares structural similarity scutellarein dihydromyricetin quercetagetin myricetin <NUMBER>dihydroxyflavone <NUMBER>dihydroxyflavone chrysin herbacetin baicalein flavonoids testes strong inhibitory effects experimental condition targeting <NUMBER>clpro chen du <NUMBER> dai et al <NUMBER> yang et al <NUMBER> structural analyses showed compounds mainly form bonds phe<NUMBER> glu<NUMBER> compounds specifically target catalytic dyad supplementary interactions active site residues thus speculate compounds could also show potential activity <NUMBER>clpro experimental assay compounds also plants derived extracts belongs group flavonoids furthermore results obtained server shows shortlisted compounds active protease target scores seen saquinavir score <NUMBER> possesses strong inhibitory effects proteases others reported score tcm<NUMBER> à<NUMBER> tcm<NUMBER> à<NUMBER> tcm<NUMBER> à<NUMBER> tcm<NUMBER> à<NUMBER> tcm<NUMBER> possess à<NUMBER> bioactivity score protease target thus results strongly suggest shortlisted compounds could efficiently inhibit <NUMBER>clpro experimental setup could tested clinical trials figure <NUMBER> rmsfs systems including <NUMBER>clprosquanavir red <NUMBER>clpro<NUMBER> green <NUMBER>clpro<NUMBER> blue <NUMBER>clpro<NUMBER> cyan <NUMBER>clpro<NUMBER> magenta <NUMBER>clpro<NUMBER> navy xaxis shows time nanoseconds yaxis shows rmsf å right panel shows secondary structure <NUMBER>clpro understand conformational dynamics features selected hits <NUMBER>clpro sarscov<NUMBER>molecular dynamics md simulation imperative method explore behavior system realtime dynamics features six selected systems saquinavir <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> calculated <NUMBER> ns simulation stability rmsd evaluate flexibility residue level rmsf complexes calculated comprehend overall stability flexibility system stability six systems calculated using root mean square deviation rmsd tested stability docked drugs active pocket effects stability whole system results suggest six systems stable acceptable deviation shown figure <NUMBER> average rmsd systems found <NUMBER> <NUMBER>å saquinavir<NUMBER>clpro exhibited average rmsd <NUMBER> å soon reaching <NUMBER> ns system attained stability remains uniform rest time seen complex <NUMBER>clpro<NUMBER> remained stable <NUMBER> ns system showed acceptable deviation little time system gained stability entered production stage complex <NUMBER>clpro<NUMBER> system showed slight deviation <NUMBER> <NUMBER>ns remained stable course simulation hand <NUMBER>clpro<NUMBER> <NUMBER>clpro<NUMBER> reported divergence <NUMBER> <NUMBER>ns system soon gained stability similarly case <NUMBER>clpro<NUMBER> examination rmsd ca backbone average rmsd <NUMBER> å system shows deviation figure <NUMBER> rogs radius gyration systems including <NUMBER>clprosquanavir red <NUMBER>clpro<NUMBER> green <NUMBER>clpro<NUMBER> blue <NUMBER>clpro<NUMBER> cyan <NUMBER>clpro<NUMBER> magenta <NUMBER>clpro<NUMBER> navy rmsd first <NUMBER> ns remained uniformed rest simulation time thus results revealed stable internal motions negligible fluctuations course simulation differences rmsd system due binding unbinding ligand different time intervals also systems stable behaviour show ligand remained intact system entered production phase soon compared others aside binding small molecules affects system differently ligandbinding orientation changes simulation time rmsf depicts flexibility residues level shown figure <NUMBER> pattern flexibility almost similar recorded around <NUMBER>å secondary components except loop regions slightly fluctuated residues however active site residues seem stable course simulation due ligand recognition ligandbinding regions seen <NUMBER>clprosquanavir <NUMBER>clpro<NUMBER> showed average rmsf <NUMBER> å significant fluctuations regions <NUMBER> <NUMBER> <NUMBER> <NUMBER> similar pattern fluctuation also observed systems including <NUMBER>clpro<NUMBER> <NUMBER>clpro<NUMBER> <NUMBER>clpro<NUMBER> however average rmsf remained <NUMBER> å system <NUMBER>clpro<NUMBER> wed higher fluctuation rest residual flexibility pattern similar average rmsf five systems around <NUMBER>å clearly seen figure <NUMBER> left panel findings show target protein stabilized binding five chosen drugs docked thus binding ligand significantly affected residue fluctuation due internal residues disturbed binding different ligands correlated noncorrelated motions affected secondary structure components also given figure <NUMBER> right panel radius gyration rog conveys information stable unstable folding protein interacting ligands less compactness unfolded shows higher rog values whereas low rog values indicate strong compactness higher structural stiffness folded thus rog determined assess systems compactness time shown figure <NUMBER> simulated complexes show gyration scores <NUMBER> <NUMBER>å case <NUMBER>clprosquanavir gyration score initial <NUMBER> frames reported <NUMBER> å however little fluctuation <NUMBER> frames observed soon <NUMBER> values become lower uniform case <NUMBER>clpro<NUMBER> <NUMBER>clpro<NUMBER> <NUMBER>clpro<NUMBER> <NUMBER>clpro<NUMBER> showed average gyration <NUMBER> å similarly <NUMBER>clpro<NUMBER> also showed similar fluctuation last frames values fluctuated little higher assumed acceptable range binding unbinding ligands greatly affected overall compactness complexes given figure <NUMBER> <NUMBER>clprosquanavir <NUMBER>clpro<NUMBER> <NUMBER>clpro<NUMBER> complexes hydrogen bond his<NUMBER> reported <NUMBER> <NUMBER> <NUMBER> trajectories hydrogen bond cys<NUMBER> residue reported <NUMBER> trajectories <NUMBER>clprosquanavircomplex furthermore leu<NUMBER> glu<NUMBER> found almost complexes however another important residue gln<NUMBER> found <NUMBER> <NUMBER>clprosquanavir trajectories <NUMBER> <NUMBER>clpro<NUMBER> <NUMBER> <NUMBER>clprotcm<NUMBER> trajectories active site residues detected significant population md trajectories binding free energy mmgbsa popular approach used estimate binding free energy six systems binding free energy determines binding affinity ligands <NUMBER>clpro energy term including van der waals energy electrostatic energy polar solvation energy solvent accessible surface area energy total binding free energy systems given table <NUMBER> seen <NUMBER>clprosaquinavir system possesses highest total binding energy à<NUMBER> kcalmol thus confirms saquinavir antihiv drug reported inhibit hiv protease experimentally possesses strong inhibitory effects <NUMBER>clpro sarscov<NUMBER> recently published results also shortlisted saquinavir potential candidate performed <NUMBER> ns simulation khan et al <NUMBER> could reflect better results revealed adding <NUMBER>folds simulation time furthermore top five hits tcm virtual screening results also subjected free binding energy reported virtual screening results tcm<NUMBER> reported best docking score interaction herein tcm<NUMBER> also possesses best total binding energy<NUMBER> kcalmol <NUMBER>clpro also hits including tcm<NUMBER> tcm<NUMBER> tcm<NUMBER> tcm<NUMBER> possess total binding energy à<NUMBER> kcal mol à<NUMBER> kcalmol à<NUMBER> kcalmol à<NUMBER> kcal mol energy terms van der waals energy electrostatic energy polar solvation energy solventaccessible surface area given table <NUMBER> thus results strongly suggest saquinavir tcm<NUMBER> tested experimentally sarscov<NUMBER> earliest date total <NUMBER> confirmed cases <NUMBER> deaths reported sarscov<NUMBER> epidemic indicates current viral treatment satisfactory diverse studies needed incorporation various natural fda approved compounds effective treatment sarscov<NUMBER> existing capacity treating zoonotic coronavirus infections still trial available resources seem limited fight lifethreatening hazard although extensive research efforts initiated <NUMBER> <NUMBER> outbreaks sars merscov respectively however effective drugs far synthesized matter may taken seriously prevent future pandemics zoonotic coronavirus drug repositioning universal strategy neglected diseases due reduced number clinical trial steps required could reduce time cost medicine reach market existing pharmaceutical supply chains could facilitate formulation distribution drug known possibility combining drugs could enable efficient treatment repositioning could encourage development new modes action old drugs new types medicines eliminating activation obstacles early stages study could allow project progress rapidly towards diseaseoriented development pushpakom et al <NUMBER> one primary reasons prototype coronavirus inhibitor progressed early preclinical stage far due transient nature epidemic like sars virus <NUMBER> years ago new sarscov<NUMBER> new evolving coronaviruses may continue pose threat global public health future hence discovering broadspectrum inhibitors reduce symptoms human coronavirus infection remains formidable subject study considering timeconsuming process designing documenting antiviral medications proven therapies certain diseases may fastest therapeutic choice emerging infectious diseases prescription ample experience dosage medications formulated health adme properties well known study based results bioinformatics analysis targeted <NUMBER>clpro sarscov<NUMBER> using drugs repurposing antihiv drugs virtual drugs screening tcm approaches shortlist potent compounds possible treatment results entire article stressed potential inhibitory role saquinavir tcm<NUMBER> based computerbased virtual drug screening conducted vivo vitro antiviral experiments yet want share results scientists antisarscov<NUMBER> research soon possible study help repurpose drug design perform vivo vitro evaluations candidate drugs obtained study prepare clinical trial applications <NUMBER>clike protease <NUMBER>clpro also called main protease attractive target treatment sarscov<NUMBER> role viral replication cycle current study focused structure based approaches repurposed antihiv drugs screened traditional chinese medicines databases active site residues <NUMBER>clpro initial analysis molecular docking scores interactions important residues shortlisted one drug saquinavir antihiv drugs five compounds tcm databasethese compounds subjected molecular dynamics simulation postsimulation analysis among six complexes subjected molecular dynamics simulation saquinavir tcm<NUMBER> showed highest hydrogen bond occupancy rest also found good activity <NUMBER>clpro addition bioactivity compounds predicted reported saquinavir strong potential inhibitor followed othersbinding free energy calculations complexes suggested compounds significantly interacting binds receptor thus analyses suggest saquinavir tcm<NUMBER> tested experimentally possible treatment sarscov<NUMBER> ak zb mk ssa conceptualized study analysis aa ms ss wrote manuscript ak ss ssa revised manuscript improved writeup dqw academic supervisor supervised study covid<NUMBER> severe viral pneumonia first reported december <NUMBER> <NUMBER> city wuhan hubei province china chinese centre disease control cdc china causative virus shortly identified novel betacoronavirus dubbed sarscov<NUMBER> virus belongs order nidovirales coronaviridae family comprising alphaand betacoronaviruses enveloped positivesense rna viruses comparatively large genomes among known rna viruses <NUMBER> kb zheng <NUMBER> su et al <NUMBER> six members family previously known infect humans including sarscov merscov known cause severe respiratory ailments host paules et al <NUMBER> corman et al <NUMBER> sarscov<NUMBER> latest addition group presented potent human respiratory pathogen due mutation receptor binding domain rbd spike protein enables high affinity binding ace<NUMBER> receptor humans polybasic furin cleavage site junction s<NUMBER> s<NUMBER> subunits spike protein andersen et al <NUMBER> hasan et al <NUMBER> since first report virus spread across continents inflicting global healthcare economic emergency view global spread outbreak world health organization declared pandemic january <NUMBER> <NUMBER>th may <NUMBER> number infections reported <NUMBER> number deaths <NUMBER> numbers increasing relentlessly despite concerted efforts contain spread virus using rigorous diagnostic testing isolation positive cases tracing contacts scenario made grim fact specific drugs vaccines virus currently current treatments focus symptom management supportive therapy government agencies pharmaceutical companies research institutes across globe taken formidable challenge inventing specific viable validated therapeutic agent sarscov<NUMBER> probably solution ongoing crisis drug repurposing refers identification novel applicationstargets approved investigational drug outside premise medical indication ashburn thor <NUMBER> present strategy would logical choice developing therapy covid<NUMBER> considering substantial timescales attrition rates associated new drug discovery trialbased validation safety efficacy major advantage lies fact repurposed drug already evaluated safety preclinical clinical trials would save significant amounts time money pushpakom et al <NUMBER> priority concern sarscov<NUMBER> drug discovery indeed drugs currently investigation efficacy sarscov<NUMBER> repurposed known medicines drugs either development prescribed offlabel covid<NUMBER> include ribavirin interferona mycophenolic acid ritonavir lopinavir oseltamivir remdesivir mitj clotet <NUMBER> baden rubin <NUMBER> cao et al <NUMBER> muralidharan et al <NUMBER> hendaus <NUMBER> arya dwivedi <NUMBER> among hydroxychloroquine approved antimalarial drug two known antivirals ritonavir remdesivir reported effective sarscov<NUMBER> vitro yan <NUMBER> however recent studies reported harmful effects chloroquine hydroxychloroquine inhibition autophagy drugs may induce tissue damage worsen organ injury covid<NUMBER> patients edelstein et al <NUMBER> number computational studies aim repurpose drugs covid<NUMBER> reported drug targets selected studies include host cell protease tmprss<NUMBER> elmezayen et al <NUMBER> spike protein oliveira et al <NUMBER> sinha et al <NUMBER> envelope e protein ion channel gupta et al <NUMBER> putative immune evasion molecule <NUMBER> <NUMBER> oribosemethyltransferase nucleocapsid protein salma et al <NUMBER> rna dependant rna polymerase rdrp enzyme elfiky azzam <NUMBER> elfiky <NUMBER> aim present study identify clinically approved drugs targeted main protease pro also called <NUMBER>cl pro enzyme similar structural fold cleavage site specificity picornavirus <NUMBER> c protease huang et al <NUMBER> pro attractive well characterized drug target corona viruses owing pivotal role plays propagation virus inside host boopathi et al <NUMBER> nonstructural proteins virus n ¼ <NUMBER> encoded orf<NUMBER>ab rna genome gets transcribed translated two polyproteins pp<NUMBER>a pp<NUMBER>ab proteolytic cleavage pps components required derive functionally active proteins autocleavage pp<NUMBER>a pp<NUMBER>ab pro cleaves pp<NUMBER>ab <NUMBER> sites pp<NUMBER>ab contains subunits replicase complex including rna dependant rna polymerase rdrp hence cleavage becomes essential requirement viral replication mousavizadeh ghasemi <NUMBER> thus inhibition pro would effectively stop viral spread preventing replication since human proteases cleavage specificity sarscov<NUMBER> protease leuglnseralagly known unlikely inhibitor would cross react human protease recently jin coworkers reported structure sarscov<NUMBER> pro complex potent inhibitor jin et al <NUMBER> protein <NUMBER> residues long molecular weight <NUMBER> kda pivotal drug target sarscov<NUMBER> various groups reported silico drug repurposing studies using different approaches pro wide range druggable molecules aanouz al <NUMBER> pant et al <NUMBER> joshi et al <NUMBER> enmozhi et al <NUMBER> choudhury <NUMBER> kumar et al <NUMBER> umesh et al <NUMBER> das et al <NUMBER> alkhafaji et al <NUMBER> gyebi et al <NUMBER> present study inorder identify clinically approved drugs would bind catalytic site pro epharmacophore model based virtual screening performed chemical library known drugs superdrug<NUMBER> database database contains <NUMBER> active pharmaceuticals marketed approved siramshetty et al <NUMBER> subset drugs selected based pharmacophore screening screened using molecular docking binding energies identified poses calculated using mmgbsa method molecular dynamics simulations carried selected poses understand dynamic behaviour complexes stability proteinligand binding computational studies like epharmacophore hypothesis generation virtual screening molecular docking mmgbsa carried using maestro version <NUMBER> schr€ odinger release <NUMBER> schrodinger inc visualization molecular interactions done using pymol crystal structure pro sarscov<NUMBER> bound noncovalent inhibitor x<NUMBER> resolution <NUMBER> å used generate energyoptimised pharmacophore hypothesis epharmacophore structural coordinates pro x<NUMBER> complex downloaded pdb id <NUMBER>w<NUMBER> structure proteinligand complex preprocessed water molecules within <NUMBER> å distance ligand removed missing hydrogens loops added structure subjected restrained energy minimization adopting opls<NUMBER> force field harder et al <NUMBER> steps performed using protein preparation wizard schrodinger suite sastry et al <NUMBER> epharmacophore model developed using develop pharmacophore proteinligand complex option phase module dixon et al <NUMBER> prepared proteinligand complex imported workspace default pharmacophore features hydrogen bond acceptor hydrogen bond donor aromatic ring r hydrophobicity h mapped epharmacophore based virtual screening performed using chemical structures <NUMBER> drugs ligands superdrug<NUMBER> database prior screening ligands structurally optimised near neutral ph <NUMBER> ± <NUMBER> plausible tautomers stereoisomers generated protonation states assigned ligands subjected energy minimisation opls<NUMBER> force field using ligprep module maestro <NUMBER> order generate subset drugs desired molecular features optimal binding pro mapped epharmacophore model pharmacophore based virtual screening carried using phase module schrodinger suite fitness scores used select best hits initial screening using epharmacophore model enabled selection <NUMBER> drugs potential make energetically favourable interactions active site pro identify promising candidate drugs form subset structure based screening performed selected drugs using molecular docking glide gridbased ligand docking energetics version <NUMBER> module maestro <NUMBER> used perform molecular docking studies receptor grid generated keeping bound ligand crystal structure x<NUMBER> centre grid box size box set <NUMBER> â <NUMBER> â <NUMBER> å <NUMBER> glide scores gscores used rank drugs based binding affinity initial screening performed using highthroughput virtual screening htvs module glide <NUMBER> top scoring compounds subjected standard precision sp docking finally <NUMBER> high scoring compounds sp docking subjected extra precision xp docking identify best hits docking procedure validated control study bound ligand crystal structure redocked preprocessed prepared protein keeping grid box glide score docking used standard value scores drugs compared control docking performed xp mode theoretical binding free energies potent inhibitors pro calculated using prime module maestro <NUMBER> lyne et al <NUMBER> mmgbsa popular method calculate binding energy uses energy properties free ligand free receptor receptorligand complex binding affinity calculation binding energies estimated <NUMBER> drugs selected based glide scores xp docking using mmgbsa method stability binding selected drugs pro explicit solvent system determined molecular dynamics md using desmond module schrodinger bowers <NUMBER> docked poses protein ligand complexes used input structures complex prepared system setup option desmond module first step complexes solvated tip<NUMBER>p water model solvated system neutralized adding na þ clions system generation minimization relaxation proteinligand complexes npt carried using default protocol desmond module md simulations conducted periodic boundary conditions npt ensemble using opls<NUMBER> force field temperature pressure kept <NUMBER> k <NUMBER> atmosphere respectively using nosehoover temperature coupling isotropic scaling operation followed <NUMBER> ns npt production run binding energy complex determined run selected md trajectory frames using mmgbsa method pharmacophore defined ensemble steric electronic features necessary ensure optimal supramolecular interactions specific biological target trigger block biological response proekt hemmings <NUMBER> pharmacophore model based screening evolved key tool computer aided drug discovery ability screen large libraries potent hits within short period time minimal computational capacities energy optimised pharmacophore models tries combine stereoelectronic features ligand energetics interactions protein structure muthusamy et al <NUMBER> present study epharmacophore hypothesis generated screen inhibitors pro protein sarscov<NUMBER> using crystal structure complex strong broad spectrum noncovalent inhibitor bound inhibitor imidazole carbaximide derivative dubbed x<NUMBER> interacts strongly active site amino acid residues based ligandprotein complex energy optimised fivefeatured pharmacophore hypothesis aarrr obtained generated epharmacophore model contains two hydrogen bond accepters three aromatic rings r figure <NUMBER> figure <NUMBER> shows planar representation pharmacophore hypothesis distances features hypothesis aarrr used <NUMBER> search query screen <NUMBER> drugs superdrug<NUMBER> database identify drugs comparable pharmacophore features screening phase module analyses fitness compounds query hypothesis ranks compounds basis fitness scores one thousand compounds selected way used molecular docking based screening best hits obtained epharmacophore based screening n ¼ <NUMBER> screened using molecular docking docking study analyses molecular interactions different plausible geometries drugs poses surrounding active site residues sarscov<NUMBER> pro ranks basis binding scores docking processes carried using three different approaches htvs sp xp methods filtering outputs stage based glide scores docking studies also revealed atomic level interactions drugs protease redocking crystallographic ligand x<NUMBER> n<NUMBER>tertbutylphenyln<NUMBER>r<NUMBER>cyclohexylamino<NUMBER>oxo<NUMBER>pyridin<NUMBER>ylethyl<NUMBER>h imidazole<NUMBER>carboxamide active site protease using protocol resulted binding ligand position orientation figure <NUMBER> verified docking parameters chosen optimal analysis crystal structure pro x<NUMBER> complex showed binding ligand stabilized three hydrogen bonds active site residues viz gly <NUMBER> <NUMBER> glu <NUMBER> silico docked structure also exhibited three hydrogen bonds figure <NUMBER> based htvs sp docking <NUMBER> drugs selected xp docking gscore calculated crystallographic ligand x<NUMBER> <NUMBER> kcalmol seventeen <NUMBER> drugs used xp docking showed gscores comparable standard inhibitor used study gscores better <NUMBER> kcalmol supplementary data s<NUMBER> three highest scoring drugs viz hidrosmin <NUMBER> kcalmol diosmin <NUMBER> kcalmol monoxerutin <NUMBER> kcal mol flavanoids similar pharmacological properties used vasoprotectives capillary stabilising agents remikirin <NUMBER> kcalmol interesting hit wellknown inhibitor renin aspartyl endoprotease acts primary enzyme reninangiotensin system himmelmann et al <NUMBER> doxorubisin <NUMBER> kcalmol anthracyne class antineoplastic used anticancer drug fluvastatin <NUMBER> kcal mol inhibitor hydroxymethylglutarylcoenzyme hmgcoa reductase used antilipemic agent also showed high binding score protease note doxorubisin derivatives previously shown effective vitro viruses like hiv hsv dengue virus yellow fever virus rauscher leukemia virus avian myeloblastosis virus kaptein et al <NUMBER> ash diekema <NUMBER> jeyaseelan et al <NUMBER> papas schafer <NUMBER> although drug targets case vary drugs able reduce virus replication vitro statins general known inhibit replication many enveloped viruses inhibition cholesterolisoprenoid pathway shrivastavaranjan et al <NUMBER> fluvastatin earlier shown inhibitory effect heamophilus influenza replication vitro peng et al <NUMBER> thus present study identifies pro sarscov<NUMBER> novel targets drugs showed high glide score subjected binding energy calculation using mmgbsa method binding energy crystallographic ligand x<NUMBER> determined mmgbsa <NUMBER> kcalmol six drugs binding free energies better <NUMBER> kcalmol selected pool <NUMBER> drugs using molecular docking drugs binifibrate macimorelin acetate bamifylline rilmazafon afatinib ezetimibe except bamyfilline gscore à<NUMBER> kcalmol drugs shown gscores better <NUMBER> kcalmol docking studies however drugs showed glide scores comparable standard inhibitor showed lower binding energies binifirbate hypolipidaemic drug showed high binding energy <NUMBER> kcalmol similar standard inhibitor x<NUMBER> binifibrate forms hydrogen bonds three active site residues viz gly <NUMBER> <NUMBER> glu <NUMBER> binding free energies protein residues interact drugs shown table <NUMBER> primary targetsactivities drugs also shown table energy contributions different components like electrostatic covalent van der waals lipophilic generalized born electrostatic solvation hydrogen bonds pipi packing towards total binding energy given table <NUMBER> results presented table <NUMBER> seen hydrogen bonding interactions gly <NUMBER> <NUMBER> glu <NUMBER> three polar aminoacid residues active site protease critical high affinity binding drugs protein figure <NUMBER> shows conformation bound drugs active site enzyme surrounding protein residues md simulations performed top <NUMBER> hits selected based binding free energies namely binifibrate macimorelin acetate bamifylline rilmazafon complex pro conformational changes protein ligand initial structure simulation expressed terms root mean square deviation rmsd rmsd within <NUMBER> å perfectly acceptable globular proteins larger deviations indicate protein undergoing large conformational changes simulation means proteinligand complex unstable four complexes subjected md simulations showed deviations protein rmsd <NUMBER> å compared initial frame figure <NUMBER> overall values root mean square fluctuation rmsf specifies flexibility protein residues interaction drug falls within <NUMBER> å hence indicates protein stable complex drugs active site analysis ligand rmsd shows binifibrate bamifylline exhibit large deviations initial position indicating binding stable however macimorelin acetate rilmazafone displayed larger rmsds md run indicating less stable binding taken together clear binifibrate bamifylline possess better binding affinity towards sarscov<NUMBER> pro active site compared two drugs interactions drugs specific residues pro md run shown figure <NUMBER> major hydrogen bonds stabilize binding binifibrate gly <NUMBER> glu <NUMBER> bamifylline gly<NUMBER> glu <NUMBER> persistent entire course md simulations hydrogen bonding interactions established macimorelin acetate gly <NUMBER> <NUMBER> glu <NUMBER> thr <NUMBER> rilmazafone thr <NUMBER> gly <NUMBER> <NUMBER> glu <NUMBER> eventually lost course simulation accounts lower stability binding md run binding energy selected frames md trajectory calculated mmgbsa structure <NUMBER> ns frame <NUMBER> ns total <NUMBER> structures md trajectory exported binding energy calculated complex binding energies obtained averaged standard deviations determined table <NUMBER> binifibrate showed highest average binding energy md run <NUMBER> ± <NUMBER> kcalmol energy value similar binding energy md run <NUMBER> <NUMBER> kcalmol binding energy values bamifylline md run <NUMBER> kcalmol <NUMBER> ± <NUMBER> kcalmol respectively also similar indicating drug interacts pro active site high stability rilmazafone initial binding free energy <NUMBER> kcalmol showed significantly lower energy <NUMBER> ± <NUMBER> kcalmol md run likewise macimorelin acetate showed large deviation binding energy <NUMBER> kcalmol md run <NUMBER> ± <NUMBER> kcalmol also rmsd macimorelin acetate showed huge variation <NUMBER> å md simulation indicates binding macimorelin pro stable figure <NUMBER> summarises comparison binding energy values md simulation table <NUMBER> summarises contribution energy parameters binding energy simulated systems md data indicates drugs binifirbate bamifylline might bind active site sarscov<NUMBER> pro inhibit activity hence drugs potential repurposed covid<NUMBER> however binifibrate hypolipidemic fibrate drug coadministered along statins presently withdrawn market reason cited withdrawal risks associated drug outweighs efficacy agent reduces triglycerides increases high density lipoproteinc hdlc abb vie inc <NUMBER> rational assessment benefits using binifibrate covid<NUMBER> potential side effects made considering drug repurposing covid<NUMBER> drug repurposing perhaps best way combat medical emergency poised sarscov<NUMBER> infections grows magnitude passing day repurposing involves screening identification known bioactives specific therapeutic targets sarscov<NUMBER> repurposed drugs gets market relatively lesser time periods costs compared novel drugs pro sarscov<NUMBER> involved proteolytic processing viral polyproteins form key nonstructural components involved viral multiplication hence attractive target drug development present study using combination epharmacophore structure based virtual screening followed binding energy estimation subset known drugs superdrug<NUMBER> database repurposed covid<NUMBER> <NUMBER> drugs database series screening four drugs selected molecular dynamic simulation studies check binding stabilities active site sarscov<NUMBER> pro based md results found binifibrate bamifylline may bind sarscov<NUMBER> pro active site inhibit activity hence binifibrate bamifylline two drugs could repurposed covid<NUMBER> however important note binifibrate currently withdrawn drug market side effects suggested rational riskbenefit analysis performed drug used repurposing covid<NUMBER> conclude bamifylline proposed potential drug worthy testing covid<NUMBER> based silico studies described december <NUMBER> novel sars coronavirus <NUMBER> sarscov<NUMBER> identified causative agent severe pneumonialike coronavirus disease covid <NUMBER> outbreak wuhan hubei province china <NUMBER> sarscov<NUMBER> enveloped positivesense singlestranded rna betacoronavirus related viruses caused higher number reported cases <NUMBER> typical covid<NUMBER> symptoms include fever cough anosmia headache anorexia myalgia severe cases viralinduced pneumonia accompanied prolonged systemic cytokine release <NUMBER> <NUMBER> notably levels il<NUMBER> reported correlate respiratory failure inhibitors currently pursued clinical studies amelioration virusinduced inflammatory responses <NUMBER> patients preexisting chronic conditions hypertension diabetes asthma well <NUMBER> years older higher risk severe disease outcome <NUMBER> underlying basis differential outcomes yet unknown together still accelerating rate community transmission severity symptoms placed unprecedented burden medical supply chain health care system italy spain us <NUMBER> <NUMBER> <NUMBER> similar scenarios playing anticipated countries fda recently granted antimalarial drug hydroxychloroquine sulfate also known hydroxychloroquine emergency use authorization eua covid<NUMBER> treatment present vaccine approved antiviral therapeutic agent available <NUMBER> thus urgent critical need identify novel medical countermeasures prophylactic treatment use since production vaccine could take <NUMBER> months <NUMBER> de novo development therapies usually requires <NUMBER> years <NUMBER> repositioning clinically evaluated drugs represents one practicable strategies rapid identification deployment treatments emerging infectious diseases toward end addition many antiimmune treatments addressed paper many investigational clinical trials using repurposed drugs evaluation direct antiviral activity already launched include multiple antiviral antimalarial medicines early results multicenter trial china suggested antimalarial drug chloroquine may limit exacerbation pneumonia shorten viral replication course disease <NUMBER> french study used hydroxychloroquine together azithromycin reported significant reduction viral load covid<NUMBER> patients used combination <NUMBER> however sufficiently powered casecontrol study yet reported thus unclear therapeutic benefits chloroquine administration sarscov<NUMBER>infected patients although several concerns raised recently due severe cardiac complications potentially resulting use treatment covid<NUMBER> patients <NUMBER> <NUMBER> repurposing several approved antiviral therapies focus clinical investigations including hiv<NUMBER> protease inhibitors lopinavirritonavir kaletra aluvia abbvie <NUMBER> hepatitis c virus protease inhibitor danoprevir ganovo ascletis pharma <NUMBER> influenza antiviral favipiravir t<NUMBER> avigan <NUMBER> notably ten clinical trials <NUMBER> global sites underway investigate remdesivir gs<NUMBER> investigational antiviral originally developed gilead sciences treat ebola virus infection <NUMBER> remdesivir adenosine analogue viral rna polymerase inhibitor causes premature termination transcription incorporated nascent viral rna <NUMBER> drug demonstrated vitro vivo activity animal models mers sars <NUMBER> <NUMBER> well potent antiviral activity vero e<NUMBER> clinical isolate sarscov<NUMBER> <NUMBER> pending results several randomized n <NUMBER> clinical trials expected provide definitive insight efficacy remdesivir therapeutic solution treatment covid<NUMBER> however wellpowered randomized controlled trial yet demonstrate definitive evidence antiviral efficacy remdesivir potential therapeutic targeted repurposing strategies provide potentially rapid trajectories toward approved treatment unbiased largescale evaluation known drugs clinical candidates identify additional unanticipated therapeutic options accelerated evaluation treatment covid<NUMBER> disease describe highthroughput repositioning screen using commercial library <NUMBER> pharmacologically active compounds lopac®<NUMBER> reframe repurposing focused rescue accelerated medchem drug collection comprehensive openaccess library <NUMBER> clinicalstaged approved small molecules respectively identify existing drugs harbor antiviral activity sarscov<NUMBER> cellbased assay <NUMBER> <NUMBER> reframe library previously used successfully identify antiinflammatory auranofin potential therapy tuberculosis <NUMBER> approved drug clofazimine potent antiparasitic compound tested efficacy cryptosporidium <NUMBER> also used identify optimize fdaapproved antifungal drug itraconazole novel efficacious molecule suitable chronic administration antifibrotic <NUMBER> importantly reframe library unique repurposing collection aware nearly <NUMBER> library derived custom synthesis commercially available sources clinical molecules available <NUMBER> molecules collection previously optimized efficacy safety bioavailability therefore enables leveraging considerable investment research development compress timeline required drug discovery development <NUMBER> example repositioning estimated reduce typical <NUMBER> year development process <NUMBER> years <NUMBER> emergency use authorization eua chemical biological radiological nuclear cbrn threats public health emergencies sarscov<NUMBER> pandemic may abbreviated <NUMBER>month time frame describe highthroughput analysis reframe library identify inhibitors sarscov<NUMBER> replication mammalian cells identified several targets mechanistic classes highly enriched including aldose reductase inhibitors retinoic acid receptor antagonists benzodiazepine receptor agonists regulators cholesterol homeostasis antimalarial compounds validation studies confirmed <NUMBER> known drugs inhibit viral replication including four molecules previously approved fda clofazimine acitretin tretinoin astemizole registered outside us tamibarotene dose response studies thus far characterized <NUMBER> compounds exhibit range effective concentrations ec <NUMBER> consistent potential clinical efficacy include pikfyve kinase inhibitor reached phase ii clinical trials apilimod cysteine protease inhibitors mdl<NUMBER> z lvg chn<NUMBER> vby<NUMBER> ono <NUMBER> various phases preclinical clinical development addition preclinical ion channel blocker amg<NUMBER> ion channer blocker antimalarial drug hanfangchin phase proton pump inhibitor yh<NUMBER> well gprotein receptor antagonists mln<NUMBER> sdz<NUMBER> <NUMBER> phase ii phase clinical evaluation respectively also found possess antiviral activity sarscov<NUMBER> rapid experimental clinical evaluation therapeutics vivo antiviral efficacy amelioration diseaseassociated pathologies provide important opportunity accelerated development potential therapies covid<NUMBER> treatment sarscov<NUMBER> hku<NUMBER>a strain isolated nasopharyngeal aspirate normalized median plate reframe library zscore calculated based log<NUMBER>fc average standard deviation plate screen performed duplicate running assay parallel lopac®<NUMBER> library two independent experiments reframe collection twentyeight compounds lopac®<NUMBER> selected according cutoff <NUMBER>stdev log<NUMBER>fc included doseresponse confirmation assay compounds reframe collection ranked according zscore top <NUMBER> hits replicate selected <NUMBER> overlapping seventyfive additional hits chosen according ranking based average zscore last <NUMBER> hits selected according drug target pathway enrichment analysis <NUMBER> prioritized hits included doseresponse confirmation assay selected hits validated immunofluorescence <NUMBER>point dose response experiment determine ec <NUMBER> compounds annotated three databases used assemble reframe library clarivate integrity gvk excelra gostar citeline pharmaprojects according variety properties including targets pathways indications mechanisms actions moa annotation property tested enrichment among screening hits using gsea software <NUMBER> <NUMBER> compounds annotated property treated gene set set vendor annotations background compound set defined set compounds annotated property vendor enrichment results p <NUMBER> fdr qvalue <NUMBER> defined significant additional enrichment analyses performed using free online metaanalysis tool metascape <NUMBER> gene expression analysis conducted using singlecell rna profiling data samples four macroanatomical locations human airway epithelium healthy living volunteers <NUMBER> generated r using pheatmap viridis packages replication one efficient ways identify antiviral candidates emergent virus sarscov<NUMBER> rapidly evaluated clinical trials repurpose clinically assessed drugs given urgent need therapeutics treat sarscov<NUMBER> infection developed highthroughput assay screen comprehensive repurposing library vero e<NUMBER> cells kidney epithelial cells derived african green monkey shown highly permissive sarscov<NUMBER> infection <NUMBER> viral replication assessed measurement viralinduced cytopathic effects cpe <NUMBER> clinical isolate sarscov<NUMBER> virus sarscov<NUMBER> hku<NUMBER>a <NUMBER> utilized assay development screening assay parameters including cell seeding density multiplicity infection moi timepoints optimized vero e<NUMBER> cells measuring virusinduced cpe using celltiterglo quantifies cellular atp levels <NUMBER>well format maximal dynamic range reproducibility found conditions <NUMBER> cellswell infection moi <NUMBER> cpe measurement <NUMBER> hours postinfection figure <NUMBER>a data shown effort assess robustness reproducibility optimized assay highthroughput screening hts configuration initially evaluated assay utilizing repositioning analysis reframe drug repurposing library since results lopac®<NUMBER> hts analysis indicated assay conditions suitable progress largescale screen used experimental design screen comprehensive reframe drug repurposing collection library inclusive collection nearly <NUMBER> chemical compounds either fdaapproved registered outside us entered clinical trials undergone significant preclinical characterization <NUMBER> specifically <NUMBER> compounds arrayed <NUMBER>well plates final concentration <NUMBER> µm previous assay vero e<NUMBER> cells seeded well prespotted compound infected <NUMBER> h later sarscov<NUMBER> moi <NUMBER> <NUMBER> hours postinfection cpe determined analysis average zʹ factor calculated activity apy<NUMBER> determined <NUMBER> reflecting acceptable assay dynamic range figure <NUMBER>c left panel screen repeated independent replicate correlation coefficient r <NUMBER> two replicates determined <NUMBER> figure <NUMBER>c based nominal pvalue cutoff <NUMBER> fdr qvalue <NUMBER> found enriched targets biological processes include allosteric modulators benzodiazepine retinoic receptors cytosolic nadphdependent oxidoreductase aldose reductase potassium channels cholesterol homeostasis serine proteases antimalarials including chloroquine derivatives ie amopyroquine aq<NUMBER> also enriched although fdr qvalue established threshold <NUMBER> figure <NUMBER>a figure s<NUMBER> table s<NUMBER> although entry receptor sarscov<NUMBER> ace<NUMBER> priming protease tmprss<NUMBER> found expressed within specific anatomical sampling locations respiratory tract figure <NUMBER>b left heatmap ace<NUMBER> expression found restricted epithelial cell types including multiciliated nasal deuterosomal secretory basal cells figure <NUMBER>b right heatmap nonetheless ace<NUMBER> expression reported induced typei interferon <NUMBER> notably majority mapped targets active compounds also harbored expression relevant respiratory epithelial cells suggesting may physiologically relevant drug targets figure <NUMBER>b pathway analyses enriched moas targets revealed enrichment genes involved nuclear receptor pathways gpcr ligand binding signaling calcium signaling figure s<NUMBER> underscoring potential critical role molecular circuits cellular control sarscov<NUMBER> life cycle <NUMBER> candidates validation studies compounds ranked according zscore primary screen figure s<NUMBER> <NUMBER> compounds replicate <NUMBER> prioritized based ranking additional <NUMBER> molecules selected found replicate <NUMBER> <NUMBER> compounds also selected according ranking calculated based average zscore replicates additional <NUMBER> hits chosen classified within enriched drug target pathway class see initially assessed activity hits half original screening concentration <NUMBER> µm using orthogonal assay readout specifically vero e<NUMBER> cells preincubated compound dilution <NUMBER> although specific compound therapeutic dose ranges typically expected track cellular ec <NUMBER> well <NUMBER> µm concentrations therefore conducted dose response analysis determine relationship compound concentration antiviral activity compound concentrations tested ranged <NUMBER> nm <NUMBER> µm immunofluorescence assay described previously total cell counts used assess compound cytotoxicity figure s<NUMBER> addition remdesivir treatment <NUMBER> compounds resulted discernable dosedependent antiviral activities could segregated based broad functional structural targetbased classes figure <NUMBER>a <NUMBER> known drugs ec <NUMBER> <NUMBER> nm values could exactly extrapolated figures <NUMBER>a figure s<NUMBER> <NUMBER> compounds harbored ec <NUMBER> <NUMBER> nm <NUMBER> reached <NUMBER> inhibiton infection highest concentration figure <NUMBER>bc suggesting effective antiviral potency could likely achieved therapeutic dosing covid<NUMBER> patient data also available reframedborg enable prioritization known drugs preclinical clinical evaluation treatment sarscov<NUMBER> summary publicly disclosed relevant preclinical clinical properties advanced among molecules annotated table <NUMBER> information retrieved cortellistm clarivate analytics drugscom since beginning january <NUMBER> extraordinary number investigational programs clinical trials initiated concerted effort identify therapeutics rapidly growing covid<NUMBER> pandemic clinical trials using report highthroughput analysis approximately <NUMBER> known drugs evaluated activity sarscov<NUMBER> replication assay conducted vero e<NUMBER> cells designed capture multicycle replication based upon low viral input moi <NUMBER> extended endpoint measurement <NUMBER> hours postinfection although cellbased assays biased towards capturing inhibitors viral entry assay constructed interrogate step viral life cycle note one potential limitation vero cells due species differences prodrugs require human host cell machinery processing active form nucleoside inhibitors may harbor potency human cells consistently found remdesivir inhibits sarscov<NUMBER> replication <NUMBER>fold potently human cells comparison vero e<NUMBER> cells figure <NUMBER>a figure s<NUMBER> data shown dynamic range viralinduced cpe assay small <NUMBER> fold robust reproducible figure <NUMBER>b optimization using lopac® <NUMBER>library first reframe collection screen displayed acceptable zʹ factors <NUMBER> <NUMBER> respectively duplicate reframe screen reduced dynamic range <NUMBER>fold corresponding zʹ factor <NUMBER> <NUMBER> although correlation two reframe replications high r <NUMBER> <NUMBER> compounds found active replicate <NUMBER> replicate <NUMBER> figure <NUMBER>c bottom right middle panel leveraged datasets select molecules validation compound selection weighted replicate <NUMBER> specifically addition <NUMBER> molecules lopac®<NUMBER> library <NUMBER> drugs selected based activity <NUMBER> additional ones belonging enriched targetmoa sets based gsea analysis also included selected compounds tested orthogonal assay directly measures viral replication contrast indirect measurement replication assessed cpe took advantage highthroughput immunofluorescence assay monitors infection levels reflected sarscov<NUMBER> n protein expression single cell resolution importantly validation step enables separation molecules function block cpe ie cell death instead direct effects replication assay found robust <NUMBER>hour timepoint using moi <NUMBER> thus antiviral activities compounds interrogated original moi <NUMBER>hour timepoint conditions earlier timepoint higher moi likely biased validation screen towards confirmation early stage inhibitors consistent hypothesis found several molecules potent ec <NUMBER> tretinoin clofazimine acitretin amongst notable validated compounds since approved fda clofazimine lipophilic riminophenazine antibiotic described antimycobacterial antiinflammatory activity <NUMBER> used treatment leprosy main adverse effects include changes skin pigmentation nausea vomiting antibacterial activity clofazimine described related ability bind bacterial dna interestingly compound also identified potent antiparasitic drug active cryptosporidium repurposing screen reframe library <NUMBER> studies required understand mechanism molecule blocks replication positivestrand rna virus determination doseresponse relationship clofazimine enable assessment whether antiviral efficacy achieved therapeutic doses acitretin approved orally bioavailable retinoid used treatment psoriasis <NUMBER> tretinoin together tamibarotene registered japan well lgd<NUMBER> tamibarotene tazarotene rbad validated compounds belonging enriched gsea class class retinoic acid agonists highly enriched gsea analysis figure <NUMBER>a currently unclear activation transcriptional program governed retinoic acid receptors may impinge upon sarscov<NUMBER> replication six additional compounds confirmed validation studies also modulate targets enriched highthroughput screen include aldose reductase inhibitor al <NUMBER> benzodiazepine receptor agonists zk<NUMBER> zaleplon gr pagoclone two antimalarial drugs aq<NUMBER> hanfangchin antimalarial drugs reported effectively block several viral infections <NUMBER> including sarscov<NUMBER> <NUMBER> however activities many particular chloroquine derivatives recapitulated clinical trials <NUMBER> <NUMBER> drugs belonging class generally reported less effective blocking viral infections compared antimalarial activity ec <NUMBER> generally µm range <NUMBER> concentration required antiviral activity could thus likely difficult reach humans without causing adverse effects taken together confirmation compounds membership enriched target classes underscore importance molecular circuits regulation sarscov<NUMBER> replication support evaluation additional preclinical clinical stage molecules target overrepresented mechanisms among <NUMBER> compounds validated show doseresponse relationship orthogonal assay <NUMBER> compounds harbored ec <NUMBER> antiviral activities <NUMBER> nm suggesting additional preclinical studies likely required determine whether administration compounds achieve sufficient systemic exposure enable antiviral activity figure s<NUMBER> seven molecules found inhibit viral replication ec <NUMBER> concentration <NUMBER> nm include z lvg chn<NUMBER> preclinical tripeptide derivative displays broadspectrum bactericidal activity specifically molecule previously shown suppress herpes simplex virus hsv replication inhibiting enzymatic activity hsvencoded cysteine protease <NUMBER> may indicate antiviral function z lvg chn<NUMBER> occurs inhibition sarscov<NUMBER> <NUMBER>clpro protease another preclinical molecule exhibits strong antiviral activity mdl <NUMBER> potent cell permeable calpain ii inhibitor interestingly mdl <NUMBER> previously found impair infection sarscov<NUMBER> ebola virus ebov <NUMBER> <NUMBER> additionally astemizole registered antihistamine h<NUMBER> receptor antagonist also reported antimalarial properties <NUMBER> inhibited replication ec <NUMBER> concentration <NUMBER> µm due fatal arrhythmias given high doses combination certain common drugs astemizole withdrawn many countries <NUMBER> therefore thorough safety studies required determine exists sufficient therapeutic index acute treatment sarscov<NUMBER> infection mln<NUMBER> ave<NUMBER> orally active chemokine ccr<NUMBER> antagonist evaluated phase ii clinical studies treatment rheumatoid arthritis ra multiple sclerosis ms <NUMBER> showing dose <NUMBER> mg daily well tolerated <NUMBER> determined inhibit sarscov<NUMBER> replication estimated ec <NUMBER> concentration <NUMBER> nm figure <NUMBER> c max compound reported <NUMBER> nm <NUMBER> mg qd therefore additional vivo studies required determine sufficient systemic concentrations reached promote antiviral activities mechanism ccr<NUMBER> antagonism inhibits sarscov<NUMBER> infection requires investigation however reported ccr<NUMBER> inhibition mln<NUMBER> potentially blocks erk phosphorylation leading suppression mitogenactivated protein kinase rafmekerk signal transduction pathway <NUMBER> interestingly rafmekerk signaling pathways employed sarscov<NUMBER> support replication via multiple welldocumented mechanisms <NUMBER> <NUMBER> thus signaling axis may also represent critical therapeutic target hostdirected sarscov<NUMBER> antivirals human cysteinyl cathepsins including cathepsin b cathepsin l cathepsin k required proteolytic processing virally encoded proteins infection <NUMBER> <NUMBER> <NUMBER> cathepsin activity seems required proper processing sarscov<NUMBER> protein within endosome order activate fusogenic acitivity <NUMBER> inhibition cathepsin l activity previously shown efficiently suppress sarscov<NUMBER> infection <NUMBER> found ono <NUMBER> cathepsin k inhibitor vby<NUMBER> reversible cathepsin protease inhibitor inhibit sarscov<NUMBER> infection dosedependent manner however additional studies required determine antiviral activities due inhibiting proteolysis viral host cellular proteins ono <NUMBER> harbored antiviral ec<NUMBER> <NUMBER> nm range previously reported <NUMBER> activity observed <NUMBER> nm osteoclastmediated bone resorption assay <NUMBER> importantly cmax compound <NUMBER> µm <NUMBER> mg qd treatment ono<NUMBER> well tolerated daily doses <NUMBER> mg <NUMBER> months without clinically relevant safety concerns ono<NUMBER> reached phase ii clinical trials treatment osteoporosis postmenopausal women development discontinued due unfavorable competitive landscape <NUMBER> <NUMBER> vby<NUMBER> preclinical development another cathepsin inhibitor harboring potential antiviral activities sarscov<NUMBER> ec<NUMBER> <NUMBER> nm shows high potency cathepsins b l v vitro <NUMBER> overall identification vby<NUMBER> ono <NUMBER> effective antiviral molecules sarcov<NUMBER> supports repositioning potentially additional protease inhibitors treatment covid<NUMBER> disease finally apilimod specific pikfyve kinase inhibitor found inhibit sarscov<NUMBER> replication ec <NUMBER> concentration <NUMBER> nm figure <NUMBER> importantly apilimod found well tolerated humans showing desirable safety profile doses ≤ <NUMBER> mg bid cmax compound <NUMBER> <NUMBER> µm <NUMBER> mg qd <NUMBER> <NUMBER> data indicate therapeutic dosing apilimod patients achieve concentrations likely promote antiviral activity apilimod evaluated phase ii clinical trials treatment active crohns disease rheumatoid arthritis ra <NUMBER> additional phase ii trials oral treatment common variable immunodeficiency cvid show efficacy indications <NUMBER> <NUMBER> <NUMBER> orphan drug designation granted apilimod us treatment follicular lymphoma <NUMBER> phase clinical trials ongoing notably reported apilimod efficiently inhibits ebov lassa virus lasv marburg virus marv human cell lines underscoring potential broadspectrum antiviral activity <NUMBER> <NUMBER> underlying mechanism inhibition sarscov<NUMBER> infection apilimod currently known however since pikfyve predominately resides early endosomes plays essential role maintenance endomembrane homeostasis apilimod likely blocks viral low phdependent entry inhibition lipid kinase activity pikfyve taken together study illuminated compendium druggable targets pathways biological processes small molecules modulate sarscov<NUMBER> replication cycle data leveraged focus studies aimed deciphering biology coronavirus guide additional directed repurposing studies particularly existing latestage preclinical assets critically campaign led identification validation <NUMBER> molecules antiviral activities sarscov<NUMBER> including four fdaapproved compounds one drug registered japan <NUMBER> molecules entered clinical trials availability human safety pharmacological data molecules expected enable rapid preclinical clinical assessment compounds however expedited regulatory review eua guidelines also provides rationale development earlier stage candidate molecules deployed use current pandemic outbreak critical multiple therapeutic options demonstrate efficacy sarscov<NUMBER> available mitigate potential emergence drug resistance well enable evaluation optimal therapeutic cocktails broadly curative covid<NUMBER> disease table <NUMBER> activity clinical profiles compounds confirmed doseactivity relationships entered clinical evaluation drug targets enriched gsea analysis hts data fdaapproved gseaenriched compounds emergence severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> virus led covid<NUMBER> coronavirus disease <NUMBER> pandemic resulted substantial overburdening healthcare systems well economic crisis global scale turn resulted widespread efforts identify suitable therapies address aggressive pathogen therapeutic antibody vaccine development actively explored phase clinical trial mrna<NUMBER> developed collaboration national institute allergy infectious diseases moderna inc currently underway timelines broad deployment vaccine antibody therapies estimated <NUMBER> months longer promising approaches may lead sustained efficacy treating covid<NUMBER> however emergence also led large number clinical trials evaluating drug combinations composed repurposed therapies study results combinations continue evaluated need move beyond traditional drug screening repurposing harnessing artificial intelligence ai optimize combination therapy design may lead rapid identification regimens mediate unexpected markedly enhanced treatment outcomes nct<NUMBER> lopinavirritonavir ribavirin interferonbeta nct<NUMBER> hydroxychloroquine azithromycin tocilizumab nct<NUMBER> others evident combinatorial drug repurposing prevalent likely fastest means identifying possible effective therapy severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> viruscovid<NUMBER> disease however current strategies used design repurposed drug combinations primarily involve codelivery therapies based mechanism action moa followed dose finding objective finding drug synergy unfortunately drug synergy guarantee successful treatment outcome approach established strongly limits range drugs considered use addition drugs consideration markedly increases parameter space searchable optimal combinations addition properly identifying right doses drug combination essential drug selection drug dosing considered sufficiently interrogating parameter space becomes insurmountable using traditional screening approaches note limited sampling parameter space virtually assured via traditional combination design screening core driver vitro results translate successfully clinic take example set <NUMBER> candidate therapies covid<NUMBER> disease indication drug <NUMBER> evaluated disease model exhibit apparent efficacy conventionally removed consideration however possible drug <NUMBER> may vital component drug combination mediates optimal treatment efficacy safety although <NUMBER>drug set represent large set candidate compounds parameter space results <NUMBER> drugs respective doses fact extraordinarily large unfortunately neither traditional drug screening traditional combination therapy design capable globally optimal drug combinations parameter space magnitude traditional screening combination therapy design may also lead insufficient surveying full drugdose parameter space resulting drug combinations comprehensively reflect unpredictable drug activity interactions leveraged globally optimize therapeutic efficacy safety addition partial drugdose parameter space screening lead combinations may exhibit suitable efficacy vitro previously mentioned cannot replicated patient level unfortunately approach often identify certain drugs combinations nonefficacious fact could clinically effective administered nonobvious combinations unexpected doses therefore lieu moabased drug selection followed synergistic dose finding simultaneous drug dose identification among highdimensional search spaces needed although well established drug dosing dosing impacts drug efficacy toxicity also determine drugs belong combination therapy regimen first place among overlooked aspects drug development barrier uniquely addressed using artificial intelligence ai importantly could enable markedly enhanced response covid<NUMBER> treatment well rapid intervention future outbreaks context deploying ai alongside infectious disease treatment roadmap important differentiate segments roadmap first aforementioned use ai drug discovery undoubtedly lead promising candidates candidates likely follow conventional longerterm drug development pathway toward clinical validation studies another segment roadmap pertains drug development involves patient matching trials note combination therapy design <NUMBER> rapid intervention needed pandemics example aibased combination therapy design represents vital strategy identify optimal regimens within matter days number promising methods previously explored effort develop infectious disease drug dr hos team spearheading multiple prospectiveinterventional clinical trials interface artificial intelligencedigital medicine disease indications including oncology infectious diseases digital therapeutics beyond elected member us national academy inventors nai fellow american institute medical biological engineering aimbe combinations <NUMBER> many resulting multidrug regimens based synergistic drug interactions amplify treatment efficacy synergy also used predict potent drug combinations design process among strategies used however aibased platforms emerged promising solutions particularly capable rapidly optimizing drug combinations without complex disease mechanism data project identifai recently developed strategy require big databased training sets rapidly pinpoint suitable drug combinations extraordinarily large parameter spaces <NUMBER> project identifai neural networkbased approach based quadratic correlation inputs defined drugs respective doses outputs defined treatment efficacy safety correlation markedly reduces number assays needed pinpoint list ranked drug combinations optimize treatment outcomes based maximized index efficacy treatment tolerability importantly project identifai implemented across vitro clinical phases drug combination validation importantly platforms served foundations development project identifai shown prior clinical successes indications ranging oncology infectious diseases specifically positive treatment outcomes observed direct ex vivo clinical validation studies hematologic cancer quadratic phenotypic optimization platform qpop <NUMBER> key role dynamic clinical dosing efficacy validated advanced solid cancer patient curateai <NUMBER> area infectious diseases lowdose treatment human immunodeficiency virus hiv shown mediate undetectable viral loads opening doors possible downstream reductions treatment complications arising side effects highdose therapy curateai <NUMBER> project identifai operates mechanism disease indicationagnostic fashion uses prospectively conducted assays composed systematically designed drugdose combinations disease model require training data prospectively conducted assays conducted way effectively survey full drugdose parameter space importantly rationally designed assays define notion way data acquired determines ability harness ai optimize treatment opposed sheer volume data prospectively executed assays completed corresponding response disease model actively drives optimization process map quadratic correlation optimized combinations identified akin agnostically crowdsourcing disease model rank us best worst drug combinations without prior knowledge drug targets addressed contrast traditional approaches involve validating set drugs set doses among massive parameter space virtually way strategy optimize right drugs right corresponding doses aidriven drug combination design serves potential first line defense determining ideal combination therapies start opposed waiting results completed trials inform subsequent treatment design aidriven combination therapy design may also avoid use suboptimal clinical treatments unnecessary patient mortality morbidity may even play role preventing downstream drug shortages looking existingongoing upcoming clinical trials covid<NUMBER> clear many varieties combinations proposed continue proposed potential solutions unfortunately many regimens may result positive outcomes range combinatorial permutations corresponding dosing ultimately assessed sufficient degree cursory examination clinical trial databases drugs repurposed resulting combinations dosing regimens reveal fraction combinatorial space addressed although clinical dosing guidelines well established part guiding protocols investigational combinations deployed opportunity harness platforms identifai substantially increase degree actionability interventions developed drug combinations eventually optimized using aidriven related methods new capabilities likely emerge example aidriven optimization conducted varying stages infection likely result drugdose compositions rankings correspond stage pathogens evolve time ability rapidly intervene using aidriven reoptimization may also enabled despite considerable challenges encountered covid<NUMBER> therapy results observed thus far represent opportunity unite multinational capabilities infectious disease drug development ai develop broadly deployable regimens benefit global community present novartis mylan teva pharmaceuticals bayer collectively committed donating <NUMBER> million chloroquine hydroxychloroquine tablets efforts backed manufacturing capabilities torrent pharmaceuticals cadila pharmaceuticals ipca laboratories among others gilead sciences committed donating <NUMBER> million doses remdesivir toyama chemical also committed favipiravir therapy free global community complement trials currently underway world health organization initiated solidarity clinical trial effort facilitate data sharing accelerate assessment treatment outcomes multiple regimens studied across globe include local standard care addition remdesivir chloroquine hydroxychloroquine ritonavir lopinavir ritonavir lopinavir interferon beta <NUMBER>alpha collection monotherapies combinations assessed represents ideal opportunity ai deployment systematic derivation actionably optimized regimens potentially provide path toward sustained preparedness future outbreaks pandemic prevention sarscov<NUMBER> previously <NUMBER>ncov wuhan coronavirus caused unprecedented fastspreading worldwide pandemic although currently rather low mortality rate virus spread rapidly world using modern worlds traffic highways coronavirus cov family members responsible several deadly outbreaks epidemics last decade governments also scientific community reacted promptly outbreak information shared quickly example genetic fingerprint shared <NUMBER>d structure key proteins rapidly solved used discovery potential treatments overview given current knowledge spread disease course molecular biology sarscov<NUMBER> discuss potential treatment developments context recent outbreaks drug repurposing development timelines december <NUMBER> outbreak pneumonia unknown cause reported wuhan hubei province china speculated first patient caught infection seafood market also traded wild animals causing agent quickly identified novel coronavirus cov cov responsible outbreak called sarscov<NUMBER> respiratory illness caused sarscov<NUMBER> called covid<NUMBER> symptoms sarscov<NUMBER> infection range asymptomatic mild severe death <NUMBER> soon became clear persontoperson transmission also occurring case previous human cov unprecedented documented speed sarscov<NUMBER> travels around globe april <NUMBER> th led <NUMBER> million infections <NUMBER> fatalities based previous experience sarscov outbreak beginning century stringent measures taken chinese government several multimillioninhabitant cities isolated put quarantine order slow pandemic spread different hosts sarscov<NUMBER> proposed including snails bats pangolins <NUMBER> covs large family zoonotic viruses outbreaks common humans although major outbreaks experienced animals especially cattle electron microscope exhibit formations reminiscent solar corona common cold often caused human covs singlestranded enveloped positive rna viruses stand rather large genome viruses general structure rather simple sarscov<NUMBER> generally less pathogenic sarscov much less pathogenic middle east respiratory syndrome merscov pathogenic practically harmless hcovoc<NUMBER> hcovhku<NUMBER> hcov<NUMBER>e hcovnl<NUMBER> reported casefatality rate covid<NUMBER> <NUMBER> thus rather low compared sars <NUMBER> table <NUMBER> however transmission rate tr number newly infected people per infected person <NUMBER> <NUMBER> high accounts danger current pandemic comparison tr yearly common cold less <NUMBER> challenges opportunities sarscov<NUMBER> pandemic changed world half year large number people died virusinduced pneumonia covid<NUMBER> global economy unprecedented low unknown nearand longterm consequences coronavirus pandemic needs twopronged approach shortterm solution find drug treat massive number seriously ill patients longterm development preventive curative drugs future corona outbreaks de novo discovery therapeutic takes years move idea q<NUMBER> preclinic market release shortterm solution current sarscov<NUMBER> pandemic drug repurposing perhaps shortterm solution vaccination middleterm solution advice guidelines diagnosis treatment sarscov<NUMBER> infected pneumonia shared rapidly <NUMBER> issues chances rapid approval new medicine treat covid<NUMBER> principle several potential strategies pharmacologically fight covid<NUMBER> vaccines monoclonal antibodies oligonucleotidebased therapies peptides interferon therapies smallmolecule drugs natural medicines eg traditional chinese medicine tcm timelines de novo development smallmolecule drug historically <NUMBER> years best case less <NUMBER> years vaccines developed much faster rapid development range <NUMBER> years challenging antibodies support bodys immune system also strategy combat viral diseases typical development timelines several years therefore hope q<NUMBER> rapid drug come market strategy promising current situation drug repurposing drug repurposing aims discover novel indication areas already approved drugs <NUMBER> overwhelming advantage drug repurposing potential much faster approval already extensive knowledge drugs behavior humans expert opinion potential repurposing existing antiviral agents treat covid<NUMBER> already clinically evaluated recently given <NUMBER> discuss molecular targets sarscov<NUMBER> known small molecules potential repurposing existing drugs despite rather large size rna virus genome <NUMBER> bases sarscov<NUMBER> genome encodes proteins figure <NUMBER> structural spike protein nucleocapsid n protein membrane protein envelope e protein needed produce structurally complete viral particle additionally sarscov<NUMBER> genome encodes <NUMBER> nonstructural proteins ns<NUMBER> ns<NUMBER> <NUMBER>chymotrypsinlike protease <NUMBER>clpro q<NUMBER> papainlike protease plpro helicase rnadependent rna polymerase rdrp virusencoded proteases q<NUMBER> involved processing two viral polyproteins coordinated manner thus comprise important drug targets structure function inhibition cov <NUMBER>clpro also called mpro recently comprehensively reviewed <NUMBER> <NUMBER>clpro cysteine protease cleaves processes viral polyproteins sarscov<NUMBER> sarscov share <NUMBER> sequence identity <NUMBER>clpro basis rapidly published virus sequence data homology model created moreover xray structure c<NUMBER>lpro covalently bound peptidomimetic acrylester <NUMBER> available figure <NUMBER> pdb id <NUMBER>lu<NUMBER> <NUMBER> high sequence similarity different cov <NUMBER>clpros lot previously described inhibitors considered great use current sarscov<NUMBER> majority inhibitors <NUMBER>clpro covalent nature binding activesite cysteine scheme <NUMBER> different electrophilic warheads known including ahalocarbonyl acrylamides sulfonyl chlorides aldehydes <NUMBER> <NUMBER> isatines <NUMBER> <NUMBER> aketoheteraromates <NUMBER> <NUMBER> many molecules rather large based extensive amide chemistry mimicking part peptide substrate protease moreover selectivity toward potential targets human body established interestingly compounds binding active site <NUMBER>clproalthough using noncovalent mechanismhave established highthroughput screening hts identified <NUMBER>dihydropyrazolidine <NUMBER> displayed <NUMBER>triaryl substitution patterns sarscov <NUMBER>clpro inhibitors <NUMBER> nitroanilides <NUMBER> derived drug niclosamide also found inhibit <NUMBER>clpro <NUMBER> aaminoacylamides identified hts strong stereochemical effect noted simple onepot accessible scaffold ugifour component condensation key rapidly generate structure activity relationship sar putative p<NUMBER>p<NUMBER> p<NUMBER> subgroups optimized version ml<NUMBER> <NUMBER> designated probe status figure <NUMBER> p<NUMBER> truncated version <NUMBER> allowing significant molecular weight mw reduction without diminishing potency developed second probe ml<NUMBER> <NUMBER> potent enzyme inhibition cellular activity compounds comprise rare examples noncovalent sarscov <NUMBER>clpro inhibitor moderate mw good enzyme antiviral inhibitory activity however molecules suffer extensive metabolism rapid clearance nonetheless promising starting point drug development even compounds cannot rapidly developed cope current situation development highly warranted prepared likely future cov outbreaks noteworthy different computational approaches including machine learning published propose approved drugs potentially binding <NUMBER>clpro drug repurposing <NUMBER> <NUMBER> one approach virtually screened commercial medicines drugbank database binding active site mpro <NUMBER> ten different commercial medicines proposed might form hydrogen bonds key residues within binding pocket sarscov<NUMBER> <NUMBER>clpro might higher mutation tolerance lopinavir ritonavir flavonoids <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> plantderived natural products diverse reported biological activities shown also able inhibit <NUMBER>clpro figure <NUMBER> <NUMBER> <NUMBER> broadspectrum established use plantbased medicines combat infectious diseases tcm basis several currently ongoing clinical trials china one largest among assesses shuanghuanglian chinese herbal medicine contains extracts dried fruit lianqiao forsythiae fructus purported used treating infections <NUMBER> years several approved hiv protease inhibitors <NUMBER> <NUMBER> <NUMBER> previously repurposed treatment sars scheme <NUMBER> <NUMBER> <NUMBER> <NUMBER> hypothesized inhibit sarscov <NUMBER>clpro hiv protease asp protease differs considerably cys protease <NUMBER>clpro also shares common elements tetrahedral transition state receptor pockets recognize amino acid side chains substrates given sarscov<NUMBER> sarscov share high identical sequence <NUMBER>clpro hiv protease inhibitors currently repurposed treatment covid<NUMBER> chinese clinical trial registry chictr<NUMBER> <NUMBER> <NUMBER> <NUMBER> plpro coronaviral plpro another attractive antiviral drug target essential cov replication structure function inhibition sarscov plpro extensively reviewed <NUMBER> although primary function plpro <NUMBER>clpro process viral polyprotein coordinated manner plpro additional function stripping ubiquitin isg<NUMBER> hostcell proteins help cov evade host innate immune responses therefore recently argued targeting plpro antiviral drugs might advantage inhibiting viral replication also inhibiting dysregulation signaling cascades infected cells might lead cell death surrounding uninfected cells <NUMBER> different compounds forming covalent bond activesite cys<NUMBER> described including epoxyketones ahaloketones alkynes aldehydes trifluoromethyl ketones abunsaturated ketone activated esters vinyl sulfones disulfiram <NUMBER> approved drug treatment chronic alcohol dependence great potential drug repurposing shown inhibit plpro merscov sarscov <NUMBER> antimetabolites <NUMBER>mercaptopurine <NUMBER> <NUMBER>thioguanine <NUMBER> additional drugs inhibiting plpro potent naphthyl methylamine q<NUMBER> hits <NUMBER> structurally characterized subsequently optimized toward better metabolic stability identified hts campaign <NUMBER> <NUMBER> <NUMBER> naphthyl methylamines work noncovalent mechanism show rather druglike appearance figure <NUMBER> envelopeanchored protein mediates cov entry host cells first binding host receptor fusing viral host membranes sarscov<NUMBER> protein solved cryoelectron microscopy released <NUMBER> knowing å resolution structure sarscov<NUMBER> spike allow additional protein engineering efforts could improve antigenicity protein expression vaccine development moreover å resolution detail enable design screening small molecules fusioninhibiting potential affinity viral receptorbinding domain rbd host receptor initial viral attachment step primarily determines host susceptible sarscov infection sarscov<NUMBER> entry receptor binding elucidated independently several groups <NUMBER> <NUMBER> basis rich knowledge sarscov sequence homology suggested sarscov<NUMBER> uses angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor figure <NUMBER> uses sarscov receptor ace<NUMBER> cellular protease tmprss<NUMBER> entry target cells <NUMBER> <NUMBER> interplay ace receptor cardiovascular diseases wellknown drug class ace inhibitors docking point sarscov<NUMBER> cellular infection current point intense debate research <NUMBER> found several critical residues sarscov<NUMBER> rbm particularly gln<NUMBER> provide favorable interactions human ace<NUMBER> consistent sarscov<NUMBER>s capacity human cell infection basis extensive modeling virushuman receptor interactions also predicted single n<NUMBER>t mutation might significantly enhance binding affinity sarscov<NUMBER> rbd human ace<NUMBER> thus potentially lead much virulent bodies <NUMBER> <NUMBER> emergency evolution novel mutations <NUMBER> position sarscov<NUMBER>infected covid<NUMBER> patients closely monitored <NUMBER> mutations protein ones causing zoonosis result lead binding ace<NUMBER> therefore drugs targeting proteinace<NUMBER> interaction might apply future covs hand spikeshaped protein surface viruses causing sars mers covid<NUMBER> provides tantalizing target antibodies compounds could prevent covs invading human cells <NUMBER> virus protein seems emerge consensus target antigen rdrp enzyme allows viral genome transcribed new rna copies using host cells machinery rdrp inhibitors emerging new strategy fight viral infections <NUMBER> chemistry biology rdrp extensively reviewed <NUMBER> rna polymerase inhibitors promising agents fight covid<NUMBER> <NUMBER> rdrp proteins sarscov<NUMBER> sarscov share <NUMBER> sequence identity favipiravir <NUMBER> approved rna polymerase inhibitor treatment influenza pandemic shown active influenza also active rna viruses figure <NUMBER> <NUMBER> favipiravir prodrug metabolized cells active purine nucleotide mimics favipiravirribofuranosyl<NUMBER>triphosphate inhibits rna replication thus viral progression <NUMBER> interestingly inhibit host dna rna synthesis inosine <NUMBER> <NUMBER> monophosphate dehydrogenase impdh activity favipiravir reportedly demonstrated efficacy minor side effects ongoing <NUMBER>patient clinical trial shenzhen guangdong province <NUMBER> drugs generic version received approval health authorities china <NUMBER> broadspectrum antiviral drug remdesivir together chloroquine effectively inhibit recently emerged novel cov sarscov<NUMBER> vitro <NUMBER> <NUMBER> remdesivir <NUMBER> reduced sarscov<NUMBER> infection monkey kidney cells ec <NUMBER> <NUMBER> mm compound latestage clinical development recently described inhibit multiple rna viruses cellular level including ebola sars presumed mode action adenosine analog prodrug remdesivir premature rna synthesis termination incorporation nascent viral rna chains <NUMBER> galidesivir <NUMBER> another antiviral drug clinical development potential covid<NUMBER> treatment figure <NUMBER> adenosine analog currently developed ebola virus disease marburg virus disease also shows broadspectrum antiviral activity rna virus families including covs <NUMBER> multiple rdrp inhibitors described literature example broadspectrum antiviral <NUMBER> <NUMBER> bis fluorinated aristeromycin analog <NUMBER> <NUMBER> chloroquine <NUMBER> existing antimalaria medicine also used treat several diseases blocked virus infection ec <NUMBER> <NUMBER> mm <NUMBER> <NUMBER> mode action unclear however chloroquine inhibits endosomal acidification thus could stop release viral dna cytoplasm assessment <NUMBER> patients ten hospitals beijing guangdong province plans additional study hunan province underway role sarscov<NUMBER> n proteins drugdiscovery targets less clear assembly replication q<NUMBER> transcription complexes vast interaction network described nonstructural proteins similarly viral particle assembly requires orchestrated interaction n e proteins interactions potential targets structural information currently minimal resolution protein complex structures provide new unique drug targets example crystal structure sarscov<NUMBER> n protein rnabinding domain published give structural insight potential drug target <NUMBER> rapidly detected antibodies serum plasma peripheral blood might therefore serve develop specific diagnostics using methods machine learningenabled scientific literature analysis biotech company benevolentai q<NUMBER> proposed ap<NUMBER>associated protein kinase <NUMBER> aak<NUMBER> host target fight sarscov<NUMBER> aak<NUMBER> key enzyme receptormediated endocytosis major mechanism viruses enter host cells thus predict approved rheumatoid arthritis kinase inhibitor baricitinib <NUMBER> reduce ability virus infect lung cells figure <NUMBER> <NUMBER> recent emergence wuhan cov sarscov<NUMBER> put world alert rapid worldwide spread high humantohuman transmissibility combined inability contain pandemic causing increasing death toll also considerable paralysis world economy table <NUMBER> q<NUMBER> covid<NUMBER> could decrease disappear could established worldwide human population reoccur seasonally future mutations zoonosis one animal reservoirs however likely upcoming years see outbreaks cov viruses basic translational public health research communities prepare much better outbreak emphasized urgent need renewed efforts develop broadspectrum antiviral agents combat covs positive side much new information virus biology spread immediately shared whereas negative side many past opportunities develop antivirals covs taken despite large number promising approaches compounds <NUMBER> past decade shown cov outbreaks regularly reoccurring less health effect human livestock remains hoped current pandemic slow end predicted summer furthermore turns containment measures effective avoid severe spread remains seen whether efficient longlasting immunity develop infected population regard future outbreaks whether pharmacological measures rapidly developed able treat severely sick people ad lg wrote manuscript drug development research infectious diseases led number effective therapies twentieth century however still many diseases drugs vaccines available diseases caused influenza virus hepatitis c virus treatments suboptimal effective subset population reductionist structurebased drug design efforts rely de novo predictions select set small molecules compounds interact targeted pathogen host proteins predictions typically difficult time consuming costly additional approaches needed discover new treatments improve existing ones one promising approach drug repurposing repositioning applying known drugs compounds new indications <NUMBER> <NUMBER> although idea new past techniques relied hypothesisdriven approaches usually involve computational matching compounds specific viral human proteins requiring large amount expert knowledge chemical compound drug target study recent developments opened door using drug repurposing approaches rely generating empirical data related binding characteristics mechanism action instead approaches use methods systems biology bioinformatics directly compare host response pathogen drug computational methods used paradigm vary complexity genomic signature comparisons complicated interaction networks combination systematic databases druginduced gene expression profiles methods utilize data variety highthroughput techniques eg transcriptomics proteomics metabolomics thus allowing identification potential host drug targets globalscale fig <NUMBER> due significantly reduced timeframe predicting host molecules effective therapeutic intervention compounds typically previously fdaapproved drugs small molecules approaches potential greatly reduce time cost associated drug development importantly already successful application approaches several disease indications <NUMBER> time therefore hand infectious disease field embrace new paradigm effort improve effective drug discovery illustrate immediate accessibility potential approach discuss examples outside infectious disease field relied systemswide host response datasets publicly available datasets known drugs small molecules computational approaches used predict potentially effective diseasedrug combinations simplest terms inverse genomic signature approach based premise effective drug generates gene expression profile inversely correlated host signature associated disease approach incorporates complexity genomewide response host disease treatment rooted scalar theory <NUMBER> <NUMBER> <NUMBER> mrna expression profiles contain information associated higherlevel protein interactions concordant either disease drug treatment examples approach use connectivity map cmap <NUMBER> public database httpwwwbroadinstituteorgcmap version <NUMBER> holds <NUMBER> transcriptome profiles established downstream treatment human cell lines <NUMBER> compounds fdaapproved drugs addition transcriptome profiles cmap resource provides analytical tools among things calculate connectivity score score measure inverse similarity negative correlation signatures example dudley et al used method identify new therapeutic agents inflammatory bowel disease ibd progressive inflammatory disorder known cure current treatments severe side effects expensive ineffective many individuals <NUMBER> study modified version computational methodology developed lamb et al <NUMBER> <NUMBER> used compare compendium <NUMBER> known drug compounds cmap ibdspecific gene expression signature derived <NUMBER> datasets available gene expression omnibus geo two strongest anticorrelated treatment signatures prednisolone wellknown treatment crohns disease major type ibd topiramate anticonvulsant drug used treat epilepsy using rodent model ibd shown topiramate significantly reduced gross pathology microscopic damage affected colon compared seen control animals importantly topiramates side effects treatment neurological symptoms humans severe current ibd treatments one first applications approach infectious disease josset et al used host transcriptional response influenza virus query cmap database <NUMBER> majority current antiviral drugs target specific viral proteins making narrow spectrum vulnerable emergence viral resistance josset coworkers reasoned treating virus infection stimulating manipulating innate immune response targeting cellular factors required viral life cycle would prove advantageous traditional approach targeting viral protein common gene expression signature consisting <NUMBER> dysregulated genes identified human a<NUMBER> lung epithelial cells infected human h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> avian h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> influenza virus cmap database queried identify candidate compounds genomic signatures inversely correlated common influenza virusinduced host transcriptome profile eight candidate drugs identified majority approved indications six drugs inhibited viral growth vitro assays importantly five eight also inhibited growth pandemic <NUMBER> h<NUMBER>n<NUMBER> influenza virus used define common signature approach therefore potential identify drugs effective spectrum related viruses additional exciting aspect inverse genomic signature approach ability rapidly identify potential drugs emerging infectious diseases demonstrated recent study laboratory determined host response newly discovered middle eastern respiratory syndrome coronavirus merscov <NUMBER> merscov first identified saudi arabia september <NUMBER> since caused least <NUMBER> confirmed infections resulting <NUMBER> deaths using human calu<NUMBER> cells cell line derived epithelial cells lining human conducting airway global transcriptional profiling host response <NUMBER>gene signature early host response identified using signature two independent bioinformatics tools cmap connectivity score ipa upstream regulator analysis ingenuity systems wwwingenuitycom two kinase inhibitors sb<NUMBER> ly<NUMBER> identified potential antimerscov treatments validate top predicted negative regulator cells treated sb<NUMBER> prior merscov infection resulted significant reduction viral titers <NUMBER> <NUMBER> hours post infection study demonstrates potential silico approaches predict drug candidates vitro efficacy sb<NUMBER> merscov whereas studies described focused use gene expression patterns also possible take advantage deeper understanding host response comes network modeling biomolecular networks connect molecular components genes proteins metabolites specific types interactions used represent functional relationship among various components network <NUMBER> functional relationships physical chemical interactions genetic regulatory interactions associations networks may constructed capture various scales ranging molecular cellular levels tissue organismal levels network dynamics analyzed provide information complex diseases infer novel relationships reveal emergent properties biological system application systems biology infectious disease research increasingly used identify host targets antimicrobial therapeutics prediction novel pathogen virulence factors <NUMBER> <NUMBER> <NUMBER> wealth functional genomics data publically available network pharmacology begin make inroads infectious disease research although indepth review networkbased approaches drug repurposing beyond scope article several recent reviews focused complexity human disease networks <NUMBER> tools analyzing network topology dynamics <NUMBER> network drug combinations <NUMBER> discuss recent studies used networkbased approaches target identification drug discovery identify novel genes drug targeting barrenäs et al <NUMBER> built upon knowledge genes containing diseaseassociated snps tend form highly connected clusters proteinprotein interaction networks genes differentially expressed complex diseases information used identify highly interconnected gene clusters coresusceptibility modules <NUMBER> highly diverse complex diseases done constructing individual diseasespecific networks using global human proteinprotein interaction network gene expression datasets disease <NUMBER> highly interconnected clusters overlapped disease networks determined use permutation test revealed significant level snp enrichment obtained <NUMBER> coresusceptibility module compared whole proteinprotein interaction network test correlation coresusceptibility modules snps could identify novel host drug targets novel genes associated disease susceptibility network construction analysis repeated using gene expression snp datasets another complex disease seasonal allergic rhinitis sar ie hay fever analysis identified two novel sarassociated genes fibroblast growth factor <NUMBER> fgf<NUMBER> mitogenactivated protein kinase <NUMBER> mapk<NUMBER> latter known play role type <NUMBER> allergic inflammation potential functional relevance fgf<NUMBER> drug target confirmed knocked polarized th<NUMBER> cells resulted dysregulation genes involved type <NUMBER> allergic inflammation drug repurposing strategies may also valuable finding therapeutics rare diseases little financial incentive drug development example mei et al <NUMBER> used multiplelevel network modeling mlnm approach identify drugs treat rare central nervous systems cns diseases using publically available diseasegene expression profiles pathophysiological pathway analysis information fdaapproved drugs latestage compounds integrated cns disease network constructed diseases linked relationship degree commonly shared pathways expression patterns responses drugs compounds using robust association statistical cutoffs hierarchical clustering hypothesis similar diseases caused dysregulation related pathways several potential drugs identified example results predicted parkinsons disease drugs could effectively repurposed therapy basal ganglia disease similarly approach showed multiple sclerosis ms neuromyelitis optica autoimmune disorder consisting simultaneous inflammation demyelination optic nerve spinal cord share common mechanistic pathways suggesting ms drugs could effective diseases novel approach daminelli et al used offtarget effects known promiscuous drugs advantage networkbased strategy integrated publically available drugtarget drugdisease interactions <NUMBER> using resulting integrated drugtargetdisease network new links drugs targets diseases identified evaluated example quercetin bioflavonoid antiinflammatory antioxidant properties <NUMBER> resveratrol polyphenolic compound found red wine speculated explain french paradox <NUMBER> predicted bind two targets pik<NUMBER>gc lta<NUMBER>h known binding partners quercetin resveratrol respectively potentially effective neoplasms cardiovascular diseases literature search revealed quercetin binding lta<NUMBER>h recently verified using vitro pulldown assay although resveratrol appear bind directly pik<NUMBER>gc inhibit pik<NUMBER>gc phosphorylation reported antitumor activity <NUMBER> <NUMBER> <NUMBER> drug repurposing approaches therefore show promise identifying drugs treat variety diseases including infectious disease however also caveats aware steps taken ensure approaches bear fruit instance publically available drug profiles obtained using cell lines model systems meaning information related intercellular mechanisms captured additional public funding needed extensive databases expand number drugs profiled model systems used equally important availability datasets host response infectious diseases end national institute allergy infectious diseases niaid sponsored five systems biology centers infectious disease research <NUMBER> centers focus modeling host response pathogens influenza virus sarscov mycobacterium tuberculosis salmonella typhimurium yersinia pestis recently malaria parasites resulting hostresponse datasets along significant amount metadata captured niaid bioinformatics resource centers thereby allowing investigators use extensive systematically obtained genomic proteomic metabolomic datasets computational studies also currently limitations computational tools used integrate drug hostresponse profiles existing patternmatching techniques use prior knowledge form gene ontology functional annotation databases gokegg ingenuity pathway analysis limits searchable patterns already known pathways additionally cmap searched simple short differentially expressed gene lists rather complex datasets obtained using multiple biological conditions covering human genes results greater bias lower throughput additional methods need developed overcome limitations course potential drugs identified approaches steps must still taken validate clinical efficacy <NUMBER> review highlighted use mrna proteomic profiles however systemwide metrics could potentially used including profiles micrornas long noncoding rnas epigenetic modifications recent us supreme court decision ban patents human genes hard imagine soon individuals genetic makeup personal genomic disease signatures screened drug databases tailored personalized medical treatment finally identifying compounds already evaluated human subjects drug repurposing approaches may particular benefit identifying treatments employed rare emerging infectious diseases adjunct common approaches highthroughput screening structurebased drug design computational drug repurposing potential rapidly translate insights gained systems biology drug discovery strategy directly applicable treatment infectious disease • infectious disease investigators need embrace new drug repurposing approaches • key components include public databases predictive computational methods • approach could significantly reduce cost time drug development • support large scale drug disease phenotype screening essential components drug repurposing paradigm systemwide phenotypic datasets mrna expression proteomics metabolomics collected characterization host response drugs pathogens submitted public repositories allows data integration comparisons using variety bioinformatics computational methods including inverse genomic signature networkbased approaches analyses result drug repurposing predictions identify potentially effective fdaapproved drugs therapeutics corresponding infection diseases drug development research infectious diseases led number effective therapies <NUMBER>th century however still many diseases drugs vaccines available diseases caused influenza virus hepatitis c virus treatments suboptimal effective subset population reductionist structurebased drug design efforts rely de novo predictions select set small molecules compounds interact targeted pathogen host proteins predictions typically difficult time consuming costly additional approaches needed discover new treatments improve existing ones one promising approach drug repurposing repositioning applying known drugs compounds new indications <NUMBER> <NUMBER> although idea new past techniques relied hypothesisdriven approaches usually involve computational matching compounds specific viral human proteins requiring large amount expert knowledge chemical compound drug target study recent developments opened door using drug repurposing approaches rely generating empirical data related binding characteristics mechanism action instead approaches use methods systems biology bioinformatics directly compare host response pathogen drug computational methods used paradigm vary complexity genomic signature comparisons complicated interaction networks combination systematic databases druginduced gene expression profiles methods utilize data variety highthroughput techniques eg transcriptomics proteomics metabolomics thus allowing identification potential host drug targets globalscale figure <NUMBER> significantly reduced timeframe predicting host molecules effective therapeutic intervention compounds typically previously fdaapproved drugs small molecules approaches potential greatly reduce time cost associated drug development importantly already successful application approaches several disease indications <NUMBER> time therefore hand infectious disease field embrace new paradigm effort improve effective drug discovery illustrate immediate accessibility potential approach discuss examples outside infectious disease field relied systemswide host response datasets publicly available datasets known drugs small molecules computational approaches used predict potentially effective diseasedrug combinations simplest terms inverse genomic signature approach based premise effective drug generates gene expression profile inversely correlated host signature associated disease approach incorporates complexity genomewide response host disease treatment rooted scalar theory <NUMBER> <NUMBER> mrna expression profiles contain information associated higherlevel protein interactions concordant either disease drug treatment examples approach use connectivity map cmap <NUMBER> public database httpwwwbroadinstituteorg cmap version <NUMBER> holds <NUMBER> transcriptome profiles established downstream treatment human cell lines <NUMBER> compounds fdaapproved drugs addition transcriptome profiles cmap resource provides analytical tools among things calculate connectivity score score measure inverse similarity negative correlation signatures example dudley et al used method identify new therapeutic agents inflammatory bowel disease ibd progressive inflammatory disorder known cure current treatments severe side effects expensive ineffective many individuals <NUMBER> study modified version computational methodology developed lamb et al <NUMBER> <NUMBER> used compare compendium <NUMBER> known drug compounds cmap ibdspecific gene expression signature derived <NUMBER> datasets available gene expression omnibus geo two strongest anticorrelated treatment signatures prednisolone wellknown treatment crohns disease major type ibd topiramate anticonvulsant drug used treat epilepsy using rodent model ibd shown topiramate significantly reduced gross pathology microscopic damage affected colon compared seen control animals importantly topiramates side effects treatment neurological symptoms humans severe current ibd treatments drug repurposing infectious disease drug discovery law et al <NUMBER> host response components drug repurposing paradigm systemwide phenotypic datasets mrna expression proteomics metabolomics collected characterization host response drugs pathogens submitted public repositories allows data integration comparisons using variety bioinformatics computational methods including inverse genomic signature networkbased approaches analyses result drug repurposing predictions identify potentially effective fdaapproved drugs therapeutics corresponding infection diseases one first applications approach infectious disease josset et al used host transcriptional response influenza virus query cmap database <NUMBER> majority current antiviral drugs target specific viral proteins making narrow spectrum vulnerable emergence viral resistance josset coworkers reasoned treating virus infection stimulating manipulating innate immune response targeting cellular factors required viral life cycle would prove advantageous traditional approach targeting viral protein common gene expression signature consisting <NUMBER> dysregulated genes identified human a<NUMBER> lung epithelial cells infected human h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> avian h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> influenza virus cmap database queried identify candidate compounds genomic signatures inversely correlated common influenza virusinduced host transcriptome profile eight candidate drugs identified majority approved indications six drugs inhibited viral growth vitro assays importantly five eight also inhibited growth pandemic <NUMBER> h<NUMBER>n<NUMBER> influenza virus used define common signature approach therefore potential identify drugs effective spectrum related viruses additional exciting aspect inverse genomic signature approach ability rapidly identify potential drugs emerging infectious diseases demonstrated recent study laboratory determined host response newly discovered middle eastern respiratory syndrome coronavirus merscov <NUMBER> merscov first identified saudi arabia september <NUMBER> since caused least <NUMBER> confirmed infections resulting <NUMBER> deaths using human calu<NUMBER> cells cell line derived epithelial cells lining human conducting airway global transcriptional profiling host response <NUMBER>gene signature early host response identified using signature two independent bioinformatics tools cmap connectivity score ipa upstream regulator analysis ingenuity systems wwwingenuitycom two kinase inhibitors sb<NUMBER> ly<NUMBER> identified potential antimerscov treatments validate top predicted negative regulator cells treated sb<NUMBER> merscov infection resulted significant reduction viral titers <NUMBER> <NUMBER> hours post infection study demonstrates potential silico approaches predict drug candidates vitro efficacy sb<NUMBER> merscov whereas studies described focused use gene expression patterns also possible take advantage deeper understanding host response comes network modeling biomolecular networks connect molecular components genes proteins metabolites specific types interactions used represent functional relationship among various components network <NUMBER> functional relationships physical chemical interactions genetic regulatory interactions associations networks may constructed capture various scales ranging molecular cellular levels tissue organismal levels network dynamics analyzed provide information complex diseases infer novel relationships reveal emergent properties biological system application systems biology infectious disease research increasingly used identify host targets antimicrobial therapeutics prediction novel pathogen virulence factors <NUMBER> <NUMBER> <NUMBER> wealth functional genomics data publicly available network pharmacology begin make inroads infectious disease research although indepth review networkbased approaches drug repurposing beyond scope article several recent reviews focused complexity human disease networks <NUMBER> tools analyzing network topology dynamics <NUMBER> network drug combinations <NUMBER> discuss recent studies used networkbased approaches target identification drug discovery identify novel genes drug targeting barrenas et al <NUMBER> built upon knowledge genes containing diseaseassociated snps tend form highly connected clusters proteinprotein interaction networks genes differentially expressed complex diseases information used identify highly interconnected gene clusters coresusceptibility modules <NUMBER> highly diverse complex diseases done constructing individual diseasespecific networks using global human proteinprotein interaction network gene expression datasets disease <NUMBER> highly interconnected clusters overlapped disease networks determined use permutation test revealed significant level snp enrichment obtained <NUMBER> coresusceptibility module compared whole proteinprotein interaction network test correlation coresusceptibility modules snps could identify novel host drug targets novel genes associated disease susceptibility network construction analysis repeated using gene expression snp datasets another complex disease seasonal allergic rhinitis sar ie hay fever analysis identified two novel sarassociated genes fibroblast growth factor <NUMBER> fgf<NUMBER> mitogenactivated protein kinase <NUMBER> mapk<NUMBER> latter known play role type <NUMBER> allergic inflammation potential functional relevance fgf<NUMBER> drug target confirmed knocked polarized th<NUMBER> cells resulted dysregulation genes involved type <NUMBER> allergic inflammation drug repurposing strategies may also valuable finding therapeutics rare diseases little financial incentive drug development example mei et al <NUMBER> used multiplelevel network modeling mlnm approach identify drugs treat rare central nervous systems cns diseases using publicly available diseasegene expression profiles pathophysiological pathway analysis information fdaapproved drugs latestage compounds integrated cns disease network constructed diseases linked relationship degree commonly shared pathways expression patterns responses drugs compounds using robust association statistical cutoffs hierarchical clustering hypothesis similar diseases caused dysregulation related pathways several potential drugs identified example results predicted parkinsons disease drugs could effectively repurposed therapy basal ganglia disease similarly approach showed multiple sclerosis ms neuromyelitis optica autoimmune disorder consisting simultaneous inflammation demyelination optic nerve spinal cord share common mechanistic pathways suggesting ms drugs could effective diseases novel approach daminelli et al used offtarget effects known promiscuous drugs advantage networkbased strategy integrated publicly available drugtarget drugdisease interactions <NUMBER> using resulting integrated drugtargetdisease network new links drugs targets diseases identified evaluated example quercetin bioflavonoid antiinflammatory antioxidant properties <NUMBER> resveratrol polyphenolic compound found red wine speculated explain french paradox <NUMBER> predicted bind two targets pik<NUMBER>gc lta<NUMBER>h known binding partners quercetin resveratrol respectively potentially effective neoplasms cardiovascular diseases literature search revealed quercetin binding lta<NUMBER>h recently verified using vitro pulldown assay although resveratrol appear bind directly pik<NUMBER>gc inhibit pik<NUMBER>gc phosphorylation reported antitumor activity <NUMBER> <NUMBER> <NUMBER> drug repurposing approaches therefore show promise identifying drugs treat variety diseases including infectious disease however also caveats aware steps taken ensure approaches bear fruit instance publicly available drug profiles obtained using cell lines model systems meaning information related intercellular mechanisms captured additional public funding needed extensive databases expand number drugs profiled model systems used equally important availability datasets host response infectious diseases end national institute allergy infectious diseases niaid sponsored five systems biology centers infectious disease research <NUMBER> centers focus modeling host response pathogens influenza virus sarscov mycobacterium tuberculosis salmonella typhimurium yersinia pestis recently malaria parasites resulting hostresponse datasets along significant amount metadata captured niaid bioinformatics resource centers thereby allowing investigators use extensive systematically obtained genomic proteomic metabolomic datasets computational studies also currently limitations computational tools used integrate drug hostresponse profiles existing patternmatching techniques use prior knowledge form gene ontology functional annotation databases gokegg ingenuity pathway analysis limits searchable patterns already known pathways additionally cmap searched simple short differentially expressed gene lists rather complex datasets obtained using multiple biological conditions covering human genes results greater bias lower throughput additional methods need developed overcome limitations course potential drugs identified approaches steps must still taken validate clinical efficacy <NUMBER> review highlighted use mrna proteomic profiles however systemwide metrics could potentially used including profiles micrornas long noncoding rnas epigenetic modifications recent us supreme court decision ban patents human genes hard imagine soon individuals genetic makeup personal genomic disease signatures screened drug databases tailored personalized medical treatment finally identifying compounds already evaluated human subjects drug repurposing approaches may particular benefit identifying treatments employed rare emerging infectious diseases adjunct common approaches highthroughput screening structurebased drug design computational drug repurposing potential rapidly translate insights gained systems biology drug discovery strategy directly applicable treatment infectious disease novel coronavirus emerging wuhan china december <NUMBER> spread <NUMBER> countriesterritories across globe httpswwwwhointemergencies diseasesnovelcoronavirus<NUMBER> virus originally named <NUMBER>ncov renamed taxonomists severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> owing genomic structural similarities earlier severe acute respiratory syndrome coronavirus sarscov <NUMBER>e<NUMBER> disease caused virus named world health organizationas coronavirus disease <NUMBER> covid <NUMBER> outbreak declared pandemic <NUMBER>th march <NUMBER> april <NUMBER> <NUMBER> virus affected <NUMBER> people killed <NUMBER> figures increasing rapidly today covid<NUMBER> pandemic become largest global health crisis burden healthcare systems affecting global trade economy far exists specific drug vaccine treatment covid<NUMBER> de novo drug discovery timeconsuming venture researchers suggested drug repurposing strategy find therapeutic virus approved drugs viruses including similar sarscov middle east respiratory syndrome coronavirus merscov human immunodeficiency virus hiv hepatitis c virus hcv suggested evaluation clinical studies <NUMBER>e<NUMBER> addition knowledge gained studies related viruses vital designing therapeutics sarscov<NUMBER> structural biology approaches deciphered structures different proteinsenzymes sarscov<NUMBER> least three rnadependent rna polymerase rdrp papainlike protease main protease important drug targets <NUMBER> <NUMBER> rdrp key enzyme replicates viral rna genome thus promising drug target rdrp sarscov<NUMBER> shares <NUMBER> sequee identity sarscov <NUMBER> thus compounds drugs effective rdrp sarscov surmised effective novel cov well makes rdrp important therapeutic target sarcov<NUMBER> recent studies suggested several known rdrpinhibiting antivirals fdaapproved drugs phytochemicals repurposing sarscov<NUMBER> using molecular docking studies <NUMBER> commonly repurposed drugs include ritonavirlopinavir remdesivir hydroxychloroquine ribavirin view previously mentioned fact present study investigates relative efficacy known rdrp inhibitors well drugscompounds predicted rdrpinhibiting potential using computational modeling drug target present study rdrp sarscov<NUMBER> threedimensional structure enzyme complex cofactors obtained research collaboratory structural bioinformatics rcsb protein data bank www rcsborgpdb bearing pdb id <NUMBER>m<NUMBER> structure determined using electron microscopy resolution <NUMBER> gao et al <NUMBER> deposited database march <NUMBER> <NUMBER> structure bears three nonstructured proteins nsps one nsp<NUMBER> two nsp<NUMBER> cofactors chain nsp<NUMBER> rdrp contains <NUMBER> amino acids structure downloaded database pdb format thirty compounds selected available literature test drugs list includes known rdrp inhibitors well drugscompounds predicted inhibit drug target table <NUMBER> threedimensional conformers compounds obtained national center biotechnology information ncbi pubchem compounds database wwwpubchemncbinlmnihgov downloaded sdf format molecular docking powerful computational modeling tool determines affinity binding compound active site receptorenzyme molecular docking also determines orientation binding compound active site enzyme amount energy thus liberated negative value determines stability ligandereceptor complex referred docking score compound higher ie negative docking score forms stable ligandeprotein complex surmised better inhibitor <NUMBER> <NUMBER> furthermore compound shows higher affinity active site enzyme compared natural substrate interferes activity enzyme may bring competitive inhibition present study molecular docking performed using molegro virtual docker software <NUMBER> mvd following standard procedures <NUMBER> <NUMBER> mvd one widely used powerful tools determining ligandeprotein interactions higher accuracy <NUMBER> many similar tools <NUMBER> briefly structure enzyme loaded software cofactors followed addition structures test compounds workspace docking performed ligands active site receptorenzyme grid resolution <NUMBER> moldock scoring function including amino acids within radius <NUMBER> around x <NUMBER> <NUMBER> z <NUMBER> active site residues docking scores obtained best pose terms rerank score compound retained binding geometry conformation assessed performing docking incorporation remdesivir test ligand present study two implications first included see relative affinity compared compounds active site enzyme thereby predict relative efficacy inhibitor rdrp sarscov<NUMBER> second drug nucleoside analog interacts active site enzyme thus serves reference ligand present study test compounds except cortisone found interact active site binding pocket fig <NUMBER>a remdesivir fig <NUMBER>b demonstrates compounds potential interact active site enzyme may interfere activity enzyme binding interaction ligands active site enzyme implicates ligands would interfere activity enzyme thereby bringing inhibition enzyme free energy binding docking score implicates efficacy inhibition affected chlorhexidine found highest affinity among studied compounds active site rdrp followed remdesivir novobiocin ceftibuten ribavirin table <NUMBER> docking score chlorhexidine à<NUMBER> found <NUMBER>fold higher remdesivir à<NUMBER> hydrogen bond score chlorhexidine à<NUMBER> found <NUMBER>fold higher remdesivir à<NUMBER> furthermore docking score remdesivir found <NUMBER>fold <NUMBER>fold <NUMBER>fold higher novobiocin ceftibuten ribavirin respectively table <NUMBER> among compounds cortisone found positive rerank score indicates compound may able interact inhibit rdrp using molecular docking studies researchers identified several known novel compounds inhibitors different drug targets sarscov<NUMBER> viruses using rdrp replication genetic material rna including covs hiv inhibition rdrp one crucial therapeutic strategies primarily affected nucleoside analogs rdrp sarscov<NUMBER> sarscov <NUMBER> sequence identity active site rdrp covs rna viruses highly conserved <NUMBER> basis drug repurposing sarscov<NUMBER> using compounds known inhibit rdrp related viruses present study reveals remdesivir highest potential binding therefore competitively inhibiting rdrp sarscov<NUMBER> among known rdrp inhibitors table <NUMBER> inhibitory potential rdrp also reported molecular modeling studies <NUMBER> <NUMBER> remdesivir adenosine analog incorporation growing viral rna leads termination rna replication high affinity compound active site rdrp sarscov<NUMBER> indicates compound would compete natural substrates ribonucleotides rdrp get incorporated growing rna chain remdesivir suggested several researchers use patients covid<NUMBER> reduce viral load <NUMBER>e<NUMBER> compound already reported inhibit replication virus vitro vero e<NUMBER> cells <NUMBER> remdesivir earlier reported inhibit spectrum human rna viruses including sarscov merscov marburg virus hendra virus nipah virus ebola virus hiv <NUMBER>e<NUMBER> remdesivir used successful treatment first covid<NUMBER> case us <NUMBER> large number clinical trials going different countries evaluate effectiveness compound patients covid<NUMBER> present study chlorhexidine found highest affinity active site rdrp sarscov<NUMBER> table <NUMBER> fig <NUMBER>c compound found bind active site rdrp therefore predicted promising inhibitor nevertheless mode inhibition compound would different nucleoside analogs remdesivir nucleoside analogs mimic natural substrates rdrp act chain terminators unlike chlorhexidine chlorhexidine mimic natural substrates rdrp incorporated viral rna rather may block active site enzyme thereby inhibit entry substrates ie nucleotides site prevent activity rdrp thereby preventing replication viral genome rather terminating compound also predicted wu et al <NUMBER> inhibitor rdrp using molecular docking approaches chlorhexidine one widely used drugs dental plaques gingivitis pharyngitis candidiasis tonsillitis <NUMBER> bactericidal fungicidal virucidal agent known alter membrane potential <NUMBER> inhibit atpase <NUMBER> concentrations ranging <NUMBER> <NUMBER> drug known inhibit wide range viruses coronaviruses shows effectiveness concentration <NUMBER> <NUMBER> however concentration drug inhibit rdrp sarscov<NUMBER> remains determined may predicted using quantitative structureeactivity relationship qsar modeling studies vitro vivo clinical studies would required ascertain addition remdesivir known nucleoside analogs including sofosbuvir ribavirin penciclovir ganciclovir favipiravir found interact active site rdrp sarscov<NUMBER> fig <NUMBER>a high affinities table <NUMBER> findings compliance study elfiky <NUMBER> reported ribavirin remdesivir sofosbuvir galidesivir tenofovir effective inhibitors sarscov<NUMBER> rdrp using molecular modeling present study sofosbuvir also found potent inhibitor enzyme ribavirin fdaapproved synthetic guanosine nucleoside widespectrum inhibitor rna viruses including sarscov merscov hcv <NUMBER>e<NUMBER> penciclovir also synthetic nucleoside analog e acyclic guanine derivative ewhich reported effective herpes simplex virus varicellazoster virus <NUMBER> ganciclovir also approved nucleoside analog effective hiv <NUMBER> favipiravir investigational nucleoside analog inhibitor rdrp reported effective ebola influenza h<NUMBER>n<NUMBER> viruses <NUMBER>e<NUMBER> however major limitation present study predicted inhibitory concentrations compounds thus suggested qsar modeling studies performed determine furthermore recommend vitro vivo studies performed first ascertain effectiveness compounds sarscov<NUMBER> proceeding clinical studies present study reports relative efficacy <NUMBER> compounds interacting active site rdrp sarscov<NUMBER> vitro studies molecular modeling approaches indicated broadspectrum antivirals including remdesivir effective therapeutics virus report chlorhexidine best inhibitor remdesivir found potent among known antivirals nucleoside analogs remdesivir mimic natural substrates rdrp consequently bring chain termination however compounds including e c l j u r n l r e f r c e n x x x x x x x x x x coronavirus disease become important public issue across globe since december <NUMBER> <NUMBER>th april <NUMBER> <NUMBER> million cases reported <NUMBER> countries territories worldometer <NUMBER> affects people worldwide vaccine yet virus certain types pneumonia implicated new coronavirus considered big threat global public health urgent need develop potent anticovid<NUMBER> agents prevention outbreak stop viral infections repurposing known small molecules seems efficient way order develop potent drugs combat coronavirus short time period recently number efforts made design novel inhibitors employ drug repurposing approach identify anticovid<NUMBER> drugs act promising inhibitors coronavirus protease sarma et al <NUMBER> known coronavirus <NUMBER>chymotrypsinlike protease <NUMBER>clpro also known mpro main protease required proteolytic maturation corona virus mpro essential role immune regulation cleaving polyproteins pp<NUMBER>a pp<NUMBER>ab making attractive important targets anticovid<NUMBER> drugs zhou et al <NUMBER> functional proteins rna polymerase endoribonuclease exoribonuclease generated cleavage pp<NUMBER>a pp<NUMBER>ab polyproteins mpro therefore targeting mpro enzyme inhibit viral maturation enhance host innate immune response covid<NUMBER> <NUMBER>d crystal structure <NUMBER>cl hydrolase specific coronavirus pdb id <NUMBER>lu<NUMBER> recently reported public domain could excellent target used screen small molecule libraries inhibit cleavage viral polyprotein stop spread infection protein data bank pdb archive also proteins whose sequence identity least <NUMBER> similar covid<NUMBER> coronavirus <NUMBER>cl hydrolase mpro proteins structures include bound inhibitors could lead repurpose novel drug coronavirus <NUMBER>cl hydrolase recent study shown cellular transmembrane protease serine <NUMBER> tmprss<NUMBER> used covid<NUMBER> purpose entering host cells blocking tmprss<NUMBER> might offer promising treatment option prevent virus entering host cells hoffmann et al <NUMBER> transmembrane serine proteases connected viral respiratory infections facilitate entry virus lungs shulla et al <NUMBER> tmprss<NUMBER> belongs serine protease transmembrane family type ii recognized involvement cleavage influenza virus hemagglutinin protein epithelial cells b€ ottcher et al <NUMBER> addition studies shown tmprss<NUMBER> drive cleavage spike protein coronavirus fusion glycoprotein spike proteins host cell surface activated tmprss<NUMBER> facilitate virus cellmembrane fusion entry virus gierer et al <NUMBER> matsuyama et al <NUMBER> targeting tmprss<NUMBER> animal studies decreased pathological severity influenza virus infection iwatayoshikawa et al <NUMBER> hence tmprss<NUMBER> attractive target designing developing antiviral drugs laporte naesens <NUMBER> herein study aims help coronavirus inhibition one two ways preventing virus entering host cells blocking virus maturation inside host cells computeraided drug design cadd used identification potent inhibitors coronavirus berry et al <NUMBER> oany et al <NUMBER> study applied virtual screening approach homology modeling human tmprss<NUMBER> enzyme molecular docking study admet profile analysis order identify novel potential inhibitors covid<NUMBER> figure <NUMBER> recent resolved crystal structure <NUMBER>cl hydrolase enzyme retrieved protein data bank pdb id <NUMBER>lu<NUMBER> resolution <NUMBER> å enzyme one chain total <NUMBER> amino acids enzyme prepared physiological ph <NUMBER> using prepare protein protocol biovia discovery studio <NUMBER> ds <NUMBER> missing residues insertion allowed found water molecules inhibitor removed structure purpose repurposing known inhibitors total <NUMBER> approved drugs downloaded sdf file format chembl httpswwwebiacukchembl drugbank httpswwwdrugbankca selleckchem https wwwselleckchemcom databases addition total <NUMBER> druglike molecules downloaded zinc<NUMBER> database httpszinc<NUMBER>dockingorg small molecules prepared protonated physiological ph <NUMBER> geometry minimized using ds <NUMBER> lack information crystal structures particular proteins delayed obstructed drug industry homology modeling widely applied create reliable structure protein using amino acid sequence vyas et al <NUMBER> date tmprss<NUMBER> enzyme structure resolved yet therefore basic local alignment search tool blast httpsblastncbinlmnihgovblastcgi search carried identify suitable template target tmprss<NUMBER> according results crystal structure human transmembrane protease serine desc<NUMBER> showed high identity <NUMBER> <NUMBER> bitscore <NUMBER>e<NUMBER> evalue query target consequently <NUMBER>d structure desc<NUMBER> retrieved pdb website pdb id <NUMBER>oq<NUMBER> <NUMBER> å kyrieleis et al <NUMBER> tmprss<NUMBER> sequence fasta file format uniprot id o<NUMBER> downloaded uniprot httpwwwuniprotorg template target sequences aligned using align sequences ds <NUMBER> twenty models created using homology modeling protocol ds <NUMBER> using modeller plugin webb sali <NUMBER> modeller used verify <NUMBER> built models best model found m<NUMBER> normalized dope score à<NUMBER> created homology modeling minimized using clean geometry tool provided ds <NUMBER> minimizes energy charmm forcefield additionally protein prepared using prepare protein protocol protonated ph <NUMBER> m<NUMBER> model refined using <NUMBER>drefine web server httpsysbiornetmissouriedu<NUMBER>drefine bhattacharya et al <NUMBER> verification homology modeling carried using webbased tools prosa wiederstein sippl <NUMBER> procheck laskowski et al <NUMBER> errat colovos yeates <NUMBER> assess quality model structure structurebased virtual screening refers silico identification potential chemical molecules large number compound libraries high affinity proteins known structure based binding small molecule protein binding pocket sliwoski et al <NUMBER> perform virtual screening approach study autodock vina used autodock vina offers accurate high performance docking tool relies empirical knowledgebased scoring functions trott olson <NUMBER> docking parameters mpro tmprss<NUMBER> given table <NUMBER> autodock vina used assess binding affinity native inhibitor n<NUMBER> obtained crystal structure mpro well binding affinity selected known inhibitors tmprss<NUMBER> retrieved literature sielaff et al <NUMBER> binding energy threshold based average binding energy scores docked known inhibitors mpro tmprss<NUMBER> found à<NUMBER> kcalmol à<NUMBER> kcal mol respectively present study threshold set à<NUMBER> kcalmol due fact hit compounds expected show lower binding energy scores narrow search space selection criterion set ensure virtual screening end molecules highest binding affinities respective targets total <NUMBER> molecules satisfied selection criterion dg à<NUMBER> kcalmol showed highest binding affinity mpro tmprss<NUMBER> enzymes respectively hits compound virtual screening study docked studied targets using autodock <NUMBER> morris et al <NUMBER> grid box mapping parameters shown table <NUMBER> grid box parameters set cover whole binding pocket adjacent residues twenty million energy evaluations performed compound total twenty runs using autodock <NUMBER> lamarckian genetic algorithm used gasteiger partial charges added onto studied proteins electrostatic potential predicted using delphi program included ds <NUMBER> employs poissonboltzmann formula cubic lattice using finitedifference technique calculate electrostatic charge distribution tmprss<NUMBER> mpro enzymes nicholls honig <NUMBER> absorption distribution metabolism excretion toxicity admet profile great importance drug industry widely used cadd reduce undesired effects study webbased tools admetsar yang et al <NUMBER> swissadme daina et al <NUMBER> used predict druglikeness admet profile molecular dynamic approach widely used assess atoms behavior structural stability study conformational changes atomic level herein topranked compounds homology model tmpss<NUMBER> well crystal structure mpro enzyme subjected md simulation nanoscale molecular dynamics namd software phillips et al <NUMBER> temperature set <NUMBER> k configuration files md simulations generated charmmgui website httpwwwcharmmguiorg jo et al <NUMBER> ligand parameterization performed using charmm general force field cgenff webbased tool httpscgenff umarylandedu systems solvated using transferable intermolecular potential water molecules tip<NUMBER>p model boonstra et al <NUMBER> md simulations performed two steps equilibration nvt ensemble <NUMBER> ns timescale systems energy minimized <NUMBER> steps production <NUMBER> ns timescale npt ensemble binding free energy dg bin protein ligand controlled three factors gasphase free energy dg mm solvation free energy dg sol change system entropy àtds calculated molecular mechanics poissonboltzmann surface area mmpbsa module expressed equation <NUMBER> kollman et al <NUMBER> present study mmpbsa calculations performed using calculation free energy cafe tool calculate interaction energy ligand residues protein active site liu hou <NUMBER> mmpbsa calculations external dielectric constant set <NUMBER> internal dielectric constant <NUMBER> reciprocal grid spacing <NUMBER> å employed <NUMBER> models generated modeller selected model m<NUMBER> lowest normalized dope score à<NUMBER> sequence alignment m<NUMBER> human desc<NUMBER>were performed unsing ds <NUMBER> sequence identity <NUMBER> sequence similarity <NUMBER> figure <NUMBER> fact target template sequences share <NUMBER> amino acid identity homology modeling considered reliable successful xiang <NUMBER> structural alignment homology modeling structure target <NUMBER> structure desc<NUMBER> template performed using ds <NUMBER> calculated rmsd <NUMBER> å suggests high similarity target template figure <NUMBER> model m<NUMBER> verified using webbased version protein structure analysis tool prosa prosa used calculate zscore specific model correlate score calculated scores publicly available structures pdb website accordingly zscore model m<NUMBER> <NUMBER> range pdb conformations figure <NUMBER>a moreover energy plot describes amino acid position depending local energy negative values relate accuracy structure figure <NUMBER>b addition procheck webbased tool used generate ramachandran plot assess energetically allowed regions model figure <NUMBER>c <NUMBER> residues favored regions <NUMBER> additional allowed regions <NUMBER> residue disallowed regions errat https servicesnmbiuclaeduerrat used calculate overall quality factor oqf nonbonded atomic interactions generally structure oqf <NUMBER> considered high quality model homology modeling overall quality factor calculated errat server <NUMBER> figure <NUMBER> calculated binding energies estimated inhibition constants topranked ligands retrieved study given table <NUMBER> molecular docking study revealed two approved drugs talampicillin lurasidone highest binding affinities mpro enzyme talampicillin found binding energy score à<NUMBER> kcalmol inhibition constant <NUMBER> nm talampicillin prodrug ampicillin antibacterial drug high potency gramnegative bacteria talampicillin formed conventional carbon hydrogen bonds residues gly<NUMBER> glu<NUMBER> gln<NUMBER> gln<NUMBER> pr bond his<NUMBER> two alkyl interactions residues met<NUMBER> met<NUMBER> two palkyl bonds residues cys<NUMBER> pro<NUMBER> pstacked interaction leu<NUMBER> many van der waals interactions found well figures <NUMBER>a <NUMBER>a lurasidone secondbest candidate inhibitor mpro showed estimated inhibition constant value <NUMBER> nm predicted binding energy score à<NUMBER> kcalmol lurasidone approved fda <NUMBER> antipsychotic drug treating schizophrenia patients corponi et al <NUMBER> different ligandprotein interactions formed molecular docking study lurasidone includes hydrogen bonds residues his<NUMBER> glu<NUMBER> alkyl interactions met<NUMBER> met<NUMBER> palkyl interaction pro<NUMBER> met<NUMBER> his<NUMBER> multiple van der waals interactions receptor figures <NUMBER>b <NUMBER>b talampicillin lurasidone showed reliable binding mode mpro blocking active site enzyme two topranked compounds zinc<NUMBER> library zinc<NUMBER> zinc<NUMBER> zinc<NUMBER> found binding energy à<NUMBER> kcalmol inhibition constant <NUMBER> pm zinc<NUMBER> binding energy <NUMBER> kcalmol inhibition constant <NUMBER> pm zinc<NUMBER> showed psulfur interaction met<NUMBER> seven hbonds residues arg<NUMBER> asp<NUMBER> gln<NUMBER> ser<NUMBER> cys<NUMBER> glu<NUMBER> alkyl interaction met<NUMBER> palkyl interaction cys<NUMBER> figures <NUMBER>c <NUMBER>c zinc<NUMBER> shared two psulfur interactions residues met<NUMBER> cys<NUMBER> hydrogen bonds glu<NUMBER> gln<NUMBER> cys<NUMBER> ser<NUMBER> gly<NUMBER> alkyl interactions met<NUMBER> met<NUMBER> lastly palkyl interactions cys<NUMBER> met<NUMBER> various van der waals interactions enzyme figures <NUMBER>d <NUMBER>d zinc<NUMBER> zinc<NUMBER> depicted hydrogen bond numbers shared enzyme comparison talampicillin lurasidone explains higher binding affinity estimated mpro enzyme figures <NUMBER> <NUMBER> rubitecan drug bound model binding energy value à<NUMBER> kcalmol inhibition constant <NUMBER> nm rubitecan potent antitumor drug high potency solid tumors pancreatic cancer clark <NUMBER> nitroso group rubitecan formed hydrogen bonds his<NUMBER> lys<NUMBER> figure <NUMBER>e <NUMBER>a rubitecan also formed pcation bond residue lys<NUMBER> alkyl interaction lys<NUMBER> palkyl interaction lys<NUMBER> according molecular docking study loprazolam found binding energy score à<NUMBER> kcalmol inhibition constant <NUMBER> nm homology modeling tmprss<NUMBER> loprazolam described treating insomnia hypnotic muscle spasm clark et al <NUMBER> loprazolam showed several interactions including pcation lys<NUMBER> hbonds lys<NUMBER> his<NUMBER> tyr<NUMBER> palkyl interaction his<NUMBER> alkyl interaction residue lys<NUMBER> figure <NUMBER>f <NUMBER>b molecular docking study showed compound zinc<NUMBER> form zinc<NUMBER> highest binding affinity tmprss<NUMBER> zinc<NUMBER> found binding energy à<NUMBER> kcalmol ki value <NUMBER> nm zinc<NUMBER> found hydrogen bonds residues gly<NUMBER> cys<NUMBER> gln<NUMBER> gly<NUMBER> plone pair interaction trp<NUMBER> pp interactions residues his<NUMBER> trp<NUMBER> amidep interaction trp<NUMBER> palkyl interactions his<NUMBER> lys<NUMBER> tyr<NUMBER> alkyl interaction lys<NUMBER> figure <NUMBER>g <NUMBER>c zinc<NUMBER> compound second hit study binding energy à<NUMBER> kcalmol ki <NUMBER> nm zinc<NUMBER> formed pr interactions lys<NUMBER> his<NUMBER> salt bridge asp<NUMBER> pcation lys<NUMBER> halogen bonds gly<NUMBER> ser<NUMBER> multiple hbonds residues lys<NUMBER> ser<NUMBER> ser<NUMBER> cys<NUMBER> gln<NUMBER> ser<NUMBER> lys<NUMBER> tyr<NUMBER> pp tshaped bond his<NUMBER> palkyl interaction lys<NUMBER> well many van der waals interactions figures <NUMBER>h <NUMBER>d electrostatic potential helps understanding structural aspects protein ligands interactions electrostatic charges mapped homology modeling tmprss<NUMBER> coronavirus protease mpro better understanding surface nature enzymes intensity positive potential found cover binding pocket protease mpro figure <NUMBER>a b inner cavity binding pocket tmprss<NUMBER> model found negative potential rest active site covered positive charge figure <NUMBER>c lipinskis rule <NUMBER> used predict druglikeness hits zinc<NUMBER> library lipinskis rule <NUMBER> states ligand considered druglike molecule obey criteria molecular weight <NUMBER> dalton number hbond donors <NUMBER> number hbond acceptors <NUMBER> logp <NUMBER> lipinski <NUMBER> accordingly hits obeyed rule thus considered druglike compounds furthermore compounds found within reference range considering water solubility logs caco<NUMBER> permeability topological polar surface area tpsa table <NUMBER> present study evaluate stability homology model drug candidates structures subjected md simulation root mean square deviation rmsd calculated considering proteins backbone respect initial conformations depicted figure <NUMBER>a rmsd free mpro enzyme remained stable <NUMBER> ns <NUMBER> ns timescale <NUMBER> å slightly increased persisted <NUMBER> å <NUMBER> ns till end run rmsd mprozinc<NUMBER> reached steady state <NUMBER> å <NUMBER> ns rmsd mprotalampicillin showed system balanced <NUMBER> ns slightly fluctuated <NUMBER> <NUMBER> å displayed greatest effect mpros stability illustrated figure <NUMBER>b rmsd curves free tmprss<NUMBER> reached equilibrium state <NUMBER> ns rmsd compounds tmprss<NUMBER>rubitecan tmprss<NUMBER>zinc<NUMBER> revealed two complexes shown almost behavior md simulation achieved structural stability last <NUMBER> ns thorough study root mean square fluctuation rmsf curves free mpro complexes showed amino acids located active site enzyme rmsf fluctuations <NUMBER> å <NUMBER> å indicate studied compounds kept close contact binding pockets md simulations however mprozinc<NUMBER> showed higher fluctuations residues <NUMBER> <NUMBER> observation consistent rmsd profiles mprozinc<NUMBER> figure <NUMBER>a higher fluctuations depicted rmsf profiles tmprss<NUMBER> complexes located within loop regions protein expected considering high flexibility nature loops figure <NUMBER>b binding free energy mmpbsa computed md simulation last <NUMBER> ns complexes results given table <NUMBER> compound zinc<NUMBER> depicted lowest binding free energy mpro enzyme talampicillin exhibited relatively higher binding energy hand rubitecan showed lowest binding free energy homology modeling tmprss<NUMBER> enzyme comparison compound zinc<NUMBER> mpro tmprss<NUMBER> shown important highly potent targets inhibition covid<NUMBER> infection study structurebased virtual screening identified four commercially available drugs talampicillin lurasidone rubitecan loprazolam potential inhibition mpro tmprss<NUMBER> enzymes drugs might repurposed covid<NUMBER> addition four novel compounds identified zinc<NUMBER> library showed promising high affinities mpro tmprss<NUMBER> enzymes hits described druglike compounds showed harmless admet properties may aid developing optimizing efficient potent covid<NUMBER> inhibitors trajectories analysis showed studied complexes displayed structural stability md runs coronavirus covid<NUMBER> newly emerged humaninfectious coronavirus cov pandemic global health emergency unfortunately present welldefined treatment therapeutics covid<NUMBER> available preventive measures recommended worldwide however clinical trials already marketed drugs lopinavir ritonavir hydroxychloroquine azithromycin tirumalaraju <NUMBER>c chloroquine clinicaltrialsgov nd remdesivir tirumalaraju <NUMBER>b etc along antibiotics evaluated treat secondary infections www clinicaltrialsgov drug options come experience treating sars mers new influenza virus previously lu <NUMBER> drugs would helpful efficacy needs confirmed covid<NUMBER> vaccines also clinical trials modernas mrna<NUMBER> first us clinical vaccine funded nihs niaid national institute allergy infectious diseases tirumalaraju <NUMBER>a thus unmet requirement specific anticovid<NUMBER> therapeutics limit severity deadly disease various clinicians researchers engaged investigating developing antivirals using different strategies combining experimental insilico approaches elfiky <NUMBER> enayatkhani et al <NUMBER> enmozhi et al <NUMBER> islam et al <NUMBER> jin et al <NUMBER> khan jha et al <NUMBER> khan zia et al <NUMBER> qamar et al <NUMBER> sinha et al <NUMBER> goal identifying novel selective potent therapeutic agents attractive drug target among coronaviruses main protease pro <NUMBER>cl pro due essential role processing polyproteins translated viral rna boopathi et al <NUMBER> present study focused main proteases covs potential target proteins covid<NUMBER> treatment pro <NUMBER>cl pro active dimer state till crystal structure available dimer form monomer inhabits <NUMBER> amino acids including <NUMBER> domains folded helices bstrands electron density map monomer protein clearly visible figure <NUMBER>a domain residues <NUMBER> ii residues <NUMBER> includes antiparallel bbarrel structure domain iii residues <NUMBER> includes five ahelices arranged largely antiparallel globular cluster connected domain ii means long loop region residues <NUMBER> jin et al <NUMBER> catalytic dyad h<NUMBER> c<NUMBER> responsible catalytic activity sarscov<NUMBER> placed junction domain domain ii figure <NUMBER>a recently crystal structures monomeric mpro apo pdbid <NUMBER>m<NUMBER> holo pdbid <NUMBER>lu<NUMBER> bound n<NUMBER> inhibitor forms crystallised pro <NUMBER>ncov shares <NUMBER> similarity pro sarscov qamar et al <NUMBER> reported <NUMBER> residues vary sarscov<NUMBER> sarscov<NUMBER> residue s<NUMBER> sarscov<NUMBER> covid<NUMBER> corresponding residue a<NUMBER> sarscov<NUMBER> part binding pocket n<NUMBER> molecule active site qamar et al <NUMBER> another cocrystal pdbid <NUMBER>y<NUMBER>f<NUMBER>y<NUMBER>g aketoamide inhibitor <NUMBER>b also reported recently providing structural residuebased architecture catalytic sites cocrystals paving route application virtual screening vs get efficacious molecules alkhafaji et al <NUMBER> kumar et al <NUMBER> lobogalo et al <NUMBER> knowledge gained previous outbreaks existing antivirals gain attraction fastest route fight current coronavirus epidemic henceforth emergency put drug repurposing fast track drug repurposing approach widely applied quickly identify therapeutic solutions due availability pharmacokinetic toxicological manufacturing data includes drugs either fda approved investigational withdrawn shelved compounds although studies repurposing marketed drugs proposed several candidates sarscov<NUMBER> treatment aanouz et al <NUMBER> elmezayen et al <NUMBER> pant et al <NUMBER> aim first used molecular dynamics simulations standardize computational model specially focused stable architecture binding site used vs eventually facilitate rapid identification potent molecules findings study may provide opportunity explore compounds anticovid<NUMBER> therapeutics crystal structures apo <NUMBER>m<NUMBER> com<NUMBER> <NUMBER>lu<NUMBER> optimized minimized using protein preparation wizard module maestro anang et al <NUMBER> maestro <NUMBER> opls<NUMBER> optimized potentials liquid simulations force field used jorgensen et al <NUMBER> sitemap sitemap <NUMBER> program schrodinger suite also used calculating binding sites crystal <NUMBER>lu<NUMBER> method implemented unbiased approach undermine presence secondary allosteric binding site sitemap ligand independent method also help calculating druggability identified site halgren <NUMBER> mattapally et al <NUMBER> srivastava et al <NUMBER> thakur et al <NUMBER> opls<NUMBER> force field jorgensen et al <NUMBER> employed standard grid used <NUMBER> site points per reported site cropped <NUMBER> å nearest site point ligand structures taken sellekchem database httpwwwselleckchemcom drugbank database https wwwdrugbankca repurposing hub httpsclueio repurposing see supplementary figure <NUMBER> ligands prepared using schr€ odingers version <NUMBER> ligprep ligprep <NUMBER> optimization done using opls<NUMBER> force field jorgensen et al <NUMBER> known pharmacological activity hits curated abovementioned databases along pubchem database httpspubchem ncbinlmnihgov apo pro pdbid <NUMBER>m<NUMBER> along com<NUMBER> com<NUMBER> docked <NUMBER>b pose mpro monomer subjected molecular dynamics simulation <NUMBER> ns using desmond v<NUMBER> module schrodinger suite bowers et al <NUMBER> addition also performed short simulation hits molecules observe stability impact protein systems built via systems builder using opls<NUMBER> force field solvated tip<NUMBER>p water solvent model complexes placed orthorhombic periodic boundary conditions size repeating buffered units <NUMBER> å counter ions also added neutralize systems energy minimisation step done system using steepest descent integrator <NUMBER> steps npt ensemble employed simulations nosehover chain thermostat martynatobiasklein barostat respa integrator used time step <NUMBER>ps short range coulombic interactions <NUMBER> å cutoff considered bonds hydrogen constrained using mshake algorithm desmond coordinates saved intervals <NUMBER> ps referred frames study site bound peptide n<NUMBER> chosen primary site ligand docking also confirmed sitemap druggable site grid generated using centroid n<NUMBER> using receptor grid generation panel glide docking studies carried using vs workflow vsw glide schrodinger suite friesner et al <NUMBER> mittal et al <NUMBER> ligands chosen database passed three stages screening workflow starting highthroughput screening <NUMBER> filtered followed standard precision <NUMBER> finally extra precision <NUMBER> stages final poses processed using prime mmgbsa panel end schrodinger suite llc new york ny <NUMBER> supplementary figure <NUMBER> control molecules n<NUMBER> <NUMBER>b also docked grid results docking quantified basis docking scores mmgbsa dg bind pharmacokinetic properties molecules evaluated swissadme server daina et al <NUMBER> joshi et al <NUMBER> also top filtered compounds crosschecked stability md simulations mentioned earlier <NUMBER> free energy analysis mmgbsa molecular mechanicsgeneralized born surface area average binding energy calculated equilibrated md trajectory binding energy calculated difference minimized energies ligand protein complexes denoted de mm dg solv difference gbsa solvation energy complexes sum solvation energies protein ligand whereas differences surface area energy complex sum protein ligand kellici et al <NUMBER> mittal et al <NUMBER> images generated using vmd schrodinger suite asthana et al <NUMBER> asthana et al <NUMBER> humphrey et al <NUMBER> graphs plotted using xmgrace mittal et al <NUMBER> turner <NUMBER> availability cocrystal <NUMBER>lu<NUMBER> peptide n<NUMBER> covalentlybonded inhibitor bound knowledge interacting residues molecule <NUMBER>b aketoamide inhibitor made understanding protein interesting since residues reported compound <NUMBER>b involve residues n<NUMBER> molecules therefore monomer crystals used analysis architecture binding site possible conformational changes concurred superimposition crystal structures com<NUMBER> apo shows overall structure protein well aligned rmsd apovscom<NUMBER> <NUMBER> å except cterminal region figure <NUMBER>b also observed noticeable differences binding site architecture com<NUMBER> apo figure <NUMBER> c found residues binding site well aligned apo except residues t<NUMBER> m<NUMBER> m<NUMBER> r<NUMBER> q<NUMBER> t<NUMBER> shows side chain conformational changes p<NUMBER> shows backbone movement also figure <NUMBER> c inhibitor forms hydrogen bond hb interactions residues g<NUMBER> h<NUMBER> e<NUMBER> q<NUMBER> t<NUMBER> bring robustness confirming final binding site performing vs performed ligand independent binding site search pro top score sitemap program also confirms cocrystal site primary binding site marked site <NUMBER> highest dscore <NUMBER> best druggability score figure <NUMBER> table <NUMBER> volume pocket <NUMBER> å <NUMBER> binding site pro encompassed domain ii loop region connecting domains ii iii sitemap result shows pocket relatively smaller size size score <NUMBER> reference value <NUMBER> exposed solvent exposure value <NUMBER> reference value <NUMBER> halgren <NUMBER> performed md simulations apo com proteins stability systems respect time evolution rmsd root mean square deviation plot apovscom<NUMBER> systems showed apo protein stable <NUMBER> ns simulation com<NUMBER> attains stability <NUMBER> ns simulation figure <NUMBER> observed sudden deviation com<NUMBER> system started around <NUMBER>ns lasted till <NUMBER>ns increase deviation mainly attributed extended loop conformation residue <NUMBER> <NUMBER> flexible nature apovscom<NUMBER> system showed systems stable throughout trajectory considerably minor deviations figure <NUMBER>b radius gyration rg simulated systems also showed systems attained compactness figure <NUMBER> c explore fluctuations systems residue wise rmsf root mean square fluctuation analysis carried rmsf plots observed binding n<NUMBER> made pro protein flexible especially domain iii compared <NUMBER>b figure <NUMBER>de since domain iii involved form homodimer might reason fluctuation region presence ligands ligand rmsd plots showed stable dynamics atoms ranging <NUMBER> <NUMBER> <NUMBER> <NUMBER> n<NUMBER> molecules observed highly fluctuated rmsf <NUMBER> å atoms <NUMBER>b observed rmsf <NUMBER> å especially atoms <NUMBER> figure <NUMBER> suggests flexible atoms ligands replaced another atom group atoms may restrict movement pocket ability increase potency inhibit pro optimum systems apo com<NUMBER> com<NUMBER> stable signifies residues undergoing least conformational changes figure <NUMBER>f also comparison apo inhibitor n<NUMBER> com<NUMBER> induced stability binding site compared inhibitor <NUMBER>b com<NUMBER> however noted slight deviation rmsd com<NUMBER> com<NUMBER> convergence simulation figure <NUMBER>f md analysis well evident binding site well compact stable state extracted vs purpose analysis stable proteinligand interactions contribution particular residue towards ligand binding pocket important aspect identify hotspots md simulation com<NUMBER> residues t<NUMBER> g<NUMBER> c<NUMBER> q<NUMBER> t<NUMBER> observed involved hb formation <NUMBER> occupancy simulation time figure <NUMBER>a residue h<NUMBER> observed form water mediated interaction ligand <NUMBER> simulation time residues n<NUMBER> s<NUMBER> q<NUMBER> t<NUMBER> q<NUMBER> also form transient water mediated interactions com<NUMBER> residues e<NUMBER> t<NUMBER> highly involved hb stability <NUMBER> occupancy figure <NUMBER>b residue e<NUMBER> also involved transient water mediated salt bridge interactions residues h<NUMBER> c<NUMBER> h<NUMBER> q<NUMBER> also establish water mediated interactions certain time interaction fingerprint proteinligand interaction fingerprinting hits obtained protease library site <NUMBER> residues involved interaction site within <NUMBER> å along control molecules presence absence residues marked <NUMBER> <NUMBER> respectively residues coloured basis polar blue hydrophobic green acidic red basic purple properties residues showing <NUMBER> occupancy considered key residues occupancy also calculated mentioned bottom line simulation time hydrophobic contributions residues h<NUMBER> m<NUMBER> p<NUMBER> observed however occupancy less <NUMBER> simulation time md simulations shows pocket hydrophilic nature stable water molecule involved dynamics binding site sasa solvent accessible surface area shows apo protein quite solvent exposed complexes figure <NUMBER>g residues c<NUMBER> q<NUMBER> t<NUMBER> common key residues observed proteinligand interactions occupancy plots overall analysis md simulation conclude two main aspects <NUMBER> obtained stable computational model com<NUMBER> showing intact binding site minor conformational changes <NUMBER> insights binding pocket hotspot residues respective interactions elucidated qualitatively quantitatively aspects applied vs library proven successful strategy inhibit viral proteases treatment viral infections cases human immunodeficiency virus hiv hepatitis c virus hcv hence screening protease inhibitors could useful approach covid<NUMBER> pro ghosh et al <NUMBER> yang et al <NUMBER> logic <NUMBER> protease molecules selleckchem curated prepared screening site<NUMBER> based filtering criteria optimum mmgbsa docking scores top <NUMBER> initial hits filtered figure <NUMBER>a docking scores mmgbsa pharmacokinetic descriptors known targets along structures hits shown table <NUMBER> quantitative parameters docking score mmgbsa energy additional qualitative parameters chosen screen docked conformations show similar interaction patterns interactions respect controls however molecules including control molecules n<NUMBER> <NUMBER>b violate pharmacokinetic properties used immediate starting point experimental validation optimization per potency efficacy facilitate identification potent druglike molecules selected molecules top hits residue mapping based interaction pattern executed figure <NUMBER> top three molecules found study leupeptin hemisulfate pepstatin nelfinavir basis mmgbsa docking scores ligand interaction diagrams shown figure <NUMBER> ac respectively however molecules observed common screening insilico studies published targeting pro nelfinavir lopinavir indinavir ritonavir darunavir das et al <NUMBER> khan zia et al <NUMBER> muralidharan et al <NUMBER> nutho et al <NUMBER> highlighted cyan colour table <NUMBER> another library fdarepurposing molecule curated different sources repurposing hub selleckchem drugbank used prepare screening purpose due high failure rates considerable costs slow pace new drug discovery development reuse old drugs treat diseases becomes quickest route find active molecules requires use known bioactive moleculeswith potentially lower production costs shorter timelines pushpakom et al <NUMBER> multistep route vs filtered best <NUMBER> hits figure <NUMBER>b docking scores mmgbsa pharmacokinetic descriptors known targets along structures hits shown table <NUMBER> residue wise interaction mapping also carried figure <NUMBER> library best three molecules birinapant lypressin octreotide ligand interaction diagrams shown figure <NUMBER> ac respectively nevertheless molecules violate pharmacokinetic properties could optimised druglike properties based experimental results finding common top molecules study also reported screening studies target claiming robustness protocols common molecules lypressin octreotide mitoxantrone hesperidin echanoside pralmorelin epicatechin diosmin flavitan flavin adenine dinucleotide curcumin saquinavir montelukast baicalin thymopentin das et al <NUMBER> highlighted cyan colour table <NUMBER> residues shown highest occupancy <NUMBER> reanalysed residues h<NUMBER> m<NUMBER> n<NUMBER> c<NUMBER> h<NUMBER> m<NUMBER> e<NUMBER> d<NUMBER> r<NUMBER> q<NUMBER> hits obtained protease library figure <NUMBER> respect control compounds n<NUMBER> <NUMBER>b residues g<NUMBER> e<NUMBER> q<NUMBER> observed majorly involved hbs interactions hits h<NUMBER> observed form pipi stacking pication interaction cases figure <NUMBER> similarly hits obtained fdarepurpose library residue interaction mapping showed residues h<NUMBER> m<NUMBER> n<NUMBER> c<NUMBER> m<NUMBER> e<NUMBER> r<NUMBER> q<NUMBER> higher occupancy <NUMBER> binding site figure <NUMBER> hbs analysis found residues t<NUMBER> g<NUMBER> e<NUMBER> q<NUMBER> highly involved hb interactions figure <NUMBER> residue interaction mapping analysis hits observed binding site pro composed <NUMBER> polar residues <NUMBER> nonpolar residues <NUMBER> acidic residues <NUMBER> basic residues encompasses diverse class molecules indicates binding site site<NUMBER> pro hydrophilic nature solvent exposed concordance site map results however flexibility adaptability pocket towards ligand explored molecular dynamics simulation matches nicely previous findings also find h<NUMBER> m<NUMBER> n<NUMBER> c<NUMBER> h<NUMBER> m<NUMBER> e<NUMBER> q<NUMBER> conserved residues high occupancy top hits reported wang <NUMBER> mers sars covid<NUMBER> four h<NUMBER> h<NUMBER> m<NUMBER> q<NUMBER> common residues hcv ns<NUMBER>a covid<NUMBER> one common hotspot residue h<NUMBER> confirming findings hits interaction residues might broad spectrum value identified six molecules lower free energy binding combined higher theoretical drug discovery value compared cocrystallized ligand n<NUMBER> <NUMBER>b figure <NUMBER> md analysis top molecules highlight nelfinavir birinapant granted maximum stability protein throughout simulation compared four selected hits supplementary figure <NUMBER> however four hits also found stable well reflected result supplementary figure <NUMBER> mmgbsa calculations equilibrated md trajectories hits control molecules showed hits except leupeptin hemisulfate shown considerably better binding energy control molecules supplementary table <NUMBER> molecules shown minor decrease binding energies also presented substantial improvement comparison cocrystallized ligand observed docking scores ranging à<NUMBER> à<NUMBER> kcalmol however molecules shown substantially good docking energy well free energy also considerably higher side consistent reflected well md simulations identified hits interacted protease least two hbs average four figures <NUMBER> <NUMBER> appearing hotspot residues whose knowledge critical structurebased hits identification furthermore identified molecules shown relevant pharmacokinetic descriptors logp values mw psa hb donorsacceptors range described lipinski though many approved successful drugs documented following standard lipinski rule especially proteinprotein interactions disruptors also encouraging identified hits available commercial suppliers mcule selleckchem identified top six molecules presented comparatively better docking postprocessing md simulation analysis free energy ie mmgbsa scores respect control molecules therefore represent excellent candidates investigation invitro figure <NUMBER> overall analysis identified set molecules considered early hit molecules albeit accept experimentally supported hitoptimization conducted though molecules looks promising cases increase day day extremely urgent need designing small compound peptide drugs cure <NUMBER>ncov based crystal structures md simulations computational model pro chosen vs important step performing vs highlights dynamical changes pocket taken account reducing falsepositives results also highlight overall impact binding compounds protein thereafter interaction fingerprinting binding sitesof static crystalsvsdynamic md simulations changes structurebased vs known existing molecule libraries performed figure <NUMBER> interaction fingerprint proteinligand interaction fingerprinting hits obtained fda repurposing library along controls site <NUMBER> residue involved interaction site within <NUMBER> å presence absence residue marked <NUMBER> <NUMBER> respectively residues coloured basis polar blue hydrophobic green acidic red basic purple properties residues showing <NUMBER> occupancy considered key residues occupancy residues calculated bottom line identify potential molecules possibly repurposed pro highresolution crystal structure covid<NUMBER> pro complex n<NUMBER> knowledge key residues <NUMBER>b molecules available time allowing us conduct drug repurposing md simulations observed quantified dynamical changes nature binding site residue level investigation solvation sites role water molecules binding site could carried explore druggability pocket might help rational designing molecules comparative analysis identified hits n<NUMBER> <NUMBER>b supports findings knowledge interactions terms hbs hydrophobic contacts saltbridges pipi stacking conformations considered exclusively filtering molecules quantitative values dscore docking dg complexes currently antineoplastic immunomodulators nucleotide inhibitors antimalarial ribonucleoside inhibitors steroid hormones protease inhibitors antiretrovirals evaluated clinical trials covid<NUMBER> identified similar category molecules vs approach hits found study belongs different chemical classes potential accommodate inside pocket quickly explored antiviral experimental assays binding affinity inhibition activity prior need synthesis molecules easily available predicted hits scaffolds good starting point developing novel hits confirmed invitro studies potential hits listed study promising candidates facilitate hunt anticovid<NUMBER> pro drug discovery figure <NUMBER> plot mmgbsa values primary yaxis docking score secondary yaxis control molecules <NUMBER> finalized potential hits along <NUMBER>d structures declared covid<NUMBER> pandemic hoffmann et al <NUMBER> affected lives hundreds millions people result compulsory isolation quarantines world sanders et al <NUMBER> sarscov<NUMBER> targets host cells via spike protein binds angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor virus uses host cell receptors ie type <NUMBER> transmembrane serine protease tmprss<NUMBER> endosomes enter cells tmprss<NUMBER> facilitates cell entry sarscov<NUMBER> spike protein entering host cell viral proteins synthesized encode replicasetranscriptase complex mousavizadeh ghasemi <NUMBER> viral rna synthesized rnadependent rna polymerase durdagi et al <NUMBER> genome sarscov<NUMBER> encodes different structural nonstructural proteins sanders et al <NUMBER> important ones drug development studies main protease rnadependent rna polymerase cao et al <NUMBER> currently proteins mainly targeted drug screening drug repurposing studies noteworthy method known drug repurposing become less costly terms time resources laboratory use molecules different indications investigated studies done field recent years et al<NUMBER> tutumlu et al <NUMBER> since preclinic clinical studies including pharmacokinetic toxicological studies approved compounds clinical investigation phases already tested require less time make suitable new indications toxicity adme absorption distribution metabolism excretion studies need long time complete required molecules considered drug repositioning pass stages already applied welldefined profiles therefore use epidemics suitable new molecules never tested hence current study performed virtual drug repurposing study small molecules ncgcnih chemical genomics center pharmaceutical collection ie npc library used virtual screening studies active site developed tmprss<NUMBER> model target protein downloaded prepared <NUMBER> small compounds npc library httpstripodnihgovnpc virtual screening remove nonspecific compounds performed filtration criteria molecular weights compounds <NUMBER> g mol smaller <NUMBER> gmol removed library compounds <NUMBER> rotatable bonds hydrogen bond acceptor donor number higher <NUMBER> also removed thus total number molecules decreased <NUMBER> docking simulations compounds prepared ligprep module ligprep schrodinger v<NUMBER> maestro molecular modeling package since crystal structure tmprss<NUMBER> available performed homology modeling study swiss model used homology modeling study swissmodel expasyorg <NUMBER>ce<NUMBER> pbb coded serine protease hepsin used template structure sequence identity template target proteins <NUMBER> structural assessment studies developed model performed residue unfavourable region ramachandrans plot protein reports showed steric clashes bond length bond angle deviations structure thus suitable use target protein supplementary materials figure s<NUMBER> docking modelled target protein prepared using protein preparation module maestro molecular modeling package determination protonation states residues target protein propka used restrained optimization protocol employed opls<NUMBER>e force field target protein model using <NUMBER> å convergence criteria docking implemented standard precision sp protocol glide using default settings top<NUMBER> docking poses allatom molecular dynamics md simulations performed mimic physiological conditions using desmond orthorhombic box used explicit water models ie tip<NUMBER>p <NUMBER> å thickness edges protein <NUMBER> nacl added simulation box neutralize system particle mesh ewald method used long range electrostatic interactions <NUMBER> å cutoff used electrostatic van der waals interactions temperature <NUMBER> k pressure <NUMBER> bar throughout simulations kept constant nosehoover thermostat evans holian <NUMBER> martynatobiasklein barostat martyna et al <NUMBER> opls<NUMBER>e force field used md simulations <NUMBER> trajectory frames system simulations collected molecular mechanics generalized born surface area mmgbsa method employed trajectories average mmgbsa score studied compound computed vsgb <NUMBER> solvation model prime module maestro employed mm gbsa calculations nowadays thanks effort nih chemical genomics center possible obtain electronic resources collections small molecules registered combining power recent advances ligandand targetdriven based virtual screening methods made easier consider drug repurposing disease especially complex diseases used homology model target tmprss<NUMBER> structure screened prepared <NUMBER> fda approved drugs compounds clinical investigation phases npc database using glidesp docking scores <NUMBER> <NUMBER> kcalmol figure s<NUMBER> due limited flexibility target protein screened ligands docking identification compounds based docking scores docking simulations lead falsepositive results tutumlu et al <NUMBER> moreover although molecular docking simulations may provide insight proteinscreened ligand interactions always important understand interactions sustained throughout performing md simulations thus used top<NUMBER> docking scored compounds employed initially short <NUMBER>ns allatom md simulations physiological body temperature conditions docking scores top <NUMBER> compounds <NUMBER> <NUMBER> kcalmol see figure <NUMBER> table supplementary materials inhouse script used prepare simulation boxes analyse md simulations desmond used md simulations table represents average mm gbsa scores using recorded <NUMBER> frames strided <NUMBER> simulations system top<NUMBER> ligands order compare docking scores average mmgbsa scores identified hit compounds virtual screening protocol also used screening protocol wellknown tmprss<NUMBER> inhibitor camostat mesylate approved small molecule compound treatment pancreatitis japan found camostat mesylate prevents sarscov<NUMBER> cell entry inhibition host serine protease tmprss<NUMBER> docking score <NUMBER> kcalmol binding pocket tmprss<NUMBER> corresponding average mmgbsa score calculated <NUMBER> kcalmol figure s<NUMBER> supplementary materials shows <NUMBER>d ligand interactions diagram camostat mesylate binding site sarscov<NUMBER> tmprss<NUMBER> target crucial residues found val<NUMBER> asp<NUMBER> ser<NUMBER> gln<NUMBER> gly<NUMBER> ser<NUMBER> ser<NUMBER> val<NUMBER> based average mmgbsa scores short md simulations selected <NUMBER> hits better scores <NUMBER> kcalmol benzquercin difebarbamate nbenzoylltyrosylpaba long <NUMBER>ns md simulations performed compounds mmgbsa scores recalculated results showed benzquercin nbenzoylltyrosylpaba difebarbamate average mmgbsa scores <NUMBER> <NUMBER> <NUMBER> kcalmol respectively results showed especially benzquercin flavonoid maintained interactions binding pocket residues although average mmgbsa score difebarbamate slightly decreased long md simulations compared short simulation still similar range mmgbsa score positive control compound camostat figure figure <NUMBER> <NUMBER> represents <NUMBER>d <NUMBER>d ligand interactions diagram benzquercin binding site tmprss<NUMBER> last frame <NUMBER>ns md simulations used crucial residues target found his<NUMBER> glu<NUMBER> pro<NUMBER> leu<NUMBER> lys<NUMBER> lys<NUMBER> gly<NUMBER> ser<NUMBER> share similar binding pocket residues positive control camostat based interaction fractions analysis lys<NUMBER> highest interaction fraction value hit compound throughout <NUMBER>ns simulations type main interactions ligand binding pocket residues hydrogen bonds water bridges hydrophobic interactions interestingly benzquercin also found potent hit compounds previous virtual screening study using protocol another important cellentry target sarscov<NUMBER> spikeace<NUMBER> durdagi et al <NUMBER> average score spikeace<NUMBER> interface found <NUMBER> kcalmol hence studies showed benzquercin may also act dual inhibitor recognized treatment one targetone molecule approach complex diseases effective usage combined drugs also appreciated due toxicity andor undesirable drugdrug interactions recent promising approach complex diseases including covid<NUMBER> instead developidentify unique compounds act multitargets simultaneously targets crucial studied disease thus based silico results benzquercin potential molecular modeling studies virtual screening reduce time required set new targets known drugs also provide advantage costeffective shoichet et al <NUMBER> durdagi et al <NUMBER> study virtual drug repurposing study performed identify new compounds tmprss<NUMBER> important target entry sarscov<NUMBER> host cell thus npc small molecule library screened initially docking simulations based docking scores top<NUMBER> compounds used short md simulations average binding free energies calculated mmgbsa method selected hits used longer md simulations results showed especially benzquercin maintains interactions crucial residues throughout simulations results validated experimental studies benzquercin considered used inhibitor tmprss<NUMBER> clinical studies prediction toxicity needed optimize minimize antiviral activity cytotoxicity respectively computational approach potential rapidly rationally identify drug candidates covid<NUMBER> since early december <NUMBER> newly emerged sarscov<NUMBER> infected almost <NUMBER> million people globally <NUMBER> united states confirmed cases increased dozen almost <NUMBER> within two weeks number rapidly grew <NUMBER> within one month <NUMBER> among patients <NUMBER> suffered severe acute respiratory distress syndrome ards approximately <NUMBER> died acute respiratory failure acute cardiac injury secondary infection serious complications <NUMBER> <NUMBER> <NUMBER> organization declared rapidly spreading highly pathogenic covid<NUMBER> first global public health emergency pandemic sarscov<NUMBER> infection continues endanger lives effective therapeutics urgently needed repurposing existing drugs could efficient timely means identifying drugs activity coronavirus repurposed drugs lopinavirritonavir baricitinib remdesivir chloroquine currently clinical investigation <NUMBER> <NUMBER> drugs expected target key steps viral entry specific proteins involved viral replication including viral proteases <NUMBER> addition viral replication viral pathogen associated molecular pattern pamp eg immune dysfunction endoplasmic reticulum stress figure <NUMBER>a could targeted improve clinical outcome <NUMBER> pampsmediated signaling pathways attractive drug targets alleviate diseases caused human pathogens therefore effectively targeting pathways stop progression ards caused sarscov<NUMBER> might save lives independent sarscov<NUMBER> infection aging adult populations ards associated mortality rates <NUMBER> <NUMBER> thus methodical unbiased search new drug candidates large drug library could uncover agents potential arrest infection ameliorate effect accomplish sought target infectioninduced genes host cells hoping mitigate disease progression alleviate symptoms others <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> utilized systemsbased approach employs gene expression profiles disease samples druginduced gene expression profiles cell lines discover new therapeutic candidates diseases essential idea identify drugs reverse disease gene expression signature suppressing overexpressed disease genes activating repressed genes figure <NUMBER>a disease signature defined list differentially expressed genes disease samples normal control samples recently found reversal gene expression namely srges correlates drug efficacy cancers <NUMBER> demonstrating feasibility applying approach predict drug candidates diseases including viral infection utilize approach drug discovery sarscov<NUMBER> first need collect virusrelated host gene expression profiles available time writing given high genomic similarity sarscov merscov sarscov<NUMBER> reasoned existing host gene expression profiles samples infected sarsor merscov could approximate infected sarscov<NUMBER> verify assumption compiled <NUMBER> virusinduced signatures enrichr geo table s<NUMBER> used established pipeline score <NUMBER> drugs repurposing library regarding reversal signature gene expression clustering signatures based drug prediction scores suggests signatures derived virus virus family similar experimental model tend cluster together figure s<NUMBER> example cluster includes one signature derived primary human microvascular endothelial cells mmve<NUMBER> <NUMBER>h merscov infection study id gse<NUMBER> another derived melanoma cells mice seven days sarscov infection study id gse<NUMBER> addition spearman correlation coefficient vitro drug efficacy data ec<NUMBER> half maximal effective concentration sarscov merscov <NUMBER> figure <NUMBER>b clustering correlation results suggested drugs predicted based signatures related sarscov merscov could also applied sarscov<NUMBER> therefore developed pipeline repurpose existing drugs merscov sarscov experimentally evaluate drugs sarscov<NUMBER> figure <NUMBER>c ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted april <NUMBER> <NUMBER> database good candidate activate repressed biological processes inhibit upregulated processes b correlation published antiviral activities <NUMBER> drugs pec<NUMBER> log<NUMBER> transformed ec<NUMBER> value moll mersand sarscov c study workflow including creation disease signatures prediction drug candidates selection final drug list vitro validation one disease signature composed differentially expressed genes comparison led one drug prediction list signature resulting prediction list known positive drugs enriched top considered valid signature dysregulated pathways sars infection <NUMBER>h compared <NUMBER>h lungs e enrichment top six dysregulated pathways primary human microvascular endothelial mmve<NUMBER> cells <NUMBER>h <NUMBER>h merscov infection left mock right one study selected e respectively dysregulated pathways dynamics studies available supplementary materials figure s<NUMBER> s<NUMBER> extended data <NUMBER> total <NUMBER> samples infected either mersor sarscov different models eg cell line mouse models across multiple time points public repositories used identification disease signatures table s<NUMBER> <NUMBER> studies total expression profiles created using either microarray rnasequencing depending profiling platform data processing signature creation methods comparison computed disease signature characterize infection status followed prediction drugs may activity could directly evaluate quality pathologic relevance disease signature turned validating action using drugs positive vitro merssars testing <NUMBER> positive drugs total <NUMBER> ec<NUMBER> values table s<NUMBER> among <NUMBER> merscov sarscov infection signatures <NUMBER> signatures led drug list positive drugs highly enriched top extended data <NUMBER> moreover ec<NUMBER> drugs significantly correlated srges figure <NUMBER>a figure s<NUMBER> contrast h<NUMBER>n<NUMBER> infection signatures didnt observe significant enrichment anticoronavirus positive drugs extended data <NUMBER> recent clinical data suggested combination two drugs lopinavirritonavir present clinical benefits patients coronavirus <NUMBER> <NUMBER> drugs profiled lincs <NUMBER> individually however none could induce substantial gene expression change absolute z score <NUMBER> <NUMBER> µm concentration cancer cell lines therefore neither predicted hit next found another dataset heparg cells treated ritonavir <NUMBER> different concentrations <NUMBER> nm <NUMBER> µm observed ritonavir could reverse nearly <NUMBER> disease signatures high concentration ie <NUMBER> µm <NUMBER> µm figure s<NUMBER> together reasoned highly ranked drugs greater negative srges valid comparisons could new therapeutic candidates obtain final drug prediction trivial merge disease signatures derived different platforms biological conditions instead merging calculated consensus score drug prediction lists derived individual valid disease signatures took median ranks across multiple comparisons drug ranked based median rank extended data <NUMBER> mechanism action moa enrichment analysis final ranked drug list revealed significant drug classes including cdk inhibitors mtor inhibitors nfκb pathway inhibitors figure <NUMBER>b lately jeon et al <NUMBER> tested antiviral efficacy <NUMBER> fdaapproved drugs sarscov<NUMBER> among <NUMBER> positive drugs overlapped screening library drugs also significantly enriched top prediction figure <NUMBER>c p <NUMBER>e<NUMBER> validating predictions interestingly three antiparasite drugs pyrvinium ivermectin niclosamide ranked among top <NUMBER> ivermectin niclosamide could inhibit replication sarscov<NUMBER> vitro <NUMBER> <NUMBER> pyrvinium niclosamide effective mers sars <NUMBER> <NUMBER> manually inspected top candidates selected ten representative candidates according reversal scores figure <NUMBER>d clinical applicability moa administration routes safety table s<NUMBER> finally evaluated cytotoxicity ability prevention cytopathic effect cpe vero e<NUMBER> cell line table <NUMBER> instead measuring ec<NUMBER> used stringent criteria required <NUMBER>day complete prevention cpe observed microcopy six proposed drugs showed less <NUMBER> µm minimum concentration could completely prevent cpe however five presented unfavorable cytotoxicity effective concentration following confirmatory experiment examined efficacy toxicity four effective drugs cpe preventing concentration <NUMBER> µm bortezomib methotrexate nvpbez<NUMBER> alvocidib well chloroquine drug used firstline treatment sarscov<NUMBER> none predicted drugs could completely prevent cpe though chloroquine could dose <NUMBER> µm figure <NUMBER>e signature comparison <NUMBER> h <NUMBER>h could capture biology viral infection thus failed recover known drugs findings also reiterate challenge choosing appropriate experimental models right time points drug treatment covid<NUMBER> <NUMBER> developed consensus score drug based potency reverse thirteen signatures prediction externally validated recent drug screening sarscov<NUMBER> <NUMBER> obtained total <NUMBER> samples sars mers related data arrayexpress gene computation rges summarization rges detailed elsewhere recently implemented standalone r package <NUMBER>  negative correlation means reversal relation ritonavir originally developed inhibitor hiv protease often used low dose protease inhibitors boost antiviral effect analysis suggests ritonavir could reverse disease signature high dose processed compound transcriptome profile categorized upand downregulated genes threshold log<NUMBER> fold change greater <NUMBER> less <NUMBER> respectively group genes submitted enrichr <NUMBER> httpsamppharmmssmeduenrichr compute gene ontology enrichment go terms pvalue less <NUMBER> adjusted pvalue less <NUMBER> taken significant vero e<NUMBER> cells crl<NUMBER> atcc grown eagles minimal essential medium emem supplemented penicillin <NUMBER> unitsml streptomycin <NUMBER> µgml <NUMBER> fetal bovine serum fbs sarscov<NUMBER> uswa<NUMBER> isolate <NUMBER> rd passage vero e<NUMBER> cells original cdc atlanta material sequence confirmed used throughout study titer viral stock <NUMBER> × <NUMBER> <NUMBER> <NUMBER> tissue culture infectious doses tcid<NUMBER>ml experiments involving using infectious virus conducted university texas medical branch approved biosafety level <NUMBER> laboratory slightly modified vero e<NUMBER>based standard microneutralization assay used rapidly evaluate analysis conducted r v<NUMBER> python v<NUMBER> programming language ggplot<NUMBER> pheatmap seaborn packages used data visualization students ttest performed normally distributed data wilcoxon ranksum test used types data compute pvalue authors declare data used study available within article supplementary information files specific files provided corresponding author upon reasonable request code available github httpsgithubcombinchenlabwars since early december <NUMBER> newly emerged sarscov<NUMBER> infected <NUMBER> million people globally covid<NUMBER> report nd united states confirmed cases increased exponentially steadily exceeding million mark within two months making united states hardest hit country globally cdc cases updates nd among infected patients approximately <NUMBER> suffered severe acute respiratory distress syndrome ards approximately <NUMBER> died acute respiratory failure acute cardiac injury secondary infection serious complications covid<NUMBER> report nd huang et al <NUMBER> highly contagious pathogenic virus spread rapidly throughout world declared pandemic named effective therapeutics urgently needed repurposing existing drugs could efficient timely means identifying novel drugs treating disease initially repurposed drugs lopinavirritonavir baricitinib remdesivir chloroquine investigated clinical efficacy covid<NUMBER> patients peeri et al <NUMBER> wang et al <NUMBER> remdesivir since shown encouraging efficacy currently used benchmark drug treating covid<NUMBER> patients moderate severe symptoms repurposed drugs study hypothesized target key steps viral entry specific proteins involved viral replication including viral proteases zumla et al <NUMBER> addition viral replication viral pathogen associated molecular pattern pamp eg immune dysfunction endoplasmic reticulum stress figure <NUMBER>a could targeted improve clinical outcomes de wit et al <NUMBER> pampsmediated signaling pathways attractive drug targets diseases caused human pathogens therefore effectively targeting pathways stop progression acute respiratory distress syndrome caused sarscov<NUMBER> might potentially reduce morbidities mortalities associated virus independent sarscov<NUMBER> infection aging adult populations ards associated mortality rates <NUMBER> bellani et al <NUMBER> thus methodical unbiased search new drug candidates large drug library could uncover drugs potential arrest infection ameliorate debilitating effects aim accomplish analyzing infectioninduced gene expressions host cells others b chen wei et al <NUMBER> lee et al <NUMBER> van noort et al <NUMBER> pessetto et al <NUMBER> qu rajpal <NUMBER> sirota et al <NUMBER> h wu et al <NUMBER> utilized systemsbased approach employs gene expression profiles disease samples druginduced gene expression profiles cell lines discover new therapeutic candidates diseases central idea identify drugs reverse disease gene expression signature suppressing overexpressed disease genes activating repressed genes figure <NUMBER>a disease signature defined list differentially expressed genes disease samples normal control samples recently established scoring system reversal gene expression named summarized reversal gene expression score srges correlates drug efficacy cancers b chen et al <NUMBER> demonstrating feasibility applying approach predict drug candidates diseases including covid<NUMBER> viral infections utilize srges drug discovery sarscov<NUMBER> first needed collect sarscov<NUMBER>induced host gene expression profiles available time writing given high genomic similarity sarscov<NUMBER> sarscov <NUMBER> merscov <NUMBER> h wang et al <NUMBER> reasoned existing host gene expression profiles samples infected sarscov merscov could approximate infected sarscov<NUMBER> verify assumption compiled <NUMBER> signatures various viruses enrichr geo table s<NUMBER> used established pipeline score <NUMBER> drugs repurposing library ability reverse virusinduced signatures b chen et al <NUMBER> zeng et al <NUMBER> clustering signatures based drug prediction scores suggests signatures derived virus virus family similar experimental conditions tend cluster together figure s<NUMBER> example cluster includes one signature derived primary human microvascular endothelial cells mmve<NUMBER> two days merscov infection study id gse<NUMBER> another derived melanoma cells mice seven days sarscov infection study id gse<NUMBER> addition spearman correlation coefficient vitro drug efficacy data ec <NUMBER> half maximal effective concentration sarscov merscov datasets close <NUMBER> figure <NUMBER>b clustering correlation results suggested drugs predicted based signatures induced sarscov merscov may potential applicability sarscov<NUMBER> therefore developed pipeline identify repurposed drugs merscov sarscov experimentally evaluate drugs sarscov<NUMBER> figure <NUMBER>c lincs database good candidate activate repressed biological processes inhibit upregulated processes b correlation published antiviral activities <NUMBER> drugs pec <NUMBER> log <NUMBER> transformed ec <NUMBER> value moll merscov sarscov c study workflow including creation disease signatures prediction drug candidates selection final drug list vitro validation one disease signature composed differentially expressed genes comparison led one drug prediction list signature resulting prediction list known positive drugs enriched top considered valid signature dysregulated pathways lungs sarscov infection <NUMBER> day compared <NUMBER> day e dynamics dysregulated pathways top downregulated pathways upregulated pathways mdc<NUMBER> cells infected merscov across different postinfection times <NUMBER> h<NUMBER> h study id gse<NUMBER> one study selected e dysregulated pathways dynamics studies available supplementary materials figure s<NUMBER> s<NUMBER> extended data <NUMBER> total <NUMBER> samples public repositories representing infection merscov sarscov strains comparison different models eg cell line mouse models across multiple time points used identify disease signatures table s<NUMBER> <NUMBER> studies total expression profiles created using either microarray rnasequencing depending profiling platform data processing signature creation methods varied see methods previous clusters figure s<NUMBER> comparison computed disease signature characterize infection status followed prediction drugs may activity ability reverse disease signature could directly evaluate quality pathologic relevance disease signature validated using drugs identified positive vitro merssarscov testing <NUMBER> positive drugs total <NUMBER> ec <NUMBER> values table s<NUMBER> among <NUMBER> merscov sarscov infection signatures <NUMBER> signatures able recover positive drugs shown highly enriched top predicted drug lists extended data <NUMBER> <NUMBER> moreover ec <NUMBER> drugs significantly correlated srges figure <NUMBER>a figure s<NUMBER> validating analysis observe significant enrichment anticoronavirus positive drugs using h<NUMBER>n<NUMBER> infection signatures extended data <NUMBER> recent clinical data suggested combination lopinavirritonavir offers clinical benefits patients infected sarscov<NUMBER> chu et al <NUMBER> lim et al <NUMBER> drugs profiled lincs subramanian et al <NUMBER> drug library primarily used individually however none alone could induce substantial gene expression changes absolute z score <NUMBER> <NUMBER> µm concentration cancer cell lines therefore neither predicted hit next found another dataset heparg cells treated ritonavir <NUMBER> different concentrations ranging <NUMBER> nm <NUMBER> µm observed ritonavir could reverse nearly <NUMBER> disease signatures high concentrations <NUMBER> µm <NUMBER> µm figure s<NUMBER> thus reasoned top ranked drugs highly negative srges valid comparisons could new therapeutic candidates merging disease signatures derived different platforms biological conditions highly complicated therefore instead merging calculated consensus score drug prediction lists derived individual valid disease signatures took median ranks across multiple comparisons drug ranked based median rank extended data <NUMBER> mechanism action moa enrichment analysis final ranked drug list revealed number significant drug classes including cdk inhibitors mtor inhibitors nfκb pathway inhibitors manually inspected top candidates selected ten representative candidates according reversal scores figure <NUMBER>d extended data <NUMBER> clinical applicability moa administration routes table s<NUMBER> evaluated cytotoxicity ability prevent cytopathic effect cpe vero e<NUMBER> cell line table <NUMBER> instead measuring ec <NUMBER> used stringent criteria required <NUMBER>day complete prevention cpe observed microscope seven proposed drugs could completely prevent cpe concentrations <NUMBER> µm however five presented unfavorable cytotoxicity effective concentration except methotrexate repeat experiment using shorter drug treatment time <NUMBER> h instead <NUMBER> h examined efficacy toxicity four effective drugs preventing cpe concentrations ≤ <NUMBER> µm bortezomib methotrexate nvpbez<NUMBER> alvocidib well chloroquine one drugs tested clinically sarscov<NUMBER> however shorter drug treatment time none predicted drugs could completely prevent cpe effectively chloroquine <NUMBER> µm table s<NUMBER> one hundred suppressed genes related cellular responses cytokine stimulus inflammatory response cytokine production etc figure <NUMBER>a corroborates studies channappanavar et al <NUMBER> de wit et al <NUMBER> showed sarscov merscov proteins interplay downregulated jakstat pathway order evade host immune response figure <NUMBER>a addition cytokinerelated genes downregulated genes include involved inflammatory mediators ap<NUMBER> atf<NUMBER> pathways eg jun fos ccl<NUMBER> figure <NUMBER>a related il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> signaling interleukins deficient early stage sarscov infection caused delayed type <NUMBER> interferon signaling rapidly led overactivated inflammatory cytokine storms channappanavar et al <NUMBER> downregulated genes also identified two recent studies sarscov<NUMBER> infection gordon et al gordon et al <NUMBER> point enrichment score pathway genes infected samples subtracted score genes mock samples ssgsea normalization across samples applied addition immune evasion enrichment analysis downregulated genes valid signatures suggested viral infection inhibited host gene transcription go positive regulation transcription rna polymerase ii probably via viral nsp<NUMBER> proteininduced host mrna degradation narayanan et al <NUMBER> host response amino acid deficiency unfolded protein pathways reactome response eif<NUMBER>ak<NUMBER> hri heme deficiency also suppressed figure <NUMBER>a virus order fully utilize host cell machinery replication moreover virus downregulated integrin pathway figure <NUMBER>a suggesting may disrupt intercellular surface interactions prevent infected cells connecting neighbors importance sarscov<NUMBER> recognition integrins highlighted luan et al luan et al nd terms overexpressed genes <NUMBER> ribosome genes commonly upregulated infection signatures figure <NUMBER>b suggesting virus already hijacked host cell machinery replication biological processes including mitotic cell cycle nuclear division dna replication significantly overrepresented might related rho gtpase plk<NUMBER> aurora b signaling activation implied upregulated genes signatures figure <NUMBER>b sarscov<NUMBER> human protein interactome gordon et al <NUMBER> <NUMBER> figure <NUMBER>c immune signaling pathways suppressed day <NUMBER> day <NUMBER> normalized baseline day <NUMBER> virus cleared body addition three processes including proteasomeubiquitin dependent protein catabolic process host gene transcription rna polymerase ii eif<NUMBER>ak<NUMBER> response heme deficiency remained inactive day <NUMBER> contrast cell cycle related viral replication processes first suppressed dramatically activated day <NUMBER> day <NUMBER> figure <NUMBER>d also observed activation nonsense mediated decay er localization g<NUMBER>s transition day <NUMBER> day <NUMBER> figure <NUMBER>d table s<NUMBER> suggests reversal hijacked gene expression changes specific time interval may useful designing novel antiviral therapeutics strategies study investigated host gene expression changes induced coronavirus replication indeed vivo experiment <NUMBER> days drug treatment performed study hoffmann et al <NUMBER> led signatures could recover known drugs developed consensus score drug based potency reverse <NUMBER> valid infection signatures prediction externally validated recent drug screen sarscov<NUMBER> jeon et al <NUMBER> justified approach based reversal host cell gene expression induced sars moa selected <NUMBER> drugs test antiviral efficacy cytotoxicity vero e<NUMBER> cell line observed four <NUMBER> drugs prevented cpe within <NUMBER> µm three toxic concentration initially excluded highly toxic compounds topoisomerase inhibitors attempt evaluate cytotoxicity since candidates fda approved drugs undergoing clinical trials therefore established safety profiles potent candidate methotrexate chemotherapeutic agent high doses immune suppressor lower doses used treat rheumatoid arthritis ra methotrexate showed considerable vitro antiviral effect relatively low toxicity direct binding target methotrexate dihydrofolate reductase dhfr important enzyme folate metabolism pathway dhrf upregulated valid signatures together folate transporter slc<NUMBER>a<NUMBER> extended data <NUMBER> folate required metabolism several amino acids vital nucleic acid synthesis could utilized virus lincs drug profiles found methotrexate could downregulate genes related g<NUMBER>m cell cycle eg melk kif<NUMBER> birc<NUMBER> upregulate genes related cytokine signaling eg ccl<NUMBER> cxcl<NUMBER> nfkbia figure <NUMBER>d congruent previous observations interferon related pathways governing inflammation overlap cancer musella et al <NUMBER> recently another ra drug tocilizumab il<NUMBER> antibody used treat sarscov<NUMBER> patients severe symptoms protect lifethreatening lung damage caused cytokine storms analysis druginduced vivo profiles geo accession gse<NUMBER> gse<NUMBER> revealed methotrexate tocilizumab could reverse several genes infection signatures govern negative regulation viral genome replication viral life cycle annotated go<NUMBER> go<NUMBER> figure s<NUMBER> chloroquine lesser reversal effect genes suggesting different moa methotrexate tocilizumab interestingly virusblocking genes also interferonstimulated genes isgs isg<NUMBER> oas<NUMBER> thus testing methotrexate interferon sufficient cell lines compared interferon deficient vero cells could great interest three candidates anticancer agents namely bortezomib nvpbez<NUMBER> alvocidib cancer cells proteasome inhibition bortezomib induces er stress constitutive er stress causes calcium release resulting apoptosis landowski et al <NUMBER> nvpbez<NUMBER> inhibits pi<NUMBER>k kinase mtor kinase pi<NUMBER>kaktmtor kinase signaling pathway may result apoptosis hyperactive cells inhibition growth pi<NUMBER>kmtoroverexpressing cells netland et al <NUMBER> alvocidib cdk inhibitor acting inhibition mcl<NUMBER> expression leads apoptosis cells arbour et al <NUMBER> independent drug repurposing efforts antisarscov<NUMBER> anticancer drugs like axl receptor tyrosine kinase inhibitor gilteritinib cdk inhibitor abemaciclib also identified vitro jeon et al <NUMBER> weston et al <NUMBER> anticancer drugs inhibit sarscov<NUMBER> infection likely targeting hijacked host cells hyperactive transcription translation however doubleedged sword good efficacy yet unfavorable cytotoxicity especially severely ill patients weakened overactivation inflammatory system importantly <NUMBER> valid infection signatures also provided comprehensive understanding impact coronavirus infection host response especially timedependent dynamics changes biological processes may provide useful insights designing clinically useful treatment strategies signatures captured several critical viral processes related merscov sarscov infections also sarscov<NUMBER> infection thus might applicable studying future pathogens within coronaviruses family rationally targeting dysregulated pathways specific time intervals may result promising therapeutics coronavirus infection study restricted limitations lincs datasets eg limited coverage transcriptome another limitation use druginduced gene expression profiles derived cancer cells different virusinfected cells used generate infection signatures may partially explain antiviral drugs predicted hits nevertheless given currently limited resources imperative need find treatments covid<NUMBER> existing fdaapproved drugs identified regardless established moa studied infectious disease models conclusion open science initiatives allowed us leverage public resources rationally predict drug candidates might reverse coronavirusinduced transcriptomic changes unbiased search drug candidates based reversal gene expression could offer effective rapid means propose drug candidates experimental testing even may unexpected moa however layers information toxicity experimental validation conditions clinical applicability could incorporated find improved therapeutics predicted drug list valid infection signatures resulting study may provide starting point researchers validate candidates time urgency obtained total <NUMBER> samples sarscov merscov related data arrayexpress rnaseq datasets raw sequence data downloaded sra processed toil pipeline liu et al <NUMBER> vivian et al <NUMBER> edger used compute de genes using criteria used microarray data gene ontology enrichment analysis de genes comparison performed using clusterprofiler r package gene set enrichment ssgsea biological process performed using ssgsea method gsva r package infection group enumerated comparisons across time points corresponding comparisons performed mock group de genes uniquely present infection group selected analysis also compared de genes infection mock groups time point together consistently dysregulated genes first last time point computation reversal gene expression score rges summarization rges give summarized rges srges detailed elsewhere recently implemented standalone r package zeng et al <NUMBER> short quantified reversal disease gene expression rges measure modified connectivity score developed studies sirota et al <NUMBER> subramanian et al <NUMBER> compute rges first rank genes based expression values drug profile enrichment scores set upand downregulated disease genes computed separately using kolmogorovsmirnovlike statistic followed merging scores sets updown score based extent genes downregulated disease genes located either top bottom ranked drug profile one compound may multiple available expression profiles tested various cell lines drug concentrations treatment durations occationally different replicates resulting multiple rges one disease prediction set reference condition ie concentration <NUMBER> µm treatment duration <NUMBER> h used model estimate new rges drug profile reference condition available summarized scores srges without weighting cell lines considered predictions insignificant maximum absolute srges <NUMBER> downloaded compiled virusperturbed signatures enrichr <NUMBER> total since enrichr dataset include merscov signatures manually added signatures two merscov datasets gse<NUMBER> gse<NUMBER> <NUMBER> total computed comparisons separate infected groups mock groups virus signatures containing <NUMBER> lincs landmark genes selected virus signature queried lincs library using established pipeline signatures maximum absolute srges <NUMBER> chosen subsequent analysis viruses clustered based srges scores using pvclust suzuki shimodaira <NUMBER> distance method spearman correlation nboot <NUMBER> ritonavir originally developed inhibitor hiv protease often used low dose protease inhibitors boost antiviral effect found one rnaseq dataset sra srx<NUMBER> heparg cells treated multiple compounds including ritonavir multiple concentrations ranging <NUMBER> nm <NUMBER> µm processed <NUMBER> profiles plate <NUMBER>drgplate<NUMBER> consisting <NUMBER> concentrations concentration nine profiles log <NUMBER> tpm transcripts per million profile subtracted median log <NUMBER> tpm dmsotreated samples plate resulting one druginduced gene expression profile spearman correlation druginduced gene expression disease gene expression used lincs prediction computed negative correlation means reversal relationship allow easier visualization selected drug candidates ability reverse coronavirusinduced gene expression changes combined <NUMBER> valid infection signatures one meta signature summarized drug profiles different experiments one profile dysregulated genes included meta infection signature <NUMBER> quantile log <NUMBER> fold changes <NUMBER> <NUMBER> quantile <NUMBER> drug profiles zscores level <NUMBER> l<NUMBER> measured <NUMBER> µm extracted including different cell lines treatment times value gene summarized profile defined median head tail <NUMBER> depending absolute value larger quantile absolute value <NUMBER> defined median zscores gene across profiles extracted matrix composed meta signature genes signatures selected drug candidates also included profiles two drugs predicted negative hits ordered rows fold change infection signature genes heatmap used visualize effect selected drugs reversing virusinduced genes visualizing transcriptome datasets figure s<NUMBER> geo processed gene expression matrix manner disease signature mentioned computation infection signature log<NUMBER> fold change values genes converted ranking percentages finally clustermap computed genes interest colored red upregulation blue downregulation processed compound transcriptome profile categorized upor downregulated genes threshold log <NUMBER> fold change <NUMBER> <NUMBER> respectively group genes submitted enrichr e chen et al <NUMBER> httpsamppharmmssmeduenrichr compute gene ontology go enrichment analysis go terms pvalue <NUMBER> adjusted pvalue <NUMBER> considered significant also used msigdb subramanian et al <NUMBER> httpswwwgseamsigdborggseamsigdbindexjsp calculate enriched go c<NUMBER> canonical pathways cp c<NUMBER> enriched common dysregulated genes shown half valid infection signatures vero e<NUMBER> cells crl<NUMBER> atcc grown eagles minimal essential medium emem supplemented penicillin <NUMBER> unitsml streptomycin <NUMBER> µgml <NUMBER> fetal bovine serum fbs sarscov<NUMBER> uswa<NUMBER> isolate <NUMBER> rd passage vero e<NUMBER> cells original cdc atlanta material sequence confirmed used throughout study titer viral stock <NUMBER> × <NUMBER> <NUMBER> <NUMBER> tissue culture infectious doses tcid <NUMBER> ml experiments involving infectious virus conducted university texas medical branch approved biosafety level <NUMBER> laboratory slightly modified vero e<NUMBER>based standard microneutralization assay used rapidly evaluate efficacy predicted drugs sarscov<NUMBER> infection briefly confluent vero e<NUMBER> cells grown <NUMBER>wells microtiter plates pretreated serially <NUMBER>folds diluted individual drugs <NUMBER> h first instance <NUMBER> h repeat experiment infection <NUMBER> infectious sarscov<NUMBER> particles <NUMBER> μ l emem supplemented <NUMBER> fbs vero e<NUMBER> cells treated similarly diluted dimethyl sulfoxide dmso without virus included positive negative controls respectively cultivation <NUMBER> °c <NUMBER> days individual wells observed microscope determine virusinduced cpe effects tested drugs efficacy individual drugs calculated expressed lowest concentration capable completely preventing virusinduced cpe <NUMBER> wells toxicity treated cells assessed observing floating cells altered morphology adhered vero e<NUMBER> cells wells microscope compounds ordered selleckchem usa cayman chemical usa compounds dissolved <NUMBER> dmso <NUMBER> mm stock solutions diluted culture media analyses conducted r v<NUMBER> python v<NUMBER> programming language ggplot<NUMBER> pheatmap seaborn packages used data visualization students ttest performed normally distributed data wilcoxon ranksum test used types data compute pvalue authors declare data used study available within article supplementary information files specific files provided corresponding author upon reasonable request code available github httpsgithubcombinchenlabwars since early december <NUMBER> newly emerged sarscov<NUMBER> infected <NUMBER> million people globally covid<NUMBER> report nd united states confirmed cases increased exponentially steadily exceeding million mark within two months making united states hardest hit country globally cdc cases updates nd among infected patients approximately <NUMBER> suffered severe acute respiratory distress syndrome ards approximately <NUMBER> died acute respiratory failure acute cardiac injury secondary infection serious complications covid<NUMBER> report nd huang et al <NUMBER> highly contagious pathogenic virus spread rapidly throughout world declared pandemic named effective therapeutics urgently needed repurposing existing drugs could efficient timely means identifying novel drugs treating disease initially repurposed drugs lopinavirritonavir baricitinib remdesivir chloroquine investigated clinical efficacy covid<NUMBER> patients peeri et al <NUMBER> wang et al <NUMBER> remdesivir since shown encouraging efficacy currently used benchmark drug treating covid<NUMBER> patients moderate severe symptoms repurposed drugs study hypothesized target key steps viral entry specific proteins involved viral replication including viral proteases zumla et al <NUMBER> addition viral replication viral pathogen associated molecular pattern pamp eg immune dysfunction endoplasmic reticulum stress figure <NUMBER>a could targeted improve clinical outcomes de wit et al <NUMBER> pampsmediated signaling pathways attractive drug targets diseases caused human pathogens therefore effectively targeting pathways stop progression acute respiratory distress syndrome caused sarscov<NUMBER> might potentially reduce morbidities mortalities associated virus independent sarscov<NUMBER> infection aging adult populations ards associated mortality rates <NUMBER> bellani et al <NUMBER> thus methodical unbiased search new drug candidates large drug library could uncover drugs potential arrest infection ameliorate debilitating effects aim accomplish analyzing infectioninduced gene expressions host cells others b chen wei et al <NUMBER> lee et al <NUMBER> van noort et al <NUMBER> pessetto et al <NUMBER> qu rajpal <NUMBER> sirota et al <NUMBER> h wu et al <NUMBER> utilized systemsbased approach employs gene expression profiles disease samples druginduced gene expression profiles cell lines discover new therapeutic candidates diseases central idea identify drugs reverse disease gene expression signature suppressing overexpressed disease genes activating repressed genes figure <NUMBER>a disease signature defined list differentially expressed genes disease samples normal control samples recently established scoring system reversal gene expression named summarized reversal gene expression score srges correlates drug efficacy cancers b chen et al <NUMBER> demonstrating feasibility applying approach predict drug candidates diseases including covid<NUMBER> viral infections ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint utilize srges drug discovery sarscov<NUMBER> first needed collect sarscov<NUMBER>induced host gene expression profiles available time writing given high genomic similarity sarscov<NUMBER> sarscov <NUMBER> merscov <NUMBER> h wang et al <NUMBER> reasoned existing host gene expression profiles samples infected sarscov merscov could approximate infected sarscov<NUMBER> verify assumption compiled <NUMBER> signatures various viruses enrichr geo table s<NUMBER> used established pipeline score <NUMBER> drugs repurposing library ability reverse virusinduced signatures b chen et al <NUMBER> zeng et al <NUMBER> clustering signatures based drug prediction scores suggests signatures derived virus virus family similar experimental conditions tend cluster together figure s<NUMBER> example cluster includes one signature derived primary human microvascular endothelial cells mmve<NUMBER> two days merscov infection study id gse<NUMBER> another derived melanoma cells mice seven days sarscov infection study id gse<NUMBER> addition spearman correlation coefficient vitro drug efficacy data ec <NUMBER> half maximal effective concentration sarscov merscov datasets close <NUMBER> figure <NUMBER>b clustering correlation results suggested drugs predicted based signatures induced sarscov merscov may potential applicability sarscov<NUMBER> therefore developed pipeline identify repurposed drugs merscov sarscov experimentally evaluate drugs sarscov<NUMBER> figure <NUMBER>c ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint lincs database good candidate activate repressed biological processes inhibit upregulated processes b correlation published antiviral activities <NUMBER> drugs pec <NUMBER> log <NUMBER> transformed ec <NUMBER> value moll merscov sarscov c study workflow including creation disease signatures prediction drug candidates selection final drug list vitro validation one disease signature composed differentially expressed genes comparison led one drug prediction list signature resulting prediction list known positive drugs enriched top considered valid signature dysregulated pathways lungs sarscov infection <NUMBER> day compared <NUMBER> day e dynamics dysregulated pathways top downregulated pathways upregulated pathways mdc<NUMBER> cells infected merscov across different postinfection times <NUMBER> h<NUMBER> h study id gse<NUMBER> one study selected e dysregulated pathways dynamics studies available supplementary materials figure s<NUMBER> s<NUMBER> extended data <NUMBER> total <NUMBER> samples public repositories representing infection merscov sarscov strains comparison different models eg cell line mouse models across multiple time points used identify disease signatures table s<NUMBER> <NUMBER> studies total expression profiles created using either microarray rnasequencing depending profiling platform data processing signature creation methods varied see methods previous clusters figure s<NUMBER> tissue data showed various biological processes including viral gene expression dna replication nuclear division lymphocytes differentiation translationrelated processes activated figure <NUMBER>d s<NUMBER> extended data <NUMBER> contrast interleukin autophagyrelated processes repressed infected samples figure <NUMBER>d s<NUMBER> extended data <NUMBER> interestingly processes displayed timedependent dynamics infected samples eg <NUMBER> h <NUMBER> h figure <NUMBER>e examples infection dynamics studies shown figure s<NUMBER> instance immune signaling pathways downregulated dramatically within first <NUMBER> hours infection dna replication related ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint pathways first suppressed period activated <NUMBER> h postinfection observed host dynamic responses virus infection suggests comparisons different time points important capture representative biological events throughout course viral infection comparison computed disease signature characterize infection status followed prediction drugs may activity ability reverse disease signature could directly evaluate quality pathologic relevance disease signature validated using drugs identified positive vitro merssarscov testing <NUMBER> positive drugs total <NUMBER> ec <NUMBER> values table s<NUMBER> among <NUMBER> merscov sarscov infection signatures <NUMBER> signatures able recover positive drugs shown highly enriched top predicted drug lists extended data <NUMBER> <NUMBER> moreover ec <NUMBER> drugs significantly correlated srges figure <NUMBER>a figure s<NUMBER> validating analysis observe significant enrichment anticoronavirus positive drugs using h<NUMBER>n<NUMBER> infection signatures extended data <NUMBER> recent clinical data suggested combination lopinavirritonavir offers clinical benefits patients infected sarscov<NUMBER> chu et al <NUMBER> lim et al <NUMBER> drugs profiled lincs subramanian et al <NUMBER> drug library primarily used individually however none alone could induce substantial gene expression changes absolute z score <NUMBER> <NUMBER> µm concentration cancer cell lines therefore neither predicted hit next found another dataset heparg cells treated ritonavir <NUMBER> different concentrations ranging <NUMBER> nm <NUMBER> µm observed ritonavir could reverse nearly <NUMBER> disease signatures high concentrations <NUMBER> µm <NUMBER> µm figure s<NUMBER> thus reasoned top ranked drugs highly negative srges valid comparisons could new therapeutic candidates ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint merging disease signatures derived different platforms biological conditions highly complicated therefore instead merging calculated consensus score drug prediction lists derived individual valid disease signatures took median ranks across multiple comparisons drug ranked based median rank extended data <NUMBER> mechanism action moa enrichment analysis final ranked drug list revealed number significant drug classes including cdk inhibitors mtor inhibitors nfκb pathway inhibitors ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint manually inspected top candidates selected ten representative candidates according reversal scores figure <NUMBER>d extended data <NUMBER> clinical applicability moa administration routes table s<NUMBER> evaluated cytotoxicity ability prevent cytopathic effect cpe vero e<NUMBER> cell line table <NUMBER> instead measuring ec <NUMBER> used stringent criteria required <NUMBER>day complete prevention cpe observed microscope seven proposed drugs could completely prevent cpe concentrations <NUMBER> µm however five presented unfavorable ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint cytotoxicity effective concentration except methotrexate repeat experiment using shorter drug treatment time <NUMBER> h instead <NUMBER> h examined efficacy toxicity four effective drugs preventing cpe concentrations ≤ <NUMBER> µm bortezomib methotrexate nvpbez<NUMBER> alvocidib well chloroquine one drugs tested clinically sarscov<NUMBER> however shorter drug treatment time none predicted drugs could completely prevent cpe effectively chloroquine <NUMBER> µm table s<NUMBER> one hundred suppressed genes related cellular responses cytokine stimulus inflammatory response cytokine production etc figure <NUMBER>a corroborates studies channappanavar et al <NUMBER> de wit et al <NUMBER> showed sarscov merscov proteins interplay downregulated jakstat pathway order evade host immune response figure <NUMBER>a addition cytokinerelated genes downregulated genes include involved inflammatory mediators ap<NUMBER> atf<NUMBER> pathways eg jun fos ccl<NUMBER> figure <NUMBER>a related il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> il<NUMBER> signaling interleukins deficient early stage ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint sarscov infection caused delayed type <NUMBER> interferon signaling rapidly led overactivated inflammatory cytokine storms channappanavar et al <NUMBER> downregulated genes also identified two recent studies sarscov<NUMBER> infection gordon et al gordon et al <NUMBER> identified <NUMBER> high confidence sarscov<NUMBER>human proteinprotein interactions among <NUMBER> host genes also found valid signatures instance tbkbp<NUMBER> related type <NUMBER> interferons production trim<NUMBER> several cytokine signaling related proteins bind sarscov<NUMBER> proteins eg nsp<NUMBER> copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint biological processes bottom upregulated canonical pathways valid signatures study id gse<NUMBER> point enrichment score pathway genes infected samples subtracted score genes mock samples ssgsea normalization across samples applied addition immune evasion enrichment analysis downregulated genes valid signatures suggested viral infection inhibited host gene transcription go positive regulation transcription rna polymerase ii probably via viral nsp<NUMBER> proteininduced host mrna degradation narayanan et al <NUMBER> host response amino acid deficiency unfolded protein pathways reactome response eif<NUMBER>ak<NUMBER> hri heme deficiency also suppressed figure <NUMBER>a virus order fully utilize host cell machinery replication moreover virus downregulated integrin pathway figure <NUMBER>a suggesting may disrupt intercellular surface interactions prevent infected cells connecting neighbors importance sarscov<NUMBER> recognition integrins highlighted luan et al luan et al nd terms overexpressed genes <NUMBER> ribosome genes commonly upregulated infection signatures figure <NUMBER>b suggesting virus already hijacked host cell machinery replication biological processes including mitotic cell cycle nuclear division dna replication significantly overrepresented might related rho gtpase plk<NUMBER> aurora b signaling activation implied upregulated genes signatures figure <NUMBER>b sarscov<NUMBER> human protein interactome gordon et al <NUMBER> <NUMBER> revealed nsp<NUMBER> binds host rho gtpase agreeing infection signature multiple rho gtpase effectors upregulated perhaps providing survival benefits virus van den broeke jacob favoreel <NUMBER> interactome also revealed high overlap sarscov<NUMBER> nsp<NUMBER>human protein interactome proteins specific g<NUMBER>s transition mitotic cell cycle interestingly coronavirus infection also promoted atr signaling figure <NUMBER>b probably response dna replication stress suggests potential strategy intervene dna replication stress induced viral proteins eg via replication protein complex xu et al <NUMBER> figure <NUMBER>c immune signaling pathways suppressed day <NUMBER> day <NUMBER> normalized baseline day <NUMBER> virus cleared body addition three processes including proteasomeubiquitin dependent protein catabolic process host gene transcription rna polymerase ii eif<NUMBER>ak<NUMBER> response heme deficiency remained inactive day <NUMBER> contrast cell cycle related viral replication processes first suppressed dramatically activated day <NUMBER> day <NUMBER> figure <NUMBER>d also observed activation nonsense mediated decay er localization g<NUMBER>s transition day <NUMBER> day <NUMBER> figure <NUMBER>d dynamics host cells hijacked virus resulting immune suppression host gene translation silencing activation protein synthesis findings also supported analysis infection signatures derived comparison day <NUMBER> day <NUMBER> rather comparison day <NUMBER> day <NUMBER> resulted significant enrichment positive drugs p <NUMBER> srges ec <NUMBER> correlation <NUMBER> table s<NUMBER> suggests reversal hijacked gene expression changes specific time interval may useful designing novel antiviral therapeutics strategies first submission work gene expression profiles induced sarscov<NUMBER> infection released computed sarscov<NUMBER> signatures a<NUMBER> calu<NUMBER> nhbe cells nhbe a<NUMBER> cells low viral load moi <NUMBER> show substantial transcriptional changes less <NUMBER> differentially expressed genes mapped lincs partially due poor permissibility sarscov<NUMBER> hoffmann et al <NUMBER> low viral load greater number signature genes identified calu<NUMBER> a<NUMBER> cells high viral load moi <NUMBER> however positive control drugs showed virusmimicking effect rather reversal disease gene expression table s<NUMBER> calu<NUMBER> a<NUMBER> cells <NUMBER> h postinfection profiles available however studies shown many infection signature genes reverted back normal time point figure s<NUMBER> considering ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint infection dynamics varying cell permissibility signatures <NUMBER> h might capture characteristics host cell immune response virus processes viral replication indeed vivo experiment <NUMBER> days drug treatment performed study hoffmann et al <NUMBER> led signatures could recover known drugs developed consensus score drug based potency reverse <NUMBER> valid infection signatures prediction externally validated recent drug screen sarscov<NUMBER> jeon et al <NUMBER> justified approach based reversal host cell gene expression induced sars moa selected <NUMBER> drugs test antiviral efficacy cytotoxicity vero e<NUMBER> cell line observed four <NUMBER> drugs prevented cpe within <NUMBER> µm three toxic concentration initially excluded highly toxic compounds topoisomerase inhibitors attempt evaluate cytotoxicity since candidates fda approved drugs undergoing clinical trials therefore established safety profiles potent candidate methotrexate chemotherapeutic agent high doses immune suppressor lower doses used treat rheumatoid arthritis ra methotrexate showed considerable vitro antiviral effect relatively low toxicity direct binding target methotrexate dihydrofolate reductase dhfr important enzyme folate metabolism pathway dhrf upregulated valid signatures together folate transporter slc<NUMBER>a<NUMBER> extended data <NUMBER> folate required metabolism several amino acids vital nucleic acid synthesis could utilized virus lincs drug profiles found methotrexate could downregulate genes related g<NUMBER>m cell cycle eg melk kif<NUMBER> birc<NUMBER> upregulate genes related cytokine signaling eg ccl<NUMBER> cxcl<NUMBER> nfkbia figure <NUMBER>d congruent previous observations interferon related pathways governing inflammation overlap cancer musella et al <NUMBER> recently another ra drug tocilizumab il<NUMBER> antibody used treat sarscov<NUMBER> ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint patients severe symptoms protect lifethreatening lung damage caused cytokine storms analysis druginduced vivo profiles geo accession gse<NUMBER> gse<NUMBER> revealed methotrexate tocilizumab could reverse several genes infection signatures govern negative regulation viral genome replication viral life cycle annotated go<NUMBER> go<NUMBER> figure s<NUMBER> chloroquine lesser reversal effect genes suggesting different moa methotrexate tocilizumab interestingly virusblocking genes also interferonstimulated genes isgs isg<NUMBER> oas<NUMBER> thus testing methotrexate interferon sufficient cell lines compared interferon deficient vero cells could great interest three candidates anticancer agents namely bortezomib nvpbez<NUMBER> alvocidib cancer cells proteasome inhibition bortezomib induces er stress constitutive er stress causes calcium release resulting apoptosis landowski et al <NUMBER> nvpbez<NUMBER> inhibits pi<NUMBER>k kinase mtor kinase pi<NUMBER>kaktmtor kinase signaling pathway may result apoptosis hyperactive cells inhibition growth pi<NUMBER>kmtoroverexpressing cells netland et al <NUMBER> alvocidib cdk inhibitor acting inhibition mcl<NUMBER> expression leads apoptosis cells arbour et al <NUMBER> independent drug repurposing efforts antisarscov<NUMBER> anticancer drugs like axl receptor tyrosine kinase inhibitor gilteritinib cdk inhibitor abemaciclib also identified vitro jeon et al <NUMBER> weston et al <NUMBER> anticancer drugs inhibit sarscov<NUMBER> infection likely targeting hijacked host cells hyperactive transcription translation however doubleedged sword good efficacy yet unfavorable cytotoxicity especially severely ill patients weakened overactivation inflammatory system importantly <NUMBER> valid infection signatures also provided comprehensive understanding impact coronavirus infection host response especially timedependent dynamics changes biological processes may provide useful insights designing clinically useful treatment strategies signatures captured several critical viral processes related merscov ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint sarscov infections also sarscov<NUMBER> infection thus might applicable studying future pathogens within coronaviruses family rationally targeting dysregulated pathways specific time intervals may result promising therapeutics coronavirus infection study restricted limitations lincs datasets eg limited coverage transcriptome another limitation use druginduced gene expression profiles derived cancer cells different virusinfected cells used generate infection signatures may partially explain antiviral drugs predicted hits nevertheless given currently limited resources imperative need find treatments covid<NUMBER> existing fdaapproved drugs identified regardless established moa studied infectious disease models conclusion open science initiatives allowed us leverage public resources rationally predict drug candidates might reverse coronavirusinduced transcriptomic changes unbiased search drug candidates based reversal gene expression could offer effective rapid means propose drug candidates experimental testing even may unexpected moa however layers information toxicity experimental validation conditions clinical applicability could incorporated find improved therapeutics predicted drug list valid infection signatures resulting study may provide starting point researchers validate candidates time urgency ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> obtained total <NUMBER> samples sarscov merscov related data arrayexpress gene expression omnibus geo sequence read archive sra metainformation sample manually annotated including virus strain model organism time point expression matrix microarray data downloaded via geoquery r package matrix filtered removing probes expression half samples expression values normalized using quantile normalization log <NUMBER> transformation applied matrix probe values collapsed based entrez gene id significance analysis microarrays sam method used compute differentially expressed de genes criteria fold change <NUMBER> false discovery rate fdr <NUMBER> gene symbols organisms converted hugo gene symbols rnaseq datasets raw sequence data downloaded sra processed toil pipeline liu et al <NUMBER> vivian et al <NUMBER> edger used compute de genes using criteria used microarray data gene ontology enrichment analysis de genes comparison performed using clusterprofiler r package gene set enrichment ssgsea biological process performed using ssgsea method gsva r package infection group enumerated comparisons across time points corresponding comparisons performed mock group de genes uniquely present infection group selected analysis also compared de genes infection mock groups time point together consistently dysregulated genes first last time point computation reversal gene expression score rges summarization rges give summarized rges srges detailed elsewhere recently implemented standalone r package zeng et al <NUMBER> short quantified reversal disease gene expression rges measure modified connectivity score developed studies sirota et al <NUMBER> subramanian et al <NUMBER> compute rges first rank genes based expression values drug profile enrichment scores set upand downregulated disease genes computed separately using kolmogorovsmirnovlike statistic followed merging scores sets updown score based extent genes downregulated disease genes located either top bottom ranked drug profile one compound may multiple available expression profiles tested various cell lines drug concentrations treatment durations occationally different replicates resulting multiple rges one disease prediction set reference condition ie concentration <NUMBER> µm treatment duration <NUMBER> h used model estimate new rges drug profile reference condition available summarized scores srges without weighting cell lines considered predictions insignificant maximum absolute srges <NUMBER> downloaded compiled virusperturbed signatures enrichr <NUMBER> total since enrichr dataset include merscov signatures manually added signatures two merscov datasets gse<NUMBER> gse<NUMBER> <NUMBER> total computed comparisons separate infected groups mock groups virus signatures containing <NUMBER> lincs landmark genes selected virus signature queried lincs library using established pipeline signatures maximum absolute srges <NUMBER> chosen subsequent analysis viruses clustered based srges scores using pvclust suzuki shimodaira <NUMBER> distance method spearman correlation nboot <NUMBER> ritonavir originally developed inhibitor hiv protease often used low dose protease inhibitors boost antiviral effect found one rnaseq dataset sra srx<NUMBER> heparg cells treated multiple compounds including ritonavir multiple concentrations ranging <NUMBER> nm <NUMBER> µm processed <NUMBER> profiles plate <NUMBER>drgplate<NUMBER> consisting <NUMBER> concentrations concentration nine profiles log <NUMBER> tpm transcripts per ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint million profile subtracted median log <NUMBER> tpm dmsotreated samples plate resulting one druginduced gene expression profile spearman correlation druginduced gene expression disease gene expression used lincs prediction computed negative correlation means reversal relationship allow easier visualization selected drug candidates ability reverse coronavirusinduced gene expression changes combined <NUMBER> valid infection signatures one meta signature summarized drug profiles different experiments one profile dysregulated genes included meta infection signature <NUMBER> quantile log <NUMBER> fold changes <NUMBER> <NUMBER> quantile <NUMBER> drug profiles zscores level <NUMBER> l<NUMBER> measured <NUMBER> µm extracted including different cell lines treatment times value gene summarized profile defined median head tail <NUMBER> depending absolute value larger quantile absolute value <NUMBER> defined median zscores gene across profiles extracted matrix composed meta signature genes signatures selected drug candidates also included profiles two drugs predicted negative hits ordered rows fold change infection signature genes heatmap used visualize effect selected drugs reversing virusinduced genes visualizing transcriptome datasets figure s<NUMBER> geo processed gene expression matrix manner disease signature mentioned computation infection signature log<NUMBER> fold change values genes converted ranking percentages finally clustermap computed genes interest colored red upregulation blue downregulation ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint processed compound transcriptome profile categorized upor downregulated genes threshold log <NUMBER> fold change <NUMBER> <NUMBER> respectively group genes submitted enrichr e chen et al <NUMBER> httpsamppharmmssmeduenrichr compute gene ontology go enrichment analysis go terms pvalue <NUMBER> adjusted pvalue <NUMBER> considered significant also used msigdb subramanian et al <NUMBER> httpswwwgseamsigdborggseamsigdbindexjsp calculate enriched go c<NUMBER> canonical pathways cp c<NUMBER> enriched common dysregulated genes shown half valid infection signatures vero e<NUMBER> cells crl<NUMBER> atcc grown eagles minimal essential medium emem supplemented penicillin <NUMBER> unitsml streptomycin <NUMBER> µgml <NUMBER> fetal bovine serum fbs sarscov<NUMBER> uswa<NUMBER> isolate <NUMBER> rd passage vero e<NUMBER> cells original cdc atlanta material sequence confirmed used throughout study titer viral stock <NUMBER> × <NUMBER> <NUMBER> <NUMBER> tissue culture infectious doses tcid <NUMBER> ml experiments involving infectious virus conducted university texas medical branch approved biosafety level <NUMBER> laboratory slightly modified vero e<NUMBER>based standard microneutralization assay used rapidly evaluate efficacy predicted drugs sarscov<NUMBER> infection briefly confluent vero e<NUMBER> cells grown <NUMBER>wells microtiter plates pretreated serially <NUMBER>folds diluted individual drugs <NUMBER> h first instance <NUMBER> h repeat experiment infection <NUMBER> infectious sarscov<NUMBER> particles <NUMBER> μ l emem supplemented <NUMBER> fbs vero e<NUMBER> cells treated similarly diluted dimethyl sulfoxide dmso without virus included positive negative controls respectively ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint cultivation <NUMBER> °c <NUMBER> days individual wells observed microscope determine virusinduced cpe effects tested drugs efficacy individual drugs calculated expressed lowest concentration capable completely preventing virusinduced cpe <NUMBER> wells toxicity treated cells assessed observing floating cells altered morphology adhered vero e<NUMBER> cells wells microscope compounds ordered selleckchem usa cayman chemical usa compounds dissolved <NUMBER> dmso <NUMBER> mm stock solutions diluted culture media analyses conducted r v<NUMBER> python v<NUMBER> programming language ggplot<NUMBER> pheatmap seaborn packages used data visualization students ttest performed normally distributed data wilcoxon ranksum test used types data compute pvalue authors declare data used study available within article supplementary information files specific files provided corresponding author upon reasonable request code available github httpsgithubcombinchenlabwars bc conceived supervised study jx rs bc performed computational analyses input sp ec ad performed biological experiments supervised ctkt sr provided clinical insights td prepared reagents jx rs bc ad ctkt wrote ccbyncnd <NUMBER> international license certified peer review authorfunder made available copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi biorxiv preprint manuscript input coauthors msc provided feedback reviewed edited manuscript since december <NUMBER> outbreak caused pathogen resulting respiratory disease occurred wuhan china disease termed coronavirus disease <NUMBER> covid<NUMBER> world health organization causative agent identified severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> disease global threat <NUMBER> march <NUMBER> recognized outbreak pandemic <NUMBER> sarscov<NUMBER> infected <NUMBER> killed <NUMBER> people according <NUMBER> coronaviruses large family enveloped highly diverse positivesense singlestranded rna viruses known infect humans animals resulting respiratory hepatic neuronal gastrointestinal diseases <NUMBER> <NUMBER> <NUMBER> recently hcovsnl<NUMBER> hcovshku<NUMBER> hcovs<NUMBER>e hcovsoc<NUMBER> middle east respiratory syndromecov merscov severe acute respiratory syndromecov sarscov six coronaviruses affected humans <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> sarscov merscov coronaviruses responsible highest mortality rates human <NUMBER> <NUMBER> respectively <NUMBER> hence recently discovered sarscov<NUMBER> seventh member coronavirus family affect humans genome sarscov<NUMBER> isolated patients analyzed revealed <NUMBER> similar sarscov <NUMBER> similar rdrp region batcov ratg<NUMBER> bat coronavirus <NUMBER> although believed originate bats yet patients pneumonia <NUMBER> patients lymphopenia observed increased prothrombin time well increased level lactate dehydrogenase identified patients <NUMBER> radiologic analysis lungs revealed groundglass shadow form patchy groundglass opacities patchy consolidation mostly located middle outer zone lungs <NUMBER> <NUMBER> patients abnormal liver function elevated aspartate aminotransferase alanine aminotransferase well myocardial zymogram showing elevated levels lactate dehydrogenase creatine kinase identified <NUMBER> covid<NUMBER> cases classified mild severe critical types mild patients mild pneumonia severe patients exhibited dyspnea increased respiratory frequency blood oxygen saturation within <NUMBER> <NUMBER> h critical patients suffered respiratory failure acute heart injury septic shock multiple organ failure <NUMBER> <NUMBER> median incubation period covid<NUMBER> first symptoms dyspnea admission hospital severe acute respiratory syndrome <NUMBER> <NUMBER> <NUMBER> days respectively <NUMBER> autopsy revealed bilateral diffuse alveolar damage linked fibromyxoid exudates accumulation mononuclear infiltrates mostly lymphocytes <NUMBER> microvesicular steatosis patients pneumonia <NUMBER> patients lymphopenia observed increased prothrombin time well increased level lactate dehydrogenase identified patients <NUMBER> radiologic analysis lungs revealed groundglass shadow form patchy groundglass opacities patchy consolidation mostly located middle outer zone lungs <NUMBER> <NUMBER> patients abnormal liver function elevated aspartate aminotransferase alanine aminotransferase well myocardial zymogram showing elevated levels lactate dehydrogenase creatine kinase identified <NUMBER> covid<NUMBER> cases classified mild severe critical types mild patients mild pneumonia severe patients exhibited dyspnea increased respiratory frequency blood oxygen saturation within <NUMBER> <NUMBER> h critical patients suffered respiratory failure acute heart injury septic shock multiple organ failure <NUMBER> <NUMBER> median incubation period covid<NUMBER> first symptoms dyspnea admission hospital severe acute respiratory syndrome <NUMBER> <NUMBER> <NUMBER> days respectively <NUMBER> autopsy revealed bilateral diffuse alveolar damage linked fibromyxoid exudates accumulation mononuclear infiltrates mostly lymphocytes <NUMBER> microvesicular steatosis lobular portal activity observed liver unclear whether damage induced sarscov<NUMBER> drugs interstitial mononuclear inflammatory infiltrates also found heart <NUMBER> observed main symptom sarscov<NUMBER> infection fever <NUMBER> hence identifying individuals exhibiting high temperature essential step diagnosis covid<NUMBER> physical examination may help identify patients severe condition since likely exhibit shortness breath weakened breath sounds speech tremor dullness percussion <NUMBER> chest xrays reveal patchy shadows changes lungs mostly outer zone lungs develop multiple groundglass opacity pulmonary consolidation infiltrating shadows infrequent pleural effusion <NUMBER> computed tomographic ct scans chest provide clearer images pulmonary lesions compared xrays whereby segmental consolidation groundglass opacity observed mainly periphery lungs <NUMBER> although symptoms radiographic analysis indicate possibility sarscov<NUMBER> infection laboratory diagnosis definitive since allows differentiation sarscov<NUMBER> infection viral infections merscov sarscov infections <NUMBER> samples swabs nasal swabs trachea nasopharynx extracts lung tissue sputum feces blood isolated used testing <NUMBER> virus detected polymerase chain reaction pcr molecular diagnosis method relies sequence nucleic acids detection <NUMBER> several primers established detection sarscov<NUMBER> realtime reversetranscription pcr rtpcr allows rapid specific identification virus <NUMBER> immunological methods immunofluorescence assay direct fluorescent antibody assay protein microarray semiconductor quantum dots mabbased rapid nucleocapsid protein detection microneutralization test used rapidly investigate presence sarscov<NUMBER> <NUMBER> figure <NUMBER> shows diagnosis method sarscov<NUMBER> pathogens <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> lobular portal activity observed liver unclear whether damage induced sarscov<NUMBER> drugs interstitial mononuclear inflammatory infiltrates also found heart <NUMBER> observed main symptom sarscov<NUMBER> infection fever <NUMBER> hence identifying individuals exhibiting high temperature essential step diagnosis covid<NUMBER> physical examination may help identify patients severe condition since likely exhibit shortness breath weakened breath sounds speech tremor dullness percussion <NUMBER> chest xrays reveal patchy shadows changes lungs mostly outer zone lungs develop multiple groundglass opacity pulmonary consolidation infiltrating shadows infrequent pleural effusion <NUMBER> computed tomographic ct scans chest provide clearer images pulmonary lesions compared xrays whereby segmental consolidation groundglass opacity observed mainly periphery lungs <NUMBER> although symptoms radiographic analysis indicate possibility sarscov<NUMBER> infection laboratory diagnosis definitive since allows differentiation sarscov<NUMBER> infection viral infections merscov sarscov infections <NUMBER> samples swabs nasal swabs trachea nasopharynx extracts lung tissue sputum feces blood isolated used testing <NUMBER> virus detected polymerase chain reaction pcr molecular diagnosis method relies sequence nucleic acids detection <NUMBER> several primers established detection sarscov<NUMBER> realtime reversetranscription pcr rtpcr allows rapid specific identification virus <NUMBER> immunological methods immunofluorescence assay direct fluorescent antibody assay protein microarray semiconductor quantum dots mabbased rapid nucleocapsid protein detection microneutralization test used rapidly investigate presence sarscov<NUMBER> <NUMBER> figure <NUMBER> shows diagnosis method sarscov<NUMBER> people fever identified groundglass opacity detected using xrays ct scans presence sarscov<NUMBER> confirmed using molecular detection techniques pcr although main laboratory technique used detect sarscov<NUMBER> pcr methods suggested developed detection virus clustered regularly interspaced short people fever identified groundglass opacity detected using xrays ct scans presence sarscov<NUMBER> confirmed using molecular detection techniques pcr although main laboratory technique used detect sarscov<NUMBER> pcr methods suggested developed detection virus clustered regularly interspaced short palindromic repeats crispr technology evoked detect sarscov<NUMBER> using crisprs ability hunt genetic snippets <NUMBER> immunoassays use monoclonal antibodies detect viral antigens use viral antigens detect patient antibodies produced virus lateral assay format employed detection sarscov<NUMBER> <NUMBER> main advantage immunoassays especially lateral assay format used detect virus less <NUMBER> minutes without need trained personnel instruments merscov transmitted close persontoperson contact although primary cases infection linked contact infected dromedary camels identified reservoir host merscov transmission virus occurred via respiratory secretions released infected individuals coughing sneezing <NUMBER> similarly respiratory droplets coughing sneezing method transmission sarscov occurred persontoperson contact although less common fecal transmission fomites handling animals also resulted transmission virus <NUMBER> although completely clear mode transmission sarscov<NUMBER> thought similar merscov sarscov <NUMBER> transmission sarscov<NUMBER> thought occur human human via respiratory secretions released infected individuals coughing sneezing <NUMBER> <NUMBER> asymptomatic carriers may also transmit virus hence play crucial role spread disease <NUMBER> recently prospect fecaloral transmission sarscov<NUMBER> raised since virus detected feces covid<NUMBER> patients <NUMBER> indicates virus exist replicate digestive tract clear whether eating sarscov<NUMBER>contaminated food causes infection another note perinatal infection sarscov<NUMBER> may cause problems including respiratory distress abnormal liver function newborn transmission virus birth yet confirmed zhu et al showed transmission occur <NUMBER> moreover recently reported sarscov<NUMBER> able remain viable aerosols three hours virus survive plastics stainless steel <NUMBER> h <NUMBER> limited knowledge suggests cases tend groups occur waves developing larger outbreaks first documented outbreak occurred wuhan china <NUMBER> sarscov<NUMBER> infected <NUMBER> killed <NUMBER> people according <NUMBER> based report <NUMBER> cases confirmed western pacific region death toll <NUMBER> <NUMBER> cases <NUMBER> deaths reported european region southeast asia region african region <NUMBER> <NUMBER> cases leading <NUMBER> <NUMBER> deaths respectively reported <NUMBER> cases <NUMBER> deaths reported eastern mediterranean region numbers clearly indicate sarscov<NUMBER> worldwide threat figure <NUMBER> shows number cases span two months <NUMBER> january <NUMBER> <NUMBER> march <NUMBER> five countries cases covid<NUMBER> china italy united states america spain germany <NUMBER> march <NUMBER> <NUMBER> total number cases reported china <NUMBER> <NUMBER> recovered <NUMBER> resulted death <NUMBER> mild condition <NUMBER> serious condition <NUMBER> italy <NUMBER> cases <NUMBER> recovered <NUMBER> resulted death <NUMBER> mild condition <NUMBER> serious condition <NUMBER> total number cases reported united states america <NUMBER> <NUMBER> recovered <NUMBER> resulted death <NUMBER> <NUMBER> mild cases <NUMBER> serious cases <NUMBER> recovered cases <NUMBER> deaths total number reported cases spain <NUMBER> <NUMBER> country fifth highest reported number covid<NUMBER> cases <NUMBER> germany <NUMBER> mild cases <NUMBER> serious cases <NUMBER> patients recovered <NUMBER> cases resulted fatality <NUMBER> total <NUMBER> cases reported united kingdom <NUMBER> mild condition <NUMBER> serious condition <NUMBER> recovered <NUMBER> ended fatality <NUMBER> five countries cases covid<NUMBER> china italy united states america spain germany <NUMBER> march <NUMBER> <NUMBER> total number cases reported china <NUMBER> <NUMBER> recovered <NUMBER> resulted death <NUMBER> mild condition <NUMBER> serious condition <NUMBER> italy <NUMBER> cases <NUMBER> recovered <NUMBER> resulted death <NUMBER> mild condition <NUMBER> serious condition <NUMBER> total number cases reported united states america <NUMBER> <NUMBER> recovered <NUMBER> resulted death <NUMBER> <NUMBER> mild cases <NUMBER> serious cases <NUMBER> recovered cases <NUMBER> deaths total number reported cases spain <NUMBER> <NUMBER> country fifth highest reported number covid<NUMBER> cases <NUMBER> germany <NUMBER> mild cases <NUMBER> serious cases <NUMBER> patients recovered <NUMBER> cases resulted fatality <NUMBER> total <NUMBER> cases reported united kingdom <NUMBER> mild condition <NUMBER> serious condition <NUMBER> recovered <NUMBER> ended fatality <NUMBER> virion spike protein responsible receptor binding s<NUMBER> domain cell fusion s<NUMBER> domain coronavirus essential determining host tropism virus <NUMBER> s<NUMBER> s<NUMBER> subunits formed cleavage precursor whereby s<NUMBER> dictates cellular tropism viral host range receptorbinding domain <NUMBER> s<NUMBER> divided heptad repeats <NUMBER> hr<NUMBER> <NUMBER> hr<NUMBER> mediates fusion virus cell membrane hr<NUMBER> attach together bind hr<NUMBER> form sixhelix bundle bringing cell membranes virus close proximity trigger fusion <NUMBER> using hela cells expressing expressing angiotensinconverting enzyme ii ace<NUMBER> proteins humans used cell receptor sarscov entry revealed sarscov<NUMBER> able gain entry cells expressing ace<NUMBER> suggesting ace<NUMBER> cell receptor used virus <NUMBER> structural biophysical analysis showed sarscov<NUMBER> <NUMBER> <NUMBER> times higher affinity compared sarscov towards ace<NUMBER> <NUMBER> sarscov<NUMBER> recently discovered virus effective treatment options established hence antiviral drugs including ribavirin oseltamivir ganciclovir ritonavir virion spike protein responsible receptor binding s<NUMBER> domain cell fusion s<NUMBER> domain coronavirus essential determining host tropism virus <NUMBER> s<NUMBER> s<NUMBER> subunits formed cleavage precursor whereby s<NUMBER> dictates cellular tropism viral host range receptorbinding domain <NUMBER> s<NUMBER> divided heptad repeats <NUMBER> hr<NUMBER> <NUMBER> hr<NUMBER> mediates fusion virus cell membrane hr<NUMBER> attach together bind hr<NUMBER> form sixhelix bundle bringing cell membranes virus close proximity trigger fusion <NUMBER> using hela cells expressing expressing angiotensinconverting enzyme ii ace<NUMBER> proteins humans used cell receptor sarscov entry revealed sarscov<NUMBER> able gain entry cells expressing ace<NUMBER> suggesting ace<NUMBER> cell receptor used virus <NUMBER> structural biophysical analysis showed sarscov<NUMBER> <NUMBER> <NUMBER> times higher affinity compared sarscov towards ace<NUMBER> <NUMBER> sarscov<NUMBER> recently discovered virus effective treatment options established hence antiviral drugs including ribavirin oseltamivir ganciclovir ritonavir lopinavir used reduce development respiratory complications reducing viral load <NUMBER> secondary infections also observed treatments administered based sensitivity bacterial cultures drugs <NUMBER> general strategies fight sarscov<NUMBER> infection respiratory support organ function support bronchoalveolar lavage extracorporeal membrane oxygenation blood purification <NUMBER> spike protein major vaccine target coronaviruses assessed different types vaccines designed infections caused coronaviruses including inactivated wholevirus particle protein subunit vaccine viruslike particle protein incorporated influenza virus hepatitis virus protein live attenuated virus gene deletion virus vectors modified adenovirus carrying protein deoxyribonucleic acid dna vaccine encodes part full length protein gene <NUMBER> double inactivated vaccine developed sarscov inactivating virus using sequential formaldehyde ultraviolet inactivation evaluated mice models able elicit production high levels antibodies virus <NUMBER> recombinant sars viruslike particle vaccine consisting influenza m<NUMBER> protein sarscov protein developed using baculovirusinsect cell expression system tested mouse models resulting reduction virus lungs detectable levels complete protection death well triggering production high levels antibodies sarscov <NUMBER> recombinant sarscov lacking envelope protein tested mice shown vaccine able completely prevent death resulted rapid virus clearance <NUMBER> small fragment protein sarscov linked human igg<NUMBER> fc fragment able induce high titers antibody production mice neutralized infection caused sarscov <NUMBER> dna vaccine encoding first <NUMBER> amino acids merscov protein shown induce high titers neutralizing antibodies mice dna vaccine encoding protein sarscov shown induce production neutralizing antibodies humans phase <NUMBER> clinical trial <NUMBER> <NUMBER> aforementioned methods led development vaccines sarscov merscov already undergone phase <NUMBER> clinical trials <NUMBER> <NUMBER> coronaviruses similar infection pathway structure research strategies mentioned could used framework developing effective vaccines sarscov<NUMBER> remdesivir drug recently shown possess activity merscov <NUMBER> effective result reported remdesivir used treatment patient covid<NUMBER> <NUMBER> would suggest strategies similar used development treatments coronavirus infections sarscov merscov could used development effective treatments sarscov<NUMBER> antisarscov peptide derived hr<NUMBER> domain sarscov protein s<NUMBER> subunit bind hr<NUMBER> domain resulting inhibition proteinmediated membrane fusion hence sarscov infection identified <NUMBER> technique used successfully develop antimerscov peptide could inhibit infection virus <NUMBER> therefore technique could used develop antisarscov<NUMBER> peptide could inhibit infection virus neutralizing antibodies could used target sarscov<NUMBER> previously mice immunized receptorbinding domain protein coronaviruses antibodies produced mice humanized isolated <NUMBER> another approach use phagedisplay antibody library combination cloning single b cells human survivors produce human antibodies <NUMBER> several neutralizing antibodies identified use sarscov merscov <NUMBER> <NUMBER> hence novel neutralizing monoclonal antibodies could developed use sarscov<NUMBER> using technique drug repurposing lead new treatment options faster discovery novel drugs since safety profiles available drugs already available one method effectively selecting drugs repurposing purposes use bioinformatics analyze interactions drugs proteins target organism case sarscov<NUMBER> bioinformatics recently used identify drugs could target sarscov<NUMBER> <NUMBER> drugs identified possible repurposed drugs <NUMBER> refining list drugs removing drugs found unfit repurposing based effects drugs symptoms sarscov<NUMBER> side effects <NUMBER> drugs identified <NUMBER> pseudoephedrine andrographolide atiprimod ysil<NUMBER> tapinarof etanercept adalimumab infliximab chloroquine epinephrine thalidomide clenbuterol pranlukast afelimomab golimumab siltuximab olsalazine ibalizumab cefazolin abacavir myricetin nformylmethionine ruplizumab framycetin ketoprofen maraviroc vicriviroc proline quercetin artenimol <NUMBER> drugs identified possible drugs repurpose use sarscov<NUMBER> another study also used bioinformatics tools identify existing drugs could repurposed use sarscov<NUMBER> fifteen approved drugs <NUMBER> drugs currently undergoing phase <NUMBER> clinical trials <NUMBER> drugs preclinical stage identified chemoinformatics <NUMBER> approved drugs <NUMBER> drugs currently undergoing phase <NUMBER> clinical trials <NUMBER> drugs preclinical stage revealed specialist knowledge <NUMBER> announced clinical trials involving remdesivir lopinavir ritonavir chloroquine would conducted since drugs showed antisarscov<NUMBER> activity either vitro andor animal studies <NUMBER> however reported use ritonavir lopinavir combination improve survival speed recovery <NUMBER> however announced drugs tested larger scale variety patients <NUMBER> remdesivir initially developed fight ebola chloroquine antimalarial drug ritonavir lopinavir used treatment human immunodeficiency virus <NUMBER> vitamin c also evoked use cases sarscov<NUMBER> infection since high doses could result immunosuppression hyperactivation immune effector cells cause lung injury covid<NUMBER> cases safe treatment option <NUMBER> sarscov<NUMBER> transmitted easily hard control shortage stocks face masks worldwide facilitates transmission virus due overwhelming number cases ease transmission many countries issued movement bans hence air travel banned many countries countries still air travel usually impose <NUMBER> days quarantine travelers identify infected sarscov<NUMBER> one way people diagnosed whether fever predominant symptom sarscov<NUMBER> infection however many people lying showing symptoms fever avoiding temperature checkpoints taking drugs suppress fever one main challenges covid<NUMBER> people show mild symptoms hence might detected infected <NUMBER> study shown <NUMBER> cases covid<NUMBER> wuhan confirmed asserting presence potential asymptomatic mildsymptomatic cases may contagious <NUMBER> observation <NUMBER> individuals tested positive sarscov<NUMBER> laboratory testing <NUMBER> days reported four show symptoms suggesting presence asymptomatic carriers <NUMBER> however mean <NUMBER> <NUMBER> covid<NUMBER> cases asymptomatic need take account limitations statistics due sensitivity detection window period viral shedding occurs detectable level support reported viral shedding still occurs symptoms end <NUMBER> viral loads asymptomatic symptomatic patients reported similar suggesting similar transmission potential people showing mild symptoms compared symptomatic individuals <NUMBER> fact people showing mild symptoms may transmit virus hard detect carriers increases chance transmission future studies focus studying pathogenesis sarscov<NUMBER> identifying mechanism virus causes pathogenicity insight might obtained various molecules affected drugs vaccines effectively treat prevent covid<NUMBER> cases mentioned several methodologies used development vaccines coronaviruses sarscov merscov explored development vaccines sarscov<NUMBER> furthermore considering sarscov<NUMBER> affects respiratory tract drug delivery options effectively deliver drugs respiratory tract developed repurposing drugs identified potential drugs sarscov<NUMBER> screened vitro confirm activity sarscov<NUMBER> drugs show effects vitro investigated animal models followed clinical trials current knowledge sarscov<NUMBER> limited current treatment vaccine covid<NUMBER> cases symptoms covid<NUMBER> include fever <NUMBER> cough <NUMBER> vomiting <NUMBER> diarrhoea <NUMBER> transmission sarscov<NUMBER> thought occur human human via respiratory secretions released infected individuals coughing sneezing therefore preventive measures used encouraging people stay home discouraging mass gatherings exercising social distancing prevent spread virus future research focus understanding pathogenicity virus since knowledge pathogenicity might help development vaccines effective drugs funding research received external funding work paper supported part open access program american university sharjah since unusual type pneumonia distinct common pneumonia symptoms lethality reported wuhan china december <NUMBER> nations across globe paid attention new infectious disease <NUMBER> january <NUMBER> world health organization httpswwwwhoint temporarily designated virus causing disease <NUMBER> novel coronavirus <NUMBER>ncov february <NUMBER> <NUMBER> officially renamed infectious disease coronavirus disease coronavirus study group within international committee taxonomy viruses also renamed <NUMBER>ncov severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> present covid<NUMBER> pandemic spreading world cases reported china <NUMBER> <NUMBER> countries areas territories <NUMBER> march <NUMBER> covid<NUMBER> disease caused <NUMBER> deaths noted httpswwwwhoint fight pandemic scientists healthcare workers started share knowledge given rapid spread covid<NUMBER> smaller timeframe available developing new therapies drug repurposing may ideal strategy allows healthcare workers treat covid<NUMBER> using previously approved investigational drugs <NUMBER> gathered information may pertinent drug discovery covid<NUMBER> via systemic review pubmed database httpswwwncbinlmnihgovpubmed <NUMBER> <NUMBER> searched papers corona covid mers sars keywords publications described concerning biological characteristics interaction human homo sapiens therapeutic targets therapeutic medications viruses included review <NUMBER> <NUMBER> since information protected patents article surveyed published shared information establish therapeutic strategy covid<NUMBER> several drugs chloroquine favipiravir remdesivir umifenovir currently undergoing clinical trials test efficacy safety treatment covid<NUMBER> studies currently taking place china <NUMBER> <NUMBER> favipiravir developed antiinfluenza drug licensed antiinfluenza drug japan <NUMBER> one unique features favipiravir broadspectrum activity rna viruses including influenza virus rhinovirus respiratory syncytial virus previous studies demonstrated favipiravir effective treating infections ebola virus lassa virus rabies severe fever thrombocytopenia syndrome <NUMBER> however favipiravir effective dna viruses regard mechanism reported favipiravir antagonizes viral rna synthesis acting chain terminator site rna incorporated host cell contrast oseltamivir tamiflu neuraminidase inhibitor blocks cleavage sialic acid subsequent entry virus cell <NUMBER> importantly favipiravir unlike oseltamivir seem generate resistant viruses <NUMBER> property favipiravir suggests potential benefit treatment critical infectious diseases covid<NUMBER> figure <NUMBER> proposed acting points antisarscov<NUMBER> replication cycle virus sarscov<NUMBER> particles bind receptors angiotensinconverting enzyme <NUMBER> ace<NUMBER> aminopeptidase n apn cd<NUMBER> dipeptidyl peptidase <NUMBER> dpp<NUMBER> cd<NUMBER> viral rna passed host cell rnadependent rna polymerase rdrp produces viral rnas rna methylation rna cap formed protects host innate immune response involves secretion interferons ifns cytokines cks viral guaninen<NUMBER>methyltransferase n<NUMBER>mtase plays critical role rna capping using methyl donor sadenosylmethionine sam process viral rna synthesis translation proteins associated phdependent membrane stress elicit adverse effects immune nonimmune cells viral replication cycle inhibited infected cells eradicated packed viruses disseminated cells host proposed drugs possible acting points covid<NUMBER> shown bold lines remdesivir nucleotide analog used treatment infections caused ebola virus marburg virus <NUMBER> however also shown activity respiratory syncytial virus junin virus lassa fever virus nipah virus hendra virus mers sars coronaviruses <NUMBER> <NUMBER> <NUMBER> remdesivir inhibits rnadependent rna polymerases likely delay rna chain termination cell <NUMBER> therefore one promising compounds treating covid<NUMBER> <NUMBER> potent russianmade broadspectrum antiviral agent used treat influenza b viruses hepatitis c virus hcv <NUMBER> although mechanism slightly differs depending virus reported umifenovir inhibits viral fusion host cell membrane subsequent entry host cell <NUMBER> recently trial involving use lopinavirritonavir lpvr protease inhibitors used treat hiv adults hospitalized severe covid<NUMBER> showed observable benefit lpvr treatment beyond standard care <NUMBER> sarscov<NUMBER> particles bind receptors angiotensinconverting enzyme <NUMBER> ace<NUMBER> aminopeptidase n apn cd<NUMBER> dipeptidyl peptidase <NUMBER> dpp<NUMBER> cd<NUMBER> viral rna passed host cell rnadependent rna polymerase rdrp produces viral rnas rna methylation rna cap formed protects host innate immune response involves secretion interferons ifns cytokines cks viral guaninen<NUMBER>methyltransferase n<NUMBER>mtase plays critical role rna capping using methyl donor sadenosylmethionine sam process viral rna synthesis translation proteins associated phdependent membrane stress elicit adverse effects immune nonimmune cells viral replication cycle inhibited infected cells eradicated packed viruses disseminated cells host proposed drugs possible acting points covid<NUMBER> shown bold lines remdesivir nucleotide analog used treatment infections caused ebola virus marburg virus <NUMBER> however also shown activity respiratory syncytial virus junin virus lassa fever virus nipah virus hendra virus mers sars coronaviruses <NUMBER> <NUMBER> <NUMBER> remdesivir inhibits rnadependent rna polymerases likely delay rna chain termination cell <NUMBER> therefore one promising compounds treating covid<NUMBER> <NUMBER> methylindole<NUMBER>carboxylate hydrochloride monohydrate trade name arbidol potent russianmade broadspectrum antiviral agent used treat influenza b viruses hepatitis c virus hcv <NUMBER> although mechanism slightly differs depending virus reported umifenovir inhibits viral fusion host cell membrane subsequent entry host cell <NUMBER> recently trial involving use lopinavirritonavir lpvr protease inhibitors used treat hiv adults hospitalized severe covid<NUMBER> showed observable benefit lpvr treatment beyond standard care <NUMBER> another retrospective cohort study tested umifenovir combined lpvr versus lpvr alone covid<NUMBER> <NUMBER> results showed favorable clinical response umifenovir lpvr compared lpvr alone <NUMBER> nevertheless studies necessary determine efficacy occurrence resistance since sarscov<NUMBER> needs undergo activation cell surface umifenovir combined lpvr help prevent entry virus identification specific mechanisms may beneficial future clinical applications reported chloroquine phosphate wellestablished drug used treat malaria shown apparent efficacy acceptably safe used covid<NUMBER> multicenter clinical trials conducted china <NUMBER> china recommended chloroquine phosphate included next version guidelines prevention diagnosis treatment pneumonia caused covid<NUMBER> issued national health commission peoples republic china <NUMBER> chloroquine used since <NUMBER> several antiinflammatory antiviral effects reported previous studies <NUMBER> instance chloroquine exerts direct antiviral effects inhibiting ph replication several viruses including flaviviruses coronaviruses retroviruses hiv <NUMBER> moreover reported chloroquine immunomodulatory effects involve decreasing production release tumor necrosis factorα tnfα interleukin il<NUMBER> <NUMBER> viral infection immune response activated production release proinflammatory cytokines tnfα il<NUMBER> il<NUMBER> interferongamma ifnγ increased chloroquine however blocks events <NUMBER> accordingly chloroquine also prevents deleterious mechanisms may lead acute respiratory syndrome alteration tight junctions release proinflammatory cytokines increases microvascular permeability <NUMBER> previous studies showed inhibitory effects involve inhibition autophagy <NUMBER> autophagy response mechanism cellular membrane stress induced nutrient deprivation hypoxia exposure radiation chemotherapeutic agents <NUMBER> animal experiments chloroquine highly effective treating avian influenza h<NUMBER>n<NUMBER> virus infection inhibiting autophagy <NUMBER> since chloroquine analog hydroxychloroquine clinically relevant inhibitors autophagy <NUMBER> application chloroquine may reasonable facilitated recent study using cancer stem cells demonstrated mefloquine hydrochloride antimalarial drug used treat patients resistance chloroquine efficiently eliminated colorectal cancer stem cells disrupting endolysosomal proteins rab<NUMBER> <NUMBER> given lysosomaldependent mechanism common platform viral infection <NUMBER> inhibitors autophagy may worth examining treatment emerging infectious diseases covid<NUMBER> context drug repurposing covid<NUMBER> also suggested resistance inhibitors autophagy may worth examination previous studies indicated angiotensinconverting enzyme <NUMBER> ace<NUMBER> functional receptor sarscov <NUMBER> determined via singlecell sequencing <NUMBER> structural analysis proteins <NUMBER> latter study demonstrated receptorbinding domain rbd viral spike sprotein sarscov<NUMBER> shows strong interaction human ace<NUMBER> molecules despite sequence diversity <NUMBER> authors also suggested sarscov<NUMBER> poses significant public health risk human transmission via sproteinace<NUMBER> binding pathway <NUMBER> interestingly study showed ace<NUMBER> preferentially expressed small population type ii alveolar cells males higher ace<NUMBER> expression females <NUMBER> <NUMBER> study also suggests binding sarscov<NUMBER> ace<NUMBER> increase expression ace<NUMBER> <NUMBER> many human rodent studies ace<NUMBER> expression induced treatment ace inhibitors aceis angiotensin ii receptor blockers arbs commonly used antihypertensive drugs <NUMBER> expression sodiumdependent neutral amino acid transporter b<NUMBER>at<NUMBER> depends presence ace<NUMBER> respiratory tract <NUMBER> given covid<NUMBER> includes symptoms fever <NUMBER> cough <NUMBER> dyspnea <NUMBER> fatiguemuscle pain <NUMBER> <NUMBER> symptoms may relevant respiratory expression ace<NUMBER> recent retrospective study indicated covid<NUMBER> patients cardiovascular disease cvd higher risk mortality <NUMBER> lower lymphocyte counts higher body mass indices bmi often seen patients serious conditions <NUMBER> recent study showed use aceis arbs treating cvd affect morbidity mortality covid<NUMBER> <NUMBER> addition reported small intestine organ expressing ace<NUMBER> highly <NUMBER> given sarscov<NUMBER> detected excrement covid<NUMBER> patients <NUMBER> <NUMBER> observed cases might involve cells small intestine infected sarscov<NUMBER> binding receptor crystal structures sprotein binding ace<NUMBER> revealed important interaction host sarscov<NUMBER> <NUMBER> <NUMBER> addition known ace<NUMBER> binds angiotensin ii receptor type <NUMBER> atr<NUMBER> sodiumdependent neutral amino acid transporter b <NUMBER> at<NUMBER> also known slc<NUMBER>a<NUMBER> bindings affect binding ace<NUMBER> sprotein <NUMBER> <NUMBER> moreover phosphatidylinositol <NUMBER>phosphate <NUMBER>kinase pikfyve twopore channel subtype <NUMBER> tpc<NUMBER> cathepsin l important entry cells <NUMBER> among reported sarscov murine polyclonal antibodies targeting conserved epitopes inhibited sarscov<NUMBER> entry <NUMBER> many therapeutic targets entry pathway via ace<NUMBER> reported meaning ace<NUMBER> would therefore promising target therapy sarscov<NUMBER> reported dipeptidyl peptidase <NUMBER> dpp<NUMBER> functional receptor emerging human coronavirus via sprotein well ace<NUMBER> <NUMBER> interaction virus host cell membrane allows viral sproteindirected cellcell fusion resultant spread viral infections <NUMBER> another example relevant drug repurposing ideal strategy confronting covid<NUMBER> specific role dpp<NUMBER> covid<NUMBER> remains investigated research necessary utilize dpp<NUMBER> therapeutic target covid<NUMBER> previously reported aminopeptidase n apn involved broad receptor engagement promotes crossspecies transmission covid<NUMBER> <NUMBER> interestingly previous studies identified apn surface marker cancer stem cells human liver <NUMBER> repurposing previous studies also allowed development polyethylene glycolpolylysine block copolymerconjugate ubenimex targets apn specifically <NUMBER> drugs repurposed low doses apn inhibitors including ubenimex derivatives may beneficial inhibiting spread virus although modification rna methylation critical biology methylation also important process rna capping coronaviruses <NUMBER> like coronaviruses cause sars mers mechanism rna capping may also draggable target sarscov<NUMBER> rna capping plays role transcription viral rna well stability replication evasion hosts immune response many rna viruses including coronaviruses evolved mechanisms generating cap structures methylation n<NUMBER> position capped guanine ribose <NUMBER>oposition first nucleotide mechanism plays critical role premrna splicing mrna export <NUMBER> rna stability via blocking degradation <NUMBER> exoribonuclease <NUMBER> translation initiation promoting host eukaryotic translation initiation factor <NUMBER>e eif<NUMBER>e binding <NUMBER> escaping hosts innate immune system <NUMBER> general <NUMBER>endcapped mrnas produced several steps <NUMBER> although evidence demonstrate existence rna guanylyltransferase gtase unique coronaviruses coronaviral guaninen<NUMBER>methyltransferase n<NUMBER>mtase plays role processing rna produce cap<NUMBER> structure <NUMBER> gpppn <NUMBER> proceeding reaction <NUMBER>omtase form cap<NUMBER> <NUMBER> gpppnm cap<NUMBER> <NUMBER> gpppnmpnm structures <NUMBER> n<NUMBER>mtase <NUMBER>omtase catalyzed via transfer methyl group sadenosylmethionine sam rna substrate dxgxpxga sambinding motif methylation process sadenosylhomocysteine sah generated byproduct given proposed function viral rna cap structure preventing <NUMBER>triphosphate terminal <NUMBER>pppn activating host innate immune response cap<NUMBER> cap<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> antagonizing interferonmediated antiviral response cap<NUMBER> <NUMBER> <NUMBER> <NUMBER> enhancing viral rna translation cap<NUMBER> <NUMBER> proposed coronaviral n<NUMBER>mtase attractive target new antiviral drugs <NUMBER> suggested drug discovery worthwhile testing antiviral activity repositioning drugs case covid<NUMBER> although specific treatments including vaccines yet developed covid<NUMBER> effective prevention methods recommended global scale accordingly overcome pandemic developing specific inhibitors viral entry replication well drug repositioning necessary several clinical trials drug repositioning studies currently ongoing eventually new studies allow us better control pandemic identify new treatments computational calculation artificial intelligence would help rapid development therapeutic method hand accurate crystal structure determination much drugresponse data necessary success efficient sharing information important overcoming pandemic era globalization funding work supported part grantinaid scientific research ministry education culture sports science technology <NUMBER>h<NUMBER> <NUMBER>h<NUMBER> <NUMBER>k<NUMBER> <NUMBER>k<NUMBER> <NUMBER>k<NUMBER> amed japan <NUMBER>cm<NUMBER>h<NUMBER> <NUMBER>cm<NUMBER>h<NUMBER> partial support received princess takamatsu cancer research fund difference compared control group p<NUMBER> lopinavirritonavir shown improvement time clinical improvement seen metaanalyses p<NUMBER> remdesivir shown significant improvement time clinical improvement trial insufficient power discussion due paucity evidence difficult establish efficacy drugs treatment covid<NUMBER> currently significant clinical effectiveness repurposed drugs large clinical trials required achieve reliable findings riskbenefit analysis required individual basis weigh potential improvement clinical outcome viral load reduction compared risks adverse events <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> introduction starting december <NUMBER> pneumonia outbreak unknown cause wuhan hubei province china <NUMBER> origin virus unknown epidemiological link huanan seafood wholesale market sale wild animals bats <NUMBER> notification world health organisation <NUMBER> december <NUMBER> scientists able isolate <NUMBER>ncov patient subsequently perform genome sequencing <NUMBER> th january since many cases emerged internationally leading declaring novel <NUMBER>ncov covid<NUMBER> outbreak global pandemic <NUMBER> similar clinical features previous betacoronavirus infections noted including presentations fever dry cough dyspnoea presentations prominent upper respiratory tract signs symptoms rhinorrhoea sneezing sore throat <NUMBER> imaging bilateral groundglass opacities chest computed tomography ct scans noted patients severe illness developed acute respiratory distress syndrome ards required intensive care unit icu admission oxygen therapy features bear resemblances severe acute respiratory distress syndrome sarscov middle east respiratory syndrome coronavirus merscov infections however covid<NUMBER> patients rarely develop intestinal symptoms diarrhoea present <NUMBER> sarscov merscov mortality rate similarly described cohorts <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> many describing memories novel coronavirus outbreak china sarscov <NUMBER> <NUMBER> drugs used sarscov middle east respiratory syndrome coronavirus merscov considered <NUMBER> current universally agreed treatment covid<NUMBER> current care advised supportive management depending patients needs including antipyretics fever oxygen therapy repurposing drugs provide avenue find treatment options covid<NUMBER> currently infected <NUMBER> million people <NUMBER> may <NUMBER> reported <NUMBER> hydroxychloroquine hcq chloroquine cq antimalarial drugs authorised us french authorities adequate approved available alternative treat covid<NUMBER> <NUMBER> drugs shown potent antiviral activity covid<NUMBER> invitro studies <NUMBER> <NUMBER> adverse effects hcq derivative cq less toxic used long term therefore recently highdosage cq <NUMBER>g either azithromycin oseltamir recommended patients severe covid<NUMBER> due safety issues <NUMBER> use antivirals also trialled previously screening approved drugs identified antivirals inhibitory activity sarscov lopinavir antiviral also activity merscov vitro animal models <NUMBER> therefore due homogeneity sarscov<NUMBER> compared mentioned zoonotic viruses antivirals previously used repurposed remdesivir also demonstrated effective control covid<NUMBER> invitro <NUMBER> since authorised emergency use food drug administration fda <NUMBER> aim systematic review evaluate data currently available regarding repurposing different drugs covid<NUMBER> treatment systematic review adheres preferred reporting items systematic reviews metaanalyses prisma guidelines <NUMBER> searched ovidmedline embase cochrane library articles published time april <NUMBER> <NUMBER> also searched clinical trial registration sites uk nihr europe clinicaltrialsregistereu us clinicaltrialsgov internationally isrctncom examined reference lists articles identify additional studies following search term used favipiravir remdesivir galidesivir ivermectin oseltamivir ganciclovir lopinavir ritonavir darunavir cq hcq arbidol azithromycin amoxicillin moxifloxacin ceftriaxone antifungals androgen receptor blockers tea traditional chinese medicine <NUMBER> ncov <NUMBER>ncov <NUMBER> novel coronavirus covid <NUMBER> covid<NUMBER> new coronavirus novel coronavirus sars cov<NUMBER> wuhan coronavirus covid <NUMBER> sarscov <NUMBER>ncov sarscov<NUMBER> studies english evaluated efficacy listed drugs included included randomized controlled trials rcts well observational studies including cohort control studies case reports also collated patients suspected consequently diagnosed novel coronavirus covid<NUMBER> included following interventions favipiravir remdesivir galidesivir ivermectin oseltamivir ganciclovir lopinavir ritonavir darunavir chloroquine hydroxychloroquine arbidol azithromycin amoxicillin moxifloxacin ceftriaxone antifungals androgen receptor blockers tea traditional chinese medicine considered comparators include standard care treatment placebo main outcomes time clinical recovery benefits reducing mortality reduction viral load excluded studies languages translation available review articles commentaries letters editors one reviewer pk extracted data using spreadsheet second al validated data extraction descriptive quantitative data entered spreadsheet protocol available prospero crd<NUMBER> one author pk extracted data confirmed another author al duplicate studies clinical trials removed shown prisma diagram figure <NUMBER> quality studies risk bias assessed using cochrane rob <NUMBER> rcts figure <NUMBER> robinsi <NUMBER> nonrcts figure <NUMBER> trials examined similar outcomes considered suitably homogenous metaanalysis performed adverse events rates negative seroconversion odds ratios <NUMBER> confidence intervals calculated chi squared test used assess heterogeneity p<NUMBER> heterogeneity random effects model used otherwise fixed effects model used metaanalyses performed using cochrane review manager v<NUMBER> <NUMBER> cochrane initiative literature search identified <NUMBER> studies clinical trials <NUMBER> included removal duplicates abstract screening <NUMBER> included fulltext screening <NUMBER> included qualitative synthesis figure <NUMBER> <NUMBER> randomized controlled trials characteristics studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> included summarized table <NUMBER> primary outcome studies included also variables including time clinical recovery viral clearance clinical improvement data individual studies summarized table <NUMBER> data virology radiology shown table <NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint <NUMBER> studies examined effects cq <NUMBER> compared antiviral treatment <NUMBER> case series used news briefing <NUMBER> study analysed clinical recovery viral clearance cq initially mentioned news briefing <NUMBER> results <NUMBER> patients showed superior control treatment shortening disease course well inhibiting exacerbation pneumonia improving lung imaging findings promoting virus negative conversion subsequently huang et al <NUMBER> compared another proposed therapy lpvr cohort study <NUMBER> patients cq arm <NUMBER> patients lopinavirritonavir arm cq <NUMBER> patients negative reverse transcriptasepolymerase chain reaction rtpcr day <NUMBER> <NUMBER> day <NUMBER> <NUMBER> day <NUMBER> compared lpvr group <NUMBER> patients negative rtpcr day <NUMBER> <NUMBER> day <NUMBER> <NUMBER> day <NUMBER> delay lung clearance based ct imaging suggesting viral clearance translate immediately pathological improvement lungs cq <NUMBER> ct scan improvement day <NUMBER> <NUMBER> day <NUMBER> compared antivirals <NUMBER> showing improvement day <NUMBER> <NUMBER> day <NUMBER> cq discharge rates hospital <NUMBER> day <NUMBER> antivirals <NUMBER> patients discharged day <NUMBER> <NUMBER> studies examined effects hcq <NUMBER> also added azithromycin <NUMBER> compared standardized care <NUMBER> case series hcq azithromycin <NUMBER> studies analysed clinical recovery whilst <NUMBER> studied viral clearance <NUMBER> rcts china study chen et al <NUMBER> eligibility criteria known <NUMBER> patients recruited <NUMBER> patients arm showed significant difference p<NUMBER> negative seroconversion rate day <NUMBER> <NUMBER> negative hcq group <NUMBER> control group time negative seroconversion p<NUMBER> time normalization body temperature also comparable <NUMBER> arms radiological progression using ct imaging showed <NUMBER> cases progressed hcq group compared <NUMBER> control group chen et al <NUMBER> included mild cases oxygen saturation sao<NUMBER> <NUMBER> confirmed chest ct pneumonia comparing hcq n<NUMBER> standard treatment n<NUMBER> undefined primary outcome time clinical recovery defined cough relief return body temperature <NUMBER>ºc surface <NUMBER>ºc armpit mouth <NUMBER>ºc rectum tympanic membrane maintained <NUMBER> hours shown normalization body temperature significantly p<NUMBER> shorter <NUMBER> day hcq group <NUMBER> days compared control group <NUMBER> days also significantly p<NUMBER> reduced cough remission time hcq group <NUMBER> days compared control group <NUMBER> days also noted overall <NUMBER> patients progressed severe illness occurred control group receiving hcq <NUMBER> testing haemodynamic monitoring intensive care study included anyone age <NUMBER> confirmed sarscov<NUMBER> infection primary outcome negative conversion sarscov<NUMBER> within <NUMBER> days secondary outcomes included alleviation clinical symptoms defined resolving fever axillary temperature <NUMBER>ºc normalization sao<NUMBER> room air disappearance respiratory symptoms laboratory parameters chest radiology within <NUMBER> days viral clearance similar arms negative seroconversion rate <NUMBER> days <NUMBER> <NUMBER> hcq arm soc arm respectively time negative seroconversion also similar <NUMBER> days <NUMBER> days hcq soc arms respectively overall rate symptom alleviation within <NUMBER> days also similar hcq <NUMBER> soc alone <NUMBER> median time alleviation clinical symptoms also similar <NUMBER> days hcq arm <NUMBER> days soc arm however subgroup analysis confounding effects antiviral agents removed efficacy hcq alleviation symptoms evident hazard ratio <NUMBER> <NUMBER>ci <NUMBER> changes creactive protein crp lymphocyte count also analysed hcq arm showing significantly greater decline p<NUMBER> crp baseline <NUMBER> compared soc arm <NUMBER> greater elevation lymphocyte count baseline hcq <NUMBER> compared soc <NUMBER> significant p<NUMBER> french cohort study <NUMBER> enrolled <NUMBER> patients hcq <NUMBER> patients control regardless clinical status shown hcq provide clearing nasopharyngeal carriage <NUMBER> patients day <NUMBER> compared <NUMBER> without research group reported case series <NUMBER> <NUMBER> patients combination azithromycin hcq showed negative virus cultures <NUMBER> included day <NUMBER> <NUMBER> requiring oxygen <NUMBER> requiring icu however results rapidly questioned another study <NUMBER> followed regime azithromycin hcq showed day <NUMBER> <NUMBER> <NUMBER> <NUMBER> patients still positive covid<NUMBER> rna total <NUMBER> studies regarding antivirals included <NUMBER> studies examined effects lpvr <NUMBER> compared standardized care <NUMBER> compared favipavir <NUMBER> compared combination lpvr arbidol <NUMBER> compared arbidol <NUMBER> compared arbidol control group <NUMBER> study compared favipavir arbidol case series regarding remdesivir also included <NUMBER> studies analysed clinical recovery whilst <NUMBER> studied viral clearance <NUMBER> rcts comparing lpvr control one compares arbidol cao et al <NUMBER> largest rct systematic review enrolling <NUMBER> patients pneumonia confirmed chest imaging sao<NUMBER> breathing ambient air <NUMBER> lpvr group <NUMBER> standardcare group primary outcome time clinical improvement defined time randomization improvement two points seven category ordinal scale live discharge <NUMBER> days lpvr standardcare alone subgroups treatment within <NUMBER> days later treatment association shorter time clinical improvement secondary outcomes measured included <NUMBER> day mortality lower lpvr <NUMBER> standardcare rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> <NUMBER> group stay intensive care shorter lpvr <NUMBER> days group standardcare <NUMBER> days group percentage patients clinical improvement day <NUMBER> higher lpvr group <NUMBER> standardcare group <NUMBER> time discharge shorter lpvr group <NUMBER> days standardcare group <NUMBER> days secondary outcomes included duration oxygen therapy duration hospitalization time randomization death significant difference two groups terms virology percentage patients detectable viral rna similar groups sampling day <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> example day <NUMBER> <NUMBER> lpvr group compared <NUMBER> standardcare group however mortality trial <NUMBER> significantly higher mortality reported descriptive studies potentially indicating severely ill population recruited therefore question whether antiviral treatment may effective early treatment remains unaddressed another rct <NUMBER> recruiting patients mild mild symptoms signs pneumonia imaging moderate fever respiratory symptoms pneumonia imaging covid<NUMBER> compared lpvr arbidol control group antiviral medication primary outcome time positivetonegative conversion sarscov<NUMBER> initiation treatment day <NUMBER> significantly different p<NUMBER> time viral clearance <NUMBER> days <NUMBER> days <NUMBER> days lpvr arbidol control group respectively also significant difference negative conversion rates day <NUMBER> p<NUMBER> day <NUMBER> p<NUMBER> treatment also significant difference secondary outcomes included rate antipyresis rate cough resolution rate improvement chest ct imaging day <NUMBER> <NUMBER> p<NUMBER> take account influence time onset treatment evaluated deteriorate severe clinical status <NUMBER> days compared deteriorate <NUMBER> days showed significant difference p<NUMBER> however one cohort study <NUMBER> comparing <NUMBER> patients treated lpvr <NUMBER> patients control group shown significant reduction time body temperature normalization <NUMBER> days lpvr group compared <NUMBER> days control group p<NUMBER> one study <NUMBER> lpvr also used arbidol higher negative seroconversion rate day <NUMBER> <NUMBER> negative combination group compared <NUMBER> lpvr group p<NUMBER> day <NUMBER> <NUMBER> negative combination group compared <NUMBER> negative lpvr group p<NUMBER> also significant difference p<NUMBER> chest ct scans showing improvement combination group <NUMBER> compared lpvr group <NUMBER> another cohort study <NUMBER> suggested favipavir superior higher clinical recovery rate day <NUMBER> defined <NUMBER>h recovery body axillary temperature <NUMBER>ºc respiratory rate sao<NUMBER> <NUMBER> cough relief mild none significantly different p<NUMBER> <NUMBER> patients clinically recovered favipavir group compared <NUMBER> lpvr group case series <NUMBER> involving remdesivir compassionate use <NUMBER> patients showed <NUMBER> patients improved category oxygen support day <NUMBER> <NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> patients worsening cumulative incidence clinical improvement defined either decrease <NUMBER> points six point ordinal scale live discharge <NUMBER> improvement case series <NUMBER> <NUMBER> patients died <NUMBER> receiving noninvasive ventilation overall mortality date admission <NUMBER> per <NUMBER> hospitalisation days comparing patients receiving invasive ventilation <NUMBER> receiving non invasive ventilation <NUMBER> substantial difference however risk death greater among patients age <NUMBER> hazard ratio <NUMBER> higher serum creatinine hazard ration <NUMBER> postsearching rct done <NUMBER> hospitals wuhan published <NUMBER> enrolled <NUMBER> patients covid<NUMBER> positive pneumonia confirmed chest imaging sao<NUMBER> room air within <NUMBER> days symptoms onset <NUMBER> remdesivir arm <NUMBER> placebo arm however <NUMBER> <NUMBER> remdesivir placebo arm respectively included perprotocol population due withdrawal consent receiving medication less days protocol starting study primary clinical endpoint time clinical improvement defined twopoint reduction patients admission status sixpoint scale significantly different remdesivir group <NUMBER> days compared placebo group <NUMBER> days receiving treatment within <NUMBER> days numerically faster time clinical improvement remdesivir arm <NUMBER> days compared placebo arm <NUMBER> days clinical improvement rates day <NUMBER> <NUMBER> day <NUMBER> significantly different remdesivir group placebo group however numerically day <NUMBER> higher clinical improvement rate day <NUMBER> <NUMBER> remdesivir compared <NUMBER> placebo day <NUMBER> <NUMBER> remdesivir compared <NUMBER> placebo <NUMBER> day mortality similar remdesivir group <NUMBER> placebo group <NUMBER> clinical outcomes duration oxygen support duration invasive mechanical ventilation duration hospital stay time discharge time death significantly different however numerically days invasive mechanical ventilation lower remdesivir group <NUMBER> days compared placebo group <NUMBER> days terms viral load differences observed groups similar decrease viral load study adverse events reported <NUMBER> patients <NUMBER> serious remdesivir group common ones constipation hypoalbuminaemia hypokalaemia anaemia thrombocytopaemia increased total bilirubin adverse events also reported <NUMBER> <NUMBER> serious patients control group including hypoalbuminaemia constipation anaemia hypokalaemia increased aspartate aminotransferase increased bloods lipids increased total bilirubin overall patients discontinued drug due adverse events remdesivir group <NUMBER> placebo group <NUMBER> antiviral side effects ranged <NUMBER> across studies reported side effects liver injury high transaminases high bilirubin leucopenia gastrointestinal cutaneous side effects diarrhea vomiting nausea rash one randomized controlled trial reported lpvr adverse effects <NUMBER> <NUMBER> serious ones compared <NUMBER> <NUMBER> serious ones control group study reported <NUMBER> patients could complete <NUMBER> day course lpvr due adverse events one case series regarding remdesivir reported <NUMBER> adverse event rate including increased hepatic enzymes renal impairment diarrhea rash hypotension included <NUMBER> severe adverse events including multiple organ dysfunction syndrome septic shock acute kidney injury hypotension <NUMBER> case reports <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> summarised table <NUMBER> cases number medications trialed antibiotics <NUMBER> cases hcq <NUMBER> lpvr <NUMBER> remdesivir <NUMBER> cases interestingly <NUMBER> reported adverse effects use hcq azithromycin high transaminases atrial fibrillation long qt syndrome figure <NUMBER> <NUMBER> show risk bias assessment study using rob<NUMBER> rcts robinsi nonrcts <NUMBER> rcts <NUMBER> <NUMBER> high risk whilst <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> moderate risk non rcts <NUMBER> appropriate analysis <NUMBER> <NUMBER> <NUMBER> moderate risk <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> serious risk <NUMBER> studies included metaanalysis adverse events using hcq figure <NUMBER> <NUMBER> studies included metaanalysis negative seroconversion rate using hcq figure <NUMBER> metaanalysis seroconversion rate cheng et al measured rate day <NUMBER> tang et al measured day <NUMBER> show significant difference p<NUMBER> regarding adverse events hcq compared control group odd ratio <NUMBER> <NUMBER> ci <NUMBER> however difference found p<NUMBER> negative seroconversion rate hcq control group odds ratio <NUMBER> <NUMBER> ci <NUMBER> <NUMBER> studies included metaanalyses adverse events lpvr figure <NUMBER> shows significant difference p<NUMBER> lpvr control group regarding adverse events odds ratio <NUMBER> <NUMBER> ci <NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint declared global pandemic numbers cases rising everyday covid<NUMBER> unprecedented challenge number areas subsequent reorganization clinical activities <NUMBER> clinicians across world trialed repurposing number medications regarding cq suggested effective inexpensive option compared antivirals <NUMBER> recent trial <NUMBER> compared use highdosage <NUMBER>g lowdosage cq suggested highdosage regimen azithromycin oseltamivir safe continue due concerns regarding cardiotoxic events myocarditis qtc interval prolongation associated increase fatal arrhythmias ventricular tachycardia however age confounder associated unfavourable outcomes therefore advised high dosage cq recommended treatment severe covid<NUMBER> findings cannot extrapolated patients nonsevere covid<NUMBER> results randomized controlled trials using hcq shown similar negative seroconversion rate time clinical recovery compared standard care however recorded hcq may fasten normalization body temperature cough remission smaller cohorts showing benefit hcq important cautious results therefore overall role hcq management covid<NUMBER> may still remain promising larger scale studies required showing difference compared standardcare alone however one rct shown lpvr may lower <NUMBER>day mortality shorter stay intensive care shorter time discharge effect clinical improvement study <NUMBER> regarding remdesivir identified search observational study compassionate use patients severe covid<NUMBER> showed <NUMBER> clinical improvement improved category oxygen support <NUMBER> cases search carried rct <NUMBER> published comparing remdesivir placebo showing significant advantage time clinical improvement mortality time viral clearance remdesivir even well tolerated however power study insufficient reach target enrolment due marked reductions new patient presentations midmarch wuhan initiation treatment might quite late disease course restrictions hospital bed availability significant improvement outcomes summarizing case reports challenging draw conclusions however clinical improvement patients reported use cocktail medications important aspect consider present systematic review several limitations paucity rcts gold standard comparing interventions probably due difficulties randomization blinding unprecedented stressful environment faced healthcare services therefore large number studies observational cohort studies quicker organize implement therefore obtaining results rapidly essential number worldwide cases rising alarming rate another limitation studies vary outcomes measured therefore sidebyside comparisons become difficult due heterogeneity studies able perform metaanalysis maximum <NUMBER> studies one analyses regarding negative seroconversion rate measured different time points therefore giving accurate view large proportion studies included also measure survival morbidity outcomes important many studies included also formally peer reviewed yet due urgency pandemic draft manuscripts uploaded included every study found systematic review may introduced bias therefore important analyse studies cautiously selection patients important different studies recruited patients different severity covid<NUMBER> also important consider timeline administration medication early administration medication could beneficial later course disease using risk bias assessment tools nonrcts serious risk bias due confounders including baseline confounding factors presence comorbidities could affect outcome patient blinding patients assessors also pose risk bias due potential unreliable measurement outcomes knowledge first systematic review regarding repurposing drugs covid<NUMBER> summarizing <NUMBER> studies well <NUMBER> case reports conclusion difficult establish efficacy drugs management covid<NUMBER> due lack evidence however likewise also sufficient evidence show drugs successful improving clinical outcomes reducing viral load therefore important balance benefits trialing medication adverse events described spectrum clearly understood accordingly need high quality data especially rcts evaluate benefits repurposed drugs treatment patients covid<NUMBER> recognise large global effort biggest covid<NUMBER> trial recovery trial <NUMBER> recruited <NUMBER> participants across <NUMBER> sites date <NUMBER> may <NUMBER> randomized trial inviting clinically suspected laboratory confirmed covid<NUMBER> adult <NUMBER> years patients hospitalised united kingdom participate randomisation one <NUMBER> arms usual care usual care plus lpvr usual care plus lowdose dexamethasone usual care plus hcq usual care plus azithromycin deteriorate randomized tocilizumab control group study indicates clinical effectiveness regarding role chloroquine hydroxychloroquine antiviral treatment covid<NUMBER> patients however potential medications large clinical trials required achieve reliable findings therefore riskbenefit analysis required individual basis weigh potential improvement clinical outcome viral load reduction compared risks adverse events rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint tables table <NUMBER> characteristics study certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted june <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint december <NUMBER> cluster atypical pneumonia cases reported wuhan china wu et al <NUMBER> zhu et al <NUMBER> coronavirus disease rapidly spread countries march <NUMBER> th disease declared pandemic world health organization cucinotta vanelli <NUMBER> according date situation report <NUMBER> april <NUMBER> th <NUMBER> <NUMBER> covid<NUMBER> cases <NUMBER> covid<NUMBER>associated deaths worldwide world health organization <NUMBER> causal agent covid<NUMBER> sarsrelated coronavirus named sarscov<NUMBER> likely passed humans liveanimal markets jalava <NUMBER> strong evidence sarscov<NUMBER> originated bats likely transmitted humans intermediate animal probably pangolin lam et al <NUMBER> sarscov<NUMBER> betacoronavirus closely related merscov sarscov also caused outbreaks pandemic potential outbreaks affected global economy causing high economic losses tripp tompkins <NUMBER> sarscov<NUMBER> genome singlestranded positivesense rna <NUMBER> kb length contains least six open reading frames orfs code minimum <NUMBER> nonstructural proteins <NUMBER> structural proteins lai et al <NUMBER> orf <NUMBER>ab translated large protein undergoes extensive proteolytic processing yield replicase complex mediates viral transcription replication protease j u r n l p r e p r f responsible proteolytic processing main protease mpro <NUMBER>clike protease <NUMBER>clpro matured autocleavage dimeric active conformation xia kang <NUMBER> given relevance viral replication cycle mpro proposed target development inhibitors coronaviruses yang et al <NUMBER> drug repurposing also known drug repositioning use active pharmaceutical ingredient treat novel medical condition different original intended condition arisen mainly serendipity beneficial offtarget secondary effects noticed pacios et al <NUMBER> pushpakom et al <NUMBER> use currently approved drugs treat different diseases advantage assuring medical safety drugs already tested animal models undergone clinical trials additionally infrastructure manufacture largescale already place cha et al <NUMBER> pushpakom et al <NUMBER> drug repurposing also strategy used discover novel antibiotics antiviral drugs dyall et al <NUMBER> pacios et al <NUMBER> case sarscov<NUMBER> many drugs repurposing potential already tested li de clercq <NUMBER> attractiveness repurposing led evaluation least <NUMBER> drugs one medical condition another advantage drug repurposing quick approval emergencies current covid<NUMBER> pandemic taking consideration performed silico evaluation set approved drugs potential inhibitors mpro sarscov<NUMBER> findings show several molecules warrant analysis treatment options covid<NUMBER> total <NUMBER> sarscov<NUMBER> genome sequences retrieved gisaid platform shu mccauley <NUMBER> aligned clustal omega ugene platform okonechnikov et al <NUMBER> sievers higgins <NUMBER> homology modeling betacovwuhanwiv<NUMBER> genome analyzed vgas zhang et al <NUMBER> predict open reading frame orf corresponding orf<NUMBER>a contains mpro sequence sequence used predict structure mpro biologically active conformation dimer using modeller ho et al <NUMBER> webb sali <NUMBER> following structures used templates pdb ids <NUMBER>amd j u r n l p r e p r f <NUMBER>wof <NUMBER>amq <NUMBER>d<NUMBER>d <NUMBER>e<NUMBER> <NUMBER>ea<NUMBER> total <NUMBER> models generated dope discrete optimized protein energy score used select best structural model global local structural quality evaluated qmean scoring function measures global local quality protein models estimating degree structural nativeness qmean uses linear combination structural descriptors include longrange interactions torsion angles solvation potential scores calculated form structural descriptors transformed zscores compare highresolution crystal structures qmean available swissmodel server benkert et al <NUMBER> waterhouse et al <NUMBER> sequence conservation analysis done chimera pettersen et al <NUMBER> predicted structural model submitted charmmgui server prepare system brooks et al <NUMBER> jo et al <NUMBER> jo et al <NUMBER> lee et al <NUMBER> solution builder module used prepare protein inside water cube tip<NUMBER>p model potassium chloride kcl used neutralize system charge adjust salt concentration <NUMBER> charmm<NUMBER>m force field used input files gromacs generated downloaded huang et al <NUMBER> molecular dynamics simulation performed gromacs abraham et al <NUMBER> abraham et al <NUMBER> three stages first minimization stage steepest descent consisting <NUMBER> steps performed eliminate major atomic clashes system equilibration stage performed protein movement constrained allow solvent ions contact protein harmonic force constants <NUMBER> kj mol <NUMBER> nm <NUMBER> protein backbone <NUMBER> kj mol <NUMBER> nm <NUMBER> sidechains used total equilibration time <NUMBER> ps time step <NUMBER> fs <NUMBER> k lastly production stage performed without position restrains total <NUMBER> ns timestep <NUMBER> fs <NUMBER> k resulting trajectory visualized analyzed vmd humphrey et al <NUMBER> gromacs conformers resulting trajectory clustered gromos method danura et al <NUMBER> generates nonoverlapping clusters briefly method starts rmsd calculation pairs conformers trajectory first cluster formed biggest set conformers sharing less cutoff detected conformers eliminated pool clusters process repeated remaining conformers cutoff <NUMBER> nm used generate approximately <NUMBER> clusters <NUMBER> conformers resulting molecular dynamics simulation strategy discover molecules potentially inhibit mpro involved molecular docking molecule active site mpro idock li et al <NUMBER> used molecular docking engine procedure first validated redocking ligand <NUMBER>ni sarsmpro structure pdb id <NUMBER>amd idock molecular docking program developed focus virtual screening capable processing massive number ligands relatively short time similar autodock vina fast accurate evolution autodock regard scoring function optimization algorithm emphasis faster execution sarscov<NUMBER> mpro structure two main conformers extracted molecular dynamics simulation trajectory file processed autodocktools morris et al <NUMBER> smallmolecule database consisted <NUMBER> molecules downloaded zinc<NUMBER> sterling irwin <NUMBER> molecules corresponded world subset according zinc<NUMBER> molecules approved human use major jurisdictions including us food drug administration database processed prepareligand<NUMBER>py script included autodocktools obtain input files needed virtual screening box coordinates virtual screening center x z <NUMBER> <NUMBER> <NUMBER> size x z <NUMBER> <NUMBER> <NUMBER> candidate molecules selected according docking score predicted idock top <NUMBER> molecules conformer analyzed select potential inhibitors mpro <NUMBER> complexes inspected visually pymol httpspymolorg discovery studio visualizer httpswww<NUMBER>dsbioviacom molecules made contact catalytic residues mpro his<NUMBER> cys<NUMBER> subjected molecular dynamics simulations input files prepared charmmgui mentioned simulation times <NUMBER> ns several experimental structures reported sarscov<NUMBER> mpro vary amino acid sequence resolution presence additional molecules inhibitors solvents consequently decided include structures <NUMBER>amd <NUMBER>wof <NUMBER>amq <NUMBER>d<NUMBER>d <NUMBER>e<NUMBER> <NUMBER>ea<NUMBER> model structure sarscov<NUMBER> main protease sequence identity sarscov<NUMBER> mpro sarscov<NUMBER> sequences ranged <NUMBER> sequence corresponding pdb code <NUMBER>amq <NUMBER> conservation indicates active site mpro highly conserved among analyzed isolates figure s<NUMBER> next solventexplicit molecular dynamics simulations performed mpro resulting trajectory showed protein highly flexible active site amino acids surrounding binding site high rmsf rootmeansquare fluctuation values regions surrounding binding site mobile simulation figures <NUMBER> s<NUMBER> flexibility makes drug discovery challenge ligand could bind closed site could bind open state vice versa therefore proceeded analyze md trajectory <NUMBER> clusters encompass trajectory two representative conformers selected figure s<NUMBER> thus virtual screening done starting structure well two conformers mpro<NUMBER> initial structure mpro<NUMBER> conformer <NUMBER> representative cluster <NUMBER> mpro<NUMBER> conformer <NUMBER> representative cluster <NUMBER> highlighted area zoomed right ligand in<NUMBER> displayed sticks shown identify active site virtual screening performed mpro conformers <NUMBER>molecule bank top <NUMBER> binders conformer selected analysis table <NUMBER> docking score values ranged <NUMBER> kcalmol dihydroergotamine <NUMBER> kcalmol bisoctrizole noticeably several drug metabolites glucuronides drugs used chemotherapy sorafenib betadglucoronide ntrifluoroacetyladriamycin amrubicin daunorubicin idarubicin midostaurin maraviroc celsentri ligands contacted catalytic amino acids his<NUMBER> cys<NUMBER> promising candidates thus selected molecular dynamics simulations md simulations selected mproligand complexes carried relative mobility ligand within active site mpro monitored evaluation ligand rmsd figure <NUMBER> case mpro<NUMBER> mobile ligand ergoloid average rmsd <NUMBER> å stable ligand ergotamine average rmsd <NUMBER> å case mpro<NUMBER> mobile ligand daunorubicin average rmsd <NUMBER> å stable ligand lorazepam glucoronide average rmsd <NUMBER> å lastly mpro<NUMBER> mobile ligand lorazepam glucoronide average rmsd <NUMBER> å stable ligand ketotifennglucoronide average rmsd <NUMBER> å binding free energy calculated complex initial <NUMBER> ns considered calculation results indicated table <NUMBER> noteworthy complexes conformer mpro<NUMBER> mpro<NUMBER> lowest binding free energy values considering bioinformatics analyses posit ligands daunorubicin ergotamine bromocriptine meclocycline amrubicin ergoloid ketotifennglucoronide ntrifluoroacetyladriamycin <NUMBER>a reductase inhibitor good candidates mpro inhibitors therefore warrant evaluation potential treatment sarscov<NUMBER> infection j u r n l p r e p r f race time currently underway develop safe effective antivirals sarscov<NUMBER> drug repurposing straightforward strategy time critical factor covid<NUMBER> pandemic phadke saunik <NUMBER> pushpakom et al <NUMBER> indeed us food drug administration encouraged use app cure id health care professionals report novel uses existing medicines treatment infectious diseases httpscurencatsio several studies clinical phases involve repurposing approved drugs pacios et al <NUMBER> hand bioinformatic studies useful detecting drugs used vitro studies clinical trials treatment options covid<NUMBER> work set nine currently approved drugs identified potential inhibit sarscov<NUMBER> mpro therefore could used covid<NUMBER> treatment either alone combination drugs promising strategies involve use chloroquine alone combined azithromycin well remdesivir gautret et al <NUMBER> however efficacy therapies yet unknown regarding mpro currently least one clinical trial involving use protease inhibitors treatment covid<NUMBER> clinical trial nct<NUMBER> several reports potential inhibitors sarscov<NUMBER> mpro w khan et al <NUMBER> li de clercq <NUMBER> ton et al <NUMBER> zhang et al <NUMBER> reports use computational approaches identify molecules mpro inhibitory potential however work one considers flexibility active site allowed us propose greater diversity potential mpro inhibitors mpro excellent target computerassisted drug discovery critical early stages viral replication however found substratebinding site highly flexible therefore virtualassisted drug design approaches take flexibility account work started structures available sarscov<NUMBER> mpro however two experimental structures reported date pdb id <NUMBER>lu<NUMBER> <NUMBER>w<NUMBER> jin et al <NUMBER> rapid analysis showed bfactors <NUMBER>lu<NUMBER> agree results supplementary figure s<NUMBER> therefore homology model constructed work valid purposes md simulations duration <NUMBER> ns first <NUMBER> ns discarded bindingfree energy analysis allow system equilibrate consensus duration molecular dynamics simulation found longer simulations necessarily j u r n l p r e p r f improve binding free energy calculations hou et al <NUMBER> chose <NUMBER> ns result literature search simulation times ranged <NUMBER> ns one proteinligand complex <NUMBER> ns several proteinligand complexes mittal et al <NUMBER> define duration simulation run complexity phenomena study size system considered also depending directly available computer power overall studies involving one complex normally used longer simulation times n studies involving several complexes used shorter simulation times ge <NUMBER> razzaghiasl et al <NUMBER> binding free energies ranged <NUMBER> kcalmol <NUMBER> <NUMBER> kcalmol first sight values noticeably higher expected considering experimental δg value avidinbiotin complex <NUMBER> kcalmol reason discrepancy solute dielectric variable used calculations fact use different solute dielectric values significatively shift binding free energy calculation negative positive value case avidinbiotin complex solute dielectric variable <NUMBER> agrees well experimental values since calculations made cafe plugin indicate δg <NUMBER> kcalmol solute dielectric <NUMBER> used value close experimental binding free energy <NUMBER> kcalmol green <NUMBER> three proposed drugs used chemotherapy daunorubicin amrubicin valrubicin metabolite ntrifluoroacetyladriamycin piska et al <NUMBER> drugs well meclocycline highly toxic antibiotic treated carefully side effects organism two drugs identified study indomethacin glycyrrhizinate also tested vitro proposed potential therapies coronavirus amici et al <NUMBER> hoever et al <NUMBER> however binding free energy analysis suggests mpro might primary target molecules despite increasing number publications related virtual screening focused mpro jin et al <NUMBER> ton et al <NUMBER> j wang <NUMBER> little agreement potential j u r n l p r e p r f candidates identified reported drugs found work valrubicin also identified another study potential inhibitor mpro j wang <NUMBER> may explained diversity selected databases algorithms used docking virtual screening however original purpose drug considered similarities arise findings jin et al <NUMBER> drugs used chemotherapy antihistamines potentially inhibit mpro given emergency currently facing diversity results may turn beneficial options available repurpose drugs covid<NUMBER> treatment options drugs mentioned article used treatment covid<NUMBER> unless tested proper clinical trials main protease sarscov<NUMBER> flexible active site aspect must considered rational drug design approach involved use three conformers mpro led identification nine molecules warrant vivo testing even clinical trials repurposed treatment covid<NUMBER> find credit author statement participant elaboration manuscript alicia jiménezalberto conceptualization investigation writingreview editing funding acquisition visualization rosa ribasaparicio conceptualization resources writingreview editing funding acquisition supervision formal analysis gerardo aparicioozores conceptualization investigation writingreview editing funding acquisition data curation juan castelánvega methodology software validation formal analysis data curation writingoriginal draft visualization funding acquisition authors declare known competing financial interests personal relationships could appeared influence work reported paper early january <NUMBER> world health organisation reported cases pneumonia unknown cause wuhan city hubei province china <NUMBER> january <NUMBER> escalated warning public health emergency international concern <NUMBER> march <NUMBER> novel coronavirus ncov outbreak achieved global pandemic status recognised novel journal translational medicine correspondence nitinchitranshimqeduau vivekguptamqeduau <NUMBER> faculty medicine health human sciences macquarie university f<NUMBER>a <NUMBER> technology place north ryde nsw <NUMBER> australia full list author information available end article page <NUMBER> <NUMBER> chitranshi et al j transl med <NUMBER> <NUMBER> covid<NUMBER> disease ncovid<NUMBER> <NUMBER> present coronavirus outbreak associated severe acute respiratory syndrome <NUMBER> sarscov<NUMBER> phylogeny taxonomy designated <NUMBER> worldometer reported total sarscov<NUMBER> infected cases <NUMBER> may <NUMBER> <NUMBER> deaths <NUMBER> worldwide https wwwworld omete rsinfocoron aviru scount ries pathogen established transmit human human contact quickly spread <NUMBER> countries across globe https gisan ddata mapsarcgi scom coronaviruses single positive stranded rna viruses belonging genus coronavirus family coronaviridae cause acute chronic respiratory central nervous system illnesses animals including humans <NUMBER> <NUMBER> infection also cause mild episodes follicular conjunctivitis certain patients animal models infection shown induce anterior uveitis retinitis optic neuritis like symptoms <NUMBER> recent study shown formation hyperreflective lesions ganglion cell inner plexiform layers retina particularly around papillomacular bundles <NUMBER> disease also shown affect sense smell taste bud sensitivity patients <NUMBER> coronaviruses minimum <NUMBER> basic viral proteins envelope protein e highly hydrophobic protein involved several aspects virus life cycle assembly envelope formation <NUMBER> ii spike protein glycoprotein involved receptor recognition membrane fusion <NUMBER> iii membrane protein plays key role virion assembly <NUMBER> fig <NUMBER> viral genome also encodes two open reading frames orf orfa orfb activate intracellular pathways triggers host innate immune response <NUMBER> polyprotein encoded virus initially processed two main viral proteases include papainlike cysteine protease pl pro <NUMBER> <NUMBER> nucleocapsid n nt <NUMBER> proteins green orf<NUMBER>a gene encodes papainlike protease <NUMBER>cl protease orf<NUMBER>b gene encodes rnadependent rna polymerase helicase endo ribonuclease e n gene encodes spike membrane glycoprotein nucleocapsid phosphoprotein respectively threedimensional crystal structure <NUMBER>clprotese endoribonuclease sarscov<NUMBER> spike protein receptor binding domain rbd engaged human angiotensin converting enzyme <NUMBER> ace<NUMBER> receptor collected protein data bank chymotrypsinlike cysteine protease known <NUMBER>clike protease <NUMBER>cl pro intermediate mature nonstructural proteins <NUMBER> main proteinase <NUMBER>cl pro one primary targets development antiviral drug therapies plays critical role viral replication <NUMBER> k<NUMBER> camostat est cysteine protease inhibitors shown inhibit sarscov <NUMBER>cl pro replication cell culture conditions <NUMBER> <NUMBER> recent release highresolution crystal structure main proteinase <NUMBER>cl pro protein data bank pdb id <NUMBER>y<NUMBER>g describing additional amide bond αketoamide inhibitor pyridone ring enhance halflife compound plasma <NUMBER> suggested accelerate targeted drug discovery efforts two hiv<NUMBER> proteinase inhibitors lopinavir ritonavir considered target sarscov <NUMBER> interestingly substrate binding cleft located domains ii sarscov <NUMBER>cl pro sarscov<NUMBER> <NUMBER>cl pro enzymes <NUMBER> <NUMBER> since initial stages sarscov<NUMBER> outbreak laboratories hospitals around world sequenced viral genome data unprecedented speed enabling realtime understanding novel disease process hopefully contribute development novel candidate drugs complete genomes sarscov<NUMBER> world deposited global initiative sharing avian influenza data gisaid <NUMBER> database sequences continue deposited passage time development novel vaccine sarscov<NUMBER> far remains elusive requires thorough understanding molecular changes viral genetics may attained freely accessing gisaid database processing data enhance understanding fine biochemical genetic differences differentiate virus previously known strains <NUMBER> well known viruses nonliving require host cells survive reproduce sole aim perpetuate virus jumps animal human termed zoonotic virus occurred sars outbreak <NUMBER> new coronavirus spread around world resulted death hundreds people <NUMBER> <NUMBER> another novel coronavirus outbreak termed middle east respiratory syndrome mers caused <NUMBER> fatalities spread <NUMBER> different countries <NUMBER> currently many circulating viruses sarscov<NUMBER> achieved devastating pandemic status whether pandemic subside remain unanswered purpose study characterise known viral variants spread across different countries especially hotspot regions focus recurrent mutations south american african geographical regions also focused sarscov<NUMBER> main proteinase <NUMBER>cl pro highly conserved coronaviruses suggested potential drug target fight ncovid<NUMBER> repurposed drugs flavonoids biflavanoids known antimalarial antiviral drugs inhibitory effects vitamins could selectively inhibit enzyme used either alone combination disease management approaches suppress virulence sarscov<NUMBER> bioinformatics computational modelling molecular docking approaches using repurposed drugs could particularly useful current ncovid<NUMBER> outbreak global initiative sharing avian influenza data gisaid headquartered munich germany publicprivate partnership project german government nonprofit organization founded leading medical researchers <NUMBER> since december <NUMBER> gisaid become repository storage database ncovid<NUMBER> genome genome analysis carried data deposited <NUMBER> may <NUMBER> https www gisai dorg severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> wuhan genome collected ncbi nc<NUMBER> multiple sequence alignment msa nucleotide sequences carried emblebi clustal omega server investigate sequence conservation <NUMBER> <NUMBER> newick format multiple align sequence used generate phylogeny <NUMBER> phylogenetic tree constructed interactive tree life itol online tool <NUMBER> itol server generate phylogeny trees circular radial normal standard trees circular trees rooted displayed different arc sizes <NUMBER> <NUMBER> <NUMBER> crystal structure sars sarscov<NUMBER> <NUMBER>cl pro bound inhibitors collected protein data bank pdb <NUMBER> pdb id <NUMBER>tnt sars main protease selected reference analyse variants sarscov<NUMBER> <NUMBER>cl pro pdb id <NUMBER>y<NUMBER>g pdbs visualised using ucsf chimera software <NUMBER> multiple alignment ribbon surface superimposition module chimera software used analysis image generation <NUMBER> <NUMBER> dataset comprises flavones biflavanoids antiviral antimalarial vitamins sarscov<NUMBER> <NUMBER>cl pro inhibitors <NUMBER> total <NUMBER> repurposed drugs collected pubchem database <NUMBER> twodimensional <NUMBER>d structures downloaded pubchem database insdf format inhibitor energies minimized using austin model<NUMBER> am<NUMBER> root mean square rms gradient value became smaller <NUMBER> kcalmol å later reoptimization done mopac molecular orbital package method <NUMBER> <NUMBER> later inhibitors converted topdb format open babel software <NUMBER> submitted molecular docking studies crystal structure sarscov<NUMBER> <NUMBER>cl pro retrieved pdb pdb id <NUMBER>y<NUMBER>g protein macromolecule sarscov<NUMBER> <NUMBER>cl pro optimization carried ucsf chimera software <NUMBER> <NUMBER> <NUMBER> adding polar hydrogen atoms removing water molecules implying amber parameters followed minimization mmtk method <NUMBER> steps step size <NUMBER> å sarscov<NUMBER> <NUMBER>cl pro contained chain b <NUMBER> amino acids sequence length chain pdb id <NUMBER>y<NUMBER>g containing alphaketoamide o<NUMBER>k inhibitor used identification substrate binding site docking sarscov<NUMBER> <NUMBER>cl pro specific pharmacological inhibitors catalytic site performed autodock <NUMBER> program <NUMBER> alphaketoamide o<NUMBER>k inhibitor extracted sarscov<NUMBER> <NUMBER>cl pro protein polar hydrogen atoms added nonpolar hydrogen atoms merged gasteiger charges assigned solvation parameters added protease sarscov<NUMBER> <NUMBER>cl pro protein protonation state inhibitors o<NUMBER>k set physiological ph rotatable bonds ligands set free autogrid program also used generate grid maps cys<NUMBER> residue sarscov<NUMBER> <NUMBER>cl pro protein selected grid box dimensions <NUMBER> × <NUMBER> × <NUMBER> å formed around cys<NUMBER> protease residue present substrate binding site protein rigid docking performed using empirical free energy function together lamarckian genetic algorithm lga <NUMBER> lga default parameters used docking procedure <NUMBER> different poses calculated chimera discovery studio ds visualizer<NUMBER> <NUMBER> software used visualisation calculation proteinligand interactions total <NUMBER> sarscov<NUMBER> genomes retrieved gisaid database https wwwgisai dorg contain <NUMBER> sequences bat betacoronavirus <NUMBER> sequences malayan pangolin manis javanica additional file <NUMBER> table s<NUMBER> <NUMBER> genome sequences <NUMBER> complete genome sequences sarscov<NUMBER> selected randomly aligned compared wuhan sarscov<NUMBER> nc<NUMBER> reference genome divided dataset <NUMBER> different geographic areas europe <NUMBER> north america <NUMBER> asia <NUMBER> oceania <NUMBER> south america <NUMBER> africa <NUMBER> european group comprises sarscov<NUMBER> infected patient data following countries austria belgium czech republic denmark estonia finland france germany greece hungary iceland ireland italy latvia lithuania luxembourg netherlands poland portugal slovakia slovenia spain sweden switzerland united kingdom north american group contains genomes united states canada asian group comprises genomes obtained patients located china indonesia pakistan philippines taiwan turkey kuwait georgia south korea japan iran india thailand hong kong malaysia singapore vietnam oceanian group comprises genomes australia new zealand south america includes brazil peru chile colombia argentina ecuador fig <NUMBER>ac sequences batsarscov pangolinsarscov aligned compared wuhan sarscov<NUMBER> nc<NUMBER> reference genome determine evolutionary relationship among batcov pangolincov sarscov<NUMBER> estimated phylogenetic tree based nucleotide sequences wholegenome sequence batsarscov sarscov<NUMBER> grouped together observed share <NUMBER> similarity whereas pangolinsarscov closest evolutionary ancestor fig <NUMBER>d isolate human wuhan sarscov<NUMBER> nc<NUMBER> shared <NUMBER> identity pangolinsarscov suggests pangolin may associated sarscov<NUMBER> evolution subsequent outbreak <NUMBER> <NUMBER> recently pachetti et al <NUMBER> reported eight novel recurrent mutations sarscov<NUMBER> identified positions <NUMBER> <NUMBER> <NUMBER> <NUMBER> locus indicates high susceptibility genetic regions change virus evolves actions singlestranded sarscov<NUMBER> rna viral genome encodes two protease polyproteins papainlike cysteineprotease pl pro ii chymotrypsinlike cysteine protease known <NUMBER>clike protease <NUMBER>cl pro <NUMBER>cl pro main protease therefore important order examine incidence mutation sarscov<NUMBER> <NUMBER>cl pro multiple sequence alignment sarscov<NUMBER> genome collected patients six different geographical locations exhibited <NUMBER> similarity discernible variations sequences obtained diverse geographical regions enzyme sars sarscov<NUMBER> complete genomes collected ncbi genbank database nc<NUMBER> nc<NUMBER> protease nucleotide sequences extracted sars nc<NUMBER> aligned sarscov<NUMBER> nc<NUMBER> clustal omega alignment <NUMBER> sars nucleotides showed around <NUMBER> similarity sarscov<NUMBER> additional file <NUMBER> table s<NUMBER> higher amino acid sequence identity also observed sarscov sarscov<NUMBER> main protease <NUMBER>cl pro derived wuhan us patients sarscov sarscov<NUMBER> <NUMBER>cl pro showed highly conserved region catalytic sites his<NUMBER> cys<NUMBER> <NUMBER> substrate previously confirmed mutations positions nt<NUMBER> nt<NUMBER> nt<NUMBER> nt<NUMBER> nt<NUMBER> nt<NUMBER> nt<NUMBER> also present south american african populations normalize mutation frequency percentage estimating frequency genomes carrying mutation comparing overall number collected genomes per geographical area graph shows cumulative mutation frequency given mutations present south american african regions mutation localisation viral genes reported legend well proteins ie nonstructural protein nsp presenting mutations b also evident south american african clusters show differential pattern novel mutations mutation <NUMBER> black <NUMBER> pink <NUMBER> green <NUMBER> red south american whereas mutation <NUMBER> black <NUMBER> orange <NUMBER> yellow <NUMBER> magenta present greater frequency african patients fig <NUMBER>a inferring proteases exhibit high similarities furthermore <NUMBER> variant positions thr<NUMBER>val ala<NUMBER>ser ser<NUMBER>asn leu<NUMBER>val arg<NUMBER>lys ser<NUMBER>ala his<NUMBER>phe lys<NUMBER>asn leu<NUMBER>val ala<NUMBER>ser thr<NUMBER>ala ile<NUMBER>leu observed sarscov<NUMBER> <NUMBER>cl pro fig <NUMBER>b c effects mutations potential resultant amino acids sarscov<NUMBER> <NUMBER>cl pro structure expected conserve polarity hydrophobicity except resulting amino acid leucine <NUMBER> position however important mention <NUMBER> variants present catalytic substrate binding regions involved critical proteolytic activity sarscov<NUMBER> protease molecule sarscov<NUMBER> <NUMBER>cl pro receptor binding pocket determined superimposing sars sarscov<NUMBER> <NUMBER>cl pro respective inhibitors fig <NUMBER> interestingly needlemanwunsch alignment algorithm blosum<NUMBER> matrix analysis revealed <NUMBER> sequence identity sars fig <NUMBER>a grey sarscov<NUMBER> <NUMBER>cl pro fig <NUMBER>a cyan cyshis catalytic dyad cys<NUMBER> his<NUMBER> comprises active catalytic binding site sarscov<NUMBER> <NUMBER>cl pro fig <NUMBER>a b indicated strong possibility intended pharmacological inhibitors sarscov<NUMBER> <NUMBER>cl pro may also suppress activity sarscov<NUMBER> <NUMBER>cl pro viral enzymes docking protocol autodock <NUMBER> program optimized extracting redocking alphaketoamide inhibitor named o<NUMBER>k binding pocket sarscov<NUMBER> <NUMBER>cl pro lowest binding energy − <NUMBER> kcalmol <NUMBER> µm inhibitory constant ki predicted alphaketoamide inhibitor shown table <NUMBER> redocking o<NUMBER>k inhibitor occupied similar docking pose sarscov<NUMBER> <NUMBER>cl pro catalytic dyad active site previously reported crystal structure pdb id <NUMBER>y<NUMBER>g fig <NUMBER>c seven flavonoids biflavonoid three antimalarial compounds seven antiviral drugs three vitamin molecules subjected automated docking within active site sarscov<NUMBER> <NUMBER>cl pro catalyticdyad superimposition docked flavones biflavones fig <NUMBER>a antimalarial drugs fig <NUMBER>b antiviral drugs fig <NUMBER>c vitamins fig <NUMBER>d shown fig <NUMBER> various binding parameter tabulated detail table <NUMBER> amentaflavone biflavonoid showed highest binding energy − <NUMBER> kcalmol implicating strong affinity sarscov<NUMBER> <NUMBER>cl pro corresponded previously reported enzyme inhibitory assays amentaflavone showed highest ic <NUMBER> value low concentrations molecule <NUMBER> ± <NUMBER> µm <NUMBER> however bilobetin demonstrated lowest ic <NUMBER> value higher concentration <NUMBER> ± <NUMBER> µm sarscov enzyme activity assays <NUMBER> contrast docking studies revealed bilobetin predicted almost comparable binding energy amentaflavone − <NUMBER> kcalmol suggesting mutation sarscov<NUMBER> <NUMBER>cl pro could potentially disrupt hydrogen bonding induce conformational change could result alterations binding site thus affecting inhibitor interactions enzyme active site residues amentaflavone showed hbond interactions catalytic dyad residues cys<NUMBER> his<NUMBER> well noteworthy interactions sarscov<NUMBER> <NUMBER>cl pro residues thr<NUMBER> ser<NUMBER> ser<NUMBER> glu<NUMBER> whereas his<NUMBER> gln<NUMBER> amino acids contributed hydrophobic interactions sarscov<NUMBER> <NUMBER>cl pro inhibitors fig <NUMBER>a three antimalarial drugs selected study inhibitory actions sarscov<NUMBER> <NUMBER>cl pro found artemisinin natural compound derived chinese herb artemisia annua produces highest docking score − <NUMBER> kcalmol compared o<NUMBER>k chloroquine <NUMBER> kcalmol hydroxychloroquine − <NUMBER> kcalmol antimalarial molecules importantly artemisinin demonstrated broad antiviral activity human cytomegalovirus herpes simplex virus type <NUMBER> epsteinbarr virus hepatitis b virus hepatitis c virus bovine viral diarrhea virus <NUMBER> artemisinin shown exhibit hydrogen bonding his<NUMBER> leu<NUMBER> asn<NUMBER> gly<NUMBER> ser<NUMBER> glu<NUMBER> sarscov<NUMBER> <NUMBER>cl pro aminoacid residues fig <NUMBER>b amongst seven antiviral drugs ritonavir showed highest binding energy <NUMBER> kcalmol lowest inhibitory constant ki value <NUMBER> µm ritonavir produced hydrogen bond interactions thr<NUMBER> his<NUMBER> cys<NUMBER> sarscov<NUMBER> amino acids fig <NUMBER>c combination two hiv<NUMBER> protease inhibitors lopinavir ritonavir given critically ill sarscov <NUMBER> infected patients <NUMBER> however combination therapy lopinavir ritonavir also stopped early <NUMBER> patients total recruitment <NUMBER> patients due associated gastrointestinal adverse events <NUMBER> severity antiviral therapy adverse events led researchers explore potential macro microand phytonutrients potentially promote immune response suppress viral induced effects vitamins known modulate host immune functions providing antioxidants antiinflammatory activity <NUMBER> <NUMBER> therefore selected vitamins ascorbic acid vitamin c cholecalciferol vitamin alphatocopherol vitamin e investigate potential interactions enzyme sarscov<NUMBER> <NUMBER>cl pro docking results interestingly showed vitamin lowest binding energy ki − <NUMBER> kcalmol <NUMBER> µm respectively compared vitamin c vitamin e amino acid residues thr<NUMBER> thr<NUMBER> his<NUMBER> cys<NUMBER> sarscov<NUMBER> <NUMBER>cl pro showed hydrogen bond formation vitamin fig <NUMBER>d amino acid thr extensively involved intracellular signalling changes phosphorylation changes observed cholecalciferol formed strong hydrogen bond thr residues could potentially block phosphorylation thr residue sarscov<NUMBER> <NUMBER>cl pro enzyme evidence serious sarscov<NUMBER> infected cases reported severe vitamin deficiency thus therapeutic concentrations molecule could potentially used clinically sarscov<NUMBER> cases <NUMBER> <NUMBER> novel coronavirus termed ncovid<NUMBER> known third largescale epidemic coronavirus introduced human population twentyfirst century time writing <NUMBER> million confirmed cases globally nearly <NUMBER> deaths reported clinically ncovid<NUMBER> similar sars regarding presentation however sheer capacity speed ncovid<NUMBER> spread global pandemic levels left researchers asking makes outbreak similar presentation yet different virulence previous coronaviruses genome sequence analysis looked investigate similarities phylogeny sarscov<NUMBER> like sars mers placed betacoronavirus genus <NUMBER> known severe often fatal pathogenicity betacoronaviruses highlighted previous epidemics reported higher transmission pathogenicity milder lesser known acovs often compared common cold <NUMBER> study compares similarities sarscov sarscov<NUMBER> using clustal omega alignment show <NUMBER> sars nucleotides similarity approximately <NUMBER> furthermore report high amino acid sequence identity sarscov sarscov<NUMBER> main protease <NUMBER>cl pro regulates coronavirus replication complexes <NUMBER> highly conserved regions catalytic sites substrate binding regions enzymes also validated previously studies huang et al muramatsu et al <NUMBER> <NUMBER> region provides attractive target antiviral drug design also begin elucidate viral origins uncover ease transmission based recent virus genome sequencing results evolutionary analysis origins transmission ncovid<NUMBER> uncovered bats natural host virus origins <NUMBER> studies earlier year queried unknown intermediate host bats humans recent studies pointed pangolins <NUMBER> <NUMBER> determine extent evolutionary relationship batcov pangolincov sarscov<NUMBER> corroborate based nucleotide sequences wholegenome sequence batsarscov sarscov<NUMBER> grouped together share <NUMBER> similarity pangolinsarscov closest evolutionary ancestor <NUMBER> <NUMBER> furthermore report isolates human wuhan sarscov<NUMBER> <NUMBER> similarity identity pangolinsarscov suggests pangolin may associated evolution subsequent outbreaks covid<NUMBER> regarding ncovid<NUMBER> similarity transmission sarscov recent studies also demonstrated transmission occurs via receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> <NUMBER> may indicate sarscov<NUMBER> often led severe many cases fatal respiratory tract infections like two sarcov predecessors since sarscov epidemic <NUMBER> also known use ace<NUMBER> receptor infect humans <NUMBER> bronchoalveolar lavage fluid taken ncovid<NUMBER> patients shown ace<NUMBER> widely distributed lower respiratory tracts humans <NUMBER> furthermore virion sglycoproteins expressed surface coronaviruses adhere ace<NUMBER> receptors human cells <NUMBER> location provides target uncovering mechanistic insights severity disease region assisted zoonosis sarscov<NUMBER> specifically additionally mutations genomic structure sarscov<NUMBER> also might elucidate aggressiveness pathogenicity viruses may turn help explain strains evolutionarily much virulent contagious angeletti et al described mutations endosomeassociatedproteinlike domain nsp<NUMBER> nsp<NUMBER> proteins former possibly accounting high virulence contagion latter suggesting mechanism differentiates ncovid<NUMBER> sarscov <NUMBER> studies build knowledge assist begin identify subclinical causes virulence unique pandemic pattern outbreak identifying evolving mutations region region additionally previous studies pachetti et al reported novel recurrent mutations sarscov<NUMBER> study corroborates mutations south america africa regions <NUMBER> drug discovery vaccine development sarscov<NUMBER> infection require time lengthy processes however drug repurposing represents alternative strategy current scenario antivirals currently used clinically sarscov<NUMBER> treatment including lopinavir <NUMBER> ritonavir <NUMBER> remdesivir <NUMBER> oseltamivir <NUMBER> however clinical setting lopinavirritonavir <NUMBER>cl pro rdrp inhibitors showed benefit covid<NUMBER> adult patients <NUMBER> double point mutation rdrp gene identified study potentially lead drugresistance event moreover classes drugs chloroquine hydroxychloroquine shown antiviral properties blocking viral entry cells inhibiting glycosylation host receptors <NUMBER> observed differences sarscov<NUMBER> main proteinase <NUMBER>cl pro genome sequences important differences sarscov<NUMBER> <NUMBER>cl pro sarscov protein underlining extreme need identification inhibitors target viral life cycle known whether mutations induce alterations gene transcription localisation affected proteins investigated near future using biochemical immunological approaches <NUMBER> <NUMBER> various theories proposed regarding origin highly virulent sarscov<NUMBER> particle analysis shows batsarscov shares <NUMBER> similarity sarscov<NUMBER> however possible bat coronavirus infected another intermediate host pangolin subsequently transmitted virus humans pangolin isolates share sequence identity sarscov<NUMBER> genomes could intermediate host identified novel mutation hotspot regions south american african isolates sarscov<NUMBER> genome sequences interestingly double point mutations rdrp position <NUMBER> <NUMBER> triple point mutations nucleocapsid protein position <NUMBER> <NUMBER> <NUMBER> identified south american african genomic sequences suggesting vulnerability genetic loci undergo change addition novel mutation pattern specifically oriented towards nucleocapsid phosphoprotein south american african sequences noted novel orf<NUMBER>a rdrp specific variants observed particularly african genomic sequences potential effects double triple point mutations translated proteins virulence sarscov<NUMBER> requires investigations sarscov<NUMBER> main proteinase <NUMBER>cl pro genome observed conserved across collected genomic sequences despite significant similarities sarscov <NUMBER>cl pro structure sarscov protein sarscov<NUMBER> <NUMBER>cl pro revealed certain key differences highlight extreme need identification novel mechanismbased drugs target virus processing repurposed drugs including natural flavonoids bioflavonoids antimalarial antiviral vitaminsbased compounds previously shown beneficial several viral infections outbreaks novel data generated study enhances knowledge fine molecular differences differentiate sarscov<NUMBER> virus sarscov also highlights emerging variations viral genome across different populations virus evolves local genetic environmental factors findings likely play key role development mechanismbased targeted therapeutic strategies treat sarscov<NUMBER> infection reduce virulence supplementary information accompanies paper https doi org<NUMBER>s<NUMBER> <NUMBER> z additional file <NUMBER> table s<NUMBER> acknowledgement table containing information authors originating submitting laboratories sequences deposited gisaid database additional file <NUMBER> table s<NUMBER> sarscov sarscov<NUMBER> sequence alignment <NUMBER>clpro shares around <NUMBER> similarity j u r n l p r e p r f chronic treatment drugs gets accumulated tissues <NUMBER> selected antimalarial drugs used last <NUMBER> years economic proven safety profile categorized essential medicines world health organization <NUMBER> aminoquinolines effectively reduced viral replication zika virus chikungunya virus sarsassociated coronavirus cov merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> chloroquine hydroxychloroquine shown inhibition sarscov<NUMBER> replication <NUMBER> clinical trials demonstrated effective role chloroquine phosphate dose <NUMBER> mgday covid<NUMBER> <NUMBER> nhydroxyethyl substituted derivative chloroquine hydroxychloroquine less toxic soluble similar activity towards covid<NUMBER> inhibition continuous requirement explore molecular mechanism towards underlying antiviral action clinical benefits aminoquinolines toxicity profile detailed outcomes help design randomized clinical trials <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> present manuscript provides systematic review mechanism action efficacy safety chloroquine hydroxychloroquine treatment covid<NUMBER> viral replication stable acidic ph endosomes lysososmes golgi complex host required bioaccumulation properties selected aimnoquinolines explain antiviral mechanism action <NUMBER> chloroquine increases ph intracellular vacuoles lysosomes alters catalysis protein degradation pathways acidic hydrolases also alters endosomal macromolecule synthesis golgi apparatus affects posttranslational modifications antirheumatic response produced interfering j u r n l p r e p r f compared pharmacological profile chloroquine hydroxychloroquine possess equivalent antimalarial activity later preferred due lower ocular toxicity <NUMBER> theoretically antiviral activity chloroqunie hydroxychloroquine similar reported clinical details chloroquine number <NUMBER> use chloroquine less due associated adverse effects lack availability countries patients covid<NUMBER> infection hydroxychloroquine preferred chloroquine used combination lopinavir ritonavir shows prolongation qt interval antiviral therapeutics interfere hydroxychloroquine oseltamivir lopinavirritonavir robavirin interferons immunoglobulins intravenous <NUMBER> toxicological properties reported use chloroquine hydroxychloroquine retinopathy neuromyopathy cardiomyopathy drugs possess affinity melanin affect macular cones phagocytic activity lysosomes declined photoreceptors migrate towards central peripheral regions well induces epithelial atrophy irreversible alterations photoreceptors <NUMBER> lysosomes hydroxychloroquine protonated accumulated due basic nature inhibits activity lysosomal phospholipases causing vacuolization cardiac skeletal muscle cells <NUMBER> prolong use hydroxychloroquine producesi toxicity retina tissue may lead irreversible retinopathy <NUMBER> <NUMBER> ii cardiotoxicity cns toxicity neuromyopathy symptoms alterations gastrointestinal tract <NUMBER> toxicity liver cells genetic material <NUMBER> genotoxicity <NUMBER> <NUMBER> studies shown substantial increase retinal toxicity chronic treatment based hypothesis bioaccumulation <NUMBER> investigators report <NUMBER> incidences retinopathy common asian patients <NUMBER> <NUMBER> studies failed report cardiac complications neuromyopathy may rare longterm treatment <NUMBER> <NUMBER> monitoring side effects need continued even discontinuation treatment due prolong halflife chloroquine hydroxychloroquine side effects keratopathy maculopathy may delayed current anticovid<NUMBER> therapeutic regimen suggests longer duration treatment chloroquine antimalarial drug thus close monitoring adverse reactions pharmacological effects poisoning toxicological mechanisms provide help worldwide clinical work <NUMBER> table <NUMBER> ease access medical fraternity therapeutic use aminoquinolines chloroquine hydroxychoroquine important aspects arei administered millions infected patients covid<NUMBER> ii administered medical workers preventive measure iii acute approach covid<NUMBER> higher dose administered compared use treatment chronic rheumatic diseases <NUMBER> following points concluded considered use ix toxicity associated dose calculated real weight therefore dose suitable patients potential high risk adverse effects cumulative dose <NUMBER> mgkg body weightday high risk category <NUMBER> absence sufficient clinical data detailed information safety adverse effects dose aminoquinolines chloroquine hydroxychloroquine etc made available among health professionals dissipate among patients successful application available resources needs grounded practices minimize risk rigorous screening dose calculation nowadays despite recent scientific progress infectious diseases must always taken consideration world health organization closely examines concerns order effective health system world health organization <NUMBER> <NUMBER> years confronted end golden age antibiotic discovery antimicrobial substances existed years gould <NUMBER> due significant progress largely contributed reducing number deaths infectious diseases pharmaceutical companies developed decreasing interest drugs conly johnston <NUMBER> addition use antibiotic emergence resistance inevitable intrinsically linked mohr <NUMBER> although new phenomenon natural one analysis warns serious situation impact nature spread global antimicrobial resistance global antimicrobial resistance surveillance system <NUMBER> report early implementation resistant bacteria found every kind environment water animals humans plants food rolain <NUMBER> zenati et al <NUMBER> bachiri et al <NUMBER> tafoukt et al <NUMBER> inappropriate use antimicrobial agents spread antibacterial resistance among factors lead high rate resistance clinical animals even environmental isolates roca et al <NUMBER> bassetti et al <NUMBER> partly drug pressure resistance occur easily affect types antibiotics lastline antibiotics used human medicine drug resistant bacterial infections biswas et al <NUMBER> recent years seen increase use carbapenems result increase carbapenem resistance gramnegative bacteria gnb diene rolain <NUMBER> example monaco et al showed italy among <NUMBER> clinical strains isolated november <NUMBER> april <NUMBER> <NUMBER> <NUMBER> klebsiella pneumoniae kpc enzymes carbapenemases <NUMBER> <NUMBER> resistant colistin monaco et al <NUMBER> although situation reported colistin olaitan et al <NUMBER> received attention lastline treatments may longer effective increasing risk spreading infections biswas et al <NUMBER> combat frequent epidemics challenge rapid spread new alternatives last resort treatments must considered avoid treatment failure result alternatives antibiotics treat resistant germs priority bassetti et al <NUMBER> use old drugs solution like forgotten antibiotics polymyxins fosfomycin minocycline mecillinam still used clinical settings cassir et al <NUMBER> also renewed interest antibiotic combinations circumvent resistance lenhard et al <NUMBER> example synergistic activity sulfonamideassociated colistin evaluated colistinresistant clinical bacteria okdah et al <NUMBER> non antibiotic solutions also considered alternatives therapeutic management infections aslam et al <NUMBER> various studies showed clostridium difficile inhibited using bacteriophages several ongoing trials use antimicrobial peptides alternatives preventive treatments future aslam et al <NUMBER> fight treat multidrug resistant mdr infections must also include change mentality rolain baquero denounced fact society accept use toxic effective antibiotics treatment lifethreatening infections hand society tolerate potential toxicities drugs anticancer progress medicine management adverse reactions improved monitoring antibiotic concentrations old drugs dosages rejected due adverse effects reconsidered rolain baquero <NUMBER> way one promising alternative review focuses drug repurposing also called repositioning mercorelli et al <NUMBER> therapeutic shift subject several studies different pathologies including cancer sleire et al <NUMBER> heart diseases alzheimers disease kim <NUMBER> depression ebada <NUMBER> infectiology repurposing studies carried torres et al <NUMBER> soo et al <NUMBER> dangelo et al <NUMBER> zheng et al <NUMBER> mirócanturri et al <NUMBER> general common bacteria first tested risk therapeutic deadlock review focuses drug repurposing tested mdr bacteria seems important precise resistance rarely crossed molecule active specific species compound potentially active regardless resistance mechanisms molecule affects new target generally independent antibiotic target see ciclopirox carlsonbanning et al <NUMBER> gallium goss et al <NUMBER> zidovudine elwell et al <NUMBER> therefore expand scope combinations tested sensitive gnb minocycline polymyxin b tested nonantibiotics drugs offers diversified still exploitable field possibilities carbapenem colistinresistant isolates articles published specificity striving synthesize aim thus identify innovative therapeutic strategy bacteria costeffective efficient way review define drug repurposing characteristics make inventory already published drug reuse general particular address problem carbapenem colistinresistant bacteria finally see prospects exist therapeutic strategy drug class assigned molecule describe group similary together drugs therapeutic use biochemical mechanism way action chemical structure defined waksman <NUMBER> antibiotic chemical substance produced microorganisms capacity inhibit growth even destroy bacteria microorganisms mohr <NUMBER> current trend therefore seems moving away definition indeed recent years drug repositioning seems promising field drug discovery identifies new therapeutic opportunities existing drugs doan et al <NUMBER> common idea accelerate discovery new treatment using old drugs could potentially treat disease treatments used longer work longer therapeutic solutions must used langedijk et al <NUMBER> sir james black pharmacologist nobel laureate said <NUMBER> fruitful basis discovery new drug start old drug chen et al <NUMBER> could help overcome initial bottleneck drug development process may therefore better compromise risk reward approaches drug development ashburn thor <NUMBER> drug repurposing present real economic advantages studies structure pharmacological properties bioavailability safety profiles example already conducted drugs possible skip preclinical trials toxicity pharmacokinetic already known certain hindsight taken several years drugs move directly phase <NUMBER> test effectiveness mercorelli et al <NUMBER> repurposing drugs offer new pathways targets study new perspectives curing diseases many antibiotics already affect dna membrane protein translation pathways essential bacterial growth remain available activity molecules assimilation pathways essential compounds like sugars amino acids combined strategies reduce resistance used achieve several targets could affect bacterial metabolism mercorelli et al <NUMBER> zheng et al <NUMBER> moreover method favorable academic small laboratories disinterest pharmaceutical industries without patents industries see fruitful interest rapid emerging resistance fernandes martens <NUMBER> narrower spectrum activity zheng et al <NUMBER> hand solution cannot totally miraculous drug repurposing work time due high minimal inhibitory concentration mic mercorelli et al <NUMBER> inconsistent plasma concentrations tolerated humans dose tested new indication important lead human toxicity zheng et al <NUMBER> society fears rolain baquero <NUMBER> concerning galenic optimization formulation also foreseen physicochemical incompatibility observed considered innovative strategy doan et al <NUMBER> three major methods lead drug repurposed shown figure <NUMBER> first phenotypic assay performed high throughput screening commercial public pharmaceutical compound libraries jung et al <NUMBER> kim <NUMBER> assays consist classical broth microdilution identify hit torres et al <NUMBER> antibacterial activity found mic assay performed confirm results according clsi guidelines sun et al <NUMBER>b compared methods phenotypic tests advantage highly physiologically relevant effect observed directly bacteria zheng et al <NUMBER> advances genomics bioinformatics modified drug repositioning approach consists silico structure mechanismbased assays work virtual databases made possible prospective development drug databases activities exchange information compounds collaborative networks abundance resources internet hodos et al <NUMBER> new calculation tools make possible analyse different data accumulated field man alone cannot study complex ensure understanding prediction molecules generating hypotheses biological mechanisms hodos et al <NUMBER> limit approaches pathways targets data must already known moreover false positive toxicity problematic issues found identification hit mercorelli et al <NUMBER> however emerging diseases could quick way find effective molecule done coronavirus <NUMBER> law et al <NUMBER> last approach random discovery include types configurations indeed side effects one drug one disease may effective another antidepressant bupropion reoriented antitobacco drug hodos et al <NUMBER> mere coincidence sulfamides known antibacterial properties finally also employed antidiabetic ones deuil <NUMBER> however unexpected observations could also potentially identified informatics methods view knowledge compound side effects hodos et al <NUMBER> despite techniques molecule identified must go steps clinical evaluation studies generally screen mdr bacteria ensure broader spectrum action hijazi et al <NUMBER> sometimes bacteria table <NUMBER> seven nonantibacterial compounds inhibited growth acinetobacter baumannii strain resistant antibiotics including carbapenems <NUMBER> antineoplastics <NUMBER>fluorouracil <NUMBER>thioguanine pifithrinµ <NUMBER> antirheumatic auranofin <NUMBER> antipsychotic fluspirilene <NUMBER> antiinflammatory bay <NUMBER> <NUMBER> alcohol deterrent disulfiram fivefluorouracil <NUMBER>thioguanine seemed best candidates repurposing treat mdr clinical baumannii ic<NUMBER> values mic lower standard plasma drug concentration levels human suggesting possible use without major adverse events cheng et al <NUMBER> mechanisms action targets considered objective escape therapeutic drug classes repurposed molecule used study new pathway figure <NUMBER> antifungal agent developed nearly forty years ago ciclopirox also good repurposing criteria shown american study conducted <NUMBER> carlsonbanning et al <NUMBER> due excellent safety profile already repurposed various pathologies myeloma antihuman immunodeficiency virus drug prevents enzyme actions essential cellular metabolism functions inhibiting availability cofactors activity proved mdr e coli k pneumoniae baumannii strains demonstrated novel mechanism action ciclopirox affects galactose lps salvage pathways carlsonbanning et al <NUMBER> addition bacterial activity gallium known <NUMBER> years first used anticancer agent due chemical similarity iron gallium inhibits ferric redox reactions pathways bacterial growth matter broad spectrum activity particular mdr eskape pathogens rangelvega et al <NUMBER> hijazi et al <NUMBER> fact phase <NUMBER> trial cystic fibrosis patients assess activity gallium suggests safety figure <NUMBER> annual number publications pubmed search engine drug repurposing keyword frontiers cellular infection microbiology wwwfrontiersinorg efficacy human infections goss et al <NUMBER> represents potential promising targets control infectious germs noticed pharmaceutical classes involved anticancer antiinflammatory also antiparasitic drugs pachónibáñez et al study stokes stokes et al <NUMBER> previous year showed pentamidine effective polymyxin resistant strains antiprotozoal agent usually effective trypanosomiasis leishmaniasis fungal infections tested <NUMBER> enterobacteriaceae <NUMBER> k pneumoniae <NUMBER> e coli <NUMBER> enterobacter cloacae pentamidine bactericidal <NUMBER> strains carried carbapenemases showed colistin resistance moreover effects potentiated activity antibiotics due synergistic activity rifampicin aminoglycosides e cloacae rifampicin combination effective strains tested cebrerocangueiro et al <NUMBER> context drug reprofiling various studies identified antiretroviral zidovudine also called azidothymidine azt active molecule resistant enterobacteriaceae doléansjordheim et al <NUMBER> peyclit et al <NUMBER> interest drug repurposing mdr enterobacterial infections revived forgotten antibacterial properties drug mentioned first time <NUMBER> elwell et al <NUMBER> series enterobacteriaceae different colistin resistance profiles mcr<NUMBER> gene mgrb pmrb mutations antibacterial action confirmed mics ranging <NUMBER> <NUMBER> µm pharmacokinetic data showed azt concentrations found would compatible plasma concentrations obtained doses used human medicine peyclit et al <NUMBER> due relatively rapid mutation frequency doléansjordheim et al <NUMBER> resistant strains already reported lewin et al <NUMBER>a would appear zidovudine suitable use combination indeed zidovudine tested various associations antibiotics different class lewin et al <NUMBER>b mascellino et al <NUMBER> recent article checkerboard analysis colistin showed synergistic activity <NUMBER> extended spectrum ßlactamases esbl e coli <NUMBER> esbl k pneumoniae <NUMBER> ndm<NUMBER> producing strains <NUMBER> colistin resistant mcr<NUMBER> e coli bactericidal combination activity colistin improved could reduce dose colistin better effect patented <NUMBER> hu coates <NUMBER> enrolled phase <NUMBER> clinical trial results showed association bactericidal activity plasma concentration mcr<NUMBER> positive strains well tolerated healthy volunteers involved study loose et al <NUMBER> human studies undertaken confirm results confirm azt recovery therapy mdr bacteria thus help clinicians avoid therapeutic impasses finally order anticipate emergence resistance bacteria molecules significant advantage used alone focusing multiple targets thus eradicating infection quickly possible finding positive response new use sufficiently meet criteria efficacy safety pharmacodynamics nontoxicity combination studies another drug may considered order use effectively drug combinations consist association two drugs order enhance efficacy therapeutic strategy increase chances clinical applications broadens spectrum activity useful antibiotics example serious infections requiring urgent effective treatment zheng et al <NUMBER> use two drugs impact different targets increasing impairment microbial function reducing risk resistance emergence zheng et al <NUMBER> main goal drug association produce synergistic effect effect produced combination greater achieved drugs used alone moreover one compound low activity another potentiate increase reduces concentration individual molecule therefore used lower doses real advantage one knows toxicity certain drugs sun et al <NUMBER>a zheng et al <NUMBER> sun et al showed use drug combinations reduced toxicity increased activity compared single therapy cytotoxicity proven allowing use drugs human medicine conceivable sun et al <NUMBER>a research drug repurposing combination known antibiotics carbapenem andor colistinresistant bacteria mainly conducted association polymyxins drugs table <NUMBER> niclosamide anthelmintic drug known active tapeworms seems interact negatively charged outer membrane colistinresistant strains leading synergistic effect colistin effect observed <NUMBER> strains <NUMBER> colistinresistant baumannii pmrb altered <NUMBER> colistinresistant k pneumoniae mgrb pmrb altered ayerbealgaba et al <NUMBER> colistin combination therapy selective estrogen receptor modulators serm tamoxifen raloxifen toremifen also exhibited good activity polymyxinresistant p aeruginosa k pneumoniae baumannii tested invitro concentrations could achievable human concentration hussein et al <NUMBER> schneider et al <NUMBER> <NUMBER> fluspirilene bay <NUMBER> shown promising results resensitizing resistant baumannii overcome colistin resistance cheng et al <NUMBER> regarding polymyxin b synergistic activity mitotane antineoplastic approved carcinoma treatment studied invitro <NUMBER> strains including carbapenem polymyxinresistant gnb tests also carried infections mouse burn wounds led promising result treatment type infection tran et al <NUMBER> using knowledge mechanisms action approach also tested channelblocking molecules indeed efflux pump inhibitors effect bacteria alone combined antibiotic demonstrated restoration activity effect less strong neuroleptics prochlorperazine chlorpromazine promazine associated meropenem appear effective mdr baumannii yang chua <NUMBER> otto et al showed potential efficacy <NUMBER> drugs including <NUMBER> antidepressants amitriptyline imipramine sertraline <NUMBER> antipsychotics chlorpromazine clonazepam haloperidol levopromazine polymyxin b <NUMBER> tested gnb displaying various resistance mechanisms including carbapenemases otto et al <NUMBER> sertraline chlorpromazine levopromazine synergism effect polymyxin b baumannii e coli k pneumoniae isolates among nonantibiotics spironolactone good efficacy e coli isolates showed nontoxic levels minimum concentration synergy polymyxin b otto et al <NUMBER> findings show nonantibiotics molecules effective combination studies need pursued develop association effective concentrations clinically tolerated otto et al <NUMBER> although natural compounds fdaapproved may also part process compound used another known property stilbene polyphenol resveratrol produced various plants grapes blueberries known various antioxidant properties chemopreventive activities bark nauclea pobeguinii cameroonian researchers found compound tested gnb mdr phenotypes active alone synergy streptomycin ciprofloxacin seukep et al <NUMBER> rossolini et al demonstrated <NUMBER> activity resveratrol antimicrobial agent combination colistin panel colistinresistant chromosomic plasmid resistance gnb cannatelli et al <NUMBER> resveratrol seems potentiate colistin activity thus makes possible restore action among different species resistance pathways thus another natural compound pterostilbene derived blueberries grapes known anticancer antiinflammatory antioxidant effects appears enhance polymyxin activity vitro vivo zhou et al <NUMBER> demonstrated synergistic figure <NUMBER> proceed dtr difficulttotreat resistant bacteria frontiers cellular infection microbiology wwwfrontiersinorg effects colistin polymyxin b mcr<NUMBER> positive strains <NUMBER>fold reducing mic polymyxin b <NUMBER>µgml zhou et al <NUMBER> pterostilbene could therefore affect mcr<NUMBER> function restore antibacterial activity polymyxin b resistant isolates probably safe human clinical practice possibly exerting selective pressure associated current atb therefore considered good candidate drug repurposing zhou et al <NUMBER> lastly eugenol phenylpropanoid present essential oil many plants thirteen animal e coli strains colistin resistance subjected mic time kill checkerboard assays evaluate combination colistin eugenol observed mcr<NUMBER> gene expression regulated eugenol suggested possible binding eugenol mcr<NUMBER> protein molecules still tested vitro clinical trials none yet received new indication mdr infection treatment however research drug repurposing gaining new dynamism refer number annual publications recent years figure <NUMBER> conclusion review therefore addresses two main aspects emerging drug repurposing strategy resistance lastline antibiotics carbapenems colistin new economic model considered antibiotic development industries seem interested new strategy zheng et al <NUMBER> indeed antibiotics part chronic treatment strategies could economically attractive conly johnston <NUMBER> disinterest antibiotics research reflected absence programs future developments major pharmaceutical companies spellberg et al <NUMBER> startups small companies hand see interest taking back antibiotics failed clinical phases example believe different drug development strategies require many benefits cover costs compared multinational pharmaceutical companies fernandes martens <NUMBER> however phase <NUMBER> clinical trials new repurposed drugs remain expensive estimated <NUMBER> million <NUMBER> million usd azvolinsky <NUMBER> budget work favor small firms question treat bacterial resistance one answer found future offers us new possibilities various strategies considered treatment using fecal microbiota davido et al <NUMBER> antimicrobial peptides hashemi et al <NUMBER> bacteriophages parmar et al <NUMBER> streptomyces sp present alkaline soil ireland spotlight recently inhibit growth mdr bacteria terra et al <NUMBER> reminds flemming discovery additionally discovery studies crisprcase<NUMBER> system may suggest may ultimate weapon fight infectious diseases thus control antibiotic resistance doerflinger et al <NUMBER> question drug repurposing remains rather wide although seems better solution drug combinations also lead adverse interactions first toxic side effects increased concerning compound galenic physicochemical interactions differences stability solubility conservation result combination two molecules making incompatible formulation becomes complicated sun et al <NUMBER>a hand must change vision drug belongs one box clinicians may difficulty understanding biologist recommends use anticancer antiinflammatory drug treat cystic fibrosis patients bacteremia rather last resort antibiotic always used communication sense remains essential health professionals clinical studies prove activities critical however current knowledge drug repurposing antibacterial agents problematic find alternative therapeutic situations screening nonantibiotics à la carte way issue figure <NUMBER> area personalized medicine could imagine personalized antibiotic susceptibility testing case infection caused highly resistant bacterium lastline antibiotics tested appear insufficient successfully treat patient testing nonantibiotic drugs potentially active pathogen alone combination antibiotics could help clinicians use drugs previously reported kadri et al difficulttothreat bacteria refer bacteria resistant firstline antibiotics represents less <NUMBER> isolates resistant secondline antibiotics even rare kadri et al <NUMBER> solution combined monitoring serum levels adverse events dialysis nephrotoxic drug rolain baquero <NUMBER> could offer great potential treating patient mdr bacterium problem remains able routinely test large panel molecules automated reproducible expensive way lp sb jmr drafted revised manuscript authors read approved final manuscript work supported french government ≪investissements davenir≫ investments future program managed agence nationale de la recherche anr fr national agency research reference méditerranée infection <NUMBER>iahu<NUMBER> work supported région provencealpescôte dazur european funding feder primi secret covid<NUMBER> caught global public health community surprise number laboratoryconfirmed human cases surpassing <NUMBER> mark late march <NUMBER> leading declaring pandemic efforts made toward prevention andor containment <NUMBER> outbreak evident contingency measures experimental therapeutics must urgently sought average cost de novo drug development reportedly <NUMBER> billion usd viable strategies discover potential candidate drugs combat severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> take snapshot look strategy drug repurposing also known drug reprofiling repositioning promises identify antiviral agents novel coronavirus disease timecritical fashion also offer perspective antiviral combinations double hit effect may offer best chance success clinical translatability broadspectrum antiviral agents bsaas deemed safeinman testing early phase clinical trials touted good drug repurposing candidates <NUMBER> andersen et al recently summarized <NUMBER> potential candidates covid<NUMBER> highly accessible database <NUMBER> experimental investigational approved agents <NUMBER> conceptually bsaas take advantage promiscuity viral replicative mechanisms host interactions target two viral families <NUMBER> following covid<NUMBER> outbreak december <NUMBER> existing bsaas rapidly introduced clinical trials spanning phases ii though iv umifenovir membrane fusion inhibitor targeting viral entry lopinavirritonavir drug combination targeting viral protease approved indications influenza hiv currently considered different combinations phase iv clinical trial pneumonia associated covid<NUMBER> clinicaltrialsgov id nct<NUMBER> <NUMBER> phase iii level remdesivir viral rnadependent rna polymerase inhibitor investigation mild moderate sarscov<NUMBER> clinicaltrialsgov identifier nct<NUMBER> <NUMBER> remdesivir activity preclinical studies species coronaviridae implicated sarscov middle east respiratory syndrome merscov <NUMBER> notably already studied randomized controlled trial ebola virus disease demonstrating antiviral effect <NUMBER> phase iii agents evaluated combination therapy viral pneumonia interestingly include antimalarial hydroxychloroquine based promising vitro data clinicaltrialsgov identifier nct<NUMBER> <NUMBER> chloroquine addition immunomodulating properties shown antiviral activity entry postentry stages sarscov<NUMBER> infection enhance antiviral activity remdesivir potentially serve synergizer bsaas <NUMBER> early stages viral rna polymerase inhibitor favipiravir combination also phase ii clinical trial novel coronavirusassociated pneumonia chinese clinical trial registry identifier chictr<NUMBER> <NUMBER> finally preclinical studies ribavirin ribonucleic analog shown vitro activity sarscov<NUMBER> <NUMBER> one limitation phenotypic screens low potency hit compounds single agents maximal tolerated dose often subtherapeutic new indications sought <NUMBER> one way circumvent issue evaluate two drugs acting different cellular signaling pathways involving viral replication minimal redundancy another strategy highthroughput screening compound libraries synergistic combinations hostvirus interactome level emerging reemerging infectious diseases may allow researchers narrow spectrum individual antimicrobials <NUMBER> <NUMBER> <NUMBER> strategies promise address oftenweak activity bsaas improving efficacy potentiating dose reductions reducing duration cost drug development pipeline lowering toxicity minimizing emergence secondary resistance notion determine effectiveness drug repurposing strategy whether agents compare favorably virusspecific vaccines small molecules options traditionally considered gold standards modern drug development one extrapolate experience precision oncology targeted cancer therapies immunotherapeutics made major gains cancer broadspectrum strategy fundamental flaws importantly lack specificity bsaas may become implicated emergence drug resistance virulent strains example nonstructural protein nsp<NUMBER>exon together cofactor nsp<NUMBER> coronaviridae found repair nucleotide mismatches caused nucleoside analogs ribavirin thus potentially negating antiviral effect bsaas <NUMBER> elegantly demonstrated ferron et al nsp<NUMBER>exon sarscov forms part highly flexible complex multienzymatic properties likely facilitating compensated low fidelity replication viable strategies circumvent remarkable innate ability coronaviridae proofread rna maintain genomic integrity allowing degree evolutionary freedom mutate highthroughput screening come rescue possibilities include compounds affinity toward nsp<NUMBER>exon catalytic subunit allosteric effects critical sites conserved residues causing conformational change entire viral rna repair complex therefore hunt identify inhibitor viral nuclease drug repurposing compete structurebased design preventativetherapeutic vaccines small molecules efficacy offtarget toxicity turfs cov spike glycoprotein used sarscov<NUMBER> atomic resolution human ace<NUMBER> enzyme port cellular entry determined discoveries hoped spur rapid efforts develop vaccines antibodies however processes typically take decade hindered potential blunted antigenicity epitopes due genetic drift virus <NUMBER> <NUMBER> <NUMBER> another important dimension quest repurposed drugs involves patent protection issues current national andor international regulations <NUMBER> global health emergency magnitude calls bold international response governmental political levels therefore regulatory community must act fast minimize financial hurdles implicating private industry update guidelines drug licensure repurposing necessary escape us vital behindthescene act efforts underway seek new indications existing compounds urgently launched clinical trials worldwide investigational medicinal products current covid<NUMBER> outbreak read within weeks months anticipate notion drug repurposing emerging viral diseases scrutinized based results deeper level battle covid<NUMBER> soul concept new antimicrobials clinical indications one drug one virus versus one drug multiple viruses multiple drugs one virus contenders <NUMBER> <NUMBER> authors relevant affiliations financial involvement organization entity financial interest financial conflict subject matter materials discussed manuscript includes employment consultancies honoraria stock ownership options expert testimony grants patents received pending royalties writing assistance utilized production manuscript work licensed attributionnoncommercialnoderivatives <NUMBER> unported license view copy license visit httpcreativecommonsorglicensesbyncnd<NUMBER> covid‐<NUMBER> first surfaced china already emerged global pandemic total <NUMBER> cases including <NUMBER> deaths june <NUMBER> <NUMBER> worldometersinfocoronavirus covid‐<NUMBER> similar previous outbreaks sars middle east respiratory syndrome mers share common signs symptoms sore throat persistent high fever pneumonia common pathologies immune dysfunction multi‐organ failure andersen rambaut lipkin holmes garry <NUMBER> forster forster renfrew forster <NUMBER> like coronaviruses sars‐cov‐<NUMBER> possesses several structural nonstructural proteins implicated crucial cell functions ashour elkhatib rahman elshabrawy <NUMBER> structural proteins spike glycoproteins facilitate attachment virus host cells helicase main protease mpro papain‐like protease plpro rna dependent rna polymerase rdrp among nonstructural proteins critical viral replication forster et al <NUMBER> siu et al <NUMBER> significant roles viral life cycle proteins present promising pharmacological targets developing potential therapeutics sars‐cov‐<NUMBER> infection target‐based drug discovery tdd one successful efficient strategies find remedy disease estimated <NUMBER> first‐class drugs approved united states food drug administration <NUMBER> <NUMBER> based tdd croston <NUMBER> eder sedrani wiesmann <NUMBER> tdd restricted discovery small molecules drug targets also extends protein biologics genetic materials antibodies advantages target‐based strategies phenotypic approaches include high throughput convenient less expensive croston <NUMBER> zheng thorne mckew <NUMBER> molecular pharmacology biochemistry genomics computational modeling structural biology system biology mutational analysis usually employed carry tdd complete understanding drug candidate also ensuring effective therapeutics upcoming days croston <NUMBER> although research communities responded rapidly still vaccine effective therapeutics covid‐<NUMBER> harrison <NUMBER> existing antiviral drugs viral diseases including remdesivir considered repurposing medicine treat covid‐<NUMBER> patients resulted mixed outcomes gautret et al <NUMBER> molina et al <NUMBER> therefore crucial focus alternative rational strategies development urgent therapeutics control ongoing pandemic developing new therapeutic drugs vaccines requires proper understanding disease immune response pattern infection pathogenesis virus accelerate effort present scoping review summarizing potential drug targets therapeutics trials critically analyzing relevant published literature field review would provide concrete evidence concerning drug targets previous use drugs early findings possible drug mechanisms moreover review would provide insightful evidence future sars‐cov‐<NUMBER> research might support researchers discover potential remedy sars‐cov‐<NUMBER> member betacoronavirus genera possesses <NUMBER> nonstructural proteins nsp four structural proteins spike envelope e membrane nucleocapsid n proteins n protein clamps ribonucleic acid rna genome whereas e proteins together shape viral envelope glycoprotein spikes render coronaviruses form unique crown‐like appearance figure <NUMBER>a anthony et al <NUMBER> ashour et al <NUMBER> addition knowledge structural makeup critical understanding life cycle pathogenesis sars‐cov general essential discover potential vaccines therapeutics prevent treat sars‐cov sars‐like coronavirus sl‐cov including sars‐cov‐<NUMBER> infections future crucial steps sars‐cov life cycle therefore illustrated figure <NUMBER>b also highlighted belowreceptor recognition first step virus entry host cell occurs recognition receptor spike protein virus first receptor‐binding domain rbd protein attaches host cell receptor angiotensin‐converting enzyme <NUMBER> ace<NUMBER> protein proteolytically cleaved type ii transmembrane protease tmprss<NUMBER> resulting two subunits called s<NUMBER> s<NUMBER> s<NUMBER> crucial membrane fusion virus entry glowacka et al <NUMBER> holmes <NUMBER> li <NUMBER> li et al <NUMBER> wan shang graham baric li <NUMBER> wong li moore choe farzan <NUMBER> splitting protein proteases essential viral entry host cells ph‐dependent manner simmons et al <NUMBER> yang shen <NUMBER>after uncoating covs release rna <NUMBER>′ methylated cap <NUMBER>′ polyadenylated tail host cell cytoplasm replication fehr perlman <NUMBER> kim et al <NUMBER> li <NUMBER>genomic rna cov acts mrna translation replicase polyproteins <NUMBER>a pp<NUMBER>a <NUMBER>ab pp<NUMBER>ab using translation machinery host cell polyprotein split effector proteins viral proteinases <NUMBER>clpro plpro resulting number nsps including rdrp helicase form replicase–transcriptase complex báez‐santos st john mesecar <NUMBER> fehr perlman <NUMBER> gorbalenya et al <NUMBER> kim et al <NUMBER> ratia et al <NUMBER> sola almazán zúñiga enjuanes <NUMBER>rdrp helicase localize double‐membrane vesicles produce subgenomic rna proteins structural proteins produced translation time full‐length positive‐strand rna synthesized genomic rna fehr perlman <NUMBER> c j gordon et al <NUMBER> sola et al <NUMBER> kim et al <NUMBER>nsp <NUMBER> <NUMBER> <NUMBER> responsible anchoring coronavirus replication transcription complex recruitment intracellular endoplasmic reticulum er membrane form double‐membrane vesicles fehr perlman <NUMBER> sola et al <NUMBER> stertz et al <NUMBER>viral nucleocapsids assembled genomic rna n protein cytoplasm followed budding lumen ergic endoplasmic reticulum–golgi intermediate compartment sola et al <NUMBER> stertz et al <NUMBER>the virions released cell exocytosis sola et al <NUMBER> stertz et al <NUMBER> two large overlapping replicase polyproteins pp<NUMBER>a pp<NUMBER>ab encoded two linked ribosomal frameshift hydrolyzed extensive proteolytic action viral proteases fehr perlman <NUMBER> graham sparks eckerle sims denison <NUMBER> pillaiyar manickam namasivayam hayashi jung <NUMBER> one crucial viral proteases mpro also known <NUMBER>c‐like proteinase nsp<NUMBER> homodimeric cysteine protease belonging coronavirus polyprotein group fan et al <NUMBER> automatic cleavage polyproteins leads generation mpro cleaves large polyprotein <NUMBER>ab <NUMBER> cleavage sites generate nsps identification cleaving sequence sites leu‐gln↓ser ala gly release nsp<NUMBER>–nsp<NUMBER> pillaiyar et al <NUMBER> yang et al <NUMBER> zhang penninger li zhong slutsky <NUMBER> mpro directly mediates maturation nsps critical initiation sars‐cov‐<NUMBER> replication cycle could therefore potential druggable target zhang wu zhang <NUMBER> instance pyridone‐containing α‐ketoamides inhibited mpro activity showing early promise development anti‐viral drugs zhang et al <NUMBER> moreover hundred pdb structures sars‐cov‐<NUMBER> mpro already deposited rcsb database httpswwwrcsborg added regularly structures elucidated cryo‐electron microscopy nmr x‐ray crystallography even high‐throughput network‐based inhibitor screening direct ligand‐based study jin et al <NUMBER> vuong et al <NUMBER> ligand‐based inhibitors screening leads determination complexed crystal structure sars‐cov‐<NUMBER> mpro approach aids structure‐assisted drug design high‐throughput screening potential inhibitors jin et al <NUMBER> inhibitors targeting sars‐cov‐<NUMBER> mpro virus‐specific therefore interfere host cell proteases bzówka et al <NUMBER> proteolytic enzymes play essential role viral replication hence could target choice development effective therapy viral infections plpro also termed nsp <NUMBER> extensively studied coronaviruses báez‐santos et al <NUMBER> lei et al <NUMBER> ratia et al <NUMBER> efficacy plpro inhibitors chloroquine formoterol investigated recently treatment covid‐<NUMBER> rimanshee amit vishal mukesh <NUMBER> wu et al <NUMBER> plpro cleaves n‐terminal part polyproteins producing mature nsp<NUMBER> nsp<NUMBER> nsp<NUMBER> process crucial viral replication cleavage specificity plpro corresponds pattern rklrkgg↓x moreover enzyme acts deubiquitinase removes poly ubiquitin units proteins tagged barretto et al <NUMBER> lindner et al <NUMBER> deubiquitinase activity plpro interferes nuclear import interferon‐regulatory factor <NUMBER> phosphorylation thereby preventing production type‐i interferons ifn‐α ifn‐β infected host cell also helps peptide substrate recognition barretto et al <NUMBER> clementz et al <NUMBER> devaraj et al <NUMBER> frieman ratia johnston mesecar baric <NUMBER> ratia et al <NUMBER> additionally plpro clears ubiquitin interferon‐sensitive gene <NUMBER> host‐cell proteins mechanism aids coronaviruses evade host innate immune responses finally plpro reported interfere nuclear factor κb pathway assists sars‐cov counteract innate immune response infected cells clementz et al <NUMBER> therefore pharmacological targeting plpro developing plpro inhibitors might constitute potential therapeutic strategy would advantageous preventing viral replication also ensuring normal regulation signal networks infected cells rdrp also termed nsp <NUMBER> pivotal enzyme rna viruses including coronavirus catalyzes replication rna rna template probably assistance nsp<NUMBER> nsp<NUMBER> co‐factors guo huang lin lv <NUMBER> kirchdoerfer ward <NUMBER> subissi et al <NUMBER> venkataraman prasad selvarajan <NUMBER> protein complex consisting nsp <NUMBER> nsp <NUMBER> nsp <NUMBER> sars‐cov‐<NUMBER> related sars‐cov root‐mean‐square deviation value <NUMBER> <NUMBER> cɑ atoms gao et al <NUMBER> rdrp protein sars‐cov‐<NUMBER> sars‐cov share <NUMBER> amino acid sequence identity <NUMBER> sequence identity genomic rna level morse lalonde xu liu <NUMBER> rdrp sars‐cov‐<NUMBER> contains large deep groove active site polymerization rna residues show variations sars‐cov‐<NUMBER> sars‐cov rdrps mostly distal active site high sequence conservation structural homogeneity rdrp coronaviruses suggest nucleotide analogs developed sars‐cov rdrp likely effective sars‐cov‐<NUMBER> rdrp morse et al <NUMBER> previously published literature provides convincing evidence rdrp could druggable target development potent therapy sars‐cov‐<NUMBER> infection kandeel ibrahim fayez al‐nazawi <NUMBER> lung et al <NUMBER> includes nucleotide analog targeting rdrp deval jin chuang kao <NUMBER> gordon et al <NUMBER> stephen lin <NUMBER> tchesnokov feng porter götte <NUMBER> remdesivir gs‐<NUMBER> prodrug adenosine analog incorporated nascent viral rna subsequently inhibit rdrp siegel et al <NUMBER> furthermore remdesivir showed high considerable efficacy controlling sars‐cov‐<NUMBER> infection recent vitro study wang et al <NUMBER> β‐d‐n<NUMBER>‐hydroxycytidine ribonucleoside analog also inhibits sars‐cov‐<NUMBER> replication evidenced reducing viral genomic rna sheahan et al <NUMBER> sars‐cov helicase nsp<NUMBER> one <NUMBER> nsps generated proteolytic cleavage two large polyproteins pp<NUMBER>a pp<NUMBER>ab helicase one components replicase–transcriptase complex plays significant roles life cycle sars‐cov marra et al <NUMBER> subissi et al <NUMBER> constitutes basis targeting enzyme development potential antiviral agent helicases motor proteins unwind double‐stranded nucleic acids two single‐strands replication adedeji et al <NUMBER> shum tanner <NUMBER> moreover nsp<NUMBER> n‐terminus carries <NUMBER> cysteines <NUMBER> positions highly conserved assumed possess binuclear zn<NUMBER>‐binding cluster seybert et al <NUMBER> importantly antiviral compound bananin adamantane derivative reported inhibit helicase activities thereby preventing replication sars‐cov tanner et al <NUMBER> also evaluated sars‐cov‐<NUMBER> spike protein giving crown‐like appearance virion surface render diverse molecular actions usually mediates coronavirus entry specific host belouzard chu whittaker <NUMBER> spike protein sars‐cov sars‐cov‐<NUMBER> shares ∼<NUMBER> amino acid identity however sars‐cov‐<NUMBER> protein binds <NUMBER> times strongly sars‐cov protein common host cell receptor du et al <NUMBER> hoffmann et al <NUMBER> li <NUMBER> tortorici et al <NUMBER> wrapp et al <NUMBER> heavily glycosylated spike protein possesses large ectodomain single‐pass transmembrane anchor short intracellular tail li <NUMBER> ectodomain consists receptor‐binding subunit s<NUMBER> membrane‐fusion subunit s<NUMBER> broer boson spaan cosset corver <NUMBER> li <NUMBER> virus entry s<NUMBER> subunit recognizes interacts host receptors conformational changes s<NUMBER> subunit assist fusion viral envelope protein host cell membrane du et al <NUMBER> li <NUMBER> tortorici et al <NUMBER> s<NUMBER> subunit two major domains n‐terminal domain ntd c‐terminal domain ctd depending coronavirus type either ctd ntd function rbd bind diverse proteins sugars li <NUMBER> notably sars‐cov mers‐cov utilize ctd bind receptors kubo yamada taguchi <NUMBER> li et al <NUMBER> ou et al <NUMBER> n wang et al <NUMBER> proteases found cellular environment cause cleavage proteins ensures viral fusion sars‐cov‐<NUMBER> possesses furin cleavage site s<NUMBER> s<NUMBER> subunit permits efficient cleavage proteases including furin determines viral infectivity host range andersen et al <NUMBER> coutard et al <NUMBER> ou et al <NUMBER> walls et al <NUMBER> protein sars‐cov‐<NUMBER> contains furin‐like cleavage site absent coronaviruses clade coutard et al <NUMBER> protein also activates immune response host cell toward coronaviruses dosch mahajan collins <NUMBER> walls et al <NUMBER> since protein coronaviruses reported vital associations initial receptor binding critical membrane fusion steps could putative targets blocking infection prior studies revealed peptide inhibitors sars‐cov‐<NUMBER> protein provide promising avenues sars‐cov‐<NUMBER> treatment blocking protein interaction ace<NUMBER> thus efficiently preclude virus entry human cells moreover inhibitors used inhaled therapeutics preventing virus activation lungs ou et al <NUMBER> walls et al <NUMBER> recently wan et al <NUMBER> tai et al <NUMBER> sequenced characterized rbd sars‐cov‐<NUMBER> including receptor‐binding motif rbm directly associates ace<NUMBER> also identified important amino acid residues sars‐cov‐<NUMBER> rbm especially gln<NUMBER> facilitates interactions human ace<NUMBER> reveals high capacity sars‐cov‐<NUMBER> human infection moreover crucial amino acid residues sars‐cov‐<NUMBER> rbm particularly asn<NUMBER> contributed sars‐cov‐<NUMBER> gaining ability human‐to‐human transmission tai et al <NUMBER> wan et al <NUMBER> also found five important amino acids rbd conserved pangolin‐cov sars‐cov‐<NUMBER> zhang lin et al <NUMBER> findings would give valuable information finding antigens improved sensitivity sars‐cov‐<NUMBER> serological detection vaccine development e protein coronavirus short polypeptide integral membrane protein involved different steps life cycle virus assembly budding envelope formation pathogenesis masters <NUMBER> reported absence inactivation e protein could impact either virion morphology tropism khattari et al <NUMBER> pervushin et al <NUMBER> e proteins coronaviruses shown cation‐selective ion channel activity thus membrane permeabilizing property wilson mckinlay gage ewart <NUMBER> sars‐covs lacking e protein show lower viral titer immature inefficient progenies kuo hurst masters <NUMBER> thereby recommending e protein suitable drug target prevent viral replication infection ace<NUMBER> type membrane protein expressed heart lungs kidneys intestine n‐terminal peptidase domain pd c terminal collectrin‐like domain cld usually found full‐length ace<NUMBER> donoghue et al <NUMBER> h zhang et al <NUMBER> recent report demonstrated ectodomain sars‐cov‐<NUMBER>s protein interacts pd ace<NUMBER> wrapp et al <NUMBER> like sars‐cov sars‐cov‐<NUMBER> virus exploits ace<NUMBER> receptor gain entry host cells human cell‐derived proteases cleave sars‐cov‐<NUMBER> protein s<NUMBER> s<NUMBER> s<NUMBER> initially interacts receptor molecule ace<NUMBER> fragment s<NUMBER> leads membrane fusion cleavage human cell surface serine protease tmprss<NUMBER> hoffmann et al <NUMBER> findings provide valuable insights molecular basis coronavirus recognition infection protein sars‐cov‐<NUMBER> approximately <NUMBER>‐ <NUMBER>‐fold likely bind human ace<NUMBER> protein protein sars‐cov wrapp et al <NUMBER> increase affinity might facilitated favorable person‐to‐person transmission sars‐cov‐<NUMBER> infection sars‐cov hoffmann et al <NUMBER> ace<NUMBER> thus act unique adhesion protein molecule sars‐cov‐<NUMBER> infection promising drug target prevention sars‐cov‐<NUMBER> infection disrupting interaction spike protein ace<NUMBER> might therefore possible way developing drug sars‐cov‐<NUMBER> phase <NUMBER> phase <NUMBER> clinical trial human recombinant soluble ace<NUMBER> hrsace<NUMBER> <NUMBER>‐mer peptide fragment carried recently suggested use treatment covid‐<NUMBER> khan et al <NUMBER> zhang penninger et al <NUMBER> sars‐cov‐<NUMBER> infected vero‐e<NUMBER> lines incubated hrsace<NUMBER> found hrsace<NUMBER> preclude early entrance sars‐cov‐<NUMBER> infections host cells perhaps binding rbd protein monteil et al <NUMBER> although ace<NUMBER> available vascular endothelial cells organs lungs susceptible sars‐cov infection hamming et al <NUMBER> phenomenon strengthens possibility factors associated actual pathogenesis sars‐cov‐<NUMBER> one factor accounts viral entry host cells tmprss<NUMBER> well‐known human alveolar airway protease shulla et al <NUMBER> tmprss<NUMBER>a tmprss<NUMBER> related protein found cleave sars‐cov protein moderately accelerate viral infections kam et al <NUMBER> tmprss<NUMBER> probably facilitates viral pathogenesis transmission two ways first tmprss<NUMBER> might activate sars‐cov protein virus–cell cell–cell fusion second tmprss<NUMBER> might protect viral recognition different neutralizing antibodies host glowacka et al <NUMBER> evidence suggests entry sars‐cov‐<NUMBER> host cells requires ace<NUMBER> tmprss<NUMBER> hoffmann et al <NUMBER> thereby suggesting tmprss<NUMBER> might potential drug target matsuyama et al <NUMBER> showed tmprss<NUMBER>‐expressing veroe<NUMBER> cell line highly susceptible sars‐cov‐<NUMBER> infection displaying critical role tmprss<NUMBER> pathogenesis viral disease previously bromhexine hydrochloride fda approved component mucolytic cough suppressants showed specific inhibition tmprss<NUMBER> adverse effect prostate cancer patients reduction progression metastasis lucas et al <NUMBER> bromhexine hydrochloride might repurposed tmprss<NUMBER> inhibitor preventing sars‐cov‐<NUMBER> infection well hoffmann et al <NUMBER> sars‐cov‐<NUMBER> causes imbalanced exuberant immune responses termed cytokine release syndrome cytokine storm triggers lung impairment reduces survival infected patients pedersen ho <NUMBER> tisoncik et al <NUMBER> inflammatory cytokines usually produced different macrophages associated cytokine storm luo et al <NUMBER> pedersen ho <NUMBER> sars‐cov‐<NUMBER> significantly increases levels proinflammatory cytokines il‐<NUMBER> il‐<NUMBER> tnfα infected patients channappanavar et al <NUMBER> diao et al <NUMBER> nikolich‐zugich et al <NUMBER> furthermore sars‐cov‐<NUMBER> induced activation cluster differentiation four positive cd<NUMBER> cells stimulate generation helper cells secrete interleukin il‐<NUMBER> granulocyte‐macrophage colony‐stimulating factor gm‐csf gm‐csf triggers monocytes release il‐<NUMBER> factors resulting generation cytokine storm cytokine storm results acute respiratory distress syndrome multiple organ failure even death chen zhang et al <NUMBER>a zhou et al <NUMBER> targeted immunomodulation decrease cytokine storm might feasible option reduce pulmonary inflammation mortality since antiviral candidates may enough combat cytokine storm complications respiratory tract identifying effective targets immune therapeutics along antiviral agents could potential strategy preliminary results study suggest hydroxychloroquine might anti‐cytokine storm properties yao et al <NUMBER> additionally lenziluman reported protective cytokine storm neurotoxicity mouse models furthermore lenzilumab anti‐gm‐csf monoclonal antibody considered viable therapeutic option covid‐<NUMBER> patients sterner et al <NUMBER> innate immune response without association cd<NUMBER> cells antibodies capable controlling sars‐cov frieman heise baric <NUMBER> nk cells part innate lymphocyte subsets mediate anti‐tumor antiviral responses therefore potential clinical use abel yang thakar malarkannan <NUMBER> previous studies showed nk cells showed significant roles mitigating sars‐cov chen et al <NUMBER> national research project sars nsps <NUMBER> recent epidemiological studies showed sars‐cov‐<NUMBER> infection children less frequent lethal compared adults might due increased lymphocyte count especially nk cells trained immunity children cristiani et al <NUMBER> therefore approaches focused valorizing innate antiviral immune responses possible way find remedy sars‐cov‐<NUMBER> arabinoxylan treatment resulted upregulation nk cells neuroblastoma vitro vivo studies pérez‐martínez et al <NUMBER> arabinoxylan therefore possesses potentiality treatment covid‐<NUMBER> patients however clinical trials needed determine effectivity autophagy natural mechanism cell ensures maintenance cellular homeostasis lysosomal catabolic action leading degradation recycling intracellular endogenous macromolecules abnormal proteins damaged organelles exogenous viruses bacteria particles galluzzi et al <NUMBER> levine klionsky <NUMBER> viruses developed strategies escape autophagic degradation use host autophagy machinery self‐replication dong dong levine <NUMBER> significance autophagy process therapeutic development sars‐cov mers‐cov sars‐cov‐<NUMBER> reviewed yang shen <NUMBER> recent study showed mers‐cov halts fusion autophagosomes lysosomes whereas inhibitors like s‐phase kinase‐associated protein <NUMBER> induced autophagy leads reduction replication mers‐cov gassen et al <NUMBER> thus seems considerable relationship exists autophagy machinery coronavirus infections therefore relationships need elucidated sars‐cov‐<NUMBER> understand disease prognosis also enhance autophagocytosis possible treatment corridor virus entry crucial step pathogenesis covid‐<NUMBER> provide comprehensive list repurposed drugschemicals reported block viral entry via different mechanisms table <NUMBER> monotherapy combined therapy drugs preclinical phase <NUMBER> phase <NUMBER> phase <NUMBER> clinical trials hoffmann et al <NUMBER> showed camostat mesylate interferes tmprss<NUMBER>‐mediated viral entry thus reduces severity covid‐<NUMBER> disease similarly arbidol antiviral inhibits hemagglutinin influenza virus blocks entry cell recommended use influenza viruses arboviruses kadam wilson <NUMBER> wang et al <NUMBER> open prospectiveretrospective randomized controlled cohort study underway tongji hospital china study safety efficacy arbidol hydrochloride arbidol hydrochloride combined interferon atomization humans table <NUMBER> study interventional subjects given standard supportive therapy arbidol hydrochloride <NUMBER> g three times day arbidol hydrochloride combined interferon pegifn‐α‐<NUMBER>b atomization <NUMBER> g nct<NUMBER> trials arbidol hydrochloride along drugs also undergoing ruijin hospital china tongji hospital china nct<NUMBER> nct<NUMBER> moreover recent study demonstrated fusion protein made rhace<NUMBER> fc fragment crystalization region human immunoglobulin igg<NUMBER> shows high‐affinity binding receptor‐binding domain sars‐cov‐<NUMBER> potently neutralized sars‐cov‐<NUMBER> vitro provides basis drug development lei et al <NUMBER> monteil et al <NUMBER> fusion protein considered studies animals humans see effectiveness moreover protein‐specific monoclonal antibodies generated neutralize spike protein may lead inhibition viral entry recently tian et al <NUMBER> identified monoclonal antibody cr<NUMBER> binds rbd spike protein sars‐cov‐<NUMBER> vitro cr<NUMBER> therefore might potential drug candidate sars‐cov‐<NUMBER> infection despite role ace<NUMBER> viral entry targeting interruption ace<NUMBER> may best strategy prevent sars‐cov‐<NUMBER> guo et al <NUMBER> ace<NUMBER> also maintains blood pressure entry inhibition strategy must pathogen‐specific rather host‐specific studies carried discover potential entry inhibitors block viral entry without disturbing maintenance blood pressure potential therapeutics block virus entry target cells summarized tables <NUMBER> <NUMBER> already discussed role endosomallysosomal acidification role acidic ph‐dependent proteases virus life cycle yang shen <NUMBER> inhibition pathway might potential therapeutic strategy several therapeutics chloroquine cq well‐studied lysosomotropic antimalarial drug derivatives hydroxychloroquine colchicine would option blocking target cq effectively blocks viral progression raising endosomal ph needed membrane fusion host cell viral candidates releasing rna endosomes savarino boelaert cassone majori cauda <NUMBER> although cq hydroxychloroquine found effective sars‐cov‐<NUMBER> gautret et al <NUMBER> wang et al <NUMBER> several recent evidence claimed unprecedented effects recent study reported hydroxychloroquine either alone combination azithromycin showed positive outcome patients covid‐<NUMBER> magagnoli et al <NUMBER> instead linked increased overall mortality <NUMBER> hydroxychloroquine <NUMBER> hydroxychloroquine plus azithromycin versus <NUMBER> control group multinational observational real‐world study patients covid‐<NUMBER> also claimed hydroxychloroquine chloroquine showed evidence benefit rather associated increase risk ventricular arrhythmias greater hazard in‐hospital death covid‐<NUMBER> mehra desai ruschitzka patel <NUMBER> moreover recent systematic review found difference hydroxychloroquine treated group untreated group covid‐<NUMBER> patients sarma et al <NUMBER> recently postponed clinical trials hydroxychloroquine due unexpected results previous trials however repurposed drug allowed re‐evaluation evidence points significance waiting final results ongoing prospective randomized controlled studies considering drugs therapeutic option covid‐<NUMBER> proteases crucial role many signaling pathways represent promising drug targets fora wide range diseases including viral diseases protease blockers currently phase <NUMBER> phase <NUMBER> phase <NUMBER> clinical trials potential drugs treating covid‐<NUMBER> tables <NUMBER> <NUMBER> asc<NUMBER>ritonavir lopinavirritonavir asc<NUMBER>f oseltamivir ritonavir oseltamivir protease inhibitor drug candidates inhibit <NUMBER>clpro prevent subsequent progression replication table <NUMBER> example monotherapy combination lopinavir ritonavir studied mers‐cov vitro animal model found effective chan et al <NUMBER> de wilde et al <NUMBER> studies showed combination lopinavir ritonavir ribavirin interferon alfa ifn‐α resulted survival mers‐patients viral clearance kim kee jung jang <NUMBER> investigators operating randomized open‐label trials evaluate compare efficacy safety lopinavir ritonavir covid‐<NUMBER> patients table <NUMBER> recent case report claimed <NUMBER>‐year‐old patient administered lopinavirritonavir showed significant reduction viral loads little coronavirus titers lim et al <NUMBER> recent clinical trial chictr<NUMBER> however showed lopinavir–ritonavir treatment caused benefit hospitalized patients severe covid‐<NUMBER> compared standard care cao et al <NUMBER> treatment lopinavir–ritonavir associated time clinical improvement mortality <NUMBER> days detectable viral rna gastrointestinal adverse events compared standard‐care group cao et al <NUMBER> contradictory yet promising findings highlight importance conducting clinical trials using drug therapeutic candidate rdrp vital enzyme viral replication machinery hence rdrp blockers could effective antiviral therapy sars‐cov‐<NUMBER> infection depending mechanism action rdrp inhibitors two types nucleoside nucleotide structural analogs mimic structure natural nucleoside triphosphate substrates could interact competitively active site rdrp polymerase b non‐nucleoside inhibitors allosteric inhibitors interact noncompetitive fashion substrates brown <NUMBER> velkov et al <NUMBER> favipiravir t‐<NUMBER> broad‐spectrum prodrug metabolized active ribofuranosyl triphosphate derivative selectively inhibits viral rdrp polymerase activity velkov et al <NUMBER> favipiravir shown inhibit replication respiratory syncytial virus also proven effective influenza japan delang abdelnabi neyts <NUMBER> furuta komeno nakamura <NUMBER> indicates might effective sars‐cov‐<NUMBER> multicenter randomized controlled clinical trial study <NUMBER> participants underway favipiravir combined tocilizumab treatment covid‐<NUMBER> peking university first hospital table <NUMBER> recently prospective randomized controlled open‐label multicenter trial chictr<NUMBER> involving adult covid‐<NUMBER> patients treated favipiravir versus arbidol showed favipiravir increased clinical recovery rate improved latency relief pyrexia cough along mild manageable adverse effects chen xiong bao shi <NUMBER> furthermore cai et al <NUMBER> studied effects favipiravir versus lopinavirritonavir treatment covid‐<NUMBER> two arms favipiravir interferon‐α versus lopinavirritonavir open‐label control study <NUMBER> patients registered control arm lopinavirritonavir <NUMBER> patients favipiravir arm favipiravir interferon‐α baseline characteristics compared two arms favipiravir arm showed significant improvement chest imaging associated faster viral clearance lower adverse events compared control arm cai et al <NUMBER> remdesivir adenosine nucleoside analog prodrug developed gilead sciences foster city ca ebola virus incorporates nascent viral rna chains resulting premature termination rna synthesis wang cao et al <NUMBER> monotherapy combination therapy remdesivir cq interferon‐beta ifn‐β halted sars‐cov‐<NUMBER> replication treated patients clinically recuperated sheahan et al <NUMBER> wang zhang et al <NUMBER> phase <NUMBER> randomized double‐blind placebo‐controlled multicenter study remdesivir hospitalized adult patients severe covid‐<NUMBER> completed nct<NUMBER> primary endpoint trial concluded patients covid‐<NUMBER> receiving remdesivir showed faster time clinical improvement numerically statistically significant compared patients receiving placebo group wang cao et al <NUMBER> moreover double‐blind randomized placebo‐controlled clinical trial nct<NUMBER> evidenced intravenous remdesivir efficacious compared placebo reducing time recovery lower respiratory tract infection beigel et al <NUMBER> recently fda approved emergency use remdesivir experimental drug hand ribavirin synthetic purine nucleoside derivative could interfere guanosine triphosphate formation hinders capping viral mrna thus inhibits viral rna‐dependent rna polymerase activity khalili zhu mak yan zhu <NUMBER> could used broad‐spectrum antiviral therapeutic agent already reported wide range dna rna viruses paramyxovirus influenza b hepatitis c respiratory syncytial virus parainfluenza hiv elfiky <NUMBER> khalili et al <NUMBER> tam lau hong <NUMBER> tan et al <NUMBER> several phases clinical trials undergoing study efficacy remdesivir ribavirin treatment sars‐cov‐<NUMBER> alone combination drugs table <NUMBER> khalili et al <NUMBER> inflammation obvious outcome sars‐cov‐<NUMBER> however effective therapeutics targeting inflammatory responses sars‐cov‐<NUMBER> approved date fu cheng wu <NUMBER> reviewed potential mechanism fc receptor fcr blockers intravenous immunoglobulin anti‐fc specific antibodies small molecules might therapeutic tool reducing sars‐cov‐<NUMBER> induced pulmonary inflammation moreover anti‐inflammatory drugs corticosteroids might also effectively alleviate early proinflammatory response reduce sars‐cov‐<NUMBER>‐induced inflammatory responses blocking fcr activation besides administration intravenous immunoglobulin fcr could effective urgent remedy pulmonary inflammation associated severe lung injury effectively block fcr activation approaches may also applied corticosteroids systemic anti‐inflammatory drugs shang zhao hu du cao <NUMBER> needs clinical trials study effectiveness sars‐cov‐<NUMBER> infection russell millar baillie <NUMBER> another potential option reducing inflammation siltuximab chimeric monoclonal antibody mab binds halts effect il‐<NUMBER> sarosiek shah munshi <NUMBER> chen et al <NUMBER> recently study covid‐<NUMBER> patients showed intravenous administration siltuximab improved clinical conditions <NUMBER> patients stabilized demonstrated clinically relevant changes <NUMBER> patients whereas condition deteriorated <NUMBER> patients gritti et al <NUMBER> results exhibit potential role siltuximab treating patients sars‐cov‐<NUMBER> infection gritti et al <NUMBER> furthermore observational case–control study <NUMBER> covid‐<NUMBER> patients serious respiratory complications ongoing italy determine effectivity siltuximab nct<NUMBER> another group researchers di giambenedetto et al <NUMBER> used tocilizumab humanized anti‐human interleukin‐<NUMBER> receptor antibody igg<NUMBER> subclass thwarting treating cytokine storm three patients covid‐<NUMBER> found promising results reduction fever c‐reactive proteins quick relief respiratory symptoms clinical trial undergoing test whether anti‐il<NUMBER> treatment effective reducing sars‐cov‐<NUMBER>‐induced cytokine storm improving lung function nct<NUMBER> therapeutics anti‐inflammatory immunomodulation property summarized table <NUMBER> vaccine ultimate hope prevent reduce spread covid‐<NUMBER> vaccine either prophylactic prevents future infection therapeutic used treat diseases cancer infectious diseases frazer <NUMBER> guo et al <NUMBER> whole pathogen either killed live‐attenuated parts pathogen nucleic acid proteins peptides used vaccines haque shah paul barua <NUMBER> shah md kawsar <NUMBER> whole virus vaccines widely studied showed protection influenza virus fiore bridges cox <NUMBER> human papillomavirus chickenpox virus liesegang <NUMBER> whereas subunit peptide‐based vaccines shown immunity vitro khan hossain rakib‐uz‐zaman morshed <NUMBER> animal studies islam clemens qadri <NUMBER> efforts develop vaccines sars‐cov mers‐cov tested animal models gao et al <NUMBER> kim et al <NUMBER> however benign operational vaccine available sars‐cov development vaccines sars‐cov sars outbreak <NUMBER>–<NUMBER> attempted greenough et al <NUMBER> roberts et al <NUMBER> tripp et al <NUMBER> however efforts result finding effective vaccines mers prevalence believed sars‐cov would provide foundation template developing vaccines mers‐cov infection jiang lu du <NUMBER> however one mers‐cov dna vaccine far completed phase <NUMBER> clinical trial yong ong yeap ho tan <NUMBER> several viral vectored‐mers‐cov vaccines progress yong et al <NUMBER> reviewed zumla chan azhar hui yuen <NUMBER> suitable vaccine sars‐cov‐<NUMBER> prevent spread current pandemic covid‐<NUMBER> save millions lives billions money currently different research groups around world working <NUMBER> candidate vaccines sars‐cov‐<NUMBER> based <NUMBER> inactivated weakened whole virus <NUMBER> nucleic acid <NUMBER> viral vector <NUMBER> protein subunit virus‐like particles figure <NUMBER> preclinical evaluation sars‐cov‐<NUMBER> amanat krammer <NUMBER> chen xiong bao shi <NUMBER> may <NUMBER> vaccines different phases clinical trials table <NUMBER> five vaccines phase <NUMBER> clinical trials six phase <NUMBER> trials one vaccine candidate phase <NUMBER> clinical trials table <NUMBER> candidate vaccines dna based <NUMBER> inactivated virus <NUMBER> modified antigen‐presenting cell apc <NUMBER> nonreplicating virus <NUMBER> protein subunit based <NUMBER> table <NUMBER> nonreplicating virus‐based vaccine namely chadox<NUMBER> ncov‐<NUMBER> developed consortium jenner institute oxford biomedica university oxford phase three clinical trial considered promising vaccine candidate far chadox<NUMBER> construct contains protein elicit immune response body might prevent subsequent infection sars‐cov‐<NUMBER> lane <NUMBER> phase <NUMBER> trial initiated april <NUMBER> plus immunizations accomplished follow‐up currently continuing commencing phase <NUMBER> phase <NUMBER> trials assess well vaccine provokes immune responses older adults examine whether render protection wider population httpwwwoxacuknews<NUMBER>oxfordcovid<NUMBER>vaccinebeginphaseiiiiihumantrials another vaccine mrna‐<NUMBER> vaccine synthetic strand mrna translates prefusion‐stabilized viral spike protein mrnas intramuscular injection predicted generate antiviral responses toward spike protein sars‐cov‐<NUMBER> furthermore synthesis lipid nanoparticle‐encapsulated mrna vaccine require virus‐like conventional vaccines therefore harmless ready tested nct<NUMBER> however vaccine completed clinical trial yet vaccines available prevent sars‐cov‐<NUMBER> infection amanat krammer <NUMBER> chen zhang et al <NUMBER>b passive antibody therapy approach antibodies blood plasma serum convalescent plasma sera people recuperated sars‐cov‐<NUMBER> infection used enhance immunity newly infected patients risk disease frontline caregivers essential service providers serum antibodies bind neutralize sars‐cov‐<NUMBER> casadevall pirofski <NUMBER> precise timing collecting blood recovered patient crucial boost immunity patients casadevall pirofski <NUMBER> approaches using convalescent sera plasma used effectively past mumps measles epidemics casadevall pirofski <NUMBER> approach already applied china five sars‐cov‐<NUMBER> infected severely ill patients acute respiratory distress syndrome treated convalescent plasma transfusion five different recovered patients chen zhang et al <NUMBER>a teixeira da silva <NUMBER> initiative showed promising results improved clinical condition treated patients shen et al <NUMBER> however limited number participants study precludes definitive statement potential effectiveness administering convalescent plasma emphasizes need evaluation clinical trials larger sample size proper randomized study design shen et al <NUMBER> recently convalescent plasma therapy started treat <NUMBER> covid‐<NUMBER> patients casadevall pirofski <NUMBER> study focus feasibility effectiveness plasma therapy another possible treatment option monoclonal antibody therapy bevacizumab humanized monoclonal antibody blocks vascular endothelial growth factor vegf halt angiogenesis cancer patients ellis <NUMBER> phase <NUMBER> randomized double‐blind placebo‐controlled multicenter study remdesivir hospitalized adult patients severe covid‐<NUMBER> completed nct<NUMBER> multicenter randomized controlled clinical trial undergoing qilu hospital shandong university check safety efficacy bevacizumab severe critical patients covid‐<NUMBER> nct<NUMBER> covid‐<NUMBER> patients encounter severe hypoxia upregulate vegf bevacizumab might reduce vegf level reduce severity disease wang cai et al <NUMBER> covid‐<NUMBER> spreads rapidly shortest fastest approaches drug repurposing could right choice needs employed discover potential therapeutics currently repurposed drugs shown therapeutic promise thus favipiravir instance already received temporary approval use covid‐<NUMBER> patients compounds antiviral potential example β‐d‐n<NUMBER>‐hydroxycytidine showing inhibitory effects chikungunya virus also need evaluated sars‐cov‐<NUMBER> however recent hype hydroxychloroquine chloroquine example covid‐<NUMBER> therapy handled carefully studies claimed unprecedented side‐effects posed anti‐malarial drugs mehra et al <NUMBER> simultaneously path vaccine development also needs minimized long‐term protection course addressing possible side‐effects viruses prone frequent mutation vaccines based single target might work longer time recently silico studies identified several protein subunits vaccine candidates combining single vaccine multiple epitope vaccines might give better results sars‐cov‐<NUMBER> review revisited current knowledge potential drug targets therapeutic promise sars‐cov‐<NUMBER> infection highlighted application drug repurposing approach possible therapeutic options currently clinical preclinical studies discussed also compiled current clinical trials mostly based repurposing therapeutic agents formerly designed indications rapidly started early phase pandemic currently undergoing although far practical application significant progress made vaccine development overall current effort leaves valuable information prospective druggable targets current options possible therapeutic well preventive strategies providing comprehensive systematic guideline dedicated covid‐<NUMBER> research beyond approaches addressed review strategies aimed priming host immune responses great potential individuals compromised immune system particularly vulnerable covid‐<NUMBER> moreover along viral‐specific therapeutics immunomodulatory anti‐inflammatory agents acting nonspecific inflammatory responses also need focused lessons learned emerging pandemic help us prepare advance possible future epidemics live era big data systematic multidisciplinary approaches need employed find drug targets repurposing drugs instant drug discovery authors declare conflict interest recent outbreak novel coronavirus disease considered pandemic threat global population <NUMBER> coronaviruses belong family viruses mainly found animals recent outbreak transmitted humans new coronavirus <NUMBER>ncov termed severe acute respiratory syndromerelated coronavirus sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> affected <NUMBER> countries <NUMBER> cases confirmed <NUMBER> deaths reported world <NUMBER> april <NUMBER> could potentially bring major challenges global healthcare disastrous effect global economy virus contained within months <NUMBER> common symptoms include cough fever shortness breath fatigue etc makes confusing patients differentiate symptoms typical cold flu <NUMBER> <NUMBER> <NUMBER> <NUMBER> reports suggest virus transmitted body fluids infected patients especially contact sneezing even though exact reasons known unfortunately drugs approved regulatory agencies treat sarscov<NUMBER> infection efforts ongoing war footing find effective drug vaccine treat pandemic coronaviruses classified four classes designated alpha beta gamma delta <NUMBER> sarscov<NUMBER> spikes also bind receptors human cell surface called angiotensinconverting enzyme <NUMBER> ace<NUMBER> <NUMBER> like sarscov merscov sarscov<NUMBER> also attacks lower respiratory system causing viral pneumonia however also reports could affect gastrointestinal system heart kidney liver central nervous system resulting multiple organ failure <NUMBER> compiling medical reports data available patients sarscov<NUMBER> found transmissiblecontagious sarscov <NUMBER> rapid development computer aided technology like ml based artificial intelligence ai help accelerate drug development process different diseases <NUMBER> <NUMBER> <NUMBER> advantage ai approaches like ml applied learn examples build predictive models even understanding underlying biological processes limited computational simulations based fundamental physical models expensive carried away another advantage ml automatically learn identify complex patterns categorize sets input rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint data thereby make intelligent decisions based independent datasets <NUMBER> ml accurately predict drugtarget interactions enormous amount complex information studying hydrophobic interactions ionic interactions hydrogen bonding van der waals forces etc molecules bioactivity datasets available numerous high throughput screens deliver useful means machine learning classifiers contain binary information activeinactive well numerical values classify different compounds consideration <NUMBER> <NUMBER> huge number datasets available biological activities molecules derived high throughput screens allows create predictive computational models study applied machine learning approach predict several new potential drugs treatment sarscov<NUMBER> validated predicted drugs initially trained model inhibitors sars coronavirus <NUMBER>clike protease fda approved drugs taken drug bank test model predict new drugs new drugs validated using docking method ensure drugs match active site protein ranked list drugs based energy value given tested experimentally study hypothesizes commercial fda approved antiretroviral drug saquinavir may potential candidate requiring limit viral recognition host cells disrupt hostvirus interactions thus requiring clinical trial first taken inhibitors sarscov<NUMBER> doesnt allow replicate host screened collected bioassay aid <NUMBER> used main component modeling training model using ml <NUMBER> attributes taken consideration <NUMBER> compounds used unsupervised learning filter dataset would made dataset much weaker mentioned method section used classifying algorithm train model best among used testing predicting drugs drug bank schematic process shown figure <NUMBER> used naïve bayes dataset shown accuracy approximately <NUMBER> model used drugs drug bank get predicted identification potential drugs used treatment disease caused sars coronavirus along model predicted <NUMBER> true positives <NUMBER> true negatives rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> table <NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> pdb structure sars spike protein receptor binding domain retrieved protein data bank pdb id <NUMBER>ghv docking experiment done patchdock server httpsbioinfo<NUMBER>dcstauacilpatchdock results refinement energy calculation performed per algorithm used firedock server result minimum global energy taken consideration <NUMBER> drugs predicted saquinavir drugbank id db<NUMBER> figure <NUMBER>a shown minimum global energy figure <NUMBER>b shows ligplot analysis conventional hbonding ligand tyrc<NUMBER> study taken drugs docking purpose show protease inhibition activity docking sars protein approved drug saquinavir drugbank id db<NUMBER> global energy around <NUMBER>ev confirms numerous steric clashes adjoining strands thus highlight potential inhibit novel sars coronavirus saquinavir small molecule antiretroviral drug figure <NUMBER>b rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> addition docking drug also docked several approved drugs available drug bank predicted ml model confidence level <NUMBER> also shows activity protease inhibition reference found drugs predicted model inclusion parameters taken consideration also quite effective rapid identification active therapeutic agents sarscov<NUMBER> major challenge analyzing available knowledge safety profiles cases efficacy coronaviruses repurposing existing antiviral drugs potentially crucial shortterm strategy tackle covid<NUMBER> current scenario takes <NUMBER> years bring drug investigational stages market availability trial error process socalled edisonian approach one keeps analyzing several compounds find best possible one days inclusion digital medicine time span reduced great extent people able approach rational manner drug discovery process targeted repurpssed drugs towards development effective treatment covid<NUMBER> speed clinical trial found ml model created basis naive bayes algorithm effective one accuracy almost equal <NUMBER> drugs predicted model verified docking process speculate expect predicted drugs show immense potential treatment covid<NUMBER> considering ongoing efforts prevent spread covid<NUMBER> world optimistic outbreak may subside months like sars mers however outbreak stressed urgent need renewed efforts towards development braodspectrum therapeutic agents combat coronaviruses repeatedly found realistic threat century till findinging provide base enhanced drug discovery programs rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> drug bank online database contains detailed data various medications <NUMBER> today widely used facilitate silico drug target discovery drug design drug docking screening drug metabolism prediction drug interaction prediction general pharmaceutical education database <NUMBER> drugs categorized many different types trial stages drugs approved drugs withdrawn drugs database <NUMBER> drugs approved various medication purposes <NUMBER> research focused fda approved drugs repurposing purpose around <NUMBER> intention minimize clinical trial present situation drugs downloaded form sdfs processing descriptions generated taken test model developing train model made basis database containing inhibitors sars coronavirus developed model predicted potential drugs ncbi protein database used process getting fasta sequence desired protein sars coronavirus fasta sequence used modeling threedimensional protein structure basis structure docking known predicted drugs carried <NUMBER> since datasets present form sdfs generated attributes present sdfs first information present sdfs generated csv files used training dataset test dataset preparing ml models csv files containing actives inactive points split <NUMBER> training rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint dataset <NUMBER> test dataset entire splitting process random process done selfwritten python code split per conditions used machine learning ml model selected dataset pubchem considered inhibitors tested drugs drug bank find suitable drugs coronavirus<NUMBER> <NUMBER> using ml implemented classification algorithms described classification type supervised learning computer system learn dataset contains detail practical results algorithmic procedure classification assign input value according description datasets <NUMBER> requires mathematical classifier assign specific class active inactive labels instances defined attributes process training model made learn using dataset classification already assigned basis able run different datasets classify according present instances study compared results classifier naïve bayes classification algorithm naive bayesian classification algorithm simple elegant approach assuming classification attributes independent dont correlation <NUMBER> type classifier depends bayes hypothesis naive bayes work best two cases complete independent feature expected functionally dependent features expected widely tested method probabilistic induction classifier functions well advantages many induction algorithms entangled iterative parameter makes work vast data sets algorithm useful induction algorithms computation speed reliability useful binary classification well multiclassification <NUMBER> training model prepared <NUMBER> original dataset dataset completely classified computer learns finds relations among various attributes crossvalidation used along algorithm train model case crossvalidation n set nfolds dataset supposed divide training dataset n parts n<NUMBER> parts used training data one used validate rest process iteration goes n iteration times used <NUMBER>fold chosen per size dataset <NUMBER> <NUMBER> rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint generally datasets containing binary classification based several attributes imbalanced observe similar tred imbalanced datasets possible handled normal classifiers since give importance attributes equally could lead misclassification errors decrease accuracy dataset trained model <NUMBER> <NUMBER> therefore used misclassification cost trained model becomes cost sensitive able find lowest expected cost approach actually much randomized neither depends upon number attributes minority class ration rather depends base classifier <NUMBER> <NUMBER> two methods introduce misclassification cost imbalance dataset first method classify algorithm costsensitive one proceed rest settings <NUMBER> use wrapper helps base classifiers cost sensitive ones used naïve bayes classifier uses cost insensitive algorithm predict probability estimations test instances using predicts class labels examples test dataset report classified datasets two classes ie active inactive used <NUMBER>x<NUMBER> matrix generally used binary classification matrix sections true positives active classified active false positives inactive classified active false negatives active classified inactive true negatives inactive classified inactive case percent false negatives important percent false positives upper limit false positives set <NUMBER> <NUMBER> <NUMBER> process increase misclassification set percent also helps increasing true positives since actives less number replicated around <NUMBER> times match inactives make model less biased various methods validation binary classifiers true positive rate ratio actual actives predicted positives obtained tptpfn false positive rate ratio predicted false actives actual inactives obtained fptnfp accuracy shows models performance relative real values calculated tntptntpfpfn sensitivity shows models ability identify positive results calculated tpfntp specificity shows models ability identify negative results calculated tntnfp model high specificity sensitivity low error rate balanced classification rate bcr mean sensitivity specificity provides accuracy model applied imbalanced dataset bcr calculated <NUMBER>specificitysensitivity rights reserved reuse allowed without permission certified peer review authorfunder granted medrxiv license display preprint perpetuity copyright holder preprint version posted april <NUMBER> <NUMBER> httpsdoiorg<NUMBER> doi medrxiv preprint apart bcr mathews correlation coefficient mcc also used whose range varies <NUMBER> <NUMBER> receiver operating characteristic roc curve visualization ratio fpr tpr case fpr tpr placed xand yaxis respectivel area curve shows probability prediction classifier ability classify randomly chosen instance correct class around <NUMBER> drugs predicted ml model effective treatment diseases caused sarscov<NUMBER> available drugs since epidemic recently accelerated <NUMBER> cases <NUMBER>th april <NUMBER> predicted compounds <NUMBER> confidence docked using firedock server coronavirus family recently gained new member sarscov<NUMBER> go along sarscov merscov infection sarscov<NUMBER> causes covid<NUMBER> rapidly become pandemic time writing millions infected hundreds thousands dead requiring social distancing leading global shutdowns resulting recession pushing healthcare infrastructures breaking point pandemic demanding urgent response need rapidly find treatments accomplished using existing drugs thus drug repurposing covid<NUMBER> garnered mainstream attention occur previous epidemics <NUMBER> initially response china elsewhere scientists look compounds tested previously sars mers almost exclusively <NUMBER> ritonavirlopinavir remdesivir repurposed ebola fda emergency approved chloroquine hydroxychloroquine fda emergency approved see supplementary material wellknown compounds currently clinical trials drug repurposing efforts used computational approaches docking biological network mining identify molecules candidates future testing <NUMBER> supplementary material date largescale highthroughput repurposing screens antiviral inhibition described literature <NUMBER> data well earlier sars mers data <NUMBER> could ultimately useful machine learning models order predict new molecules much wider array sources select compounds test vitro vivo however small number compounds date <NUMBER> reported reliable vitro data exhaustive bibliometric analysis drug repurposing decades conducted team recently described many drugs tested indications <NUMBER> analysis highlighted chloroquine one repurposed approved drugs tested hundreds diseases <NUMBER> surprisingly chloroquine also identified several groups china south korea usa <NUMBER> micromolar activity sarscov<NUMBER> vitro along derivative hydroxychloroquine even entered multiple clinical trials supplementary material results suggested good efficacy yet <NUMBER> limited clinical trial reports could due number reasons metabolism disposition drugs therapeutic window used text mining approach focus solely drugs used treatment coronaviruses supplementary material table s<NUMBER> analysis identified ammonium chloride commonly used treatment option severe cases metabolic alkalosis drug interest ammonium chloride quaternary ammonium compound known also antiviral activity <NUMBER> <NUMBER> coronavirus supplementary material mechanism action raising endocytic lysosomal ph shares chloroquine <NUMBER> review textmined literature also indicated highfrequency quaternary ammonium disinfectants treatments many viruses supplementary material <NUMBER> <NUMBER> including coronaviruses act deactivating protective lipid coating enveloped viruses like sarscov<NUMBER> rely quaternary ammonium compounds widely recommended kill viruses <NUMBER> products epas list n disinfectants use sarscov<NUMBER> supplementary material disinfectant concentrations contact times associated multiple viruses many disinfecting chemicals epa list reported <NUMBER> deactivate virus minutes <NUMBER> information led us larger search quaternary ammonium compounds activity coronaviruses possible identification chemicals already tested clinic could used potential treatment covid<NUMBER> table s<NUMBER> one disinfectants shown destructive viruses supplementary material widely used personal care products cetylpyridinium chloride table <NUMBER> <NUMBER> <NUMBER> compound found predominantly mouthwashes listed fda generally regarded safe gras also used antimicrobial agent meat poultry products <NUMBER> cetylpyridinium chloride used multiple clinical trials <NUMBER> including treatment respiratory infections <NUMBER> validating use antiviral cetylpyridinium likely promotes virus inactivation destroying capsid well lysosomotropic action discussed common quaternary ammonium compounds raises question whether drugs identified antiviral activity sarscov<NUMBER> vitro behave similarly namely may destroy virus capsid well accumulating lysosome endosomes ultimately blocking viral entry additional published studies suggested effect attenuated use cathepsinl inhibitors <NUMBER> another potential treatment candidate miramistin table <NUMBER> drug belonging group cationic antiseptics also quaternary ammonium compound reported wide array biological activities including antiviral hiv <NUMBER> miramistin approved broadspectrum antiinfective agent russia <NUMBER> appear adopted rest world numerous fda approved drugs quaternary nitrogen possible could also similar broad antiseptic effect current covid<NUMBER> pandemic sweeping globe unprecedented rate fanned global connectivity date spurred drug discovery activity albeit considerably impacted research laboratory shutdowns much interest drug repurposing hope delivering effective drugs patient faster success approach take time validate await clinical trial data earliest compounds clinic hypothesized text mining available published literature pubmed would enable us identify compounds faster tested coronaviruses currently evaluated clinically studies guided approach suggest many drugs tested lysosomotropic agent ammonium chloride quaternary ammonium compounds cetylpyridinium chloride miramistin may produce desired antiviral effect yet tested sarscov<NUMBER> vitro clinical trials briefly described data mining process identified classes compounds interest provide analysis others expand table s<NUMBER> limitations text mining approach time writing reports approximately <NUMBER> molecules associated coronaviruses many could likely discounted due reported antiviral activity toxicity perhaps important lack fda approved status propose particular cetylpyridinium chloride simple molecule cheap safe clinically approved widely accessible hospitals consumer sector could enter clinical trials immediately reported activity vitro sarscov<NUMBER> subsequent delivery form mouthwash nasal spray containing compound may effective way combat virus point entry reduce sarscov<NUMBER> transmission similarly compound could added shampoo body cleansers one could effectively bathe low concentrations compound destroy shed coronavirus cetylpyridinium chloride many quaternary ammonium compounds already demonstrated antiviral activity wide array related coronaviruses disinfectants antiseptics therefore represent especially low hanging fruit testing humans due reported mechanisms may also much broader activity viruses could useful address future enveloped viruses certainly additional studies may warranted assess potential drugdrug drugtransporter interactions work may also point related compounds could utilized least enable generation new antiviral compounds leverage quaternary ammonium substructural fragment potential warhead simple sounds entirely possible looking bathroom cupboards potential remedies covid<NUMBER> work reviewed us epa approved publication views expressed publication authors necessarily represent views policies united states environment protection agency reference commercial products services constitute endorsement kindly acknowledge nih funding r<NUMBER>gm<NUMBER>a<NUMBER> nigms r<NUMBER>tr<NUMBER> ncats r<NUMBER>at<NUMBER>s<NUMBER> nccam pi sean ekins <NUMBER>ot<NUMBER>tr<NUMBER> pi alexander tropsha conflict interest se ceo owner collaborations pharmaceuticals coauthors conflicts interest identification new targets chemotherapeutic intervention often paralleled development licensing new drugs antiviral agents treating viral infectious diseases exception <NUMBER> <NUMBER> <NUMBER> new antivirals approved food drug administration fda usa <NUMBER> treatment hepatitis c virus hcvrelated pathologies <NUMBER> combinations antihuman immunodeficiency virus hiv drugs wwwfdagov hand governments world health organization deal critical reemerging viruses characterized pandemic potential responsible alarming outbreaks recent years still lack specific treatment zika virus zikv ebola virus ebov middle east respiratory syndrome coronavirus merscov drug discovery approach recently become popular drug repurposing dr consists giving old drugs new indication exploring new molecular pathways targets intervention <NUMBER> <NUMBER> dr applied viral infectious diseases takes account different strategies integrating screenings bioactive smallmolecule collections computational methods silico screenings mining database transcriptomic profiles etc order find molecule pathway biological activity could recycled fighting viral pathogen beyond unquestionable economic advantage derived approach drug development process repurposed drugs quickly enter clinical trials employed compassionate use especially case viral diseases lacking specific treatment moreover dr represents constant source new knowledge virus biology well molecules previously undescribed antiviral properties used molecular tools uncovering molecular mechanisms virus replication pathogenesis many cases dr points previously unexplored cellular pathways turning targets new therapeutic strategies even identified molecules cannot introduced clinical therapy review describe meaningful results bed bench approach discuss promising drugs could repurposed treat viral infections analyze possible caveats trendy strategy drug discovery whose advantages pitfalls summarized table <NUMBER> repurposing existing drugs emerging strategy expediting approval effective safe therapeutics treatment orphan drug diseases new indications antiviral activity identified molecules different origins showing repurposing potential acting previously known target new antiviral target innovative approaches target validation eg gene editing crispr cas<NUMBER> new experimental models eg organoids allowed identification novel antiviral agents unraveling molecular pathways underlying viral pathogenesis drug repurposing successfully identified promising candidate drugs open new therapeutic avenues counteract current viral pathogens possible emerging viruses three different scenarios antiviral dr identified depending whether repurposed molecule previously known antiviral activity figure <NUMBER> key figure targetnew virus first option antiviral drug known target specific viral cellular functionpathway found possess activity viruses antiviral activity relies structural homology common enzymatic features viral target shared pathways exploited virus replication viral rna polymerase inhibitors favipiravir sofosbuvir approved treatment influenza virus hcv infections respectively showed repurposing potential ebov zikv see another example represented drugs eg chloroquine interfere latestage entry process viruses filoviruses coronaviruses exploit cellular endocytic pathways enter host cell ii targetnew indication occurs pharmacological target ie protein pathway modulated approved drug found essential pathogenic process associated viral infection case approved drug exploited also antiviral therapeutic agent new indication case exemplified anticancer drug imatinib inhibits cellular abelson abl kinase found also active pathogenic coronaviruses <NUMBER> iii new targetnew indication occurs approved drug established bioactivity specific pathway mechanism found new molecular target ie shows polypharmacology see glossary essential virus replication examples antimicrobial agents eg teicoplanin ivermectin itraconazole nitazoxanide found target also virusinfected cells whose inhibition detrimental effects viral replication <NUMBER> <NUMBER> drugs repurposing potential viral diseases identified mostly screening smallmolecule libraries consisting drugs approved developmental compounds known bioactivity including compounds natural origin libraries available public institutions commercially however number glossary arbovirus arthropod borne virus virus replicate arthropods transmitted vertebrates including humans hematophagous vectors mainly mosquitoes flies ticks humans animals arthropods therefore reservoirs gene editing crisprcas<NUMBER> system type genetic engineering based use clustered regularly interspaced short palindromic repeats crispr cas<NUMBER> nuclease system acts molecular scissors delete insert genetic material precise location within genome single cell living organism microcephaly medical condition due congenital defect circumference newborns head abnormally smaller expected consequence smaller brains microcephalic babies may developed properly stopped growing microcephaly caused viral infections toxin exposure drugs alcohol abuse pregnancy organoids threedimensional <NUMBER>d cell cultures simplified yet representative version organ resembling microanatomy celltype composition able recapitulate represented organs functions culture systems obtained vitro one cells derived tissue stem cells induced pluripotent stem cells able selfrenew differentiate multiple organspecific cell types several <NUMBER>d organ structures obtained date represent essential physiological models study biological pathogenic processes including viral infections polypharmacology describes ability approved drug pharmaceutical molecule act multiple targets related toxic sideeffects molecule represents important opportunity drug repurposing pseudovirus noninfectious recombinant viruslike particle resembles envelope capsid specific virus constituted components pseudoviruses may may contain genetic material proprietary inhousemade collections also exist often consisting one class drugs eg kinase apoptosis inhibitors etc useful target deconvolution table <NUMBER> lists drug collections widely used antiviral dr past <NUMBER> years partnerships public private institutions strongly encouraged governments expedite identification new candidate drugs particular orphan diseases several pharmaceutical companies opened proprietary collections collaboration programs academic research groups <NUMBER> despite restricted number available collections fact often drugs present various libraries several cases different outcomes viral pathogen obtained possible explanation different experimental setup used including differences cell type virus strain dose readout method conversely screening different libraries drugs independently identified cases eg mers possible strategies drug repurposing antiviral drug discovery figure <NUMBER> repurposing existing drugs candidate drugs bioactive molecules different origin pursued three main strategies molecule previous known antiviral activity efficacy viruses hypothesized tested based similarity target dependence common pathways absence previously identified antiviral activity repurposed molecule either act target show polypharmacology interfere different function cellular viral latter case target validation cannot avoided skipping preclinical phase <NUMBER> clinical studies first two approaches followed conceivable however may possible repurposed molecule shows polypharmacology testing efficacy suitable animal models remains essential step cov see finally virtual screening chemical structures also performed find new potential antiviral drugs however approach dependent upon availability structural information priori knowledge target usually required dr screenings aimed discovery new antiviral drugs validate target screening fact expost target validation even identification possible active molecule identified thus dr screenings mainly undertake two different experimental approaches unknown targetphenotypic assay ii known target à mechanismbased assay first case target generally unknown phenotypic assay employed identification hit compounds phenotypic assays based readout synonymous antiviral activity easily monitored highthroughput format example protection infected cell monolayers virusinduced cytopathic effect detection lateexpressed structural viral protein envelope protein cases frequently exploited hit identification phenotypic assay next step identification validation target protein pathway etc sometimes deduced mechanism action identified hit compound validation required demonstrate target indeed essential virus replication andor pathogenesis subordinated demonstration modulation leads protection virus infection inhibition virusassociated pathogenic effects experimental approaches antiviral target validation exemplified genetic knockdown rna interference gene editing crisprcas<NUMBER> system mutational analysis use pharmacological inhibitors available evaluated cultured cells organoids ex vivo experimental models well animal models finally possible clinical validation patientderived samples data also performed indeed routinely employed drug found potentially effective treatment viral infection possible positive correlation drug administration target patients inhibition viral infection retrospectively analyzed clinical studies <NUMBER> bioactive compounds including fdaapproved drugs candidate drugs <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> detailed description libraries found <NUMBER> alternatively mechanismbased dr screenings target validation mandatory prior screening design frequent targets druggable viral cellular enzymes receptors experimental setup mechanismbased assays specifically designed identify molecules able interfere particular process previously identified essential productive virus replication involved viral pathogenesis assays based specific mechanism inhibition transcription factor protection apoptosis interfering specific activating mechanism inhibition virus entry popular approaches dr screenings cellfree systems vitro assays purified proteins used however cellular assays engineered cell lines recombinant viruses andor replicon systems pseudoviruses preferred information target modulation obtained directly physiological environment compounds identified mechanismbased assays dr screenings zikv ebov dna viruses described although dr screenings based mechanismbased assays could convenient target known sometimes false positives identified limits possible toxicity hits due offtarget effects missing antiviral compounds acting different mechanisms antiviral activity restricted single process established priori following sections describe recent advances repurposing existing candidate drugs treat infections caused rna dna viruses table <NUMBER> priority given drugs showed efficacy clinical trials animal models investigational drugs exhibiting effective concentrations compatible clinically achievable plasma levels humans zikv flaviviruses zikv arbovirus recently caused large outbreak latin america generally zikv causes selflimiting disease however zikv infection also associated neurologic disorders guillainbarré syndrome others severe congenital defects newborns microcephaly ophthalmological alterations infection occurs pregnancy virus capable humantohuman spread vertical transplacental sexual transmission possible zikv pandemics particular concern global public health <NUMBER> neither specific antiviral treatment vaccine counteract zikv diffusion available date dr campaigns reported shortly whos declaration zikv public health emergency early <NUMBER> cases collections fdaapproved drugs bioactive molecules randomly screened others specific class compounds considered based previous activity flaviviruses molecular pathways relevant pathogenesis particular zikvinduced neuropathogenesis first dr study among identified inhibitors zikv replication immunosuppressant drug mycophenolic acid antibiotic daptomycin promising wide use pregnancy treat diseases ability cross placenta <NUMBER> importantly drugs effective antizikv concentration falls range achievable humans thus represent promising candidates clinical trials successive dr screenings identified fdaapproved antihelminthic drug niclosamide macrolide azithromycin approved antibacterial agent potent inhibitors zikv replication different neural cell lines targeted zikv fetal infection <NUMBER> <NUMBER> niclosamide azithromycin widely used drugs also administered pregnancy category b active concentration zikv clinically achievable thus although studies needed evaluate antiviral efficacy vivo also represent promising candidates antizikv repurposing finally structurebased silico screenings followed vitro vivo experimental studies led identification another antibiotic novobiocin fdaapproved drugs including niclosamide temoporfin novel inhibitors zikv act targeting ns<NUMBER>ns<NUMBER>b protease <NUMBER> <NUMBER> another study nanchangmycin polyether bacterial origin blocked zikv infection different cell lines well ex vivo midbrain neuronglia mixed cultures embryonic mice <NUMBER> importantly nanchangmycin showed antiviral activity also viruses share clathrindependent entry mechanism another natural compound alkaloid hippeastrine hydrobromide hh recently emerged promising inhibitor zikv replication microcephalyrelated effects <NUMBER> antizikv effect hh human fetallike forebrain organoids reported well rescue organoid cells virusinduced death importantly <NUMBER>day treatment zikvinfected organoids hh resulted size thickness comparable uninfected organoids thus suggesting potential inhibitory effect compound virusinduced microcephaly fetal infection finally hh also effective mouse model zikv infection even added <NUMBER> days postinfection thus highlighting impressive therapeutic potential studies reporting repurposing potential zikv drugs approved treatment hcv infections ribavirin sofosbuvir worth mentioning although conflicting results efficacy latter reported <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> discrepancies may due different cell lines animal models used explained molecular level moreover deeper investigation safety sofosbuvir pregnancy needed considering antihcv drug candidate treatment zikv fetal infections moreover several antimalarial drugs showed antizikv activity <NUMBER> <NUMBER> particular chloroquine effective reducing zikv vertical transmission infected pregnant mice <NUMBER> neuroprotection coupled drugs able block directly virus replication fetal infection could able attenuate neurodegenerative effects zikv brain ophthalmological damage derived virus infection optic nerve ocular tissues nmethyldaspartate receptor antagonists particular memantine approved treatment alzheimers disease promising neuroprotective drugs human primary neurons mice infected zikv <NUMBER> many drugs repurposing potential zikv also active flaviviruses suggesting conserved pathways could explored development broadspectrum antiflavivirus agents case mycophenolic acid niclosamide nanchangmycin cloroquine antimalarial drugs hand independent dr screenings japanese encephalitis virus jev hcv dengue virus denv led identification antiviral activity different fdaapproved drugs <NUMBER> <NUMBER> <NUMBER> particular dopamine d<NUMBER> receptor antagonist prochlorperazine identified potent inhibitor hcv denv acts interfering virus attachment entry <NUMBER> <NUMBER> another drug antihcv repurposing potential antihistamine chlorcyclizine showed antiviral activity infectious assay chimeric mouse model <NUMBER> date however none compounds yet evaluated clinical trials ebola virus ebov filovirus responsible several outbreaks since discovery late <NUMBER>s last one <NUMBER> alarming due size spread indeed caused international health emergency since accidentally imported ebov cases recorded nonendemic geographical areas usa europe ebov causes lethal disease characterized acute hemorrhagic fever high fatality rate <NUMBER> despite ease transmission specific therapeutics available yet worsened high level biocontainment bsl<NUMBER> necessary manipulation virus considerably hampers development antiviral drugs vaccines context dr studies prompted last outbreak extensively reviewed <NUMBER> <NUMBER> <NUMBER> ebov provides unique example dr approach applied directly clinical trials last outbreak several drugs evaluated infected patients clinical trials compassionate use test ability protect lethal ebov infection included viral rna polymerase inhibitors favipiravir approved japan treatment influenza virus <NUMBER> <NUMBER> gs<NUMBER> adenosine analog active highly pathogenic coronaviruses <NUMBER> <NUMBER> amodiaquine antimalarial drug widely used africa treatment ebovinfected patients drugs associated decrease fatality rate compared control patients <NUMBER> however efficacy remains confirmed randomized clinical studies preclinical dr studies also performed live viruses pseudoviruses led identification series approved drugs able confer protection lethal ebov infection animal models however drugs tested humans yet drugs exert antiviral activity blocking ebov entry step biased fact use pseudoviruses allows identification compounds inhibiting viral entry promising antiebov activity determined selective estrogen receptor modulators cloremiphene toremiphene <NUMBER> <NUMBER> chloroquine related antimalarial drugs <NUMBER> sertraline bepridil <NUMBER> teicoplanin <NUMBER> cationic amphiphilic drugs amiodarone <NUMBER> broadspectrum rna polymerase inhibitor bcx<NUMBER> <NUMBER> finally frontier dr directly test combination drugs shown antiviral activity although concentrations clinically reachable humans approved regimen gave successful results <NUMBER> indeed targeted drug combination approach resulted identification two sets threedrug cocktails ie toremifenemefloquineposaconazole toremifeneclarithromycinposaconazole previously identified dr act synergistically ebov entryinhibition assay concentrations achievable humans <NUMBER> coronaviruses covs rna viruses responsible gastrointestinal respiratory neurologic diseases animals zoonotic infections humans particular importance established potential crossspecies transmission domesticated animals act intermediate hosts responsible infections humans major concerns cov infections significant morbidity mortality emergence new viruses competent humantohuman transmission potential domestic animal adaptation difficulty identifying intermediate host severe acute respiratory syndrome cov sarscov highly pathogenic cov emerged china <NUMBER> responsible pandemic <NUMBER> infected people <NUMBER> mortality wwwcdcgov merscov emerged <NUMBER> spread <NUMBER> countries far characterized <NUMBER> mortality rate <NUMBER> thus covs represent huge threat public health scenario search effective therapeutic strategies priority global public health management prompted merscov outbreak three independent studies reporting approach dr anticov drug discovery published <NUMBER> <NUMBER> <NUMBER> approved drugs tested mersand sarscov two molecules identified two independent screenings dopamine receptor antagonist chlorpromazine antimalarial drug chloroquine reported also antiflavivirus activity two drugs exhibited antiviral activity viruses range clinically achievable humans however progress preclinical studies dr approach also allowed identification abl tyrosine kinase oncogene pathway essential entry covs <NUMBER> <NUMBER> indeed abl kinase inhibitor imatinib approved oral anticancer agent inhibited replication mersand sarscov preventing fusion virus endosomal membrane important example dr determinant identification host factors required pathogen replication finding novel targets antiviral intervention hosttargeting anticov drugs cyclophylin inhibitors cyclosporin alispovir <NUMBER> latter drug antiviral activity mersand sarscov cell culture failed show protective effect mouse model sarscov infection nonetheless cyclophylin inhibitors deserve investigation pan anticov activity hiv protease inhibitors also identified dr screenings showed efficacy combination interferon b<NUMBER>b merscov infected cells nonhuman primate model <NUMBER> currently combination lopinavirritonavir interferon b<NUMBER>b treatment merscov syndrome clinical evaluation <NUMBER> influenza virus belongs family orthomyxoviridae human pathogen global public health importance causes seasonal pandemic zoonotic influenza disease outbreaks pandemic zoonotic influenza strains particular concern high potential transmission given absence preexisting immunity human populations opposed rna viruses described far review current antiviral treatment options influenza infections however adamantanes inhibitors viral ion channel m<NUMBER> neuraminidase inhibitors suffer rapid emergence drugresistant viral strains side effects thus limiting therapeutic efficacy therefore new antiinfluenza drugs developed <NUMBER> dr campaigns identified drugs already approved clinical evaluation showed antiinfluenza properties bay <NUMBER> approved intravenous aspirin exerting antiviral activity blocking nfkb pathway activation <NUMBER> dapivirine nonnucleoside inhibitor hiv<NUMBER> retrotranscriptase <NUMBER> naproxen targets influenza nucleoprotein <NUMBER> antibiotic clarithromycin clarithromycin naproxen à along oseltamivir threedrug combinationhave evaluated phase <NUMBER>b<NUMBER> clinical trial showed efficacy treatment severe influenza <NUMBER> also nalidixic acid dorzolamide identified silico screening specifically targeting mutant viral neuraminidase showed efficacy oseltamivirresistant influenza wildtype viruses <NUMBER> perhaps advanced example dr case antiparasitic drug nitazoxanide safe drug used treatment giardia cryptosporidium spp infections currently repurposed treatment influenza <NUMBER> <NUMBER> nitazoxanide promising antiinfluenza drug candidate interferes maturation viral hemagglutinin posttranslational level showed efficacy different latestage clinical trials <NUMBER> moreover broadspectrum antiviral activity demonstrated drug able block replication <NUMBER> different viruses raises hopes possible future indications antiviral dr also explored search new antiviral strategies directed dna viruses considered emerging viral pathogens responsible latent lifelong infections cause high morbidity lifethreatening atrisk populations human cytomegalovirus hcmv bherpesvirus establishes persistent infection reactivate conditions immunosuppression <NUMBER> hcmv one best characterized examples host adaptation ability viruses subvert completely cellular physiological processes infected cell context different dr campaigns identified several approved investigational drugs antihcmv mechanism different currently available drugs <NUMBER> <NUMBER> case statins <NUMBER> cardiac glycosides <NUMBER> antiparasitic drugs emetine nitazoxanide <NUMBER> <NUMBER> kinase inhibitors <NUMBER> antihypertensive drug manidipine <NUMBER> drugs pharmacologically modulate host proteins thus although specific viral target cannot excluded antihcmv activity likely relies interference host pathways intercepted virus studies needed identify precise molecular mechanism dr campaign also performed identify inhibitors hepatitis b virus hbv calciumchannel blockers dopamine receptor antagonist antifungal terbinafine emerged promising inhibitors hbv rna transcription dna synthesis <NUMBER> virustargeting drugs also showed repurposing potential case hiv integrase inhibitors demonstrated broadspectrum activity different herpesviruses inhibiting viral terminase <NUMBER> <NUMBER> hiv protease inhibitors lopinavirritonavir clinically evaluated potential treatment human papilloma virus hpvrelated preinvasive cervical malignancies <NUMBER> lack specific therapy viral infectious diseases remains major medical need development effective therapeutics subordinated understanding molecular mechanisms underlying virus replication pathogenesis well virushost interactions remain puzzling several known viral pathogens also represent main challenge future emerging viruses context evaluating repurposing potential existing candidate drugs represent effective strategy development readytouse antiviral agents well identification new pathways targets intervention active drugs identified dr could principle skip preclinical phase <NUMBER> safetytolerability clinical trials directly enter phase <NUMBER> clinical trials testing efficacy even though strategy already demonstrated feasibility development new anticancer drugs antifungal drug itraconazole second life anticancer drug <NUMBER> antiviral drug discovery still successful examples influenza <NUMBER> ebov <NUMBER> merscov <NUMBER> see outstanding questions important issues related dr summarized table <NUMBER> still remain addressed particular translational aspects approach well possible obstacles pharmaceutical development drugs showing repurposing potential main obstacle successful repurposing relies perhaps effective concentrations required antiviral activity often higher clinically achievable approved regimens reconsidering administration protocols order reach higher plasma levels convenient would mean losing one advantages dr could feasible due toxicity issues effective solution issue seems development combination therapies exploiting synergism two three drugs different mechanisms action <NUMBER> <NUMBER> promising results direction accomplished ebov <NUMBER> influenza <NUMBER> could obtained viruses combination therapy overcome issue low potency drugs identified drug repurposing gap left lack effective animal models recapitulate human viral diseases virusassociated pathogenesis filled dr approach antiviral drug discovery translate evaluation repurposed drugs directly phase ii clinical trials similar occurs diseases cancer neurodegenerative disorders dr benefit productive public private partnerships aimed overcoming intellectual property program restriction business issues prepared clinical evaluation potentially repurposed drugs future outbreak highly pathogenicpandemic viruses ebov zikv respiratory viruses could information experience acquired dr campaigns useful determinant containment newly emerging viruses future besides lower toxicity obtained decreasing doses combined drugs combination therapy also advantage reducing resistance issues still caveat act synergistically lower dose drugs need interfere different mechanisms action antiviral combination therapies effective drugs inhibit early possible different viral functions host pathways involved virus replication reason search new antiviral targets therapeutic interventions different approaches still remains mandatory addressed dr campaigns coronaviruses covs belonging family coronaviridae positivesense enveloped rna viruses cause infections birds mammals humans <NUMBER> <NUMBER> <NUMBER> family includes four genera alphacoronavirus betacoronavirus deltacoronavirus gammacoronavirus <NUMBER> two infamous infectious coronaviruses genus betacoronavirus severe acute respiratory syndrome coronavirus sarscov <NUMBER> middle east respiratory syndrome coronavirus merscov <NUMBER> infected <NUMBER> people around world past two decades unfortunately incidence accompanied high mortality rates <NUMBER> sarscov <NUMBER> merscov indicating urgent need effective treatment beginning outbreak prevent spread <NUMBER> <NUMBER> however cannot achieved current drug development application system taking several years newly developed drugs come market unexpectedly world facing situation previous outbreak due recent epidemic atypical pneumonia caused novel coronavirus <NUMBER>ncov wuhan china <NUMBER> <NUMBER> thus rapid drug application strategy immediately applied patient necessary currently way address matter repurpose commercially available drugs pathogen socalled drugrepurposing however theory artificial intelligence aibased architectures must taken account order accurately predict drugtarget interactions dtis enormous amount complex information eg hydrophobic interactions ionic interactions hydrogen bonding andor van der waals forces molecules end previously developed deep learningbased drugtarget interaction prediction model called molecule transformerdrug target interaction mtdti <NUMBER> study applied pretrained mtdti model identify commercially available antiviral drugs could potentially disrupt <NUMBER>ncovs viral components proteinase rnadependent rna polymerase andor helicase since model utilizes simplified molecularinput lineentry system smiles strings amino acid aa sequences <NUMBER>d string inputs possible quickly apply target proteins experimentally confirmed <NUMBER>d crystal structures viral proteins <NUMBER>ncov share list top commercially available antiviral drugs could potentially hinder multiplication cycle <NUMBER>ncov hope effective drugs developed based aiproposed drug candidates act <NUMBER>ncov amino acid sequences <NUMBER>clike proteinase accession yp<NUMBER> rnadependent rna polymerase accession yp<NUMBER> helicase accession yp<NUMBER> <NUMBER>to<NUMBER> exonuclease accession yp<NUMBER> endornase accession yp<NUMBER> <NUMBER>oribose methyltransferase accession yp<NUMBER> <NUMBER>ncov replication complex extracted <NUMBER>ncov whole genome sequence accession nc<NUMBER> national center biotechnology information ncbi database raw prediction results screened antiviral drugs fda approved target viral proteins kd value less <NUMBER> nm molecule transformerdrug target interaction mtdti used predict binding affinity values commercially available antiviral drugs target proteins briefly natural language processing nlp based bidirectional encoder representations transformers bert framework core algorithm model good performance robust results diverse drugtarget interaction datasets pretraining chemical language smiles approximately <NUMBER> compounds train model drug target common dtc database <NUMBER> bindingdb <NUMBER> database manually curated combined three types efficacy value ki kd ic<NUMBER> integrated consistencescorebased averaging algorithm <NUMBER> make pearson correlation score <NUMBER> terms ki kd ic<NUMBER> since bindingdb database includes wide variety species target proteins mtdti model potential power predict interactions antiviral drugs <NUMBER>ncov proteins <NUMBER>ncov <NUMBER>clike proteinase predicted bind atazanavir kd <NUMBER> nm followed efavirenz ritonavir antiviral drugs predicted affinity kd <NUMBER> nm potency table <NUMBER> protease inhibitor antiviral drug found kd <NUMBER> nm range although realworld evidence whether drugs act predicted <NUMBER>ncov yet case studies identified example docking study lopinavir along hiv proteinase inhibitors cov proteinase pdbid <NUMBER>uk<NUMBER> suggests atazanavir ritonavir listed present prediction results may inhibit cov proteinase line inhibitory potency lopinavir <NUMBER> according prediction viral proteinasetargeting drugs predicted act favorably viral replication process viral proteinase dti model table <NUMBER> <NUMBER> results include antiviral drugs proteinase inhibitors guanosine analogues eg acyclovir ganciclovir penciclovir reverse transcriptase inhibitors integrase inhibitors among prediction results atazanavir predicted potential binding affinity bind table <NUMBER> suggested potential mers therapeutics <NUMBER> recently approximately <NUMBER> million worth kaletra doses donated china <NUMBER> previous clinical study sars chu et al <NUMBER> may support decision <NUMBER> another antihiv drug prezcobix johnson johnson consists darunavir cobicistat sent china <NUMBER> darunavir also predicted kd <NUMBER> nm <NUMBER>ncovs helicase table <NUMBER> however current supporting literature found darunavir used cov therapeutic many cases dti prediction models serve tool repurpose drugs develop novel usages existing drugs however application dti prediction present study may useful control table <NUMBER> drugtarget interaction dti prediction results antiviral drugs available markets novel coronavirus <NUMBER>ncov ncbi reference sequence nc<NUMBER> helicase accession yp<NUMBER> ritonavir expressed canonical isomeric form smiles indicates isomeric form smiles ritonavir coronaviruses covs belonging family coronaviridae positivesense enveloped rna viruses cause infections birds mammals humans <NUMBER> <NUMBER> <NUMBER> family includes four genera alphacoronavirus betacoronavirus deltacoronavirus gammacoronavirus <NUMBER> two infamous infectious coronaviruses genus betacoronavirus severe acute respiratory syndrome coronavirus sarscov <NUMBER> middle east respiratory syndrome coronavirus merscov <NUMBER> infected <NUMBER> people around world past two decades unfortunately incidence accompanied high mortality rates <NUMBER> sarscov <NUMBER> merscov indicating urgent need effective treatment beginning outbreak prevent spread <NUMBER> <NUMBER> however cannot achieved current drug development application system taking several years newly developed drugs come market unexpectedly world facing situation previous outbreak due recent epidemic atypical pneumonia caused novel coronavirus <NUMBER>ncov wuhan china <NUMBER> <NUMBER> thus rapid drug application strategy immediately applied patient necessary currently way address matter repurpose commercially available drugs pathogen socalled drugrepurposing however theory artificial intelligence aibased architectures must taken account order accurately predict drugtarget interactions dtis enormous amount complex information eg hydrophobic interactions ionic interactions hydrogen bonding andor van der waals forces molecules end previously developed deep learningbased drugtarget interaction prediction model called molecule transformerdrug target interaction mtdti <NUMBER> study applied pretrained mtdti model identify commercially available antiviral drugs could potentially disrupt <NUMBER>ncovs viral components proteinase rnadependent rna polymerase andor helicase since model utilizes simplified molecularinput lineentry system smiles strings amino acid aa sequences <NUMBER>d string inputs possible quickly apply target proteins experimentally confirmed <NUMBER>d crystal structures viral proteins <NUMBER>ncov share list top commercially available antiviral drugs could potentially hinder multiplication cycle <NUMBER>ncov hope effective drugs developed based aiproposed drug candidates act <NUMBER>ncov ccbyncnd <NUMBER> international license authorfunder made available copyright holder preprint peerreviewed httpsdoiorg <NUMBER> <NUMBER> <NUMBER> amino acid sequences <NUMBER>clike proteinase accession yp<NUMBER> rnadependent rna polymerase accession yp<NUMBER> helicase accession yp<NUMBER> <NUMBER>to<NUMBER> exonuclease accession yp<NUMBER> endornase accession yp<NUMBER> <NUMBER>oribose methyltransferase accession yp<NUMBER> <NUMBER>ncov replication complex extracted <NUMBER>ncov whole genome sequence accession nc<NUMBER> national center biotechnology information ncbi database raw prediction results screened antiviral drugs fda approved target viral proteins kd value less <NUMBER> nm molecule transformerdrug target interaction mtdti used predict binding affinity values commercially available antiviral drugs target proteins briefly natural language processing nlp based bidirectional encoder representations transformers bert framework core algorithm model good performance robust results diverse drugtarget interaction datasets pretraining chemical language smiles approximately <NUMBER> compounds train model drug target common dtc database <NUMBER> bindingdb <NUMBER> database manually curated combined three types efficacy value ki kd ic<NUMBER> integrated consistencescorebased averaging algorithm <NUMBER> make pearson correlation score <NUMBER> terms ki kd ic<NUMBER> since bindingdb database includes wide variety species target proteins mtdti model potential power predict interactions antiviral drugs <NUMBER>ncov proteins <NUMBER>ncov <NUMBER>clike proteinase predicted bind atazanavir kd <NUMBER> nm followed efavirenz ritonavir antiviral drugs predicted affinity kd <NUMBER> nm potency table <NUMBER> protease inhibitor antiviral drug found kd <NUMBER> nm range although ccbyncnd <NUMBER> international license authorfunder made available copyright holder preprint peerreviewed httpsdoiorg <NUMBER> <NUMBER> <NUMBER> realworld evidence whether drugs act predicted <NUMBER>ncov yet case studies identified example docking study lopinavir along hiv proteinase inhibitors cov proteinase pdbid <NUMBER>uk<NUMBER> suggests atazanavir ritonavir listed present prediction results may inhibit cov proteinase line inhibitory potency lopinavir <NUMBER> according prediction viral proteinasetargeting drugs predicted act favorably viral replication process viral proteinase dti model table <NUMBER> <NUMBER> results include antiviral drugs proteinase inhibitors guanosine analogues eg acyclovir ganciclovir penciclovir reverse transcriptase inhibitors integrase inhibitors among prediction results atazanavir predicted potential binding affinity bind table <NUMBER> <NUMBER> also ganciclovir predicted bind three subunits replication complex <NUMBER>ncov rnadependent rna polymerase kd <NUMBER> nm <NUMBER>to<NUMBER> exonuclease kd <NUMBER> nm rna helicase kd <NUMBER> nm lopinavir ritonavir active materials abbvies kaletra predicted potential affinity <NUMBER>ncov helicase table <NUMBER> suggested potential mers therapeutics <NUMBER> recently approximately <NUMBER> million worth kaletra doses donated china <NUMBER> previous clinical study sars chu et al <NUMBER> may support decision <NUMBER> another antihiv drug prezcobix johnson johnson consists darunavir cobicistat sent china <NUMBER> darunavir also predicted kd <NUMBER> nm <NUMBER>ncovs helicase table <NUMBER> however current supporting literature found darunavir used cov therapeutic many cases dti prediction models serve tool repurpose drugs develop novel usages existing drugs however application dti prediction present study may useful control copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint table <NUMBER> drugtarget interaction dti prediction results fda approved antviral drugs available markets novel coronavirus <NUMBER>ncov ncbi reference sequence nc<NUMBER> <NUMBER>clike proteinase accession yp<NUMBER> ritonavir expressed canonical isomeric forms smiles indicates isomeric form smiles ritonavir table <NUMBER> drugtarget interaction dti prediction results antiviral drugs available markets novel coronavirus <NUMBER>ncov ncbi reference sequence nc<NUMBER> helicase accession yp<NUMBER> ritonavir expressed canonical isomeric form smiles indicates isomeric form smiles ritonavir copyright holder preprint peerreviewed httpsdoiorg <NUMBER> <NUMBER> <NUMBER> copyright holder preprint peerreviewed httpsdoiorg<NUMBER> doi biorxiv preprint table <NUMBER> drugtarget interaction dti prediction results antiviral drugs available markets novel coronavirus <NUMBER>ncov ncbi reference sequence nc<NUMBER> <NUMBER>oribose methyltransferase accession yp<NUMBER> copyright holder preprint peerreviewed httpsdoiorg <NUMBER> <NUMBER> <NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> well known covid<NUMBER> become current health distress entire world pandemic scenario research rapid development new drug molecules highly risky tedious process current covid<NUMBER> emergency demands urgent development possible strategies protect people high risk infection hence drug repurposing became emerging approach fight covid<NUMBER> review summarizes update various therapeutic strategies special attention repurposing drugs fight sarscov<NUMBER> worldwide investigation existing drugs new therapeutic purposes one line scientific research followed develop safe effective covid<NUMBER> treatments broadspectrum antiviral agents bsaas believed safe testing early phase clinical trials hyped good drug repurposing candidates broadspectrum antiviral drugs ribavirin umifenovir advised covid<NUMBER> treatment antibiotics may repurposed covid<NUMBER> treatments teicoplanin oritavancin dalbavancin monensin azithromycin ivermectin antiparasitic recently repurposed hydroxychloroquine chloroquine immunomodulating effect humans shown antiviral activity starting postentry stages sarscov<NUMBER> infection need global health emergency call courageous global response political governmental levels therefore regulatory agencies must act swiftly lessen financial obstacles involving private companies update guidelines drug licenses repurposing necessary update therapeutic repurposing strategies covid<NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> responsible first global pandemic decade coronavirus disease <NUMBER> covid<NUMBER> initial reports novel sarslike acute respiratory syndrome emerged late <NUMBER> wuhan china<NUMBER> since covid<NUMBER> spread <NUMBER> countries continents except antarctica<NUMBER> time writing one million people infected <NUMBER> deaths attributed outbreak<NUMBER> millions additional infections projected occur globally upcoming months<NUMBER> covid<NUMBER> less infectious sarscov<NUMBER> lethal common flu<NUMBER> estimated mortality rate <NUMBER> incubation period average <NUMBER> days severe cases median time course disease onset death <NUMBER> days<NUMBER> fever cough fatigue myalgias<NUMBER> common mild presentations covid<NUMBER> disease fatally evolve severe pneumonia complicated acute respiratory distress syndrome hypoxemic respiratory failure cytokine storm secondary prolonged infection<NUMBER> addition significant medical burden imposed outbreak estimated global economic cost covid<NUMBER> <NUMBER> trillion <NUMBER> emotional toll individuals incalculable prolonged quarantine policies restricting personal freedom social contacts current treatment supportive focused managing disease complications secondary symptoms<NUMBER> drugs indicated infectious diseases antiviral antiparasitic therapies used covid<NUMBER> patients paucity evidence supporting efficacy<NUMBER> immediate need identify therapeutic compounds rapidly repurposed covid<NUMBER> treatment recent efforts address pressing public health concern include comprehensive networkbased approach identify <NUMBER> candidate drugs drug combinations may repurposed treatment disease<NUMBER> expand area novel research present study employ bioinformatics approach goal datamining extensive drug signature resource distill list drug therapies may prove fruitful search covid<NUMBER> therapies accomplish apply signaturebased connectivity analysis<NUMBER> utilizing extensive chemical perturbagen omics datasets deposited library integrated networkbased signatures lincs database<NUMBER> lincs repository systematically generated gene signatures based l<NUMBER> assay<NUMBER> gene signatures reflect cellular perturbations response pharmacological treatments lincs contains datasets <NUMBER> small molecules drugs various cell lines different small molecules produce signatures composed highly similar patterns gene expression changes concordant signatures reflect shared connections small molecules apply twopronged approach identify novel compounds treatment covid<NUMBER> first identify pharmacologic therapies effective treatment pathogens coronavirus family like sars middle east respiratory syndrome mers well viral illnesses<NUMBER> generate gene signatures targets ilincs httpilincscom highlight connected small molecule signatures identify candidate drugs highly concordant current therapies simultaneously generate gene signatures coronavirus infected human cell line transcriptomic datasets analyze data ilincs directly match disease signatures discordant small molecule signatures thereby identifying drugs reverse disease signature finally compile list drugs two approaches identify highyield candidate drugs may therapeutic utility treatment covid<NUMBER> applying workflow outlined figure <NUMBER> identified nine drugs known efficacy treating coronavirus family pathogens gene signatures ilincs table <NUMBER> extended information table s<NUMBER> drugs clustered five groupings according mechanism action anatomical therapeutic chemical atc classification andor structural similarity table <NUMBER> simultaneously extracted differential gene expression data <NUMBER> genes comprise l<NUMBER> publically available sars gse<NUMBER> transcriptomic dataset gene signatures composed genes changed lfc ≥ <NUMBER> ≤ <NUMBER> generated disease signature table s<NUMBER> ilincs conducted connectivity analysis identify chemical perturbagens highly concordant drug target groupings ≥ <NUMBER> highly discordant disease signatures ≤ <NUMBER> established minimum ilincs concordance score cutoffs <NUMBER> resulted identification <NUMBER> chemical perturbagens common two cell lines mcf<NUMBER> ha<NUMBER>e figure <NUMBER> fourteen chemical perturbagens identified concordance scores ≥ <NUMBER> cell lines considered candidate drugs treatment covid<NUMBER> table <NUMBER> tanimoto scores candidate drugs original <NUMBER> drug targets generated showing structural similarity drugs currently use treatment coronavirus family pathogens newly identified candidate drugs figure s<NUMBER> unsupervised clustering l<NUMBER> disease gene signatures demonstrates significant differences patterns gene expression induced sars mers influenza figure s<NUMBER> influenza utilized control dataset represents noncoronavirus pathogen also causes respiratory illness promising genistein yet explored antiviral therapy humans at<NUMBER> broad protein kinase inhibitor<NUMBER> canonically acts receptor nonreceptor tyrosine kinase inhibitor also effectively inhibits serinethreonine kinases aurora ab kinases janus kinases jak <NUMBER> abl kinases<NUMBER> clinical setting at<NUMBER> predominantly studied antineoplastic hematologic malignances several trials underway<NUMBER> at<NUMBER> explored directly antiviral although abl kinase inhibitor imatinib efficacious preventing coronavirus sarscov merscov viral fusion endosomes effectively halting viral activity<NUMBER> given role broadspectrum kinase inhibitor researching antiviral properties at<NUMBER> may prove fruitful serine threonine kinase inhibitors alvocidib also known flavopiridol panspecific cyclindependent kinases cdk inhibitor inhibits cdk<NUMBER> cdk<NUMBER> cdk<NUMBER> cdk<NUMBER> cdk<NUMBER> cdk<NUMBER> cdk<NUMBER> alvocidib clinical investigation antineoplastic solid tumors hematologic malignancies<NUMBER> like cdk kinase inhibitors alvocidib implicated broad antiviral several dna virus families<NUMBER> alvocidib studied inhibitor transcriptional activation elongation infectious lifecycle dna viruses hsv<NUMBER> hsv<NUMBER> retroviruses hiv<NUMBER> also suppresses replication influenza a<NUMBER> suggests alvocidib strong candidate drug repurposing antiviral activity following serinethreonine kinase candidate drugs yet studied directly research required determine potential repurposable antiviral therapies however candidates members drug families demonstrated antiviral antimicrobial properties could exploited treatment covid<NUMBER> gsk<NUMBER> reversible atpcompetitive thiazolidinedione inhibitor phosphoinositide <NUMBER>kinase pi<NUMBER>k studied antineoplastic solid tumors<NUMBER> though antiviral activity gsk<NUMBER> yet determined thiazolidinedione drug family broad range antibacterial antiparasitic activity<NUMBER> idelalisib phosphoinositol <NUMBER>kinase idebenone synthetic derivative ubiquinone also known coenzyme q<NUMBER> drug acts increase production atp enhancing oxidative phosphorylation general antioxidant idebenone may prevent lipid peroxidation reduce membrane oxidative stress scavenge free radicals<NUMBER> idebenone used number human neurodegenerative disorders safety validated<NUMBER> antioxidants idebenone hypothesized mitigate deleterious effects reactiveoxygen species burst<NUMBER> viruses pulmonary respiratory predilections influenza sars<NUMBER> however work required determine utility antioxidants like idebenone adjunct treatments covid<NUMBER> penicillin v betalactam antibiotic indicated primarily treating gram covid<NUMBER> outbreak escalating public health concern requires swift baricitinib may reduce ability virus enter cells currently clinical use treatment rheumatoid arthritis advance therapeutic discovery identification candidate drugs covid<NUMBER> employ alternative signaturebased bioinformatic approach study data mine extensive lincs database acts repository l<NUMBER> gene signatures generated treating various cell lines <NUMBER> small molecules l<NUMBER> genes reduced representation transcriptome method select group genes account <NUMBER> information content transcriptome<NUMBER> approach involved feature selectionreduction techniques applied <NUMBER> gene expression samples profiled microarrays geo<NUMBER> benchmarking l<NUMBER> assay versus rnaseq yielded crossplatform correlation <NUMBER> suggesting l<NUMBER> assay represents efficient alternative rnaseq utilizing resource twopronged connectivity analysis approach identified candidate drugs <NUMBER> highly concordant current drugs employed treat coronavirus family pathogens <NUMBER> highly discordant sars disease gene signatures interestingly antibiotic quinacrine also identified recent networkbased covid<NUMBER> drug screen<NUMBER> another βlactam antibody ceftriaxone clinical trial adjunct treatment covid<NUMBER> nct<NUMBER> immunosuppressant sirolimus identified study albeit less stringent threshold well another silico drug screen<NUMBER> candidate repurposable drug treating covid<NUMBER> immunosuppressants may address symptoms resulting overactivation immune system cytokine storm response covid<NUMBER> infection<NUMBER> class drug also clinical trial adjunct treatments eg thalidomide nct<NUMBER> antimicrobial drugs comprise drug target groupings limited gene signatures ilincs analyze gene signatures generated two cell lines mcf<NUMBER> ha<NUMBER>e data available drug targets cell lines workflow study outlined figure <NUMBER> conducted pubmed search using search terms coronavirus covid<NUMBER> antiviral drug therapy generated list compounds utilized treat coronavirus family pathogens identified putative covid<NUMBER> therapeutics identified seventeen drugs potential analysis table s<NUMBER> l<NUMBER> gene signature datasets available nine seventeen drugs table <NUMBER> next grouped nine drug targets based canonical mechanism action anatomical therapeutic chemical atc classification structural similarity drugs grouped together categorized least two three methods database drugbank httpswwwdrugbankca used group drugs canonical mechanisms actions drug identification referenced drug bank id drug bank id available indicated table <NUMBER> table s<NUMBER> listed moa drug bank moa appropriately cited referenced ilincs referenced gene ontology go molecular function <NUMBER> accessed via enrichr httpamppharmmssmeduenrichrenrich next drugs classified based atc classification system httpswwwwhoccnoatcdddindex particular drug atc classification marked unclassified drugbank also collected clinical indications gene targets trade names addition probed atc index httpswwwwhoccnoatcdddindex identify firstand secondlevel drug classifications firstlevel classification used confirm drug grouping finally group drugs based structural similarity structural data files sdf nine drugs investigation downloaded drugbank package chemminer used generate <NUMBER>bit binary fingerprints compound tanimoto coefficient pairs fingerprints computed also using r package chemminer tanimoto coefficient also known jaccard similarity represents popular measure chemical similarity<NUMBER> ratio intersection two fingerprints divided union two fingerprints data visualized using corrplot package final list drug clusters individual drug signatures within grouping collected averaged across l<NUMBER> using ilincs portal acquired lincs chemical perturbagen signatures <NUMBER> genes comprise l<NUMBER> drug candidate genes log fold change lfc value ≥ <NUMBER> ≤ <NUMBER> indicating differential gene expression induced drug target compared corresponding control cell line exported microsoft excel gene lists pooled averaged master list differentially expressed genes generated drug candidate family example genes lfc ≥ <NUMBER> ≤ <NUMBER> appeared hydroxychloroquine gene signature chloroquine gene signature averaged calculate mean values differentially expressed gene drug target grouping <NUMBER> next upregulated genes lfc ≥ <NUMBER> clustered downregulated genes ≤ <NUMBER> clustered clusters uploaded user generated signatures ilincs next identified connected chemical perturbagens utilizing concordance threshold score ≥ <NUMBER> established minimum concordance score cutoff <NUMBER> identify chemical perturbagen signatures considered highly correlated drug target grouping signatures selected datasets <NUMBER>h conducted differential gene expression analysis datasets comparing virus infected samples corresponding control samples rnaseq raw count data analyzed using edger r package v<NUMBER> differential gene expression<NUMBER> quality control step require gene count least <NUMBER> least libraries considered expressed normalization performed using default method trimmed mean mvalues tmm step performed using calcnormfactor function returns dgelist argument set calculated normalization factors one sample eliminate composition biases libraries orghsegdb r package v<NUMBER> used complement gene annotation following analysis disease transcriptomic datasets subset genes comprise lincs l<NUMBER> extracted differentially expressed gene list dataset l<NUMBER> genes extracted sars mers rnaseq datasets <NUMBER> <NUMBER> overlapping genes respectively extracted used existing gene raw counts geo remap genes thus l<NUMBER> genes mapped unable access expression addition applied gene raw count cutoff <NUMBER> quality control step also reduced number l<NUMBER> genes found final differential expression gene lists extracted l<NUMBER> genes uploaded ilincs genes lfc expression within three thresholds <NUMBER> lfc <NUMBER> lfc l<NUMBER> genes identified custom r script processing described upregulated regulated disease gene signatures generated disease dataset within threshold uploaded ilincs identify connected perturbagens disease gene signatures chemical perturbagen signatures highly discordant discordance score ≤ <NUMBER> indicating perturbagens may reverse disease signature identified genes lfc ≥ <NUMBER> ≤ <NUMBER> threshold carried forward analysis utilizing gene threshold generated optimal sars disease signatures identify large number discordant chemical perturbagens addition identified microarray dataset human airway epithelium cells infected influenza h<NUMBER>n<NUMBER> serotype gse<NUMBER> <NUMBER>h time point microarray data extracted using geoquery r package v<NUMBER> <NUMBER> specifically soft format files geo containing information geo records parsed normalized gene expression values associated soft files selected samples filewere analyzed using limma r package v<NUMBER> linear model microarray<NUMBER> described l<NUMBER> genes extracted since dataset performed microarray platform limits gene detection probes available arrays extracted <NUMBER> l<NUMBER> genes addition mers dataset represents pathogenic coronavirus like sars influenza dataset used comparison dataset unsupervised clustering biological pathway analyses described influenza represents noncorona family virus also causes respiratory disease<NUMBER> total <NUMBER> overlapping l<NUMBER> genes used clustering analysis heat map generation candidate drugs identified chemical perturbagen connectivity analysis using custom script r script downloaded data ilincs api used following criteria chemical perturbagens concordance score ≥ <NUMBER> compared drug target grouping signatures discordance score ≤ <NUMBER> compared disease signatures cell lines mcf<NUMBER> total <NUMBER> chemical perturbagens common cell lines chemical perturbagens concordance scores ≥ <NUMBER> mcf<NUMBER> ha<NUMBER>e cell lines considered candidate drugs resulting final list <NUMBER> candidate drugs heat maps l<NUMBER> gene data drug target groupings candidate drugs disease sars mers datasets generated described addition l<NUMBER> gene data furosemide fur drug used treat viral pathogens related illnesses influenza noncoronavirus family pathogen associated respiratory illness included heat maps datasets acts controls suggesting drug target groupings candidate drugs unrelated drugs discordant coronavirus disease signatures specifically sdf <NUMBER> drugs comprise drug target groupings downloaded drugbank sdf files <NUMBER> candidate drugs downloaded pubchem chembl chemminer used convert sdf files binary chemical fingerprints tanimoto coefficients chemical fingerprints <NUMBER> drugs comprise drug target groupings <NUMBER> candidate drugs pairs computed using chemminer library tanimoto coefficient also known jaccard similarity represents established measure chemical similarity data visualized heat map using gplots package r scripts utilized data processing accessed httpsgithubcomalisajidcovid<NUMBER> unsupervised clustering analysis performed log fold change values disease drug target signatures heat map generated using pheatmap package<NUMBER> r programming language generate biological pathways associated drug targets disease datasets gene list list supplementary files associated preprint click download supplementalmaterialpdf severe acute respiratory syndrome sars emerged <NUMBER> following outbreak new sarsrelated coronavirus scv resulted hundreds deaths worldwide infecting thousands individuals fouchier et al <NUMBER> since plethora research aiming understanding etiology disease weiss navasmartin <NUMBER> developing reliable faster diagnostic solutions yamaoka et al <NUMBER> innovating antiviral drugs keyaerts et al <NUMBER> vaccines yong et al <NUMBER> many studies successfully repurposed previous findings solve new challenges biology medicine example group viruses shares common protein structure therapies one viral infection repurposed new diseases like covid<NUMBER> unfortunately viruses often mutate several challenging strains capable infecting humans highly contagious manner eventually triggers onset zoonotic infections ie animaltohuman humantohuman transmission virus strain ozawa kawaoka <NUMBER> ongoing global pandemic coronavirus disease emerged due new strain scv named sars coronavirus <NUMBER> sarscov<NUMBER> arguably hosted bats march <NUMBER>st <NUMBER> <NUMBER> people <NUMBER> countries infected virus three months taking toll <NUMBER> human lives numbers continue grow exponentially dong et al <NUMBER> outbreak already started cause unprecedented impact humankind scale threatens reshape global economy human lives world beyond unfortunately entails substantial time effort study new strains viruses arxiv<NUMBER>v<NUMBER> csir <NUMBER> apr <NUMBER> developing targeted failsafe drug vaccine without immediate solution several countries recently approved use hydroxychloroquine treat critically ill patients diagnosed covid<NUMBER> despite known sideeffects masuelli et al <NUMBER> notably hydroxychloroquine drug treating patients diagnosed malaria benzvi et al <NUMBER> repurposing malaria drug treat coronavirus related patients suggests topics virology genetic engineering bioinformatics pharmacology literature may valuable recommendations covid<NUMBER> research since <NUMBER> outbreak coronavirus many scholarly articles published topics sars scv feasible scientists survey massive volume diverse literature derive useful crossdisciplinary insights within short period time computerbased modeling text documents powerful approach search valuable information large collection diverse literature paper developed graphbased model using large volume scientific literature discover latent keywords may recommend new information combat battle covid<NUMBER> text analytics keywords searching plays important role document summarization hernándezcastañeda et al <NUMBER> classification diazmanriquez et al <NUMBER> topic modeling jelodar et al <NUMBER> however task preserving semantic syntactic information language numerical models trivial three broad categories texttonumeric representation models first termfrequencyinversedocument frequency tfidf yuntao et al <NUMBER> one earliest methods text representation based word count however models capture semantic relevance syntactic ordering words second manifold learning techniques skip gram cheng et al <NUMBER> glove pennington et al <NUMBER> developed efficiently capture semantic relevance words numeric data vectors numeric embeddings directly map intricate relationship words within document third graphs used develop interconnected network words document directly model syntactic ordering connectivity words graphbased keyword extraction model using collective node weight kecnw proposed based nodeedge rank centrality measure biswas et al <NUMBER> several attributes distance central node selectivity node based number connecting edges importance neighboring nodes taken account determine weight node node weights used rank individual words keyword selection additionally graphbased models provide informative interactive visualization complex interconnected network words document rusu et al <NUMBER> goal paper develop dense graphical network words summarize thousands research articles topics related coronavirus collection influential nodes keywords may provoke new research topics ongoing covid<NUMBER> research steps involved proposed research methodology discussed work use publicly available covid<NUMBER> open research dataset cord<NUMBER> released collaborative initiative allen institute ai chan zuckerberg initiative czi georgetown universitys center security emerging technology cset microsoft national library medicine nlm national institutes health nih request white house office science technology policy dataset includes <NUMBER> scholarly articles full texts areas life science including pharmacology immunology physiology microbiology clinical medicine genetics veterinary many articles related study covid<NUMBER> sarscov<NUMBER> similar coronaviruses dataset comes metadata actual article texts structured data fields identify title paper publication information abstract main body texts details dataset found kaggle website httpswwwkagglecomalleninstituteforai cord<NUMBER>researchchallenge communitybased data science platform solving problems around world propose directed graph gn e based model represented set nodes n set edges e directions node n ∈ n represents unique word directed edge e ∈ e connects two adjacent words based positioning sentence direction edge points preceding word succeeding word sentence shown figure <NUMBER> using principle sequencebased text graph first generated using texts articles next step determine importance node graph based concept centrality general node higher centrality central positioning graph example node relatively shortest paths nodes graph highest measure centrality hage harary <NUMBER> paper measure centrality node using betweenness centrality bc algorithm widely applied social network analysis however bc algorithm well studied topic selection modeling large volume texts propose article bc algorithm originally proposed freeman <NUMBER> later upgraded brandes <NUMBER> improve computational performance bc measurement node highest centrality located highest number shortest paths node pairs graph words word frequently appears shortest paths word pairs word high value centrality thus bc algorithm finds influential words imperative understanding relationship word pairs transitive words weighted representative nodes graph selected key topics subsequent analysis intuitively approach sophisticated informative using distancebased centrality measurement u v w∈ n u v w shortest path two nodes calculated using standard dijkstras algorithm measure bc node w graph number shortest paths node pairs first obtained denoted σ uv next number shortest paths σ uv w counted node pairs include target node w path ratio two counting numbers calculated pair nodes pairdependency δ uv sum pairdependency across possible pairs excluding w graph yields bc target node w node representing unique word representative topic corpus words ranked bc measurements select semantically important key topics relatively high bc values key topics used create corresponding subgraphs topic word center subgraph neighboring words constituents topic proposed method require number topics advance compared topic modeling algorithms latent dirichlet allocation lda hoffman et al <NUMBER> latent semantic analysis lsa landauer et al <NUMBER> develop proposed model perform text analysis python programming environment using several python packages packages include natural language tool kit nltk basic text analysis regular expressions package text preprocessing graph database neo<NUMBER>j python database connector library py<NUMBER>neo used build graph first step text processing identify remove stop words words little merit keywords corpus step reduces complexity graph modeling also puts weights relevant candidate words graph dataset includes research articles composed chinese russian arabic korean languages confine analysis english articles excluding nonenglish words using regular expression regex regex also used filter undesired symbols numeric data graph data including nodes edges exported gephi bastian et al <NUMBER> better visualization manipulation graph models modeldriven results notebooks source code data publicly shared github project repository httpsgithubcommsahamedcovid<NUMBER>textnetwork proposed graph model developed using available article abstracts dataset assume abstract succinct sufficient information represent overall content research article global graph developed using article abstracts find several influential words based bc values linked coronavirus next build separate subgraph selected key topic shown figure <NUMBER> within subgraph neighboring nodes key topic expected reveal variety information topic word neighboring words grouped several categories within category rank order neighboring words using bc values obtained subgraph model identify relative importance discuss findings approach next section cord<NUMBER> dataset substantial number articles missing abstracts therefore use available abstracts <NUMBER> research articles build proposed graph model data processing step created list <NUMBER> stop words based word frequency visual scrutiny exclude corpus first find word coronavirus global graph select three neighboring nodes high bc values since bc values exponentially large take natural logarithm values log bc select three key topics transmission drug gene log bc values <NUMBER> <NUMBER> <NUMBER> respectively following subsections discuss findings three subgraph models corresponding transmission drug gene topics respectively studies related infectious disease transmission important understanding spread growth pathogens different media table <NUMBER> shows neighboring words transmission subgraph subgraph reveals number hostpathogen interactions animal hosts poultry camel dogs pigs monkeys chimpanzees may candidates studying transmission mechanism different zoonotic pathogens related coronavirus coronavirus related topic transmission also connects number diseases pathogens including rabies dengue tuberculosis adenovirus malaria measles handfootandmouth disease hfmd pathogens may interesting traits common transmission coronavirus keywords multidrug resistant organism mdro tropism growth movement organisms zoonosis topic disease transmission animals humans sanitization bioaerosols expectedly appeared subgraph transmission topic additionally subgraph includes words related different transmission media blood respiratory lung water aerosol oronasal gut mouth trachea glands droplet saliva airborne semen miscellaneous keywords presented table <NUMBER> includes infants pregnancy important topics transmission studies figure <NUMBER> shows important keywords transmission subgraph based bc measurements among pathogen hosts pigs dogs camels topped list although bats appear list hosts appear later gene subgraph top diseases rank ordering dengue rabies malaria adenovirus may topics common study coronavirus transmission rhinovirus related common cold lyssavirus often hosted bats appeared ranking adenovirus ranked third position causes symptoms similar coronavirus infection study drugs pharmacology plays big role battle diseases group neighboring words within drug subgraph four categories drug chemical compound disease miscellaneous figure <NUMBER> shows important keywords four different categories interestingly antiviral drug amantadine highest rank even chloroquine amantadine administered treat symptoms related flu viruses although may effective treating illness due types virus strains dexamethasone almost similar bc measurement chloroquine drug aid immune system fight inflammation disease category drug subgraph zikavirus pneumonia appear top two keywords followed hiv dengue rank ordering quite different transmission subgraph figure <NUMBER> dengue topped list may common pharmaceutical interests shared drugs used zikavirus coronavirus treatment chemical category glycoprotein chemical reaction known glycosylation topped list oligonucleotides single strands rna ranked fourth category presumably known effect inhibiting replication influenza virus kumar et al <NUMBER> interestingly plantbased compound glycyrrhizin ranks fifth list used cure bronchitis gastritis jaundice proteins enzymes list require discussion field experts miscellaneous category suggests research studies focusing metabolism prophylaxis actions prevent disease pharmacokinetics movement drugs body seroprevalence number individuals tested positive based blood serum ovirus vsv polyomavirus atherosclerosis hsv brsv kshv cpv torovirus hku<NUMBER> circovirus brd gbs rrv cirrhosis orthoreovirus hypoxia bunyavirus phev hartmanivirus pvx dyskinesia lassa pr<NUMBER> vwd hpyv<NUMBER> host macaque pigs cats bat mice swine poultry birds porcine cattle camels cynomolgus horses ades biomolecular pcr rna dna ace<NUMBER> ngs aptamers metagenomics qpcr sirna cd<NUMBER> ceacam<NUMBER> haplotypes mirna dpp<NUMBER> kda stat<NUMBER> apod ifnar shrnas apoe vsirnas apom ifn glycoprotein corticosteroids prp macrolide macrophages cytokine interferon nucleotide polymerase demyelination immunoglobulin astrocytes chemokines myelin prf th<NUMBER> kinases pleiotropic orf<NUMBER> phosphoprotein kegg caspase peptidase eukaryotes mycoplasma cryptosporidium mycobacterium mbl<NUMBER> study genes imperative distinguishes different virus strains identifies target proteins successful discovery drugs vaccines gene subgraph includes large number diseases pathogens shown table <NUMBER> list includes hepatitis viruses hcv hbv hev influenza viruses h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> h<NUMBER>n<NUMBER> pr<NUMBER> viruses related dengue denv chikungunya chikv hiv zikavirus malaria many viruses share similar genomic structure replication strategy repurposed pathogenic study drug discovery novel virus strains cov<NUMBER> coronaviruses related pigs porcine epidemic diarrhea virus pedv porcine hemagglutinating encephalomyelitis virus phev mouse hepatitis virus mhv feline infectious peritonitis fip virus mice originated human coronavirus hku<NUMBER> alphaand betacoronaviruses mainly infect bats appear subgraph belong coronaviridae virus family host list several species monkey macaque cynomolgus appeared addition pigs bats result proofofconcept bats subjects genetic research related coronavirus discovery coronavirus strains hosts like pangolin recent discovery still active research lam et al <NUMBER> group neighboring words gene subgraph four categories host disease biomolecular miscellaneous biomolecular category includes proteins cellular mechanisms drugs biochemical compounds figure <NUMBER> shows rank ordering keywords category based bc measurements interestingly cancer appears sars influenza pneumonia suggests link genomic studies cancer virus porcine epidemic diarrhea virus pedv appears fifth position suggesting important pathogen genetic study flu viruses bimolecular category polymerase chain reaction pcr mechanism used molecular biology testing coronavirus ranked second rna abbreviation interferon ifn appears fourth category second miscellaneous keyword category set proteins released host response virus attack host category mice rank top followed bat cat pig species monkey macaque potentially intriguing keywords ranking require space scope discussion developed graphbased model mine information covid<NUMBER> research major findings follows figure <NUMBER> rank ordering influential keywords gene subgraph linked coronavirus node subgraph keywords grouped disease host biomolecular miscellaneous categories log bc natural logarithm betweenness centrality research cancer flu virus <NUMBER> list antiviral drugs identified amantadine ranks chloroquine treatment flu virus infection importantly authors recent review finding therapies covid<NUMBER> li de clercq <NUMBER> highlight importance repurposing antiviral agents used treating hiv hbv hcv influenza b oligonucleotide interferonbased therapies c glycoprotein target antiviral agent reference rna viruses influenza ebola chikungunya enterovirus e drug nitazoxanide inhibit cov<NUMBER> appear subgraph models rank order believe similar keywords intrigue scientists find repurposing candidates covid<NUMBER> research despite promising findings several limitations study first high bc values top ranked keywords may partly attributed high prevalence literature possibility keywords lower rank order less prevalent literature however lowranked keywords still strong candidates future covid<NUMBER> research second analysis limited article abstracts without incorporating full article texts richer source information third use explicit metric evaluate graph model performance findings since study entirely exploratory fourth graph model includes broad array diverse health science literature grouping research articles subsequent analysis within individual subgroups may yield focused results leave tasks future work paper demonstrates one first studies mining large volume health science literature search information ongoing battle covid<NUMBER> results presented tables figures different topics effectively summarize key information contents literature aid graphbased computational model betweenness centrality based keyword ranking proposed model able recommend informative drug types pathogens hosts chemical biomolecules covid<NUMBER> research may always evident concerned researchers findings may useful reference guide provoke new ideas expedite new directions research fight covid<NUMBER> pandemic time writing piece pandemic atypical pneumonia coronavirus disease <NUMBER> covid<NUMBER> caused novel coronavirus severe acute respiratory syndrome sarscoronavirus <NUMBER> cov<NUMBER> spread globally <NUMBER> million cases close <NUMBER> <NUMBER> deaths httpswwwworldometersinf ocoronavirus current epidemiological economical potentially political disaster making follows wake earlier outbreaks respiratory infections sars middle east respiratory syndrome mers also caused coronaviruses <NUMBER> currently known cure covid<NUMBER> available medical treatment largely limited alleviation respiratory dysfunction associated severe course disease result enormous effort across biomedical sciences mounting develop therapeutic means treating covid<NUMBER> one key area development vaccination may <NUMBER> five candidate vaccines clinical evaluation many <NUMBER> preclinical stage <NUMBER> yet necessities research development process dictate none abovein best possible scenariowill clinically available earlier <NUMBER> months time <NUMBER> given unprecedented scale current outbreak immense pressure find faster cheaper therapeutic solutions rapidly worsening global health crisis broad agreement perhaps best way produce affordable treatment faster timescale repurpose existing drugs much interest directed way especially focusing drugs previously demonstrated antiviral capabilities <NUMBER> however lack basic understanding cell biology sarscov<NUMBER> infection limits efficacy approach although recent years yielded insight cell biology related human virus sarscov two viruses may bind surface receptor protein angiotensinconverting enzyme <NUMBER> ace<NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> genomes still differ <NUMBER> <NUMBER> associated epidemiological picture different indeed furthermore extent ace<NUMBER> protein expression airways subject controversy <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> preliminary evidence hints surface receptors may involved sarscov<NUMBER> infection <NUMBER> resulting gap knowledge forms major obstacle road towards effective drug repurposing treating covid<NUMBER> critical step viral infection involves penetration viral particles cytosol end viruses take advantage endocytic membrane trafficking host cell <NUMBER> canonical endocytic pathways mammalian cells involve budding clathrincoated vesicles action large gtpase dynamin also multiple pathways noncanonical endocytosis caveolae flotillin<NUMBER>associated endocytosis clathrinindependent carrierglycosylphosphatidylinositolanchored proteinenriched endosomal compartment endocytosis macropinocytosis <NUMBER> viruses shown use <NUMBER> fig <NUMBER> mechanistic details pathways may vary considerably cell types diversity endocytosis airway epithelium currently poorly understood understanding endocytic viral entry respiratory tract may therefore offer promising therapeutic strategy treat viral infections far coronaviruses concerned current evidence suggests mode entry vary viruses host cell types include clathrindependent endocytosis <NUMBER> caveolae <NUMBER> clathrinand caveolaeindependent mechanism involving lipid rafts <NUMBER> <NUMBER> fusion cell surface proposed potential entry mechanism <NUMBER> directly demonstrated sarscov sarscov<NUMBER> appear require endocytosis cultured cell lines <NUMBER> <NUMBER> <NUMBER> <NUMBER> sarscov may endocytosed via one pathway depending cell line <NUMBER> <NUMBER> however little knowledge regarding details epidemiologically relevant mode viral entry human lung therefore imperative consider sarscov<NUMBER> endocytic trafficking context correct host cell type preliminary evidence suggests infection sarscov<NUMBER> may begin upper respiratory tract example nasal epithelium expresses highest levels sarscov<NUMBER> receptors <NUMBER> significant morbidity indeed mortality however appear associated severe stage disease infection spreads lower airways lung resulting respiratory failure possibly multiorgan failure due cytokine storm <NUMBER> although histopathology data still scant two case studies preliminary findings primate disease model indicate lower airway sarscov<NUMBER> infection may specifically affect alveolar epithelial cells termed pneumocytes <NUMBER> <NUMBER> <NUMBER> clearly blockade sarscov<NUMBER> entry either stages likely yield considerable therapeutic benefits establish endocytic pathways likely operate nasal epithelial cells pneumocytes clues gleaned local expression profile key endocytic proteins evidenced human protein atlas httpswwwproteinatlasorg nasal epithelial cells abundantly express wide variety endocytic markers suggesting presence multiple active pathways agreement ultrastructural evidence <NUMBER> conversely pneumocytes show restricted expression pattern key proteins associated conventional endocytosis either low missing importantly large gtpase dynamin required endocytosis clathrincoated vesicles caveolae abundant nasal epithelium undetectable pneumocytes contrast mediumtohigh expression levels proteins involved macropinocytosis cterminal binding protein ctbp<NUMBER> <NUMBER> p<NUMBER>activated kinase <NUMBER> therefore macropinocytosis may important endocytic pathway pneumocytes potentially distinct endocytic profile upper lower airways reflected relevant infection mechanisms known pathogens upper respiratory epithelium infected numerous airborne pathogens multiple pathways dynamindependent dynaminindependent endocytosis <NUMBER> conversely pneumocyte infection much less well understood however entry macropinocytosis consistently demonstrated airborne bacterial viral pathogens mycobacterium tuberculosis <NUMBER> francisella tularensis <NUMBER> influenza virus <NUMBER> adenovirus adenovirus serotype <NUMBER> <NUMBER> haemophilus influenzae <NUMBER> well various nanoparticles <NUMBER> <NUMBER> intriguingly macropinocytosis alveolar epithelial cell line upregulated waterpipe smoke condensate suggesting possible mechanism underlying association covid<NUMBER> morbidity smoking <NUMBER> taken together evidence suggests sarscov<NUMBER> may employ distinct endocytic pathways cell entry upper lower respiratory tract fig <NUMBER> pathways address question directly need investigate cell biology sarscov<NUMBER> endocytosis detail potential experimental model investigating key events sarscov<NUMBER> cell entry vitro suitable starting model initial investigation sarscov<NUMBER> endocytosis involve established immortalised cell lines derived respiratory tract epithelium httpswwwatccorgmediapdfs cancer<NUMBER>and<NUMBER>normal<NUMBER>cell<NUMBER>lines<NUMBER>table slung<NUMBER>cancer<NUMBER>and<NUMBER>normal<NUMBER>cell<NUMBER>line sashx lines provide several key methodological advantages wellcharacterised easy maintain using standard cell culture protocols retain key characteristics primary cell type origin emulation respiratory tract environment cell lines grown airliquid interface culture described <NUMBER> <NUMBER> immortalised cell cultures offer simple costeffective platform investigation cell biology however important caveats associated immortalised cell cultures vitro need addressing validation one key consideration expression profile cell line may different original tissue especially relevant regard membrane trafficking discrepancy expression certain key proteins may affect organisation whole network example lung cell line a<NUMBER> express multiple isoforms dynamin <NUMBER> case pneumocytes human lung tissue result findings arising cell lines need investigated expensive clinically relevant system primary cells cell preparations lower upper <NUMBER> <NUMBER> preliminary evidence shows systems efficiently infected sarscov<NUMBER> <NUMBER> alternatively cells directly obtained human subjects example nasal epithelium alveolar epithelial cells isolated surgically resected lung tissue material <NUMBER> regardless validation findings primary cells key step investigation investigation membrane trafficking sarscov<NUMBER> requires probe adequately recapitulate intracellular itinerary virus using active clinically isolated live virus samples would course allow closest approximation however major drawback approach highly infectious nature virus necessitating use biosafety level <NUMBER> laboratory alternative approach would involve pseudoviruses combining viral surface proteins responsible cell receptor binding lack sarscov<NUMBER> genetic material renders incapable replication allowing work biosafety level <NUMBER> laboratory pseudoviruses successfully used investigate trafficking sarscov merscov <NUMBER> <NUMBER> sarscov<NUMBER> pseudovirus models recently published <NUMBER> <NUMBER> infection viral probe added cells different lengths time order determine endocytic pathways involved sarscov<NUMBER> endocytosis one employ standard methods multicolour fluorescence immunocytochemistry light microscopy colocalisation analysis proportion internalised virus colocalising classical markers membrane trafficking compartments indicate intracellular itinerary virus <NUMBER> approach multiple wellcharacterised antibody markers intracellular compartments example early endosomes late endosomes lysosomes available detailed investigation endocytic route virus viral infection combined uptake typical cargoes different endocytic pathways approach would allow tracking virus relation endocytic pathways also investigate effect viral infection general membrane trafficking network host cell suitable cargo molecules include transferrin clathrindependent endocytosis <NUMBER> cholera toxin b subunit caveolae <NUMBER> dextran fluidphase macropinocytosis flotillindependent endocytosis <NUMBER> relative contribution different endocytic pathways sarscov<NUMBER> infection address question lossoffunction analysis performed involving knockdown key regulatory proteins different endocytic pathways example dynamin <NUMBER> caveolin<NUMBER> flotillin<NUMBER> ctbp <NUMBER> <NUMBER> fig <NUMBER> resulting findings corroborated using available pharmacological blockers endocytic pathways including dynasore pitstop clathrindependent endocytosis nystatin caveolae methylbetacyclodextrin dynaminindependent endocytosis amiloride macropinocytosis however care must exercised interpretation results due offtarget effects agents endocytic pathways target pathway may inhibited <NUMBER> <NUMBER> <NUMBER> taken together combination adequate cell models newly developed sarscov<NUMBER> toolkit established tools membrane trafficking research wellpoised deliver key insight mechanisms underlying covid<NUMBER> infection two broad approaches developing drugs sarscov<NUMBER> involve targeting biology host versus targeting biology virus one clear drawback associated global perturbation general cell biological function potential unwelcome side effects whether target tissue elsewhere body conversely key advantage focusing cell biological mechanism relatively immutability host cell compared virus may evolve drug resistance due high mutation rate <NUMBER> <NUMBER> furthermore considering various viruses may use endocytic pathways host cell <NUMBER> targeting viral entry point endocytosis holds general promise development broadspectrum antiviral drugs <NUMBER> endocytic route sarscov<NUMBER> primary lung epithelial cells established insight capitalised upon translational needs specifically cellbased model sarscov<NUMBER> infection <NUMBER> lend establishment screening platform drug development aiming identify compounds capable blocking hindering sarscov<NUMBER> endocytic entry already vivid interest chloroquine hydroxychloroquine two related drugs may block viral entry endosomal acidification fig <NUMBER> although evidence effectiveness currently scant safety hazards major concern <NUMBER> <NUMBER> <NUMBER> largescale screening sort require considerable time effort meantime shortterm screening limited number candidate drugs highly warranted end range candidates limited following <NUMBER> approved drugs table <NUMBER> fig <NUMBER> although drugs currently prescribed infection shown ability block various pathways endocytosis cell culture may therefore potential blocking sarscov<NUMBER> endocytosis another addition list cholesterol chelating agent methylbetacyclodextrin used carrier enhance bioavailability drug formulations generally recognised safe food drug administration usa importantly <NUMBER> <NUMBER> drugs chlorpromazine nystatin amiloride vinblastine itraconazole world health organizations list essential medicines ensuring wide availability across world also several tested tested topical delivery respiratory tract table <NUMBER> factors favourable rapid integration successful drugs global clinical practice subject development relevant clinical epidemiological applications despite frenzied efforts find effective treatments covid<NUMBER> little currently known fundamental cell biology sarscov<NUMBER> infection pivotal event underpinning sarscov<NUMBER> infection likely endocytosis viral particles therefore blockade process may provide major therapeutic breakthrough tools membrane trafficking research readily applied rapidly characterise endocytic route virus entry cellbased model disease providing key insight disease mechanism fig <NUMBER> crucially model used screening platform rapid repurposing existing approved drugs blockers sarscov<NUMBER> endocytic entry table <NUMBER> longer term insight poorly understood membrane trafficking mechanisms airway epithelium aid development novel drugs generalised strategy targeting membrane trafficking host cell biology prevent viral infection holds great promise future therapeutic applications considering existence zoonotic coronaviruses capable binding human cells <NUMBER> broadly rapid repurposing approved drugs cellbased screening platforms poised play instrumental role futureproofing global health care interspecies transmission events age unparalleled spending pharmaceutical research development humankind cannot afford neglect one valuable allies fight current future pandemicsthe basic foundations human cell biology coronaviruses represent large group medically relevant viruses historically associated common cold however recent years members coronavirus family emerged animal reservoirs humans caused novel diseases <NUMBER> first severe acute respiratory syndrome sarscov emerged china <NUMBER> followed middle east respiratory syndrome merscov <NUMBER> <NUMBER> <NUMBER> sars end eradicated mers continues cause infections middle east beginning december <NUMBER> continuing january <NUMBER> became clear new respiratory virus spreading wuhan china rapid sequencing efforts revealed coronavirus closely related sars named sarscov<NUMBER> <NUMBER> unfortunately virus highly infectious spread rapidly around world identification broadly acting sarscov<NUMBER> antivirals essential clinically address sarscov<NUMBER> infections potential route candidate antivirals deployment drugs show activity related viruses previous studies found antiviral drug remdesivir developed rnadependent rna polymerase ebola virus also active sarscov<NUMBER> vitro promising results clinical trials <NUMBER> <NUMBER> <NUMBER> chloroquine derivatives including hydroxychloroquine approved use malaria many vitro studies found drugs also active coronaviruses including sarscov<NUMBER> <NUMBER> <NUMBER> led early adoption agents treat covid<NUMBER> disease caused sarscov<NUMBER> infection however little efficacy agents demonstrated subsequent clinical trials <NUMBER> remains unclear agents active humans currently <NUMBER> fda approved drugs many others tested humans created inhouse library <NUMBER> drugs including <NUMBER> fda approved drugs <NUMBER> druglike molecules defined molecular targets validated pharmacological activity addition purchased drugs reported antisarscov<NUMBER> activity eg remdesivir viruses encode unique proteins essential infection approved antivirals target virally encoded essential targets class antivirals termed directacting antivirals viruses also dependent host cellular machineries successful infection drugs block activities hosttargeted antivirals given dearth effective treatments developed screening platform would allow us identify directacting hosttargeted antivirals potentially repurposed use sarscov<NUMBER> <NUMBER> developed specific sensitive assay quantify viral infection using cellbased highcontent approach began studies african green monkey cercopithecus aethiops kidney epithelial cells vero routinely used propagate sarscov<NUMBER> robustly infected thus vero cells widely used model system screen antivirals <NUMBER> <NUMBER> <NUMBER> <NUMBER> screened inhouse repurposing library identifying six drugs antiviral low toxicity primary screen given candidates emerged reasoned human cells might better model infection thus tested panel human cell lines identify cells easy grow permissive infection found human hepatocyte cell line huh<NUMBER> readily infected sarscov<NUMBER> screening human cell line validated <NUMBER> drugs active doseresponse experiments showed favorable selective index versus toxicity <NUMBER> candidates targeted wide variety cellular activities active vero cells however one class chloroquines derivatives active cell types entry pathway sarscov<NUMBER> begun elucidated much know inferred studies related sarscov<NUMBER> <NUMBER> <NUMBER> coronavirus glycoprotein spike requires proteolytic processing entry <NUMBER> <NUMBER> <NUMBER> processing occur outside cell within endolysosomal compartment <NUMBER> <NUMBER> sarscov<NUMBER> <NUMBER> engage angiotensinconverting enzyme <NUMBER> ace<NUMBER> plasma membrane receptor <NUMBER> <NUMBER> <NUMBER> upon binding viruses along receptor endocytosed cell low ph endosomal compartment proteases including cathepsins cleave spike allow entry cytosol <NUMBER> <NUMBER> <NUMBER> since cathepsins require low ph activity chloroquine derivatives neutralize low ph effectively block viral entry <NUMBER> <NUMBER> <NUMBER> recent studies also identified plasma membraneassociated serine protease tmprss<NUMBER> active spike cleaving protein extracellularly thereby bypassing requirement endosomal proteases <NUMBER> <NUMBER> <NUMBER> whether sarscov<NUMBER> enters different routes different cell types remains unclear lung epithelial cells major cellular target sarscov<NUMBER> vivo used explore role tmprss<NUMBER> infection perhaps surprisingly found remdesivir antiviral calu<NUMBER> hydroxychloroquine since panel quinolines activity calu<NUMBER> cells data suggest entry lung epithelial cells independent lowph processing endosomal compartment contrast tmprss<NUMBER> inhibitor camostat highly active calu<NUMBER> cells inactive vero huh<NUMBER> cells data demonstrate distinct modes entry lung cells <NUMBER> data suggest may fundamentally different cellular requirements different cell types screened <NUMBER> validated candidates calu<NUMBER> cells found <NUMBER> drugs showed activity including <NUMBER> fda approved drugs cyclosporine dacomitinib salinomycin additional studies found cyclosporine analogs target cyclophilin active sarscov<NUMBER> compounds target calcineurin identifying broadly acting antivirals essential move forward clinical treatments sarscov<NUMBER> vero cells permissive infection used antiviral screening direct acting antivirals sarscov<NUMBER> routinely propagated vero e<NUMBER> cells <NUMBER> <NUMBER> <NUMBER> growing virus either vero e<NUMBER> vero ccl<NUMBER> cells two different strains vero cells atcc observed sarscov<NUMBER> cytopathic vero e<NUMBER> vero ccl<NUMBER> data shown <NUMBER> moreover viral stocks propagated either cells produced similar titers virus <NUMBER>x<NUMBER> <NUMBER> pfuml suggesting viral replication cytotoxicity separable therefore set develop quantitative microscopybased assay measure level replication sarscov<NUMBER> directly infected cells chose vero ccl<NUMBER> uncouple toxicity infection first validated antibodies could detect infection sarscov<NUMBER> used antibody dsrna sarscov<NUMBER> spike figure <NUMBER>a <NUMBER> <NUMBER> created inhouse library <NUMBER> drugs purchased selleckchem library contains <NUMBER> fda approved drugs <NUMBER> druglike molecules defined molecular targets validated pharmacological activity library contains <NUMBER> known kinase inhibitors <NUMBER> annotated cancer therapeutics <NUMBER> epigenetic regulators <NUMBER> antiviralinfectives <NUMBER> gpcr ion channel regulators remaining compounds falling diverse target classes next optimized dose timing infection performing doseresponse studies known antivirals indeed found hydroxychloroquine remdesivir active vero cells presented little cytotoxicity active doses figure <NUMBER>b <NUMBER> next validated assay metrics observed z<NUMBER> figure s<NUMBER> <NUMBER> used assay pipeline screen inhouse repurposing library <NUMBER> well plates final concentration <NUMBER> µm figure <NUMBER>c <NUMBER> quantified percentage infected cells well total cell number per well allow exclusion toxic compounds robustly identified positive control remdesivir antiviral figure s<NUMBER> <NUMBER> using threshold <NUMBER> infection <NUMBER> viability compared vehicle control identified six drugs antiviral primary screen table s<NUMBER> included natural product nanchangmycin previously found drug repurposing screen zika virus <NUMBER> nanchangmycin broadly antiviral viruses enter cells endocytosis consistent role endosomal acidification sarscov<NUMBER> entry cells <NUMBER> repurchased powders validated four candidates doseresponse assays observed antiviral activity absence toxicity figure <NUMBER>d since vero cells derived african green monkeys set identify human cell line permissive infection end infected panel human cell lines sarscov<NUMBER> monitored infection microscopy initially tested a<NUMBER> calu<NUMBER> huh<NUMBER> huh<NUMBER> hepg<NUMBER> hacat imr<NUMBER> ncih<NUMBER> cfbe<NUMBER>o u<NUMBER>os cells detected less <NUMBER> infection a<NUMBER> calu<NUMBER> huh<NUMBER> hepg<NUMBER> hacat imr<NUMBER> ncih<NUMBER> cfbe<NUMBER>o u<NUMBER>os cells data shown interestingly huh<NUMBER> largely nonpermissive derivative cell line huh<NUMBER> cells permissive sarscov<NUMBER> fig <NUMBER>a huh<NUMBER> cells defective innate immune signaling rigi known permissive many viruses including hepatitis c virus <NUMBER> remdesivir hydroxylchloroquine antiviral sarscov<NUMBER> huh<NUMBER> cells ic<NUMBER>s greater <NUMBER>fold lower observed vero cells fig <NUMBER>b also found nanchangmycin antiviral sarscov<NUMBER> huh<NUMBER> cells fig s<NUMBER> observations suggest huh<NUMBER> cells may sensitive classes inhibitors may reveal antivirals selectively active human targets optimized imagebased assay huh<NUMBER> cells using remdesivir observed z<NUMBER> fig s<NUMBER> <NUMBER> screened repurposing library <NUMBER>nm quantifying percentage infected cells well cell number exclude toxic compounds fig <NUMBER>c found <NUMBER> drugs antiviral activity absence cytotoxicity <NUMBER> infection <NUMBER> viability compared vehicle control table s<NUMBER> included three six drugs identified vero cells zfafmk y<NUMBER> salinomycin repurchased powders <NUMBER> drugs tested activity doseresponse assays huh<NUMBER> cells sarscov<NUMBER> cell number percent infected cells quantified remdesivir hydroxychloroquine used positive controls vehicle controls dmso included negative control <NUMBER> tested <NUMBER> drugs showed activity fell diverse classes fig <NUMBER>d doseresponse curves shown <NUMBER> candidates ic<NUMBER>s cc<NUMBER>s calculated fig <NUMBER>e selectivity index si ratio antiviral cytotoxicity potencies calculated <NUMBER> candidates antiviral si<NUMBER> figure <NUMBER>e table s<NUMBER> doseresponses curves candidates validate huh<NUMBER> cells shown fig s<NUMBER> directacting antivirals likely active virus multiple cell types observed remdesivir addition hostdirected antivirals target key steps viral lifecycle highly conserved broadly expressed also likely emerge across cell types one example endosomal acidification blocker hydroxychloroquine indeed scored antiviral cell types <NUMBER> <NUMBER> <NUMBER> total identified three drugs antiviral screens performed doseresponses vero cells candidates huh<NUMBER> screen found <NUMBER> additional compounds antiviral vero cells si<NUMBER> azd<NUMBER> bix<NUMBER> ebastine mg<NUMBER> wye<NUMBER> albeit higher concentrations figure s<NUMBER> however majority antivirals validated huh<NUMBER> cells active vero cells next focused lung epithelial models relevant human infections found number lungderived epithelial cell lines refractory infection eg a<NUMBER> calu<NUMBER> ncih<NUMBER> cfbe<NUMBER>o however found calu<NUMBER> cells shown permissive many coronaviruses including sarscov<NUMBER> highly readily infected fig <NUMBER>a <NUMBER> <NUMBER> <NUMBER> optimized assays using calu<NUMBER> cells tested sensitivity remdesivir hydroxycholorquine expected found direct acting antiviral remdesivir antiviral however hydroxychloroquine little activity calu<NUMBER> cells fig <NUMBER>b led us test antiviral activity panel chloroquine derivatives found none activity sarscov<NUMBER> fig <NUMBER>c compounds antiviral vero cells huh<NUMBER> cells fig <NUMBER>d suggests major differences requirement endosomal acidification infection sarscov<NUMBER> lung epithelial cells endosomal acidification thought required sarscov<NUMBER> entry maintain low ph necessary endosomal cysteine protease activity required priming spike membrane fusion <NUMBER> consistent requirement acidification vero huh<NUMBER> cathepsin inhibitor zfafmk emerged antiviral cell types fig <NUMBER>d fig <NUMBER>e tested zfafmk calu<NUMBER> cells found antiviral activity fig <NUMBER>d consistent lack requirement endosomal acidification recent studies found plasma membraneassociated serine protease tmprss<NUMBER> prime viral glycoprotein entry lung epithelial cells <NUMBER> therefore tested role tmprss<NUMBER> treating cells inhibitor camostat found camostat antiviral calu<NUMBER> cells activity either vero huh<NUMBER> cells figure <NUMBER>e f <NUMBER> moreover main endosomal kinase phosphatidylinositiol<NUMBER>phosphatephosphatidylinositol <NUMBER>kinase pikfyve promotes internalization diverse viruses recently shown impact entry coronaviruses including sarscov<NUMBER> hela cells <NUMBER> using pikfyve inhibitor apilimod found pikfyve promotes infection sarscov<NUMBER> huh<NUMBER> vero cells little importance calu<NUMBER> cells fig s<NUMBER> data suggest entry pathway used sarscov<NUMBER> celltype specific determine <NUMBER> antiviral candidates validated huh<NUMBER> cells also antiviral activity calu<NUMBER> cells performed doseresponse studies found <NUMBER> drugs antiviral sarscov<NUMBER> calu<NUMBER> cells selectivity index greater <NUMBER> fig <NUMBER> include two drugs unclear targets salinomycin y<NUMBER> kinase inhibitors azd<NUMBER> bemcentinib dacomitinib wye<NUMBER> histamine receptor inhibitor ebastine iron chelator dp<NUMBER>mt cyclophilin inhibitor cyclosporine many kinase inhibitors quite potent suggesting important role intracellular signaling infection drugs tested calu<NUMBER> si<NUMBER> shown fig s<NUMBER> full table candidates huh<NUMBER> screen ic<NUMBER> cc<NUMBER> si shown figure s<NUMBER> cyclosporine fda approved generic drug readily available showed submicromolar ic<NUMBER> high selectivity huh<NUMBER> calu<NUMBER> cells fig <NUMBER> fig <NUMBER> fig s<NUMBER> cyclosporine binds cyclophilin prevents activation phosphatase calcineurin required nuclear translocation nuclear factor activated cells nfat <NUMBER> <NUMBER> <NUMBER> inhibition pathway cells used immunosuppressant <NUMBER> cyclosporins shown antiviral activity wide variety viruses including coronaviruses <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> activity cyclosporine previously studied coronaviruses cyclophilindependent independent calcineurin <NUMBER> <NUMBER> set perform initial structureactivity relationships sar determine activity inhibition cyclophilin inhibition calcineurin studies obtained panel cyclosporine analogs including cyclosporin cyclosporin b cyclosporin c cyclosporin h isocyclosoporin <NUMBER> found isocyclosporin cyclosporin cyclosporin b cyclosporin c active increasing ic<NUMBER>s fig <NUMBER>ac cyclosporine h shows weak binding cyclophilin immunosuppressant activity inhibit phosphatase activity calcineurin <NUMBER> <NUMBER> cyclosporin h log reduction activity compared cyclosporine retains activity psc <NUMBER> nonimmunosuppressant derivative cyclosporine inhibit calcineurin similar activity cyclosporin c<NUMBER> tmn<NUMBER> cyclophilin inhibitor <NUMBER> times potent cyclosporine inhibiting prolyl isomerase activity cyclophilin <NUMBER> found latter lack antiviral activity suggesting enzymatic activity cyclophilin dispensable validated cyclosporine antiviral cell types performing rtqpcr fig <NUMBER>d addition nim<NUMBER> another nonimmunosuppressive cyclosporine derivative cyclosporine found potently antiviral fig <NUMBER>e suggesting antiviral activity cyclophilindependent separable calcineurin strikingly activity panel drugs similar two cell lines data suggest cyclosporine target mechanismofaction also found none drugs antiviral vero cells figure s<NUMBER> assess mechanism cyclosporine antiviral tested fk<NUMBER> inhibitor calcineurin fk<NUMBER> binds related immunophilin fkbp rather cyclophilin block phosphatase activity calcineurin thus also potent immunosuppressant <NUMBER> found fk<NUMBER> activity sarscov<NUMBER> fig <NUMBER>ac moreover since one major targets calcineurin activation nfat also tested whether nfat inhibitor impacted viral infection <NUMBER> found nfat inhibitor effect infection fig <NUMBER>ac altogether found cyclosporins potent antivirals sarscov<NUMBER> lung epithelial cells activity independent calcineurin nfat emergence sarscov<NUMBER> led devastating global morbidity mortality creating immediate need new therapeutics vaccines repurposing existing drugs allow rapid deployment therapeutics already tested humans <NUMBER> remdesivir developed ebola virus rnadependent rna polymerase also found robust activity sarscov<NUMBER> <NUMBER> importantly found remdesivir active sarscov<NUMBER> across cell types chloroquine hydroxychlorquine used decades treat malaria shown vitro antiviral activity sarscov<NUMBER> <NUMBER> <NUMBER> however find antiviral activity celltype specific lung epithelial cells resistant drugs may explain lack efficacy seen many trials <NUMBER> determine additional drugs active sarscov<NUMBER> vitro screened repurposing library includes <NUMBER> fda approved drugs <NUMBER> additional drugs tested humans repurposing used reveal new similar pathways targets also time monetary investment associated repurposing potentially less since drugs often bypass phase<NUMBER> trials <NUMBER> <NUMBER> initial screens vero cells yielded active drugs leading us pursue screen human huh<NUMBER> cells transformed hepatocyte line deficient innate immune signaling using model system identified <NUMBER> drugs validated <NUMBER> doseresponse assays includes many drugs previously shown activity coronaviruses tetrandrine cepharanthine cyclosporine alixostatin mg<NUMBER> salinomycin sarscov<NUMBER> salinomycin tetrandrine cepharanthine cyclosporine ebastine <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> drugs fall distinct classes known targets however two drugs active across cell types salinomycin y<NUMBER> clear targets salinomycin polyether antibiotic chemotherapy drug shown antiviral many viruses including coronaviruses <NUMBER> <NUMBER> <NUMBER> <NUMBER> salinomycin also identified vero cell screen <NUMBER> mechanistically studies suggested salinomycin ionophore attenuate viral entry disrupting acidification endosome <NUMBER> studies implicated salinomycin er stress <NUMBER> studies mice shown antiviral activity influenza <NUMBER> salinomycin also characterized activator autophagy may influence sarscov<NUMBER> infection <NUMBER> <NUMBER> <NUMBER> y<NUMBER> phenylpyrazoleanilide immunomodulatory agent shown inhibit il<NUMBER> production cells activity monkeys <NUMBER> interestingly treatment y<NUMBER> associated decreased il<NUMBER> production cytokine thought highly expressed sarscov<NUMBER> infection <NUMBER> <NUMBER> <NUMBER> however unclear y<NUMBER> could attenuate sarscov<NUMBER> nonimmune cells ebastine potent h<NUMBER>histamine receptor antagonist used allergic disorders outside us particularly asia <NUMBER> found ebastine antiviral three cell types although <NUMBER>fold less active vero cells <NUMBER> ebastine orally available side effects clinical trials underway china testing whether ebastine impact covid<NUMBER> outcomes <NUMBER> since h<NUMBER>histamine receptor antagonists active unclear particular agent effective inhibiting sarscov<NUMBER> infection interestingly ebastine active metabolite carebastine reported inhibit expression il<NUMBER> many h<NUMBER>histamine receptor antagonists <NUMBER> <NUMBER> also identified <NUMBER> protease inhibitors antiviral huh<NUMBER> cells two cysteine protease inhibitors zfafmk mg<NUMBER> activity vero huh<NUMBER> cells none protease inhibitors active calu<NUMBER> cells observation suggests targeting viral proteases consistent zfafmk inhibitor cathepsins required sarscov<NUMBER> entry cells endosomal proteases required spike cleavage thus observe requirement calu<NUMBER> cells tmprss<NUMBER> required infection <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> important implications diverse sarscov<NUMBER> studies may celltype specific requirements different steps replication cycle also identified two inhibitors cellular histone methyltransferase g<NUMBER>a antiviral huh<NUMBER> cells however drugs active calu<NUMBER> cells suggesting cell type specific requirements am<NUMBER> selective cannabinoid cb<NUMBER> receptor agonist found antiviral huh<NUMBER> cells gw<NUMBER>x another cb<NUMBER> agonist <NUMBER>fold higher ec<NUMBER> active moreover doseresponse studied found am<NUMBER> active either vero calu<NUMBER> cells cepharanthine tetrandrine bisbenzylisoquinoline alkaloids produced natural products herbal plants <NUMBER> tetrandrine traditional chinese medicine calcium channel blocker shown antagonize calmodulin antitumor antiinflammatory effects effectively inhibit fibroblasts thereby inhibiting pulmonary fibrosis <NUMBER> <NUMBER> multiple studies suggested tetrandrine antiviral activity including dengue virus herpes simplex <NUMBER> virus <NUMBER> <NUMBER> tetrandrine also shown inhibit entry ebola virus host cells vitro showed therapeutic efficacy ebola preliminary studies mice <NUMBER> currently ongoing clinical trial using tetrandrine covid<NUMBER> patients improve pulmonary function <NUMBER> cepharanthine reported antiinflammatory immunoregulatory properties used treat variety acute chronic conditions outside us <NUMBER> cepharanthine tetrandrine previously shown antiviral activity human coronavirus oc<NUMBER> recent studies sarscov<NUMBER> vero cell screens <NUMBER> <NUMBER> <NUMBER> molecules antiviral huh<NUMBER> screen neither active calu<NUMBER> cells may suggest modulating endosomal entry pathways identified metabolic regulators dp<NUMBER>mt potent iron chelator found antiviral sarscov<NUMBER> huh <NUMBER> calu<NUMBER> cells <NUMBER> clinical trial iron chelator deferoxamine underway nct<NUMBER> however iron chelators library deferasirox deferiprone identified antiviral making mechanism action unclear identified several kinase inhibitors antivirals sarscov<NUMBER> frax<NUMBER> p<NUMBER>activated kinase pak inhibitor antiviral huh<NUMBER> cells modestly impacted infection calu<NUMBER> cells <NUMBER> pak inhibitors identified screens pak required entry many viruses<NUMBER> pd<NUMBER> potent wee<NUMBER> chk<NUMBER> inhibitor antiviral huh<NUMBER> cells shows strong toxicity calu<NUMBER> cells <NUMBER> also found three mtor inhibitors azd<NUMBER> pf<NUMBER> wye<NUMBER> antiviral sarscov<NUMBER> huh<NUMBER> calu<NUMBER> cells highly potent atp competitive mtor inhibitors target torc<NUMBER> torc<NUMBER> library none rapamycin analogs selectively inhibit mtorc<NUMBER> active also identified two potent selective irreversible inhibitors egfr dacomitinib naquotinib <NUMBER> egfr inhibitors showed activity huh<NUMBER> cells importantly dacomitinib potent antiviral calu<NUMBER> cells unclear target indeed egfr many viruses egfr activation promotes viral entry may also case sarscov<NUMBER> <NUMBER> cyclosporine commonly used immunosuppressant binds cyclophilin inhibits calciumdependent phosphatase calcineurin required nuclear translocation nuclear factor activated cells nfat <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> inhibition pathway cells used immunosuppressant found cyclosporine active huh<NUMBER> calu<NUMBER> cells activity vero cells cyclosporine analogs recent screen vero cells find activity cyclosporine sarscov<NUMBER> <NUMBER> cyclophilin ubiquitously expressed peptidylprolyl cistrans isomerase <NUMBER> cyclophilin cyclophilins chaperonelike activity take part proteinfolding processes <NUMBER> cyclophilin shown important cellular factor facilitated many diverse viral infections includes human immunodeficiency virus type <NUMBER> hiv<NUMBER> influenza virus hepatitis c virus hcv hepatitis b virus hbv vesicular stomatitis virus vsv vaccinia virus vv severe acute respiratory syndrome coronavirus sarscov rotavirus rv <NUMBER> <NUMBER> <NUMBER> coronaviruses hcov<NUMBER>e hcovnl<NUMBER> fpiv mouse hepatitis virus mhv avian infectious bronchitis virus sarscov found attenuated cyclosporin <NUMBER> <NUMBER> <NUMBER> cyclosporine nonimmunosuppressive derivatives inhibit replication number viruses including coronaviruses cases responsible cyclophilin cypa <NUMBER> <NUMBER> cypa cypb found required fcov replication <NUMBER> hcovnl<NUMBER> hcov<NUMBER>e cyclophilin required infection caco<NUMBER> cells <NUMBER> huh<NUMBER> cells respectively <NUMBER> <NUMBER> generally thought activity cyclosporine coronaviruses cyclophilindependent independent calcineurin found number cyclosporins antiviral similar potencies including cyclosporine cyclosporin cyclosporin b metabolic breakdown product cyclosporin isoscyclosporin also found cyclophilin likely required cyclosporin h weak binder reduced activity however enzymatic activity cyclophilin likely dispensable tmn<NUMBER> inactive address role calcineurin tested nonimmunosuppressant derivative cyclosporine inhibit calcineurin similar activity cyclosporin c also found fk<NUMBER> calcineurin inhibitor independent cyclophilin nfat inhibitors also antiviral activity altogether found cyclosporins potent antivirals sarscov<NUMBER> lung epithelial cells activity independent calcineurins nim<NUMBER> cyclophilin inhibitor independent calcineurin found highly active huh<NUMBER> cells suggesting cyclophilin required sarscovo<NUMBER> infection strikingly activities drugs similar two cell lines suggesting target mechanismofaction cyclosporine would block sarscov<NUMBER> diverse infected tissues vivo one approach would use cyclophilin inhibitors immunosuppressive activity nim<NUMBER> others tested hcv infection alisporivir debio<NUMBER> scy<NUMBER> <NUMBER> hiv infection nim<NUMBER> <NUMBER> <NUMBER> another possibility use cyclophilin inhibitors also target calcineurin eg cyclosporine one major complications covid<NUMBER> hyperinflammatory response cytokine storm associated increased immune activation prevent hyperactivation interest treating covid<NUMBER> patients immunosuppressants <NUMBER> ongoing trials variety agents including antiil<NUMBER> jak inhibitors two clinical trials using sirolimus fda approved mtor inhibitor selectively inhibits mtorc<NUMBER> find antiviral activity sirolimus rapamycin derivatives contrast cyclosporin approved immunosuppressant found also antiviral concentrations achieved vivo <NUMBER> therefore may useful implement clinical trials using cyclosporin immunosuppressant would potentially ameliorate symptoms two mechanisms <NUMBER> large number screens posted literature suggest antiviral activity several existing drugs eg azithromycin faviprivir lopinavir ribavirin ritonavir tetracycline etc drugs screens performed vero cells toxicity readouts medicines malaria venture mmv compiled list drugs support antiviral activity sarscov<NUMBER> httpswwwmmvorgmmvopencovidbox tested <NUMBER> <NUMBER> compounds find addition quinolines drugs found screen additional compounds show activity less <NUMBER> um possible drugs false negatives screens likely many candidates antiviral activity either measuring viral antigen production looking different cell types important identified antivirals tested impact viral replication directly moreover given striking differences sensitivities across cell types important validate activity new antivirals lung epithelial cells altogether studies highlight roles cellular genes viral infection cell type differences discovery nine broadly active antivirals suggest new avenues therapeutic interventions found <NUMBER> drugs antiviral lung epithelial cells <NUMBER> used humans <NUMBER> fda approved us cyclosporine dacomitinib salinomycin ebastine approved outside us clinical trials underway candidates additional trials needed determine efficacy antivirals covid<NUMBER> patients inform future treatment strategies vero e<NUMBER> cells vero ccl<NUMBER> obtained atcc cultured dmem supplemented <NUMBER> vv fetal bovine serum <NUMBER> vv penicillinstreptomycin <NUMBER> vv lglutamax maintained <NUMBER>°c <NUMBER> co<NUMBER> huh<NUMBER> cells obtained c rice rockefeller cultured dmem supplemented <NUMBER> vv fetal bovine serum <NUMBER> vv penicillinstreptomycin <NUMBER> vv lglutamine maintained <NUMBER>°c <NUMBER> co<NUMBER> calu<NUMBER> cells htb<NUMBER> obtained atcc cultured mem supplemented <NUMBER> vv fetal bovine serum <NUMBER> vv penicillinstreptomycin <NUMBER> vv lglutamine maintained <NUMBER>°c <NUMBER> co<NUMBER> sarscov<NUMBER> obtained bei wa<NUMBER> strain stocks prepared infection vero e<NUMBER> cells <NUMBER> serum plus <NUMBER>mm hepes five days freezethawed clarified centrifugation po titer stock determined plaque assay using vero e<NUMBER> cells <NUMBER>x<NUMBER> <NUMBER> pfuml <NUMBER>x<NUMBER> <NUMBER> tcid<NUMBER>ml <NUMBER> seed stock amplified vero ccl<NUMBER> p<NUMBER> <NUMBER>x<NUMBER> <NUMBER> tcid<NUMBER>ml work infectious virus performed biosafety level <NUMBER> laboratory approved institutional biosafety committee environmental health safety infections cells plated <NUMBER> well plates <NUMBER>µlwell <NUMBER> cells per well vero <NUMBER> cells per well huh<NUMBER> <NUMBER> cells per well calu<NUMBER> next day <NUMBER>nl drugs added positive control remdesivir negative control dmso spotted plate one hour later cells infected sarscov<NUMBER> vero moi<NUMBER> huh<NUMBER> moi<NUMBER> calu<NUMBER> moi<NUMBER> cells fixed <NUMBER>hpi vero huh<NUMBER> <NUMBER>hpi calu<NUMBER> <NUMBER> formaldehydepbs <NUMBER>min room temperature washed three times pbst cells blocked <NUMBER> bsapbst <NUMBER> minutes incubated primary antibody antidsrna j<NUMBER> overnight <NUMBER>c cells washed <NUMBER>x pbst incubated secondary antimouse alexa <NUMBER> hoescht <NUMBER> <NUMBER>h room temperature cells washed <NUMBER>x pbst imaged using imagxpress micro using <NUMBER>x objective four sites per well captured total number cells number infected cells measured using metaxpress <NUMBER> cell scoring module percentage infected cells calculated aggregated infection dmso remdesivir control wells n<NUMBER> assay plate used calculate zfactors measure assay performance data quality sample well infection normalized aggregated dmso plate control wells expressed percentage control poc infection sample average infection dmso <NUMBER> zscore z infection sample average infection dmso standard deviation infection dmso spotfire perkinelmer candidate hits selected compounds poc<NUMBER> viability <NUMBER> compared vehicle control candidate drugs repurchased powders selleckchem medchemexpress medkoo suspended dmso drugs arrayed <NUMBER>pt doseresponse <NUMBER> well plates infections performed using screening conditions dmso n<NUMBER> <NUMBER> µm remdesivir n<NUMBER> included validation plate controls normalization infection drug concentration normalized aggregated dmso plate control wells expressed percentageofcontrol poc infection sample avg infection dmso cont nonlinear regression curve fit analysis graphpad prism <NUMBER> performed poc infection cell viability using log<NUMBER> transformed concentration values calculate ic<NUMBER> values infection cc<NUMBER> values cell viability drugcell line combination selectivity index si calculated ratio drugs cc<NUMBER> ic<NUMBER> values si cc<NUMBER>ic<NUMBER> rtqpcr huh<NUMBER> <NUMBER> cellswell calu<NUMBER> cells <NUMBER> cellswell plated <NUMBER> well plates next day drugs added one hour later infected sarscov<NUMBER> moi<NUMBER> total rna purified using trizol invitrogen followed rna clean concentrate kit zymo researc <NUMBER> hpi huh<NUMBER> <NUMBER> hpi calu<NUMBER> cdna synthesis reverse transcription performed random hexamers moloney murine leukemia virus mmlv reverse transcriptase invitrogen synthesized rna used standard bei gene specific primers sarscov<NUMBER> wuhan v<NUMBER> nsp<NUMBER> sybr green master mix applied biosystems used amplify viral rna <NUMBER>s rrna primers used amplify cellular rna using quantstudio <NUMBER> flex rtpcr system applied biosystems relative quantities viral cellular rna calculated using standard curve method <NUMBER> viral rna normalized <NUMBER>s rna sample wuhan v<NUMBER>s wuhanv<NUMBER>forward <NUMBER>s rrnaforward <NUMBER>aacccgttgaaccccatt<NUMBER> <NUMBER>s rrna reverse <NUMBER>ccatccaatcggtagtagcg<NUMBER> thank weiss li sharing sarsrelated coronavirus <NUMBER> isolate usawa<NUMBER> obtained centers disease control bei resources thank bei resources quantitative sarscov<NUMBER> rna thank diamond hensley providing antispike antibody cr<NUMBER> c coyne j<NUMBER> antibody diamond oligo sequences thank e grice hacat cells thank c kovacsics biosafety support thank cherry lab highthroughput screening core david roth john epstein discussions thank timothy wells medicines malaria venture helpful discussions compounds thank nih deans innovation fund linda laddy montague bwf funding novel coronavirus sarscov<NUMBER> caused major outbreak humans world latest pandemic series infectious diseases concept drug repurposing used successfully many years known diseases considering emergency urgency drug repurposing concept explored coronavirus disease covid<NUMBER> well recently combination three known drugs lopinavir oseltamivir ritonavir proposed control virulence great extent covid<NUMBER> affected patients within <NUMBER> hours hence tried understand effect synergism drugs sarscov<NUMBER> protease using sequential docking studies result combination three drugs showed better binding energy individual drugs complex subjected molecular dynamics simulations get insights stability complex considering simultaneous interactions three drugs protein protein complexed three drugs remained stable simulations hence drugs explored drug repurposing successful inhibition covid<NUMBER> computational studies drug repurposing synergism lopinavir oseltamivir ritonavir binding sarscov<NUMBER> protease covid<NUMBER> older individuals immunosuppressed patients <NUMBER> outbreak severe acute respiratory syndrome sars guangdong china traced sarscov new betacoronavirus outbreak nearly <NUMBER> patients diagnosed overall mortality <NUMBER> increased <NUMBER> patients <NUMBER> years age <NUMBER> disease thought originated infected bats easily contained transmission appeared require direct contact infected individuals distinct group <NUMBER>c bcoronavirus genetically related bat coronaviruses responsible another outbreak saudi arabia <NUMBER> disease termed middle east respiratory syndrome mers virus associated initial <NUMBER> mortality spread appreciably outside region <NUMBER> outbreak unknown respiratory illness wuhan china reported late december <NUMBER> causative agent identified sars coronavirus sarscov<NUMBER> disease called coronavirus disease <NUMBER> covid<NUMBER> <NUMBER> disease rapidly become global pandemic major priority placed finding drugs prevent limit viral propagation infection coronaviruses share large genome around <NUMBER> kb express large replicase genes encoding nonstructural proteins involving approximately <NUMBER> kb genome undergo early transcription replicase gene contain viral envelope utilize ribosomal frameshifting nonstructural gene expression <NUMBER> viral genome composed <NUMBER>′cap structure leader sequence untranslated region utr composed multiple stem loop structures needed rna replication <NUMBER> <NUMBER>′end contains utr rna structures necessary viral rna synthesis well <NUMBER>′polya tail mimics mrna allowing translation replicaseencoded nonstructural proteins transcriptional regulatory sequences trss found <NUMBER>′end structural accessory genes accessory genes nonessential modulating viral pathogenesis <NUMBER> four main structural proteins termed spike membrane envelope e nucleocapsid n protein <NUMBER> kd responsible spike viral surface trimeric protein used viral attachment cell entry receptors <NUMBER> life cycle human coronaviruses begins viral attachment via protein cell entry receptors typically peptidases sarscov virus uses angiotensin converting enzyme <NUMBER> ace<NUMBER> main cellular receptor membrane serine protease tmprss<NUMBER> acting accessory protein stabilize cell entry cleavage protein following viral fusion cell membrane <NUMBER> <NUMBER> virus enters replicates within cytoplasm starting translation replicase gene assembly viral replicase complex <NUMBER> complex nonstructural genes act inhibit host cell translation promoting host mrna degradation enhancing viral rna synthesis replication <NUMBER> process results genomic subgenomic rna generated via negativestrand intermediates e structural proteins enter endoplasmic reticulum er move ergolgi intermediate compartment viral genomic progeny encapsidated n protein <NUMBER> assembly virions transported cell surface released exocytosis coronaviruses excess protein mediate cell fusion neighboring cells process may allow rapid viral transmission without detection host humoral immune response <NUMBER> accelerate pharma rd across targets disease areas immuneering developed disease cancelling technology dct identify targets drugs reversing disease gene expression fluency computational platform large scale high throughput silico screening dct quantifies similarity genomewide signatures disease signatures drug induced gene expression changes using cosine similarity uniquely relative methods dct quantifies pergene contribution overall disease amplification cancellation biased specific targets pathways fluency predicts quantitative binding affinity purely sequence unlike methods fluency single universal quantitative structureactivity relationship qsar model able accept molecule protein sequence input trained <NUMBER> million ic<NUMBER> values chembl fluency achieves near experimental level binding prediction accuracy well generating predictions binding site applied platforms determine repurposing existing drugs may helpful covid<NUMBER> infection <NUMBER> assessing established drugs binding ace<NUMBER> tmprss<NUMBER> two proteins used virus enter cells <NUMBER> scanning fda approved compounds transcriptomic disease cancellation coronavirus associated gene expression changes given covid<NUMBER> virus uses angiotensin converting enzyme <NUMBER> ace<NUMBER> main cellular receptor enter cell ran two fluency models ace<NUMBER> target input two different fluency models model model b run predict binding ace<NUMBER> chemicals selleckchem fda approved drug library initial ranking performance model shown table <NUMBER> included multiple known ace inhibitors scoring well enalaprilat ramipril lisinopril monopril captopril drugs enalaprilat best binding score model given reports possibility ace<NUMBER> induction driven ace<NUMBER> inhibition <NUMBER> multiple subsequent reports hinting benefit ace inhibition <NUMBER> <NUMBER> <NUMBER> <NUMBER> interested observe ace<NUMBER> specificity comparison ace<NUMBER> top hits binding ace<NUMBER> ace<NUMBER> compared calculating difference predicted binding ace<NUMBER> binding minus ace<NUMBER> binding using two fluency models table <NUMBER> according model brigatinib tirofiban hydrochloride aleuritic acid top ranked pbind brigatinib also highest ranked model specific ace<NUMBER> ace<NUMBER> glutathione ranked <NUMBER>th place model specific ace<NUMBER> ace<NUMBER> next consensus ranking using results models b used select top ace<NUMBER> binders table <NUMBER> enalaprilat tirofiban hydrochloride sotagliflozin showed balanced performance models order assess specificity fluency run top hits reverse predicting binding small molecule human proteome metric ramipril piperacillin sodium captopril high ranking ace<NUMBER> table <NUMBER> worst score far top hits considered r<NUMBER> explore potential covid<NUMBER> associated hits ran fluency models tmprss<NUMBER> target selleckchem fda approved drug library ranked hits based performance model ombitasvir elbasvir capecitabine top predicted binding hits tmprss<NUMBER> cefotiam hexetil hydrochloride bictegravir top <NUMBER> predicted hits models table <NUMBER> interestingly chloroquine diphosphate predicted model b bind ace<NUMBER> pbind <NUMBER> ranked <NUMBER> fda approved drugs predicted binding tmprss<NUMBER> pbind <NUMBER> ranked <NUMBER> hydroxychloroquine sulfate predicted model b bind ace<NUMBER> pbind <NUMBER> rank <NUMBER> tmprss<NUMBER> pbind <NUMBER> rank <NUMBER> results shown order confirm deny findings fluency applied disease cancelling technology approach searching fda approved drugs reverse coronavirus associated gene expression changes unlike version fluency run models b predicted binding rank reported higher pbind signifies higher binding affinity difference pbind ace<NUMBER> ace reported last two columns larger values reflecting increased predicted binding specificity ace<NUMBER> ace fluency dct applied target pathway agnostic way capturing full gene expression change data driven way publicly available gene expression data downloaded geo gse<NUMBER> healthy mice c<NUMBER>bl<NUMBER>nj infected ma<NUMBER> mouse version sarscov <NUMBER> lung tissue collected gene expression analysis robust differential expression signal detected infected uninfected mice day <NUMBER> fig <NUMBER>a table <NUMBER> genes changing opposite direction ma<NUMBER> infection glutamine treatment plotted fig <NUMBER>b interestingly glutamine precursor glutathione ranked highly fluency results table <NUMBER> thus two orthogonal approaches neural networks cosine distance used two different data types binding prediction gene expression arrived potential hit glutamineglutathione first utilized unbiased aibased systems algorithm interrogate <NUMBER> fda approved repurposing drugs binding ace<NUMBER> main sarscov<NUMBER> table <NUMBER> top ranked fluency hits binding ace<NUMBER> based consensus ranking using results models version fluency run models b predicted binding rank reported higher pbind signifies higher binding affinity lower reverse fluency rank signifies higher predicted specificity intended target human cell entry receptor rapid analysis repurposing approved drugs new indications allows immediate access potential agents could used urgent emerging diseases covid<NUMBER> ability identify drugs requires additional biologic validation vitro studies confirming receptor blockade inhibition sarscov<NUMBER> cell entry replication vivo ideally randomized table <NUMBER> top ranked fluency hits models binding tmprss<NUMBER> rank column indicates ranked position given model binding prediction controlled clinical trials global pandemic however time may allow usual drug development processes repurposing commonly available drugs may critical indeed anecdotal reports hydroxychloroquine azithromycin antiil<NUMBER> therapies received attention <NUMBER> <NUMBER> hydroxychloroquine predicted bind ace<NUMBER> model b supporting anecdotal reports detect azithromycin antiil<NUMBER> agents would anticipated mediate therapeutic activity ace<NUMBER> modulation validation needed determine unbiased aibased systems approaches superior anecdotal observations binding prediction analysis multiple known drugs identified potential ace<NUMBER> inhibitors table <NUMBER> surprisingly twelve ace inhibitors adds confirmation unbiased selection accurately identified drugs high likelihood receptor binding ace inhibitors agents commonly used treatment hypertension heart failure family drugs based various peptide compositions initially selected binding ace<NUMBER> catalyzes conversion angiotensin angiotensin ii thereby blocking reninangiotensin system ras lowering systemic blood pressure increasing sodium excretion increased renal water output ace inhibitors known bind ace<NUMBER> lacks carboxypeptidase activity ace<NUMBER> contain zincbinding domain exhibits metallopeptidase activity shares approximately <NUMBER> homology ace<NUMBER> <NUMBER> <NUMBER> model selected preferential ace<NUMBER> binding agents better predicted binding values prioritized see table <NUMBER> early studies largely used angiotensin catalysis major readout inhibition whether current ace inhibitors may block sarscov<NUMBER> binding remains speculative <NUMBER> addition due counter regulatory nature ace<NUMBER> ace<NUMBER> expression possible agents downregulate ace<NUMBER> receptors may increase ace<NUMBER> receptor expression could worsen coronavirus infection thus scanned binding ace<NUMBER> ace<NUMBER> top hits ranked predicted difference binding metric captopril enalaprilat monopril looked likely inhibit potentially solicit undesired feedback effect table <NUMBER> ramipril longacting ace inhibitor prodrug converted active metabolite ramiprilat liver may associated hepatic injury likewise monopril prodrug undergoes transformation liver active metabolite fosinoprilat contrast lisinopril orally active ace inhibitor undergo metabolic transformation excreted urine bind serum proteins may also associated hepatic toxicity drugs need used cautiously patients underlying liver disease captopril sulfhydrylcontaining proline analog potent specific activity blocking ace peptidyldipeptidase activity captopril may also antitumor activity inhibition tumor angiogenesis promotion antitumor immunity <NUMBER> analysis also identified drug involved glucose homeostasis used patients diabetes mellitus antihyperglycemic agents nateglinide table <NUMBER> derivative phenylalanine acts betaislet pancreatic cells atpsensitive potassium channels stimulates insulin secretion <NUMBER> drug used treatment type <NUMBER> diabetes mellitus sotaglifozin table <NUMBER> oral inhibitor sodiumglucose cotransporter subtype <NUMBER> sglt<NUMBER> expressed gastrointestinal gi tract sglt<NUMBER> expressed kidneys <NUMBER> knowledge agent previously known bind ace ace<NUMBER> glutathione another interesting agent predicted binding ai gene expression disease cancellation antioxidant demonstrating improved airway clearance pulmonary function cystic fibrosis <NUMBER> glutathione also evaluated adjunct patients receiving certain chemotherapy agents following lung transplantation management hiv parkinsons disease mixed results <NUMBER> fostamatinib r<NUMBER> table <NUMBER> oral inhibitor spleen tyrosine kinase syk converted active metabolite tamatinib approved treatment chronic immune thrombocytopenic purpura evaluated autoimmune disorders rheumatoid arthritis <NUMBER> r<NUMBER> may also mediate signal transduction downstream classical immunoreceptors including bcell receptor explaining may useful treating autoimmune diseases b cell hematologic malignancies <NUMBER> emricasan table <NUMBER> also called idn<NUMBER> thiol protease acts caspase<NUMBER> inhibitor received orphan g status us fda treatment liver disease chronic hepatitis c functions protect excessive hepatic cell apoptosis emricasan shown decrease hepatic aminotransferases patients hepatitis c viralinduced nonviral liver diseases <NUMBER> drug also shown activity zika virusmediated caspase <NUMBER> induction blocked viral infection neural cells vitro <NUMBER> potential antiviral activity emricasan identified drug repurposing screen following zika virus outbreak <NUMBER> <NUMBER> fosamprenavir identified table <NUMBER> protease inhibitor prodrug amprenavir antiretroviral drug approved treatment hiv disease agents known antiviral activity rna viruses especially interesting evaluation coronaviruses orlistat table <NUMBER> carboxyl ester reversible inhibitor gi lipases <NUMBER> orlistat initially isolated streptomyces toxytricini grampositive bacterium blocks hydrolysis absorption dietary fats approved us uk treatment obesity two drugs identified activity anticoagulants tirofiban hydrochloride table <NUMBER> argatroban table <NUMBER> tirofiban nonpeptide tyrosine derivative functions antagonist purinergic receptor platelet glycoproteiniibiia <NUMBER> drug inhibits platelet aggregation used treating acute coronary syndrome studied management ischemic stroke <NUMBER> contrast argatroban small molecule directly inhibits thrombin used management heparininduced thrombocytopenia <NUMBER> piperacillin table <NUMBER> broad spectrum semisynthetic betalactam ureidopenicillin antibiotic derived ampicillin piperacillin active gramnegative bacteria initially used treating pseudomonas aeruginosa infections later part combination antibiotics complex infectious indications <NUMBER> contrast macrolide antibiotics azithromycin inhibit bacterial protein synthesis piperacillin blocks bacterial wall synthesis since commonly used agents management patients pneumonia merit studies understand role ace<NUMBER> modulation potential role management covid<NUMBER> infection search potential covid<NUMBER> therapeutic approaches orthogonal unbiased way applied disease cancellation technology gene expression data animal model sarscov ranked compounds ability induce gene expression signals counteract diseaseassociated signals gene expression method glutamine top hit reversing coronavirus associated changes gene expression glutathione highly ranked fluency ace<NUMBER> binding precursor glutamine highly ranked gene expression dct suggesting deserve testing explore potential benefits sarscov<NUMBER> glutamine glutathione previously demonstrated antiviral activity herpes virus hsv infections <NUMBER> summary used novel aibased systems approach identify potential drugs currently available predicted bind ace <NUMBER> agents readily available could rapidly assessed laboratory clinic activity sarscov<NUMBER> infection clinical course covid<NUMBER> disease studies agents may provide new clinical strategies patients coronavirus diseases normal circumstances would conduct experimental validation prior submitting report publication given current public health emergency publishing work event others set quickly validate assess build upon findings although validation still needed report highlights aibased systems may utilized rapidly identify drugs repurposing new emerging human diseases ace<NUMBER> uniprot id q<NUMBER>byf<NUMBER> ace<NUMBER> uniprot id p<NUMBER> tmprss<NUMBER> uniprot id o<NUMBER> run separately protein target immuneerings fluency query fluency single universal quantitative structureactivity relationship qsar deep learning model takes protein amino acid sequence small molecule smiles input fluency trained experimental binding data chembl <NUMBER> model chembl <NUMBER> model b fluency predictions previously experimentally validated multiple targets case fluency used predict binding selleckchem fda approved drug library https wwwselle ckche mcomscree ningfdaappro veddruglibra ryhtml separately ace<NUMBER> ace<NUMBER> tmprss<NUMBER> top hits fluency run reverse predicting binding single small molecule <NUMBER> human proteins score specificity predicted binding scores ace<NUMBER> ace<NUMBER> compared top hits assess predicted specificity ace<NUMBER> ace<NUMBER> model reflected pbindxace<NUMBER>pbindxace columns similarity known binders reported pchembl value greater <NUMBER> chembl database ace<NUMBER> computed using tanimoto distance molecular fingerprints rdkit python top ranked fluency hits filtered evaluating individual rankings model model b well average rank predictions combined pbind scores models gene expression data downloaded geo gse<NUMBER> processed data background corrected quantile normalized summarized outlier removal author used <NUMBER> time points differential expression calculated ma<NUMBER> sarscov virus infected wild type mice lung samples mockinoculated wild type mice using limma rpackage version <NUMBER> <NUMBER> immuneering leveraged previously described <NUMBER> validated <NUMBER> <NUMBER> dct ran sarscov disease signature lincs drug perturbation database <NUMBER> results filtered adjusted pvalue significance maximal disease cancellation score advancements lowcost highthroughput sequencing data acquisition technologies given rise massive proliferation data describing biological systems biomedical knowledge graphs kgs becoming increasingly popular backbones artificial intelligence tasks personalized medicine predictive diagnosis drug discovery dörpinghaus jacobs <NUMBER> machine learning perspective reasoning biomedical kgs presents new challenges existing approaches unique structural characteristics graphs one challenge arises due highly coupled nature entities biological systems leads many highdegree densely interlinked entities second challenge requirement information beyond secondorder neighborhoods reasoning relationship two entities himmelstein et al <NUMBER> approaches longrange interactions incorporated via node embeddings e g rescal nickel et al <NUMBER> transe bordes et al <NUMBER> tend underperform unfortunately approaches explicitly take entire multihop neighborhoods account e g graph convolutional models rgcn schlichtkrull et al <NUMBER> often diminishing performance beyond twohop neighborhoods e two convolutional layers furthermore highdegree entities cause aggregation operations smooth signals alternatively symbolic reasoning approaches e g rulen meilicke et al <NUMBER> anyburl meilicke et al <NUMBER> learn logical rules employ inference however due massive scale diverse topologies many realworld kgs combinatorial complexity often prevents usage symbolic approaches also logical inference difficulties handling noise data recently pathbased reasoning methods become popular present seemingly ideal balance combining information multihop neighborhoods propose novel neurosymbolic kg reasoning approach arxiv<NUMBER>v<NUMBER> cs lg <NUMBER> jul <NUMBER> figure <NUMBER> subgraph hetionet illustrates drug repurposing use case two paths connect chemical compound sorafenib disease kidney cancer used predict direct edge two entities combines pathbased approaches representation learning logical rules rules either mined data obtained domain experts inspired existing methods das et al <NUMBER> lin et al <NUMBER> hildebrandt et al <NUMBER>a b use reinforcement learning train agent conduct policyguided random walks kg propose modification introducing reward function allows agent leverage background knowledge formalized metapaths summary paper makes following contributions • propose novel neurosymbolic approach combines neural multihop reasoning based reinforcement learning logical rules • conduct empirical study several stateoftheart algorithms applied large biomedical kg • show proposed approach outperforms stateoftheart alternatives highly relevant biomedical prediction task drug repurposing application method focus drug repurposing problem characterized finding new treatment targets existing drugs repurposing existing drugs available knowledge drugdiseaseinteractions leveraged reduce time cost developing new drugs significantly recent example repositioning medication remdesivir novel coronavirus disease covid<NUMBER> aim generating candidates drug repurposing task machine learning reasoning methods formulate task link prediction problem compounds diseases correspond entities kg let e denote set entities kg r set binary relations elements e correspond biomedical entities including e g chemical compounds diseases genes entity belongs unique type defined mapping τ e → example τ aurkc gene indicates entity aurkc type gene define kg kg ⊂ e × r × e collection triples form h r consists head relation tail head tail entities correspond nodes graph relation indicates type edge relation r ∈ r denote corresponding inverse relation r −<NUMBER> e h r equivalent r −<NUMBER> h triples kg interpreted true known facts example triple sorafenib treats liver cancer ∈ kg figure <NUMBER> corresponds fact kinase inhibitor drug sorafenib approved treatment liver cancer distinguish two types paths instance paths metapaths instance path length ∈ n kg given sequence constitutes instance path length <NUMBER> corresponding metapath logical rules eg commonly used horn clauses usually written form head ← body head written triple body expressed metapath define ctd compound treats disease rule respect edges type treats generic form particular body rule corresponds metapath starting compound terminating disease goal find instance paths corresponding metapaths match body rule predict new relation source target instance path confidence rule indicates often rule correct defined rule support divided body support data pose task drug repurposing link prediction problem based graph traversal starting query entity eg compound repurposed agent performs walk graph sequentially transitioning neighboring node decision transition make determined stochastic policy subsequent transition added current path extending reasoning chain finite number transitions reached general approach inspired reinforcement learning method minerva das et al <NUMBER> primary contribution coming incorporation logical rules training process state environment consists entity e agent located time source entity e c target entity e e c e correspond compound aim repurpose target disease respectively thus state time ∈ n represented e e c e agent given information target disease observed part state space given e e c ∈ e <NUMBER> let e ∈ r denote embedding entity e r ∈ r embedding relation r set available actions contains outgoing edges node e corresponding target nodes option stay current node transition denote ∈ st action agent performed time environment evolves deterministically updating state according previous action agent encodes previous actions via multilayered lstm hochreiter schmidhuber <NUMBER> t−<NUMBER> r t−<NUMBER> e ∈ r <NUMBER>d corresponds vector space embedding previous action zero vector time <NUMBER> action distribution given w <NUMBER> w <NUMBER> weight matrices rows ∈ r ×<NUMBER>d contain latent representations admissible actions action ∈ st sampled according ∼ categorical overall transitions sampled resulting path denoted maximum path length equations <NUMBER> <NUMBER> induce stochastic policy represented π θ θ denotes set trainable parameters including entity relation embeddings furthermore let <NUMBER> <NUMBER> set metapaths element corresponds body rule every metapath assign score sm ∈ r indicates quality measure corresponding rule confidence support respect making correct prediction path p denote withp corresponding metapath training terminal reward computed according first term indicates whether agent reached correct target disease second term checks whether metapath corresponds body rule adds score accordingly heuristically speaking want reward agent higher score extracting metapath corresponds body hyperparameter λ ≥ <NUMBER> balances two components reward λ <NUMBER> recover minerva employ reinforce williams <NUMBER> maximize expected rewards thus agents maximization problem given e c denotes true underlying distribution set chemical compounds hetionet himmelstein et al <NUMBER> biomedical kg integrates data <NUMBER> highly reputable cited public databases consists <NUMBER> entities <NUMBER> different types <NUMBER> edges <NUMBER> different types aim predict edges type treats entities correspond compounds diseases goal perform candidate ranking according likelihood successful drug repurposing novel treatment application <NUMBER> compounds <NUMBER> diseases hetionet <NUMBER> observed links type treats compounds diseases himmelstein et al <NUMBER> compiled list <NUMBER> metapaths corresponding various pharmacological efficacy mechanisms connect entities type compound entities type disease hypothesis testing domain expertise identified <NUMBER> effective metapaths served features logistic regression model metapaths select <NUMBER> metapaths background information path length <NUMBER> exhibit positive regression coefficients indicating importance predicting drug efficacy metapaths included rule bodies rule head always compound treats disease estimate confidence score rule sampling <NUMBER> paths whose metapaths correspond rule body use confidence score sm see section <NUMBER> table <NUMBER> shows three metapaths highest confidences apply method denoted minerva hetionet calculate hits<NUMBER> hits<NUMBER> hits<NUMBER> mean reciprocal rank mrr inference beam search carried entities ranked probability corresponding paths moreover consider another evaluation scheme minerva pruned retrieves ranks paths test rollouts correspond one metapaths extracted paths considered ranking compare approach pathbased method minerva rulebased method anyburl embeddingbased methods transe rescal rgcn anyburl learns one rule relation treats length least <NUMBER> see effect applying larger number rules try setting use metapaths prediction step leads significantly improved results transe rgcn show similar performance rescal performs best among embeddingbased methods applying modified ranking scheme method yields performance gains <NUMBER> hits<NUMBER> <NUMBER> hits<NUMBER> <NUMBER> hits<NUMBER> <NUMBER> mrr respect best performing baseline method method act generic mechanism inject domain knowledge reinforcement learningbased reasoning methods kgs lin et al <NUMBER> xiong et al <NUMBER> employ rules extracted datadriven fashion method agnostic towards source background information additional reward extracting rule see equation <NUMBER> considered regularization enforces agent walk along metapaths generalize unseen instances anyburl strictly outperformed minerva method likely large amount highdegree nodes hetionet lead outcome hardly strong predictive rules extracted multihop reasoning methods contain natural transparency mechanism providing explicit inference paths surprisingly experimental findings show pathbased reasoning methods outperform existing blackbox methods drug repurposing task without tradeoff explainability performance transe rescal trained minimize reconstruction error immediate firstorder neighborhood results indicate methods seem suitable drug repurposing task rgcn principle capable modeling longterm dependencies due receptive field containing entire set nodes multihop neighborhood however aggregation combination step rgcn essentially acts lowpass filter incoming signals presence many highdegree nodes center nodes may receive uninformative signal smooths neighborhood embeddings illustrate applicability method consider compound sorafenib figure <NUMBER> three highest predictions model new target diseases include hematologic cancer breast cancer barretts esophagus database clinicaltrailsgov u national library medicine <NUMBER> lists <NUMBER> clinical studies testing effect sorafenib three diseases showing predictions meaningful targets investigation proposed novel neurosymbolic knowledge graph reasoning approach leverages pathbased reasoning representation learning logical rules apply method highly relevant task drug repurposing compare approach embeddingbased rulebased methods achieve better performance improvement <NUMBER> hits<NUMBER> <NUMBER> mean reciprocal rank compared popular baselines j u r n l p r e p r f coronavirus cov belonging coronaviridae family spikes outer surface making look like crown thus deriving name corona latin crown enveloped viruses made singlestranded rna genomic material along helical nucleocapsid bound rna bead string type continuous conformation diameter size range <NUMBER>nm length varying <NUMBER> kbs virus family subgroups based genomic structure namely α β ϒ δ cov <NUMBER> till four covs identified human circulation low pathogenicity caused mild respiratory symptoms viz nl<NUMBER> <NUMBER>e α covs oc<NUMBER> hku<NUMBER> βcovs <NUMBER> st fatality rate <NUMBER> <NUMBER> respectively intermediary hosts bats humans sars palm civet cats mers dromedary camels sars mers caused respiratory distress lung injury leading pulmonary failure fatality <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> wuhan capital hubei province china late december <NUMBER> clusters cases severe pneumonia due unknown causes initial cases identified common exposure huanan seafood market involved selling dead seafood animals trading live animals china quick surveillance j u r n l p r e p r f sarscov<NUMBER> causative agent current pandemic situation similar sars genome analysis tremendously helped gaining insights sars cov<NUMBER> sequence analysis revealed major distinction spike orf<NUMBER>b orf <NUMBER> regions previously reported recombination hotspots <NUMBER> several transcriptional regulatory elements stemloop structures present <NUMBER> <NUMBER> utrs frameshift elements contribute complex transcription translational properties viral rna <NUMBER> <NUMBER> <NUMBER> <NUMBER> besides understanding genetic annotation understanding sequences subgenomic mrnas insight secondary structures genomic rna would enable development genome targeted therapeutics spike protein densely glycosylated class fusion protein surface virus particles comprises large ectodomain singlepass transmembrane domain anchors protein lipid bilayer small intracellular segment ectodomain two j u r n l p r e p r f protein surface virus particle present prefusion form <NUMBER> upon contact host cell protein undergo priming host cell membrane proteases tmprss<NUMBER> serine protease induce membrane wrapping efficient internalization <NUMBER> <NUMBER> structural analysis demonstrated rbd sarscov<NUMBER> bound <NUMBER> times advanced affinity ace<NUMBER> sarscov receptor unbound state s<NUMBER> domain flexible <NUMBER> another notable change spike protein sarscov<NUMBER> presence s<NUMBER>s<NUMBER> furinlike rift spot absent sarscov several reports suggest presence proteolytic site increases pathogenicity virus furin like rift spot also reported increase tissue tropism viruses <NUMBER> <NUMBER> far sarscov<NUMBER> thought infect upper respiratory tissue surprisingly recent report shows ability sarscov<NUMBER> infect tlymphocytes also membrane fusion process <NUMBER> spike protein first contact site viruses cells subjected tremendous evolutionary pressure changes spike protein would profound effect infectivity transmission viruses spike protein present pandemic sarscov<NUMBER> changes acquired furinlike cleavage site structural changes receptor binding sites correlated species jumping efficient humantohuman transmission virus also found form syncytium enables virus spreading cellcell fusion might also leads rapid infectivity sarscov<NUMBER> virus <NUMBER> main protease pro also recognized <NUMBER>clike protease encoded nsp<NUMBER> first protein autocleaved cleaves polyprotein individual members nonstructural proteins cleavage site leugln↓ ser ala gly attains stable active form octamer monomer dimer exist equilibrium <NUMBER> j u r n l p r e p r f upon infection microbes proteins exposed surface intruders first recognized immune system systematic specific immune response elicited fight back infectious agents however certain infections immune system might taken infectivity microbes results pathological conditions thus condition supporting immune system synthetic drugs would help combating infection might also enable recovery defence body similar approach immune system surface structures always first class probable candidates addressed therapeutics development cq inexpensive effective drug use <NUMBER> years making potential clinically beneficial towards covid<NUMBER> hydroxychloroquine hcq demonstrates highly related structure shown figure <NUMBER> antiviral activity cq may function safer treatment method covid <NUMBER> demonstrates antisarscov activity vitro <NUMBER> better clinical safety profile cq longterm use allow high daily dose <NUMBER> <NUMBER> however debate lpv rtv could efficiently block covid<NUMBER> <NUMBER>chymotrypsinlike papainlike proteases hiv protease family aspartic proteases two coronavirus proteases belong family cysteine proteases fact hiv protease inhibitors precisely designed match c<NUMBER> structure hiv protease dimer catalytic site however c<NUMBER>symmetric structure missing coronavirus proteases <NUMBER> assuming hiv protease inhibitors modify host pathways interact coronavirus infection indirectly potency remains matter concern recent study <NUMBER> covid<NUMBER> patients conventional chinese medicine interferon lpv rtv briefterm <NUMBER> <NUMBER> days corticosteroids successfully treated <NUMBER> patients recovered discharged <NUMBER> done lung tissue lung function <NUMBER> another study showed metabolite rdv gs<NUMBER> operative array covs like prepandemic bat covs bat covs circulating contemporary human cov primary human lung cells <NUMBER> also showed gs<NUMBER> halts replication merscov sarscov thereby reduces viral load primary human epithelial cell cultures rdv blocks sarscov infection micromolecular half cytotoxic concentration <NUMBER> sufficient data available pharmacokinetics rdv however data extrapolated vivo mouse nonhuman primate data rdv metabolized prodrug anabolic intracellular kinase <NUMBER> oncedaily dosing found reach maximum concentration halflife approximately <NUMBER>hrs vivo nonhuman primate model vitro human lung cell model <NUMBER> data relating protein binding hepatic clearance adverse effects dosing information yet available per clinical study data currently loading dose <NUMBER>mg intravenous rdv given followed <NUMBER>mg intravenously <NUMBER> initiated multicenter doubleblind randomized adaptive placebocontrolled trial assess safety efficacy rdv hospitalized adults diagnosed covid<NUMBER> <NUMBER> ribavirin rbv antiviral purine nucleoside analog approved chronic hepatitis c virus hcv broadspectrum antiviral drug activity hepatitis b respiratory syncytial virus merscov sarscov<NUMBER> <NUMBER> rbv metabolized adenosine kinase prodrug mono di triphosphate metabolites synthesis viral mrna polymerase inhibited direct binding rbv triphosphate rtp nucleotidebinding site enzyme results reduction production defective virions decreases viral load <NUMBER> rbv also competitively inhibits host inosine monophosphate dehydrogenase impdh inhibits guanine nucleotides synthesis decrease guanosine triphosphate leads depletion viral protein synthesis halts process viral genome replication <NUMBER> rbv also immunomodulatory effect host promoting production cytokines stimulates humoral response enhances immunity towards virus mechanism action rbv includes inhibition mrna capping results induction mutation viral replication main reason considering rbv potential treatment approach treat sarscov<NUMBER> <NUMBER> high doses rbv required treatment rbv given monotherapy shows resistance sars mers therefore given combination antiviral drugs like lopinavir chloroquine analogs interferonα <NUMBER> study vero llcmk<NUMBER> cells showed combination rbv interferonα inhibits replication novel coronavirus ncov isolate hcovemc<NUMBER> cell lines lower concentration rbv interferonα thus making rbv promising treatment covid<NUMBER> <NUMBER> pharmacokinetic profile rbv well established rapidly extensively absorbed orally oral bioavailability <NUMBER> metabolized liver adenosine kinase mono di tri phosphate metabolites halflife rbv <NUMBER> hours russia prophylaxis treatment respiratory viral infections influenza <NUMBER> arb shown activity sarscov<NUMBER> virus thus currently investigated potential treat covid<NUMBER> prophylactically <NUMBER> broadspectrum activity arb mainly dual action host targeting agent hta acts one multiple stages viral life cycle directacting antiviral daa induces direct virucidal effects virus <NUMBER> daa action mainly ability arb form interactions amino acid residues arb interferes intracellular trafficking clathrinmediated endocytosis directly viral lipid envelope <NUMBER> interaction arb viral glycoprotein aromatic residues involved fusion cellular recognition main reason arbs antiviral activity <NUMBER> following oral administration maximum concentration drug plasma estimated <NUMBER> ngml time taken reach maximum plasma concentration <NUMBER>hrs <NUMBER> undergoes cytochrome p<NUMBER> dependent hepatic metabolism also metabolized intestinal microsomes <NUMBER> phase<NUMBER> metabolic pathways include hydroxylation sulfoxidation ndemethylation whereas phase<NUMBER> pathway mainly due glucuronide sulfate conjugation reactions <NUMBER> <NUMBER> combination currently approved fda treating aids drv hiv protease inhibitor cobicistat supplement enhance drvs pharmacodynamics pharmacokinetics inhibiting cytochrome p<NUMBER> cyp<NUMBER>a <NUMBER> <NUMBER> antiviral drugs also widely used covid<NUMBER> treatment around world oseltamivir another medication licensed treatment influenza b prevents viral neuraminidase thereby prevents releasing viral particles host cells thus minimising spread throughout respiratory tract <NUMBER> usage oseltamivir without antibiotics corticosteroids reported china <NUMBER> oseltamivir also used clinical trials chloroquine fpv multiple combinations <NUMBER> infections <NUMBER> along antibacterial activity az also shown antiviral activity inducing production interferonstimulated genes rhino virus infected bronchial epithelial cells <NUMBER> studies showed az also effective zika ebola virus az acts virus host multiple mechanism az inhibits viral genetic shedding lysosome blocks endocytosis getting accumulated intracellularly lysosomes endosomal vesicles leading increase ph levels thereby limits replication viral genetic material <NUMBER> antiviral activity az also attributed ability induce interferon mediated antiviral response reduces replication virus <NUMBER> az also decreases mucus secretion enables lung function directly acting bronchial epithelial cells <NUMBER> az shown potential action sarscov<NUMBER> interacts among sarscov<NUMBER> spike protein host angiotensin converting enzyme<NUMBER> ace<NUMBER> protein thereby inhibits viral entry host cell <NUMBER> bioavailability az following oral administration <NUMBER> high tissue penetration <NUMBER>yrs age deduce efficacy combination therapy hydroxychloroquine az <NUMBER> concluded hydroxychloroquine <NUMBER>mgday az <NUMBER>mg day <NUMBER> days successfully reduced viral load activity hydroxychloroquine reducing viral load reinforced az tetracyclines doxycycline tetracyclines minocycline class polyketide antibiotics broadspectrum bacteriostatic activity various bacterial infections bactericidal activity tetracycline mainly due ability reversibly bind teicoplanin glycopeptide antibiotic produced actinomycete actinoplanes teichomyceticus <NUMBER> currently approved treat grampositive bacterial infections like staphylococcal infections <NUMBER> teicoplanin also shown activity array viruses like influenza virus hepatitis c virus ebola hiv flavivirus corona viruslike sarscov merscov <NUMBER> teicoplanin inhibits transpeptidase activities transglycosylation reaction nonspecifically binding outside layers peptidoglycan structure followed binding terminal amino acids constitute building blocks peptidoglycan cell wall <NUMBER> thus teicoplanin specifically stops bacterial growth inhibiting biosynthesis bacterial cell wall <NUMBER> teicoplanin binds peptidoglycan inhibits cell wall lytic enzymes resulting cell freezing <NUMBER> teicoplanin acts coronavirus inhibiting genome viral rna release thereby preventing replication viruscell cycle inhibition activity teicoplanin acting early stage viral life cycle inhibiting low ph cleavage viral spike protein cathepsin l late endosome <NUMBER> case sarscov<NUMBER> teicoplanin acts way targeting cleavage site cathepsin l present spike protein study test efficacy teicoplanin <NUMBER>ncov showed teicoplanin efficiently inhibits entry <NUMBER>ncov spike pseudovirus cytoplasm dosedependent manner <NUMBER> teicoplanin poorly absorbed oral administration <NUMBER> bioavailability upon administering intramuscularly protein binding drug <NUMBER> metabolized liver hydroxylation reaction give metabolites <NUMBER> <NUMBER> <NUMBER> mean volume distribution steady state teicoplanin found <NUMBER>l eliminated renal pathway <NUMBER> hypersensitivity site injection major side effect associated teicoplanin may cause bronchospasm anaphylactic shock teicoplanin also cause nephrotoxicity ototoxicity tachycardia fatigue headache tremors diarrhea elevation liver enzymes reported side effects <NUMBER> baricitinib immunosuppressant approved fda treatment moderate severe rheumatoid arthritis janus kinase jak inhibitor acts selectively reversibly binding jak receptors inhibiting jak<NUMBER> jak<NUMBER> inhibition leads halting signal transduction growth receptors cytokines leading reduction immune cell function haematopoiesis baricitinib also prevents formation viral particles intracellular passage viral cells binding associated protein kinase <NUMBER> aak<NUMBER> <NUMBER> baricitinib considered one drug candidates test covid<NUMBER> patients covid<NUMBER> prone secondary hemophagocytic lymphohistocytosis shl <NUMBER> leads elevated inflammatory ferritin marker progression patients develop conditions like acute interstitial pneumonia fever lung injury arthralgia leukopenia thrombocytopenia myocarditis biological inflammatory changes caused due hyper production cytokines resulting cytokine storm <NUMBER> cytokine storm induced replication virus activates innate immune system produce ils tcz binds il receptors blunts hyper secretion ils thereby reducing inflammation related conditions <NUMBER> halflife tcz concentration dependent unlike mabs tcz also metabolized smaller proteins action proteolytic enzymes <NUMBER> dose <NUMBER>mg intravenous tcz daily administered patients covid<NUMBER> <NUMBER> ivermectin broadspectrum antiparasite drug approved treatment onchocerciasis intestinal strongyloidiasis ivermectin acts selectively binding glutamategated chloride channels parasite leads hyperpolarization cell results paralysis death parasite antiviral activity ivermectin first discovered ability block interaction nuclear transport receptor importin αβimp integrase molecule hiv <NUMBER> also known block viral replication host viruses including influenza flavivirus dengue virus <NUMBER> vitro study ivermectin antiviral activity sarscov<NUMBER> virus showed inhibition viral replication <NUMBER>fold within <NUMBER>hrs mediated inhibiting imp αβ mediated nuclear import viral proteins <NUMBER> phaseiii double blind randomized clinical trial started aim determine safety efficacy profile combination therapy hydroxychloroquine ivermectin treatment hospitalized covd<NUMBER> patients <NUMBER> ace<NUMBER> inhibitors captopril ramipril widely used treating hypertension ace<NUMBER> receptors overexpressed epithelial cells oral mucosa also present immune reactive cells like lungs blood vessels macrophages intestine <NUMBER> case sarscov sarscov<NUMBER> ace<NUMBER> receptors serves door way virus enter host cell <NUMBER> sarscov transmembrane spike glycoprotein sprotein outer shell binds ace<NUMBER> receptors virus attached ace<NUMBER> receptors host cell cellular proteases starts priming sprotein j u r n l p r e p r f potential therapeutic strategy treat covid<NUMBER> regard many clinical trials initiated particular corticosteroids approved treating covid<NUMBER> viral pneumonia <NUMBER> septic shock corticosteroids benefit blunting hosts immune reaction release bacterial toxins frequency shock remarkably low patients covid<NUMBER> <NUMBER> cases deliver oxygenated blood flow thoracic pressure breathing results increased heart activity leading cardiogenic ards patients <NUMBER> retrospective openlabel trial chictr<NUMBER> planned examine clinical progress patients administered methylprednisolone iv <NUMBER> <NUMBER> another study zhou et al indicated <NUMBER> covid<NUMBER> patients briefterm optimumdose corticosteroid <NUMBER> mgday immunoglobulin <NUMBER> g day substantially decreased lung damage stabilized body temperature creactive protein lymphocyte oxygenation levels <NUMBER> however examining <NUMBER> covid<NUMBER> patients shang et al observed corticosteroid treatment administration gamma globulin raised fatalities considered effective patients low lymphocyte levels <NUMBER> delivery corticosteroids covid<NUMBER> patients also uncertain according scientific findings inflammation researchers also reported levels neutralizing antibodies patients either increased stayed elevated following cp transfusion <NUMBER> covid<NUMBER> outbreak stated pandemic directorgeneral dr tedros <NUMBER>th march world started noticing alarming levels upswing covid<NUMBER> cases hitherto patients suffering covid<NUMBER> receiving j u r n l p r e p r f symptomatic treatment due unavailability specific therapy severe cases treatment includes support functioning vital organs <NUMBER> understanding whole genome sequence covid<NUMBER> allows refinement current technologies developing potent targeted therapeutics <NUMBER> monoclonal antibodies progress <NUMBER> though window usefulness steroids covid<NUMBER> patients narrower still preferred capability preventing lung fibrosis stopping cytokine storm <NUMBER> j u r n l p r e p r f j u r n l p r e p r f considerable progress made vitro diagnostic test ivd covid<NUMBER> realtime reverse transcriptasepolymerase chain reaction rtpcr basic ideology ivd takes hours results industries managed reduce test time <NUMBER> hours cepheid <NUMBER> minutes abbot wide array serology immunoassays ias primarily detect igm igg also developed automated chemiluminescence ia manual elisa rapid lateral flow ia complementing covid<NUMBER> diagnostic molecular assays <NUMBER> <NUMBER> future research must carried using effective animal model analyses viruss replication transmission pathogenesis also integrating imaging molecular diagnosis help efficiently track treat covid<NUMBER> <NUMBER> <NUMBER> <NUMBER> rapid increase covid<NUMBER> cases world research development drugs vaccines gained momentum prevailing condition pandemic fast development vaccines required take time prepared threedimensional model sarscov<NUMBER> aka <NUMBER>ncov <NUMBER>clike protease <NUMBER>cl pro using crystal structure highly similar <NUMBER> identity ortholog sarscov residues involved catalysis substrate binding dimerisation <NUMBER> conserved comparison polyprotein pp<NUMBER>ab sequences showed <NUMBER> identity <NUMBER>clike cleavage sites coronaviral polyproteins highly conserved based nearidentical substrate specificities high sequence identities opinion previous progress specific inhibitors development sarscov enzyme conferred sarscov<NUMBER> counterpart <NUMBER>cl pro molecular model performed virtual screening purchasable drugs proposed <NUMBER> candidates consideration among antivirals ledipasvir velpatasvir particularly attractive therapeutics combat new coronavirus minimal side effects commonly fatigue headache drugs epclusa velpatasvirsofosbuvir harvoni ledipasvirsofosbuvir could effective owing dual inhibitory actions two viral enzymes prediction sarscov<NUMBER> <NUMBER>ncov <NUMBER>clike protease <NUMBER>clpro structure virtual screening reveals velpatasvir ledipasvir drug repurposing candidates <NUMBER> january <NUMBER> new coronavirus <NUMBER>ncov officially named sarscov<NUMBER> implicated alarming outbreak pneumonialike illness covid<NUMBER> originating wuhan city hubei china humantohuman transmission first confirmed guangdong china <NUMBER> world health organisation declared global public health emergency <NUMBER> february <NUMBER> <NUMBER> confirmed cases reported death toll <NUMBER> height crisis virus spreading rate scale far worse previous coronaviral epidemics immediately evident genome coronavirus evolutionarily related <NUMBER> identity betacoronavirus implicated severe acute respiratory syndrome sars originated bats causative global outbreak <NUMBER> momentum research developing antiviral agents sarscov carried epidemic subsided despite sars treatment yet come fruition however knowledge acquired extensive research development efforts may use inform current therapeutic options viral genome encodes <NUMBER> proteins among two proteases pl pro <NUMBER>cl pro vital virus replication cleave two translated polyproteins pp<NUMBER>a pp<NUMBER>ab individual functional components <NUMBER>chymotrypsinlike protease <NUMBER>cl pro aka main protease pro considered promising drug target tremendous effort spent studying protein order identify therapeutics sarscov particular pathogenic coronaviruses eg merscov middle east respiratory syndrome coronavirus general share similar active sites enzymatic mechanisms purpose study build molecular model <NUMBER>cl pro sarscov<NUMBER> carry virtual screening identify readily usable therapeutics intention however comment structurebased drug design research timely current epidemic translated polyprotein pp<NUMBER>ab sequence obtained annotation genbank entry sarscov<NUMBER> genome accession number mn<NUMBER> comparing sequence sarscov pp<NUMBER>ab sequence accession number abi<NUMBER> protease cleavage sites mature protein sequences obtained sequence comparison alignment performed blastp highresolution apoenzyme structure sarscov <NUMBER>cl pro pdbid <NUMBER>duc <NUMBER> employed template variant residues mutated silico scwrl<NUMBER> <NUMBER> followed manual adjustment ensure best sidechain rotamer employed table <NUMBER> rebuilt model subjected steepest descent energy minimisation gromacs <NUMBER> using gromos <NUMBER>a<NUMBER> forcefield restraint force constant <NUMBER> kj mol <NUMBER> nm <NUMBER> applied backbone atoms atoms vital residues table <NUMBER> accessible surface area residues calculated areaimol ccp<NUMBER> suite v<NUMBER> mtiopenscreen web service <NUMBER> used screening library <NUMBER> purchasable drugs drugslib binding site grid specified activesite residues active sites chain chain b screened independently autodock vina <NUMBER> crystal structure released stripped inhibitor subjected screening list <NUMBER> targetligand docking combinations ranked binding energies produced screen top <NUMBER> <NUMBER> ranked using binding energy cutoff hits chains b examined visually pymol version <NUMBER>x <NUMBER> earlier version article found chemrxiv doi <NUMBER>chemrxiv<NUMBER>v<NUMBER> first available genome genbank mn<NUMBER> ncbi reference sequence nc<NUMBER> pp<NUMBER>ab sequence sarscov<NUMBER> extracted aligned sarscov overall aminoacid sequence identity high <NUMBER> conservation noticeable polyprotein cleavage sites <NUMBER> <NUMBER>cl pro sites <NUMBER> highly conserved identical extended data <NUMBER> table s<NUMBER> inferring respective proteases similar specificities <NUMBER>cl pro sequence sarscov<NUMBER> <NUMBER> <NUMBER> residues different sarscov identity <NUMBER> compared polyprotein pp<NUMBER>ab <NUMBER>cl pro sequences among <NUMBER> sarscov<NUMBER> genomes genbank mn<NUMBER> <NUMBER>d model sarscov<NUMBER> <NUMBER>cl pro amino acids known important enzymes functions listed table <NUMBER> unexpectedly none <NUMBER> variant positions involved major roles therefore confident prepare structural model sarscov<NUMBER> <NUMBER>cl pro molecular modelling extended data <NUMBER> figure s<NUMBER> immediately useful silico development targeted treatment submitted first draft study crystal structure sarscov<NUMBER> <NUMBER>cl pro solved released pdb id <NUMBER>lu<NUMBER> confirms predicted model good within experimental errors extended data <NUMBER> figure s<NUMBER> examined molecular graphics <NUMBER> solutions found fit respective active sites convincingly binding energies chain complexes generally higher chain b approximately <NUMBER> kcal mol <NUMBER> table <NUMBER> presumably demonstrates intrinsic conformational variability aand bchain active sites crystal structure average rootmeansquare deviation rmsd cα atomic positions activesite residues <NUMBER> å screen differences binding energies small suggesting ranking discriminatory top scorers examined combined two screens found <NUMBER> candidates give promising binding models etoposide phosphate counted one table <NUMBER> checked actions targets side effects <NUMBER> candidates among first noticed velpatasvir figure <NUMBER>a ledipasvir inhibitors ns<NUMBER>a protein hepatitis c virus hcv marketed approved drugs combination sofosbuvir prodrug nucleotide analogue inhibitor rnadependent rna polymerase rdrp ns<NUMBER>b interestingly sofosbuvir recently proposed antiviral sarscov<NUMBER> based similarity replication mechanisms hcv coronaviruses <NUMBER> results strengthen dualcomponent hcv drugs epclusa velpatasvirsofosbuvir harvoni ledipasvirsofosbuvir may attractive candidates repurpose may inhibit two coronaviral enzymes drug target two viral proteins substantially reduces ability virus develop resistance directacting antiviral drugs also associated minimal side effects conveniently orally administered table <NUMBER> flavonoid glycosides diosmin figure <NUMBER>b hesperidin figure <NUMBER>e obtained citrus fruits fit well block substrate binding site yet compounds table <NUMBER> silico mutagenesis sarscov<NUMBER> <NUMBER>cl pro <NUMBER> variant residues reference sarscov enzyme shown respective treatment rotamer b refers individual chains dimeric model chains crystal asymmetric unit identical rotamer symbol bracketed defined according conventions richardson <NUMBER> followed respective rank popularity asa accessible surface area average b chains residue sarscov <NUMBER>cl pro structure å <NUMBER> relative asa residue x glyxgly conformation residue rotamer asa å <NUMBER> remarks replacement table <NUMBER> hesperidin hits showed multiple times suggesting many modes binding figure <NUMBER>a teniposide etoposide phosphate chemically related turned multiple hits good binding models figure <NUMBER>f however chemotherapy drugs lot strong side effects need intravenous administration table <NUMBER> approved drug venetoclax figure <NUMBER>c investigational drugs mk<NUMBER> r<NUMBER> scored well screens venetoclax another chemotherapy drug burdened side effects including upper respiratory tract infection table <NUMBER> much disclosed mk<NUMBER> r<NUMBER> subjected crystal structure virtual screening procedures similar list candidates showed consistently extended data <NUMBER> table s<NUMBER> high scores although ledipasvir found noticed compounds list molecular weights mw <NUMBER> except lumacaftor mw<NUMBER> largest one ledipasvir mw<NUMBER> size peptide substrate deeply buried protease active site demand large molecule many rotatable dynamics fit identified five trials clinicaltrialsgov involving antiviral immunomodulatory drug treatments sars one record receives lot attention amid current outbreak lopinavirritonavir combination <NUMBER> protease inhibitors originally developed hiv <NUMBER> sars outbreak despite lacking clinical trial tried emergency measure found offer improved clinical outcome <NUMBER> however scientists express scepticism <NUMBER> analogy compounds speculated act sarscov <NUMBER>cl pro specifically yet crystal structure support although docking studies carried propose various binding modes <NUMBER> ic <NUMBER> value lopinavir <NUMBER> μm k <NUMBER> μm ritonavir cannot established <NUMBER> although far cure based results two cov <NUMBER>cl pro enzymes identical far protein sequences substrate specificities concerned opinion still one recommended routes immediate treatment time writing early february <NUMBER> look beyond <NUMBER>cl pro earlier screen produced <NUMBER> candidates could repurposed sarscov merscov <NUMBER> addition coronaviral proteins could targeted screening treatment covid<NUMBER> remdesivir repurposed drug development targeting rdrp showing improved clinical outcome reported clinical trial underway <NUMBER> consider work part global efforts responding timely fashion fight deadly communicable disease aware similar modelling screening repurposing exercises targeting <NUMBER>cl pro reported announced <NUMBER> methods overlap share common results studies extended results folder contains following extended data • tab s<NUMBER>docx sequence homology <NUMBER>cl pro cleavage junctions pp<NUMBER>ab sarscov<NUMBER> sarscov • tab s<NUMBER>docx results virtual screening drugs active site sarscov<NUMBER> <NUMBER>cl pro crystal structure • fig s<NUMBER> pptx structural model sarscov<NUMBER> <NUMBER>cl pro protease • compare crystaldocx comparison figure s<NUMBER> active sites model chains b crystal structure data available terms creative commons zero rights reserved data waiver cc<NUMBER> <NUMBER> public domain dedication applicable statistical analysis interpretation appropriate yes <NUMBER> <NUMBER> details docking provided whats binding energy cutoff used hits reported table <NUMBER> used <NUMBER>clpro catalytically active dimer considered virtual screening b top scorers mean extended data virtual screening one compound could multiple entries different zinc numbers example hesperidin corresponds least <NUMBER> different compounds difference different results assembled table <NUMBER> clear please columnbycolumn comparison different sites sarscov sarscov<NUMBER> also please add oneletter amino acid codes residues constructed protein structure similar recently solved crystal structure <NUMBER>lu<NUMBER> confirms predicted model good within experimental errors docking results seem differ significantly could authors explain source data underlying results available ensure full reproducibility yes competing interests disclosed competing interests confirm read submission believe appropriate level expertise confirm acceptable scientific standard since discovery <NUMBER> ebola virus pathogen responsible increasing number epidemics <NUMBER> widespread epidemic took place western africa december <NUMBER> june <NUMBER> resulted total <NUMBER> reported cases <NUMBER> reported deaths april <NUMBER> <NUMBER> world health organization declared recent epidemic public health emergency international concern called intensified efforts develop therapeutic agents targeting ebola virus <NUMBER> although largescale epidemic may ended emergence sporadic new cases continues pose risk future outbreaks <NUMBER> ebola virus disease evd often considered disease poverty takes place form sudden outbreaks amongst poor populations limited resources <NUMBER> many diseases poverty research drug development evd neglected many years commercially unattractive drug developers invest significant contents lists available sciencedirect journal homepage wwwelseviercomlocatecuthre resources example study <NUMBER> revealed period <NUMBER> <NUMBER> <NUMBER> <NUMBER> new approved drugs specifically indicated tropical diseases accounting o<NUMBER> new approved drugs <NUMBER> nonetheless recent evd outbreak led accelerated de novo drug development efforts evd <NUMBER> efforts promoted expedited approval process regulators us food drug administration fda european medicines agency <NUMBER> <NUMBER> yet <NUMBER> years since start epidemic results many experimental drugs considered either questionable negative <NUMBER> potential vaccine considered true breakthrough <NUMBER> date none experimental drugs fully approved treatment prevention evd due urgent need effective accessible evd treatment additional efforts study approved established drugs potential antievd therapeutic agents concept known drug repurposing drug repositioning <NUMBER> concept may significant advantages case evd overcomes limitations experimental drug development first repurposed drugs usually wellknown safety pharmacokinetic profiles leads shorter development cycles lower costs <NUMBER> addition drugs may often tap already established manufacturing distribution network shortens production delivery times cases rapidly spreading epidemics finally depending repurposed drugs identified may already marketed generics clear advantage countries resourcepoor health care systems variety literature reviews published potential therapeutic targets evd also include overview possible candidates drug repurposing <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> however systematic review dedicated repurposed therapeutic agents targeting evd exists date herein present systematic review aim identifying potential drug repurposing candidates assessing scientific evidence available efficacy undertook systematic review based priori protocol registered prospero crd<NUMBER> published peerreviewed journal <NUMBER> systematic review reported according preferred reporting items systematic reviews metaanalyses prisma statement <NUMBER> eligibility criteria study designs included drug library screening studies yielding least <NUMBER> approved therapeutic agent including high throughput screening studies virtual silico drug screens preclinical trials including vitro trials studies animal models clinical trials including randomized controlled trials controlled clinical trials prospective retrospective comparative cohort studies caseã control studies crosssectional studies case series case reports potential repurposed drugs selected assessment must fulfill following criteria drugs already approved least <NUMBER> regulatory authority us food drug administration fda european medicines agency ema japan pharmaceuticals medical devices agency pmda drugs positive vitro study outcomes least <NUMBER> additional animal clinical trial restrictions type participants preclinical clinical trials addition restrictions type setting included studies published <NUMBER> year discovery evd restrictions type comparator primary outcomes included mortality sequelae infection serious adverse events secondary outcomes include adverse events outcomes collected reported extracted outcomes data forms eg dichotomous continuous reported included studies included articles reported english german french spanish languages included articles published scientific journals well unpublished ones literature search strategies developed using medical subject headings text words related evd performed systematic literature search medline embase cochrane central register controlled trials search carried january <NUMBER> <NUMBER> studies published january <NUMBER> <NUMBER> date searches run identify ongoing unpublished studies searched world health organization international clinical trials registry platform clinicaltrialsgov european union clinical trials register addition searched reference lists selected studies well websites regulatory authorities fda european medicines agency developed search strategy help information specialist supplementary file <NUMBER> database records yielded search strategies exported endnote version x<NUMBER> clarivate analytics usa duplicates manually removed results database searches records identified sources documented depicted prisma flow diagram formal screening preliminary study screen used <NUMBER> authors hs oe carry pilot screening <NUMBER> randomly chosen studies search results spreadsheet following pilot screening authors independently screened titles abstracts yielded search inclusion criteria addition screened reference lists selected articles studies selected title abstract levels screened eligibility assessing full text article retrieved additional information study authors necessary resolve questions eligibility opinion third reviewer skl sought arrive consensus case disagreement study inclusion documented reasons excluding trials fulltext screening level neither review authors blinded journal titles study authors institutions reported results study selection process reasons exclusion fulltext screening level using prisma flow diagram preliminary data extraction spreadsheet used conduct pilot test carried authors using <NUMBER> randomly selected articles data extraction sheet refined accordingly pilot studies refined spread sheet used authors independently extract data items included screening preclinical clinical studies opinion third reviewer skl sought arrive consensus case disagreement study authors contacted clarification necessary selected study included items <NUMBER> study type extracted eligible items available qualitative data reported studies excluded review thus extracted however included study drew conclusions based qualitative data reported conclusions separately characteristics study table following study selection data extraction <NUMBER> authors hs oe independently selected drugs potentially promising results based aforementioned drug selection criteria opinion third reviewer skl sought arrive consensus case disagreement drug inclusion two authors oe hs independently assessed risk bias included studies risk bias vitro studies screen studies assessed due nonexistence appropriate risk bias tool studies internal validity preclinical studies animal studies assessed using systematic review centre laboratory animal experimentation risk bias tool <NUMBER> per instructions outlined cochrane handbook systematic reviews interventions newcastle ottawa scale used assess risk bias nonrandomized studies national heart lung blood instituteãs quality assessment tool case series used assess quality reporting case reports case series due lack suitable risk bias tool studies <NUMBER> overall risk bias judged low risk unclear risk high risk whereas overall quality reporting judged good fair poor comparing individual assessments oe hs initially intended conduct quantitative analysis primary secondary outcomes accordance protocol systematic review <NUMBER> however due lack adequate number sufficiently homogenous studies synthesized study results narratively search results presented prisma flow diagram figure <NUMBER> search yielded <NUMBER> records <NUMBER> total <NUMBER> selected studies classified based principal study type drug screening preclinical studies clinical studies resulted <NUMBER> drug screening <NUMBER> <NUMBER> preclinical studies <NUMBER> <NUMBER> clinical studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> drug screening studies summarized main characteristics selected drug screening studies listed positively testing drugs confirmed regulatory approval supplementary file <NUMBER> studies heterogeneous group included <NUMBER> highthroughput screens <NUMBER> virtual drug screens six studies introduced new drug screening methodologies carried pilot screens addition different studies used varying methods detect positively testing drugs commonly applied technique measurement luciferase activity infected cells technique used <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> applied techniques included measurement inhibition enhanced green fluorescent protein expression inhibition betalactamase activity addition conduction drug library screens <NUMBER> studies included additional preclinical trials vitro vivo selected drug candidates <NUMBER> <NUMBER> <NUMBER> relevant items trials extracted analyzed together results preclinical studies summarized main characteristics preclinical studies examining effects potential drug candidates evd table addition data <NUMBER> preclinical studies selected also included relevant data <NUMBER> drug screening studies <NUMBER> <NUMBER> <NUMBER> included vitro vivo trials vitro trials carried varying cell lines half maximal inhibitory concentration half maximal effective concentration ec <NUMBER> tested drugs extracted unavailable reported half maximal inhibitory concentration ec <NUMBER> values world health organization categorization prioritization table <NUMBER> total <NUMBER> studies included experiments animals <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> three trials carried monkey species <NUMBER> <NUMBER> <NUMBER> rhesus macaques whilst remaining <NUMBER> studies carried small animal models mice hamsters guinea pigs summarized main characteristics <NUMBER> clinical studies selected table ii include <NUMBER> case reports <NUMBER> <NUMBER> case series <NUMBER> <NUMBER> nonrandomized cohort studies <NUMBER> convalescent blood products included treatment regimen total <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> finally end point extracted mortality rate adequately documented end point shared studies total <NUMBER> selected studies <NUMBER> animal studies <NUMBER> <NUMBER> clinical studies <NUMBER> assessed risk bias within studies supplementary file <NUMBER> animal studies found high risk bias except <NUMBER> study unclear risk bias high risk bias animal studies mainly due selection bias performance bias detection bias animal studies failed mitigate selection bias test animals selected without proper randomization process thus samples obtained representative population intended analyzed animal studies also failed mitigate performance bias detection bias blinding investigators clinical studies single case reports case series <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> nonrandomized cohort studies <NUMBER> studies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> case studies <NUMBER> studies <NUMBER> judged poor reporting quality <NUMBER> study <NUMBER> judged fair reporting quality last study <NUMBER> good reporting quality nonrandomized cohort studies <NUMBER> found low risk bias due significant variation selected study types designs participants reported outcome measures chose carry narrative synthesis results rather metaanalysis based eligibility criteria selected total <NUMBER> potential therapeutic agents treatment evd analysis summarized data extracted potential drug table iii subsequent section discusses evidence available <NUMBER> selected drugs potential therapeutic effects evd also takes additional factors consideration proposed mechanism action history antiviral activity safety applicability setting evd epidemic details potential repurposed drugs treatment evd shown table iii chloroquine readily available welltolerated antimalarial agent long history use treatment prophylaxis malaria also well documented antiviral effects various stages viral life cycle including antihiv<NUMBER> activity <NUMBER> well inhibitory effects severe acute respiratory virus syndrome coronavirus <NUMBER> addition studies show systemic antiinflammatory effects chloroquine downregulating production proinflammatory factors interferon ifnö̊and tumor necrosis factorö <NUMBER> potential activity chloroquine ebola virus may achieved inhibiting virus entry host cells believed take place inhibiting various factors vesicle sorting endosomemembrane fusion well increasing endosomal ph <NUMBER> chloroquine shown successfully inhibit ebola virus vitro different studies various cell lines <NUMBER> <NUMBER> <NUMBER> <NUMBER> animal studies hand revealed mixed results <NUMBER> madrid et al <NUMBER> carried animal trial <NUMBER> <NUMBER> mice survived ebola infection treated chloroquine twice daily <NUMBER> mgkg ip another study intraperitoneal treatment chloroquine dose showed significant protection high toxicity mouse hamster model <NUMBER> <NUMBER> madrid et al <NUMBER> able reproduce positive results upon repeat testing chloroquine ebolainfected mice identical conditions <NUMBER> mgkg ip twice daily chloroquine administered orally <NUMBER> mgkg daily showed increase survival <NUMBER> search yield clinical trials chloroquine activity involves enhancing host defenses eg activating macrophages m<NUMBER>phenotype antiviral proinflammatory mice ifnö̊administered <NUMBER> h infection significantly reduced mortality lethallychallenged mice reduced morbidity monkeys ifnö<NUMBER>b treated monkeys showed slight delay death delay development viremia none survived different study ifnö̇prolonged survival change mortality convalescent blood donation use human blood products approved applied worldwide indications include anemia monkeys improved survival rhesus macaques treated convalescent serum macaque convalescent sera inhibition via ebov neutralizing antibodies present convalescent plasma humans <NUMBER> nonrandomized comparativecontrolled studies treatment patients <NUMBER> ml convalescent plasma whole blood significantly improve survival studies include <NUMBER> case report <NUMBER> patient survived <NUMBER> observational study <NUMBER> patients <NUMBER> survival additional case report describes use convalescent serum well favipiravir azithromycin antibiotic approved treatment many bacterial infections mixed results provided animal studies may explained range doses tested ec <NUMBER> <NUMBER> ö¥m higher doses may necessary produce consistently positive results may lead poor outcome due increase drug related toxicity furthermore chloroquine may effective given prophylactically due activity early stages viral cycle hence additional animal studies dose finding recommendable clinical trials amodiaquine antimalarial agent structurally related chloroquine widely used africa <NUMBER> vitro study <NUMBER> amodiaquine shown inhibit ebola virus well marburg virus potently chloroquine demonstrated lower ec <NUMBER> values however animal study yielded search mice treated <NUMBER> mgkg ip amodiaquine twice daily <NUMBER> days showed survival benefit <NUMBER> retrospective observational study patients evd switch antimalarial containing lumefantrine amodiaquine associated significant decrease case fatality rates mûdecins sans frontiûŕesled evd treatment units <NUMBER> remains unknown whether improved survival rate due antiviral activity amodiaquine possible toxicity lumefantrine another limitation study unmeasured patient characteristics ie confounding variables could influenced mortality rate toremiphene clomiphene wellestablished selective estrogen reuptake modulators approved treatment breast cancer infertility respectively drugs able inhibit ebola virus entry vitro <NUMBER> likely result latestage entry inhibition affects triggering fusion <NUMBER> mouse model <NUMBER> <NUMBER> animals treated <NUMBER> mgkg ip clomiphene survived lethal dose ebola virus toremiphene treatment group <NUMBER> <NUMBER> mice treated drug <NUMBER> mgkg survived two control groups showed <NUMBER> survival rates <NUMBER> another animal study mice treated <NUMBER> mgkg ip clomiphene twice daily showed survival benefit compared control group <NUMBER> additional animal trials different doses essential confirm survival benefit association drugs certain concerns limit practicality use toremiphene clomiphene evd therapeutic agents higher doses standard clinical range may necessary achieve therapeutic effect evd would increase risk serious side effects include ocular adverse effects clomiphene serious electrolyte derangements toremiphene drugs may therefore better suited candidates combination treatments ifns signaling proteins produced secreted host cells response pathogens tumor cells currently approved treatment hepatitis c <NUMBER> well certain autoimmune disorders like multiple sclerosis <NUMBER> recent viral outbreaks ifns suggested potential treatment emerging viral infections severe acute respiratory syndrome coronavirus <NUMBER> antiviral activity ifns appears occur via induction ifnsinduced transmembrane proteins inhibit broad range viruses different stages virus life cycle including viral entry fusion <NUMBER> <NUMBER> potential use ifns treatment evd assessed several studies since <NUMBER>s <NUMBER> <NUMBER> <NUMBER> <NUMBER> vitro studies shown potent inhibition evd across multiple cell types <NUMBER> animal study ifnö̊was shown protect mice challenged lethal dose ebola virus <NUMBER> two additional studies involving nonhuman primates treated ifnö̇or ifnö<NUMBER>b revealed increase survival time change mortality <NUMBER> <NUMBER> despite potential increase availability ifns therapeutic agents <NUMBER> several concerns practicality use evd outbreak certain side effects ifn fever myalgia may difficult control evd treatment unit addition important rule comorbidity malaria interferon treatment may difficult achieve may delay treatment transfusion blood products established treatment method variety noninfectious conditions case infectious diseases several reports offlabel use convalescent blood products <NUMBER> <NUMBER> chose include convalescent blood products assessment due similar properties shared repurposed therapeutics include presumed availability setting evd epidemic positive reports tolerability absence safetyrelated events <NUMBER> nonrandomized studies <NUMBER> <NUMBER> nonetheless important note transfusiontransmitted infections remain significant problem africa may difficult distinguish transfusionrelated complications evd progression <NUMBER> <NUMBER> use whole blood form passive immunotherapy treatment evd reported evd outbreak democratic republic congo <NUMBER> <NUMBER> observational study <NUMBER> <NUMBER> patients received convalescent blood transfusion survived contrast <NUMBER> mortality rate outbreak however <NUMBER> survivors received convalescent blood day <NUMBER> day <NUMBER> onset symptoms separate analysis shown high rate survival due treatment patients later course disease higher probability survival <NUMBER> recent west africa evd outbreak world health organization approved use blood plasma transfusions convalescent patients <NUMBER> search yielded <NUMBER> single case reports foreign patients contracted evd stay western africa survived following transfusion therapy <NUMBER> <NUMBER> <NUMBER> additional potential therapeutic agent administered <NUMBER> cases <NUMBER> <NUMBER> largest study treatment evd convalescent blood enrolled <NUMBER> confirmed evd patients mûdecins sans frontiûŕesled treatment unit guinea <NUMBER> included primary analysis <NUMBER> study showed significant improvement survival patients receiving <NUMBER> ml convalescent plasma unknown levels neutralizing antibodies even adjusting age cyclethreshold value recently published study sierra leone <NUMBER> similarly show significant improvement survival revealed significant drop viral load <NUMBER> hours treatment convalescent whole blood furthermore results recent animal study mire et al <NUMBER> show protection treatment rhesus monkeys convalescent sera remains unknown whether convalescent blood products known titers antiebola virus antibodies alternative administration regimens subselection patients would yield different results amiodarone widely available commonly used multiion channel blocker approved treatment atrial fibrillation ventricular tachycardic arrhythmias identified potent inhibitor ebola virus various endothelial epithelial cell lines concentrations commonly reached humans treated drug <NUMBER> <NUMBER> mechanism action appears rely induction niemannpick clike phenotype inhibits late endosomal filovirus entry <NUMBER> small animal study yielded search treatment <NUMBER> mgkg amiodarone ip twice daily significantly improved survival ebola viruschallenged mice repeat trial identical conditions unable reproduce significant improvement survival rates <NUMBER> furthermore amiodarone reportedly used sierra leone treat evd patients <NUMBER> treatment unit compassionate basis potential effects statistical significance could determined <NUMBER> therapeutic agents appear inhibit filovirus entry similar fashion amiodarone sertraline bepridil sertraline selective serotonin reuptake inhibitor used treatment depression bepridil calcium channel blocker used treat angina pectoris drugs found effectively inhibit ebola virus vitro <NUMBER> <NUMBER> murine model <NUMBER> <NUMBER> mice treated <NUMBER> mgkg sertraline twice daily survived compared <NUMBER> mortality control group study <NUMBER> <NUMBER> mice treated <NUMBER> mgkg bepridil survived <NUMBER> favipiravir relatively new viral rna polymerase inhibitor approved <NUMBER> japan pharmaceuticals medical devices agency treatment influenza virus infections considered broadspectrum antiviral activity rna viruses demonstrated activity hemorrhagic fevercausing viruses arenaviruses bunyaviruses <NUMBER> <NUMBER> unfold antiviral activity favipiravir initially converted active metabolite acts rna polymerase inhibitor mainly via direct competition guanosine<NUMBER>triphosphate gtp addition favipiravir causes lethal mutagenesis incorporated viral rna <NUMBER> studies ebola virus involving favipiravir shown promising outcomes vitro small animal trials <NUMBER> <NUMBER> <NUMBER> <NUMBER> animal studies different mice models treatment regimens treatment favipiravir associated <NUMBER> survival rate <NUMBER> <NUMBER> however outcome phase ii clinical trial clear <NUMBER> nonrandomized cohort study patients stratified based baseline cycle threshold value reflecting viral load patients moderate high viremia cycle threshold value z <NUMBER> showed tendency lower mortality rate compared historical records although difference statistically significant <NUMBER> singlecenter retrospective study bai et al <NUMBER> series <NUMBER> treated patients medium high viral load showed significantly higher survival rate compared control group additional randomized multicenter trials necessary confirm efficacy target groups eliminate confounding variables azithromycin wellestablished antibiotic commonly prescribed treatment various bacterial infections addition proposed antiviral activity treatment upper respiratory tract viral infections <NUMBER> effects believed result amplification systemic antiviral response mediated ifn pathway known direct antiviral inhibitory effect azithromycin among several drugs investigated antiebola virus activity vitro small animal models <NUMBER> shown potent vitro inhibition ebola virus small animal studies generated mixed results murine model treatment <NUMBER> mgkg azithromycin twice daily initially associated <NUMBER> survival rate compared <NUMBER> control group p ¼ <NUMBER> repeat testing identical conditions reproduce statistically significant results addition different treatment regimen <NUMBER> mgkg oral azithromycin po daily associated <NUMBER> survival rate efficacy screening using different doses azithromycin guinea pigs similarly yield positive outcomes <NUMBER> systematic review carried basis previously published protocol comprehensively search select relevant studies identify potential repurposed drugs evd however limitations either inherent methodology applied review studies included still exist first despite search strategy designed highly sensitive cannot certain studies topic captured due pressing nature acute evd epidemic resulted rapidly evolving research scene many studies currently underway <NUMBER> second review synthesized narratively may increase risk bias <NUMBER> study given weight compared others <NUMBER> efforts avoid bias review include systematic selection articles extraction data identification potential drugs <NUMBER> authors independently multireviewer extraction previously shown decrease risk error compared singlereviewer extraction <NUMBER> several limitations inherent studies included review first clear majority included studies categorized screening vitro animal studies results studies cannot used reliably predict positive response humans <NUMBER> <NUMBER> review <NUMBER> studies carried nonhuman primates considered gold standard filovirus models resemble human clinical manifestation filoviral disease <NUMBER> remaining <NUMBER> animal studies carried using adapted small animal models mice hamsters guinea pigs naturally susceptible ebola virus studies necessary use genetically adapted virus undergone numerous mutations achieve virulence lethality genetic variation adapted ebola virus together differences disease development compared infected humans limit ability extrapolate results studies furthermore risk bias assessment revealed high risk bias <NUMBER> <NUMBER> animal studies limitation appears shared concern amongst fields drug development <NUMBER> review included total <NUMBER> clinical studies high level internal validity high level evidence based oxford <NUMBER> levels evidence <NUMBER> <NUMBER> <NUMBER> studies case reports case series low level evidence <NUMBER> <NUMBER> trials nonrandomized studies midrange level evidence <NUMBER> lack highlevel evidence may several reasons first recent evd epidemic condition neglected major clinical research attempts carried second clinical research outbreak faces many ethical practical obstacles influence study design number participants settings <NUMBER> <NUMBER> conclusions systematic review offers comprehensive overview current state art regard drug repurposing evd addresses different stages repurposed drug development evd screening chemical libraries clinical trials authors review identified <NUMBER> therapeutic agents potentially promising therapeutic influence evd stage none therapeutic agents recommended treatment evd review highlights need welldesigned wellconducted preclinical clinical research establish efficacy drugs proposed indication may useful aid researchers identify gaps evidence various drugs presented h sweiti wrote protocol manuscript study h sweiti ekwunife carried study selection data interpretation jaschinski planned carried literature search lhachimi involved conception design study authors involved critical revision manuscript authors indicated conflicts interest regarding content article j u r n l p r e p r f inclusion loops ie selfedges neighborhood density calculation degree cutoff <NUMBER> number connections necessary node scored cluster finding cutoff parameters node score cutoff <NUMBER> cluster size selection new members hairfall included deletion single connected nodes clusters fluff included allowance cluster expansion one neighbor shells node density cutoff <NUMBER> controls neighbor inclusion criteria fluffing kcore cutoff <NUMBER> filters clusters eliminating small interconnected subcluster maximum depth network cutoff <NUMBER> limiting distance seed node within cluster member searched chemoprotein components overall ppicpi interactome analyzed centiscape <NUMBER> <NUMBER> plugin cytoscape using key network centrality parameters like node degree number neighboring nodes node interest directly connected shortest path betweenness number information streams passing given node stress extent node hold network communications identify potential nodes j u r n l p r e p r f list genes interest identifiers id found top subnetwork ppicpi interactome submitted enrichr webtool platform httpamppharmmssmeduenrichr <NUMBER> <NUMBER> enrichment ie representation common annotated biological features analysis functional annotations implemented across number resources including gene ontology biological process cellular component molecular function kegg biological pathways jensen disease enrichr analysis performed using statistical parameters viz pvalue fisher exact test qvalue adjusted pvalue false discovery rate old pvalue adjusted old pvalue odd ratio zscore combined score logpvalue×zvalue enriched results functional annotations ranked based levels significance pvalues <NUMBER> corresponding combined scores followed selection terms certain cutoff top <NUMBER> terms logpvalue×zvalue j u r n l p r e p r f results found present mechanistic systems biology analysis systematically documented flow diagram findings potential drugs targeted biomolecules covid<NUMBER> fig <NUMBER> silico analysis sars microarray dataset identified <NUMBER> differentially expressed genes among <NUMBER> genes upregulated <NUMBER> genes downregulated details differentially expressed genes including gene identifiers id false discovery rate fdr adjusted pvalues <NUMBER> log <NUMBER> fold change values <NUMBER> summarized figure <NUMBER> interactome model ppi network constructed using proteins corresponding respective degs sarscov patients string webtool total <NUMBER> protein nodes <NUMBER> connections found ppi network data shown literature survey provided total <NUMBER> potential drugs proposed treatment covid<NUMBER> table <NUMBER> drugs included analysis selection potent drugs putative protein targets interactome model cpi network constructed using covid<NUMBER> drug candidates j u r n l p r e p r f degs sarscov patients stitch webtool total <NUMBER> nodes proteins drugs <NUMBER> connections found cpi network data shown characterization proteindrug interactions covid<NUMBER> executed development interactome model ppicpi network cytoscape merging already identified ppi cpi network found composed <NUMBER> nodes proteins drugs interconnected <NUMBER> interactions fig <NUMBER>a identification nodes gene productsproteins drugs designated corresponding gene ids name drugs respectively present study accordingly respective gene ids used node protein identifiers descriptions interactome model ppicpi network mcode module cytoscape identified one topranked subnetwork cluster mcode score <NUMBER> comprised <NUMBER> nodes j u r n l p r e p r f gene enrichment analysis study fig <NUMBER> indicated gene products topranked subnetwork associated biological processes including neutrophil related processes neutrophil activation neutrophil degranulation neutrophil mediated immunity immune responses innate immune responses mucosa humoral immune responses mediated antimicrobial peptides antibacterial humoral responses defence responses bacteria high statistical significances enrichr pvalue <NUMBER> combined score association gene products subnetwork found statistically significant enrichr pvalue <NUMBER> combined score cellular components involving subcellular granular secretary functions statistically significant enrichr pvalue <NUMBER> combined score molecular functions like nuclear hormone receptor bindings iron transition metal ion bindings serinetype endopeptidase activities endonuclease ribonuclease activities rna polymeraseii core promoter proximal region sequencespecific dna bindings also associated gene products subnetwork addition kegg pathway enrichment study included present study developed chemoprotein interactome network fig <NUMBER>a basis differentially expressed genes sarscov infection fig <NUMBER> repurposed drugs covid<NUMBER> table <NUMBER> subnetwork fig <NUMBER>b identified appeared involved neutrophil activation degranulation pathways ards main cause morbidities covid<NUMBER> infections coronaviruses <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> cytokine storm key mechanism ards materialization leading multiorgan failure death <NUMBER> <NUMBER> <NUMBER> <NUMBER> till date molecular pathogenesis covid<NUMBER> unclear therefore similar mechanism sarscovmerscov infection confer lot molecular level understanding pathogenesis covid<NUMBER> <NUMBER> present study identified subnetwork fig <NUMBER>b includes statistically significant pathways neutrophil activation degranulation fig <NUMBER> subnetwork comprised <NUMBER> nodes proteins provided <NUMBER> connectivities overall network indicated colossal importance subnetwork whole network model fig <NUMBER>ab global local topological analyses provided ten potential protein molecules consisting six proteins corresponding ten nodes appeared hub nodes ppicpi interactome network chosen study fig <NUMBER>c molecules found highly enriched blood antimicrobialinduced neutrophilmediated humoral innate immunity responses covid<NUMBER> fig <NUMBER> present study mmp<NUMBER> found functionally important hub node protein target drugs central hub node ppicpi interactome network fig <NUMBER>b fig <NUMBER>c matrix metallopeptidases mmps zinccontaining calciumdependent proteolytic endopeptidases released intracellular stores become active extracellularly <NUMBER> mmps cause deterioration number extracellular matrix proteins help extracellular matrix remodelling various physiological pathological processes including inflammation <NUMBER> <NUMBER> <NUMBER> <NUMBER> mmps widely distributed tissues expressions controlled cytokines growth factors hormones mmp<NUMBER> <NUMBER>kd glycoprotein typeiv collagenase activity found neutrophils lymphocytes dendritic cells involved angiogenesis inflammatory cytokine generation <NUMBER> <NUMBER> notably enrichr functional analysis current study revealed mmp<NUMBER> associated transition ion binding molecular function gene ontology diverse pathophysiological conditions viz fig <NUMBER> mmp<NUMBER> reported relate tertiary lumens release cytokines neutrophil activation <NUMBER> monocytes macrophages mmp<NUMBER> overactivated plasmin reacts toll like receptor <NUMBER> tlr<NUMBER> signalling induce formation tumour necrosis factor tnf leads development proinflammatory cytokine storm <NUMBER> <NUMBER> involvement mmp<NUMBER> serine protease activities also noticed enrichr functional analysis molecular function gene ontology fig <NUMBER> mmp<NUMBER> deficiency found protective severe h<NUMBER>n<NUMBER> influenza virus infection mice model <NUMBER> therefore j u r n l p r e p r f findings reports support view approach mmp<NUMBER> inhibition andor alterations activators plasmin inhibitors timp<NUMBER> may prevent deadly cytokine storm liferisk covid<NUMBER> patients chloroquine melatonin identified repurposed drug candidates appeared interacting partners mmp<NUMBER> fig <NUMBER>b fig <NUMBER> chloroquine treatment decreases serum mmp<NUMBER> level systemic lupus erythematosus <NUMBER> suppresses mmp<NUMBER> activity mrna expression breast cancer <NUMBER> chloroquine also lower tnfmediated neutrophil apoptosis neutrophil degranulation cytokine burst <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> chloroquinehydroxychloroquine efficiently inhibits human retrovirus activities vitro <NUMBER> recently number studies <NUMBER> <NUMBER> <NUMBER> clinical trial <NUMBER> support use chloroquinehydroxychloroquine treatment covid<NUMBER> conversely certain clinical studies strongly disagree uses <NUMBER> <NUMBER> <NUMBER> develops cardiac failure covid<NUMBER> patients <NUMBER> indicating clinical data chloroquinehydroxychloroquine conclusive <NUMBER> notably hydroxychloroquine appear subnetwork present study fig<NUMBER>b remained unattained consideration melatonin responsible normal sleep maintenance biological clock human <NUMBER> antiinflammatory properties <NUMBER> <NUMBER> exerts potential role antiviral mechanism <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> also used ebola virus infection <NUMBER> pathophysiological observation covid<NUMBER> patients supports chronobiological uses melatonin treatment <NUMBER> <NUMBER> therapeutic algorithm regard also proposed recently <NUMBER> addition melatonin reported promising adjuvant covid<NUMBER> treatment <NUMBER> <NUMBER> j u r n l p r e p r f deficiencies may enhance susceptibility diabetic hypertensive elderly patients sarscov<NUMBER> infection <NUMBER> first clinical trial melatonin small cohort indicates involvement abating ards covid<NUMBER> patients <NUMBER> interestingly melatonin bind active site mmp<NUMBER> inhibit latter arrest immunoinflammation <NUMBER> thus present network based metaanalysis justified involvement melatonin interaction mmp<NUMBER> immunocompromised covid<NUMBER> cell culture study kidney cell line vero e<NUMBER> network analysis reveal chloroquine <NUMBER> melatonin <NUMBER> respectively may potential antiviral role targeting human cell membranebound ace<NUMBER> receptor zinc dependent carboxypeptidase associated protein partners covid<NUMBER> interestingly separate studies report mmp<NUMBER> level increases ace<NUMBER>knockout mice model <NUMBER> ace inhibitors lisinopril imidapril also target mmp<NUMBER> along ace<NUMBER> <NUMBER> therefore metallopeptidases ie ace<NUMBER> mmp<NUMBER> may cooperativities immunoinflammation covid<NUMBER> potential targets chloroquine melatonin therapies <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> ectodomain membranebound ace<NUMBER> shed extracellular fluid soluble form <NUMBER> <NUMBER> <NUMBER> <NUMBER> vitro studies also indicate soluble ace<NUMBER> bind sarscovsarscov<NUMBER> supposed limit availability viruses interact membranebound ace<NUMBER> receptors thus minimizing chances viral load <NUMBER> <NUMBER> <NUMBER> notably ace<NUMBER> converts angiotensinii angiotensin<NUMBER> peptide causes modification inflammatory processes <NUMBER> angiotensin<NUMBER> also vasodilatory effect <NUMBER> enhances heart rate acting caudal ventrolateral medulla brain <NUMBER> may contribute development hypotension tachycardia found sarscovid<NUMBER> patients <NUMBER> moreover interaction sarssarscov<NUMBER> ace<NUMBER> receptors support cells olfactory mucosa also results inflammationinduced anosmia <NUMBER> without ifn corticosteroids primary treatment mers outbreak retrospective analysis cohort <NUMBER> patients treated oral ribavirin sc pegylated ifnα<NUMBER>a dose <NUMBER> μgweek <NUMBER> weeks table <NUMBER> <NUMBER> initial dose ribavirin <NUMBER> mg followed <NUMBER> mg dose depending creatinine clearance group <NUMBER> patients received supportive care corticosteroids considered control group <NUMBER> days confirmed diagnosis mers survival increased treated group <NUMBER> compared control group <NUMBER> <NUMBER> days postdiagnosis <NUMBER> treated subjects survived versus <NUMBER> control group <NUMBER> additional case study <NUMBER>yearold greek patient contracted mers jeddah treated oral lopinavirritonavir <NUMBER> mg twice daily pegylated ifn <NUMBER> μg sc per week <NUMBER> weeks ribavirin <NUMBER> mg initial dose <NUMBER> mg every <NUMBER> h <NUMBER> days initiated day <NUMBER> postdiagnosis two days treatment initiation viremia could detected however viral rna detected several patient samples feces respiratory secretions serum <NUMBER> weeks postdiagnosis despite prolonged survival patient succumbed septic shock <NUMBER> months postdiagnosis <NUMBER> ongoing randomized clinical trial saudi arabia evaluating treatment mers patients ifnβ<NUMBER>b combination lopinavirritonavir <NUMBER> drug repurposing attractive alternative drug discovery strategy eliminates many steps usually required early phase drug development past decade interest drug repurposing increased pharmaceutical companies challenged decreasing product pipelines high costs associated de novo drug discovery imminent expiration many drug patents examples successfully repurposed drugs include viagra pfizer erectile dysfunction original indication angina raloxifene eli lilly treatment invasive breast cancer original indication osteoporosis time required traditional drug development often discordant urgent need novel therapies emerging infectious diseases sars mers outbreaks occur anywhere world frequently resourcelimited settings commonly treatment strategies available emerging infectious diseases less adequate improve patient outcome although specific antivirals merscov sarscov development drug repurposing could present important arm generating additional therapeutics future coronaviruses first drugs confirmed beneficial effects vitro animal studies could used build panel approved drugs use firstline defense newly emerging coronaviruses secondly drugs could made accessible relatively quickly patients emergency use authorization extending choices treatment generating panel broadspectrum antivirals would provide real improvement healthcare community struggling cope outbreak emerging infections great example repurposing benefit search treatments emerging infections drug zidovudine zidovudine originally developed <NUMBER> cancer drug <NUMBER> zidovudine found active human immunodeficiency virus hiv <NUMBER> years later became first drug approved treatment acquired immunodeficiency syndrome aids <NUMBER> number research groups identified investigated usefulness approved drugs treatment viral infections including coronaviruses summarize several drug classes antiviral activity merscov sarscov repurposing potential fig <NUMBER> table <NUMBER> drugs described activity virus families indicating potential broadspectrum applications already clinical use treating viral infections would like emphasize none therapeutics described section recommended clinical use outside clinical trial setting approved antidiarrheal agent world health organization model list essential medicines available many countries drug acts opioid receptor reduces intestinal motility <NUMBER> results pharmacokinetic pk studies show oral loperamide well absorbed gut less <NUMBER> drug entering systemic circulation <NUMBER> loperamide demonstrated antimerscov antisars antihcov<NUMBER>e activity vitro screen approved drugs <NUMBER> although mechanism action unknown interestingly loperamide suggested limiting gastrointestinal fluid electrolyte losses patients ebola virus disease evd <NUMBER> several mechanisms action identified antiviral effect cq suggest drug acts nonspecifically virus entry later stages virus production cq accumulates within acidic organelles endosomes golgi vesicles lysosomes drug protonated resulting increased ph within vesicle <NUMBER> viruses depend acidic organelles entry viral replication maturation virus progeny similarly merscov entry cells depends several proteases dipeptidyl peptidase <NUMBER> dpp<NUMBER> acts functional virus receptor <NUMBER> cellular proteases eg type ii transmembrane serine protease tmprss<NUMBER> members cathepsin family activate viral spike glycoprotein <NUMBER> cq may effect proteases cq also affects glycosylation step within golgi directs trafficking maturation viral proteins <NUMBER> sarscov antiviral activity cq also attributed deficit glycosylation receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> <NUMBER> broadspectrum antiviral activity makes cq attractive antiviral repurposing treating coronaviral emerging viral infections vivo activity cq mers evaluated viruses preclinical clinical studies mixed results cq plasma steady state concentrations mice similar reported humans <NUMBER> μm summary cq broadspectrum potential information gained studies viruses used plan appropriate strategies evaluating specific clinical value treating merscov sarscov infections cq several advantages including rapid absorption gastrointestinal tract low cost effective biodistribution cq may excellent candidate combinatorial treatments antivirals however considerable challenges remain treatment viral infections including increased understanding pharmacodynamics cq achievement sufficient plasma concentrations patients toxicity concerns <NUMBER> importantly hydroxychloroquine cq derivate may provide alternative due lower toxicity similar pharmacology profile <NUMBER> related antimalarial drug amodiaquine also activity vitro merscov sarscov <NUMBER> previous investigations demonstrated amodiaquine inhibits filovirus replication mechanism action hypothesized similar cq <NUMBER> amodiaquine well tolerated commonly used malaria treatments many countries amodiaquine combination artesunate administered evd patients <NUMBER> epidemic resulting decrease fatality rates may associated use amodiaquine antimalarial agent <NUMBER> nonhuman primate nhp studies currently underway investigate effect amodiaquine treatment evd <NUMBER> mefloquine synthetic analog quinine another antimalarial drug activity merscov sarscov <NUMBER> belongs model list essential medicines mefloquine known penetrate bloodbrain barrier found inhibit jc virus infection replication concentrations generally achieved brains patients given mefloquine malaria <NUMBER> leading clinical evaluation drug treatment progressive multifocal leukoencephalopathy <NUMBER> <NUMBER> <NUMBER> fda added boxed warning us label mefloquine regarding potential neuropsychiatric side effects additional investigations warranted determine amodiaquine mefloquine value repurposing treatment mers sars ubiquitous host proteins believed multiple roles trafficking protein folding cell activation <NUMBER> cyclosporine cysa forms complex cyclophilin thereby blocking cell activation cysa licensed use organ transplantation suppress immune response cysa also shown inhibit coronaviruses including sarscov merscov effectively cell culture <NUMBER> <NUMBER> however mechanism yet determined increasing evidence cyclophilins involved viral replication rna viruses hepatitis c virus hcv west nile virus may also apply coronaviruses <NUMBER> although immunosuppressive properties cysa considered risk treating viral infections patients nonimmunosuppressive analogs cysa bind cyclophilins higher affinity developed clinical trials hcv therapeutics <NUMBER> <NUMBER> <NUMBER> ifns approved fda indications hepatitis c although ifnα reduced sarscov replication mice nhps <NUMBER> <NUMBER> efficacy ifnα treatment sars patients mixed see section <NUMBER> vitro studies another type interferon ifnβ<NUMBER>a may effective ifnα either alone combination ifnγ <NUMBER> <NUMBER> <NUMBER> combinations ifnβ γ synergistic sarscov vitro <NUMBER> regards mers vitro vivo preclinical studies indicated ifnα<NUMBER>b alone combination ribavirin may therapeutic effect given early disease <NUMBER> <NUMBER> clinical trials however ifnα<NUMBER>b given combination treatments lead significant benefit patients see section <NUMBER> ifnβ<NUMBER>a ec <NUMBER> <NUMBER> iuml superior activity merscov infection vitro compared ifnα<NUMBER>a ifnα<NUMBER>b ifnγ ifns ec <NUMBER> values <NUMBER> <NUMBER> <NUMBER> iuml respectively <NUMBER> ifnβ<NUMBER>b currently evaluation merscov randomized clinical trial combination lopinavirritonavir <NUMBER> investigating ifnβ subtypes <NUMBER>a <NUMBER>b combination antivirals may worthwhile potential synergistic combinations could reduce effective drug dosage ifnassociated adverse effects inhibitorsmany cellular processes regulated independently changes transcription translation kinasemediated cell signaling pathways testament biological importance kinases <NUMBER> kinases identified along <NUMBER> genes encoding proteins kinase activity <NUMBER> <NUMBER> april <NUMBER> <NUMBER> kinase inhibitors granted approval united states fda half gaining approval <NUMBER> kinases frequently targeted gene class cancer therapy second g proteincoupled receptors therapeutic targets <NUMBER> <NUMBER> therapeutic potential hosttargeted immunomodulatory agents viral infections received considerable attention <NUMBER> <NUMBER> <NUMBER> recently dyall et al identified two abelson abl kinase inhibitors imatinib dasatinib inhibited merscov sarscov infection cellscreening assay <NUMBER> compounds significantly inhibited merscov sarscov micromolar ec <NUMBER> values low cytotoxicity abl<NUMBER> identified critical merscov sarscov virus entry may target imatinib inhibits block entry viruses <NUMBER> recent systems kinome analysis investigation vitro merscov infection suggested erkmapk pi<NUMBER>kakt mtor signaling pathways specifically modulated infection <NUMBER> subsequent analysis licensed kinase inhibitors targeting pathways demonstrated kinase inhibitors targeting erkmapk signal pathway selumetinib trametinib inhibited merscov infection ≥<NUMBER> added preor postinfection <NUMBER> trametinib demonstrated significantly stronger inhibitory activity merscov selumetinib suggesting specific intermediates erkmapk signaling pathway may represent crucial foci early viral entry late viral replication events viral life cycle contrast sorafenib inhibitor raf<NUMBER> braf components erkmapk signaling pathway vascular endothelial growth factor receptor <NUMBER> vegfr<NUMBER> inhibited merscov infection <NUMBER> added cells prior infection however inhibitory activity reduced <NUMBER> added postinfection suggesting raf kinases primarily involved early viral life cycle events addition inhibitory activity dabrafenib raf kinase inhibitor also largely ablated added postinfection miltefosine alkyl phospholipid considered inhibitor protein kinase b akt garnered fda approval infectious diseaserelated treatments cutaneous mucosal leishmaniasis <NUMBER> <NUMBER> us centers disease control prevention made miltefosine available treatment freeliving amoeba infections <NUMBER> pretreatment cells miltefosine reduced merscov infection <NUMBER> effect added postinfection <NUMBER> contrast inhibition mtor sirolimus everolimus reduced merscov infection <NUMBER> added prior preor postinfection suggesting critical role mtor merscov infection recent clinical investigation wang et al evaluated sirolimus corticosteroids addition standard antiviral treatment randomized controlled trial patients severe h<NUMBER>n<NUMBER> pneumonia acute respiratory failure <NUMBER> importantly addition sirolimus associated improved patient outcomes including decreased hypoxia multiorgan dysfunction reduced mean times liberation mechanical ventilation increased clearance virus thus may prudent extend study repurposed kinase inhibitors beyond standalone therapeutic investigations also consider potential adjunctive therapies showed activity merscov sarscov infection <NUMBER> drugs initially developed antipsychotics antihistamines sedatives five neurotransmitter receptor antagonists belong chemical class phenothiazines chlorpromazine triflupromazine thiethylperazine promethazine fluphenazine phenothiazines breakthrough medications developed <NUMBER>s treating mental health patients reduced episodes bizarre behavior hallucinations irrational thoughts <NUMBER> although phenothiazines primarily block dopamine receptors also anticholinergic antihistamine antiemetic effects phenothiazines chlorpromazine triflupromazine approved antipsychotics chlorpromazine used offlabel shortterm treatment nausea migraines triflupromazine used treat severe emesis drug serious side effects chlorpromazine including akathisia tardive dyskinesia antiviral effect chlorpromazine extensively studied drug interferes clathrinmediated endocytosis process many viruses exploit host cell entry chlorpromazine inhibits virus entry junin virus <NUMBER> west nile virus <NUMBER> ebov <NUMBER> hcv <NUMBER> japanese encephalitis virus <NUMBER> suggesting broadspectrum activity could exploited early novel virus outbreak chlorpromazine may similar effects coronaviruses drug effectively inhibits merscov sarscov human coronavirus <NUMBER>e expressing green fluorescent protein <NUMBER> <NUMBER> however timeofaddition studies indicate inhibitory activity merscov retained whether added preor postinfection suggesting additional effects clathrinmediated entry impairment <NUMBER> thiethylperazine approved antiemetic chlorpromazine thiethylperazine shown inhibit alphaviruses semliki forest virus sfv chikungunya virus chikv <NUMBER> <NUMBER> drugs cross brainblood barrier use drugs could beneficial treatment chikv including common neurologic complications promethazine antihistamine used sedative many countries different brand names also acts weak antipsychotic activity fluphenazine common antipsychotic used treat chronic psychoses primarily schizophrenia belongs benztropine mesylate approved anticholinergic used treat parkinsons activity merscov sarscov <NUMBER> benztropine also identified screens clinically approved drugs antiviral activities hcv ebov <NUMBER> <NUMBER> <NUMBER> although detailed mechanism action unknown hcv studies indicate benztropine inhibits virus entry step interfering viral genome replication transcription production viral progeny virus production viral progeny <NUMBER> argued virus entry inhibitor may value decreasing incidence relapse chronic hcv patients receive liver transplants <NUMBER> however peak plasma concentrations benztropine may low effective treating acute infection <NUMBER> benztropine also independently identified two drug screens ebov antivirals <NUMBER> <NUMBER> recent report suggests step virus attachment prior viralcell membrane fusion targeted benztropine <NUMBER> clomipramine tricyclic antidepressant thiothixene thioxanthene antipsychotic also shown inhibit merscov sarscov infection vitro <NUMBER> addition found inhibit ebov vlp entry <NUMBER> approved clinically clomipramine belongs model list essential medicines several neurotransmitter inhibitors astemizole promethazine chlorphenoxamine fluspirilene active merscov sarscov cell culture able find reports activity viruses <NUMBER> astemizole h<NUMBER>histamine receptor antagonist treating allergic rhinitis withdrawn market cardiac adverse events due drug overdose reported extremely rare <NUMBER> recently astemizole gained renewed interest anticancer antimalarial drug <NUMBER> <NUMBER> chlorphenoxamine antihistamine anticholinergic currently preclinical trials malaria fluspirilene approved antipsychotic treatment schizophrenia known autophagy inducer <NUMBER> autophagy cellular degradative pathway viruses exploit propagation <NUMBER> modulators autophagy may perturb merscov sarscov infection investigation broadspectrum potential treatment coronaviral infections would interesting <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> inosine monophosphate dehydrogenase impdh inhibitors ribavirin mycophenolic acid mizoribine inhibit important step de novo synthesis nucleic acids although potency drugs viruses varies ribavirin used combination ifn clinic treatment viral infections hepatitis c treatment regimens ribavirin well characterized used sars mers patients mixed results see <NUMBER> ribavirin weakly inhibits merscov vitro conflicting data reported activity ribavirin sarscov <NUMBER> <NUMBER> <NUMBER> many studies ribavirin performed vero cells reportedly defect ribonucleoside uptake could explain lack activity ribavirin cells <NUMBER> another coronavirus mouse hepatitis virus mhv becomes sensitive ribavirin exoribouclease activity inactivated presence exoribonuclease ribavirin inhibit mhv replication <NUMBER> mhv exoribonuclease suggested function proofreading viral enzyme necessary highfidelity replication mhv similarly exoribonuclease activity merscov sarscov could possibly counteract inhibitory activity ribavirin mycophenolic acid mpa immunosuppressant used prevent organ rejection broadspectrum antiviral activities antifungal antibacterial anticancer antipsoriatic properties <NUMBER> <NUMBER> <NUMBER> although mpa weak inhibitory activity sarscov vitro promising activity merscov <NUMBER> <NUMBER> potential alternative mpa prodrug mycophenolate mofetil improved oral bioavailability <NUMBER> mycophenolate mofetil evaluated common marmoset model mers reduce disease manifestations compared observed control subjects <NUMBER> however mers marmoset model recapitulate human disease due rapid onset pathology associated exposure methods <NUMBER> mizoribine approved immunosuppressant organ transplantation limited adverse side effects shown vitro activity hcv bovine viral diarrhea virus bvdv considered alternative ribavirinifn combinations treatment hcv infections <NUMBER> vivo analysis ribavirin impdh inhibitors sarscovinfected mice suggested agents would limited benefit <NUMBER> chemotherapeutic gemcitabine shown vitro activity merscov sarscov <NUMBER> drugs anticancer mechanism attributed ability inhibit ribonucleotide reductase essential de novo pyrimidine biosynthesis gemcitabine shown suppress influenza virus rna transcription replication targeting ribonucleotide reductase showed antiretroviral activity vivo mouse model murine leukemia virus <NUMBER> <NUMBER> sarscov require activation envelope glycoproteins host proteases cell entry endosomal nonendosomal pathways inhibitors host cell proteases investigated possible antivirals <NUMBER> serine protease tmprrss<NUMBER> mediates entry via nonendosomal pathway merscov sarscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> camostat mesylate used treatment chronic pancreatitis inhibits tmpssr<NUMBER>mediated glycoprotein activation merscov sarscov influenza virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> k<NUMBER> cysteine protease inhibitor clinical development treating parasitic infections k<NUMBER> broadspectrum activity coronaviruses merscov sarscov hcov<NUMBER>e filoviruses ebov marburg virus paramyxoviruses nipah virus <NUMBER> interestingly zhou et al demonstrated camostat k<NUMBER> inhibitory activity sarscov whereas ebov inhibited k<NUMBER> suggesting differential host protease requirements viruses <NUMBER> e<NUMBER>d inhibitor endosomal cysteine protease currently phase iii trials treatment muscular dystrophy inhibits merscov sarscov vitro <NUMBER> e<NUMBER>d also inhibits filovirus cell entry <NUMBER> <NUMBER> dependency viruses specific serine cysteine host proteases must considered selection protease inhibitors antiviral therapeutic applications therefore increased understanding relationship host proteases viral pathogenesis determine effective treatment options viral infections mechanistic studies revealed er functionally associated hcv replication <NUMBER> er promotes interaction hcv replication complex hcv polymerase ns<NUMBER>b ermediated regulation hcv genome replication abrogated tamoxifen toremifene tamoxifen also effectively inhibit ebov infection vitro <NUMBER> however contrast hcv mechanistic studies shown toremifenemediated ebov inhibition independent er pathway toremifene still active ebov cells express er <NUMBER> <NUMBER> toremifene acts late step virus entry internalization ebov may prevent fusion viral endosomal membranes <NUMBER> <NUMBER> <NUMBER> based chemical structure toremifene cationic amphiphilic drug cad known lysosomotropic could affect endosomal processes virus entry <NUMBER> <NUMBER> treatment toremifene led <NUMBER> survival ebovinfected mice confirming drug effect vivo well <NUMBER> terms clinical application toremifene tamoxifen good bioavailability safety tolerability profiles combined long history use clinic however prolongation qt interval noted toremifene prescribed patients congenital acquired long qt syndrome uncorrected hypokalemia uncorrected hypomagnesemia <NUMBER> tamoxifen increase uterine malignancies stroke pulmonary embolism women ductal carcinoma situ high risk breast cancer <NUMBER> despite side effects drugs may substantial value shortterm treatment acute coronaviral infections advanced patient studies careful evaluation phamacokinetic profiles may facilitate dosing strategies limit risk adverse events studies viruslike particles vlps demonstrated terconazole inhibits coronavirus cell entry including merscov sarscov sterol synthesis pathway shown required infection several viruses including hcv <NUMBER> <NUMBER> tercanozole approved vaginal yeast infections administered orally topically suppository triparanol approved lowering plasma cholesterol withdrawn due numerous side effects cationic amphiphilic drugs cads induce accumulation cholesterol late endosomes shown inhibit ebov entry <NUMBER> drug repurposing development novel antiviral countermeasures needed emerging coronaviruses end design development strategies targeted viral replication cycle host pathways essential viral replication table <NUMBER> two nucleoside inhibitors viral rnadependent rna polymerases gs<NUMBER> bcx<NUMBER> potential broadspectrum antivirals <NUMBER> <NUMBER> drugs active merscov sarscov cell culture vivo efficacy remains investigated addition new class nucleosides flexible purine base anticoronaviral activity optimization could generate potent inhibitors coronaviral polymerase <NUMBER> surface glycoprotein sarscov merscov coronaviruses consists two domains s<NUMBER> containing receptorbinding domain rbd needed extracellular binding s<NUMBER> containing fusion peptide needed membrane fusion release endocytosis sarscov facilitated binding rbd angiotensin converting enzyme <NUMBER> ace<NUMBER> receptor host cells membranebound cathepsin l cleaves protein revealing s<NUMBER> fusion protein fuses membrane releases viral rna inhibitors cathepsin l ace<NUMBER>sarss<NUMBER> complex s<NUMBER> fusion peptide could suitable targets inhibit sarscov entry <NUMBER> results recent studies identified inhibitors viral entry viral proteases helicases potently inhibit merscov sarscov <NUMBER> proteases papainlike protease <NUMBER>clike protease could also useful antiviral targets drug development required cleaving nonstructural proteins viral maturation protease inhibitors suicide protease inhibitors bind target irreversibly however reversible protease inhibitors may greater potential less toxic better tolerated <NUMBER> recent studies helicase inhibitors show <NUMBER> domain targets nterminal metal binding domain hinge domain ntphelicase domain potential development new drugs <NUMBER> rna interference rnai presents powerful approach development novel virusspecific therapeutics based gene silencing <NUMBER> recent studies shown small interfering rnas sirnas short hairpin rnas inhibit expression viral genes thereby block replication sarscov cultured cells <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> intranasal delivery combination small interfering rna sisc<NUMBER> targeting sarscov open reading frame <NUMBER> protein decreased sars pathogenesis nhps <NUMBER> potential rnai candidates identified computational modeling merscov require vitro preclinical investigation <NUMBER> several rnai therapeutics treatment viral infections entered clinical trials including tkmebola sirnalipid nanoparticle platform targeting ebov <NUMBER> <NUMBER> <NUMBER> technology great potential therapeutics emerging viruses viral genome sequencing completed short time frame crucial situations epidemic novel emerging viral infection unfolds main obstacle rnai strategies lies identification suitable viral targets delivery efficiency nucleic acids target cells vivo share common physicochemical properties cads facilitates interaction cell membranes interference fusion cellular viral membranes virus entry researchers making progress defining mechanism action peptide entry inhibitors enveloped viruses enfuvirtide approved hiv inhibitor <NUMBER> enfuvirtide <NUMBER>residue peptide derived amphipathic loopchelix heptad repeat domain hiv gp<NUMBER> rational approach based scanning fusion protein sequences amphipathic sequences led discovery additional peptide inhibitors viruses including merscov sarscov <NUMBER> <NUMBER> <NUMBER> chemical modifications peptides increased vivo stability bioavailability improving potential clinical applications novel broadspectrum viral entry inhibitors <NUMBER> <NUMBER> <NUMBER> success palivizumab treatment respiratory syncytial virus infection reinvigorated efforts develop monoclonal antibodybased therapeutics infectious diseases <NUMBER> zmapp monoclonal antibody cocktail targeting ebov tested nhps success moved phase ii clinical trials humans evd epidemic see details section <NUMBER> section <NUMBER> <NUMBER> <NUMBER> similarly monoclonal antibody hendra virus administered humans compassionate use basis <NUMBER> <NUMBER> <NUMBER> examples demonstrate potential antibody therapy combat emergingreemerging viruses similar strategies pursued multiple groups development antibodies merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> monoclonal antibodies merscov sourced humanized mice libraries human antibody libraries <NUMBER> <NUMBER> <NUMBER> <NUMBER> antibodies target rbd s<NUMBER> s<NUMBER> subunits demonstrated efficacy animal models reviewed ying et al <NUMBER> monoclonal antibody therapy impart selective pressure generation resistant viruses although mutants escaping monoclonal antibody pressure tend less fit analysis emergence mutations confer resistance monoclonal antibody need performed alternative monoclonal antibody therapy polyclonal antibody therapy using convalescent sera sera sourced nonhuman humanized animal polyclonal antibodies provide advantage monoclonal antibodies escape mutants less likely emerge <NUMBER> <NUMBER> convalescent sera recommended mers phase ii interventional clinical trial ongoing determine efficacy <NUMBER> however availability suitable donor subject presents significant complication approach nonhuman animal sera considered safety concerns limit option fractionation nonhuman sera alternative however antibodymediated clearance limited due failure human fc receptors recognize antibody heavy chain alternative despeciating antibodies using fab antibody fragment however cost sufficient material may make mass production fab fragments difficult use sera humanized mice small laboratory animals complicated sample acquisitionvolume restraints larger laboratory animals may provide potential alternative sab biotherapeutics developed transchromosomic bovine platform generation human igg antibodies <NUMBER> vaccination transchromosomic cattle protein nanoparticles inactivated whole virus generated fully humanized polyclonal antibodies demonstrated efficacy addpp<NUMBER> murine model mers one important lessons regarding antiviral drug development highly specific broadspectrum antivirals bring unique advantages table antiviral agents fall anywhere spectrum broadspectrum highly specific <NUMBER> drug targets specific virus virus family narrow activity high potency low toxicity however drug may also promote resistance <NUMBER> contrast broadspectrum antivirals typically target host factor pathway often agents higher toxicities lower potencies delayed treatment effects however selective pressure resistance often lower broadspectrum agents large part knowledge antiviral development stems studies chronic viral infections antiviral development strategies dna viruses successful identifying single drug specifically targets viral protein strategy less successful rna viruses rna viruses mutate higher rate dna viruses resulting enhanced development drug resistance despite extensive efforts past <NUMBER> years therapeutic prophylactic hiv vaccine remained elusive antiviral agents available treatments aids <NUMBER> antivirals belonging <NUMBER> different drug classes targeting different stages viral replication available eg reverse transcriptase protease fusion entry integrase <NUMBER> combination treatments <NUMBER> <NUMBER> drugs effective result sustained virologic response <NUMBER> two aspects found important avoiding resistance selecting drugs least two different targets ii selecting drugs belong different chemical classes considerations may also apply drug combinations synergistic effects mersand sarscov broadspectrum antiviral therapies great value treating emerging infections takes time develop directacting antivirals treatment chronic hepatitis c clinicians depended ifn ribavirin number years <NUMBER> eventually ifn ribavirin combination replaced effective fixedcombination therapies using directacting antivirals target multiple steps hcv life cycle <NUMBER> ifn ribavirin contribute significantly treatment viral infections directacting antivirals exist however major side effects <NUMBER> options broadspectrum antivirals improved safety profiles would beneficial use emerging coronavirus infections influenza viruses characterized high mutation rate rna genome available vaccines may protective novel pandemic strain antiviral agents considered essential component preparedness combinations directacting antivirals evaluation additive synergistic effects prevention resistance <NUMBER> <NUMBER> one triple combination oseltamivir amantadine ribavirin synergistic prevents resistance vivo <NUMBER> <NUMBER> highlighting potential combinatorial therapy recent epidemic evd western africa renewed urgency development treatments emerging viruses although vaccines directacting antiviral treatment investigation none approved clinical use <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> prioritized panel drugs approved indications considered repurposing fdas emergency use authorization <NUMBER> two drugs also activity merscov sarscov amodiaquine antimalarial agent toremifene citrate breast cancer treatment additional broadspectrum antiviral agents including repurposed drugs top priority future emerging infections including coronavirus infections panel broadspectrum drugs carefully validated efficacy safety could used combination would supply minimum protection patients healthcare workers outbreak locations panel drugs could used situations known reemerging pathogen specific antiviral agents vaccines approved unknown novel pathogen could arise effective development countermeasures depends developing appropriate animal models uniformly recapitulate human disease progression severity pathological manifestations animal models human disease one animal model fully reflects sars mers therefore researchers faced exploring several small animal models choosing bestfit model date animal models fully recapitulate human disease thus animal models mers sars need refinement many small animal models evaluated potential mers sars models including mice hamsters ferrets mers syrian hamsters guinea pigs sars <NUMBER> <NUMBER> <NUMBER> four murine models reported mers first model demonstrated promise involved transduction respiratory tract putative merscov receptor human dpp<NUMBER> cd<NUMBER> <NUMBER> major indicator disease model viral load lung <NUMBER> days postinoculation although clinical signs disease including weight loss limited model used pathogenesis countermeasure studies <NUMBER> <NUMBER> lethal disseminated mers infection demonstrated transgenic mice expressing human dpp<NUMBER> <NUMBER> inflammatory processes observed brains mice contrast human disease cns involvement reported transgenic mouse mers model developed mouse dpp<NUMBER> gene replaced human dpp<NUMBER> gene control endogenous mouse dpp<NUMBER> promoter using model merscovinfected mice developed lung pathology <NUMBER> addition administration human monoclonal antibodies spike protein transgenic mice provided protection merscov infection <NUMBER> clustered regularly interspaced short palindromic repeatcrisprassociated protein <NUMBER> crisprcas<NUMBER> gene editing technology used modify mouse dpp<NUMBER> match human dpp<NUMBER> altering amino acids positions <NUMBER> <NUMBER> interestingly wild type virus infection mice result improved model mers however serial passage merscov resulted merscov<NUMBER> intranasal exposure merscov<NUMBER> <NUMBER>mice led weight loss severe respiratory disease included ardslike signs reduced pulmonary function <NUMBER> merscov infection rabbits also evaluated model mers haagmans et al demonstrated merscov infected rabbits develop obvious clinical signs infectious virus could detected upper respiratory tract <NUMBER> furthermore epithelial cells bronchioles terminal bronchioles respiratory tract positive merscov immunohistochemistry insitu hybridization reflects tissue tropism human disease <NUMBER> using rabbit model houser et al demonstrated human monoclonal antibody <NUMBER> given preexposure reduced viral rna lung titer <NUMBER> days postexposure given postexposure <NUMBER> due phylogenetic similarities humans nhp models disease long considered necessary evaluation countermeasures infectious diseases rhesus monkey common marmoset evaluated potential models mers following intratracheal instillation merscov rhesus monkey models lung pathology observed <NUMBER> <NUMBER> <NUMBER> <NUMBER> experiments using rhesus monkeys indicated develop limited systemic disease transient respiratory disease radiologic evaluations indicated inflammatory infiltrates develop shortly exposure analysis lung tissues reverse transcriptasequantitative polymerase chain reaction indicated virus replication lung similar mers african green monkeys agms rhesus monkeys cynomolgus monkeys common marmosets identified potential models sars <NUMBER> smits et al compared sars cov infection young agms cynomolgus monkeys observed neither species developed clinical signs <NUMBER>day experiment <NUMBER> gross pathology indicated multifocal pulmonary consolidation consolidated greyred firm lungs lesions affected <NUMBER> lungs one subject comparison cynomolgus monkeys developed small patchy macroscopic lesions similar merscov infection nhps viral load decreases exposure day day <NUMBER> comparison agms rhesus monkeys cynomolgus monkeys support agms best available nhp model sars <NUMBER> agms developed highest viral load disease compared cynomolgus rhesus monkeys lethal disease observed species therefore development sars model warranted since lethal respiratory tract disease hallmark sars alternative old world nhps many groups employed marmosets models human disease infectious diseases <NUMBER> <NUMBER> <NUMBER> common marmosets evaluated mers model <NUMBER> <NUMBER> <NUMBER> studies demonstrated common marmosets develop disease following exposure merscov shown histopathological analysis radiological analysis rtqpcr however variable results reported exposure methodology impact disease progression therefore mockinfected groups must included account pathological artifacts virusspecific pathology could quantified using computed tomography future experiments using large group sizes could used countermeasure evaluation greenough et al performed serial euthanasia study sarscov infected marmosets <NUMBER> subjects intratracheally exposed sarscov observed mild inconsistent clinical signs disease viral loads peaked day <NUMBER> postinfection histopathology indicated interstitial pneumonitis multinucleated syncytia described mild observed late timepoint subjects overall research needed develop animal models sars reflect human disease presentation drugs repurposing potential discussed table <NUMBER> advantage easy access availability decreased cost development provide wide array options combination studies pharmacological knowledge available compounds may also reduce concerns regarding adverse effects patients generation translational database encompassing pharmacodynamics data infectious disease biology data proposed would greatly facilitate decision making pursue new drug combinations <NUMBER> many drugs potential broadspectrum antiviral activity already clinical use treating viral infections novel drugs development move preclinical clinical phase also become available combination therapy care taken pharmacological evaluation combination avoid possible contraindications drugs regards disease adverse effects novel broadspectrum replication inhibitors gs<NUMBER> gilead sciences phase clinical trial immunomodulators nitazoxanide steroids statins along directacting antiviral agents coronaviruses development represent interesting partners combinations combinations involve broadspectrum versus specific antiviral agents drugs different mechanism action drugs target different steps viral life cycle identifying one potent combinations activity animal model would greatly increase preparedness next coronavirus outbreak elucidation crystal structure viral proteins led novel approaches rational drug design rational design investigations using protein structure information silico screening affinity active sites viral proteins holds promise hiv<NUMBER> protease inhibitors one big successes rational drug design <NUMBER> years publication hiv<NUMBER> protease structure saquinavir developed record time bench bedside licensed use aids <NUMBER> <NUMBER> <NUMBER> <NUMBER> total <NUMBER> antivirals hiv<NUMBER> protease designed approved <NUMBER> <NUMBER> similarly hcv computeraided approaches based known crystal structure viral protein successfully guided design synthesis inhibitors hcv ns<NUMBER>ns<NUMBER>a proteases peptidomimetics telaprevir boceprivir <NUMBER> <NUMBER> <NUMBER> due power computational modeling using crystal structures known coronaviruses crystal structures viral proteases pro pl pro sarscov merscov determined relatively quickly <NUMBER> structures already used discovery inhibitors high binding affinity active site proteases structures additional merscov sarscov viral proteins yet determined would offer additional viral targets drug discovery structural design help development inhibitors preparing future outbreaks yet unknown emerging coronaviruses based potential zoonotic transmission coronaviruses bats humans crystal structures main protease pro different bat coronavirus families proposed screening identifying broadspectrum antiviral agents <NUMBER> proofofprinciple shown novel protease inhibitor sg<NUMBER> inhibits bat coronavirus hku<NUMBER> <NUMBER> <NUMBER> sg<NUMBER> quickly identified inhibitor merscov silico docking studies pro merscov bat coronavirus hku<NUMBER> several drugs eg toremifene citrate terconazole fig <NUMBER> belong group compounds termed cationic amphiphilic drugs cads <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> phenothiazines eg fluphenazine chlorpromazine fig <NUMBER> cads shown inhibit hcv entry virushost cell fusion intercalating cholesterolrich domains host cell membrane increasing membrane fluidity <NUMBER> drugs act mechanism may present interesting new class broadspectrum antivirals cads known lysomotropic accumulate acidic compartments tertiary amine groups protonated compounds act mild bases neutralize low ph acidic environment endolysosomes cads intercalate membranes alter biophysical properties membranes thereby could potentially interfere fusion virus endolysosomal membrane concept interfering virus entry budding physicochemical properties drugs intriguing many viruses would susceptible type inhibition cads could used broadspectrum antiviral agents detailed structureactivity relationship studies cads required determine chemical core structures physicochemical properties important type antiviral agent future investigations regarding conservation mechanism action coronaviruses well emerging viruses warranted approved drugs activity merscov sarscov could used lead compounds antiviral drug development pharmaceuticals usually undergone multiple rounds structureactivity relationship studies generating analogs improve drug activity original indication target analogs drugs activity merscov sarscov may still available could screened identify analogs increased antiviral activity although drug analogs would go full licensure process would little added initial cost associated producing structureactivity relationship compounds recycling old analogs one approach may value developing novel drugs viral infections streamlined process needed development effective treatment measures emerging reemerging pathogens availability panel approved broadspectrum drugs would clearly beneficial could used treating disease symptoms reducing morbidity specific acting antivirals vaccines developed large number potential drugs therapeutics treatment mers sars discussed greatest challenge best downselect evaluate different approaches learned drug development aids hepatitis alleviating disease symptoms increasing life span may achievable goal rather looking treatment provide complete recovery broadspectrum antivirals specific antivirals immune modulators important role treating viral infections either individually combination effective communication different institute partners government industry academic national international partners essential combining drug discovery efforts increase chance one potential therapeutic agents advanced development stage time another outbreak emerging coronavirus occurs outbreaks middle east respiratory syndrome mers severe acute respiratory syndrome sars caused emerging coronaviruses • variety approaches developing therapeutics discussed emphasis drugs approved indications could repurposed treating emerging coronaviral infections recent mers sars outbreaks highlight importance panel wellcharacterized broadspectrum antivirals treating emerging viral infections table <NUMBER> drug regimens used treatment mers table <NUMBER> clinically developed drugs activity merscov sarscov drugs development treatment mers sars <NUMBER>clike protease benzotriazole esters ce<NUMBER> <NUMBER> papainlike protease thiopurines <NUMBER>thioguanine <NUMBER>mercaptopurine <NUMBER> helicase triazole ssya<NUMBER> <NUMBER> rnadependent rna polymerase nucleotide prodrug gs<NUMBER> <NUMBER> rnadependent rna polymerase nucleoside analog bcx<NUMBER> <NUMBER> membranebound rna synthesis small molecule inhibitor k<NUMBER> <NUMBER> furin inhibitior small molecule inhibitor decanoylrvkr <NUMBER> sarscov viralcellular target drug class drug <NUMBER>clike protease benzotriazole esters ce<NUMBER> <NUMBER> <NUMBER>clike protease anilides peptide nitroanilides <NUMBER> <NUMBER>clike protease c <NUMBER> symmetric inhibitors containing diol cores tl<NUMBER> <NUMBER> <NUMBER>clike protease pyrazole analogs pyrazolones <NUMBER> <NUMBER>clike protease serine inhibitor trifluoromethyl ketones <NUMBER> <NUMBER>clike protease serotonin receptor antagonist cinanserin <NUMBER> <NUMBER>clike protease zincconjugated inhibitor jmf <NUMBER> <NUMBER> papainlike protease thiopurines <NUMBER>thioguanine <NUMBER>mercaptopurine <NUMBER> helicase triazole ssya<NUMBER> <NUMBER> helicase bananin derivatives vanillinbananin idobananin <NUMBER> ntpasehelicase aryl diketoacids dihydroxychromone hydroxychromone derivatives electronic literature search countermeasures middle east respiratory syndrome coronavirus merscov severe acute respiratory syndrome coronavirus sarscov performed using pubmed google results recent study support bats may reservoir merscov however camels goats thought intermediate hosts <NUMBER> study merscov isolated nasal secretions merscovinfected dromedary camels short mild disease progression suspected reservoir sarscov chinese horseshoe bat <NUMBER> however mechanism emergence adaptation make virus zoonotic still definitely understood <NUMBER> sarscovlike isolates bats <NUMBER> sequence similarity human civet sarscov initial outbreak sarscov originally isolated palm civets found chinese market sarscov found wild palm civet population <NUMBER> bats harbor many coronaviruses considered main reservoir later infections intermediate host civets camels spread disease humans <NUMBER> humantohuman transmission commonly associated healthcare workers close unprotected contact infected patients <NUMBER> <NUMBER> clinical features mers sars similar range asymptomatic mild disease severe pneumonia acute respiratory distress syndrome ards multiorgan failure <NUMBER> although mers sars clinically similar mers mortality rate <NUMBER> sarss mortality rate <NUMBER> <NUMBER> approximately <NUMBER> mers cases associated underlying comorbidities <NUMBER> mortality rate subgroup including cardiopulmonary abnormalities obesity diabetes contrast <NUMBER> patients sars comorbidities mortality rate <NUMBER> within subgroup <NUMBER> <NUMBER> development symptomatic mers sars mostly occurs adults median age <NUMBER> years <NUMBER> years sars mers sars symptoms typically follow mean incubation time <NUMBER> days range <NUMBER> <NUMBER> days respectively include fever chills cough associated blood shortness breath myalgia headache nausea vomiting diarrhea sore throat malaise <NUMBER> <NUMBER> <NUMBER> progression mild severe disease rapid mers compared sars means <NUMBER> <NUMBER> days respectively <NUMBER> secondary bacterial infections occurred patients severe mers however role coinfections mers pathogenesis yet determined <NUMBER> <NUMBER> <NUMBER> laboratory abnormalities associated mers sars patients include elevated lactate dehydrogenase elevated liver enzymes thrombocytopenia lymphopenia leukopenia <NUMBER> <NUMBER> <NUMBER> radiographic abnormalities consistent viral pneumonitis ards common mers sars radiographic progression lower lobes reported rapid mers sars <NUMBER> <NUMBER> <NUMBER> sars disease lower lobes mimics pneumonia radiographic progression includes groundglass opacification lobe thickening <NUMBER> merscov intact virus viral genome found higher concentrations lower respiratory tract upper respiratory tract mers patients may account inefficient interhuman transmission <NUMBER> <NUMBER> currently approved therapeutics patients mers sars available clinical management relied primarily supportive care effectiveness antiviral treatments used sars epidemic mainly based case studies retrospective analysis patient cohorts randomized blinded clinical trials antisars treatments performed adds complexity interpreting available data table <NUMBER> ribavirin nucleoside analog prevents rna dna virus replication initially used treatment sars due broadspectrum efficacy example taiwanese study <NUMBER> sars patients treated daily fluoroquinolone antibiotics levofloxacin <NUMBER> mg moxifloxacin <NUMBER> mg following diagnosis <NUMBER> patients <NUMBER> sars patients also treated intravenously iv <NUMBER> mg ribavirin orally daily <NUMBER> mg <NUMBER> sars patients receive ribavirin corticosteroids iv methylprednisolone oral prednisolone administered needed treat worsening lung infiltrates fever <NUMBER> ribavirin treatment led hypoxia anemia increased risk death sars patients retrospective analysis cohort <NUMBER> patients hong kong singapore toronto treated ribavirin conjunction corticosteroids immunoglobulins andor antibiotics <NUMBER> ribavirin demonstrate efficacy patients hong kong singapore treated ribavirin <NUMBER> mg orally diagnosis followed oral treatments <NUMBER> mg daily continual iv ribavirin therapy <NUMBER> mgkg every <NUMBER> h h toronto patients received ribavirin iv treatment <NUMBER> mg followed <NUMBER> mg every <NUMBER> h <NUMBER> days <NUMBER> mg every <NUMBER> h <NUMBER> days unfortunately fatality rates similar ribavirintreated control groups later researchers demonstrated ribavirin dosage required effective sarscov vitro clinically achievable <NUMBER> ribavirin treatment also resulted adverse effects including anemia hypoxemia decreased hemoglobin levels improve patient outcome <NUMBER> due increasing adverse effects lack efficacy health canada stopped permitting use ribavirin sars <NUMBER> increased positive outcome ribavirin compared controls <NUMBER> <NUMBER> increased risk anemia hypomagnesemia hypoxia bradycardia ribavirin compared ribavirinnaive patients <NUMBER> <NUMBER> ribavirin oraliv lopinavirritonavir ± corticosteroids fatality acute respiratory distress syndrome ards reduced significantly <NUMBER> <NUMBER> <NUMBER> ifnalfacon<NUMBER> ± corticosteroids ± antibiotics increased oxygen saturation increased clearance lung abnormalities slight increase creatinine kinase concentrations <NUMBER> <NUMBER> fluoroquinolone iv azithromycin iv ± corticosteroids ± immunoglobulins ± thymic peptides proteins increased positive outcome <NUMBER> quinolone iv ± ifna ± corticosteroids increased positive outcome <NUMBER> levofloxacin azithromycin ± ifna ± corticosteroids increased clearance lung abnormalities <NUMBER> ifn interferon im intramuscular iv intravenous sars severe acute respiratory syndrome additional studies tested efficacy ribavirin conjunction lopinavir antiretroviral agent lopinavir demonstrated vitro activity sarscov <NUMBER> nonrandomized openenrollment trial <NUMBER> suspected sars patients <NUMBER> patients treated ribavirin corticosteroids similar previously described studies addition <NUMBER> confirmed sars patients also treated combination lopinavir <NUMBER> mg ritonavir <NUMBER> mg mean viral loads nasopharyngeal swabs within treatment group decreased undetectable levels day <NUMBER> overall sarsrelated symptoms subsided disease progression milder adverse effects reported compared historical control group openlabel nonrandomized study <NUMBER> sars patients <NUMBER> patients received subcutaneous sc injections interferon ifna alfacon<NUMBER> <NUMBER> days initial dose <NUMBER> lgday <NUMBER> days increasing <NUMBER> lgday disease progression <NUMBER> patients survived minor adverse effects <NUMBER> evaluation treatments mers patients hampered highquality clinical data randomized clinical trials limited ribavirin without ifn corticosteroids primary treatment mers outbreak retrospective analysis cohort <NUMBER> patients treated oral ribavirin sc pegylated ifna<NUMBER>a dose <NUMBER> lgweek <NUMBER> weeks table <NUMBER> <NUMBER> initial dose ribavirin <NUMBER> mg followed <NUMBER> mg dose depending creatinine clearance group <NUMBER> patients received supportive care corticosteroids considered control group <NUMBER> days confirmed diagnosis mers survival increased treated group <NUMBER> compared control group <NUMBER> <NUMBER> days postdiagnosis <NUMBER> treated subjects survived versus <NUMBER> control group <NUMBER> additional case study <NUMBER>yearold greek patient contracted mers jeddah treated oral lopinavirritonavir <NUMBER> mg twice daily pegylated ifn <NUMBER> lg sc per week <NUMBER> weeks ribavirin <NUMBER> mg initial dose <NUMBER> mg every <NUMBER> h <NUMBER> days initiated day <NUMBER> postdiagnosis two days treatment initiation viremia could detected however viral rna detected several patient samples feces respiratory secretions serum <NUMBER> weeks postdiagnosis despite prolonged survival patient succumbed septic shock <NUMBER> months postdiagnosis <NUMBER> ongoing randomized clinical trial saudi arabia evaluating treatment mers patients ifnb<NUMBER>b combination lopinavirritonavir <NUMBER> drug repurposing attractive alternative drug discovery strategy eliminates many steps usually required early phase drug development past decade interest drug repurposing increased pharmaceutical companies challenged decreasing product pipelines high costs associated de novo drug discovery imminent expiration many drug patents examples successfully repurposed drugs include viagra pfizer erectile dysfunction original indication angina raloxifene eli lilly treatment invasive breast cancer original indication osteoporosis time required traditional drug development often discordant urgent need novel therapies emerging infectious diseases sars mers outbreaks occur anywhere world frequently resourcelimited settings commonly treatment strategies available emerging infectious diseases less adequate improve patient outcome although specific antivirals merscov sarscov development drug repurposing could present important arm generating additional therapeutics future coronaviruses first drugs confirmed beneficial effects vitro animal studies could used build panel approved drugs use firstline defense newly emerging coronaviruses second drugs could made accessible relatively quickly patients emergency use authorization extending choices treatment generating panel ifn interferon iv intravenous mers middle east respiratory syndrome broadspectrum antivirals would provide real improvement healthcare communities struggling cope outbreak emerging infections great example repurposing benefit search treatments emerging infections drug zidovudine zidovudine originally developed <NUMBER> cancer drug <NUMBER> zidovudine found active human immunodeficiency virus hiv <NUMBER> years later became first drug approved treatment acquired immunodeficiency syndrome aids <NUMBER> number research groups identified investigated usefulness approved drugs treatment viral infections including coronaviruses summarize several drug classes antiviral activity merscov sarscov repurposing potential fig <NUMBER> table <NUMBER> drugs described activity virus families indicating potential broadspectrum applications already clinical use treating viral infections would like emphasize none therapeutics described section recommended clinical use outside clinical trial setting loperamide approved antidiarrheal agent world health organization model list essential medicines available many countries drug acts opioid receptor reduces intestinal motility <NUMBER> results pharmacokinetic pk studies show oral loperamide well absorbed gut less <NUMBER> drug entering systemic circulation <NUMBER> loperamide demonstrated antimerscov antisars antihcov<NUMBER>e activity vitro screen approved drugs <NUMBER> although mechanism action unknown interestingly loperamide suggested limiting gastrointestinal fluid electrolyte losses patients ebola virus disease evd <NUMBER> antimalarial agents chloroquine cq amodiaquine mefloquine activity sarscov merscov vitro <NUMBER> <NUMBER> <NUMBER> cq us food drug administration fdaapproved antimalarial agent also used treat autoimmune disease rheumatoid arthritis due antiinflammatory effects <NUMBER> cq activity number viruses vitro vivo including flaviviruses dengue virus denv togaviruses chikungunya virus chikv paramyxoviruses hendra nipah virus influenza viruses hiv filoviruses ebola virus ebov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> several mechanisms action identified antiviral effect cq suggest drug acts nonspecifically virus entry later stages virus production cq accumulates within acidic organelles endosomes golgi vesicles lysosomes drug protonated resulting increased ph within vesicle <NUMBER> viruses depend acidic organelles entry viral replication maturation virus progeny similarly merscov entry cells depends several proteases dipeptidyl peptidase <NUMBER> dpp<NUMBER> acts functional virus receptor <NUMBER> cellular proteases eg type ii transmembrane serine protease tmprss<NUMBER> members cathepsin family activate viral spike glycoprotein <NUMBER> cq may effect proteases cq also affects glycosylation step within golgi directs trafficking maturation viral proteins <NUMBER> <NUMBER> <NUMBER> sarscov antiviral activity cq also attributed deficit glycosylation receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> <NUMBER> broadspectrum antiviral activity makes cq attractive antiviral repurposing treating coronaviral emerging viral infections vivo activity cq mers sars animal models yet reported however antiviral activity drug evaluated viruses preclinical clinical studies mixed results cq plasma steady state concentrations mice similar reported humans <NUMBER> lm within range ec <NUMBER> values determined merscov <NUMBER> lm sarscov <NUMBER> lm <NUMBER> <NUMBER> preclinical studies cq mice viruses shown survival benefits influenza ebov infections clinical studies cq effective reducing viral loads asymptomatic hiv patients <NUMBER> <NUMBER> results cq treatment chikv denv infections mixed <NUMBER> <NUMBER> summary cq broadspectrum potential information gained studies viruses used plan appropriate strategies evaluating specific clinical value treating merscov sarscov infections cq several advantages including rapid absorption gastrointestinal tract low cost c fig <NUMBER> candidate drugs repurposing coronaviral infections several drug classes studied steps processes viral replication cycle likely target indicated akt serinethreonine kinase cad cationic amphiphilic drug cyps cytochrome p<NUMBER>s e envelope er endoplasmic reticulum ergic ergolgi intermediate compartment erk extracellular signalreduction kinase ifn interferon mapk mitogenactivated protein kinase membrane mpa mycophenolic acid mtor mechanistic target rapamycin n nucleocapsid nfat nuclear factor activated cells orf open reading frame pi<NUMBER>k phosphoinositide <NUMBER>kinase spike effective biodistribution cq may excellent candidate combinatorial treatments antivirals however considerable challenges remain treatment viral infections including increased understanding pharmacodynamics cq achievement sufficient plasma concentrations patients toxicity concerns <NUMBER> importantly hydroxychloroquine cq derivate may provide alternative due lower toxicity similar pharmacology profile <NUMBER> related antimalarial drug amodiaquine also activity vitro merscov sarscov <NUMBER> previous investigations demonstrated amodiaquine inhibits filovirus replication mechanism action hypothesized similar cq <NUMBER> amodiaquine well tolerated commonly used malaria treatments many countries amodiaquine combination artesunate administered evd patients <NUMBER> epidemic resulting decrease fatality rates may associated use amodiaquine antimalarial agent <NUMBER> nonhuman primate nhp studies currently underway investigate effect amodiaquine treatment evd <NUMBER> mefloquine synthetic analog quinine another antimalarial drug activity merscov sarscov <NUMBER> belongs model list essential medicines mefloquine known penetrate bloodbrain barrier found inhibit jc virus infection replication concentrations generally achieved brains patients given mefloquine malaria <NUMBER> leading clinical evaluation drug treatment progressive multifocal leukoencephalopathy <NUMBER> <NUMBER> <NUMBER> fda added boxed warning us label mefloquine regarding potential neuropsychiatric side effects additional investigations warranted determine amodiaquine mefloquine value repurposing treatment mers sars cyclophilins ubiquitous host proteins believed multiple roles trafficking protein folding cell activation <NUMBER> cyclosporine cysa forms complex cyclophilin thereby blocking cell activation cysa licensed use organ transplantation suppress immune response cysa also shown inhibit coronaviruses including sarscov merscov effectively cell culture <NUMBER> <NUMBER> however mechanism yet determined increasing evidence cyclophilins involved viral replication rna viruses hepatitis c virus hcv west nile virus may also apply coronaviruses <NUMBER> although immunosuppressive properties cysa considered risk treating viral infections patients nonimmunosuppressive analogs cysa bind cyclophilins higher affinity developed clinical trials hcv therapeutics <NUMBER> <NUMBER> <NUMBER> interferons ifns approved fda indications hepatitis c although ifna reduced sarscov replication mice nhps <NUMBER> <NUMBER> efficacy ifna treatment sars patients mixed see sect <NUMBER> vitro studies another type interferon ifnb<NUMBER>a may effective ifna either alone combination ifnc <NUMBER> <NUMBER> <NUMBER> combinations ifnb c synergistic sarscov vitro <NUMBER> regards mers vitro vivo preclinical studies indicated ifna<NUMBER>b alone combination ribavirin may therapeutic effect given early disease <NUMBER> <NUMBER> clinical trials however ifna<NUMBER>b given combination treatments lead significant benefit patients see sect <NUMBER> ifnb<NUMBER>a ec <NUMBER> <NUMBER> iuml superior activity merscov infection vitro compared ifna<NUMBER>a ifna<NUMBER>b ifnc ifns ec <NUMBER> values <NUMBER> <NUMBER> <NUMBER> iuml respectively <NUMBER> ifnb<NUMBER>b currently evaluation merscov randomized clinical trial combination lopinavirritonavir <NUMBER> investigating ifnb subtypes <NUMBER>a <NUMBER>b combination antivirals may worthwhile potential synergistic combinations could reduce effective drug dosage ifnassociated adverse effects many cellular processes regulated independently changes transcription translation kinasemediated cell signaling pathways testament biological importance kinases <NUMBER> kinases identified along <NUMBER> genes encoding proteins kinase activity <NUMBER> <NUMBER> april <NUMBER> <NUMBER> kinase inhibitors granted approval us fda half gaining approval <NUMBER> kinases frequently targeted gene class cancer therapy second g proteincoupled receptors therapeutic targets <NUMBER> <NUMBER> therapeutic potential hosttargeted immunomodulatory agents viral infections received considerable attention <NUMBER> <NUMBER> <NUMBER> recently dyall et al identified two abelson abl kinase inhibitors imatinib dasatinib inhibited merscov sarscov infection cellscreening assay <NUMBER> vitro chikv <NUMBER> <NUMBER> denv <NUMBER> <NUMBER> hev niv <NUMBER> hiv<NUMBER> <NUMBER> fluav <NUMBER> ebov marv <NUMBER> sfv sinv <NUMBER> vivo mixed data efficacy ebov mice <NUMBER> <NUMBER> efficacy ebov hamsters guinea pigs <NUMBER> fluav <NUMBER> survival mice <NUMBER> approved treatment malaria clinical trials treatment chikv denv fluav flubv infections showed impact disease <NUMBER> <NUMBER> <NUMBER> well tolerated commonly use list essential medicines list potential evd treatments dosing formulation need optimized treatment viral infections <NUMBER> hydroxychloroquine sulfate merscov vitro denv <NUMBER> hiv<NUMBER> <NUMBER> jcv <NUMBER> approved treatment malaria vitro bkpyv <NUMBER> ebov <NUMBER> hiv<NUMBER> <NUMBER> denv <NUMBER> vivo vacv activity mice <NUMBER> approved treatment cancers vitro bkpyv <NUMBER> hhv <NUMBER> hcv <NUMBER> mpxv vacv varv <NUMBER> vivo vacv <NUMBER> survival mice <NUMBER> approved treatment cancers <NUMBER> chikv <NUMBER> fluav <NUMBER> sfv sinv <NUMBER> approved immunosuppressant organ transplantation fda alert risk activation latent herpes infections vivo sars activity mice <NUMBER> vitro fluav flubv <NUMBER> inhibition ebov <NUMBER> cellular serine protease inhibitor clinical development chronic pancreatitis well tolerated sarscov spread driven serine protease rather cysteine protease <NUMBER> protein synthesis inhibitors anisomycin hbv <NUMBER> approved chronic myeloid leukemia well tolerated abl<NUMBER> identified critical merscov sarscov virus entry may target imatinib inhibits block entry viruses <NUMBER> recent systems kinome analysis investigation vitro merscov infection suggested erkmapk pi<NUMBER> kakt mtor signaling pathways specifically modulated infection <NUMBER> subsequent analysis licensed kinase inhibitors targeting pathways demonstrated kinase inhibitors targeting erkmapk signal pathway selumetinib trametinib inhibited merscov infection c <NUMBER> added preor postinfection <NUMBER> trametinib demonstrated significantly stronger inhibitory activity merscov selumetinib suggesting specific intermediates erk mapk signaling pathway may represent crucial foci early viral entry late viral replication events viral life cycle contrast sorafenib inhibitor raf<NUMBER> braf components erkmapk signaling pathway vascular endothelial growth factor receptor <NUMBER> vegfr<NUMBER> inhibited merscov infection <NUMBER> added cells prior infection however inhibitory activity reduced <NUMBER> added postinfection suggesting raf kinases primarily involved early viral life cycle events addition inhibitory activity dabrafenib raf kinase inhibitor also largely ablated added postinfection miltefosine alkyl phospholipid considered inhibitor protein kinase b akt garnered fda approval infectious diseaserelated treatments cutaneous mucosal leishmaniasis <NUMBER> <NUMBER> miltefosine became directly available us centers diseases control prevention treatment freeliving amoeba infections <NUMBER> pretreatment cells miltefosine reduced merscov infection <NUMBER> effect added postinfection <NUMBER> contrast inhibition mtor sirolimus everolimus reduced merscov infection <NUMBER> added prior preor postinfection suggesting critical role mtor merscov infection recent clinical investigation wang et al <NUMBER> evaluated sirolimus corticosteroids addition standard antiviral treatment randomized controlled trial patients severe h<NUMBER>n<NUMBER> pneumonia acute respiratory failure <NUMBER> importantly addition sirolimus associated improved patient outcomes including decreased hypoxia multiorgan dysfunction reduced mean times liberation mechanical ventilation increased clearance virus thus may prudent extend study repurposed kinase inhibitors beyond standalone therapeutic investigations also consider potential adjunctive therapies numerous neurotransmitter receptors inhibitors showed activity merscov sarscov infection <NUMBER> drugs initially developed antipsychotics antihistamines sedatives five neurotransmitter receptor antagonists belong chemical class phenothiazines chlorpromazine triflupromazine thiethylperazine promethazine fluphenazine phenothiazines breakthrough medications developed <NUMBER>s treating mental health patients reduced episodes bizarre behavior hallucinations irrational thoughts <NUMBER> although phenothiazines primarily block dopamine receptors also anticholinergic antihistamine antiemetic effects phenothiazines chlorpromazine triflupromazine approved antipsychotics chlorpromazine used offlabel shortterm treatment nausea migraines triflupromazine used treat severe emesis drug serious side effects chlorpromazine including akathisia tardive dyskinesia antiviral effect chlorpromazine extensively studied drug interferes clathrinmediated endocytosis process many viruses exploit host cell entry chlorpromazine inhibits entry junin virus <NUMBER> west nile virus <NUMBER> ebov <NUMBER> hcv <NUMBER> japanese encephalitis virus <NUMBER> suggesting broadspectrum activity could exploited early novel virus outbreak chlorpromazine may similar effects coronaviruses drug effectively inhibits merscov sarscov human coronavirus <NUMBER>e expressing green fluorescent protein <NUMBER> <NUMBER> however timeofaddition studies indicate inhibitory activity merscov retained whether added preor postinfection suggesting additional effects clathrinmediated entry impairment <NUMBER> thiethylperazine approved antiemetic chlorpromazine thiethylperazine shown inhibit alphaviruses semliki forest virus sfv chikungunya virus chikv <NUMBER> <NUMBER> drugs cross brainblood barrier use drugs could beneficial treatment chikv including common neurologic complications promethazine antihistamine used sedative many countries different brand names also acts weak antipsychotic activity fluphenazine common antipsychotic used treat chronic psychoses primarily schizophrenia belongs model list essential medicines promethazine fluphenazine shown vitro activity merscov sarscov may value candidates repurposing coronaviral infections <NUMBER> benztropine mesylate approved anticholinergic used treat parkinsons activity merscov sarscov <NUMBER> benztropine also identified screens clinically approved drugs antiviral activities hcv ebov <NUMBER> <NUMBER> <NUMBER> although detailed mechanism action unknown hcv studies indicate benztropine inhibits virus entry step interfering viral genome replication transcription production viral progeny virus production viral progeny <NUMBER> argued virus entry inhibitor may value decreasing incidence relapse chronic hcv patients receive liver transplants <NUMBER> however peak plasma concentrations benztropine may low effective treating acute infection <NUMBER> benztropine also independently identified two drug screens ebov antivirals <NUMBER> <NUMBER> recent report suggests step virus attachment prior viralcell membrane fusion targeted benztropine <NUMBER> clomipramine tricyclic antidepressant thiothixene thioxanthene antipsychotic also shown inhibit merscov sarscov infection vitro <NUMBER> addition found inhibit evd vlp entry <NUMBER> approved clinically clomipramine belongs model list essential medicines several neurotransmitter inhibitors astemizole promethazine chlorphenoxamine fluspirilene active merscov sarscov cell culture able find reports activity viruses <NUMBER> astemizole h<NUMBER>histamine receptor antagonist treating allergic rhinitis withdrawn market cardiac adverse events due drug overdose reported extremely rare <NUMBER> recently astemizole gained renewed interest anticancer antimalarial drug <NUMBER> <NUMBER> chlorphenoxamine antihistamine anticholinergic currently preclinical trials malaria fluspirilene approved antipsychotic treatment schizophrenia known autophagy inducer <NUMBER> autophagy cellular degradative pathway viruses exploit propagation <NUMBER> modulators autophagy may perturb merscov sarscov infection investigation broadspectrum potential treatment coronaviral infections would interesting <NUMBER> several rnadna synthesis inhibitors broadspectrum activity viruses including sarscov merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> inosine monophosphate dehydrogenase impdh inhibitors ribavirin mycophenolic acid mizoribine inhibit important step de novo synthesis nucleic acids although potency drugs viruses varies ribavirin used combination ifn clinic treatment viral infections hepatitis c treatment regimens ribavirin well characterized used sars mers patients mixed results see <NUMBER> ribavirin weakly inhibits merscov vitro conflicting data reported activity ribavirin sarscov <NUMBER> <NUMBER> <NUMBER> many studies ribavirin performed vero cells reportedly defect ribonucleoside uptake could explain lack activity ribavirin cells <NUMBER> another coronavirus mouse hepatitis virus mhv becomes sensitive ribavirin exoribouclease activity inactivated presence exoribonuclease ribavirin inhibit mhv replication <NUMBER> mhv exoribonuclease suggested function proofreading viral enzyme necessary highfidelity replication mhv similarly exoribonuclease activity merscov sarscov could possibly counteract inhibitory activity ribavirin mycophenolic acid mpa immunosuppressant used prevent organ rejection broadspectrum antiviral activities antifungal antibacterial anticancer antipsoriatic properties <NUMBER> <NUMBER> <NUMBER> although mpa weak inhibitory activity sarscov vitro promising activity merscov <NUMBER> <NUMBER> potential alternative mpa prodrug mycophenolate mofetil improved oral bioavailability <NUMBER> mycophenolate mofetil evaluated common marmoset model mers reduce disease manifestations compared observed control subjects <NUMBER> however mers marmoset model recapitulate human disease due rapid onset pathology associated exposure methods <NUMBER> mizoribine approved immunosuppressant organ transplantation limited adverse side effects shown vitro activity hcv bovine viral diarrhea virus bvdv considered alternative ribavirinifn combinations treatment hcv infections <NUMBER> vivo analysis ribavirin impdh inhibitors sarscovinfected mice suggested agents would limited benefit <NUMBER> chemotherapeutic gemcitabine shown vitro activity merscov sarscov <NUMBER> drugs anticancer mechanism attributed ability inhibit ribonucleotide reductase essential de novo pyrimidine biosynthesis gemcitabine shown suppress influenza virus rna transcription replication targeting ribonucleotide reductase showed antiretroviral activity vivo mouse model murine leukemia virus <NUMBER> <NUMBER> merscov sarscov require activation envelope glycoproteins host proteases cell entry endosomal nonendosomal pathways inhibitors host cell proteases investigated possible antivirals <NUMBER> serine protease tmprrss<NUMBER> mediates entry via nonendosomal pathway merscov sarscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> camostat mesylate used treatment chronic pancreatitis inhibits tmpssr<NUMBER>mediated glycoprotein activation merscov sarscov influenza virus <NUMBER> <NUMBER> <NUMBER> <NUMBER> k<NUMBER> cysteine protease inhibitor clinical development treating parasitic infections k<NUMBER> broadspectrum activity coronaviruses merscov sarscov hcov<NUMBER>e filoviruses ebov marburg virus paramyxoviruses nipah virus <NUMBER> interestingly zhou et al <NUMBER> demonstrated camostat k<NUMBER> inhibitory activity sarscov whereas ebov inhibited k<NUMBER> suggesting differential host protease requirements viruses <NUMBER> e<NUMBER>d inhibitor endosomal cysteine protease currently phase iii trials treatment muscular dystrophy inhibits merscov sarscov vitro <NUMBER> e<NUMBER>d also inhibits filovirus cell entry <NUMBER> <NUMBER> dependency viruses specific serine cysteine host proteases must considered selection protease inhibitors antiviral therapeutic applications therefore increased understanding relationship host proteases viral pathogenesis determine effective treatment options viral infections lopinavir identified inhibitor merscov sarscov vitro timeofaddition experiments indicate drug acts early stage viral entry <NUMBER> lopinavir inhibitor hiv protease used clinically treatment hiv infections <NUMBER> given combination ritonavir inhibitor cytochrome p<NUMBER> <NUMBER>a<NUMBER> increase blood concentrations low bioavailability lopinavir <NUMBER> lopinavir also inhibits human papilloma virus currently development topical treatment cervical cancer <NUMBER> treatment lopinavirritonavir resulted reduced mortality nhp model mers <NUMBER> lopinavir shown target main protease pro sarscov <NUMBER> however lopinavir also shown act intracellular processes involved coronavirus replication additional studies needed fully understand mechanism action lopinavir involving cellular proteases <NUMBER> sars outbreak patients open clinical trials treated lopinavirritonavir combination ribavirin milder disease course reduction fatality rate compared observed historical controls <NUMBER> <NUMBER> three protein synthesis inhibitors activity coronaviruses identified emetine anisomycin omacetaxine mepesuccinate <NUMBER> <NUMBER> emetine natural plant alkaloid anisomycin antibiotic inhibit protein elongation identified antiprotozoals <NUMBER> <NUMBER> emetine approved amoebiasis treatment anisomycin move beyond clinical trials <NUMBER> <NUMBER> dehydroemetine synthetic emetine derivative fewer side effects available investigational new drug <NUMBER> <NUMBER> anisomycin originally discovered peptidyl transferase inhibitor also activates map kinase signaling pathway <NUMBER> addition activity merscov sarscov emetine anisomycin inhibit animal picornavirus encephalomyocarditis virus <NUMBER> anisomycin vitro activity poliovirus <NUMBER> omacetaxine mepesuccinate plantderived alkaloid anticancer therapeutic received fda approval <NUMBER> treatment chronic myeloid leukemia omacetaxine inhibits merscov bovine coronavirus human enteric coronavirus hepatitis b virus <NUMBER> <NUMBER> spite omacetaxine broad spectrum anticoronavirus activity drug activity sarscov <NUMBER> drugs inhibit coronaviruses targeting protein synthesis may potential development combination therapies drugs target antiviral pathways recent investigations demonstrated potential estrogen receptor er antagonists repurposing anticoronavirus compounds <NUMBER> example toremifene citrate tamoxifen citrate activity sarscov merscov developed approved anticancer therapeutics drugs shown activity hcv replication vitro <NUMBER> <NUMBER> mechanistic studies revealed er functionally associated hcv replication <NUMBER> er promotes interaction hcv replication complex hcv polymerase ns<NUMBER>b ermediated regulation hcv genome replication abrogated tamoxifen toremifene tamoxifen also effectively inhibit ebov infection vitro <NUMBER> however contrast hcv mechanistic studies shown toremifenemediated ebov inhibition independent er pathway toremifene still active ebov cells express er <NUMBER> <NUMBER> toremifene acts late step virus entry internalization ebov may prevent fusion viral endosomal membranes <NUMBER> <NUMBER> <NUMBER> based chemical structure toremifene cationic amphiphilic drug cad known lysosomotropic could affect endosomal processes virus entry <NUMBER> <NUMBER> treatment toremifene led <NUMBER> survival ebovinfected mice confirming drug effect vivo well <NUMBER> terms clinical application toremifene tamoxifen good bioavailability safety tolerability profiles combined long history use clinic however prolongation qt interval noted toremifene prescribed patients congenital acquired long qt syndrome uncorrected hypokalemia uncorrected hypomagnesemia <NUMBER> tamoxifen increase uterine malignancies stroke pulmonary embolism women ductal carcinoma situ high risk breast cancer <NUMBER> despite side effects drugs may substantial value shortterm treatment acute coronaviral infections advanced patient studies careful evaluation pharmacokinetic profiles may facilitate dosing strategies limit risk adverse events two sterol synthesis inhibitors terconazole triparanol shown activity merscov sarscov <NUMBER> studies viruslike particles vlps demonstrated terconazole inhibits coronavirus cell entry including merscov sarscov sterol synthesis pathway shown required infection several viruses including hcv <NUMBER> <NUMBER> terconazole approved vaginal yeast infections administered orally topically suppository triparanol approved lowering plasma cholesterol withdrawn due numerous side effects cads induce accumulation cholesterol late endosomes shown inhibit ebov entry <NUMBER> addition drug repurposing development novel antiviral countermeasures needed emerging coronaviruses end design development strategies targeted viral replication cycle host pathways essential viral replication table <NUMBER> two nucleoside inhibitors viral rnadependent rna polymerases gs<NUMBER> bcx<NUMBER> potential broadspectrum antivirals <NUMBER> <NUMBER> drugs active merscov sarscov cell culture vivo efficacy remains investigated addition new class nucleosides flexible purine base anticoronaviral activity optimization could generate potent inhibitors coronaviral polymerase <NUMBER> surface glycoprotein sarscov merscov coronaviruses consists two domains s<NUMBER> containing receptorbinding domain rbd needed extracellular binding s<NUMBER> containing fusion peptide needed membrane fusion release endocytosis sarscov facilitated binding rbd angiotensin converting enzyme <NUMBER> ace<NUMBER> receptor host cells membranebound cathepsin l cleaves protein revealing s<NUMBER> fusion protein fuses membrane releases viral rna inhibitors cathepsin l ace<NUMBER>sarss<NUMBER> complex s<NUMBER> fusion peptide could suitable targets inhibit sarscov entry <NUMBER> results recent studies identified inhibitors viral entry viral proteases helicases potently inhibit merscov sarscov <NUMBER> proteases papainlike protease <NUMBER>clike protease could also useful antiviral targets drug development required cleaving nonstructural proteins viral maturation protease inhibitors suicide protease inhibitors bind target irreversibly however reversible protease inhibitors may greater potential less toxic better tolerated <NUMBER> recent studies helicase inhibitors show three domain targets nterminal metal binding domain hinge domain ntphelicase domain potential development new drugs <NUMBER> directed rna interference rnai presents powerful approach development novel virusspecific therapeutics based gene silencing <NUMBER> recent studies shown small interfering rnas sirnas short hairpin rnas inhibit expression viral genes thereby block replication sarscov cultured cells <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> intranasal delivery combination small interfering rna sisc<NUMBER> targeting sarscov open reading frame <NUMBER> protein decreased sars pathogenesis nhps <NUMBER> potential rnai candidates identified computational modeling merscov require vitro preclinical investigation <NUMBER> several rnai therapeutics treatment viral infections entered clinical trials including tkmebola sirnalipid nanoparticle platform targeting ebov <NUMBER> <NUMBER> <NUMBER> technology great potential therapeutics emerging viruses viral genome sequencing completed short time frame crucial situations epidemic novel emerging viral infection unfolds main obstacle rnai strategies lies identification suitable viral targets delivery efficiency nucleic acids target cells vivo peptides share common physicochemical properties cads facilitate interaction cell membranes interference fusion cellular viral membranes virus entry researchers making progress defining mechanism action peptide entry inhibitors enveloped viruses enfuvirtide approved hiv inhibitor <NUMBER> enfuvirtide <NUMBER>residue peptide derived amphipathic loopchelix heptad repeat domain hiv gp<NUMBER> rational approach based scanning fusion protein sequences amphipathic sequences led discovery additional peptide inhibitors viruses including merscov sarscov <NUMBER> <NUMBER> <NUMBER> chemical modifications peptides increased vivo stability bioavailability improving potential clinical applications novel broadspectrum viral entry inhibitors <NUMBER> <NUMBER> <NUMBER> <NUMBER>clike protease zincconjugated inhibitor jmf <NUMBER> <NUMBER> papainlike protease thiopurines <NUMBER>thioguanine <NUMBER>mercaptopurine <NUMBER> helicase triazole ssya<NUMBER> <NUMBER> helicase bananin derivatives vanillinbananin idobananin <NUMBER> ntpasehelicase aryl diketoacids dihydroxychromone hydroxychromone derivatives adk analogs <NUMBER> <NUMBER>iodobenzyloxy<NUMBER>chlorobenzyloxy<NUMBER>hydroxychromone <NUMBER> rnadependent rna polymerase nucleoside analogs bcx<NUMBER> <NUMBER> <NUMBER>aza<NUMBER>dideazaadenosine cnucleosides <NUMBER> fleximer nucleoside analogs <NUMBER> cathepsin l cellular protease small molecule inhibitor oxocarbazate <NUMBER> ssaa<NUMBER>e<NUMBER> <NUMBER> ace<NUMBER>sarss<NUMBER> complex small molecule inhibitor ssaa<NUMBER>e<NUMBER> <NUMBER> s<NUMBER>cell membrane fusion small molecule inhibitor ssaa<NUMBER>e<NUMBER> <NUMBER> ace<NUMBER>sarss<NUMBER> complex small molecule inhibitor naae <NUMBER> ace<NUMBER> angiotensin converting enzyme merscov middle east respiratory syndrome coronavirus s<NUMBER> spike protein <NUMBER> domain s<NUMBER> spike protein <NUMBER> domain success palivizumab treatment respiratory syncytial virus infection reinvigorated efforts develop monoclonal antibodybased therapeutics infectious diseases <NUMBER> zmapp monoclonal antibody cocktail targeting ebov tested nhps success moved phase ii clinical trials humans evd epidemic <NUMBER> <NUMBER> similarly monoclonal antibody hendra virus administered humans compassionate use basis <NUMBER> <NUMBER> <NUMBER> examples demonstrate potential antibody therapy combat emergingreemerging viruses similar strategies pursued multiple groups development antibodies merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> monoclonal antibodies merscov sourced humanized mice libraries human antibody libraries <NUMBER> <NUMBER> <NUMBER> <NUMBER> antibodies target rbd s<NUMBER> s<NUMBER> subunits demonstrated efficacy animal models reviewed ying et al <NUMBER> monoclonal antibody therapy impart selective pressure generation resistant viruses although mutants escaping monoclonal antibody pressure tend less fit analysis emergence mutations confer resistance monoclonal antibody need performed alternative monoclonal antibody therapy polyclonal antibody therapy using convalescent sera sera sourced nonhuman humanized animal polyclonal antibodies provide advantage monoclonal antibodies escape mutants less likely emerge <NUMBER> <NUMBER> convalescent sera recommended mers phase ii interventional clinical trial ongoing determine efficacy <NUMBER> however availability suitable donor subject presents significant complication approach nonhuman animal sera considered safety concerns limit option fractionation nonhuman sera alternative however antibodymediated clearance limited due failure human fc receptors recognize antibody heavy chain alternative despeciating antibodies using fab antibody fragment however cost sufficient material may make mass production fab fragments difficult use sera humanized mice small laboratory animals complicated sample acquisitionvolume restraints larger laboratory animals may provide potential alternative sab biotherapeutics developed transchromosomic bovine platform generation human igg antibodies <NUMBER> vaccination transchromosomic cattle protein nanoparticles inactivated whole virus generated fully humanized polyclonal antibodies demonstrated efficacy addpp<NUMBER> murine model mers one important lessons regarding antiviral drug development highly specific broadspectrum antivirals bring unique advantages table antiviral agents fall anywhere spectrum broadspectrum highly specific <NUMBER> drug targets specific virus virus family narrow activity high potency low toxicity however drug may also promote resistance <NUMBER> contrast broadspectrum antivirals typically target host factor pathway often agents higher toxicities lower potencies delayed treatment effects however selective pressure resistance often lower broadspectrum agents large part knowledge antiviral development stems studies chronic viral infections antiviral development strategies dna viruses successful identifying single drug specifically targets viral protein strategy less successful rna viruses rna viruses mutate higher rate dna viruses resulting enhanced development drug resistance despite extensive efforts past <NUMBER> years therapeutic prophylactic hiv vaccine remained elusive antiviral agents available treatments aids <NUMBER> antivirals belonging <NUMBER> different drug classes targeting different stages viral replication available eg reverse transcriptase protease fusion entry integrase <NUMBER> combination treatments <NUMBER> <NUMBER> drugs effective result sustained virologic response <NUMBER> two aspects found important avoiding resistance <NUMBER> selecting drugs least two different targets <NUMBER> selecting drugs belong different chemical classes considerations may also apply drug combinations synergistic effects mersand sarscov broadspectrum antiviral therapies great value treating emerging infections takes time develop directacting antivirals treatment chronic hepatitis c clinicians depended ifn ribavirin number years <NUMBER> eventually ifn ribavirin combination replaced effective fixedcombination therapies using directacting antivirals target multiple steps hcv life cycle <NUMBER> ifn ribavirin contribute significantly treatment viral infections directacting antivirals exist however major side effects <NUMBER> options broadspectrum antivirals improved safety profiles would beneficial use emerging coronavirus infections influenza viruses characterized high mutation rate rna genome available vaccines may protective novel pandemic strain antiviral agents considered essential component preparedness combinations directacting antivirals evaluation additive synergistic effects prevention resistance <NUMBER> <NUMBER> one triple combination oseltamivir amantadine ribavirin synergistic prevents resistance vivo <NUMBER> <NUMBER> highlighting potential combinatorial therapy recent epidemic evd western africa renewed urgency development treatments emerging viruses although vaccines directacting antiviral treatment investigation none approved clinical use <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> prioritized panel drugs approved indications considered repurposing fdas emergency use authorization <NUMBER> two drugs also activity merscov sarscov amodiaquine antimalarial agent toremifene citrate breast cancer treatment additional broadspectrum antiviral agents including repurposed drugs top priority future emerging infections including coronavirus infections panel broadspectrum drugs carefully validated efficacy safety could used combination would supply minimum protection patients healthcare workers outbreak locations panel drugs could used situations known reemerging pathogen specific antiviral agents vaccines approved unknown novel pathogen could arise effective development countermeasures depends developing appropriate animal models uniformly recapitulate human disease progression severity pathological manifestations animal models human disease one animal model fully reflects sars mers therefore researchers faced exploring several small animal models choosing bestfit model date animal models fully recapitulate human disease thus animal models mers sars need refinement many small animal models evaluated potential mers sars models including mice hamsters ferrets mers syrian hamsters guinea pigs sars <NUMBER> <NUMBER> <NUMBER> four murine models reported mers first model demonstrated promise involved transduction respiratory tract putative merscov receptor human dpp<NUMBER> cd<NUMBER> <NUMBER> major indicator disease model viral load lung <NUMBER> days postinoculation although clinical signs disease including weight loss limited model used pathogenesis countermeasure studies <NUMBER> <NUMBER> lethal disseminated mers infection demonstrated transgenic mice expressing human dpp<NUMBER> <NUMBER> inflammatory processes observed brains mice contrast human disease cns involvement reported transgenic mouse mers model developed mouse dpp<NUMBER> gene replaced human dpp<NUMBER> gene control endogenous mouse dpp<NUMBER> promoter using model merscovinfected mice developed lung pathology <NUMBER> addition administration human monoclonal antibodies spike protein transgenic mice provided protection merscov infection <NUMBER> clustered regularly interspaced short palindromic repeatcrisprassociated protein <NUMBER> crisprcas<NUMBER> gene editing technology used modify mouse dpp<NUMBER> match human dpp<NUMBER> altering amino acids positions <NUMBER> <NUMBER> interestingly wild type virus infection mice result improved model mers however serial passage merscov resulted merscov<NUMBER> intranasal exposure merscov<NUMBER> <NUMBER> mice led weight loss severe respiratory disease included ardslike signs reduced pulmonary function <NUMBER> merscov infection rabbits also evaluated model mers haagmans et al <NUMBER> demonstrated merscov infected rabbits develop obvious clinical signs infectious virus could detected upper respiratory tract <NUMBER> furthermore epithelial cells bronchioles terminal bronchioles respiratory tract positive merscov immunohistochemistry insitu hybridization reflects tissue tropism human disease <NUMBER> using rabbit model houser et al <NUMBER> demonstrated human monoclonal antibody <NUMBER> given preexposure reduced viral rna lung titer <NUMBER> days postexposure given postexposure <NUMBER> due phylogenetic similarities humans nhp models disease long considered necessary evaluation countermeasures infectious diseases rhesus monkey common marmoset evaluated potential models mers following intratracheal instillation merscov rhesus monkey models lung pathology observed <NUMBER> <NUMBER> <NUMBER> <NUMBER> experiments using rhesus monkeys indicated develop limited systemic disease transient respiratory disease radiologic evaluations indicated inflammatory infiltrates develop shortly exposure analysis lung tissues reverse transcriptasequantitative polymerase chain reaction indicated virus replication lung similar mers african green monkeys agms rhesus monkeys cynomolgus monkeys common marmosets identified potential models sars <NUMBER> smits et al <NUMBER> compared sars cov infection young agms cynomolgus monkeys observed neither species developed clinical signs <NUMBER>day experiment <NUMBER> gross pathology indicated multifocal pulmonary consolidation consolidated greyred firm lungs lesions affected <NUMBER> lungs one subject comparison cynomolgus monkeys developed small patchy macroscopic lesions similar merscov infection nhps viral load decreases exposure day day <NUMBER> comparison agms rhesus monkeys cynomolgus monkeys support agms best available nhp model sars <NUMBER> agms developed highest viral load disease compared cynomolgus rhesus monkeys lethal disease observed species therefore development sars model warranted since lethal respiratory tract disease hallmark sars alternative old world nhps many groups employed marmosets models human infectious disease <NUMBER> <NUMBER> <NUMBER> common marmosets evaluated mers model <NUMBER> <NUMBER> <NUMBER> studies demonstrated common marmosets develop disease following exposure merscov shown histopathological analysis radiological analysis rtqpcr however variable results reported exposure methodology impact disease progression therefore mockinfected groups must included account pathological artifacts virusspecific pathology could quantified using computed tomography future experiments using large group sizes could used countermeasure evaluation greenough et al <NUMBER> performed serial euthanasia study sarscov infected marmosets <NUMBER> subjects intratracheally exposed sarscov observed mild inconsistent clinical signs disease viral loads peaked day <NUMBER> postinfection histopathology indicated interstitial pneumonitis multinucleated syncytia described mild observed late timepoint subjects overall research needed develop animal models sars reflect human disease presentation drugs repurposing potential discussed table <NUMBER> advantage easy access availability decreased cost development provide wide array options combination studies pharmacological knowledge available compounds may also reduce concerns regarding adverse effects patients generation translational database encompassing pharmacodynamics data infectious disease biology data proposed would greatly facilitate decision making pursue new drug combinations <NUMBER> many drugs potential broadspectrum antiviral activity already clinical use treating viral infections novel drugs development move preclinical clinical phase also become available combination therapy care taken pharmacological evaluation combination avoid possible contraindications drugs regards disease adverse effects novel broadspectrum replication inhibitors gs<NUMBER> gilead sciences phase clinical trial immunomodulators nitazoxanide steroids statins along directacting antiviral agents coronaviruses development represent interesting partners combinations combinations involve broadspectrum versus specific antiviral agents drugs different mechanism action drugs target different steps viral life cycle identifying one potent combinations activity animal model would greatly increase preparedness next coronavirus outbreak elucidation crystal structure viral proteins led novel approaches rational drug design rational design investigations using protein structure information silico screening affinity active sites viral proteins holds promise hiv<NUMBER> protease inhibitors one big successes rational drug design <NUMBER> years publication hiv<NUMBER> protease structure saquinavir developed record time bench bedside licensed use aids <NUMBER> <NUMBER> <NUMBER> <NUMBER> total six antivirals hiv<NUMBER> protease designed approved <NUMBER> <NUMBER> similarly hcv computeraided approaches based known crystal structure viral protein successfully guided design synthesis inhibitors hcv ns<NUMBER>ns<NUMBER>a proteases peptidomimetics telaprevir boceprivir <NUMBER> <NUMBER> <NUMBER> due power computational modeling using crystal structures known coronaviruses crystal structures viral proteases pro pl pro sarscov merscov determined relatively quickly <NUMBER> structures already used discovery inhibitors high binding affinity active site proteases structures additional merscov sarscov viral proteins yet determined would offer additional viral targets drug discovery structural design help development inhibitors preparing future outbreaks yet unknown emerging coronaviruses based potential zoonotic transmission coronaviruses bats humans crystal structures main protease pro different bat coronavirus families proposed screening identifying broadspectrum antiviral agents <NUMBER> proofofprinciple shown novel protease inhibitor sg<NUMBER> inhibits bat coronavirus hku<NUMBER> <NUMBER> <NUMBER> sg<NUMBER> quickly identified inhibitor merscov silico docking studies pro merscov bat coronavirus hku<NUMBER> several drugs eg toremifene citrate terconazole fig <NUMBER> belong group compounds termed cationic amphiphilic drugs cads <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> phenothiazines eg fluphenazine chlorpromazine fig <NUMBER> cads shown inhibit hcv entry virushost cell fusion intercalating cholesterolrich domains host cell membrane increasing membrane fluidity <NUMBER> drugs act mechanism may present interesting new class broadspectrum antivirals cads known lysomotropic accumulate acidic compartments tertiary amine groups protonated compounds act mild bases neutralize low ph acidic environment endolysosomes cads intercalate membranes alter biophysical properties membranes thereby could potentially interfere fusion virus endolysosomal membrane concept interfering virus entry budding physicochemical properties drugs intriguing many viruses would susceptible type inhibition cads could used broadspectrum antiviral agents detailed structureactivity relationship studies cads required determine chemical core structures physicochemical properties important type antiviral agent future investigations regarding conservation mechanism action coronaviruses well emerging viruses warranted approved drugs activity merscov sarscov could used lead compounds antiviral drug development pharmaceuticals usually undergone multiple rounds structureactivity relationship studies generating analogs improve drug activity original indication target analogs drugs activity merscov sarscov may still available could screened identify analogs increased antiviral activity although drug analogs would go full licensure process would little added initial cost associated producing structureactivity relationship compounds recycling old analogs one approach may value developing novel drugs viral infections streamlined process needed development effective treatment measures emerging reemerging pathogens availability panel approved broadspectrum drugs would clearly beneficial could used treating disease symptoms reducing morbidity specific acting antivirals vaccines developed large number potential drugs therapeutics treatment mers sars discussed greatest challenge best downselect evaluate different approaches learned drug development aids hepatitis alleviating disease symptoms increasing life span may achievable goal rather looking treatment provide complete recovery broadspectrum antivirals specific antivirals immune modulators important role treating viral infections either individually combination effective communication different institute partners government industry academic national international partners essential combining drug discovery efforts increase chance one potential therapeutic agents advanced development stage time another outbreak emerging coronavirus occurs acknowledgements authors thank laura bollinger jiro wada providing technical writing services graphical support respectively content publication necessarily reflect views policies us department health human services dhhs institutions companies affiliated authors q<NUMBER> two major ebola virus outbreaks africa <NUMBER> zika virus brazil <NUMBER> current severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> declared world health organization pandemic <NUMBER> <NUMBER> occurred past decade case strong sense déjà vu scientists involved drug discovery lack available antivirals treat infected patients leads clamoring test anything available pharmaceutical companies charge offer drugs also seem see similar patterns response across outbreaks rush first sense priority might lead best even outcome patients always immediate proposal create vaccine pronouncements available short time end year actual outbreak question never happens within optimistic artificial deadlines experienced current outbreak ebola vaccine ready second outbreak approved <NUMBER> governments calm populations time needing seen something vanquish virus case sarscov<NUMBER> results pneumonia <NUMBER> shares aspects pathology pathogenesis severe acute respiratory syndrome sars middle east respiratory syndrome mers <NUMBER> sarscov<NUMBER> sarscov merscov belong family coronaviridae genus betacoronavirus several drug companies immediately made antivirals available example abbvie made hiv approved drug lopinavirritonavir combination available chinese government <NUMBER> drug previously suggested promising based combination study results marmoset study <NUMBER> publications already appeared describing use drug patient korea significantly decreasing viral load <NUMBER> simultaneously gilead made available remdesivir previously failed clinical trials ebola <NUMBER> recently shown activity mers rhesus macaques <NUMBER> remdesivir chloroquine several drugs tested vitro sarscov<NUMBER> table <NUMBER> shown active <NUMBER> researchers also suggested early january <NUMBER> treatment options might likely included lopinavirritonavir remdesivir favilavir arbidol well broad array nucleoside analogs neuraminidase inhibitors peptides rna synthesis inhibitors antiinflammatory drugs traditional chinese medicines <NUMBER> <NUMBER> <NUMBER> need treatment options important learn transmission <NUMBER> see increases number travelrelated infections <NUMBER> already past weeks seen rapid spread italy many countries including brazil beyond virus outbreaks greatly straining healthcare systems affected countries test every aspect infrastructure supply chains preparedness <NUMBER> raises question learn past drug discovery efforts attempt develop additional drugs sarscov<NUMBER> efficiently acceleration global sarscov<NUMBER> data generation effectively couple months remarkable however scientific information gaps impede progress toward smallmolecule treatments still perceived many persist first outlined ebola back <NUMBER> <NUMBER> thus make thenandnow comparisons see supplementary material figs s<NUMBER>s<NUMBER> table s<NUMBER> online well share experiences research virus outbreaks efforts ebola drug discovery initially started <NUMBER> computational pharmacophore analysis small number vitro ebola active compounds <NUMBER> followed identifying summarizing fdaapproved drugs could used virus <NUMBER> <NUMBER> highlighting various strategies next virus outbreak <NUMBER> steps preceded pivotal point us developing machine learning models ebola virus derived vitro data <NUMBER> <NUMBER> early drug <NUMBER> identified screens antimalarial amodiaquine subsequently shown associated decreased mortality <NUMBER> drug artesunate amodiaquine used malaria treatment ebola patients whereas others took different malaria medicine artemetherlumefantrine <NUMBER> ebola machine learning models used select three molecules vitro testing <NUMBER> identified pyronaridine tilorone quinacrine good vitro activity nm ebola virus <NUMBER> preliminary data enabled us obtain funding nih take one compounds vivo testing also leveraged nih support collaborator test two compounds well molecules tested mouse model ebola infection demonstrated significant efficacy <NUMBER> <NUMBER> <NUMBER> pyronaridine currently pursued larger animal models ebola virus infection working computational models vitro testing happened space months whereas took several years obtain funding first mouse studies means streamlined approach drug discovery cost effective amount data ultimately generated led revitalized interest molecules <NUMBER> pulled together team researchers brazil usa provide suggestions open drug discovery effort zika virus included various computational strategies repurpose molecules docking zika proteins <NUMBER> also described resources molecules could prioritized testing followed homology modeling every zika virus protein <NUMBER> weeks first crystal structures zika proteins released work performed open attracted attention ibm world community grid team requested submit proposal zika project using distributed computing facilities became openzika project led team brazil usa involved docking millions molecules zinc database zika virus related flavivirus protein crystal structures <NUMBER> since also performed modeling zika proteins <NUMBER> analysis first <NUMBER> years following outbreak <NUMBER> recent efforts led discovery inhibitor ns<NUMBER> helicase <NUMBER> learn openzika project streamline future open science projects would follows would pick fewer targets dock molecules openzika project created billions docking results tens targets take many years process would also suggest best work highresolution crystal structures versus homology models soon possible would also start library commercially available drugs antivirals would massively limit number molecules docked thousand found docking zinc library available time led compounds readily available focused libraries interesting options perform targetdirected virtual screening examples chemdiv <NUMBER> asinex <NUMBER> databases specific subsets protease inhibitors example facilitating accelerating experimental screening openzika learnt multiple biology labs committed testing vitro also important access experimental results quickly validate computational approach working ibm world community grid include funding found difficult obtain nih funding support project beginning computational also attempted small business grants academic collaborators without success even though leveraging massive computational resources world community grid would recommend open efforts like need funding vitro validation millions dollars invested nih fund zika research projects since <NUMBER> outbreak yet small molecule note drug discovery pipeline <NUMBER> still therefore unmet medical need treatments zika virus computational efforts could aid costeffective whole genome sequences sarscov<NUMBER> isolated patients several countries brazil canada china germany korea usa made rapidly available global initiative sharing influenza data gsaid platform <NUMBER> <NUMBER> genomes sampled december <NUMBER> february <NUMBER> samples found closely related mutations relative common ancestor preliminary genetic analysis indicates brazilian genome differs three mutations wuhan reference strain <NUMBER> two mutations shared closest sequencethe germany strain <NUMBER> space weeks acknowledgement latest coronavirus outbreak several laboratories started deposit homology models main viral protease <NUMBER> <NUMBER> sarscov<NUMBER> proteins using server itasser <NUMBER> others performed docking models <NUMBER> developed models understand virus enters cells modeling spike protein human angiotensinconverting enzyme <NUMBER> ace<NUMBER> protein interaction <NUMBER> time writing structures available sarscov<NUMBER> main protease complex inhibitor n<NUMBER> pdb id <NUMBER>lu<NUMBER> <NUMBER> s<NUMBER> s<NUMBER> subunits spike glycoprotein receptorbinding domain <NUMBER>vsb post fusion core subunit <NUMBER>lxt hr<NUMBER> domain <NUMBER>lvn <NUMBER> <NUMBER> useful overview provided searching entire virus sequence protein data bank pdb see supplementary material fig s<NUMBER> online comparison zika took several months beginning outbreak single protein available pdb <NUMBER> spike glycoprotein responsible fusion viral membrane hostcell membrane virus maturation cleaved subunits s<NUMBER> attaches virion cell membrane interacting host receptor s<NUMBER> mediates fusion virion cellular membranes recent study reports sarscov<NUMBER> spike protein binds ace<NUMBER> higher affinity sarscov <NUMBER> one cryoem structure sarscov<NUMBER> spike protein low resolution <NUMBER> å without human ace<NUMBER> protein <NUMBER> time writing paper preferred build model homology modeling see supplementary material methods online using sarscov<NUMBER> spike protein model available sarscov spike protein crystal structure pdb <NUMBER>ajf aligned structures compare residues spikeace<NUMBER> interface residues viruses seen fig <NUMBER> residues sarscov asn<NUMBER> tyr<NUMBER> tyr<NUMBER> tyr<NUMBER> tyr<NUMBER> leu<NUMBER> tyr<NUMBER> asn<NUMBER> sarscov<NUMBER> asn<NUMBER> tyr<NUMBER> tyr<NUMBER> tyr<NUMBER> gln<NUMBER> phe<NUMBER> leu<NUMBER> gln<NUMBER> moreover sarscov<NUMBER> residues gln<NUMBER> phe<NUMBER> leu<NUMBER> gln<NUMBER> conserved physicalchemical features except residues sarscov<NUMBER> gln<NUMBER> polar sars tyr<NUMBER> hydrophobic fig <NUMBER> main protease pro coronaviruses cysteine protease participates viral replication cleaving polyprotein pro organized three domains active homodimer form <NUMBER> aligned crystal structures pro sarscov merscov sarscov<NUMBER> compare structures residues catalytic site catalytic site sarscov sarscov<NUMBER> his<NUMBER>cys<NUMBER> <NUMBER> whereas merscov his<NUMBER>cys<NUMBER> <NUMBER> fig <NUMBER> catalytic site localized interface domain residues <NUMBER> ii <NUMBER> third domain residues <NUMBER> cterminal consists loop region required dimerization <NUMBER> <NUMBER> <NUMBER> <NUMBER> recently reported structures pro sarscov sarscov<NUMBER> high identity <NUMBER> <NUMBER> function structural equivalence pro sarscov merscov sarscov<NUMBER> demonstrate coronavirus proteases promising targets development broadspectrum antivirals viruses drug repurposing offers potentially faster approach identify drugs already approved uses might work disease interest <NUMBER> <NUMBER> <NUMBER> type strategy attempted merscov sarscov <NUMBER> <NUMBER> repurposing hostbased therapies also proposed coronaviruses <NUMBER> several studies screened hundred molecules tested activity merscov sarscov table <NUMBER> <NUMBER> <NUMBER> first screen <NUMBER> fdaapproved drugs identified four fdaapproved drugs including chloroquine chlorpromazine loperamide lopinavir <NUMBER> time second study screened <NUMBER> compounds identified <NUMBER> fdaand nonfdaapproved drugs including chloroquine among many hits <NUMBER> abl<NUMBER> kinase inhibitors imatinib impacts early stages infection internalization endosomal trafficking latter molecule appears work inhibiting fusion viral membrane <NUMBER> chloroquine widely used malaria loperamide used diarrhea represent drugs readily available many locations around world physicians also familiar sideeffect profile ligand datasets screens used apply machine learning methods produce predictive models used screen compound libraries suggest superposition sarscov sarscov<NUMBER> spike proteins highlighting spikeace<NUMBER> interface binding pocket zoom residues sarscov<NUMBER> spike s<NUMBER> asn<NUMBER> tyr<NUMBER> tyr<NUMBER> tyr<NUMBER> gln<NUMBER> phe<NUMBER> leu<NUMBER> gln<NUMBER> correspondent sarscov spike s<NUMBER> asn<NUMBER> tyr<NUMBER> tyr<NUMBER> tyr<NUMBER> tyr<NUMBER> leu<NUMBER> tyr<NUMBER> asn<NUMBER> superposition sarscov merscov sarscov<NUMBER> main proteases respective catalytic biding site sarscov pdb id <NUMBER>q<NUMBER>w sarscov<NUMBER> pdb id <NUMBER>lu<NUMBER> share residues catalytic site his<NUMBER>cys<NUMBER> merscov pdb id <NUMBER>wkl his<NUMBER> cys<NUMBER> situated domains ii fig <NUMBER> experimental details described supplementary material online bayesian models also available httpmodelscollabchemcom<NUMBER> advantage approach method fast require crystal structures enables smallmolecule structures scored many models simultaneously wellestablished principle sarscov<NUMBER> relevant enzyme assay proteinprotein interaction antagonism viral infectivity determination run collection approved drugs however neither trivial get definitive list structures silico prepared docking acquire physical collection ready screening even though various repurposing subsets available vendors notwithstanding approximation definitive approved set alternative screening every approved drug take one class compounds example taken opportunity dock fdaapproved hiv<NUMBER> protease inhibitors amprenavir atazanavir darunavir fosamprenavir indinavir lopinavir nelfinavir ritonavir saquinavir tipranavir hepatitis c ns<NUMBER>a protease inhibitors asunaprevir boceprevir grazoprevir paritaprevir simeprevir telaprevir pro structure sarscov<NUMBER> docking performed two different commercial docking software products biovia discovery studio schrödinger glide <NUMBER> <NUMBER> <NUMBER> <NUMBER> best docking results compared see supplementary material table s<NUMBER> online results docking approaches indicated azatanavir lopinavir could interest vitro vivo testing fig <NUMBER> atazanavir interact pro hbonding cys<NUMBER> amide group aromatic ring atazanavir ligandfit score <NUMBER> also formed hydrophobic interactions residues cys<NUMBER> met<NUMBER> leu<NUMBER> tyr<NUMBER> cys<NUMBER> relation lopinavir ligandfit score <NUMBER> hbonds established residues cys<NUMBER> glu<NUMBER> nitrogen atoms carbamate groups similar hydrophobic interactions observed lopinavir fig <NUMBER> china south korea lopinavir <NUMBER> mg ritonavir <NUMBER> mg already used treatment covid<NUMBER> day lopinavirritonavir administration viral load started decrease detectable little coronavirus titers observed since <NUMBER> lopinavir coformulated ritonavir commercially available known kaletra<NUMBER> around worldit formularies hiv contrast atazanavir less commonly used kaletra<NUMBER> widely produced distributed quickly existing channels important ensure hiv patients lose access medications need also medication clinicians familiar terms side effects unlike less commonly used medications broader analysis fdaapproved drugs docked protease structure could point drugs worth testing also performed docking calculations sarscov<NUMBER> spike glycoprotein complexed host ace<NUMBER> protein fdaapproved drugs <NUMBER> molecules using schrödinger glide software <NUMBER> <NUMBER> <NUMBER> <NUMBER> one cryoem structure sarscov<NUMBER> spike protein low resolution <NUMBER> å without human ace<NUMBER> protein <NUMBER> time analysis preferred build model homology modeling lowerresolution structures <NUMBER> å higher show basic contours protein chain atomic structure must inferred built sarscov<NUMBER> spike subunit s<NUMBER> model using swissmodel server <NUMBER> template used sarscov spike s<NUMBER> protein pdb id <NUMBER>ghv <NUMBER> resolution <NUMBER> å <NUMBER> sequence identity sarscov<NUMBER> spike protein protein refinement added human ace<NUMBER> protein model based sarscov spikeace<NUMBER> structure pdb id <NUMBER>ajf <NUMBER> built full sarscov<NUMBER> spike s<NUMBER>ace<NUMBER> model see fig s<NUMBER> supplementary material online quality statistics intermolecular <NUMBER>d <NUMBER>d interactions atazanavir lopinavir b main protease structure sarscov<NUMBER> pdb id <NUMBER>lu<NUMBER> obtained docking <NUMBER>d representation left hbonds presented magenta dashed lines color code carbon oxygen nitrogen hydrogen atoms grey red blue white respectively <NUMBER>d interaction diagrams right hbonds presented magenta arrows pymol software <NUMBER> used visual inspection <NUMBER>d docking poses render <NUMBER>d molecular images <NUMBER>d <NUMBER>d intermolecular interactions rizatriptan dasabuvir b pravastatin c empagliflozin spikeace<NUMBER> interface light blue green respectively <NUMBER>d representation left hbonds presented magenta dashed lines color code carbon oxygen nitrogen hydrogen atoms grey red blue white respectively sarscov<NUMBER> spike s<NUMBER> subunit colored blue human ace<NUMBER> light blue <NUMBER>d ligandinteraction diagram right hbonds pp stacking pcation interactions presented magenta green red lines respectively glide software <NUMBER> <NUMBER> used dock ligands grid centered asn<NUMBER> tyr<NUMBER> tyr<NUMBER> tyr<NUMBER> gln<NUMBER> phe<NUMBER> leu<NUMBER> gln<NUMBER> residues wwwdrugdiscoverytodaycom <NUMBER> modeled sarscov<NUMBER> spikeace<NUMBER> good <NUMBER> residues lie favorable regions ramachandran plot molprobity score <NUMBER> sarscov<NUMBER> spikeace<NUMBER> model available see supplemental material pdb file online subsequently performed dockingbased virtual screening grid centered spikeace<NUMBER> interface seen table <NUMBER> docking scores indicated rizatriptan antimigraine agent glide score à<NUMBER> kcal mol à<NUMBER> dasabuvir antiviral hepatitis c glide score à<NUMBER> kcal mol à<NUMBER> pravastatin lipidlowering agent glide score à<NUMBER> kcal mol à<NUMBER> empagliflozin hypoglycemic agent glide score à<NUMBER> kcal mol à<NUMBER> could interest vitro testing details intermolecular interactions drugs interface spikeace<NUMBER> shown fig <NUMBER> summary drugs form pcation interactions lys<NUMBER>a pp interactions phe<NUMBER>b hbonds his<NUMBER>a asp<NUMBER>a gly<NUMBER>b ser<NUMBER>b good agreement results previous study suggests early high dose statin pravastatin could crucial surviving merscov infection <NUMBER> suggested molecules could validated future vitro experiments modern drug discovery efforts try eliminate inefficiency increasing knowledge extensive utilization generated data guide new experiments therefore also taken drug repurposing approach based polypharmacology using method called molecular biological signature <NUMBER> profiling approach guided artificial intelligence capable presenting complex relationships chemical substance molecular targets cells andor organs could create complete understanding multibiological profile caused drug analyzed response disease example applied drugs ritonavir <NUMBER> favipiravir ribavirin chloroquine scaffolds find new potential molecular biological signature profiles search nonobvious mechanismofactionbased associations drugs molecular targets diseases fig <NUMBER> supplementary material fig s<NUMBER> table s<NUMBER> online comparing molecular biological signature ritonavir drugs found drugs cobicistat carfilzomib ombitasvir presented highest matching scores <NUMBER> suggesting drugs could interest sarscov<NUMBER> molecular biological signature profiles generated ritonavir compared drugs using artificial intelligence create thousands decisionmakers mimic biological response interaction small molecule multiple enzyme targets offtargets vitro vivo endpoints drugs cobicistat carfilzomib ombitasvir presented higher matching scores <NUMBER> ritonavir although already several drugs assessed clinically sarscov<NUMBER> still need identify additional treatments alternatives offset drug shortages possibly discover molecules increased efficacy safety costeffectiveness previously proposed applied computational drug discovery approaches machine learning docking aid discovery new candidate molecules ebola zika respectively learnt efforts applied sarscov<NUMBER> demonstrated however research case moved much faster pace initially delivering first crystal structure weeks first public notification virus companies mobilized bring drugs patients clinicians used prior vitro research proposed compounds active merscov sarscov suggest treatments sarscov<NUMBER> currently clinically use broadspectrum antivirals usa would invaluable situations like sarscov<NUMBER> viruses identifying medications sideeffect profiles known clinicians already produced scale available local pharmacies around world allow patients treated especially travel restrictions quarantines could reduce production distribution certain drugs remain important need medications baseline hiv patients take ritonavirlopinavir able continue access medications need else risk poor clinical outcomes antiviral resistance patients although viruses flu might killed patients usa season far crippling financial impact sarscov<NUMBER> remains seen globally past ebola zikv merscov sarscov outbreaks anything go sarscov<NUMBER> pandemic far significant multiple effective treatments available sarscov<NUMBER> rapidly delivered patients could save lives also supplement treatments combination computational screening machine learning docking select additional drugs test proposed herein repeated future virus outbreaks sense déjà vu probably repeated next virus outbreaks develop broaderspectrum antivirals time hope better prepared hope however save lives effective antiviral treatments need ready future • covid<NUMBER> global pandemic currently approved cure vaccine <NUMBER> • expedited approval scientists turned repurposing available drugs market <NUMBER> search cure • high volume emerging therapies covid<NUMBER> reported far demonstrating varying <NUMBER> results need compared evaluated effective medical options <NUMBER> • emerging nonconventional drug discovery strategies ai ml show potential <NUMBER> developing alternative drugs treatment prevention covid<NUMBER> <NUMBER> novel coronavirus belongs coronaviridae family order nidovirales divided <NUMBER> four genera viz α β γ δ coronaviridae family covs outer envelope <NUMBER> genetic material consists positive sense rna gorbalenya et al <NUMBER> reported <NUMBER> largest known viruses size <NUMBER> kb bosch et al <NUMBER> international committee coronavirus <NUMBER> sarscov<NUMBER> gorbalenya et al <NUMBER> sarscov<NUMBER> identified <NUMBER> belonging β genus covs family contains least four structural proteins spike envelope <NUMBER> membrane nucleocapsid bosch et al <NUMBER> named disease caused sars <NUMBER> cov<NUMBER> virus covid<NUMBER> spikes viral surface composed homotrimers <NUMBER> protein acts link host receptors furthermore spike glycoproteins two subunits s<NUMBER> <NUMBER> s<NUMBER> mediating attachment membrane fusion respectively s<NUMBER> subunit contains fusion endothelial cells smooth muscle cells various organs bavishi et al <NUMBER> protein priming <NUMBER> serine protease transmembrane protease serine <NUMBER> tmprss<NUMBER> essential sarscov<NUMBER> <NUMBER> infection target cells spreading throughout host <NUMBER> endothelium arguably largest organ body perhaps explains viral <NUMBER> effects spread extrapulmonary organs enters blood circulation given <NUMBER> wide number targets human body pathophysiological approach explains <NUMBER> covid <NUMBER> patients present cardiovascular diverse complications hamming et al <NUMBER> <NUMBER> zhang et al <NUMBER>b exceptionally high proportion aberrant coagulation seen severe <NUMBER> critical patients covid<NUMBER> revealing hypercoagulable state elevated levels ddimer <NUMBER> fibrinogen near normal activated partial thromboplastin time patients progressing <NUMBER> overt disseminated intravascular coagulation dic <NUMBER> recent studies investigating expression viral entryassociated genes using singlecell rna<NUMBER> sequencing data multiple tissues healthy human donors identified transcripts <NUMBER> tissues cells previously analysed including coexpression tmprss<NUMBER> sungnak et al <NUMBER> <NUMBER> importantly sungnak et al <NUMBER> codetected transcripts specific cells <NUMBER> respiratory corneal intestinal epithelium furthermore found genes co<NUMBER> expressed nasal epithelial cells genes involved innate immunity impacts upon initial <NUMBER> viral infection spread clearance work accordance previous studies qi et al <NUMBER> <NUMBER> zou et al <NUMBER> found ace<NUMBER> expressed cells airways cornea <NUMBER> oesophagus ileum colon liver gallbladder heart kidney testis tmprss<NUMBER> highly <NUMBER> expressed broader distribution suggesting ace<NUMBER> may limiting factor viral entry <NUMBER> initial infection stage rather tmprss<NUMBER> sungnak et al <NUMBER> cells respiratory tree manifestations severe covid<NUMBER> lymphopenia disorders central peripheral <NUMBER> nervous system acute cardiac kidney liver injury addition cardiac arrhythmias <NUMBER> rhabdomyolysis coagulopathy shock notably sarscov<NUMBER> viral load reaches peak within <NUMBER> days symptom onset severe <NUMBER> covid<NUMBER> cases progress acute respiratory distress syndrome ards average around <NUMBER> days <NUMBER> symptom onset tay et al <NUMBER> timeline symptoms severe disease described <NUMBER> berlin et al <NUMBER> virus enters cells via ace <NUMBER> internalized described triggers series events <NUMBER> intracellularly leading disease manifestation based targeting key regulatory pathways <NUMBER> cells organs however main target respiratory tree lung tissue therefore <NUMBER> described detail notably characteristic pulmonary ground glass opacification seen <NUMBER> even asymptomatic patients mason <NUMBER> best support mason <NUMBER> <NUMBER> tay et al <NUMBER> describes chronology events upon cell entry describing interaction sars<NUMBER> cov<NUMBER> immune system leading either normal healthy response dysfunctional <NUMBER> immune response ir brief virus enters cell ace<NUMBER> tmprrss<NUMBER> <NUMBER> replicates leading viral release thereafter cell undergoes pyroptosis releases overproduction proinflammatory cytokines resulting cytokine storm damages lung <NUMBER> structure leads multiorgan damage spreads parts body cytokine release <NUMBER> syndrome crs storm characterized multiorgan pathology fever lin et al <NUMBER> <NUMBER> importantly nonneutralizing antibodies may exacerbate organ damage however healthy <NUMBER> immune response initial inflammation attracts following cells site infection debates concern firstly purported upregulation ace<NUMBER> due acei use since mechanism <NUMBER> action ultimately leads decreased ang ii main effector octapeptide raas widely reported host cellular entry involves endocytic pathway nonendosomal <NUMBER> pathway inhibition pathway could strategy inhibit viral entry infection mechanism drug targets could include drugs ability penetrate lysosomes however ivermectin cross brain react gabagated chlorine channels causing <NUMBER> neurotoxicity usually prevented blood brain barrier bbb particularly p cost known safety profile due long usage malaria treatment requires intense <NUMBER> scientific scrutiny covid<NUMBER> use immunemodulating activity cq hypothesized enhance antiviral effect vivo <NUMBER> however toxicity side effects prolonging qt interval trigger tachycardias side effects associated hcq treatment still major cause concern <NUMBER>th april le identification suitable drugs therefore require innovative superior delivery approaches <NUMBER> maximise therapeutic efficacy nanosystems provide increased drug accumulation target <NUMBER> site disease increase intracellular penetration protect drugs degradation increase stability <NUMBER> prevent mechanisms drug resistance fig <NUMBER> addition nanosystems ability innate immune response body viruses initiated cells must ability <NUMBER> identify pathogen trying invade currently several clinical trials directed <NUMBER> develop vaccine based several different strategies sarscov<NUMBER> illustrated table <NUMBER> <NUMBER> approaches include target spike glycoprotein protein major inducer sarscov<NUMBER> replication circle involves cellular entry via fusion endocytosis entry translation occurs virus uses host cells enzyme creates dna followed proteolysis translation back rna packaging viral release occurs circles figure <NUMBER> networkbased methodology combining pharmacologybased network medicine platform quantify interplay virushost interactome drug targets human proteinprotein interactions network human coronavirus hcov associated host protein sourced literature pooled generate protein subnetwork b network proximity drug targets hcovassociated proteins calculated screen candidate repurposability c gene set utilized validate networkbased prediction different drugs encapsulated nanodrug delivery system ability specifically target virus infection sites enzymes specific lungs conditions peculiar covid<NUMBER> ph receptors employed specifically increase drug concentration sarscov<NUMBER> infection sites graphic abstract fipv feline infectious peritonitis coronavirus hcovoc<NUMBER> human coronavirus sarscov<NUMBER> severe acute respiratory syndrome associated coronavirus<NUMBER> new therapeutic options address ongoing covid<NUMBER> pandemic urgently needed one possible strategy repurposing existing drugs approved indications antiviral agents sarscov<NUMBER> due commercial unavailability sarscov<NUMBER> drugs treating covid<NUMBER> screened approximately <NUMBER> existing drugs pharmacologically active compounds inhibitory activities feline infectious peritonitis coronavirus fipv human coronavirus oc<NUMBER> hcovoc<NUMBER> human coronavirus genus betacoronavirus sarscov<NUMBER> fipv proliferated feline fcwf<NUMBER> cells hcovoc<NUMBER> human hct<NUMBER> cells viral proliferation assayed visualization cytopathic effects infected fcwf<NUMBER> cells immunofluorescent assay detection nucleocapsid proteins hcovoc<NUMBER> hct<NUMBER> cells concentrations ec <NUMBER> drug necessary diminish viral activity <NUMBER> untreated controls determined viabilities fcwf<NUMBER> hct<NUMBER> cells measured crystal violet staining mtspms assay respectively fifteen <NUMBER> drugs pharmacologically active compounds screened found active fipv hcovoc<NUMBER> ec <NUMBER> values ranging <NUMBER> nm <NUMBER> µm old drugs follows anisomycin antimycin atovaquone chloroquine conivaptan emetine gemcitabine homoharringtonine niclosamide nitazoxanide oligomycin salinomycin tilorone valinomycin vismodegib old drugs identified activity fipv hcovoc<NUMBER> seen clinical use respective indications associated known dosing schedules adverse effect toxicity profiles humans later confirmed antiviral effect sarscov<NUMBER> considered immediate uses covid<NUMBER> patients covid<NUMBER> disease caused severe acute respiratory syndrome associated coronavirus<NUMBER> sarscov<NUMBER> infected <NUMBER> people killed <NUMBER> <NUMBER> countries since first outbreak wuhan china <NUMBER> reported december <NUMBER> control disease effective treatments including sarscov<NUMBER> inhibitors actively pursued <NUMBER> one potentially efficient approach repurposing drugs previously approved treat diseases since immediately available use clinical trials covid<NUMBER> patients known safety profiles coronavirus cov large genome mutation rate higher rna viruses <NUMBER> <NUMBER> animal covs cause persistent enzootic infections inevitably infect new host species become zoonotic happened sarscov middle east respiratory syndrome coronavirus merscov sarscov<NUMBER> due diversity relentlessness viruses individual mitigation difficult <NUMBER> therefore broadspectrum inhibitors emerging endemic covs needed especially prone periodically cycling humans livestock therefore small molecule inhibitors either old drugs new chemical entities actively pursued developed aiming prevent cure sarscov merscov infections <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> previous work established clinical efficacy pegylated interferonα<NUMBER>a ribavirin lopinavirritonavir treatment merscov <NUMBER> <NUMBER> therefore strategy repurposing existing drugs treat patients infected novel zoonotic cov validated merits consideration contest tackling sarscov<NUMBER> covid<NUMBER> pandemic two representative covs selected existing drugs tested feline infectious peritonitis coronavirus fipv belongs genus alphacoronavirus causes enteritis domestic wild cats approximately <NUMBER> infected cats develop feline infectious peritonitis usually fatal <NUMBER> <NUMBER> pathogenesis epidemiology pulmonary lesions associated fipv similar associated human sars <NUMBER> human coronavirus oc<NUMBER> hcovoc<NUMBER> belongs viral genus betacoronavirus sarscov sarscov<NUMBER> infects humans cattle one viruses responsible common cold <NUMBER> <NUMBER> approximately <NUMBER> old drugs pharmacologically active compounds assessed inhibitory activity fipv <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> found exhibit antifipv activity advanced testing hcovoc<NUMBER> total <NUMBER> exerted inhibitory effect fipv hcovoc<NUMBER> turned old drugs included chloroquine recently demonstrated capable inhibiting sarscov<NUMBER> vitro exhibited efficacy clinical treatment covid<NUMBER> patients <NUMBER> moreover gs<NUMBER> active metabolite remdesivir <NUMBER> <NUMBER> currently investigated clinical trials severe cases covid<NUMBER> <NUMBER> <NUMBER> also exerted potent inhibitory activities fipv hcovoc<NUMBER> herein felis catus whole fetus<NUMBER> fcwf<NUMBER> cells atcc ® crl<NUMBER> maintained dulbeccos modified eagles medium dmem hyclone laboratories logan ut usa containing <NUMBER> fetal bovine serum fbs <NUMBER> penicillinstreptomycin <NUMBER> c <NUMBER> co <NUMBER> serotype ⅱ fipv taiwan isolate ntu<NUMBER> strain kind gift national taiwan university propagated titrated fcwf<NUMBER> cells <NUMBER> confluent fcwf<NUMBER> cells seeded <NUMBER>well plates treated various concentrations testing compounds <NUMBER> µm <NUMBER>°c atmosphere <NUMBER> co <NUMBER> <NUMBER> h sixteen h post inoculation cells infected fipv ntu<NUMBER> strain <NUMBER> tcid <NUMBER> per well incubated <NUMBER> c <NUMBER> h supernatant discarded series <NUMBER> concentrations different dilution testing compounds dmem containing <NUMBER> fbs added plates incubated <NUMBER> c atmosphere <NUMBER> co <NUMBER> additional <NUMBER> h cells fixed <NUMBER> formalin stained <NUMBER> crystal violet cytopathic effect cpe virus assumed correlate intensity crystal violet staining measured visually determination <NUMBER> effective concentrations ec <NUMBER> cell cytotoxicity also measured crystal violet staining <NUMBER> cytotoxicity concentration cc <NUMBER> calculated according reed muench method <NUMBER> hct<NUMBER> colon epithelial cells atcc ® ccl<NUMBER>™ grown monolayers growth medium consisting dmem <NUMBER> fbs biological industries cromwell ct usa hcovoc<NUMBER> atcc ® vr<NUMBER>™ grown propagated hct<NUMBER> ells cultured dmem <NUMBER> fbs ec <NUMBER> measured using indirect immunofluorescent assay ifa hct<NUMBER> cells deposited <NUMBER>well plates pretreated solutions compounds tested <NUMBER> minutes infected hcovoc<NUMBER> multiplicity infection moi <NUMBER> incubated <NUMBER> drugs collected screened inhibitory activity fipv activity ascertained visual observation cytopathic effects <NUMBER> <NUMBER> also tested inhibition hcovoc<NUMBER> ifa hcovoc<NUMBER> nucleocapsid protein table <NUMBER> fifteen old drugs exhibited inhibitory activity hcovoc<NUMBER> exhibited ec <NUMBER> values ranging <NUMBER> nm <NUMBER> µm fipv <NUMBER> nm <NUMBER> µm hcovoc<NUMBER> table <NUMBER> representative results cytopathy fipv ifa assays hcovoc<NUMBER> depicted figures <NUMBER> <NUMBER> <NUMBER> showed vitro activity sarscov <NUMBER> atovaquone hydroxy<NUMBER>naphthoquinone antipneumocystic activity <NUMBER> exhibited ec <NUMBER> values <NUMBER> µm fipv <NUMBER> µm hcovoc<NUMBER> conivaptan nonpeptide inhibitor receptor vasopressin originally approved hyponatremia <NUMBER> exhibited ec <NUMBER> values <NUMBER> µm fipv <NUMBER> µm hcovoc<NUMBER> atovaquone predicted inhibit sarscov<NUMBER> targeting viral rnadependent rna polymerase <NUMBER>c like protease <NUMBER> chloroquine intensively studied clinical treating covid<NUMBER> preclinical efficacies sarscov<NUMBER> vitro vivo <NUMBER> ec <NUMBER> values fipv <NUMBER> µm hcovoc<NUMBER> <NUMBER> µm higher compounds mentioned nonetheless identified ec <NUMBER> <NUMBER> µm comparable better clinically used effective dosages chloroquine <NUMBER> <NUMBER> mg qd bid <NUMBER> <NUMBER> <NUMBER> addition also tested nucleotide analogue gs<NUMBER> active metabolite remdesivir <NUMBER> <NUMBER> exhibited ec <NUMBER> <NUMBER> µm fipv compared ec <NUMBER> <NUMBER> µm hcovoc<NUMBER> gs<NUMBER> reported exhibit good vivo efficacy fipv cats <NUMBER> sarscov vitro <NUMBER> fda approved drug yet remdesivir gs<NUMBER> prodrug gs<NUMBER> also shown efficacy treatment covid<NUMBER> patients <NUMBER> <NUMBER> moreover identified ec <NUMBER> <NUMBER> <NUMBER> µm gs<NUMBER> also equivalent better clinically used effective dosages remdesivir <NUMBER> mg <NUMBER> <NUMBER> thus concentrations tested particular study clinical significance drugs already repurposed context covid<NUMBER> include ivermectin type avermectin used treat many types parasite infestations <NUMBER> combination hydroxychloroquine antibiotic azithromycin <NUMBER> therefore abovementioned drugs therefore proposed potential treatments covid<NUMBER>in conclusion several existing drugs identified good inhibitory activities fipv hcovoc<NUMBER> doses currently used respective disease indications authors declare conflict interest twentyfirst century experienced emergence epidemic three previously unidentified coronaviruses severe acute respiratory syndrome coronavirus sarscov <NUMBER> middle east respiratory syndrome coronavirus merscov <NUMBER> <NUMBER> novel coronavirus <NUMBER>ncov later officially named sarscov<NUMBER> late december <NUMBER> belong coronaviridae family viruses possess positivesense singlestranded rna genome similar rna viruses family characterized significant genetic variability high recombination rate enable easily distributed among humans animals worldwide result numerous coronaviruses exist within human animal populations without causing lifethreatening diseases however occasionally genetic recombination viruses within random intermediate hosts produces contagious strains highly pathogenic humans whereas sarscov<NUMBER> genetically structurally related sarscov becoming increasingly clear unique features contributed rapid spread around globe since currently effective treatment available coronavirus infections significant efforts made development vaccines therapeutic drugs preclinical evidence proven potential several countermeasures yet large scale trials still needed review current understanding sarscov<NUMBER> epidemiological clinical features well unique contagious characteristics different sarscov merscov providing essential information adjusting responses sarscov<NUMBER> pandemic also summarize stateoftheart innovations targeting sarscov<NUMBER> biological pathological point view april <NUMBER> <NUMBER> total <NUMBER> cases covid<NUMBER> occurring least <NUMBER> countries territories reported approximately <NUMBER> fatality rate <NUMBER> prior overview china included <NUMBER> confirmed suspected asymptomatic patients revealed several important epidemiological features covid<NUMBER> general majority confirmed cases aged <NUMBER> yearsold <NUMBER> <NUMBER> among <NUMBER> deaths majority among patients ≥<NUMBER> years age ≥<NUMBER> age group characterized highest fatality rate <NUMBER> among age groups ref <NUMBER> relatively fewer cases reported among young children <NUMBER> yearsold ref <NUMBER> males affected disease maletofemale ratio varies focusing different population scales <NUMBER> china overall <NUMBER> hubei province <NUMBER> wuhan city fortunately affected patients covid<NUMBER> pneumonia presentation mild moreover pathogen extraordinarily contagious deaths occurred mild even severe cases expected fatality rate reached <NUMBER> among patients classified critical cases usual symptoms covid<NUMBER> include fever <NUMBER> cough <NUMBER> shortness breath <NUMBER> muscle ache <NUMBER> similar sars mers ref <NUMBER> patients may sore throat rhinorrhea headache confusion days onset fever indicating fever critical symptom initial manifestation infection ref <NUMBER> pattern fever yet fully understood small proportion patients hemoptysis <NUMBER> <NUMBER> number cases found relatively asymptomatic ref <NUMBER> covid<NUMBER> patients may normal lower white blood cell counts lymphopenia thrombocytopenia increased creactive protein level ref <NUMBER> <NUMBER> <NUMBER> people fever upper respiratory tract symptoms leukopenia lymphopenia suspected disease especially patients travel history endemic area close exposure record however clinical course covid<NUMBER> pneumonia exhibits broad spectrum severity progression patterns patients dyspnea develops within median <NUMBER> days onset illness range <NUMBER> days others respiratory distress may absent ref <NUMBER> around <NUMBER> patients may need admission intensive care unit severely ill patients may poor disease course rapid progression multiple organ dysfunction even death <NUMBER> <NUMBER> shortness breath hypoxemia quickly progress acute respiratory distress syndrome ards severe sepsis shock even multiple organ dysfunction within one week ref <NUMBER> <NUMBER> ards observed develop <NUMBER> hospitalized patients approximately <NUMBER> days symptoms onset global mortality rate reached approximately <NUMBER> <NUMBER> also worth noting gastrointestinal symptoms covid<NUMBER> may caused direct viral damage intestine rather immunopathogenic response lung infection host since angiotensinconverting enzyme <NUMBER> ace<NUMBER> main cellular receptor sarscov<NUMBER> expressed human gastrointestinal epithelial cells believed viral shedding gastrointestinal tract fecaloral transmission highly plausible ref <NUMBER> indeed reported rectal swabs showed positive results even nasopharyngeal tests constitutively negative <NUMBER> besides live virus also detected stool samples diseased patients evidence strongly indicate stool contagious long time discharge patients based two negative nasopharyngeal swabs thus adding rectal swabs discharge criteria considered prevention nosocomial community spread covid<NUMBER> aside gastrointestinal symptoms retrospective study <NUMBER> patients china reported <NUMBER> patients experienced hypogeusia <NUMBER> experienced hyposmia <NUMBER> though loss olfaction sarscov<NUMBER> infection could explained swelling nasal mucosa larger population patients included determine whether hypogeusia hyposmia could common neurological manifestation covid<NUMBER> nevertheless hyposmia hypogeusia recommended early warning signs indication early selfisolation radiological examinations including chest x ray cxr chest computed tomography ct scan important early detection treatment covid<NUMBER> <NUMBER> imaging findings covid<NUMBER> pneumonia mimic influenza sarscov merscov pneumonia <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> primary wuhan study revealed upon diagnosis <NUMBER> <NUMBER> patients showed bilateral pneumonia remaining <NUMBER> <NUMBER> patients showed unilateral pneumonia ref <NUMBER> addition <NUMBER> <NUMBER> patients showed multiple mottling groundglass opacities <NUMBER> subsequent study reported predominant pattern abnormality observed peripheral <NUMBER> <NUMBER> illdefined <NUMBER> <NUMBER> mainly involved right lower lobes <NUMBER> <NUMBER> <NUMBER> affected segments <NUMBER> bilateral multiple consolidation usually occurs severe cases <NUMBER> chest ct efficient detecting pneumonia early stages covid<NUMBER> however imaging findings covid<NUMBER> pneumonia chest ct variable nonspecific <NUMBER> <NUMBER> <NUMBER> common patterns covid<NUMBER> chest ct scans include multiple ggo lesions <NUMBER> bilateral patchy shadowing <NUMBER> patterns consist local patchy shadowing <NUMBER> interstitial abnormalities <NUMBER> severe cases tend yield prominent radiologic findings chest ct scan bilateral patchy shadowing <NUMBER> multiple ggo lesions <NUMBER> local patchy shadowing <NUMBER> nonsevere cases cxr chest ct abnormality identified <NUMBER> nonsevere cases <NUMBER> severe cases <NUMBER> <NUMBER> <NUMBER> pure ggo lesions found early stages focal multifocal ggo lesions may progress consolidation ggo lesions superimposed interlobularintralobular septal thickening crazypaving pattern disease progression expansion consolidation represented disease progression <NUMBER> <NUMBER> <NUMBER> pure consolidative lesions relatively less common pulmonary cavitary lesion pleural effusion lymphadenopathy rarely reported <NUMBER> <NUMBER> <NUMBER> <NUMBER> however interestingly also reported asymptomatic patients could show early ct changes <NUMBER> conversely mentioned earlier another study shown positive rtpcr results sarscov<NUMBER> absence ct changes <NUMBER> despite limited number cases available thorough radiographic study observe trend varied presentations covid<NUMBER> pneumonia asymptomatic patients showing positive ct findings undoubtedly pose challenges current diagnostic protocol especially patients falsenegative rtpcr results moreover different radiographic patterns seen covid<NUMBER> progresses typically first second week onset lesions progress bilateral diffused pattern consolidations contrast groundglass opacification consolidation present relatively early sars <NUMBER> could indicative significant difference diagnostic sensitivity two diseases especially early asymptomatic stage conclusion correlating imaging features clinical laboratory findings assess patients may essential facilitate early diagnosis covid<NUMBER> pneumonia figure <NUMBER> whereas several human coronaviruses cause mild respiratory diseases hcov<NUMBER>e hcovoc<NUMBER> hcovnl<NUMBER> hcovhku<NUMBER> estimated circulate human population centuries sarscov merscov sarscov<NUMBER> zoonotically transferred mammalian species last <NUMBER> years <NUMBER> <NUMBER> <NUMBER> <NUMBER> horseshoe bats natural reservoirs novel coronaviruses intermediate hosts transmitted virus human identified masked palm civet sarscov dromedary camel merscov table <NUMBER> recent metagenomics study detected similar coronaviruses sarscov<NUMBER> malayan pangolin manis javanica one species presumably smuggled huanan wet market wuhan <NUMBER> diverse focal faint patchy groundglass opacities bilateral illdefined air space consolidations plain chest radiograph nonspecific distinguish three different diseases <NUMBER> <NUMBER> <NUMBER> <NUMBER> asymptomatic mild disease acute upper respiratory distress multiorgan failure leading death varies individuals <NUMBER> vomiting diarrhea also reported difference transmission patterns sarscov merscov sarscov<NUMBER> also indicative specific intrinsic characteristics sarscov<NUMBER> <NUMBER> case sarscov merscov substantial virus shedding happens onset symptoms therefore transmission mainly occurs nosocomial manner namely infected patients sought medical help <NUMBER> however humantohuman transmission sarscov<NUMBER> occurs predominantly communities family members might indicate pathogen could spread far onset symptoms recent study suggested halflives sarscov<NUMBER> sarscov similar aerosols median infectious period estimated around <NUMBER> <NUMBER> hour <NUMBER> therefore echo sarscov possibility airborne fecaloral transmission sarscov<NUMBER> cannot ruled however evidence still needed addition preexisting factors contribute blind spot disease control previous studies found active surveillance two individuals close contact history confirmed cases showed positive results rtpcr another report revealed patients proven recover covid<NUMBER> two consecutive rtpcr tests turned show positive results days later patients continued asymptomatic people within close contact infected still considered infectious viral carriers <NUMBER> conclusion evidence exists infected cases contagious onset treatment covid<NUMBER> pneumonia thus current criteria hospital discharge discontinuation quarantine may reevaluated order achieve intact protocol adequate disease control table <NUMBER> compares different features sarscov merscov sarscov<NUMBER> sarscov merscov sarscov<NUMBER> belong coronaviridae family family viruses contains relatively large singlestranded positivesense rna genome around <NUMBER> kb ref <NUMBER> genomes typically composed <NUMBER> methylguanosine cap beginning <NUMBER> polya tail end total <NUMBER> genes <NUMBER> order genes usually highly conserved first one replicationand transcriptionrelated rest structural replicationand transcriptionrelated gene translated two large nonstructural polyproteins two open reading frames ref <NUMBER> two different yet overlapping open reading frames translated ribosomal frameshifting hand structural proteins including spike envelope e membrane constitute viral coat nucleocapsid n protein packages viral genome translated subgenomic rnas proteins undergo glycosylation golgi apparatus form glycoproteins among structural proteins important potential therapeutic target spike glycoprotein responsible binding virus host cells protein primed host cell protease recognized cellular receptor ref <NUMBER> human serine protease tmprss<NUMBER> responsible priming protein sarscov sarscov<NUMBER> angiotensinconverting enzyme <NUMBER> ace<NUMBER> engaged receptor entry two viruses merscov binds specifically another receptor dipeptidyl peptidase <NUMBER> dpp<NUMBER> <NUMBER> worth noting ace<NUMBER> expression level also allele frequency varies among populations several ace<NUMBER> variants identified correlation disease susceptibility sequence polymorphism hypothesized however previous study confirmed cases found heterogeneity among residues implicated viral protein binding indicating sarscov<NUMBER> may associate highlyconserved site human genome indistinguishable susceptibility individuals another reason rapid spread sarscov<NUMBER> across continents different human populations <NUMBER> characteristics cellular receptor ace<NUMBER> also explain pathogenesis features sarscov sarscov<NUMBER> reported binding viral protein ace<NUMBER> induces negative feedback loop ultimately results downregulation ace<NUMBER> decrease ace<NUMBER> subsequently directs substrate angiotensin towards related enzyme ace increased ace activity consequently results elevated levels angiotensin ii angiotensin ii binds receptor agtr<NUMBER>a pulmonary vascular permeability increased <NUMBER> recommended centers disease control prevention health care professionals obtain specimens upper respiratory tract either nasopharyngeal oropharyngeal lower respiratory tract either endotracheal tube bronchoalveolar lavage diagnosis covid<NUMBER> pneumonia primarily based rtpcr analysis specimens rtpcr unavailable serology test may also considered currently us food drug administration fda approved sarscov<NUMBER> commercial test system roche cobas ® sarscov<NUMBER> qualitative test requires samples nasopharyngeal oropharyngeal swabs takes <NUMBER> h yield results based rtpcr methodology cobas sarscov<NUMBER> test dual target assay detecting specific sarscov<NUMBER> rna well highly conserved fragment e gene invariant members sarbecovirus subgenus assay fullprocess negative control positive control internal control ensure specificity accuracy <NUMBER> march <NUMBER> fda granted another emergency use authorization xpert ® xpress sarscov<NUMBER> cepheid inc usa also qualitative test claimed yield results within <NUMBER> min utilize samples nasopharyngeal swabs nasal wash aspirate specimens highlights handsoff automated sample processing results viewed positive one targeted gene present detected current screening methods rely presence abundant viral genome site sample collection studies demonstrated levels igm antibodies high symptomatic subclinical patients <NUMBER> days onset illness thus proposed igm elisa assay combined pcr enhance detection sensitivity <NUMBER> currently specific treatment covid<NUMBER> pneumonia clinical management emphasizes importance supportive care prevention complications nosocomial transmission patients experience respiratory distress oxygen given immediately however sign tissue hypoperfusion fluid resuscitation relatively conservative may result lung edema worsen oxygen status concept particularly important treatment severe acute respiratory infections <NUMBER> could shorten duration ventilation systemic corticosteroids recommended either considering potential delay viral clearance nevertheless exceptions could made corticosteroids indicated reasons standard precautions including respiratory eye protection recommended healthcare professionals caring patients known suspected covid<NUMBER> pneumonia removal droplet precautions considered two consecutive rtpcr obtained least <NUMBER> h apart clinically recovered patient show negative results however based previous discussion even two sets negative tests still possibilities patients become viral carriers later thereby suggest decision remove precautions based laboratory radiological clinical evidence also professional assessment clinicians specialized healthcare personnel currently sufficient evidence existing antiviral drugs efficiently treat covid<NUMBER> pneumonia however several clinical trials potential antiviral therapies taking place therapies divided two categories depending target one acting coronavirus directly either inhibiting crucial viral enzyme responsible genome replication blocking viral entry human cells designed modulate human immune system either boosting innate response particularly important role viruses inhibiting inflammatory processes cause lung injury drugs originally designed pathogens promptly repurposed current covid<NUMBER> trials time several trials initiated test specific vaccines antibodies specifically targeting sarscov<NUMBER> summarize ongoing therapeutic options may lead us combating novel pathogen figure <NUMBER> remdesivir gs<NUMBER> far promising drug exhibits broadspectrum antiviral activities rna viruses prodrug whose structure resembles adenosine ref <NUMBER> therefore incorporate nascent viral rna inhibit rnadependent rna polymerase results premature termination viral rna chain consequently halts replication viral genome remdesivir originally developed gilead sciences usa ebola virus undergone clinical trial recent ebola outbreak democratic republic congo <NUMBER> although shown effective ebola trial proved safety humans allowed enter clinical trials immediately conditions covid<NUMBER> emergency <NUMBER> importantly previously shown exhibit antiviral activities different coronaviruses including sarscov merscov vitro vivo <NUMBER> <NUMBER> recent vitro study remdesivir also shown inhibit sarscov<NUMBER> <NUMBER> reported case report first covid<NUMBER> patient usa remdesivir used <NUMBER>th day hospitalization without noticeable adverse effect patients condition improved <NUMBER>th day <NUMBER> remdesivir tested multiple trials different countries including two randomized phase iii trials china nct<NUMBER> nct<NUMBER> expected completed aprilmay <NUMBER> similar remdesivir favipiravir developed toyama chemical division fujifilm japan functions inhibitor rnadependent rna polymerase structurally resembling endogenous guanine <NUMBER> competitive inhibition efficacy viral replication hugely reduced although approved treatment influenza less preclinical support established favipiravir treat sarscov<NUMBER> compared remdesivir nevertheless patients recruited evaluate efficacy favipiravir plus interferonα chictr<NUMBER> based expected synergistic effect viral inhibition immune enhancement indeed march <NUMBER> favipiravir approved national medical products administration china first anticovid<NUMBER> drug china clinical trial demonstrated efficacy minimal side effects ivermectin fdaapproved antiparasitic agent also proven exert antiviral activities toward human immunodeficiency virus hiv dengue virus <NUMBER> dissociate preformed impαβ<NUMBER> heterodimer responsible nuclear transport viral protein cargos <NUMBER> nuclear transport viral proteins essential replication cycle inhibition hosts antiviral response targeting nuclear transport process may viable therapeutic approach toward rna viruses <NUMBER> <NUMBER> recently vivo study proven ivermectins capability reduce viral rna <NUMBER>fold <NUMBER> h infection sarscov<NUMBER> <NUMBER> established safety profile antiparasitic use next step prove ivermectins efficacy treating covid<NUMBER> involves trials figure adequate dosing aspartyl protease enzyme encoded pol gene human immunodeficiency virus hiv cleaves precursor polypeptides hiv thus playing essential role replication cycle hiv protease inhibitors lopinavir ritonavir therefore used combination hiv therapeutic drugs although coronaviruses encode different enzymatic class protease cysteine protease theoretical evidence exists lopinavir ritonavir also inhibit coronaviral <NUMBER>cl<NUMBER> pro protease <NUMBER> <NUMBER> <NUMBER> <NUMBER> importantly number clinical animal vitro model studies performed sars mers proved effective respective viruses <NUMBER> <NUMBER> <NUMBER> <NUMBER> lopinavirritonavir combination engaged clinical trial covid<NUMBER> patients mild moderate covid<NUMBER> nct<NUMBER> however showed little benefit improving clinical outcome <NUMBER> another trial performed patients severe covid<NUMBER> chictr<NUMBER> benefits lopinavirritonavir beyond standard care observed <NUMBER> soluble recombinant human angiotensinconverting enzyme <NUMBER> rhace<NUMBER> expected block entry sarscov<NUMBER> blocking protein interacting cellular ace<NUMBER> indeed recent study reported rhace<NUMBER> could inhibit sarscov<NUMBER> replication cellular embryonic stem cellderived organoids factor <NUMBER> times <NUMBER> believed administration recombinant human angiotensinconverting enzyme <NUMBER> rhace<NUMBER> decrease serum level angiotensin ii directing substrate away related enzyme ace like mentioned earlier could prevent activation ace<NUMBER> receptor thereby preserve pulmonary vascular integrity prevent ards <NUMBER> apn<NUMBER> originally developed apeiron biologics already undergone phase ii trial ards small pilot study china nct<NUMBER> evaluating biological physiological role rhace<NUMBER> covid<NUMBER> pneumonia especially treatment ards later apeiron biologics initiated placebo controlled double blinded doseescalation study access safety tolerability intravenous apn<NUMBER> believed measuring plasma level angiotensin ii angiotensin <NUMBER> bioproducts interfered potential drug biological physiological role rhace<NUMBER> covid<NUMBER> pneumonia could evaluated wellknown antimalarial antiautoimmune agent hydroxychloroquine also block virus infection increasing endosomal ph required membrane fusion virus host cell <NUMBER> moreover shown specifically inhibit replication sarscov interfering glycosylation cellular receptor ace<NUMBER> <NUMBER> recently vitro testing revealed ability effectively reduce viral copy number sarscov<NUMBER> <NUMBER> therefore number clinical trials quickly conducted china demonstrated hydroxychloroquine various degree effective treatment covid<NUMBER>associated pneumonia similarly small openlabel nonrandomized clinical trial france hydroxychloroquine demonstrated positive effect combination azithromycin <NUMBER> wake evidence us fda issued emergency use authorization use hydroxychloroquine treat covid<NUMBER> usa noteworthy latest study found evidence clinical benefit combination hydroxychloroquine azithromycin treatment <NUMBER> patients severe covid<NUMBER> <NUMBER> thus larger randomized controlled trials needed evaluation approved russia china arbidol entry inhibitor influenza viruses arboviruses <NUMBER> targeting hemagglutinin ha major glycoprotein surface influenza virus arbidol prevents fusion viral membrane endosome endocytosis currently undergoing trials single agent nct<NUMBER> nct<NUMBER> randomized clinical trial aimed comparing arbidol favipiravir chictr<NUMBER> latter demonstrated far superior treatment outcome <NUMBER> highest mortality rate inflicted covid<NUMBER> observed among elderly patients may explained weakening immune system age therefore approaches aimed boosting innate antiviral immune responses great potential natural killer nk cells constitute important component innate immune system ensures rapid response viral infection previous study shown pulmonary migration nk cells macrophages plays significant role clearance sarscov <NUMBER> innate response without assistance cd<NUMBER> cells antibodies able control sarscov infection increasing production cytokines chemokines whether addition nk cells could help reach viral clearance covid<NUMBER> pneumonia phase trial nct<NUMBER> china estimated completed end <NUMBER> several companies aim repurpose anticancer nkbased products treat covid<NUMBER> among jointly developed product green cross labcell south korea kleo pharmaceuticals us usabased company celularity developed placenta haematopoetic stem cellderived nk cells cynk<NUMBER> type interferons secreted virusinfected cells used alone combination drugs exert broadspectrum antiviral effect hcv respiratory syncytial virus sarscov <NUMBER> merscov <NUMBER> trials focusing safety efficacy treating covid<NUMBER> pneumonia nct<NUMBER> mesenchymal stem cells mscs proven exert antiinflammatory function decreasing proinflammatory cytokines producing paracrine factors repair tissues preclinical evidence also shown mscs able restore endothelial permeability also reduce inflammatory infiltrate <NUMBER> immunomodulating effects mscs proven avian influenza viruses <NUMBER> role covid<NUMBER> pneumonia still evaluation present mscs umbilical cord dental pulp tested nct<NUMBER> nct<NUMBER> nct<NUMBER> nct<NUMBER> intravenous immunoglobulin ivig widely applied field neurology dermatology rheumatology dosedependent manner ivig exerts diverse effects immune system generally low doses <NUMBER>gkg ivig used replacement therapy antibody deficiencies higher doses <NUMBER>gkg ivig exhibits immunomodulatory functions suppressing inflammatory cells proliferation inhibiting phagocytosis interfering antibodydependent cytotoxicity <NUMBER> current trials focus supplementary effects low dose ivig <NUMBER>gkg <NUMBER> days nct<NUMBER> humoral immune response mediated antibodies crucial preventing viral infections therefore development specific surface epitopetargeting neutralizing antibodies longterm albeit specific approach target covid<NUMBER> <NUMBER> abcellera canada eli lilly company usa codeveloping functional antibody could neutralize sarscov<NUMBER> infected patients purpose screened <NUMBER> million immune cells one first us patients recovered covid<NUMBER> identified <NUMBER> potential antisarscov<NUMBER> antibody sequences currently undergoing screening find effective ones whereas approach timeconsuming effortdemanding encouraging successfully applied manufacture specific functional antibodies west nile virus <NUMBER> vir biotechnology inc immunoprecise mount sinai health system harbour biomed hbm also screening find monoclonal antibodies tackle sarscov<NUMBER> although still preclinical stages eligible candidates expected exert prophylactic therapeutic effects complement activation demonstrated acute lung injury c<NUMBER>a bioactive molecule cleaved c<NUMBER> responsible full development tissue injury role c<NUMBER>a includes recruitment neutrophils tlymphocytes increasing pulmonary vascular permeability <NUMBER> also proved antic<NUMBER>a treatment could reduce lung injury decreasing vascular leakage neutrophil influx alveolar space hence bdb<NUMBER> launched beijing defengrei biotechnology co ifx<NUMBER> produced beijing staidson biopharma inflarx antic<NUMBER>a monoclonal antibodies targeting foundation inflammatory response expected attenuate level lung injury caused sarscov<NUMBER> interleukin il<NUMBER> tnfα il<NUMBER> important proinflammatory cytokines human body specifically il<NUMBER> predictive factor poor prognosis patients ards <NUMBER> recently also reported elevated interleukin<NUMBER> il<NUMBER> strongly associated need mechanical ventilation <NUMBER> classical pathway il<NUMBER> signaling occurs il<NUMBER> receptors expressed neutrophils monocytes macrophages leukocyte populations <NUMBER> besides binding membranebound il<NUMBER> receptor mil<NUMBER>r cd<NUMBER> il<NUMBER> also bind soluble form il<NUMBER> receptor created proteolytic cleavage mil<NUMBER>r alternative splicing mrna elevated level circulating il<NUMBER> associated faster decline lung elasticity severe bronchoalveolar inflammation hence specific blockade il<NUMBER>regulated signaling pathways represents promising approach attenuate inflammationassociated damage <NUMBER> moreover reported tuberculosis model mice il<NUMBER> blockade lead increase bacterial burden lung contrary neutralizing tnfα antibodies resulted significant increase mycobacterial colony units eusa pharma initiated study evaluate effectiveness siltuximab monocloncal antibody il<NUMBER> treating covid<NUMBER> patients ards hand tiziana life sciences developing antiinterleukin<NUMBER> receptor antibody tzls<NUMBER> treat disease another perspective company believes administrating antiil<NUMBER> antibody could result inhibition downstream signaling either membrane bound soluble il<NUMBER> receptors reduction circulating il<NUMBER> levels regeneron pharmaceuticals sanofi also conducting phase ii phase iii trial kevzara sarilumab il<NUMBER> receptor antagonist severe critical covid<NUMBER> patients nct<NUMBER> though kevzara proven efficacy treating arthritis <NUMBER> efficacy treating sarscov<NUMBER> still unknown recently thalidomide reemerged antiangiogenic antiinflammatory antifibrotic agent decreasing synthesis tnfalpha thalidomide used treatment multiple inflammatory diseases crohns disease behcets disease <NUMBER> addition preclinical studies proved thalidomide effective treating h<NUMBER>n<NUMBER>infected mice reducing infiltration inflammatory cells production proinflammatory cytokines <NUMBER> current studies focusing immunomodulatory effects could lessen lung injury caused excessive immune response sarscov<NUMBER> nct<NUMBER> nct<NUMBER> mentioned earlier systemic glucocorticoids currently contraindicated sarscov<NUMBER> infection may prolong viral clearance however also known underlying pathogenesis covid<NUMBER> pneumonia composed direct damage caused virus excessive immune response host thus whether methylprednisolone administration would help suppress unwanted immune reactions controversial therefore studies initiated explore effectiveness safety nct<NUMBER> nct<NUMBER> fingolimod oral immunomodulating agent primarily used treat refractory multiple sclerosis structurally resembling lipid sphingosine<NUMBER>phosphate s<NUMBER>p fingolimod act highly potent functional antagonist s<NUMBER>p<NUMBER> receptors lymph node cells effective binding s<NUMBER>p<NUMBER> receptors internalized lymph node cells subsequently sequestered <NUMBER> decreased pulmonary influx lymphocytes another approach attenuate uncontrolled immunopathogenesis nct<NUMBER> bevacizumab elevated vascular endothelial growth factor vegf level observed patients acute respiratory distress syndrome vegf functions mediator induce endothelial injury increase microvascular permeability <NUMBER> bevacizumab recombinant humanized monoclonal antibody widely used treating multiple types cancers capable blocking angiogenesis specific binding vegf ongoing trial evaluating effectiveness bevacizumab unique approach treat sarscov<NUMBER> infection nct<NUMBER> development vaccine represents longterm strategy prevent covid<NUMBER> outbreaks future sequencing sarscov<NUMBER> genome multiple nucleic acidbased vaccine candidates proposed mostly based proteincoding sequence early january <NUMBER> soon outbreak covid<NUMBER> pneumonia genome sarscov<NUMBER> sequenced modernas mrna<NUMBER> synthetic strand mrna encodes prefusionstabilized viral spike protein intramuscular injection human bodies expected elicit antiviral response specifically toward spike protein sarscov<NUMBER> besides unlike conventional vaccines either made inactivated pathogen small subunits live pathogen synthesis lipid nanoparticleencapsulated mrna vaccine require virus therefore relatively safe ready tested mrna<NUMBER> proves safe humans pass phase trial successive evaluation efficacy carried immediately nct<NUMBER> ino<NUMBER> dna vaccine candidate created inovio pharmaceuticals like modernas mrna<NUMBER> ino<NUMBER> also genetic vaccine delivered human cells translated proteins elicit immune responses compared conventional vaccines genetic vaccines require lower costs production easier way purification simple structure nucleic acids also obviates risk incorrect folding could occur recombinant proteinbased vaccines <NUMBER> <NUMBER> however amount plasmid delivered adequate interval route administration factors may influence immunogenicity genetic vaccines vaccine created university oxford composed nonreplicating adenovirus vector genetic sequence protein sarscov<NUMBER> entered phase iii clinical trial nct<NUMBER> nonreplicating nature adenovirus host makes relatively safe children individuals underlying diseases besides adenovirusbased vectors characterized broad range tissue tropism covers respiratory gastrointestinal epithelium two main sites express ace<NUMBER> receptor sarscov<NUMBER> however possibility dominant immunogenicity toward vector genes rather transgenes always considered <NUMBER> enveloped viruses require fusion viral membrane host cell membrane infection process involves conformational change viral glycoprotein prefusion form postfusion form although prefusion glycoproteins relatively unstable still able elicit strong immune responses <NUMBER> thus university queensland developing stabilized subunit vaccine based molecular clamp technology would allow recombinant viral proteins stably remain prefusion form previously applied influenza virus ebola virus molecular clamp vaccines proved capacity induce production neutralizing antibodies also reported potent two weeks <NUMBER> • c <NUMBER> nanoparticlebased vaccines nanoparticlebased platforms represent alternative strategy incorporate antigens encapsulation covalent functionalization nanoparticles conjugated antigenic epitopes mimic viruses provoke antigenspecific lymphocyte proliferation well cytokine production addition mucosal vaccination intranasal oral spray stimulate immune reactions mucosal surface also provoke systemic responses <NUMBER> demonstrates potential nanoparticlebased vaccines protect humans respiratory viruses cause systemic symptoms novavax inc producing nanoparticlebased vaccine using antigens derived coronavirus protein protein stably expressed baculovirus system product anticipated enter phase trial summer based knowledge antigenspecific cells able eradicate cancer cells well viral infections generating large amounts cells viral antigen specificity timely manner may well help us withstand invasion sarscov<NUMBER> efficient methods produce massive amounts cells include appropriate antigenpresenting cells activate effector cells differentiation proliferation corresponding effector cytotoxic cells <NUMBER> hence genetically modified artificial antigenpresenting cells aapcs express conserved domains viral structural proteins delivered lentivirus vector supposed evoke naïve cells human body lead differentiation proliferation trials evaluating safety immunogenicity aapcs alone combination antigenspecific cytotoxic cells nct<NUMBER> nct<NUMBER> article present overview current state knowledge sarscov<NUMBER> covid<NUMBER> pandemic addition overview epidemiological clinical radiological features sarscov<NUMBER> figure <NUMBER> also summarize possible therapeutic options currently investigation future outlook disease also speculate several mechanisms contributing novel profile covid<NUMBER> pneumonia including high transmissibility caused unvaried ace<NUMBER> structure viral binding site among different populations unique progression pattern patients could asymptomatic yet presenting positive radiographic laboratory findings summarize current clinical trials rapidly initiated upon onset pandemic emergency currently undergoing april <NUMBER> based repurposing therapeutic agents previously designed applications agents divided two broad categories directly target virus replication cycle based immunotherapy approaches either aimed boost innate antiviral immune responses alleviate damage induced dysregulated inflammatory responses whereas vaccines therapeutic antibodies aimed specifically target sarscov<NUMBER> also tested solution longterm require thorough testing safety hand drug repurposing happens practical approach rapid response measure emergent pandemic agents already tested safety demonstrated action viruses including related sarscov merscov drugs target different viral infection response pathways directly interfere virus replication cycle summarized figure <NUMBER> already demonstrated promising results initial clinical trials performed wake pandemic approved wider use promising examples include favipiravir influenza drug interferes viral replication hydroxychloroquine repurposed antimalarial drug interferes virus endosomal entry pathway posing significant challenge toward public health system existing antiviral strategies sarscov<NUMBER> undoubtedly grabbed globes attention beginning <NUMBER> believe may trigger systematic approaches prepare advance potential future pandemics era big data systematic approaches identify potential agents drug repurposing applied noteworthy recent study zhou et al whereby integrative analysis interactome networks associated human coronaviruses drugs targeting components networks applied reveal <NUMBER> novel candidates drug repurposing <NUMBER> believe computational techniques combined followup experimental studies aimed test computationally predicted antiviral agents help us wider arsenal potentially repurposed drugs case future virus outbreaks emerging reemerging viral diseases public health concern whole world pose major threat human health life last decades numerous major outbreaks emerging reemerging viral diseases gross public concern recorded different regions including ebola western africa zika south america h<NUMBER>n<NUMBER> china many asian countries h<NUMBER>n<NUMBER> influenza worldwide particular coronaviruses regarded ones cause mild symptoms like common cold three new types coronaviruses emerged <NUMBER>st century cause severe diseases high fatality morbidity severe acute respiratory syndrome sars coronavirus sarscov emerged november <NUMBER> guangdong china caused globally <NUMBER> human infections <NUMBER> deaths <NUMBER> middle east respiratory syndrome mers coronavirus merscov emerged <NUMBER> saudi arabia caused <NUMBER> infections <NUMBER> associated deaths <NUMBER> november <NUMBER> <NUMBER>a b december <NUMBER> dozen patients unusual pneumonia hospitalized wuhan central china causative agent identified new type coronavirus zhu et al <NUMBER> huang et al <NUMBER> new virus temporarily named <NUMBER> novel coronavirus <NUMBER>ncov world health organization january <NUMBER> <NUMBER> <NUMBER> confirmed cases <NUMBER>ncov infection <NUMBER> deaths reported china additional <NUMBER> cases <NUMBER> countries national health commission peoples republic china <NUMBER> <NUMBER>c since emerging viruses previously unknown pathogens specific effective drugs available therefore urgent need antiviral treatment fighting emerging viral diseases however development antiviral drugs timeand resourceconsuming thus repurposing existing drugs treat emerging viral diseases represents one efficient strategies drug development recent work research team led drs gengfu xiao wu zhong zhihong hu antiviral efficiency fdaapproved drugs including ribavirin penciclovir nitazoxanide nafamostat chloroquine cq two wellknown broadspectrum antiviral drugs remdesivir rdv gs<NUMBER> favipiravir t<NUMBER> evaluated clinical isolate <NUMBER>ncov cell culture infection model authors found two compounds cq ec <NUMBER> value <NUMBER> lmoll rdv adenosine analogue prodrug incorporated nascent chains viral rna resulting premature termination rna synthesis rdv shown possess potent broadspectrum antiviral activity diverse panel rna viruses sarscov merscov ebola virus ebov marburg virus nipah virus hendra virus respiratory syncytial virus cell culture mouse infection models warren et al <NUMBER> sheahan et al <NUMBER> lo et al <NUMBER> currently clinical trials evaluate efficacy ebola virus infections study wang et al <NUMBER> extends antiviral activity new deadly coronavirus <NUMBER>ncov however rdv used clinical treatment clinical effectiveness safety needs investigated remarkably cq identified potent inhibitor <NUMBER>ncov cell culture infection model cq weak base <NUMBER>aminoquinolone derivative used standard antimalarial drug centre infection immunity studies school medicine sun yatsen university guangzhou <NUMBER> china half century rapid schizonticidal activity malarial parasite infections cq also antiinflammatory properties approved clinical treatment autoimmune diseases lupus erythematosus rheumatoid arthritis rainsford et al <NUMBER> cq efficiently enter cells accumulate acidic compartments like lysosomes endosomes transgolgi network vesicles consequently raising ph value many viruses need acidic endocytic organelles stages replication viral uncoating cellular entry via membrane fusion cq also able impair maturation viral proteins posttranslational modification viral receptors like ace<NUMBER> sarscov inhibition phdependent enzymes proteases glycosyltransferases savarino et al <NUMBER> view antiviral activity sarscov merscov unexpected cq possesses antiviral activity <NUMBER>ncov however finding clinically important timely <NUMBER>ncov currently spreading rapidly china causing severe respiratory diseases deaths many patients cq firstline drug treatment malaria illnesses proven safe record several decades likely represents best candidate applied evaluated immediately clinical treatment acute <NUMBER>ncov infections benefits <NUMBER>ncov patients suggested potential clinical use cq exploited efficacy evaluated <NUMBER>ncov epidemics repurposed uses cq treatment viral diseases comply regulations administrative authorities medical ethics although cq belongs safest antimalarial drugs ever discovered adverse effects cq alone combination drugs also observed among patients showed mild symptoms dizziness nausea diarrhoea chattopadhyay et al <NUMBER> rare occasions longterm use cq may associated neuromyopathy retinopathy chattopadhyay et al <NUMBER> cq considered safe use pregnancy administration contraindicated patients known hypersensitivity severe renal hepatic diseases history epilepsy psoriasis therefore used control viral diseases contraindication cq taken account evaluation physical condition underlying diseases comorbidities patients hoped cq many approved clinical drugs repurposed antiviral treatment emerging viral diseases effective antiviral treatment speed disruptive nature covid<NUMBER> pandemic taken public health biomedical research surprise demanding rapid deployment new interventions development testing effective cure vaccine given compressed timescales traditional methodologies relying iterative development experimental testing clinical validation approval new compounds feasible realistic strategy relies drug repurposing requiring us identify clinically approved drugs known toxicities side effects may therapeutic effect covid<NUMBER> patients past decade network medicine developed validated series computational tools help us identify drug repurposing opportunities <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> deploy tools analyze molecular perturbations induced virus sarscov<NUMBER> causing pathophenotype disease known covid<NUMBER> coronavirus disease <NUMBER> identify potential drug repurposing candidates start characterizing covid<NUMBER> disease module fig <NUMBER>a representing network neighborhood human interactome perturbed sarscov<NUMBER> integrity <NUMBER> tissues identify tissues organs virus could invade explore multiple networkbased strategies prioritize existing drugs based ability interact protein targets thereby perturb disease module network proximitybased methods use graph theoretic repurposing strategy <NUMBER> diffusionbased methods capture node similarity <NUMBER> approaches relying artificial intelligence network ainet embed available data detect efficacy <NUMBER> <NUMBER> three predictive approaches offer us twelve ranked lists normally applied independently validated different datasets combine using rank aggregation algorithm <NUMBER> allowing exploit relative advantages obtain final prioritized ranking drug repurposing candidates offers higher accuracy pipelines alone eliminating drugs based toxicity delivery appropriateness use covid<NUMBER> patients selected <NUMBER> approved drugs candidates drug repurposing finally integrate experimental data vitro models help identify networkbased mechanism action selected compounds offer validation using existing gene expression data fig <NUMBER>b <NUMBER> <NUMBER> sarscov<NUMBER> infects human cells hijacking hosts translation mechanisms generate <NUMBER> viral proteins bind multiple human proteins initiate molecular processes required viral replication additional host infection <NUMBER> gordon et al <NUMBER> expressed <NUMBER> <NUMBER> sarscov<NUMBER> proteins used affinitypurification followed mass spectrometry identify <NUMBER> human proteins viral proteins bind table s<NUMBER> <NUMBER> mapped <NUMBER> proteins human interactome consisting <NUMBER> <NUMBER> proteins <NUMBER> <NUMBER> pairwise interactions see methods <NUMBER> viral targets <NUMBER> proteins form multiply connected subnetwork viral targets fig <NUMBER>a <NUMBER> viral targets interact targets human proteins find <NUMBER> viral targets form large connected component lcc fig <NUMBER>a test whether observed lcc could emerged chance randomly placed <NUMBER> proteins interactome matching degrees original viral targets obtained random lcc size <NUMBER> ± <NUMBER> proteins comparative zscore <NUMBER> indicates sarscov<NUMBER> targetproteins aggregate network vicinity <NUMBER> <NUMBER> defining location covid<NUMBER> disease module within human interactome potential drug repurposing candidates must either target proteins within network vicinity disease module previous work indicates expression gene associated disease particular tissue insufficient disease manifest tissue statistically significant disease lcc must expressed <NUMBER> therefore measured statistical significance covid<NUMBER> lcc <NUMBER> tissues using data gtex <NUMBER> gtex median value <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> proteins interactome expressed lung <NUMBER> <NUMBER> <NUMBER> viral targets fig <NUMBER>c <NUMBER> <NUMBER> expressed find <NUMBER> viral targets form tissue specific lcc given random expectation <NUMBER> ± <NUMBER> lcc obtain zscore <NUMBER> lung larger zscore <NUMBER> lcc fullnetwork overall <NUMBER> tissues lcc exceeds zscore fullnetwork helping us identify tissues virusinduced disease could manifested table <NUMBER> list contains pulmonary cardiovascular tissues supporting clinical observations covid<NUMBER> manifests respiratory system <NUMBER> <NUMBER> infected patients often present significant cardiovascular involvement <NUMBER> <NUMBER> patients underlying cardiovascular diseases show increased risk death <NUMBER> interestingly table <NUMBER> indicates lcc also expressed multiple brain regions likely explaining recently reported neurological manifestations <NUMBER> disease also observe multiple tissues related digestive system colon esophagus pancreas analysis consistent clinical observations finally equally unexpected fact table <NUMBER> indicates expression multiple reproductive system tissues vagina uterus testis cervix ovary well spleen potentially related disruptions regulation immune system <NUMBER> <NUMBER> table <NUMBER> preexisting conditions worsen prognosis recovery covid<NUMBER> patients <NUMBER> previous work shown disease relevance human proteins targeted virus predict symptomssigns diseases caused pathogen <NUMBER> prompting us identify diseases whose molecular mechanisms overlap cellular processes targeted sarscov<NUMBER> allowing us predict potential comorbidity patterns <NUMBER> <NUMBER> <NUMBER> retrieved <NUMBER> <NUMBER> diseasecausing genes <NUMBER> diseases <NUMBER> finding <NUMBER> <NUMBER> proteins targeted sarscov<NUMBER> implicated disease however overlap sarscov<NUMBER> targets pool disease genes statistically significant fishers exact test fdrbh p adj value <NUMBER> therefore evaluated networkbased overlap proteins associated <NUMBER> diseases targets sarscov<NUMBER> using vb metric <NUMBER> vb <NUMBER> signals networkbased overlap sarscov<NUMBER> viral targets v gene pool associated disease b find vb <NUMBER> disease indicating sarscov<NUMBER> disease module directly overlap major disease module fig s<NUMBER> table s<NUMBER> diseases closest covid<NUMBER> proteins smallest vb include several cardiovascular diseases cancer whose comorbidity covid<NUMBER> patients well documented <NUMBER> <NUMBER> <NUMBER> fig <NUMBER> metric predicts comorbidity neurological diseases line observation viral targets expressed brain table <NUMBER> summary find sarscov<NUMBER> targets overlap disease genes associated major diseases indicating potential covid<NUMBER> treatment derived arsenal therapies approved specific diseases findings argue strategy maps drug targets without regard localization within particular disease module however diseases modules closest sarscov<NUMBER> viral targets noted comorbidity covid<NUMBER> infection pulmonary cardiovascular diseases cancer also find multiple networkbased evidence linking virus nervous system less explored comorbidity consistent observations many infected patients initially lose olfactory function taste <NUMBER> <NUMBER> patients severe infection requiring hospitalization neurological manifestations <NUMBER> traditional repurposing strategies focus drugs target human proteins viral proteins bind <NUMBER> drugs previously approved pathogens network medicine approach described driven recognition approved drugs target directly disease proteins bind proteins network vicinity <NUMBER> hence goal identify drug candidates may may target proteins virus binds nevertheless potential perturb network vicinity virus disease module achieve end utilized several network repurposing strategies network proximity strategy identifying drugs whose targets immediate network vicinity viral targets <NUMBER> diffusionbased strategy <NUMBER> ainet based strategy uses machine learning combine multiple sources evidence <NUMBER> fig <NUMBER>b test predictive power method independently using list drugs clinical trial covid<NUMBER> combine evidence provided method arriving ranked list drug repurposing candidates derived complete list drugs drugbank see methods proximitybased methods allow us measure distance two sets nodes network also determining statistical significance observed proximity use proximity explore distance viral protein targets approximating covid<NUMBER> disease module targets approved drugs ii differentially expressed genes induced drug arriving three drug ranking lists • pipeline p<NUMBER> drug measured network distance closest protein targeted covid<NUMBER> applied degreepreserving randomization procedure assess statistical significance expecting zscore <NUMBER> proximal drugs example chloroquine rheumatological antimalarial drug currently clinical trial covid<NUMBER> zscore−<NUMBER> indicating proximity sarscov<NUMBER> targets contrast etanercept another antiinflammatory drug supported covid<NUMBER> relevance zscore<NUMBER> indicating drugs protein targets far sarscov<NUMBER> viral targets fig <NUMBER>a tested proximity <NUMBER> <NUMBER> drugs least one target drugbank identifying <NUMBER> drugs zscores −<NUMBER> <NUMBER> <NUMBER> drugs zscores −<NUMBER> representing potential repurposing candidates fig <NUMBER>b • pipeline p<NUMBER> computed proximity zscore disregarding drug targets enzymes carriers transporters proteins targeted multiple drugs often unrelated known pharmacological effects profiled drugs <NUMBER> <NUMBER> drugs obtained filtering metric identified <NUMBER> drugs zscores −<NUMBER> <NUMBER> zscores −<NUMBER> using measure chloroquine hydroxychloroquine less proximal covid<NUMBER> targets ribavin antiviral drug clinical trial gain proximity fig <NUMBER>c • pipeline p<NUMBER> effect drug rarely limited directly target proteins drug activate repress biological cascades biochemical pathways change expression patterns multiple proteins network neighborhood drugs targets drugbank compiles <NUMBER> <NUMBER> differentially expressed genes degs linked <NUMBER> drugs multiple cell lines measured proximity degs covid<NUMBER> targets <NUMBER> drugs finding <NUMBER> drugs zscores −<NUMBER> <NUMBER> drugs zscores −<NUMBER> summary pipelines p<NUMBER>p<NUMBER> offer list drug candidates ranked proximity zscore respective pipeline diffusion state distance dsd methods rank drugs based network similarity targets covid<NUMBER> protein targets similarity two nodes captures overlap two global networkwide states following independent perturbation two nodes implemented three statistical measures resulted five ranking pipelines see methods • pipeline d<NUMBER> l<NUMBER> norm manhattan distance calculates similarity sum absolute value differences elements two vectors providing symmetric measure whose lower values reflect higher similarity • pipeline d<NUMBER> l<NUMBER> norm may result loss information <NUMBER> also implemented kullbackleibler kl divergence <NUMBER> calculates relative entropy vector representation two nodes reporting average asymmetric similarity value minimum pairwise similarity values klmin resulting values <NUMBER> <NUMBER> • pipeline d<NUMBER> deployed kl divergence measure discussed reporting average similarity value median pairwise similarity klmedian • pipeline d<NUMBER> implemented jensenshannon js divergence <NUMBER> modified symmetrized smoothed version kl divergence reporting average minimum value pairwise similarities jsmin • pipeline d<NUMBER> similar d<NUMBER> report average median value pairwise similarities jsmedian used five metrics rank <NUMBER> <NUMBER> drugs potential treatments covid<NUMBER> baricitinib example rheumatological drug currently trial covid<NUMBER> diffusionbased pipelines rank higher tocilizumab drug also indicated rheumatological severe inflammatory diseases proven covid<NUMBER> relevance adopted machine learning tools previously developed drug repurposing using proteinprotein interaction network input <NUMBER> <NUMBER> resulting ainet pipeline exploits power ai network context <NUMBER> see methods method learns represent ie embed multimodal graph compact lowdimensional vector space algebraic operations learned embedding space reflect topology input network fig s<NUMBER>a specifies deep transformation function maps drugs diseases points learned space termed drug disease embeddings diseases independent genes often shared distinct diseases method embeds diseases associated similar genes close together embedding space similarly effects drugs limited proteins directly bind effects spread throughout proteinprotein interaction network capture effects method embeds closely together drugs whose target proteins similar local neighborhoods underlying proteinprotein interaction network use learned embeddings generate four lists candidate drugs covid<NUMBER> ranked list containing <NUMBER> <NUMBER> treatment recommendations obtain four rankings use four distinct decoders decode structure small network neighborhoods around drug disease node learned embeddings • pipeline a<NUMBER> search drugs vicinity covid<NUMBER> disease module calculating cosine distance covid<NUMBER> drugs decoded embedding space <NUMBER> decoding based n <NUMBER> nearest neighboring nodes embedding space minimum distance nodes <NUMBER> • pipeline a<NUMBER> prevent nodes decoding embedding space pack together closely choose <NUMBER> keep n unchanged pushing structures apart softer general features offering better overarching view embedding space loss detailed structure • pipeline a<NUMBER> alternatively force decoding concentrate local structure detriment overall goal exercise choose n <NUMBER> explore smaller neighborhood setting minimum distance midrange point <NUMBER> • pipeline a<NUMBER> instead focusing finer local structure specify decoder preserves broad structure n <NUMBER> <NUMBER> offering broader view embedding space loss detailed structure inspecting <NUMBER> highest ranked drug candidates offered ainet pipeline table s<NUMBER> observe several drugs covid<NUMBER> clinical studies eg chloroquine ritonavir topranked drugs include antimalarial medications drugs used treat autoimmune pulmonary cardiovascular diseases predictive pipelines discussed offered altogether twelve rankings reflecting different networkbased criterion estimate drugs likelihood show efficacy treating covid<NUMBER> patients start list drugs drugtargets operate ppi network rankings provided expected fully independent quantify similarity measure kendall τ rank correlation rankings provided pipeline find two target proximitybased pipelines p<NUMBER> p<NUMBER> show high correlation four ainet pipelines a<NUMBER>a<NUMBER> five diffusionbased pipelines d<NUMBER>d<NUMBER> yet correlations across three basic methods much lower p<NUMBER> relying gene expression patterns also somewhat uncorrelated pipelines indicating different methods offer complementary ranking information fig <NUMBER>a evaluate predictive power pipelines test ability recover drugs currently clinical trials covid<NUMBER> treatment purpose obtained list <NUMBER> drugs currently undergoing clinical trials clinicaltrialsgov table s<NUMBER> use resulting list ranking predicted pipeline compute roc receiver operating characteristics curves auc area curve scores model selection performance analysis measuring quality separation positive negative instances fig <NUMBER>b shows best individual roc curves <NUMBER> − <NUMBER> obtained four ainet based methods note performance four ainet pipelines largely indistinguishable line finding ranking lists provided highly correlated fig <NUMBER>a secondbest performance <NUMBER> provided proximity method p<NUMBER> close behind p<NUMBER> auc <NUMBER> find eliminating drug targets p<NUMBER> decreases auc <NUMBER> group diffusion methods offer roc <NUMBER> lower performance somewhat unexpected diffusionbased methods capture higher order correlations compared proximity methods thus one would expect performance proximitybased ainet methods successfully integrate high order correlates method extracts networkbased signal prioritizing drugs however scores method biased differently offering different rankings used rank aggregation algorithm <NUMBER> combine <NUMBER> ranking lists aiming maximize number pairwise agreements final ranking input ranking objective known kemeny consensus nphard compute <NUMBER> <NUMBER> hence used algorithm approximate see methods first tested whether combining ranking within method class could improve predictive power list provided individual pipelines fig <NUMBER>c joint performance ainet group <NUMBER> a<NUMBER> observe however improvement proximity pipelines joint ranking increasing performance <NUMBER> <NUMBER> interestingly combined diffusion pipelines lower performance <NUMBER> best diffusion pipeline <NUMBER> observed d<NUMBER> d<NUMBER> d<NUMBER> particularly encouraging however combine <NUMBER> pipelines obtain roc <NUMBER> highest individual combinationbased pipelines confirming individual pipelines offer complementary information harnessed combined ranking combined list therefore defines final ranked list predicted drugs repurposing finally manually inspected joint ranking list removing drugs significant toxicities eliminating appropriate removing lowerranked members drug class exceptions process arrived list <NUMBER> drugs selected top <NUMBER> total combined rank list representing final repurposing candidates covid<NUMBER> table <NUMBER> selection contains drugs used disorders respiratory eg theophylline montelukast cardiovascular eg verapamil atorvastatin systems antibiotics used treat viral eg ribavirin lopinavir parasitic eg hydroxychloroquine ivermectin praziquantel bacterial eg rifaximin sulfanilamide mycotic egfluconazole mycobacterial eg isoniazid infections immunomodulatingantiinflammatory drugs eg interferonβ auranofin montelukast colchicine antiproteasomal drugs eg bortezomib carfilzomib range less obvious drugs warrant exploration eg aminoglutethimide melatonin levothyroxine calcitriol selegiline deferoxamine mitoxantrone metformin nintedanib cinacalcet sildenafil among others table <NUMBER> final list includes <NUMBER> previously proposed <NUMBER> potential drugrepurposing candidates covid<NUMBER> <NUMBER> drugs currently tested clinical trials table <NUMBER> drug repurposing list provided table <NUMBER> ranks drugs based networkbased relationship viral targets however drug effective may sufficient proximalit also needs induce right perturbation cell suppressing example expression proteins virus needs activating expression proteins essential cell function survival suppressed virus section use expression data understand drug affects activity proteins within covid<NUMBER> disease module offering insights mechanism action selected drugs connectivity map retrieved gene expression perturbation profiles <NUMBER> <NUMBER> repurposing candidates connectivity map cmap database <NUMBER> altogether including <NUMBER> <NUMBER> experimental instances combination different drugs cell lines doses time treatment evaluate degree drugs modulate activity covid<NUMBER> targets measured overlap perturbed genes covid<NUMBER> targets example mitoxantrone antineoplastic drug table <NUMBER> find <NUMBER> <NUMBER> covid<NUMBER> targets significant overlap <NUMBER> <NUMBER> genes highly perturbed drug <NUMBER>µm lung cell line hcc<NUMBER> fishers exact test fdrbh p adj value <NUMBER> fig <NUMBER>a evaluated across experimental instances find <NUMBER> <NUMBER> drugs statistically significant overlap perturbed genes covid<NUMBER> targets fig <NUMBER>b random selections <NUMBER> drugs pool drugs <NUMBER> ± <NUMBER> drugs average statistically significant overlap perturbed genes covid<NUMBER> targets fig s<NUMBER> indicating repurposing candidates effectively perturb network covid<NUMBER> disease module observed highest number perturbed covid<NUMBER> targets carfilzomib <NUMBER> p adj value <NUMBER> ha<NUMBER>e <NUMBER>µm flutamide <NUMBER> p adj value <NUMBER> mcf<NUMBER> <NUMBER>µm bortezomib <NUMBER> p adjvalue <NUMBER> ha<NUMBER>e <NUMBER>µm cell lines derived lung tissues a<NUMBER> hcc<NUMBER> drugs highest overlap covid<NUMBER> targets mitoxantrone ponatinib results help us extract direct experimental evidence drug repurposing candidates selected methods modulate processes targeted virus offer mechanistic insights biological processes affected drugs example find mitoxantrone huvec <NUMBER> µm <NUMBER>h perturbs covid<NUMBER> targets related cell cycle viral life cycle protein transport organelle organization suppressing covid<NUMBER> induced expression next asked whether selected drugs counteract gene expression perturbations caused virus ie whether downregulate genes upregulated virus vice versa analysis begin <NUMBER> differentially expressed genes degs sarscov<NUMBER> infected a<NUMBER> cell line <NUMBER> compare list drug perturbation profiles example bortezomib treatment cell line yapc <NUMBER> µm counteracts effects sarscov<NUMBER> infection <NUMBER> genes fig <NUMBER>c resulting inverted expression profile spearman correlation ρ −<NUMBER> fig <NUMBER>c measured spearman correlation ρ perturbations caused drug perturbations caused virus a<NUMBER> cell line negative correlation values indicate drug could counteract effects infection find <NUMBER> <NUMBER> drugs profiled connectivity map negative correlation coefficients spearman ρ <NUMBER> fdrbh p adj value <NUMBER> indicating could beneficially modulate effects virus infection random selections <NUMBER> drugs pool drugs <NUMBER> ± <NUMBER> drugs average statistically significant negative correlation coefficients fig s<NUMBER> supporting covid<NUMBER> relevance repurposing list among <NUMBER> drugs significant perturbation overlap covid<NUMBER> targets degs sarscov<NUMBER> infection find ivermectin carfilzomib clinical trial covid<NUMBER> table s<NUMBER> altogether results provide vitro experimental support selected repurposing candidates possible modulators biological processes targeted virus also indicates networkbased tools utilize gene expression profiles explore potential efficacy drugs study took advantage recent advances network medicine define list <NUMBER> drug repurposing candidates treatment covid<NUMBER> using vitro data show drugs affect biological processes targeted virus accuracy predictions improve input validation data improve example relied results gordon et al <NUMBER> <NUMBER> map interactions virus human proteins however additional interactions detected study <NUMBER> example ace<NUMBER> <NUMBER> protein recently linked initial viral association airway epithelial cells current data set <NUMBER> viral proteins target note utilized predictive pipelines select drugs virtue networkbased relationship targets sarscov<NUMBER> viral targets positioned perturb effectively covid<NUMBER> disease module perturbations may block virus ability invade host cells limit molecular level disruption caused infection potentially alleviating disease symptoms shortening timeline disease others however may cause perturbations aggravate symptoms seriousness phenotype therefore ordinary circumstances would need molecular experiments test efficacy drugs covid<NUMBER> infected cell lines table <NUMBER> yet many drugs wellknown side effects toxicities given imminent need cure may possible move drugs directly clinical trials currently pursuing possibility releasing list could offer opportunities groups appropriate resources toolset move drugs screening directly rapid clinical trials course cognizant remote yet real possibility approved drugs known side effects may exert unique toxicities setting novel infection outcome identified clinical trial study focused ranking existing drugs based expected efficacy covid<NUMBER> patients mean drugs make final list could efficacy must excluded consideration input data improves currently highly ranked drugs could move lower ranking developing case experimental testing clinical trial vice versa proposed methodology general allowing us profile potential efficacy drug family drugs whether included current reference list normally bioinformatic validation would followed experimental screening potentially clinical validation publication currently pursuing avenues screening human cell lines clinical trials feel however given strength bioinformatics validation obtained auc generating confidence methodologies urgency covid<NUMBER> crisis imminent need disclosure offer rationale guidance upcoming clinical trials human interactome assembled <NUMBER> public databases compile experimentallyderived proteinprotein interactions ppi data <NUMBER> binary ppis derived highthroughput yeasttwo hybrid y<NUMBER>h expereriments hiunion <NUMBER> <NUMBER> differentiating binary interactions among several experimental methods present literaturecurated databases specifically inweb interactions curation scores <NUMBER> <NUMBER>th percentile considered proteins mapped corresponding entrez id ncbi proteins could mapped removed final interactome used study contains <NUMBER> <NUMBER> proteins <NUMBER> <NUMBER> interactions retrieved interactions <NUMBER> sarscov<NUMBER> proteins <NUMBER> human proteins detected gordon et al <NUMBER> drugtarget information drugbank database containing <NUMBER> <NUMBER> interactions <NUMBER> <NUMBER> drugs <NUMBER> <NUMBER> targets used gtex database <NUMBER> contains median gene expression rnaseq <NUMBER> different tissues assuming genes median count lower <NUMBER> expressed particular tissue lcc calculated using degree preserving approach <NUMBER> preventing repeated selection high degree nodes choosing <NUMBER> degree bins <NUMBER> <NUMBER> simulations given v set covid<NUMBER> virus targets set drug targets dv shortest path length nodes v ∈ v ∈ network define <NUMBER> also determined expected distances two randomly selected groups proteins matching size degrees original v sets avoid repeatedly selecting high degree nodes use degreebinning <NUMBER> see mean µ dvt standard deviation σ dvt reference distribution allows us convert absolute distance c relative distance z dc defined diffusion state distance dsd <NUMBER> algorithm uses graph diffusion property derive similarity metric pairs nodes takes account similarly impact rest network calculate expected number times hea b random walk starting node visits node b representing node vector <NUMBER> describes perturbation initiated node impacts nodes interactome similarity nodes b provided l<NUMBER> norm corresponding vector representations inspired dsd developed five new metrics calculate impact drug targets sarscov<NUMBER> targets v first pipeline d<NUMBER> defined dsds represents diffusion state distance nodes v since l<NUMBER> norm two large vectors may result loss information <NUMBER> also used metric pipeline d<NUMBER> pipeline d<NUMBER> kl kullbackleibler kl divergence vector representations nodes finally provide symmetric measures tested measures pipeline d<NUMBER> pipeline d<NUMBER> js jensen shannon js divergence vector representations nodes five measures consider v designed graph neural network covid<NUMBER> treatment recommendations based previously developed graph convolutional architecture <NUMBER> multimodal graph heterogeneous graph g v r n nodes v ∈ v representing three distinct types biomedical entities ie drugs proteins diseases labeled edges v r v j ∈ r representing four semantically distinct types edges r entities ie proteinprotein interactions drugtarget associations diseaseprotein associations drugdisease treatments covid<NUMBER> treatment recommendation task cast covid<NUMBER> treatment recommendation link prediction problem multimodal graph task predict new edges drug disease nodes predicted link drug node v disease node v j indicate drug v promising treatment disease v j eg covid<NUMBER> graph neural network endtoend trainable model link prediction multimodal graph two main components <NUMBER> encoder graph convolutional network operating g producing embeddings nodes g <NUMBER> decoder model optimizing embeddings predictive successful drug treatments overview graph neural architecture neural message passing encoder takes input graph g produces node ddimensional embedding z ∈ r every drug disease node graph use encoder <NUMBER> learns message passing algorithm <NUMBER> aggregation procedure compute function entire graph transforms propagates information across graph g graph convolutional operator takes account firstorder neighborhood node applies transformation across locations graph successive application operations effectively convolves information across kth order neighborhood ie embedding node depends nodes k steps away k number successive operations convolutional layers neural network model graph convolutional operator takes form h hidden state node v kth layer neural network k dimensionality layers representation r edge type matrix w k r edgetype specific parameter matrix φ denotes nonlinear elementwise activation function ie rectified linear unit α r denote attention coefficients <NUMBER> arrive final embedding z ∈ r node v compute representation next decoder takes node embeddings combines reconstruct labeled edges g particular decoder scores v r v j triplet function g whose goal assign score gv r v j representing likely drugs v treat disease v j ie r denotes treatment relationship training graph neural network model training optimize model parameters using maxmargin loss functions encourage model assign higher probabilities successful drug indications v r v j random drugdisease pairs take endtoend optimization approach jointly optimize trainable parameters propagates loss function gradients encoder decoder optimize model train maximum <NUMBER> epochs training iterations using adam optimizer <NUMBER> learning rate <NUMBER> initialize weights using initialization described <NUMBER> make model comparable drug repurposing methodologies study integrate additional side information node feature vectors instead use onehot indicator vectors <NUMBER> node features order model generalize well unobserved edges apply regular dropout <NUMBER> hidden layer units eq <NUMBER> practice use efficient sparse matrix multiplications complexity linear number edges g implement model use <NUMBER>layer neural architecture <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> hidden units input output intermediate layer respectively dropout rate <NUMBER> maxmargin <NUMBER> use minibatching <NUMBER> sampling triples multimodal graph process multiple training minibatches minibatches size <NUMBER> obtained sampling fixed number triplets resulting dynamic batches change training retrieved drug perturbation profiles connectivity map cmap database <NUMBER> <NUMBER> using python package cmappy <NUMBER> perturbation profile calculated significance overlap perturbed genes z − score <NUMBER> sarscov<NUMBER> targets derived gordon et al <NUMBER> using fishers exact test also retrieved gene expression data cell line a<NUMBER> infection sarscov<NUMBER> <NUMBER> correlation perturbation scores provided cmap gene expression fold change caused sarscov<NUMBER> infection evaluated using spearman correlation coefficient cases applied benjaminihochberg method multiple testing correction fdr <NUMBER> used crank algorithm <NUMBER> combine rankings returned different methodologies single rank drug determined drugs repurposing priority rank aggregation algorithm starts ranked lists drugs r r one arising different methodology r ranked list partitioned equally sized groups called bags bag ranked list r r attached importance weight k r whose initial values equal crank uses twostage iterative procedure aggregate individual rankings taking account uncertainty present across ranked lists initializing aggregate ranking r weighted average ranked lists r r crank alternates following two stages changes observed aggregated ranking r <NUMBER> first uses current aggregated ranking r update importance weights k r ranked list purpose topranked drugs r serve temporary gold standard given bag ranked list r r crank updates importance weight k r based many drugs temporary gold standard appear bag using bayes factors <NUMBER> <NUMBER> second ranked lists reaggregated based importance weights calculated previous stage updated importance weights used revise r new rank rc drug c expressed indicates importance weight bag r c drug c ranking r r r c rank c according r using iterative approach crank allows importance ranking predetermined vary across drugs final output global ranked list r drugs represents collective opinion different repurposing methodologies python source code implementation crank available httpsgithubcommimsharvardcrank experiments set number bags <NUMBER> size temporary gold standard <NUMBER> total number drugs r maximum number iterations <NUMBER> cases algorithm converged fewer <NUMBER> iterations employed different methodologies rank drug candidates since lack groundtruth labels drugs effective disease rely clinical trials gather names drugs currently trial made assumption drugs tested clinical trials relevant based prior vitro vivo observations used information ranking method compute roc receiver operating characteristics curves auc area curve scores model selection performance analysis auc score measures quality separation positive negative instances ranked list applied different thresholds compute falsepositive truepositive rates plot roc scores auc range <NUMBER> <NUMBER> <NUMBER> corresponds perfect performance <NUMBER> indicates performance random classifier methods fail provide ranking drug provide fair comparison methods assumed missing ranks listed bottom ranking use python package scikitlearn <NUMBER> computing auc scores plotting roc curves groundtruth list consider clinicaltrialsgov website primary source ongoing trials drugs fo covid<NUMBER> cognizant limitations primarily one time lags implementation trial appearance site also quantified performance models different constraints considering drugs least n trials considering evidence provided certain date fig s<NUMBER> work supported part nih grants hg<NUMBER> hl<NUMBER> hl<NUMBER> aha grant d<NUMBER> jl alb supported nih grant <NUMBER>p<NUMBER>hl<NUMBER> american heart association grant <NUMBER> erc grant <NUMBER>dynaset wish thank nicolette lee grecia providing support marc santolini suggestions diffusionbased methods random expectation lcc size indicating observed covid<NUMBER> lcc whose size indicated red arrow larger expected chance c similarly lungbased lcc also greater expected chance measured network proximity covid<NUMBER> targets <NUMBER> diseases figure represents disease circle whose radius reflects number disease genes associated <NUMBER> diseases closest center whose names marked expected higher comorbidity covid<NUMBER> outcome farther disease center distant disease proteins covid<NUMBER> viral targets table s<NUMBER> c performance overall crank combines pipelines final ranking list higher performance method individually cranks ais ps ds table s<NUMBER> table s<NUMBER> quantified performance models considering evidence provided certain date coronaviruses cause major outbreaks fatal pneumonia eg severe acute respiratory syndrome coronavirus sarscov <NUMBER> fatality rate around <NUMBER> lee et al <NUMBER> middle east respiratory syndrome coronavirus merscov <NUMBER> fatality rate <NUMBER> de groot et al <NUMBER> <NUMBER> severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> caused disease covid<NUMBER> led pandemic zhu et al <NUMBER> common symptoms covid<NUMBER> include fever cough shortness breath dyspnea severe progression covid<NUMBER> disease may lead pneumonia severe acute respiratory syndromes unfortunately specific drugs vaccines approved treatment covid<NUMBER> yet huang et al <NUMBER> traditionally de novo drug design drug repurposing common strategies scientists use combat viral diseases however designing new drug timeconsuming needs extensive testing clinical use humans contrast repurposing approved drugs drugs clinical trials promising particular since already tested sideeffects toxicity bioavailability etc moment huge amount data studies analyze potential drugs based computer simulations vitro studies case studies clinical trials however none proposed treatments covid<NUMBER> proven clinically effective yet potential drugs target viral proteins human proteins time writing important viral target molecules investigated drug repurposing sarscov<NUMBER> spike protein main protease <NUMBER>clpro mpro papainlike proteinase plpro rnadependent rna polymerase rdrp et al <NUMBER> zhang et al <NUMBER> main targets human cell membrane angiotensinconverting enzyme <NUMBER> ace<NUMBER> transmembrane protease serine <NUMBER> tmprss<NUMBER> aronson ferner <NUMBER> besides targets several candidates investigated potential targets investigations occurred viral human sides eg methyltransferase furin respectively bestle et al <NUMBER> khan et al <NUMBER> also several potential drugs announced beginning pandemic later proved insufficiently effective even harmful patients hydroxychloroquine chloroquine phosphate instance gautret et al <NUMBER> reported significant decrease viral load patients treated hydroxychloroquine compared controls however others shown potential drugs severe side effects cardiac toxicity also increased mortality mehra et al <NUMBER> nevertheless studies showing higher mortality later retracted lack transparency concerning data mehra et al <NUMBER>b potential drug candidates combination lopinavir ritonavir also known kaletra first considered promising candidate jeon et al <NUMBER> later shown ineffective sarscov<NUMBER> cao et al <NUMBER> nevertheless many new drug candidates proposed using different computational approaches address different viral human targets expressed membranebound protein lungs heart kidneys stomach spleen intestine bone marrow kidney liver brain testis placenta shenoy et al <NUMBER> donoghue et al <NUMBER> soler et al <NUMBER> moreover hoffmann et al <NUMBER> showed sarscov<NUMBER> depends tmprss<NUMBER> therefore serve target therapy well tmprss<NUMBER> primes spike protein sarscov<NUMBER> enable cellentry ace<NUMBER> authors suggested ace<NUMBER> binding spike protein might higher affinity compared sars may explain infection upper respiratory system sarscov<NUMBER> observed sars since upper respiratory system less ace<NUMBER> expressed structurally virion approximately <NUMBER> nm diameter chen et al <NUMBER> like coronaviruses sarscov<NUMBER> four structural polyproteins known spike e envelope membrane n nucleocapsid proteins latter n protein holds rna genome e proteins together part viral envelope upon successful attachment virus membrane host cell via spike protein virus fuses membrane wu et al <NUMBER> hoffmann et al <NUMBER> next endosome sees drop ph genomic rnass released cells cytoplasm yang et al <NUMBER> shown figure <NUMBER> knowledge life cycle sarscov<NUMBER> virus offers great potential find suitable drugs already known targets combine large amounts current knowledge centralize aggregated information published articles preprints potential drugs targets interactions cordite corona drug interactions database includes web interface api cordite integrates many functionalities enable users access sort download relevant data conduct metaanalyses design new clinical trials even conduct curated literature search cordite automatically incorporates publications pubmed httpswwwncbinlmnihgovpubmed biorxiv httpswwwbiorxivorg chemrxiv httpswwwchemrxivorg medrxiv httpswwwmedrxivorg report information computational vitro case studies potential drugs covid<NUMBER> besides original research also included reviews comments database information articles preprints manually curated moderators accessed via web interface open api users directly access publications interactions drugs targets clinical trials interactions effectiveness certain drugs also shown positivenegative results transparent way thus user easily see contradictory results different studies take account eg metaanalyses access may offer easier integration future software apps may need curated data moreover include registered clinical trials national institute health nih httpsclinicaltrialsgov covid<NUMBER> cordite database updated manual curation current summary interactions drugs etc reported table <NUMBER> introductory video use cordite found website cordite provides easytouse web interface also access easytouse api allows wide use software applications eg metaanalysis design new clinical studies simple literature search cordite currently largest curated database drug interactions sarscov<NUMBER> therefore offers opportunity accelerate research knowledge domains virology drug design popularity impact cordite website database plan continue hosting managing cordite throughout covid<NUMBER> pandemic moreover continuously improve website database establish standard tool future diseases believe efforts essential help researchers clinicians get overview existing studies accelerate global search new treatments cordite aggregates available knowledge drugs covid<NUMBER> however particular preprints peerreviewed thus cordite cannot guarantee reliability studies results particularly effectiveness drugs authors thank hagen dreßler technical assistance rm developed implemented database api hfl developed implemented web interface curated approximately <NUMBER> data mw developed automated literature crawler curated approximately <NUMBER> data gh created figure <NUMBER> visual identity web interface contributed initial draft ach contributed project design created figure <NUMBER> curated approximately <NUMBER> data dh designed supervised project wrote manuscript curated approximately <NUMBER> data authors revised final manuscript authors declare competing interests interactions <NUMBER> drugs <NUMBER> publications <NUMBER> clinical trials <NUMBER> information requests resources directed fulfilled lead contact dominik heider dominikheiderunimarburgde study generate new unique data study generate data curated data accessed freely via api data integrated cordite aggregated three procedural steps automated literature aggregation b manual database curation c web interface enabling users search export subsets curated data complete diagram depicting steps shown figure <NUMBER> literature aggregation carried using crawler written python <NUMBER> pubmed httpswwwncbinlmnihgovpubmed entries accessed using biopython <NUMBER> via requests entrez metasearch engine access chemrxiv httpswwwchemrxivorg entries carried using figshare api httpsfigsharecom literature available medrxiv httpswwwmedrxivorg biorxiv httpswwwbiorxivorg aggregated feed parser information regarding ongoing clinical trials fetched url requests aggregated data filtered relevant publications clinical trials moreover suggested papers received via email added database well curated list automatically aggregated entries different resources manually curated appropriate clinical trials publications selected publication clinical trial extract proposed drugs drugviraltarget drughosttarget interactions integrate cordite database particular store evidence confirmed disproven interactions indicate positive negative cordite relational database implemented mariadb <NUMBER> consisting eight tables fourteen views publications clinical trials interactions molecules including drugs targets stored individual tables tables implement crossreferences content tables corresponding api read database implemented php <NUMBER> new data easily inserted modified deleted via hidden editorial website written php bootstrap <NUMBER> editorial website ensures quality content performing additional integrity checks removing duplicates cordite web interface enables extensive search drugs targets interactions publications clinical trials associated covid<NUMBER> functionality allows user sort select drugs targets interest view corresponding information moreover possible order drugs according number publications end peerreviewed research articles taken account ensure smooth user interface interactions use javascript react v <NUMBER> molecules angiotensin receptor <NUMBER> blocker commonly used antihypertensive drug control covid<NUMBER> virus gaining entry host cell blocking angiotensin receptor clinical trials also undertaken use statins lipidlowering drugs antiinflammatory immunomodulatory properties prevent acute lung injury covid<NUMBER> infection backdrop novel coronavirus covid<NUMBER>sarscov<NUMBER> creating pandemic situation creating desertion city wuhan china epicenter emergent need medical scientific community undertake quick measures virus made social political economic financial medical scientific fraternity go state emergency spread virus fast dis zhu zhang <NUMBER> bat coronavirus hku<NUMBER> also betacoronavirus large <NUMBER> kb enveloped positivestranded rna virus viral genome packed inside helical capsid formed nucleocapsid protein surrounded envelope virus four proteins membrane protein envelope protein e spike protein nucleocapsid protein n spike forms large protrusions viral surface giving crownlike appearance hence name corona spike protein mediates entry virus host cells lellan wrapp <NUMBER> also critical determinant viral host range tissue tropism major inducer host immune response li <NUMBER> spike protein charge receptor binding subsequent viral entry host cells therefore major therapeutic target binds cellular receptor angiotensin converting enzyme <NUMBER> ace<NUMBER> cellular receptor dipeptidyl peptidase <NUMBER> dpp <NUMBER> cd <NUMBER> former sars latter mers cd <NUMBER> l alternative receptor lower affinity respiratory tract song et al <NUMBER> scientists wan shang graham baric li <NUMBER> analyzed potential receptor usage <NUMBER>ncov based knowledge sequencing sarscov found sequence <NUMBER> ncov receptor binding motif rbm directly contacts ace<NUMBER> receptor similar sarscov suggest <NUMBER>ncov wuhan uses ace<NUMBER> receptor structural analysis predicted wuhan coronavirus uses ace<NUMBER> host receptor stated single mutation significantly enhances ability ncov wuhan bind human ace<NUMBER> zhu zhang <NUMBER> spike protein s<NUMBER> s<NUMBER> subunits minimal receptorbinding domain rbd located s<NUMBER> subunit combine host cell receptor ace<NUMBER> rbd rbm located responsible complete contact ace<NUMBER> definite treatment covid<NUMBER> important method prevent viral transmission rapid isolation disease containment measures spread covid<NUMBER> mainly respiratory origin droplet infection utmost care required use personal protective gadgets masks assessment notification true picture prevention spread controlling travel isolation screening individuals forth treatment pneumonia acute lung injury largely empiric urgent need device develop various treatment modalities form vaccine newer drug molecules repurpose existing drugs health care community biotech industry need take urgent call undertake quick clinical trials humanitarian grounds various modalities treatment tried <NUMBER> antiviral drugsviral polymerases protease inhibitors components hiv hcv antiviral regimen find immediate place lopinavir ritonavir protease inhibitors oseltamivir neuraminidase study remdesivir interferes viral polymerase tried shown efficacy mers wan et al <NUMBER> <NUMBER> vaccine trials need started antibodies raised s<NUMBER> subunit protective antibodies rbd fragment spike proteinbased vaccine also produce antibodies offer protection passive antibody transfer convalescent sera recovered patients polyclonal antibodies plasma transfused new idea target viral receptor protein cell surface ace<NUMBER> rbd protein attached fc fragment used attack virus extracellular domain ace<NUMBER> protein fused human immunoglobulin g fc domain may hold promise david fedson <NUMBER> ace<NUMBER> fc fusion protein covid may neutralize virus prevent lung injury also used give passive immunity health care workers still highly experimental interesting paper hoffmann et al <NUMBER> chloroquine tried <NUMBER> also hypothesize use angiotensin ii receptor blockers arb available clinical use antihypertensives potential drugs given control viral spread novel coronavirus wuhan infection unpublished observation one us mp people using losartan telmisartan arb antihypertensives get fewer attacks cold flulike illnesses drugs also produce cough side effect commonly seen ace inhibitors losartan telmisartan strongly binds at<NUMBER> receptors valsartan phadke saunik <NUMBER> therefore use former could suitable use zinc supplement help intracellular killing phagocytosis modulate immune function may tried thus use arb telmisartan losartan given therapeutic doses along zinc control viral replication warrants attention ace<NUMBER> receptors widely expressed epithelial cells alveoli trancheobronchial free may help virus entry song et al <NUMBER> therefore use arbs form nebulization tried developing scientific treatment target viruses form vaccines new molecules topdown approach timeconsuming though eventually required however one think bottomup approach repurposing commonly used lowcost generic drugs arb zinc controlling viral multiplication statins control lung injury found useful make immeasurable contribution global health equity global viral security human coronaviruses hcovs middleeast respiratory syndrome coronavirus merscov severe acute respiratory syndrome coronavirus sarscov <NUMBER> novel coronavirus <NUMBER>ncov also called sarscov<NUMBER> emerged animal reservoirs aggravate pandemic high mortality morbidity coronaviruses covs positivesense singlestranded rna ssrna virus contain largest rna genome <NUMBER>kb six ten open reading frames orfs enclosed enveloped protein form spherical particles <NUMBER> nm size <NUMBER> <NUMBER> genetic material hcovs highly susceptible frequent recombination process suggested direct establishment new hcov strains altered virulence <NUMBER> result total seven main hcovs recorded viz hcov<NUMBER>e hcovnl<NUMBER> hcovoc<NUMBER> hcovhku<NUMBER> merscov sarscov sarscov<NUMBER> viruses held accountable fatal infections respiratory system system symptoms including diarrhea nausea <NUMBER> <NUMBER> hcovs belong coronaviridae family order nidovirales classified four genera α β γ δ <NUMBER> recently discovered sarscov<NUMBER> belongs β genus shares <NUMBER> sequence similarity sarsrelated coronavirus <NUMBER> identical wholegenome level bat coronavirus <NUMBER> <NUMBER> genome analysis coronaviruses including sarscov<NUMBER> genome genbankmn<NUMBER> revealed four nonstructural proteins ie papainlike protease pl pro <NUMBER>chymotrypsinlike <NUMBER>cl pro helicase rna polymerase four structural proteins viz nucleocapsid n protein membrane protein envelope e protein spike protein accessory proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER>cl pro pl pro reported transcription replication virus <NUMBER> remarkably vitro inhibition proteases selected inhibitors shown antiviral activity coronaviruses covs <NUMBER> <NUMBER> observations concluded <NUMBER>cl pro main coronavirus protease pro <NUMBER> essentially required conduct replication cycle virus <NUMBER> <NUMBER> like hcovs sarscov<NUMBER> pro digests polyprotein conserved sites starts autolytic cleavage pp<NUMBER>a pp<NUMBER>ab site encoded virus orf<NUMBER>ab shares <NUMBER> sequence similarity pro sarscov strain <NUMBER> <NUMBER> conquer coronavirus infections inhibition viral pro functionally important viral life cycle absence human homologues approved conventional antiviral therapeutic strategy <NUMBER> current scenario despite numerous efforts drug vaccine yet approved hcovs expected take months years new interventions <NUMBER> recently various pro inhibitors demonstrated broadspectrum vitro activities covs via interacting conserved key residues required substrate recognition respective pro enzymes <NUMBER> <NUMBER> moreover urgency sarscov<NUMBER> outbreak drug repurposing represented effective drug discovery approach existing drugs suggestively shorten time condense cost comparison de novo drug discovery strategy randomized clinical trials <NUMBER> facilitate rapid drug discovery computational drug repurposing approaches established effective method reveal new indications already known drugs aid computational algorithms molecular docking simulation molecular dynamics simulation predict drugtarget interactions binding stability respectively <NUMBER> <NUMBER> previously computational drug repurposing approaches employed identify potential drug candidates viral infections including ebola zika dengue influenza infections <NUMBER> hcovs sarscov merscov <NUMBER> <NUMBER> <NUMBER> also nonpeptidic activesitedirected inhibition sarscov pro discovered combination screening docking methods <NUMBER> likewise bifunctional aryl boronic acid compounds discovered inhibit sarscov pro using combination experimental computational methods <NUMBER> sarscov<NUMBER> outbreak computational drug repurposing also applied find potential drugs investigations already reported <NUMBER> <NUMBER> <NUMBER> area drug repurposing antibiotics tetracyclines derivatives repurposed viral infections <NUMBER> <NUMBER> antibiotics well designated broadspectrum bacteriostatic inhibitors selectively inhibit microbial protein synthesis including naturally occurring polyketide compounds chlortetracycline oxytetracycline tetracycline semisynthetic derivatives minocycline doxycycline methacycline <NUMBER> notably tetracycline derivatives ie doxycycline reported exert antiviral effects antimurine retrovirus <NUMBER> chikungunga infection <NUMBER> blockage dengue virus replication infected cell lines <NUMBER> <NUMBER> besides demeclocycline known exert antiviral activity west nile virus wnv <NUMBER> included list antiviral compounds <NUMBER> another broad spectrum tetracycline derivative minocycline initially reported human immunodeficiency virus hiv type <NUMBER> infection <NUMBER> later studied viruses wnv japanese encephalitis virus j u r n l p r e p r f <NUMBER> jev simian immunodeficiency virus siv sindbis human tlymphocytic virus type<NUMBER> htlv<NUMBER> rabies reoviruses <NUMBER> moreover tertacyclines eg tetracycline doxycycline minocycline known zinc chelating agents postulated inhibit covid<NUMBER> infection restricting viral replication host <NUMBER> additionally synthetic halogenated tetracycline eravacycline demonstrated inhibitory effect sarscov sarscov<NUMBER> merscov hepatitis c virus hcv using computational studies <NUMBER> hence impression tetracyclines derivatives inhibits viral infections hypothesized antibiotics reported antiviral activities may helpful sarscov<NUMBER> inhibition blockage main protease viz pro thereof employed structure based molecular docking selected four tetracyclines ie doxycycline tetracycline demeclocycline minocycline known antiviral activities viruses pro sarscov<NUMBER> similar virtual screening approach recently applied identify tetracycline derivatives flavivirus inhibitors <NUMBER> following docked proteinantibiotics complexes evaluated complex stability via classical molecular dynamics simulation binding affinity stability selected viral proteaseantibiotics complexes also compared docked complexes protease native ligand n<NUMBER> generate comparative study mentioned known n<NUMBER> inhibitor <NUMBER> validate docking procedure comparative analysis selected antibiotics best scored poses receptorligand complexes evaluated complex stability <NUMBER> ns molecular dynamics md simulations using free academic desmond v<NUMBER> module schrödingermaestro v<NUMBER> <NUMBER> linux environment hp z<NUMBER> workstation md systems proteinligand complexes fabricated orthorhombic grid box <NUMBER>å×<NUMBER>å×<NUMBER>å buffer followed addition tip<NUMBER>p transferable intermolecular potential <NUMBER> point water molecules system minimization using system builder tools desmondmaestro interface later salt ion placement omitted <NUMBER> å ligand whole system neutralized addition counter ions besides <NUMBER> ps time interval set anisotropic diagonal position scaling reserve constant pressure md simulation additionally temperature system set <NUMBER> k coupled <NUMBER> ps npt reassembly <NUMBER> atm pressure furthermore system density preserved near <NUMBER> gcm <NUMBER> calculations conducted default parameters finally md simulation complex conducted <NUMBER> ns interval similar conditions subsequently simulation trajectories analyzed simulation interaction diagram tool desmond v<NUMBER> module schrödingermaestro v<NUMBER> <NUMBER> molecular docking algorithms widely used predict bioactive compounds drug repurposing various drug targetable proteins diseases infections <NUMBER> <NUMBER> likewise study also employed molecular docking simulation approach selected antibiotic tetracyclines ie doxycycline tetracycline demeclocycline minocycline predict instinctively potential sarscov<NUMBER> infection pro inhibition docked drugs n<NUMBER> inhibitor showed significant docking confirmation binding affinity energies <NUMBER> kcalmol least rmsd <NUMBER> value default autodock vina default parameters active pocket sarscov<NUMBER> pro respect n<NUMBER> inhibitor fig <NUMBER> fig s<NUMBER> docked sarscov<NUMBER> pro doxycycline complex recorded significant <NUMBER> j u r n l p r e p r f <NUMBER> kcalmol docking score formed five hydrogen bonds viral protease active residues thr<NUMBER> <NUMBER>å <NUMBER>å leu<NUMBER> <NUMBER>å gly<NUMBER> <NUMBER>å cys<NUMBER> <NUMBER>å additional interactions ie hydrophobic leu<NUMBER> met<NUMBER> leu<NUMBER> cys<NUMBER> met<NUMBER> polar thr<NUMBER> thr<NUMBER> thr<NUMBER> hie<NUMBER> thr<NUMBER> asn<NUMBER> ser<NUMBER> his<NUMBER> gln<NUMBER> negative glu<NUMBER> glycine gly<NUMBER> logged sarscov<NUMBER> pro doxycycline complex fig <NUMBER>ab whereas sarscov<NUMBER> pro docked complex tetracycline logged docking energy <NUMBER> kcalmol formation four hydrogen bonds active residues his<NUMBER> <NUMBER>å asn<NUMBER> <NUMBER>gh substantial docking energy formation strong hydrogen bonds atoms respective antibiotics active residues sarscov<NUMBER> pro indicate substantial stability docked proteaseantibiotics complexes fig s<NUMBER> interestingly sarscov<NUMBER> pro antibiotic complexes doxycycline also generated five hydrogen bonds minimum three hydrogen bonds noted minocycline docked active pocket viral protease besides antibiotics n<NUMBER> inhibitor exhibited significant hydrophobic polar negative positive glycine interactions common residues sarscov<NUMBER> pro fig <NUMBER> fig s<NUMBER> interestingly selected antibiotics docked sarscov<NUMBER> pro exhibited one type interaction catalytic dyad cys<NUMBER> his<NUMBER> substrate binding residues phe<NUMBER> leu<NUMBER> gly<NUMBER> ser<NUMBER> his<NUMBER> met<NUMBER> glu<NUMBER> essential residues required substrate binding pocket thr<NUMBER> thr<NUMBER> met<NUMBER> phe<NUMBER> asn<NUMBER> his<NUMBER> met<NUMBER> asp<NUMBER> gln<NUMBER> fig <NUMBER> fig s<NUMBER> reported viral protease crystal structure n<NUMBER> inhibitor <NUMBER> additionally gln<NUMBER> residue absolute requirement s<NUMBER> subsite p<NUMBER> position logged interaction profile selected antibiotics sarscov<NUMBER> pro inhibitors <NUMBER> antibiotics logged intermolecular interaction residues active site substratebinding pocket located clefts domain domain ii vial main protease suggested inhibit proteolytic function sarscov<NUMBER> pro required viral replication pathogenesis <NUMBER> moreover interacted residues sarscov<NUMBER> pro antibiotics docked complexes highly conserved substraterecognition pocket covs suggested selected screened antibiotics employed development broad spectrum antiviral drugs hcovs hence molecular docking simulation analysis screened antibiotics respect n<NUMBER> inhibitor suggested selected drug molecules potential inhibit sarscov<NUMBER> pro interacting catalytic dyad substrate binding residues molecular dynamics simulation employed docked complexes study stability intermolecular interaction profiling respect time <NUMBER> <NUMBER> study docked complexes antibiotics n<NUMBER> inhibitors viral protease subjected <NUMBER> ns molecular dynamics md simulation predict respective complex confirmation change stability intermolecular interactions active residues receptor atoms ligand molecules initially last pose simulation trajectory extracted studied intermolecular interaction respective complexes maximum three hydrogen j u r n l p r e p r f bonds recorded sarscov<NUMBER> pro demeclocycline two hydrogen bonds sarscov<NUMBER> pro tetracycline one hydrogen bond sarscov<NUMBER> pro doxycycline sarscov<NUMBER> pro minocycline complex sarscov<NUMBER> pro n<NUMBER> inhibitor hydrogen bonding fig s<NUMBER> fig s<NUMBER> observations predicted selected antibiotics significantly substantial affinity active pocket sarscov<NUMBER> pro comparison quantify degree conformational changes protein ligand docked complexes initially rmsd protein cα backbone sidechain heavy fit ligand protein calculated <NUMBER> ns simulation trajectories complex cα atoms sarscov<NUMBER> pro docked selected antibiotics n<NUMBER> inhibitor showed acceptable fluctuations mean<NUMBER> <NUMBER>å equilibration till end simulation fig <NUMBER> fig s<NUMBER> likewise backbone sidechain heavy atoms sarscov<NUMBER> pro respective complexes noted stable deviations <NUMBER>å except receptor complex tetracycline <NUMBER>å showed fluctuation around <NUMBER> ns followed state equilibrium till end <NUMBER> ns simulation fig s<NUMBER> besides rmsd four antibiotics fit protein exhibited acceptable deviations fig <NUMBER> notably tetracycline minocycline showed maximum variation <NUMBER>å <NUMBER> ns interval followed equilibrium <NUMBER>å <NUMBER>å respectively end <NUMBER> ns simulation fig <NUMBER> rmsd n<NUMBER> fit protein showed variations <NUMBER>å <NUMBER> ns higher deviations <NUMBER>å <NUMBER> ns till end <NUMBER> ns interval fig s<NUMBER> results indicate antibiotics docked protease complexes attained equilibrium <NUMBER> ns simulation n<NUMBER> inhibitor docked complex required longer simulation interval achieve complex stability thereof based mean rmsd trajectories selected antibiotics furthermore flexibility sarscov<NUMBER> pro docked selected compounds analyzed monitor deviations protein residues ligand atoms simulation fig s<NUMBER> complexes acceptable rmsf values protein residues recorded respect time residues nterminal <NUMBER>å exhibited low fluctuation compared cterminal last <NUMBER> residues variation <NUMBER>å besides ligands also monitored significant contacts residues βstrands containing active pocket protein supports integration docked ligands residues active region sarscov<NUMBER> pro fig s<NUMBER> moreover intermolecular interactions ligands secondary structure elements αhelices βstrands protein indicate induction slight rigidity j u r n l p r e p r f protein structure hence acceptable rmsf values protein structure residueligand contact mapping suggested structural stability sarscov<NUMBER> pro complexes antibiotics comparison native ligand n<NUMBER> inhibitor crystal structure <NUMBER> ns simulation likewise rmsf calculated selected antibiotics fit sarscov<NUMBER> pro respect simulation time suggested acceptable deviations <NUMBER>å mean structure ligand expect tetracycline atoms position <NUMBER> <NUMBER> minocycline atoms position <NUMBER> <NUMBER> fig s<NUMBER> variations heteroatoms ligands also concluded contribute relatively higher ligand fit protein rmsd antibiotics simulation furthermore rmsf calculated n<NUMBER> fit sarscov<NUMBER> pro exhibited higher deviation <NUMBER>å fig s<NUMBER> suggested contribute higher rmsd fit ligand protein md simulation fig s<NUMBER> conclusion rmsd rmsf indicates acceptable changes antibiotics docked sarscov<NUMBER> pro complexes comparison sarscov<NUMBER> pro n<NUMBER> inhibitor <NUMBER> ns md simulations protein sse αhelices βstrands monitored sse distribution sse composition analysis respective residue index simulation observed changes domains sarscov<NUMBER> pro docked respective ligands fig s<NUMBER> selected complexes sarscov<NUMBER> pro antibiotics n<NUMBER> inhibitor exhibited αhelix structures cterminal region <NUMBER> formed domain iii viral protease whilst nterminal region showed αhelices βstrands <NUMBER> constitute domain domain iii viral protease defined crystal structure formation active pocket <NUMBER> observations concluded secondary structure sarscov<NUMBER> pro complexed selected ligands total sse<NUMBER>±<NUMBER> interestingly βstrand total <NUMBER>±<NUMBER> secondary structures active pocket sarscov<NUMBER> pro monitored significantly occupied selected antibiotics n<NUMBER> inhibitor fig s<NUMBER> furthermore torsion angle potential plot also studied selected ligands exhibits relation torsion angle respective ligands respective potential energy <NUMBER> torsion angle provides necessary information number rotatable bonds ligand molecule fig s<NUMBER> doxycycline tetracycline demeclocycline minocycline n<NUMBER> inhibitor predicted <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rotatable bonds structures torsion potential histogram relationships provide standard method get insight conformational strain introduced ligands simulation assisted understand proteinbound ligand conformation results indicate ligand smaller number rotatable bonds showed stronger rigidity viceversa may contribute generate optimum geometry ligand active pocket attained higher stability correlated docking score number intermolecular interactions respective docked complexes fig <NUMBER> fig s<NUMBER> moreover modifications introduced fit ligand protein md simulation also calculated terms ligand rmsd radius gyration intramolecular hydrogen bonds molecular surface area molsa solvent accessible surface area sasa polar surface area psa fig s<NUMBER> results suggested stability selected antibiotics active pocket sarscov<NUMBER> pro comparison n<NUMBER> inhibitor binding mode ligand active pocket sarscov<NUMBER> pro analyzed atomic level interactions includes hydrogen bond formation hydrophobic contact ionic interaction salt bridge formation md simulation hence proteinligand interactions extracted <NUMBER> ns simulation trajectories support respective complex stability md simulation antibiotics comparison n<NUMBER> inhibitor showed significant interactions essential catalytic residues ie his<NUMBER> cys<NUMBER> addition substrate binding residues active pocket sarscov<NUMBER> pro fig <NUMBER> fig s<NUMBER> residues also recorded intermolecular interaction ligand molecular docking simulation fig <NUMBER> fig s<NUMBER> interestingly antibiotics observed higher number interactions residues proteinligand mapping formation hydrogen bond active residues protein <NUMBER> simulation interval exception sarscov<NUMBER> pro tetracycline complex fig <NUMBER> however asn<NUMBER> glu<NUMBER> predicted substantial hydrogen boning water bridges formation sarscov<NUMBER> pro n<NUMBER> inhibitor complex proteinligand interaction mapping data analysis fig s<NUMBER> furthermore total number contacts density respect time also j u r n l p r e p r f <NUMBER> calculated fig s<NUMBER> plots suggested multiple interactions selected antibiotics comparison n<NUMBER> inhibitor essential residues his<NUMBER> asn<NUMBER> gly<NUMBER> cys<NUMBER> glu<NUMBER> gln<NUMBER> active pocket sarscov<NUMBER> pro observations suggested substantial proteinligand intermolecular interactions stability four antibiotics comparison n<NUMBER> inhibitor throughout <NUMBER> ns md simulations inhibitor recently combinational therapy lopinavir potent compounds sarscov<NUMBER> virus suggested increase synergy decrease effective concentration lopinavir <NUMBER> instance triple antiviral therapy composed interferon β<NUMBER>b lopinavirritonavir ribavirin sarscov<NUMBER> pro reported superior safe lopinavirritonavir alone reduce virus shedding lessening symptoms facilitating discharge infected patients mild moderate degree sarscov<NUMBER> infection <NUMBER> regard based computational studies selected antibiotics ie doxycycline minocycline demeclocycline tetracycline may helpful combinational therapy lopinavirritonavir ribavirin sarscov<NUMBER> infection study aimed repurpose antibiotics known antiviral activity potential docking structures molecular dynamics simulations trajectories available upon request corresponding authors author declares competing interest work figure s<NUMBER>s<NUMBER> journal preproof human coronaviruses hcovs middleeast respiratory syndrome coronavirus merscov severe acute respiratory syndrome coronavirus sarscov <NUMBER> novel coronavirus <NUMBER>ncov also called sarscov<NUMBER> emerged animal reservoirs aggravate pandemic high mortality morbidity coronaviruses covs positivesense singlestranded rna ssrna virus contain largest rna genome <NUMBER> kb six ten open reading frames orfs enclosed enveloped protein form spherical particles <NUMBER> nm size <NUMBER> <NUMBER> genetic material hcovs highly susceptible frequent recombination process suggested direct establishment new hcov strains altered virulence <NUMBER> result total seven main hcovs recorded viz hcov<NUMBER>e hcovnl<NUMBER> hcovoc<NUMBER> hcovhku<NUMBER> merscov sarscov sarscov<NUMBER> viruses held accountable fatal infections respiratory system system symptoms including diarrhea nausea <NUMBER> <NUMBER> hcovs belong coronaviridae family order nidovirales classified four genera α β γ δ <NUMBER> recently discovered sarscov<NUMBER> belongs β genus shares <NUMBER> sequence similarity sarsrelated coronavirus <NUMBER> identical wholegenome level bat coronavirus <NUMBER> <NUMBER> genome analysis coronaviruses including sarscov<NUMBER> genome genbankmn<NUMBER> revealed four nonstructural proteins ie papainlike protease pl pro <NUMBER>chymotrypsinlike <NUMBER>cl pro helicase rna polymerase four structural proteins viz nucleocapsid n protein membrane protein envelope e protein spike protein accessory proteins <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER>cl pro pl pro reported transcription replication virus <NUMBER> remarkably vitro inhibition proteases selected inhibitors shown antiviral activity coronaviruses covs <NUMBER> <NUMBER> observations concluded <NUMBER>cl pro main coronavirus protease pro <NUMBER> essentially required conduct replication cycle virus <NUMBER> <NUMBER> like hcovs sarscov<NUMBER> pro digests polyprotein conserved sites starts autolytic cleavage pp<NUMBER>a pp<NUMBER>ab site encoded virus orf<NUMBER>ab shares <NUMBER> sequence similarity pro sarscov strain <NUMBER> <NUMBER> conquer coronavirus infections inhibition viral pro functionally important viral life cycle absence human homologues approved conventional antiviral therapeutic strategy <NUMBER> current scenario despite numerous efforts drug vaccine yet approved hcovs expected take months years new interventions <NUMBER> recently various pro inhibitors demonstrated broadspectrum vitro activities covs via interacting conserved key residues required substrate recognition respective pro enzymes <NUMBER> <NUMBER> moreover urgency sarscov<NUMBER> outbreak drug repurposing represented effective drug discovery approach existing drugs suggestively shorten time condense cost comparison de novodrug discovery strategy randomized clinical trials <NUMBER> facilitate rapid drug discovery computational drug repurposing approaches established effective method reveal new indications already known drugs aid computational algorithms molecular docking simulation molecular dynamics simulation predict drugtarget interactions binding stability respectively <NUMBER> <NUMBER> previously computational drug repurposing approaches employed identify potential drug candidates viral infections including ebola zika dengue influenza infections <NUMBER> hcovs sarscov merscov <NUMBER> <NUMBER> <NUMBER> also nonpeptidic activesitedirected inhibition sarscov pro discovered combination screening docking methods <NUMBER> likewise bifunctional aryl boronic acid compounds discovered inhibit sarscov pro using combination experimental computational methods <NUMBER> sarscov<NUMBER> outbreak computational drug repurposing also applied find potential drugs investigations already reported <NUMBER> <NUMBER> <NUMBER> area drug repurposing antibiotics tetracyclines derivatives repurposed viral infections <NUMBER> <NUMBER> antibiotics well designated broadspectrum bacteriostatic inhibitors selectively inhibit microbial protein synthesis including naturally occurring polyketide compounds chlortetracycline oxytetracycline tetracycline semisynthetic derivatives minocycline doxycycline methacycline <NUMBER> notably tetracycline derivatives ie doxycycline reported exert antiviral effects antimurine retrovirus <NUMBER> chikungunya infection <NUMBER> blockage dengue virus replication infected cell lines <NUMBER> <NUMBER> besides demeclocycline known exert antiviral activity west nile virus wnv <NUMBER> included list antiviral compounds <NUMBER> another broad spectrum tetracycline derivative minocycline initially reported human immunodeficiency virus hiv type <NUMBER> infection <NUMBER> later studied viruses wnv japanese encephalitis virus jev simian immunodeficiency virus siv sindbis human tlymphocytic virus type<NUMBER> htlv<NUMBER> rabies reoviruses <NUMBER> moreover tetracyclines eg tetracycline doxycycline minocycline known zinc chelating agents postulated inhibit covid<NUMBER> infection restricting viral replication host <NUMBER> additionally synthetic halogenated tetracycline eravacycline demonstrated inhibitory effect sarscov sarscov<NUMBER> merscov hepatitis c virus hcv using computational studies <NUMBER> hence impression tetracyclines derivatives inhibits viral infections hypothesized antibiotics reported antiviral activities may helpful sarscov<NUMBER> inhibition blockage main protease viz pro thereof employed structure based molecular docking selected four tetracyclines ie doxycycline tetracycline demeclocycline minocycline known antiviral activities viruses pro sarscov<NUMBER> similar virtual screening approach recently applied identify tetracycline derivatives flavivirus inhibitors <NUMBER> following docked proteinantibiotics complexes evaluated complex stability via classical molecular dynamics simulation binding affinity stability selected viral proteaseantibiotics complexes also compared docked complexes protease native ligand n<NUMBER> inhibitor generate comparative study mentioned fig <NUMBER> crystal structure novel sarscov<NUMBER> main protease sarscov<NUMBER> pro downloaded pdb database httpswwwrcsb org pdb id<NUMBER>lu<NUMBER> <NUMBER> viral pro elucidated <NUMBER> å resolution dimer monomer contained three domains domain residues <NUMBER> domain ii residues <NUMBER> domain iii residues <NUMBER> connected long interconnecting loop residues <NUMBER> domains ii iii catalytic dyad his<NUMBER> cys<NUMBER> substrate binding sites also defined domains ii crystal structure n<NUMBER> inhibitor <NUMBER> besides <NUMBER>d structures selected antibiotics ie doxycycline cid <NUMBER> tetracycline cid <NUMBER> demeclocycline cid <NUMBER> minocycline cid <NUMBER> also downloaded pubchem database httpspubchemncbinlmnihgov molecular docking simulation sarscov<NUMBER> pro selected antibiotics conducted chimeraautodock vina plugin setup determine interacting residues protein respective ligands briefly protein ligand structures minimized using default parameters structure minimization tool uscf chimera<NUMBER> <NUMBER> following receptor ligands prepared using dock prep tool chimera default parameters native ligand crystal structure removed polar hydrogen atoms charges added finally molecular docking simulations performed using autodock vina <NUMBER> plugin default setting native ligand binding pocket adopting docking grid size <NUMBER> × <NUMBER> × <NUMBER> å along three x z axes covering essential residues center −<NUMBER> <NUMBER> <NUMBER> å region provide copious space ligand conformations docking least <NUMBER> conformers generated conformer lowest binding energy rmsd chosen analysis free academic maestro v<NUMBER> schrödinger release <NUMBER> maestro schrödinger llc new york ny <NUMBER> herein noncovalent interactions viz hydrogen bonding hydrophobic ππ interaction πcation interaction positive basic positive amino acids negative acidic negative amino acids polar polar amino acids glycine nonpolar interaction salt bridges interactions calculated cutoff radius <NUMBER> å default conditions <NUMBER>d <NUMBER>d interaction images generated similar docking methodology also employed crystal structure ligand ie michael acceptor inhibitor known n<NUMBER> inhibitor <NUMBER> validate docking procedure comparative analysis selected antibiotics best scored poses receptorligand complexes evaluated complex stability <NUMBER> ns molecular dynamics md simulations using free academic desmond v<NUMBER> module schrödingermaestro v<NUMBER> <NUMBER> linux environment hp z<NUMBER> workstation md systems proteinligand complexes fabricated orthorhombic grid box <NUMBER> å × <NUMBER> å × <NUMBER> å buffer followed addition tip<NUMBER>p transferable intermolecular potential <NUMBER> point water molecules system minimization using system builder tools desmondmaestro interface later salt ion placement omitted <NUMBER> å ligand whole system neutralized addition counter ions besides <NUMBER> ps time interval set anisotropic diagonal position scaling reserve constant pressure md simulation additionally temperature system set <NUMBER> k coupled <NUMBER> ps npt reassembly <NUMBER> atm pressure furthermore system density preserved near <NUMBER> gcm <NUMBER> calculations conducted default parameters finally md simulation complex conducted <NUMBER> ns interval similar conditions subsequently simulation trajectories analyzed simulation interaction diagram tool desmond v<NUMBER> module schrödingermaestro v<NUMBER> <NUMBER> molecular docking algorithms widely used predict bioactive compounds drug repurposing various drug targetable proteins diseases infections <NUMBER> <NUMBER> likewise study also employed molecular docking simulation approach selected antibiotic tetracyclines ie doxycycline tetracycline demeclocycline minocycline predict instinctively potential sarscov<NUMBER> infection pro inhibition docked drugs n<NUMBER> inhibitor showed significant docking confirmation binding affinity energies −<NUMBER> kcalmol least rmsd <NUMBER> value default autodock vina default parameters active pocket sarscov<NUMBER> pro respect n<NUMBER> inhibitor figs <NUMBER> s<NUMBER> docked sarscov<NUMBER> pro doxycycline complex recorded significant −<NUMBER> kcalmol docking score formed five hydrogen bonds viral protease active residues thr<NUMBER> <NUMBER> å <NUMBER> å leu<NUMBER> <NUMBER> å gly<NUMBER> <NUMBER> å cys<NUMBER> <NUMBER> å additional interactions ie hydrophobic leu<NUMBER> met<NUMBER> leu<NUMBER> cys<NUMBER> met<NUMBER> polar thr<NUMBER> thr<NUMBER> thr<NUMBER> hie<NUMBER> thr<NUMBER> asn<NUMBER> ser<NUMBER> his<NUMBER> gln<NUMBER> negative glu<NUMBER> glycine gly<NUMBER> logged sarscov<NUMBER> pro doxycycline complex fig <NUMBER>ab whereas sarscov<NUMBER> pro docked complex tetracycline logged docking energy −<NUMBER> kcalmol formation four hydrogen bonds active residues his<NUMBER> <NUMBER> å asn<NUMBER> <NUMBER> å gly<NUMBER> <NUMBER> å gln<NUMBER> <NUMBER> å also recorded moreover hydrophobic interactions leu<NUMBER> met<NUMBER> phe<NUMBER> leu<NUMBER> cys<NUMBER> met<NUMBER> polar interactions thr<NUMBER> thr<NUMBER> his<NUMBER> thr<NUMBER> ser<NUMBER> asn<NUMBER> ser<NUMBER> his<NUMBER> his<NUMBER> gln<NUMBER> negative interactions glu<NUMBER> glycine interactions gly<NUMBER> also observed residues sarscov<NUMBER> pro atoms tetracycline fig <NUMBER>cd similarly sarscov<NUMBER> pro demeclocycline complex exhibited significant docking score −<NUMBER> kcalmol along formation three hydrogen bonds essential residues asn<NUMBER> <NUMBER> å gly<NUMBER> <NUMBER> å gln<NUMBER> <NUMBER> å sarscov<NUMBER> pro additionally respective complex noted hydrophobic interactions leu<NUMBER> met<NUMBER> leu<NUMBER> cys<NUMBER> met<NUMBER> polar interactions thr<NUMBER> thr<NUMBER> hie<NUMBER> ser<NUMBER> asn<NUMBER> ser<NUMBER> his<NUMBER> gln<NUMBER> thr<NUMBER> gln<NUMBER> negative interactions glu<NUMBER> asp<NUMBER> positive interactions arg<NUMBER> glycine interactions gly<NUMBER> fig <NUMBER>ef sarscov<NUMBER> pro minocycline complex showed substantial binding energy −<NUMBER> kcalmol followed formation three hydrogen bonds residues asn<NUMBER> <NUMBER> å gly<NUMBER> <NUMBER> å glu<NUMBER> <NUMBER> å active pocket viral protease intermolecular interactions viz hydrophobic interactions leu<NUMBER> met<NUMBER> pro<NUMBER> tyr<NUMBER> leu<NUMBER> cys<NUMBER> met<NUMBER> polar interactions thr<NUMBER> thr<NUMBER> his<NUMBER> ser<NUMBER> asn<NUMBER> ser<NUMBER> his<NUMBER> gln<NUMBER> negative interactions glu<NUMBER> asp<NUMBER> positive interactions arg<NUMBER> glycine interactions gly<NUMBER> also observed sarscov<NUMBER> prominocycline docked complex fig <NUMBER>gh substantial docking energy formation strong hydrogen bonds atoms respective antibiotics active residues sarscov<NUMBER> pro indicate substantial stability docked proteaseantibiotics complexes furthermore docked poses antibiotics sarscov<NUMBER> s<NUMBER> interestingly sarscov<NUMBER> pro antibiotic complexes doxycycline also generated five hydrogen bonds minimum three hydrogen bonds noted minocycline docked active pocket viral protease besides antibiotics n<NUMBER> inhibitor exhibited significant hydrophobic polar negative positive glycine interactions common residues sarscov<NUMBER> pro figs <NUMBER> s<NUMBER> interestingly selected antibiotics docked sarscov<NUMBER> pro exhibited one type interaction catalytic dyad cys<NUMBER> his<NUMBER> substrate binding residues phe<NUMBER> leu<NUMBER> gly<NUMBER> ser<NUMBER> his<NUMBER> met<NUMBER> glu<NUMBER> essential residues required substrate binding pocket thr<NUMBER> thr<NUMBER> met<NUMBER> phe<NUMBER> asn<NUMBER> his<NUMBER> met<NUMBER> asp<NUMBER> gln<NUMBER> figs <NUMBER> s<NUMBER> reported viral protease crystal structure n<NUMBER> inhibitor <NUMBER> additionally gln<NUMBER> residue absolute requirement s<NUMBER> subsite p<NUMBER> position logged interaction profile selected antibiotics sarscov<NUMBER> pro inhibitors <NUMBER> antibiotics logged intermolecular interaction residues active site substratebinding pocket located clefts domain domain ii vial main protease suggested inhibit proteolytic function sarscov<NUMBER> pro required viral replication pathogenesis <NUMBER> moreover interacted residues sarscov<NUMBER> pro antibiotics docked complexes highly conserved substraterecognition pocket covs suggested selected screened antibiotics employed development broad spectrum antiviral drugs hcovs hence molecular docking simulation analysis screened antibiotics respect n<NUMBER> inhibitor suggested selected drug molecules potential inhibit sarscov<NUMBER> pro interacting catalytic dyad substrate binding residues molecular dynamics simulation employed docked complexes study stability intermolecular interaction profiling respect time <NUMBER> <NUMBER> study docked complexes antibiotics n<NUMBER> inhibitor viral protease subjected <NUMBER> ns molecular dynamics md simulation predict respective complex confirmation change stability intermolecular interactions active residues receptor atoms ligand molecules initially last pose simulation trajectory extracted studied intermolecular interaction respective complexes maximum three hydrogen bonds recorded sarscov<NUMBER> pro demeclocycline two hydrogen bonds sarscov<NUMBER> protetracycline one hydrogen bond sarscov<NUMBER> pro doxycycline sarscov<NUMBER> pro minocycline complex sarscov<NUMBER> pro n<NUMBER> inhibitor hydrogen bonding figs s<NUMBER> s<NUMBER> observations predicted selected antibiotics substantial affinity active pocket sarscov<NUMBER> pro comparison n<NUMBER> inhibitor verified selected receptorligand complex stabilities four properties calculated respective simulation trajectories ie root mean square deviation rmsd b root mean square fluctuation rmsf c protein secondary structure element sse changes nullify abnormal structural changes conformational modification docked ligands respect simulation time proteinligand contacts mapping performed analyze type interaction ligand atoms residues protein md simulation quantify degree conformational changes protein ligand docked complexes initially rmsd protein cα backbone sidechain heavy fit ligand protein calculated <NUMBER> ns simulation trajectories complex cα atoms sarscov<NUMBER> pro docked selected antibiotics n<NUMBER> inhibitor showed acceptable fluctuations mean <NUMBER> <NUMBER> å equilibration till end simulation figs <NUMBER> s<NUMBER> likewise backbone sidechain heavy atoms sarscov<NUMBER> pro respective complexes noted stable deviations <NUMBER> å except receptor complex tetracycline <NUMBER> å showed fluctuation around <NUMBER> ns followed state equilibrium till end <NUMBER> ns simulation fig s<NUMBER> besides rmsd four antibiotics fit protein exhibited acceptable deviations fig <NUMBER> notably tetracycline minocycline showed maximum variation <NUMBER> å <NUMBER> <NUMBER> ns interval followed equilibrium <NUMBER> å <NUMBER> å respectively end <NUMBER> ns simulation fig <NUMBER> rmsd n<NUMBER> inhibitor fit protein showed variations <NUMBER> å <NUMBER> <NUMBER> ns higher deviations <NUMBER> å <NUMBER> ns till end <NUMBER> ns interval fig s<NUMBER> results indicate antibiotics docked protease complexes attained equilibrium <NUMBER> ns simulation n<NUMBER> inhibitor docked complex required longer simulation interval achieve complex stability thereof based mean rmsd trajectories selected antibiotics concluded significant complex stability comparison n<NUMBER> inhibitor docked sarscov<NUMBER> pro furthermore flexibility sarscov<NUMBER> pro docked selected compounds analyzed monitor deviations protein residues ligand atoms simulation fig s<NUMBER> complexes acceptable rmsf values protein residues recorded respect time residues nterminal <NUMBER> å exhibited low fluctuation compared cterminal last <NUMBER> residues variation <NUMBER> å besides ligands also monitored significant contacts residues βstrands containing active pocket protein supports integration docked ligands residues active region sarscov<NUMBER> pro fig s<NUMBER> moreover intermolecular interactions ligands secondary structure elements αhelices βstrands protein indicate induction slight rigidity protein structure hence acceptable rmsf values protein structure residueligand contact mapping suggested structural stability sarscov<NUMBER> pro complexes antibiotics comparison native ligand n<NUMBER> inhibitor crystal structure <NUMBER> ns simulation likewise rmsf calculated selected antibiotics fit sarscov<NUMBER> pro respect simulation time suggested acceptable deviations <NUMBER> å mean structure ligand expect tetracycline atoms position <NUMBER> <NUMBER> minocycline atoms position <NUMBER> <NUMBER> fig s<NUMBER> variations heteroatoms ligands also concluded contribute relatively higher ligand fit protein rmsd antibiotics simulation furthermore rmsf calculated n<NUMBER> inhibitor fit sarscov<NUMBER> pro exhibited higher deviations <NUMBER> å fig s<NUMBER> suggested contribute higher rmsd fit ligand protein md simulation fig s<NUMBER> conclusion rmsd rmsf indicate acceptable changes antibiotics docked sarscov<NUMBER> pro complexes comparison sarscov<NUMBER> pro n<NUMBER> inhibitor <NUMBER> ns md simulations protein sse αhelices βstrands monitored sse distribution sse composition analysis respective residue index simulation observed changes domains sarscov<NUMBER> pro docked respective ligands fig s<NUMBER> selected complexes sarscov<NUMBER> pro antibiotics n<NUMBER> inhibitor exhibited αhelix structures cterminal region <NUMBER> formed domain iii viral protease nterminal region showed αhelices βstrands <NUMBER> constitute domain domain iii viral protease defined crystal structure formation active pocket <NUMBER> observations concluded secondary structure sarscov<NUMBER> pro complexed selected ligands total sse <NUMBER> ± <NUMBER> interestingly βstrand total <NUMBER> ± <NUMBER> secondary structures active pocket sarscov<NUMBER> pro monitored significantly occupied selected antibiotics n<NUMBER> inhibitor fig s<NUMBER> furthermore torsion angle potential plot also studied selected ligands exhibits relation torsion angle respective ligands respective potential energy <NUMBER> torsion angle provides necessary information number rotatable bonds ligand molecule fig s<NUMBER> doxycycline tetracycline demeclocycline minocycline n<NUMBER> inhibitor predicted <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> rotatable bonds structures torsion potential histogram relationships provide standard method get insight conformational strain introduced ligands simulation assisted understand proteinbound ligand conformation results indicate ligand smaller number rotatable bonds showed stronger rigidity viceversa may contribute generate optimum geometry ligand active pocket attained higher stability correlated docking score number intermolecular interactions respective docked complexes figs <NUMBER> s<NUMBER> moreover modifications introduced fit ligand protein md simulation also calculated terms ligand rmsd radius gyration intramolecular hydrogen bonds molecular surface area molsa solvent accessible surface area sasa polar surface area psa fig s<NUMBER> results suggested stability selected antibiotics active pocket sarscov<NUMBER> pro comparison n<NUMBER> inhibitor binding mode ligand active pocket sarscov<NUMBER> pro analyzed atomic level interactions includes hydrogen bond formation hydrophobic contact ionic interaction salt bridge formation md simulation hence proteinligand interactions extracted <NUMBER> ns simulation trajectories support respective complex stability md simulation antibiotics comparison n<NUMBER> inhibitor showed significant interactions essential catalytic residues ie his<NUMBER> cys<NUMBER> addition substrate binding residues active pocket sarscov<NUMBER> pro figs <NUMBER> s<NUMBER> residues also recorded intermolecular interaction ligands molecular docking simulation figs <NUMBER> s<NUMBER> interestingly antibiotics observed higher number interactions residues proteinligand mapping formation hydrogen bond active residues protein <NUMBER> simulation interval exception sarscov<NUMBER> pro tetracycline complex fig <NUMBER> however asn<NUMBER> glu<NUMBER> predicted substantial hydrogen boning water bridges formation sarscov<NUMBER> pro n<NUMBER> inhibitor ab doxycycline cd tetracycline ef demeclocycline gh minocycline extracted <NUMBER> ns md simulations <NUMBER>d interaction diagram residues cystine green glutamic acid red histidine glutamine blue glycine grey exhibit hydrophobic negative polar nonpolar interactions respectively along hydrogen bonding pink arrow ionic interaction sodium ion black line receptor extracted <NUMBER> total md simulation interaction interval interpretation references color figure legend reader referred web version article complex proteinligand interaction mapping data analysis fig s<NUMBER> furthermore total number contacts density respect time also calculated fig s<NUMBER> plots suggested multiple interactions selected antibiotics comparison n<NUMBER> inhibitor essential residues his<NUMBER> asn<NUMBER> gly<NUMBER> cys<NUMBER> glu<NUMBER> gln<NUMBER> active pocket sarscov<NUMBER> pro observations suggested substantial proteinligand intermolecular interactions stability four antibiotics comparison n<NUMBER> inhibitor throughout <NUMBER> ns md simulations hence based docking score simulation trajectory analysis selected four antibiotics predicted potential sarscov<NUMBER> pro inhibitor order viz doxycycline minocycline demeclocycline tetracycline challenge sarscov<NUMBER> infection comparison n<NUMBER> inhibitor recently combinational therapy lopinavir potent compounds sarscov<NUMBER> virus suggested increase synergy decrease effective concentration lopinavir <NUMBER> instance triple antiviral therapy composed interferon β<NUMBER>b lopinavirritonavir ribavirin sarscov<NUMBER> pro reported superior safe lopinavirritonavir alone reduce virus shedding lessening symptoms facilitating discharge infected patients mild moderate degree sarscov<NUMBER> infection <NUMBER> regard based computational studies selected antibiotics ie doxycycline minocycline demeclocycline tetracycline may helpful combinational therapy lopinavirritonavir ribavirin sarscov<NUMBER> infection study aimed repurpose antibiotics known antiviral activity potential inhibitor sarscov<NUMBER> pro aid molecular simulation approaches total four potent antibiotics viz doxycycline tetracycline demeclocycline minocycline evaluated sarscov<NUMBER> pro inhibitor comparison native ligand sarscov<NUMBER> pro crystal structure n<NUMBER> inhibitor molecular docking simulation selected antibiotics showed docking score −<NUMBER> kcalmol interaction catalytic dyad sarscov<NUMBER> pro ie his<NUMBER> cys<NUMBER> complexes analyzed structural stability <NUMBER> ns classical molecular dynamics simulation suggested considerable stability sarscov<NUMBER> pro docked complexes antibiotics comparison n<NUMBER> inhibitor sarscov<NUMBER> pro via strong multiple intermolecular interactions binding mode analysis molecular dynamics simulation analysis followed interaction profiles collected simulation interval supported selected antibiotics substantial stability active pocket sarscov<NUMBER> pro conclusion based docking score molecular dynamics simulation trajectory analysis selected four antibiotics used potential sarscov<NUMBER> pro inhibitor order viz doxycycline minocycline demeclocycline tetracycline challenge sarscov<NUMBER> infection hence screened computationally validated antibiotics evaluated vitro sarscov<NUMBER> pro inhibition viral infection single dose synergistic concentrations drug development combinational therapy sarscov<NUMBER> infection work supported <NUMBER> yeungnam university research grant <NUMBER>a<NUMBER> shiv bharadwaj vivek dhar dwivedi designed study shiv bharadwaj performed computational experiments shiv bharadwaj vivek dhar dwivedi analyzed data kyung eun lee sang gu kang assisted data analysis shiv bharadwaj wrote original revised manuscript sang gu kang responsible conduction evaluation present work docking structures molecular dynamics simulations trajectories available upon request corresponding authors author declares competing interest work supplementary data article found online https doiorg<NUMBER>jlfs<NUMBER> outbreak pneumonia named covid<NUMBER> caused novel coronavirus sarscov<NUMBER> <NUMBER>ncov infected <NUMBER> people worldwide <NUMBER>th march <NUMBER> apart china countries regions including south korea iran europe reported rapid increase number covid<NUMBER> cases implying novel coronavirus posed global health threat current circumstance absence specific vaccines medicines sarscov<NUMBER> urgent discover effective therapies especially drugs treat resulting covid<NUMBER> disease prevent virus spreading considering development new drug generally takes years probably best therapeutic shortcut apply drug repositioning strategy ie finding new uses old drugs <NUMBER> <NUMBER> <NUMBER> identify potential antiviral effects sarscov<NUMBER> existing drugs approved clinical use enter clinical trials existing drugs potent antiviral efficacy directly applied treat covid<NUMBER> short time safety verified principle clinical trials study applied datadriven framework combines machine learning statistical analysis methods systematically integrate largescale available coronavirusrelated data identify drug candidates sarscov<NUMBER> set <NUMBER> drug candidates mainly including approved investigational experimental drugs silico screening process followed experimental validation revealed polyadpribose polymerase <NUMBER> parp<NUMBER> inhibitor cvl<NUMBER> currently phase clinical trial may serve potential drug candidate treat vitro assays demonstrated cvl<NUMBER> exhibit effective inhibitory activity sarscov<NUMBER> replication dosedependent manner obvious cytopathic effect addition found human peripheral blood mononuclear cells pbmcs cvl<NUMBER> able suppress cpginduced production il<NUMBER> reported previously high relevance viral pathogenesis covid<NUMBER> especially intensive care unit icu patients infected sarscov<NUMBER> vivo pharmacokinetic toxicokinetic studies rats monkeys showed cvl<NUMBER> highly distributed lung tissue apparent sign toxicity observed makes appealing potential drug candidate treatment novel pneumonia caused sarscov<NUMBER> infection moreover molecular docking study suggested cvl<NUMBER> may bind nterminal domain nucleocapsid n protein sarscov<NUMBER> providing possible mode antiviral action sarscov<NUMBER> based data present study previous known evidences reported literature also discussed several putative mechanisms antisarscov<NUMBER> effects cvl<NUMBER> parp<NUMBER> inhibitors involved treatment covid<NUMBER> overall results indicated parp<NUMBER> inhibitor cvl<NUMBER> identified drug repositioning pipeline may serve effective therapeutic agent covid<NUMBER> overview datadriven drug repositioning framework shown figure <NUMBER>a first constructed virus related knowledge graph consisting drugtarget interactions proteinprotein interactions similarity networks publically available databases methods three different types nodes ie drugs human targets virus targets within knowledge graph connected edges describing interactions associations similarities establish bridges information aggregation knowledge mining applied networkbased knowledge mining algorithm predict initial list drug candidates potentially used treat sarscov<NUMBER> infection figure <NUMBER>b methods next narrowed list drug candidates previously reported evidences antiviral activities based text mining results largescale literature texts derived deep learning based relation extraction method named bere <NUMBER> figure <NUMBER>c methods followed minimum manual checking used connectivity map analysis approach <NUMBER> gene expression profiles ten sarscovinfected patients <NUMBER> refine list drug candidates sarscov<NUMBER> figure <NUMBER>d table <NUMBER> table s<NUMBER> methods screening process revealed polyadpribose polymerase <NUMBER> parp<NUMBER> inhibitor pj<NUMBER> could potentially antiviral activities sarscov<NUMBER> demonstrate computational pipeline drug repositioning yield reasonably accurate prediction results also validated networkbased knowledge mining algorithm figure <NUMBER>b using retrospective data two coronaviruses closely related sarscov<NUMBER> relatively well studied literature ie sarscov merscov aid developed text mining tool bere found many drugs reported previously literature antiviral activities corresponding coronavirus also among top list predicted results table <NUMBER> example chloroquine fdaapproved drug treating malaria <NUMBER> previously reported exhibit micromolar antisarscov activity vitro <NUMBER> also repurposed targeting virus prediction framework gemcitabine originally approved treating certain types cancers <NUMBER> also predicted targeting sarscov validation previous vitro studies <NUMBER> cyclosporine calcineurin inhibitor approved immunomodulatory drug <NUMBER> observed block replication sarscov <NUMBER> also successfully predicted approach among predicted top list merscov miltefosine approved treating leishmaniasis <NUMBER> previously identified antimerscov activity <NUMBER> chlorpromazine imatinib used treating schizophrenia <NUMBER> leukemia <NUMBER> respectively also selected computational pipeline antimerscov drugs validated previous vitro experiments <NUMBER> thus retrospective study illustrated computational framework able predict effective drug candidates specific coronavirus pj<NUMBER> still currently preclinical trial stage drugbank id db<NUMBER> <NUMBER> selected two parp<NUMBER> inhibitors including olaparib mefuparib hydrochloride cvl<NUMBER> figure s<NUMBER> currently fdaapproved phase clinical trial respectively initial study first conducted pilot experimental test vitro methods antisarscov<NUMBER> activities olaparib cvl<NUMBER> several related drugs figure <NUMBER>a found parp<NUMBER> inhibitors olaparib cvl<NUMBER> exhibited inhibitory effects sarscov<NUMBER> replication nevertheless cvl<NUMBER> showed much higher inhibition rate olaparib specifically olaparib inhibited sarscov<NUMBER> replication <NUMBER> concentration <NUMBER> µm cvl<NUMBER> reached <NUMBER> reduction concentration <NUMBER> µm notably antiviral efficacy cvl<NUMBER> even surpassed arbidol one standard treatments covid<NUMBER> diagnosis treatment protocol novel coronavirus pneumonia trial version <NUMBER> promulgated chinese government httpwwwnhcgovcnyzygjs<NUMBER>p<NUMBER>a<NUMBER>dd<NUMBER>d<NUMBER>df <NUMBER>d<NUMBER>da<NUMBER>aefc<NUMBER>filesb<NUMBER>cfeb<NUMBER>bc<NUMBER>af<NUMBER>f<NUMBER>bf<NUMBER>b<NUMBER>pdf particular arbidol inhibited sarscov<NUMBER> replication <NUMBER> <NUMBER> µm much lower cvl<NUMBER> concentration figure <NUMBER>a contrast oseltamivir zanamivir drugs used preventing influenza virus infection baricitinib jak<NUMBER> inhibitor recommended <NUMBER> treat showed inhibitory activities sarscov<NUMBER> concentration <NUMBER> µm <NUMBER> µm based pilot experimental results chose cvl<NUMBER> subsequent experimental studies vitro assays methods showed cvl<NUMBER> exhibited effective inhibitory activity sarscov<NUMBER> replication dosedependent manner ec <NUMBER> <NUMBER> µm figure <NUMBER>b also assessed cytotoxicity cvl<NUMBER> cck<NUMBER> assay methods found cvl<NUMBER> cc <NUMBER> systematically assess inhibitory activities cvl<NUMBER> sarscov<NUMBER> also performed timeofaddition assay methods determine stage cvl<NUMBER> inhibits viral infection remdesivir entered clinical trials treatment covid<NUMBER> httpsclinicaltrialsgovct<NUMBER>shownct<NUMBER> <NUMBER> also tested assay comparison particular compared dmso control group cvl<NUMBER> remdesivir showed potent antiviral activities fulltime procedure sarscov<NUMBER> infection vero e<NUMBER> cells figure <NUMBER>d results timeofaddition assay indicated cvl<NUMBER> partially work viral entry significantly inhibit replication virus postentry remdesivir function postentry stage figure <NUMBER>d <NUMBER>e together results vitro assays indicated cvl<NUMBER> evaluated potential therapeutic agent treating covid<NUMBER> recently become evident interleukin<NUMBER> il<NUMBER> one important cytokines viral infection <NUMBER> emerging clinical studies humans animals linked excessive synthesis il<NUMBER> persistence many viruses human immunodeficiency virus hiv <NUMBER> foot mouth disease virus <NUMBER> vesicular stomatitis virus vsv <NUMBER> addition vivo study friend retrovirus fv mouse model showed il<NUMBER> blockage reduce viral loads enhance virusspecific cd<NUMBER> tcell immunity <NUMBER> findings supported hypothesis rapid production il<NUMBER> might possible mechanism leading deleterious clinical manifestations viral pathogenesis <NUMBER> recently published researches clinical characteristics severe patients sarscov<NUMBER> infection showed il<NUMBER> significantly elevated especially icu patients caused excessive activated immune response <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> pathological role il<NUMBER> sarscov<NUMBER> infection indicated il<NUMBER> blockade may provide feasible therapy treatment covid<NUMBER> test whether cvl<NUMBER> able regulate il<NUMBER> production vitro stimulated il<NUMBER> production peripheral blood mononuclear cells pmbcs cpgodn <NUMBER> effective stimulator cytokines chemokines incubation pbmcs <NUMBER> µm cpgodn <NUMBER> <NUMBER> h methods induced il<NUMBER> production <NUMBER> compared untreated cells figure <NUMBER> presence cvl<NUMBER> stimulatory effect cpgodn <NUMBER> counteracted study showed cvl<NUMBER> inhibited cpginduced il<NUMBER> upregulation timeand dosedependent manner figure <NUMBER> specifically exposure cvl<NUMBER> concentrations <NUMBER> µm <NUMBER> µm <NUMBER> h attenuated cpginduced il<NUMBER> production <NUMBER> <NUMBER> respectively results provided vitro evidence support cvl<NUMBER> potential therapeutic agent treating proinflammatory response caused sarscov<NUMBER> infection table s<NUMBER> also previously reported <NUMBER> among seven tissues ie lung spleen liver kidney stomach heart brain observed lung highest cvl<NUMBER> concentration <NUMBER>fold higher compared plasma table <NUMBER> observation lung highest concentration cvl<NUMBER> line fact sarscov<NUMBER> virus pathological impact lung high viral loads suggested cvl<NUMBER> potential used indications lung lesions caused sarscov<NUMBER> infection antiviral profile established animal models clinical trials furthermore compared pharmacokinetic data cvl<NUMBER> arbidol broadspectrum antiviral drug commercialized china since <NUMBER> recommended treat sarscov<NUMBER>infected patients chinese government found pharmacokinetic parameters cvl<NUMBER> arbidol comparable similar plasma concentrations drug exposures table s<NUMBER> arbidol mostly distributed stomach plasma post administration rats contrast higher distributions cvl<NUMBER> tissues especially lung rather plasma compared arbidol indicated superior pharmacokinetic profile cvl<NUMBER> may render better potential antiviral treatment sarscov<NUMBER> infection lung rats orally administrated <NUMBER> mgkg cvl<NUMBER> <NUMBER> consecutive days followed <NUMBER> days without drug administration methods observed significant difference body weight rats among different dosage control groups figure <NUMBER>a next conducted toxicokinetic analysis cvl<NUMBER> rats methods particular rats given cvl<NUMBER> <NUMBER> mgkg oral gavage day consecutive <NUMBER> days followed <NUMBER> days without cvl<NUMBER> administration investigate reversibility toxic effects compound examine whether potential delayedonset toxicity drug rats results showed maximum tolerable dose mtd noobserved adverse effect level noael <NUMBER> mgkg <NUMBER> mgkg respectively exposure female rats cvl<NUMBER> auc <NUMBER>−<NUMBER> <NUMBER> h·ngml day <NUMBER> <NUMBER> h·ngml day <NUMBER> male rats auc <NUMBER>−<NUMBER> <NUMBER> h·ngml day <NUMBER> <NUMBER> h·ngml day <NUMBER> table s<NUMBER> based toxicokinetic results repeated dose studies rats survived <NUMBER>day treatment period showed apparent signs toxicity monkeys administered cvl<NUMBER> <NUMBER> <NUMBER> <NUMBER> mgkg nasogastric feeding tubes consecutive daily dosing schedule <NUMBER> days followed <NUMBER>day recovery period methods slight decrease body weight observed highdose <NUMBER> mgkg group changes reversed <NUMBER>day recovery period overall vivo data showed cvl<NUMBER> possesses good pharmacokinetic toxicokinetic characteristics rats monkeys highlevel distribution therapeutically targeted tissue ie lung may greatly favor treatment sarscov<NUMBER> infection previous studies reported parp<NUMBER> inhibitor pj<NUMBER> target nterminal domain ntd coronavirus nucleocapsid n protein reduce rna binding thus impede viral replication <NUMBER> <NUMBER> <NUMBER> speculated olaparib cvl<NUMBER> may also interact n protein sarscov<NUMBER> perform similar antiviral function test hypothesis conducted molecular docking study potential interactions two drugs nntd sarscov<NUMBER> methods overall structure hcovoc<NUMBER> another coronavirus phylogenetically closely related sarscov<NUMBER> sarscov<NUMBER> share similar compositions secondary structure elements including five conserved β strands flexible loops figure <NUMBER>a addition sequences covering corresponding binding pocket regions well conserved figure <NUMBER>c thus structures may provide common molecular features terms interactions small molecules binding pocket therefore also used experimentally solved structure hcovoc<NUMBER>nntd complexed pj<NUMBER> reference analyze docking results docking results details also found supplementary study reported top data integration approach combining machine learning statistical analysis techniques followed weblab experimental validation identify potential drug candidates treating sarscov<NUMBER> infection showed parp<NUMBER> inhibitor cvl<NUMBER> discovered silico drug repurposing framework may therapeutic potential treatment covid<NUMBER> although mainly conducted vitro assays experimentally validate antisarscov<NUMBER> effects olaparib cvl<NUMBER> due limited time natural speculate parp<NUMBER> inhibitors may also antiviral activities sarscov<NUMBER> infection based computational prediction experimental validation results based data present study previously known evidences reported literature propose several potential mechanisms help understand involvement parp<NUMBER> inhibitors treatment covid<NUMBER> figure <NUMBER> first life cycle coronavirus parp<NUMBER> inhibitors may inhibit viral growth suppressing viral replication impeding binding nucleocapsid protein viral rnas <NUMBER> <NUMBER> <NUMBER> <NUMBER> also supported molecular docking results see section <NUMBER> second parp<NUMBER> inhibitors previously reported play critical role regulating inflammatory response modulating expression proinflammatory factors nfκb ap<NUMBER> il<NUMBER> downstream cytokines chemokines <NUMBER> <NUMBER> <NUMBER> <NUMBER> also shown overactivation parp<NUMBER> promotes energy nad atp consumption drives cell death exacerbating inflammation response <NUMBER> <NUMBER> <NUMBER> <NUMBER> parp<NUMBER> inhibitors thus may repress nfκbmediated proinflammatory signals reduce energy failure subsequent cell death induced necrosis thus providing clinical potential attenuating cytokine storm inflammatory response caused sarscov<NUMBER> infection third adpribosylation conserved posttranslational modification nucleocapsid proteins across different coronavirus lineages implying may important regulatory role structure packing viral genome several previous studies demonstrated parp<NUMBER> critical viral replication <NUMBER> <NUMBER> <NUMBER> example parp<NUMBER> reported interact hemagglutinin ha influenza virus iav promote replication triggering degradation host type ifn receptor <NUMBER> addition adpribosylation adenoviral core proteins displays antiviral defense mechanism <NUMBER> therefore intervening adpribosylation mediated interplay parp<NUMBER> viral proteins may another important pathway parp<NUMBER> inhibitors prevent sarscov<NUMBER> infection course throughly understand antisarscov<NUMBER> roles parp<NUMBER> inhibitors experimental studies direct clinical evidences needed future considering proinflammatory role parp<NUMBER> therapeutic effects parp<NUMBER> inhibitors inflammatorymediated diseases extensively studied past two decades <NUMBER> <NUMBER> pj<NUMBER> early generation parp<NUMBER> inhibitor suggested previous studies neuroprotective effects stroke model protect mice necroptosisassociated liver injuries repressing il<NUMBER> expression <NUMBER> <NUMBER> addition fdaapproved parp<NUMBER> inhibitor olaparib reported protect lps lipopolysaccharideinduced acute lung kidney injuries nfκbdependent manner mice <NUMBER> numerous preclinical studies demonstrated parp<NUMBER> inhibitors play essential role range inflammatory injuries related diseases especially lung inflammatory disorders including ards acute respiratory distress syndrome copd chronic obstructive pulmonary disease asthma <NUMBER> <NUMBER> <NUMBER> <NUMBER> studies suggest parp<NUMBER> inhibitors high relevance treatment novel pneumonia caused sarscov<NUMBER> infection possibly via roles modulating inflammatory response notably current pathological studies shown severe patients infected sarscov<NUMBER> generally higher plasma levels il<NUMBER> il<NUMBER> il<NUMBER> tnfα ifnγ <NUMBER> <NUMBER> <NUMBER> <NUMBER> implying high risk inflammatoryassociated cytokine storm viral infection addition reduction functional exhaustion cells also observed covid<NUMBER> patients <NUMBER> therefore blocking overactive inflammatory response may effective strategy treatment covid<NUMBER> particularly icu patients infected sarscov<NUMBER> recently tocilizumab monoclonal antibody drug targeting il<NUMBER> recommended treatment covid<NUMBER> diagnosis treatment protocol novel coronavirus pneumonia trial version <NUMBER> promulgated chinese government httpwwwnhcgovcnyzygjs<NUMBER>p<NUMBER> e<NUMBER>pdf also highlights vital role antiinflammatory response current therapeutics sarscov<NUMBER> vitro study showed cvl<NUMBER> effectively inhibit il<NUMBER> production induced cpg pbmcs figure <NUMBER> finding indicates cvl<NUMBER> may also possess il<NUMBER> specific antiinflammatory effect applicable severe patients infected sarscov<NUMBER> parp<NUMBER> inhibitors originally used targeting homologous recombination repair defects cancers mainly categorized oncology drugs thus would generally need safety data justify repurposing parp<NUMBER> inhibitors nononcology indications fortunately numerous existing preclinical clinical studies repurposing parp<NUMBER> inhibitors nononcological diseases including aforementioned acute diseases eg acute respiratory distress syndrome ards stroke <NUMBER> chronic diseases eg rheumatoid arthritis vascular diseases <NUMBER> <NUMBER> evidences indicate possibility repurposing parp<NUMBER> inhibitors safe therapeutic agent treat current acute lung disease caused sarscov<NUMBER> infection addition pharmacokinetic toxicokinetic data rats monkeys shown study indicate cvl<NUMBER> may relatively acceptable safety profile repositioned antiviral purpose moreover cvl<NUMBER> approved enter phase clinical trial <NUMBER> national medical products administration nmpa china cancer treatment preliminary data phase clinical trial shown cvl<NUMBER> well tolerated ascending dose studies doses high <NUMBER> mg qd <NUMBER> mg bid grade ii adverse events observed indicates cvl<NUMBER> also quite safe well tolerated human pharmacokinetic examination rats shown cvl<NUMBER> highest level distribution lung tissue <NUMBER>fold higher concentration compared plasma tissue specific enrichment lung may bring extra advantage cvl<NUMBER> used antisarscov<NUMBER> purpose lung therapeutically targeted tissue covid<NUMBER> moreover high level distribution lung may also suggest low dosage needed order ensure therapeutic efficacy cvl<NUMBER> sarscov<NUMBER> may reduce risk adverse events thus cvl<NUMBER> may great potential repurposed effective therapeutic agent combat sarscov<NUMBER> prevent future epidemic outbreak virusrelated knowledge graph constructed predicting coronavirus related drugs total seven networks considered constructed knowledge graph figure <NUMBER>b including human targetdrug interaction network virus targetdrug interaction network human proteinprotein interaction network virus proteinhuman protein interaction network drug molecular similarity network human protein sequence similarity network virus protein sequence similarity network human targetdrug interaction network derived drugbank version <NUMBER> <NUMBER> virus targetdrug interaction network constructed integrated data drugbank version <NUMBER> <NUMBER> chembl release <NUMBER> <NUMBER> ttd last update <NUMBER> nov <NUMBER> <NUMBER> iuphar bps release <NUMBER> nov <NUMBER> <NUMBER> bindinddb <NUMBER> ghddi httpsghddiailabgithubiotargeting<NUMBER>nco vcovexperimentdata cutoff threshold ic <NUMBER> ec <NUMBER> k k <NUMBER> µm human proteinprotein interaction network virus proteinhuman protein interaction network constructed integrated data biogrid release <NUMBER> <NUMBER> huri <NUMBER> instruct <NUMBER> mint <NUMBER> update <NUMBER> pina v<NUMBER> <NUMBER> signalink v<NUMBER> <NUMBER> innatedb <NUMBER> drug molecular similarity network obtained calculating tanimoto similarities morgan fingerprints radius <NUMBER> computed using rdkit tool <NUMBER> protein sequence similarity networks human virus obtained calculating smithwaterman similarities amino acid sequences derived uniprot <NUMBER> using sequence alignment software provided <NUMBER> noted collected additional protein sequences sarscov<NUMBER> uniprot <NUMBER> added corresponding networks final prediction drugs without drugtarget interactions outside drugbank database removed corresponding networks constructed virusrelated knowledge graph merging together nodes edges seven networks figure <NUMBER>b constructed knowledge graph g v e undirected graph node v ∈ v node set v belongs one node types including drugs human proteins virus proteins edge e ∈ e edge set e ⊂ v × v × r belongs one relation types relation type set r including two drugtarget interactions two proteinprotein interactions three similarities initial list drug candidates targeting sarscov<NUMBER> first screened using networkbased knowledge mining algorithm modified previous work <NUMBER> <NUMBER> goal capture hidden virusrelated feature information accurately predict potential drug candidates constructed knowledge graph realized learning network topologypreserving embedding node specifically model used graph convolution algorithm <NUMBER> gather update feature information node constructed heterogeneous knowledge graph network neighborhoods network topology information fully exploited suppose perform iterations graph convolution iteration <NUMBER> ≤ ≤ message v passed node v expressed vur stands weight edge e u v r uvr avur u avur w r ∈ r d×d b r ∈ r stand learnable parameters relu x max<NUMBER> x n r v u u ∈ v u v u v r ∈ e denotes set adjacent nodes connected v ∈ v edges type r ∈ r feature h v node v updated w ∈ r d×d b ∈ r stand learnable parameters concat· · stands concatenation operation finally confidence score uv relation r node u node v derived learned node embeddings corresponding projection matrices g r h r ∈ r d×k stand edgetype specific projection matrices minimized bayesian personalized ranking bpr loss <NUMBER> drugtarget interaction reconstruction regarding edges edge set e missing values rather negative samples uv wx stand confidence scores relation r u v w x respectively σ· stands sigmoid activation function intuitively loss function confidence scores node pairs u v edge set ie u v r ∈ e encouraged higher unseen pairs w x ie w x r ∈ e predicted confidence scores relation virus targetdrug interactions virus targetdrug pair using equation <NUMBER> confidence scores averaged across proteins certain virus eg sarscov merscov sarscov<NUMBER> corresponding pvalues obtained ztest virus selected predictions pvalue <NUMBER> drug candidates used deep learning based relation extraction method named bere <NUMBER> extract coronavirus related drugs largescale literature texts specifically sentences mentioning two entities interest ie name alias coronavirus coronavirus target name alias drug first collected using dictionarybased name entity recognition method string matching pair entities e <NUMBER> e <NUMBER> usually one sentence describing underlying relations therefore used bag sentences e <NUMBER> e <NUMBER> denoting set sentences mentioning e <NUMBER> e <NUMBER> predict relation two entities first encoded sentence ∈ e <NUMBER> e <NUMBER> semantic syntactic manner using hybrid deep neural network h → r including selfattention module <NUMBER> bidirectional gated recurrent unit gru module <NUMBER> gumbel treegru module <NUMBER> <NUMBER> sentence representation hs scored sentencelevel attention module indicate contribution relation prediction βs ∈ r stands weight score w ∈ r d×<NUMBER> stands learnable weight parameters finally relation predicted binary classifier based weighted sum sentence representations r e <NUMBER> e <NUMBER> classifier r e <NUMBER> e <NUMBER> stands probability relation interest entities e <NUMBER> e <NUMBER> mentioned bag sentences e <NUMBER> e <NUMBER> training corpus used curated automatically nearly <NUMBER> million pubmed httpwwwpubmedgov abstracts distant supervision technique <NUMBER> detail names aliases drugs targets sentences first annotated dictionarybased named entity recognition method string matching name dictionary derived drugbank version <NUMBER> <NUMBER> ambiguous names eg common words removed next label bag sentences comentioning drugtarget pair interest annotated automatically known drugtarget interactions drugbank unlabeled corpus used work textmining coronavirus related drugs obtained approximately <NUMBER> million pmc fulltext articles entities interest annotated using aforementioned named entity recognition approach coronavirus related drug extracted hit candidate model found bag sentences describing relation drug target coronavirus interest used transcriptome analysis approach filter potential drug candidates treating covid<NUMBER> patients infected sarscov<NUMBER> due lack gene expression data sarscov<NUMBER> infected patients used sarscov infected patients screen potential therapeutic drug candidates covid<NUMBER> strategy reasonable sarscov sarscov<NUMBER> two closely related highly similar coronavirus first genome sarscov<NUMBER> phylogenetically close sarscov <NUMBER> sequence identity <NUMBER> membrane n nucleocapsid e envelope proteins two coronaviruses <NUMBER> sequence similarities <NUMBER> addition pathogenic mechanisms sarscov<NUMBER> sarscov highly similar <NUMBER> particularly collected gene expression profiles peripheral blood mononuclear cells pbmcs ten sarscov infected patients geogse<NUMBER> <NUMBER> raw gene expression values first converted logarithm scale differential expression values zscores computed comparing healthy persons using protocol described <NUMBER> madx healthy medianx healthy − medianx healthy african green monkey kidney vero e<NUMBER> cell line purchased cell thirty spraguedawley rats randomly divided three time point groups <NUMBER>sexgroup <NUMBER> <NUMBER> <NUMBER>h cvl<NUMBER> administration animals sacrificed brain heart lung liver spleen stomach kidney tissues collected tissue samples washed icecold saline blotted paper towel remove excess fluid weighed tissue samples fluid weighted stored −<NUMBER> ± <NUMBER> • c determination drug concentration lcmsms healthy male female cynomolgus monkeys aged <NUMBER> years purchased guangdong landau biotechnology china animals maintained accordance guide care use laboratory animals cynomolgus monkey <NUMBER>sexgroup selected using computerized randomization procedure administered cvl<NUMBER> nasogastric feeding dose levels <NUMBER> control <NUMBER> <NUMBER> <NUMBER> mgkg individual dose volumes adjusted weekly based body weight monkeys monkeys observed twice daily viabilitymortality change behavior reaction treatment illhealth electrocardiograms intraocular pressure rectal temperature body weight recorded groups <NUMBER> animals randomly selected euthanized day <NUMBER> remaining animals euthanized <NUMBER>day drug free period blood samples taken <NUMBER> data represent means ± standard deviations sds n values n corresponds number data points used figures prepared using graphpad prism graphpad software usa statistical significance calculated spss ver<NUMBER> two values considered significantly different pvalue <NUMBER> docking program autodock<NUMBER> <NUMBER> noticed binding surface hcovoc<NUMBER>nntd pj<NUMBER> consists nterminal loop β<NUMBER> β<NUMBER> strands figure <NUMBER>b pharmacokinetic data arbidol obtained <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> current emerging infectious disease declared pandemic world health organization covid<NUMBER> caused severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> <NUMBER> dr zhengli shi famous scientist field sars proposed origin sarscov<NUMBER> could bats yunan province <NUMBER> km away wuhan hubei province <NUMBER> based history sars middle east respiratory syndrome mers swine acute diarrhea syndrome sads two originated china bats researchers china early <NUMBER> speculated sarsor merslike coronaviruses likely originate bats china <NUMBER> <NUMBER> although immediate origin transfer humans debatable rapid humantohuman transfer widely confirmed although severe cases covid<NUMBER> remain contagious asymptomatic recovered patients impede efforts control spread virus unique among infectious diseases patients recovered sarscov<NUMBER> infection continue exhibit positive realtime polymerase chain reaction rtpcr tests <NUMBER> thus center disease control cdc guidelines suggest social distancing least <NUMBER> ft primary means controlling viral spread <NUMBER> significant loss human life already occurred around world new modeling predicts substantial loss horizon since initial outbreak wuhan december <NUMBER> <NUMBER> cases covid<NUMBER> confirmed across mainland china <NUMBER> april <NUMBER> <NUMBER> world health organization declared covid<NUMBER> pandemic <NUMBER> march <NUMBER> <NUMBER> china seen rates infection peak subside dramatically confirmed cases experiencing exponential growth europe united states increasing number cases observed indian subcontinent south america <NUMBER> <NUMBER> april <NUMBER> johns hopkins center systems science engineering csse tracked <NUMBER> million cases worldwide including <NUMBER> cases united states alone additionally <NUMBER> deaths <NUMBER> recoveries observed worldwide united states leads world total number confirmed cases <NUMBER> assuming full social distancing enforced united states end may <NUMBER> modeling university washingtons institute health metrics evaluation ihme predicts daily deaths peak <NUMBER> april <NUMBER> <NUMBER> deaths per day curve decay may june flatten july <NUMBER> august ihme projects total <NUMBER> deaths covid<NUMBER> united states alone <NUMBER> important note total number confirmed cases worldwide may reflect actual number due part limitations testing undetected cases <NUMBER> <NUMBER> therefore high likelihood large numbers cases remain undetected increases urgency facilitating widespread testing finding sustainable treatment strategies covid<NUMBER> similar coronaviruses sarscov<NUMBER> spherical particle approximately <NUMBER> nm diameter contains membrane envelope protein nucleocapsid importantly spike protein projecting surface well singlestranded rna ssrna <NUMBER> sarscov<NUMBER> spike protein binds receptor human cell surface called angiotensinconverting enzyme <NUMBER> ace<NUMBER> abundant type ii alveolar cells lungs <NUMBER> <NUMBER> latching spike protein onto human cells causes undergo structural change allows viral membrane fuse host cell membrane viral genes enter host cells translate polypeptides mature individual proteins required form viral core surface protein spike virus matures produces multiple copies escapes host cells infect new cells genome sarscov<NUMBER> <NUMBER> identical coronaviruses genomes much <NUMBER> identity certain part genome coronaviruses bat coronaviruses <NUMBER> sarscov<NUMBER> encodes four structural genes spike envelope membrane nucleocapsid largest gene sarscov<NUMBER> orflab open reading frames <NUMBER>a <NUMBER>b encoding pplab peptide pheromone encoding lipoprotein b <NUMBER> nsps viral nonstructural proteins also encodes ppla protein peptide pheromone encoding lipoprotein contains <NUMBER> nsps absence <NUMBER>a protein fluctuation number amino acids <NUMBER>b <NUMBER>c proteins sarscov<NUMBER> differentiates coronaviruses major factor makes sarscov<NUMBER> infective coronaviruses spike protein highly specific binding human ace<NUMBER> enzyme <NUMBER> single n<NUMBER>it mutation significantly enhances binding affinity spike protein sarscov<NUMBER>with ace<NUMBER> based known life cycle sarscov<NUMBER> proposed several targets drug development well repurposing existing drugs <NUMBER> first target attacking virus monoclonal antibodies convalescent plasma plasma obtained recovered patients second target inhibition ace<NUMBER> using novel existing drugs may crossreactivity aces third target could inhibition viral endocytosis using antimalaria drugs eg chloroquine hydroxychloroquine fourth potential important target could inhibition proteolysis polypeptides using general specific proteases many antihiv antihcv antiviral antiretroviral drugs developed target proteases <NUMBER> <NUMBER> finally fifth target could inhibition rna polymerization using rna polymerase developed rna viruses could inhibit formation multiple copies rna ultimately viral replication due current absence effective therapies covid<NUMBER> several existing drugs known treat rna viruses hiv coronaviruses addition antimalarial drugs drugs used infectious diseases tried many countries <NUMBER> among available choices promising candidates appear plasma antibody treatments anticov drug remdesivir antimalaria drugs chloroquine hydroxychloroquine antihiv drugs lopinavirritonavir launched global megatrials drugs coronavirus treatments <NUMBER> antitumor necrosi factor tnf antibody tocilizumab shown benefits controlling cytokine release syndrome covid<NUMBER> patients <NUMBER> healthcare professionals china italy already started recruiting patients tocilizumab studies evaluate efficacy covid<NUMBER> patients severe symptoms antiinflammatory drugs baricitinib thalidomide proposed regulating immunity inhibiting inflammatory cytokine surge covid<NUMBER> patients based clinical case reports <NUMBER> <NUMBER> several clinical studies registered baricitinib thalidomide study antiinflammatory efficacy covid<NUMBER> patients table <NUMBER> summary popular drugs investigation treat covid<NUMBER> technique plasma purified monoclonal antibodies produced covid<NUMBER> obtained recovered patients given new patients treatment recent study convalescent plasma treatments administered five critically ill covid<NUMBER> patients shenzhen china <NUMBER> january <NUMBER> march <NUMBER> <NUMBER> study patients received convalescent plasma sarscov<NUMBER>specific antibody <NUMBER> <NUMBER> days admission among five patients four showed decreased score sequential organ failure assessments viral loads viral test also became negative within <NUMBER> days transfusion four patients also removed mechanical ventilation within <NUMBER> weeks treatment finally three patients discharged hospital approximately <NUMBER> days although trial small sample size results convalescent plasma treatment still encouraging method proposed treatment option us <NUMBER> tocilizumab recombinant humanized antihuman il<NUMBER> receptor monoclonal antibody originally developed treat rheumatoid arthritis based specific binding sil<NUMBER>r mil<NUMBER>r inhibition signal transduction <NUMBER> importantly humans high tolerance tocilizumab reported significant abnormalities clinicopathological studies histopathological evaluations scientists physicians china suspect il<NUMBER> may play role treatment covid<NUMBER> findings concluded tocilizumab effective treatment patients severe cases covid<NUMBER> thalidomide immunomodulatory antiinflammatory agent designed boost cells treat inflammation inhibit cell proliferation reduce lung injury pulmonary fibrosis <NUMBER> covid<NUMBER> main role protect lungs damage caused immunological reactions however thalidomide needs used antiviral agents since eliminate suppress viral load case report wenzhou medical university proved thalidomide adjuvant effects covid<NUMBER> treatment remdesivir originally developed combat ebola related viruses works inhibiting rnadependent rna polymerase <NUMBER> since target similar vitro vivo experiments showed drug inhibit coronaviruses cause sars mers <NUMBER> first covid<NUMBER> patient washington us given remdesivir condition worsened case report suggests condition improved <NUMBER> another latestage patient california also survived upon receiving remdesivir case reports alone cannot prove remdesivir safe effective therefore clinical trials underway since welltolerated relatively high doses possible remdesivir likely work given high dose early infection without causing significant toxicity antimalaria drugs chloroquine hydroxychloroquine shown efficacy covid<NUMBER> patients vitro experiments currently several countries recruiting patients test safety efficacy chloroquine including brazil spain norway china italy first clinical trial hydroxychloroquine completed shanghai <NUMBER> drugs generally work decreasing acidity endosomes ingest outside materials including viruses <NUMBER> although entry mechanism sarscov<NUMBER> spikeace<NUMBER> interaction vitro studies using cell culture suggested chloroquines inhibition activity sarscov<NUMBER> relatively high doses potential risk side effects <NUMBER> chloroquines also work inhibiting cytokine storm occurs result massive viral replication <NUMBER> usefulness chloroquines especially hydroxychloroquine may explained retrospectively fact reduced spreading sarscov<NUMBER> malariarich regions hydroxychloroquine used routine basis hydroxychloroquine may work prophylaxis covid<NUMBER> depending clinical trial results shanghai <NUMBER> opinion among scientists health care professionals increasingly supports use hydroxychloroquine therapeutic agent result fda cdc allowed hydroxyquinoline potential therapy covid<NUMBER> clinics upon physicians prescription extra precautions earlier literature suggests protease inhibitors pis including alcoholdependence drug disulfiram antiviral drugs lopinavir ritonavir reported active sars mers <NUMBER> although clinical studies lacking disulfiram reported inhibit papainlike protease mers sars cell culture <NUMBER> regard hiv pis lopinavir ritonavir clinical trials patients infected <NUMBER>ncov initiated multiple countries <NUMBER> lopinavir ritonavir initially shown improved clinical outcomes patients sars nonrandomized trial however yet determined whether hiv pis could effectively inhibit <NUMBER>chymotrypsinlike papainlike proteases <NUMBER>ncov <NUMBER> hiv protease belongs aspartic protease family sarscov<NUMBER> proteases cysteine protease family separate study martinez showed lpvrtv interferon beta lpvrtvinfb combination effective patients infected sarscov <NUMBER> drugs also showed improved clinical parameters mice infected merscov countries including china india antihiv drugs lpvrtv used covid<NUMBER> <NUMBER> <NUMBER> although drugs showed encouraging results vitro studies data wuhan china using small sample size show significant difference <NUMBER> recipients drugs receiving standard care differ significantly time clinical improvement median <NUMBER> days duration intensive care unit stay days mechanical ventilation days oxygen support similar study bhatnagar et al using lpvrtv treating covid<NUMBER> patients india underway <NUMBER> treatment outcomes amongst initial cases found useful managing initial covid<NUMBER> patients randomized controlled trial would performed guide future therapeutic use combination another study korea kim et al use lpvrtv covid<NUMBER> patients suggests decrease viral titer may result antiviral effect natural cause viral suppression <NUMBER> <NUMBER> however authors optimistic lpvrtv administration reduces viral load limitation study patients given lpvrtv day <NUMBER> patients shown naturally improve symptoms including fever effect lpvrtv yet seen drugs given early soon individuals infected sarscov<NUMBER> regardless case report authors believe lpvrtv promising antihiv drugs treatment covid<NUMBER> however prior recommendation welldesigned studies need carried gain evidence although results promising using silico proteindrug modeling approach ortega et al determined main sarscov<NUMBER> protease target hiv pis <NUMBER> <NUMBER> results showed strong interaction hiv pis eg lpv rtv active site sarscov<NUMBER> protease tested library <NUMBER> pis revealed potential interactions sarscov<NUMBER> protease pis results suggest development series derivatives optimized activity sarscov<NUMBER> coronaviruses antihiv drugs pi class could effective targeted sarscov<NUMBER>infected cells andor higher doses however higher dose pis effective covid<NUMBER> would also cause toxicity severe side effects pis known toxic higher doses <NUMBER> addition substrate well inhibitor major drugmetabolizing enzyme cytochrome p<NUMBER> <NUMBER>a<NUMBER> cyp<NUMBER>a<NUMBER> drugs cause drugdrug interactions ddi approximately half marketed drugs <NUMBER> <NUMBER> since covid<NUMBER> elevated symptoms complications elderly patients patients underlying diseases heart problems diabetes respiratory complications pis could cause major ddi ultimately drug toxicity similarly drugs substrates inhibitors major drug efflux transporter pglycoprotein pgp also potential cause ddi via pgp pathway <NUMBER> therefore need bypass cyp<NUMBER>a<NUMBER>and pgpmediated ddi reduce toxicity effective covid<NUMBER> treatment especially high doses unique drug delivery system ability target infected cells would also provide increased drug concentrations target cells reduced offtarget effects figure <NUMBER> viruses <NUMBER> <NUMBER> x <NUMBER> <NUMBER> also provide increased drug concentrations target cells reduced offtarget effects figure <NUMBER> bypass drug efflux transporters metabolic enzymes target disease site nano particlebased drug delivery system highly desirable <NUMBER> however use chemicalbased nanoparticles toxic difficult eliminate body may require fda approval hand extracellular vesicles evs membranederived nanovesicles circulated extracellular body fluids plasma urine <NUMBER> therefore longterm safety ability carry biological therapeutic molecules target site highly desirable develop evs biological nanoparticles capable delivering therapeutic agents infected tissues <NUMBER> literature supports development evbased drug delivery platform potential use therapeutic interventions suppressing hiv reservoirs brain reducing hivassociated neurocognitive disorders hand <NUMBER> literature also supports application evbased drug delivery system treatment many cancers cns diseasesdisorders <NUMBER> extracellular vesicles evs produced cellstissuesorgans natural carriers biological molecules including dna rna mirna proteins lipids small molecules <NUMBER> evs involved many biological processes via intercellular communications especially case disease conditions cancer infectious diseases neurodegenerative disorders <NUMBER> natural carriers biomolecules evs may also used unique drugdelivery systems drugs variety diseases conditions <NUMBER> evs already used encapsulate small molecules nucleic acids peptides proteins treat different diseases majority cancers <NUMBER> among anticancer agents curcumin doxorubicin paclitaxel top three drugs investigated example kim et al developed evencapsulated paclitaxel overcome multidrug resistance cancer cells <NUMBER> ev encapsulation improved cytotoxicity <NUMBER>fold drugresistant cancer cells compared paclitaxel treatment alone importantly almost complete localization evencapsulated paclitaxel detected mouse model evs used drug delivery mainly derived endolysosomal pathway also called exosomes <NUMBER> common features endolysosomalderived vesiclesexosomes size bypass drug efflux transporters metabolic enzymes target disease site nano particlebased drug delivery system highly desirable <NUMBER> however use chemicalbased nanoparticles toxic difficult eliminate body may require fda approval hand extracellular vesicles evs membranederived nanovesicles circulated extracellular body fluids plasma urine <NUMBER> therefore longterm safety ability carry biological therapeutic molecules target site highly desirable develop evs biological nanoparticles capable delivering therapeutic agents infected tissues <NUMBER> literature supports development evbased drug delivery platform potential use therapeutic interventions suppressing hiv reservoirs brain reducing hivassociated neurocognitive disorders hand <NUMBER> literature also supports application evbased drug delivery system treatment many cancers cns diseasesdisorders <NUMBER> extracellular vesicles evs produced cellstissuesorgans natural carriers biological molecules including dna rna mirna proteins lipids small molecules <NUMBER> evs involved many biological processes via intercellular communications especially case disease conditions cancer infectious diseases neurodegenerative disorders <NUMBER> natural carriers biomolecules evs may also used unique drugdelivery systems drugs variety diseases conditions <NUMBER> evs already used encapsulate small molecules nucleic acids peptides proteins treat different diseases majority cancers <NUMBER> among anticancer agents curcumin doxorubicin paclitaxel top three drugs investigated example kim et al developed evencapsulated paclitaxel overcome multidrug resistance cancer cells <NUMBER> ev encapsulation improved cytotoxicity <NUMBER>fold drugresistant cancer cells compared paclitaxel treatment alone importantly almost complete localization evencapsulated paclitaxel detected mouse model evs used drug delivery mainly derived endolysosomal pathway also called exosomes <NUMBER> common features endolysosomalderived vesiclesexosomes size varies <NUMBER> nm <NUMBER> nm contain endosomalassociated proteins including tetraspanins cd<NUMBER> cd<NUMBER> cd<NUMBER> <NUMBER> evbased drug delivery provides opportunity utilization personalized medicine evs isolated plasma patient loaded drugs interest administered back patient <NUMBER> figure <NUMBER> method referred exogenous drug loading also done evs isolated media cellscell lines <NUMBER> requires isolation characterizations evs particular size <NUMBER> nm plasma media ability interact deliver drugs recipient cells <NUMBER> many drugs especially nucleotides mrna mirna sirna dsdna loaded using exogenous techniques <NUMBER> technique utilizes direct incubation sonication electroporation freezethaw extrusion methods <NUMBER> particular loading method selected optimized based drug interest terms size shape needs treatment outcomes prepare larger quantity evloaded drugs general population target affected cells one load drugs evs using endogenous drugloading method endogenous loading method uses cells excrete evs target drugs encapsulated <NUMBER> endogenous loading evs already target drugs loaded purified cell culture media done incubating drugs cellscell lines disease targets using vitro method method ability scale technology preparing large quantity drugloaded evs <NUMBER> drugloaded evs ability target diseased tissue likely increased efficacy reduced offtarget effects compared free drugs <NUMBER> endogenous drugloading method used load small molecules especially anticancer agents <NUMBER> method also used load nucleotides various diseases <NUMBER> <NUMBER> <NUMBER> least eight pis developed used alone combination ritonavir treatment hiv <NUMBER> pi regimens still used first line therapy parts world <NUMBER> <NUMBER> cases pis especially lpvrtv drvrtv used second line therapy <NUMBER> thus development evbased drug delivery platform hiv pis individually combination pharmacoenhancer rtv highly desirable also possible single protease inhibitorloaded evs effective evs loaded along rtv rtv strongly inhibits cyp<NUMBER>a<NUMBER> increases pi plasma concentrations principle would unnecessary drugs loaded evs evs likely bypass cyp<NUMBER>a<NUMBER> successful drug delivery technology expanded existing antiviral antiretroviral pis antibacterial drugs shown efficacy treating case covid<NUMBER> antihiv pis pis antiviral antibacterial drugs encapsulated vero ccl<NUMBER> vero e<NUMBER> andor stat<NUMBER> knockout cell lines using endogenous loading technique model cell lines developed atcc infected sarscov<NUMBER> <NUMBER> drugs loaded evs isolated cells would ability target cells pis also loaded evs isolated plasma patients using exogenous loading method personalized therapy evencapsulated drugs first tested efficacy vero ccl<NUMBER> vero e<NUMBER> andor stat<NUMBER> knockout cell lines followed pharmacokinetics tissue distribution finally efficacy animal model lead formulations used human clinical trials multiple sites clinical trials repurposing pis drugs using evs could rapid drugs already fdaapproved evs natural nanovesicles literature suggests evs derived particular cell type eg immune cells seek diseased andor inflammatory immune cells targeting cell surface proteins <NUMBER> therefore likely evs derived sarscov<NUMBER> model cell lines eg vero ccl<NUMBER> vero e<NUMBER> surface proteins recognize sarscov<NUMBER>infected alveolar macrophages may secrete evencapsulated drugs cells however also possible ev isolation drug encapsulation techniques may result loss functional properties evs perhaps destroying surface proteins thus difficult rule nonspecific interactions evs cells leading offtarget effects offtarget effects cause toxicity suboptimal efficacy evs may need engineered target sarscov<NUMBER>infected cells done engineering evs isolated plasma vero ccl<NUMBER> vero e<NUMBER> cells surface proteins antibodies bind specific proteins target cells addition new techniques may developed encapsulate evs another biomimetic nanostructure eg liposomes delivery evencapsulated drugs <NUMBER> evs shown deliver biological cargos via multiple mechanisms fusion evs recipient cells engulfing evs variety recipient cells <NUMBER> although mechanism drug delivery recipient cells evs fully studied likely similar mechanism deliver drugencapsulated evs may also exist cases evbased drug products need administered form injections hence sterility drug product critical evs recently shown maintain stability autoclave temperatures <NUMBER> importantly evbased drug products reported eligible sterile filtration using filters <NUMBER> nm pore sizes <NUMBER> autoclave sterile filtration fdaapproved methods sterile drug preparation hence evbased pis eligible sterile drug manufacturing case covid<NUMBER> fda already granted orphan drug approval remdesivir even though gilead rescinded additionally fda granting facilitated regulatory pathways clinical trial applications given background evbased pis might bypass preclinical stage move phase ii directly evs natural carriers solid safety data phase studies might waived fda facilitated regulatory pathway strategy used regulatory agencies around world resolve pandemic diseases including covid<NUMBER> sars ebola etc <NUMBER> <NUMBER> strategies save time resources best scenario peoples lives evbased drug products prepared similar methods lipid nanoparticles using exogenous loading methods typical life cycle potential evbased drug product cgmp standards include production ev raw materials ev characterization drug loading cgmp conditions inprocess testing fillfinish finalrelease testing stability testing similar lipid nanoparticlebased drug products major quality control focuses raw ev size distribution postprocessing encapsulated drug amount free drug amount size distribution zeta potential product stability scalability production problem current technologies bottleneck evbased drug production drug loading evs current highpressure homogenizers process <NUMBER> l drug liquid <NUMBER> <NUMBER> furthermore ultracentrifugation technique used process elimination <NUMBER> l free drugs <NUMBER> university tennessee health science center fdaregistered gmp facility named plough center one coauthor working facility provides top tier cleanroom environment sterile injectable equipment ensuring evbased drug production could rapid feasible may move forward clinical stages <NUMBER> although evs ability circulate via plasma deliver components distant tissuesorgans general limitations important addressed realizing clinical potential <NUMBER> interaction drugs ev components <NUMBER> robust understanding administered evs transported vivo <NUMBER> vivo pharmacokinetics evdrugs <NUMBER> delivery drugs target <NUMBER> immune clearance <NUMBER> <NUMBER> importantly evs similar structures liposomes two layers lipids hydrophilic surface core layer hydrophobic membrane layer antiretroviral pis water soluble therefore drugs mainly reside inside membrane due partition coefficient however unlike liposomes comprehensive understanding changes size <NUMBER> nm charge zeta potential −<NUMBER> −<NUMBER> presence specific surface proteins based origin evs affect systemic circulation overcoming barriers eg bbb delivery cargo targeted tissuesorgans clearance although evs expected poor entrapment plasma clearance phagocytic system may lead enhanced distribution increased halflife biochemical complexity needs considered <NUMBER> <NUMBER> furthermore although strong preclinical evidence systemic circulation tissueorgan targeting exists evs eg brain <NUMBER> <NUMBER> important fully understand transport delivery mechanisms however case covid<NUMBER> may sufficient time perform comprehensive preclinical studies understand delivery antiretroviral pis target tissues therefore important fda expedites approval evbased delivery method pis treat covid<NUMBER> upon determining relative safety efficacy compared free drugs small clinical trial covid<NUMBER> global risk humanity impacts health yet determined since development new drugs vaccines take least year critical consistently work mitigation world recovers spread disease spreading exponentially especially us several drugs tested either reduce symptoms disease treat patients plasma treatment isolating antibodies recovered patients administering new patients controlled manner likely promising several drugs initially developed diseases also tried patients well tested cell culture experiments among several antibodybased immunosuppressive drugs anticov drug remdesivir antimalaria drug hydroxychloroquine antihiv drugs lopinavirritonavir shown promising results drugs therefore subjects investigation clinical trials treatment covid<NUMBER> also initiative repurpose antihiv pis using unique drug delivery systems utilize natural nanocarriers evs evencapsulated drugs ability bypass liver metabolism target diseased tissues enhancing efficacy reducing offtarget effects drug toxicity coronaviruses covs belonging family coronaviridae positivesense enveloped rna viruses cause infections birds mammals humans <NUMBER> <NUMBER> <NUMBER> family includes four genera alphacoronavirus betacoronavirus deltacoronavirus gammacoronavirus <NUMBER> two infamous infectious coronaviruses genus betacoronavirus severe acute respiratory syndrome coronavirus sarscov <NUMBER> middle east respiratory syndrome coronavirus merscov <NUMBER> infected <NUMBER> people around world past two decades unfortunately incidence accompanied high mortality rates <NUMBER> sarscov <NUMBER> merscov indicating urgent need effective treatment beginning outbreak prevent spread <NUMBER> <NUMBER> however cannot achieved current drug development application system taking several years newly developed drugs come market unexpectedly world facing situation previous outbreak due recent epidemic atypical pneumonia designated coronavirus disease <NUMBER> covid <NUMBER> caused novel coronavirus severe acute respiratory syndrome coronavirus <NUMBER> sarscov<NUMBER> wuhan china <NUMBER> <NUMBER> sarscov<NUMBER> belongs betacoronavirus contains positivesense singlestranded rna ssrna genome <NUMBER> bp contains genes encoding <NUMBER>clike proteinase rnadependent rna polymerase rdrp <NUMBER>oribose methyltransferase spike protein envelope protein nucleocapsid phosphoprotein several unknown proteins according genome sequencing data sarscov<NUMBER> httpswwwncbinlmnihgovgenbanksarscov<NUMBER>seqs typical clinical symptoms covid<NUMBER> fever dry cough fatigue within <NUMBER> days latency average infection relatively slower severe acute respiratory syndrome sars caused sarscov <NUMBER> life cycle coronaviruses virus replicates via following processes entering host cell <NUMBER> translation genomic rna grna <NUMBER> proteolysis translated polyprotein viral <NUMBER>clike proteinase <NUMBER> replication grna viral replication complex consists rnadependent rna polymerase rdrp helicase <NUMBER>to<NUMBER> exonuclease endornase <NUMBER>oribose methyltransferase <NUMBER> assembly viral components <NUMBER> replicationassociated proteins primary targets postentry treatment drugs suppress viral replication although much intensive effort made worldwide develop drugs vaccines sarscov<NUMBER> patients currently suffering covid<NUMBER> cannot expect benefits due slow development process novel drugs vaccines thus rapid drug application strategy immediately applied patient necessary currently way address matter repurpose commercially available drugs pathogen socalled drugrepurposing however theory artificial intelligence aibased architectures must taken account order accurately predict drugtarget interactions dtis enormous amount complex information eg hydrophobic interactions ionic interactions hydrogen bonding andor van der waals forces molecules end previously developed deep learningbased drugtarget interaction prediction model called molecule transformerdrug target interaction mtdti <NUMBER> study applied pretrained mtdti model identify commercially available antiviral drugs could potentially disrupt sarscov<NUMBER>s viral components proteinase rnadependent rna polymerase andor helicase since model utilizes simplified molecularinput lineentry system smiles strings amino acid aa sequences <NUMBER>d string inputs possible quickly apply target proteins experimentally confirmed <NUMBER>d crystal structures viral proteins sarscov<NUMBER> share list top commercially available antiviral drugs could potentially hinder multiplication cycle sarscov<NUMBER> hope effective drugs developed based aiproposed drug candidates act sarscov<NUMBER> amino acid sequences <NUMBER>clike proteinase accession yp<NUMBER> rnadependent rna polymerase accession yp<NUMBER> helicase accession yp<NUMBER> <NUMBER>to<NUMBER> exonuclease accession yp<NUMBER> endornase accession yp<NUMBER> <NUMBER>oribose methyltransferase accession yp<NUMBER> sarscov<NUMBER> replication complex extracted sarscov<NUMBER> whole genome sequence accession nc<NUMBER> national center biotechnology information ncbi database molecule transformerdrug target interaction mtdti used predict binding affinity values commercially available antiviral drugs target proteins mtdti based selfattention mechanism showed remarkable success natural language process nlp literature mtdti inspired idea chemist understanding molecule sequence analogous understanding language apply nlp model drugtarget interaction dti tasks mtdti pretrained chemical language represented smiles approximately <NUMBER> compounds similar nlp model successfully extracts complex patterns word sequences mtdti successfully finds useful information dti tasks therefore shows best performance robust results diverse dti datasets according previous study <NUMBER> train model drug target common dtc database <NUMBER> bindingdb <NUMBER> database manually curated combined three types efficacy value ki kd ic<NUMBER> integrated consistencescorebased averaging algorithm <NUMBER> make pearson correlation score <NUMBER> terms ki kd ic<NUMBER> since bindingdb database includes wide variety species target proteins mtdti model potential power predict interactions antiviral drugs sarscov<NUMBER> proteins mtdti prediction raw prediction results screened antiviral drugs fda approved target viral proteins kd value less <NUMBER> nm smiles containing salt forms excluded final results prediction focused pairs single molecule target protein addition remdesivir also incoprated analysis therapeutic potential covid<NUMBER> recently suggested wang et al <NUMBER> gliead sciences announcements httpswwwgileadcompurposeadvancingglobalhealthcovid<NUMBER> autodock vina version <NUMBER> molecular docking virtual screening application <NUMBER> used predict binding affinities kcalmol <NUMBER>clike proteinase sarscov<NUMBER> <NUMBER> fdaapproved drugs smiles <NUMBER> fdaapproved drugs converted pdbqt format using open babel version <NUMBER> <NUMBER> following options gen<NUMBER>d p <NUMBER> hydrogens added <NUMBER>clike proteinase model using mgltools version <NUMBER> <NUMBER> binding affinities protein fdaapproved drugs calculated using autodock vina exhaustiveness parameter set <NUMBER> identify potent fdaapproved drugs may inhibit functions sarscov<NUMBER>s core proteins used mtdti deep learningbased model accurately predict binding affinities based chemical sequences smiles amino acid sequences fasta target protein without structural information <NUMBER> deep learningbased approach particularly useful since require protein structural information bottleneck identifying drugs targeted uncharacterized proteins traditional threedimensional <NUMBER>d structurebased docking approaches <NUMBER> neverthless mtdti showed best performance <NUMBER> compared deep learningbased deepdta approach <NUMBER> two traditional machine learningbased algorithms simboost <NUMBER> kronrls <NUMBER> kiba <NUMBER> davis <NUMBER> data sets taking advantage sequencebased drugtarget affinity prediction approach binding affinities <NUMBER> fdaapproved drugs <NUMBER>clike proteinase rdrp helicase <NUMBER>to<NUMBER> exonuclease endornase <NUMBER>oribose methyltransferase sarscov<NUMBER> predicted confirm performance mtdti least silico compared binding affinities <NUMBER> fdaapproved drugs predicted mtdti estimated autodock vina widely used <NUMBER>d structurebased docking algorithm possible since <NUMBER>d structure <NUMBER>clike proteinase protein recently unveiled xray crystallography pdbid <NUMBER>lu<NUMBER> <NUMBER> significant negative correlations meaning results algorithms showed moderate similarities higher better mtdti whereas lower better autodock vina observed antiviral drug dataset r <NUMBER> pvalue <NUMBER> fdaapproved drug dataset r <NUMBER> pvalue <NUMBER>e<NUMBER> fig <NUMBER> possible determine algorithm reliable without various experimental evaluations previous study showed mtdti model one best deep learningbased models predict binding affinity given protein compound <NUMBER> therefore applied mtdti model repurpose fdaapproved drugs potential inhibit key proteins sarscov<NUMBER> sarscov<NUMBER> <NUMBER>clike proteinase predicted bind atazanavir kd <NUMBER> nm followed remdesivir efavirenz ritonavir antiviral drugs predicted affinity kd <NUMBER> nm potency table <NUMBER> protease inhibitor antiviral drug found kd <NUMBER> nm range although realworld evidence whether drugs act predicted covid<NUMBER> yet case studies identified example docking study lopinavir along hiv proteinase inhibitors cov proteinase pdbid <NUMBER>uk<NUMBER> suggests atazanavir ritonavir listed present prediction results may inhibit cov proteinase line inhibitory potency lopinavir <NUMBER> according prediction viral proteinasetargeting drugs predicted act favorably viral replication process viral proteinase dti model tables <NUMBER> results include antiviral drugs proteinase inhibitors guanosine analogues eg acyclovir ganciclovir penciclovir reverse transcriptase inhibitors integrase inhibitors among prediction results atazanavir predicted potential binding affinity bind rnadependent rna polymerase kd <NUMBER> nm helicase kd <NUMBER> nm <NUMBER>to<NUMBER> exonuclease kd <NUMBER> nm <NUMBER>oribose methyltransferase kd <NUMBER> nm endornase kd <NUMBER> nm suggests subunits covid<NUMBER> replication complex may inhibited simultaneously atazanavir tables <NUMBER> also ganciclovir predicted bind three subunits replication complex covid<NUMBER> rnadependent rna polymerase kd <NUMBER> nm <NUMBER>to<NUMBER> exonuclease kd <NUMBER> nm rna helicase kd <NUMBER> nm lopinavir ritonavir active materials abbvies kaletra predicted potential affinity covid<NUMBER> helicase table <NUMBER> suggested potential mers therapeutics <NUMBER> recently approximately <NUMBER> million worth kaletra doses donated china <NUMBER> previous clinical study sars chu et al <NUMBER> may support decision <NUMBER> another antihiv drug prezcobix johnson johnson consists darunavir cobicistat sent china <NUMBER> darunavir also predicted kd <NUMBER> nm covid<NUMBER>s helicase table <NUMBER> however current supporting literature found darunavir used cov therapeutic although remdesivir fda approved drug predicted potency covid<NUMBER> resulted follows rnadependent rna polymerase kd <NUMBER> many cases dti prediction models serve tool repurpose drugs develop novel usages existing drugs application dti prediction present study may useful control unexpected rapidly spreading infections sarscov middle east respiratory syndrome merscov sarscov<NUMBER> frontline disease control better therapeutic measures developed several recent studies identified promising drug candidates may help reduce symptoms covid<NUMBER> inhibiting aspects sarscov<NUMBER> example remdesivir chloroquine showed inhibitory effects sarscov<NUMBER> vitro <NUMBER> another invitro study showed hydroxychloroquine found potent chloroquine inhibiting sarscov<NUMBER> <NUMBER> remdesivir lopinavirritonavir kaletra also reduced pneumoniaassociated symptoms covid<NUMBER> patients <NUMBER> <NUMBER> however studies based previous knowledge drugs showed inhibitory effects similar coronaviruses sarscov andor merscov contrast approach truly based pretrained mtdti deeplearning model understands drugtarget interactions without domain knowledge <NUMBER> fact mtdti successfully identified epidermal growth factor receptor egfrtargeted drugs used clinics top<NUMBER> predicted candidates among <NUMBER> chemical compounds registered drugbank database previous study <NUMBER> suggesting <NUMBER>d structural information proteins andor molecules necessarily required predict drugtarget interactions results showed following intriguing findings need tested experimentally clinically near future first mtdti generally showed similar results overall compared conventional <NUMBER>d structurebased prediction model autodock vina differences observed example atazanavir remdesivir efavirenz top three predicted drugs may bind <NUMBER>clike proteinase sarscov<NUMBER> saquinavir nelfinavir grazoprevir top three drugs identified autodock vina fig <NUMBER> secondly search space expanded fdaapproved drugs immunosuppressant drugs rapamycin everolimus drug tiotropium bromide asthma chronic obstructive pulmonary disease copd identified promising candidates mtdti contrast autodock vina predicted purmorphanime lumacaftor verrucarin top three drugs could bind <NUMBER>clike proteinase sarscov<NUMBER> however currently supporting evidence drugs may effective inhibiting sarscov<NUMBER> lastly atazanavir appears effective treatment covid<NUMBER> showing overall high binding affinities among tested antivirals six proteins sarscov<NUMBER> including <NUMBER>clike proteinase replication complex components tables <NUMBER> s<NUMBER> prediction also needs validated vitro vivo wide range clinical trials efficacy safety hope prediction results may support experimental therapeutic options china countries suffering sarscov<NUMBER> pandemic align recent clinical trials <NUMBER> beck br choi park employed company deargen inc shin b employed deargen inc parttime advisor kang k one cofounders shareholder deargen inc comparison mtdti autodock vina results <NUMBER> known fdaapproved antiviral drugs left <NUMBER> fdaapproved drugs right evaluated means mtdti deep learningbased affinity score higher better autodock vina docking score lower better remdesivir fdaapproved drug regarded promising antiviral drug sarscov<NUMBER> included analysis table <NUMBER> drugtarget interaction dti prediction results antiviral drugs available markets novel coronavirus sarscov<NUMBER> ncbi reference sequence nc<NUMBER> rnadependent rna polymerase accession yp<NUMBER> indicates isomeric form smiles coronaviruses covs enveloped singlestranded rna viruses belonging family coronaviridae within order nidovirales coronaviruses cov four different genera α β γ δ covs among β covs like sarscov middle east respiratory syndrome merscov novel coronavirus sarscov<NUMBER> responsible severe potentially fatal respiratory infections <NUMBER> <NUMBER> <NUMBER> reported covs enter host cells angiotensinconverting enzyme<NUMBER> ace<NUMBER> receptormediated endocytosis phdependent process process spike protein plays major role receptor binding membrane fusion sarscov<NUMBER> entry host cells contains large ectodomain transmembrane anchor short intracellular tail ectodomain sarscov<NUMBER> consists two subunits s<NUMBER> subunit sarscov<NUMBER> responsible binding ace<NUMBER> receptor viral entry host cells following receptor binding sarscov<NUMBER> enter cytosol host cell phdependent proteolytic cleavage spike protein tmprss<NUMBER> fusion viral host cell membranes occurs acidified endosomes allowing viral genomes affect host cells aid s<NUMBER> subunit <NUMBER> <NUMBER> <NUMBER> coronavirus disease <NUMBER> covid<NUMBER> caused sarscov<NUMBER> pandemic affected nearly <NUMBER> people worldwide <NUMBER> april <NUMBER> according however rapid spread potential mortality lack clinically approved drugs vaccines covid<NUMBER> major challenges need therefore quick discovery drugs emerging infectious disease however slow phase discovery associated costs major challenges discovering drugs sarscov<NUMBER> drug repurposing using existing drugs attractive strategy accelerate drug discovery covid<NUMBER> recently researchers focused screening fda approved drugs sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> salinomycin sal carboxylic polyether ionophore isolated streptomyces albus ionophores show broad spectrum bioactivity like antibacterial antifungal antiparasitic antiviral recently also used antitumor agents <NUMBER> however poor absorption low bioavailability offtarget effects potential limitations effective repurposing sal antiviral agent sarscov<NUMBER> present study therefore propose pulmonary delivery sal using nanostructured lipid carriers nlcs present study proposed prepare nlcs intrapulmonary delivery sal prevent sarscov<NUMBER> infection fig <NUMBER> proposed drug delivery system following advantages  noninvasive means administration  localized delivery lung epithelium directly  avoid firstpass metabolism  reduced offtarget effects  rapid effective drug absorption enveloped viruses significant step entry host cell fusion sarscov<NUMBER> fusion occurs low ph halfmaximal rate fusion ph <NUMBER> compelling body evidence suggests sal inhibits replication viral rna cytoplasm altering ph sal therefore potential prevent entry sarscov<NUMBER> cytosol prevent membrane fusion phdependent process <NUMBER> reported sal antiviral propensity preventing migration nuclear protein np form viral ribonuclear complex vnp fails acidify endosomallysosomal compartments due cytoplasmic accumulation np host cells <NUMBER> <NUMBER> also reported sal could interact sprotein influence ace<NUMBER> binding prevent release viral rna cytoplasm <NUMBER> besides recent drug screen identified sal potential antiviral agent sarscov<NUMBER> ic <NUMBER> <NUMBER>µm <NUMBER> however clinical efficacy sal sarscov<NUMBER> needs evaluated pulmonary delivery attractive strategy localized delivery therapeutics infection sites besides inhaled nanoparticles overcomes limitations poor bioavailability drug absorption nlcs biocompatible nanocarriers good tolerability pulmonary delivery due size nanometers nlcs easily aerosolized droplets suitable aerodynamical properties enables deep lung deposition active compound furthermore nlcs adhere mucosal surface lung extended period compared larger particles due small size particle adhesion accumulation retention lung well prolongedrelease due nlcs results enhanced sustained therapeutic effects nlcs advantage better patient compliance <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> advantages inhaled nlcs play essential role treatment respiratory infections like covid<NUMBER> several investigational drugs drugs preclinical trials preventioncurative purposes covid<NUMBER> still current approved drug sal ability disruption concentration across cell membrane prevents virus entry host cells selective targeting sal encapsulation sal nlc pulmonary delivery attractive approach effective repurposing sal antiviral agent improving absorption infection site coronaviruses covs typically cause mild severe respiratory intestinal infections mammals including humans <NUMBER> <NUMBER> belongs family coronaviridae comes order nidovirales <NUMBER> <NUMBER> covs classified four genera alphacoronavirus betacoronavirus gammacoronavirus deltacoronavirus first two genera ie alphaand betacoronavirus mainly infect mammals whereas gammacoronaviruses deltacoronaviruses foul avian species <NUMBER> years passed since identification first human cov hcov documented respiratory tract modulator <NUMBER> <NUMBER> december <NUMBER> several clusters epidemiologically associated seafood animal market wuhan china patients suffering fever illness severe respiratory tract infections pneumonia unknown origin reported <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> finally leaded isolation novel coronavirus <NUMBER>ncov disease recently named covid<NUMBER> world health organization already characterized covid<NUMBER> world pandemic <NUMBER> infection spread <NUMBER> countries territories <NUMBER> covid<NUMBER> outbreak six species hcovs reported association respiratory tract infections table <NUMBER> table <NUMBER> <NUMBER> seventh strain hcov novel coronavirus <NUMBER>ncov aka sarscov<NUMBER> taxonomically belongs betacoronavirus genre possesses high nucleotide sequence similarity sarscov merscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> positivesense singlestranded rna viruses surrounded envelope figure <NUMBER> sarscov<NUMBER> <NUMBER> bp singlestranded rna virus utilizes host cellular components accomplish physiological affairs viral entry assembly budding virions genomic replication protein synthesis subsequently executes pathological damage host <NUMBER> <NUMBER> <NUMBER> thus punctuating juncture viral life cycle small molecules peptides vaccines physical elements may potentially gain therapeutic benefit host depending several viral targets figure <NUMBER> related stages viral life cycle novel antiviral agents may designed discovered nonetheless different structurebased modeling techniques numerous ligandbased computational techniques may fruitful strategy design newer inhibitors sarscov<NUMBER> <NUMBER> <NUMBER> <NUMBER> meanwhile hefty menace posed current outbreak covid<NUMBER> obvious scientific community looking effective drugs within plausible time coherent development well organised strategies remains hope triumph battle partially known sarscov<NUMBER> repurposing existing antiviral drugs based previous ground work closely related coronavirus rapid screening drug databases one strategic economic ways eradicate covid<NUMBER> pandemic <NUMBER> <NUMBER> <NUMBER> traditional bioinformatics chemoinformatics approaches readily generated new data sarscov<NUMBER> research explosive pace considering severity spread covid<NUMBER> study inline concept finding chemotypes expedite process antihcov drug discovery exquisite picture recent research including targetbased biological screening provided includes virtual silico well experimental vitro screening approaches response sarscov<NUMBER> reported april <NUMBER> main aim provide scientific community overview medicinal chemistry sarscov<NUMBER> allow rapid development antiviral agents work part rational drug design discovery <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> initiative pave way antisarscov<NUMBER> drug discovery paradigm could help facilitate global efforts fight covid<NUMBER> details structural biology sarscov<NUMBER> virus yet discovered contains <NUMBER> bp singlestranded positive sense rna genome encapsulated within membrane envelope figure <NUMBER> <NUMBER> <NUMBER> <NUMBER> recruits multisubunit replication machinery <NUMBER> genome sarscov<NUMBER> comprises <NUMBER> nucleotides ten open reading frames orfs <NUMBER>′ terminal regions encodes several structural proteins including spike membrane envelope e nucleocapsid n proteins figure <NUMBER> whereas <NUMBER>′ terminal orf<NUMBER>ab responsible two viral replicase polyproteins pp<NUMBER>a pp<NUMBER>b upon proteolytic cleavage two viral replicase polyproteins fabricate sixteen nonstructural proteins nsp figure <NUMBER> <NUMBER> table <NUMBER> may placed spike glycoprotein coronavirus main conciliator entry host cells <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> spike glycoprotein contains large ectodomain ii singlepass transmembrane anchor iii short cterminal intracellular tail <NUMBER> ectodomain consists receptorbinding unit s<NUMBER> membranefusion s<NUMBER> stalk basically receptorbinding unit s<NUMBER> binds specific cell surface receptor via receptor binding domain rbd whereas trimeric s<NUMBER> fuses viral membranes host cell enable entry viral genomes host cells figure <NUMBER> researchers already identified angiotensin converting enzyme <NUMBER> ace<NUMBER> functional receptor sarscov <NUMBER> <NUMBER> <NUMBER> <NUMBER> crowned shaped spike glycoprotein covs binds directly ace<NUMBER> host cells surface plays critically virus infection ace<NUMBER> expressed widely conserved primary structures throughout animal kingdom ace<NUMBER> fish amphibians reptiles birds mammals potentially interact rbd sarscov<NUMBER> <NUMBER> therefore blocking rbd ace<NUMBER> interaction obvious therapeutic intervention treat diseases caused covs specific antibodies small molecular inhibitors disrupt interaction rbd ace<NUMBER> among set sixteen nonstructural proteins nsp<NUMBER> identified play pivotal role life cycle sarscov<NUMBER> replication well maturation figure <NUMBER> key component nsp<NUMBER> termed main protease mpro like rna viruses functional significance mpro chymotrypsinlike protease <NUMBER>clpro sarscov<NUMBER> emerges attractive drug target development antiviral agents recently <NUMBER>d structure <NUMBER>clpro sarscov<NUMBER> reported <NUMBER> like coronaviruses mpro also consists three domains domain comprising <NUMBER> amino acids ii rdrp active site appointing two successive aspartate residues projected betaturn structure making surface accessible nucleotide channel configured sarscov robson <NUMBER> performed preliminary bioinformatics studies propose synthetic vaccine peptidomimetic antagonist spike glycoprotein sarscov<NUMBER> author employed quel language perform bioinformatics approach krsfiedllfnkv identified well conserved sequence motif corresponds known cleavage sites sars virus sequence motif formed basis design specific synthetic vaccine epitope peptidomimetic agent <NUMBER> group scientists cairo university egypt predicted covid<NUMBER> spike binding site cellsurface receptor namely glucose regulated protein <NUMBER> grp<NUMBER> employing structural bioinformatics combination proteinprotein docking <NUMBER> notably region iv supposed pivotal driving force grp<NUMBER> binding predicted binding affinity <NUMBER> kcalmol prediction binding site sheds light mode envelope protein recognition grp<NUMBER> substratebinding domain future endeavours <NUMBER> molecular modeling study explore potential inhibitors rna binding n terminal domain ntd nucleocapsid protein n protein sarma et al <NUMBER> pointed two potential hits namely zinc<NUMBER> zinc<NUMBER> figure <NUMBER> authors employed two ntd structures n proteins namely <NUMBER>ofz <NUMBER>ssk firstly set diverse compounds asinex maybridge library docked <NUMBER> compounds targets prioritized significant docking scores mmgbsa binding free energy pharmacokinetic properties qikprop druglikeness swissadme molecular dynamics md studies performed screen compounds two potential hits one compound theophylline derivative since theophylline derivative commonly used bronchodilator hence author screened approved bronchodilators n protein <NUMBER> rna binding site covid<NUMBER> <NUMBER> approved bronchodilators showed mmgbsa binding affinity following order formeterol terbutaline ipratropium bromide tiotropium bromide theophylline salbutamol recently native nonnative proteinprotein interactions ppis emerged target structurebased screening small molecule may alternative drug design paradigm could accelerate antiviral drug discovery various pathogens <NUMBER> <NUMBER> <NUMBER> since orthostaticallosteric stabilization nonnative ppis sarscov<NUMBER> nucleocapsid protein results abnormal protein oligomerizaion finally leading loss viral activity scientists national chung hsing university taiwan acclaimed nonnative ppis nterminal domain merscov nucleocapsid protein merscov nntd <NUMBER> reported crystal structure merscov nntd nonnative dimeric configuration turned target virtual screening orthosteric stabilizers acros zinc drug databases finding provides valuable insight motivations design new antivirals based stabilizing nonnative protein interaction interface n protein <NUMBER> gupta coworkers <NUMBER> employed computational techniques explore best possible structure sarscov<NUMBER> e protein present pdb database author reported e protein sarscov<NUMBER> pentameric protein comprised <NUMBER> αhelices <NUMBER> loops near <NUMBER> compounds docked whereas <NUMBER> compounds prioritized significant affinities docking scores docking study e protein sarscov<NUMBER> phytochemicals like belachinal macaflavanone e vibsanol divulged amino acids v<NUMBER> f<NUMBER> play crucially binding interactions functional behaviour e protein sarscov<NUMBER> <NUMBER>ns molecular dynamics studies revealed αhelix loops e protein escapades random movement modulates normal ion channel activity succour pathogenesis human vertebrates unlikely random manoeuvre e protein sarscov<NUMBER> gets reduced binding inhibitors <NUMBER> khan et al <NUMBER> pinpointed three fdaapproved drugs remdesivir saquinavir darunavir two small molecules flavone coumarin derivatives possible inhibitors <NUMBER>clpro targetbased virtual screening number <NUMBER> compounds docked top <NUMBER> primary hits distinguished significant affinities docking scores binding interaction active site residue <NUMBER>clpro selected compounds extensively scrutinized using plif module moe md simulation binding free energy calculations recorded evaluate dynamic behaviour stability proteinligand contact binding affinity hit compounds <NUMBER> kandeel alnazawi <NUMBER> reported statistics pairwise sequence comparison matrix among main protease mpro covs high pairwise sequence alignment identity <NUMBER> found sarscov<NUMBER> sarscov<NUMBER> mpro whereas <NUMBER> identity exposed sarscov<NUMBER> merscov mpro consequence number amino acid differences sarscov<NUMBER> sarscov<NUMBER> mpro <NUMBER> <NUMBER> sarscov<NUMBER> merscov mpro early virtual screening vs study fda approved drugs retrieved selleckchem inc first resolved sarscov<NUMBER> mpro crystal structure pdb <NUMBER>lu<NUMBER> performed helps repurposing already approved drugs eradicate covid<NUMBER> <NUMBER> detailed scanning binding mode drugs sarscov<NUMBER> mpro conferred hydrophobic hydrogen bonding interactions main imperators binding interestingly telbivudine figure <NUMBER> antihepatitis b virus agent bind sarscov<NUMBER> mpro hydrogen bond interactions amino acid residues s<NUMBER> q<NUMBER> moreover broad spectrum antiviral agent ribavirin figure <NUMBER> interacted sarscov<NUMBER> mpro forming hydrogen bonds side chain amino acid residue q<NUMBER> backbone amino acid residue t<NUMBER> ribavirin officially approved respiratory syncytial virus rsv infection also used combination interferon α<NUMBER>b hepatitis c virus moreover also exhibited potency sarscov infection <NUMBER> study distinguish potential active herbs <NUMBER>ncov et al leading viral eradication <NUMBER> another study elfiky <NUMBER> reported sarscov<NUMBER> rdrp targeted molecular docking study antipolymerase drugs approved use various viruses surprisingly ribavirin remdesivir sofosbuvir galidesivir tenofovirexhibited promising binding affinity sarscov<NUMBER> rdrp results also consistence previous one <NUMBER> guanosine derivative idx<NUMBER> setrobuvir yak potential block sarscov<NUMBER> strain since drugs already passed adme toxicity measurements may used new therapeutic drug candidate sarscov<NUMBER> lung coworkers <NUMBER> identified theaflavin polyphenolic constituent present black tea hydrophobic interactions found driving force binding theaflavin formed hydrogen bonds d<NUMBER> r<NUMBER> r<NUMBER> sarscov<NUMBER> rdrp additionally πcation interaction found r<NUMBER> <NUMBER> calligari et al <NUMBER> autodockvina scoring −<NUMBER> kcalmol recognised best autodock vina scoring drug spite hcv main protease measure low identity sarscov<NUMBER> homolog <NUMBER> thus finding thunderbolt <NUMBER> therefore may inferred similar topology active site proteases main driving force binding simeprevir fitted well two hydrophobic pockets fringed catalytic dyad h<NUMBER>c<NUMBER> sarscov<NUMBER> mpro also fitted hydrophobic loop f<NUMBER>f<NUMBER> moreover binding simeprevir sarscov<NUMBER> protease anchored three hydrogen bonding interactions e<NUMBER> g<NUMBER> n<NUMBER> <NUMBER> article homology modelling sarscov<NUMBER> protein aid itasser server done using sarscov spike pdb <NUMBER>wrg <NUMBER> × <NUMBER> <NUMBER>xlr template global pairwise sequence alignment measured sarscov<NUMBER> protein shares <NUMBER> primary sequence homolog addition overall similarity <NUMBER> autodock vina molecular docking homology modelled structure protein predicted umifenovir db<NUMBER> enfuvirtide db<NUMBER> pleconaril db<NUMBER> potential inhibitors <NUMBER> study repurposing existing drugs current pandemic covid<NUMBER> wu et al <NUMBER> predicted potential drugs acting certain target multiple targets sarscov<NUMBER> bioinformatics based homology modelling utilised build possible targets viral mpro plpro rdrp helicase spike etc next modelled proteins human relative proteins including human ace<NUMBER> typeii transmembrane serine protease enzymes forwarded systematically analyse screen zinc drug database zdd along database traditional chinese medicine natural products database commonly used <NUMBER> antiviral drugs <NUMBER> study seems interesting due deep discussions vast target predictability lead candidates emerged study required vitro vivo studies conformations new drug discovery development takes five ten years investigations well cost billions dollars thus drug repositioning cheap strategy respond immediately fdaapproved drugs justify safe alternatives least modest antisarscov<NUMBER> activity achieved currently academia industry personnel involved testing approved drugs andor ii drug candidates clinical trials vitro screenings fda approved drugs well compounds currently clinical trials phases well documented <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> need vivo testing facilitate drug discovery efforts sarscov<NUMBER> nafamostat figure <NUMBER> potent membrane fusion inhibitor merscov <NUMBER> found inhibit <NUMBER>ncov infection ec <NUMBER> besides agent marketed antiprotozoal drug <NUMBER> also reported possess antiviral broad range viruses <NUMBER> article wang et al <NUMBER> remdesivir illustrated years ago <NUMBER> found effectively block sarscov<NUMBER> infection lowmicromolar concentration <NUMBER> exhibited halfmaximal effective concentration ec <NUMBER> <NUMBER> μm <NUMBER>ncov vero e<NUMBER> cells half cytotoxic concentration cc <NUMBER> <NUMBER> μm selectivity index si <NUMBER> remdesivir also inhibited virus infection sarscov<NUMBER> sensitive human liver cancer huh<NUMBER> cells <NUMBER> widelyused antimalarial drug chloroquine cq figure <NUMBER> used <NUMBER> years <NUMBER> found shows clinical potency covid<NUMBER> figure <NUMBER> may placed molecular mechanism chloroquine sarscov known <NUMBER> <NUMBER> recently wang et al <NUMBER> reported timeofaddition assay explained function cq ec <NUMBER> <NUMBER> μm cc <NUMBER> <NUMBER> μm si <NUMBER> entry well postentry stages novel corona virus infection vero e<NUMBER> cells group researches evaluated vitro antisarscov<NUMBER> effect hydroxychloroquine hcq figure <NUMBER> sulphate derivative cq comparison cq <NUMBER> hydroxychloroquine sulphate <NUMBER> introduced long first synthesized <NUMBER> <NUMBER> upon introduction hydroxyl group cq resulted <NUMBER> less toxic agent cq animals cq hcq weak bases restrict virus infection byi triggering endosomal ph essential viruscell fusion ii interfering glycosylation ace<NUMBER> receptor spike protein coronavirus <NUMBER> additionally cq hcq obstructed sarscov<NUMBER> transport early endosomes ees endolysosomes els interestingly exhibited distinct binding mode covalent peptidomimetic <NUMBER>clpro inhibitors <NUMBER> vitro screening <NUMBER> drugs screened hcovs infection <NUMBER> immunofluorescence analysis antibody specific viral n protein sarscov<NUMBER> scored drug treated cells doseresponse curve drc developed analysing confocal microscope images viral n protein cell nuclei remdesivir sarscov<NUMBER> ic <NUMBER> <NUMBER> µm lopinavir sarscov<NUMBER> ic <NUMBER> <NUMBER> µm chloroquine sarscov<NUMBER> ic <NUMBER> <NUMBER> µm used reference drugs consequently <NUMBER> drugs showed good activities ic <NUMBER> ranges <NUMBER> <NUMBER> μm antihelminthic drug niclosamide corticosteroid used treat asthma allergic rhinitis ciclesonide emerged sarscov<NUMBER> inhibitors ic <NUMBER> <NUMBER> μm <NUMBER> μm respectively notably niclosamide reduces merscov replication inhibiting skp<NUMBER> activity leading enhancement autophagy <NUMBER> thus similar mechanism may introduced niclosamide hamper sarscov<NUMBER> infection <NUMBER> zhang et al <NUMBER> reported structurebased design synthesis activity assessment αketoamides broadspectrum inhibitors coronavirus enterovirus replication showed good inhibitory properties isolated proteases viral replicons virusinfected huh<NUMBER> cells nearequipotency enteroviruses alphacoronaviruses betacoronaviruses observed upon optimization p<NUMBER> substituent αketoamides cyclopentylmethyl cyclohexylmethyl p<NUMBER> substituent disposed lowmicromolar ec <NUMBER> values three virus genera cell cultures compound <NUMBER>r found promising merscov virusinfected huh<NUMBER> cells <NUMBER> dint high similarity among <NUMBER>clproteases coronavirus awaited compound <NUMBER>r expected display good antiviral activity covid<NUMBER> near future meanwhile clinical trial studies molecules started covid<NUMBER> mainly drug repurposing <NUMBER> depicted table <NUMBER> medicinal chemistry sarscov<NUMBER> infection still infancy target specific lead molecules yet identify study deals information currently available potential targets therapeutic invention screening new compounds drug repurposing sarscov<NUMBER> figure <NUMBER> <NUMBER>d structure sarscov<NUMBER> <NUMBER>clike protease bears <NUMBER> identity ortholog sarscov interestingly residues involved catalysis substrate binding dimerization <NUMBER>clpro <NUMBER> conserved addition polyprotein pp<NUMBER>ab sequences highly similar <NUMBER> identity depending upon alike substrate specificities high identities opinion previous progress specific sarscov inhibitors development undertaking course action design discovery inhibitors sarscov<NUMBER> group already explored structural properties important sarscov viral <NUMBER>clike protease inhibitors <NUMBER> recently collaborative work research team suggested implications naphthyl derivatives sarscov<NUMBER> plpro enzyme though indepth ligandreceptor interaction analysis <NUMBER> already predicted inhouse glutaminebased molecules use seed drug design optimization plpro sarscov<NUMBER> <NUMBER> fact antiviral drugs also taken consideration regards targetbased vs one important approaches used drug repurposing computational analyses subordinate right choice enrich basal knowledge long process leading drug development figure <NUMBER> clearcut treatment approach prescribed covid<NUMBER> use already approved drugs alternative strategy howbeit relatively limited computational resource biased silico screening may scattered linearity drug discovery novel coronavirus near future virtual hits may serve promising drug like molecule sarscov<NUMBER> details vitro vivo laboratory investigations moreover availability xray crystal structures important viral proteins trigger exhaustive docking calculation diverse chemotypes crystal clear prevention covid<NUMBER> requires strong sustainable global collaborative work <NUMBER> data sharing exigent fill knowledge gaps global pandemic progress scientific understanding regarding structural molecular biology sarscov<NUMBER> legitimate shape lead compounds achieve therapeutic goals development medicinal chemistry bioinformatics chemoinformatics studies remains indispensable bit savoir faire authors conflict interests sk abdul amin senior research fellow department pharmaceutical technology jadavpur university kolkata india working guidance tarun jha research area includes design synthesis small molecules anticancer antiviral properties computational chemical biology largescale structureactivity relationship analysis published sixty two researchreview articles different reputed peerreviewed journals three book chapters enjoys good conversation science regional history contemporary art books tarun jha professor department pharmaceutical technology jadavpur university kolkata india supervised <NUMBER> phd students guided nine research projects funded different organizations published <NUMBER> research articles different reputed peerreviewed journals research area includes design synthesis anticancer small molecules prof jha member academic advisory committee national board accreditation nba new delhi india caused novel highly contagious zoonotic pathogen severe acute respiratory syndrome coronavirus<NUMBER> sarscov<NUMBER> hui et al <NUMBER> may <NUMBER> th <NUMBER> <NUMBER> deaths <NUMBER> <NUMBER> case fatality rate confirmed covid<NUMBER> cases reported continents world health organization <NUMBER> two novel coronavirus zoonotic diseases humans sars mers specific treatments reducing mortality morbidity yet available hui zumla <NUMBER> management covid<NUMBER> patients remains largely symptomatic supportive organ support severely ill patients deaths covid<NUMBER> continue rise globally effective appropriate treatments vaccines found specific treatments available treating covid<NUMBER> patients global medical scientific pharma funding communities rapidly initiated <NUMBER> covid<NUMBER> related trials httpsclinicaltrialsgovct<NUMBER>whotable clinical trials fasttracked ethical committees worldwide range therapeutic interventions registered clinical trialsgov taking forward phase <NUMBER> <NUMBER> <NUMBER> trials antiviral drug regimens biologics repurposed drugs various combinations herbal remedies nutritional supplements cellular therapies results ongoing clinical trials new antiviral regimens biologics repurposed drugs various combinations eagerly awaited focus editorial specifically background rationale use evaluation mesenchymal stromal stem cells mscs treatment trials patients severe covid<NUMBER> disease area eclipsed current emphasis huge number trials evaluating new antiviral drugs repurposed drugs combinations thereof defining underlying pathogenesis pathology covid<NUMBER> disease developing appropriate therapeutic interventions may prevent end organ damage longterm functional disability survive severe disease autopsy minimally invasive biopsy studies indicate covid<NUMBER> multisystem disease lungs particular manifest significant pathological lesions alveolar exudative inflammation interstitial inflammation alveolar epithelium proliferation hyaline membrane formation menter et al <NUMBER> tian et al <NUMBER> significant proliferation type ii alveolar epithelia focal desquamation alveolar bronchial epithelia hyaline membrane formation j u r n l p r e p r f seen xu et al <NUMBER> predominantly macrophage monocyte immune cell infiltration alveoli multinucleated giant cells lymphocytes mostly cd<NUMBER>positive cells eosinophils neutrophils blood vessels alveolar septum congested edematous widened modest infiltration monocytes lymphocytes hyaline thrombi microvessels focal hemorrhage lung tissue organization exudates pulmonary interstitial fibrosis observed furthermore degeneration necrosis parenchymal cells formation hyaline thrombus small vessels observed organs tissues menter et al <NUMBER> tian et al <NUMBER> immunohistochemical staining showed alveolar epithelia macrophages positive sarscov<NUMBER> antigen evidence sarscov<NUMBER> antigens organs tissues detected suggests host immune responses evoked sarscov<NUMBER> infection involved pathogenesis multiorgan injury yao et al <NUMBER> covid<NUMBER> like mers sars systemic illness multiorgan involvement sarscov<NUMBER> enters host cells via cell surface angiotensin converting enzyme <NUMBER> ace<NUMBER> receptor target cell surface ace<NUMBER> cardioregulator numerous cells ace<NUMBER> receptors blood vessels alveolar type ii cells at<NUMBER> lungs several organs heart kidneys appears three lethal zoonotic coronaviruses merscov sarscov sarscv<NUMBER> seem induce excessive aberrant host immune responses associated severe lung pathology leading acute respiratory distress syndrome ards li g et al <NUMBER> li g et al <NUMBER> characteristic findings chest imaging covid <NUMBER> include bilateral ground glass consolidative changes associated cytokine storm may play role pathogenesis elevated proinflammatory cytokines chemokines including tumour necrosis factor tnfα interleukin <NUMBER>β il<NUMBER>β il<NUMBER> granulocytecolony stimulating factor interferon gammainduced protein<NUMBER> monocyte chemoattractant protein<NUMBER> macrophage inflammatory proteins <NUMBER>α significantly elevated covid<NUMBER> patients huang c et al <NUMBER> liu j et al <NUMBER> patients evidence hyperinflammation increased risk mortality mehta et al <NUMBER> ruan et al <NUMBER> survive intensive care longterm consequences aberrant excessive immune responses may lead long term pulmonary damage fibrosis functional disability reduction quality life important therapeutic interventions dampen excess j u r n l p r e p r f inflammation thus preventing end organ damage longterm functional disability survive severe disease past decade medical pharma communities focused developing therapeutics targeting pathogen rather role underlying host factors zumla et al <NUMBER>a <NUMBER>b human immune defenses dependent complex array mechanical innate acquired immune mechanisms disturbance internal lung milieu results serious fatal consequences improved understanding inflammatory immune pathways governing protective deleterious outcomes provide novel opportunities target specific pathways mediate immune pathology figure <NUMBER> httpsipscellcomrmatlist <NUMBER> first allogeneic msc product received marketing approval european union since commercial stem cell clinics marketing dubious therapies cardiovascular disease cancer sissung figg <NUMBER> fda cdc cautions regarding use httpswwwfdagovconsumersconsumerupdatesfdawarnsaboutstemcelltherapies httpswwwcdcgovhaioutbreaksstemcellproductshtml mesenchymal stromal cells interact cell types innate acquired mscs also express atpases possess ectonucleotidase activity cd<NUMBER> expression capacity deplete atp immunomodulatory effects mscs may also triggered activation tlr receptor mscs stimulated pathogenassociated molecules lps importantly mscs ace<NUMBER> receptor makes immune sarscov<NUMBER> whilst generally regarded safe editorial <NUMBER> mscs immunologically inert previously thought lohan et al <NUMBER> ankrum ja et al <NUMBER> recent systematic review j u r n l p r e p r f metaanalysis intravascular msc therapy reviewed <NUMBER> randomised controlled trials msc therapy compared controls thompson et al <NUMBER> mscs compared controls associated increased risk fever nonfever acute infusional toxicity infection thromboticembolic events malignancy <NUMBER> <NUMBER> <NUMBER> x <NUMBER> <NUMBER> cellskg recruiting total <NUMBER> patients <NUMBER> patients per dose cohort msc infusion associated mild adverse reactions <NUMBER> patients however serious treatment related adverse events identified mscs used potential therapy treating covid<NUMBER> patients order reduce mortality although use mscs found safe used treatment diseases important evaluate whether safe use excessive host response seen patients covid<NUMBER> appears induced paradigm shift longstanding focus drug treatment interventions targeting pathogen sarscov<NUMBER> case targeting host response currently clinicaltrialsgov world health organization international clinical trials registry platform ictrp report combined <NUMBER> trials exploring potential mscs products treatment prevention covid<NUMBER> table <NUMBER> lists clinical trials mscs products registered clinicaltrialsgov registered trials pursued recent weeks five trials registered chinese clinical trial register chictr one trial registered clinicaltrialsgov marked cancelled investigator xxxxx open interested parties join us help define optimal msc therapy regimens change course covid<NUMBER> sustain growing portfolio cellular therapies range acute chronic infectious diseases viable mscs rescue injured cells mitochondrial transfer produce broad array immunomodulatory cytokines mscs may taken phagocytic cells may prolong augment biological effect intravenous delivery risks include generally reduced immune competence including antiviralbacterialfungal activity well potential protumorigenic effects beneficial reduction proinflammatory cytokines increased treg il<NUMBER> production <NUMBER> million confirmed cases <NUMBER> deaths human coronavirus disease <NUMBER> covid<NUMBER> pandemic caused novel severe acute respiratory syndrome coronavirus sarscov<NUMBER> united states alone however currently lack proven effective medications covid<NUMBER> drug repurposing offers promising way development prevention treatment strategies covid<NUMBER> study reports integrative networkbased deep learning methodology identify repurposable drugs covid<NUMBER> termed covkge specifically built comprehensive knowledge graph includes <NUMBER> million edges across <NUMBER> types relationships connecting drugs diseases proteinsgenes pathways expression large scientific corpus <NUMBER> million pubmed publications using amazons aws computing resources networkbased deep learning framework identified <NUMBER> repurposable drugs including dexamethasone indomethacin niclosamide toremifene whose therapeutic association covid<NUMBER> validated transcriptomic proteomic data sarscov<NUMBER> infected human cells data ongoing clinical trials study means recommends specific drugs demonstrates powerful deep learning methodology prioritize existing drugs investigation holds potential accelerating therapeutic development covid<NUMBER> repurpose open data discover therapeutics covid<NUMBER> using deep learning newly identified coronavirus sarscov<NUMBER> causes severe pneumonia coronavirus disease <NUMBER>covid <NUMBER> rapidly spread across world initial outbreak point wuhan china late <NUMBER> <NUMBER> become global health emergency march <NUMBER> <NUMBER> world health organization declared pandemic status novel coronavirus outbreak since approved drug specifically targeted virus exists point time drug repositioningrepurposing thought effective feasible approach toward clear present threat researchers initiated studies employing various means order find potential therapeutics <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> sarscov<NUMBER> genome close severe acute respiratory syndrome coronavirus sarscov <NUMBER> past efforts cure rna virus infections including experiences sars middle east respiratory syndrome mers epidemics several potential target proteins drugs proposed <NUMBER> <NUMBER> <NUMBER>clike main proteinase surface glycoprotein <NUMBER> rnadependent rna polymerase thought promising targets anticovid<NUMBER> therapeutics example antihiv drug lopinavirritonavir proposed treat sars <NUMBER> <NUMBER> expected effective toward sarscov<NUMBER> <NUMBER>clike proteinase <NUMBER> <NUMBER> additionally antiviral drug remdesivir expected target rnadependent rna polymerase <NUMBER> recent studies drug repositioningrepurposing involve variety computational methods network analysis text mining machine learning structurebased drug repositioning sbdr <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> among methods sbdr promising find abbreviations ace<NUMBER> angiotensin iconverting enzyme <NUMBER> mers middle east respiratory syndrome rbd receptorbinding domain sarscov severe acute respiratory syndrome coronavirus sbdr structurebased drug repositioning world health organization specific drugs toward defined target protein prompted quick structure analyses sarscov<NUMBER> <NUMBER>clike proteinase surface glycoprotein <NUMBER> <NUMBER> although structure analyses many sarscov<NUMBER> proteins would soon follow predictions protein structures homologyknowledgebased theoretical methods would required structure analyses completed especially proteins currently focus drug targets presented study therefore homology models sarscov<NUMBER> proteins ligand complexes comprehensively constructed also structural models complexes sarscov<NUMBER> proteins potential drugs proposed comparing ligand molecules proteins approved experimental natural drugs amino acid sequences sarscov<NUMBER> proteins table <NUMBER> retrieved refseq database ncbi <NUMBER> structural modeling templates sought sird system httpsirdnagahamaibioacjpsird accepted multiple query sequences sought similar sequences <NUMBER> sequence identity query known structures protein data bank pdb <NUMBER> using blast <NUMBER> system also sought templates protein complex structures two proteins multiple query associated ligand bound query proteins coordinates template structures obtained pdb <NUMBER> rendered biological quaternary structures initial structural models constructed using modeller <NUMBER> cases resultant models contain residues rare dihedral angles ramachandran outliers rare shape side chains rotamer outliers short atomatom distances atomic crashes models modified iteratively applying molecular dynamics geometry minimization procedures phenix <NUMBER> eliminate aforementioned outliers finally manual model modifications visual inspection coot resolving rotamer outliers atomic crashes <NUMBER> model quality evaluated molprobity <NUMBER> percentages rotamer outlier ramachandran outlier crash score monitored model achieve less <NUMBER> <NUMBER> <NUMBER> respectively modeling sarscov<NUMBER> protein complexes potential drugs molecular formula <NUMBER> drugs total retrieved kegg database <NUMBER> drugbank database <NUMBER> molecular formula <NUMBER> metabolites total used natural medicines natural drugs obtained knapsack database <NUMBER> structures ligand molecules known complex structures sought template search process exhaustively compared drugs using complig <NUMBER> complig matches molecular graphs evaluates similarity score two molecules b minm selected drug molecules built protein models superposing drug molecules known original ligand molecules complig according graph matching results dihedral angles drug molecules adjusted toward corresponding angles original ligand molecules corresponding atoms superposed drug known ligand fixing coordinates latter models proteindrug complexes modified phenix coot constraints drug molecules generated using elbow application phenix hydrogen bonds evaluated canonical parameters constraints relaxed <NUMBER> å <NUMBER> degrees <NUMBER> using chimera <NUMBER> proteinligand complexes also assessed using dsx score function <NUMBER> sarscov<NUMBER> genome encodes <NUMBER> genes open reading frames polyprotein orf<NUMBER>ab processed <NUMBER> proteins polypeptides cleavages papainlike proteinase <NUMBER>clike proteinase activities <NUMBER> <NUMBER> <NUMBER> result template search appropriate structural templates found <NUMBER> sarscov<NUMBER> proteins among total <NUMBER> homology models constructed table <NUMBER> <NUMBER> unmodeled proteins included short orfs namely nsp<NUMBER> <NUMBER> amino acid residues orf<NUMBER>b <NUMBER> residues orf<NUMBER> <NUMBER> residues probable membrane proteins nsp<NUMBER> orf<NUMBER>a orf<NUMBER> orf<NUMBER> annotated sosui server <NUMBER> since considerable amount structural studies already done sarscov merscov proteins available templates viruses highsequence similarity <NUMBER> sarscov<NUMBER> proteins two proteins namely papainlike proteinase nsp<NUMBER> nucleocapsid phosphoprotein could modeled single structural model result homology search template structures covering entire protein unavailable template structures separated <NUMBER> <NUMBER> fragmentdomain models respectively consequently coverages structural model <NUMBER> <NUMBER> total residues papainlike proteinase nsp<NUMBER> nucleocapsid phosphoprotein respectively table <NUMBER> third region papainlike proteinase nsp<NUMBER> nsp<NUMBER> <NUMBER>clike proteinase nsp<NUMBER> endornase surface glycoprotein envelope protein cterminal region nucleocapsid phosphoprotein modeled homomultimer heteromultimeric models nsp<NUMBER> nsp<NUMBER> modeled hetero<NUMBER>mer rnadependent rna polymerase nsp<NUMBER> nsp<NUMBER> modeled heterotetramer <NUMBER> stoichiometry <NUMBER>to<NUMBER> exonuclease nsp<NUMBER> formed heterodimer <NUMBER>oribose methyltransferase nsp<NUMBER> also formed heterodimer homotrimer surface glycoprotein modeled complex human angiotensin iconverting enzyme <NUMBER> ace<NUMBER> table <NUMBER> although models sarscov<NUMBER> protein would useful structurebased virtual screening potential drugs proteins sought rather simple knowledgebased method presented study ligand molecules complexed homologs sarscov<NUMBER> protein pdb extracted structurally similar molecules ligands sought among approvedexperimental drugs retrieved kegg database <NUMBER> drugbank database <NUMBER> many approved drugs morphine aspirin penicillin adapted natural medicines <NUMBER> <NUMBER> molecules natural medicines expected serve argent therapeutics therefore ligand structures also compared components natural medicines natural drugs registered knapsack database <NUMBER> original ligand molecules detected drug molecules summarized table <NUMBER> total <NUMBER> ligand molecules matched <NUMBER> approvedexperimental <NUMBER> natural drugs complex models sarscov<NUMBER> proteins several promising drugs high similarity score placed higher ranking constructed follows <NUMBER>clike proteinase involved processing viral polyprotein <NUMBER> enzyme one extensively studied drug targets thus analyzed complex various peptide mimetic inhibitors <NUMBER> <NUMBER> <NUMBER> <NUMBER> unexpectedly ligands show high similarity known drug molecules table <NUMBER> peptide mimetic drug carfilzomib showed highest score template ligand ligand code azp <NUMBER>clike proteinase homolog fig <NUMBER>a however similarity score ligand drug <NUMBER> carfilzomib irreversible proteasome inhibitor targeted subunits chymotrypsinlike activity approved refractory multiple myeloma waldenstr€ oms macroglobulinemia <NUMBER> <NUMBER> complex model carfilzomibsarscov<NUMBER> <NUMBER>clike proteinase constructed model carfilzomib formed parallel bsheet his<NUMBER>glu<NUMBER> side chains his<NUMBER> cys<NUMBER> met<NUMBER> leu<NUMBER> phe<NUMBER> gln<NUMBER> contributed major interactions fig <NUMBER>bc residues conserved template sarscov model sarscov<NUMBER> proteins carfilzomib covalently binds active site threonine epoxy moiety epoxy moiety also reactive thiol group cysteine although possible covalent linkage carfilzomib catalytic cys<NUMBER> sarscov<NUMBER> <NUMBER>clike proteinase explicitly modeled epoxy moiety placed close catalytic residue model fitness ligand sarscov<NUMBER> <NUMBER>clike proteinase model evaluated dsx function score carfilzomib <NUMBER> even better à<NUMBER> inhibitor n<NUMBER> complex crystal structure sarscov<NUMBER> <NUMBER>clike proteinase pdb id <NUMBER>lu<NUMBER> surface glycoprotein used viral entrance host cell cell surface receptor human angiotensin iconverting enzyme <NUMBER> ace<NUMBER> <NUMBER> ace homolog ace<NUMBER> sharing <NUMBER> amino acid sequence identity major target hypertension medicating drugs several acedrug complexes reported <NUMBER> <NUMBER> <NUMBER> lisinopril enalaprilat captopril show similar structures fig <NUMBER>a targeted toward ace approved hypertension treatments <NUMBER> <NUMBER> <NUMBER> <NUMBER> structural complex models drugs bound protein zn <NUMBER> coordination glu<NUMBER> his<NUMBER> his<NUMBER> fig <NUMBER>bc residues conserved template ace model ace<NUMBER> structures drug molecules also formed electrostatic interactions arg<NUMBER> arg<NUMBER> even though residues conserved ace ace<NUMBER> gln<NUMBER> ser<NUMBER> ace sarscov<NUMBER> surface glycoprotein interacted ace<NUMBER> receptorbinding domain rbd bound drugs direct interaction rbd fig <NUMBER>c suggesting drugs would directly interfere hostpathogen interaction dsx scores lisinopril enalaprilat captopril models à<NUMBER> à<NUMBER> à<NUMBER> respectively scores considerably inferior à<NUMBER> specific inhibitor mln<NUMBER> crystal structure human ace<NUMBER> complex pdb id <NUMBER>r<NUMBER>l <NUMBER> complex <NUMBER>oribose methyltransferase nsp<NUMBER> nsp<NUMBER> involved modification viral rna caps <NUMBER> structure <NUMBER>oribose methyltransferase subunit determined complex sadenosyllmethionine ligand code sam <NUMBER>methylguanosine<NUMBER>triphosphate<NUMBER>guanosine gtg sinefungin sfg <NUMBER> <NUMBER> <NUMBER> among ligands sadenosyllmethionine used therapeutic depression liver disorders fibromyalgia osteoarthritis <NUMBER> also authentic substrate enzyme sinefungin natural drug produced streptomyces griseolus experimentally used antibiotics <NUMBER> <NUMBER> <NUMBER> fig <NUMBER>a residues <NUMBER>oribose methyltransferase ser<NUMBER> asp<NUMBER> asn<NUMBER> asp<NUMBER> met<NUMBER> involved major interactions sinefungin fig <NUMBER>bc residues conserved among template proteins sarscov betacoronavirus sarscov<NUMBER> drugs similar ligands several investigational adenosine a<NUMBER> receptor agonists namely tecadenoson selodenoson trabodenoson found fig <NUMBER>a molecules share adenosine moiety moiety interacts aforementioned <NUMBER> conserved residues complex models dsx scores sinefungin tecadenoson selodenoson trabodenoson à<NUMBER> à<NUMBER> à<NUMBER> à<NUMBER> respectively scores sinefungin selodenoson comparable à<NUMBER> genuine substrate sadenosyllmethionine complex crystal structure merscov <NUMBER>oribose methyltransferase pdb id <NUMBER>yni presented study knowledgebased models sarscov<NUMBER> proteins constructed homology modeling comparison known ligands drugs since considerable number structure analyses already reported coronavirus proteins including sarscov <NUMBER> <NUMBER> sarscov<NUMBER> proteins could modeled based highly similar <NUMBER> sequence identity <NUMBER> coverage average templates table <NUMBER> several drugs suggested bind sarscov<NUMBER> targets table <NUMBER> procedure employed presented study largely limit extent search depends presence ligands known complex structures however noteworthy binding suggested drugs homologous proteins sarscov<NUMBER> targets would probable presence structural evidences complex models constructed several highscored andor highranked drugs unexpectedly drug detected one promising drug targets <NUMBER>clike proteinase similarity score higher <NUMBER> previous study score <NUMBER> suggested required highly similar interactions ligand protein <NUMBER> implied inhibitors bound <NUMBER>clike proteinase known structures considerably deviated approved proteasetargeted drugs example antihiv drug lopinavirritonavir expected target sarscov<NUMBER> <NUMBER>clike proteinase <NUMBER> <NUMBER> showed limited similarity score <NUMBER> known ligand ligand code axp sarscov <NUMBER>clike proteinase fig <NUMBER>a one possible reason low similarity drugs protease inhibitors tend higher molecular weight thus molecular structures showed large variety another reason would majority protease inhibitory drugs targeted toward serine zinc proteases <NUMBER> <NUMBER> also expected drug lopinavirritonavir designed hiv protease aspartic protease proteases structurally distinct <NUMBER>clike proteinase known cysteine protease observation implies structure optimizations would likely required repurposed drugs sarscov<NUMBER> <NUMBER>clike proteinase consequently presented study suggested carfilzomib targeted toward threonine protease approved multiple myeloma treatment <NUMBER> <NUMBER> marginally resembling drug model showed however carfilzomib fits well even better specific inhibitor n<NUMBER> according dsx score active site forming considerable stabilizing interactions severe steric hindrance fig <NUMBER>c another potential target complex surface glycoprotein ace<NUMBER> prevent virus entry cell <NUMBER> <NUMBER> many hypertension drugs targeted ace presented study highlighted approved drugs namely lisinopril enalaprilat captopril potential ligands ace<NUMBER> expectation advance find drug bound ace<NUMBER> also interfered interactions surface glycoprotein ace<NUMBER> however models revealed drugbinding site ace<NUMBER> existed inside deep cleft center ace<NUMBER> molecule ligands interact directly surface glycoprotein fig <NUMBER>c human ace<NUMBER> demonstrated change conformation open close forms pdb ids <NUMBER>r<NUMBER>l <NUMBER>r<NUMBER> respectively upon inhibitor binding <NUMBER> thus conformational change involves interface rbd surface glycoprotein drug bound drugbinding site might interfere binding ace<NUMBER> surface glycoprotein indirectly allosteric inhibition mechanism however highly expected obvious conformational change observed interface region comparing open close conformations ace<NUMBER> predicted drugs targeted toward ace ace<NUMBER> ace ace<NUMBER> diverge considerably amino acid sequences <NUMBER> identity fitness drugs evaluated lower specific inhibitor ace<NUMBER> therefore effects predicted ace drugs preventing surface glycoproteinace<NUMBER> interactions would highly promising another target presented results highlighted <NUMBER>oribose methyltransferase nsp<NUMBER>nsp<NUMBER> complex less focused target drug repurposing <NUMBER>oribose methyltransferase required finalize cap structure <NUMBER>me gpppa <NUMBER>ome coronavirus rnas transferring methyl group <NUMBER> oh group ribonucleotide sadenosyllmethionine <NUMBER> <NUMBER> cap structure essential viral mrnas translated escape innate immune system host cell thus inhibition enzyme might prevent virus propagation despite overall sequence identities templates sarscov human betacoronavirus sarscov<NUMBER> enzymes relatively low <NUMBER> residues interacting drugs conserved among suggested drugs enzyme sinefungin naturally occurring verified inhibitor <NUMBER>oribose methyltransferase since toxicity detected <NUMBER> however appreciation natural drug carefully considered although tecadenoson examined clinical trial atrial fibrillation passed phase ii test final results formally reported point time <NUMBER> trabodenoson designed treating ocular hypertension primary openangle glaucoma <NUMBER> failed phase iii clinical trial test due lack superiority placebo selodenoson designed control heart rate <NUMBER> seems still developmental stage since tecadenoson trabodenoson appeared cleared phase tests drugs would worth examining covid<NUMBER> dsx score suggested fitness sinefungin selodenoson comparable genuine substrate <NUMBER>oribose methyltransferase several structure determinations sarscov<NUMBER> proteins example endornase pdb ids <NUMBER>vww <NUMBER>vw<NUMBER> nucleocapsid phosphoprotein <NUMBER>vyo nsp<NUMBER> rnadependent rna polymerasensp<NUMBER>nsp<NUMBER> complex pdb id <NUMBER>bv<NUMBER> reported modeling presented study executed although many proteins analyses undoubtedly would take considerable time structures potential targets experimentally elucidated period structural determinations theoretical models might useful presented structural models freely available binds webpage httpswwwbind sjpsarscov<NUMBER> also deposited bsmarc repository bsm<NUMBER> <NUMBER> work partly supported platform project supporting drug discovery life science mo sk ts conceived designed study ah cs sn ms ts constructed models ah cs ts wrote manuscript authors commented manuscript discovery covid<NUMBER> led global panic substantial challenges rapidly systematically identifying suitable interventions unpredictable disease <NUMBER> similar challenges associated severe acute respiratory syndrome sars <NUMBER> h<NUMBER>n<NUMBER> <NUMBER> h<NUMBER>n<NUMBER> <NUMBER> middle east respiratory syndrome mers <NUMBER> ebola virus disease evd <NUMBER> among others addressing infectious diseases well understood capable exhibiting aggressive clinical courses subsequent patient mortality rapid intervention optimally suited target pathogen critical due unpredictability severity pathogens combination therapy based drug repurposing often indicated due urgency intervention requirement previously established drug safety humans unfortunately drug combinations often designed using trialanderror strategies specifically drugs selected based targets mechanism action administered using clinical standard dosing guidelines dose adjustments made toxicity observed unfortunately approaches likely preclude optimal treatment outcomes previously broad spectrum methodologies used part multiple important studies develop combination therapies address multiple disease indications <NUMBER> substantial efforts also directed toward new drug development confronted novel pathogen strain high virulence potential capacity rapid continuous mutation poor patient outcomes global community often requires rapidly actionable responses due patient mortality may quickly follow initial diagnosis address covid<NUMBER> crisis substantial number clinical trials initiated <NUMBER> treatment options explored address covid<NUMBER> included repurposed human immunodeficiency virus hiv influenzarelated monotherapies drug cocktails trials investigational therapies remdesivir gilead sciences sparked worldwide effort develop vaccine among large sets candidate therapies drug repurposing combination therapy standard approaches involve drug selection based mechanism action drug dosing subsequently determined established clinical guidelines traditional design approaches based trialanderror barriers include suboptimal efficacy doselimiting toxicities sum lack systematic way interrogate massive drugdose parameter space created pools candidate therapies preclude ability optimize treatment outcomes address challenge work reports outcomes project identifai harnesses aibased platform interrogate drug dose parameter spaces insurmountably large bruteforce testing possible combinations project identifai sought determine duration time required simultaneously identify best drugs doses pool <NUMBER> candidate therapies optimally inhibited infection a<NUMBER> lung cell line vsv efficacy maintaining a<NUMBER> efficacy therapies included amantadine hcl dexamethasone azithromycin chloroquine diphosphate naproxen sodium fluoxetine hcl loratadine omeprazole sodium ritonavir lopinavir doxycycline ribavirin <NUMBER> candidate therapies selected based multiple factors may considered pandemics including prior studies examining role repurposed monotherapies addressing diverse range viral pathogens global adoption availability therapies well tolerability broad classes patients among others specifically amantadine hcl organic compound developed address influenza infections <NUMBER> repurposed treatment motor impairment parkinsons disease <NUMBER> explored improvement fatigue patients multiple sclerosis <NUMBER> dexamethasone potent antiinflammatory immunosuppressant glucocorticoid used therapies wide range indications including oncology bacterial infections <NUMBER> successfully used treat denguerelated hemophagocytic syndrome <NUMBER> azithromycin antibiotic given patients bacterial infections lower respiratory tract <NUMBER> including communityacquired pneumonia <NUMBER> explored novel antimalarial agent <NUMBER> chloroquine disphosphate widely used drug malaria recent years found target infectious diseases including hiv fungal infections <NUMBER> naproxen sodium established nonselective nonsteroidal antiinflammatory drug nsaid commonly used treating mild moderate pain inflammation <NUMBER> recently shown act influenza b viruses <NUMBER> fluoxetine hcl widely known prozac antidepressant used treat range depressive disorders <NUMBER> antiviral properties explored treating coxsackievirus <NUMBER> loratadine secondgeneration nonsedating antihistamine used allergies <NUMBER> recent clinical trials evaluated use abortive therapy pegfilgrastimassociated bone pain <NUMBER> omeprazole sodium proton pump inhibitor ppi used treat gastrointestinal reflux disease helicobacter pylori eradication therapy gastritis peptic ulcers <NUMBER> omeprazole ppis recently investigated demonstrated antitumor activity antiinflammatory effects <NUMBER> ritonavir lopinavir antiretroviral medications commonly used combination treatment patients infected hiv ritonavir used booster protease inhibitors like lopinavir <NUMBER> lopinavir ritonavir combination demonstrated vitro antiviral wwwadvancedsciencenewscom wwwadvtherapcom activity sars favorable clinical response patients sars <NUMBER> ritonavir also explored shown highly effective booster fixeddose combinations patients hepatitis c <NUMBER> doxycycline tetracycline antibiotic broad antimicrobial spectrum activity <NUMBER> recent clinical trials doxycycline shown treat nasal polyps rosacea antiinflammatory <NUMBER> ribavirin antiviral medication often administered combination interferonbased therapies patients chronic hepatitis c <NUMBER> additionally ribavirin shown effective treatment respiratory syncytial virus hemorrhagic fevers <NUMBER> within <NUMBER> days studies successfully identified repeatedly validated multiple drug combinations simultaneously reduced vsv infection <NUMBER> apparent adverse impact a<NUMBER> viability addition platform identified multiple highly efficacious tolerable regimens presenting potential multiple options treatment study demonstrated project identifai potentially used patientspecific populationwide development actionable combination therapy implementation also require complex disease mechanism drug target information implementation may enable immediate application toward dynamicallyoptimized drug repurposing novel combination therapy development high priority pathogens covid<NUMBER> others addition reporting rapid experimentally identified validated combination therapies vsv infection a<NUMBER> work also discusses key studies needed provides global health healthcare economics policy perspectives may provide roadmap toward broader clinical deployment project identifai collectively analyses demonstrate technology innovative policy considerations needed drive advances clinical practice addressing prepandemic pandemic challenges vsv model used study encoded green fluorescent protein gfp monitor cell infection gfp intensity corresponding viral infection efficiency gfp intensity vsvinfected cells different moi parameters <NUMBER> <NUMBER> <NUMBER> <NUMBER> assessed cell densities well <NUMBER> well plate varied <NUMBER> <NUMBER>k <NUMBER> <NUMBER>k <NUMBER> <NUMBER> <NUMBER>k per well infection allowed <NUMBER> <NUMBER> h figure <NUMBER>ab indicated figure microscopic images moi low <NUMBER> sufficient mediate nearly <NUMBER> cell infection <NUMBER> h <NUMBER>k per well initial cell density therefore utilized <NUMBER>k per well initial cell density throughout study reduced moi incubation time microscope images bright field fluorescence merged visualization different moi parameters <NUMBER> <NUMBER> <NUMBER> vsv infection occurred <NUMBER> h figure <NUMBER>c <NUMBER> h figure <NUMBER>d note indicated figure <NUMBER>c imagej cell counting results <NUMBER> ± <NUMBER> n <NUMBER> cells infected moi <NUMBER> <NUMBER> h moi <NUMBER> infected majority cells <NUMBER> h incubation overall gfp intensity continued increase <NUMBER> h checkpoint indicating virus continued reproduction inside cells period time order assess single drug toxicity antiviral efficacy single drugdose response curves acquired cell viability assessed <NUMBER> h vsv infection recorded <NUMBER> <NUMBER> h initial cell density <NUMBER>k per well moi maintained <NUMBER> vsv drugs simultaneously added host cells coincubation dose response curves amantadine hcl amt dexamethasone dex azithromycin azt chloroquine diphosphate clr npx naproxen sodium npx fluoxetine hcl flx lrt loratadine lrt omeprazole sodium omp ritonavir rtn lopinavir lpn doxycycline dox ribavirin rbv figure <NUMBER> npx rbv tested concentrations <NUMBER> <NUMBER> <NUMBER> <NUMBER> × <NUMBER> −<NUMBER> remaining drugs tested concentrations <NUMBER> <NUMBER> <NUMBER> <NUMBER> × <NUMBER> −<NUMBER> table s<NUMBER> supporting information monotherapies none drugs able mediate viral infection levels <NUMBER> exception azt flx lrt lpn dox mediated observable toxicity high concentrations candidate monotherapies studied concentration ranges appeared tolerable <NUMBER> cell viability note final dmso concentration tests exceed <NUMBER> ensure cell viability attributed drug treatments core aim project identifai simultaneously identify combinatorial drugs doses optimally inhibited vsv infection a<NUMBER> maximizing a<NUMBER> viability lieu using prior information pertaining synergistic affects among <NUMBER> candidate drugs identify suitable drug combinations project identifai harnessed quadratic relationship drugdose inputs efficacysafety outputs effectively identify drugdose parameter space optimal drug combinations could pinpointed drug synergy identified optimization process completed therefore process agnostic disease mechanism well drug target information viral infection outcomes drug treatment recorded <NUMBER> <NUMBER> h purposes evaluating speed optimization would also yield experimentally validated vsv inhibition <NUMBER>drug set minimum threshold <NUMBER> drug combinations broad range corresponding dose levels initially assessed moi <NUMBER> table s<NUMBER> supporting information viral infection drug treatment simultaneously applied host cells efficacy corresponding accumulative equivalent dose <NUMBER> drug combinations revealed broad spectrum vsv infection rates figure <NUMBER>a capacity infection inhibition drug well quantitative interaction drugs <NUMBER>drug pool evaluated strict algorithm <NUMBER> h figure <NUMBER>b <NUMBER> h figure <NUMBER>c note key therapies shown contribute toward viral inhibition delivered combination candidates merit optimization included amantadine hcl azithromycin chloroquine diphosphate omeprazole sodium ribavirin note candidate drugs performed well monotherapies however common observation vitro platforms subsequent need ultimately incorporate drugs clinically actionable combination therapy regimens order optimize use pathogen question despite promising single drug activity importantly sufficient testing drugdose parameter space may also reveal drugs promising monotherapy activity belong optimal combination therapy regimens commonly observed using platform <NUMBER> validate combination regimens <NUMBER> candidate drugs advanced consideration conducted subsequent round experiments <NUMBER> combinations consisting <NUMBER> drugs moi <NUMBER> table s<NUMBER> supporting information viral infection drug treatment simultaneously applied host cells viral infection drug treatment recorded <NUMBER> h figure <NUMBER>a parabolic polynomial model built stepwise regression following combinatorial optimization studies assessing drug interaction coefficients well parabolic response surfaces broad synergy subsequently observed figure <NUMBER>bd equation s<NUMBER> supporting information optimal combination optimal combo <NUMBER> mediated <NUMBER> vsv infection rate compared drug treatment comprised amantadine hcl <NUMBER> × <NUMBER> −<NUMBER> azithromycin <NUMBER> × <NUMBER> −<NUMBER> chloroquine diphosphate <NUMBER> × <NUMBER> −<NUMBER> ribavirin <NUMBER> × <NUMBER> −<NUMBER> optimal combo <NUMBER> mediated infection rate <NUMBER> compared drug treatment comprised amantadine hcl <NUMBER> × <NUMBER> −<NUMBER> azithromycin <NUMBER> × <NUMBER> −<NUMBER> chloroquine diphosphate <NUMBER> × <NUMBER> −<NUMBER> omeprazole sodium <NUMBER> × <NUMBER> −<NUMBER> table <NUMBER> note combinations based individual drug doses lower high doses needed adv therap <NUMBER> <NUMBER> achieve sufficient efficacy monotherapies important note many topranked combinations component therapies exhibited unfavorable efficacy delivered monotherapies played key role mediating optimal efficacy coadministered example amantadine hcl chloroquine diphosphate omeprazole sodium monotherapy shown relatively ineffective high doses compared drug treatment amantadine hcl treatment exhibited infection rates ≈<NUMBER> chloroquine diphosphate treatment exhibited infection rates ≈<NUMBER> omeprazole sodium treatment exhibited infection rates ≈<NUMBER> evaluate importance drug dose optimization systematic combination therapy design important note optimal combo <NUMBER> suboptimal combo <NUMBER> comprised therapies different doses alone resulted infection rates <NUMBER> <NUMBER> approximately sevenfold difference efficacy demonstrating importance simultaneous drug dose optimization confirmed scenario replacing amantadine hcl omeprazole sodium administering combination suboptimal dose results <NUMBER> infection rate represents <NUMBER>fold difference efficacy compared optimal combo <NUMBER> regards factors contributing toward optimal treatment outcomes analysis interaction terms showed effects primarily due singledrug contributions drug quadratic effects <NUMBER>drug interaction synergy well <NUMBER>drug interaction synergy figure <NUMBER>e equation s<NUMBER>s<NUMBER> supporting information fluorescence microscopy also used evaluate viral infection rate optimal drug combinations nonoptimal drug combinations figure <NUMBER> note apparent adverse effects cell density optimal combo <NUMBER> <NUMBER> observed identification validation process implemented project identifai demonstrated rapid optimization combination therapy development roadmap could completed within <NUMBER> days figure <NUMBER> covid<NUMBER> outbreak immediately deployable combination therapies based drug repurposing used clinic included kaletra ritonavirlopinavir combination oseltamivir tamiflu ® regimens repurposed monotherapies combination therapies carry benefit previously demonstrated safety patients threshold efficacy indications therefore common scenarios select small pool established therapies coadminister adjust drug doses accordingly toxicity issues ensue shown potentially clinically effective patients largely trialanderror strategy globally optimizing drug repurposing starkly different approach yield combinations comprised unexpected therapies far outperform traditional drug combination development based targetmechanismbased drug selection followed dose finding constrained drug selection based targets mechanism action pool candidate therapies enlarged include broader diversity compounds repurposing unfortunately also noted drug dosing impacts single drug efficacy safety context drug combination design dosing considerations also impact drugs ultimately comprise best combinations effectively creates parameter space large interrogate using bruteforce testing possible combinations project identifai sought overcome barrier pervasive across drug development roadmap virtually indications demonstrate rapid interrogation <NUMBER>drug parameter space could completed within timespan days lieu drug selection followed dose finding used previously established quadratic correlation <NUMBER>drug table <NUMBER> aioptimized regimens two optimal suboptimal nonoptimal combinations experimentally tested ai optimization process shown units micromolar pool drug doses input well inhibition a<NUMBER> infection vsv a<NUMBER> viability outputs systematically identify top drug combinations achieved independent prior knowledge drug targets mechanismofaction complex disease biology furthermore implementation platform require training based existing data sets big data instead specified set experiments based broad spectrum drugdose combinations sufficiently represents parameter space created <NUMBER>drug set prospectively conducted optimization process driven completely prospectively validated data cell line patient sample many efforts evaluate drug sets single drug treatment sampled combinations conducted global optimization combination therapy design large drug set opens doors broader spectrum actionable regimens study shown even combinations comprised drugs administered varying doses sevenfold difference efficacy observed even greater differences <NUMBER>fold observed one drug substituted omeprazole sodium another amantadine hcl yielding combination azithromycinchloroquine diphosphateomeprazole sodiumribavirin suboptimal dosing conditions interesting finding considering single drug substitution resulted profound disparity treatment outcomes even drugs considered comprised top <NUMBER> optimal combinations demonstrated importance simultaneous drugdose optimization importantly process produced multiple drugdoseoptimized combinations within <NUMBER> days approach potential providing pipeline alternatives patients issues drug resistance encountered important emphasize study conducted using vitro vsv model top ranked drug combination subsequently clinically validated addition vsv model selected primarily due wellcharacterized readily available platform different disease platform andor host model used highly probable ranking drugs comprise combinations number drugs mediate optimal performance change also study conducted diverse range potential drug candidates clinical setting especially address covid<NUMBER> clinically relevant pathogens pool drug candidates developed consultation treating clinical team likely differ substantially pool used study furthermore approach applied toward clinical samples patientspecific rankings optimal combinations potentially emerge importance findings study centered ability rapidly interrogate massive parameter spaces created right drugs right respective doses simultaneously reconciled ability reconcile extraordinarily large set possible combinations timely fashion actionable globally optimized combinations may effective wwwadvancedsciencenewscom wwwadvtherapcom scenarios prevention community spread novel aggressive pathogens critical additional clinical validation pointofcare required several key factors pertaining broad clinical relevance prior validation technologies related project identifai noted firstly previous oncology studies using quadratic phenotypic optimization platform qpop curateai foundational project identifai demonstrated benchtopbased implementation approach directly led markedly enhanced patient outcomes compared traditionally observed results <NUMBER> <NUMBER> additional clinical validation studies including one study harnessed related aiguided dosing platform hiv humans demonstrated critical importance drug dosage mediating optimal treatment efficacy tolerability <NUMBER> <NUMBER> note doses lower expected well dosages dynamically modulated commonly used optimize patient outcomes deploying aioptimized infectious disease intervention may result impact beyond technical clinical innovation scale platforms toward broader use healthcare policy economics infrastructure implications apply patient payer system considered platform many ways simultaneously serves diagnostic intervention identifies actionable intervention calibrating prospectivelyobtained patient populationbased data added possible benefits include fact optimizing drug repurposing use wellestablished potentially costeffective therapies manage unpredictable clinical courses reductions treatment complications associated doselimiting toxicities lack efficacy may encountered trialanderrornonoptimized repurposing outcomes may lead reduced healthcare cost burden opens important discussions platforms scaled efficiently integrated healthcare workflows enable better informed healthcare spending decisions patients <NUMBER> outcomes may also serve foundation broader clinical deployment ai intervene effectively earlier stages epidemic effective tailoring treatment populations individuals may also increase healthcare quality efficiency enabling opportunity personalize healthcare costs via qualitybased pricing specifically technologies realize actionable data patientspecific drugdose profiles play key role establishing relationship individualizing treatment improved quality care relationship also driven emergence quality variation patients hospital systems payers willing others make available andor pay testing may generate better data patientspecific drugdose profiles turn may lead introduction performancebased contracting qualitybased price discrimination suitable pathways explore especially result better health outcomes reducing cost care <NUMBER> concept led proposed personalized treatment plan diabetes patients using patients doseeffect characteristics subsequently reported substantial cost reductions improvements health outcomes <NUMBER> perspective healthcare providers financial incentives improve health care quality efficiency coverage <NUMBER> many countries implemented performancebased approach contracting medical services also led improvements domains beyond healthcare quality efficiency example approach us implemented name pay performance payment results uk strategies shown performancebased contracting improve social welfare <NUMBER> important consideration considering pandemic mortality rates linked social inequality higher mortality rates observed lower socioeconomic status patients <NUMBER> therefore context global health addressing epidemics pandemics impact aiguided healthcare likely expand beyond technical advances also influence broader domains healthcare economics equality addition considering patientcentric healthcare coverage emerging ai platforms tailor treatment latest circumstances show larger scale global health emergencies substantially impact economies example prolonged overburdening providers patients payers policymakers due pandemics coupled ageing populations lead unsustainable healthcare infrastructures considering core disease areas receive attention cancer diabetes cardiovascular reality communicable infection remains formidable healthcare infrastructural burden <NUMBER> example many parts world remains need develop better infectious disease interventions fight overuse antibiotics positioned consume <NUMBER> million lives annually <NUMBER> <NUMBER> challenge alone could dramatic economic consequences considering regional relevance problem ≈<NUMBER> malaria parasites parts thailand vietnam resistant artemisinin piperaquine failure rates among potent frontline combination therapy regimens comprised dihydroartemisininpiperaquine dhappq reached high <NUMBER> northern thailand <NUMBER> many solutions ranging vaccines novel drug designs proposed address covid<NUMBER> situation however maintaining agility modulating drug regimens account potentially rapid viral mutation factors could dynamically predict patient responses identify corresponding optimized interventions critical dengue affects <NUMBER> million people year highlydynamic based variables geographical climate recent study suggested <NUMBER> cases tb could prevented year solely use advanced analytics <NUMBER> economic evaluation interventions may become increasingly important extraordinary circumstances strain healthcare systemwide operations well industry operations therefore governments healthcare systems may pressure substantially impact qualityadjustedlifeyears qaly disabilityadjustedlifeyears daly also noted compound annual growth rate cagr global spend drug research development <NUMBER> <NUMBER> <NUMBER> outpacing global sales prescription drugs grew cagr <NUMBER> period <NUMBER> analysis shown wwwadvancedsciencenewscom wwwadvtherapcom life expectancy countries could achieved <NUMBER> current healthcare expenditures <NUMBER> therefore importance accomplishing using less resources making healthcare systems economicallyviable maximizing potential deploying ai agile dynamic deployment therapeutic regimens cannot overstated global health surveillance perspective merging reemerging infectious diseases continue pose threat mankind necessary develop arsenal tools utilized combatting pathogens epidemicpandemic potential based historical experience next big outbreak something seen february <NUMBER> world health organization added rd blueprint list priority diseases disease x <NUMBER> clade x previously considered hypothetical variant existing family organisms evolved cause human disease preparedness exercise using modelled pandemiccausing pathogen demonstrated lack actionable interventions could cause devastating global outcomes <NUMBER> exhibited recent emergence covid<NUMBER> adequate tools rapidly identify obtain genomic details near real time modern sequencing techniques often enable swift development effective diagnostics <NUMBER> however ability develop medical therapeutics effective easily deployable remains critical gap epidemic response efforts vaccines therapeutics past two outbreaks benefited greater <NUMBER> years development efforts allowed rapid advancement human use clinical studies epidemic situations interventions address individual patient illness controlprevention continued transmission necessary spectrum disease caused emergingreemerging infectious diseases vary considerably including severe symptomatic disease moderatemild symptomatic disease asymptomatic spreaders moreover convalescence remains challenge recovering patients may continue shed virus sometimes extended periods time initial infection therefore effective therapeutics interventions must ability address full spectrum disease contribute controlling transmission spread pathogen recently efforts around monoclonal antibodies mabs proposed possible solution <NUMBER> traditional development times mabs frame <NUMBER> months years overall costs ≥<NUMBER> per gram <NUMBER> laborious clinical administration intravenous previously limited utility emergency situations especially austere resourcelimited clinical settings substantial efforts directed overcome challenges <NUMBER> play key role bringing critically important potentially highefficacy highspecificity interventions toward broader use numerous efforts considered drug repurposing infectious disease indications approach quickly respond outbreak small molecule therapeutics ideal rapid deployment response epidemic often stable room temperature easily available known human pharmacokinetic safety profiles <NUMBER> successful cases drug repurposing largely serendipitous clinical discoveries however tremendous effort also focused rational drug repurposing pathogenic phenotypic silico vitro screening efforts drugs works often complex ontarget offtarget original indication ontarget mechanisms actions moas often useful targets block pathogen attachment entry replication within host existing viral drugs usually first applied novel viral threats additional benefit repurposed molecules potential offtarget impacts pathogen offtarget effects usually harder define development major challenge drug repurposing efforts drugs demonstrate safety potency alone achieve therapeutic antiviral activity therefore studies focused combinational strategies meet potency safety dose requirements considered response new threat <NUMBER> efforts rely vitro vivo testing evaluate considerably difficult demonstrate even two drug combinations <NUMBER> vitro especially vivo testing single drugs combinations lengthy process months years <NUMBER> higher complexity combinational approaches offer greatest benefit traditional methods developing higherorder combinations emerging silico modelling ai approaches driven prospective experimental validation converging allow potentially rapid responses outbreak pandemic events <NUMBER> approach described recently reported methods key steps higher order combinational treatment formulations overcomes past limitations repurposing allow disease specific likely personalized antivirals <NUMBER> optimized combinations table <NUMBER> derived identified experimentally tested thus studies using optimized combinations determined identifai required work provided foundation toward rapid identification dynamically optimized actionable combination therapies address broad spectrum infectious disease applications also accounting new strains may eventually circulate given mechanismand diseaseagnostic foundation project identifai studies evaluate platform rapid covid<NUMBER> intervention establish readiness pinpoint regimens toward downstream pathogens aggressive clinical courses pairing technical capabilities aidriven drug development platforms important policybased considerations lessons learned global response sars h<NUMBER>n<NUMBER> evd epidemicspandemics may ultimately lead expedited intervention scale cell culture lung cancer cell line a<NUMBER> atcc usa cultured highglucose dulbeccos modified eagles medium dmem invitrogen usa supplemented <NUMBER> fetal bovine serum fbs invitrogen usa <NUMBER> penicillinstreptomycin invitrogen usa culture maintained <NUMBER>°c containing <NUMBER> vv co <NUMBER> cells harvested upon reaching <NUMBER> confluence <NUMBER> µl cell suspension <NUMBER>k cells per well seeded <NUMBER>well plates preincubated <NUMBER> h treatment candidate drugs viral platform cells without drug treatment without viral infection served control condition run triplicate druginduced cytotoxicity measured using cell counting kit<NUMBER> cck<NUMBER> dojindo japan briefly <NUMBER> µl cck<NUMBER> solution added well containing <NUMBER> µl solution incubated <NUMBER> h <NUMBER>°c order conduct cytotoxicity assay cell viability assessed measuring absorbance <NUMBER> nm via microplate reader biotek synergy ht usa viral infection plate reader vesicular stomatitis virus vsv rna virus used pathogen model work vsv engineered encoded green fluorescent protein gfp concentration vsv stock <NUMBER> × <NUMBER> <NUMBER> pfu µl −<NUMBER> different multiplicity infection moi parameters used optimize final moi cell infection moi used optimization process included <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> control cells infected vsv different moi parameters <NUMBER> <NUMBER> <NUMBER> h optimization process moi conditions run triplicate <NUMBER> µl cell suspension <NUMBER>k cells per well seeded <NUMBER> wellplate preincubated <NUMBER> h infected vsv following viral infection gfp fluorescence intensity cells induced vsv reproduction measured microplate reader biotek synergy ht usa using topreading mode excitation wavelength <NUMBER> nm emission wavelength <NUMBER> nm dilution candidate therapies <NUMBER> drugs purchased selleckchem tx usa included study included amantadine hcl dexamethasone azithromycin chloroquine diphosphate naproxen sodium fluoxetine hcl loratadine omeprazole sodium ritonavir lopinavir doxycycline ribavirin amantadine hcl chloroquine diphosphate naproxen sodium fluoxetine hcl omeprazole sodium doxycycline ribavirin diluted using complete cell culture medium dexamethasone azithromycin loratadine ritonavir lopinavir diluted dmso final stock concentration drugs <NUMBER> × <NUMBER> −<NUMBER> exception naproxen sodium ribavirin <NUMBER> drugs diluted four concentrations including <NUMBER> <NUMBER> <NUMBER> <NUMBER> × <NUMBER> −<NUMBER> drug optimization process concentrations naproxen sodium ribavirin drug optimization process <NUMBER> <NUMBER> <NUMBER> <NUMBER> × <NUMBER> −<NUMBER> maximum possible final concentration dmso added cells monotherapies combination therapies <NUMBER> drug optimization process triplicates run per treatment condition designofexperiment doe experimental design first stage testing generated according uniform design theory <NUMBER> <NUMBER> combinations chosen largest sum multidrug interaction distances smallest variance accumulative doses trillions randomly generated experiment designs design second stage validation generated according orthogonal array design oad accumulative equivalent dose cancel disparity therapeutic concentration ranges drugs well facilitate expression dose concentrations concept equivalent dose adopted <NUMBER> equivalent dose refers <NUMBER> × <NUMBER> −<NUMBER> naproxen sodium ribavirin <NUMBER> × <NUMBER> −<NUMBER> others thus accumulative equivalent dose combination therapy defined sum equivalent doses constituents data analysis parabolic response surface analysis multidrug interaction regression analysis conducted via buildin function stepwiselm matlab <NUMBER>a selfwritten code algorithm derived quadratic model accounting collinearity using bidirectional elimination approach adjusted rvalue selection criterion strict algorithm used identify quantitative drug interactions strict scoring algorithm based projection distance assesses capacity infection inhibition giving antiviral score drug pairwise interaction study <NUMBER> consider combination k x k<NUMBER> x k<NUMBER> … x k n normalized euclidean distance point k projection p axis k normalized <NUMBER> mapped decreasing function single drug strict score defined sum productions outputs projections function distance denoted using definition strict score easily expanded multidrug interactions point k projected plane j instead axis normalized distance thus drugpair strict score defined supporting information available wiley online library author artificial intelligence ai technology recent addition bioinformatics shows much promise streamlining discovery pharmacologically active compounds <NUMBER> machine learning ml provides particular benefits identifying drugs effective one context might utility unknown clinical context novel pathology <NUMBER> application ml biomedical research provides new means conduct exploratory studies highthroughput analyses using information already available addition deriving value past research researchers develop ml tools relatively short periods time past research provides sizable bank information concerning drugbiomolecule interactions using drug repurposing example train predictive algorithms identify patterns antiviral compounds bind proteins diverse virus species aim train ml model presented proteome novel virus suggest antivirals based protein segments present proteome final output model bestfit prediction known antivirals likely associate familiar protein segments benefits particular interest current covid<NUMBER> health crisis novelty sarscov<NUMBER> requires execute health interventions based past observations grappling unforeseen pandemic known treatments vaccines potential rapid innovation ml utmost significance ability conduct complex analyses ml enables us research insights quickly help steer us right direction future studies likely produce fruitful results present multiple models produced number antiviral candidates treating covid<NUMBER> <NUMBER> top predicted drugs <NUMBER> shown positive results recent findings based cell culture results clinical trials promising antivirals lopinavir ritonavir ribavirin <NUMBER> cyclosporine <NUMBER> rapamycin <NUMBER> nitazoxanide <NUMBER> <NUMBER> predicted drugs research needed evaluate effectiveness sarscov<NUMBER> used two main data sources study first database drugvirus database <NUMBER> drugvirus provides database broadspectrum antiviral agents bsaas associated viruses inhibit database covers <NUMBER> viruses <NUMBER> compounds provides information status antiviral compoundvirus pair statuses fall eight categories representing progressive drug trial phases cell culturescocultures primary cells organoids animal model phases iiv approved see appendix intuitive pivot table view database second database national center biotechnology information ncbi virus portal <NUMBER> april <NUMBER> database provides approximately <NUMBER> million aminoacid <NUMBER> million nucleotide sequences viruses humans hosts row database contains amino acid sequence specimen study well metadata includes associated virus species work considered sequences <NUMBER> virus species drugvirus database subspecies order able merge two data sources successfully also constrained aminoacid sequences current iteration main reasons twofold <NUMBER> aminoacid sequences essentially derived dna sequences may encode overlapping information different levels somewhat simplified terms aminoacid sequences outputs layer preprocessing genetic material form dnarna <NUMBER> nucleotide triplets codons map aminoacids making aminoacid sequences much shorter easier extract features preprocessing machine learning methods shorter sequences also mean ml pipeline resourceefficient ie easier train aminoacids downloaded three datasets hiv types <NUMBER> <NUMBER> <NUMBER> <NUMBER> <NUMBER> sequences influenza types b c <NUMBER> sequences main dataset types including sarscov<NUMBER> <NUMBER> sequences dataset came two components sequence component composed accession ids aminoacid sequence metadata component includes data eg virus species date specimen taken identifier related study well accession id enable merging two components amount research focus influenza hiv naturally lead viruses comprising samples experiments excluded viruses worked dataset <NUMBER> though datasets integrated main one class balancing process idea discuss section <NUMBER> future work first step preparation phase merge sequence metadata components single ncbi dataset based sequence ids afterwards mapped species column main dataset virus name column drugvirus database step required two columns denote virus species respective datasets match due subspecies present sequence dataset alternative naming viruses afterwards processed drugvirus dataset format suitable merging ncbi data frame every row drugvirus dataset consists single drugvirus pairing respective interactiondrug trial phase meaning given drug virus appeared multiple rows dataset derived new drugvirus dataset functioned dictionary unique virus key interactions antivirals encoded multilabel binary vector <NUMBER> viable antiviral according original dataset <NUMBER> length <NUMBER> number antivirals corresponded value came three versions depending decided antiviral viable candidate inhibit virus criteria depended drug trial phases <NUMBER> first version interaction drugvirus pair designated <NUMBER> means drugs go past cell culturescocultures primary cellsorganoids testing still considered viable candidates <NUMBER> second version expands upon first stemming discovery attained trial phase database necessarily mean previous phases also listed database example found given virus given drug undergone phase iii testing designated <NUMBER> phase ii listed <NUMBER>s undermined assumption drug trials hierarchical though reality usually case caused missing data reporting possibly skipped phases proceeded hierarchy assumption extended database <NUMBER> account previous phases meant second version approved drug phases designated <NUMBER>s example keeping track <NUMBER> phases meant size database also grew <NUMBER> <NUMBER> third version considered drugvirus pair viable attained phase ii drug trials signifying success human trials observed results presented section <NUMBER> training database based third version drugvirus database full dataset generated merging new version drugvirus dataset ncbi dataset generated two versions full dataset one consists sarscov<NUMBER> sequences one consists viruses available enabled us compare successful models case trained virus species detect peptide substructures sequences suggest antivirals sample final database columns excluded brevity available appendix b upon inspection data found replete duplicate extremely similar virus sequences reduce exploitability pose challenging problem removed duplicate sequences belonged species exact length reduced size dataset approximately <NUMBER> counts virus species dropping duplicate viruses available appendix c<NUMBER> c<NUMBER> main database also contained class imbalance number times certain virus species appeared database oversampled rare viruses eg west nile virus <NUMBER> sequences excluded rare species compose less <NUMBER> available unique samples dataset eg andes virus <NUMBER> sequences undersampled common viruses eg hepatitis c <NUMBER> sequences produced modest database <NUMBER> amino acid sequences virus samples <NUMBER> range see appendix c<NUMBER> kept size dataset small enable easier model training validation early iterations handle data imbalance smoothly class imbalance problem also presented antiviral compounds even balanced virus classes number times drug occurred within dataset varied simply drugs apply viruses others alleviate computed class weights drug provided models training enabled fairer assessment varied distribution antivirals predicted outputs final step data processing involved generating training validation sets split data two different ways resulting two different experiments see section <NUMBER> experiment setup full experiment pipeline experiment based standard randomized <NUMBER> training<NUMBER> validation split main dataset experiment ii split data virus species meaning models forced predict drugs species trained detect peptide substructures aminoacid sequences suggest drugs setup also guaranteed sarscov<NUMBER> sequences always test set addition three viruses randomly picked dataset used variant setup trains virus sequences except sarscov<NUMBER> validated sarscov<NUMBER> generate results presented section <NUMBER> growing number studies demonstrate success using artificial neural networks ann evaluating biological sequences drug repositioning repurposing <NUMBER> <NUMBER> previous work training neural networks nucleotide aminoacid sequences successful recurrent models gated recurrent units gru long shortterm memory networks lstm bidirectional lstms bilstm well <NUMBER>d convolutions <NUMBER>d convolutional neural networks cnn <NUMBER> <NUMBER> therefore focused network architectures conducted experiments lstm <NUMBER>d convolutions bidirectional layers well cnn network architectures explained briefly lstm <NUMBER>d convolutions lstm characterlevel tokenizer used encode fasta sequences vectors consumable network sequences padded zeros cut fixed length <NUMBER> maintain fixed input size network architecture consisted embedding layer followed <NUMBER>d convolution bidirectional lstm layers followed maxpooling two fully connected layers detailed architecture diagram available appendix convolutional neural network cnn cnn input features onehot encoded based fasta alphabetcharset assisted interpretability examining <NUMBER>d input arrays images inputs also fixed length <NUMBER> resulting <NUMBER> x <NUMBER> images <NUMBER> number elements fasta charset network architecture consists four <NUMBER>d convolutions filter sizes <NUMBER>x<NUMBER> <NUMBER>x<NUMBER> <NUMBER>x<NUMBER> <NUMBER>x<NUMBER> respectively maxpooled concatenated passed fully connected layer detailed architecture diagram available appendix e experiments run computer <NUMBER> ghz intel broadwell cpu <NUMBER> gb ram nvidia k<NUMBER> gpu <NUMBER> gb models completed <NUMBER>epoch experiment <NUMBER> minutes one three training evaluation runs made setup model hyperparameter selections ten training evaluation runs done produce average metrics section <NUMBER> experiments start determining model use apply appropriate preprocessing steps mentioned section <NUMBER> proceed determining dataset train validate part experiment setup extensively covered section <NUMBER> traintest splitting used binary cross entropy bce loss adam optimizer precision recall f<NUMBER>score metrics since accuracy tends unreliable metric given class imbalance sparse nature outputs training validation predictions done validation set results postprocessed interpretability postprocessing applied threshold sigmoid function outputs neural network assigned drug probability potential antiviral given amino acid sequence experimenting different values settled threshold value <NUMBER> postprocessing outputs list drugs selected along respective probabilities drugs effective virus given amino acid sequence hyperparameters involved well information hyperparameter tuning see appendix f present results two experiments described section <NUMBER> traintest splitting figures tables presented section based lstm cnn architectures described section <NUMBER> trained <NUMBER> batch size <NUMBER> <NUMBER> learning rates respectively <NUMBER> epochs adam optimizer regular setup performed <NUMBER> traintest split data <NUMBER> sequences metrics best set hyperparameters based validation set f<NUMBER>score cnn lstm architectures respectively presented table <NUMBER> similarly plots set models hyperparameters <NUMBER> epochs presented figures <NUMBER> <NUMBER> models handled task successfully achieving <NUMBER> f<NUMBER>score multilabel multiclass problem setting means models able match virus species sequence substructures appropriately assign inhibiting antivirals accuracy satisfactory results led us implementing experiment ii experiment ii models predicted antiviral drugs virus species havent trained meant models able recommend drugs recognizing virus sequence therefore rely peptide substructures sequences assign drugs results presented test set consists sarscov<NUMBER> herpes simplex virus <NUMBER> human astrovirus ebola virus whose sequences removed training set see cnn lstm issues convergence accuracies clearly counterparts regular setup though certainly expected turn actual predictions sequences attempt interpret upon examination drug predictions herpes simplex virus <NUMBER> hsv<NUMBER> however see cnn fact quite successful table <NUMBER> table <NUMBER> count represents many times drug flagged potentially effective hsv<NUMBER> sequences mean probability denotes average confidence predicted instances drug sample outputs metrics derived available appendix g antivirals used phase ii trials hsv<NUMBER> highlighted bold meaning six drugs database used phase ii trials predicted model three top five predictions approved antivirals hsv<NUMBER> remaining one predicted <NUMBER>th among <NUMBER> antivirals high level accuracy remarkable given model trained hsv<NUMBER> sequences predictions sarscov<NUMBER> variation two lstm table <NUMBER>a cnn table <NUMBER>b seem converge number drugs ritonavir lopinavir phase iii merscov tilorone approved merscov brincidofovir top five candidates valacyclovir ganciclovir rapamycin cidofovir rank high lists remaining drugs present lists well lstm conservative predictions cnn overall counts sarscov<NUMBER> significantly lower herpes simplex virus <NUMBER> pointing comparable lack confidence models part predicting sarscov<NUMBER> sequences step took sarscov<NUMBER> sequences visualizing layer activations zetane engine validate model processing data finegrained level done similar fashion study integrated gradients used generate attributions neural network performing molecule classification <NUMBER> layer activations models showed different antivirals activated different subsequences given sequence amino acid level thus validating approach filter activations available appendix h preliminary results experiments show promise merit investigation note ml models predict antivirals show promise treatments merscov may also effective sarscov<NUMBER> include broadspectrum antiviral tilorone <NUMBER> drug lopinavir <NUMBER> latter phase iv clinical trials determine efficacy covid<NUMBER> <NUMBER> observations suggest confidence models recognize reliable patterns particular antivirals species viruses containing homologous amino acid sequences proteome additional observations support findings come light study lancet published shortly article <NUMBER> openlabel randomized phase ii trial observed combined administration drugs interferon beta<NUMBER>b lopinavir ritonavir ribavirin provides effective treatment covid<NUMBER> patients mild moderate symptoms models flagged three drugs trial note interferon part datasets terms number occurrences aka count ritonavir lopinavir ribavirin ranked <NUMBER>th <NUMBER>th <NUMBER>th lstm cnn model ranked <NUMBER>rd <NUMBER>th <NUMBER>th respectively studies also focused treatment sarscov<NUMBER> drugs predicted experiments wang et al discovered nitazoxanide lstm rank <NUMBER>th cnn rank <NUMBER>th inhibited sarscov<NUMBER> lowmicromolar concentration <NUMBER> gordon <NUMBER>th known effective diverse coronaviruses <NUMBER> observations encouraging demonstrate predictive models may value identifying potential therapeutics merit priority advanced clinical trials also add growing observations support using ml streamline drug discovery perspective models suggest broad spectrum antiviral tilorone instance may top candidate covid<NUMBER> clinical trials near future candidates highlighted results may merit studies brincidofovir foscarnet artesunate cidofovir valacyclovir ganciclovir antivirals identified discrepancies emerging research findings well instance models highlight widely available antiparasitic ivermectin one research study observed ivermectin could inhibit replication sarscov<NUMBER> vitro <NUMBER> another largescale drug repositioning survey screened library nearly <NUMBER> drugs identified six candidate antivirals sarscov<NUMBER> pikfyve kinase inhibitor apilimod cysteine protease inhibitors mdl<NUMBER> z lvg chn<NUMBER> vby<NUMBER> ono <NUMBER> ccr<NUMBER> antagonist mln<NUMBER> <NUMBER> comes surprise models identify compounds data sources contain future efforts strengthen ml models thus require us integrate growing bank novel data emerging research findings ml pipeline terms machine learning models better feature extraction improve predictions drastically step involves improvements better data engineering working domain experts familiar applied bioinformatics better understand nature data find ways improve data processing pipeline proposals future work could strengthen performance machine learning process follows <NUMBER> deeper interaction domain experts lab testing would lead better understanding antivirals aminoacid sequences target leading building better ml pipelines drug repurposing <NUMBER> better handling duplicates improve quality data available current approach based species sequence length improved using string similarity measures dice coefficient cosine similarity levenshtein distance etc <NUMBER> influenza hiv datasets integrated data generation processing pipeline enhance available data <NUMBER> vectorizers used extract features ngrams small sequences chars attained success similar problems <NUMBER> unsupervised learning methods singular value decomposition also may applicable study <NUMBER> hope machine learning approaches pipelines developed may provide longterm benefit public health fact results show much promise streamlining drug discovery sarscov<NUMBER> motivates us adapt current models conduct identical drug repurposing assessments known viruses moreover experimental data suggests approaches generalizable viruses see hsv<NUMBER> example section <NUMBER> experiment ii therefore confident could adapt models conduct equivalent studies next outbreak novel virus also means methods used repurpose existing drugs order find potent treatments known viruses direct beneficiaries findings members clinical research community using relatively resources mlguided drug repurposing technology help prioritize clinical investigations streamline drug discovery addition reducing costs expediting clinical innovation efficiency gains may reduce number clinical trials thus human subjects used risky research needed find effective treatments pertains ethical imperative avoid harm possible also importance insilico analyses using machine learning provide yet another means employ past research findings new investigations mlguided drug repurposing thus provides means obtain value knowledge onhand maximizing value case laudable many fronts especially terms providing maximum benefit publiclyfunded research negative consequences could arise models fail appear limited noteworthy nonetheless note models aim indicate possible therapeutics merit clinical investigation order prove antiviral activity sarscov<NUMBER> models fail recommending spurious treatments incorrect predictions may divert limited time resources towards frivolous investigations also noted methods aim primarily work guidance medical experts beallendall solution incorrect inferences made models bound detected early medical experts communicating machinelearning predictions tentative antiviral drugs study requires much caution current pandemic continues demonstrate fear misinformation lack knowledge novel communicable disease encourage counterproductive healthseeking behaviour amongst public soon coronavirus became widely understood threat internet awash false sometimes downright harmful information preventing treating covid<NUMBER> included within misleading health information premature claims prominent government officials therapeutics like chloroquine hydroxychloroquine might hold promise repurposed drug covid<NUMBER> unfounded advice caused avoidable poisonings people selfmedicating chloroquine subsequent clinical investigations demonstrated notable benefit potential adverse reactions chloroquine used treat covid<NUMBER> unfortunate events remind us preliminary findings may misinterpreted conclusive treatments evidence support inconclusive health claims hyperparameters tested experiments presented section f certainly possible improve accuracies experiments conducting vaster coverage loss landscape extensive training eg running longer experiments smaller learning rates complex network architectures especially results experiment ii however due performance constraints scope hyperparameter tuning well ann architectures experimented relatively constrained focused methodology opposed optimal performance study noted much improvement possible front pointed discussion future work additional notes regarding observations hyperparameter tuning presented • threshold wanted predict eagerly ie considered false negatives costly errors false positives high threshold would mean outputs would composed antivirals models confident per amino acid sequence deem undesirable hope outputs narrow scope antivirals focus overrestricting could prevent antivirals predicted frequently yet low probability detected low threshold <NUMBER> filtered number antivirals sufficiently also left enough breathing room domain experts draw conclusions perdrug basis • larger sequence length cutoff possible detrimental results deemed <NUMBER> suitable tradeoff terms performance versus accuracy many sequences reach lengths thousands begin • mentioned number epochs trained could increased see dramatic signs overfitting <NUMBER> epochs however flattening metrics evident around <NUMBER> epochs hyperparameters listed therefore selected suitable stopping point table <NUMBER> section sample outputs amino acid sequences associated antivirals postprocessing outputs list drugs selected along respective probabilities drugs effective virus given amino acid sequence patients sarscov<NUMBER> merscov remain unvalidated newly emerged sarscov<NUMBER> <NUMBER> remdesivir nucleotide analog prodrug broad antiviral activity works rnadependent rna polymerase inhibitor reported effective merscov sarscov<NUMBER> infections animal models <NUMBER> <NUMBER> <NUMBER> repositioning remdesivir treatment sarscov<NUMBER> infection recently demonstrated positive clinical endpoints phase <NUMBER> adaptive covid<NUMBER> treatment trial median time recovery shortened <NUMBER> <NUMBER> days <NUMBER> justified emergency use authorization remdesivir us food drug administration treatment hospitalized covid<NUMBER> patients <NUMBER> effectiveness repurposed drug remdesivir current formulation requiring administration iv infusion highlights importance investigating preexisting drugs combat sarscov<NUMBER> infections need discovery new supplemental therapies result greater clinical improvements administered outside hospital setting ie orally reframe repurposing focused rescue accelerated medchem drug collection extensive drug repurposing library containing nearly <NUMBER> smallmolecule drugs shown appropriate direct use humans <NUMBER> provides rich resource discover new treatments may used additional monotherapies even combination remdesivir enhance efficacy reduce drug resistance potential identify compounds could inhibit entry replication sarscov<NUMBER> human cells developed highcontent imaging hci <NUMBER>well format assay using hela cells expressing human sarscov<NUMBER> receptor angiotensinconverting enzyme <NUMBER> ace<NUMBER> helaace<NUMBER> assay helaace<NUMBER> cells infected sarscov<NUMBER> virus presence compounds interest viral infection quantified <NUMBER> hours later fig <NUMBER>a assay relies immunofluorescent detection sarscov<NUMBER> proteins sera purified patients exposed virus together host cell nuclear staining allows quantification percent infected cells well fig <NUMBER>b validated assay using compounds reported activity ebola suspected previously verified activity sarscov<NUMBER> remdesivir gs<NUMBER> <NUMBER> ec <NUMBER> <NUMBER> ± <NUMBER> nm average ± sem <NUMBER> independent experiments pikfyve inhibitor apilimod ec <NUMBER> <NUMBER> ± <NUMBER> nm average ± sem <NUMBER> independent experiments fig <NUMBER>b remdesivir elevated concentrations able eliminate infected cells almost completely fig <NUMBER>c used concentration <NUMBER> µm positive control data normalized neutral dmso control wells apilimod potent remdesivir fractionally lower maximal efficacy <NUMBER> uninfected cells highest effective concentrations compared remdesivir additionally assessed compound toxicity context infection quantifying total cell numbers per well cytotoxic protein synthesis inhibitor puromycin positive control average ec <NUMBER> <NUMBER> ± <NUMBER> nm average ± sem <NUMBER> independent experiments helaace<NUMBER> cc <NUMBER> <NUMBER> ± <NUMBER> µm average ± sem <NUMBER> independent experiments notably concomitant increase cell numbers coincided antiviral activity remdesivir apilimod likely due reduction proliferation infected cells fig <NUMBER>be altering multiplicity infection modest effects potency control compounds experiment <NUMBER>fold increase remdesivirs ec <NUMBER> moi<NUMBER> moi<NUMBER> <NUMBER>fold increase apilimods ec <NUMBER> puromycin fig s<NUMBER> using developed assay ran pilot screen assess activity <NUMBER> small molecules suspected therapeutic potential coronavirus infections mined available literature <NUMBER> rz <NUMBER> identified <NUMBER> compounds ec <NUMBER> <NUMBER> µm based data obtained uninfected helaace<NUMBER> <NUMBER>hour livedead assay <NUMBER> selective uninfected helaace<NUMBER> cc <NUMBER> sarscov<NUMBER> ec <NUMBER> <NUMBER> uninfected helaace<NUMBER> cc <NUMBER> <NUMBER> µm table s<NUMBER> included libraryscreening lots apilimod ec <NUMBER> <NUMBER> nm cc <NUMBER> <NUMBER> µm remdesivir ec <NUMBER> <NUMBER> nm cc <NUMBER> <NUMBER> µm rediscovered assay higher ec <NUMBER> apilimod remdesivir likely due slight degradation time screening deck compared freshly prepared control powder stock screening reframe bestinclass drug repurposing library next screened <NUMBER>compound reframe repurposing library final concentration <NUMBER> µm <NUMBER> µm assay quality maintained throughout screens rz <NUMBER> <NUMBER> respectively table <NUMBER> clear distinction apparent activity profiles dmso vehicleneutral control remdesivirpositive control apilimod puromycintoxicity controltreated wells fig <NUMBER>d <NUMBER>e hits selected based demonstration <NUMBER> reduction number infected cells per well <NUMBER> activity normalized neutral controls minus inhibitors <NUMBER> toxicity based total cell number per well <NUMBER> activity normalized compound activities including <NUMBER> µm puromycin fig <NUMBER>e <NUMBER>f identifying <NUMBER> primary hits <NUMBER> µm <NUMBER> primary hits <NUMBER> µm screening concentrations hit rates <NUMBER> <NUMBER> respectively total <NUMBER> hits hit rate primary screen reframe library high <NUMBER> unexpected collection bioactive small molecules many approved drugs clinical phases development used wide assortment indications fig <NUMBER>a reconfirm assess potency selectivity primary hits tested <NUMBER> available compounds <NUMBER>point <NUMBER> dilution dose response format top concentration <NUMBER> µm <NUMBER> <NUMBER> demonstrated activity ec <NUMBER> <NUMBER> µm sarscov<NUMBER> however many primary screen hits also cytotoxic unacceptably low selectivity ratio determined uninfected helaace<NUMBER> cells uninfected cc <NUMBER> ec <NUMBER> <NUMBER> table <NUMBER> fig <NUMBER>b viruses rely host machinery replication unexpected many compounds antiviral activity also affected vital host processes interestingly toxicity sometimes masked infected cells reduction viral infection compounds like protein synthesis inhibitor puromycin even hydroxychloroquine provided benefit cell health context infection uninfected cells fig <NUMBER>c table s<NUMBER> small pilot reframe screen including remdesivir identified <NUMBER> <NUMBER> unique two different lots gw<NUMBER> identified potent ec <NUMBER> <NUMBER> µm selective cc <NUMBER> ec <NUMBER> <NUMBER> cc <NUMBER> <NUMBER> µm compounds fig <NUMBER>b table s<NUMBER> top four classes potent selective compounds oncolytic compounds ion channel modulators antipsychotics receptor binding compounds fig <NUMBER>d fifth potent selective hits could classified oncolytic drugs reflecting reliance virus host cell processes present rapidly proliferating cells identification compounds belonging antipsychotic cardiovascular even antiparasitic neglected tropical diseases classes may reflect cationic amphiphilic nature molecules ability accumulate impact acidic intracellular compartments eg late endosomeslysosomes resultant dysregulation endolysosomal pathway lipid homeostasis suggested impair viral entry andor replication <NUMBER> mode action speculated amiodarone hydroxychloroquine identified potent selective hits sarscov<NUMBER> screen table <NUMBER> table s<NUMBER> also identified two selective estrogen receptor modulators bazedoxifene ec <NUMBER> <NUMBER> µm raloxifene ec <NUMBER> <NUMBER> µm class compounds previously found inhibit ebola virus infection <NUMBER> identified hits highest interest newly identified approved oral drugs halofantrine hcl amiodarone nelfinavir mesylate simperevir manidipine ozanimod andosimertinib due relatively high exposures long history use therapeutic agents therefore potential quickly repurposed covid<NUMBER> treatments following efficacy vetting animal models viral protease inhibitors nelfinavir simeprevir good exposures based described mode action speculate inhibit sarscov<NUMBER> directly selective sphingosine<NUMBER>phosphate s<NUMBER>p<NUMBER> receptor modulator ozanimod also intriguing potential covid<NUMBER> therapy selective s<NUMBER>p<NUMBER> agonists shown provide significant protection influenza virus infection murine models reducing inflammation site infection reducing release cytokines pulmonary endothelial cells infiltration lymphocytes lungs <NUMBER> thus ozanimod may serve good combination partner directacting antiviral drug approved calciumchannel blocker manidipine low exposure may potential improve covid<NUMBER> disease outcomes patients interestingly amiodarone previously identified broadspectrum antiviral activity vitro screen <NUMBER> nineteen compounds various stages development apilimod assay control may inhibit viral entry disruption endolysosomal trafficking found filoviruses <NUMBER> protease inhibitors nco <NUMBER> cathepsin b dutacatib cathepsin k may also impact viral entry potential show efficacy due potency pharmacokinetic profiles table <NUMBER> except potent apilimod modest ec <NUMBER> <NUMBER> µm surpass potency remdesivir however remdesivirs requirement intravenous administration potentially limited efficacy warrants investigation alternative supplemental therapies therefore investigated whether hits identified screen would suitable partners combination therapy remdesivir combination therapies potential increase efficacy treatment reducing drug dose either combinations partners thus prevent side effects may associated administration higher doses drug combinations also slow acquisition drug resistance drug synergy increase activity combination therapy beyond expected additive interaction rare yet additive effects potential improve therapy regimens conversely antagonism inhibition activity overall combination beyond would expected compounds acted independently undesirable property identify synergistic additive antagonistic interactions remdesivir reframe hits performed synergy interactions studies checkerboard experiment comparing full dose response remdesivir dose responses <NUMBER> hits attractive safety pharmacokinetic profiles <NUMBER> × <NUMBER> matrix fig <NUMBER>e used synergyfinder package <NUMBER> r assess interactions tested compounds using zero interaction potency model zip <NUMBER> δ score <NUMBER> indicates likely synergy δ <NUMBER> indicates antagonism δ <NUMBER> <NUMBER> suggests additive interaction found genuine synergy remdesivir compounds tested however combinations additive including nelfinavir remdesivir fig <NUMBER>a table <NUMBER> table s<NUMBER> suggesting drugs prove efficacious vivo could potentially coadministered remdesivir increase overall safety efficacy treatment limiting evolution drug resistance identify compounds interact synergistically remdesivir carried second unbiased reframe screen presence low concentrations <NUMBER> nm remdesivir activity novel hits screen assessed presence absence remdesivir based perceived shift activity presence remdesivir compounds tested checkerboard synergy matrix identified nucleoside analog riboprine n<NUMBER>isopentenyladenosine previously investigated antineoplastic agent treatment nausea surgical site infections component citranatal <NUMBER> dha prescription prenatalpostnatal multivitaminmineral tablet folate antagonist <NUMBER>deazaaminopterin antineoplastic compound currently phase ii stage development activities synergized remdesivir synergistic effects compounds observed across specific concentrations signified peaks within <NUMBER>dimensional synergy score landscape figure <NUMBER>b <NUMBER>c prompting closer scrutiny activity compound riboprine achieved maximal <NUMBER> efficacy range concentrations tested addition ec <NUMBER> remdesivir shifted ec <NUMBER> <NUMBER> µm <NUMBER> µm addition ec <NUMBER> remdesivir increased potency ec <NUMBER> <NUMBER> µm figure <NUMBER>b <NUMBER>deazaaminopterin showed <NUMBER> maximal efficacy range concentrations tested addition ec <NUMBER> remdesivir caused increase maximal efficacy <NUMBER> nearly <NUMBER> shift <NUMBER> would expected addition ec <NUMBER> remdesivir increased maximal efficacy combination <NUMBER> <NUMBER> figure <NUMBER>c mechanism action behind observed synergies remains determined riboprine reported block uridine cytidine import <NUMBER> inhibition protein prenylation inhibit autophagy <NUMBER> could impact rna catabolism <NUMBER> whereas <NUMBER>deazaaminopterin suggested inhibit folate dependent enzymes purine biosynthesis pathway <NUMBER> <NUMBER> <NUMBER> <NUMBER> therefore treatment either riboprine <NUMBER>deazaminopterin may result reduced intracellular nucleoside pools way synergize rdrp inhibition adenosine nucleoside analog remdesivir however another direct specific interaction cannot excluded remains elucidated findings indicate promising avenue investigation combination therapies treatment covid<NUMBER> adverse effects agents eg inhibition immunity <NUMBER>deazaaminopterin would need carefully considered design dose selection vivo validation experiments summary screening highvalue repurposing reframe library identified <NUMBER> unique known drugs preclinical molecules activity sarscov<NUMBER> human cells <NUMBER> tested showed additive interaction combination antiviral compound remdesivir recently granted emergency approval treatment sarscov<NUMBER> infection also identified synergistic interaction remdesivir <NUMBER>deazaaminopterin riboprine data support advancement identified compounds profiling vivo models assess utility alone combination remdesivir combating covid<NUMBER> pandemic vero e<NUMBER> cells atcc crl<NUMBER> plated t<NUMBER> flask complete dmem corning <NUMBER>cv containing <NUMBER> fbs <NUMBER>×penstrep corning <NUMBER>cl <NUMBER> mm lglutamine corning <NUMBER>cl overnight <NUMBER> <NUMBER> co <NUMBER> media flask removed <NUMBER> ml sarscov<NUMBER> strain usawa<NUMBER> bei resources nr<NUMBER> complete dmem added flask moi <NUMBER> allowed incubate <NUMBER> minutes <NUMBER> <NUMBER> co <NUMBER> incubation <NUMBER> ml complete dmem added flask flask placed <NUMBER> incubator <NUMBER> co <NUMBER> <NUMBER> days day <NUMBER> post infection supernatant harvested centrifuged <NUMBER>×g <NUMBER> minutes supernatant filtered <NUMBER> µm filter stored <NUMBER> reframe library collection consists nearly <NUMBER> highpurity compounds <NUMBER> dissolved highquality dimethyl sulfoxide dmso compound quality control performed liquid chromatographymass spectrometry andor <NUMBER> hnmr required library prepared two concentrations <NUMBER> <NUMBER> mm support lowconcentration <NUMBER> µm highconcentration <NUMBER> µm screening formats echoqualified <NUMBER>well low dead volume plus microplates lp<NUMBER>bc labcyte inc used library source plates support acoustic transfer echo <NUMBER> liquid handler labcyte inc compounds soluble dmso plated water <NUMBER> compounds compounds lacking longterm solubility dmso suspended dispensing avoid precipitation <NUMBER> compounds additional details available httpsreframedborgabout associated compound annotation supported three widely used commercial drug competitive intelligence databases clarivate integrity gvk excelra gostar citeline pharmaprojects available annotation data may include status clinical development highest stage development achieved mechanism action drug indications route administration accordance reframe data policies open access data assured expedited immediate disclosure httpsreframedborg helaace<NUMBER> cells generated transduction human ace<NUMBER> lentivirus lentivirus created cotransfection hek<NUMBER>t cells pbobhace<NUMBER> construct lentiviral packaging plasmids pmdl prev pvsvg addgene using lipofectamine <NUMBER> thermo fisher scientific <NUMBER> supernatant collected <NUMBER> h transfection used transduce preseeded hela cells <NUMBER> h transduction stable cell lines collected scaled stored cells maintained dmem gibco <NUMBER> <NUMBER> fbs gibco <NUMBER> <NUMBER>× sodium pyruvate gibco <NUMBER> <NUMBER> <NUMBER> co <NUMBER> compounds acoustically transferred <NUMBER>well µclearbottom plates greiner part <NUMBER>b helaace<NUMBER> cells seeded <NUMBER> µl dmem <NUMBER> fbs density <NUMBER>×<NUMBER> <NUMBER> cells per well plated cells transported bsl<NUMBER> facility <NUMBER> µl sarscov<NUMBER> diluted assay media added per well concentration <NUMBER>×<NUMBER> <NUMBER> pfuml assay multiplicity infection moi <NUMBER> plates incubated <NUMBER> h <NUMBER> <NUMBER> co <NUMBER> fixed <NUMBER> µl <NUMBER> formaldehyde <NUMBER> h <NUMBER> <NUMBER> co <NUMBER> plates washed <NUMBER>xpbs <NUMBER> tween <NUMBER> fixation subsequent primary secondary antibody staining human polyclonal sera diluted <NUMBER> permwash buffer bd biosciences <NUMBER> added plate incubated rt <NUMBER> h six µgml goat antihuman hl conjugated alexa <NUMBER> thermo fisher scientific a<NUMBER> together <NUMBER> µm antifade<NUMBER>diamidino<NUMBER>phenylindole dapi thermo fisher scientific d<NUMBER> superblock t<NUMBER> pbs buffer thermo fisher scientific <NUMBER> added plate incubated rt <NUMBER> h dark plates imaged using imagexpress micro confocal highcontent imaging system molecular devices <NUMBER>× objective <NUMBER> fields imaged per well images analyzed using multiwavelength cell scoring application module metaxpress dapi staining identifying hostcell nuclei total number cells images sarscov<NUMBER> immunofluorescence signal leading identification infected cells compounds acoustically transferred <NUMBER>well µclear plates greiner part <NUMBER> helaace<NUMBER> cells maintained described infection assay seeded assayready plates <NUMBER> cellswell dmem <NUMBER> fbs plates incubated <NUMBER> hours <NUMBER> <NUMBER> co <NUMBER> assess cell viability imageit dead green reagent thermo fisher used according manufacturer instructions cells fixed <NUMBER> paraformaldehyde counterstained dapi fixed cells imaged using imagexpress micro confocal highcontent imaging system molecular devices <NUMBER>× objective total live cells per well quantified acquired images using live dead application module metaxpress image analysis carried metaxpress version <NUMBER> primary vitro screen host cell cytotoxicity counter screen data uploaded genedata screener version <NUMBER>standard data normalized neutral dmso minus inhibitor controls <NUMBER> µm remdesivir antiviral effect <NUMBER> µm puromycin infected host cell toxicity uninfected host cell cytotoxicity counter screen <NUMBER> µm puromycin sigma used positive control dose response experiments compounds tested technical triplicates different assay plates dose curves fitted four parameter hill equation technical replicate data analyzed using median condensing synergyfinder package <NUMBER> r version <NUMBER> used synergy analysis data available main text supplementary materials results screen reframe library deposited reframedborg data portal tables s<NUMBER> antisarscov<NUMBER> activities known drugs bioactive molecules identified potent selective hits pilot reframe screens fig <NUMBER> primary cellbased hci assay identifies compounds active sarscov<NUMBER> infection simplified assay workflow b representative images dimethyl sulfoxide dmso remdesiviror apilimodtreated wells entire imaged area per well <NUMBER> fields view taken <NUMBER>× objective stitched together shown treatment well <NUMBER>fold magnified segment demarcated white box dna signal <NUMBER>′<NUMBER>diamidino<NUMBER>phenylindole dapi colored green virus visualized immunofluorescence colored magenta infected arrow uninfected arrowhead cells indicated <NUMBER> µm <NUMBER> µm scale bars shown composite magnified images respectively raw normalized norm values calculated images shown c box whiskers plot sarscov<NUMBER> assay control ec <NUMBER> obtained independent biological experiments mean indicated bar data points shown whiskers indicate minimums maximums heat map images normalized data <NUMBER> µm reframe screening plates normalized activity values infected cells total cell numbers indicated according scale bar density plot compound control wells shown dmsotreated wells column <NUMBER> positive controltreated wells blocks wells <NUMBER> µm remdesivir <NUMBER> µm apilimod <NUMBER> µm puromycin column <NUMBER> density plots representing frequency values associated well type shown right e distribution <NUMBER> µm reframe screen data compound control wells f screen hit selection thresholds composition reframe repurposing library respect clinical stage development disease indication b dose response reconfirmation results sarscov<NUMBER> ec <NUMBER> compound plotted host cell toxicity cc <NUMBER> assessed uninfected helaace<NUMBER> cells dotted lines represent maximal concentrations tested doseresponse studies assay compounds <NUMBER> µm controls apilimod remdesivir <NUMBER> µm activities controls black diamonds assay compounds pink diamonds shown activity reframe library copy puromycin screened part hit reconfirmation also indicated red diamond c sarscov<NUMBER> ec <NUMBER> blue infected helaace<NUMBER> ec <NUMBER> orange uninfected helaace<NUMBER> cc <NUMBER> dose response curves remdesivir apilimod puromycin control compounds ran part reframe hit reconfirmation classification <NUMBER> potent selective compounds according functional annotation today <NUMBER> april <NUMBER> <NUMBER> people around world died coronavirus disease <NUMBER> covid<NUMBER> pandemic approved drug vaccine covid<NUMBER> although <NUMBER> clinical trials launched test potential drugs urgent response pandemic developed bioinformatics pipeline identify compounds drug candidates potentially treat covid<NUMBER> pipeline based publicly available singlecell rna sequencing scrnaseq data drug perturbation database “library integrated networkbased cellular signatures” lincs developed ranking score system prioritizes drugs small molecules four drugs highest total score didanosine benzylquinazolin<NUMBER>ylamine camptothecin ro<NUMBER> conclusion demonstrated utility bioinformatics identifying drugs repurposed potentially treating covid<NUMBER> patients repurposing didanosine potential treatment covid<NUMBER> using singlecell rna sequencing data today <NUMBER> april <NUMBER> <NUMBER> people around world died coronavirus disease <NUMBER> covid<NUMBER> pandemic approved drug vaccine covid<NUMBER> although <NUMBER> clinical trials launched test potential drugs potential drugs included drugs based promising effects severe acute respiratory syndrome sars middle east respiratory syndrome mers ability block host target proteins angiotensinconverting enzyme <NUMBER> ace<NUMBER> may sars receptor <NUMBER> bioinformaticians data scientists help identifying potential candidates available big data narrow scope research accelerate discovery focusing efforts repurposing drugs already approved applications known safety profiles saves cost shortens time approval accelerates benchtobedside time bringing aid covid<NUMBER> patients sooner urgent response pandemic developed bioinformatics pipeline identify compounds drug candidates potentially treat covid<NUMBER> results pipeline still preliminary validated vitro pipeline based publicly available singlecell rna sequencing scrnaseq data <NUMBER> drug perturbation database library integrated networkbased cellular signatures lincs <NUMBER> scrnaseq data contains samples eight healthy human lung transplant donors eight samples patients pulmonary fibrosis gene expression omnibus repository accession gse<NUMBER> <NUMBER> analyzing scrnaseq data reveals ace<NUMBER> mainly expressed type ii alveolar cells at<NUMBER> cells first identified significantly differentiated genes degs adjusted p value ͻ<NUMBER> at<NUMBER> cells express ace<NUMBER> at<NUMBER> cells express ace<NUMBER> found <NUMBER> upregulated degs including slc<NUMBER>a<NUMBER> cxadr cav<NUMBER> nup<NUMBER> ctbp<NUMBER> gsn hspa<NUMBER>b stom rab<NUMBER>b downregulating genes important treatment approach regulate viral reproduction transmission <NUMBER> next used connectivity map linked user environment clue platform connects lincs database smallmolecule perturbations gene expression identify drugs compounds reverse upregulated genes <NUMBER> clue selected <NUMBER> <NUMBER> drugs negative connectivity score cs less ϫ<NUMBER> closer cs ϫ<NUMBER> greater chance drug reversing upregulated degs instance drugs reverse expression degs upregulated ace<NUMBER>expressing at<NUMBER> cells complete drug list downloaded httpsgithubcomfadhlyemencovid<NUMBER> none drugs validated third developed ranking score system prioritizes drugs small molecules based three developed scores cs clue s<NUMBER> genetic perturbation score s<NUMBER> class score s<NUMBER> definitions equations scores found httpsgithubcomfadhlyemencovid<NUMBER> four drugs highest total score st didanosine benzylquinazolin<NUMBER>ylamine camptothecin ro<NUMBER> table <NUMBER> didanosine hiv antiviral drug belongs nucleoside reverse transcriptase inhibitor class <NUMBER> drugs belonging class negative scores s<NUMBER> addition cs knocking purine nucleoside phosphorylase pnp target gene didanosine also negative s<NUMBER> didanosine prescription drug approved us food drug administration fda treating hiv infection second benzylquinazolin<NUMBER>ylamine compound belongs family epidermal growth factor receptor egfr inhibitors interestingly knocking egfr also produced negative score third molecule list camptothecin topoisomerase inhibitor alkaloid present camptotheca acuminata used traditional chinese medicine knocking camptothecins target gene also generates negative scores top<NUMBER> ϫ<NUMBER> tif<NUMBER>a ϫ<NUMBER> sixteen <NUMBER> <NUMBER> drugs belonging class topoisomerase inhibitors negative scores s<NUMBER> last drug ro<NUMBER> targets amyloid precursor protein app gene amyloid␤<NUMBER> aggregation inhibitor candidate alzheimers disease molecule <NUMBER> conclusion demonstrated utility bioinformatics identifying drugs repurposed potentially treating covid<NUMBER> patients drugs listed preliminary need vitro validation also call approaches covd<NUMBER> targets ace<NUMBER> nominate additional candidates vitro vivo testing could accelerate drug discovery covid<NUMBER> novel severe acquired respiratory syndrome sarscov<NUMBER> coronavirus <NUMBER> etiologic agent coronavirus disease <NUMBER> spread everywhere <NUMBER> causing global pandemic <NUMBER> <NUMBER> date <NUMBER> million reported <NUMBER> cases <NUMBER> deaths worldwide urging global effort tackle disease <NUMBER> <NUMBER> sarscov<NUMBER> belongs genus betacoronavirus orderfamilysubfamily <NUMBER> nidoviralescoronaviridaecoronavirinae virion enveloped contains single <NUMBER> rna genome positive polarity morphologically sarscov<NUMBER> <NUMBER> nm <NUMBER> diameter large projections heavily glycosylated trimeric spike proteins <NUMBER> surface proteins include membrane envelope e proteins inside <NUMBER> envelope helical nucleocapsid n wraps viral rna virus targets cells <NUMBER> upper lower respiratory tract epithelia viral spike binds <NUMBER> angiotensinconverting enzyme <NUMBER> ace<NUMBER> receptor process facilitated host type <NUMBER> <NUMBER> transmembrane serine protease tmprss<NUMBER> inside cell viral polyproteins <NUMBER> synthesized encode replication machinery required synthesize new rna via <NUMBER> rnadependent rna polymerase activity replication cytoplasmatic level <NUMBER> endoplasmic reticulum er heavily rearranged structural proteins <NUMBER> synthesized leading completion assembly release viral particles <NUMBER> <NUMBER> <NUMBER> currently specific treatment sarscov<NUMBER> available antiviral <NUMBER> therapy comes repurposing drugs developed viral infections lopinavir <NUMBER> ritonavir remdesivir hydroxychloroquine umifenovir favipiravir examples <NUMBER> currently evaluated none conclusively shown effective <NUMBER> <NUMBER> <NUMBER> iminosugar miglustat zavesca nbutyl<NUMBER>deoxynojirimycin nbdnj inhibits α<NUMBER> glucosidases ii involved early stages glycoprotein nlinked <NUMBER> oligosaccharide processing er <NUMBER> enveloped viruses require <NUMBER> glycosylation surface protein folding secretion modulation oligosaccharide <NUMBER> induce reduction infectivity became strategy treatment immune <NUMBER> deficiency virus type <NUMBER> hiv<NUMBER> culminating phase iii clinical trials <NUMBER> <NUMBER> use <NUMBER> iminosugars misfold viral glycoprotein therapeutic approach far <NUMBER> applied several viral infections including hepatitis b c viruses dengue <NUMBER> flaviviruses ebola virus <NUMBER> additional property certain iminosugars <NUMBER> glucosyltransferase inhibition activity basis current therapy rare <NUMBER> genetic lysosome storage diseases gaucher niemannpick type c <NUMBER> <NUMBER> activity miglustat could impact virus entry modification plasma membrane <NUMBER> vero e<NUMBER> cells atcc<NUMBER> hek <NUMBER>t atcc crl<NUMBER> a<NUMBER> atcc ccl<NUMBER> u<NUMBER>os <NUMBER> atcc htb<NUMBER> human hepatocarcinoma huh<NUMBER> cells kindly provided ralf <NUMBER> bartenschlager university heidelberg germany cultured dulbeccos modified <NUMBER> eagles medium dmem supplemented <NUMBER> fetal bovine serum fbs gibco <NUMBER> antibiotics cell cultures maintained <NUMBER> °c <NUMBER> co <NUMBER> cells routinely <NUMBER> tested mycoplasma contamination <NUMBER> working stocks sarscov<NUMBER> icgebfvg<NUMBER> isolated trieste italy routinely <NUMBER> propagated titrated vero e<NUMBER> cells <NUMBER> plaque assay performed incubating <NUMBER> dilutions sarscov<NUMBER> vero e<NUMBER> monolayers <NUMBER> °c <NUMBER> hour <NUMBER> washed phosphate buffered saline pbs overlaid dmem <NUMBER> fbs <NUMBER> containing <NUMBER> carboxymethylcellulose <NUMBER> days cells fixed <NUMBER> <NUMBER> paraformaldehyde pfa stained crystal violet <NUMBER> cytotoxicity assay <NUMBER> performed alamar blue thermofisher according manufacturers instructions <NUMBER> <NUMBER> miglustat nbdnj purchased sigma b<NUMBER> drug dissolved <NUMBER> dmso obtain stock solution following dilutions made directly growth <NUMBER> sarscov<NUMBER> spike protein receptorbinding domain rbd expressed <NUMBER> pcaggs using construct generously provided florian krammer mount sinai new <NUMBER> york <NUMBER> plasmid transfected <NUMBER>t cells cell extracts supernatants <NUMBER> harvested <NUMBER> hours posttransfection miglustat <NUMBER> µm added transfection <NUMBER> maintained medium end experiment <NUMBER> sequence coding full length spike protein obtained isolate wuhanhu<NUMBER> <NUMBER> ncbi reference sequence nc<NUMBER> nucleotide sequence fused <NUMBER> immunoglobulin leader sequence sec nterminus codon optimized expression <NUMBER> mammalian cells obtained synthetic dna fragment genscript biotech <NUMBER> netherlands cloned hindiiiapai pcdna<NUMBER> vector <NUMBER> <NUMBER> vero e<NUMBER> cells seeded <NUMBER>x<NUMBER> <NUMBER> cellswell density <NUMBER> wells plate incubated <NUMBER> <NUMBER> °c overnight cells infected <NUMBER> viral pfuwell incubated <NUMBER> °c <NUMBER> <NUMBER> hour following incubation virus removed wells washed <NUMBER>x pbs <NUMBER> infected cells maintained <NUMBER> µl overlay medium containing <NUMBER> <NUMBER> carboxymethylcellulose cmc dmem <NUMBER> heatinactivated fbs miglustat <NUMBER> dilutions cells incubated <NUMBER> °c <NUMBER> days finally cells fixed <NUMBER> <NUMBER> pfa stained crystal violet plaques counted values normalized <NUMBER> vehicle dmso plaque reduction assays conducted <NUMBER> double replicates three independent experiments inhibition calculated <NUMBER> formula <NUMBER>average plaques miglustataverage plaques vehicle<NUMBER> plotted <NUMBER> dilutions antilog cytotoxicity assay fluorescence readings normalized <NUMBER> vehicle percent plotted dilutions half maximal effective concentration <NUMBER> ec <NUMBER> cytotoxic concentration cc <NUMBER> calculated using graphpad prism version healthcare binding buffer <NUMBER> mm sodium phosphate ph <NUMBER> eluted acetic <NUMBER> acid <NUMBER>mm ph <NUMBER> eluted antibody immediately neutralized <NUMBER>m tris ph <NUMBER> <NUMBER> analyzed rphplc sds page maintain dimeric structure production <NUMBER> yield <NUMBER> mgml immunofluorescence cells fixed <NUMBER> pfa permeabilized <NUMBER> <NUMBER> triton processed msip<NUMBER> per standard procedure <NUMBER> since <NUMBER> msip<NUMBER> react denatured protein convalescent serum <NUMBER> covid<NUMBER> patient used immunoblotting <NUMBER> dilution images acquired <NUMBER> zeiss lsm<NUMBER> confocal microscope immunoblotting wholecell lysates <NUMBER> resolved <NUMBER> sdspage blotted onto nitrocellulose membranes membranes <NUMBER> blocked <NUMBER> nonfat milk trisbuffered saline tbs plus <NUMBER> tween <NUMBER> tbst <NUMBER> followed incubation human serum diluted <NUMBER> solution <NUMBER> hour <NUMBER> room temperature washing three times tbst secondary horseradish <NUMBER> peroxidase hrpconjugated antibodies incubated <NUMBER> hour room temperature <NUMBER> blots developed using chemioluminescent hrp substrate millipore anti<NUMBER> antibody monoclonal <NUMBER> sigma used <NUMBER> concentration immunoblot asterisks graphs p <NUMBER> highly significant p <NUMBER> significant <NUMBER> asterisks missing differences calculated nonsignificant ns <NUMBER> <NUMBER> antiviral properties miglustat assessed performing plaque assay sars<NUMBER> cov<NUMBER> strain icgebfvg<NUMBER> used infect vero e<NUMBER> <NUMBER> hour removal <NUMBER> inoculum wash pbs cells overlaid medium containing <NUMBER> cmc <NUMBER> dilutions drug indicated figure <NUMBER>a <NUMBER> hours postinfection cells fixed <NUMBER> stained reveal plaques visually counted data three independent <NUMBER> experiments duplicate biological replicates parallel cytotoxicity assessed <NUMBER> alamar blue method indicated dilutions drug effective concentration <NUMBER> <NUMBER> inhibition ec <NUMBER> miglustat <NUMBER>±<NUMBER> µm apparent cyototoxicity <NUMBER> <NUMBER> mm cc <NUMBER> <NUMBER> mm plaque assay performed vero e<NUMBER> cells standard <NUMBER> growth sarscov<NUMBER> however analysis would better performed <NUMBER> cells human origin better characterize hypothesis timeofaddition toa experiment <NUMBER> performed different conditions used pretreatment cotreatment post<NUMBER> treatment huh<NUMBER> cells pretreated <NUMBER> µm miglustat <NUMBER>h infected <NUMBER> <NUMBER>h absence drug moi <NUMBER> afterwards virus removed cells <NUMBER> cultured drugfree medium end experiment cotreatment <NUMBER> drug added together virus infection cells maintained <NUMBER> drugfree medium postentry experiment drug added <NUMBER> h postinfection <NUMBER> maintained end experiment shown figure <NUMBER>a drug didnt affect viral <NUMBER> entry neither virucidal administered concomitant infection replication <NUMBER> intracellular viral rna slightly affected <NUMBER>hpi significantly <NUMBER>hpi consistent <NUMBER> idea miglustat effective postentry level reflected <NUMBER> reduction intracellular nucleocapsid n protein observed time points figure <NUMBER>b detected conformationdependent msip<NUMBER> antibody shown figure <NUMBER>j <NUMBER> <NUMBER>k miglustat reduce amount protein cell surface host directed antiviral therapy strategy inhibiting virus infection targeting host <NUMBER> factors essential viral replication <NUMBER> currently pressing need <NUMBER> antiviral drugs immediate use context sarscov<NUMBER> infection miglustat <NUMBER> drug current clinical use treatment certain genetic disorders <NUMBER> shown active variety viral infections making suitable candidate <NUMBER> drug repurposing towards sarscov<NUMBER> work activity miglustat <NUMBER> sarscov<NUMBER> demonstrated vitro ec <NUMBER> micromolar range <NUMBER> standard dosage lysosomal storage diseases gaucher niemann pick <NUMBER> <NUMBER> mg<NUMBER> times day maximum daily dose <NUMBER> mgday single dose <NUMBER> mg <NUMBER> miglustat reaches peak plasma concentration around <NUMBER> µm within <NUMBER> hours <NUMBER> halflife approximately <NUMBER> hours dose administered every <NUMBER> hours<NUMBER> times per <NUMBER> day plasma concentration miglustat would stabilize around <NUMBER> µm <NUMBER> <NUMBER> mg <NUMBER> miglustat administered every <NUMBER> hours<NUMBER> times day plasma concentration could <NUMBER> also higher <NUMBER> µm <NUMBER> hours however increased dosage could lead well<NUMBER> described adverse reactions include tremors diarrhea numbness <NUMBER> miglustat shown act two different mechanisms level virus <NUMBER> entry perturbing plasma membrane level folding secretion <NUMBER> virion proteins affecting essential glycosylation steps er latter mechanism <NUMBER> supported data presented work strong antiviral activity detected <NUMBER> drug added postinfection correct folding secretion glycoproteins <NUMBER> process tightly controlled er chaperons calnexin recognize <NUMBER> specific glycosylation intermediates <NUMBER> miglustat interferes process resulting <NUMBER> accumulation misfolded proteins defect secretion consistently spike <NUMBER> protein sarscov<NUMBER> shown bind calnexin disruption function <NUMBER> caused decrease virus infectivity <NUMBER> <NUMBER> conclusion work provides vitro evidence use miglustat inhibitor <NUMBER> sarscov<NUMBER> proposes use clinical trials covid<NUMBER> patients monolayers infected sarscov<NUMBER> following incubation three days cells <NUMBER> fixed stained count viral plaques vehicle control plotted <NUMBER> percent inhibitory activity black dots cytotoxicity measured alamar blue <NUMBER> method data plotted percent viability red squares pandemic obesity growing worrying pace estimated direct indirect cost us <NUMBER> billion per year us alone <NUMBER> recent studies suggest one five deaths linked one way another obesity <NUMBER> since <NUMBER> obesity prevalence almost tripled <NUMBER> obesity main risk factor many serious diseases type ii diabetes fatty liver cardiovascular diseases cancer among others <NUMBER> <NUMBER> additionally obesity important psychological impacts patients resulting lower quality life <NUMBER> although obesity recognized world health organization one major challenges public health twentyfirst century <NUMBER> still clearcut solution <NUMBER> date food drug administration fda approved five drugs drug combinations longterm obesity treatment orlistat lorcaserin liraglutide bupropionnaltrexone phenterminetopiramate <NUMBER> four drugs fdaapproved shortterm use benzphetamine phentermine phendimetrazine diethylpropion <NUMBER> recently lorcaserin withdrawn us market safety clinical trial showed increased occurrence cancer <NUMBER> meanwhile european medicines agency approved three medicines orlistat bupropionnaltrexone liraglutide obesity management european union <NUMBER> thus developing new pharmacotherapies treat obesity imminent importance fulfill highly unmet medical need drug repurposing strategy also called repositioning approach identifying new therapeutic uses approved investigational drugs <NUMBER> new uses usually outside original medical indication <NUMBER> high attrition rate escalating costs long timeframes new drug discovery drug repurposing rapidly gaining ground <NUMBER> average cost successful drug repurposing estimated us <NUMBER> million tenth bringing new chemical entity market <NUMBER> since repurposed drug successfully passed safety assessment preclinical studies clinical trials risk failure significantly lower <NUMBER> redirection sildenafil originally developed antihypertensive agent treat erectile dysfunction great example successful drug repurposing approval thalidomide <NUMBER> treat multiple myeloma yet another example <NUMBER> drug repurposing could also useful approach outbreaks emerging diseases recent attempts use fdaapproved human immunodeficiency virus hiv type <NUMBER> aspartate protease inhibitor lopinavir <NUMBER> combination antimalaria agent hydroxychloroquine macrolide antibiotic azithromycin overcome current pandemic coronavirus disease <NUMBER> covid<NUMBER> <NUMBER> disulfiram dsf figure <NUMBER> irreversible aldehyde dehydrogenase inhibitor disulfiram blocks alcohol metabolism acetaldehyde stage leading accumulation latter blood turn produces highly unpleasant reaction includes low blood pressure tachycardia facial flushing vomiting vertigo patient treated disulfiram ingests even small amounts alcohol <NUMBER> <NUMBER> disulfiram first drug approved fda treat chronic alcoholism many studies since shown potential repurposing disulfiram anticancer agent <NUMBER> currently disulfiram progressing different stages clinical trials treat diverse types malignant tumors metastatic breast cancer glioblastoma recurrent pancreatic carcinoma disulfiram also shown therapeutic potential latencyreversing agent treating aids patients <NUMBER> <NUMBER> recently disulfiram shown beneficial treating lyme disease babesiosis <NUMBER> addition inhibiting aldh<NUMBER> isoform responsible alcohol metabolism disulfiram even potently inhibits aldh<NUMBER>a<NUMBER> <NUMBER> cytosolic isoform irreversibly converts retinaldehyde rald retinoic acid <NUMBER> <NUMBER> expression aldh<NUMBER>a<NUMBER> significantly higher obese patients compared lean subjects <NUMBER> furthermore disruption expression function enzyme rats rendered resistant dietinduced obesity <NUMBER> moreover aldh<NUMBER>a<NUMBER> deficient adipocytes shown effectively reduce body weight mice fed highfat diet hfd <NUMBER> <NUMBER> also markedly reduced waist circumference body weight fat mass implanted visceral fat depots obese large animal models dogs <NUMBER> additionally aldh<NUMBER>a<NUMBER>deficient mice viable show growth survival defects <NUMBER> thus inhibiting function aldh<NUMBER>a<NUMBER> clearly attractive approach treating obesity study showed disulfiram effectively reduce body weight obese rats also prevents weight gain induced hfd rats standard diet sd purchased grains silos flour mills organization sa item f<NUMBER> sd composed <NUMBER> protein <NUMBER> fat <NUMBER> carbohydrates highfat diet prepared weekly lab according following prescription <NUMBER> cow fat <NUMBER> eggs <NUMBER> sugar <NUMBER> standard diet thirty male albino rats <NUMBER> ± <NUMBER> g purchased king fahad medical research center jeddah ksa rats kept <NUMBER> ± <NUMBER>°c <NUMBER> h lightanddark cycle condition five days acclimation rats <NUMBER> weeks age divided randomly six groups g<NUMBER>g<NUMBER> five animals g<NUMBER> control group given standard diet sd g<NUMBER> g<NUMBER> positive control group given highfat diet hfd g<NUMBER> given high fatdiet dsf <NUMBER> mgkgday administered orally day one six weeks g<NUMBER> given hfd dsf <NUMBER> mgkgday administered orally day one six weeks g<NUMBER> given hfd six weeks treatment started <NUMBER> mgkgday dsf orally g<NUMBER> given highfat diet six weeks treatment started <NUMBER> mgkgday dsf orally groups free access water designated diet end week six hfdfed rats redistributed three new groups g<NUMBER> g<NUMBER> g<NUMBER> five animals order ensure close body weight average <NUMBER> ± <NUMBER> g protocols approved biomedical ethics committee faculty medicine king abdulaziz university experiments carried according regulations saudi national committee bioethics disulfiram usp purchased xenex laborotories inc coquitlam ca catalogue di<NUMBER> dsf dose calculated according rat body weight dsf dispersed vegetable oil <NUMBER> ml given daily rats gavage ogtt performed end study rats made fast <NUMBER> h baseline blood draw lateral tail vein collected plasma fasting glucose animals gavaged glucose solution <NUMBER> gkg body weight blood droplets tail vein thereafter collected measure glycemia <NUMBER> <NUMBER> <NUMBER> <NUMBER> min <NUMBER> descriptive statistics performed variables data expressed mean ± sd normality tests done shapirowilk test data check normality primary outcome analysis anova kruskal wallis test depending normality done compare groups post hoc analysis performed using either tukey hsd test equal variance assumed gameshowell test equal variances assumed paired ttest mann whitney test depending normality used check statistical significance difference within every group significance level p <NUMBER> used detect statistical differences sample excluded analysis secondary analysis ogtt done using area curve auc anova test visualize difference different group response oral glucose statistical analysis carried using spss <NUMBER> ibm spss inc chicago il usa graphs created using graphpad prism <NUMBER> graphpad software inc san diego ca usa first six weeks study using paired test notice body weight rats receiving standard diet g<NUMBER> increased <NUMBER> ± <NUMBER> <NUMBER> ± <NUMBER> g <NUMBER> ± <NUMBER> g p <NUMBER> rats hfd g<NUMBER> gained <NUMBER> ± <NUMBER> <NUMBER> g ± <NUMBER> <NUMBER> ± <NUMBER> g p <NUMBER> meanwhile body weight gain hfdfed rats receiving <NUMBER> mgkgday dsf g<NUMBER> <NUMBER> ± <NUMBER> <NUMBER> ± <NUMBER> g <NUMBER> ± <NUMBER> g p <NUMBER> hand high dose dsf <NUMBER> mgkgday g<NUMBER> limited body weight gain caused hfd <NUMBER> ± <NUMBER> <NUMBER> ± <NUMBER> g <NUMBER> ± <NUMBER> g p <NUMBER> figure <NUMBER> week six rats fed hfd redistributed three groups g<NUMBER> g<NUMBER> g<NUMBER> ensure close body weight average using paired test notice g<NUMBER> continued receiving hfd body weight increased <NUMBER> ± <NUMBER> <NUMBER> ± <NUMBER> g <NUMBER> ± <NUMBER> g p <NUMBER> period three weeks whereas body figure <NUMBER> statistically significant difference four groups six weeks intervention using oneway anova f <NUMBER> <NUMBER> p <NUMBER> levenes test significant p<NUMBER> post hoc analysis results tukey hsd test multiple comparison showed statistically significance difference g<NUMBER> g<NUMBER> p <NUMBER> additionally statistically significant difference neither g<NUMBER> g<NUMBER> p <NUMBER> g<NUMBER> g<NUMBER> p <NUMBER> however statistically significant difference g<NUMBER> g<NUMBER> p <NUMBER> figure <NUMBER>e redistribution hfd groups week six statistically significant difference four groups three weeks intervention using oneway anova f <NUMBER> <NUMBER> p <NUMBER> levenes test significant p <NUMBER> post hoc analysis results tukey hsd test multiple comparison showed statistically significance difference g<NUMBER> g<NUMBER> p <NUMBER> neither g<NUMBER> g<NUMBER> p <NUMBER> g<NUMBER> g<NUMBER> p <NUMBER> hand statistically significant difference g<NUMBER> g<NUMBER> p <NUMBER> g<NUMBER> g<NUMBER> p <NUMBER> furthermore statistically significant difference <NUMBER> mg g<NUMBER> g<NUMBER> p <NUMBER> figure <NUMBER>d food water intakes calculated three separate days middle study dsf administration statistically significant effect food intake treated animals either dose however dsf significantly increased water consumption treated rats compared counterparts receiving hfd table <NUMBER> ogtt performed week six evaluate effect dsf glycemic response hfdfed rats figure <NUMBER> total auc glycemic response calculated groups g<NUMBER>g<NUMBER> dsf decreased auc doses however reduction statistically significant table <NUMBER> retinoids enzymes controlling metabolism form complex system controls important biological processes fuel metabolism adipogenesis <NUMBER> <NUMBER> <NUMBER> aldh<NUMBER>a<NUMBER> −mice known resistant dietinduced obesity show better insulin sensitivity wildtype counterparts <NUMBER> <NUMBER> disulfiram known inhibitor aldehyde dehydrogenases <NUMBER> fdaapproved drug treating chronic alcoholism disulfiram considered safe well tolerated drug <NUMBER> single oral dose <NUMBER> g daily doses <NUMBER> g administered months generally tolerated human adults without symptoms <NUMBER> <NUMBER> disulfiram also characterized high oral ld <NUMBER> dose <NUMBER> gkg rats <NUMBER> indeed disulfiram potent inhibitor isoforms aldehyde dehydrogenase ald<NUMBER>a<NUMBER> aldh<NUMBER> since aldh<NUMBER>a<NUMBER> bigger substrate entrance tunnel aldh<NUMBER> disulfiram rather large hydrophobic compound higher affinity aldh<NUMBER>a<NUMBER> <NUMBER> work investigated potential use disulfiram treatment obesity results showed despite fact dsf significant effect food intake considerably limited body weight gain treated animals caused hfd administered moderate dose <NUMBER> mg kgday rats along hfd dsf completely cancelled obesogenic effect diet six weeks treatment hfdfed rats treated higher doses dsf <NUMBER> mgkgday showed strong resistance body weight increase gained less weight compared counterparts receiving hfd also standard diet dsf also considerably decreased body weight obese animals doses <NUMBER> <NUMBER> mgkgday three weeks dsf treatment obese rats lost <NUMBER> weight thus restoring body weight matching received standard diet note data presented mean ± sem n <NUMBER> rats per group glycaemic response oral glucose tolerance test data presented mean ± sem n <NUMBER> rats per group disulfiram fdaapproved drug showed promising antiobesity activity highfat dietfed rats tried doses findings suggest disulfiram potential treatment obesity future studies focus molecular mechanisms disulfiram clinical trials healthy obese adults could also envisaged 